Common name;GPCRdb ID;Reference ligand;Vendors;Species;Assay Type;Activity Type;Activity Relation;Activity Value;p-value (-log);Fold selectivity;Tested GPCRs;Assay Description;Source;Mol weight;Rot Bonds;H don;H acc;LogP;Smiles;DOI
α-ergocryptine;358;None;18;Human;Binding;IC50;=;1,95;8,71;-1;21;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;575,3;5;3;6;2,43;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
α-ergocryptine;358;None;18;Human;Binding;Ki;=;0,65;9,19;-1;21;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;575,3;5;3;6;2,43;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
α-ergocryptine;358;None;18;Human;Binding;pKi;=;9,19;8,04;-1;21;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;575,3;5;3;6;2,43;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
(+)-AJ76;322;None;18;Human;Binding;Ki;=;145,00;6,84;2;8;Binding affinity was measured at cloned mammalian dopamine D2 receptor expressed in CHO-K1 cells (using [3H]U-86170);ChEMBL;233,2;4;1;2;3,11;CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C;https://dx.doi.org/10.1016/S0960-894X(01)80181-5
(+)-butaclamol;746;None;9;Human;Binding;IC50;=;1,10;8,96;-1;25;Displacement of [3H]methylspiperone from human recombinant Dopamine D2S receptor expressed in HEK293 cells;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://dx.doi.org/10.1016/j.bmc.2016.03.006
(+)-butaclamol;746;None;9;Human;Binding;IC50;=;0,81;9,09;-1;25;Displacement of [3H]methyl-spiperone from human recombinant D2S receptor in HEK293 cells after 60 mins by scintillation counting;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01422
(+)-butaclamol;746;None;9;Human;Binding;Ki;=;0,27;9,57;-1;25;Displacement of [3H]methyl-spiperone from human recombinant D2S receptor in HEK293 cells after 60 mins by scintillation counting;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01422
(+)-butaclamol;746;None;9;Human;Binding;Ki;=;0,04;10,40;-1;25;Displacement of [3H]methylspiperone from human recombinant D2S receptor expressed in HEK293 cells;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://dx.doi.org/10.1021/jm401895u
(+)-butaclamol;746;None;9;Human;Binding;Ki;=;0,04;10,40;-1;25;Displacement of [3H]methylspiperone from human D2S receptor expressed in HEK293 cells;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
(+)-butaclamol;746;None;9;Human;Binding;pKi;None;-;8,10;-1;25;Unclassified;Guide to Pharmacology;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://pubmed.ncbi.nlm.nih.gov/7576010
(+)-butaclamol;746;None;9;Human;Binding;pKi;None;-;8,10;-1;25;Unclassified;Guide to Pharmacology;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://pubmed.ncbi.nlm.nih.gov/8301592
(+)-butaclamol;746;None;9;Human;Binding;pKi;None;-;8,10;-1;25;Unclassified;Guide to Pharmacology;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://pubmed.ncbi.nlm.nih.gov/8301582
(+)-butaclamol;746;None;9;Human;Binding;pKi;None;-;8,10;-1;25;Unclassified;Guide to Pharmacology;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://pubmed.ncbi.nlm.nih.gov/7907989
(+)-butaclamol;746;125I-Epidepride;9;Human;Binding;pKi;=;1,20;8,92;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;3H-SPIPERONE;9;Human;Binding;pKi;=;0,80;9,10;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;3H-SPIPERONE;9;Human;Binding;pKi;=;0,09;10,05;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;3H-YM 09151-2;9;Human;Binding;pKi;=;1,00;9,00;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;125I-IODOSULPRIDE;9;Human;Binding;pKi;=;0,44;9,36;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;3H-S-Sulpiride;9;Human;Binding;pKi;=;7,70;8,11;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;3H-SPIPERONE;9;Human;Binding;pKi;=;0,09;10,05;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;125I-Epidepride;9;Human;Binding;pKi;=;0,68;9,17;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;125I-Epidepride;9;Human;Binding;pKi;=;0,74;9,13;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;125I-Epidepride;9;Human;Binding;pKi;=;0,83;9,08;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;UNDEFINED;9;Human;Binding;pKi;=;0,05;10,30;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;125I-Epidepride;9;Human;Binding;pKi;=;1,80;8,74;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;3H-SPIPERONE;9;Human;Binding;pKi;=;1,10;8,96;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;3H-domperidone;9;Human;Binding;pKi;=;0,94;9,03;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-butaclamol;746;3H-SPIPERONE;9;Human;Binding;pKi;=;3,20;8,49;-1;25;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;-
(+)-S-14297;3427;None;8;Human;Binding;Ki;=;251,19;6,60;-50;2;Inhibition of [125 I]iodosulpiride binding to human Dopamine receptor D2 expressed in CHO cell membranes;ChEMBL;273,2;5;0;2;3,60;CCCN(CCC)C1CCc2cc3c(cc2C1)OCC3;https://dx.doi.org/10.1016/S0960-894X(97)00126-1
(+)-S-14297;3427;None;8;Human;Binding;pKi;None;-;5,50;-50;2;Unclassified;Guide to Pharmacology;273,2;5;0;2;3,60;CCCN(CCC)C1CCc2cc3c(cc2C1)OCC3;https://pubmed.ncbi.nlm.nih.gov/7473180
(+)-SCH-23390;3548;None;8;Human;Binding;Ki;=;20,00;7,70;-1;4;Ability to partially antagonise [3H]-SCH- 23388 binding to the Dopamine receptor D2;ChEMBL;287,1;1;1;2;3,67;CN1CCc2cc(Cl)c(O)cc2[C@H](c2ccccc2)C1;https://dx.doi.org/10.1021/jm00119a003
(+)-SCH-23390;3548;None;8;Human;Binding;pKi;None;-;5,30;-1;4;Unclassified;Guide to Pharmacology;287,1;1;1;2;3,67;CN1CCc2cc(Cl)c(O)cc2[C@H](c2ccccc2)C1;https://pubmed.ncbi.nlm.nih.gov/8301582
(+)-sulpiride;3703;None;66;Human;Binding;AC50;=;803,30;6,09;-1;23;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
(+)-sulpiride;3703;None;66;Human;Binding;IC50;=;128,00;6,89;-1;23;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;None;66;Human;Binding;IC50;=;205,00;6,69;-1;23;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;None;66;Human;Binding;Kd;=;2,82;8,55;-1;23;Competitive antagonist activity at D2 long receptor (unknown origin) expressed in CHOK1 cells assessed as inhibition of dopamine induced beta-arrestin recruitment after 90 mins by DiscoveRx PathHunter assay;ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;120,00;6,92;-1;23;Binding affinity for human dopamine receptor D2 long;ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1021/jm049612a
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;7,60;8,12;-1;23;Antagonist activity at dopamine D2 receptor (unknown origin);ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1039/C1MD00074H
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;68,00;7,17;-1;23;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;120,00;6,92;-1;23;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;51,00;7,29;-1;23;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;120,00;6,92;-1;23;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;9,80;8,01;-1;23;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1016/j.bmcl.2021.128275
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;51,00;7,29;-1;23;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
(+)-sulpiride;3703;None;66;Human;Binding;Ki;=;43,00;7,37;-1;23;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;None;66;Human;Binding;pKi;=;8,12;8,09;-1;23;Antagonist activity at dopamine D2 receptor (unknown origin);Drug Central;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;None;66;Human;Binding;pKi;=;7,29;8,14;-1;23;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;Drug Central;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;None;66;Human;Binding;pKi;=;-;7,14;-1;23;Unclassified;Guide to Pharmacology;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://pubmed.ncbi.nlm.nih.gov/8301592
(+)-sulpiride;3703;None;66;Human;Binding;pKi;=;-;8,22;-1;23;Unclassified;Guide to Pharmacology;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://pubmed.ncbi.nlm.nih.gov/8301582
(+)-sulpiride;3703;None;66;Human;Binding;pKi;=;-;7,14;-1;23;Unclassified;Guide to Pharmacology;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://pubmed.ncbi.nlm.nih.gov/8301582
(+)-sulpiride;3703;None;66;Human;Binding;pKi;=;-;7,57;-1;23;Unclassified;Guide to Pharmacology;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://pubmed.ncbi.nlm.nih.gov/7576010
(+)-sulpiride;3703;None;66;Human;Binding;pKi;=;-;7,14;-1;23;Unclassified;Guide to Pharmacology;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;https://pubmed.ncbi.nlm.nih.gov/1354163
(+)-sulpiride;3703;3H-YM 09151-2;66;Human;Binding;pKi;=;4,20;8,38;-1;23;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;R-SAT;66;Human;Binding;pKi;=;11,00;7,96;-1;23;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;R-SAT;66;Human;Binding;pKi;=;8,60;8,07;-1;23;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-sulpiride;3703;3H-domperidone;66;Human;Binding;pKi;=;206,00;6,69;-1;23;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCC[C@@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
(+)-UH232;3933;None;0;Human;Binding;pKi;None;-;6,75;-2;4;Unclassified;Guide to Pharmacology;273,2;6;0;2;4,32;CCCN(CCC)[C@@H]1C=Cc2c(OC)cccc2[C@@H]1C;https://pubmed.ncbi.nlm.nih.gov/1975644
(+)-UH232;3933;None;0;Human;Binding;pKi;None;-;6,75;-2;4;Unclassified;Guide to Pharmacology;273,2;6;0;2;4,32;CCCN(CCC)[C@@H]1C=Cc2c(OC)cccc2[C@@H]1C;https://pubmed.ncbi.nlm.nih.gov/8301582
(+/-)-NUCIFERINE;92011;None;17;Human;Binding;Ki;=;173,78;6,76;1;7;Displacement of [3H] raclopride from D2DR (unknown origin);ChEMBL;295,2;2;0;3;3,46;COc1cc2c3c(c1OC)-c1ccccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.ejmech.2020.112792
(-)-adrenaline;291;None;40;Human;Binding;Ki;=;910,00;6,04;-13;35;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;183,1;3;4;4;0,35;CNC[C@H](O)c1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
(-)-adrenaline;291;None;40;Human;Binding;pKi;=;6,04;8,22;-13;35;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;Drug Central;183,1;3;4;4;0,35;CNC[C@H](O)c1ccc(O)c(O)c1;-
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;EC50;=;1,18;8,93;-1;5;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;EC50;=;1,18;8,93;-1;5;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Kd;=;20,00;7,70;-1;5;Equilibrium dissociation constant against recombinant Dopamine receptor D2A expressed in COS7 cells;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm950447w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;0,07;10,13;-1;5;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm401384w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;0,38;9,42;-1;5;Displacement of [3H]-spiperone from high-affinity state of recombinant human dopamine D2L receptor expressed in CHO cells after 45 mins by scintillation counting analysis;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm401384w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;0,11;9,96;-1;5;Binding affinity to high-affinity state of D2L receptor (unknown origin) expressed in CHO cell membranes;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm401384w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;50,00;7,30;-1;5;Affinity towards Dopamine receptor D2;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm9800292
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;1,73;8,76;-1;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm401384w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;0,07;10,12;-1;5;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm401384w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;10,60;7,97;-1;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm401384w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;4,90;8,31;-1;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm401384w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;Ki;=;1,62;8,79;-1;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm401384w
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;pKi;None;-;8,20;-1;5;Unclassified;Guide to Pharmacology;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://pubmed.ncbi.nlm.nih.gov/8301582
(-)-N-porphynorapomorphine;2876;None;8;Human;Binding;pKi;None;-;8,20;-1;5;Unclassified;Guide to Pharmacology;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://pubmed.ncbi.nlm.nih.gov/7756621
(-)-N-porphynorapomorphine;2876;125I-IODOSULPRIDE;8;Human;Binding;pKi;=;0,12;9,92;-1;5;-;PDSP KiDatabase;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;-
(-)-noradrenaline;2857;None;46;Human;Binding;Ki;=;1300,00;5,89;-17;32;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;169,1;2;4;4;0,09;NC[C@H](O)c1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
(-)-noradrenaline;2857;None;46;Human;Binding;pKi;=;5,89;8,23;-17;32;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;Drug Central;169,1;2;4;4;0,09;NC[C@H](O)c1ccc(O)c(O)c1;-
(-)-stepholidine;3691;None;40;Human;Binding;IC50;=;105,41;6,98;-21;35;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
(-)-stepholidine;3691;None;40;Human;Binding;Ki;=;56,17;7,25;-21;35;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
(-)-stepholidine;3691;None;40;Human;Binding;Ki;=;974,00;6,01;-21;35;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
(-)-stepholidine;3691;None;40;Human;Binding;Ki;=;105,41;6,98;-21;35;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
(-)-stepholidine;3691;None;40;Human;Binding;Ki;=;974,00;6,01;-21;35;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2009.08.028
(-)-stepholidine;3691;None;40;Human;Binding;Ki;=;11,00;7,96;-21;35;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.12.016
(-)-stepholidine;3691;None;40;Human;Binding;pKi;=;-;7,94;-21;35;Unclassified;Guide to Pharmacology;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://pubmed.ncbi.nlm.nih.gov/25231919
(-)-stepholidine;3691;3H-NMSP;40;Human;Binding;pKi;=;974,30;6,01;-21;35;-;PDSP KiDatabase;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;-
(1R,2S)-PHENYLPROPANOLAMINE;27120;3H-NMSP;13;Human;Binding;pKi;=;10000,00;5,00;-38;42;-;PDSP KiDatabase;151,1;2;2;2;1,07;C[C@H](N)[C@H](O)c1ccccc1;-
(1S,2S)-1-[(S)-2-[4-(2,4-Dimethylphenyl)piperazyl]-ethyl]-2-methyl-2-phenylcyclopropane;219635;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-;1;-;PDSP KiDatabase;348,3;4;0;2;4,79;Cc1ccc(N2CCN(C(C)C3CC3(C)c3ccccc3)CC2)c(C)c1;-
(1S,2S)-1-[(S)-2-[4-(2,4-Dimethylphenyl)piperazyl]-ethyl]-2-methyl-2-phenylcyclopropane;219635;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-;1;-;PDSP KiDatabase;348,3;4;0;2;4,79;Cc1ccc(N2CCN(C(C)C3CC3(C)c3ccccc3)CC2)c(C)c1;-
(1S,2S)-1-[4-(2,4-Dimethylphenyl)piperazyl]methyl-2-methyl-2-phenylcyclopropane;219636;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-;1;-;PDSP KiDatabase;334,2;4;0;2;4,40;Cc1ccc(N2CCN(CC3CC3(C)c3ccccc3)CC2)c(C)c1;-
(3R)-3-((3-((2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)methyl)-8-azabicyclo[3.2.1]octan-8-yl)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;220141;UNDEFINED;0;Human;Binding;pKi;=;16,00;7,80;-;1;-;PDSP KiDatabase;473,2;4;2;5;3,69;O=C1CCc2ccc(CC3CC4CCC(C3)N4CC3COc4c(ccc5c4CC(=O)N5)O3)cc2N1;-
(3S)-3-(((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-2-yl)methylamino)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;219952;UNDEFINED;0;Human;Binding;pKi;=;100,00;7,00;-;1;-;PDSP KiDatabase;421,2;4;3;4;3,34;O=C1Cc2c(ccc3c2OCC(CNCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;-
(3S)-3-(((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methylamino)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;219955;UNDEFINED;0;Human;Binding;pKi;=;3,00;8,52;-1;3;-;PDSP KiDatabase;421,2;4;3;4;3,34;O=C1Cc2c(ccc3c2OCC(CNCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;-
(3S)-3-(((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methylamino)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;219955;UNDEFINED;0;Human;Binding;pKi;=;3,00;8,52;-1;3;-;PDSP KiDatabase;421,2;4;3;4;3,34;O=C1Cc2c(ccc3c2OCC(CNCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;-
(3S)-3-((2-(6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-2-yl)ethylamino)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;219953;UNDEFINED;0;Human;Binding;pKi;=;36,00;7,44;-;1;-;PDSP KiDatabase;435,2;5;3;4;3,73;O=C1Cc2c(ccc3c2OCC(CNCCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;-
(3S)-3-((2-(6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)ethylamino)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one hydrochloride;219956;UNDEFINED;0;Human;Binding;pKi;=;24,00;7,62;-;1;-;PDSP KiDatabase;435,2;5;3;4;3,73;O=C1Cc2c(ccc3c2OCC(CNCCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;-
(3S)-3-((2-(6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)ethylamino)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one hydrochloride;219956;UNDEFINED;0;Human;Binding;pKi;=;24,00;7,62;-;1;-;PDSP KiDatabase;435,2;5;3;4;3,73;O=C1Cc2c(ccc3c2OCC(CNCCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;-
(3S)-3-((3-( 6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-2-yl)propylamino)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;219954;UNDEFINED;0;Human;Binding;pKi;=;45,00;7,35;-7;3;-;PDSP KiDatabase;449,2;6;3;4;4,12;O=C1Cc2c(ccc3c2OCC(CNCCCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;-
(3S)-3-((3-( 6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-2-yl)propylamino)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;219954;UNDEFINED;0;Human;Binding;pKi;=;50,00;7,30;-7;3;-;PDSP KiDatabase;449,2;6;3;4;4,12;O=C1Cc2c(ccc3c2OCC(CNCCCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;-
(R)-1-(bis(4-fluorophenyl)methyl)-4-(3-(3-(3,4-dimethoxyphenyl)-4,5-dihydroisoxazol-5-yl)propyl)piperazine;219105;UNDEFINED;0;Human;Binding;pKi;=;400,00;6,40;-27;3;-;PDSP KiDatabase;535,3;10;0;6;5,66;COc1ccc(C2=NOC(CCCN3CCN(C(c4ccc(F)cc4)c4ccc(F)cc4)CC3)C2)cc1OC;-
(R)-1-(bis(4-fluorophenyl)methyl)-4-(3-(3-(3,4-dimethoxyphenyl)-4,5-dihydroisoxazol-5-yl)propyl)piperazine;219105;UNDEFINED;0;Human;Binding;pKi;=;80,00;7,10;-27;3;-;PDSP KiDatabase;535,3;10;0;6;5,66;COc1ccc(C2=NOC(CCCN3CCN(C(c4ccc(F)cc4)c4ccc(F)cc4)CC3)C2)cc1OC;-
(R)-11-(2-methylallyloxy)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline;220014;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-26;3;-;PDSP KiDatabase;333,2;5;0;2;5,17;C=C(C)COc1cccc2c1-c1cccc3c1C(C2)N(CCC)CC3;-
(R)-11-(3-methylbut-2-enyloxy)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline;220013;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-67;3;-;PDSP KiDatabase;347,2;5;0;2;5,56;CCCN1CCc2cccc3c2C1Cc1cccc(OCC=C(C)C)c1-3;-
(R)-11-(allyloxy)-6-propyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline;220015;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-35;3;-;PDSP KiDatabase;319,2;5;0;2;4,78;C=CCOc1cccc2c1-c1cccc3c1C(C2)N(CCC)CC3;-
(R)-2-(4-Hydroxy-phenyl)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;219624;UNDEFINED;0;Human;Binding;pKi;=;3,80;8,42;199;2;-;PDSP KiDatabase;359,2;1;3;4;4,22;CN1CCc2cc(-c3ccc(O)cc3)cc3c2C1Cc1ccc(O)c(O)c1-3;-
(R)-3-((4-((2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)methyl)piperidin-1-yl)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;220143;UNDEFINED;0;Human;Binding;pKi;=;8,00;8,10;-;1;-;PDSP KiDatabase;447,2;4;2;5;3,16;O=C1CCc2ccc(CC3CCN(CC4COc5c(ccc6c5CC(=O)N6)O4)CC3)cc2N1;-
(R)-3-((4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)piperidin-1-yl)methyl)-7,9-dihydro-2H-[1,4]dioxino[2,3-e]indol-8(3H)-one;220142;UNDEFINED;0;Human;Binding;pKi;=;2,50;8,60;-;1;-;PDSP KiDatabase;449,2;4;2;6;2,75;O=C1CCc2ccc(OC3CCN(CC4COc5c(ccc6c5CC(=O)N6)O4)CC3)cc2N1;-
(R)-6-Methyl-2-phenyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol;219623;UNDEFINED;0;Human;Binding;pKi;=;88,00;7,06;-1;2;-;PDSP KiDatabase;343,2;1;2;3;4,52;CN1CCc2cc(-c3ccccc3)cc3c2C1Cc1ccc(O)c(O)c1-3;-
(R)-6-Methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-11-ol;219262;UNDEFINED;0;Human;Binding;pKi;=;208,00;6,68;-7;4;-;PDSP KiDatabase;251,1;0;1;2;3,14;CN1CCc2cccc3c2C1Cc1cccc(O)c1-3;-
(R)-7-[8-(2-Oxo-1,2,3,4-tetrahydro-quinolin-7-ylmethyl)-3-aza-bicyclo[3.2.1]oct-3-ylmethyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one;220140;UNDEFINED;0;Human;Binding;pKi;=;6,30;8,20;-;1;-;PDSP KiDatabase;473,2;4;2;5;3,41;O=C1CCc2ccc(CC3C4CCC3CN(CC3COc5c(ccc6c5CC(=O)N6)O3)C4)cc2N1;-
(R)-Carvedilol;139775;None;38;Human;Binding;Ki;=;26,00;7,58;-30;5;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;406,2;10;3;5;3,74;COc1ccccc1OCCNC[C@@H](O)COc1cccc2[nH]c3ccccc3c12;https://dx.doi.org/10.1016/j.bmc.2016.04.028
(R)-SKF-38393;91633;None;9;Human;Binding;Kd;=;9500,00;5,02;-660;6;Equilibrium dissociation constant against recombinant Dopamine receptor D2A expressed in COS7 cells;ChEMBL;255,1;1;3;3;2,38;Oc1cc2c(cc1O)[C@@H](c1ccccc1)CNCC2;https://dx.doi.org/10.1021/jm950447w
(R)-SKF-38393;91633;None;9;Human;Binding;Ki;=;4670,00;5,33;-660;6;Binding affinity against cloned human Dopamine receptor D2 using [3H]spiperone as radioligand transfected in HEK cells;ChEMBL;255,1;1;3;3;2,38;Oc1cc2c(cc1O)[C@@H](c1ccccc1)CNCC2;https://dx.doi.org/10.1021/jm00018a002
(R)-SKF-38393;91633;None;9;Human;Binding;Ki;=;6500,00;5,19;-660;6;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;255,1;1;3;3;2,38;Oc1cc2c(cc1O)[C@@H](c1ccccc1)CNCC2;https://dx.doi.org/10.1021/jm00115a012
(R)-SKF-38393;91633;None;9;Human;Binding;Ki;=;9550,00;5,02;-660;6;Affinity towards Dopamine receptor D2;ChEMBL;255,1;1;3;3;2,38;Oc1cc2c(cc1O)[C@@H](c1ccccc1)CNCC2;https://dx.doi.org/10.1021/jm9800292
(R)-ZINC-3573;3426;None;17;Human;Binding;Ki;=;369,37;6,43;2;6;GPCRScan assay: inhibition of D2;ChEMBL;307,2;3;0;5;2,54;CN(C)[C@@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1;https://dx.doi.org/10.6019/CHEMBL4507322
(R)-ZINC-3573;3426;None;17;Human;Binding;Ki;=;369,37;6,43;2;6;Selectivity interaction (PRESTO-Tango GPCR-ome screening) EUB0000353a DRD2;ChEMBL;307,2;3;0;5;2,54;CN(C)[C@@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1;https://dx.doi.org/10.6019/CHEMBL5212743
(R)-ZINC-3573;3426;None;17;Human;Binding;Ki;=;369,37;6,43;2;6;Selectivity interaction (GPCR panel (PDSP screen)) EUB0000353a DRD2;ChEMBL;307,2;3;0;5;2,54;CN(C)[C@@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1;https://dx.doi.org/10.6019/CHEMBL5212743
(R)-ZINC-3573;3426;None;17;Human;Binding;Ki;=;354,81;6,45;2;6;GPCRScan assay: inhibition of D2;ChEMBL;307,2;3;0;5;2,54;CN(C)[C@@H]1CCN(c2cc(-c3ccccc3)nc3ccnn23)C1;https://dx.doi.org/10.6019/CHEMBL4507322
(S)-1-(3-(3-(3,4-dimethoxyphenyl)-4,5-dihydroisoxazol-5-yl)propyl)-4-(2-ethoxyphenyl)piperazine;219106;UNDEFINED;0;Human;Binding;pKi;=;46,00;7,34;-16;3;-;PDSP KiDatabase;453,3;10;0;7;4,20;CCOc1ccccc1N1CCN(CCCC2CC(c3ccc(OC)c(OC)c3)=NO2)CC1;-
(S)-1-(3-(3-(3,4-dimethoxyphenyl)-4,5-dihydroisoxazol-5-yl)propyl)-4-(2-ethoxyphenyl)piperazine;219106;UNDEFINED;0;Human;Binding;pKi;=;70,00;7,15;-16;3;-;PDSP KiDatabase;453,3;10;0;7;4,20;CCOc1ccccc1N1CCN(CCCC2CC(c3ccc(OC)c(OC)c3)=NO2)CC1;-
(S)-3-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine;219978;UNDEFINED;0;Human;Binding;pKi;=;3884,00;5,41;-;1;-;PDSP KiDatabase;281,1;4;0;3;2,68;CCCN1CCCC(c2cccc(S(C)(=O)=O)c2)C1;-
(S)-3-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine;219978;UNDEFINED;0;Human;Binding;pKi;=;755,00;6,12;-;1;-;PDSP KiDatabase;281,1;4;0;3;2,68;CCCN1CCCC(c2cccc(S(C)(=O)=O)c2)C1;-
(S)-UH 301;3702;None;13;Human;Binding;Ki;=;3760,00;5,42;-125;7;Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride;ChEMBL;265,2;5;1;2;3,51;CCCN(CCC)[C@H]1CCc2c(F)ccc(O)c2C1;https://dx.doi.org/10.1021/jm9911433
(S)-UH-301;218510;3H-8-OH-DPAT;0;Human;Binding;pKi;=;7080,00;5,15;-109;7;-;PDSP KiDatabase;265,2;5;1;2;3,51;CCCN(CCC)C1CCc2c(F)ccc(O)c2C1;-
10-(2-Methylallyl)-11-hydroxy-N-propylnoraporphine;220024;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;333,2;4;1;2;5,04;C=C(C)Cc1ccc2c(c1O)-c1cccc3c1C(C2)N(CCC)CC3;-
10-Allyl-11-hydroxy-N-methylaporphine;220006;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-74;3;-;PDSP KiDatabase;291,2;2;1;2;3,87;C=CCc1ccc2c(c1O)-c1cccc3c1C(C2)N(C)CC3;-
10-Allyl-11-hydroxy-N-propylnoraporphine;220012;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-12;3;-;PDSP KiDatabase;319,2;4;1;2;4,65;C=CCc1ccc2c(c1O)-c1cccc3c1C(C2)N(CCC)CC3;-
11-(2-Butynyloxy)-N-propylnoraporphine;220010;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-79;3;-;PDSP KiDatabase;331,2;4;0;2;4,62;CC#CCOc1cccc2c1-c1cccc3c1C(C2)N(CCC)CC3;-
11-Allyloxy-N-methylaporphine;220007;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-831;3;-;PDSP KiDatabase;291,2;3;0;2;4,00;C=CCOc1cccc2c1-c1cccc3c1C(C2)N(C)CC3;-
11-Propargyloxy-N-methylaporphine;220005;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-707;3;-;PDSP KiDatabase;289,1;2;0;2;3,45;C#CCOc1cccc2c1-c1cccc3c1C(C2)N(C)CC3;-
2-(4-{[(2S)-8-Methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl}piperazin-1-yl)-quinoline-6-carbonitrile;219843;UNDEFINED;0;Human;Binding;pKi;=;1306,00;5,88;-354;4;-;PDSP KiDatabase;451,2;3;0;7;3,92;Cc1ccc2c3c(ccc2n1)OCC(CN1CCN(c2ccc4cc(C#N)ccc4n2)CC1)O3;-
2-Methoxy-10-allyl-11-hydroxy-N-methylaporphine;220002;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-69;3;-;PDSP KiDatabase;321,2;3;1;3;3,88;C=CCc1ccc2c(c1O)-c1cc(OC)cc3c1C(C2)N(C)CC3;-
2-Methoxy-11-allyloxy-N-methylaporphine;220003;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-151;3;-;PDSP KiDatabase;321,2;4;0;3;4,01;C=CCOc1cccc2c1-c1cc(OC)cc3c1C(C2)N(C)CC3;-
2-Methoxy-11-hydroxyaporphine;219261;UNDEFINED;0;Human;Binding;pKi;=;235,00;6,63;-5;4;-;PDSP KiDatabase;281,1;1;1;3;3,15;COc1cc2c3c(c1)-c1c(O)cccc1CC3N(C)CC2;-
2-methyl-5-HT;81;3H-YM 09151-2;43;Human;Binding;pKi;=;10000,00;5,00;-107;21;-;PDSP KiDatabase;190,1;2;3;2;1,68;Cc1[nH]c2ccc(O)cc2c1CCN;-
2-MPP;83;None;65;Human;Binding;Ki;=;4110,00;5,39;-1380;11;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;192,1;2;1;3;1,10;COc1ccccc1N1CCNCC1;https://dx.doi.org/10.1021/jm500457x
2-MPP;83;None;65;Human;Binding;Ki;=;679,60;6,17;-1380;11;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;192,1;2;1;3;1,10;COc1ccccc1N1CCNCC1;https://dx.doi.org/10.1021/jm300482h
2-MPP;83;None;65;Human;Binding;Ki;=;4073,80;5,39;-1380;11;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;192,1;2;1;3;1,10;COc1ccccc1N1CCNCC1;https://dx.doi.org/10.1021/jm500457x
2-{1-ferra-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2',4,4'-tetraen-6-yl}-N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}acetamide;166155;None;0;Human;Binding;Ki;=;66,00;7,18;-27;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 long expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
2-{1-ferra-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2',4,4'-tetraen-6-yl}-N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}acetamide;166155;None;0;Human;Binding;Ki;=;45,00;7,35;-27;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 short expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
2-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-(3,4-dihydroisoquinoline);219467;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;387,2;8;0;3;4,92;COc1cccc(CCc2ccccc2OCCN2CCc3ccccc3C2)c1;-
2-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-(6,7-dimethoxy-3,4-dihydroisoquinoline);219471;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;447,2;10;0;5;4,93;COc1cccc(CCc2ccccc2OCCN2CCc3cc(OC)c(OC)cc3C2)c1;-
2-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-4-(2'-pyrimidil)piperazine;219460;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;418,2;9;0;6;3,47;COc1cccc(CCc2ccccc2OCCN2CCN(c3ncccn3)CC2)c1;-
2-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-4-(3'-chlorophenyl)piperazine;219475;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;450,2;9;0;4;5,33;COc1cccc(CCc2ccccc2OCCN2CCN(c3cccc(Cl)c3)CC2)c1;-
2-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-4-(3'-trifluoromethyl)piperazine;219451;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;484,2;9;0;4;5,70;COc1cccc(CCc2ccccc2OCCN2CCN(c3cccc(C(F)(F)F)c3)CC2)c1;-
2-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-4-(N-methyl)piperazine;219463;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;354,2;8;0;4;3,11;COc1cccc(CCc2ccccc2OCCN2CCN(C)CC2)c1;-
2{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-4-(2'-methoxyphenyl)piperazine;219454;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;446,3;10;0;5;4,69;COc1cccc(CCc2ccccc2OCCN2CCN(c3ccccc3OC)CC2)c1;-
2{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}ethyl-4-(4'-fluorophenyl)piperazine;219456;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;434,2;9;0;4;4,82;COc1cccc(CCc2ccccc2OCCN2CCN(c3ccc(F)cc3)CC2)c1;-
3-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}propyl-(3,4-dihydroisoquinoline);219468;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;401,2;9;0;3;5,31;COc1cccc(CCc2ccccc2OCCCN2CCc3ccccc3C2)c1;-
3-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}propyl-(6,7-dimethoxy-3,4-dihydroisoquinoline);219472;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;461,3;11;0;5;5,33;COc1cccc(CCc2ccccc2OCCCN2CCc3cc(OC)c(OC)cc3C2)c1;-
3-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}propyl-4-(3'-chlorophenyl)piperazine;219448;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;464,2;10;0;4;5,72;COc1cccc(CCc2ccccc2OCCCN2CCN(c3cccc(Cl)c3)CC2)c1;-
3-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}propyl-4-(3'-methyl)piperazine;219464;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;368,2;9;0;4;3,50;COc1cccc(CCc2ccccc2OCCCN2CCN(C)CC2)c1;-
3-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}propyl-4-(3'-trifluoromethylphenyl)piperazine;219452;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;498,2;10;0;4;6,09;COc1cccc(CCc2ccccc2OCCCN2CCN(c3cccc(C(F)(F)F)c3)CC2)c1;-
3-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}propyl-4-(4'-fluorophenyl)piperazine;219457;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;448,3;10;0;4;5,21;COc1cccc(CCc2ccccc2OCCCN2CCN(c3ccc(F)cc3)CC2)c1;-
4-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}butyl-(6,7-dimethoxy-3,4-dihydroisoquinoline);219473;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;475,3;12;0;5;5,71;COc1cccc(CCc2ccccc2OCCCCN2CCc3cc(OC)c(OC)cc3C2)c1;-
4-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}butyl-4-(2'-pyrimidyl)piperazine;219461;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;446,3;11;0;6;4,25;COc1cccc(CCc2ccccc2OCCCCN2CCN(c3ncccn3)CC2)c1;-
4-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}butyl-4-(3'-trifluoromethylphenyl)piperazine;219449;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;478,2;11;0;4;6,12;COc1cccc(CCc2ccccc2OCCCCN2CCN(c3cccc(Cl)c3)CC2)c1;-
4-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}butyl-4-(N-methyl)piperazine;219465;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;382,3;10;0;4;3,89;COc1cccc(CCc2ccccc2OCCCCN2CCN(C)CC2)c1;-
4{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}butyl-(3,4-dihydroisoquinoline);219469;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;415,3;10;0;3;5,70;COc1cccc(CCc2ccccc2OCCCCN2CCc3ccccc3C2)c1;-
4{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}butyl-4-(3'-trifluoromethylphenyl)piperazine;219453;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;512,3;11;0;4;6,48;COc1cccc(CCc2ccccc2OCCCCN2CCN(c3cccc(C(F)(F)F)c3)CC2)c1;-
4{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}butyl-4-(4'-fluorophenyl)piperazine;219458;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;462,3;11;0;4;5,60;COc1cccc(CCc2ccccc2OCCCCN2CCN(c3ccc(F)cc3)CC2)c1;-
5-hydroxytryptamine;139;3H-YM 09151-2;45;Human;Binding;pKi;=;10000,00;5,00;-23442;61;-;PDSP KiDatabase;176,1;2;3;2;1,38;NCCc1c[nH]c2ccc(O)cc12;-
5-OH-DPAT;149;None;8;Human;Binding;Ki;=;6,00;8,22;-13;8;In vitro binding affinity is the ability to displace [3H]N-0437 from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00016a016
5-OH-DPAT;149;None;8;Human;Binding;Ki;=;26,00;7,58;-13;8;In vitro binding affinity is the ability to displace [3H]spiperone from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00016a016
5-OH-DPAT;149;None;8;Human;Binding;Ki;=;58,80;7,23;-13;8;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901184n
5-OH-DPAT;149;None;8;Human;Binding;Ki;=;58,80;7,23;-13;8;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901618d
5-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}pentyl-(3,4-dihydroisoquinoline);219470;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;429,3;11;0;3;6,09;COc1cccc(CCc2ccccc2OCCCCCN2CCc3ccccc3C2)c1;-
5-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}pentyl-4-(2'-methoxyphenyl)piperazine;219455;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;488,3;13;0;5;5,86;COc1cccc(CCc2ccccc2OCCCCCN2CCN(c3ccccc3OC)CC2)c1;-
5-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}pentyl-4-(2'-pyrimidyl)piperazine;219462;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;460,3;12;0;6;4,64;COc1cccc(CCc2ccccc2OCCCCCN2CCN(c3ncccn3)CC2)c1;-
5-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}pentyl-4-(3'-chlorophenyl)piperazine;219450;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;492,3;12;0;4;6,50;COc1cccc(CCc2ccccc2OCCCCCN2CCN(c3cccc(Cl)c3)CC2)c1;-
5-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}pentyl-4-(4'-fluorophenyl)piperazine;219459;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;476,3;12;0;4;5,99;COc1cccc(CCc2ccccc2OCCCCCN2CCN(c3ccc(F)cc3)CC2)c1;-
5-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}pentyl-4-(N-methyl)piperazine;219466;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;396,3;11;0;4;4,28;COc1cccc(CCc2ccccc2OCCCCCN2CCN(C)CC2)c1;-
5-{2-[2-(3-Methoxyphenyl)ethyl]phenoxy}propyl-(6,7-dimethoxy-3,4-dihydroisoquinoline);219474;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;489,3;13;0;5;6,11;COc1cccc(CCc2ccccc2OCCCCCN2CCc3cc(OC)c(OC)cc3C2)c1;-
7-((1R,4R)-5-((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzo[d]oxazol-2(3H)-one;219957;UNDEFINED;0;Human;Binding;pKi;=;12,00;7,92;12;3;-;PDSP KiDatabase;432,2;3;2;4;3,81;O=c1[nH]c2cccc(N3CC4CC3CN4CC3CCc4[nH]c5ccc(F)cc5c4C3)c2o1;-
7-((1R,4R)-5-((6-fluoro-2,3,4,9-tetrahydro-1H-carbazol-3-yl)methyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)benzo[d]oxazol-2(3H)-one;219957;UNDEFINED;0;Human;Binding;pKi;=;14,00;7,85;12;3;-;PDSP KiDatabase;432,2;3;2;4;3,81;O=c1[nH]c2cccc(N3CC4CC3CN4CC3CCc4[nH]c5ccc(F)cc5c4C3)c2o1;-
7-OH-DPAT;184;None;17;Human;Binding;Ki;=;142,00;6,85;-54;9;Inhibitory activity against [125I]- NCQ298 binding to dopamine receptor D2 in Sf 9 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm00073a016
7-OH-DPAT;184;None;17;Human;Binding;Ki;=;142,00;6,85;-54;9;Tested for the inhibitory activity against D2H (high-affinity states) receptor in infected HEK 293 cells.;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm00050a021
7-OH-DPAT;184;None;17;Human;Binding;Ki;=;202,00;6,70;-54;9;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901618d
7-OH-DPAT;184;None;17;Human;Binding;Ki;=;143,00;6,84;-54;9;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
7-OH-DPAT;184;None;17;Human;Binding;Ki;=;2,27;8,64;-54;9;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
7-OH-DPAT;184;None;17;Human;Binding;Ki;=;1430,00;5,84;-54;9;Displacement of [3H]-N-methylspiperone from human dopamine D2long receptor expressed in HEK293 cells after 30 mins by scintillation counting;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/j.bmc.2012.08.058
7-OH-DPAT;184;None;17;Human;Binding;pKi;None;-;6,60;-54;9;Unclassified;Guide to Pharmacology;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://pubmed.ncbi.nlm.nih.gov/7576010
7-OH-DPAT;184;None;17;Human;Binding;pKi;None;-;6,60;-54;9;Unclassified;Guide to Pharmacology;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://pubmed.ncbi.nlm.nih.gov/7907989
7-OH-DPAT;184;None;17;Human;Binding;pKi;None;-;6,60;-54;9;Unclassified;Guide to Pharmacology;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;https://pubmed.ncbi.nlm.nih.gov/8301582
7-OH-DPAT;184;125I-IODOSULPRIDE;17;Human;Binding;pKi;=;1780,00;5,75;-54;9;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;-
7-OH-DPAT;184;125I-IODOSULPRIDE;17;Human;Binding;pKi;=;60,00;7,22;-54;9;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;-
7-OH-DPAT;184;125I-IODOSULPRIDE;17;Human;Binding;pKi;=;103,00;6,99;-54;9;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;-
7-OH-DPAT;184;3H-SPIPERONE;17;Human;Binding;pKi;=;158,48;6,80;-54;9;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;-
7-OH-DPAT;184;125I-IODOSULPRIDE;17;Human;Binding;pKi;=;89,00;7,05;-54;9;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;-
7-OH-DPAT;184;3H-thymidine;17;Human;Binding;pKi;=;2,70;8,57;-54;9;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2ccc(O)cc2C1;-
7-trans-OH-PIPAT;185;None;1;Human;Binding;pKi;None;-;5,60;-125;3;Unclassified;Guide to Pharmacology;371,1;5;1;2;3,91;CCCN(C/C=C\I)[C@@H]1CCc2cccc(O)c2C1;https://pubmed.ncbi.nlm.nih.gov/7990123
8-(2-Methyl-2-buten-4-yl)-11-hydroxy-N-propylnoraporphine;220023;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;347,2;4;1;2;5,43;CCCN1CCc2cccc3c2C1Cc1c(CC=C(C)C)ccc(O)c1-3;-
8-OH-DPAT;187;None;44;Human;Binding;Ki;=;84,00;7,08;-758;46;Binding affinity against Dopamine receptor D2;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2cccc(O)c2C1;https://dx.doi.org/10.1021/jm950759z
8-OH-DPAT;187;None;44;Human;Binding;Ki;=;86,00;7,07;-758;46;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2cccc(O)c2C1;https://dx.doi.org/10.1021/jm00060a014
8-OH-DPAT;187;None;44;Human;Binding;Ki;=;3243,00;5,49;-758;46;Inhibitory activity against [125I]- NCQ298 binding to dopamine receptor D2 in Sf 9 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2cccc(O)c2C1;https://dx.doi.org/10.1021/jm00073a016
8-OH-DPAT;187;None;44;Human;Binding;Ki;=;86,00;7,07;-758;46;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2cccc(O)c2C1;https://dx.doi.org/10.1021/jm00060a015
8-OH-DPAT;187;3H-YM 09151-2;44;Human;Binding;pKi;=;1788,00;5,75;-758;46;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2cccc(O)c2C1;-
8-OH-DPAT;187;125I-IODOSULPRIDE;44;Human;Binding;pKi;=;1082,00;5,97;-758;46;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2cccc(O)c2C1;-
8-OH-DPAT;187;125I-IODOSULPRIDE;44;Human;Binding;pKi;=;1746,00;5,76;-758;46;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2cccc(O)c2C1;-
8-OH-DPAT;187;125I-IODOSULPRIDE;44;Human;Binding;pKi;=;10000,00;5,00;-758;46;-;PDSP KiDatabase;247,2;5;1;2;3,37;CCCN(CCC)C1CCc2cccc(O)c2C1;-
A-85380;218616;3H-SPIPERONE;0;Human;Binding;pKi;=;10000,00;5,00;-1;13;-;PDSP KiDatabase;164,1;3;1;3;0,82;c1cncc(OCC2CCN2)c1;-
A-86929;99573;None;4;Human;Binding;EC50;=;3900,00;5,41;-50;5;Adenylate cyclase assay carried out in LTK cells transfected with human Dopamine receptor D2;ChEMBL;315,1;2;3;4;3,66;CCCc1cc2c(s1)CN[C@@H]1CCc3cc(O)c(O)cc3[C@@H]21;https://dx.doi.org/10.1021/jm00018a002
A-86929;99573;None;4;Human;Binding;Ki;=;710,00;6,15;-50;5;Binding affinity against cloned human Dopamine receptor D2 using [3H]spiperone as radioligand transfected in HEK cells;ChEMBL;315,1;2;3;4;3,66;CCCc1cc2c(s1)CN[C@@H]1CCc3cc(O)c(O)cc3[C@@H]21;https://dx.doi.org/10.1021/jm00018a002
A-86929;99573;None;4;Human;Binding;Ki;=;710,00;6,15;-50;5;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;315,1;2;3;4;3,66;CCCc1cc2c(s1)CN[C@@H]1CCc3cc(O)c(O)cc3[C@@H]21;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
A412997;201;None;23;Human;Binding;Ki;=;2900,00;5,54;-208;4;Displacement of [125I]7-OH-PIPAT from human D2L receptor expressed in HEK293 cell membrane;ChEMBL;309,2;4;1;3;3,21;Cc1cccc(NC(=O)CN2CCC(c3ccccn3)CC2)c1;https://dx.doi.org/10.1021/jm060662k
A77636;208;None;8;Human;Binding;Ki;=;1550,00;5,81;-512;27;Binding affinity against cloned human Dopamine receptor D2 using [3H]spiperone as radioligand transfected in HEK cells;ChEMBL;329,2;2;3;4;3,25;NC[C@@H]1O[C@H](C23CC4CC(CC(C4)C2)C3)Cc2c1ccc(O)c2O;https://dx.doi.org/10.1021/jm00018a002
A77636;218872;3H-SPIPERONE;0;Human;Binding;pKi;=;1550,00;5,81;-74;2;-;PDSP KiDatabase;365,2;2;3;4;3,68;Cl.NCC1OC(C23CC4CC(CC(C4)C2)C3)Cc2c1ccc(O)c2O;-
ABT-418;218617;3H-SPIPERONE;0;Human;Binding;pKi;=;10000,00;5,00;-1;8;-;PDSP KiDatabase;166,1;1;0;3;1,75;Cc1cc(C2CCCN2C)on1;-
ABT-594;219818;3H-SPIPERONE;0;Human;Binding;pKi;=;1000,00;6,00;-2;37;-;PDSP KiDatabase;198,1;3;1;3;1,48;Clc1ccc(OCC2CCN2)cn1;-
ABT-724;169299;None;37;Human;Binding;EC50;=;12,00;7,92;-56;4;Agonist activity at human D2R expressed in HEK293 cells incubated for 3 mins by FLIPR analysis;ChEMBL;293,2;3;1;4;2,28;c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
ABT-724;169299;None;37;Human;Binding;Ki;=;15000,00;4,82;-56;4;In vitro binding affinity tested on human Dopamine receptor D2 (long) using [3H]spiperon as a radioligand;ChEMBL;293,2;3;1;4;2,28;c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1;https://dx.doi.org/10.1021/jm030505a
ABT-724;169299;None;37;Human;Binding;Ki;=;51000,00;4,29;-56;4;In vitro binding affinity tested on human Dopamine receptor D2 (short) using [3H]spiperone as a radioligand;ChEMBL;293,2;3;1;4;2,28;c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1;https://dx.doi.org/10.1021/jm030505a
ABT-724;169299;None;37;Human;Binding;Ki;=;160,00;6,80;-56;4;In vitro binding affinity tested on human Dopamine receptor D2 using [3H]spiperon as a radioligand;ChEMBL;293,2;3;1;4;2,28;c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1;https://dx.doi.org/10.1021/jm030505a
ABT-925;169118;None;32;Human;Binding;Ki;=;351,00;6,46;-120;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;456,2;6;1;8;3,59;CC(C)(C)c1nc(N2CCN(CCCSc3nccc(O)n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
AC-42;242;None;13;Human;Binding;Ki;=;77,00;7,11;-7;14;Binding affinity to human dopamine D2S receptor by radioligand displacement assay;ChEMBL;301,2;8;0;2;4,86;CCCCC1CCN(CCCC(=O)c2ccccc2C)CC1;https://dx.doi.org/10.1021/jm100697g
ACEPROMAZINE;150786;None;16;Human;Binding;AC50;=;78,50;7,11;-;11;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;326,1;5;0;4;4,44;CC(=O)c1ccc2c(c1)N(CCCN(C)C)c1ccccc1S2;https://dx.doi.org/10.1038/s41467-023-40064-9
ACETOPHENAZINE;7074;None;25;Human;Binding;AC50;=;11,80;7,93;-;16;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;411,2;7;1;6;3,49;CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2;https://dx.doi.org/10.1038/s41467-023-40064-9
ADINAZOLAM;111655;3H-SPIPERONE;23;Human;Binding;pKi;=;10000,00;5,00;-1;9;-;PDSP KiDatabase;351,1;3;0;5;3,33;CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2;-
ADOPRAZINE;84379;None;31;Human;Binding;Ki;=;3,98;8,40;-5;9;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;405,2;4;0;5;3,98;Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1;https://dx.doi.org/10.1021/jm070516u
ADOPRAZINE;84379;None;31;Human;Binding;Ki;=;3,98;8,40;-5;9;Displacement of [3H]spiperone from recombinant human D2S receptor expressed in CHO cell membrane measured after 60 mins by scintillation counting method;ChEMBL;405,2;4;0;5;3,98;Fc1ccc(-c2cncc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112214
ADTN 5,6;218621;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;530,00;6,28;-3;2;-;PDSP KiDatabase;387,1;4;1;5;3,94;NC1CCc2cc(OC(=O)c3ccccc3)c(OC(=O)c3ccccc3)cc2C1;-
ADTN 6,7;218620;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;55,00;7,26;-32;3;-;PDSP KiDatabase;259;0;3;3;1,49;Br.NC1CCc2cc(O)c(O)cc2C1;-
ADTN DIPROPYL 6,7;218622;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;25,00;7,60;-37;2;-;PDSP KiDatabase;263,2;5;2;3;3,08;CCCN(CCC)C1CCc2cc(O)c(O)cc2C1;-
ADTN, (+);218719;3H-SPIPERONE;0;Human;Binding;pKi;=;595,00;6,23;-1;4;-;PDSP KiDatabase;226,2;0;2;2;1,35;O=C1CCCCCNC(=O)CCCCCN1;-
AJ76(+);218648;3H-YM 09151-2;0;Human;Binding;pKi;=;120,30;6,92;1;4;-;PDSP KiDatabase;233,2;4;1;2;3,11;CCCNC1CCc2c(OC)cccc2C1C;-
alizapride;345;None;31;Human;Binding;pKi;=;7,15;8,15;-1;3;None;Drug Central;315,2;6;2;5;1,35;C=CCN1CCCC1CNC(=O)c1cc2[nH]nnc2cc1OC;-
ALTANSERIN;205402;None;31;Human;Binding;Ki;=;62,00;7,21;-316;9;Binding affinity to dopamine D2 receptor by competitive binding experiment;ChEMBL;411,1;5;1;5;3,79;O=C(c1ccc(F)cc1)C1CCN(CCn2c(=S)[nH]c3ccccc3c2=O)CC1;https://dx.doi.org/10.1016/j.bmc.2009.03.021
amiodarone;398;None;47;Human;Binding;AC50;=;3146,40;5,50;-4;40;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;645;11;0;4;6,94;CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
amiodarone;398;None;47;Human;Binding;IC50;=;19952,00;4,70;-4;40;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;645;11;0;4;6,94;CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1;-
amiodarone;398;None;47;Human;Binding;Ki;=;6651,00;5,18;-4;40;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;645;11;0;4;6,94;CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1;-
amiodarone;398;None;47;Human;Binding;pKi;=;5,18;8,29;-4;40;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;645;11;0;4;6,94;CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1;-
amisulpride;400;None;72;Human;Binding;AC50;=;15,00;7,82;-2;53;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
amisulpride;400;None;72;Human;Binding;Ki;=;3,00;8,52;-2;53;Displacement of [3H]N-methyl-spiperone from D2R (unknown origin) assessed as inhibition constant by competition binding assay;ChEMBL;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2021.128275
amisulpride;400;None;72;Human;Binding;Ki;=;12,59;7,90;-2;53;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;https://dx.doi.org/10.1021/jm070516u
amisulpride;400;None;72;Human;Binding;pKi;=;8,55;8,07;-2;53;None;Drug Central;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;-
amisulpride;400;None;72;Human;Binding;pKi;=;-;7,80;-2;53;Unclassified;Guide to Pharmacology;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;https://pubmed.ncbi.nlm.nih.gov/1975644
amisulpride;400;None;72;Human;Binding;pKi;=;-;7,95;-2;53;Unclassified;Guide to Pharmacology;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;https://pubmed.ncbi.nlm.nih.gov/8099194
amisulpride;400;None;72;Human;Binding;pKi;=;-;7,95;-2;53;Unclassified;Guide to Pharmacology;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;https://pubmed.ncbi.nlm.nih.gov/1354163
amisulpride;400;125I-IODOSULPRIDE;72;Human;Binding;pKi;=;1,30;8,89;-2;53;-;PDSP KiDatabase;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;-
amisulpride;400;3H-NMSP;72;Human;Binding;pKi;=;3,00;8,52;-2;53;-;PDSP KiDatabase;369,2;7;2;6;1,28;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC;-
amitriptyline;401;None;38;Human;Binding;AC50;=;550,00;6,26;-323;51;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;277,2;3;0;1;4,17;CN(C)CCC=C1c2ccccc2CCc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
amitriptyline;401;None;38;Human;Binding;IC50;=;1009,00;6,00;-323;51;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;277,2;3;0;1;4,17;CN(C)CCC=C1c2ccccc2CCc2ccccc21;-
amitriptyline;401;None;38;Human;Binding;Ki;=;196,00;6,71;-323;51;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;277,2;3;0;1;4,17;CN(C)CCC=C1c2ccccc2CCc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
amitriptyline;401;None;38;Human;Binding;Ki;=;336,00;6,47;-323;51;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;277,2;3;0;1;4,17;CN(C)CCC=C1c2ccccc2CCc2ccccc21;-
amitriptyline;401;None;38;Human;Binding;pKi;=;6,71;8,17;-323;51;None;Drug Central;277,2;3;0;1;4,17;CN(C)CCC=C1c2ccccc2CCc2ccccc21;-
amitriptyline;401;3H-SPIPERONE;38;Human;Binding;pKi;=;1460,00;5,84;-323;51;-;PDSP KiDatabase;277,2;3;0;1;4,17;CN(C)CCC=C1c2ccccc2CCc2ccccc21;-
amitriptyline;401;UNDEFINED;38;Human;Binding;pKi;=;196,00;6,71;-323;51;-;PDSP KiDatabase;277,2;3;0;1;4,17;CN(C)CCC=C1c2ccccc2CCc2ccccc21;-
AMLODIPINE;41527;None;58;Human;Binding;AC50;=;2900,00;5,54;-;24;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;408,1;8;2;7;2,27;CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl;https://dx.doi.org/10.1038/s41467-023-40064-9
AMODIAQUINE;206241;None;47;Human;Binding;AC50;=;8900,00;5,05;-;8;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;355,1;6;2;4;5,18;CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O;https://dx.doi.org/10.1038/s41467-023-40064-9
AMOSULALOL;44861;None;29;Human;Binding;AC50;=;440,00;6,36;-;12;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;380,1;9;3;6;1,35;COc1ccccc1OCCNCC(O)c1ccc(C)c(S(N)(=O)=O)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
amoxapine;403;None;60;Human;Binding;AC50;=;120,00;6,92;-12;42;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;313,1;0;1;4;3,43;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;https://dx.doi.org/10.1038/s41467-023-40064-9
amoxapine;403;None;60;Human;Binding;IC50;=;200,00;6,70;-12;42;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;313,1;0;1;4;3,43;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;-
amoxapine;403;None;60;Human;Binding;Ki;=;67,00;7,17;-12;42;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;313,1;0;1;4;3,43;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;-
amoxapine;403;None;60;Human;Binding;pKi;=;7,80;8,11;-12;42;None;Drug Central;313,1;0;1;4;3,43;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;-
amoxapine;403;R-SAT;60;Human;Binding;pKi;=;3,60;8,44;-12;42;-;PDSP KiDatabase;313,1;0;1;4;3,43;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;-
amoxapine;403;UNDEFINED;60;Human;Binding;pKi;=;16,00;7,80;-12;42;-;PDSP KiDatabase;313,1;0;1;4;3,43;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;-
amoxapine;403;R-SAT;60;Human;Binding;pKi;=;38,00;7,42;-12;42;-;PDSP KiDatabase;313,1;0;1;4;3,43;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2;-
AMSACRINE;167616;None;49;Human;Binding;AC50;=;6900,00;5,16;-;15;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;393,1;5;2;5;4,51;COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12;https://dx.doi.org/10.1038/s41467-023-40064-9
apomorphine;445;None;20;Human;Binding;AC50;=;1542,70;5,81;-4;29;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1038/s41467-023-40064-9
apomorphine;445;None;20;Human;Binding;EC50;=;575,44;6,24;-4;29;Agonist activity at dopamine D2 receptor short isoform (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;-
apomorphine;445;None;20;Human;Binding;EC50;=;5,80;8,24;-4;29;In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D2 using FLIPR assay;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm030505a
apomorphine;445;None;20;Human;Binding;EC50;=;10,00;8,00;-4;29;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
apomorphine;445;None;20;Human;Binding;EC50;=;10,10;8,00;-4;29;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
apomorphine;445;None;20;Human;Binding;EC50;=;1,70;8,77;-4;29;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
apomorphine;445;None;20;Human;Binding;IC50;=;117,00;6,93;-4;29;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
apomorphine;445;None;20;Human;Binding;Kd;=;0,66;9,18;-4;29;Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as high affinity state;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
apomorphine;445;None;20;Human;Binding;Kd;=;127,00;6,90;-4;29;Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as low affinity state;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
apomorphine;445;None;20;Human;Binding;Kd;=;24,00;7,62;-4;29;Equilibrium dissociation constant against recombinant Dopamine receptor D2A expressed in COS7 cells;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm950447w
apomorphine;445;None;20;Human;Binding;Ki;=;42,00;7,38;-4;29;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
apomorphine;445;None;20;Human;Binding;Ki;=;41,90;7,38;-4;29;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm960189i
apomorphine;445;None;20;Human;Binding;Ki;=;41,90;7,38;-4;29;Ability to displace [3H]raclopride binding to cloned human Dopamine receptor D2A;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00004a011
apomorphine;445;None;20;Human;Binding;Ki;=;28,00;7,55;-4;29;Tested for binding affinity towards human D2L receptor using [3H]spiperone as radioligand;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00047a010
apomorphine;445;None;20;Human;Binding;Ki;=;41,90;7,38;-4;29;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm960188q
apomorphine;445;None;20;Human;Binding;Ki;=;98,00;7,01;-4;29;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2008.05.077
apomorphine;445;None;20;Human;Binding;Ki;=;53,00;7,28;-4;29;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2013.05.014
apomorphine;445;None;20;Human;Binding;Ki;=;41,60;7,38;-4;29;In vitro binding affinity towards cloned human Dopamine receptor D2A using [3H]- Raclopride as radioligand.;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/s0960-894x(00)00655-7
apomorphine;445;None;20;Human;Binding;Ki;=;82,00;7,09;-4;29;Displacement of [125I]iodosulpride from human D2 receptor expressed in CHO cells incubated for 40 mins by radio ligand binding assay;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmcl.2020.127053
apomorphine;445;None;20;Human;Binding;Ki;=;26,00;7,58;-4;29;Compound was evaluated for the binding affinity against [3H]U-86,170-labeled D2 sites in cloned CHO cells;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00060a014
apomorphine;445;None;20;Human;Binding;Ki;=;244,00;6,61;-4;29;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm901689v
apomorphine;445;None;20;Human;Binding;Ki;=;32,00;7,50;-4;29;Displacement of [3H]raclopride from human cloned dopamine D2 receptor expressed in CHO cell membrane;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2008.02.038
apomorphine;445;None;20;Human;Binding;Ki;=;41,60;7,38;-4;29;Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm9911433
apomorphine;445;None;20;Human;Binding;Ki;=;0,62;9,21;-4;29;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm901689v
apomorphine;445;None;20;Human;Binding;Ki;=;41,90;7,38;-4;29;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm0108505
apomorphine;445;None;20;Human;Binding;Ki;=;42,00;7,38;-4;29;Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.ejmech.2019.01.031
apomorphine;445;None;20;Human;Binding;Ki;=;26,00;7,58;-4;29;Compound was evaluated for the binding affinity against [3H]U-86,170-labeled D2 sites in cloned CHO cells;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00060a015
apomorphine;445;None;20;Human;Binding;Ki;=;3,60;8,44;-4;29;Displacement of [125I]7-OH-PIPAT from human D2L receptor expressed in HEK293 cell membrane;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm060662k
apomorphine;445;None;20;Human;Binding;Ki;=;50,00;7,30;-4;29;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
apomorphine;445;None;20;Human;Binding;pKi;=;9,21;8,04;-4;29;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;Drug Central;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;-
apomorphine;445;None;20;Human;Binding;pKi;=;-;6,60;-4;29;Unclassified;Guide to Pharmacology;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://pubmed.ncbi.nlm.nih.gov/7576010
apomorphine;445;None;20;Human;Binding;pKi;=;-;6,60;-4;29;Unclassified;Guide to Pharmacology;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://pubmed.ncbi.nlm.nih.gov/1354163
apomorphine;445;None;20;Human;Binding;pKi;=;-;6,60;-4;29;Unclassified;Guide to Pharmacology;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://pubmed.ncbi.nlm.nih.gov/12388666
apomorphine;445;None;20;Human;Binding;pKi;=;-;6,60;-4;29;Unclassified;Guide to Pharmacology;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://pubmed.ncbi.nlm.nih.gov/7756621
apomorphine;445;None;20;Human;Binding;pKi;=;-;6,60;-4;29;Unclassified;Guide to Pharmacology;267,1;0;2;3;2,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://pubmed.ncbi.nlm.nih.gov/8301582
APOMORPHINE;218450;3H-YM 09151-2;0;Human;Binding;pKi;=;391,60;6,41;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;83,18;7,08;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;UNDEFINED;0;Human;Binding;pKi;=;32,00;7,49;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;UNDEFINED;0;Human;Binding;pKi;=;98,00;7,01;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;34,67;7,46;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;UNDEFINED;0;Human;Binding;pKi;=;244,00;6,61;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;30,00;7,52;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;3H-YM 09151-2;0;Human;Binding;pKi;=;42,00;7,38;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;3H-thymidine;0;Human;Binding;pKi;=;2,30;8,64;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;3H-SPIPERONE;0;Human;Binding;pKi;=;86,00;7,07;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;UNDEFINED;0;Human;Binding;pKi;=;0,62;9,21;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;63,00;7,20;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;63,00;7,20;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APOMORPHINE;218450;3H-SPIPERONE;0;Human;Binding;pKi;=;286,00;6,54;-21;26;-;PDSP KiDatabase;267,1;0;2;3;2,85;CN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
APRINDINE;15289;None;20;Human;Binding;AC50;=;15000,00;4,82;-;12;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;322,2;8;0;2;4,39;CCN(CC)CCCN(c1ccccc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1038/s41467-023-40064-9
ARFORMOTEROL;26817;None;34;Human;Binding;AC50;=;10999,90;4,96;1;7;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;344,2;9;4;5;2,22;COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
ARFORMOTEROL;26817;None;34;Human;Binding;pKi;=;4,89;8,31;1;7;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;Drug Central;344,2;9;4;5;2,22;COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1;-
aripiprazole;470;None;70;Human;Binding;AC50;=;23,70;7,62;-1;60;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1038/s41467-023-40064-9
aripiprazole;470;None;70;Human;Binding;EC50;=;8,70;8,06;-1;60;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
aripiprazole;470;None;70;Human;Binding;EC50;=;1100,00;5,96;-1;60;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
aripiprazole;470;None;70;Human;Binding;EC50;=;2,40;8,62;-1;60;Partial agonist activity at human D2 receptor assessed as beta arrestin-2 recruitment;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
aripiprazole;470;None;70;Human;Binding;EC50;=;740,00;6,13;-1;60;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
aripiprazole;470;None;70;Human;Binding;EC50;=;14,90;7,83;-1;60;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
aripiprazole;470;None;70;Human;Binding;EC50;=;38,00;7,42;-1;60;Partial agonist activity at human D2 receptor assessed as increase in cAMP accumulation;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
aripiprazole;470;None;70;Human;Binding;EC50;=;4,00;8,40;-1;60;Inverse agonist activity at dopamine D2 receptor (unknown origin) assessed as increase in beta-arrestin-2 recruitment;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
aripiprazole;470;None;70;Human;Binding;EC50;=;17,50;7,76;-1;60;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
aripiprazole;470;None;70;Human;Binding;EC50;=;4,80;8,32;-1;60;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
aripiprazole;470;None;70;Human;Binding;EC50;=;19,40;7,71;-1;60;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
aripiprazole;470;None;70;Human;Binding;IC50;=;38,02;7,42;-1;60;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
aripiprazole;470;None;70;Human;Binding;IC50;=;11,22;7,95;-1;60;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm5004039
aripiprazole;470;None;70;Human;Binding;IC50;=;1,00;9,00;-1;60;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
aripiprazole;470;None;70;Human;Binding;IC50;=;11,00;7,96;-1;60;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm5004039
aripiprazole;470;None;70;Human;Binding;Ki;=;4,00;8,40;-1;60;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
aripiprazole;470;None;70;Human;Binding;Ki;=;0,30;9,52;-1;60;Modulation of human D2L receptor;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
aripiprazole;470;None;70;Human;Binding;Ki;=;4,50;8,35;-1;60;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
aripiprazole;470;None;70;Human;Binding;Ki;=;0,53;9,28;-1;60;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
aripiprazole;470;None;70;Human;Binding;Ki;=;3,90;8,41;-1;60;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
aripiprazole;470;None;70;Human;Binding;Ki;=;0,69;9,16;-1;60;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
aripiprazole;470;None;70;Human;Binding;Ki;=;9,70;8,01;-1;60;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
aripiprazole;470;None;70;Human;Binding;Ki;=;3,30;8,48;-1;60;Displacement of [3H]-N-methylspiperone from human D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
aripiprazole;470;None;70;Human;Binding;Ki;=;0,48;9,32;-1;60;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
aripiprazole;470;None;70;Human;Binding;Ki;=;3,10;8,51;-1;60;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
aripiprazole;470;None;70;Human;Binding;Ki;=;1,80;8,74;-1;60;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
aripiprazole;470;None;70;Human;Binding;Ki;=;0,48;9,32;-1;60;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
aripiprazole;470;None;70;Human;Binding;Ki;=;1,60;8,80;-1;60;Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;None;70;Human;Binding;Ki;=;2,60;8,59;-1;60;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm901689v
aripiprazole;470;None;70;Human;Binding;Ki;=;5,01;8,30;-1;60;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm070516u
aripiprazole;470;None;70;Human;Binding;Ki;=;0,80;9,10;-1;60;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm501119j
aripiprazole;470;None;70;Human;Binding;Ki;=;0,45;9,35;-1;60;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm5004039
aripiprazole;470;None;70;Human;Binding;Ki;=;3,30;8,48;-1;60;Displacement of [3H]methylspiperone from human D2 receptor by radio ligand binding assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
aripiprazole;470;None;70;Human;Binding;Ki;=;3,30;8,48;-1;60;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
aripiprazole;470;None;70;Human;Binding;Ki;=;0,80;9,10;-1;60;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 after 1 hr;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2012.11.042
aripiprazole;470;None;70;Human;Binding;Ki;=;2,80;8,55;-1;60;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm901689v
aripiprazole;470;None;70;Human;Binding;Ki;=;0,54;9,27;-1;60;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm5004039
aripiprazole;470;None;70;Human;Binding;Ki;=;2180,00;5,66;-1;60;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
aripiprazole;470;None;70;Human;Binding;Ki;=;1,82;8,74;-1;60;Binding affinity to dopamine D2;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm0611152
aripiprazole;470;None;70;Human;Binding;Ki;=;0,38;9,42;-1;60;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
aripiprazole;470;None;70;Human;Binding;Ki;=;0,52;9,28;-1;60;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
aripiprazole;470;None;70;Human;Binding;Ki;=;0,34;9,47;-1;60;Partial agonist activity at human D2 receptor assessed as inhibition constant;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
aripiprazole;470;None;70;Human;Binding;Ki;=;2,14;8,67;-1;60;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
aripiprazole;470;None;70;Human;Binding;Ki;=;2,13;8,67;-1;60;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
aripiprazole;470;None;70;Human;Binding;Ki;=;0,80;9,10;-1;60;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
aripiprazole;470;None;70;Human;Binding;Ki;=;0,38;9,42;-1;60;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
aripiprazole;470;None;70;Human;Binding;Ki;=;0,20;9,70;-1;60;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
aripiprazole;470;None;70;Human;Binding;Ki;=;0,34;9,47;-1;60;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
aripiprazole;470;None;70;Human;Binding;Ki;=;3,30;8,48;-1;60;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
aripiprazole;470;None;70;Human;Binding;Ki;=;0,34;9,46;-1;60;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm501512b
aripiprazole;470;None;70;Human;Binding;Ki;=;0,52;9,28;-1;60;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
aripiprazole;470;None;70;Human;Binding;Ki;=;3,30;8,48;-1;60;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2020.115943
aripiprazole;470;None;70;Human;Binding;Ki;=;0,45;9,35;-1;60;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
aripiprazole;470;None;70;Human;Binding;Ki;=;8,00;8,10;-1;60;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;None;70;Human;Binding;pKi;=;8,71;8,06;-1;60;None;Drug Central;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;None;70;Human;Binding;pKi;=;-;9,10;-1;60;Unclassified;Guide to Pharmacology;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://pubmed.ncbi.nlm.nih.gov/23279866
aripiprazole;470;UNDEFINED;70;Human;Binding;pKi;=;2,60;8,59;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;3H-NMSP;70;Human;Binding;pKi;=;0,66;9,18;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;R-SAT;70;Human;Binding;pKi;=;4,40;8,36;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;UNDEFINED;70;Human;Binding;pKi;=;2,80;8,55;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;3H-NMSP;70;Human;Binding;pKi;=;3,30;8,48;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;3H-NMSP;70;Human;Binding;pKi;=;0,95;9,02;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;3H-NMSP;70;Human;Binding;pKi;=;0,74;9,13;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;3H-SPIPERONE;70;Human;Binding;pKi;=;0,70;9,15;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole;470;125I-7-OH-PIPAT;70;Human;Binding;pKi;=;0,34;9,47;-1;60;-;PDSP KiDatabase;447,1;7;1;4;4,86;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
aripiprazole lauroxil;220230;None;0;Human;Binding;pKi;=;9,47;8,02;-1;14;Mechanism of Action;Drug Central;659,3;19;0;6;8,68;CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21;-
ARMODAFINIL;14469;None;23;Human;Binding;IC50;=;2,10;8,68;-;2;Antagonist activity at DRD2 (unknown origin) expressed in HEK293T cells transfected with Galphai1-RLuc8 and gamma2-GFP10 assessed as inhibition of quinpirole-induced Gi1 activation pre-incubated with quinpirole for 10 mins before compound incubation for 10 mins by BRET assay;ChEMBL;273,1;5;1;2;2,01;NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.6b01373
asenapine;494;None;23;Human;Binding;pKi;=;-;8,92;-19;7;Unclassified;Guide to Pharmacology;285,1;0;0;2;4,26;CN1C[C@@H]2c3ccccc3Oc3ccc(Cl)cc3[C@H]2C1;https://pubmed.ncbi.nlm.nih.gov/18308814
ASENAPINE;107587;None;16;Human;Binding;AC50;=;57,00;7,24;-18;54;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;285,1;0;0;2;4,26;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;https://dx.doi.org/10.1038/s41467-023-40064-9
ASENAPINE;107587;None;16;Human;Binding;Ki;=;8,90;8,05;-18;54;Displacement of [3H]N-methylspiperone from human cloned D2 dopamine receptor expressed in human fibroblasts incubated for 90 mins by scintillation counting based radioligand binding assay;ChEMBL;285,1;0;0;2;4,26;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;https://dx.doi.org/10.1039/C5MD00258C
ASENAPINE;107587;None;16;Human;Binding;pKi;=;8,75;8,06;-18;54;None;Drug Central;285,1;0;0;2;4,26;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;-
ASENAPINE;107587;3H-SPIPERONE;16;Human;Binding;pKi;=;1,87;8,73;-18;54;-;PDSP KiDatabase;285,1;0;0;2;4,26;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;-
ASENAPINE;107587;3H-SPIPERONE;16;Human;Binding;pKi;=;2,00;8,70;-18;54;-;PDSP KiDatabase;285,1;0;0;2;4,26;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;-
ASENAPINE;107587;3H-NMSP;16;Human;Binding;pKi;=;1,40;8,85;-18;54;-;PDSP KiDatabase;285,1;0;0;2;4,26;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;-
ASENAPINE;107587;3H-SPIPERONE;16;Human;Binding;pKi;=;2,60;8,59;-18;54;-;PDSP KiDatabase;285,1;0;0;2;4,26;CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1;-
ASPIRIN;94286;3H-NMSP;63;Human;Binding;pKi;=;10000,00;5,00;-1;30;-;PDSP KiDatabase;180;2;1;3;1,31;CC(=O)Oc1ccccc1C(=O)O;-
astemizole;505;None;55;Human;Binding;AC50;=;8600,00;5,07;-53;48;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;458,2;8;1;5;5,35;COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
astemizole;505;None;55;Human;Binding;IC50;=;4521,00;5,34;-53;48;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;458,2;8;1;5;5,35;COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1;-
astemizole;505;None;55;Human;Binding;Ki;=;1507,00;5,82;-53;48;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;458,2;8;1;5;5,35;COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1;-
astemizole;505;None;55;Human;Binding;pKi;=;5,82;8,23;-53;48;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;458,2;8;1;5;5,35;COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1;-
ATOMOXETINE;205585;3H-SPIPERONE;33;Human;Binding;pKi;=;1000,00;6,00;-3;37;-;PDSP KiDatabase;255,2;6;1;2;3,73;CNCC[C@@H](Oc1ccccc1C)c1ccccc1;-
ATOMOXETINE;205585;3H-SPIPERONE;33;Human;Binding;pKi;=;10000,00;5,00;-3;37;-;PDSP KiDatabase;255,2;6;1;2;3,73;CNCC[C@@H](Oc1ccccc1C)c1ccccc1;-
AZAPERONE;117874;None;64;Human;Binding;Ki;=;229,00;6,64;-16;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;327,2;6;0;4;3,01;O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
AZAPERONE;117874;None;64;Human;Binding;Ki;=;52,00;7,28;-16;9;Displacement of [3H]spiperone from CHO-K1 cell membranes expressing human dopamine receptor D2;ChEMBL;327,2;6;0;4;3,01;O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00076a022
AZAPERONE;117874;None;64;Human;Binding;Ki;=;229,09;6,64;-16;9;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;327,2;6;0;4;3,01;O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
AZAPERONE;117874;None;64;Human;Binding;Ki;=;229,09;6,64;-16;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;327,2;6;0;4;3,01;O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
AZAPERONE;117874;None;64;Human;Binding;Ki;=;228,00;6,64;-16;9;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;327,2;6;0;4;3,01;O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
AZATADINE;209982;None;33;Human;Binding;AC50;=;7300,00;5,14;-;11;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;290,2;0;0;2;3,71;CN1CCC(=C2c3ccccc3CCc3cccnc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
AZD-3759;123872;None;51;Human;Binding;IC50;=;797,00;6,10;-;1;Inhibition of recombinant D2 receptor (unknown origin);ChEMBL;459,1;4;1;7;4,31;COc1cc2ncnc(Nc3cccc(Cl)c3F)c2cc1OC(=O)N1CCN(C)C[C@H]1C;https://dx.doi.org/10.1021/acs.jmedchem.5b01073
azelastine;559;None;45;Human;Binding;Ki;=;1176,52;5,93;-954;25;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;381,2;3;0;4;4,30;CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1;https://dx.doi.org/10.6019/CHEMBL5442175
BAY-294;216439;None;12;Human;Binding;Ki;=;2333,64;5,63;-100;26;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1;https://dx.doi.org/10.6019/CHEMBL4507273
BAY-294;216439;None;12;Human;Binding;Ki;=;1995,26;5,70;-100;26;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1;https://dx.doi.org/10.6019/CHEMBL4507273
BAY-294;216439;None;12;Human;Binding;Ki;=;2333,64;5,63;-100;26;Selectivity interaction (GPCR panel (PDSP screen)) EUB0000743a DRD2;ChEMBL;-;-;-;-;-;CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1;https://dx.doi.org/10.6019/CHEMBL5212743
BAY-309;216448;None;0;Human;Binding;Ki;=;10000,00;5,00;-5;6;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1;https://dx.doi.org/10.6019/CHEMBL4507270
BAY-309;216448;None;0;Human;Binding;Ki;=;10000,00;5,00;-5;6;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1;https://dx.doi.org/10.6019/CHEMBL4507270
BAZEDOXIFENE;178724;None;43;Human;Binding;AC50;=;4700,00;5,33;-;19;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;470,3;7;2;5;6,33;Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12;https://dx.doi.org/10.1038/s41467-023-40064-9
BEFIRADOL;173599;None;32;Human;Binding;Ki;=;15000,00;4,82;-30902;7;Displacement of [3H]Spiperone from human dopamine D2 long receptor;ChEMBL;393,1;5;1;3;3,92;Cc1ccc(CNCC2(F)CCN(C(=O)c3ccc(F)c(Cl)c3)CC2)nc1;https://dx.doi.org/10.1021/jm100835q
BEFIRADOL;173599;None;32;Human;Binding;Ki;=;46000,00;4,34;-30902;7;Displacement of [3H]Spiperone from human dopamine D2 short receptor;ChEMBL;393,1;5;1;3;3,92;Cc1ccc(CNCC2(F)CCN(C(=O)c3ccc(F)c(Cl)c3)CC2)nc1;https://dx.doi.org/10.1021/jm100835q
BENIDIPINE;77126;None;16;Human;Binding;AC50;=;29999,90;4,52;-;11;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;505,2;7;1;8;4,21;COC(=O)C1=C(C)NC(C)=C(C(=O)OC2CCCN(Cc3ccccc3)C2)C1c1cccc([N+](=O)[O-])c1;https://dx.doi.org/10.1038/s41467-023-40064-9
benperidol;596;None;33;Human;Binding;AC50;=;7,70;8,11;1;24;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;381,2;6;1;4;3,77;O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
benperidol;596;None;33;Human;Binding;Ki;=;0,03;10,57;1;24;Binding affinity to human dopamine D2 receptor by radioligand displacement assay;ChEMBL;381,2;6;1;4;3,77;O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
benperidol;596;None;33;Human;Binding;pKi;=;10,57;7,98;1;24;None;Drug Central;381,2;6;1;4;3,77;O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;-
benperidol;596;None;33;Human;Binding;pKi;=;-;10,57;1;24;Unclassified;Guide to Pharmacology;381,2;6;1;4;3,77;O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;https://pubmed.ncbi.nlm.nih.gov/9577836
benperidol;596;UNDEFINED;33;Human;Binding;pKi;=;0,03;10,57;1;24;-;PDSP KiDatabase;381,2;6;1;4;3,77;O=C(CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;-
benzatropine;597;None;17;Human;Binding;AC50;=;17999,90;4,75;-;27;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;307,2;4;0;2;4,42;CN1[C@H]2CC[C@@H]1C[C@H](OC(c1ccccc1)c1ccccc1)C2;https://dx.doi.org/10.1038/s41467-023-40064-9
BENZETHONIUM;11852;None;18;Human;Binding;AC50;=;3794,70;5,42;-;35;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;412,3;11;0;2;6,07;CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
benzofuranyl;218918;3H-YM 09151-2;0;Human;Binding;pKi;=;119,00;6,92;-512;4;-;PDSP KiDatabase;160,1;1;0;2;2,63;CC(=O)c1cc2ccccc2o1;-
benzofuranyl;218918;3H-SPIPERONE;0;Human;Binding;pKi;=;5740,00;5,24;-512;4;-;PDSP KiDatabase;160,1;1;0;2;2,63;CC(=O)c1cc2ccccc2o1;-
benzofuranyl;218918;3H-SPIPERONE;0;Human;Binding;pKi;=;320,00;6,49;-512;4;-;PDSP KiDatabase;160,1;1;0;2;2,63;CC(=O)c1cc2ccccc2o1;-
benzofuranyl;218918;125I-IABN;0;Human;Binding;pKi;=;44,80;7,35;-512;4;-;PDSP KiDatabase;160,1;1;0;2;2,63;CC(=O)c1cc2ccccc2o1;-
BENZOTHIAZYL DISULFIDE;189057;None;54;Human;Binding;IC50;=;5866,00;5,23;-26;13;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;332;3;0;6;5,71;c1ccc2sc(SSc3nc4ccccc4s3)nc2c1;-
BENZOTHIAZYL DISULFIDE;189057;None;54;Human;Binding;Ki;=;1955,00;5,71;-26;13;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;332;3;0;6;5,71;c1ccc2sc(SSc3nc4ccccc4s3)nc2c1;-
benzquinamide;599;None;30;Human;Binding;AC50;=;2500,00;5,60;-26;9;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;404,2;6;0;6;2,42;CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O;https://dx.doi.org/10.1038/s41467-023-40064-9
benzquinamide;599;None;30;Human;Binding;pKi;=;5,40;8,27;-26;9;None;Drug Central;404,2;6;0;6;2,42;CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O;-
benzquinamide;599;None;30;Human;Binding;pKi;=;-;5,40;-26;9;Unclassified;Guide to Pharmacology;404,2;6;0;6;2,42;CCN(CC)C(=O)C1CN2CCc3cc(OC)c(OC)cc3C2CC1OC(C)=O;https://pubmed.ncbi.nlm.nih.gov/22711801
BEPRIDIL;4301;None;35;Human;Binding;AC50;=;12999,90;4,89;-;22;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;366,3;10;0;3;4,83;CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1;https://dx.doi.org/10.1038/s41467-023-40064-9
BETAMETHASONE DIPROPIONATE;14419;None;30;Human;Binding;AC50;=;770,00;6,11;-;3;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;504,3;6;1;7;3,82;CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C;https://dx.doi.org/10.1038/s41467-023-40064-9
BI-605906;216444;None;38;Human;Binding;Ki;=;341,44;6,47;1;2;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12;https://dx.doi.org/10.6019/CHEMBL4800722
BI-605906;216444;None;38;Human;Binding;Ki;=;331,13;6,48;1;2;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12;https://dx.doi.org/10.6019/CHEMBL4800722
BI-605906;216444;None;38;Human;Binding;Ki;=;341,44;6,47;1;2;Selectivity interaction (GPCR panel (PDSP screen)) EUB0001492b DRD2;ChEMBL;-;-;-;-;-;CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12;https://dx.doi.org/10.6019/CHEMBL5465560
BIFEPRUNOX;83077;None;29;Human;Binding;Ki;=;0,60;9,22;6;4;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
BIFEPRUNOX;83077;None;29;Human;Binding;Ki;=;2,29;8,64;6;4;Displacement of [3H]nemonapride from dopamine D2L receptor (unknown origin) expressed in African green monkey COS7 cells;ChEMBL;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1;https://dx.doi.org/10.1021/jm5003759
BIFEPRUNOX;83077;None;29;Human;Binding;Ki;=;2,20;8,66;6;4;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
BIFEPRUNOX;83077;None;29;Human;Binding;Ki;=;0,10;10,00;6;4;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1;https://dx.doi.org/10.1021/jm901689v
BIFEPRUNOX;83077;None;29;Human;Binding;Ki;=;0,04;10,40;6;4;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1;https://dx.doi.org/10.1021/jm901689v
BIFEPRUNOX;83077;None;29;Human;Binding;Ki;=;2,30;8,64;6;4;Displacement of [3H]nemonapride from dopamine D2L receptor (unknown origin) expressed in African green monkey COS7 cells;ChEMBL;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1;https://dx.doi.org/10.1021/jm5003759
BIFEPRUNOX;83077;UNDEFINED;29;Human;Binding;pKi;=;0,10;10,00;6;4;-;PDSP KiDatabase;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1;-
BIFEPRUNOX;83077;UNDEFINED;29;Human;Binding;pKi;=;0,04;10,40;6;4;-;PDSP KiDatabase;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1;-
bifeprunox;219977;UNDEFINED;0;Human;Binding;pKi;=;2,20;8,66;4;2;-;PDSP KiDatabase;385,2;4;1;4;4,11;O=c1[nH]c2cccc(N3CCN(Cc4ccc(-c5ccccc5)cc4)CC3)c2o1;-
blonanserin;666;None;64;Human;Binding;Ki;=;0,14;9,85;3;7;In vitro binding affinity against recombinant human dopamine receptor D2L in human liver microsomes;ChEMBL;367,2;3;0;3;4,69;CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.12.028
blonanserin;666;None;64;Human;Binding;pKi;=;9,85;8,01;3;7;None;Drug Central;367,2;3;0;3;4,69;CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1;-
blonanserin;666;None;64;Human;Binding;pKi;=;-;9,85;3;7;Unclassified;Guide to Pharmacology;367,2;3;0;3;4,69;CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCCCCC3)CC1;https://pubmed.ncbi.nlm.nih.gov/15686911
BMY-14802;693;None;23;Human;Binding;Ki;=;3346,00;5,47;-53;5;Displacement of [3H]spiperone from CHO-K1 cell membranes expressing human dopamine receptor D2;ChEMBL;348,2;6;1;5;2,39;OC(CCCN1CCN(c2ncc(F)cn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00076a022
BMY-7378;695;None;21;Human;Binding;Ki;=;14,00;7,85;-17;13;Binding affinity for human Dopamine receptor D2;ChEMBL;385,2;5;0;5;2,53;COc1ccccc1N1CCN(CCN2C(=O)CC3(CCCC3)CC2=O)CC1;https://dx.doi.org/10.1021/jm0491391
BODILISANT;87006;None;0;Human;Binding;Ki;=;1971,00;5,71;-301;7;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO-K1 cells;ChEMBL;465,3;6;0;3;5,79;CC1=CC(C)=[N+]2C1=C(c1ccc(OCCCN3CCCCC3)cc1)c1c(C)cc(C)n1[B-]2(F)F;https://dx.doi.org/10.1021/ml300383n
BOPINDOLOL;121354;None;36;Human;Binding;AC50;=;6900,00;5,16;-;12;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;380,2;7;2;4;4,47;Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1;https://dx.doi.org/10.1038/s41467-023-40064-9
BOSUTINIB;100270;None;65;Human;Binding;AC50;=;930,00;6,03;-;23;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;529,2;9;1;8;5,19;COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl;https://dx.doi.org/10.1038/s41467-023-40064-9
BP 897;708;None;33;Human;Binding;Ki;=;210,00;6,68;-75;31;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm025558r
BP 897;708;None;33;Human;Binding;Ki;=;220,00;6,66;-75;31;Inhibition of [3H]spiperone binding to human dopamine receptor D2 long expressed in Chinese hamster ovary cells;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm050170s
BP 897;708;None;33;Human;Binding;Ki;=;61,00;7,21;-75;31;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
BP 897;708;None;33;Human;Binding;Ki;=;220,00;6,66;-75;31;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm060138d
BP 897;708;None;33;Human;Binding;Ki;=;200,00;6,70;-75;31;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm060138d
BP 897;708;None;33;Human;Binding;Ki;=;247,00;6,61;-75;31;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
BP 897;708;None;33;Human;Binding;Ki;=;61,00;7,21;-75;31;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm030836n
BP 897;708;None;33;Human;Binding;Ki;=;200,00;6,70;-75;31;Inhibition of [3H]spiperone binding to human dopamine receptor D2 short;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm050170s
BP 897;708;None;33;Human;Binding;Ki;=;186,00;6,73;-75;31;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
BP 897;708;None;33;Human;Binding;Ki;=;61,00;7,21;-75;31;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2 receptor expressed in CHO cells;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm040190e
BP 897;708;None;33;Human;Binding;Ki;=;208,93;6,68;-75;31;Binding affinity to dopamine D2;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm0611152
BP 897;708;None;33;Human;Binding;Ki;=;33,60;7,47;-75;31;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm200288r
BP 897;708;None;33;Human;Binding;Ki;=;144,06;6,84;-75;31;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.6019/CHEMBL5442175
BP 897;708;None;33;Human;Binding;Ki;=;210,00;6,68;-75;31;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm025558r
BP 897;708;None;33;Human;Binding;Ki;=;69,00;7,16;-75;31;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
BP 897;708;None;33;Human;Binding;Ki;=;52,00;7,28;-75;31;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;417,2;8;1;4;4,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
BP-897;218902;3H-SPIPERONE;0;Human;Binding;pKi;=;210,00;6,68;-102;6;-;PDSP KiDatabase;453,2;8;1;4;4,60;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1.Cl;-
BP-897;218902;3H-SPIPERONE;0;Human;Binding;pKi;=;210,00;6,68;-102;6;-;PDSP KiDatabase;453,2;8;1;4;4,60;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1.Cl;-
BP-897;218902;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;61,00;7,21;-102;6;-;PDSP KiDatabase;453,2;8;1;4;4,60;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1.Cl;-
brexpiprazole;721;None;58;Human;Binding;EC50;=;6,30;8,20;-1;28;Agonist activity at D2 receptor (unknown origin);ChEMBL;433,2;7;1;5;4,72;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;https://dx.doi.org/10.1016/j.bmcl.2020.127027
brexpiprazole;721;None;58;Human;Binding;Ki;=;0,30;9,52;-1;28;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;433,2;7;1;5;4,72;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
brexpiprazole;721;None;58;Human;Binding;Ki;=;5,99;8,22;-1;28;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;433,2;7;1;5;4,72;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;https://dx.doi.org/10.6019/CHEMBL5442175
brexpiprazole;721;None;58;Human;Binding;Ki;=;0,51;9,29;-1;28;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;433,2;7;1;5;4,72;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
brexpiprazole;721;None;58;Human;Binding;Ki;=;0,51;9,29;-1;28;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;433,2;7;1;5;4,72;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
brexpiprazole;721;None;58;Human;Binding;Ki;=;0,30;9,52;-1;28;Displacement of [3H]raclopride from human D2 long receptor expressed in CHO cells measured after 60 mins;ChEMBL;433,2;7;1;5;4,72;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;https://dx.doi.org/10.1016/j.ejmech.2020.112709
brexpiprazole;721;None;58;Human;Binding;pKi;=;9,52;8,02;-1;28;None;Drug Central;433,2;7;1;5;4,72;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;-
brexpiprazole;721;None;58;Human;Binding;pKi;=;-;9,52;-1;28;Unclassified;Guide to Pharmacology;433,2;7;1;5;4,72;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5sccc45)CC3)cc2[nH]1;https://pubmed.ncbi.nlm.nih.gov/24947465
bromocriptine;729;None;28;Human;Binding;AC50;=;27,80;7,56;-6;45;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://dx.doi.org/10.1038/s41467-023-40064-9
bromocriptine;729;None;28;Human;Binding;EC50;=;0,50;9,30;-6;45;Agonist activity at dopamine D2 receptor short isoform (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay;ChEMBL;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;None;28;Human;Binding;IC50;=;1,58;8,80;-6;45;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;None;28;Human;Binding;Ki;=;15,00;7,82;-6;45;Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins;ChEMBL;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://dx.doi.org/10.1021/jm5003759
bromocriptine;729;None;28;Human;Binding;Ki;=;14,79;7,83;-6;45;Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins;ChEMBL;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://dx.doi.org/10.1021/jm5003759
bromocriptine;729;None;28;Human;Binding;Ki;=;0,53;9,28;-6;45;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;None;28;Human;Binding;Ki;=;10,00;8,00;-6;45;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://dx.doi.org/10.1021/jm960360q
bromocriptine;729;None;28;Human;Binding;Ki;=;0,62;9,21;-6;45;Binding affinity to dopamine D2 receptor (unknown origin) assessed as inhibition constant;ChEMBL;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://dx.doi.org/10.1039/d3md00677h
bromocriptine;729;None;28;Human;Binding;pKi;=;9,70;8,01;-6;45;None;Drug Central;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;None;28;Human;Binding;pKi;=;-;7,80;-6;45;Unclassified;Guide to Pharmacology;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://pubmed.ncbi.nlm.nih.gov/8301582
bromocriptine;729;None;28;Human;Binding;pKi;=;-;7,80;-6;45;Unclassified;Guide to Pharmacology;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://pubmed.ncbi.nlm.nih.gov/12388666
bromocriptine;729;None;28;Human;Binding;pKi;=;-;7,80;-6;45;Unclassified;Guide to Pharmacology;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://pubmed.ncbi.nlm.nih.gov/7756621
bromocriptine;729;3H-RACLOPRIDE;28;Human;Binding;pKi;=;2,80;8,55;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;3H-SPIPERONE;28;Human;Binding;pKi;=;19,00;7,72;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;125I-IODOSULPRIDE;28;Human;Binding;pKi;=;0,62;9,21;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;125I-IODOSULPRIDE;28;Human;Binding;pKi;=;14,79;7,83;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;3H-N-Methylspiporone;28;Human;Binding;pKi;=;3,00;8,52;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;UNDEFINED;28;Human;Binding;pKi;=;2,00;8,70;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;3H-NEMONAPRIDE;28;Human;Binding;pKi;=;9,00;8,05;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;3H-SPIPERONE;28;Human;Binding;pKi;=;12,60;7,90;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;UNDEFINED;28;Human;Binding;pKi;=;2,00;8,70;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;3H-SPIPERONE;28;Human;Binding;pKi;=;5,00;8,30;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;125I-IODOSULPRIDE;28;Human;Binding;pKi;=;5,01;8,30;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;3H-thymidine;28;Human;Binding;pKi;=;1,80;8,74;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
bromocriptine;729;125I-IODOSULPRIDE;28;Human;Binding;pKi;=;5,30;8,28;-6;45;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
BROMOCRIPTINE,(+);218479;3H-YM 09151-2;0;Human;Binding;pKi;=;8,20;8,09;-3;7;-;PDSP KiDatabase;653,2;5;3;6;3,19;CC(C)CC1C(=O)N2CCCC2C2(O)OC(NC(=O)C3C=C4c5cccc6[nH]c(Br)c(c56)CC4N(C)C3)(C(C)C)C(=O)N12;-
BROMOPRIDE;154743;None;46;Human;Binding;pKi;=;7,85;8,11;-;5;None;Drug Central;343,1;7;2;4;2,11;CCN(CC)CCNC(=O)c1cc(Br)c(N)cc1OC;-
BROMPERIDOL;99377;None;50;Human;Binding;AC50;=;22,00;7,66;-1;24;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;419,1;6;1;3;4,54;O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
BROMPERIDOL;99377;None;50;Human;Binding;pKi;=;8,43;8,07;-1;24;None;Drug Central;419,1;6;1;3;4,54;O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1;-
BROMPERIDOL;99377;R-SAT;50;Human;Binding;pKi;=;2,10;8,68;-1;24;-;PDSP KiDatabase;419,1;6;1;3;4,54;O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1;-
BROMPERIDOL;99377;R-SAT;50;Human;Binding;pKi;=;1,00;9,00;-1;24;-;PDSP KiDatabase;419,1;6;1;3;4,54;O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1;-
BULBOCAPNINE;218619;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;1500,00;5,82;-1;5;-;PDSP KiDatabase;325,1;1;1;5;2,88;COc1ccc2c(c1O)-c1c3c(cc4c1C(C2)N(C)CC4)OCO3;-
BUPROPION;209124;3H-SPIPERONE;29;Human;Binding;pKi;=;10000,00;5,00;-2089;18;-;PDSP KiDatabase;239,1;3;1;2;3,30;CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1;-
buspirone;745;None;38;Human;Binding;AC50;=;520,00;6,28;-13;34;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
buspirone;745;None;38;Human;Binding;IC50;=;323,00;6,49;-13;34;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;-
buspirone;745;None;38;Human;Binding;Ki;=;108,00;6,97;-13;34;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;-
buspirone;745;None;38;Human;Binding;Ki;=;90,00;7,05;-13;34;Binding affinity for DA2 receptor;ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/jm00075a006
buspirone;745;None;38;Human;Binding;Ki;=;484,00;6,32;-13;34;Displacement of [3H]methylspiperone from human D2 receptor expressed in HEK cells;ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.7b00315
buspirone;745;None;38;Human;Binding;Ki;=;1000,00;6,00;-13;34;Binding affinity against Dopamine receptor D2;ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/jm950759z
buspirone;745;None;38;Human;Binding;Ki;=;13,00;7,89;-13;34;Binding affinity to D2 receptor by radioligand binding assay;ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/jm0508641
buspirone;745;None;38;Human;Binding;Ki;=;484,00;6,32;-13;34;Displacement of [3H]methylspiperone from human D2 receptor expressed in HEK-GIRK-M4 cell membrane by radioligand binding assay;ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
buspirone;745;None;38;Human;Binding;Ki;=;13,00;7,89;-13;34;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/jm00067a003
buspirone;745;None;38;Human;Binding;pKi;=;7,68;8,11;-13;34;None;Drug Central;385,2;6;0;6;2,09;O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1;-
BUTACLAMOL;218427;3H-SPIPERONE;0;Human;Binding;pKi;=;0,86;9,07;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;3H-SPIPERONE;0;Human;Binding;pKi;=;0,16;9,80;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;3H-S-Sulpiride;0;Human;Binding;pKi;=;6300,00;5,20;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;UNDEFINED;0;Human;Binding;pKi;=;0,86;9,07;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;125I-7-OH-PIPAT;0;Human;Binding;pKi;=;0,43;9,37;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;R-SAT;0;Human;Binding;pKi;=;0,40;9,40;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;1000,00;6,00;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;3H-domperidone;0;Human;Binding;pKi;=;10000,00;5,00;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;R-SAT;0;Human;Binding;pKi;=;0,30;9,52;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;3H-SPIPERONE;0;Human;Binding;pKi;=;10000,00;5,00;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTACLAMOL;218427;3H-SPIPERONE;0;Human;Binding;pKi;=;950,00;6,02;-48;21;-;PDSP KiDatabase;361,2;0;1;2;4,84;CC(C)(C)C1(O)CCN2CC3c4ccccc4CCc4cccc(c43)C2C1;-
BUTRIPTYLINE;78430;None;26;Human;Binding;AC50;=;16000,00;4,80;-;10;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;293,2;4;0;1;4,50;CC(CC1c2ccccc2CCc2ccccc21)CN(C)C;https://dx.doi.org/10.1038/s41467-023-40064-9
BW-723C86;218937;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-660;27;-;PDSP KiDatabase;322,1;5;2;3;4,12;CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12.Cl;-
cabergoline;778;None;41;Human;Binding;AC50;=;13,00;7,89;-1;19;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;451,3;8;2;4;3,19;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1038/s41467-023-40064-9
cabergoline;778;None;41;Human;Binding;pKi;=;9,20;8,04;-1;19;None;Drug Central;451,3;8;2;4;3,19;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
cabergoline;778;None;41;Human;Binding;pKi;=;-;9,10;-1;19;Unclassified;Guide to Pharmacology;451,3;8;2;4;3,19;C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/12388666
Cabergoline;218828;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;0,62;9,21;1;19;-;PDSP KiDatabase;451,3;8;2;4;3,19;C=CCN1CC(C(=O)N(CCCN(C)C)C(=O)NCC)CC2c3cccc4[nH]cc(c34)CC21;-
Cabergoline;218828;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;0,95;9,02;1;19;-;PDSP KiDatabase;451,3;8;2;4;3,19;C=CCN1CC(C(=O)N(CCCN(C)C)C(=O)NCC)CC2c3cccc4[nH]cc(c34)CC21;-
CANADINE;187082;None;25;Human;Binding;Ki;=;119,00;6,92;-1;6;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;339,1;2;0;5;3,09;COc1ccc2c(c1OC)CN1CCc3cc4c(cc3[C@@H]1C2)OCO4;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CANADINE;187082;None;25;Human;Binding;Ki;=;80,20;7,10;-1;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor after 1 hr;ChEMBL;339,1;2;0;5;3,09;COc1ccc2c(c1OC)CN1CCc3cc4c(cc3[C@@H]1C2)OCO4;https://dx.doi.org/10.1016/j.bmcl.2017.01.090
carbamazepine;796;3H-YM 09151-2;68;Human;Binding;pKi;=;10000,00;5,00;-48;8;-;PDSP KiDatabase;236,1;0;1;1;3,39;NC(=O)N1c2ccccc2C=Cc2ccccc21;-
cariprazine;800;None;50;Human;Binding;EC50;=;0,18;9,74;-7;28;Partial agonist activity at human D2 receptor assessed as increase in cAMP accumulation;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
cariprazine;800;None;50;Human;Binding;EC50;=;3,47;8,46;-7;28;Partial agonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm5004039
cariprazine;800;None;50;Human;Binding;IC50;=;1,66;8,78;-7;28;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm5004039
cariprazine;800;None;50;Human;Binding;IC50;=;1,70;8,77;-7;28;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm5004039
cariprazine;800;None;50;Human;Binding;Ki;=;0,50;9,30;-7;28;Modulation of human D2L receptor;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
cariprazine;800;None;50;Human;Binding;Ki;=;0,49;9,31;-7;28;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.7b00010
cariprazine;800;None;50;Human;Binding;Ki;=;0,69;9,16;-7;28;Displacement of [3H]Spiperone from human D2S receptor expressed in CHO cells;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.7b00010
cariprazine;800;None;50;Human;Binding;Ki;=;17,78;7,75;-7;28;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm401318w
cariprazine;800;None;50;Human;Binding;Ki;=;102,33;6,99;-7;28;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm401318w
cariprazine;800;None;50;Human;Binding;Ki;=;0,47;9,33;-7;28;Displacement of [3H]spiperone from human D2-long receptor expressed in CHO cell membranes;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
cariprazine;800;None;50;Human;Binding;Ki;=;0,41;9,39;-7;28;Displacement of [3H]spiperone from human D2-short receptor expressed in CHO cell membranes;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
cariprazine;800;None;50;Human;Binding;Ki;=;1,45;8,84;-7;28;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
cariprazine;800;None;50;Human;Binding;Ki;=;1,45;8,84;-7;28;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
cariprazine;800;None;50;Human;Binding;Ki;=;0,49;9,31;-7;28;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127681
cariprazine;800;None;50;Human;Binding;Ki;=;6,38;8,20;-7;28;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.6019/CHEMBL5442175
cariprazine;800;None;50;Human;Binding;Ki;=;0,41;9,39;-7;28;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm5004039
cariprazine;800;None;50;Human;Binding;Ki;=;0,47;9,33;-7;28;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm5004039
cariprazine;800;None;50;Human;Binding;Ki;=;0,78;9,11;-7;28;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
cariprazine;800;None;50;Human;Binding;Ki;=;1,30;8,89;-7;28;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
cariprazine;800;None;50;Human;Binding;Ki;=;5,70;8,24;-7;28;Binding affinity to human dopamine D2L receptor;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.03.104
cariprazine;800;None;50;Human;Binding;Ki;=;0,81;9,09;-7;28;Binding affinity to human dopamine D2S receptor;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.03.104
cariprazine;800;None;50;Human;Binding;Ki;=;0,49;9,31;-7;28;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
cariprazine;800;None;50;Human;Binding;pKi;=;9,31;8,03;-7;28;CHO cells, [3H]Spiperone (0.16nM);Drug Central;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;-
cariprazine;800;None;50;Human;Binding;pKi;=;-;8,24;-7;28;Binding affinity to human dopamine D2L receptor;Guide to Pharmacology;426,2;5;1;3;4,34;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://pubmed.ncbi.nlm.nih.gov/22537450
CARPIPRAMINE;78426;None;10;Human;Binding;pKi;=;8,06;8,09;1;11;None;Drug Central;446,3;6;1;4;4,12;NC(=O)C1(N2CCCCC2)CCN(CCCN2c3ccccc3CCc3ccccc32)CC1;-
CARPIPRAMINE;78426;125I-IODOSULPRIDE;10;Human;Binding;pKi;=;8,70;8,06;1;11;-;PDSP KiDatabase;446,3;6;1;4;4,12;NC(=O)C1(N2CCCCC2)CCN(CCCN2c3ccccc3CCc3ccccc32)CC1;-
carvedilol;803;None;59;Human;Binding;AC50;=;130,00;6,89;-38;35;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;406,2;10;3;5;3,74;COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12;https://dx.doi.org/10.1038/s41467-023-40064-9
carvedilol;803;None;59;Human;Binding;IC50;=;146,00;6,84;-38;35;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;406,2;10;3;5;3,74;COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12;-
carvedilol;803;None;59;Human;Binding;Ki;=;49,00;7,31;-38;35;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;406,2;10;3;5;3,74;COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12;-
carvedilol;803;None;59;Human;Binding;pKi;=;7,31;8,14;-38;35;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;406,2;10;3;5;3,74;COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12;-
Cathinone, (-);218812;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-13;40;-;PDSP KiDatabase;149,1;2;1;2;1,22;CC(N)C(=O)c1ccccc1;-
CEFEPIME;66823;None;25;Human;Binding;AC50;=;18999,80;4,72;-;3;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;480,1;7;2;10;-1,28;CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)c1csc(N)n1;https://dx.doi.org/10.1038/s41467-023-40064-9
CEFPROZIL;112658;None;8;Human;Binding;AC50;=;25999,80;4,58;-;2;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;389,1;5;4;6;0,71;CC=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1;https://dx.doi.org/10.1038/s41467-023-40064-9
CELECOXIB;11388;3H-NMSP;77;Human;Binding;pKi;=;10000,00;5,00;-41;32;-;PDSP KiDatabase;381,1;3;1;4;3,51;Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1;-
CGS 12066B;218441;3H-YM 09151-2;0;Human;Binding;pKi;=;1739,00;5,76;-1380;16;-;PDSP KiDatabase;450,2;3;2;6;2,97;CN1CCN(c2nc3cc(C(F)(F)F)ccc3n3cccc23)CC1.O=C(O)C=CC(=O)O;-
CHEMBL100203;4208;None;0;Human;Binding;Ki;=;111,00;6,96;-36;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;236;0;0;4;3,37;Cc1sc(C)c2c1SCc1cnn(C)c1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL100454;4248;None;28;Human;Binding;Ki;=;22,00;7,66;-3;3;In vitro binding affinity of compound against neuronal Dopamine receptor D2;ChEMBL;328,1;1;2;6;2,62;CN1CCN(C2=Nc3ccccc3Nc3sc(CO)cc32)CC1;https://dx.doi.org/10.1016/S0960-894X(96)00567-7
CHEMBL101285;4382;None;0;Human;Binding;Ki;=;456,00;6,34;-10;4;Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone;ChEMBL;243,1;6;2;3;2,56;Oc1ccccc1OCCNCc1ccccc1;https://dx.doi.org/10.1016/s0960-894x(98)00014-6
CHEMBL101535;4427;None;0;Human;Binding;Ki;=;1,50;8,82;-3;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;443,2;3;2;6;2,61;N#Cc1cc2c3c(ccc2[nH]1)OCC(CN1CCC2(CC1)C(=O)NCN2c1ccccc1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL102175;4512;None;0;Human;Binding;Ki;=;5,70;8,24;-1;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;518,3;7;2;7;3,69;CCCCOC(=O)c1cc2c3c(ccc2[nH]1)OCC(CN1CCC2(CC1)C(=O)NCN2c1ccccc1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL102414;4554;None;0;Human;Binding;Ki;=;3676,00;5,43;-44;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;315,1;3;1;4;3,38;Oc1ccc2c(c1)C1OCCN(CCc3cccs3)C1CC2;https://dx.doi.org/10.1021/jm001015a
CHEMBL102490;4565;None;0;Human;Binding;Ki;=;9,00;8,05;-2;4;Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone;ChEMBL;360;8;2;5;2,94;CS(=O)(=O)Nc1cc(OCCNCc2cccs2)ccc1Cl;https://dx.doi.org/10.1016/s0960-894x(98)00014-6
CHEMBL102582;4578;None;4;Human;Binding;Ki;=;6,24;8,21;-288;4;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;247,2;2;1;3;2,49;CCCN1CCOC2c3cc(O)ccc3CCC21;https://dx.doi.org/10.1021/jm001015a
CHEMBL102582;4578;3H-SPIPERONE;4;Human;Binding;pKi;=;1000,00;6,00;-288;4;-;PDSP KiDatabase;247,2;2;1;3;2,49;CCCN1CCOC2c3cc(O)ccc3CCC21;-
CHEMBL102582;4578;3H-SPIPERONE;4;Human;Binding;pKi;=;147,00;6,83;-288;4;-;PDSP KiDatabase;247,2;2;1;3;2,49;CCCN1CCOC2c3cc(O)ccc3CCC21;-
CHEMBL102582;4578;125I-IODOSULPRIDE;4;Human;Binding;pKi;=;8,50;8,07;-288;4;-;PDSP KiDatabase;247,2;2;1;3;2,49;CCCN1CCOC2c3cc(O)ccc3CCC21;-
CHEMBL102632;4587;None;0;Human;Binding;Ki;=;630,00;6,20;-2;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;237,1;2;0;3;2,85;CCCN1CCOC2c3ccsc3CCC21;https://dx.doi.org/10.1021/jm001015a
CHEMBL10270;4596;None;0;Human;Binding;Ki;=;6,70;8,17;-33;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;243,2;3;0;2;2,98;C=CCN1CCC2c3c(cccc3OC)CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL103441;4701;None;0;Human;Binding;Ki;=;1080,00;5,97;-9;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;279,1;8;0;3;4,31;CCCN(CCc1ccsc1)CCc1cccs1;https://dx.doi.org/10.1021/jm001015a
CHEMBL103622;4733;None;0;Human;Binding;Ki;=;20,00;7,70;1;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;237,2;5;0;2;3,73;CCCN(CCC)C1CCc2sccc2C1;https://dx.doi.org/10.1021/jm001015a
CHEMBL103857;4765;None;0;Human;Binding;Ki;=;27,00;7,57;1;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;237,2;5;0;2;3,73;CCCN(CCC)C1CCc2ccsc2C1;https://dx.doi.org/10.1021/jm001015a
CHEMBL103871;4766;None;0;Human;Binding;Ki;=;254,00;6,59;-63;3;Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151;ChEMBL;318,2;4;1;3;3,40;c1ccc(-c2nc(CN3CCN(c4ccccc4)CC3)c[nH]2)cc1;https://dx.doi.org/10.1021/jm960637m
CHEMBL103912;4771;None;0;Human;Binding;Ki;=;3107,00;5,51;-51;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;251,2;6;0;2;3,98;CCCN(CCC)CC1CCc2ccsc2C1;https://dx.doi.org/10.1021/jm001015a
CHEMBL103983;4777;None;0;Human;Binding;Ki;=;41,00;7,39;-25;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;483,3;11;3;4;4,89;O=C(NCCCc1ccccc1)c1cc2c3c(ccc2[nH]1)OCC(CNCCCc1ccccc1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL104058;4787;None;0;Human;Binding;Ki;=;286,00;6,54;-57;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;367,2;4;0;3;2,92;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL104063;4790;None;0;Human;Binding;Ki;=;8053,00;5,09;-112;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;371,1;5;0;5;3,07;O=c1oc2ccccc2n1CCN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL10408;4794;None;0;Human;Binding;Ki;=;108,00;6,97;-2;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;229,1;2;1;2;2,68;C=CCN1CCC2c3cccc(O)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL104092;4797;None;1;Human;Binding;Ki;=;10000,00;5,00;-2;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;340,2;3;0;2;4,72;C(#Cc1cccn1C1CCN(Cc2ccccc2)CC1)c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL104092;4797;None;1;Human;Binding;Ki;=;8300,00;5,08;-2;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;340,2;3;0;2;4,72;C(#Cc1cccn1C1CCN(Cc2ccccc2)CC1)c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL104135;4805;None;0;Human;Binding;Ki;=;2037,00;5,69;-8;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;251,2;6;0;2;3,98;CCCN(CCC)CC1CCc2sccc2C1;https://dx.doi.org/10.1021/jm001015a
CHEMBL104138;4807;None;0;Human;Binding;Ki;=;4742,00;5,32;-3;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;398,2;4;0;2;3,58;C[C@@H]1CN(Cc2ccc(Cl)cc2)CC[N@@+]1(C)CC(=O)N1CCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104155;4812;None;0;Human;Binding;Ki;=;1414,00;5,85;-35;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;366,2;4;0;2;4,41;CC1Cc2ccccc2N1C(=O)CC1CCN(Cc2ccccc2F)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104160;4815;None;0;Human;Binding;Ki;=;35,00;7,46;1;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;425,2;4;0;3;4,78;CC1CC(C)(C)N(C(=O)CN2CCN(Cc3ccc(Cl)cc3)CC2)c2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104196;4829;None;0;Human;Binding;Ki;=;2610,00;5,58;-6;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;385,2;4;0;4;2,88;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCOc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104201;4833;None;0;Human;Binding;Ki;=;13000,00;4,89;-66;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;316,2;4;0;4;3,76;N#CC(C#N)=Cc1ccn(C2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL104201;4833;None;0;Human;Binding;Ki;=;18000,00;4,75;-66;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;316,2;4;0;4;3,76;N#CC(C#N)=Cc1ccn(C2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL104256;4847;None;0;Human;Binding;Ki;=;1530,00;5,82;-213;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;363,2;4;0;3;3,09;Cc1ccccc1CN1CCN(CC(=O)N2c3ccccc3CC2C)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104273;4849;None;0;Human;Binding;Ki;=;23,00;7,64;-7;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;380,2;4;0;2;4,71;Cc1ccc(CN2CCC(CC(=O)N3c4ccccc4CC3C)CC2)cc1F;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104321;4861;None;0;Human;Binding;Ki;=;5287,00;5,28;-478;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;417,2;4;0;3;3,80;CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(C(F)(F)F)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104323;4862;None;0;Human;Binding;Ki;=;2583,00;5,59;-426;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;419,2;4;0;3;3,71;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2cc(F)c(Cl)cc2F)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL104380;4875;None;0;Human;Binding;Ki;=;979,00;6,01;-75;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;419,1;6;0;4;3,20;O=S1(=O)Cc2ccccc2N1CCCN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104399;4878;None;0;Human;Binding;Ki;=;5839,00;5,23;-416;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;383,2;4;0;3;3,44;C[C@@H]1CN(Cc2ccc(Cl)cc2)CCN1CC(=O)N1CCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104453;4886;None;0;Human;Binding;Ki;=;320,00;6,50;-6;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;307,2;4;0;4;3,98;c1ccc(CN2CCC(n3cccc3-c3cnco3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL104453;4886;None;0;Human;Binding;Ki;=;610,00;6,21;-6;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;307,2;4;0;4;3,98;c1ccc(CN2CCC(n3cccc3-c3cnco3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL104498;4897;None;0;Human;Binding;Ki;=;5847,00;5,23;-8;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;383,2;5;0;3;3,44;O=C(CCN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104571;4908;None;0;Human;Binding;Ki;=;420,00;6,38;-14;2;Binding affinity to dopamine D2 receptor;ChEMBL;295,2;1;3;3;3,21;CCc1ccc2c(c1)[C@@H]1c3cc(O)c(O)cc3CC[C@H]1NC2;https://dx.doi.org/10.1016/j.ejmech.2011.11.039
CHEMBL104579;4911;None;0;Human;Binding;Ki;=;158,00;6,80;-15;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;378,2;5;0;3;4,28;COc1ccc(CN2CCC(CC(=O)N3c4ccccc4CC3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104614;4917;None;0;Human;Binding;Ki;=;887,00;6,05;-125;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;367,2;4;0;3;2,92;CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104678;4927;None;0;Human;Binding;Ki;=;43,00;7,37;1;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;417,1;4;0;3;4,09;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)c(Cl)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL104713;4938;None;0;Human;Binding;Ki;=;341,00;6,47;1;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;425,2;6;0;3;4,46;CC(C)CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104716;4940;None;0;Human;Binding;Ki;=;39,00;7,41;-19;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;362,2;4;0;2;4,58;Cc1ccc(CN2CCC(CC(=O)N3c4ccccc4CC3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104719;4942;None;0;Human;Binding;Ki;=;52,00;7,28;-7;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;366,2;4;0;2;4,41;CC1Cc2ccccc2N1C(=O)CC1CCN(Cc2cccc(F)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104751;4947;None;0;Human;Binding;Ki;=;28,00;7,55;-5;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;413,2;5;0;4;3,44;COc1ccc(Cl)cc1CN1CCN(CC(=O)N2c3ccccc3C[C@H]2C)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL104756;4950;None;0;Human;Binding;Ki;=;8620,00;5,06;-;1;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;397,2;4;0;3;3,82;C[C@H]1CN(CC(=O)N2CCc3ccccc32)C[C@@H](C)N1Cc1ccc(Cl)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104788;4954;None;0;Human;Binding;Ki;=;92,00;7,04;-22;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;382,2;4;0;2;4,92;CC1Cc2ccccc2N1C(=O)CC1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL104832;4967;None;0;Human;Binding;Ki;=;62,00;7,21;-15;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;382,2;4;0;2;4,92;CC1Cc2ccccc2N1C(=O)CC1CCN(Cc2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL105011;5003;None;0;Human;Binding;Ki;=;166,00;6,78;-33;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;362,2;4;0;2;4,58;Cc1cccc(CN2CCC(CC(=O)N3c4ccccc4CC3C)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL105172;5036;None;0;Human;Binding;Ki;=;95,00;7,02;-7;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;417,1;4;0;3;4,09;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2cc(Cl)ccc2Cl)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL105304;5058;None;0;Human;Binding;Ki;=;119,00;6,92;-15;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;377,2;4;0;3;3,40;Cc1ccc(C)c(CN2CCN(CC(=O)N3c4ccccc4CC3C)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL105317;5060;None;0;Human;Binding;Ki;=;673,00;6,17;-67;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;379,2;5;0;4;2,79;COc1ccc(CN2CCN(CC(=O)N3c4ccccc4C[C@H]3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL105354;5063;None;0;Human;Binding;Ki;=;2364,00;5,63;-36;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;363,2;4;0;3;3,09;Cc1ccc(CN2CCN(CC(=O)N3c4ccccc4C[C@@H]3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL105454;5077;None;0;Human;Binding;Ki;=;5940,00;5,23;-1174;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;417,2;4;0;3;3,80;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(C(F)(F)F)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL105509;5088;None;0;Human;Binding;Ki;=;1202,00;5,92;-7;2;In vitro binding affinity is the ability to displace [3H]N-0437 from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;262,2;6;0;3;3,07;CCCN(CCC)C1CCc2nc(OC)ccc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL105512;5089;None;5;Human;Binding;Ki;=;57,00;7,24;-85;2;In vitro binding affinity is the ability to displace [3H]N-0437 from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;253,2;5;1;4;2,71;CCCN(CCC)C1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL105512;5089;None;5;Human;Binding;Ki;=;462,00;6,33;-85;2;In vitro binding affinity is the ability to displace [3H]spiperone from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;253,2;5;1;4;2,71;CCCN(CCC)C1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL105595;5106;None;0;Human;Binding;Ki;=;6357,00;5,20;-8;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;383,2;4;0;3;3,35;Cc1ccc2c(c1)N(C(=O)CN1CCN(Cc3ccc(Cl)cc3)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL105601;5108;None;0;Human;Binding;Ki;=;1000,00;6,00;-165;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;367,2;4;0;3;2,92;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2cccc(F)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL105623;5114;None;0;Human;Binding;Ki;=;439,00;6,36;-4;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;279,1;8;0;3;4,31;CCCN(CCc1ccsc1)CCc1ccsc1;https://dx.doi.org/10.1021/jm001015a
CHEMBL105625;5115;None;0;Human;Binding;Ki;=;450,00;6,35;-;1;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;414,1;5;0;5;2,96;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2ccc([N+](=O)[O-])cc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL10570;5131;None;0;Human;Binding;Ki;=;78,00;7,11;-1;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;243,2;3;0;2;2,98;C=CCN1CCC2c3cccc(OC)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL105745;5139;None;0;Human;Binding;Ki;=;491,00;6,31;-61;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;407,2;5;0;5;2,24;COC(=O)[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(C)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL105977;5177;None;0;Human;Binding;Ki;=;466,00;6,33;-70;2;In vitro binding affinity is the ability to displace [3H]N-0437 from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;232,2;5;0;2;3,06;CCCN(CCC)C1CCc2ncccc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL105977;5177;None;0;Human;Binding;Ki;=;272,00;6,57;-70;2;In vitro binding affinity is the ability to displace [3H]spiperone from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;232,2;5;0;2;3,06;CCCN(CCC)C1CCc2ncccc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL106047;5189;None;0;Human;Binding;Ki;=;3940,00;5,41;-10;2;In vitro binding affinity is the ability to displace [3H]N-0437 from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;261,2;6;0;2;3,67;CCCN(CCC)C1CCc2cc(OC)ccc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL106119;5208;None;0;Human;Binding;Ki;=;9395,00;5,03;-67;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;383,2;4;0;3;3,44;C[C@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL106169;5213;None;0;Human;Binding;Ki;=;758,00;6,12;-251;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;377,2;5;0;3;3,34;CCc1ccc(CN2CCN(CC(=O)N3c4ccccc4C[C@H]3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL106208;5219;None;0;Human;Binding;Ki;=;3823,00;5,42;-758;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;433,2;5;0;4;3,68;CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(OC(F)(F)F)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL106283;5237;None;0;Human;Binding;Ki;=;58,00;7,24;-3;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;462,2;4;3;6;2,43;O=C(O)c1cc2c3c(ccc2[nH]1)OCC(CN1CCC2(CC1)C(=O)NCN2c1ccccc1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL106598;5296;None;0;Human;Binding;Ki;=;2145,00;5,67;-2;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;403,1;4;0;3;3,70;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2c(Cl)cccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL106635;5305;None;18;Human;Binding;Ki;=;5300,00;5,28;-4;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;366,1;3;0;2;3,93;Ic1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL106635;5305;None;18;Human;Binding;Ki;=;8500,00;5,07;-4;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;366,1;3;0;2;3,93;Ic1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL106660;5307;None;0;Human;Binding;Ki;=;59,00;7,23;1;3;Binding affinity at human dopamine receptor D2;ChEMBL;445,2;8;0;2;7,07;Clc1cccc(C(OC2CC3CCC(C2)N3CCCc2ccccc2)c2ccccc2)c1;https://dx.doi.org/10.1021/jm010146o
CHEMBL106737;5314;None;11;Human;Binding;Ki;=;158,00;6,80;-758;5;Compound is evaluated for binding affinity towards Dopamine receptor D2 using [3H]spiperone in CHO cells;ChEMBL;391,2;4;1;5;2,49;COc1ccccc1N1CCN(CC2CN=C3c4ccccc4NC(=O)N32)CC1;https://dx.doi.org/10.1021/jm970159v
CHEMBL106737;5314;None;11;Human;Binding;Ki;=;239,00;6,62;-758;5;Compound is evaluated for binding affinity towards recombinant human Dopamine receptor D2 using [3H]spiperone in CHO cells;ChEMBL;391,2;4;1;5;2,49;COc1ccccc1N1CCN(CC2CN=C3c4ccccc4NC(=O)N32)CC1;https://dx.doi.org/10.1021/jm970159v
CHEMBL106742;5316;None;0;Human;Binding;Ki;=;306,00;6,51;-77;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;376,3;4;0;2;4,88;Cc1ccc(CN2CCC(CC(=O)N3c4ccccc4CC3C)CC2)cc1C;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL106751;5319;None;0;Human;Binding;Ki;=;1252,00;5,90;-18;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;397,2;4;0;3;4,00;CC(c1ccc(Cl)cc1)N1CCN(CC(=O)N2c3ccccc3CC2C)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL106862;5343;None;0;Human;Binding;Ki;=;273,00;6,56;-91;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;413,2;5;0;4;3,44;COc1cc(Cl)ccc1CN1CCN(CC(=O)N2c3ccccc3C[C@H]2C)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL106897;5352;None;0;Human;Binding;Ki;=;4126,00;5,38;-43;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;397,2;4;0;3;3,83;CC1CCc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL106914;5361;None;0;Human;Binding;Ki;=;834,00;6,08;-28;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;382,2;4;0;2;4,92;CC1Cc2ccccc2N1C(=O)CC1CCN(Cc2ccccc2Cl)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL106916;5362;None;0;Human;Binding;Ki;=;209,00;6,68;1;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;383,2;4;0;3;3,44;CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL106917;5363;None;0;Human;Binding;Ki;=;3780,00;5,42;-16;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;476,2;6;0;5;2,30;CN(C)S(=O)(=O)c1ccc2c(c1)CCN2C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL106998;5378;None;0;Human;Binding;Ki;=;1692,00;5,77;-45;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;383,2;4;0;3;3,35;Cc1ccc2c(c1)CCN2C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107020;5381;None;0;Human;Binding;Ki;=;214,00;6,67;-14;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;417,1;4;0;3;4,09;CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2cc(Cl)cc(Cl)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107151;5403;None;0;Human;Binding;Ki;=;3027,00;5,52;-301;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;399,2;5;1;4;2,41;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1c2ccccc2C[C@H]1CO;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL107229;5416;None;0;Human;Binding;Ki;=;4623,00;5,33;-97;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;383,2;4;0;3;3,35;Cc1cccc2c1N(C(=O)CN1CCN(Cc3ccc(Cl)cc3)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107338;5435;None;0;Human;Binding;Ki;=;1926,00;5,71;-23;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;439,2;4;0;3;5,08;Cc1ccc2c(c1)N(C(=O)CN1CCN(Cc3ccc(Cl)cc3)CC1)C(C)(C)CC2C;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107351;5436;None;0;Human;Binding;Ki;=;6740,00;5,17;-19;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;397,2;4;0;3;3,82;C[C@H]1CN(Cc2ccc(Cl)cc2)[C@H](C)CN1CC(=O)N1CCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107384;5442;None;0;Human;Binding;Ki;=;883,00;6,05;-8;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;411,2;4;0;3;4,17;CC1N(C(=O)CN2CCN(Cc3ccc(Cl)cc3)CC2)c2ccccc2C1(C)C;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107391;5445;None;0;Human;Binding;Ki;=;2220,00;5,65;-60;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;415,2;4;0;3;3,96;CC1CCc2cc(F)ccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107529;5475;None;0;Human;Binding;Ki;=;3400,00;5,47;-25;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;307,2;4;0;4;3,98;c1ccc(CN2CCC(n3ccc(-c4cnco4)c3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL107529;5475;None;0;Human;Binding;Ki;=;3200,00;5,50;-25;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;307,2;4;0;4;3,98;c1ccc(CN2CCC(n3ccc(-c4cnco4)c3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL107631;5503;None;0;Human;Binding;Ki;=;1178,00;5,93;-234;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;427,2;5;0;5;2,59;COC(=O)[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL107742;5621;None;0;Human;Binding;IC50;=;188,00;6,73;-35;2;Inhibitory concentration against dopamine receptor D2;ChEMBL;363,2;4;0;3;3,09;Cc1ccc(CN2CCN(CC(=O)N3c4ccccc4CC3C)CC2)cc1;https://dx.doi.org/10.1021/jm058225d
CHEMBL107742;5621;None;0;Human;Binding;Ki;=;188,00;6,73;-35;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;363,2;4;0;3;3,09;Cc1ccc(CN2CCN(CC(=O)N3c4ccccc4CC3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107755;5625;None;0;Human;Binding;Ki;=;5847,00;5,23;-8;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;389,2;4;0;3;3,64;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCCC2CCCCC21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107793;5686;None;0;Human;Binding;Ki;=;509,00;6,29;-85;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;397,2;5;0;3;3,83;CCC1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107804;5701;None;0;Human;Binding;Ki;=;3011,00;5,52;-251;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;385,2;4;0;3;3,06;CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2cc(F)cc(F)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107962;5910;None;0;Human;Binding;Ki;=;3325,00;5,48;-2;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;437,2;4;0;3;4,75;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1c2ccccc2CC12CCCCC2;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL107974;5929;None;0;Human;Binding;Ki;=;550,00;6,26;-;1;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;410,1;6;0;4;6,75;CSc1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL107988;5959;None;0;Human;Binding;Ki;=;1100,00;5,96;8;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;422,1;6;0;5;5,82;COC(=O)c1cccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)c1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108011;5991;None;0;Human;Binding;Ki;=;218,00;6,66;-21;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;425,2;5;0;3;4,56;CC(C)c1ccc(Cl)cc1CN1CCN(CC(=O)N2c3ccccc3C[C@H]2C)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL108146;6232;None;0;Human;Binding;Ki;=;140,00;6,85;85;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;422,1;6;1;4;6,26;CC(C)(O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108157;6253;None;0;Human;Binding;Ki;=;1207,00;5,92;-398;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;387,1;5;0;5;3,53;O=c1sc2ccccc2n1CCN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL108160;6258;None;0;Human;Binding;Ki;=;6200,00;5,21;-2;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;336,2;3;0;2;4,55;C[Si](C)(C)C#Cc1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL108160;6258;None;0;Human;Binding;Ki;=;4900,00;5,31;-2;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;336,2;3;0;2;4,55;C[Si](C)(C)C#Cc1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL108242;6434;None;0;Human;Binding;Ki;=;550,00;6,26;3;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;438,1;6;0;5;4,83;COC(=O)c1ccc(C[S+]([O-])c2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108242;6434;None;0;Human;Binding;Ki;=;1500,00;5,82;3;2;Binding affinity against human recombinant dopamine receptor D2 in presence of 0.5% human serum albumin;ChEMBL;438,1;6;0;5;4,83;COC(=O)c1ccc(C[S+]([O-])c2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108243;6435;None;0;Human;Binding;Ki;=;8000,00;5,10;2;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;376,1;4;0;4;5,19;COC(=O)c1ccc(-c2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108243;6435;None;0;Human;Binding;Ki;=;800,00;6,10;2;2;Binding affinity against human recombinant dopamine receptor D2 in presence of 0.5% human serum albumin;ChEMBL;376,1;4;0;4;5,19;COC(=O)c1ccc(-c2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108282;6530;None;0;Human;Binding;Ki;=;191,00;6,72;-31;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;383,2;4;0;3;3,44;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL108289;6544;None;0;Human;Binding;Ki;=;24,00;7,62;38;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;404,1;6;0;4;5,31;COC(=O)c1ccc(CCc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108289;6544;None;0;Human;Binding;Ki;=;137,00;6,86;38;2;Binding affinity against human recombinant dopamine receptor D2 in presence of 0.5% human serum albumin;ChEMBL;404,1;6;0;4;5,31;COC(=O)c1ccc(CCc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108297;6554;None;0;Human;Binding;Ki;=;1200,00;5,92;-;1;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;443,1;6;1;5;4,68;NS(=O)(=O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108463;6987;None;0;Human;Binding;EC50;=;1,70;8,77;-;6;In vivo Dopamine receptor D2 mitogenesis measured as [3H]thymidine incorporation in CHO p-5 cells expressing human D2 receptors;ChEMBL;288,2;3;0;2;3,61;C(#Cc1cccnc1)CCN1CC=C(c2ccccc2)CC1;https://dx.doi.org/10.1021/jm950721m
CHEMBL108527;7130;None;0;Human;Binding;Ki;=;1680,00;5,78;-9;3;Binding affinity at human dopamine receptor D2;ChEMBL;479,2;6;1;3;5,51;O=C(NCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc2c1Cc1ccccc1-2;https://dx.doi.org/10.1021/jm010146o
CHEMBL108531;7138;None;2;Human;Binding;EC50;=;0,50;9,30;-;4;Compound was evaluated for effective concentration in vivo for Dopamine receptor D2 mitogenesis. (95% confidence intervals);ChEMBL;302,2;3;1;2;3,80;Nc1ccc(C#CCCN2CC=C(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm950721m
CHEMBL108532;7139;None;0;Human;Binding;EC50;=;9,80;8,01;-;4;Compound was evaluated for effective concentration in vivo for Dopamine receptor D2 mitogenesis. (95% confidence intervals);ChEMBL;302,2;3;1;2;3,80;Nc1cccc(C#CCCN2CC=C(c3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm950721m
CHEMBL108564;7209;None;0;Human;Binding;Ki;=;1100,00;5,96;5;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;405,1;6;1;5;5,14;COC(=O)c1ccc(CNc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108616;7329;None;0;Human;Binding;Ki;=;270,00;6,57;5;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;408,1;6;1;4;6,08;CC(O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL108637;7380;None;0;Human;Binding;Ki;=;825,00;6,08;-1;3;Binding affinity at human dopamine receptor D2;ChEMBL;411,2;6;1;3;4,20;O=C(NCCCN1CCN(c2ccccc2)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm010146o
CHEMBL1086626;7436;None;0;Human;Binding;IC50;=;1071,00;5,97;-;8;Inhibition of dopamine D2 receptor;ChEMBL;470,2;7;2;3;5,24;Cc1[nH]c(-c2ccccc2)cc1C(=O)NCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.01.093
CHEMBL1086754;7452;None;0;Human;Binding;IC50;=;2542,00;5,59;-;8;Inhibition of dopamine D2 receptor;ChEMBL;484,2;7;1;4;5,25;Cc1c(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(-c2ccccc2)n1C;https://dx.doi.org/10.1016/j.bmcl.2010.01.093
CHEMBL1086756;7454;None;0;Human;Binding;IC50;=;3736,00;5,43;-;8;Inhibition of dopamine D2 receptor;ChEMBL;512,2;9;1;4;6,12;CCCn1c(-c2ccccc2)cc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1C;https://dx.doi.org/10.1016/j.bmcl.2010.01.093
CHEMBL1086789;7458;None;0;Human;Binding;Ki;=;1476,00;5,83;1;2;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in HEK293 cells by microplate scintillation counting;ChEMBL;274,1;0;1;1;3,67;c1ccc2c(c1)CCN1CCc3[nH]c4ccccc4c3C21;https://dx.doi.org/10.1021/jm901291r
CHEMBL1086790;7459;None;0;Human;Binding;Ki;=;4458,00;5,35;-2;3;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in HEK293 cells by microplate scintillation counting;ChEMBL;274,1;0;1;1;3,67;c1ccc2c(c1)CCN1CCc3cccc4[nH]cc(c34)C21;https://dx.doi.org/10.1021/jm901291r
CHEMBL108698;7477;None;0;Human;Binding;Ki;=;300,00;6,52;12;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;406,1;6;0;4;6,23;CC(=O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL1087300;7524;None;0;Human;Binding;Ki;=;4,00;8,40;-1;5;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in HEK293 cells by microplate scintillation counting;ChEMBL;290,2;0;1;1;3,79;CN1CCc2ccccc2Cc2c[nH]c3cccc(c23)CC1;https://dx.doi.org/10.1021/jm901291r
CHEMBL1087301;7525;None;0;Human;Binding;Ki;=;55,10;7,26;-5;5;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in HEK293 cells by microplate scintillation counting;ChEMBL;290,2;0;1;1;3,79;CN1CCc2ccccc2Cc2c([nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm901291r
CHEMBL1087452;7536;None;0;Human;Binding;Ki;=;8,60;8,07;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;408,2;5;2;6;2,21;O=C1CCc2ccc(OCCN3CCN(c4cccc5[nH]c(=O)oc45)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087452;7536;UNDEFINED;0;Human;Binding;pKi;=;8,60;8,07;-;1;-;PDSP KiDatabase;408,2;5;2;6;2,21;O=C1CCc2ccc(OCCN3CCN(c4cccc5[nH]c(=O)oc45)CC3)cc2N1;-
CHEMBL1087453;7537;None;0;Human;Binding;Ki;=;8,60;8,07;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;422,2;6;2;6;2,60;O=C1CCc2ccc(OCCCN3CCN(c4cccc5[nH]c(=O)oc45)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087453;7537;UNDEFINED;0;Human;Binding;pKi;=;8,60;8,07;-;1;-;PDSP KiDatabase;422,2;6;2;6;2,60;O=C1CCc2ccc(OCCCN3CCN(c4cccc5[nH]c(=O)oc45)CC3)cc2N1;-
CHEMBL1087454;7538;None;0;Human;Binding;Ki;=;8,30;8,08;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;436,2;7;2;6;2,99;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5[nH]c(=O)oc45)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087454;7538;UNDEFINED;0;Human;Binding;pKi;=;8,30;8,08;-;1;-;PDSP KiDatabase;436,2;7;2;6;2,99;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5[nH]c(=O)oc45)CC3)cc2N1;-
CHEMBL1087455;7539;None;0;Human;Binding;Ki;=;8,00;8,10;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;447,2;4;2;5;3,16;O=C1CCc2ccc(CC3CCN(C[C@@H]4COc5c(ccc6c5CC(=O)N6)O4)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087585;7554;None;0;Human;Binding;Ki;=;7,00;8,15;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;501,2;8;2;5;3,66;CS(=O)(=O)Nc1cc(OCCN2CC3CCC(C2)C3Cc2ccc3c(c2)NC(=O)CC3)ccc1F;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087585;7554;UNDEFINED;0;Human;Binding;pKi;=;7,00;8,15;-;1;-;PDSP KiDatabase;501,2;8;2;5;3,66;CS(=O)(=O)Nc1cc(OCCN2CC3CCC(C2)C3Cc2ccc3c(c2)NC(=O)CC3)ccc1F;-
CHEMBL1087743;7576;None;0;Human;Binding;Ki;=;19,00;7,72;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;475,2;8;2;5;3,42;CS(=O)(=O)Nc1cc(OCCN2CCC(Cc3ccc4c(c3)NC(=O)CC4)CC2)ccc1F;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087743;7576;UNDEFINED;0;Human;Binding;pKi;=;19,00;7,72;-;1;-;PDSP KiDatabase;475,2;8;2;5;3,42;CS(=O)(=O)Nc1cc(OCCN2CCC(Cc3ccc4c(c3)NC(=O)CC4)CC2)ccc1F;-
CHEMBL1087744;7577;None;0;Human;Binding;Ki;=;2,50;8,60;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;449,2;4;2;6;2,75;O=C1CCc2ccc(OC3CCN(C[C@@H]4COc5c(ccc6c5CC(=O)N6)O4)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087745;7578;None;0;Human;Binding;Ki;=;18,00;7,75;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;459,2;8;2;6;2,87;CS(=O)(=O)Nc1cccc(OCCN2CCC(Oc3ccc4c(c3)NC(=O)CC4)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087745;7578;UNDEFINED;0;Human;Binding;pKi;=;18,00;7,74;-;1;-;PDSP KiDatabase;459,2;8;2;6;2,87;CS(=O)(=O)Nc1cccc(OCCN2CCC(Oc3ccc4c(c3)NC(=O)CC4)CC2)c1;-
CHEMBL1087817;7585;None;0;Human;Binding;Ki;=;6,30;8,20;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;473,2;4;2;5;3,41;O=C1CCc2ccc(CC3C4CCC3CN(C[C@@H]3COc5c(ccc6c5CC(=O)N6)O3)C4)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087818;7586;None;0;Human;Binding;Ki;=;11,00;7,96;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;483,2;8;2;5;3,52;CS(=O)(=O)Nc1cccc(OCCN2CC3CCC(C2)C3Cc2ccc3c(c2)NC(=O)CC3)c1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087818;7586;UNDEFINED;0;Human;Binding;pKi;=;11,00;7,96;-;1;-;PDSP KiDatabase;483,2;8;2;5;3,52;CS(=O)(=O)Nc1cccc(OCCN2CC3CCC(C2)C3Cc2ccc3c(c2)NC(=O)CC3)c1;-
CHEMBL1087872;7591;None;0;Human;Binding;Ki;=;9,00;8,05;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;477,2;8;2;6;3,00;CS(=O)(=O)Nc1cc(OCCN2CCC(Oc3ccc4c(c3)NC(=O)CC4)CC2)ccc1F;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1087872;7591;UNDEFINED;0;Human;Binding;pKi;=;9,00;8,05;-;1;-;PDSP KiDatabase;477,2;8;2;6;3,00;CS(=O)(=O)Nc1cc(OCCN2CCC(Oc3ccc4c(c3)NC(=O)CC4)CC2)ccc1F;-
CHEMBL1088000;7610;None;0;Human;Binding;Ki;=;16,00;7,80;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;473,2;4;2;5;3,69;O=C1CCc2ccc(CC3CC4CCC(C3)N4C[C@@H]3COc4c(ccc5c4CC(=O)N5)O3)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL108856;7672;None;0;Human;Binding;Ki;=;96,00;7,02;-;1;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;446,1;6;0;6;6,39;Cc1nc(-c2ccc(CSc3nc4ccccc4n3Cc3ccc(Cl)cc3)cc2)no1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL1088560;7673;None;0;Human;Binding;Ki;=;9,00;8,05;-;1;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;457,2;8;2;5;3,28;CS(=O)(=O)Nc1cccc(OCCN2CCC(Cc3ccc4c(c3)NC(=O)CC4)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
CHEMBL1088560;7673;UNDEFINED;0;Human;Binding;pKi;=;9,00;8,05;-;1;-;PDSP KiDatabase;457,2;8;2;5;3,28;CS(=O)(=O)Nc1cccc(OCCN2CCC(Cc3ccc4c(c3)NC(=O)CC4)CC2)c1;-
CHEMBL108979;7851;None;0;Human;Binding;Ki;=;330,00;6,48;4;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;436,1;7;0;5;5,75;COC(=O)Cc1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL109063;7991;None;0;Human;Binding;EC50;=;0,50;9,30;-;5;In vivo Dopamine receptor D2 mitogenesis measured as [3H]thymidine incorporation in CHO p-5 cells expressing human D2 receptors;ChEMBL;303,2;3;1;3;3,19;Nc1ccc(C#CCCN2CC=C(c3ccccc3)CC2)cn1;https://dx.doi.org/10.1021/jm950721m
CHEMBL109101;8054;None;0;Human;Binding;EC50;=;1,30;8,89;-;5;In vivo Dopamine receptor D2 mitogenesis measured as [3H]thymidine incorporation in CHO p-5 cells expressing human D2 receptors;ChEMBL;303,2;3;1;3;3,19;Nc1ccc(C#CCCN2CC=C(c3ccccc3)CC2)nc1;https://dx.doi.org/10.1021/jm950721m
CHEMBL109173;8132;None;18;Human;Binding;Ki;=;1400,00;5,85;-7;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;268,2;4;0;3;3,14;O=Cc1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL109173;8132;None;18;Human;Binding;Ki;=;1500,00;5,82;-7;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;268,2;4;0;3;3,14;O=Cc1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL109179;8148;None;0;Human;Binding;Ki;=;3500,00;5,46;1;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;408,1;6;1;4;5,73;O=C(O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL109189;8166;None;0;Human;Binding;Ki;=;800,00;6,10;2;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;435,1;6;0;4;5,73;CN(C)C(=O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL109299;8353;None;0;Human;Binding;Ki;=;218,00;6,66;-4;3;Binding affinity at human dopamine receptor D2;ChEMBL;458,2;6;1;2;6,75;Fc1ccc(C(OC2CC3CCC(C2)N3Cc2cc3ccccc3[nH]2)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/jm010146o
CHEMBL109472;8580;None;0;Human;Binding;Ki;=;6400,00;5,19;-6;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;460,2;5;1;3;5,25;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(C#Cc2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL109472;8580;None;0;Human;Binding;Ki;=;4000,00;5,40;-6;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;460,2;5;1;3;5,25;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(C#Cc2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL109472;8580;None;0;Human;Binding;Ki;=;5500,00;5,26;-6;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;460,2;5;1;3;5,25;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(C#Cc2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL109472;8580;None;0;Human;Binding;Ki;=;7700,00;5,11;-6;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;460,2;5;1;3;5,25;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(C#Cc2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL109532;8655;None;0;Human;Binding;Ki;=;7,94;8,10;-10;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;426,2;9;1;4;5,07;CCN(Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1)[C@H](C)c1ccccc1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL109684;8825;None;12;Human;Binding;Kd;=;4,32;8,37;-5;4;Binding affinity to SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL109684;8825;None;12;Human;Binding;Ki;=;19,00;7,72;-5;4;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL109684;8825;None;12;Human;Binding;Ki;=;13,30;7,88;-5;4;Displacement of [3H] spiperone from human D2 dopamine receptor expressed in monkey caudate-putamen membranes;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmcl.2019.126644
CHEMBL109684;8825;None;12;Human;Binding;Ki;=;0,50;9,30;-5;4;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL109684;8825;None;12;Human;Binding;Ki;=;13,30;7,88;-5;4;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL109684;8825;125I-IODOSULPRIDE;12;Human;Binding;pKi;=;5,90;8,23;-5;4;-;PDSP KiDatabase;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)C1CCc2c(O)cccc2C1;-
CHEMBL109787;8939;None;0;Human;Binding;Ki;=;0,45;9,35;380;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;487,2;9;2;8;5,39;CCCN(CCc1ccc(Nc2ccc([N+](=O)[O-])c3nonc23)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL1098230;8986;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;-4365;13;-;PDSP KiDatabase;260,1;4;1;2;4,04;CC(C)(C)c1ccc(SCCc2c[nH]cn2)cc1;-
CHEMBL109897;9073;None;0;Human;Binding;Ki;=;4,80;8,32;54;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;713,3;8;5;8;8,21;CCCN(CCc1ccc(N/C(S)=N/c2ccc3c(c2)C(=O)OC32c3ccc(O)cc3Oc3cc(O)ccc32)cc1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL109912;9090;None;0;Human;Binding;Ki;=;8,00;8,10;-6;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;401,2;6;2;4;4,03;CNc1cc(OC)c(C(=O)N[C@H]2CCN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL109912;9090;None;0;Human;Binding;Ki;=;39,00;7,41;-6;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;401,2;6;2;4;4,03;CNc1cc(OC)c(C(=O)N[C@H]2CCN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL109912;9090;None;0;Human;Binding;Ki;=;54,00;7,27;-6;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;401,2;6;2;4;4,03;CNc1cc(OC)c(C(=O)N[C@H]2CCN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL109912;9090;None;0;Human;Binding;Ki;=;6,40;8,19;-6;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;401,2;6;2;4;4,03;CNc1cc(OC)c(C(=O)N[C@H]2CCN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL110063;9153;None;0;Human;Binding;Ki;=;5400,00;5,27;-3;2;Binding affinity against human recombinant dopamine receptor D2 in presence of 0.5% human serum albumin;ChEMBL;391,1;5;1;5;5,27;COC(=O)c1ccc(Nc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL110063;9153;None;0;Human;Binding;Ki;=;1500,00;5,82;-3;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;391,1;5;1;5;5,27;COC(=O)c1ccc(Nc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL110120;9162;None;0;Human;Binding;Ki;=;180,00;6,75;22;2;Binding affinity at human dopamine receptor D2;ChEMBL;389,2;5;1;4;3,70;OC1CCc2c(c3ccccc3n2CCCN2CCN(c3ccccc3)CC2)C1;https://dx.doi.org/10.1021/jm010146o
CHEMBL110239;9178;None;14;Human;Binding;Ki;=;265,00;6,58;-70;5;Tested for the inhibitory activity against Dopamine D2 receptor in infected Sf9 cells;ChEMBL;371,1;5;1;2;3,91;CCCN(C/C=C/I)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm00050a021
CHEMBL110239;9178;None;14;Human;Binding;Ki;=;6,60;8,18;-70;5;Tested for the inhibitory activity against D2H (high-affinity states) receptor in infected HEK 293 cells.;ChEMBL;371,1;5;1;2;3,91;CCCN(C/C=C/I)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm00050a021
CHEMBL110349;9194;None;0;Human;Binding;Ki;=;473,00;6,33;-1;3;Binding affinity at human dopamine receptor D2;ChEMBL;411,2;6;1;3;4,20;O=C(NCCCN1CCN(c2ccccc2)CC1)c1cccc2c1Cc1ccccc1-2;https://dx.doi.org/10.1021/jm010146o
CHEMBL110365;9197;None;0;Human;Binding;Ki;=;55,40;7,26;-138;6;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;455,3;8;1;4;4,60;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3c(c2)Cc2ccccc2-3)CC1;https://dx.doi.org/10.1021/jm0704200
CHEMBL110411;9204;None;0;Human;Binding;Ki;=;217,00;6,66;-154;2;Binding affinity at human dopamine receptor D2;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)-c1ccccc1C2;https://dx.doi.org/10.1021/jm010146o
CHEMBL110431;9207;None;0;Human;Binding;Ki;=;2600,00;5,58;-;1;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;432,1;5;0;3;7,05;FC(F)(F)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL110435;9208;None;0;Human;Binding;Ki;=;1120,00;5,95;2;2;Binding affinity at human dopamine receptor D2;ChEMBL;373,2;7;1;3;4,37;Fc1ccc(C(OCCOC2CC3CCC(C2)N3)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/jm010146o
CHEMBL110489;9214;None;0;Human;Binding;EC50;=;1,00;9,00;-;5;In vivo Dopamine receptor D2 mitogenesis measured as [3H]thymidine incorporation in CHO p-5 cells expressing human D2 receptors;ChEMBL;288,2;3;0;2;3,61;C(#Cc1ccncc1)CCN1CC=C(c2ccccc2)CC1;https://dx.doi.org/10.1021/jm950721m
CHEMBL11065;9231;None;0;Human;Binding;Ki;=;917,00;6,04;-1;2;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;231,2;2;1;2;2,59;CCCN1CC[C@H]2Cc3c(O)cccc3C[C@@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL11066;9235;None;0;Human;Binding;Ki;=;0,50;9,30;5;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;231,2;2;1;2;2,59;CCCN1CC[C@@H]2Cc3c(O)cccc3C[C@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL11066;9235;None;0;Human;Binding;Ki;=;2,40;8,62;5;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;231,2;2;1;2;2,59;CCCN1CC[C@@H]2Cc3c(O)cccc3C[C@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL110774;9259;None;0;Human;Binding;Ki;=;6700,00;5,17;-1;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;364,1;5;0;3;6,03;Clc1ccc(Cn2c(SCc3ccccc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL110793;9261;None;0;Human;Binding;Ki;=;15,85;7,80;-1;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;442,2;10;1;5;4,51;CCN(Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1)Cc1ccccc1OC;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL110888;9285;None;0;Human;Binding;Ki;=;17,10;7,77;-10;2;In vitro binding affinity is the ability to displace [3H]spiperone from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;247,2;5;1;3;2,64;CCCN(CCC)C1CCc2nc(N)ccc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL110888;9285;None;0;Human;Binding;Ki;=;5,00;8,30;-10;2;In vitro binding affinity is the ability to displace [3H]N-0437 from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;247,2;5;1;3;2,64;CCCN(CCC)C1CCc2nc(N)ccc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL111006;9311;None;0;Human;Binding;Ki;=;4200,00;5,38;-4;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;389,1;5;0;4;5,90;N#Cc1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL111054;9318;None;0;Human;Binding;Ki;=;67,00;7,17;-;1;Binding affinity against human recombinant dopamine receptor D2 in presence of 0.5% human serum albumin;ChEMBL;402,1;5;0;4;5,70;COC(=O)c1ccc(/C=C/c2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL111054;9318;None;0;Human;Binding;Ki;=;38,00;7,42;-;1;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;402,1;5;0;4;5,70;COC(=O)c1ccc(/C=C/c2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL111532;9399;None;8;Human;Binding;Ki;=;6,80;8,17;104;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;324,2;6;2;3;3,79;CCCN(CCc1ccc(N)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL111749;9442;None;0;Human;Binding;Ki;=;11,00;7,96;-8;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;6;2;4;3,64;CNc1cc(OC)c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL111749;9442;None;0;Human;Binding;Ki;=;19,00;7,72;-8;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;6;2;4;3,64;CNc1cc(OC)c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL111749;9442;None;0;Human;Binding;Ki;=;21,00;7,68;-8;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;6;2;4;3,64;CNc1cc(OC)c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL111749;9442;None;0;Human;Binding;Ki;=;15,00;7,82;-8;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;6;2;4;3,64;CNc1cc(OC)c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL111884;9464;None;0;Human;Binding;Ki;=;39,81;7,40;-3;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;438,2;7;1;4;5,38;CCN1[C@H](c2ccccc2)CC[C@H]1c1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL112065;9502;None;0;Human;Binding;Ki;=;42,00;7,38;-15;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins;ChEMBL;443,3;9;1;4;4,69;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm101639t
CHEMBL112065;9502;None;0;Human;Binding;Ki;=;48,00;7,32;-15;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;443,3;9;1;4;4,69;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm101639t
CHEMBL112065;9502;None;0;Human;Binding;Ki;=;75,00;7,12;-15;4;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;443,3;9;1;4;4,69;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL112219;9533;None;0;Human;Binding;Ki;=;25,12;7,60;-31;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;466,2;7;1;4;5,91;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3c3ccc(C)cc3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL112268;9542;None;0;Human;Binding;Ki;=;7,94;8,10;-5;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;426,2;9;1;4;4,81;CCN(Cc1cccc(C)c1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL112395;9571;None;0;Human;Binding;Ki;=;24,00;7,62;-2;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;6;2;4;3,79;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)CC2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112395;9571;None;0;Human;Binding;Ki;=;15,00;7,82;-2;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;6;2;4;3,79;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)CC2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112505;9592;None;0;Human;Binding;Ki;=;79,43;7,10;-10;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;442,2;10;1;5;4,51;CCN(Cc1cccc(OC)c1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL11262;9613;None;0;Human;Binding;IC50;=;2570,40;5,59;-;6;Binding affinity towards Dopamine receptor D2 by displacement of [3H]-Raclopride.;ChEMBL;277,2;7;0;3;3,37;CCCN(CCC)CC1COc2cccc(OC)c2C1;https://dx.doi.org/10.1016/0960-894X(96)00174-6
CHEMBL11265;9625;None;0;Human;Binding;IC50;=;1096,48;5,96;-;7;Compound was evaluated for the binding affinity towards Dopamine receptor D2 by displacement of [3H]SCH-23390.;ChEMBL;440,3;6;0;5;3,95;COc1cccc2c1CC1(CCCN1CCCCN1C(=O)CC3(CCCC3)CC1=O)CO2;https://dx.doi.org/10.1016/0960-894X(96)00174-6
CHEMBL112705;9638;None;0;Human;Binding;Ki;=;0,40;9,40;-1;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;426,2;9;1;4;4,81;CCN(Cc1ccc(C)cc1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL112735;9644;None;0;Human;Binding;Ki;=;2,00;8,70;-7;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;442,2;10;1;5;4,51;CCN(Cc1ccc(OC)cc1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL112831;9662;None;0;Human;Binding;Ki;=;7900,00;5,10;-8;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;373,2;5;2;4;3,33;COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112831;9662;None;0;Human;Binding;Ki;=;1600,00;5,80;-8;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;373,2;5;2;4;3,33;COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112831;9662;None;0;Human;Binding;Ki;=;1100,00;5,96;-8;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;373,2;5;2;4;3,33;COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112831;9662;None;0;Human;Binding;Ki;=;4200,00;5,38;-8;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;373,2;5;2;4;3,33;COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112833;9664;None;0;Human;Binding;Ki;=;500,00;6,30;-50;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;384,2;5;1;3;3,83;C#Cc1cc(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)c(OC)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112833;9664;None;0;Human;Binding;Ki;=;250,00;6,60;-50;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;384,2;5;1;3;3,83;C#Cc1cc(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)c(OC)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112833;9664;None;0;Human;Binding;Ki;=;190,00;6,72;-50;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;384,2;5;1;3;3,83;C#Cc1cc(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)c(OC)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL112833;9664;None;0;Human;Binding;Ki;=;82,00;7,09;-50;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;384,2;5;1;3;3,83;C#Cc1cc(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)c(OC)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL113196;9715;None;0;Human;Binding;Ki;=;0,30;9,52;426;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;487,2;9;2;8;5,39;CCCN(CCc1ccc(Nc2ccc([N+](=O)[O-])c3nonc23)cc1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL113229;9720;None;0;Human;Binding;Ki;=;3,16;8,50;-5;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;456,2;9;1;6;4,24;CCN(Cc1ccc2c(c1)OCO2)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL113471;9754;None;0;Human;Binding;Ki;=;2800,00;5,55;-4;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;466,1;7;1;3;5,25;COc1c(C(=O)NCC[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL113471;9754;None;0;Human;Binding;Ki;=;2500,00;5,60;-4;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;466,1;7;1;3;5,25;COc1c(C(=O)NCC[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL113471;9754;None;0;Human;Binding;Ki;=;1900,00;5,72;-4;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;466,1;7;1;3;5,25;COc1c(C(=O)NCC[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL113471;9754;None;0;Human;Binding;Ki;=;2000,00;5,70;-4;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;466,1;7;1;3;5,25;COc1c(C(=O)NCC[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL113523;9768;None;0;Human;Binding;Ki;=;6,31;8,20;-1;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;426,2;9;1;4;4,81;CCN(Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1)Cc1ccccc1C;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL113524;9769;None;0;Human;Binding;Ki;=;12,59;7,90;-2;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;452,2;8;1;4;5,38;CCN(Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1)C1CCCc2ccccc21;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL113527;9770;None;0;Human;Binding;Ki;=;3,20;8,49;1148;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;487,2;9;2;8;5,39;CCCN(CCc1ccc(Nc2ccc([N+](=O)[O-])c3nonc23)cc1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL113606;9783;None;0;Human;Binding;Ki;=;19,95;7,70;-3;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;446,1;9;1;4;5,16;CCN(Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1)Cc1ccccc1Cl;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL11363;9788;None;0;Human;Binding;Ki;=;235,00;6,63;1;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;229,1;2;1;2;2,37;C=CCN1CC[C@@H]2Cc3c(O)cccc3C[C@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL11363;9788;None;0;Human;Binding;Ki;=;0,30;9,52;1;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;229,1;2;1;2;2,37;C=CCN1CC[C@@H]2Cc3c(O)cccc3C[C@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL11386;9820;None;0;Human;Binding;Ki;=;464,00;6,33;-42;2;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;259,2;3;0;2;3,28;CCCN1[C@@H](C)C[C@@H]2Cc3cccc(OC)c3C[C@@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL11388;9823;None;0;Human;Binding;Ki;=;100,00;7,00;-3;4;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;245,2;3;0;2;2,89;CCCN1CC[C@@H]2Cc3c(cccc3OC)C[C@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL11388;9823;None;0;Human;Binding;Ki;=;75,00;7,12;-3;4;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;245,2;3;0;2;2,89;CCCN1CC[C@@H]2Cc3c(cccc3OC)C[C@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL113956;9830;None;0;Human;Binding;IC50;=;2890,00;5,54;-;16;Inhibition of human dopamine receptor D2;ChEMBL;521,3;11;1;3;5,85;CCOc1ccc(CCNC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1021/jm010878g
CHEMBL11425;9883;None;0;Human;Binding;IC50;=;67,61;7,17;-;5;Binding affinity towards Dopamine receptor D2 by displacement of [3H]-Raclopride.;ChEMBL;384,2;7;1;4;3,32;O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00174-6
CHEMBL114484;9932;None;0;Human;Binding;IC50;=;480,00;6,32;-;11;Inhibition of human dopamine receptor D2;ChEMBL;355,1;3;1;4;4,54;Cc1ccc(CN2CCC(n3c(O)nc4ccccc43)CC2)c(Cl)c1;https://dx.doi.org/10.1021/jm010878g
CHEMBL114510;9933;None;8;Human;Binding;Ki;=;501,19;6,30;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;204,2;3;0;2;2,22;CCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL114510;9933;None;8;Human;Binding;Ki;=;470,00;6,33;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;204,2;3;0;2;2,22;CCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL11493;10009;None;0;Human;Binding;Ki;=;68,10;7,17;-1;4;Displacement of [3H]N-methylspiperone from human D2R expressed in HEK293 cell membranes incubated for 1 hr by radioligand binding assay;ChEMBL;385,2;7;0;2;5,87;CCCCN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2;https://dx.doi.org/10.1021/acs.jmedchem.6b01373
CHEMBL115222;10051;None;0;Human;Binding;IC50;=;2120,00;5,67;-;6;Inhibition of human dopamine receptor D2;ChEMBL;470,2;5;1;6;2,46;CNC(=O)CN1CN(c2ccccc2)C2(CCN(Cc3cc4c(cc3Cl)OCO4)CC2)C1=O;https://dx.doi.org/10.1021/jm010878g
CHEMBL115280;10067;None;0;Human;Binding;IC50;=;538,00;6,27;-;9;Inhibition of human dopamine receptor D2;ChEMBL;413,2;5;1;4;4,41;O=C1NCN(c2ccccc2)C12CCN(Cc1cccc(Oc3ccccc3)c1)CC2;https://dx.doi.org/10.1021/jm010878g
CHEMBL115402;10086;None;0;Human;Binding;Ki;=;1000,00;6,00;-2;2;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;293,2;2;0;2;4,23;COc1cccc2c1-c1cccc3c1[C@@H](C2)N(C(C)C)CC3;https://dx.doi.org/10.1021/jm960189i
CHEMBL115524;10103;None;0;Human;Binding;Ki;=;2050,00;5,69;-223;3;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;279,2;1;1;2;3,71;CCc1ccc2c(c1O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL11592;10168;None;5;Human;Binding;IC50;=;10,00;8,00;-;12;Binding affinity towards Dopamine receptor D2 by displacement of [3H]-Raclopride.;ChEMBL;442,3;9;0;5;4,20;CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)C1COc2cccc(OC)c2C1;https://dx.doi.org/10.1016/0960-894X(96)00174-6
CHEMBL1159663;10179;None;0;Human;Binding;Ki;=;170,00;6,77;28;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;323,2;6;1;2;4,51;CCCN(CCc1ccc(C)cc1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL115969;10180;None;0;Human;Binding;Ki;=;183,00;6,74;-4;3;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;260,1;0;0;2;3,31;CN1CCc2cccc3c2[C@H]1Cc1cccc(C#N)c1-3;https://dx.doi.org/10.1021/jm960189i
CHEMBL1160787;10241;None;5;Human;Binding;Ki;=;8000,00;5,10;-263;3;Affinity towards Dopamine receptor D2;ChEMBL;289,1;1;3;3;3,03;Oc1cc2c(c(Cl)c1O)CCNC[C@@H]2c1ccccc1;https://dx.doi.org/10.1021/jm9800292
CHEMBL11615;10289;None;4;Human;Binding;Ki;=;416,00;6,38;-4;5;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;261,2;6;0;2;3,67;CCCN(CCC)C1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL116372;10437;None;0;Human;Binding;Ki;=;47,00;7,33;-1;3;in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]-0437 as radioligand.;ChEMBL;305,2;5;1;5;3,30;CCCN(CCC)C1COc2ccc3nc(N)sc3c2C1;https://dx.doi.org/10.1021/jm000087z
CHEMBL116372;10437;None;0;Human;Binding;Ki;=;5920,00;5,23;-1;3;in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]spiperone as radioligand.;ChEMBL;305,2;5;1;5;3,30;CCCN(CCC)C1COc2ccc3nc(N)sc3c2C1;https://dx.doi.org/10.1021/jm000087z
CHEMBL116448;10465;None;0;Human;Binding;Ki;=;794,33;6,10;-398;7;Binding affinity towards Dopamine receptor D2 (human cloned receptor) in CHO cells using [125I]iodosulpiride radioligand.;ChEMBL;414,1;5;0;3;3,72;CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(Br)c2)CC1;https://dx.doi.org/10.1021/jm991151j
CHEMBL116463;10469;None;0;Human;Binding;IC50;=;551,00;6,26;-;19;Inhibition of human dopamine receptor D2;ChEMBL;517,3;10;1;4;6,18;N#Cc1ccc(CCOC(=O)NC2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1021/jm010878g
CHEMBL1169904;10590;None;0;Human;Binding;Ki;=;4,20;8,38;60;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;370,1;4;2;3;4,31;COc1cccc2[nH]cc(CN3CCC(O)(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1170094;10612;None;0;Human;Binding;Ki;=;4,20;8,38;48;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;370,1;4;2;3;4,31;COc1ccc2[nH]cc(CN3CCC(O)(c4ccc(Cl)cc4)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1170095;10613;None;0;Human;Binding;Ki;=;2,30;8,64;83;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;414,1;4;2;3;4,42;COc1cccc2[nH]cc(CN3CCC(O)(c4ccc(Br)cc4)CC3)c12;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1170096;10614;None;8;Human;Binding;Ki;=;2,50;8,60;38;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;414,1;4;2;3;4,42;COc1ccc2[nH]cc(CN3CCC(O)(c4ccc(Br)cc4)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1170683;10686;None;4;Human;Binding;Ki;=;4,80;8,32;22;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;384,1;3;2;2;4,41;OC1(c2ccc(Br)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL117730;11058;None;0;Human;Binding;Ki;=;4710,00;5,33;-371;2;In vitro affinity at human cloned Dopamine receptor D2A by [3H]raclopride displacement.;ChEMBL;265,1;1;1;2;3,41;COc1c(C)ccc2c1-c1cccc3c1[C@@H](C2)NCC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL117841;11168;None;0;Human;Binding;Ki;=;551,00;6,26;-107;4;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;265,1;1;0;2;3,45;COc1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960189i
CHEMBL1179;11259;3H-YM 09151-2;43;Human;Binding;pKi;=;10000,00;5,00;-2344;8;-;PDSP KiDatabase;133,1;1;1;1;1,50;N[C@@H]1C[C@H]1c1ccccc1;-
CHEMBL1179312;11319;None;0;Human;Binding;Ki;=;10000,00;5,00;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;259,2;1;0;3;2,36;CN1CCC2(CC1)OC(C)(c1ccccc1)CC2=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1179502;11336;None;0;Human;Binding;Ki;=;543,00;6,26;-10;3;Binding affinity at cloned human D2 dopamine receptor in CHO cells using [3H]-YM 09151 as radioligand;ChEMBL;379,2;7;1;6;3,09;c1ccc(N2CCN(CCCCCNC3=Nc4ccccc4OC3)CC2)nc1;https://dx.doi.org/10.1016/S0960-894X(97)00442-3
CHEMBL1179503;11337;None;0;Human;Binding;Ki;=;2540,00;5,59;-134;3;Binding affinity at cloned human D2 dopamine receptor in CHO cells using [3H]-YM 09151 as radioligand;ChEMBL;380,2;7;1;7;2,48;c1cnc(N2CCN(CCCCCNC3=Nc4ccccc4OC3)CC2)nc1;https://dx.doi.org/10.1016/S0960-894X(97)00442-3
CHEMBL1179506;11339;None;0;Human;Binding;Ki;=;280,00;6,55;-93;2;Binding affinity at cloned human D2 dopamine receptor in CHO cells using [3H]-YM 09151 as radioligand;ChEMBL;380,2;6;1;6;2,92;COc1ccccc1N1CCN(CCCNC2=Nc3ccccc3OC2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00442-3
CHEMBL1180033;11391;None;0;Human;Binding;IC50;=;4900,00;5,31;-;1;Displacement of [3H]-spiperone from dopamine D2 receptor;ChEMBL;332,2;3;0;2;3,16;CN(C(=O)C#Cc1ccccc1)C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(01)80138-4
CHEMBL1180044;11394;None;0;Human;Binding;IC50;=;1500,00;5,82;-;1;Displacement of [3H]-spiperone from dopamine D2 receptor;ChEMBL;394,2;4;0;2;4,74;O=C(C#Cc1ccccc1)N(c1ccccc1)C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(01)80138-4
CHEMBL1180083;11403;None;0;Human;Binding;IC50;=;4100,00;5,39;-;1;Displacement of [3H]-spiperone from dopamine D2 receptor;ChEMBL;318,2;4;0;2;3,63;CN(CC#Cc1ccccc1)C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(01)80138-4
CHEMBL1180091;11406;None;0;Human;Binding;IC50;=;890,00;6,05;-;1;Displacement of [3H]-spiperone from dopamine D2 receptor;ChEMBL;380,2;5;0;2;5,21;C(#Cc1ccccc1)CN(c1ccccc1)C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(01)80138-4
CHEMBL1180095;11409;None;0;Human;Binding;IC50;=;2500,00;5,60;-;1;Displacement of [3H]-spiperone from dopamine D2 receptor;ChEMBL;318,2;3;1;2;2,82;O=C(C#Cc1ccccc1)NC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(01)80138-4
CHEMBL1180187;11418;None;1;Human;Binding;IC50;=;4700,00;5,33;-;1;Displacement of [3H]-spiperone from dopamine D2 receptor;ChEMBL;320,2;5;1;2;3,48;O=C(/C=C/c1ccccc1)NC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(01)80138-4
CHEMBL1180325;11444;None;0;Human;Binding;Ki;=;515,00;6,29;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;355,2;3;0;2;4,42;O=C1c2c(F)cc(F)cc2CCC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1180355;11457;None;0;Human;Binding;Ki;=;2192,00;5,66;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;373,2;2;0;2;5,12;O=C1c2ccccc2CCC12CCN(Cc1ccc(C(F)(F)F)cc1)CC2;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1180370;11465;None;0;Human;Binding;Ki;=;37,00;7,43;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;333,2;3;0;2;4,65;Cc1ccc(CN2CCC(C3CCc4ccccc4C3=O)CC2)cc1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1180407;11488;None;0;Human;Binding;Ki;=;47,00;7,33;-14;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;435,2;8;1;6;3,13;COc1ccccc1N1CCN(CCCCNC(=O)c2coc3ccccc3c2=O)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180412;11490;None;0;Human;Binding;Ki;=;128,00;6,89;-12;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;449,3;9;1;4;4,72;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(C(C)(C)C)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180430;11494;None;0;Human;Binding;Ki;=;13,54;7,87;-40;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;393,2;9;1;4;3,43;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccccc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180430;11494;None;0;Human;Binding;Ki;=;13,54;7,87;-40;2;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;393,2;9;1;4;3,43;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.09.142
CHEMBL1180434;11495;None;0;Human;Binding;Ki;=;630,00;6,20;1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;490,3;6;0;6;4,21;COc1ccccc1N1CCN(C2CC3CC(N4CCN(c5ccccc5OC)CC4)CC3C2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180436;11497;None;0;Human;Binding;Ki;=;28,40;7,55;26;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;465,2;7;1;4;5,10;COc1ccccc1N1CCN(Cc2ccccc2CNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180437;11498;None;0;Human;Binding;Ki;=;94,60;7,02;2;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;461,3;9;1;5;4,29;COc1ccc2cc([C@H](C)C(=O)NCCCN3CCN(c4ccccc4OC)CC3)ccc2c1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180439;11499;None;0;Human;Binding;Ki;=;114,00;6,94;-5;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;485,3;11;1;5;5,22;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2cccc(Oc3ccccc3)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180446;11501;None;0;Human;Binding;Ki;=;68,00;7,17;-7;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;493,1;8;1;4;3,63;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(I)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180454;11504;None;0;Human;Binding;Ki;=;44,00;7,36;2;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;417,2;8;1;4;3,72;COc1ccccc1N1CCN(CCCNC(=O)Cc2cccc3ccccc23)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180455;11505;None;0;Human;Binding;Ki;=;22,60;7,65;-51;2;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;427,2;9;1;4;4,08;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.09.142
CHEMBL1180455;11505;None;0;Human;Binding;Ki;=;22,60;7,65;-51;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;427,2;9;1;4;4,08;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180459;11506;None;0;Human;Binding;Ki;=;20,90;7,68;-2;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;418,2;8;1;5;3,58;COc1ccccc1N1CCN(CCCCNC(=O)c2nccc3ccccc23)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180460;11507;None;0;Human;Binding;Ki;=;63,00;7,20;-25;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;471,3;10;1;5;4,26;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(C(=O)c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180464;11511;None;0;Human;Binding;Ki;=;200,00;6,70;-31;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;467,2;9;1;5;4,94;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(Cl)cc3)o2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180466;11512;None;0;Human;Binding;Ki;=;56,00;7,25;-1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;469,3;9;1;4;4,88;COc1ccccc1N1CCN(CCCCNC(=O)C2(c3ccc(Cl)cc3)CCCC2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180467;11513;None;0;Human;Binding;Ki;=;81,00;7,09;-5;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;407,3;9;1;4;3,52;COc1ccccc1N1CCN(CCCCNC(=O)C2CC2c2ccccc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180482;11521;None;0;Human;Binding;Ki;=;15,00;7,82;-28;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;427,2;9;1;4;4,08;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccccc2Cl)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180489;11526;None;0;Human;Binding;Ki;=;45,00;7,35;2;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;465,2;7;1;4;5,10;COc1ccccc1N1CCN(Cc2cccc(CNC(=O)c3ccc4ccccc4c3)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180494;11531;None;0;Human;Binding;Ki;=;20,00;7,70;-43;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;427,2;9;1;4;4,08;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180495;11532;None;0;Human;Binding;Ki;=;38,50;7,42;-2;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;579,2;11;1;6;4,05;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2cc(I)c(OC)c(OC)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180499;11536;None;0;Human;Binding;Ki;=;56,00;7,25;2;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;417,2;8;1;4;3,72;COc1ccccc1N1CCN(CCCNC(=O)Cc2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180536;11553;None;0;Human;Binding;Ki;=;14,00;7,85;-19;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;438,2;10;1;6;3,33;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc([N+](=O)[O-])cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180538;11554;None;0;Human;Binding;Ki;=;330,00;6,48;-1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;419,2;8;0;5;3,05;COc1ccccc1N1CCN(CCCCN2C(=O)C=C(c3ccccc3)C2=O)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180540;11556;None;0;Human;Binding;Ki;=;235,00;6,63;1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;479,1;7;1;4;3,24;COc1ccccc1N1CCN(CCCNC(=O)c2cccc(I)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1180589;11571;None;0;Human;Binding;Ki;=;77,00;7,11;-3;5;Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.;ChEMBL;303,1;4;2;3;3,53;Oc1cc2c(cc1Cl)CC[C@@H](CNCc1ccccc1)O2;https://dx.doi.org/10.1021/jm9703653
CHEMBL1180604;11582;None;0;Human;Binding;Ki;=;4,30;8,37;-8;5;Compound was tested to inhibit Dopa accumulation in to Dopamine receptor D2 at 10 mg/kg, sc;ChEMBL;295,2;2;1;3;3,14;Oc1ccc2c(c1)OC(CN1CCc3ccccc3C1)CC2;https://dx.doi.org/10.1021/jm9703653
CHEMBL1180609;11587;None;0;Human;Binding;Ki;=;2,50;8,60;-12;5;Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.;ChEMBL;295,2;2;1;3;3,14;Oc1ccc2c(c1)O[C@@H](CN1CCc3ccccc3C1)CC2;https://dx.doi.org/10.1021/jm9703653
CHEMBL1180627;11601;None;0;Human;Binding;Ki;=;7,00;8,15;-6;5;Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.;ChEMBL;303,1;4;2;3;3,53;Oc1cc2c(cc1Cl)CC[C@H](CNCc1ccccc1)O2;https://dx.doi.org/10.1021/jm9703653
CHEMBL1180629;11603;None;0;Human;Binding;Ki;=;9,70;8,01;-7;5;Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)OC(CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm9703653
CHEMBL1180636;11609;None;0;Human;Binding;Ki;=;73,90;7,13;-74;5;Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.;ChEMBL;295,2;2;1;3;3,14;Oc1ccc2c(c1)O[C@H](CN1CCc3ccccc3C1)CC2;https://dx.doi.org/10.1021/jm9703653
CHEMBL1180675;11628;None;0;Human;Binding;Ki;=;228,00;6,64;-8;5;Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm9703653
CHEMBL1181665;11771;None;0;Human;Binding;Ki;=;1258,93;5,90;-25;12;Binding affinity towards human dopamine receptor D2 expressed in CHO cells using the radioligand [125I]iodosulpiride;ChEMBL;537,3;12;1;3;7,32;O=C(/C=C/c1ccccc1)N(Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)Cc1cccnc1;https://dx.doi.org/10.1016/j.bmcl.2005.06.024
CHEMBL1181680;11775;None;0;Human;Binding;Ki;=;794,33;6,10;-31;12;Binding affinity towards human dopamine receptor D2 expressed in CHO cells using the radioligand [125I]iodosulpiride;ChEMBL;517,3;13;1;3;6,29;CN(C)CCN(Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)C(=O)/C=C/c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2005.06.024
CHEMBL118254;11910;None;0;Human;Binding;Ki;=;79,20;7,10;-17;4;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;263,2;1;0;1;4,00;CCc1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960189i
CHEMBL1182728;11933;None;0;Human;Binding;Ki;=;126,00;6,90;1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;479,1;7;1;4;3,24;COc1ccccc1N1CCN(CCCNC(=O)c2ccccc2I)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1183657;12071;None;0;Human;Binding;Ki;=;2745,00;5,56;-14;2;Binding affinity at cloned human D2 dopamine receptor in CHO cells using [3H]-YM 09151 as radioligand;ChEMBL;364,2;6;1;5;3,30;c1ccc(N2CCN(CCCCNC3=Nc4ccccc4OC3)CC2)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00442-3
CHEMBL1183940;12101;None;0;Human;Binding;IC50;=;7100,00;5,15;-;1;Displacement of [3H]-spiperone from dopamine D2 receptor;ChEMBL;334,2;5;0;2;3,82;CN(C(=O)/C=C/c1ccccc1)C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(01)80138-4
CHEMBL1184179;12154;None;0;Human;Binding;Ki;=;5,20;8,28;-1;5;Binding affinity in humans to Dopamine receptor D2 expressed in CHO cells was determined using the agonist [3H]-spiperone.;ChEMBL;303,1;4;2;3;3,53;Oc1cc2c(cc1Cl)CCC(CNCc1ccccc1)O2;https://dx.doi.org/10.1021/jm9703653
CHEMBL1184186;12159;None;0;Human;Binding;Ki;=;21,00;7,68;-16;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;461,2;9;1;4;4,73;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(Cl)cc2Cl)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184196;12167;None;0;Human;Binding;Ki;=;9,50;8,02;-16;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;399,2;9;1;5;3,49;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2cccs2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184199;12169;None;0;Human;Binding;IC50;=;41,00;7,39;-;5;Compound is evaluated for in vitro receptor binding affinity against Dopamine receptor D2;ChEMBL;471,3;7;0;7;3,37;Cn1c(=O)c2c(ncn2CCCN2CCC(C(c3ccccc3)c3ccccc3)CC2)n(C)c1=O;https://dx.doi.org/10.1021/jm00020a018
CHEMBL1184210;12177;None;0;Human;Binding;Ki;=;11,50;7,94;-15;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;421,2;10;1;5;3,24;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(C=O)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184212;12178;None;0;Human;Binding;Ki;=;35,00;7,46;-1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;431,3;9;1;4;4,11;COc1ccccc1N1CCN(CCCCNC(=O)Cc2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184215;12180;None;0;Human;Binding;Ki;=;200,00;6,70;-5;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;465,2;7;1;4;5,10;COc1ccccc1N1CCN(Cc2ccc(CNC(=O)c3ccc4ccccc4c3)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184228;12184;None;0;Human;Binding;Ki;=;48,70;7,31;-10;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;395,3;10;1;4;3,35;COc1ccccc1N1CCN(CCCCNC(=O)CCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184233;12187;None;0;Human;Binding;Ki;=;178,00;6,75;-4;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;469,3;5;1;4;4,96;COc1ccccc1N1CCN(C2CC3CC(NC(=O)c4ccc5ccccc5c4)CC3C2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184251;12195;None;0;Human;Binding;Ki;=;23,70;7,62;-56;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;471,2;9;1;4;4,19;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(Br)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184254;12196;None;0;Human;Binding;Ki;=;10,00;8,00;-21;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;418,2;9;1;5;3,30;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(C#N)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184256;12198;None;0;Human;Binding;Ki;=;11,10;7,96;-18;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;383,2;9;1;5;3,02;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccco2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184257;12199;None;0;Human;Binding;Ki;=;103,00;6,99;3;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;613,4;8;1;7;5,35;COc1ccccc1N1CCN(C2CC3CC(NC4CC5CC(N6CCN(c7ccccc7OC)CC6)CC5C4)CC3C2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1184260;12201;None;0;Human;Binding;Ki;=;14,50;7,84;-28;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;394,2;9;1;5;2,82;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2cccnc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL11845;12245;None;7;Human;Binding;EC50;=;0,70;9,15;-;3;Tested for intrinsic activity towards Dopamine receptor D2 in CHO cells;ChEMBL;263,2;5;2;3;3,08;CCCN(CCC)C1CCc2c(ccc(O)c2O)C1;https://dx.doi.org/10.1021/jm0307786
CHEMBL1185415;12354;None;0;Human;Binding;Ki;=;2011,00;5,70;-112;3;Binding affinity at cloned human D2 dopamine receptor in CHO cells using [3H]-YM 09151 as radioligand;ChEMBL;350,2;5;1;5;2,91;c1ccc(N2CCN(CCCNC3=Nc4ccccc4OC3)CC2)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00442-3
CHEMBL1185449;12361;None;0;Human;Binding;Ki;=;50,20;7,30;-12;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;461,2;9;1;4;4,45;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1185556;12379;None;0;Human;Binding;Ki;=;23,00;7,64;-17;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;461,2;9;1;4;4,73;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(Cl)c(Cl)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL118636;12484;None;0;Human;Binding;Ki;=;500,00;6,30;-45;3;in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]NPA as radioligand.;ChEMBL;289,2;5;1;4;3,47;CCCN(CCC)C1Cc2ccc3nc(N)sc3c2C1;https://dx.doi.org/10.1021/jm000087z
CHEMBL118637;12485;None;0;Human;Binding;Ki;=;1350,00;5,87;-;1;in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]NPA as radioligand.;ChEMBL;247,1;3;2;4;2,35;CCCNC1Cc2cc3nc(N)sc3cc2C1;https://dx.doi.org/10.1021/jm000087z
CHEMBL1186652;12544;None;0;Human;Binding;Kd;=;776,25;6,11;-1348;8;Binding affinity to dopamine D2 receptor;ChEMBL;475,2;7;0;3;5,14;CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2-c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2009.01.072
CHEMBL1186967;12610;None;0;Human;Binding;Ki;=;210,00;6,68;-30;3;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;373,2;2;2;3;5,00;Cc1cccc(-c2c(O)c(O)cc3c2CCN(C)CC3c2cccc(C)c2)c1;https://dx.doi.org/10.1016/j.bmc.2008.09.049
CHEMBL1187177;12649;None;0;Human;Binding;Ki;=;41,69;7,38;-16;3;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;368,2;3;0;5;4,18;O=C1C[C@@H](CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2occc21;https://dx.doi.org/10.1021/jm800602w
CHEMBL118771;12733;None;0;Human;Binding;Ki;=;238,00;6,62;-22;2;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;307,2;3;0;2;4,54;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(C)c(OC)c1-3;https://dx.doi.org/10.1021/jm960188q
CHEMBL1187785;12744;None;0;Human;Binding;Ki;=;29,00;7,54;-5;3;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;409,2;2;2;3;5,85;Cc1cccc(C2CN(C)CCc3c2cc(O)c(O)c3-c2ccc3ccccc3c2)c1;https://dx.doi.org/10.1016/j.bmc.2008.09.049
CHEMBL1187842;12760;None;0;Human;Binding;Ki;=;15,85;7,80;-3;3;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;368,2;3;0;5;4,18;O=C1C[C@H](CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2occc21;https://dx.doi.org/10.1021/jm800602w
CHEMBL1188090;12797;None;1;Human;Binding;Ki;=;64,40;7,19;-7;8;Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells;ChEMBL;283,2;8;1;2;3,89;CCCN(CCc1ccccc1)CCc1cccc(O)c1;https://dx.doi.org/10.1021/jm301258w
CHEMBL1188714;12870;None;0;Human;Binding;Ki;=;189,80;6,72;1;2;Binding affinity for dopamine D2 receptor;ChEMBL;385,2;6;0;2;5,85;O=C(CCCN1C2CCC1CC(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.09.046
CHEMBL1189040;12915;None;0;Human;Binding;Ki;=;95,00;7,02;-5;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;450,2;10;0;7;4,79;CCOc1ccccc1N1CCN(CCCCc2cc(-c3cccc([N+](=O)[O-])c3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1189188;12937;None;0;Human;Binding;Ki;=;2110,00;5,68;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;353,1;3;0;3;4,32;O=C1C(c2ccccc2)=COC12CCN(Cc1cccc(Cl)c1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1189290;12951;None;2;Human;Binding;Ki;=;3366,00;5,47;-190;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;361,2;7;0;4;4,49;c1ccc(-c2cc(CCCCN3CCN(c4ccccc4)CC3)on2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1189407;12968;None;0;Human;Binding;Ki;=;119,00;6,92;-46;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;465,3;11;0;7;4,90;CCOc1ccccc1N1CCN(CCCCc2cc(-c3ccc(OC)c(OC)c3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1189437;12974;None;0;Human;Binding;Ki;=;2030,00;5,69;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;347,2;4;0;3;4,09;O=C1CC2(CCN(CCc3ccccc3)CC2)OC=C1c1ccccc1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1189537;12986;None;0;Human;Binding;Ki;=;1470,00;5,83;-24;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;406,2;8;0;6;4,39;O=[N+]([O-])c1cccc(-c2cc(CCCCN3CCN(c4ccccc4)CC3)on2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1189563;12989;None;0;Human;Binding;Ki;=;1530,00;5,82;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;367,2;4;0;3;3,98;O=C1CC2(CCN(CCc3ccccc3)CC2)OCC1c1ccc(F)cc1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1189601;12993;None;0;Human;Binding;Ki;=;82,00;7,09;-10;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;291,2;1;0;2;4,67;CN1CCC(C2=Cc3ccccc3Oc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL1189648;12997;None;0;Human;Binding;Ki;=;2530,00;5,60;-208;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;379,2;7;0;4;4,63;Fc1ccc(-c2cc(CCCCN3CCN(c4ccccc4)CC3)on2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1189696;13004;None;0;Human;Binding;Ki;=;600,00;6,22;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;333,2;4;0;2;4,39;O=C1c2ccccc2CCC1C1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1189802;13019;None;0;Human;Binding;Ki;=;152,00;6,82;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;393,2;6;0;4;4,26;O=C(CCCN1CCCC2(C1)OC(c1ccccc1)=CC2=O)c1ccc(F)cc1;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1189807;13020;None;0;Human;Binding;Ki;=;4200,00;5,38;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;347,2;4;0;3;4,09;O=C1C=C(c2ccccc2)OC2(CCN(CCc3ccccc3)CC2)C1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1189897;13035;None;0;Human;Binding;Ki;=;964,00;6,02;-63;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;417,2;9;0;5;5,00;COc1ccccc1N1CCN(CCCCc2cc(/C=C/c3ccccc3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1190010;13053;None;0;Human;Binding;Ki;=;1461,00;5,83;-48;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;469,3;9;0;4;6,21;Fc1ccc(-c2cc(CCCCN3CCN(C(c4ccccc4)c4ccccc4)CC3)on2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1190037;13056;None;0;Human;Binding;Ki;=;10000,00;5,00;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;231,1;4;0;3;1,95;CN(C)CCC1(c2ccccc2)OC=CC1=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1190042;13059;None;1;Human;Binding;Ki;=;10000,00;5,00;-758;5;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;320,2;4;1;4;2,23;c1ccc(C2=NC[C@H](CN3CCN(c4ccccc4)CC3)N2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL1190042;13059;None;1;Human;Binding;Ki;=;11000,00;4,96;-758;5;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;320,2;4;1;4;2,23;c1ccc(C2=NC[C@H](CN3CCN(c4ccccc4)CC3)N2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL1190042;13059;None;1;Human;Binding;Ki;=;14000,00;4,85;-758;5;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;320,2;4;1;4;2,23;c1ccc(C2=NC[C@H](CN3CCN(c4ccccc4)CC3)N2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL1190042;13059;None;1;Human;Binding;Ki;=;10000,00;5,00;-758;5;In vitro for its ability to displace [3H]- spiperone from cloned human Dopamine receptor D2L expressed in CHO cells;ChEMBL;320,2;4;1;4;2,23;c1ccc(C2=NC[C@H](CN3CCN(c4ccccc4)CC3)N2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL1190268;13092;None;0;Human;Binding;Ki;=;10000,00;5,00;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;273,2;6;0;3;3,12;CCN(CC)CCC1(C)OC=C(c2ccccc2)C1=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1190393;13112;None;0;Human;Binding;Ki;=;70,00;7,16;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;393,2;6;0;4;4,26;O=C(CCCN1CCC2(CC1)OC=C(c1ccccc1)C2=O)c1ccc(F)cc1;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1190494;13130;None;3;Human;Binding;Ki;=;418,00;6,38;-79;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;451,2;10;0;7;4,51;COc1ccc(-c2cc(CCCCN3CCN(c4ccccc4OC)CC3)on2)cc1OC;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1190522;13136;None;0;Human;Binding;Ki;=;10000,00;5,00;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;269,1;1;0;3;2,62;CN1C2CCC1CC1(C2)OC=C(c2ccccc2)C1=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1190607;13146;None;0;Human;Binding;Ki;=;295,00;6,53;-48;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;436,2;9;0;7;4,40;COc1ccccc1N1CCN(CCCCc2cc(-c3cccc([N+](=O)[O-])c3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1190732;13159;None;0;Human;Binding;Ki;=;486,00;6,31;-32;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;451,3;9;0;4;6,07;c1ccc(-c2cc(CCCCN3CCN(C(c4ccccc4)c4ccccc4)CC3)on2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1190761;13162;None;3;Human;Binding;Ki;=;2000,00;5,70;-23;2;The compound was evaluated for the binding affinity towards Dopamine receptor D2 at low affinity state.;ChEMBL;333;1;3;3;3,14;Oc1cc2c(c(Br)c1O)CCNCC2c1ccccc1;https://dx.doi.org/10.1021/jm00116a004
CHEMBL1190761;13162;None;3;Human;Binding;Ki;=;39,00;7,41;-23;2;The compound was evaluated for the binding affinity towards Dopamine receptor D2 at high affinity state.;ChEMBL;333;1;3;3;3,14;Oc1cc2c(c(Br)c1O)CCNCC2c1ccccc1;https://dx.doi.org/10.1021/jm00116a004
CHEMBL1190866;13170;None;0;Human;Binding;Ki;=;1401,00;5,85;-37;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;435,3;9;0;6;4,81;COc1ccc(-c2cc(CCCCN3CCN(c4ccccc4C)CC3)on2)cc1OC;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1190888;13176;None;0;Human;Binding;Ki;=;10000,00;5,00;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;229,1;1;1;3;1,75;O=C1C(c2ccccc2)=COC12CCNCC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1190896;13178;None;0;Human;Binding;Ki;=;94,00;7,03;-1;3;Binding affinity at cloned human D2 dopamine receptor in CHO cells using [3H]-YM 09151 as radioligand;ChEMBL;378,2;7;1;5;3,69;c1ccc(N2CCN(CCCCCNC3=Nc4ccccc4OC3)CC2)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00442-3
CHEMBL1190993;13189;None;0;Human;Binding;Ki;=;44,00;7,36;-6;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;301,2;2;0;1;4,78;CCN1CC=C(C2=Cc3ccccc3Cc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL1191103;13207;None;10;Human;Binding;Ki;=;77,00;7,11;-512;2;The compound was evaluated for the binding affinity towards dopamine receptor D2 at high affinity state.;ChEMBL;303,1;1;2;3;3,37;CN1CCc2c(cc(O)c(O)c2Cl)C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
CHEMBL1191103;13207;None;10;Human;Binding;Ki;=;2700,00;5,57;-512;2;The compound was evaluated for the binding affinity towards dopamine receptor D2 at low affinity state.;ChEMBL;303,1;1;2;3;3,37;CN1CCc2c(cc(O)c(O)c2Cl)C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
CHEMBL1191160;13217;None;0;Human;Binding;Ki;=;776,00;6,11;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;297,2;3;0;2;3,94;CC(C1CC1)N1CCC(C2CCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1191251;13229;None;0;Human;Binding;Ki;=;4136,00;5,38;-275;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;367,2;7;0;5;4,55;c1ccc(N2CCN(CCCCc3cc(-c4cccs4)no3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1191252;13230;None;0;Human;Binding;Ki;=;726,00;6,14;-154;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;397,2;8;0;6;4,56;COc1ccccc1N1CCN(CCCCc2cc(-c3cccs3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1191317;13236;None;0;Human;Binding;Ki;=;2420,00;5,62;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;337,1;3;0;3;3,80;O=C1C(c2ccccc2)=COC12CCN(Cc1ccc(F)cc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1191320;13238;None;1;Human;Binding;Ki;=;962,00;6,02;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;343,2;3;0;3;4,18;O=C1C(c2ccc(F)cc2)=COC12CCN(CC1CCCCC1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1191322;13239;None;0;Human;Binding;Ki;=;2330,00;5,63;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;365,2;4;0;3;4,23;O=C1CC2(CCN(CCc3ccccc3)CC2)OC=C1c1ccccc1F;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1191374;13246;None;0;Human;Binding;Ki;=;389,00;6,41;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;361,2;2;0;2;5,39;CC(C)(C)c1ccc(CN2CCC3(CCc4ccccc4C3=O)CC2)cc1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1191467;13261;None;0;Human;Binding;Ki;=;2618,00;5,58;-131;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;511,3;11;0;6;6,09;COc1ccc(-c2cc(CCCCN3CCN(C(c4ccccc4)c4ccccc4)CC3)on2)cc1OC;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1191469;13262;None;0;Human;Binding;Ki;=;2196,00;5,66;-138;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;421,2;9;0;6;4,50;COc1ccc(-c2cc(CCCCN3CCN(c4ccccc4)CC3)on2)c(OC)c1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL119150;13267;None;0;Human;Binding;Ki;=;582,00;6,24;1;3;In vitro affinity at human cloned Dopamine receptor D2A by [3H]raclopride displacement.;ChEMBL;331,2;2;0;3;4,71;COc1c(-c2ccco2)ccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL1191537;13269;None;0;Human;Binding;Ki;=;7600,00;5,12;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;337,2;4;0;4;3,69;O=C1C=C(c2ccco2)OC2(CCN(CCc3ccccc3)CC2)C1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL119154;13270;None;7;Human;Binding;Ki;=;826,00;6,08;-26;2;Displacement of [3H]-raclopride fromd human Dopamine receptor D2A expressed in LtK- cells;ChEMBL;293,2;3;0;2;4,23;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OC)c1-3;https://dx.doi.org/10.1021/jm960189i
CHEMBL1191591;13273;None;0;Human;Binding;Ki;=;1417,00;5,85;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;335,2;3;0;3;4,11;COc1ccc(CN2CCC3(CCc4ccccc4C3=O)CC2)cc1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1191675;13285;None;0;Human;Binding;Ki;=;341,00;6,47;-38;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;405,2;9;0;5;4,88;CCOc1ccccc1N1CCN(CCCCc2cc(-c3ccccc3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1191738;13290;None;0;Human;Binding;Ki;=;20000,00;4,70;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;305,1;3;0;3;3,27;O=C1C(c2ccccc2)=COC12CCN(Cc1ccccc1)C2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1191882;13308;None;0;Human;Binding;Ki;=;620,00;6,21;-11;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;457,2;9;0;5;6,13;c1ccc(C(c2ccccc2)N2CCN(CCCCc3cc(-c4cccs4)no3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1191883;13309;None;0;Human;Binding;Ki;=;491,00;6,31;-12;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;477,3;10;0;4;6,58;C(=C/c1cc(CCCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)on1)\c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1192000;13320;None;0;Human;Binding;Ki;=;1079,00;5,97;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;283,2;3;0;2;3,55;O=C1c2ccccc2CCC1C1CCN(CC2CC2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1192095;13331;None;0;Human;Binding;Ki;=;9724,00;5,01;-363;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;387,2;8;0;4;4,99;C(=C/c1cc(CCCCN2CCN(c3ccccc3)CC2)on1)\c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1192096;13332;None;0;Human;Binding;Ki;=;440,00;6,36;-67;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;451,2;10;0;7;4,51;COc1ccc(-c2cc(CCCCN3CCN(c4ccccc4OC)CC3)on2)c(OC)c1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1192157;13340;None;0;Human;Binding;Ki;=;3130,00;5,50;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;383,2;4;0;3;4,86;O=C1C(c2ccc3ccccc3c2)=COC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1192158;13341;None;0;Human;Binding;Ki;=;47,00;7,33;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;339,2;3;0;3;3,54;O=C1C(c2ccc(F)cc2)COC12CCN(Cc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1192158;13341;None;0;Human;Binding;Ki;=;47,00;7,33;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;339,2;3;0;3;3,54;O=C1C(c2ccc(F)cc2)COC12CCN(Cc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1192258;13352;None;0;Human;Binding;Ki;=;4408,00;5,36;-6;2;In vitro ability to inhibit [3H]spiperone binding to Dopamine receptor D2;ChEMBL;239,1;1;2;2;2,67;Oc1ccc2c(c1)C(c1ccccc1)CNCC2;https://dx.doi.org/10.1021/jm00079a008
CHEMBL1192259;13353;None;0;Human;Binding;Ki;=;629,00;6,20;-707;2;In vitro ability to inhibit [3H]spiperone binding to Dopamine receptor D2;ChEMBL;357,1;3;1;2;4,33;C=CCN1CCc2cc(Br)c(O)cc2C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00079a008
CHEMBL1192367;13362;None;0;Human;Binding;Ki;=;8400,00;5,08;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;363,2;5;0;4;3,71;COc1ccc(C2=CC(=O)C3(CCN(CCc4ccccc4)CC3)O2)cc1;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1192566;13385;None;0;Human;Binding;Ki;=;2900,00;5,54;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;365,2;4;0;3;4,23;O=C1CC2(CCN(CCc3ccccc3)CC2)OC=C1c1ccc(F)cc1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1192567;13386;None;0;Human;Binding;Ki;=;1080,00;5,97;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;353,1;4;0;4;4,16;O=C1CC2(CCN(CCc3ccccc3)CC2)OC=C1c1cccs1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1192620;13391;None;0;Human;Binding;Ki;=;202,00;6,70;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;351,2;4;0;2;4,53;O=C1c2cccc(F)c2CCC1C1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1192820;13420;None;0;Human;Binding;Ki;=;1969,00;5,71;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;350,2;3;0;4;4,01;O=C1c2ccccc2CCC12CCN(Cc1ccc([N+](=O)[O-])cc1)CC2;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1192902;13433;None;0;Human;Binding;Ki;=;321,00;6,49;-14;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;409,2;8;0;5;4,63;COc1ccccc1N1CCN(CCCCc2cc(-c3ccc(F)cc3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1193072;13455;None;0;Human;Binding;Ki;=;110,00;6,96;-2;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;315,2;3;0;2;5,15;C=CCN1CC=C(C2=Cc3ccccc3Oc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL1193100;13459;None;0;Human;Binding;Ki;=;2108,00;5,68;-12;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;381,2;7;0;5;4,86;Cc1ccccc1N1CCN(CCCCc2cc(-c3cccs3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1193170;13467;None;0;Human;Binding;Ki;=;1460,00;5,84;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;333,2;3;0;3;4,05;O=C1CC2(CCN(Cc3ccccc3)CC2)OC=C1c1ccccc1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1193225;13472;None;0;Human;Binding;Ki;=;1000,00;6,00;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;319,2;3;0;2;4,34;O=C1c2ccccc2CCC1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1193307;13490;None;0;Human;Binding;Ki;=;1727,00;5,76;-181;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;391,2;8;0;5;4,50;COc1ccccc1N1CCN(CCCCc2cc(-c3ccccc3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1193508;13507;None;0;Human;Binding;Ki;=;3828,00;5,42;-239;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;511,3;11;0;6;6,09;COc1ccc(-c2cc(CCCCN3CCN(C(c4ccccc4)c4ccccc4)CC3)on2)c(OC)c1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1193567;13514;None;0;Human;Binding;Ki;=;642,00;6,19;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;325,2;3;0;3;4,04;O=C1C(c2ccccc2)=COC12CCN(CC1CCCCC1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1193619;13521;None;0;Human;Binding;Ki;=;125,00;6,90;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;367,2;4;0;2;5,04;O=C1c2ccc(Cl)cc2CCC1C1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1193760;13541;None;0;Human;Binding;Ki;=;7180,00;5,14;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;333,2;4;0;3;3,70;O=C1C=C(c2ccccc2)OC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1193817;13547;None;0;Human;Binding;Ki;=;1137,00;5,94;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;323,2;2;0;2;4,24;O=C1c2ccccc2CCC12CCN(Cc1ccc(F)cc1)CC2;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1193819;13548;None;0;Human;Binding;Ki;=;61,00;7,21;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;337,2;3;0;2;4,48;O=C1c2ccccc2CCC1C1CCN(Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1193963;13570;None;0;Human;Binding;Ki;=;2690,00;5,57;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;307,2;5;0;3;3,47;CN(C)CCC1(c2ccccc2)OC=C(c2ccccc2)C1=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1194168;13605;None;0;Human;Binding;Ki;=;217,00;6,66;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;351,2;4;0;3;3,84;O=C1C(c2ccc(F)cc2)=COC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1194170;13607;None;0;Human;Binding;Ki;=;1656,00;5,78;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;355,1;3;0;3;3,94;O=C1C(c2ccc(F)cc2)=COC12CCN(Cc1ccc(F)cc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1194172;13608;None;0;Human;Binding;Ki;=;1496,00;5,83;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;377,2;5;0;4;4,10;COc1ccc(C2=COC3(CCN(CCc4ccccc4)CC3)CC2=O)cc1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1194374;13633;None;0;Human;Binding;Ki;=;577,00;6,24;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;387,2;3;0;2;5,36;O=C1c2ccccc2CCC1C1CCN(Cc2ccc(C(F)(F)F)cc2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1194466;13647;None;0;Human;Binding;Ki;=;2370,00;5,62;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;319,2;3;0;3;3,66;O=C1C(c2ccccc2)=COC12CCN(Cc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL119455;13657;None;0;Human;Binding;Ki;=;58,50;7,23;-11;6;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;251,1;0;1;2;3,14;CN1CCc2cccc3c2[C@H]1Cc1cccc(O)c1-3;https://dx.doi.org/10.1021/jm960189i
CHEMBL119455;13657;None;0;Human;Binding;Ki;=;58,50;7,23;-11;6;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;251,1;0;1;2;3,14;CN1CCc2cccc3c2[C@H]1Cc1cccc(O)c1-3;https://dx.doi.org/10.1021/jm960188q
CHEMBL119455;13657;None;0;Human;Binding;Ki;=;208,00;6,68;-11;6;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting;ChEMBL;251,1;0;1;2;3,14;CN1CCc2cccc3c2[C@H]1Cc1cccc(O)c1-3;https://dx.doi.org/10.1021/jm9015763
CHEMBL119455;13657;None;0;Human;Binding;Ki;=;58,50;7,23;-11;6;Ability to displace [3H]raclopride binding to cloned human Dopamine receptor D2A;ChEMBL;251,1;0;1;2;3,14;CN1CCc2cccc3c2[C@H]1Cc1cccc(O)c1-3;https://dx.doi.org/10.1021/jm00004a011
CHEMBL1194558;13659;None;0;Human;Binding;Ki;=;4100,00;5,39;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;245,1;3;0;3;2,34;CN(C)CC1(C)CC(=O)C(c2ccccc2)=CO1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1194672;13675;None;0;Human;Binding;Ki;=;32000,00;4,50;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;324,1;3;0;5;2,96;Cc1cc(CN2CCC3(CC2)OC=C(c2ccccc2)C3=O)on1;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1194793;13691;None;0;Human;Binding;Ki;=;25,00;7,60;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;379,2;5;0;3;4,70;O=C(CCCN1CCC2(CCc3ccccc3C2=O)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1194812;13693;None;0;Human;Binding;IC50;=;43,00;7,37;-;4;Compound is evaluated for in vitro receptor binding affinity against Dopamine receptor D2;ChEMBL;508,2;7;0;8;2,51;Cn1c(=O)c2c(ncn2CCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)n(C)c1=O;https://dx.doi.org/10.1021/jm00020a018
CHEMBL1194838;13697;None;0;Human;Binding;Ki;=;550,00;6,26;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;333,2;4;0;3;3,70;O=C1C(c2ccccc2)=COC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1194956;13713;None;0;Human;Binding;Ki;=;794,33;6,10;-63;4;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;398,2;7;2;3;4,01;N#Cc1ccc2c(c1)CN(CCCCNC(=O)/C=C/c1c[nH]c3ccccc13)CC2;https://dx.doi.org/10.1021/jm000090i
CHEMBL1194992;13719;None;0;Human;Binding;Ki;=;24000,00;4,62;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;267,1;2;0;3;2,10;C#CCN1CCC2(CC1)OC=C(c1ccccc1)C2=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1195032;13724;None;24;Human;Binding;Ki;=;5000,00;5,30;-10;3;Agonist activity at dopamine D2 receptor (unknown origin);ChEMBL;179,1;0;3;3;1,30;C[C@@H]1NCCc2cc(O)c(O)cc21;https://dx.doi.org/10.1021/np4009927
CHEMBL1195060;13733;None;0;Human;Binding;Ki;=;5320,00;5,27;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;351,2;4;0;3;3,84;O=C1C=C(c2ccc(F)cc2)OC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1195074;13735;None;0;Human;Binding;Ki;=;1522,00;5,82;-79;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;496,2;10;0;6;5,98;O=[N+]([O-])c1cccc(-c2cc(CCCCN3CCN(C(c4ccccc4)c4ccccc4)CC3)on2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1195115;13739;None;0;Human;Binding;Ki;=;8780,00;5,06;-;1;Binding affinity towards dopamine D2 receptor using radiolabeled ligand [3H]spiperone;ChEMBL;351,2;3;0;3;4,19;O=C1CC2(CCCN(Cc3ccccc3)C2)OC=C1c1ccc(F)cc1;https://dx.doi.org/10.1016/S0960-894X(01)80880-5
CHEMBL1195188;13746;None;0;Human;Binding;Ki;=;490,00;6,31;-1148;2;The compound was evaluated for the binding affinity towards dopamine receptor D2 at high affinity state.;ChEMBL;347,1;1;2;3;3,48;CN1CCc2c(cc(O)c(O)c2Br)C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
CHEMBL1195188;13746;None;0;Human;Binding;Ki;=;4000,00;5,40;-1148;2;The compound was evaluated for the binding affinity towards dopamine receptor D2 at low affinity state.;ChEMBL;347,1;1;2;3;3,48;CN1CCc2c(cc(O)c(O)c2Br)C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
CHEMBL1195194;13748;None;0;Human;Binding;Ki;=;585,00;6,23;-58;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;405,2;8;0;4;5,13;Fc1ccccc1N1CCN(CCCCc2cc(/C=C/c3ccccc3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1195292;13760;None;0;Human;Binding;Ki;=;50,00;7,30;4;4;In vitro binding affinity towards dopamine D2 receptor by using [3H]U-86170 as radioligand;ChEMBL;337,1;5;1;4;2,77;CCCN[C@@H]1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL1195367;13774;None;0;Human;Binding;Ki;=;1420,00;5,85;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;337,1;3;0;3;3,80;O=C1C(c2ccc(F)cc2)=COC12CCN(Cc1ccccc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1195388;13780;None;0;Human;Binding;Ki;=;1168,00;5,93;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;311,2;2;0;2;4,48;O=C1c2ccccc2CCC12CCN(CC1CCCCC1)CC2;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1195497;13793;None;0;Human;Binding;Ki;=;89,00;7,05;-7;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;287,2;1;0;1;4,39;CN1CC=C(C2=Cc3ccccc3Cc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL1195566;13802;None;0;Human;Binding;Ki;=;2189,00;5,66;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;319,2;3;0;2;4,14;O=C1c2ccccc2CCC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm00029a008
CHEMBL1195587;13805;None;0;Human;Binding;Ki;=;5148,00;5,29;-257;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;439,2;9;0;6;4,64;COc1ccc(-c2cc(CCCCN3CCN(c4ccccc4F)CC3)on2)cc1OC;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1195797;13835;None;0;Human;Binding;Ki;=;83,00;7,08;-1;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;313,2;3;0;1;4,95;C=CCN1CC=C(C2=Cc3ccccc3Cc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL119593;13861;None;0;Human;Binding;Ki;=;249,00;6,60;-20;4;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;293,2;2;1;2;4,23;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(C)c(O)c1-3;https://dx.doi.org/10.1021/jm960188q
CHEMBL1195933;13862;None;0;Human;Binding;Ki;=;4870,00;5,31;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;269,1;3;0;3;2,65;C=CCN1CCC2(CC1)OC=C(c1ccccc1)C2=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1196094;13886;None;0;Human;Binding;Ki;=;2600,00;5,58;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;261,1;1;0;3;2,23;CN1CCC2(CC1)OC=C(c1ccc(F)cc1)C2=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1196171;13896;None;0;Human;Binding;Ki;=;2070,00;5,68;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;363,2;5;0;4;3,71;COc1ccc(C2=COC3(CCN(CCc4ccccc4)CC3)C2=O)cc1;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1196200;13898;None;0;Human;Binding;Ki;=;2900,00;5,54;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;243,1;1;0;3;2,09;CN1CCC2(CC1)OC(c1ccccc1)=CC2=O;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1196414;13925;None;0;Human;Binding;Ki;=;153,00;6,82;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;339,1;4;0;4;3,77;O=C1C(c2ccccc2)=COC12CCN(CCc1ccsc1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1196433;13928;None;0;Human;Binding;Ki;=;61,00;7,21;-4;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;303,2;2;0;2;4,99;CCN1CC=C(C2=Cc3ccccc3Oc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL119656;13942;None;0;Human;Binding;Ki;=;177,00;6,75;-29;3;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;261,2;1;0;1;4,08;C=Cc1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960189i
CHEMBL1196566;13943;None;0;Human;Binding;Ki;=;3388,00;5,47;-141;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;421,2;9;0;6;4,50;COc1ccc(-c2cc(CCCCN3CCN(c4ccccc4)CC3)on2)cc1OC;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1196674;13960;None;0;Human;Binding;Ki;=;5760,00;5,24;-1412;2;In vitro ability to inhibit [3H]spiperone binding to Dopamine receptor D2;ChEMBL;317;1;2;2;3,43;Oc1cc2c(cc1Br)CCNCC2c1ccccc1;https://dx.doi.org/10.1021/jm00079a008
CHEMBL1196692;13964;None;0;Human;Binding;Ki;=;194,00;6,71;-50;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;411,2;9;0;6;4,95;CCOc1ccccc1N1CCN(CCCCc2cc(-c3cccs3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1196753;13972;None;0;Human;Binding;Ki;=;6512,00;5,19;-22;3;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;375,2;7;0;4;4,79;Cc1ccccc1N1CCN(CCCCc2cc(-c3ccccc3)no2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
CHEMBL1197025;14005;None;0;Human;Binding;Ki;=;7630,00;5,12;-;1;Binding affinity for dopamine receptor D2 in guinea pig striatal membrane using radiolabeled ligand [3H]spiperone;ChEMBL;309,1;3;0;4;3,25;O=C1C(c2ccccc2)=COC12CCN(Cc1ccco1)CC2;https://dx.doi.org/10.1016/S0960-894X(01)80879-9
CHEMBL1198948;14221;None;2;Human;Binding;Kd;=;741,31;6,13;-151;11;Binding affinity to dopamine D2 receptor;ChEMBL;526,3;7;0;5;4,63;COc1ccc(C[C@H](C)CN2C[C@@H](C(=O)N3CCN(c4ccc(F)c(F)c4)CC3)[C@H]3CCCC[C@H]3C2)cn1;https://dx.doi.org/10.1016/j.bmcl.2010.01.063
CHEMBL119900;14223;None;0;Human;Binding;Ki;=;403,00;6,39;8;2;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;441,1;5;0;5;4,46;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(OS(=O)(=O)C(F)(F)F)c(OC)c1-3;https://dx.doi.org/10.1021/jm960188q
CHEMBL1199909;14313;None;2;Human;Binding;Ki;=;71,40;7,15;-1;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;391,2;3;0;4;4,17;CN1CN(c2ccccc2)C2(CCN(Cc3csc4ccccc34)CC2)C1=O;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1199932;14314;None;0;Human;Binding;Ki;=;37,80;7,42;1;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;363,1;3;1;4;4,38;O=c1[nH]c2ccccc2n1C1CCN(Cc2csc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1199933;14315;None;0;Human;Binding;Ki;=;7,10;8,15;-3;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;375,2;3;0;4;3,70;CN1CN(c2ccccc2)C2(CCN(Cc3coc4ccccc34)CC2)C1=O;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1199947;14320;None;0;Human;Binding;Ki;=;8,00;8,10;1;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;407,2;5;0;4;4,04;O=C1N(CCF)CN(c2ccccc2)C12CCN(Cc1coc3ccccc13)CC2;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1199971;14325;None;0;Human;Binding;Ki;=;14,30;7,84;3;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;433,1;3;1;3;4,52;OC1(c2ccc(I)cc2)CCN(Cc2cc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200020;14338;None;0;Human;Binding;Ki;=;212,00;6,67;2;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;385,1;3;2;3;3,81;OC1(c2ccc(Br)cc2)CCN(Cc2c[nH]c3ncccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200077;14349;None;0;Human;Binding;Ki;=;2,40;8,62;4;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;433,1;3;1;3;4,52;OC1(c2ccc(I)cc2)CCN(Cc2coc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200106;14356;None;0;Human;Binding;Ki;=;2,00;8,70;-2;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;488,2;7;0;7;3,83;O=C1N(Cc2cn(CCF)nn2)CN(c2ccccc2)C12CCN(Cc1coc3ccccc13)CC2;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200149;14361;None;0;Human;Binding;Ki;=;61,00;7,21;10;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;433,1;3;2;3;3,65;OC1(c2ccc(I)cc2)CCN(Cc2c[nH]c3ncccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200150;14363;None;0;Human;Binding;Ki;=;254,00;6,59;3;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;353,2;4;2;4;3,77;CSc1ccc(C2(O)CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200151;14364;None;0;Human;Binding;Ki;=;17,30;7,76;1;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;385,1;3;1;3;4,68;OC1(c2ccc(Br)cc2)CCN(Cc2cc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200152;14365;None;0;Human;Binding;Ki;=;46,80;7,33;3;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;323,1;3;1;3;4,38;OC1(c2ccccc2)CCN(Cc2cc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200153;14366;None;0;Human;Binding;Ki;=;6,60;8,18;1;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;385,1;3;1;3;4,68;OC1(c2ccc(Br)cc2)CCN(Cc2coc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200154;14367;None;0;Human;Binding;Ki;=;13,60;7,87;-4;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;347,2;3;1;4;3,91;O=c1[nH]c2ccccc2n1C1CCN(Cc2coc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200269;14396;None;0;Human;Binding;Ki;=;3,80;8,42;14;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;432,1;3;2;2;4,26;OC1(c2ccc(I)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200270;14397;None;0;Human;Binding;Ki;=;0,90;9,05;67;3;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;462,1;4;2;3;4,26;COc1cccc2[nH]cc(CN3CCC(O)(c4ccc(I)cc4)CC3)c12;https://dx.doi.org/10.1021/jm500126s
CHEMBL1200270;14397;None;0;Human;Binding;Ki;=;0,90;9,05;67;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;462,1;4;2;3;4,26;COc1cccc2[nH]cc(CN3CCC(O)(c4ccc(I)cc4)CC3)c12;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200271;14398;None;0;Human;Binding;Ki;=;0,90;9,05;112;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;462,1;4;2;3;4,26;COc1ccc2[nH]cc(CN3CCC(O)(c4ccc(I)cc4)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200277;14399;None;0;Human;Binding;Ki;=;1396,00;5,86;2;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;336,2;4;2;3;3,66;COc1ccc2[nH]cc(CN3CCC(O)(c4ccccc4)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200278;14400;None;0;Human;Binding;Ki;=;13,80;7,86;13;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;446,1;6;2;3;4,76;OC1(c2ccc(Br)cc2)CCN(Cc2c[nH]c3ccc(OCCF)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200285;14403;None;0;Human;Binding;Ki;=;23,30;7,63;5;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;376,2;4;2;4;3,66;COc1cccc2[nH]cc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)c12;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200302;14411;None;0;Human;Binding;Ki;=;27,70;7,56;24;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;446,1;6;2;3;4,76;OC1(c2ccc(Br)cc2)CCN(Cc2c[nH]c3cccc(OCCF)c23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL1200306;14414;None;0;Human;Binding;Ki;=;12,50;7,90;5;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;376,2;4;2;4;3,66;COc1ccc2[nH]cc(CN3CCC(n4c(=O)[nH]c5ccccc54)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
CHEMBL12004;14420;None;0;Human;Binding;Ki;=;379,00;6,42;-3;4;Binding affinity at human dopamine receptor D2;ChEMBL;469,2;6;0;2;7,42;Fc1ccc(C(OC2CC3CCC(C2)N3Cc2cccc3ccccc23)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/jm010146o
CHEMBL1201343;14507;None;0;Human;Binding;Ki;=;3,90;8,41;-7;2;Binding affinity to human dopamine D2 receptor;ChEMBL;213,1;3;2;4;1,34;CCCN[C@H]1CCC2N=C(N)SC2C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL120590;14695;None;0;Human;Binding;Ki;=;16,00;7,80;-2;3;Compound was measured for the binding affinity in homogenated mouse fibroblast (LTK) cells transfected with human Dopamine receptor D2A using [3H]raclopride as radioligand.;ChEMBL;364,2;6;0;5;3,38;O=c1ccc2ccc(OCCCN3CCN(c4ccccc4)CC3)cc2o1;https://dx.doi.org/10.1016/s0960-894x(98)00646-5
CHEMBL120661;14783;None;0;Human;Binding;Ki;=;5,92;8,23;-1;3;Compound was measured for the binding affinity in homogenated mouse fibroblast (LTK) cells transfected with human Dopamine receptor D2A using [3H]raclopride as radioligand.;ChEMBL;392,2;6;0;5;4,00;Cc1c(C)c2ccc(OCCCN3CCN(c4ccccc4)CC3)cc2oc1=O;https://dx.doi.org/10.1016/s0960-894x(98)00646-5
CHEMBL120927;15038;None;0;Human;Binding;Ki;=;1330,00;5,88;-48;3;In vitro binding affinity towards cloned human Dopamine receptor D2A using [3H]- Raclopride as radioligand.;ChEMBL;260,1;0;0;2;3,47;CN1CCc2ccc3cnc4cccc5c4c3c2[C@H]1C5;https://dx.doi.org/10.1016/s0960-894x(00)00655-7
CHEMBL1214830;15416;None;0;Human;Binding;Ki;=;2700,00;5,57;-177;3;Binding affinity to dopamine D2;ChEMBL;336,2;5;0;4;3,76;COc1ccc(CN2CCN(Cc3cc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1214831;15417;None;0;Human;Binding;Ki;=;4868,00;5,31;-18;3;Binding affinity to dopamine D2;ChEMBL;350,2;6;0;4;4,15;CCOc1ccc(CN2CCN(Cc3cc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1214894;15426;None;0;Human;Binding;Ki;=;5728,00;5,24;-204;3;Binding affinity to dopamine D2;ChEMBL;336,2;5;0;4;3,76;COc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1214895;15427;None;0;Human;Binding;Ki;=;4542,00;5,34;-15;3;Binding affinity to dopamine D2;ChEMBL;350,2;6;0;4;4,15;CCOc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1214958;15435;None;0;Human;Binding;Ki;=;2281,00;5,64;-9;3;Binding affinity to dopamine D2;ChEMBL;368,2;7;0;4;4,10;FCCOc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1214959;15436;None;0;Human;Binding;Ki;=;2977,00;5,53;-11;3;Binding affinity to dopamine D2;ChEMBL;364,2;7;0;4;4,54;CCCOc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1214960;15437;None;0;Human;Binding;Ki;=;2920,00;5,54;-15;3;Binding affinity to dopamine D2;ChEMBL;382,2;8;0;4;4,49;FCCCOc1cccc(CN2CCN(Cc3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1214961;15438;None;0;Human;Binding;Ki;=;5122,00;5,29;-524;3;Binding affinity to dopamine D2;ChEMBL;336,2;5;0;4;3,76;COc1ccccc1CN1CCN(Cc2cc3ccccc3o2)CC1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1214962;15439;None;0;Human;Binding;Ki;=;6005,00;5,22;-83;3;Binding affinity to dopamine D2;ChEMBL;350,2;6;0;4;4,15;CCOc1ccccc1CN1CCN(Cc2cc3ccccc3o2)CC1;https://dx.doi.org/10.1021/jm100639f
CHEMBL1221498;15610;None;1;Human;Binding;Ki;=;890,00;6,05;-524;4;Displacement of [3H]spiperone from human D2L receptor after 60 mins;ChEMBL;389,2;6;1;4;3,40;COc1ccccc1N1CCN(CCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.002
CHEMBL1221512;15618;None;4;Human;Binding;IC50;=;157,00;6,80;-5;8;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;559,3;18;4;9;1,75;CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS;-
CHEMBL1221512;15618;None;4;Human;Binding;Ki;=;52,00;7,28;-5;8;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;559,3;18;4;9;1,75;CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS;-
CHEMBL1221545;15624;None;0;Human;Binding;Ki;=;46,50;7,33;-11;4;Displacement of [3H]spiperone from human D2L receptor after 60 mins;ChEMBL;453,2;9;1;5;3,73;COc1ccccc1N1CCN(CCCCNS(=O)(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.002
CHEMBL1221591;15632;None;0;Human;Binding;Ki;=;254,00;6,59;-27;4;Displacement of [3H]spiperone from human D2L receptor after 60 mins;ChEMBL;431,3;9;1;4;4,57;COc1ccccc1N1CCN(CCCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.002
CHEMBL1221592;15633;None;0;Human;Binding;Ki;=;438,00;6,36;-51;4;Displacement of [3H]spiperone from human D2L receptor after 60 mins;ChEMBL;467,2;10;1;5;4,12;COc1ccccc1N1CCN(CCCCCNS(=O)(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.002
CHEMBL1221593;15634;None;0;Human;Binding;Ki;=;121,00;6,92;-19;4;Displacement of [3H]spiperone from human D2L receptor after 60 mins;ChEMBL;445,3;10;1;4;4,96;COc1ccccc1N1CCN(CCCCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.002
CHEMBL1221594;15635;None;0;Human;Binding;Ki;=;99,00;7,00;-34;3;Displacement of [3H]spiperone from human D2L receptor after 60 mins;ChEMBL;481,2;11;1;5;4,51;COc1ccccc1N1CCN(CCCCCCNS(=O)(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.002
CHEMBL1223615;16027;None;0;Human;Binding;Ki;=;0,80;9,10;28;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;340,2;8;1;5;3,10;COc1ccccc1N1CCN(CCCCNc2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223616;16028;None;0;Human;Binding;Ki;=;0,40;9,40;63;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;378,1;7;1;4;4,40;Clc1cccc(N2CCN(CCCCNc3ccccn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223617;16029;None;0;Human;Binding;Ki;=;17,00;7,77;11;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;378,2;7;1;4;4,12;FC(F)(F)c1cccc(N2CCN(CCCCNc3ccccn3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223680;16040;None;0;Human;Binding;Ki;=;11,00;7,96;1;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;328,2;7;1;4;3,23;Fc1ccccc1N1CCN(CCCCNc2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223681;16041;None;0;Human;Binding;Ki;=;32,00;7,50;-2;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;324,2;7;1;4;3,40;Cc1ccccc1N1CCN(CCCCNc2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223682;16042;None;0;Human;Binding;Ki;=;12,00;7,92;3;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;338,2;7;1;4;3,71;Cc1cccc(N2CCN(CCCCNc3ccccn3)CC2)c1C;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223683;16043;None;0;Human;Binding;Ki;=;0,60;9,22;6;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;428,2;7;1;4;5,56;Clc1cccc(N2CCN(CCCCNc3ccc4ccccc4n3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223747;16057;None;0;Human;Binding;Ki;=;1,60;8,80;7;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;428,2;7;1;4;5,27;FC(F)(F)c1cccc(N2CCN(CCCCNc3ccc4ccccc4n3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223748;16058;None;0;Human;Binding;Ki;=;1,00;9,00;6;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;390,2;8;1;5;4,26;COc1ccccc1N1CCN(CCCCNc2nccc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223749;16059;None;0;Human;Binding;Ki;=;3,10;8,51;1;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;428,2;7;1;4;5,56;Clc1cccc(N2CCN(CCCCNc3nccc4ccccc34)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223750;16060;None;0;Human;Binding;Ki;=;1,00;9,00;5;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;428,2;7;1;4;5,27;FC(F)(F)c1cccc(N2CCN(CCCCNc3nccc4ccccc34)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223799;16079;None;0;Human;Binding;Ki;=;2,50;8,60;3;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;404,2;8;1;4;4,90;Fc1ccccc1N1CCN(CCCCNc2ccc(-c3ccccc3)cn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223800;16081;None;0;Human;Binding;Ki;=;0,59;9,23;35;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;454,2;8;1;4;6,07;Clc1cccc(N2CCN(CCCCNc3ccc(-c4ccccc4)cn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223801;16082;None;0;Human;Binding;Ki;=;1,10;8,96;131;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;454,2;8;1;4;5,78;FC(F)(F)c1cccc(N2CCN(CCCCNc3ccc(-c4ccccc4)cn3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223802;16083;None;0;Human;Binding;Ki;=;1,50;8,82;5;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;404,2;8;1;4;4,90;Fc1ccccc1N1CCN(CCCCNc2cc(-c3ccccc3)ccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223856;16105;None;0;Human;Binding;Ki;=;0,55;9,26;104;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;454,2;8;1;4;6,07;Clc1cccc(N2CCN(CCCCNc3cc(-c4ccccc4)ccn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223857;16106;None;0;Human;Binding;Ki;=;0,76;9,12;158;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;454,2;8;1;4;5,78;FC(F)(F)c1cccc(N2CCN(CCCCNc3cc(-c4ccccc4)ccn3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223858;16107;None;0;Human;Binding;Ki;=;9,60;8,02;28;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;444,2;8;1;5;5,38;FC(F)(F)c1cccc(N2CCN(CCCCNc3ncc(-c4ccccc4)o3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1223859;16108;None;0;Human;Binding;Ki;=;13,00;7,89;5;3;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;460,2;8;1;5;5,84;FC(F)(F)c1cccc(N2CCN(CCCCNc3nc(-c4ccccc4)cs3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL1224527;16264;None;0;Human;Binding;Ki;=;230,00;6,64;-1;7;Displacement of [3H]-N-methylspiperone from human dopamine D2long receptor expressed in HEK293 cells after 30 mins by scintillation counting;ChEMBL;295,2;1;3;3;3,13;Oc1ccc2c(c1O)C[C@@H](c1ccccc1)[C@@H]1CCNC[C@@H]21;https://dx.doi.org/10.1016/j.bmc.2012.08.058
CHEMBL122453;16266;None;0;Human;Binding;Ki;=;327,00;6,49;-9;3;In vitro binding affinity towards cloned human Dopamine receptor D2A using [3H]- Raclopride as radioligand.;ChEMBL;260,1;0;0;2;3,47;CN1CCc2ccc3ncc4cccc5c4c3c2[C@H]1C5;https://dx.doi.org/10.1016/s0960-894x(00)00655-7
CHEMBL122485;16299;None;0;Human;Binding;Ki;=;541,00;6,27;-1;4;In vitro binding affinity towards cloned human Dopamine receptor D2A using [3H]- Raclopride as radioligand.;ChEMBL;277,1;0;0;3;3,03;CN1CCc2ccc3c(=O)oc4cccc5c4c3c2[C@H]1C5;https://dx.doi.org/10.1016/s0960-894x(00)00655-7
CHEMBL122533;16309;None;0;Human;Binding;Ki;=;0,25;9,60;-6;2;Binding affinity towards dopamine D2 receptor;ChEMBL;413,2;5;2;4;4,25;COc1cc(N)c(Cl)cc1C(=O)NC1CC2CCCC(C1)N2Cc1ccccc1;https://dx.doi.org/10.1016/0960-894X(94)00453-M
CHEMBL122538;16311;None;0;Human;Binding;Ki;=;62,00;7,21;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;337,2;3;0;2;4,48;O=C1c2ccc(F)cc2CCC1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL122761;16333;None;0;Human;Binding;Ki;=;1100,00;5,96;-69;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;353,2;3;0;2;4,79;O=C1c2ccc(Cl)cc2CCC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm011030v
CHEMBL123014;16397;None;0;Human;Binding;Ki;=;540,00;6,27;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;349,2;4;0;3;4,35;COc1ccc2c(c1)CCC(C1CCN(Cc3ccccc3)CC1)C2=O;https://dx.doi.org/10.1021/jm00029a008
CHEMBL12375;16557;None;0;Human;Binding;Ki;=;132,00;6,88;-2;4;Binding affinity at human dopamine receptor D2;ChEMBL;419,2;6;0;2;6,27;Fc1ccc(C(OC2CC3CCC(C2)N3Cc2ccccc2)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/jm010146o
CHEMBL1242923;16706;None;3;Human;Binding;Ki;=;831,76;6,08;-3;11;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;407,2;7;1;4;2,63;O=C(Cc1ccccc1)NC1CCN(CCCN2C(=O)COc3ccccc32)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL1242923;16706;None;3;Human;Binding;Ki;=;834,00;6,08;-3;11;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;407,2;7;1;4;2,63;O=C(Cc1ccccc1)NC1CCN(CCCN2C(=O)COc3ccccc32)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL124411;16776;None;0;Human;Binding;Ki;=;410,00;6,39;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;375,3;3;0;2;5,64;CC(C)(C)c1ccc(CN2CCC(C3CCc4ccccc4C3=O)CC2)cc1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL124419;16777;None;0;Human;Binding;Ki;=;265,00;6,58;2;4;In vitro binding affinity towards cloned human Dopamine receptor D2A using [3H]- Raclopride as radioligand.;ChEMBL;277,1;0;0;3;3,03;CN1CCc2ccc3oc(=O)c4cccc5c4c3c2[C@H]1C5;https://dx.doi.org/10.1016/s0960-894x(00)00655-7
CHEMBL124444;16780;None;0;Human;Binding;Ki;=;110,00;6,96;-109;12;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;5;3,77;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3o2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL124444;16780;None;0;Human;Binding;Ki;=;84,00;7,08;-109;12;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;5;3,77;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3o2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL124444;16780;None;0;Human;Binding;Ki;=;110,00;6,96;-109;12;Binding affinity for human dopamine receptor D2 long;ChEMBL;407,2;8;1;5;3,77;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3o2)CC1;https://dx.doi.org/10.1021/jm049612a
CHEMBL124444;16780;None;0;Human;Binding;Ki;=;170,00;6,77;-109;12;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;407,2;8;1;5;3,77;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL124444;16780;None;0;Human;Binding;Ki;=;109,65;6,96;-109;12;Binding affinity to dopamine D2;ChEMBL;407,2;8;1;5;3,77;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3o2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL125455;17051;None;0;Human;Binding;IC50;=;64,00;7,19;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;360,1;4;0;2;4,92;Clc1ccc(N2CCN(C[C@@H]3C[C@H]3c3ccccc3)CC2)c(Cl)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL125459;17058;None;0;Human;Binding;Ki;=;8,00;8,10;-14;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;437,2;9;1;6;3,16;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2cccc3c2OCO3)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1255588;17141;None;11;Human;Binding;IC50;=;8,70;8,06;-1;8;Displacement of radiolabeled (+)butaclamol from human dopamine D2S receptor;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1021/jm8007618
CHEMBL1255588;17141;None;11;Human;Binding;IC50;=;1,40;8,85;-1;8;Binding affinity to human dopamine D2S receptor by radioligand displacement assay;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1016/j.bmc.2013.03.016
CHEMBL1255588;17141;None;11;Human;Binding;IC50;=;12,00;7,92;-1;8;Inhibition of human dopamine D2 receptor;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1016/j.bmc.2010.07.034
CHEMBL1255588;17141;None;11;Human;Binding;IC50;=;15,00;7,82;-1;8;Inhibition of human dopamine D2 receptor;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1021/jm701575k
CHEMBL1255588;17141;None;11;Human;Binding;IC50;=;8,90;8,05;-1;8;Percent inhibition against Dopamine receptor D2 at 1 uM;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1021/jm058018d
CHEMBL1255588;17141;None;11;Human;Binding;IC50;=;2,20;8,66;-1;8;Binding affinity to human dopamine D2S receptor by radioligand displacement assay;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1016/j.ejmech.2013.01.044
CHEMBL1255588;17141;None;11;Human;Binding;Ki;=;0,37;9,43;-1;8;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1021/jm5004123
CHEMBL1255588;17141;None;11;Human;Binding;Ki;=;0,74;9,13;-1;8;Binding affinity to human dopamine D2S receptor by radioligand displacement assay;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1016/j.ejmech.2013.01.044
CHEMBL1255588;17141;None;11;Human;Binding;Ki;=;2,90;8,54;-1;8;Displacement of radiolabeled (+)butaclamol from human dopamine D2S receptor;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1021/jm8007618
CHEMBL1255588;17141;None;11;Human;Binding;Ki;=;0,50;9,30;-1;8;Displacement of [3H]methyl-spiperone from human dopamine D2s receptor;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1021/jm2006782
CHEMBL1255588;17141;None;11;Human;Binding;Ki;=;2,58;8,59;-1;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1021/jm401798r
CHEMBL1255588;17141;None;11;Human;Binding;Ki;=;0,60;9,22;-1;8;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@H]2C1;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
CHEMBL125580;17167;None;0;Human;Binding;Ki;=;145,00;6,84;-6;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;443,2;7;0;5;4,05;COc1ccccc1N1CCN(CCCCN2C(=O)c3cc4ccccc4cc3C2=O)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1256169;17176;None;0;Human;Binding;Ki;=;140,00;6,85;-5;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;583,3;6;1;3;7,40;O=C(CCCN1CCC(O)(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1256169;17176;None;0;Human;Binding;Ki;=;200,00;6,70;-5;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;583,3;6;1;3;7,40;O=C(CCCN1CCC(O)(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1256170;17177;None;0;Human;Binding;Ki;=;17,00;7,77;-5;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;567,4;6;0;2;8,30;O=C(CCCN1CCC(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1256170;17177;None;0;Human;Binding;Ki;=;30,00;7,52;-5;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;567,4;6;0;2;8,30;O=C(CCCN1CCC(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1256171;17178;None;0;Human;Binding;Ki;=;48,00;7,32;-9;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;597,4;7;1;3;6,79;O=C(NCCCCN1CCN(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1256171;17178;None;0;Human;Binding;Ki;=;32,00;7,50;-9;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;597,4;7;1;3;6,79;O=C(NCCCCN1CCN(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257144;17296;None;0;Human;Binding;Ki;=;58,00;7,24;-6;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;7;1;4;4,20;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5cc(F)ccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257145;17297;None;0;Human;Binding;Ki;=;10,20;7,99;-57;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;437,2;6;1;4;3,95;O=C1NCc2ccc(OCCCN3CCN(c4cccc5cc(F)c(F)cc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257146;17298;None;0;Human;Binding;Ki;=;9,01;8,04;-29;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;453,2;6;1;4;4,47;O=C1NCc2ccc(OCCCN3CCN(c4cccc5cccc(F)c45)CC3)c(Cl)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257147;17299;None;0;Human;Binding;Ki;=;9,86;8,01;-8;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;467,2;7;1;4;4,86;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5cccc(F)c45)CC3)c(Cl)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257261;17329;None;0;Human;Binding;Ki;=;8,23;8,09;-6;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;451,2;7;1;4;4,34;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5cc(F)c(F)cc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257262;17330;None;0;Human;Binding;Ki;=;0,30;9,52;10;2;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;391,2;6;1;4;3,01;O=C1NCc2ccc(OCCCN3CCN(c4cccc5c4CCC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257263;17331;None;0;Human;Binding;Ki;=;51,60;7,29;-63;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;435,2;6;1;4;4,33;O=C1NCc2cc(Cl)c(OCCCN3CCN(c4cccc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257264;17332;None;0;Human;Binding;Ki;=;9,31;8,03;-3;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;449,2;7;1;4;4,72;O=C1NCc2cc(Cl)c(OCCCCN3CCN(c4cccc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257382;17361;None;0;Human;Binding;Ki;=;0,06;10,24;12;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;405,2;7;1;4;3,40;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4CCC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257382;17361;None;0;Human;Binding;Ki;=;0,06;10,24;12;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;405,2;7;1;4;3,40;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4CCC5)CC3)cc21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1257383;17362;None;0;Human;Binding;Ki;=;12,10;7,92;-8;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;393,2;6;1;5;2,46;O=C1NCc2ccc(OCCCN3CCN(c4cccc5c4CCO5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257384;17363;None;0;Human;Binding;Ki;=;24,50;7,61;-28;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;453,2;6;1;4;4,47;O=C1NCc2cc(Cl)c(OCCCN3CCN(c4cccc5cccc(F)c45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257385;17364;None;0;Human;Binding;Ki;=;5,91;8,23;-3;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;467,2;7;1;4;4,86;O=C1NCc2cc(Cl)c(OCCCCN3CCN(c4cccc5cccc(F)c45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257492;17401;None;0;Human;Binding;Ki;=;2,08;8,68;-1;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;407,2;7;1;5;2,85;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4CCO5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257492;17401;None;0;Human;Binding;Ki;=;2,09;8,68;-1;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;407,2;7;1;5;2,85;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4CCO5)CC3)cc21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1257493;17402;None;0;Human;Binding;Ki;=;0,58;9,24;12;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;407,2;7;1;5;2,94;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4COC5)CC3)cc21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1257493;17402;None;0;Human;Binding;Ki;=;0,57;9,24;12;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;407,2;7;1;5;2,94;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4COC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257494;17403;None;0;Human;Binding;Ki;=;6,81;8,17;-10;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;415,2;6;1;4;3,98;Cc1c(OCCCN2CCN(c3cccc4ccccc34)CC2)ccc2c1C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257495;17404;None;0;Human;Binding;Ki;=;13,10;7,88;-10;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;429,2;7;1;4;4,37;Cc1c(OCCCCN2CCN(c3cccc4ccccc34)CC2)ccc2c1C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257613;17442;None;0;Human;Binding;Ki;=;2,63;8,58;-9;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;405,2;6;1;4;3,40;O=C1NCc2ccc(OCCCN3CCN(c4cccc5c4CCCC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257614;17443;None;0;Human;Binding;Ki;=;1,55;8,81;1;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;419,3;7;1;4;3,79;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4CCCC5)CC3)cc21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1257614;17443;None;0;Human;Binding;Ki;=;1,54;8,81;1;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;419,3;7;1;4;3,79;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4CCCC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257615;17444;None;0;Human;Binding;Ki;=;13,60;7,87;-6;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;6;1;4;4,12;Cc1c(OCCCN2CCN(c3cccc4cccc(F)c34)CC2)ccc2c1C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257616;17445;None;0;Human;Binding;Ki;=;3,03;8,52;-1;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;447,2;7;1;4;4,51;Cc1c(OCCCCN2CCN(c3cccc4cccc(F)c34)CC2)ccc2c1C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257688;17459;None;0;Human;Binding;Ki;=;3,60;8,44;-5;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;471,3;6;1;3;5,66;O=C(CCCN1CCC(O)(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257688;17459;None;0;Human;Binding;Ki;=;4,80;8,32;-5;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;471,3;6;1;3;5,66;O=C(CCCN1CCC(O)(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257689;17460;None;0;Human;Binding;Ki;=;6,50;8,19;4;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;369,2;6;1;3;4,39;Cc1ccc(C)c(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257689;17460;None;0;Human;Binding;Ki;=;3,40;8,47;4;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;369,2;6;1;3;4,39;Cc1ccc(C)c(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257734;17480;None;0;Human;Binding;Ki;=;4,47;8,35;-89;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;407,2;6;1;5;2,85;O=C1NCc2ccc(OCCCN3CCN(c4cccc5c4OCCC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257735;17481;None;0;Human;Binding;Ki;=;0,58;9,24;1;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;421,2;7;1;5;3,24;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4OCCC5)CC3)cc21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1257735;17481;None;0;Human;Binding;Ki;=;0,58;9,24;1;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;421,2;7;1;5;3,24;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4OCCC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257736;17482;None;0;Human;Binding;Ki;=;1,70;8,77;-1;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;6;1;4;4,12;Cc1c(OCCCN2CCN(c3cccc4cc(F)ccc34)CC2)ccc2c1C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257737;17483;None;0;Human;Binding;Ki;=;9,44;8,03;1;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;447,2;7;1;4;4,51;Cc1c(OCCCCN2CCN(c3cccc4cc(F)ccc34)CC2)ccc2c1C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257810;17495;None;0;Human;Binding;Ki;=;21,00;7,68;1;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;487,2;6;1;3;6,17;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257810;17495;None;0;Human;Binding;Ki;=;13,00;7,89;1;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;487,2;6;1;3;6,17;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257811;17496;None;0;Human;Binding;Ki;=;43,00;7,37;2;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;385,2;6;1;3;4,90;Cc1ccc(C)c(C(=O)CCCN2CCC(O)(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257811;17496;None;0;Human;Binding;Ki;=;15,00;7,82;2;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;385,2;6;1;3;4,90;Cc1ccc(C)c(C(=O)CCCN2CCC(O)(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257856;17515;None;0;Human;Binding;Ki;=;290,00;6,54;-2691;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;407,2;6;1;5;2,59;O=C1NCc2ccc(OCCCN3CCN(c4cccc5c4COCC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257857;17516;None;0;Human;Binding;Ki;=;22,30;7,65;-79;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;421,2;7;1;5;2,98;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4COCC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257857;17516;None;0;Human;Binding;Ki;=;22,39;7,65;-79;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;421,2;7;1;5;2,98;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4COCC5)CC3)cc21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1257858;17517;None;0;Human;Binding;Ki;=;21,80;7,66;-32;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;415,2;6;1;4;3,98;Cc1cc2c(cc1OCCCN1CCN(c3cccc4ccccc34)CC1)C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257859;17518;None;0;Human;Binding;Ki;=;2,46;8,61;-3;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;429,2;7;1;4;4,37;Cc1cc2c(cc1OCCCCN1CCN(c3cccc4ccccc34)CC1)C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257927;17530;None;0;Human;Binding;Ki;=;55,00;7,26;-1;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;379,3;6;1;3;4,87;Cc1ccc(C)c(C(=O)CCCN2CCC(O)(c3cc(C)ccc3C)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257927;17530;None;0;Human;Binding;Ki;=;46,00;7,34;-1;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;379,3;6;1;3;4,87;Cc1ccc(C)c(C(=O)CCCN2CCC(O)(c3cc(C)ccc3C)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1257968;17544;None;0;Human;Binding;Ki;=;11,50;7,94;-5;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;421,2;7;1;5;2,98;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4CCOC5)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257968;17544;None;0;Human;Binding;Ki;=;11,48;7,94;-5;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;421,2;7;1;5;2,98;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5c4CCOC5)CC3)cc21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1257969;17545;None;0;Human;Binding;Ki;=;13,80;7,86;-107;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;419,2;6;1;4;3,81;O=C1NCc2ccc(OCCCN3CCN(c4cccc5ccccc45)CC3)c(F)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257970;17546;None;0;Human;Binding;Ki;=;16,60;7,78;-11;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;6;1;4;4,12;Cc1cc2c(cc1OCCCN1CCN(c3cccc4cccc(F)c34)CC1)C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1257971;17547;None;0;Human;Binding;Ki;=;2,34;8,63;1;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;447,2;7;1;4;4,51;Cc1cc2c(cc1OCCCCN1CCN(c3cccc4cccc(F)c34)CC1)C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258036;17559;None;0;Human;Binding;Ki;=;19,00;7,72;-2;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;456,3;6;0;3;5,50;O=C(CCCN1CCN(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258036;17559;None;0;Human;Binding;Ki;=;22,00;7,66;-2;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;456,3;6;0;3;5,50;O=C(CCCN1CCN(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258037;17560;None;0;Human;Binding;Ki;=;13,00;7,89;1;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;354,2;6;0;3;4,23;Cc1ccc(C)c(N2CCN(CCCC(=O)c3ccc(F)cc3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258037;17560;None;0;Human;Binding;Ki;=;16,00;7,80;1;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;354,2;6;0;3;4,23;Cc1ccc(C)c(N2CCN(CCCC(=O)c3ccc(F)cc3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258084;17578;None;0;Human;Binding;Ki;=;22,39;7,65;-20;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;433,2;7;1;4;4,20;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)c(F)c21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1258084;17578;None;0;Human;Binding;Ki;=;22,30;7,65;-20;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;7;1;4;4,20;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)c(F)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258085;17579;None;0;Human;Binding;Ki;=;5,49;8,26;-1;2;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;437,2;6;1;4;3,95;O=C1NCc2ccc(OCCCN3CCN(c4cccc5cccc(F)c45)CC3)c(F)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258086;17580;None;0;Human;Binding;Ki;=;3,81;8,42;-7;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;6;1;4;4,12;Cc1cc2c(cc1OCCCN1CCN(c3cccc4cc(F)ccc34)CC1)C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258087;17581;None;0;Human;Binding;Ki;=;0,81;9,09;2;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;447,2;7;1;4;4,51;Cc1cc2c(cc1OCCCCN1CCN(c3cccc4cc(F)ccc34)CC1)C(=O)NC2;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258154;17592;None;0;Human;Binding;Ki;=;620,00;6,21;-4;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;472,2;6;0;3;6,01;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258154;17592;None;0;Human;Binding;Ki;=;440,00;6,36;-4;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;472,2;6;0;3;6,01;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258155;17593;None;0;Human;Binding;Ki;=;190,00;6,72;-19;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;369,2;6;0;2;5,80;Cc1ccc(C)c(C(=O)CCCN2CCC(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258155;17593;None;0;Human;Binding;Ki;=;200,00;6,70;-19;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;369,2;6;0;2;5,80;Cc1ccc(C)c(C(=O)CCCN2CCC(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258199;17613;None;0;Human;Binding;Ki;=;35,20;7,45;-63;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;451,2;7;1;4;4,34;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5cccc(F)c45)CC3)c(F)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258199;17613;None;0;Human;Binding;Ki;=;35,48;7,45;-63;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;451,2;7;1;4;4,34;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5cccc(F)c45)CC3)c(F)c21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1258200;17614;None;0;Human;Binding;Ki;=;10,30;7,99;-11;2;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;437,2;6;1;4;3,95;O=C1NCc2ccc(OCCCN3CCN(c4cccc5ccc(F)cc45)CC3)c(F)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258270;17625;None;0;Human;Binding;Ki;=;260,00;6,58;-7;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;363,3;6;0;2;5,76;Cc1ccc(C)c(C(=O)CCCN2CCC(c3cc(C)ccc3C)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258270;17625;None;0;Human;Binding;Ki;=;400,00;6,40;-7;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;363,3;6;0;2;5,76;Cc1ccc(C)c(C(=O)CCCN2CCC(c3cc(C)ccc3C)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258312;17643;None;0;Human;Binding;Ki;=;34,00;7,47;-229;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;387,2;6;1;4;4,03;c1ccc2c(N3CCN(CCCOc4ccc5c(c4)CNC5)CC3)cccc2c1;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258313;17644;None;0;Human;Binding;Ki;=;5,75;8,24;-2;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;451,2;7;1;4;4,34;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5ccc(F)cc45)CC3)c(F)c21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1258313;17644;None;0;Human;Binding;Ki;=;5,75;8,24;-2;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;451,2;7;1;4;4,34;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5ccc(F)cc45)CC3)c(F)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258314;17645;None;0;Human;Binding;Ki;=;8,59;8,07;-2;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;437,2;6;1;4;3,95;O=C1NCc2ccc(OCCCN3CCN(c4cccc5cc(F)ccc45)CC3)c(F)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258382;17659;None;0;Human;Binding;Ki;=;83,00;7,08;-70;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;523,3;7;1;4;6,12;O=C(NCCCCN1CCN(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258382;17659;None;0;Human;Binding;Ki;=;150,00;6,82;-70;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;523,3;7;1;4;6,12;O=C(NCCCCN1CCN(c2cc3ccc2CCc2ccc(cc2)CC3)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258383;17660;None;0;Human;Binding;Ki;=;84,00;7,08;-29;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;421,2;7;1;4;4,85;Cc1ccc(C)c(N2CCN(CCCCNC(=O)c3cc4ccccc4s3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258383;17660;None;0;Human;Binding;Ki;=;65,00;7,19;-29;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;421,2;7;1;4;4,85;Cc1ccc(C)c(N2CCN(CCCCNC(=O)c3cc4ccccc4s3)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258425;17678;None;0;Human;Binding;Ki;=;40,70;7,39;-199;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;401,2;7;1;4;4,42;c1ccc2c(N3CCN(CCCCOc4ccc5c(c4)CNC5)CC3)cccc2c1;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258426;17679;None;0;Human;Binding;Ki;=;24,70;7,61;-239;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;405,2;6;1;4;4,17;Fc1ccc2cccc(N3CCN(CCCOc4ccc5c(c4)CNC5)CC3)c2c1;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258427;17680;None;0;Human;Binding;Ki;=;15,80;7,80;-5;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;451,2;7;1;4;4,34;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5cc(F)ccc45)CC3)c(F)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258427;17680;None;0;Human;Binding;Ki;=;15,85;7,80;-5;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;451,2;7;1;4;4,34;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5cc(F)ccc45)CC3)c(F)c21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1258428;17681;None;0;Human;Binding;Ki;=;8,92;8,05;-13;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;419,2;6;1;4;3,81;O=C1NCc2cc(F)c(OCCCN3CCN(c4cccc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258494;17697;None;0;Human;Binding;Ki;=;22,00;7,66;-4;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;395,3;8;1;4;3,64;COc1ccccc1N1CCN(CCCCNC(=O)c2cc(C)ccc2C)CC1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258494;17697;None;0;Human;Binding;Ki;=;17,00;7,77;-4;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;395,3;8;1;4;3,64;COc1ccccc1N1CCN(CCCCNC(=O)c2cc(C)ccc2C)CC1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258495;17698;None;0;Human;Binding;Ki;=;86,00;7,07;-3;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;393,3;7;1;3;4,25;Cc1ccc(C)c(C(=O)NCCCCN2CCN(c3cc(C)ccc3C)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258495;17698;None;0;Human;Binding;Ki;=;99,00;7,00;-3;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;393,3;7;1;3;4,25;Cc1ccc(C)c(C(=O)NCCCCN2CCN(c3cc(C)ccc3C)CC2)c1;https://dx.doi.org/10.1021/jm100899z
CHEMBL1258532;17714;None;0;Human;Binding;Ki;=;80,70;7,09;-331;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;419,2;7;1;4;4,56;Fc1ccc2cccc(N3CCN(CCCCOc4ccc5c(c4)CNC5)CC3)c2c1;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258533;17715;None;0;Human;Binding;Ki;=;16,30;7,79;-177;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;401,2;6;1;4;3,67;O=C1NCc2ccc(OCCCN3CCN(c4cccc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258534;17716;None;0;Human;Binding;Ki;=;0,88;9,06;-1;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;7;1;4;4,20;O=C1NCc2cc(F)c(OCCCCN3CCN(c4cccc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258535;17717;None;0;Human;Binding;Ki;=;9,54;8,02;-7;2;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;437,2;6;1;4;3,95;O=C1NCc2cc(F)c(OCCCN3CCN(c4cccc5cccc(F)c45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258647;17751;None;0;Human;Binding;Ki;=;7,41;8,13;-12;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;415,2;7;1;4;4,06;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)cc21;https://dx.doi.org/10.1039/C5MD00566C
CHEMBL1258647;17751;None;0;Human;Binding;Ki;=;7,39;8,13;-12;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;415,2;7;1;4;4,06;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258648;17752;None;0;Human;Binding;Ki;=;27,80;7,56;-616;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;419,2;6;1;4;3,81;O=C1NCc2ccc(OCCCN3CCN(c4cccc5ccc(F)cc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258649;17753;None;0;Human;Binding;Ki;=;1,41;8,85;-12;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;451,2;7;1;4;4,34;O=C1NCc2cc(F)c(OCCCCN3CCN(c4cccc5cccc(F)c45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258650;17754;None;0;Human;Binding;Ki;=;5,81;8,24;-16;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;437,2;6;1;4;3,95;O=C1NCc2cc(F)c(OCCCN3CCN(c4cccc5ccc(F)cc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258760;17789;None;0;Human;Binding;Ki;=;33,80;7,47;-40;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;7;1;4;4,20;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5ccc(F)cc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258761;17790;None;0;Human;Binding;Ki;=;13,60;7,87;-954;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;419,2;6;1;4;3,81;O=C1NCc2ccc(OCCCN3CCN(c4cccc5cccc(F)c45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258762;17791;None;0;Human;Binding;Ki;=;11,20;7,95;-6;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;451,2;7;1;4;4,34;O=C1NCc2cc(F)c(OCCCCN3CCN(c4cccc5ccc(F)cc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258763;17792;None;0;Human;Binding;Ki;=;1,86;8,73;-2;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;437,2;6;1;4;3,95;O=C1NCc2cc(F)c(OCCCN3CCN(c4cccc5cc(F)ccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258879;17823;None;0;Human;Binding;Ki;=;3,18;8,50;-14;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;433,2;7;1;4;4,20;O=C1NCc2ccc(OCCCCN3CCN(c4cccc5cccc(F)c45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258880;17824;None;0;Human;Binding;Ki;=;44,50;7,35;-28;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;419,2;6;1;4;3,81;O=C1NCc2ccc(OCCCN3CCN(c4cccc5cc(F)ccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258881;17825;None;0;Human;Binding;Ki;=;0,89;9,05;3;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;451,2;7;1;4;4,34;O=C1NCc2cc(F)c(OCCCCN3CCN(c4cccc5cc(F)ccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258882;17826;None;0;Human;Binding;Ki;=;10,60;7,97;-13;3;Displacement of [3H]-Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;435,2;6;1;4;4,33;O=C1NCc2ccc(OCCCN3CCN(c4cccc5ccccc45)CC3)c(Cl)c21;https://dx.doi.org/10.1016/j.bmcl.2010.08.023
CHEMBL1258987;17850;None;0;Human;Binding;Ki;=;2,30;8,64;-11;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;390,2;2;0;5;4,08;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4cnn(C)c4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1258988;17851;None;0;Human;Binding;Ki;=;5,90;8,23;-69;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;391,2;2;0;6;3,48;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4ncn(C)n4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1258999;17853;None;0;Human;Binding;Ki;=;28000,00;4,55;-46;6;Displacement of [3H]Spiperone from human dopamine D2 short receptor;ChEMBL;381,2;5;1;4;3,87;Cc1ccc(CNCC2(F)CCN(C(=O)c3coc4ccccc34)CC2)nc1;https://dx.doi.org/10.1021/jm100835q
CHEMBL1258999;17853;None;0;Human;Binding;Ki;=;27000,00;4,57;-46;6;Displacement of [3H]Spiperone from human dopamine D2 long receptor;ChEMBL;381,2;5;1;4;3,87;Cc1ccc(CNCC2(F)CCN(C(=O)c3coc4ccccc34)CC2)nc1;https://dx.doi.org/10.1021/jm100835q
CHEMBL1259005;17857;None;0;Human;Binding;Ki;=;2,90;8,54;-5;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;406,2;2;0;4;5,72;Cc1ccc(-c2ccc3c(c2)C(N2CCN(C)CC2)Cc2ccccc2S3)s1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259006;17858;None;0;Human;Binding;Ki;=;1,90;8,72;-7;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;387,2;2;0;4;4,74;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4ccccn4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259023;17864;None;0;Human;Binding;Ki;=;0,62;9,21;-3;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;387,2;2;0;4;4,74;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4cccnc4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259024;17865;None;0;Human;Binding;Ki;=;1,10;8,96;1;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;387,2;2;0;4;4,74;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4ccncc4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259042;17873;None;0;Human;Binding;Ki;=;0,73;9,14;-4;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;388,2;2;0;5;4,14;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4cncnc4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259043;17874;None;0;Human;Binding;Ki;=;1,80;8,74;-4;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;386,2;2;0;3;5,35;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4ccccc4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259062;17879;None;0;Human;Binding;Ki;=;1,60;8,80;-1;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;400,2;2;0;3;5,66;Cc1ccccc1-c1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259063;17880;None;0;Human;Binding;Ki;=;3,40;8,47;-3;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;400,2;2;0;3;5,66;Cc1cccc(-c2ccc3c(c2)C(N2CCN(C)CC2)Cc2ccccc2S3)c1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259071;17881;None;0;Human;Binding;Ki;=;73000,00;4,14;-42;6;Displacement of [3H]Spiperone from human dopamine D2 long receptor;ChEMBL;425,1;5;1;4;3,95;Cc1ccc(CNCC2(F)CCN(C(=O)c3cc(Br)cs3)CC2)nc1;https://dx.doi.org/10.1021/jm100835q
CHEMBL1259071;17881;None;0;Human;Binding;Ki;=;100000,00;4,00;-42;6;Displacement of [3H]Spiperone from human dopamine D2 short receptor;ChEMBL;425,1;5;1;4;3,95;Cc1ccc(CNCC2(F)CCN(C(=O)c3cc(Br)cs3)CC2)nc1;https://dx.doi.org/10.1021/jm100835q
CHEMBL1259079;17885;None;0;Human;Binding;Ki;=;6,30;8,20;-7;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;400,2;2;0;3;5,66;Cc1ccc(-c2ccc3c(c2)C(N2CCN(C)CC2)Cc2ccccc2S3)cc1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259080;17886;None;0;Human;Binding;Ki;=;2,00;8,70;-1;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;414,2;2;0;3;5,97;Cc1cccc(-c2ccc3c(c2)C(N2CCN(C)CC2)Cc2ccccc2S3)c1C;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259097;17892;None;0;Human;Binding;Ki;=;4,60;8,34;-4;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;414,2;2;0;3;5,97;Cc1cccc(C)c1-c1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259098;17893;None;0;Human;Binding;Ki;=;4,90;8,31;-2;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;428,2;2;0;3;6,28;Cc1cc(C)c(-c2ccc3c(c2)C(N2CCN(C)CC2)Cc2ccccc2S3)c(C)c1;https://dx.doi.org/10.1021/jm100652h
CHEMBL125910;17894;None;0;Human;Binding;IC50;=;171,00;6,77;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;322,2;5;0;3;3,62;COc1cccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL1259112;17898;None;1;Human;Binding;Ki;=;1,40;8,85;-16;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;335,1;1;0;4;3,55;CN1CCN(C2Cc3ccccc3Sc3ccc(C#N)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259113;17899;None;0;Human;Binding;Ki;=;35,00;7,46;-891;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;339,2;2;1;4;3,14;CN1CCN(C2Cc3ccccc3Sc3ccc(CN)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259128;17904;None;0;Human;Binding;Ki;=;0,35;9,46;-3;2;Displacement of [3H]spiperone from human cloned dopamine D2 receptor expressed in HEK293 cells;ChEMBL;406,2;3;0;7;2,80;CN1CCN(C2Cc3ccccc3Sc3ccc(Cc4nnn(C)n4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259129;17905;None;0;Human;Binding;Ki;=;1,90;8,72;-12;2;Displacement of [3H]spiperone from human cloned dopamine D2 receptor expressed in HEK293 cells;ChEMBL;406,2;3;0;7;2,80;CN1CCN(C2Cc3ccccc3Sc3ccc(Cc4nnnn4C)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259144;17908;None;0;Human;Binding;Ki;=;7,10;8,15;-87;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;381,2;3;1;4;3,32;CC(=O)NCc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259145;17909;None;0;Human;Binding;Ki;=;12,00;7,92;-100;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;409,2;4;1;4;3,96;CC(C)C(=O)NCc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259158;17913;None;0;Human;Binding;Ki;=;6,10;8,21;-11;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;423,2;3;1;4;4,34;CN1CCN(C2Cc3ccccc3Sc3ccc(CNC(=O)C(C)(C)C)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL125916;17914;None;0;Human;Binding;Ki;=;37,40;7,43;-114;9;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;406,2;8;2;4;3,51;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL125916;17914;None;0;Human;Binding;Ki;=;37,40;7,43;-114;9;Displacement of [125I]-IABN from D2 receptor;ChEMBL;406,2;8;2;4;3,51;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1021/jm301017v
CHEMBL1259172;17916;None;0;Human;Binding;Ki;=;37,00;7,43;-204;5;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;435,2;6;2;4;3,43;NCc1ccc2c(c1)c(C1CCN(CCN3CCNC3=O)CC1)cn2-c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259173;17917;None;0;Human;Binding;Ki;=;27,00;7,57;-64;5;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;381,2;3;1;4;3,32;CC(=O)NCc1ccc2c(c1)[C@H](N1CCN(C)CC1)Cc1ccccc1S2;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259174;17918;None;0;Human;Binding;Ki;=;3,30;8,48;-9;5;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;381,2;3;1;4;3,32;CC(=O)NCc1ccc2c(c1)[C@@H](N1CCN(C)CC1)Cc1ccccc1S2;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259187;17921;None;0;Human;Binding;Ki;=;3,10;8,51;-4;5;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;477,3;7;2;4;3,61;CC(=O)NCc1ccc2c(c1)c(C1CCN(CCN3CCNC3=O)CC1)cn2-c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259188;17922;None;0;Human;Binding;Ki;=;2,70;8,57;-4;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;502,3;7;1;7;3,09;Cn1nnc(Cc2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)n1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259189;17923;None;0;Human;Binding;Ki;=;31,00;7,51;-114;5;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;409,2;4;1;4;3,96;CC(C)C(=O)NCc1ccc2c(c1)[C@H](N1CCN(C)CC1)Cc1ccccc1S2;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259190;17924;None;0;Human;Binding;Ki;=;4,50;8,35;-28;5;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;409,2;4;1;4;3,96;CC(C)C(=O)NCc1ccc2c(c1)[C@@H](N1CCN(C)CC1)Cc1ccccc1S2;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259203;17928;None;0;Human;Binding;Ki;=;260,00;6,58;-338;5;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;386,2;3;0;4;5,04;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4cncnc4)cc23)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259203;17928;None;0;Human;Binding;Ki;=;120,00;6,92;-338;5;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;386,2;3;0;4;5,04;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4cncnc4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL1259216;17931;None;0;Human;Binding;Ki;=;2,30;8,64;-6;4;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;392,2;2;0;7;2,87;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4nnn(C)n4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259216;17931;None;0;Human;Binding;Ki;=;0,44;9,36;-6;4;Displacement of [3H]spiperone from human cloned dopamine D2 receptor expressed in HEK293 cells;ChEMBL;392,2;2;0;7;2,87;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4nnn(C)n4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259231;17936;None;0;Human;Binding;Ki;=;0,86;9,07;-2;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;390,2;2;0;5;4,08;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4ccnn4C)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259232;17937;None;0;Human;Binding;Ki;=;1,60;8,80;-6;3;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;390,2;2;0;5;4,08;CN1CCN(C2Cc3ccccc3Sc3ccc(-c4ccn(C)n4)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL1259241;17938;None;0;Human;Binding;Ki;=;20000,00;4,70;-72;6;Displacement of [3H]Spiperone from human dopamine D2 long receptor;ChEMBL;397,2;5;1;4;4,34;Cc1ccc(CNCC2(F)CCN(C(=O)c3csc4ccccc34)CC2)nc1;https://dx.doi.org/10.1021/jm100835q
CHEMBL1259241;17938;None;0;Human;Binding;Ki;=;54000,00;4,27;-72;6;Displacement of [3H]Spiperone from human dopamine D2 short receptor;ChEMBL;397,2;5;1;4;4,34;Cc1ccc(CNCC2(F)CCN(C(=O)c3csc4ccccc34)CC2)nc1;https://dx.doi.org/10.1021/jm100835q
CHEMBL126032;17959;None;0;Human;Binding;IC50;=;17,00;7,77;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;356,2;5;0;3;4,27;COc1cc(Cl)ccc1N1CCN(C[C@H]2C[C@@H]2c2ccccc2)CC1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126126;17973;None;0;Human;Binding;IC50;=;12,00;7,92;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;376,1;4;1;3;4,63;Oc1ccc([C@H]2C[C@@H]2CN2CCN(c3ccc(Cl)cc3Cl)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126136;17974;None;0;Human;Binding;Ki;=;15,20;7,82;-1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;493,1;8;1;4;3,63;COc1ccccc1N1CCN(CCCCNC(=O)c2ccccc2I)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126182;17985;None;0;Human;Binding;IC50;=;146,00;6,84;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;326,2;4;0;2;4,27;Clc1cccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126269;18006;None;0;Human;Binding;IC50;=;10,00;8,00;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;340,2;5;0;3;3,76;COc1cc(F)ccc1N1CCN(C[C@H]2C[C@@H]2c2ccccc2)CC1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126280;18008;None;0;Human;Binding;Ki;=;13,00;7,89;-19;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;399,2;9;1;5;3,49;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccsc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126285;18010;None;0;Human;Binding;Ki;=;40,00;7,40;-1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;443,2;7;0;5;4,05;COc1ccccc1N1CCN(CCCCN2C(=O)c3cccc4cccc(c34)C2=O)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126313;18011;None;0;Human;Binding;Ki;=;71,90;7,14;-10;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;457,2;8;1;5;4,90;COc1ccccc1N1CCN(CCCCNC(=O)c2sc3ccccc3c2Cl)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126318;18012;None;0;Human;Binding;IC50;=;263,00;6,58;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;293,2;4;0;3;3,01;c1ccc([C@H]2C[C@@H]2CN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126322;18014;None;0;Human;Binding;IC50;=;13,00;7,89;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;344,1;4;0;2;4,41;Fc1ccc([C@H]2C[C@@H]2CN2CCN(c3ccccc3Cl)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126340;18020;None;0;Human;Binding;Ki;=;750,00;6,12;-251;9;Binding affinity against dopamine receptor D2 using [3H]spiperone radioligand in CHO cells;ChEMBL;432,2;7;0;5;4,21;CN(C)CCc1cccc2c1cc(C(=O)c1ccccc1)n2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1021/jm010943m
CHEMBL126429;18037;None;0;Human;Binding;IC50;=;208,00;6,68;-15;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;360,1;4;0;2;4,92;Clc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)cc1Cl;https://dx.doi.org/10.1021/jm990562x
CHEMBL126429;18037;None;0;Human;Binding;Ki;=;93,00;7,03;-15;2;Inhibition of human dopamine D2 receptor;ChEMBL;360,1;4;0;2;4,92;Clc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)cc1Cl;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL126441;18039;None;0;Human;Binding;Ki;=;14,00;7,85;-25;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;423,3;10;1;5;3,44;COc1ccccc1/C=C/C(=O)NCCCCN1CCN(c2ccccc2OC)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126474;18043;None;0;Human;Binding;Ki;=;17,50;7,76;-17;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;409,2;9;1;5;3,23;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(C(C)=O)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126493;18048;None;0;Human;Binding;IC50;=;73,00;7,14;-4;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;320,2;4;0;2;4,23;Cc1ccc(N2CCN(C[C@@H]3C[C@H]3c3ccccc3)CC2)c(C)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126509;18051;None;0;Human;Binding;IC50;=;5,00;8,30;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;322,2;5;0;3;3,62;COc1ccccc1N1CCN(C[C@H]2C[C@@H]2c2ccccc2)CC1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126604;18068;None;0;Human;Binding;IC50;=;5,00;8,30;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;356,2;5;0;3;4,27;COc1ccc(Cl)cc1N1CCN(C[C@H]2C[C@@H]2c2ccccc2)CC1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126633;18074;None;0;Human;Binding;IC50;=;5,00;8,30;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;326,2;4;0;2;4,27;Clc1ccccc1N1CCN(C[C@H]2C[C@@H]2c2ccccc2)CC1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126667;18082;None;0;Human;Binding;Ki;=;165,96;6,78;-1;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;285,2;5;0;2;3,65;Fc1ccc(OCCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL126667;18082;None;0;Human;Binding;Ki;=;166,00;6,78;-1;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;285,2;5;0;2;3,65;Fc1ccc(OCCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL126746;18093;None;0;Human;Binding;Ki;=;37,00;7,43;-2;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;469,3;10;1;4;5,09;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126749;18094;None;0;Human;Binding;Ki;=;32,00;7,50;-46;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;443,3;9;1;4;4,58;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126780;18099;None;0;Human;Binding;Ki;=;23,00;7,64;-5;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;435,2;8;1;6;3,13;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3oc2=O)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126780;18099;None;0;Human;Binding;Ki;=;146,00;6,84;-5;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;435,2;8;1;6;3,13;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3oc2=O)CC1;https://dx.doi.org/10.1021/jm050734s
CHEMBL126792;18101;None;0;Human;Binding;IC50;=;202,00;6,70;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;344,1;4;0;2;4,41;Fc1ccc([C@H]2C[C@@H]2CN2CCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126793;18102;None;0;Human;Binding;IC50;=;56,00;7,25;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;344,1;4;0;2;4,41;Fc1ccc([C@H]2C[C@@H]2CN2CCN(c3cccc(Cl)c3)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL126834;18111;None;0;Human;Binding;Ki;=;18,00;7,75;-6;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;469,2;8;1;5;4,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc3c2-c2ccccc2C3=O)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL126847;18114;None;0;Human;Binding;IC50;=;766,00;6,12;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;294,2;4;0;4;2,40;c1ccc([C@H]2C[C@@H]2CN2CCN(c3ncccn3)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL127038;18270;None;0;Human;Binding;Ki;=;10,30;7,99;-10;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;437,2;9;1;6;3,16;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc3c(c2)OCO3)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL127230;18496;None;0;Human;Binding;Ki;=;65,20;7,19;-6;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;485,3;11;1;5;5,22;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(Oc3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL127234;18500;None;0;Human;Binding;Ki;=;18,00;7,75;18;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;441,2;8;1;4;4,35;COc1ccccc1N1CCN(Cc2ccccc2CNC(=O)/C=C/c2ccccc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL127288;18505;None;0;Human;Binding;Ki;=;26,50;7,58;-3;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;423,3;8;1;4;4,33;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(C(C)(C)C)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL127311;18508;None;0;Human;Binding;Ki;=;12,00;7,92;-31;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;423,3;10;1;5;3,44;COc1ccc(/C=C/C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/jm030836n
CHEMBL127317;18509;None;0;Human;Binding;Ki;=;53,20;7,27;-12;5;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;418,2;8;1;5;3,58;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3n2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL127317;18509;None;0;Human;Binding;Ki;=;66,80;7,17;-12;5;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;418,2;8;1;5;3,58;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3n2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL127400;18527;None;0;Human;Binding;Ki;=;27,50;7,56;-56;8;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;418,2;8;1;5;3,58;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3cn2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL1275630;18554;None;0;Human;Binding;Ki;=;1903,00;5,72;-416;4;Displacement of [3H]LSD from human cloned dopamine D2 receptor expressed in human HeLa cells;ChEMBL;448,2;5;1;6;4,09;CC(C)Cn1nc(S(=O)(=O)c2cccc3ccccc23)c2cc(N3CCNCC3)ccc21;https://dx.doi.org/10.1021/jm1007825
CHEMBL1277104;18681;None;0;Human;Binding;Ki;=;334,00;6,48;-208;4;Displacement of [3H]LSD from human cloned dopamine D2 receptor expressed in human HeLa cells;ChEMBL;406,1;3;1;5;3,30;CN1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)CC1;https://dx.doi.org/10.1021/jm1007825
CHEMBL1277565;18730;None;0;Human;Binding;Ki;=;2243,00;5,65;-1412;7;Displacement of [3H]LSD from human cloned dopamine D2 receptor expressed in human HeLa cells;ChEMBL;406,1;3;1;6;2,97;Cn1nc(S(=O)(=O)c2cccc3ccccc23)c2cc(N3CCNCC3)ccc21;https://dx.doi.org/10.1021/jm1007825
CHEMBL1277837;18757;None;0;Human;Binding;Ki;=;2036,00;5,69;-707;4;Displacement of [3H]LSD from human cloned dopamine D2 receptor expressed in human HeLa cells;ChEMBL;434,2;4;1;6;4,01;CC(C)n1nc(S(=O)(=O)c2cccc3ccccc23)c2cc(N3CCNCC3)ccc21;https://dx.doi.org/10.1021/jm1007825
CHEMBL1277917;18769;None;0;Human;Binding;Ki;=;355,00;6,45;-186;5;Displacement of [3H]LSD from human cloned dopamine D2 receptor expressed in human HeLa cells;ChEMBL;356,1;3;1;5;2,15;CN1CCN(c2ccc3[nH]nc(S(=O)(=O)c4ccccc4)c3c2)CC1;https://dx.doi.org/10.1021/jm1007825
CHEMBL1278001;18781;None;0;Human;Binding;Ki;=;605,00;6,22;-79;4;Displacement of [3H]LSD from human cloned dopamine D2 receptor expressed in human HeLa cells;ChEMBL;482,2;5;1;6;4,48;O=S(=O)(c1cccc2ccccc12)c1nn(Cc2ccccc2)c2ccc(N3CCNCC3)cc12;https://dx.doi.org/10.1021/jm1007825
CHEMBL128232;18879;None;1;Human;Binding;Ki;=;61,00;7,21;-134;2;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;285,2;9;1;3;3,43;Cc1cccc(OCCNCCCOc2ccccc2)c1;https://dx.doi.org/10.1021/jm970422s
CHEMBL128232;18879;None;1;Human;Binding;Ki;=;61,66;7,21;-134;2;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;285,2;9;1;3;3,43;Cc1cccc(OCCNCCCOc2ccccc2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL128276;18885;None;0;Human;Binding;Ki;=;1949,84;5,71;-363;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;301,2;10;1;4;3,13;COc1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL128276;18885;None;0;Human;Binding;Ki;=;1950,00;5,71;-363;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;301,2;10;1;4;3,13;COc1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL128281;18887;None;0;Human;Binding;Ki;=;222,00;6,65;-7;2;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;301,1;9;1;3;4,15;Cc1ccc(SCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL128313;18891;None;0;Human;Binding;Ki;=;20,00;7,70;3;2;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;285,2;9;1;3;3,43;Cc1ccccc1OCCNCCCOc1ccccc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL128313;18891;None;0;Human;Binding;Ki;=;19,95;7,70;3;2;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;285,2;9;1;3;3,43;Cc1ccccc1OCCNCCCOc1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL128524;18927;None;1;Human;Binding;Ki;=;251,19;6,60;-125;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;271,2;9;1;3;3,12;c1ccc(OCCCNCCOc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL128524;18927;None;1;Human;Binding;Ki;=;251,00;6,60;-125;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;271,2;9;1;3;3,12;c1ccc(OCCCNCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL128647;18957;None;0;Human;Binding;Ki;=;269,15;6,57;-512;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;285,2;9;1;3;3,43;Cc1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL128647;18957;None;0;Human;Binding;Ki;=;268,00;6,57;-512;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;285,2;9;1;3;3,43;Cc1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL129035;19287;None;0;Human;Binding;Ki;=;7,20;8,14;-1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;708,4;18;2;8;5,17;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(/C=C/C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL129159;19377;None;2;Human;Binding;Ki;=;279,00;6,55;-1;4;Displacement of [3H]spiperone from CHO-K1 cell membranes expressing human dopamine receptor D2;ChEMBL;377,2;6;2;3;4,28;O[C@H](CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00076a022
CHEMBL129237;19392;None;2;Human;Binding;Ki;=;73,00;7,14;-1;4;Displacement of [3H]spiperone from CHO-K1 cell membranes expressing human dopamine receptor D2;ChEMBL;377,2;6;2;3;4,28;O[C@@H](CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00076a022
CHEMBL129324;19409;None;0;Human;Binding;IC50;=;32,00;7,50;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;360,1;4;0;2;4,92;Clc1cc(Cl)cc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL129429;19427;None;0;Human;Binding;Ki;=;36,79;7,43;-17;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;461,2;9;1;4;4,45;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(C(F)(F)F)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL129534;19448;None;0;Human;Binding;Ki;=;22,00;7,66;-70;2;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;305,1;9;1;3;3,78;Clc1cccc(OCCNCCCOc2ccccc2)c1;https://dx.doi.org/10.1021/jm970422s
CHEMBL129534;19448;None;0;Human;Binding;Ki;=;21,88;7,66;-70;2;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;305,1;9;1;3;3,78;Clc1cccc(OCCNCCCOc2ccccc2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL129556;19450;None;0;Human;Binding;IC50;=;7,00;8,15;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;390,1;5;0;3;4,93;COc1ccc([C@H]2C[C@@H]2CN2CCN(c3ccc(Cl)cc3Cl)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL129757;19469;None;0;Human;Binding;Ki;=;245,00;6,61;-295;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;323,1;9;1;3;3,92;Fc1ccc(OCCCNCCOc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL129757;19469;None;0;Human;Binding;Ki;=;245,47;6,61;-295;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;323,1;9;1;3;3,92;Fc1ccc(OCCCNCCOc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL129767;19471;None;0;Human;Binding;Ki;=;19,00;7,72;-12;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;419,3;10;1;4;3,98;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/C=C/c2ccccc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL129852;19485;None;0;Human;Binding;Ki;=;100,00;7,00;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;427,2;7;1;3;5,03;Cc1cccc2c1C(=O)N(CCCCCN1CC=C(c3c[nH]c4ccccc34)CC1)C2=O;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL129927;19504;None;0;Human;Binding;Ki;=;144,54;6,84;-416;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;299,2;9;1;3;3,74;Cc1ccc(OCCNCCCOc2ccccc2)cc1C;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL129927;19504;None;0;Human;Binding;Ki;=;143,00;6,84;-416;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;299,2;9;1;3;3,74;Cc1ccc(OCCNCCCOc2ccccc2)cc1C;https://dx.doi.org/10.1021/jm970422s
CHEMBL129931;19508;None;1;Human;Binding;Ki;=;519,00;6,29;-154;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;269,2;9;1;2;3,68;c1ccc(CCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL129979;19567;None;0;Human;Binding;Ki;=;20,00;7,70;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;447,2;7;1;3;5,38;O=C1c2ccccc2C(=O)N1CCCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL129997;19579;None;0;Human;Binding;Ki;=;1258,93;5,90;-35;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;415,2;9;1;3;5,60;CCCN(CCC)[C@@H]1CCc2c(ccc(C(O)Cc3ccc(Cl)cc3)c2OC)C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL129997;19579;None;0;Human;Binding;Ki;=;316,23;6,50;-35;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;415,2;9;1;3;5,60;CCCN(CCC)[C@@H]1CCc2c(ccc(C(O)Cc3ccc(Cl)cc3)c2OC)C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL130101;19721;None;0;Human;Binding;Ki;=;251,19;6,60;-125;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;407,3;10;0;3;5,63;CCCN(CCC)C1CCc2cc(CCc3ccc(C(=O)OCC)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL130261;19923;None;0;Human;Binding;Ki;=;40,00;7,40;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;427,2;7;1;3;5,03;Cc1ccc2c(c1)C(=O)N(CCCCCN1CC=C(c3c[nH]c4ccccc34)CC1)C2=O;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL130282;19949;None;0;Human;Binding;Ki;=;794,33;6,10;-398;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;392,3;9;1;3;5,65;CCCN(CCC)C1CCc2cc(CCc3ccc(/C(C)=N\O)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL130304;19977;None;0;Human;Binding;Ki;=;316,23;6,50;-25;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;351,3;8;1;2;5,16;CCCN(CCC)C1CCc2cc(CCc3ccc(O)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL130347;20033;None;0;Human;Binding;Ki;=;352,00;6,45;-10;2;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;321,1;9;1;3;4,49;Clc1ccc(SCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL130370;20061;None;0;Human;Binding;Ki;=;277,00;6,56;-25;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;299,2;9;1;3;3,74;Cc1ccc(OCCCNCCOc2ccc(C)cc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL130370;20061;None;0;Human;Binding;Ki;=;275,42;6,56;-25;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;299,2;9;1;3;3,74;Cc1ccc(OCCCNCCOc2ccc(C)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL130402;20099;None;0;Human;Binding;Ki;=;118,00;6,93;-147;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;301,1;9;1;3;4,15;Cc1ccc(OCCNCCCSc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL130423;20129;None;0;Human;Binding;Ki;=;1000,00;6,00;-15;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;381,3;9;1;3;4,95;CCCN(CCC)[C@@H]1CCc2c(ccc(C(O)Cc3ccccc3)c2OC)C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL130665;20419;None;0;Human;Binding;Ki;=;398,11;6,40;-100;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;335,3;8;0;1;5,45;CCCN(CCC)C1CCc2cc(CCc3ccccc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL130678;20432;None;0;Human;Binding;Ki;=;199,53;6,70;-1258;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;511,1;8;0;3;5,24;CCCN(CCC)[C@@H]1CCc2cc(CS(=O)(=O)c3ccc(I)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL130843;20644;None;0;Human;Binding;Ki;=;199,53;6,70;-158;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;383,2;9;0;3;5,97;CCCN(CCC)C1CCc2cc(CSc3ccc(OC)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL131299;21217;None;0;Human;Binding;Ki;=;64,57;7,19;-23;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;285,2;9;1;3;3,43;Cc1ccc(OCCCNCCOc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL131299;21217;None;0;Human;Binding;Ki;=;64,00;7,19;-23;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;285,2;9;1;3;3,43;Cc1ccc(OCCCNCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL131357;21293;None;0;Human;Binding;Ki;=;389,05;6,41;-407;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;303,2;9;1;3;3,57;Cc1ccc(OCCNCCCOc2ccc(F)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL131357;21293;None;0;Human;Binding;Ki;=;391,00;6,41;-407;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;303,2;9;1;3;3,57;Cc1ccc(OCCNCCCOc2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL131396;21338;None;0;Human;Binding;Ki;=;112,00;6,95;-25;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;305,1;9;1;3;3,78;Clc1ccccc1OCCNCCCOc1ccccc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL131396;21338;None;0;Human;Binding;Ki;=;112,20;6,95;-25;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;305,1;9;1;3;3,78;Clc1ccccc1OCCNCCCOc1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL131484;21418;None;0;Human;Binding;Ki;=;1318,26;5,88;-234;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;319,1;9;1;3;4,09;Cc1ccc(OCCCNCCOc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL131484;21418;None;0;Human;Binding;Ki;=;1320,00;5,88;-234;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;319,1;9;1;3;4,09;Cc1ccc(OCCCNCCOc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL131495;21423;None;17;Human;Binding;Ki;=;16,00;7,80;-8;10;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;417,2;6;1;3;4,47;O=C1c2ccccc2C(=O)N1CCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL131495;21423;None;17;Human;Binding;Ki;=;3,16;8,50;-8;10;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;417,2;6;1;3;4,47;O=C1c2ccccc2C(=O)N1CCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1021/jm070516u
CHEMBL131851;21706;None;0;Human;Binding;Ki;=;694,00;6,16;-1;2;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;233,2;5;1;2;2,94;CCCCNC1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL131926;21798;None;0;Human;Binding;Ki;=;1,26;8,90;-;1;Binding affinity towards dopamine D2 receptor;ChEMBL;414,2;5;2;5;3,64;COc1nc(N)c(Cl)cc1C(=O)NC1CC2CCCC(C1)N2Cc1ccccc1;https://dx.doi.org/10.1016/0960-894X(94)00453-M
CHEMBL131997;21878;None;0;Human;Binding;Ki;=;302,00;6,52;-575;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;319,1;9;1;3;4,09;Cc1ccc(OCCNCCCOc2ccccc2)cc1Cl;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL131997;21878;None;0;Human;Binding;Ki;=;299,00;6,52;-575;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;319,1;9;1;3;4,09;Cc1ccc(OCCNCCCOc2ccccc2)cc1Cl;https://dx.doi.org/10.1021/jm970422s
CHEMBL132261;22186;None;0;Human;Binding;Ki;=;1046,00;5,98;-5;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;383,2;8;0;3;5,88;CCCN(CCc1cccs1)C1CCc2c(cccc2OC2CCCC2)C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL132455;22407;None;0;Human;Binding;Ki;=;1412,54;5,85;-323;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;316,1;10;1;5;3,03;O=[N+]([O-])c1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL132455;22407;None;0;Human;Binding;Ki;=;1400,00;5,85;-323;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;316,1;10;1;5;3,03;O=[N+]([O-])c1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL132574;22532;None;0;Human;Binding;Ki;=;630,96;6,20;-25;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;429,2;9;1;3;6,17;CCCN(CCC)[C@@H]1CCc2c(ccc(C(O)Cc3ccc(Cl)cc3)c2OC)[C@@H]1C;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL132575;22534;None;0;Human;Binding;EC50;=;170,00;6,77;1;2;Tested for intrinsic activity towards Dopamine receptor D2 in CHO cells;ChEMBL;264,2;5;1;3;3,97;CCCN(CCC)C1CCC2=C(CCC/C2=N\O)C1;https://dx.doi.org/10.1021/jm0307786
CHEMBL132724;22699;None;0;Human;Binding;Ki;=;125,89;6,90;-12;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;369,2;8;0;1;6,10;CCCN(CCC)[C@H]1CCc2cc(CCc3ccc(Cl)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL132769;22746;None;0;Human;Binding;Ki;=;125,89;6,90;-25;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;399,2;9;0;2;6,11;CCCN(CCC)[C@@H]1CCc2c(ccc(CCc3ccc(Cl)cc3)c2OC)C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL132789;22780;None;1;Human;Binding;Ki;=;398,11;6,40;-100;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;369,2;8;0;1;6,10;CCCN(CCC)[C@@H]1CCc2cc(CCc3ccc(Cl)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL132884;22891;None;0;Human;Binding;Ki;=;228,00;6,64;-436;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;305,1;9;1;3;3,78;Clc1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL132884;22891;None;0;Human;Binding;Ki;=;229,09;6,64;-436;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;305,1;9;1;3;3,78;Clc1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL133085;23129;None;0;Human;Binding;Ki;=;10,80;7,97;-13;3;Tested for the inhibitory activity against D2H (high-affinity states) receptor in infected HEK 293 cells.;ChEMBL;373,1;5;1;3;3,36;CCCN(C/C=C/I)C1COc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00050a021
CHEMBL133085;23129;None;0;Human;Binding;Ki;=;784,00;6,11;-13;3;Tested for the inhibitory activity against Dopamine D2 receptor in infected Sf9 cells;ChEMBL;373,1;5;1;3;3,36;CCCN(C/C=C/I)C1COc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00050a021
CHEMBL133166;23249;None;0;Human;Binding;Ki;=;794,33;6,10;-125;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;424,3;9;0;4;5,45;CCCN(CCC)C1CCc2cc(CN(C(=O)OC)c3ccc(OC)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL133519;23703;None;0;Human;Binding;Ki;=;794,33;6,10;-251;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;377,3;9;0;2;5,65;CCCN(CCC)[C@@H]1CCc2cc(CCc3ccc(C(C)=O)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL133524;23710;None;0;Human;Binding;Ki;=;5,00;8,30;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;431,2;7;1;3;4,86;O=C1c2ccccc2C(=O)N1CCCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL133800;24026;None;0;Human;Binding;Ki;=;1000,00;6,00;-251;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;377,3;9;0;2;5,65;CCCN(CCC)C1CCc2cc(CCc3ccc(C(C)=O)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL133830;24071;None;29;Human;Binding;Ki;=;78,00;7,11;-3;2;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;163,1;0;2;2;1,21;NC1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL133830;24071;None;29;Human;Binding;Ki;=;3,30;8,48;-3;2;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;163,1;0;2;2;1,21;NC1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL133938;24189;None;0;Human;Binding;Ki;=;250,00;6,60;-4;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;329,2;7;0;3;4,57;CCCN(CCc1cccs1)[C@H]1CCc2ccc(OC)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL133938;24189;None;0;Human;Binding;Ki;=;1241,00;5,91;-4;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;329,2;7;0;3;4,57;CCCN(CCc1cccs1)[C@H]1CCc2ccc(OC)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL134326;24644;None;0;Human;Binding;Ki;=;5882,00;5,23;-9;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;261,2;6;0;2;3,67;CCCN(CCC)[C@@H]1CCc2ccc(OC)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL134423;24753;None;0;Human;Binding;IC50;=;140,00;6,85;-;1;Binding affinity towards dopamine D2 receptor;ChEMBL;434,2;4;0;2;4,12;Fc1ccc([Si]2(c3ccc(F)cc3)CCC(N3CCN(c4ccccc4)CC3)C2)cc1;https://dx.doi.org/10.1016/0960-894X(94)80007-3
CHEMBL134423;24753;None;0;Human;Binding;IC50;=;100,00;7,00;-;1;Binding affinity towards dopamine D2 receptor;ChEMBL;434,2;4;0;2;4,12;Fc1ccc([Si]2(c3ccc(F)cc3)CCC(N3CCN(c4ccccc4)CC3)C2)cc1;https://dx.doi.org/10.1016/0960-894X(94)80007-3
CHEMBL134571;24918;None;0;Human;Binding;Ki;=;173,00;6,76;-29;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;205,1;2;1;2;2,20;CCN(C)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL134571;24918;None;0;Human;Binding;Ki;=;2,50;8,60;-29;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;205,1;2;1;2;2,20;CCN(C)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL134701;25081;None;0;Human;Binding;Ki;=;120,00;6,92;7;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;233,2;4;0;2;2,89;CCN(CC)C1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL134747;25140;None;2;Human;Binding;Ki;=;524,00;6,28;-263;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL134759;25158;None;12;Human;Binding;Ki;=;180,00;6,75;2;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;205,1;3;1;2;2,16;CCNC1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL134866;25270;None;0;Human;Binding;Ki;=;181,00;6,74;1;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;205,1;2;0;2;2,11;COc1cccc2c1CCC(N(C)C)C2;https://dx.doi.org/10.1021/jm960345l
CHEMBL135048;25487;None;9;Human;Binding;Ki;=;131,00;6,88;3;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;191,1;2;1;2;1,77;CNC1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL135152;25612;None;26;Human;Binding;Ki;=;380,00;6,42;-2;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;219,2;4;1;2;2,55;CCCNC1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL135932;26397;None;1;Human;Binding;Ki;=;5,40;8,27;-12;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;191,1;1;1;2;1,81;CN(C)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL135932;26397;None;1;Human;Binding;Ki;=;55,00;7,26;-12;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;191,1;1;1;2;1,81;CN(C)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL135944;26415;None;0;Human;Binding;Ki;=;3351,00;5,47;-12;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;261,2;6;0;2;3,67;CCCN(CCC)[C@H]1CCc2ccc(OC)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL135954;26426;None;2;Human;Binding;Ki;=;59,00;7,23;-8;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1cccs1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL135954;26426;None;2;Human;Binding;Ki;=;0,76;9,12;-8;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1cccs1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL1365455;27105;3H-YM 09151-2;28;Human;Binding;pKi;=;10000,00;5,00;-10;11;-;PDSP KiDatabase;313,1;2;0;3;3,77;CN1[C@H]2CC[C@@H]1CC(OC(=O)c1cc(Cl)cc(Cl)c1)C2;-
CHEMBL137781;28710;None;0;Human;Binding;Ki;=;60,00;7,22;-54;16;Binding affinity against Dopamine receptor D2;ChEMBL;335,2;1;1;2;3,05;C[C@H]1C[C@@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1;https://dx.doi.org/10.1021/jm020153s
CHEMBL138792;29893;None;0;Human;Binding;Ki;=;585,00;6,23;-4;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;165,1;0;1;1;1,64;N[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL138792;29893;None;0;Human;Binding;Ki;=;864,00;6,06;-4;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;165,1;0;1;1;1,64;N[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL138989;30147;None;0;Human;Binding;Ki;=;330,00;6,48;-165;14;Binding affinity towards Dopamine receptor D2;ChEMBL;335,2;1;1;2;3,05;C[C@@H]1C[C@@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1;https://dx.doi.org/10.1021/jm020153s
CHEMBL138998;30155;None;0;Human;Binding;Ki;=;16,90;7,77;-37;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;428,3;8;0;3;4,88;CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL138998;30155;None;0;Human;Binding;Ki;=;4,94;8,31;-37;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;428,3;8;0;3;4,88;CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL139089;30256;None;0;Human;Binding;Ki;=;37,00;7,43;-10;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;386,2;6;1;3;3,76;O=C1CC2(CCCC2)CC(=O)N1CCCCN[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL139089;30256;None;0;Human;Binding;Ki;=;68,20;7,17;-10;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;386,2;6;1;3;3,76;O=C1CC2(CCCC2)CC(=O)N1CCCCN[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL139345;30554;None;0;Human;Binding;Ki;=;582,00;6,24;-8;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;207,1;3;1;1;2,68;CCCN[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL139345;30554;None;0;Human;Binding;Ki;=;167,00;6,78;-8;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;207,1;3;1;1;2,68;CCCN[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL139600;30783;None;0;Human;Binding;Ki;=;30,00;7,52;3;5;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;421,2;9;1;6;3,06;COc1ccccc1N1CCN(CCCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL139600;30783;None;0;Human;Binding;Ki;=;30,20;7,52;3;5;Binding affinity to dopamine D2;ChEMBL;421,2;9;1;6;3,06;COc1ccccc1N1CCN(CCCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL139600;30783;None;0;Human;Binding;Ki;=;25,00;7,60;3;5;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;421,2;9;1;6;3,06;COc1ccccc1N1CCN(CCCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL139600;30783;None;0;Human;Binding;Ki;=;7,10;8,15;3;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;421,2;9;1;6;3,06;COc1ccccc1N1CCN(CCCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL139722;30872;None;0;Human;Binding;Ki;=;480,00;6,32;-16;4;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;379,2;6;1;6;1,90;COc1ccccc1N1CCN(CCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL139722;30872;None;0;Human;Binding;Ki;=;520,00;6,28;-16;4;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;379,2;6;1;6;1,90;COc1ccccc1N1CCN(CCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL139722;30872;None;0;Human;Binding;Ki;=;524,81;6,28;-16;4;Binding affinity to dopamine D2;ChEMBL;379,2;6;1;6;1,90;COc1ccccc1N1CCN(CCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;119,00;6,92;-346;8;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm040190e
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;44,80;7,35;-346;8;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm040190e
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;44,80;7,35;-346;8;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm200288r
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;44,80;7,35;-346;8;Binding affinity for human dopamine D2 receptor;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm049465g
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;82,00;7,09;-346;8;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;5740,00;5,24;-346;8;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm020952a
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;320,00;6,50;-346;8;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm025558r
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;80,00;7,10;-346;8;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm025558r
CHEMBL139926;31043;None;0;Human;Binding;Ki;=;323,59;6,49;-346;8;Binding affinity to dopamine D2;ChEMBL;445,1;7;1;4;5,07;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm0611152
CHEMBL140006;31133;None;0;Human;Binding;Ki;=;43000,00;4,37;-5128;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;384,1;3;1;3;4,67;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140006;31133;None;0;Human;Binding;Ki;=;36000,00;4,44;-5128;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;384,1;3;1;3;4,67;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140099;31227;None;3;Human;Binding;Ki;=;3100,00;5,51;-1047;5;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2[nH]c(CN3CCN(c4ccccc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140099;31227;None;3;Human;Binding;Ki;=;3100,00;5,51;-1047;5;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2[nH]c(CN3CCN(c4ccccc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm060166w
CHEMBL140099;31227;None;3;Human;Binding;Ki;=;3100,00;5,51;-1047;5;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2[nH]c(CN3CCN(c4ccccc4)CC3)cc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL140099;31227;None;3;Human;Binding;Ki;=;290,00;6,54;-1047;5;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2[nH]c(CN3CCN(c4ccccc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm060166w
CHEMBL140099;31227;None;3;Human;Binding;Ki;=;290,00;6,54;-1047;5;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2[nH]c(CN3CCN(c4ccccc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140165;31309;None;0;Human;Binding;Ki;=;2400,00;5,62;-18;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;334,2;3;1;3;3,50;N#Cc1ccc2[nH]cc(CN3CCN(c4ccc(F)cc4)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140165;31309;None;0;Human;Binding;Ki;=;1800,00;5,75;-18;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;334,2;3;1;3;3,50;N#Cc1ccc2[nH]cc(CN3CCN(c4ccc(F)cc4)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140258;31421;None;0;Human;Binding;Ki;=;220,00;6,66;-97;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2cc(CN3CCN(c4ccccc4Cl)CC3)[nH]c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140258;31421;None;0;Human;Binding;Ki;=;500,00;6,30;-97;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2cc(CN3CCN(c4ccccc4Cl)CC3)[nH]c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140594;31763;None;0;Human;Binding;Ki;=;7900,00;5,10;-3715;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(Cl)cc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140594;31763;None;0;Human;Binding;Ki;=;7600,00;5,12;-3715;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(Cl)cc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL140612;31786;None;0;Human;Binding;Ki;=;11,00;7,96;1;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL140612;31786;None;0;Human;Binding;Ki;=;13,00;7,89;1;4;Displacement of [3H]spiperone from wild type human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL140612;31786;None;0;Human;Binding;Ki;=;83,00;7,08;1;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor E181V/I183S mutant expressed in HEK293 cells;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL140612;31786;None;0;Human;Binding;Ki;=;3,90;8,41;1;4;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL140612;31786;None;0;Human;Binding;Ki;=;11,00;7,96;1;4;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL140872;32111;None;0;Human;Binding;Ki;=;98,00;7,01;-15;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;328,2;6;0;5;2,40;O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL140872;32111;None;0;Human;Binding;Ki;=;98,00;7,01;-15;11;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;328,2;6;0;5;2,40;O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL140872;32111;UNDEFINED;0;Human;Binding;pKi;=;98,00;7,01;-15;11;-;PDSP KiDatabase;328,2;6;0;5;2,40;O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1;-
CHEMBL140968;32235;None;0;Human;Binding;Ki;=;70,79;7,15;-1;5;Binding affinity to dopamine D2;ChEMBL;421,2;9;1;6;3,06;COc1ccccc1N1CCN(CCCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL140968;32235;None;0;Human;Binding;Ki;=;35,00;7,46;-1;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;421,2;9;1;6;3,06;COc1ccccc1N1CCN(CCCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL140968;32235;None;0;Human;Binding;Ki;=;71,00;7,15;-1;5;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;421,2;9;1;6;3,06;COc1ccccc1N1CCN(CCCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL140968;32235;None;0;Human;Binding;Ki;=;76,00;7,12;-1;5;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;421,2;9;1;6;3,06;COc1ccccc1N1CCN(CCCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL141035;32326;None;0;Human;Binding;Ki;=;950,00;6,02;-1047;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2[nH]c(CN3CCN(c4ccccc4Cl)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL141035;32326;None;0;Human;Binding;Ki;=;2300,00;5,64;-1047;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2[nH]c(CN3CCN(c4ccccc4Cl)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL141343;32701;None;12;Human;Binding;IC50;=;16760,00;4,78;-16;11;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;520,4;5;1;8;4,21;Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2;-
CHEMBL141343;32701;None;12;Human;Binding;Ki;=;5587,00;5,25;-16;11;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;520,4;5;1;8;4,21;Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2;-
CHEMBL141419;32800;None;1;Human;Binding;Ki;=;63,00;7,20;-74;5;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;521,1;8;1;4;3,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3[te]2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL141419;32800;None;1;Human;Binding;Ki;=;39,00;7,41;-74;5;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;521,1;8;1;4;3,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3[te]2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL141510;32898;None;0;Human;Binding;Ki;=;45,60;7,34;-22;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;263,2;6;0;1;4,20;CCCCN(CCC)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL141510;32898;None;0;Human;Binding;Ki;=;210,00;6,68;-22;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;263,2;6;0;1;4,20;CCCCN(CCC)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL141511;32899;None;0;Human;Binding;Ki;=;790,00;6,10;-2;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;221,2;4;1;1;3,07;CCCCN[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL141511;32899;None;0;Human;Binding;Ki;=;254,00;6,59;-2;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;221,2;4;1;1;3,07;CCCCN[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL141537;32930;None;0;Human;Binding;Ki;=;2830,00;5,55;-3;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;255,1;3;1;1;3,47;Fc1cccc2c1CC[C@@H](NCc1ccccc1)C2;https://dx.doi.org/10.1021/jm960350p
CHEMBL141537;32930;None;0;Human;Binding;Ki;=;779,00;6,11;-3;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;255,1;3;1;1;3,47;Fc1cccc2c1CC[C@@H](NCc1ccccc1)C2;https://dx.doi.org/10.1021/jm960350p
CHEMBL141845;33279;None;0;Human;Binding;Ki;=;85,00;7,07;-223;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;379,2;6;1;6;1,90;COc1ccccc1N1CCN(CCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL141845;33279;None;0;Human;Binding;Ki;=;288,40;6,54;-223;5;Binding affinity to dopamine D2;ChEMBL;379,2;6;1;6;1,90;COc1ccccc1N1CCN(CCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL141845;33279;None;0;Human;Binding;Ki;=;140,00;6,85;-223;5;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;379,2;6;1;6;1,90;COc1ccccc1N1CCN(CCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL141845;33279;None;0;Human;Binding;Ki;=;290,00;6,54;-223;5;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;379,2;6;1;6;1,90;COc1ccccc1N1CCN(CCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL141845;33279;None;0;Human;Binding;Ki;=;290,00;6,54;-223;5;Binding affinity for human dopamine receptor D2 long;ChEMBL;379,2;6;1;6;1,90;COc1ccccc1N1CCN(CCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm049612a
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;120,00;6,92;-7;7;Displacement of [3H]spiperone from human cloned dopamine D2L receptor E181V/I183S mutant expressed in HEK293 cells;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;99,00;7,00;-7;7;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;310,00;6,51;-7;7;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;310,00;6,51;-7;7;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;200,00;6,70;-7;7;Displacement of [3H]spiperone from human D2-short receptor expressed in CHO cell membranes;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;310,00;6,51;-7;7;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;270,00;6,57;-7;7;Displacement of [3H]spiperone from human D2-long receptor expressed in CHO cell membranes;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;309,03;6,51;-7;7;Binding affinity to dopamine D2;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL142020;33495;None;1;Human;Binding;Ki;=;150,00;6,82;-7;7;Displacement of [3H]spiperone from wild type human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL142217;33721;None;0;Human;Binding;Ki;=;3500,00;5,46;-218;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2[nH]cc(CN3CCN(c4ccccc4)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL142217;33721;None;0;Human;Binding;Ki;=;34000,00;4,47;-218;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2[nH]cc(CN3CCN(c4ccccc4)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL1424807;34048;None;54;Human;Binding;Ki;=;1148,15;5,94;-3;3;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;230;1;1;2;2,40;Clc1cccc(N2CCNCC2)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL1424807;34048;None;54;Human;Binding;Ki;=;1160,00;5,94;-3;3;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;230;1;1;2;2,40;Clc1cccc(N2CCNCC2)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL1424807;34048;None;54;Human;Binding;Ki;=;137,30;6,86;-3;3;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;230;1;1;2;2,40;Clc1cccc(N2CCNCC2)c1Cl;https://dx.doi.org/10.1021/jm300482h
CHEMBL143022;34696;None;1;Human;Binding;Ki;=;151,36;6,82;-2;6;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;355,2;4;0;4;3,76;O=C1CC(CN2CCC(C(=O)c3ccc(F)cc3)CC2)Cc2occc21;https://dx.doi.org/10.1021/jm800602w
CHEMBL143027;34706;None;1;Human;Binding;Ki;=;16,22;7,79;-2;6;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;368,2;3;0;5;4,18;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2occc21;https://dx.doi.org/10.1021/jm800602w
CHEMBL143352;35090;None;0;Human;Binding;Ki;=;290,00;6,54;-21;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cccn3nccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL143352;35090;None;0;Human;Binding;Ki;=;269,15;6,57;-21;6;Binding affinity to dopamine D2;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cccn3nccc23)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL143352;35090;None;0;Human;Binding;Ki;=;270,00;6,57;-21;6;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cccn3nccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL143352;35090;None;0;Human;Binding;Ki;=;180,00;6,75;-21;6;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cccn3nccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL143355;35092;None;0;Human;Binding;Ki;=;540,00;6,27;-51;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2[nH]cc(CN3CCN(c4ccccc4Cl)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL143355;35092;None;0;Human;Binding;Ki;=;1400,00;5,85;-51;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2[nH]cc(CN3CCN(c4ccccc4Cl)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL143761;35389;None;0;Human;Binding;Ki;=;28000,00;4,55;-23442;5;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;334,2;3;1;3;3,50;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(F)cc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL143761;35389;None;0;Human;Binding;Ki;=;28000,00;4,55;-23442;5;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;334,2;3;1;3;3,50;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(F)cc4)CC3)cc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL143761;35389;None;0;Human;Binding;Ki;=;19000,00;4,72;-23442;5;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;334,2;3;1;3;3,50;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(F)cc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm060166w
CHEMBL143761;35389;None;0;Human;Binding;Ki;=;28000,00;4,55;-23442;5;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;334,2;3;1;3;3,50;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(F)cc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm060166w
CHEMBL143761;35389;None;0;Human;Binding;Ki;=;19000,00;4,72;-23442;5;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;334,2;3;1;3;3,50;N#Cc1ccc2[nH]c(CN3CCN(c4ccc(F)cc4)CC3)cc2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL144055;35723;None;0;Human;Binding;Ki;=;501,19;6,30;-79;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;557,3;10;1;4;7,02;CCN(Cc1ccccc1)S(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL144141;35817;None;0;Human;Binding;Ki;=;630,96;6,20;-7;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;515,2;8;2;4;6,61;COc1ccc(S(=O)(=O)Nc2ccccc2)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL144494;36199;None;0;Human;Binding;IC50;=;870,00;6,06;-;2;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;409,2;7;0;6;4,19;COc1cccc(-c2csc(CCN3CCN(c4ccccc4OC)CC3)n2)c1;https://dx.doi.org/10.1021/jm981041x
CHEMBL144600;36313;None;0;Human;Binding;Ki;=;398,11;6,40;-10;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;439,2;6;2;4;4,46;COc1ccc(S(N)(=O)=O)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL144811;36557;None;0;Human;Binding;IC50;=;250,00;6,60;-;2;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;399,2;8;1;6;2,26;COc1ccc(OC)c(C(=O)NCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm981041x
CHEMBL145141;36977;None;0;Human;Binding;Ki;=;125,89;6,90;-31;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;514,2;8;1;4;6,78;COc1ccc(S(=O)(=O)Cc2ccccc2)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL145408;37316;None;0;Human;Binding;Ki;=;1000,00;6,00;-158;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;555,3;7;1;4;6,95;COc1ccc(S(=O)(=O)N2CCCc3ccccc32)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL145545;37473;None;0;Human;Binding;Ki;=;630,96;6,20;-99;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;529,2;8;1;4;6,63;COc1ccc(S(=O)(=O)N(C)c2ccccc2)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL145584;37516;None;42;Human;Binding;Ki;=;20000,00;4,70;2;3;Affinity towards Dopamine receptor D2;ChEMBL;137,1;2;2;2;0,89;NCCc1cccc(O)c1;https://dx.doi.org/10.1021/jm9800292
CHEMBL1457510;37697;None;0;Human;Binding;Ki;=;49,20;7,31;-13;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor after 1 hr;ChEMBL;325,1;1;1;5;2,79;COc1c(O)ccc2c1CN1CCc3cc4c(cc3[C@@H]1C2)OCO4;https://dx.doi.org/10.1016/j.bmcl.2017.01.090
CHEMBL1457510;37697;None;0;Human;Binding;Ki;=;145,00;6,84;-13;6;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;325,1;1;1;5;2,79;COc1c(O)ccc2c1CN1CCc3cc4c(cc3[C@@H]1C2)OCO4;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL145939;37927;None;0;Human;Binding;Ki;=;1400,00;5,85;-4265;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;365,1;5;0;3;3,45;O=S(=O)(c1ccccc1)C1CCN(CCc2ccc(F)cc2F)CC1;https://dx.doi.org/10.1021/jm011030v
CHEMBL146144;38167;None;0;Human;Binding;Ki;=;1700,00;5,77;-4265;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;321,2;3;1;2;3,99;OC1c2ccccc2CCC12CCN(CCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm011030v
CHEMBL146233;38266;None;0;Human;Binding;Ki;=;570,00;6,24;-316;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;373,2;4;0;3;4,38;COc1ccc2c(c1)CCC1(CCN(CCc3ccc(F)cc3F)CC1)O2;https://dx.doi.org/10.1021/jm011030v
CHEMBL146246;38289;None;6;Human;Binding;Ki;=;5147,00;5,29;-1412;9;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;401,2;5;1;5;2,16;NS(=O)(=O)c1ccc(N2CCN(CCC3OCCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL146485;38589;None;0;Human;Binding;Ki;=;650,00;6,19;-1288;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;408,1;6;1;4;2,54;NC(=O)c1cccc(S(=O)(=O)C2CCN(CCc3ccc(F)cc3F)CC2)c1;https://dx.doi.org/10.1021/jm011030v
CHEMBL146556;38685;None;1;Human;Binding;Ki;=;738,00;6,13;-2;5;Inhibition of human dopamine D2 receptor;ChEMBL;350,2;3;0;4;3,00;c1ccc2c(c1)CC(CN1CCN(c3ccc4c(c3)OCCO4)CC1)C2;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL146595;38731;None;0;Human;Binding;Ki;=;1500,00;5,82;-3715;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;391,1;3;0;3;3,76;O=S1(=O)c2ccccc2CCC12CCN(CCc1ccc(F)cc1F)CC2;https://dx.doi.org/10.1021/jm011030v
CHEMBL146757;38936;None;0;Human;Binding;Ki;=;698,00;6,16;-181;2;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;352,2;4;1;4;3,41;COc1ccc(C2CCN(Cc3ccc4c(c3)NC(=O)CO4)CC2)cc1;https://dx.doi.org/10.1021/jm990277d
CHEMBL146856;39048;None;0;Human;Binding;Ki;=;9943,00;5,00;-91;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;403,2;2;1;5;4,69;Clc1ccc2c(c1)C(N1CCN(Cc3ccccc3)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL146998;39220;None;0;Human;Binding;Ki;=;680,00;6,17;-1288;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;390,1;5;0;4;3,32;N#Cc1ccccc1S(=O)(=O)C1CCN(CCc2ccc(F)cc2F)CC1;https://dx.doi.org/10.1021/jm011030v
CHEMBL147059;39281;None;0;Human;Binding;Ki;=;610,00;6,21;-239;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;350,2;3;1;3;4,01;Cc1ccc(C2CCN(Cc3ccc4c(c3)OCC(=O)N4)CC2)cc1C;https://dx.doi.org/10.1021/jm990277d
CHEMBL147130;39368;None;0;Human;Binding;Ki;=;2200,00;5,66;-120;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;323,2;3;1;4;2,34;O=C1COc2ccc(CN3CCN(c4ccccc4)CC3)cc2N1;https://dx.doi.org/10.1021/jm990277d
CHEMBL147159;39404;None;1;Human;Binding;Ki;=;10,30;7,99;-1;3;Binding affinity towards human Dopamine receptor D2L evaluated using [3H]spiperone;ChEMBL;361,2;4;2;3;5,07;Oc1ccc(C2=CCN(C[C@@H]3CCC=C(c4ccc(O)cc4)C3)CC2)cc1;https://dx.doi.org/10.1021/jm00026a007
CHEMBL147159;39404;None;1;Human;Binding;Ki;=;2,20;8,66;-1;3;Binding affinity towards human Dopamine receptor D2L evaluated using [3H]N-0437;ChEMBL;361,2;4;2;3;5,07;Oc1ccc(C2=CCN(C[C@@H]3CCC=C(c4ccc(O)cc4)C3)CC2)cc1;https://dx.doi.org/10.1021/jm00026a007
CHEMBL147164;39412;None;0;Human;Binding;Ki;=;710,00;6,15;-141;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;361,2;3;0;2;4,51;Fc1ccc(CCN2CCC3(CCc4c(F)cccc4O3)CC2)c(F)c1;https://dx.doi.org/10.1021/jm011030v
CHEMBL147431;39636;None;0;Human;Binding;Ki;=;750,00;6,12;-316;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;343,2;3;0;2;4,37;Fc1ccc(CCN2CCC3(CCc4ccccc4O3)CC2)c(F)c1;https://dx.doi.org/10.1021/jm011030v
CHEMBL147830;39972;None;0;Human;Binding;Kd;=;1,91;8,72;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;359,1;6;0;2;5,32;O=C(CCCN1CCC(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL147830;39972;None;0;Human;Binding;Ki;=;1,74;8,76;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;359,1;6;0;2;5,32;O=C(CCCN1CCC(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL147897;40049;None;0;Human;Binding;IC50;=;650,00;6,19;-;2;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;423,3;7;1;5;2,89;COc1ccc2c(c1)CC(NC(=O)CCN1CCN(c3ccccc3OC)CC1)CC2;https://dx.doi.org/10.1021/jm981041x
CHEMBL148024;40207;None;0;Human;Binding;Ki;=;280,00;6,55;-93;2;In vitro binding affinity was measured at the cloned human Dopamine receptor D2 using [3H]spiroperidol as radioligand.;ChEMBL;366,2;5;1;6;2,53;COc1ccccc1N1CCN(CCNC2=Nc3ccccc3OC2)CC1;https://dx.doi.org/10.1021/jm981041x
CHEMBL148042;40227;None;0;Human;Binding;Ki;=;19117,00;4,72;-117;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;341,1;0;1;5;3,51;CN1CCCN(C2=Nc3cccnc3Nc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm0104825
CHEMBL148058;40249;None;0;Human;Binding;Ki;=;1000,00;6,00;-1905;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;408,1;6;1;4;2,54;NC(=O)c1ccc(S(=O)(=O)C2CCN(CCc3ccc(F)cc3F)CC2)cc1;https://dx.doi.org/10.1021/jm011030v
CHEMBL148348;40576;None;0;Human;Binding;Ki;=;490,00;6,31;-158;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;361,2;3;0;2;4,51;Fc1ccc(CCN2CCC3(CCc4ccc(F)cc4O3)CC2)c(F)c1;https://dx.doi.org/10.1021/jm011030v
CHEMBL148352;40579;None;0;Human;Binding;Ki;=;120,00;6,92;-5;2;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;380,2;7;1;4;3,07;COc1cc2c(c(C(=O)NC[C@@H]3CCCN3CCc3ccccc3)c1)OCC2;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
CHEMBL148353;40582;None;0;Human;Binding;Ki;=;136,00;6,87;-1;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;443,2;3;2;5;5,66;Clc1ccc2c(c1)C(NC1CC3CCC(C1)N3Cc1ccccc1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL148418;40669;None;0;Human;Binding;Ki;=;530,00;6,28;-33;2;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;307,2;3;0;2;4,09;c1ccc(CCN2CCC3(CCc4ccccc4O3)CC2)cc1;https://dx.doi.org/10.1021/jm011030v
CHEMBL148559;40822;None;0;Human;Binding;Ki;=;571,00;6,24;-12;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;395,2;1;1;5;4,82;Clc1ccc2c(c1)C(N1CCN(C3CCCCC3)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL148694;40972;None;0;Human;Binding;Ki;=;149,00;6,83;-1;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;423,2;3;2;5;5,31;Cc1ccc2c(c1)C(NC1CC3CCC(C1)N3Cc1ccccc1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL14899;41366;None;0;Human;Binding;Ki;=;188,00;6,73;1;3;Binding affinity to Dopamine receptor D2 was determined;ChEMBL;349,1;4;1;6;3,08;CNc1nc(Cl)c(Sc2ccccc2)c(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/s0960-894x(01)00167-6
CHEMBL149233;41714;None;0;Human;Binding;Ki;=;129,00;6,89;-20;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;323,2;3;1;4;2,34;O=C1COc2cc(CN3CCN(c4ccccc4)CC3)ccc2N1;https://dx.doi.org/10.1021/jm990277d
CHEMBL149423;41919;None;0;Human;Binding;Ki;=;840,00;6,08;-251;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;361,2;3;0;2;4,51;Fc1ccc(CCN2CCC3(CCc4cccc(F)c4O3)CC2)c(F)c1;https://dx.doi.org/10.1021/jm011030v
CHEMBL149429;41926;None;2;Human;Binding;Ki;=;1100,00;5,96;-776;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;399,1;5;0;3;4,10;O=S(=O)(c1ccc(Cl)cc1)C1CCN(CCc2ccc(F)cc2F)CC1;https://dx.doi.org/10.1021/jm011030v
CHEMBL149497;41996;None;0;Human;Binding;Ki;=;1130,00;5,95;-165;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;352,2;4;1;4;3,41;COc1ccc(C2CCN(Cc3ccc4c(c3)OCC(=O)N4)CC2)cc1;https://dx.doi.org/10.1021/jm990277d
CHEMBL149510;42009;None;0;Human;Binding;Ki;=;1100,00;5,96;-35;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;369,2;5;1;3;3,98;OC(CCc1ccccc1)CN1CCC2(CCc3cc(F)ccc3O2)CC1;https://dx.doi.org/10.1021/jm011030v
CHEMBL149596;42090;None;0;Human;Binding;Ki;=;572,00;6,24;-316;2;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;350,2;3;1;3;4,01;Cc1ccc(C2CCN(Cc3ccc4c(c3)NC(=O)CO4)CC2)cc1C;https://dx.doi.org/10.1021/jm990277d
CHEMBL149723;42239;None;0;Human;Binding;Ki;=;6,70;8,17;14;2;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;396,2;7;1;4;3,78;CSc1cc2c(c(C(=O)NC[C@H]3CCCN3CCc3ccccc3)c1)OCC2;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
CHEMBL14998;42526;None;0;Human;Binding;Ki;=;62,00;7,21;4;3;Binding affinity to Dopamine receptor D2 was determined;ChEMBL;368,1;3;0;5;4,00;Cc1nc(Cl)c(Sc2ccc(Cl)cc2)c(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/s0960-894x(01)00167-6
CHEMBL150161;42725;None;1;Human;Binding;Ki;=;489,40;6,31;-4;12;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;361,1;6;1;3;4,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL150161;42725;None;1;Human;Binding;Ki;=;33,00;7,48;-4;12;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;361,1;6;1;3;4,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL150161;42725;None;1;Human;Binding;Ki;=;51,10;7,29;-4;12;Binding affinity to human cloned dopamine D2 receptor by radioligand binding assay;ChEMBL;361,1;6;1;3;4,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.03.057
CHEMBL150161;42725;None;1;Human;Binding;Ki;=;489,00;6,31;-4;12;Binding affinity to human cloned dopamine D2 receptor by radioligand binding assay;ChEMBL;361,1;6;1;3;4,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.03.057
CHEMBL150161;42725;None;1;Human;Binding;Ki;=;51,10;7,29;-4;12;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;361,1;6;1;3;4,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL150161;42725;UNDEFINED;1;Human;Binding;pKi;=;51,10;7,29;-4;12;-;PDSP KiDatabase;361,1;6;1;3;4,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1;-
CHEMBL150161;42725;UNDEFINED;1;Human;Binding;pKi;=;489,40;6,31;-4;12;-;PDSP KiDatabase;361,1;6;1;3;4,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1;-
CHEMBL150161;42725;UNDEFINED;1;Human;Binding;pKi;=;33,00;7,48;-4;12;-;PDSP KiDatabase;361,1;6;1;3;4,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1;-
CHEMBL150173;42739;None;0;Human;Binding;Ki;=;2980,00;5,53;-275;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;337,2;3;1;4;2,65;Cc1ccc(N2CCN(Cc3ccc4c(c3)OCC(=O)N4)CC2)cc1;https://dx.doi.org/10.1021/jm990277d
CHEMBL150181;42753;None;0;Human;Binding;Ki;=;2340,00;5,63;-457;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;351,2;3;1;4;2,96;Cc1ccc(N2CCN(Cc3ccc4c(c3)NC(=O)CO4)CC2)cc1C;https://dx.doi.org/10.1021/jm990277d
CHEMBL150210;42786;None;0;Human;Binding;Ki;=;1000,00;6,00;-346;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;341,2;3;0;1;4,78;Fc1ccc(CCN2CCC3(CCc4ccccc4C3)CC2)c(F)c1;https://dx.doi.org/10.1021/jm011030v
CHEMBL1503220;42914;None;2;Human;Binding;AC50;=;2890,00;5,54;6;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;434,1;5;1;4;3,77;CCN1C(=O)c2ccccc2[S+]([O-])c2ccc(C(=O)NCc3ccc(OC)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL1503220;42914;None;2;Human;Binding;Ki;=;300,00;6,52;6;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;434,1;5;1;4;3,77;CCN1C(=O)c2ccccc2[S+]([O-])c2ccc(C(=O)NCc3ccc(OC)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL151286;43976;None;0;Human;Binding;Ki;=;287,00;6,54;-112;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;336,2;3;1;3;3,71;Cc1ccc(C2CCN(Cc3ccc4c(c3)OCC(=O)N4)CC2)cc1;https://dx.doi.org/10.1021/jm990277d
CHEMBL15136;44023;None;0;Human;Binding;Ki;=;14,00;7,85;-26;6;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;261,2;5;1;2;3,62;CCCN(CCC)[C@@H]1Cc2cccc(O)c2C[C@H]1C;https://dx.doi.org/10.1021/jm001015a
CHEMBL15146;44083;None;1;Human;Binding;Ki;=;55,10;7,26;1;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL15146;44083;None;1;Human;Binding;Ki;=;90,00;7,05;1;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL151533;44136;None;0;Human;Binding;Ki;=;346,00;6,46;-50;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;351,2;3;1;4;2,96;Cc1ccc(N2CCN(Cc3ccc4c(c3)OCC(=O)N4)CC2)cc1C;https://dx.doi.org/10.1021/jm990277d
CHEMBL152010;44599;None;0;Human;Binding;Ki;=;107,00;6,97;-588;3;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;445,1;7;2;4;4,20;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1[nH]nc2ccccc12;https://dx.doi.org/10.1021/jm020952a
CHEMBL152159;44777;None;0;Human;Binding;Ki;=;680,00;6,17;-398;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;397,2;9;1;5;3,04;COc1cccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL152262;44887;None;0;Human;Binding;Ki;=;63,00;7,20;-67;3;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;444,1;7;2;3;4,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1c[nH]c2ccccc12;https://dx.doi.org/10.1021/jm020952a
CHEMBL152304;44938;None;0;Human;Binding;Ki;=;430,00;6,37;-588;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;456,1;7;1;4;4,87;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccnc2ccccc12;https://dx.doi.org/10.1021/jm020952a
CHEMBL152391;45026;None;0;Human;Binding;Ki;=;1410,00;5,85;-5248;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;435,1;8;1;4;4,33;COc1cccc(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL15242;45055;None;0;Human;Binding;Ki;=;31,00;7,51;2;3;Binding affinity to Dopamine receptor D2 was determined;ChEMBL;369,1;3;0;4;4,79;CN1CCN(c2nc3ccccc3c(Cl)c2Sc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00167-6
CHEMBL152576;45216;None;0;Human;Binding;Ki;=;1130,00;5,95;-489;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;421,1;7;1;4;3,94;COc1cccc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL152587;45231;None;0;Human;Binding;Ki;=;770,00;6,11;-81;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;418,2;8;1;5;3,58;COc1cccc(C(=O)NCCCCN2CCN(c3nccc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL15270;45374;None;0;Human;Binding;Ki;=;62,00;7,21;-26;3;Binding affinity to Dopamine receptor D2 was determined;ChEMBL;458,1;6;1;5;6,32;Cc1nc(Cl)c(Sc2ccc(Cl)cc2)c(NC2CCN(Cc3ccccc3)CC2)n1;https://dx.doi.org/10.1016/s0960-894x(01)00167-6
CHEMBL152756;45431;None;0;Human;Binding;Ki;=;930,00;6,03;-2187;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;417,2;8;1;4;4,18;COc1cccc(C(=O)NCCCCN2CCN(c3cccc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL152869;45561;None;0;Human;Binding;Ki;=;253,00;6,60;-56;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;411,3;10;1;5;3,43;COc1cccc(C(=O)NCCCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL153956;46756;None;0;Human;Binding;Ki;=;537,03;6,27;-22;3;Binding affinity towards dopamine receptor D2;ChEMBL;395,2;5;0;4;4,17;COc1ccc2c(c1)CC(CN1CCC(C(=O)c3ccc(F)cc3)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL153956;46756;None;0;Human;Binding;Ki;=;380,19;6,42;-22;3;Binding affinity towards dopamine receptor D2;ChEMBL;395,2;5;0;4;4,17;COc1ccc2c(c1)CC(CN1CCC(C(=O)c3ccc(F)cc3)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL153956;46756;None;0;Human;Binding;Ki;=;194,98;6,71;-22;3;Binding affinity towards dopamine receptor D2;ChEMBL;395,2;5;0;4;4,17;COc1ccc2c(c1)CC(CN1CCC(C(=O)c3ccc(F)cc3)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL154286;47149;None;0;Human;Binding;Ki;=;640,00;6,19;-91;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;263,1;2;1;2;3,12;c1ccc2c(c1)CCN(Cc1c[nH]c3ncccc13)C2;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL154482;47403;None;0;Human;Binding;Ki;=;1300,00;5,89;-51;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;329,2;5;1;2;4,40;C1=C(/C=C/c2ccccc2)CCN(CCc2cc3ccc[nH]c-3n2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL154508;47437;None;0;Human;Binding;Ki;=;1149,00;5,94;-4265;6;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;455,2;7;1;3;5,48;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL154508;47437;None;0;Human;Binding;Ki;=;5200,00;5,28;-4265;6;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;455,2;7;1;3;5,48;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL155124;48141;None;0;Human;Binding;Ki;=;398,11;6,40;2;3;Binding affinity towards dopamine receptor D2;ChEMBL;321,2;3;0;4;2,65;O=C1CC(CN2CCN(c3ccccn3)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155207;48199;None;0;Human;Binding;Ki;=;1100,00;5,96;-602;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;319,2;5;1;2;4,41;c1ccc(CCC2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL155257;48235;None;0;Human;Binding;Ki;=;107,15;6,97;-13;3;Binding affinity towards dopamine receptor D2;ChEMBL;438,2;5;0;6;4,61;COc1cc2c(cc1OC)C(=O)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155257;48235;None;0;Human;Binding;Ki;=;162,18;6,79;-13;3;Binding affinity towards dopamine receptor D2;ChEMBL;438,2;5;0;6;4,61;COc1cc2c(cc1OC)C(=O)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155257;48235;None;0;Human;Binding;Ki;=;151,36;6,82;-13;3;Binding affinity towards dopamine receptor D2;ChEMBL;438,2;5;0;6;4,61;COc1cc2c(cc1OC)C(=O)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155388;48327;None;0;Human;Binding;Ki;=;1000,00;6,00;-38;3;Binding affinity towards dopamine receptor D2;ChEMBL;425,2;6;0;5;4,18;COc1cc2c(cc1OC)C(=O)CC(CN1CCC(C(=O)c3ccc(F)cc3)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155388;48327;None;0;Human;Binding;Ki;=;275,42;6,56;-38;3;Binding affinity towards dopamine receptor D2;ChEMBL;425,2;6;0;5;4,18;COc1cc2c(cc1OC)C(=O)CC(CN1CCC(C(=O)c3ccc(F)cc3)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155388;48327;None;0;Human;Binding;Ki;=;316,23;6,50;-38;3;Binding affinity towards dopamine receptor D2;ChEMBL;425,2;6;0;5;4,18;COc1cc2c(cc1OC)C(=O)CC(CN1CCC(C(=O)c3ccc(F)cc3)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155426;48357;None;0;Human;Binding;Ki;=;223,87;6,65;-4;3;Binding affinity towards dopamine receptor D2;ChEMBL;380,2;5;0;5;3,27;COc1ccc2c(c1)CC(CN1CCN(c3ccccc3OC)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155486;48393;None;0;Human;Binding;Ki;=;57,54;7,24;-15;3;Binding affinity towards dopamine receptor D2;ChEMBL;378,2;3;0;4;4,59;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155486;48393;None;0;Human;Binding;Ki;=;213,80;6,67;-15;3;Binding affinity towards dopamine receptor D2;ChEMBL;378,2;3;0;4;4,59;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL155486;48393;None;0;Human;Binding;Ki;=;64,57;7,19;-15;3;Binding affinity towards dopamine receptor D2;ChEMBL;378,2;3;0;4;4,59;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL15564;48534;3H-S-Sulpiride;7;Human;Binding;pKi;=;37,00;7,43;-1;5;-;PDSP KiDatabase;237,2;7;2;3;2,76;CCCN(CCC)CCc1ccc(O)c(O)c1;-
CHEMBL15564;48534;3H-SPIPERONE;7;Human;Binding;pKi;=;85,00;7,07;-1;5;-;PDSP KiDatabase;237,2;7;2;3;2,76;CCCN(CCC)CCc1ccc(O)c(O)c1;-
CHEMBL155826;48746;None;0;Human;Binding;Ki;=;114,00;6,94;-30;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;421,3;9;1;4;4,56;CCCN(CCCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL155826;48746;None;0;Human;Binding;Ki;=;19,30;7,71;-30;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;421,3;9;1;4;4,56;CCCN(CCCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL155826;48746;None;0;Human;Binding;Ki;=;19,40;7,71;-30;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;421,3;9;1;4;4,56;CCCN(CCCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL155913;48853;None;0;Human;Binding;Ki;=;5400,00;5,27;-512;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;402,2;4;0;4;4,98;Clc1ccc(N2CCN(Cc3cnn4c(-c5ccccc5)cccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL155913;48853;None;0;Human;Binding;Ki;=;2800,00;5,55;-512;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;402,2;4;0;4;4,98;Clc1ccc(N2CCN(Cc3cnn4c(-c5ccccc5)cccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL156164;49110;None;0;Human;Binding;Ki;=;0,03;10,51;-;1;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;352,2;2;2;5;-0,35;NC(=O)C1CCS[C@@H]2C[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156164;49110;None;0;Human;Binding;Ki;=;0,12;9,91;-;1;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)C1CCS[C@@H]2C[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156164;49110;None;0;Human;Binding;Ki;=;246,00;6,61;-;1;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)C1CCS[C@@H]2C[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156164;49110;None;0;Human;Binding;Ki;=;196,00;6,71;-;1;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)C1CCS[C@@H]2C[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156164;49110;None;0;Human;Binding;Ki;=;0,07;10,15;-;1;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)C1CCS[C@@H]2C[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156164;49110;None;0;Human;Binding;Ki;=;168,00;6,78;-;1;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;352,2;2;2;5;-0,35;NC(=O)C1CCS[C@@H]2C[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156164;49110;None;0;Human;Binding;Ki;=;0,06;10,19;-;1;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;352,2;2;2;5;-0,35;NC(=O)C1CCS[C@@H]2C[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156164;49110;None;0;Human;Binding;Ki;=;202,00;6,70;-;1;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)C1CCS[C@@H]2C[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156198;49154;None;0;Human;Binding;Ki;=;15000,00;4,82;-524;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;420,2;4;0;4;5,12;Fc1ccc(-c2cccc3c(CN4CCN(c5ccc(Cl)cc5)CC4)cnn23)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL156198;49154;None;0;Human;Binding;Ki;=;15000,00;4,82;-524;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;420,2;4;0;4;5,12;Fc1ccc(-c2cccc3c(CN4CCN(c5ccc(Cl)cc5)CC4)cnn23)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL156369;49338;None;0;Human;Binding;Ki;=;12000,00;4,92;-251;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;340,1;3;0;4;3,62;Cc1cccn2ncc(CN3CCN(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL156369;49338;None;0;Human;Binding;Ki;=;13000,00;4,89;-251;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;340,1;3;0;4;3,62;Cc1cccn2ncc(CN3CCN(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL156599;49624;None;0;Human;Binding;Ki;=;3680,00;5,43;-204173;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;407,1;6;1;4;3,55;COc1cccc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL156639;49673;None;0;Human;Binding;Ki;=;142,00;6,85;-112;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL156639;49673;None;0;Human;Binding;Ki;=;213,00;6,67;-112;4;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL156651;49691;None;0;Human;Binding;Ki;=;190,00;6,72;-;1;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156651;49691;None;0;Human;Binding;Ki;=;0,07;10,17;-;1;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156651;49691;None;0;Human;Binding;Ki;=;211,00;6,68;-;1;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156651;49691;None;0;Human;Binding;Ki;=;0,20;9,71;-;1;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156651;49691;None;0;Human;Binding;Ki;=;0,09;10,05;-;1;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;352,2;2;2;5;-0,35;NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156651;49691;None;0;Human;Binding;Ki;=;188,00;6,73;-;1;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;352,2;2;2;5;-0,35;NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156651;49691;None;0;Human;Binding;Ki;=;0,05;10,30;-;1;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;352,2;2;2;5;-0,35;NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156651;49691;None;0;Human;Binding;Ki;=;260,00;6,58;-;1;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;352,2;2;2;5;-0,35;NC(=O)[C@H]1CS[C@@H]2CC[C@]3(CCCN3C(=O)[C@@H]3CCCN3)C(=O)N12;https://dx.doi.org/10.1021/jm980525q
CHEMBL156689;49739;None;0;Human;Binding;Ki;=;27,40;7,56;-24;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;461,2;7;1;4;5,09;CCCN(CCN1CCN(c2cccc(Cl)c2Cl)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL156732;49803;None;0;Human;Binding;Ki;=;200,00;6,70;-99;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;319,2;5;1;2;4,36;c1ccc(CCC2CCN(Cc3cc4ccc[nH]c-4n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL156816;49902;None;0;Human;Binding;Ki;=;782,00;6,11;-1;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;540,3;12;2;5;4,97;O=C(NCCCCN(CCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1)c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL156845;49935;None;0;Human;Binding;Ki;=;7460,00;5,13;-295120;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;353,2;6;1;4;2,56;COc1cccc(C(=O)NCCN2CCN(c3ccc(C)cc3)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL156851;49944;None;0;Human;Binding;Ki;=;21000,00;4,68;-15135;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;364,1;3;0;4;3,60;C#Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)c(C)nn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL156851;49944;None;0;Human;Binding;Ki;=;25000,00;4,60;-15135;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;364,1;3;0;4;3,60;C#Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)c(C)nn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL156896;49991;None;1;Human;Binding;Ki;=;600,00;6,22;-10;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;263,1;2;1;2;3,07;c1c[nH]c2nc(CN3CCc4ccccc4C3)cc-2c1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL157035;50148;None;0;Human;Binding;Ki;=;7,37;8,13;-2;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;485,2;8;1;4;5,09;C#CCN(CCCCN1CCN(c2cccc(Cl)c2Cl)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL157036;50150;None;0;Human;Binding;Ki;=;8,78;8,06;-3;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;489,2;9;1;4;5,87;CCCN(CCCCN1CCN(c2cccc(Cl)c2Cl)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL157046;50164;None;0;Human;Binding;Ki;=;831,76;6,08;2;2;Binding affinity towards dopamine receptor D2;ChEMBL;410,2;6;0;6;3,28;COc1cc2c(cc1OC)C(=O)CC(CN1CCN(c3ccccc3OC)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL157293;50435;None;0;Human;Binding;Ki;=;32,90;7,48;-52;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;417,3;8;1;4;3,79;C#CCN(CCCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL157293;50435;None;0;Human;Binding;Ki;=;68,40;7,17;-52;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;417,3;8;1;4;3,79;C#CCN(CCCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL157293;50435;None;0;Human;Binding;Ki;=;25,20;7,60;-52;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;417,3;8;1;4;3,79;C#CCN(CCCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL157923;51121;None;21;Human;Binding;Ki;=;3,70;8,43;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;413,2;7;1;4;4,21;O=C1CCc2ccc(OCCCCN3CCN(c4ccccc4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL158013;51215;None;0;Human;Binding;Ki;=;245,00;6,61;-17;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;389,2;6;1;4;3,01;C#CCN(CCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL158285;51543;None;1;Human;Binding;Ki;=;870,00;6,06;-70;5;Binding affinity towards human dopamine receptor D2 by the displacement of [3H]spiperone radioligand from the cloned receptor expressed in CHO cells;ChEMBL;260;4;0;3;2,50;CN(C)CCSc1cccc(Br)n1;https://dx.doi.org/10.1016/j.bmcl.2003.11.050
CHEMBL158402;51689;None;0;Human;Binding;Ki;=;1300,00;5,89;-1819;4;Binding affinity towards human dopamine receptor D2 by the displacement of [3H]spiperone radioligand from the cloned receptor expressed in CHO cells;ChEMBL;264,2;5;0;3;3,78;CN(C)CCSc1cccc(C2CCCCC2)n1;https://dx.doi.org/10.1016/j.bmcl.2003.11.050
CHEMBL158627;51959;None;0;Human;Binding;Ki;=;501,19;6,30;-100;5;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;486,2;8;1;5;4,26;CS(=O)(=O)Oc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccc(F)cc3)CC1)C2;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
CHEMBL158973;52370;None;1;Human;Binding;Ki;=;330,00;6,48;-257;4;Binding affinity towards human dopamine receptor D2 by the displacement of [3H]spiperone radioligand from the cloned receptor expressed in CHO cells;ChEMBL;161,1;3;0;2;2,08;CN(C)CCSC(C)(C)C;https://dx.doi.org/10.1016/j.bmcl.2003.11.050
CHEMBL159022;52415;None;0;Human;Binding;Ki;=;78,10;7,11;-87;5;Binding affinity of compound was tested for Dopamine receptor D2L;ChEMBL;407,2;9;0;6;4,40;COc1ccccc1C(=O)CCCCCN1CCN(c2noc3ccccc23)CC1;https://dx.doi.org/10.1021/jm020994z
CHEMBL159742;53077;None;0;Human;Binding;Ki;=;952,00;6,02;-28;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;433,3;4;0;4;3,80;COc1cc(C)ccc1CN1CCN(C2CCc3cccc4c3N(C2=O)C(C)(C)C4)CC1;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL159903;53258;None;0;Human;Binding;Ki;=;1196,00;5,92;-426;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;342,2;4;0;5;2,60;Fc1ccc(OC[C@@H]2CC[C@H]3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL159929;53288;None;0;Human;Binding;Ki;=;724,44;6,14;-16;4;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;369,2;5;0;4;4,15;O=C(c1ccc(F)cc1)C1CCN(CCC2CCc3occc3C2=O)CC1;https://dx.doi.org/10.1021/jm800602w
CHEMBL160266;53639;None;0;Human;Binding;Ki;=;640,00;6,19;-2;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;500,2;6;0;6;4,63;Clc1ccc(N2CCN(Cc3cnn4c(N5CCN(Cc6ccccc6)CC5)cccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160266;53639;None;0;Human;Binding;Ki;=;400,00;6,40;-2;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;500,2;6;0;6;4,63;Clc1ccc(N2CCN(Cc3cnn4c(N5CCN(Cc6ccccc6)CC5)cccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160296;53670;None;3;Human;Binding;Ki;=;0,22;9,66;47;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;409,2;8;1;5;3,56;COc1ccccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL160296;53670;None;3;Human;Binding;Ki;=;0,32;9,49;47;3;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;409,2;8;1;5;3,56;COc1ccccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;-
CHEMBL160296;53670;None;3;Human;Binding;Ki;=;0,30;9,52;47;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;409,2;8;1;5;3,56;COc1ccccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1021/jm300603y
CHEMBL160357;53739;None;0;Human;Binding;Ki;=;4,30;8,37;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;379,2;7;1;4;3,55;O=C1CCc2ccc(OCCCCN3CCN(c4ccccc4)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL160396;53801;None;0;Human;Binding;Ki;=;56000,00;4,25;-616;3;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;356,1;4;1;5;2,80;OCc1cccn2ncc(CN3CCN(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160396;53801;None;0;Human;Binding;Ki;=;79000,00;4,10;-616;3;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;356,1;4;1;5;2,80;OCc1cccn2ncc(CN3CCN(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160454;53862;None;0;Human;Binding;Ki;=;2800,00;5,55;-1047;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;398,2;4;0;4;3,85;C[Si](C)(C)c1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160454;53862;None;0;Human;Binding;Ki;=;3100,00;5,51;-1047;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;398,2;4;0;4;3,85;C[Si](C)(C)c1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160536;53951;None;0;Human;Binding;Ki;=;300,00;6,52;-7;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;514,3;6;0;6;4,94;Cc1nn2c(N3CCN(Cc4ccccc4)CC3)cccc2c1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160536;53951;None;0;Human;Binding;Ki;=;120,00;6,92;-7;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;514,3;6;0;6;4,94;Cc1nn2c(N3CCN(Cc4ccccc4)CC3)cccc2c1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160626;54070;None;2;Human;Binding;Ki;=;44000,00;4,36;-28840;5;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;351,1;3;0;5;3,18;N#Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL160626;54070;None;2;Human;Binding;Ki;=;45000,00;4,35;-28840;5;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;351,1;3;0;5;3,18;N#Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160626;54070;None;2;Human;Binding;Ki;=;44000,00;4,36;-28840;5;Binding affinity of compound was tested in vitro for its ability to compete with [3H]spiperone radioligand at cloned human Dopamine receptor D2L stably expressed in CHO cells;ChEMBL;351,1;3;0;5;3,18;N#Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160630;54075;None;2;Human;Binding;Ki;=;5,50;8,26;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;397,2;7;1;4;3,69;O=C1CCc2ccc(OCCCCN3CCN(c4ccccc4F)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL160744;54231;None;0;Human;Binding;Ki;=;8,10;8,09;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;407,3;7;1;4;4,17;Cc1cccc(N2CCN(CCCCOc3ccc4c(c3)NC(=O)CC4)CC2)c1C;https://dx.doi.org/10.1021/jm300603y
CHEMBL160749;54241;None;0;Human;Binding;Ki;=;14000,00;4,85;-173;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;434,2;4;0;4;5,42;Cc1nn2c(-c3ccc(F)cc3)cccc2c1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160749;54241;None;0;Human;Binding;Ki;=;16000,00;4,80;-173;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;434,2;4;0;4;5,42;Cc1nn2c(-c3ccc(F)cc3)cccc2c1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160817;54315;None;0;Human;Binding;Ki;=;246,00;6,61;-83;5;Binding affinity of compound was tested for Dopamine receptor D2L;ChEMBL;393,2;8;1;6;4,10;O=C(CCCCCN1CCN(c2noc3ccccc23)CC1)c1ccccc1O;https://dx.doi.org/10.1021/jm020994z
CHEMBL160921;54441;None;2;Human;Binding;Ki;=;2,90;8,54;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;404,2;7;1;5;3,42;N#Cc1ccccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1021/jm300603y
CHEMBL160932;54455;None;0;Human;Binding;Ki;=;58000,00;4,24;-25118;5;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;365,1;3;0;5;3,49;Cc1nn2c(C#N)cccc2c1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160932;54455;None;0;Human;Binding;Ki;=;59000,00;4,23;-25118;5;Binding affinity of compound was tested in vitro for its ability to compete with [3H]spiperone radioligand at cloned human Dopamine receptor D2L stably expressed in CHO cells;ChEMBL;365,1;3;0;5;3,49;Cc1nn2c(C#N)cccc2c1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160952;54481;None;0;Human;Binding;Ki;=;3700,00;5,43;-3890;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;350,1;3;0;4;3,29;C#Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160952;54481;None;0;Human;Binding;Ki;=;6200,00;5,21;-3890;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;350,1;3;0;4;3,29;C#Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL160952;54481;None;0;Human;Binding;Ki;=;3715,35;5,43;-3890;4;Binding affinity to dopamine D2;ChEMBL;350,1;3;0;4;3,29;C#Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1021/jm0611152
CHEMBL160998;54534;None;0;Human;Binding;Ki;=;2511,89;5,60;-100;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;412,2;5;2;3;4,73;N#Cc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)c3cc4ccccc4[nH]3)CC1)C2;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
CHEMBL161126;54673;None;0;Human;Binding;Ki;=;398,11;6,40;-39;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;460,2;6;1;2;5,94;O=C(/C=C/c1ccc(F)cc1)N[C@H]1CC[C@H](CCN2Cc3ccc(C(F)(F)F)cc3C2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
CHEMBL161507;54968;None;0;Human;Binding;Ki;=;2328,00;5,63;-9;4;Binding affinity was measured at cloned mammalian dopamine D2 receptor expressed in CHO-K1 cells (using [3H]U-86170);ChEMBL;261,2;4;1;3;2,89;CCCN[C@@H]1CCc2c(C(=O)OC)cccc2[C@@H]1C;https://dx.doi.org/10.1016/S0960-894X(01)80181-5
CHEMBL161765;55213;None;7;Human;Binding;Ki;=;450,00;6,35;-229;5;Binding affinity towards human dopamine receptor D2 by the displacement of [3H]spiperone radioligand from the cloned receptor expressed in CHO cells;ChEMBL;258,1;5;0;3;3,40;CN(C)CCSc1cccc(-c2ccccc2)n1;https://dx.doi.org/10.1016/j.bmcl.2003.11.050
CHEMBL161792;55258;None;46;Human;Binding;Ki;=;7,30;8,14;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;445,1;7;1;5;5,23;Oc1ccc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2n1;https://dx.doi.org/10.1021/jm300603y
CHEMBL161811;55281;None;0;Human;Binding;Ki;=;546,00;6,26;-13;3;Binding affinity was measured at cloned mammalian dopamine D2 receptor expressed in CHO-K1 cells (using [3H]U-86170);ChEMBL;393,2;7;0;4;4,46;CCCN(CCC)[C@@H]1CCc2c(OS(=O)(=O)C(F)(F)F)cccc2[C@@H]1C;https://dx.doi.org/10.1016/S0960-894X(01)80181-5
CHEMBL161853;55322;None;0;Human;Binding;Ki;=;1000,00;6,00;-100;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;429,2;7;1;4;4,66;COc1cccc(/C=C/C(=O)N[C@H]2CC[C@H](CCN3Cc4ccc(C#N)cc4C3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
CHEMBL161899;55371;None;0;Human;Binding;Ki;=;948,00;6,02;-3;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;381,2;5;1;6;2,42;CC(=O)Nc1ccc(OC[C@@H]2CC[C@H]3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL161916;55395;None;0;Human;Binding;Ki;=;199,53;6,70;-25;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;422,2;7;1;3;4,93;COc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccc(F)cc3)CC1)C2;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
CHEMBL161982;55471;None;0;Human;Binding;Ki;=;1880,00;5,73;-575;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;375,2;4;0;4;3,85;Fc1ccc(OC[C@@H]2CC[C@H]3CN(c4ccc(Cl)cn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL162102;55604;None;0;Human;Binding;Ki;=;18,00;7,75;-2;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;503,2;7;1;6;4,33;CS(=O)(=O)Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL162193;55711;None;0;Human;Binding;Ki;=;630,96;6,20;-50;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;417,2;6;1;3;4,79;N#Cc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccc(F)cc3)CC1)C2;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
CHEMBL162265;55799;None;0;Human;Binding;Ki;=;185,00;6,73;-48;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;324,2;4;0;5;2,46;c1ccc(OCC2CCC3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL1627305;56251;None;0;Human;Binding;EC50;=;170,00;6,77;-363;7;Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of quinpirole-stimulated mitogenesis;ChEMBL;460,1;7;3;4;3,78;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL1627305;56251;None;0;Human;Binding;IC50;=;4400,00;5,36;-363;7;Antagonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of quinpirole-stimulated mitogenesis;ChEMBL;460,1;7;3;4;3,78;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL1627305;56251;None;0;Human;Binding;Ki;=;750,00;6,12;-363;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in human HEK293 cell membrane for 1 hr by liquid scintillation counting analysis;ChEMBL;460,1;7;3;4;3,78;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/ml500006v
CHEMBL1627305;56251;None;0;Human;Binding;Ki;=;746,00;6,13;-363;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;460,1;7;3;4;3,78;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL1627305;56251;None;0;Human;Binding;Ki;=;746,00;6,13;-363;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;460,1;7;3;4;3,78;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL1627305;56251;None;0;Human;Binding;Ki;=;746,00;6,13;-363;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;460,1;7;3;4;3,78;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/jm401798r
CHEMBL1627306;56252;None;0;Human;Binding;Ki;=;295,00;6,53;-281;3;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;460,1;7;3;4;3,78;O=C(NCC[C@@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL1627306;56252;None;0;Human;Binding;Ki;=;433,00;6,36;-281;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;460,1;7;3;4;3,78;O=C(NCC[C@@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL1627306;56252;None;0;Human;Binding;Ki;=;300,00;6,52;-281;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in human HEK293 cell membrane for 1 hr by liquid scintillation counting analysis;ChEMBL;460,1;7;3;4;3,78;O=C(NCC[C@@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/ml500006v
CHEMBL1627307;56253;None;0;Human;Binding;Ki;=;790,00;6,10;-95;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in human HEK293 cell membrane for 1 hr by liquid scintillation counting analysis;ChEMBL;460,1;7;3;4;3,78;O=C(NCC[C@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/ml500006v
CHEMBL1627307;56253;None;0;Human;Binding;Ki;=;715,00;6,15;-95;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;460,1;7;3;4;3,78;O=C(NCC[C@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL1627310;56256;None;0;Human;Binding;Ki;=;328,00;6,48;-194;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;478,1;7;3;4;3,92;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(F)ccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL1627314;56260;None;0;Human;Binding;Ki;=;217,00;6,66;-208;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;490,2;8;3;5;3,79;COc1ccc2[nH]c(C(=O)NCCC(O)CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2c1;https://dx.doi.org/10.1021/jm501512b
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;270,00;6,57;-16;5;Binding affinity on High Affinity Site of Dopamine receptor D2L;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;12000,00;4,92;-16;5;Binding Affinity of Compound of Dopamine receptor D2S;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;14000,00;4,85;-16;5;Binding Affinity was tested on low Affinity Site of Dopamine receptor D2L;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;250,00;6,60;-16;5;Binding Affinity on High Affinity Site of Dopamine receptor D2S;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;38,00;7,42;-16;5;Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D2L;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;34,00;7,47;-16;5;Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D2S;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;19000,00;4,72;-16;5;Binding Affinity was determined in the presence of 100 micro M Gpp(NH)p for decoupling of the ternary complex of Compound to Dopamine receptor D2L;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;17000,00;4,77;-16;5;Binding Affinity was determined in the presence of 100 micro M Gpp(NH)p for decoupling of the ternary complex of Compound to Dopamine receptor D2S;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;2800,00;5,55;-16;5;Dissociation constant of compound on one-site model Dopamine receptor D2L;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162762;56275;None;2;Human;Binding;Ki;=;2900,00;5,54;-16;5;Dissociation constant of compound on one-site model Dopamine receptor D2S;ChEMBL;205,2;5;0;1;3,22;C#CC1=CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL162768;56277;None;0;Human;Binding;Ki;=;3,40;8,47;-4;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;467,2;6;1;5;4,92;CC(=O)Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL162873;56291;None;0;Human;Binding;Ki;=;195,00;6,71;-1;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;360,2;4;0;5;2,73;Fc1ccc(OC[C@H]2CC[C@@H]3CN(c4ncc(F)cn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL163009;56348;None;0;Human;Binding;Ki;=;68,00;7,17;-33;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;360,2;4;0;5;2,73;Fc1ccc(OC[C@H]2CC[C@H]3CN(c4ncc(F)cn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL163087;56365;None;0;Human;Binding;Ki;=;17,00;7,77;3;4;Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D2S;ChEMBL;277,2;5;0;1;4,47;CCCN(CCC)C1CC=C(C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL163087;56365;None;0;Human;Binding;Ki;=;16,00;7,80;3;4;Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D2L;ChEMBL;277,2;5;0;1;4,47;CCCN(CCC)C1CC=C(C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL163087;56365;None;0;Human;Binding;Ki;=;970,00;6,01;3;4;Binding Affinity on High Affinity Site of Dopamine receptor D2S;ChEMBL;277,2;5;0;1;4,47;CCCN(CCC)C1CC=C(C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL163087;56365;None;0;Human;Binding;Ki;=;160,00;6,80;3;4;Binding affinity on High Affinity Site of Dopamine receptor D2L;ChEMBL;277,2;5;0;1;4,47;CCCN(CCC)C1CC=C(C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL1631532;56402;None;0;Human;Binding;Ki;=;199,53;6,70;-794;9;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;404,2;5;1;5;4,09;COC(=O)Nc1cccc(CCN2CCN(c3cccc4nc(C)ccc34)CC2)c1;https://dx.doi.org/10.1021/jm100714c
CHEMBL1631535;56405;None;0;Human;Binding;Ki;=;398,11;6,40;-3162;9;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;424,2;6;1;5;3,28;Cc1ccc2c(N3CCN(CCc4cccc(NS(C)(=O)=O)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm100714c
CHEMBL1631542;56412;None;0;Human;Binding;Ki;=;794,33;6,10;-5011;9;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;416,2;5;0;5;3,87;Cc1ccc2c(N3CCN(CCc4cccc(N5CCOC5=O)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm100714c
CHEMBL1631545;56415;None;0;Human;Binding;Ki;=;398,11;6,40;-2511;9;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;397,2;5;0;5;4,09;Cc1ccc2c(N3CCN(CCc4cccc(-n5cccn5)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm100714c
CHEMBL1632206;56474;None;0;Human;Binding;Ki;=;398,11;6,40;-1584;9;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;388,2;5;1;4;3,87;CC(=O)Nc1cccc(CCN2CCN(c3cccc4nc(C)ccc34)CC2)c1;https://dx.doi.org/10.1021/jm100714c
CHEMBL1632210;56478;None;0;Human;Binding;Ki;=;398,11;6,40;-1258;9;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;450,2;6;1;4;5,16;Cc1ccc2c(N3CCN(CCc4cccc(NC(=O)c5ccccc5)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm100714c
CHEMBL1632217;56485;None;0;Human;Binding;Ki;=;199,53;6,70;-999;9;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;452,2;6;1;6;3,95;Cc1ccc2c(N3CCN(CCc4cccc(NC(=O)c5cnccn5)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm100714c
CHEMBL1632220;56488;None;0;Human;Binding;Ki;=;316,23;6,50;-1995;9;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;417,3;6;2;4;4,05;CCNC(=O)Nc1cccc(CCN2CCN(c3cccc4nc(C)ccc34)CC2)c1;https://dx.doi.org/10.1021/jm100714c
CHEMBL1632223;56491;None;0;Human;Binding;Ki;=;79,43;7,10;-251;7;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;465,3;6;2;4;5,55;Cc1ccc2c(N3CCN(CCc4cccc(NC(=O)Nc5ccccc5)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm100714c
CHEMBL163239;56492;None;0;Human;Binding;Ki;=;440,00;6,36;-4;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;361,2;1;0;1;6,30;CC(C)=C1c2ccccc2C=C(C2=CCN(C)CC2)c2cc(Cl)ccc21;https://dx.doi.org/10.1021/jm00004a016
CHEMBL163261;56503;None;0;Human;Binding;Ki;=;20,00;7,70;-6;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;389,2;5;1;4;4,25;Nc1ccccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCCC3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL163742;56549;None;0;Human;Binding;Ki;=;41,00;7,39;-51;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;393,2;5;1;5;4,02;Nc1ccccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL163863;56557;None;0;Human;Binding;Ki;=;230,00;6,64;-11;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;289,1;1;0;2;4,59;CN1CC=C(C2=Cc3ccccc3Oc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL163895;56561;None;0;Human;Binding;Ki;=;26,00;7,58;-2;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;496,2;7;2;5;5,10;CCNC(=O)Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL163904;56563;None;0;Human;Binding;Ki;=;29,00;7,54;-23;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;393,2;5;1;4;4,00;Nc1cc(F)ccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCC3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL164185;56638;None;0;Human;Binding;Ki;=;15,00;7,82;-8;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;407,2;5;1;5;4,41;Nc1ccccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL164185;56638;None;0;Human;Binding;Ki;=;6,00;8,22;-8;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;407,2;5;1;5;4,41;Nc1ccccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL1642118;56681;None;0;Human;Binding;IC50;=;136,00;6,87;-;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in cells;ChEMBL;449,2;3;0;5;3,76;CC1CC(=O)c2ccc(N3CCN(C)CC3)cc2N1S(=O)(=O)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2010.12.007
CHEMBL1642128;56691;None;0;Human;Binding;IC50;=;1784,00;5,75;-;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in cells;ChEMBL;463,2;3;0;5;4,07;Cc1cc(N2CCN(C)CC2)c2c(c1)N(S(=O)(=O)c1ccc3ccccc3c1)C(C)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2010.12.007
CHEMBL164338;56778;None;0;Human;Binding;Ki;=;15,10;7,82;3;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;497,2;7;1;6;5,53;CCOC(=O)Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL164471;57070;None;0;Human;Binding;Ki;=;45,71;7,34;-72;4;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;382,2;4;0;5;4,58;O=C1c2ccoc2CCC1CCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm800602w
CHEMBL1644978;57086;None;0;Human;Binding;Ki;=;194,00;6,71;1;17;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;ChEMBL;537,2;8;1;2;7,92;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.10.036
CHEMBL1644980;57087;None;0;Human;Binding;Ki;=;38,00;7,42;1;16;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;ChEMBL;487,2;7;1;2;7,25;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.10.036
CHEMBL164604;57163;None;0;Human;Binding;Ki;=;4,70;8,33;-1;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;362,2;6;1;4;4,63;C1=C(c2ccccc2)CCN(CC[C@H]2CC[C@H](Nc3ncccn3)CC2)C1;https://dx.doi.org/10.1021/jm9707378
CHEMBL164723;57175;None;0;Human;Binding;Ki;=;25,00;7,60;-5;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;366,3;6;1;6;3,06;c1cnc(N[C@H]2CC[C@H](CCN3CCN(c4cccnc4)CC3)CC2)nc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL164736;57176;None;0;Human;Binding;Ki;=;13000,00;4,89;-6;4;Binding Affinity on High Affinity Site of Dopamine receptor D2S;ChEMBL;387,3;5;0;1;6,11;CCCN(CCC)C1CCC(=C(C#C[Si](C)(C)C)C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL164736;57176;None;0;Human;Binding;Ki;=;11000,00;4,96;-6;4;Binding affinity on High Affinity Site of Dopamine receptor D2L;ChEMBL;387,3;5;0;1;6,11;CCCN(CCC)C1CCC(=C(C#C[Si](C)(C)C)C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL164744;57177;None;0;Human;Binding;Ki;=;7,70;8,11;11;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;453,2;7;1;5;4,53;O=CNc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL164792;57187;None;0;Human;Binding;IC50;=;9,90;8,00;-6;3;The in vitro intrinsic activity was measured at DA D2 receptor by measuring its ability to increase [3H]thymidine uptake in CHO-K1 cells transfected with the Dopamine receptor D2;ChEMBL;395,3;7;1;6;3,67;COc1ccccc1N1CCN(CC[C@H]2CC[C@H](Nc3ncccn3)CC2)CC1;https://dx.doi.org/10.1021/jm9707378
CHEMBL164792;57187;None;0;Human;Binding;Ki;=;3,00;8,52;-6;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;395,3;7;1;6;3,67;COc1ccccc1N1CCN(CC[C@H]2CC[C@H](Nc3ncccn3)CC2)CC1;https://dx.doi.org/10.1021/jm9707378
CHEMBL164909;57202;None;0;Human;Binding;Ki;=;50,00;7,30;1;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;423,2;5;2;6;4,11;Nc1cc(O)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL164950;57206;None;0;Human;Binding;Ki;=;15000,00;4,82;-9;2;Binding Affinity on High Affinity Site of Dopamine receptor D2S;ChEMBL;245,2;5;0;3;3,40;CCCN(CCC)C1CCC(=C(C#N)C#N)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL164979;57212;None;0;Human;Binding;Ki;=;39,00;7,41;2;2;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;338,2;8;1;4;4,01;CN(CCc1ccccc1)CC[C@H]1CC[C@H](Nc2ncccn2)CC1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165022;57256;None;0;Human;Binding;Ki;=;12000,00;4,92;-3;4;Binding affinity on High Affinity Site of Dopamine receptor D2L;ChEMBL;243,2;5;0;1;3,61;C#CC(C#C)=C1CCC(N(CCC)CCC)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL165047;57313;None;0;Human;Binding;Ki;=;4,80;8,32;-1;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;379,3;6;0;5;3,68;CN(c1ncccn1)[C@H]1CC[C@H](CCN2CCN(c3ccccc3)CC2)CC1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165056;57314;None;0;Human;Binding;Ki;=;6,00;8,22;2;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;433,2;6;1;5;4,68;FC(F)(F)c1cccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)c1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165113;57341;None;0;Human;Binding;Ki;=;254,00;6,59;-2;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;382,2;5;0;7;2,24;COC(=O)c1ccc(OC[C@@H]2CC[C@H]3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL165126;57356;None;0;Human;Binding;Ki;=;14,00;7,85;-1;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;425,2;5;1;5;4,54;Nc1c(F)cccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL165140;57358;None;1;Human;Binding;Ki;=;7,40;8,13;2;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;379,3;7;1;5;4,05;c1ccc(N2CCN(CCC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165171;57370;None;0;Human;Binding;Ki;=;5200,00;5,28;-4;4;Binding affinity on High Affinity Site of Dopamine receptor D2L;ChEMBL;395,3;5;0;1;6,45;CCCN(CCC)C1CCC(=C(C#Cc2ccccc2)C#Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL165171;57370;None;0;Human;Binding;Ki;=;7300,00;5,14;-4;4;Binding Affinity on High Affinity Site of Dopamine receptor D2S;ChEMBL;395,3;5;0;1;6,45;CCCN(CCC)C1CCC(=C(C#Cc2ccccc2)C#Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL165381;57442;None;0;Human;Binding;Ki;=;2400,00;5,62;-3;2;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;304,3;9;1;4;3,96;CCCN(CCC)CC[C@H]1CC[C@H](Nc2ncccn2)CC1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165440;57449;None;0;Human;Binding;Ki;=;110,00;6,96;-2;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;336,2;5;1;4;3,90;c1cnc(N[C@H]2CC[C@H](CCN3CCc4ccccc4C3)CC2)nc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165504;57458;None;0;Human;Binding;Ki;=;38,00;7,42;-19;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;324,2;4;0;5;2,46;c1ccc(OC[C@H]2CC[C@H]3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL165504;57458;None;0;Human;Binding;Ki;=;66,00;7,18;-19;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;324,2;4;0;5;2,46;c1ccc(OC[C@H]2CC[C@H]3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL165664;57478;None;0;Human;Binding;Ki;=;5,70;8,24;7;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;351,2;5;1;5;3,27;c1ccc(N2CCN(C[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165679;57481;None;5;Human;Binding;EC50;=;29,00;7,54;-1;3;The in vitro intrinsic activity was measured at DA D2 receptor by measuring its ability to increase [3H]thymidine uptake in CHO-K1 cells transfected with the Dopamine receptor D2;ChEMBL;365,3;6;1;5;3,66;c1ccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165679;57481;None;5;Human;Binding;Ki;=;5,20;8,28;-1;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;365,3;6;1;5;3,66;c1ccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165689;57483;None;0;Human;Binding;Ki;=;180,00;6,75;-6;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;367,2;6;1;7;2,45;c1cnc(N[C@H]2CC[C@H](CCN3CCN(c4cnccn4)CC3)CC2)nc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL165723;57486;None;0;Human;Binding;Ki;=;15,00;7,82;-1;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;425,2;5;1;5;4,54;Nc1ccc(F)cc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL165780;57493;None;0;Human;Binding;Ki;=;2,30;8,64;-11;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;395,2;5;1;5;3,44;Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCO3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL165897;57507;None;0;Human;Binding;Ki;=;19,00;7,72;-21;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;407,2;5;1;4;4,38;Nc1cc(F)ccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCCC3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL166151;57534;None;0;Human;Binding;Ki;=;4800,00;5,32;-6;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;366,3;6;1;6;3,06;c1cnc(N[C@H]2CC[C@H](CCN3CCN(c4ccncc4)CC3)CC2)nc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL166252;57549;None;0;Human;Binding;Ki;=;46,00;7,34;-4;2;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;372,2;6;1;7;3,12;c1cnc(N[C@H]2CC[C@H](CCN3CCN(c4nccs4)CC3)CC2)nc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL166269;57552;None;0;Human;Binding;Ki;=;1140,00;5,94;-331;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;324,2;4;0;5;2,46;c1ccc(OC[C@@H]2CC[C@H]3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL166310;57554;None;0;Human;Binding;Ki;=;4,10;8,39;-6;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;425,2;5;1;5;4,54;Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL166310;57554;None;0;Human;Binding;Ki;=;2,70;8,57;-6;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;425,2;5;1;5;4,54;Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL166321;57555;None;0;Human;Binding;Ki;=;206,00;6,69;-38;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;358,2;4;0;3;3,94;Fc1ccc(OC[C@@H]2CC[C@H]3CN(c4ccc(F)cc4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL166325;57556;None;0;Human;Binding;Ki;=;15000,00;4,82;-4;3;Binding Affinity was tested on High Affinity Site of Dopamine receptor D2L;ChEMBL;281,2;5;0;1;4,64;CCCN(CCC)C1CC=C(C#Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL166325;57556;None;0;Human;Binding;Ki;=;15000,00;4,82;-4;3;Binding Affinity was tested on High Affinity Site of Dopamine receptor D2S;ChEMBL;281,2;5;0;1;4,64;CCCN(CCC)C1CC=C(C#Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991098z
CHEMBL166366;57562;None;0;Human;Binding;Ki;=;60,00;7,22;-5;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;377,2;5;1;5;3,30;Nc1ccccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCO3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL166587;57586;None;0;Human;Binding;Ki;=;110,00;6,96;-4;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;387,2;7;2;4;3,64;CNc1cc(OC)c(C(=O)NC[C@H]2CCN(Cc3ccccc3)C2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL166587;57586;None;0;Human;Binding;Ki;=;86,00;7,07;-4;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;387,2;7;2;4;3,64;CNc1cc(OC)c(C(=O)NC[C@H]2CCN(Cc3ccccc3)C2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL167032;57848;None;0;Human;Binding;Ki;=;25000,00;4,60;-77;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;415,2;7;2;4;3,56;COc1cc(NC(C)=O)c(Cl)cc1C(=O)NC[C@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL167032;57848;None;0;Human;Binding;Ki;=;27000,00;4,57;-77;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;415,2;7;2;4;3,56;COc1cc(NC(C)=O)c(Cl)cc1C(=O)NC[C@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL167414;58110;None;0;Human;Binding;Ki;=;640,00;6,19;-5;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;373,2;6;2;4;3,18;COc1cc(N)c(Cl)cc1C(=O)NC[C@@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL167414;58110;None;0;Human;Binding;Ki;=;1400,00;5,85;-5;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;373,2;6;2;4;3,18;COc1cc(N)c(Cl)cc1C(=O)NC[C@@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168051;58175;None;0;Human;Binding;Ki;=;31,00;7,51;1;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;421,2;6;1;5;4,87;CNc1ccccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL168274;58346;None;0;Human;Binding;Ki;=;540,00;6,27;-2;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;429,2;9;2;4;4,67;CCC[C@H]1CN(Cc2ccccc2)C[C@@H]1CNC(=O)c1cc(Cl)c(NC)cc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168274;58346;None;0;Human;Binding;Ki;=;980,00;6,01;-2;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;429,2;9;2;4;4,67;CCC[C@H]1CN(Cc2ccccc2)C[C@@H]1CNC(=O)c1cc(Cl)c(NC)cc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168372;58524;None;0;Human;Binding;Ki;=;19000,00;4,72;-5;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;429,2;7;1;4;3,58;COc1cc(N(C)C(C)=O)c(Cl)cc1C(=O)NC[C@@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168372;58524;None;0;Human;Binding;Ki;=;30000,00;4,52;-5;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;429,2;7;1;4;3,58;COc1cc(N(C)C(C)=O)c(Cl)cc1C(=O)NC[C@@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL1684022;58565;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-181;4;-;PDSP KiDatabase;317,2;4;0;2;4,23;C#CCOc1cccc2c1-c1cccc3c1C(C2)N(CCC)CC3;-
CHEMBL1684023;58566;None;0;Human;Binding;Ki;=;1203,00;5,92;-57;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;592,4;11;0;8;5,61;CCCN1CCc2cccc3c2C1Cc1cccc(OCc2cn(CCCN4CCN(c5ccccc5OC)CC4)nn2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684028;58571;None;0;Human;Binding;Ki;=;661,00;6,18;-245;5;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;606,4;12;0;8;6,00;CCCN1CCc2cccc3c2C1Cc1cccc(OCc2cn(CCCCN4CCN(c5ccccc5OC)CC4)nn2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684029;58572;None;0;Human;Binding;Ki;=;206,00;6,69;-25;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;634,4;14;0;8;6,43;CCCN1CCc2cccc3c2C1Cc1cccc(OCCCn2cc(CCCCN4CCN(c5ccccc5OC)CC4)nn2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684125;58608;None;0;Human;Binding;Ki;=;7384,00;5,13;-6456;4;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;606,4;12;0;8;5,65;CCCN1CCc2cccc3c2C1Cc1cccc(OCCCn2cc(CCN4CCN(c5ccccc5OC)CC4)nn2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684128;58611;None;0;Human;Binding;Ki;=;88,00;7,06;-4;5;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;525,3;10;0;5;6,21;CCCN1CCc2cccc3c2C1Cc1cccc(OCCCCN2CCN(c4ccccc4OC)CC2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684129;58612;None;0;Human;Binding;Ki;=;399,00;6,40;-3;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;646,4;14;0;7;5,47;CCCN1CCc2cccc3c2C1Cc1cccc(OCCCN(CCCN2CCN(c4ccccc4OC)CC2)S(C)(=O)=O)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684130;58614;None;0;Human;Binding;Ki;=;293,00;6,53;-37;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;606,4;12;0;8;6,00;CCCN1CCc2cccc3c2[C@@H]1Cc1cccc(OCc2cn(CCCCN4CCN(c5ccccc5OC)CC4)nn2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684131;58615;None;0;Human;Binding;Ki;=;616,00;6,21;-67;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;606,4;12;0;8;6,00;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OCc2cn(CCCCN4CCN(c5ccccc5OC)CC4)nn2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684132;58616;None;0;Human;Binding;Ki;=;600,00;6,22;-331;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;606,4;12;0;8;5,65;CCCN1CCc2cccc3c2[C@@H]1Cc1cccc(OCCCn2cc(CCN4CCN(c5ccccc5OC)CC4)nn2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684133;58617;None;0;Human;Binding;Ki;=;770,00;6,11;-99;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;606,4;12;0;8;5,65;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OCCCn2cc(CCN4CCN(c5ccccc5OC)CC4)nn2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684134;58618;None;0;Human;Binding;Ki;=;174,00;6,76;1;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;525,3;10;0;5;6,21;CCCN1CCc2cccc3c2[C@@H]1Cc1cccc(OCCCCN2CCN(c4ccccc4OC)CC2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL1684135;58619;None;0;Human;Binding;Ki;=;141,00;6,85;-6;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;525,3;10;0;5;6,21;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OCCCCN2CCN(c4ccccc4OC)CC2)c1-3;https://dx.doi.org/10.1016/j.bmc.2011.01.053
CHEMBL168541;58745;None;0;Human;Binding;Ki;=;18000,00;4,75;-2;4;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 long in CHO cells;ChEMBL;348,2;4;1;4;2,14;O=C1C[C@@H](CN2CCN(c3ccccc3)CC2)N=C(c2ccccc2)N1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL168541;58745;None;0;Human;Binding;Ki;=;6400,00;5,19;-2;4;In vitro binding affinity to displace [3H]-spiperone from the cloned human dopamine receptor D2 short in CHO cells;ChEMBL;348,2;4;1;4;2,14;O=C1C[C@@H](CN2CCN(c3ccccc3)CC2)N=C(c2ccccc2)N1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL168544;58746;None;0;Human;Binding;Ki;=;54,00;7,27;3;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;429,2;9;2;4;4,67;CCC[C@@H]1CN(Cc2ccccc2)C[C@H]1CNC(=O)c1cc(Cl)c(NC)cc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168544;58746;None;0;Human;Binding;Ki;=;24,00;7,62;3;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;429,2;9;2;4;4,67;CCC[C@@H]1CN(Cc2ccccc2)C[C@H]1CNC(=O)c1cc(Cl)c(NC)cc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168566;58752;None;0;Human;Binding;Ki;=;540,00;6,27;-4;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;373,2;6;2;4;3,18;COc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168566;58752;None;0;Human;Binding;Ki;=;820,00;6,09;-4;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;373,2;6;2;4;3,18;COc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168571;58756;None;0;Human;Binding;Ki;=;2800,00;5,55;-10;4;In vitro binding affinity to displace [3H]-spiperone from the cloned human dopamine receptor D2 short in CHO cells;ChEMBL;348,2;4;1;4;2,14;O=C1C[C@H](CN2CCN(c3ccccc3)CC2)N=C(c2ccccc2)N1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL168571;58756;None;0;Human;Binding;Ki;=;7300,00;5,14;-10;4;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 long in CHO cells;ChEMBL;348,2;4;1;4;2,14;O=C1C[C@H](CN2CCN(c3ccccc3)CC2)N=C(c2ccccc2)N1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL168611;58766;None;0;Human;Binding;Ki;=;45,00;7,35;1;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;429,2;9;2;4;4,67;CCC[C@H]1CN(Cc2ccccc2)C[C@H]1CNC(=O)c1cc(Cl)c(NC)cc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL168611;58766;None;0;Human;Binding;Ki;=;28,00;7,55;1;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;429,2;9;2;4;4,67;CCC[C@H]1CN(Cc2ccccc2)C[C@H]1CNC(=O)c1cc(Cl)c(NC)cc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL1688990;58928;None;0;Human;Binding;Ki;=;34,40;7,46;-43;4;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;410,3;9;1;5;3,09;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(N(C)C)cc2)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1688990;58928;None;0;Human;Binding;Ki;=;34,40;7,46;-43;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;410,3;9;1;5;3,09;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(N(C)C)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL1688991;58929;None;0;Human;Binding;Ki;=;54,50;7,26;-22;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;413,2;10;1;4;3,54;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(CCF)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL1688991;58929;None;0;Human;Binding;Ki;=;54,50;7,26;-22;4;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;413,2;10;1;4;3,54;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(CCF)cc2)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL169193;59027;None;0;Human;Binding;Ki;=;150,00;6,82;-2;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;401,2;7;2;4;3,89;CNc1cc(OC)c(C(=O)NC[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL169193;59027;None;0;Human;Binding;Ki;=;79,00;7,10;-2;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;401,2;7;2;4;3,89;CNc1cc(OC)c(C(=O)NC[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL169222;59030;None;0;Human;Binding;Ki;=;110,00;6,96;-4;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;387,2;7;2;4;3,64;CNc1cc(OC)c(C(=O)NC[C@@H]2CCN(Cc3ccccc3)C2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL169222;59030;None;0;Human;Binding;Ki;=;58,00;7,24;-4;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;387,2;7;2;4;3,64;CNc1cc(OC)c(C(=O)NC[C@@H]2CCN(Cc3ccccc3)C2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL169322;59044;None;0;Human;Binding;Ki;=;5011,87;5,30;-39;2;Inhibition of [125 I]iodosulpiride binding to human Dopamine receptor D2 expressed in CHO cell membranes;ChEMBL;287,2;2;0;3;2,97;CC(C)CN1CCO[C@@H]2c3cc4c(cc3CC[C@H]21)CCO4;https://dx.doi.org/10.1016/S0960-894X(97)00126-1
CHEMBL169323;59045;None;0;Human;Binding;Ki;=;398,11;6,40;-39;2;Inhibition of [125 I]iodosulpiride binding to human Dopamine receptor D2 expressed in CHO cell membranes;ChEMBL;273,2;2;0;3;2,72;CCCN1CCO[C@@H]2c3cc4c(cc3CC[C@H]21)CCO4;https://dx.doi.org/10.1016/S0960-894X(97)00126-1
CHEMBL169459;59071;None;13;Human;Binding;Ki;=;29000,00;4,54;-95;4;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 long in CHO cells;ChEMBL;334,2;4;1;4;2,62;c1ccc(C2=NCC[C@@H](CN3CCN(c4ccccc4)CC3)N2)cc1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL169459;59071;None;13;Human;Binding;Ki;=;30000,00;4,52;-95;4;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 short in CHO cells;ChEMBL;334,2;4;1;4;2,62;c1ccc(C2=NCC[C@@H](CN3CCN(c4ccccc4)CC3)N2)cc1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL169562;59088;None;0;Human;Binding;Ki;=;10000,00;5,00;-53;4;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 long in CHO cells;ChEMBL;334,2;3;1;4;2,62;c1ccc(C2=NC[C@H](N3CCN(c4ccccc4)CC3)CCN2)cc1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL169562;59088;None;0;Human;Binding;Ki;=;4200,00;5,38;-53;4;In vitro binding affinity to displace [3H]-spiperone from the cloned human dopamine receptor D2 short in CHO cells;ChEMBL;334,2;3;1;4;2,62;c1ccc(C2=NC[C@H](N3CCN(c4ccccc4)CC3)CCN2)cc1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL169631;59104;None;0;Human;Binding;Ki;=;38000,00;4,42;-4;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;429,2;7;1;4;3,58;COc1cc(N(C)C(C)=O)c(Cl)cc1C(=O)NC[C@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL169631;59104;None;0;Human;Binding;Ki;=;28000,00;4,55;-4;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;429,2;7;1;4;3,58;COc1cc(N(C)C(C)=O)c(Cl)cc1C(=O)NC[C@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL169889;59164;None;0;Human;Binding;Ki;=;44000,00;4,36;-26;4;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 long in CHO cells;ChEMBL;442,1;5;1;5;3,39;COc1ccc(Br)cc1C1=NCC[C@H](CN2CCN(c3ccccc3)CC2)N1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL169889;59164;None;0;Human;Binding;Ki;=;43000,00;4,37;-26;4;In vitro binding affinity to displace [3H]-spiperone from the cloned human dopamine receptor D2 short in CHO cells;ChEMBL;442,1;5;1;5;3,39;COc1ccc(Br)cc1C1=NCC[C@H](CN2CCN(c3ccccc3)CC2)N1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL170923;59409;None;0;Human;Binding;Ki;=;12589,25;4,90;-25;2;Inhibition of [125 I]iodosulpiride binding to human Dopamine receptor D2 expressed in CHO cell membranes;ChEMBL;275,2;2;0;4;2,17;CCCN1CCO[C@@H]2c3cc4c(cc3OC[C@H]21)CCO4;https://dx.doi.org/10.1016/S0960-894X(97)00126-1
CHEMBL170976;59419;None;0;Human;Binding;Ki;=;501,19;6,30;-19;2;Inhibition of [125 I]iodosulpiride binding to human Dopamine receptor D2 expressed in CHO cell membranes;ChEMBL;271,2;2;0;2;3,53;CCCN1CCC[C@@H]2c3cc4c(cc3CC[C@H]21)CCO4;https://dx.doi.org/10.1016/S0960-894X(97)00126-1
CHEMBL171672;59563;None;0;Human;Binding;Ki;=;2511,89;5,60;-39;2;Inhibition of [125 I]iodosulpiride binding to human Dopamine receptor D2 expressed in CHO cell membranes;ChEMBL;285,2;2;0;3;2,72;c1c2c(cc3c1CC[C@@H]1[C@@H]3OCCN1CC1CC1)OCC2;https://dx.doi.org/10.1016/S0960-894X(97)00126-1
CHEMBL171825;59594;None;0;Human;Binding;Ki;=;1000,00;6,00;-5;2;Inhibition of [125 I]iodosulpiride binding to human Dopamine receptor D2 expressed in CHO cell membranes;ChEMBL;231,1;0;1;3;1,60;c1c2c(cc3c1CC[C@H]1NCCO[C@H]31)OCC2;https://dx.doi.org/10.1016/S0960-894X(97)00126-1
CHEMBL171826;59595;None;0;Human;Binding;Ki;=;398,11;6,40;-5;2;Inhibition of [125 I]iodosulpiride binding to human Dopamine receptor D2 expressed in CHO cell membranes;ChEMBL;245,1;0;0;3;1,94;CN1CCO[C@@H]2c3cc4c(cc3CC[C@H]21)CCO4;https://dx.doi.org/10.1016/S0960-894X(97)00126-1
CHEMBL1739760;60193;None;0;Human;Binding;Ki;=;20,90;7,68;-3;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;473,3;14;1;6;3,39;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(OCCOCCF)cc2)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739761;60194;None;0;Human;Binding;Ki;=;52,00;7,28;-12;3;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;517,3;17;1;7;3,41;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(OCCOCCOCCF)cc2)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739782;60199;None;0;Human;Binding;Ki;=;131,00;6,88;-5;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;411,2;9;1;4;3,31;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2ccc(CCF)cc2)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739783;60200;None;0;Human;Binding;Ki;=;57,60;7,24;-4;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;535,1;11;1;6;3,92;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2cc(Br)cc(OC)c2OCCF)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739784;60201;None;0;Human;Binding;Ki;=;15,10;7,82;-23;3;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;442,3;11;1;5;3,43;CN(C)c1ccc(C(=O)NCCCCN2CCN(c3ccccc3OCCF)CC2)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739785;60202;None;0;Human;Binding;Ki;=;21,40;7,67;-3;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;445,3;12;1;4;3,88;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc(CCF)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739786;60203;None;0;Human;Binding;Ki;=;64,80;7,19;-3;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;503,3;15;1;6;3,51;O=C(NC/C=C/CN1CCN(c2ccccc2OCCF)CC1)c1ccc(OCCOCCF)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739787;60204;None;0;Human;Binding;Ki;=;70,50;7,15;-64;3;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;479,2;10;1;5;4,87;O=C(NC/C=C/CN1CCN(c2ccccc2OCCF)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739802;60206;None;0;Human;Binding;Ki;=;35,20;7,45;-9;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;440,3;10;1;5;3,21;CN(C)c1ccc(C(=O)NC/C=C/CN2CCN(c3ccccc3OCCF)CC2)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739810;60207;None;0;Human;Binding;Ki;=;15,10;7,82;-28;3;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;461,2;13;1;5;3,71;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc(OCCF)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739811;60208;None;0;Human;Binding;Ki;=;14,20;7,85;-5;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;505,3;16;1;6;3,73;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc(OCCOCCF)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739943;60224;None;0;Human;Binding;Ki;=;55,30;7,26;-8;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;427,2;10;1;5;3,15;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2ccc(OCCF)cc2)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739944;60225;None;0;Human;Binding;Ki;=;59,20;7,23;-3;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;471,3;13;1;6;3,17;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2ccc(OCCOCCF)cc2)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739945;60226;None;0;Human;Binding;Ki;=;17,80;7,75;1;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;441,2;10;1;5;3,46;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2cc(C)ccc2OCCF)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739946;60227;None;0;Human;Binding;Ki;=;13,40;7,87;1;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;505,1;10;1;5;3,91;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2cc(Br)ccc2OCCF)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739947;60228;None;0;Human;Binding;Ki;=;13,20;7,88;-1;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;553,1;10;1;5;3,76;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2cc(I)ccc2OCCF)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739963;60229;None;0;Human;Binding;Ki;=;0,17;9,77;1;3;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;481,2;11;1;5;5,10;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL1739963;60229;None;0;Human;Binding;Ki;=;27,70;7,56;1;3;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;481,2;11;1;5;5,10;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739964;60230;None;0;Human;Binding;Ki;=;31,70;7,50;-6;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;549,3;19;1;7;3,75;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc(OCCOCCOCCF)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739965;60231;None;0;Human;Binding;Ki;=;17,70;7,75;-16;3;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;443,2;11;1;4;3,65;O=C(NC/C=C/CN1CCN(c2ccccc2OCCF)CC1)c1ccc(CCF)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739966;60232;None;0;Human;Binding;Ki;=;37,90;7,42;-4;2;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;459,2;12;1;5;3,49;O=C(NC/C=C/CN1CCN(c2ccccc2OCCF)CC1)c1ccc(OCCF)cc1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1739996;60233;None;0;Human;Binding;Ki;=;27,10;7,57;-24;3;Displacement of [125I]-IABN from human D2 receptor transfected in human HEK 293 cells by gamma-counting;ChEMBL;429,2;11;1;5;3,38;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(OCCF)cc2)CC1;https://dx.doi.org/10.1021/jm101323b
CHEMBL1744035;60330;None;0;Human;Binding;Ki;=;896,00;6,05;-2238;2;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;295,2;5;1;2;4,02;CCCN(CCC)[C@H]1CCc2ccc3[nH]c(C#N)cc3c2C1;https://dx.doi.org/10.1021/jm00067a003
CHEMBL1744036;60331;None;0;Human;Binding;Ki;=;215,00;6,67;-134;2;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;313,2;6;2;2;3,25;CCCN(CCC)[C@@H]1CCc2ccc3[nH]c(C(N)=O)cc3c2C1;https://dx.doi.org/10.1021/jm00067a003
CHEMBL1744037;60332;None;0;Human;Binding;Ki;=;38,00;7,42;-63;2;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;466,3;9;2;4;3,79;CCCN(CCCCN1C(=O)CC(C)(C)CC1=O)[C@@H]1CCc2ccc3[nH]c(C(N)=O)cc3c2C1;https://dx.doi.org/10.1021/jm00067a003
CHEMBL1744044;60338;None;1;Human;Binding;Ki;=;449,00;6,35;-478;4;Compound is evaluated for binding affinity towards Dopamine receptor D2 using [3H]spiperone in CHO cells;ChEMBL;421,2;4;0;7;3,31;COc1ccccc1N1CCN(CC2CN=C3c4ccccc4N=C(SC)N32)CC1;https://dx.doi.org/10.1021/jm970159v
CHEMBL1744088;60349;None;0;Human;Binding;Ki;=;44,00;7,36;-218;2;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;448,3;8;1;4;4,56;CCCN(CCCCN1C(=O)CC(C)(C)CC1=O)[C@@H]1CCc2ccc3[nH]c(C#N)cc3c2C1;https://dx.doi.org/10.1021/jm00067a003
CHEMBL1744089;60350;None;0;Human;Binding;Ki;=;857,00;6,07;-112;2;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;271,2;4;3;2;2,12;CCCN[C@@H]1CCc2ccc3[nH]c(C(N)=O)cc3c2C1;https://dx.doi.org/10.1021/jm00067a003
CHEMBL175462;60497;None;0;Human;Binding;Ki;=;65,50;7,18;-17;2;Binding affinity for human dopamine D2 receptor;ChEMBL;455,1;6;1;5;4,04;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2n1;https://dx.doi.org/10.1021/jm049465g
CHEMBL175466;60500;None;0;Human;Binding;Ki;=;17,50;7,76;-6;2;Binding affinity for human dopamine D2 receptor;ChEMBL;437,1;6;1;3;4,75;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL175677;60533;None;0;Human;Binding;Ki;=;8,80;8,06;-5;2;Binding affinity for human dopamine D2 receptor;ChEMBL;421,1;6;1;3;4,24;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(F)c1;https://dx.doi.org/10.1021/jm049465g
CHEMBL175734;60544;None;0;Human;Binding;Ki;=;149,00;6,83;-10;5;Binding affinity for human dopamine D2 receptor;ChEMBL;459,1;6;1;4;5,32;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm049465g
CHEMBL175734;60544;None;0;Human;Binding;Ki;=;149,00;6,83;-10;5;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;459,1;6;1;4;5,32;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm040190e
CHEMBL175734;60544;None;0;Human;Binding;Ki;=;245,00;6,61;-10;5;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;459,1;6;1;4;5,32;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm040190e
CHEMBL175832;60560;None;0;Human;Binding;Ki;=;310,00;6,51;-812;3;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;401,1;5;0;3;3,88;O=S(=O)(c1ccc(F)cc1)C1(F)CCN(CCc2ccc(F)cc2F)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.01.098
CHEMBL175832;60560;None;0;Human;Binding;Ki;=;313,00;6,50;-812;3;Binding affinity against human Dopamine receptor D2;ChEMBL;401,1;5;0;3;3,88;O=S(=O)(c1ccc(F)cc1)C1(F)CCN(CCc2ccc(F)cc2F)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.05.104
CHEMBL175838;60563;None;0;Human;Binding;Ki;=;19,60;7,71;-7;2;Binding affinity for human dopamine D2 receptor;ChEMBL;404,1;6;1;4;3,50;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccnc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL175875;60570;None;0;Human;Binding;Ki;=;39,10;7,41;-12;2;Binding affinity for human dopamine D2 receptor;ChEMBL;433,1;7;1;4;4,11;COc1cccc(C(=O)NC/C=C/CN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1021/jm049465g
CHEMBL176109;60786;None;0;Human;Binding;Ki;=;2000,00;5,70;-1995;3;Binding affinity against human Dopamine receptor D2;ChEMBL;438,2;6;0;4;3,95;O=S(=O)(c1ccc(N2CCC2)cc1)C1(F)CCN(CCc2ccc(F)cc2F)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.05.104
CHEMBL176212;60840;None;0;Human;Binding;Ki;=;10,60;7,97;-2;2;Binding affinity for human dopamine D2 receptor;ChEMBL;529;6;1;3;4,71;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1I;https://dx.doi.org/10.1021/jm049465g
CHEMBL1765629;61190;None;0;Human;Binding;Ki;=;77,00;7,11;-154;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins;ChEMBL;430,3;10;1;4;4,79;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765629;61190;None;0;Human;Binding;Ki;=;150,00;6,82;-154;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;430,3;10;1;4;4,79;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765630;61191;None;0;Human;Binding;Ki;=;100,00;7,00;-109;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;464,2;10;1;4;5,44;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCn2ncc(Cl)c2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765630;61191;None;0;Human;Binding;Ki;=;43,00;7,37;-109;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins;ChEMBL;464,2;10;1;4;5,44;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCn2ncc(Cl)c2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765631;61192;None;0;Human;Binding;Ki;=;8400,00;5,08;-158;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;458,3;11;1;5;4,60;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCn2ncc(C=O)c2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765631;61192;None;0;Human;Binding;Ki;=;4700,00;5,33;-158;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins;ChEMBL;458,3;11;1;5;4,60;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCn2ncc(C=O)c2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765632;61193;None;0;Human;Binding;Ki;=;240,00;6,62;-457;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins;ChEMBL;466,3;10;1;4;5,39;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1Cc2cccn3ncc(c23)C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765632;61193;None;0;Human;Binding;Ki;=;270,00;6,57;-457;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;466,3;10;1;4;5,39;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1Cc2cccn3ncc(c23)C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765633;61194;None;0;Human;Binding;Ki;=;5,30;8,28;-1;2;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;430,3;10;1;4;4,79;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765633;61194;None;0;Human;Binding;Ki;=;1,00;9,00;-1;2;Displacement of [3H]7-OH-DPAT from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;430,3;10;1;4;4,79;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765634;61195;None;0;Human;Binding;Ki;=;300,00;6,52;-1;2;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;430,3;10;1;4;4,79;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)[C@@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1765634;61195;None;0;Human;Binding;Ki;=;49,00;7,31;-1;2;Displacement of [3H]7-OH-DPAT from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;430,3;10;1;4;4,79;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)[C@@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL176884;61392;None;0;Human;Binding;Ki;=;15,00;7,82;-5;2;Binding affinity for human dopamine D2 receptor;ChEMBL;437,1;6;1;3;4,75;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1021/jm049465g
CHEMBL1771105;61621;None;0;Human;Binding;Ki;=;0,93;9,03;-6;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;437,3;8;0;5;3,69;COc1ccc2c(c1)CCCN(CCCCN1CCN(c3ccccc3OC)CC1)C2=O;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771105;61621;None;0;Human;Binding;Ki;=;3,20;8,49;-6;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;437,3;8;0;5;3,69;COc1ccc2c(c1)CCCN(CCCCN1CCN(c3ccccc3OC)CC1)C2=O;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771106;61622;None;0;Human;Binding;Ki;=;9,20;8,04;-9;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;411,2;7;0;4;3,44;COc1ccccc1N1CCN(CCCCN2CCc3cc(F)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771106;61622;None;0;Human;Binding;Ki;=;26,00;7,58;-9;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;411,2;7;0;4;3,44;COc1ccccc1N1CCN(CCCCN2CCc3cc(F)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771107;61623;None;0;Human;Binding;Ki;=;15,00;7,82;-95;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;469,3;8;0;4;4,96;COc1ccccc1N1CCN(CCCCN2CCc3cc(-c4ccccc4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771107;61623;None;0;Human;Binding;Ki;=;38,00;7,42;-95;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;469,3;8;0;4;4,96;COc1ccccc1N1CCN(CCCCN2CCc3cc(-c4ccccc4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771108;61624;None;0;Human;Binding;Ki;=;52,00;7,28;-5;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;469,3;8;0;4;4,96;COc1ccccc1N1CCN(CCCCN2CCc3c(cccc3-c3ccccc3)C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771108;61624;None;0;Human;Binding;Ki;=;63,00;7,20;-5;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;469,3;8;0;4;4,96;COc1ccccc1N1CCN(CCCCN2CCc3c(cccc3-c3ccccc3)C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771109;61625;None;0;Human;Binding;Ki;=;16,00;7,80;-41;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;459,3;8;0;5;4,56;COc1ccccc1N1CCN(CCCCN2CCc3cc(-c4ccco4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771109;61625;None;0;Human;Binding;Ki;=;4,80;8,32;-41;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;459,3;8;0;5;4,56;COc1ccccc1N1CCN(CCCCN2CCc3cc(-c4ccco4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771110;61627;None;0;Human;Binding;Ki;=;11,00;7,96;-72;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;475,2;8;0;5;5,02;COc1ccccc1N1CCN(CCCCN2CCc3cc(-c4cccs4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771110;61627;None;0;Human;Binding;Ki;=;6,90;8,16;-72;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;475,2;8;0;5;5,02;COc1ccccc1N1CCN(CCCCN2CCc3cc(-c4cccs4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771111;61628;None;0;Human;Binding;Ki;=;5,10;8,29;-11;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;489,2;8;0;5;5,41;COc1ccccc1N1CCN(CCCCN2CCCc3cc(-c4cccs4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771111;61628;None;0;Human;Binding;Ki;=;2,10;8,68;-11;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;489,2;8;0;5;5,41;COc1ccccc1N1CCN(CCCCN2CCCc3cc(-c4cccs4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771112;61629;None;0;Human;Binding;Ki;=;13,00;7,89;-79;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;470,3;8;0;5;4,36;COc1ccccc1N1CCN(CCCCN2CCc3cc(-c4ccncc4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771112;61629;None;0;Human;Binding;Ki;=;7,10;8,15;-79;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;470,3;8;0;5;4,36;COc1ccccc1N1CCN(CCCCN2CCc3cc(-c4ccncc4)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771113;61630;None;0;Human;Binding;Ki;=;22,00;7,66;-22;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;418,2;7;0;5;3,17;COc1ccccc1N1CCN(CCCCN2CCc3cc(C#N)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771113;61630;None;0;Human;Binding;Ki;=;38,00;7,42;-22;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;418,2;7;0;5;3,17;COc1ccccc1N1CCN(CCCCN2CCc3cc(C#N)ccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771114;61631;None;0;Human;Binding;Ki;=;24,00;7,62;-28;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;417,2;7;0;4;3,28;C#Cc1ccc2c(c1)CCN(CCCCN1CCN(c3ccccc3OC)CC1)C2=O;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1771114;61631;None;0;Human;Binding;Ki;=;8,80;8,06;-28;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;417,2;7;0;4;3,28;C#Cc1ccc2c(c1)CCN(CCCCN1CCN(c3ccccc3OC)CC1)C2=O;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL1773087;61803;None;0;Human;Binding;Ki;=;2060,00;5,69;-5;3;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;511,2;8;0;3;6,55;CN(CCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)Cc1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm200288r
CHEMBL177398;61895;None;0;Human;Binding;Ki;=;10,10;8,00;-8;2;Binding affinity for human dopamine D2 receptor;ChEMBL;421,1;6;1;3;4,24;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1F;https://dx.doi.org/10.1021/jm049465g
CHEMBL177401;61917;None;0;Human;Binding;Ki;=;791,00;6,10;-2630;3;Binding affinity against human Dopamine receptor D2;ChEMBL;401,1;5;0;3;3,88;O=S(=O)(c1cccc(F)c1)C1(F)CCN(CCc2ccc(F)cc2F)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.05.104
CHEMBL1774062;61946;None;0;Human;Binding;Ki;=;2,60;8,59;-3;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;446,2;7;1;4;4,81;O=C1CCc2ccc(CCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774063;61947;None;0;Human;Binding;Ki;=;1,00;9,00;-14;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;448,1;7;1;5;4,25;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774063;61947;None;0;Human;Binding;Ki;=;3,40;8,47;-14;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;448,1;7;1;5;4,25;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL1774064;61948;None;0;Human;Binding;Ki;=;1,00;9,00;1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;446,1;7;1;5;4,21;O=c1ccc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nc2[nH]1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774065;61949;None;0;Human;Binding;Ki;=;2,00;8,70;1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;446,1;7;1;5;4,21;O=c1ccc2cnc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774066;61950;None;0;Human;Binding;Ki;=;1,00;9,00;3;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;447,1;7;1;6;3,61;O=c1ccc2cnc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nc2[nH]1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774067;61951;None;0;Human;Binding;Ki;=;5,70;8,24;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;414,2;7;1;5;3,60;O=C1CCc2ccc(OCCCCN3CCN(c4ccccc4Cl)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774068;61952;None;0;Human;Binding;Ki;=;2,50;8,60;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;432,2;7;1;5;3,74;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(F)c4Cl)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774069;61953;None;0;Human;Binding;Ki;=;1,00;9,00;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;428,2;7;1;5;3,91;Cc1cccc(N2CCN(CCCCOc3ccc4c(n3)NC(=O)CC4)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774070;61954;None;0;Human;Binding;Ki;=;5,00;8,30;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;394,2;7;1;5;3,26;Cc1ccccc1N1CCN(CCCCOc2ccc3c(n2)NC(=O)CC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774071;61955;None;0;Human;Binding;Ki;=;2,50;8,60;-7;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;408,3;7;1;5;3,56;Cc1cccc(N2CCN(CCCCOc3ccc4c(n3)NC(=O)CC4)CC2)c1C;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774072;61956;None;0;Human;Binding;Ki;=;3,00;8,52;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;428,2;7;1;5;3,91;Cc1c(Cl)cccc1N1CCN(CCCCOc2ccc3c(n2)NC(=O)CC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774073;61957;None;1;Human;Binding;Ki;=;1,00;9,00;1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;432,2;7;1;5;3,74;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4F)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774074;61958;None;0;Human;Binding;Ki;=;1,00;9,00;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;482,2;7;1;5;4,62;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(C(F)(F)F)c4Cl)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774075;61959;None;0;Human;Binding;Ki;=;3,00;8,52;-2;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;482,2;7;1;5;4,62;O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4C(F)(F)F)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774076;61960;None;0;Human;Binding;Ki;=;1,00;9,00;-6;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;420,3;7;1;5;3,44;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4CCC5)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774077;61961;None;0;Human;Binding;Ki;=;1,40;8,85;-15;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;434,3;7;1;5;3,83;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4CCCC5)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774078;61962;None;0;Human;Binding;Ki;=;1,00;9,00;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;436,2;7;1;6;3,27;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4CCCO5)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774079;61963;None;0;Human;Binding;Ki;=;0,71;9,15;-3;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;436,2;7;1;6;3,27;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4OCCC5)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774081;61965;None;0;Human;Binding;Ki;=;1,60;8,80;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;448,2;7;1;5;4,24;O=C1CCc2ccc(OCCCCN3CCN(c4c(F)ccc5ccccc45)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774082;61966;None;0;Human;Binding;Ki;=;1,10;8,96;1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;448,2;7;1;5;4,24;O=C1CCc2ccc(OCCCCN3CCN(c4cc(F)cc5ccccc45)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774083;61967;None;0;Human;Binding;Ki;=;2,00;8,70;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;448,2;7;1;5;4,24;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(F)c5ccccc45)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774084;61968;None;0;Human;Binding;Ki;=;6,00;8,22;-1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;448,2;7;1;5;4,24;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c(F)cccc45)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774085;61969;None;0;Human;Binding;Ki;=;1,00;9,00;1;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;448,2;7;1;5;4,24;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5cc(F)ccc45)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774086;61970;None;0;Human;Binding;Ki;=;1,20;8,92;-4;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;448,2;7;1;5;4,24;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5ccc(F)cc45)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL1774087;61971;None;0;Human;Binding;Ki;=;1,70;8,77;-2;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;448,2;7;1;5;4,24;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5cccc(F)c45)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
CHEMBL177416;61985;None;0;Human;Binding;Ki;=;266,00;6,58;-812;3;Binding affinity against human Dopamine receptor D2;ChEMBL;401,1;5;0;3;3,88;O=S(=O)(c1ccccc1F)C1(F)CCN(CCc2ccc(F)cc2F)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.05.104
CHEMBL1774383;62008;None;0;Human;Binding;Ki;=;390,00;6,41;-19;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;462,2;9;1;5;4,04;COc1ccccc1N1CCN(CC(F)CCNC(=O)c2ccc(-c3ccccn3)cc2)CC1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774384;62009;None;0;Human;Binding;Ki;=;378,00;6,42;-61;5;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;500,2;8;1;4;5,34;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774385;62010;None;0;Human;Binding;Ki;=;329,00;6,48;-11;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;425,2;8;1;5;3,72;COc1ccccc1N1CCN(CC(F)CCNC(=O)c2cc3ccccc3o2)CC1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774386;62011;None;3;Human;Binding;Kd;=;0,03;10,52;-165;4;Binding affinity to wild type human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;463,1;7;1;4;5,02;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774386;62011;None;3;Human;Binding;Ki;=;14600,00;4,84;-165;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;463,1;7;1;4;5,02;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774386;62011;None;3;Human;Binding;Ki;=;9163,00;5,04;-165;4;Displacement of [125I]-IABN from wild type human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;463,1;7;1;4;5,02;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774386;62011;None;3;Human;Binding;Ki;=;960,00;6,02;-165;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in human HEK293 cell membrane for 1 hr by liquid scintillation counting analysis;ChEMBL;463,1;7;1;4;5,02;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/ml500006v
CHEMBL1774532;62051;None;0;Human;Binding;Ki;=;274,00;6,56;-19;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;455,2;9;1;6;3,73;COc1ccc2oc(C(=O)NCCC(F)CN3CCN(c4ccccc4OC)CC3)cc2c1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774533;62052;None;0;Human;Binding;Ki;=;279,00;6,55;-35;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;493,1;8;1;5;5,03;COc1ccc2oc(C(=O)NCCC(F)CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2c1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774534;62053;None;0;Human;Binding;Ki;=;421,00;6,38;-43;5;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;424,2;8;2;4;3,46;COc1ccccc1N1CCN(CC(F)CCNC(=O)c2cc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774535;62054;None;0;Human;Binding;Ki;=;526,00;6,28;-131;5;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;462,1;7;2;3;4,75;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774536;62055;None;0;Human;Binding;Ki;=;2890,00;5,54;-288;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;473,2;8;1;4;4,55;COc1ccccc1N1CCN(CC(F)CCNC(=O)c2ccc3c(c2)Cc2ccccc2-3)CC1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774537;62056;None;0;Human;Binding;Ki;=;4260,00;5,37;-1659;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;511,2;7;1;3;5,84;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774538;62057;None;0;Human;Binding;Ki;=;241,00;6,62;-63;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;441,2;8;1;5;4,19;COc1ccccc1N1CCN(CC(F)CCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774539;62058;None;0;Human;Binding;Ki;=;472,00;6,33;-162;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;479,1;7;1;4;5,49;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774540;62059;None;0;Human;Binding;Ki;=;302,00;6,52;-66;4;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;454,2;9;2;5;3,46;COc1ccc2[nH]c(C(=O)NCCC(F)CN3CCN(c4ccccc4OC)CC3)cc2c1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774541;62060;None;0;Human;Binding;Ki;=;230,00;6,64;-151;3;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;492,1;8;2;4;4,76;COc1ccc2[nH]c(C(=O)NCCC(F)CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2c1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774542;62061;None;0;Human;Binding;Ki;=;195,00;6,71;-31;3;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;473,1;7;1;3;5,43;O=C(NCCC(F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774543;62062;None;0;Human;Binding;Ki;=;69,90;7,16;-1;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;451,3;11;0;5;5,72;CCCN(CCCCN1CCN(c2ccccc2OC)CC1)Cc1csc2ccccc12;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774544;62063;None;0;Human;Binding;Ki;=;162,00;6,79;-1;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;489,2;10;0;4;7,02;CCCN(CCCCN1CCN(c2cccc(Cl)c2Cl)CC1)Cc1csc2ccccc12;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774545;62064;None;0;Human;Binding;Ki;=;196,00;6,71;-2;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;483,3;11;0;4;6,08;CCCN(CCCCN1CCN(c2ccccc2OC)CC1)Cc1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774546;62065;None;0;Human;Binding;Ki;=;269,00;6,57;-2;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;521,2;10;0;3;7,38;CCCN(CCCCN1CCN(c2cccc(Cl)c2Cl)CC1)Cc1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774547;62066;None;0;Human;Binding;Ki;=;119,00;6,92;-1;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;445,3;11;0;4;5,66;CCCN(CCCCN1CCN(c2ccccc2OC)CC1)Cc1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774548;62067;None;0;Human;Binding;Ki;=;313,00;6,50;-3;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;483,2;10;0;3;6,96;CCCN(CCCCN1CCN(c2cccc(Cl)c2Cl)CC1)Cc1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774549;62068;None;0;Human;Binding;Ki;=;2090,00;5,68;-15;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;495,2;8;2;4;5,23;OC(CCNCc1ccc2c(c1)Cc1ccccc1-2)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774550;62070;None;0;Human;Binding;Ki;=;5270,00;5,28;-11;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;497,2;8;1;3;6,21;FC(CCNCc1ccc2c(c1)Cc1ccccc1-2)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774551;62071;None;0;Human;Binding;Ki;=;869,00;6,06;-5;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;509,2;8;1;4;5,57;CN(CCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)Cc1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm200288r
CHEMBL1774552;62072;None;0;Human;Binding;Ki;=;64,70;7,19;-81;2;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1csc2ccccc12;https://dx.doi.org/10.1021/jm200288r
CHEMBL1779058;62373;None;0;Human;Binding;Ki;=;1724,00;5,76;-18;5;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in HEK cells;ChEMBL;339,2;5;1;3;2,55;O=C(CCCN1C2C3C4CC5C6C4C2C6C1(O)C53)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.04.098
CHEMBL1788191;63049;None;0;Human;Binding;Ki;=;914,00;6,04;-8;2;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;466,3;9;2;4;3,79;CCCN(CCCCN1C(=O)CC(C)(C)CC1=O)[C@H]1CCc2ccc3[nH]c(C(N)=O)cc3c2C1;https://dx.doi.org/10.1021/jm00067a003
CHEMBL1788192;63050;None;0;Human;Binding;Ki;=;389,00;6,41;-144;2;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;325,2;6;2;2;3,25;CCCN(CC1CC1)[C@@H]1CCc2ccc3[nH]c(C(N)=O)cc3c2C1;https://dx.doi.org/10.1021/jm00067a003
CHEMBL1788231;63065;None;0;Human;Binding;Ki;=;398,11;6,40;-25;6;Binding affinity towards Dopamine receptor D2 (human cloned receptor) in CHO cells using [125I]iodosulpiride radioligand.;ChEMBL;400,2;5;0;3;4,50;CC1CCN(CC[C@H]2CCCCN2S(=O)(=O)c2cccc3ccccc23)CC1;https://dx.doi.org/10.1021/jm991151j
CHEMBL1788252;63074;None;0;Human;Binding;Ki;=;501,19;6,30;-125;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;529,2;8;1;4;6,63;COc1ccc(S(=O)(=O)N(C)c2ccccc2)cc1-c1ccc(CN2CCCCC[C@@H]2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL1788258;63075;None;0;Human;Binding;Ki;=;25,12;7,60;-31;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;452,2;7;1;4;5,60;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCC[C@@H]3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL179003;63202;None;0;Human;Binding;Ki;=;10,20;7,99;-7;2;Binding affinity for human dopamine D2 receptor;ChEMBL;437,1;6;1;3;4,75;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1Cl;https://dx.doi.org/10.1021/jm049465g
CHEMBL179025;63212;None;0;Human;Binding;Ki;=;16,90;7,77;-6;2;Binding affinity for human dopamine D2 receptor;ChEMBL;404,1;6;1;4;3,50;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccn1;https://dx.doi.org/10.1021/jm049465g
CHEMBL179053;63226;None;0;Human;Binding;Ki;=;28,10;7,55;-8;2;Binding affinity for human dopamine D2 receptor;ChEMBL;529;6;1;3;4,71;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(I)c1;https://dx.doi.org/10.1021/jm049465g
CHEMBL179351;63330;None;0;Human;Binding;Ki;=;8,00;8,10;-26;2;Binding affinity for human dopamine D2 receptor;ChEMBL;469,1;7;2;4;4,49;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ncc[nH]2)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL179649;63438;None;0;Human;Binding;Ki;=;11,90;7,92;1;2;In vitro binding affinity against recombinant human dopamine receptor D2L in human liver microsomes;ChEMBL;383,2;3;1;4;3,66;CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CC[C@@H](O)CCC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.12.028
CHEMBL179960;63514;None;0;Human;Binding;Ki;=;18,20;7,74;-36;2;Binding affinity for human dopamine D2 receptor;ChEMBL;482,2;8;1;4;5,39;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2cccnc2)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL180060;63576;None;0;Human;Binding;Ki;=;192,00;6,72;-17;2;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;529;6;1;3;4,71;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(I)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL180060;63576;None;0;Human;Binding;Ki;=;35,40;7,45;-17;2;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;529;6;1;3;4,71;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(I)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL180060;63576;None;0;Human;Binding;Ki;=;35,40;7,45;-17;2;Binding affinity for human dopamine D2 receptor;ChEMBL;529;6;1;3;4,71;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(I)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL1802360;63838;None;4;Human;Binding;Ki;=;0,50;9,30;2;6;Binding affinity to dopamine D2 receptor;ChEMBL;369,2;6;1;4;3,58;O=c1[nH]c2ccccc2n1C1CCN(CCCOc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/ml100105x
CHEMBL1803023;63862;None;0;Human;Binding;Ki;=;16,00;7,80;-3;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;928,5;25;0;16;7,75;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCn2cc(COc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803023;63862;None;0;Human;Binding;Ki;=;25,00;7,60;-3;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;928,5;25;0;16;7,75;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCn2cc(COc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803024;63863;None;0;Human;Binding;Ki;=;35,00;7,46;-2;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells in presence of 100 mM sodium chloride;ChEMBL;984,6;29;0;16;8,61;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803024;63863;None;0;Human;Binding;Ki;=;22,00;7,66;-2;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;984,6;29;0;16;8,61;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803024;63863;None;0;Human;Binding;Ki;=;41,00;7,39;-2;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;984,6;29;0;16;8,61;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803024;63863;None;0;Human;Binding;Ki;=;22,00;7,66;-2;4;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;984,6;29;0;16;8,61;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1803024;63863;None;0;Human;Binding;Ki;=;41,00;7,39;-2;4;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;984,6;29;0;16;8,61;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1803025;63864;None;0;Human;Binding;Ki;=;23,00;7,64;-1;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;1012,6;31;0;16;9,39;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803025;63864;None;0;Human;Binding;Ki;=;17,00;7,77;-1;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;1012,6;31;0;16;9,39;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803026;63865;None;0;Human;Binding;Ki;=;8,20;8,09;-1;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;1040,7;33;0;16;10,17;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCCc1cn(CCCCCCCCCCn2cc(CCCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803026;63865;None;0;Human;Binding;Ki;=;17,00;7,77;-1;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;1040,7;33;0;16;10,17;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCCc1cn(CCCCCCCCCCn2cc(CCCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803027;63866;None;0;Human;Binding;Ki;=;3,40;8,47;2;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;932,5;25;0;18;5,44;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCOCCOCCn2cc(COc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803027;63866;None;0;Human;Binding;Ki;=;3,30;8,48;2;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;932,5;25;0;18;5,44;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCOCCOCCn2cc(COc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803028;63867;None;0;Human;Binding;Ki;=;2,80;8,55;3;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;988,6;29;0;18;6,30;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCOCCOCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803028;63867;None;0;Human;Binding;Ki;=;3,70;8,43;3;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;988,6;29;0;18;6,30;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCOCCOCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803029;63868;None;0;Human;Binding;Ki;=;6,20;8,21;3;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;1032,6;32;0;19;6,32;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCOCCOCCOCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803029;63868;None;0;Human;Binding;Ki;=;4,80;8,32;3;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;1032,6;32;0;19;6,32;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCOCCOCCOCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803030;63869;None;0;Human;Binding;Ki;=;63,00;7,20;-19;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;465,3;11;0;8;4,00;CCCCn1cc(COc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803030;63869;None;0;Human;Binding;Ki;=;70,00;7,16;-19;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;465,3;11;0;8;4,00;CCCCn1cc(COc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803049;63871;None;0;Human;Binding;Ki;=;67,00;7,17;-4;4;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;493,3;13;0;8;4,43;CCCCn1cc(CCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1803049;63871;None;0;Human;Binding;Ki;=;53,00;7,28;-4;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;493,3;13;0;8;4,43;CCCCn1cc(CCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803049;63871;None;0;Human;Binding;Ki;=;53,00;7,28;-4;4;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;493,3;13;0;8;4,43;CCCCn1cc(CCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1803049;63871;None;0;Human;Binding;Ki;=;12,00;7,92;-4;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells in presence of 100 mM sodium chloride;ChEMBL;493,3;13;0;8;4,43;CCCCn1cc(CCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803049;63871;None;0;Human;Binding;Ki;=;67,00;7,17;-4;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;493,3;13;0;8;4,43;CCCCn1cc(CCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803050;63872;None;0;Human;Binding;Ki;=;52,00;7,28;-4;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;507,3;14;0;8;4,82;CCCCn1cc(CCCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803050;63872;None;0;Human;Binding;Ki;=;67,00;7,17;-4;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;507,3;14;0;8;4,82;CCCCn1cc(CCCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803051;63873;None;0;Human;Binding;Ki;=;100,00;7,00;-10;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;481,3;12;0;9;3,23;CCOCCn1cc(COc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803051;63873;None;0;Human;Binding;Ki;=;68,00;7,17;-10;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;481,3;12;0;9;3,23;CCOCCn1cc(COc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803052;63874;None;0;Human;Binding;Ki;=;18,00;7,75;-2;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;509,3;14;0;9;3,67;CCOCCn1cc(CCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803052;63874;None;0;Human;Binding;Ki;=;16,00;7,80;-2;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;509,3;14;0;9;3,67;CCOCCn1cc(CCCOc2ccc(CN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803053;63875;None;0;Human;Binding;Ki;=;32,00;7,50;-2;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;658,4;21;0;11;6,21;CCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803053;63875;None;0;Human;Binding;Ki;=;36,00;7,44;-2;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;658,4;21;0;11;6,21;CCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803054;63876;None;0;Human;Binding;Ki;=;9,80;8,01;1;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;892,6;27;0;15;7,03;COc1cc(CN2CCN(C)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803054;63876;None;0;Human;Binding;Ki;=;7,30;8,14;1;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;892,6;27;0;15;7,03;COc1cc(CN2CCN(C)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803055;63877;None;0;Human;Binding;Ki;=;17,00;7,77;1;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;960,6;28;0;15;8,73;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(C5CCCCC5)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1803055;63877;None;0;Human;Binding;Ki;=;19,00;7,72;1;4;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;960,6;28;0;15;8,73;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(CN4CCN(C5CCCCC5)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2004859
CHEMBL1806867;63979;None;0;Human;Binding;Ki;=;2800,00;5,55;-12;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;378,2;3;1;3;5,11;CCCN1CCc2cccc3c2C1Cc1cccc(OC(=O)NC(C)(C)C)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806868;63980;None;0;Human;Binding;Ki;=;871,00;6,06;-9;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;378,2;3;1;3;5,11;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OC(=O)NC(C)(C)C)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806869;63981;None;0;Human;Binding;Ki;=;2005,00;5,70;-16;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;448,2;4;1;3;6,98;CCCN1CCc2cccc3c2C1Cc1cccc(OC(=O)Nc2cccc4ccccc24)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806870;63982;None;0;Human;Binding;Ki;=;4300,00;5,37;-16;4;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;412,2;5;1;3;5,51;CCCN1CCc2cccc3c2C1Cc1cccc(OC(=O)NCc2ccccc2)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806871;63983;None;0;Human;Binding;Ki;=;2200,00;5,66;-24;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;412,2;5;1;3;5,51;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OC(=O)NCc2ccccc2)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806872;63984;None;0;Human;Binding;Ki;=;851,00;6,07;-;1;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;429,2;6;0;4;5,92;CCCN1CCc2cccc3c2C1Cc1cccc(OC(=O)CSc2ccccc2)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806874;63986;None;0;Human;Binding;Ki;=;174,00;6,76;-2;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;467,2;8;0;5;6,84;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OC(=O)CCCCC2CCSS2)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806875;63987;None;0;Human;Binding;Ki;=;296,00;6,53;-6;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;467,2;8;0;5;6,84;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OC(=O)CCCC[C@@H]2CCSS2)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806876;63988;None;0;Human;Binding;Ki;=;342,00;6,47;-9;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;467,2;8;0;5;6,84;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(OC(=O)CCCC[C@H]2CCSS2)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1806877;63989;None;0;Human;Binding;Ki;=;352,00;6,45;-1;2;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;278,2;2;1;2;3,80;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(N)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL1807819;64106;None;0;Human;Binding;IC50;=;630,96;6,20;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;462,2;14;4;7;3,69;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCCOCCc3ccccc3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807820;64107;None;0;Human;Binding;IC50;=;199,53;6,70;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;498,2;13;4;7;4,45;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCOCCc3cccc4ccccc34)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807821;64108;None;0;Human;Binding;IC50;=;794,33;6,10;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;432,2;13;4;7;2,58;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCOCCOCCc3ccccc3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807823;64110;None;0;Human;Binding;IC50;=;3981,07;5,40;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;447,2;13;5;7;2,87;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3ccccc3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807824;64111;None;0;Human;Binding;IC50;=;2511,89;5,60;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;475,2;14;5;7;3,44;CCc1ccc(CCNCCCSCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807825;64112;None;0;Human;Binding;IC50;=;3981,07;5,40;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;491,2;15;5;8;3,27;CCOc1ccc(CCNCCCSCCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807826;64113;None;0;Human;Binding;IC50;=;501,19;6,30;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;515,2;13;5;7;3,89;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3cccc(C(F)(F)F)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807828;64115;None;0;Human;Binding;IC50;=;1584,89;5,80;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;481,1;13;5;7;3,53;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3ccccc3Cl)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807829;64116;None;0;Human;Binding;IC50;=;398,11;6,40;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;515,1;13;5;7;4,18;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCSCCCNCCc3cccc(Cl)c3Cl)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807831;64118;None;0;Human;Binding;IC50;=;794,33;6,10;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;513,1;13;5;8;2,21;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCS(=O)(=O)CCCNCCc3cccc(Cl)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807832;64119;None;0;Human;Binding;IC50;=;3162,28;5,50;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;465,1;13;5;7;2,81;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCOCCCNCCc3cccc(Cl)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807869;64120;None;0;Human;Binding;IC50;=;1584,89;5,80;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;481,1;13;5;7;3,53;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCNCCc3cccc(Cl)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807870;64121;None;0;Human;Binding;IC50;=;1000,00;6,00;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;481,1;13;5;7;3,53;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCNCCc3ccccc3Cl)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807871;64122;None;0;Human;Binding;IC50;=;1000,00;6,00;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;515,1;13;5;7;4,18;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCSCCNCCc3cccc(Cl)c3Cl)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807873;64124;None;0;Human;Binding;IC50;=;1995,26;5,70;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;499,1;13;5;7;3,46;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCOCCNCCc3cccc(Cl)c3Cl)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL1807874;64125;None;0;Human;Binding;IC50;=;2511,89;5,60;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;445,2;13;4;7;2,50;CN(CCOCCCNC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12)CCc1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
CHEMBL181469;64569;None;0;Human;Binding;Ki;=;6,20;8,21;2;2;In vitro binding affinity against recombinant human dopamine receptor D2L in human liver microsomes;ChEMBL;383,2;3;1;4;3,66;CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCC[C@@H](O)CC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.12.028
CHEMBL181898;64755;None;0;Human;Binding;Ki;=;28,18;7,55;3;3;Binding affinity against Dopamine receptor D2;ChEMBL;390,2;4;2;4;3,65;Oc1nc2cc(CCN3CCN(c4cccc(C(F)(F)F)c4)CC3)ccc2[nH]1;https://dx.doi.org/10.1016/j.bmcl.2004.06.005
CHEMBL182075;64872;None;0;Human;Binding;Ki;=;4000,00;5,40;-234;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;402,2;6;1;3;5,08;CSc1ccc(-c2ccc(C(=O)NC3CCN(Cc4ccccc4)C3)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL1822386;64923;None;0;Human;Binding;Ki;=;1350,00;5,87;1;2;Displacement of [125I]IABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;414,2;5;1;4;3,50;O=C(c1ccc(F)cc1)C1CCN([C@H]2CCN(Cc3ccc(F)cc3)C[C@@H]2O)CC1;https://dx.doi.org/10.1021/jm200203f
CHEMBL1822390;64924;None;0;Human;Binding;Ki;=;1489,00;5,83;-;1;Displacement of [125I]IABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;426,2;6;1;5;3,36;COc1ccc(C(=O)C2CCN([C@H]3CCN(Cc4ccc(F)cc4)C[C@@H]3O)CC2)cc1;https://dx.doi.org/10.1021/jm200203f
CHEMBL182379;65099;None;0;Human;Binding;Ki;=;59,00;7,23;-39;6;Binding affinity towards human D2 long receptor using [3H]spiperone expressed in CHO cells;ChEMBL;533,1;8;1;5;4,38;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(I)ccc3o2)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL182379;65099;None;0;Human;Binding;Ki;=;27,00;7,57;-39;6;Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells;ChEMBL;533,1;8;1;5;4,38;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(I)ccc3o2)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL182652;65251;None;0;Human;Binding;Ki;=;75,00;7,12;-21;5;Binding affinity towards human D2 long receptor using [3H]spiperone expressed in CHO cells;ChEMBL;499,1;8;1;5;3,69;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(I)s2)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL182652;65251;None;0;Human;Binding;Ki;=;35,00;7,46;-21;5;Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells;ChEMBL;499,1;8;1;5;3,69;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(I)s2)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL182721;65267;None;0;Human;Binding;Ki;=;1,66;8,78;9;5;Binding affinity against Dopamine receptor D2;ChEMBL;358,2;4;2;4;4,00;c1ccc2c(N3CCN(CCc4ccc5c(c4)NCN5)CC3)cccc2c1;https://dx.doi.org/10.1016/j.bmcl.2004.06.005
CHEMBL1831166;65588;None;0;Human;Binding;Ki;=;870,00;6,06;-1;4;Displacement of [3H]YM-09151-2 from human D2 receptor expressed in CHO cells;ChEMBL;458,2;8;0;4;6,30;COc1cc2c(cc1OC)CN(CCCCn1cc(-c3ccc(F)cc3)c3ccccc31)CC2;https://dx.doi.org/10.1016/j.ejmech.2011.08.031
CHEMBL183160;65596;None;0;Human;Binding;Ki;=;4000,00;5,40;-234;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;374,2;5;1;2;4,50;O=C(NC1CCN(Cc2ccccc2)C1)c1ccc(-c2cccc(F)c2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL1834252;65684;None;0;Human;Binding;Ki;=;1648,00;5,78;-13;2;Displacement of [3H]N-methylspiperone from D2 after 1.5 hrs by liquid scintillation counting;ChEMBL;350,2;6;0;4;3,80;COc1ccccc1CCN1CCN(Cc2cc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmcl.2011.08.029
CHEMBL1834255;65687;None;0;Human;Binding;Ki;=;1025,00;5,99;-6;2;Displacement of [3H]N-methylspiperone from D2 after 1.5 hrs by liquid scintillation counting;ChEMBL;334,2;6;0;3;4,18;c1ccc(CCCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.08.029
CHEMBL1834256;65688;None;0;Human;Binding;Ki;=;5866,00;5,23;-9;2;Displacement of [3H]N-methylspiperone from D2 after 1.5 hrs by liquid scintillation counting;ChEMBL;364,2;7;0;4;4,19;COc1ccccc1CCCN1CCN(Cc2cc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmcl.2011.08.029
CHEMBL1834257;65689;None;0;Human;Binding;Ki;=;556,00;6,25;-2;2;Displacement of [3H]N-methylspiperone from D2 after 1.5 hrs by liquid scintillation counting;ChEMBL;364,2;7;0;4;4,19;COc1cccc(CCCN2CCN(Cc3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2011.08.029
CHEMBL1834258;65690;None;0;Human;Binding;Ki;=;89,00;7,05;3;2;Displacement of [3H]N-methylspiperone from D2 after 1.5 hrs by liquid scintillation counting;ChEMBL;348,2;7;0;3;4,57;c1ccc(CCCCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.08.029
CHEMBL1834259;65691;None;0;Human;Binding;Ki;=;432,00;6,37;-1;2;Displacement of [3H]N-methylspiperone from D2 after 1.5 hrs by liquid scintillation counting;ChEMBL;378,2;8;0;4;4,58;COc1ccccc1CCCCN1CCN(Cc2cc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmcl.2011.08.029
CHEMBL1834260;65692;None;0;Human;Binding;Ki;=;484,00;6,32;-1;2;Displacement of [3H]N-methylspiperone from D2 after 1.5 hrs by liquid scintillation counting;ChEMBL;378,2;8;0;4;4,58;COc1cccc(CCCCN2CCN(Cc3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2011.08.029
CHEMBL1834261;65693;None;0;Human;Binding;Ki;=;5791,00;5,24;-16;2;Displacement of [3H]N-methylspiperone from D2 after 1.5 hrs by liquid scintillation counting;ChEMBL;378,2;8;0;4;4,58;COc1ccc(CCCCN2CCN(Cc3cc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.08.029
CHEMBL183776;66096;None;0;Human;Binding;Ki;=;5,37;8,27;8;5;Binding affinity against Dopamine receptor D2;ChEMBL;337,2;5;1;5;2,33;COc1ccccc1N1CCN(CCc2ccc3[nH]nnc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.06.005
CHEMBL183776;66096;None;0;Human;Binding;Ki;=;5,37;8,27;8;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;337,2;5;1;5;2,33;COc1ccccc1N1CCN(CCc2ccc3[nH]nnc3c2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL183871;66114;None;0;Human;Binding;Ki;=;450,00;6,35;-56;5;Binding affinity towards human D2 long receptor using [3H]spiperone expressed in CHO cells;ChEMBL;587;7;1;4;6,14;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(I)ccc2s1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL183871;66114;None;0;Human;Binding;Ki;=;140,00;6,85;-56;5;Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells;ChEMBL;587;7;1;4;6,14;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(I)ccc2s1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL184049;66146;None;0;Human;Binding;Ki;=;158,00;6,80;-87;5;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;297,2;1;0;3;3,15;COc1ccc2c(c1)OCCN(C)CCc1ccccc1C2;https://dx.doi.org/10.1021/jm049720x
CHEMBL184050;66148;None;0;Human;Binding;Ki;=;274,00;6,56;-478;5;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;283,2;0;1;3;2,85;CN1CCOc2cc(O)ccc2Cc2ccccc2CC1;https://dx.doi.org/10.1021/jm049720x
CHEMBL184073;66153;None;0;Human;Binding;Ki;=;4188,00;5,38;-6;4;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;372,2;7;0;3;4,48;c1ccc(Cc2ccccc2OCCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm049720x
CHEMBL184383;66209;None;0;Human;Binding;Ki;=;430,00;6,37;-380;6;Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells;ChEMBL;571;7;1;4;5,68;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(I)ccc2o1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL184383;66209;None;0;Human;Binding;Ki;=;3200,00;5,50;-380;6;Binding affinity towards human D2 long receptor using [3H]spiperone expressed in CHO cells;ChEMBL;571;7;1;4;5,68;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(I)ccc2o1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL184388;66212;None;0;Human;Binding;Ki;=;120,00;6,92;-15;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;374,2;5;1;2;4,50;O=C(NC1CCN(Cc2ccccc2)C1)c1ccc(-c2ccc(F)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL184551;66255;None;0;Human;Binding;Ki;=;3100,00;5,51;-85;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;384,2;6;1;3;4,17;O=Cc1ccccc1-c1ccc(C(=O)NC2CCN(Cc3ccccc3)C2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL184770;66311;None;0;Human;Binding;Ki;=;51,29;7,29;-9;5;Binding affinity against Dopamine receptor D2;ChEMBL;335,2;4;1;4;2,94;Cc1cccc(N2CCN(CCc3ccc4[nH]nnc4c3)CC2)c1C;https://dx.doi.org/10.1016/j.bmcl.2004.06.005
CHEMBL184770;66311;None;0;Human;Binding;Ki;=;51,29;7,29;-9;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;335,2;4;1;4;2,94;Cc1cccc(N2CCN(CCc3ccc4[nH]nnc4c3)CC2)c1C;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL184993;66347;None;0;Human;Binding;Ki;=;48,00;7,32;-8;5;Binding affinity towards human D2 long receptor using [3H]spiperone expressed in CHO cells;ChEMBL;549,1;8;1;5;4,85;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(I)ccc3s2)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL184993;66347;None;0;Human;Binding;Ki;=;1,00;9,00;-8;5;Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells;ChEMBL;549,1;8;1;5;4,85;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(I)ccc3s2)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL185156;66384;None;0;Human;Binding;Ki;=;600,00;6,22;-199;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;356,2;5;1;2;4,36;O=C(NC1CCN(Cc2ccccc2)C1)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL1851628;66387;None;0;Human;Binding;Ki;=;611,00;6,21;-1;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;462,3;7;1;5;3,50;CN1CN(c2ccccc2)C2(CCN(CCCCOc3ccc4c(c3)NC(=O)CC4)CC2)C1=O;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851639;66390;None;0;Human;Binding;Ki;=;0,14;9,85;38;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;407,2;8;1;5;3,52;COc1ccccc1N1CCN(CCCCOc2ccc3ccc(=O)[nH]c3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851643;66391;None;0;Human;Binding;Ki;=;309,00;6,51;1;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;468,2;7;2;5;4,36;O=C1CCc2ccc(OCCCCN3CCC(n4c(=O)[nH]c5cc(Cl)ccc54)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851753;66405;None;0;Human;Binding;Ki;=;7,30;8,14;-1;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;423,3;9;1;5;3,95;COc1ccccc1N1CCN(CCCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851787;66417;None;1;Human;Binding;Ki;=;4,60;8,34;5;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;423,3;8;1;5;3,87;COc1cc(C)ccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851831;66425;None;0;Human;Binding;Ki;=;0,26;9,59;52;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;441,2;10;1;5;3,90;O=C1CCc2ccc(OCCCCN3CCN(c4ccccc4OCCF)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851858;66431;None;2;Human;Binding;Ki;=;102,00;6,99;3;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;409,2;8;1;5;3,56;COc1ccc(N2CCN(CCCCOc3ccc4c(c3)NC(=O)CC4)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851893;66440;None;0;Human;Binding;Ki;=;0,07;10,15;38;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;439,2;10;1;5;3,86;O=c1ccc2ccc(OCCCCN3CCN(c4ccccc4OCCF)CC3)cc2[nH]1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851895;66441;None;0;Human;Binding;Ki;=;7,40;8,13;-1;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;421,2;9;1;5;3,91;COc1ccccc1N1CCN(CCCCCOc2ccc3ccc(=O)[nH]c3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851900;66443;None;0;Human;Binding;Ki;=;2604,00;5,58;-1;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;428,2;7;2;4;4,37;O=C1CCc2ccc(OCCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1851962;66454;None;0;Human;Binding;Ki;=;145,00;6,84;6;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;434,2;7;2;5;3,71;O=C1CCc2ccc(OCCCCN3CCC(n4c(=O)[nH]c5ccccc54)CC3)cc2N1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1852341;66516;None;0;Human;Binding;IC50;=;1369,00;5,86;-;7;Inhibition of dopamine D2 receptor by competition binding assay;ChEMBL;485,2;7;1;5;4,74;Cc1nc(C(=O)NCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1;https://dx.doi.org/10.1021/jm200682b
CHEMBL1852516;66596;None;0;Human;Binding;IC50;=;908,00;6,04;-;8;Inhibition of dopamine D2 receptor by competition binding assay;ChEMBL;471,2;6;1;5;4,35;Cc1nc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c(C)n1-c1ccccc1;https://dx.doi.org/10.1021/jm200682b
CHEMBL1852734;66644;None;0;Human;Binding;Ki;=;4,80;8,32;1;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;395,2;7;1;5;3,17;COc1ccccc1N1CCN(CCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1852735;66645;None;0;Human;Binding;Ki;=;2,60;8,59;2;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;393,2;7;1;5;3,13;COc1ccccc1N1CCN(CCCOc2ccc3ccc(=O)[nH]c3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL1852737;66646;None;2;Human;Binding;Ki;=;25,30;7,60;11;3;Displacement of [125I]ABN from human recombinant D2L receptor expressed in HEK cells after 60 mins by gamma counter;ChEMBL;439,2;9;1;6;3,57;COc1ccc(N2CCN(CCCCOc3ccc4c(c3)NC(=O)CC4)CC2)c(OC)c1;https://dx.doi.org/10.1016/j.bmc.2011.04.021
CHEMBL185436;66701;None;0;Human;Binding;Ki;=;31,62;7,50;5;3;Binding affinity against Dopamine receptor D2;ChEMBL;382,2;5;1;3;4,59;c1ccc(-c2nc3cc(CCN4CCN(c5ccccc5)CC4)ccc3[nH]2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.06.005
CHEMBL185436;66701;None;0;Human;Binding;Ki;=;31,62;7,50;5;3;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;382,2;5;1;3;4,59;c1ccc(-c2nc3cc(CCN4CCN(c5ccccc5)CC4)ccc3[nH]2)cc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL185875;66788;None;0;Human;Binding;Ki;=;6280,00;5,20;-2;2;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;297,2;6;1;3;3,24;OC(c1ccccc1)c1ccccc1OCCN1CCCC1;https://dx.doi.org/10.1021/jm049720x
CHEMBL18598;66816;None;5;Human;Binding;Kd;=;94,30;7,03;-14;2;Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as high affinity state;ChEMBL;285,1;0;2;3;2,99;CN1CCc2cc(F)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
CHEMBL18598;66816;None;5;Human;Binding;Kd;=;0,43;9,37;-14;2;Compound was evaluated for the ability to displace [3H]spiperone at dopamine receptor in porcine anterior pituitary gland as high affinity state;ChEMBL;285,1;0;2;3;2,99;CN1CCc2cc(F)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
CHEMBL186558;66939;None;0;Human;Binding;Ki;=;1500,00;5,82;-63;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@@H]1CCN(Cc2ccccc2)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL187113;67060;None;0;Human;Binding;Ki;=;94,00;7,03;-27;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@@H]1CCN(Cc2ccccc2)C1)c1cccc(-c2ccsc2)c1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL187122;67063;None;0;Human;Binding;Ki;=;1200,00;5,92;-602;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(NC1CCN(Cc2ccccc2)C1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL187236;67086;None;0;Human;Binding;Ki;=;840,00;6,08;-275;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(NC1CCN(Cc2ccccc2)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL187367;67121;None;0;Human;Binding;Ki;=;1006,00;6,00;-100;6;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;295,2;7;0;2;4,14;c1ccc(Cc2ccccc2OCCCN2CCCC2)cc1;https://dx.doi.org/10.1021/jm049720x
CHEMBL187804;67220;None;0;Human;Binding;Ki;=;8000,00;5,10;-467;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;424,2;5;1;2;5,38;O=C(NC1CCN(Cc2ccccc2)C1)c1ccc(-c2ccc(C(F)(F)F)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL19068;67681;None;22;Human;Binding;Ki;=;3400,00;5,47;-1;2;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;287,1;2;5;5;1,94;Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1O;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
CHEMBL1908879;67807;None;0;Human;Binding;Ki;=;12,00;7,92;-30;5;Displacement of [3H]spiperone from human dopamine D2(short) expressed in CHO cell membrane;ChEMBL;462,2;9;1;5;4,23;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(F)nc3)cc2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL1908879;67807;None;0;Human;Binding;Ki;=;15,00;7,82;-30;5;Displacement of [3H]spiperone from human dopamine D2(long) expressed in CHO cell membrane;ChEMBL;462,2;9;1;5;4,23;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(F)nc3)cc2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL19130;68040;None;2;Human;Binding;Kd;=;1,10;8,96;-2;5;Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as high affinity state;ChEMBL;283,1;0;3;4;2,56;CN1CCc2cc(O)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
CHEMBL1916548;68354;None;0;Human;Binding;Ki;=;14,00;7,85;-9;4;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;1052,7;34;1;15;9,67;CCCN(CCCCNC(=O)c1ccc(OCCCc2cn(CCCCCCCCn3cc(CCCOc4ccc(CN5CCN(c6ccccc6OC)CC5)cc4OC)nn3)nn2)c(OC)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916548;68354;None;0;Human;Binding;Ki;=;8,80;8,06;-9;4;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;1052,7;34;1;15;9,67;CCCN(CCCCNC(=O)c1ccc(OCCCc2cn(CCCCCCCCn3cc(CCCOc4ccc(CN5CCN(c6ccccc6OC)CC5)cc4OC)nn3)nn2)c(OC)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916549;68355;None;0;Human;Binding;Ki;=;16,00;7,80;-8;4;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;1120,7;39;2;14;10,73;CCCN(CCCCNC(=O)c1ccc(OCCCc2cn(CCCCCCCCn3cc(CCCOc4ccc(C(=O)NCCCCN(CCC)C5Cc6ccccc6C5)cc4OC)nn3)nn2)c(OC)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916549;68355;None;0;Human;Binding;Ki;=;16,00;7,80;-8;4;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;1120,7;39;2;14;10,73;CCCN(CCCCNC(=O)c1ccc(OCCCc2cn(CCCCCCCCn3cc(CCCOc4ccc(C(=O)NCCCCN(CCC)C5Cc6ccccc6C5)cc4OC)nn3)nn2)c(OC)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916550;68356;None;0;Human;Binding;Ki;=;110,00;6,96;-9;4;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;1154,7;37;2;18;8,63;COc1cc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916550;68356;None;0;Human;Binding;Ki;=;110,00;6,96;-9;4;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;1154,7;37;2;18;8,63;COc1cc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)ccc1OCCCc1cn(CCCCCCCCn2cc(CCCOc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3OC)nn2)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916551;68357;None;0;Human;Binding;Ki;=;12,00;7,92;-9;4;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;561,4;18;1;7;5,49;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)C3Cc4ccccc4C3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916551;68357;None;0;Human;Binding;Ki;=;4,10;8,39;-9;4;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;561,4;18;1;7;5,49;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)C3Cc4ccccc4C3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916552;68358;None;0;Human;Binding;Ki;=;17,00;7,77;-7;4;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;578,4;17;1;9;4,44;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916552;68358;None;0;Human;Binding;Ki;=;12,00;7,92;-7;4;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;578,4;17;1;9;4,44;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916720;68418;None;0;Human;Binding;Ki;=;25,00;7,60;-10;4;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;1137,7;38;2;16;9,68;CCCN(CCCCNC(=O)c1ccc(OCCCc2cn(CCCCCCCCn3cc(CCCOc4ccc(C(=O)NCCCCN5CCN(c6ccccc6OC)CC5)cc4OC)nn3)nn2)c(OC)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1021/jm2009919
CHEMBL1916720;68418;None;0;Human;Binding;Ki;=;17,00;7,77;-10;4;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;1137,7;38;2;16;9,68;CCCN(CCCCNC(=O)c1ccc(OCCCc2cn(CCCCCCCCn3cc(CCCOc4ccc(C(=O)NCCCCN5CCN(c6ccccc6OC)CC5)cc4OC)nn3)nn2)c(OC)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1021/jm2009919
CHEMBL191795;68653;None;0;Human;Binding;Ki;=;7,40;8,13;-2;2;Binding affinity for human dopamine D2 receptor;ChEMBL;448,1;7;1;5;4,01;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1[N+](=O)[O-];https://dx.doi.org/10.1021/jm049465g
CHEMBL191855;68662;None;0;Human;Binding;Ki;=;29,00;7,54;-14;2;Binding affinity for human dopamine D2 receptor;ChEMBL;418,1;6;2;4;3,68;Nc1cccc(C(=O)NC/C=C/CN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1021/jm049465g
CHEMBL192099;68697;None;0;Human;Binding;Ki;=;2200,00;5,66;-275;6;Binding affinity for human Dopamine receptor D2;ChEMBL;391,2;4;0;4;2,80;O=C1CC2(CCCC2)CC(=O)N1CCN1CCN(c2ccc(F)c(F)c2)CC1;https://dx.doi.org/10.1021/jm0491391
CHEMBL1923292;69026;None;0;Human;Binding;Ki;=;7600,00;5,12;-6025;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;328,2;3;0;4;2,92;Fc1ccc(CN2CCN(c3ccc4c(c3)OCCO4)CC2)cc1;https://dx.doi.org/10.1021/jm200762g
CHEMBL1923292;69026;None;0;Human;Binding;Ki;=;5700,00;5,24;-6025;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;328,2;3;0;4;2,92;Fc1ccc(CN2CCN(c3ccc4c(c3)OCCO4)CC2)cc1;https://dx.doi.org/10.1021/jm200762g
CHEMBL1923293;69027;None;0;Human;Binding;Ki;=;16000,00;4,80;-3890;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;358,2;4;0;5;2,93;COc1cc(CN2CCN(c3ccc4c(c3)OCCO4)CC2)ccc1F;https://dx.doi.org/10.1021/jm200762g
CHEMBL1923293;69027;None;0;Human;Binding;Ki;=;17000,00;4,77;-3890;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;358,2;4;0;5;2,93;COc1cc(CN2CCN(c3ccc4c(c3)OCCO4)CC2)ccc1F;https://dx.doi.org/10.1021/jm200762g
CHEMBL1923415;69031;None;0;Human;Binding;Ki;=;6100,00;5,21;-1023;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;344,2;3;1;5;2,63;Oc1cc(CN2CCN(c3ccc4c(c3)OCCO4)CC2)ccc1F;https://dx.doi.org/10.1021/jm200762g
CHEMBL1923415;69031;None;0;Human;Binding;Ki;=;9000,00;5,05;-1023;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;344,2;3;1;5;2,63;Oc1cc(CN2CCN(c3ccc4c(c3)OCCO4)CC2)ccc1F;https://dx.doi.org/10.1021/jm200762g
CHEMBL1923416;69032;None;0;Human;Binding;Ki;=;45000,00;4,35;-2344;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;329,2;3;0;5;2,31;Fc1ccc(CN2CCN(c3ccc4c(c3)OCCO4)CC2)cn1;https://dx.doi.org/10.1021/jm200762g
CHEMBL1923416;69032;None;0;Human;Binding;Ki;=;29000,00;4,54;-2344;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;329,2;3;0;5;2,31;Fc1ccc(CN2CCN(c3ccc4c(c3)OCCO4)CC2)cn1;https://dx.doi.org/10.1021/jm200762g
CHEMBL1926700;69217;None;0;Human;Binding;Ki;=;8,40;8,08;-1;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;976,5;28;2;17;4,39;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccc(OCCOCCOCCOCCOc4ccn5ncc(C(=O)NCCCN6CCN(c7ccccc7OC)CC6)c5c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1926700;69217;None;0;Human;Binding;Ki;=;2,70;8,57;-1;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;976,5;28;2;17;4,39;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccc(OCCOCCOCCOCCOc4ccn5ncc(C(=O)NCCCN6CCN(c7ccccc7OC)CC6)c5c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928119;69317;None;0;Human;Binding;Ki;=;140,00;6,85;-15;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;441,3;12;1;6;3,05;CCOCCOc1cccc(C(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928119;69317;None;0;Human;Binding;Ki;=;270,00;6,57;-15;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;441,3;12;1;6;3,05;CCOCCOc1cccc(C(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928120;69318;None;0;Human;Binding;Ki;=;95,00;7,02;-13;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;455,3;13;1;6;3,44;CCOCCOc1cccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928120;69318;None;0;Human;Binding;Ki;=;44,00;7,36;-13;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;455,3;13;1;6;3,44;CCOCCOc1cccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928121;69319;None;0;Human;Binding;Ki;=;6,40;8,19;-7;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;896,5;28;2;13;5,10;COc1ccccc1N1CCN(CCCNC(=O)c2cccc(OCCOCCOCCOCCOc3cccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)c3)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928121;69319;None;0;Human;Binding;Ki;=;16,00;7,80;-7;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;896,5;28;2;13;5,10;COc1ccccc1N1CCN(CCCNC(=O)c2cccc(OCCOCCOCCOCCOc3cccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)c3)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928122;69320;None;0;Human;Binding;Ki;=;6,60;8,18;-5;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;924,5;30;2;13;5,88;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(OCCOCCOCCOCCOc3cccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)c3)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928122;69320;None;0;Human;Binding;Ki;=;1,80;8,74;-5;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;924,5;30;2;13;5,88;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(OCCOCCOCCOCCOc3cccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)c3)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928123;69321;None;0;Human;Binding;Ki;=;780,00;6,11;-35;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;455,3;13;1;6;3,19;CCOCCOCc1ccc(C(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928123;69321;None;0;Human;Binding;Ki;=;320,00;6,50;-35;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;455,3;13;1;6;3,19;CCOCCOCc1ccc(C(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928124;69322;None;0;Human;Binding;Ki;=;290,00;6,54;-17;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;469,3;14;1;6;3,58;CCOCCOCc1ccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928124;69322;None;0;Human;Binding;Ki;=;83,00;7,08;-17;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;469,3;14;1;6;3,58;CCOCCOCc1ccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928125;69323;None;0;Human;Binding;Ki;=;19,00;7,72;-14;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;924,5;30;2;13;5,37;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(COCCOCCOCCOCCOCc3ccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928125;69323;None;0;Human;Binding;Ki;=;42,00;7,38;-14;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;924,5;30;2;13;5,37;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(COCCOCCOCCOCCOCc3ccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928126;69324;None;0;Human;Binding;Ki;=;25,00;7,60;-19;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;952,6;32;2;13;6,15;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(COCCOCCOCCOCCOCc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928126;69324;None;0;Human;Binding;Ki;=;11,00;7,96;-19;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;952,6;32;2;13;6,15;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(COCCOCCOCCOCCOCc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928127;69325;None;0;Human;Binding;Ki;=;47,00;7,33;-9;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;968,6;33;2;14;5,39;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928127;69325;None;0;Human;Binding;Ki;=;32,00;7,50;-9;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;968,6;33;2;14;5,39;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928128;69326;None;0;Human;Binding;Ki;=;14,00;7,85;-72;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;996,6;35;2;14;6,17;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928128;69326;None;0;Human;Binding;Ki;=;20,00;7,70;-72;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;996,6;35;2;14;6,17;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928129;69327;None;0;Human;Binding;Ki;=;20,00;7,70;-4;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;1012,6;36;2;15;5,40;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928129;69327;None;0;Human;Binding;Ki;=;51,00;7,29;-4;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;1012,6;36;2;15;5,40;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928130;69328;None;0;Human;Binding;Ki;=;25,00;7,60;-72;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;1040,6;38;2;15;6,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928130;69328;None;0;Human;Binding;Ki;=;40,00;7,40;-72;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;1040,6;38;2;15;6,18;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928131;69329;None;0;Human;Binding;Ki;=;150,00;6,82;-11;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;1100,6;42;2;17;5,44;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928131;69329;None;0;Human;Binding;Ki;=;66,00;7,18;-11;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;1100,6;42;2;17;5,44;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928132;69330;None;0;Human;Binding;Ki;=;16,00;7,80;-81;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;1128,7;44;2;17;6,22;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928132;69330;None;0;Human;Binding;Ki;=;38,00;7,42;-81;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;1128,7;44;2;17;6,22;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(COCCOCCOCCOCCOCCOCCOCCOCCOCc3ccc(C(=O)NCCCCN4CCN(c5ccccc5OC)CC4)cc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928133;69331;None;0;Human;Binding;Ki;=;29,00;7,54;-1;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;481,3;12;1;8;2,70;CCOCCOc1ccn2ncc(C(=O)NCCCN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928133;69331;None;0;Human;Binding;Ki;=;6,40;8,19;-1;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;481,3;12;1;8;2,70;CCOCCOc1ccn2ncc(C(=O)NCCCN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928134;69332;None;0;Human;Binding;Ki;=;18,00;7,75;-11;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;495,3;13;1;8;3,09;CCOCCOc1ccn2ncc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928134;69332;None;0;Human;Binding;Ki;=;3,00;8,52;-11;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;495,3;13;1;8;3,09;CCOCCOc1ccn2ncc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928135;69333;None;0;Human;Binding;Ki;=;67,00;7,17;-2;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;495,3;13;1;8;2,84;CCOCCOCc1ccn2ncc(C(=O)NCCCN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928135;69333;None;0;Human;Binding;Ki;=;32,00;7,50;-2;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;495,3;13;1;8;2,84;CCOCCOCc1ccn2ncc(C(=O)NCCCN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928136;69334;None;0;Human;Binding;Ki;=;25,00;7,60;-14;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;509,3;14;1;8;3,23;CCOCCOCc1ccn2ncc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928136;69334;None;0;Human;Binding;Ki;=;12,00;7,92;-14;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;509,3;14;1;8;3,23;CCOCCOCc1ccn2ncc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928137;69335;None;0;Human;Binding;Ki;=;1,80;8,74;-3;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;1004,5;30;2;17;5,17;COc1ccccc1N1CCN(CCCCNC(=O)c2cnn3ccc(OCCOCCOCCOCCOc4ccn5ncc(C(=O)NCCCCN6CCN(c7ccccc7OC)CC6)c5c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928137;69335;None;0;Human;Binding;Ki;=;0,59;9,23;-3;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;1004,5;30;2;17;5,17;COc1ccccc1N1CCN(CCCCNC(=O)c2cnn3ccc(OCCOCCOCCOCCOc4ccn5ncc(C(=O)NCCCCN6CCN(c7ccccc7OC)CC6)c5c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928138;69336;None;0;Human;Binding;Ki;=;3,90;8,41;-1;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;1004,5;30;2;17;4,67;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccc(COCCOCCOCCOCCOCc4ccn5ncc(C(=O)NCCCN6CCN(c7ccccc7OC)CC6)c5c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928138;69336;None;0;Human;Binding;Ki;=;4,70;8,33;-1;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;1004,5;30;2;17;4,67;COc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccc(COCCOCCOCCOCCOCc4ccn5ncc(C(=O)NCCCN6CCN(c7ccccc7OC)CC6)c5c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928139;69337;None;0;Human;Binding;Ki;=;8,30;8,08;-12;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;1032,6;32;2;17;5,45;COc1ccccc1N1CCN(CCCCNC(=O)c2cnn3ccc(COCCOCCOCCOCCOCc4ccn5ncc(C(=O)NCCCCN6CCN(c7ccccc7OC)CC6)c5c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928139;69337;None;0;Human;Binding;Ki;=;4,60;8,34;-12;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;1032,6;32;2;17;5,45;COc1ccccc1N1CCN(CCCCNC(=O)c2cnn3ccc(COCCOCCOCCOCCOCc4ccn5ncc(C(=O)NCCCCN6CCN(c7ccccc7OC)CC6)c5c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928247;69340;None;0;Human;Binding;Ki;=;9700,00;5,01;-14;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;469,3;14;1;6;3,58;CCOCCOCc1ccc(N2CCN(CCCCNC(=O)c3ccccc3)CC2)c(OC)c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928247;69340;None;0;Human;Binding;Ki;=;19000,00;4,72;-14;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;469,3;14;1;6;3,58;CCOCCOCc1ccc(N2CCN(CCCCNC(=O)c3ccccc3)CC2)c(OC)c1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928248;69341;None;0;Human;Binding;Ki;=;270,00;6,57;-2;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;952,6;32;2;13;6,15;COc1cc(COCCOCCOCCOCCOCc2ccc(N3CCN(CCCCNC(=O)c4ccccc4)CC3)c(OC)c2)ccc1N1CCN(CCCCNC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL1928248;69341;None;0;Human;Binding;Ki;=;280,00;6,55;-2;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;952,6;32;2;13;6,15;COc1cc(COCCOCCOCCOCCOCc2ccc(N3CCN(CCCCNC(=O)c4ccccc4)CC3)c(OC)c2)ccc1N1CCN(CCCCNC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL19331;69429;None;45;Human;Binding;IC50;=;1030,00;5,99;-18;2;Inhibitory concentration against binding of [3H]spiperone to human D2 dopaminergic receptor;ChEMBL;135,1;0;2;2;1,36;Oc1ccc2c(c1)CCN2;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
CHEMBL19331;69429;None;45;Human;Binding;Ki;=;9400,00;5,03;-18;2;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;135,1;0;2;2;1,36;Oc1ccc2c(c1)CCN2;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
CHEMBL193337;69465;None;0;Human;Binding;Ki;=;180,00;6,75;-5;4;High binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL193337;69465;None;0;Human;Binding;Ki;=;270,00;6,57;-5;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL193337;69465;None;0;Human;Binding;Ki;=;10000,00;5,00;-5;4;Low binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL193337;69465;None;0;Human;Binding;Ki;=;410,00;6,39;-5;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL193337;69465;None;0;Human;Binding;Ki;=;250,00;6,60;-5;4;High binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL193337;69465;None;0;Human;Binding;Ki;=;15000,00;4,82;-5;4;Low binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL193337;69465;None;0;Human;Binding;Ki;=;4,60;8,34;-5;4;Displacement of [3H]7-OH-DPAT from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL1934127;69573;None;0;Human;Binding;IC50;=;500,00;6,30;-;2;Inhibition of dopamine D2 receptor;ChEMBL;457,2;3;2;2;6,09;CC(=O)N[C@@H]1CC2(CCN(Cc3ccc4[nH]c5ccc(Cl)cc5c4c3)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2011.10.125
CHEMBL1934130;69576;None;0;Human;Binding;IC50;=;1500,00;5,82;-;2;Inhibition of dopamine D2 receptor;ChEMBL;466,2;3;2;4;4,84;CC(=O)N[C@@H]1CC2(CCN(Cc3ccc4c(c3)c3ccccc3n4C(N)=O)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2011.10.125
CHEMBL193435;69598;None;0;Human;Binding;Ki;=;66,00;7,18;-7;9;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;373,1;2;0;3;4,73;CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Br)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL193501;69674;None;0;Human;Binding;Ki;=;19,00;7,72;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;395,2;5;1;4;3,83;Fc1ccc2[nH]cc(CCCN3CCN(c4cccc5c4OCCO5)CC3)c2c1;https://dx.doi.org/10.1021/jm050148z
CHEMBL193620;69832;None;1;Human;Binding;Ki;=;700,00;6,16;-363;6;Binding affinity for human Dopamine receptor D2;ChEMBL;409,2;4;0;4;2,94;O=C1CC2(CCCC2)CC(=O)N1CCN1CCN(c2cc(F)c(F)cc2F)CC1;https://dx.doi.org/10.1021/jm0491391
CHEMBL193639;69838;None;0;Human;Binding;Ki;=;1,70;8,77;-9;9;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;329,1;2;0;3;4,47;CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL193639;69838;None;0;Human;Binding;Ki;=;2,30;8,64;-9;9;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;329,1;2;0;3;4,47;CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL193854;69880;None;0;Human;Binding;Ki;=;8,10;8,09;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;395,2;5;1;4;3,83;Fc1cccc2[nH]cc(CCCN3CCN(c4cccc5c4OCCO5)CC3)c12;https://dx.doi.org/10.1021/jm050148z
CHEMBL1940402;70178;None;0;Human;Binding;Kd;=;6,76;8,17;-6;10;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;361,2;6;1;2;4,79;OC1(c2ccc(Cl)cc2)CCN(CCCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL1940402;70178;None;0;Human;Binding;Ki;=;5,37;8,27;-6;10;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;361,2;6;1;2;4,79;OC1(c2ccc(Cl)cc2)CCN(CCCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL1940402;70178;None;0;Human;Binding;Ki;=;24,00;7,62;-6;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;361,2;6;1;2;4,79;OC1(c2ccc(Cl)cc2)CCN(CCCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL1940402;70178;None;0;Human;Binding;Ki;=;24,00;7,62;-6;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;361,2;6;1;2;4,79;OC1(c2ccc(Cl)cc2)CCN(CCCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940403;70179;None;0;Human;Binding;Kd;=;1,95;8,71;6;10;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;379,1;6;1;3;4,95;OC1(c2ccc(Cl)cc2)CCN(CCCSc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL1940403;70179;None;0;Human;Binding;Ki;=;8,80;8,06;6;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;379,1;6;1;3;4,95;OC1(c2ccc(Cl)cc2)CCN(CCCSc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940403;70179;None;0;Human;Binding;Ki;=;5,30;8,28;6;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;379,1;6;1;3;4,95;OC1(c2ccc(Cl)cc2)CCN(CCCSc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL1940403;70179;None;0;Human;Binding;Ki;=;2,09;8,68;6;10;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;379,1;6;1;3;4,95;OC1(c2ccc(Cl)cc2)CCN(CCCSc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL1940404;70180;None;1;Human;Binding;Kd;=;0,79;9,10;1;10;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;363,1;6;1;3;4,23;OC1(c2ccc(Cl)cc2)CCN(CCCOc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL1940404;70180;None;1;Human;Binding;Ki;=;5,30;8,28;1;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;363,1;6;1;3;4,23;OC1(c2ccc(Cl)cc2)CCN(CCCOc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940404;70180;None;1;Human;Binding;Ki;=;1,07;8,97;1;10;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;363,1;6;1;3;4,23;OC1(c2ccc(Cl)cc2)CCN(CCCOc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL1940404;70180;None;1;Human;Binding;Ki;=;8,80;8,06;1;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;363,1;6;1;3;4,23;OC1(c2ccc(Cl)cc2)CCN(CCCOc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL1940405;70181;None;0;Human;Binding;Ki;=;185,00;6,73;-4;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;363,1;6;0;2;5,84;Fc1ccc(SCCCN2CCC(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940406;70182;None;0;Human;Binding;Ki;=;41,00;7,39;-4;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;347,1;6;0;2;5,13;Fc1ccc(OCCCN2CCC(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940406;70182;None;0;Human;Binding;Ki;=;41,00;7,39;-4;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;347,1;6;0;2;5,13;Fc1ccc(OCCCN2CCC(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940407;70183;None;0;Human;Binding;Ki;=;998,00;6,00;-28;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;379,1;6;0;2;4,86;[O-][S+](CCCN1CCC(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940408;70184;None;0;Human;Binding;Ki;=;284,00;6,55;-36;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;346,2;6;0;2;4,62;Fc1ccc(CCCCN2CCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940408;70184;None;0;Human;Binding;Ki;=;284,00;6,55;-36;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;346,2;6;0;2;4,62;Fc1ccc(CCCCN2CCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940409;70185;None;0;Human;Binding;Ki;=;211,00;6,68;-23;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;364,1;6;0;3;4,78;Fc1ccc(SCCCN2CCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940409;70185;None;0;Human;Binding;Ki;=;211,00;6,68;-23;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;364,1;6;0;3;4,78;Fc1ccc(SCCCN2CCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940410;70186;None;0;Human;Binding;Ki;=;4753,00;5,32;-53;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;398,1;6;0;3;5,15;Fc1ccc(SCCCN2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940411;70187;None;0;Human;Binding;Ki;=;390,00;6,41;-56;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;348,1;6;0;3;4,07;Fc1ccc(OCCCN2CCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940411;70187;None;0;Human;Binding;Ki;=;390,00;6,41;-56;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;348,1;6;0;3;4,07;Fc1ccc(OCCCN2CCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940412;70188;None;2;Human;Binding;Ki;=;37,00;7,43;-5;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;314,2;6;0;3;3,42;Fc1ccc(OCCCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940413;70189;None;0;Human;Binding;Ki;=;446,68;6,35;-79;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;330,1;6;0;3;3,93;Clc1ccc(N2CCN(CCCOc3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940413;70189;None;0;Human;Binding;Ki;=;447,00;6,35;-79;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;330,1;6;0;3;3,93;Clc1ccc(N2CCN(CCCOc3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940413;70189;None;0;Human;Binding;Ki;=;447,00;6,35;-79;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;330,1;6;0;3;3,93;Clc1ccc(N2CCN(CCCOc3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940414;70190;None;4;Human;Binding;Ki;=;119,00;6,92;-26;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;296,2;6;0;3;3,28;c1ccc(OCCCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940415;70191;None;0;Human;Binding;Ki;=;269,00;6,57;-43;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;314,2;6;0;4;2,76;Fc1ccc(CCCCN2CCN(c3ncccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940415;70191;None;0;Human;Binding;Ki;=;269,00;6,57;-43;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;314,2;6;0;4;2,76;Fc1ccc(CCCCN2CCN(c3ncccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940416;70192;None;0;Human;Binding;Ki;=;424,00;6,37;-20;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;332,1;6;0;5;2,92;Fc1ccc(SCCCN2CCN(c3ncccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940416;70192;None;0;Human;Binding;Ki;=;424,00;6,37;-20;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;332,1;6;0;5;2,92;Fc1ccc(SCCCN2CCN(c3ncccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940417;70193;None;1;Human;Binding;Ki;=;636,00;6,20;-151;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;316,2;6;0;5;2,21;Fc1ccc(OCCCN2CCN(c3ncccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940417;70193;None;1;Human;Binding;Ki;=;636,00;6,20;-151;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;316,2;6;0;5;2,21;Fc1ccc(OCCCN2CCN(c3ncccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940418;70194;None;0;Human;Binding;Ki;=;124,00;6,91;-112;11;Displacement of [3H]-methylspiperone from dopamine D2 receptor (unknown origin) expressed in HEK293T cells measured after 15 mins by GloSensor cAMP assay;ChEMBL;313,2;6;0;3;3,37;Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL1940418;70194;None;0;Human;Binding;Ki;=;124,00;6,91;-112;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;313,2;6;0;3;3,37;Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL1940418;70194;None;0;Human;Binding;Ki;=;124,00;6,91;-112;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;313,2;6;0;3;3,37;Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940418;70194;None;0;Human;Binding;Ki;=;124,00;6,91;-112;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;313,2;6;0;3;3,37;Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940419;70195;None;0;Human;Binding;Ki;=;183,00;6,74;-31;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;331,2;6;0;4;3,52;Fc1ccc(SCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940419;70195;None;0;Human;Binding;Ki;=;183,00;6,74;-31;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;331,2;6;0;4;3,52;Fc1ccc(SCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL1940420;70196;None;1;Human;Binding;Ki;=;186,00;6,73;-102;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;315,2;6;0;4;2,81;Fc1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL1940420;70196;None;1;Human;Binding;Ki;=;186,00;6,73;-102;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;315,2;6;0;4;2,81;Fc1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2011.12.019
CHEMBL194099;70264;None;1;Human;Binding;Ki;=;210,00;6,68;-18;3;High binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;255,2;5;0;3;2,97;CCCN(CCC)C1CCn2ncc(Cl)c2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL194099;70264;None;1;Human;Binding;Ki;=;12000,00;4,92;-18;3;Low binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;255,2;5;0;3;2,97;CCCN(CCC)C1CCn2ncc(Cl)c2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL194099;70264;None;1;Human;Binding;Ki;=;120,00;6,92;-18;3;High binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;255,2;5;0;3;2,97;CCCN(CCC)C1CCn2ncc(Cl)c2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL194240;70300;None;0;Human;Binding;Ki;=;2,10;8,68;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;411,2;5;1;4;4,35;Clc1ccc2c(CCCN3CCN(c4cccc5c4OCCO5)CC3)c[nH]c2c1;https://dx.doi.org/10.1021/jm050148z
CHEMBL194312;70313;None;0;Human;Binding;Ki;=;59,00;7,23;-323;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;406,2;4;1;5;4,75;CC1(C)CCNc2c(CCN3CCN(c4nsc5ccccc45)CC3)cccc21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL1944689;70351;None;0;Human;Binding;IC50;=;1000,00;6,00;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;531,1;11;5;6;4,80;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CNCCc4c(Cl)cccc4Cl)cc3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1944690;70352;None;0;Human;Binding;IC50;=;630,96;6,20;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;497,2;11;5;6;4,15;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4ccccc4Cl)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1944691;70353;None;0;Human;Binding;IC50;=;398,11;6,40;-;5;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;481,2;11;5;6;3,63;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4ccccc4F)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1944692;70354;None;0;Human;Binding;IC50;=;1995,26;5,70;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;481,2;11;5;6;3,63;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CNCCc4ccccc4F)cc3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1944694;70356;None;0;Human;Binding;IC50;=;630,96;6,20;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;493,2;12;5;7;3,50;COc1ccccc1CCNCc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1944695;70357;None;0;Human;Binding;IC50;=;1995,26;5,70;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;463,2;11;5;6;3,49;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CNCCc4ccccc4)cc3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL194493;70371;None;0;Human;Binding;Ki;=;19,70;7,71;-15;2;Binding affinity for human dopamine D2 receptor;ChEMBL;448,1;7;1;5;4,01;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc([N+](=O)[O-])cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL194493;70371;None;0;Human;Binding;Ki;=;31,00;7,51;-15;2;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;448,1;7;1;5;4,01;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc([N+](=O)[O-])cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL194493;70371;None;0;Human;Binding;Ki;=;19,70;7,71;-15;2;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;448,1;7;1;5;4,01;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc([N+](=O)[O-])cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL1945031;70379;None;0;Human;Binding;IC50;=;398,11;6,40;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;516,2;11;6;6;4,28;Cc1cccc2c(CCNCc3cccc(CCNC[C@H](O)c4ccc(O)c5[nH]c(=O)sc45)c3)c[nH]c12;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945033;70381;None;0;Human;Binding;IC50;=;1584,89;5,80;-;5;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;464,2;11;5;7;2,89;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4ccccn4)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945034;70382;None;0;Human;Binding;IC50;=;2511,89;5,60;-;3;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;464,2;11;5;7;2,89;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccc(CNCCc4ccccn4)cc3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945035;70383;None;0;Human;Binding;IC50;=;794,33;6,10;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;481,2;11;5;6;3,63;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3ccccc3CNCCc3ccccc3F)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945036;70384;None;0;Human;Binding;IC50;=;2511,89;5,60;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;477,2;11;5;6;4,05;CC(CNCc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1)c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945037;70385;None;0;Human;Binding;IC50;=;316,23;6,50;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;477,2;12;5;6;3,88;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCCc4ccccc4)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945039;70387;None;0;Human;Binding;EC50;=;251,19;6,60;-;5;Binding affinity to dopamine D2 receptor expressed in HEK cells by GTPgammaS binding assay;ChEMBL;479,2;11;5;7;3,46;COc1ccccc1CNCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945039;70387;None;0;Human;Binding;IC50;=;1000,00;6,00;-;5;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;479,2;11;5;7;3,46;COc1ccccc1CNCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945040;70388;None;0;Human;Binding;IC50;=;2511,89;5,60;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;479,2;11;5;7;3,46;COc1ccccc1CNCc1ccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945041;70389;None;0;Human;Binding;IC50;=;251,19;6,60;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;483,1;10;5;6;4,10;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCc4ccccc4Cl)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945042;70390;None;0;Human;Binding;IC50;=;630,96;6,20;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;467,2;10;5;6;3,59;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCc4ccccc4F)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945043;70391;None;0;Human;Binding;IC50;=;5011,87;5,30;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;450,2;10;5;7;2,85;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCc4ccccn4)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945044;70392;None;0;Human;Binding;IC50;=;794,33;6,10;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;479,2;11;5;7;3,46;COc1cccc(CNCc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)sc34)c2)c1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL194510;70396;None;0;Human;Binding;Ki;=;15,50;7,81;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;411,2;5;1;4;4,35;Clc1cccc2c(CCCN3CCN(c4cccc5c4OCCO5)CC3)c[nH]c12;https://dx.doi.org/10.1021/jm050148z
CHEMBL1945289;70403;None;0;Human;Binding;IC50;=;794,33;6,10;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;479,2;11;5;7;3,46;COc1ccc(CNCc2cccc(CCNC[C@H](O)c3ccc(O)c4[nH]c(=O)sc34)c2)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945290;70404;None;0;Human;Binding;IC50;=;1258,93;5,90;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;493,2;12;5;7;3,85;CCOc1ccccc1CNCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945291;70405;None;0;Human;Binding;IC50;=;1000,00;6,00;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;493,2;11;4;7;3,80;COc1ccccc1CN(C)Cc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945292;70406;None;0;Human;Binding;IC50;=;794,33;6,10;-;5;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;417,2;11;5;7;1,90;COCCNCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945294;70408;None;0;Human;Binding;IC50;=;3162,28;5,50;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;413,2;8;4;6;2,76;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CN4CCCC4)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945296;70410;None;0;Human;Binding;IC50;=;79,43;7,10;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;545,1;12;5;6;5,19;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCCc3cccc(CNCCc4c(Cl)cccc4Cl)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945297;70411;None;0;Human;Binding;IC50;=;125,89;6,90;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;545,1;11;5;6;5,19;CC(Cc1cccc(CNCCc2c(Cl)cccc2Cl)c1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)sc12;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945298;70412;None;0;Human;Binding;IC50;=;398,11;6,40;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;497,2;12;5;7;3,47;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCOc3cccc(CNCCc4ccccc4F)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945299;70413;None;0;Human;Binding;IC50;=;1000,00;6,00;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;493,2;12;5;7;3,50;COc1ccccc1CNCCc1cccc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)sc23)c1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1945504;70425;None;0;Human;Binding;IC50;=;1995,26;5,70;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;479,2;11;5;7;3,46;COc1ccccc1CNCc1ccc(CCNC[C@@H](O)c2ccc(O)c3[nH]c(=O)sc23)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL1946122;70479;None;0;Human;Binding;Ki;=;22,00;7,66;-5;6;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;389,2;6;1;3;4,76;OC1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2CCCOc1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946123;70480;None;0;Human;Binding;Ki;=;33,00;7,48;-3;7;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;387,2;6;1;2;5,32;OC1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2CCCCc1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946124;70481;None;0;Human;Binding;Ki;=;1021,00;5,99;-27;8;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;386,2;4;0;3;4,44;O=C1c2ccc(F)cc2CC1CCN1CCCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946124;70481;None;0;Human;Binding;Ki;=;1023,29;5,99;-27;8;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;386,2;4;0;3;4,44;O=C1c2ccc(F)cc2CC1CCN1CCCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL1946124;70481;None;0;Human;Binding;Ki;=;1021,00;5,99;-27;8;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;386,2;4;0;3;4,44;O=C1c2ccc(F)cc2CC1CCN1CCCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL1946125;70482;None;0;Human;Binding;Ki;=;751,10;6,12;-23;7;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;378,1;6;0;3;5,17;Fc1ccc(SCCCN2CCCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946126;70483;None;0;Human;Binding;Ki;=;172,00;6,76;-2;6;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;362,2;6;0;3;4,46;Fc1ccc(OCCCN2CCCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946253;70488;None;0;Human;Binding;Ki;=;139,00;6,86;-1;7;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;360,2;6;0;2;5,01;Fc1ccc(CCCCN2CCCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946254;70489;None;0;Human;Binding;Ki;=;258,70;6,59;-8;8;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;399,2;6;0;4;5,49;Clc1ccc(N2CCCN(CCCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946254;70489;None;0;Human;Binding;Ki;=;259,00;6,59;-8;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;399,2;6;0;4;5,49;Clc1ccc(N2CCCN(CCCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL1946257;70491;None;0;Human;Binding;Ki;=;1983,00;5,70;-15;8;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;427,1;7;0;5;5,51;O=C(CCCCN1CCCN(c2ccc(Cl)cc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946257;70491;None;0;Human;Binding;Ki;=;1983,00;5,70;-15;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;427,1;7;0;5;5,51;O=C(CCCCN1CCCN(c2ccc(Cl)cc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL194659;70511;None;0;Human;Binding;Ki;=;32,00;7,50;-7;7;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;313,1;2;0;3;4,11;CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL1946744;70518;None;0;Human;Binding;Ki;=;180,00;6,75;-11;3;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;454,1;7;1;5;5,82;O=C(CCCCN1[C@H]2CC[C@@H]1CC(O)(c1ccc(Cl)cc1)C2)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1946745;70519;None;0;Human;Binding;Ki;=;44,00;7,36;-3;6;Displacement of [3H]-N-methylspiperone from dopamine D2 receptor expressed in human MES-23.5 cells;ChEMBL;426,2;6;1;4;5,79;OC1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2CCCCc1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2012.01.022
CHEMBL1947157;70563;None;0;Human;Binding;IC50;=;251,19;6,60;-;4;Displacement of radiolabeled spiperone from dopamine D2 receptor;ChEMBL;531,1;11;5;6;4,80;O=c1[nH]c2c(O)ccc([C@@H](O)CNCCc3cccc(CNCCc4c(Cl)cccc4Cl)c3)c2s1;https://dx.doi.org/10.1016/j.bmcl.2011.10.049
CHEMBL194727;70567;None;0;Human;Binding;Ki;=;98,00;7,01;-27;5;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;385,2;8;1;4;3,17;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL194727;70567;None;0;Human;Binding;Ki;=;140,00;6,85;-27;5;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;385,2;8;1;4;3,17;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL194755;70572;None;0;Human;Binding;Ki;=;72,00;7,14;-9;5;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;421,2;9;1;5;2,71;COc1ccccc1N1CCN(CCCCNS(=O)(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL194755;70572;None;0;Human;Binding;Ki;=;120,00;6,92;-9;5;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;421,2;9;1;5;2,71;COc1ccccc1N1CCN(CCCCNS(=O)(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL194844;70587;None;0;Human;Binding;Ki;=;5,10;8,29;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;391,2;6;1;4;4,08;c1cc2c(c(N3CCN(CCCCc4c[nH]c5ccccc45)CC3)c1)OCCO2;https://dx.doi.org/10.1021/jm050148z
CHEMBL194953;70613;None;0;Human;Binding;Ki;=;16,00;7,80;-25;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;496,2;5;0;5;5,82;CC1CCN(C(=O)c2ccccc2)c2c(CCN3CCN(c4nsc5ccccc45)CC3)cccc21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL1949725;70621;None;0;Human;Binding;Ki;=;85,30;7,07;-19;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in human HEK293 cells;ChEMBL;304,2;0;1;1;4,18;C[C@H]1Cc2c([nH]c3ccccc23)Cc2ccccc2CCN1C;https://dx.doi.org/10.1021/jm200676f
CHEMBL1949728;70624;None;0;Human;Binding;Ki;=;268,00;6,57;-26;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in human HEK293 cells;ChEMBL;320,2;1;2;2;3,15;CN1CCc2ccccc2Cc2[nH]c3ccccc3c2C[C@@H]1CO;https://dx.doi.org/10.1021/jm200676f
CHEMBL1949729;70625;None;0;Human;Binding;Ki;=;2923,00;5,53;-32;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in human HEK293 cells;ChEMBL;320,2;1;2;2;3,15;CN1CCc2ccccc2Cc2[nH]c3ccccc3c2C[C@H]1CO;https://dx.doi.org/10.1021/jm200676f
CHEMBL195015;70657;None;0;Human;Binding;Ki;=;62,00;7,21;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;349,2;3;1;4;3,26;c1cc2c(c(N3CCN(Cc4c[nH]c5ccccc45)CC3)c1)OCCO2;https://dx.doi.org/10.1021/jm050148z
CHEMBL195057;70723;None;0;Human;Binding;Ki;=;13,70;7,86;-36;2;Binding affinity for human dopamine D2 receptor;ChEMBL;419,1;6;2;4;3,81;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(O)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL195057;70723;None;0;Human;Binding;Ki;=;65,80;7,18;-36;2;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;419,1;6;2;4;3,81;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(O)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL195057;70723;None;0;Human;Binding;Ki;=;13,70;7,86;-36;2;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;419,1;6;2;4;3,81;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(O)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL195247;71100;None;0;Human;Binding;Ki;=;39,00;7,41;-2;5;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;459,1;8;1;4;4,01;O=S(=O)(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL195247;71100;None;0;Human;Binding;Ki;=;49,00;7,31;-2;5;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;459,1;8;1;4;4,01;O=S(=O)(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL195706;71319;None;0;Human;Binding;Ki;=;191,00;6,72;-25;7;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;313,1;2;0;3;4,11;CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL195856;71423;None;0;Human;Binding;Ki;=;369,00;6,43;-21;3;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;373,1;2;0;3;4,73;CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(Br)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL196132;71471;None;0;Human;Binding;Ki;=;15,00;7,82;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;407,2;6;1;5;3,70;COc1ccc2[nH]cc(CCCN3CCN(c4cccc5c4OCCO5)CC3)c2c1;https://dx.doi.org/10.1021/jm050148z
CHEMBL196171;71482;None;0;Human;Binding;Ki;=;21,00;7,68;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;377,2;5;1;4;3,69;c1cc2c(c(N3CCN(CCCc4c[nH]c5ccccc45)CC3)c1)OCCO2;https://dx.doi.org/10.1021/jm050148z
CHEMBL196172;71483;None;0;Human;Binding;Ki;=;5,30;8,28;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;422,2;5;2;4;3,78;C[C@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4c(F)cccc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL196476;71712;None;0;Human;Binding;Ki;=;373,00;6,43;-2884;8;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;475,1;8;1;5;5,08;COc1cccc2cc(C(=O)NCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)oc12;https://dx.doi.org/10.1021/jm020952a
CHEMBL196476;71712;None;0;Human;Binding;Ki;=;373,00;6,43;-2884;8;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;475,1;8;1;5;5,08;COc1cccc2cc(C(=O)NCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)oc12;https://dx.doi.org/10.1021/jm050734s
CHEMBL196505;71722;None;0;Human;Binding;Ki;=;45,00;7,35;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;363,2;4;1;4;3,30;c1cc2c(c(N3CCN(CCc4c[nH]c5ccccc45)CC3)c1)OCCO2;https://dx.doi.org/10.1021/jm050148z
CHEMBL196514;71724;None;24;Human;Binding;Ki;=;6,90;8,16;-4;9;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;422,2;5;2;4;3,78;C[C@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccc(F)cc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL196514;71724;None;24;Human;Binding;Ki;=;0,79;9,10;-4;9;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;422,2;5;2;4;3,78;C[C@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccc(F)cc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm070516u
CHEMBL196744;71811;None;3;Human;Binding;Ki;=;17,00;7,77;-33;5;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;423,1;7;1;3;4,46;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL196744;71811;None;3;Human;Binding;Ki;=;18,00;7,75;-33;5;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;423,1;7;1;3;4,46;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL196866;71844;None;0;Human;Binding;Ki;=;38000,00;4,42;-1148;2;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;380,1;5;1;3;4,56;O=C(N[C@H]1CCN(Cc2ccccc2F)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL196893;71851;None;0;Human;Binding;Ki;=;10,60;7,97;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;395,2;5;1;4;3,83;Fc1cccc2c(CCCN3CCN(c4cccc5c4OCCO5)CC3)c[nH]c12;https://dx.doi.org/10.1021/jm050148z
CHEMBL196928;71861;None;0;Human;Binding;Ki;=;220,00;6,66;-41;3;High binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)C1CCn2nccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL196928;71861;None;0;Human;Binding;Ki;=;160,00;6,80;-41;3;High binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)C1CCn2nccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL196928;71861;None;0;Human;Binding;Ki;=;18000,00;4,75;-41;3;Low binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)C1CCn2nccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL196928;71861;None;0;Human;Binding;Ki;=;8500,00;5,07;-41;3;Low binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)C1CCn2nccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL197159;71926;None;0;Human;Binding;Ki;=;57000,00;4,24;-19;4;Displacement of [3H]7-OH-DPAT from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL197159;71926;None;0;Human;Binding;Ki;=;55000,00;4,26;-19;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL197159;71926;None;0;Human;Binding;Ki;=;53000,00;4,28;-19;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins;ChEMBL;221,2;5;0;3;2,32;CCCN(CCC)[C@@H]1CCn2nccc2C1;https://dx.doi.org/10.1021/jm101639t
CHEMBL197162;71928;None;0;Human;Binding;Ki;=;29,00;7,54;-22;5;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;424,1;7;1;4;3,86;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(F)nc1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL197162;71928;None;0;Human;Binding;Ki;=;21,00;7,68;-22;5;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;424,1;7;1;4;3,86;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(F)nc1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL197195;71939;None;0;Human;Binding;Ki;=;44,00;7,36;-5;5;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;424,1;7;1;4;3,86;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL197195;71939;None;0;Human;Binding;Ki;=;57,00;7,24;-5;5;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;424,1;7;1;4;3,86;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL197214;71950;None;0;Human;Binding;Ki;=;260,00;6,58;-13;5;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;386,2;8;1;5;2,56;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(F)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL197214;71950;None;0;Human;Binding;Ki;=;400,00;6,40;-13;5;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;386,2;8;1;5;2,56;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(F)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL197225;71953;None;0;Human;Binding;Ki;=;1800,00;5,75;-251;2;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;406,1;5;1;5;4,15;O=C(N[C@H]1CCN(Cc2ccc3c(c2)OCO3)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL197381;72010;None;0;Human;Binding;Ki;=;230,00;6,64;-14;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;396,1;5;1;3;5,07;O=C(N[C@H]1CCN(Cc2ccc(Cl)cc2)C1)c1cccc(-c2cccs2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL197614;72063;None;0;Human;Binding;Ki;=;73,00;7,14;-67;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;406,2;4;1;5;3,79;CC1Cc2cccc(CCN3CCN(c4nsc5ccccc45)CC3)c2NC1=O;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL197656;72080;None;0;Human;Binding;Ki;=;363,20;6,44;2;3;Binding affinity to dopamine D2 receptor;ChEMBL;479,2;6;2;6;3,17;COc1ccccc1-c1cc2c(=O)n(CCN3CCN(c4ccccc4Cl)CC3)c(=O)[nH]c2[nH]1;https://dx.doi.org/10.1016/j.bmcl.2005.09.027
CHEMBL197663;72085;None;0;Human;Binding;Ki;=;17,00;7,77;-52;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;432,3;4;0;5;4,36;CC(=O)N1CCC(C)c2c(C)ccc(CCN3CCN(c4noc5ccccc45)CC3)c21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL197665;72087;None;0;Human;Binding;Ki;=;17,90;7,75;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;376,2;5;2;4;3,73;c1cc2c(c(N3CCN(CCCc4c[nH]c5ccccc45)CC3)c1)OCCN2;https://dx.doi.org/10.1021/jm050148z
CHEMBL197677;72090;None;0;Human;Binding;Ki;=;25,00;7,60;-42;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;502,3;5;0;5;6,08;CC1CCN(C(=O)C2CCCCC2)c2c(CCN3CCN(c4nsc5ccccc45)CC3)cccc21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL197839;72151;None;0;Human;Binding;Ki;=;15,00;7,82;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;388,3;5;2;3;4,53;CC1CNc2cccc(N3CCN(CCCc4c[nH]c5ccccc45)CC3)c2C1;https://dx.doi.org/10.1021/jm050148z
CHEMBL197870;72160;None;0;Human;Binding;Ki;=;15,00;7,82;-89;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;424,2;4;1;5;4,25;CC1CC(=O)Nc2c(CCN3CCN(c4nsc5ccccc45)CC3)cc(F)cc21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL197943;72176;None;0;Human;Binding;Ki;=;35,70;7,45;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;418,2;5;1;4;3,67;CC1Oc2c(N3CCN(CCCc4c[nH]c5ccccc45)CC3)cccc2N(C)C1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL197982;72200;None;0;Human;Binding;Ki;=;291,00;6,54;-6;2;Inhibition constant against dopamine receptor D2;ChEMBL;487,1;5;1;5;5,01;C[C@@H]1CN(c2cccc3cc(F)ccc23)CCN1CCC1OCCc2c1sc(C(N)=O)c2Cl;https://dx.doi.org/10.1021/jm058225d
CHEMBL197990;72203;None;0;Human;Binding;Ki;=;12,00;7,92;-15;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;448,2;4;0;5;4,83;CC(=O)N1CCC(C)c2c(C)ccc(CCN3CCN(c4nsc5ccccc45)CC3)c21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL198040;72214;None;0;Human;Binding;Ki;=;11,30;7,95;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;374,2;5;2;3;4,28;c1cc2c(c(N3CCN(CCCc4c[nH]c5ccccc45)CC3)c1)CCCN2;https://dx.doi.org/10.1021/jm050148z
CHEMBL198041;72215;None;0;Human;Binding;Ki;=;90,00;7,05;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;388,3;5;1;3;4,30;CN1CCCc2c1cccc2N1CCN(CCCc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm050148z
CHEMBL198069;72228;None;0;Human;Binding;Ki;=;4,30;8,37;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;390,2;5;2;4;3,25;O=C1COc2c(cccc2N2CCN(CCCc3c[nH]c4ccccc34)CC2)N1;https://dx.doi.org/10.1021/jm050148z
CHEMBL198070;72229;None;0;Human;Binding;Ki;=;4,50;8,35;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;404,2;5;2;4;3,64;CC1Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccccc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL198107;72242;None;0;Human;Binding;Ki;=;10,70;7,97;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;391,2;5;1;4;4,00;Cc1ccc2[nH]cc(CCCN3CCN(c4cccc5c4OCCO5)CC3)c2c1;https://dx.doi.org/10.1021/jm050148z
CHEMBL198174;72267;None;0;Human;Binding;Ki;=;4000,00;5,40;2;3;Binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;249,2;6;0;4;2,13;CCCN(CCC)C1CCn2ncc(C=O)c2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL198174;72267;None;0;Human;Binding;Ki;=;5900,00;5,23;2;3;Binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;249,2;6;0;4;2,13;CCCN(CCC)C1CCn2ncc(C=O)c2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL198216;72283;None;0;Human;Binding;Ki;=;8,70;8,06;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;404,2;5;2;4;3,64;C[C@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccccc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL198224;72284;None;0;Human;Binding;Ki;=;1,00;9,00;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;404,2;5;2;4;3,64;C[C@@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccccc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL198357;72335;None;0;Human;Binding;Ki;=;1,00;9,00;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;422,2;5;2;4;3,78;C[C@@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4c(F)cccc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL19844;72357;None;16;Human;Binding;Ki;=;1900,00;5,72;-5;2;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;301,1;2;4;5;2,28;CN1CCc2cc(O)c(O)cc2C1Cc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
CHEMBL198463;72368;None;0;Human;Binding;Ki;=;1,46;8,84;-1;9;Inhibitory activity against dopamine D2(long) receptor;ChEMBL;460,2;4;0;8;2,82;CN1CCc2c(sc3ncn(CCN4CCN(c5ccnc6ccccc56)CC4)c(=O)c23)C1;https://dx.doi.org/10.1016/j.bmcl.2005.04.077
CHEMBL198580;72392;None;0;Human;Binding;Ki;=;18000,00;4,75;-1258;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;398,1;5;1;3;4,70;O=C(N[C@H]1CCN(Cc2ccc(F)c(F)c2)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL198599;72396;None;0;Human;Binding;Ki;=;35,00;7,46;-123;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;404,2;4;1;5;3,95;Cc1cc(CCN2CCN(c3noc4ccccc34)CC2)c2c(c1)C(C)CC(=O)N2;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL198812;72464;None;0;Human;Binding;Ki;=;20,30;7,69;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;375,2;5;1;3;4,25;c1cc2c(c(N3CCN(CCCc4c[nH]c5ccccc45)CC3)c1)CCCO2;https://dx.doi.org/10.1021/jm050148z
CHEMBL198993;72518;None;0;Human;Binding;Ki;=;240,00;6,62;-13;5;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;386,2;8;1;5;2,56;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(F)nc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL198993;72518;None;0;Human;Binding;Ki;=;160,00;6,80;-13;5;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;386,2;8;1;5;2,56;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(F)nc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL199045;72536;None;0;Human;Binding;Ki;=;7,40;8,13;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;418,2;5;2;4;4,03;CC1(C)Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccccc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL199161;72573;None;0;Human;Binding;Ki;=;4,00;8,40;-3;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;540,3;7;0;6;5,75;COc1cccc(CC(=O)N2CCC(C)c3cccc(CCN4CCN(c5nsc6ccccc56)CC4)c32)c1;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL199186;72581;None;0;Human;Binding;Ki;=;29000,00;4,54;-1905;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;430,1;5;1;3;5,73;O=C(N[C@H]1CCN(Cc2ccc(Cl)c(Cl)c2)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL199226;72595;None;2;Human;Binding;Kd;=;1,78;8,75;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;357,1;6;1;3;4,29;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL199226;72595;None;2;Human;Binding;Ki;=;1,78;8,75;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;357,1;6;1;3;4,29;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL199453;72656;None;0;Human;Binding;Ki;=;82,10;7,09;-18;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;493,3;7;0;8;3,16;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(N4CCC4)nc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL199498;72668;None;0;Human;Binding;Ki;=;179,00;6,75;-2;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;419,2;8;1;6;2,97;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3nccnc3c2)CC1;https://dx.doi.org/10.1021/jm050734s
CHEMBL199663;72709;None;0;Human;Binding;Ki;=;302,00;6,52;-63;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;520,3;7;0;7;5,00;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(C4CCCCC4)nc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL199859;72761;None;0;Human;Binding;Ki;=;130,00;6,89;-6;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;423,2;9;2;6;3,01;COc1ccccc1N1CCN(CCCCNC(=O)c2cc(-c3ccco3)[nH]n2)CC1;https://dx.doi.org/10.1021/jm050734s
CHEMBL199876;72770;None;0;Human;Binding;Ki;=;2370,00;5,62;-4;4;Binding affinity to dopamine D2 receptor;ChEMBL;483,1;5;2;5;3,81;O=c1[nH]c2[nH]c(-c3ccc(Cl)cc3)cc2c(=O)n1CCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.09.027
CHEMBL200026;72811;None;0;Human;Binding;Ki;=;610,00;6,21;-52;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;468,2;6;0;8;2,26;Cn1c(=O)ccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c1=O;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL200028;72812;None;0;Human;Binding;Ki;=;168,00;6,78;-117;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;514,3;7;0;7;4,62;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(-c4ccccc4)nc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL200028;72812;None;0;Human;Binding;Ki;=;168,00;6,78;-117;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;514,3;7;0;7;4,62;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(-c4ccccc4)nc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL200802;73021;None;0;Human;Binding;Ki;=;626,50;6,20;1;3;Binding affinity to dopamine D2 receptor;ChEMBL;463,2;5;2;5;3,47;Cc1ccccc1-c1cc2c(=O)n(CCN3CCN(c4ccccc4Cl)CC3)c(=O)[nH]c2[nH]1;https://dx.doi.org/10.1016/j.bmcl.2005.09.027
CHEMBL201019;73055;None;0;Human;Binding;IC50;=;5300,00;5,28;-;2;Binding affinity to dopamine receptor D2;ChEMBL;337,2;5;2;4;2,54;CCOc1cc(N)c(Cl)cc1C(=O)NC[C@@H]1CCN2CCC[C@@H]12;https://dx.doi.org/10.1021/jm0509501
CHEMBL201027;73060;None;0;Human;Binding;Ki;=;519,00;6,29;-5;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;488,2;9;1;7;4,33;COc1ccc2ccnc(N3CCN(CCCCNC(=O)c4cc5cccc(OC)c5o4)CC3)c2c1;https://dx.doi.org/10.1021/jm050734s
CHEMBL201093;73112;None;0;Human;Binding;Ki;=;198,00;6,70;-7;5;Inhibition of binding to human D2L receptor expressed in HEK 293 cells by radioligand binding assay;ChEMBL;257,1;0;0;2;3,37;CN1CCc2ccccc2Cc2ccsc2CC1;https://dx.doi.org/10.1021/jm050846j
CHEMBL201093;73112;None;0;Human;Binding;Ki;=;190,00;6,72;-7;5;Displacement of [3H]spiperone from human cloned D2 dopamine receptor incubated for 90 mins by radioligand binding assay;ChEMBL;257,1;0;0;2;3,37;CN1CCc2ccccc2Cc2ccsc2CC1;https://dx.doi.org/10.1039/C5MD00258C
CHEMBL201115;73118;None;1;Human;Binding;Ki;=;320,00;6,50;-245;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;468,2;6;1;7;2,55;Cc1cn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)[nH]c1=O;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL20114;73148;None;0;Human;Binding;Ki;=;1995,26;5,70;-15;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;337,2;7;1;3;3,01;CC(C)C(=O)NCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL201170;73177;None;0;Human;Binding;Ki;=;17,50;7,76;-45;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting;ChEMBL;267,2;0;1;2;3,01;CN1CCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1016/j.bmc.2009.08.028
CHEMBL201170;73177;None;0;Human;Binding;Ki;=;17,50;7,76;-45;6;Inhibition of binding to human D2L receptor expressed in HEK 293 cells by radioligand binding assay;ChEMBL;267,2;0;1;2;3,01;CN1CCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1021/jm050846j
CHEMBL201170;73177;None;0;Human;Binding;Ki;=;44,50;7,35;-45;6;Displacement of [3H]spiperone from human cloned D2 dopamine receptor incubated for 90 mins by radioligand binding assay;ChEMBL;267,2;0;1;2;3,01;CN1CCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1039/C5MD00258C
CHEMBL201170;73177;None;0;Human;Binding;Ki;=;17,38;7,76;-45;6;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;267,2;0;1;2;3,01;CN1CCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL201170;73177;None;0;Human;Binding;Ki;=;17,50;7,76;-45;6;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;267,2;0;1;2;3,01;CN1CCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL201170;73177;None;0;Human;Binding;Ki;=;17,50;7,76;-45;6;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;267,2;0;1;2;3,01;CN1CCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL201232;73261;None;0;Human;Binding;Ki;=;246,00;6,61;-309;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;517,3;6;0;6;4,71;CC(C)(C)c1nc(N2CCN(CCCCN3C(=O)CCC(=O)c4ccccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL201240;73263;None;0;Human;Binding;Ki;=;220,00;6,66;-95;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;488,2;6;1;7;2,90;CC(C)(C)c1nc(N2CCN(CCCCn3cc(Cl)c(=O)[nH]c3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL201270;73317;None;0;Human;Binding;Ki;=;27,20;7,57;-9;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;433,2;9;1;6;3,21;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-n3ccnc3)cc2)CC1;https://dx.doi.org/10.1021/jm050734s
CHEMBL201270;73317;None;0;Human;Binding;Ki;=;51,70;7,29;-9;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;433,2;9;1;6;3,21;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-n3ccnc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL201270;73317;UNDEFINED;0;Human;Binding;pKi;=;51,70;7,29;-9;2;-;PDSP KiDatabase;433,2;9;1;6;3,21;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-n3ccnc3)cc2)CC1;-
CHEMBL201318;73357;None;0;Human;Binding;Ki;=;93,00;7,03;-37;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;519,3;6;1;6;4,77;CC(C)(C)c1nc(N2CCN(CCCCN3C(=O)CCCc4c(O)cccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL201326;73384;None;0;Human;Binding;Ki;=;1246,00;5,90;-4;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;459,2;8;1;7;3,72;COc1cccc2cc(C(=O)NCCCCN3CCN(c4cccc5nccnc45)CC3)oc12;https://dx.doi.org/10.1021/jm050734s
CHEMBL201376;73390;None;0;Human;Binding;Ki;=;89,40;7,05;-26;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;521,3;7;0;8;3,94;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(N4CCCCC4)nc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL201386;73393;None;0;Human;Binding;Ki;=;142,00;6,85;-3;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;503,3;6;0;6;4,32;CC(C)(C)c1nc(N2CCN(CCCCN3C(=O)CC(=O)c4ccccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL201400;73395;None;0;Human;Binding;Ki;=;669,00;6,17;-11;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;501,3;5;0;5;4,84;C/C(=C\CN1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1)CN1C(=O)CCc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL201481;73409;None;0;Human;Binding;Ki;=;65,00;7,19;-16;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;469,3;6;0;6;3,28;CC(C)(C)c1nc(N2CCN(CCCCN3CCC(=O)CCC3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL201483;73411;None;0;Human;Binding;Ki;=;712,00;6,15;-1;4;Inhibition of binding to human D2L receptor expressed in HEK 293 cells by radioligand binding assay;ChEMBL;254,2;0;0;2;2,65;CN1CCc2ccccc2Cc2ccn(C)c2CC1;https://dx.doi.org/10.1021/jm050846j
CHEMBL201509;73415;None;0;Human;Binding;Ki;=;473,00;6,33;-97;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;479,2;6;1;8;2,12;CC(C)(C)c1nc(N2CCN(CCCCn3cc(C#N)c(=O)[nH]c3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL201525;73420;None;0;Human;Binding;Ki;=;58,88;7,23;-15;6;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;251,2;0;0;1;3,31;CN1CCc2ccccc2Cc2ccccc2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL201525;73420;None;0;Human;Binding;Ki;=;56,50;7,25;-15;6;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;251,2;0;0;1;3,31;CN1CCc2ccccc2Cc2ccccc2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL201525;73420;None;0;Human;Binding;Ki;=;56,50;7,25;-15;6;Displacement of [3H]spiperone from human cloned D2 dopamine receptor incubated for 90 mins by radioligand binding assay;ChEMBL;251,2;0;0;1;3,31;CN1CCc2ccccc2Cc2ccccc2CC1;https://dx.doi.org/10.1039/C5MD00258C
CHEMBL201525;73420;None;0;Human;Binding;Ki;=;56,50;7,25;-15;6;Inhibition of binding to human D2L receptor expressed in HEK 293 cells by radioligand binding assay;ChEMBL;251,2;0;0;1;3,31;CN1CCc2ccccc2Cc2ccccc2CC1;https://dx.doi.org/10.1021/jm050846j
CHEMBL201551;73424;None;0;Human;Binding;Ki;=;86,20;7,06;-5;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;411,2;8;1;6;2,76;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3c(c2)OCO3)CC1;https://dx.doi.org/10.1021/jm050734s
CHEMBL201557;73427;None;0;Human;Binding;Ki;=;254,00;6,59;-28;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;487,3;5;0;5;4,45;CC(C)(C)c1nc(N2CCN(C/C=C/CN3C(=O)CCc4ccccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL2016607;73447;None;0;Human;Binding;IC50;=;776,00;6,11;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;480,3;8;0;4;6,78;CCCCCCCCCC(=O)N1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016607;73447;None;0;Human;Binding;IC50;=;776,25;6,11;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;480,3;8;0;4;6,78;CCCCCCCCCC(=O)N1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016608;73448;None;0;Human;Binding;IC50;=;1778,28;5,75;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;790,3;7;0;8;8,64;CN1CCN(C2=Nc3cc(Cl)ccc3N(C(=O)CCCCCCC(=O)N3c4ccc(Cl)cc4N=C(N4CCN(C)CC4)c4ccccc43)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016608;73448;None;0;Human;Binding;IC50;=;2662,00;5,58;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;790,3;7;0;8;8,64;CN1CCN(C2=Nc3cc(Cl)ccc3N(C(=O)CCCCCCC(=O)N3c4ccc(Cl)cc4N=C(N4CCN(C)CC4)c4ccccc43)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016614;73450;None;0;Human;Binding;IC50;=;8912,51;5,05;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;495,3;9;1;5;6,29;CCCCCCCCCC(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016614;73450;None;0;Human;Binding;IC50;=;8939,00;5,05;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;495,3;9;1;5;6,29;CCCCCCCCCC(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016615;73451;None;0;Human;Binding;IC50;=;2041,74;5,69;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;792,3;7;2;10;6,87;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCCCC(=O)NN3c4ccc(Cl)cc4N=C(N4CCN(C)CC4)c4ccccc43)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016615;73451;None;0;Human;Binding;IC50;=;2078,00;5,68;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;792,3;7;2;10;6,87;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCCCC(=O)NN3c4ccc(Cl)cc4N=C(N4CCN(C)CC4)c4ccccc43)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016616;73452;None;0;Human;Binding;IC50;=;2454,71;5,61;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;820,4;9;2;10;7,65;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCCCCCC(=O)NN3c4ccc(Cl)cc4N=C(N4CCN(C)CC4)c4ccccc43)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016616;73452;None;0;Human;Binding;IC50;=;2440,00;5,61;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;820,4;9;2;10;7,65;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCCCCCC(=O)NN3c4ccc(Cl)cc4N=C(N4CCN(C)CC4)c4ccccc43)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016622;73453;None;0;Human;Binding;IC50;=;1617,00;5,79;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;932,4;8;2;12;5,54;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCC(=O)N3CCN(C(=O)CCC(=O)NN4c5ccc(Cl)cc5N=C(N5CCN(C)CC5)c5ccccc54)CC3)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016622;73453;None;0;Human;Binding;IC50;=;1621,81;5,79;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;932,4;8;2;12;5,54;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCC(=O)N3CCN(C(=O)CCC(=O)NN4c5ccc(Cl)cc5N=C(N5CCN(C)CC5)c5ccccc54)CC3)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016623;73454;None;0;Human;Binding;IC50;=;2633,00;5,58;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;1142,5;14;2;14;6,16;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCCC(=O)N3CCN(C(=O)CCCC(=O)N4CCN(C(=O)CCCC(=O)NN5c6ccc(Cl)cc6N=C(N6CCN(C)CC6)c6ccccc65)CC4)CC3)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016623;73454;None;0;Human;Binding;IC50;=;2630,27;5,58;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;1142,5;14;2;14;6,16;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCCC(=O)N3CCN(C(=O)CCCC(=O)N4CCN(C(=O)CCCC(=O)NN5c6ccc(Cl)cc6N=C(N6CCN(C)CC6)c6ccccc65)CC4)CC3)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016624;73455;None;0;Human;Binding;IC50;=;2398,83;5,62;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;908,3;11;2;14;5,96;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCC(=O)OCCOC(=O)CCC(=O)NN3c4ccc(Cl)cc4N=C(N4CCN(C)CC4)c4ccccc43)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016624;73455;None;0;Human;Binding;IC50;=;2412,00;5,62;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;908,3;11;2;14;5,96;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCC(=O)OCCOC(=O)CCC(=O)NN3c4ccc(Cl)cc4N=C(N4CCN(C)CC4)c4ccccc43)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016625;73456;None;0;Human;Binding;IC50;=;1455,00;5,84;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;523,3;12;2;5;6,74;CCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016625;73456;None;0;Human;Binding;IC50;=;1445,44;5,84;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;523,3;12;2;5;6,74;CCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016625;73456;None;0;Human;Binding;Ki;=;9,10;8,04;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;523,3;12;2;5;6,74;CCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016625;73456;None;0;Human;Binding;Ki;=;8,91;8,05;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;523,3;12;2;5;6,74;CCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016626;73457;None;0;Human;Binding;IC50;=;87,10;7,06;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;848,4;13;4;10;7,77;O=C(CCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016626;73457;None;0;Human;Binding;IC50;=;87,00;7,06;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;848,4;13;4;10;7,77;O=C(CCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016626;73457;None;0;Human;Binding;Ki;=;3,16;8,50;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;848,4;13;4;10;7,77;O=C(CCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016626;73457;None;0;Human;Binding;Ki;=;3,60;8,44;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;848,4;13;4;10;7,77;O=C(CCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016627;73458;None;0;Human;Binding;IC50;=;23,00;7,64;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;876,4;15;4;10;8,55;O=C(CCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016627;73458;None;0;Human;Binding;IC50;=;23,44;7,63;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;876,4;15;4;10;8,55;O=C(CCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016627;73458;None;0;Human;Binding;Ki;=;1,35;8,87;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;876,4;15;4;10;8,55;O=C(CCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016627;73458;None;0;Human;Binding;Ki;=;1,41;8,85;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;876,4;15;4;10;8,55;O=C(CCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016628;73459;None;0;Human;Binding;IC50;=;44,00;7,36;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;904,4;17;4;10;9,33;O=C(CCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016628;73459;None;0;Human;Binding;IC50;=;44,67;7,35;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;904,4;17;4;10;9,33;O=C(CCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016628;73459;None;0;Human;Binding;Ki;=;1,35;8,87;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;904,4;17;4;10;9,33;O=C(CCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016628;73459;None;0;Human;Binding;Ki;=;1,23;8,91;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;904,4;17;4;10;9,33;O=C(CCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016629;73460;None;0;Human;Binding;IC50;=;1096,48;5,96;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;932,5;19;4;10;10,11;O=C(CCCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016629;73460;None;0;Human;Binding;IC50;=;1119,00;5,95;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;932,5;19;4;10;10,11;O=C(CCCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016630;73461;None;0;Human;Binding;IC50;=;11000,00;4,96;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;960,5;21;4;10;10,89;O=C(CCCCCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016630;73461;None;0;Human;Binding;IC50;=;10715,19;4,97;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;960,5;21;4;10;10,89;O=C(CCCCCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016631;73462;None;0;Human;Binding;IC50;=;7762,47;5,11;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;1016,6;25;4;10;12,45;O=C(CCCCCCCCCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016631;73462;None;0;Human;Binding;IC50;=;7800,00;5,11;-;1;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;1016,6;25;4;10;12,45;O=C(CCCCCCCCCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016631;73462;None;0;Human;Binding;Ki;=;269,00;6,57;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;1016,6;25;4;10;12,45;O=C(CCCCCCCCCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL2016631;73462;None;0;Human;Binding;Ki;=;245,47;6,61;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;1016,6;25;4;10;12,45;O=C(CCCCCCCCCCCCCCCCC(=O)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1)NCCCN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
CHEMBL201698;73542;None;0;Human;Binding;Ki;=;369,00;6,43;-14;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;437,2;9;1;6;3,78;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cccc(OC)c3o2)CC1;https://dx.doi.org/10.1021/jm050734s
CHEMBL201743;73567;None;0;Human;Binding;Ki;=;151,00;6,82;-13;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;487,3;6;0;6;4,71;CC(C)(C)c1nc(N2CCN(CCCCn3c(=O)ccc4ccccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL20204;73950;None;0;Human;Binding;Ki;=;398,11;6,40;-6;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;377,2;5;1;3;3,72;CC(C)(C)C(=O)NCCCCN1CCN2c3ccc(Cl)cc3CCC2C1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL202072;73958;None;0;Human;Binding;Ki;=;290,00;6,54;-38;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;482,3;8;0;8;3,35;CCOc1ccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL202175;74015;None;0;Human;Binding;Ki;=;216,00;6,67;-83;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;494,3;6;0;7;4,25;CC(C)(C)c1ccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL202229;74096;None;0;Human;Binding;Ki;=;155,00;6,81;-41;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;478,3;7;0;7;3,83;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(C4CC4)nc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL202253;74126;None;0;Human;Binding;Ki;=;307,00;6,51;-70;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;452,3;6;0;7;3,26;Cc1ccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL202253;74126;None;0;Human;Binding;Ki;=;307,00;6,51;-70;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;452,3;6;0;7;3,26;Cc1ccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL202298;74203;None;0;Human;Binding;Ki;=;273,00;6,56;-37;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;492,3;7;0;7;4,22;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(C4CCC4)nc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL20251;74428;None;0;Human;Binding;Ki;=;158,49;6,80;-10;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;381,2;7;1;4;3,41;COc1cc(Cl)ccc1N1CCN(CCCCNC(=O)C(C)(C)C)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL202670;74454;None;0;Human;Binding;Ki;=;25,50;7,59;-23;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;453,2;6;1;7;3,26;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(O)cc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL202704;74462;None;0;Human;Binding;Ki;=;243,00;6,61;-24;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;533,3;7;0;6;5,07;COc1cccc2c1CCCC(=O)N2CCCCN1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL202713;74463;None;0;Human;Binding;Ki;=;56,60;7,25;2;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;447,2;8;2;6;3,65;COc1cccc2cc(C(=O)NCCCCN3CCN(c4[nH]nc5ccccc45)CC3)oc12;https://dx.doi.org/10.1021/jm050734s
CHEMBL202774;74476;None;0;Human;Binding;Ki;=;148,00;6,83;-87;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;482,3;7;1;7;2,81;CCc1cn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)[nH]c1=O;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL202780;74478;None;0;Human;Binding;Ki;=;900,00;6,05;-112;4;Displacement of [3H]spiperone from the cloned human D2 receptor expressed in CHO cells;ChEMBL;363,2;6;0;3;4,53;CC(C)(CCCN1CC[C@@H]2CCCC[C@H]2C1)S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2005.11.067
CHEMBL2027935;74490;None;0;Human;Binding;Ki;=;311,00;6,51;-114;4;In vitro binding affinity towards Dopamine receptor D2 by using [3H]spiperone as radioligand;ChEMBL;335,1;5;1;3;2,98;CCCN[C@@H]1CCc2cccc(CS(=O)(=O)C(F)(F)F)c2C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL2027935;74490;None;0;Human;Binding;Ki;=;69,00;7,16;-114;4;In vitro binding affinity towards Dopamine receptor D2 by using [3H]U-86170 as radioligand;ChEMBL;335,1;5;1;3;2,98;CCCN[C@@H]1CCc2cccc(CS(=O)(=O)C(F)(F)F)c2C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL2028030;74507;None;0;Human;Binding;Ki;=;225,00;6,65;-17;4;In vitro binding affinity towards Dopamine receptor D2 by using [3H]U-86170 as radioligand;ChEMBL;335,1;5;1;3;2,98;CCCN[C@H]1CCc2cccc(CS(=O)(=O)C(F)(F)F)c2C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL2028033;74509;None;0;Human;Binding;Ki;=;115,00;6,94;-3;4;In vitro binding affinity towards Dopamine receptor D2 by using [3H]spiperone as radioligand;ChEMBL;335,1;5;1;3;2,98;CCCN[C@H]1CCc2c(cccc2CS(=O)(=O)C(F)(F)F)C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL2028033;74509;None;0;Human;Binding;Ki;=;8,70;8,06;-3;4;In vitro binding affinity towards Dopamine receptor D2 by using [3H]U-86170 as radioligand;ChEMBL;335,1;5;1;3;2,98;CCCN[C@H]1CCc2c(cccc2CS(=O)(=O)C(F)(F)F)C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL202827;74513;None;0;Human;Binding;Ki;=;602,00;6,22;-199;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;472,2;6;1;7;2,38;CC(C)(C)c1nc(N2CCN(CCCCn3cc(F)c(=O)[nH]c3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL202857;74519;None;0;Human;Binding;Ki;=;159,00;6,80;-23;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;498,3;8;2;5;4,58;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)NCC3CCCCC3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL202858;74520;None;0;Human;Binding;Ki;=;17,30;7,76;-19;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;458,3;8;1;5;3,75;CCN(CC)C(=O)NCCCCN1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL2029915;74645;None;0;Human;Binding;Ki;=;4189,00;5,38;-4;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;399,2;7;1;3;4,23;O=C(Cc1ccccc1)Nc1ccc(CCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029916;74646;None;0;Human;Binding;Ki;=;70,70;7,15;1;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;400,2;7;1;4;3,63;O=C(Cc1ccccn1)Nc1ccc(CCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029917;74647;None;0;Human;Binding;Ki;=;69,60;7,16;2;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;400,2;7;1;4;3,63;O=C(Cc1cccnc1)Nc1ccc(CCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029918;74648;None;0;Human;Binding;Ki;=;48,60;7,31;2;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;400,2;7;1;4;3,63;O=C(Cc1ccncc1)Nc1ccc(CCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029919;74649;None;0;Human;Binding;Ki;=;482,50;6,32;4;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;400,2;6;2;3;4,70;O=C(Nc1ccccc1)Nc1ccc(CCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029920;74650;None;0;Human;Binding;Ki;=;14,20;7,85;8;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;401,2;6;2;4;4,09;O=C(Nc1ccc(CCN2CCN(c3ccccc3)CC2)cc1)Nc1ccccn1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029921;74651;None;0;Human;Binding;Ki;=;8,20;8,09;48;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;401,2;6;2;4;4,09;O=C(Nc1ccc(CCN2CCN(c3ccccc3)CC2)cc1)Nc1cccnc1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029922;74652;None;0;Human;Binding;Ki;=;3,60;8,44;63;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;401,2;6;2;4;4,09;O=C(Nc1ccncc1)Nc1ccc(CCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029923;74653;None;0;Human;Binding;Ki;=;3575,00;5,45;-6165;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;399,2;7;1;3;4,23;O=C(Cc1ccccc1)Nc1cccc(CCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029924;74654;None;0;Human;Binding;Ki;=;277,80;6,56;-57;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;400,2;7;1;4;3,63;O=C(Cc1ccccn1)Nc1cccc(CCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029925;74655;None;0;Human;Binding;Ki;=;82,40;7,08;-60;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;400,2;7;1;4;3,63;O=C(Cc1cccnc1)Nc1cccc(CCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029926;74656;None;0;Human;Binding;Ki;=;201,60;6,70;-89;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;400,2;7;1;4;3,63;O=C(Cc1ccncc1)Nc1cccc(CCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029927;74657;None;0;Human;Binding;Ki;=;3250,00;5,49;-562;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;400,2;6;2;3;4,70;O=C(Nc1ccccc1)Nc1cccc(CCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029928;74658;None;0;Human;Binding;Ki;=;364,00;6,44;-47;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;401,2;6;2;4;4,09;O=C(Nc1cccc(CCN2CCN(c3ccccc3)CC2)c1)Nc1ccccn1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029929;74659;None;0;Human;Binding;Ki;=;29,70;7,53;-30;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;401,2;6;2;4;4,09;O=C(Nc1cccnc1)Nc1cccc(CCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029930;74660;None;0;Human;Binding;Ki;=;48,70;7,31;-97;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;401,2;6;2;4;4,09;O=C(Nc1ccncc1)Nc1cccc(CCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL2029931;74661;None;13;Human;Binding;Ki;=;478,00;6,32;-11;2;Displacement of [3H]spiperone from human D2 DA receptor expressed in CHO cell membrane after 60 mins by liquid scintillation counting;ChEMBL;266,2;4;0;2;3,05;c1ccc(CCN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.04.098
CHEMBL203016;74693;None;0;Human;Binding;Ki;=;171,00;6,77;-74;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;451,3;6;0;6;3,87;Cc1cccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c1=O;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL203047;74725;None;0;Human;Binding;Ki;=;2,00;8,70;1;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;301,1;0;1;2;3,67;CN1CCc2ccccc2Cc2cc(O)c(Cl)cc2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL2030637;74733;None;0;Human;Binding;Ki;=;9914,00;5,00;-;1;Inhibition of D2 dopamine receptor;ChEMBL;207,1;4;0;1;2,85;Fc1cccc(CCCN2CCCC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.04.077
CHEMBL203200;74975;None;0;Human;Binding;Ki;=;447,00;6,35;-34;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;438,2;6;0;7;2,95;CC(C)(C)c1nc(N2CCN(CCCCn3cccnc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL2032049;74978;None;7;Human;Binding;Ki;=;3160,00;5,50;-5248;6;Binding affinity to dopamine D2 receptor;ChEMBL;462,2;4;2;2;6,21;C[C@H]1c2c([nH]c3ccc(C(F)(F)F)cc23)C[C@H]2CCN(CCC3(C(=O)O)CCCCC3)C[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2012.04.006
CHEMBL203260;75023;None;0;Human;Binding;Ki;=;289,00;6,54;-12;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;503,3;6;0;5;5,06;C[C@@H](CCCN1C(=O)CCc2ccccc21)N1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL203302;75030;None;0;Human;Binding;Ki;=;141,00;6,85;-5;2;Displacement of [3H]spiroperidol from cloned human dopamine receptor D2(long) expressed in rat C6 glioma cells;ChEMBL;452,3;9;1;6;2,86;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(N3CCOCC3)cc2)CC1;https://dx.doi.org/10.1021/jm050734s
CHEMBL203362;75039;None;0;Human;Binding;Ki;=;137,20;6,86;3;3;Binding affinity to dopamine D2 receptor;ChEMBL;449,2;5;2;5;3,16;O=c1[nH]c2[nH]c(-c3ccccc3)cc2c(=O)n1CCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.09.027
CHEMBL203400;75049;None;0;Human;Binding;Ki;=;710,00;6,15;-29;4;Displacement of [3H]spiperone from the cloned human D2 receptor expressed in CHO cells;ChEMBL;381,2;8;0;5;3,29;CCOC(=O)[C@@H]1CCCN(CCCC(C)(C)S(=O)(=O)c2ccccc2)C1;https://dx.doi.org/10.1016/j.bmcl.2005.11.067
CHEMBL203471;75060;None;0;Human;Binding;Ki;=;467,00;6,33;-104;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;577,3;8;0;8;4,72;COc1cc2c(cc1OC)N(CCCCN1CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC1)C(=O)CCC2=O;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL203637;75199;None;0;Human;Binding;Ki;=;4,00;8,40;-81;6;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;301,1;0;1;2;3,67;CN1CCc2ccccc2Cc2ccc(O)c(Cl)c2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL203637;75199;None;0;Human;Binding;Ki;=;3,55;8,45;-81;6;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;301,1;0;1;2;3,67;CN1CCc2ccccc2Cc2ccc(O)c(Cl)c2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL20367;75221;None;0;Human;Binding;Ki;=;1000,00;6,00;-100;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;391,2;7;1;3;4,33;CC1(C(=O)NCCCCN2CCN(c3ccc(Cl)cc3)CC2)CCCCC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL203689;75278;None;0;Human;Binding;Ki;=;84,00;7,08;-2;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;267,2;0;1;2;3,01;CN1CCc2ccccc2Cc2c(O)cccc2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL203734;75317;None;0;Human;Binding;Ki;=;210,00;6,68;1;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;349,1;1;0;2;4,62;COc1c(Cl)cc2c(c1Cl)Cc1ccccc1CCN(C)CC2;https://dx.doi.org/10.1021/jm051237e
CHEMBL2037430;75321;None;0;Human;Binding;Ki;=;2321,00;5,63;-75;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;371,1;5;0;4;4,70;Clc1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037430;75321;None;0;Human;Binding;Ki;=;2321,00;5,63;-75;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;371,1;5;0;4;4,70;Clc1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL2037431;75322;None;0;Human;Binding;Ki;=;219,00;6,66;-54;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;385,1;6;0;4;5,09;Clc1ccc(N2CCN(CCCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL2037431;75322;None;0;Human;Binding;Ki;=;219,00;6,66;-54;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;385,1;6;0;4;5,09;Clc1ccc(N2CCN(CCCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037432;75323;None;0;Human;Binding;Ki;=;201,00;6,70;-1;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;400,1;6;1;4;5,26;OC1(c2ccc(Cl)cc2)CCN(CCCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037432;75323;None;0;Human;Binding;Ki;=;201,00;6,70;-1;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;400,1;6;1;4;5,26;OC1(c2ccc(Cl)cc2)CCN(CCCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL2037432;75323;None;0;Human;Binding;Ki;=;199,53;6,70;-1;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;400,1;6;1;4;5,26;OC1(c2ccc(Cl)cc2)CCN(CCCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL2037518;75372;None;0;Human;Binding;Ki;=;530,00;6,28;-11;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;364,2;6;0;4;5,14;O=C(CCCN1CCC(c2ccccc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037519;75373;None;0;Human;Binding;Ki;=;1522,00;5,82;-29;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;367,1;6;0;7;2,87;O=C(CCCN1CCN(c2ncccn2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037520;75374;None;0;Human;Binding;Ki;=;217,00;6,66;-3;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;468,1;7;1;6;5,28;O=C(CCCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL2037520;75374;None;0;Human;Binding;Ki;=;218,78;6,66;-3;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;468,1;7;1;6;5,28;O=C(CCCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL2037520;75374;None;0;Human;Binding;Ki;=;217,00;6,66;-3;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;468,1;7;1;6;5,28;O=C(CCCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037521;75375;None;0;Human;Binding;Ki;=;127,00;6,90;-70;7;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;353,2;6;0;6;3,23;c1cnc(N2CCN(CCCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL2037521;75375;None;0;Human;Binding;Ki;=;26,50;7,58;-70;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;353,2;6;0;6;3,23;c1cnc(N2CCN(CCCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037521;75375;None;0;Human;Binding;Ki;=;26,50;7,58;-70;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;353,2;6;0;6;3,23;c1cnc(N2CCN(CCCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL2037522;75376;None;0;Human;Binding;Ki;=;30,80;7,51;-6;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;322,1;5;0;3;4,68;c1ccc2c(c1)CCN(CCCCc1nc3ccccc3s1)C2;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037523;75377;None;0;Human;Binding;Ki;=;990,00;6,00;-9;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;308,1;5;0;3;4,63;c1ccc2c(c1)CN(CCCCc1nc3ccccc3s1)C2;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037524;75378;None;0;Human;Binding;Ki;=;8355,00;5,08;-24;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;399,1;6;0;5;4,74;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037526;75380;None;0;Human;Binding;Ki;=;25,70;7,59;-1;8;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;448,2;7;1;6;4,08;O=C(CCCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL2037526;75380;None;0;Human;Binding;Ki;=;25,00;7,60;-1;8;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;448,2;7;1;6;4,08;O=C(CCCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL2037526;75380;None;0;Human;Binding;Ki;=;25,00;7,60;-1;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;448,2;7;1;6;4,08;O=C(CCCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037527;75381;None;0;Human;Binding;Ki;=;2931,00;5,53;-13;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;336,1;6;0;4;4,67;O=C(CCCCN1Cc2ccccc2C1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037528;75382;None;0;Human;Binding;Ki;=;4793,00;5,32;-169;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;413,1;7;0;5;5,13;O=C(CCCCN1CCN(c2ccc(Cl)cc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037529;75383;None;0;Human;Binding;Ki;=;505,00;6,30;-138;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;381,2;7;0;7;3,26;O=C(CCCCN1CCN(c2ncccn2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037530;75385;None;0;Human;Binding;Ki;=;198,00;6,70;-54;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;379,2;7;0;5;4,47;O=C(CCCCN1CCN(c2ccccc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL2037531;75386;None;0;Human;Binding;Ki;=;642,00;6,19;-190;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;378,2;7;0;4;5,53;O=C(CCCCN1CCC(c2ccccc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
CHEMBL203943;75421;None;0;Human;Binding;Ki;=;195,00;6,71;-16;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;451,3;6;0;6;3,87;Cc1cccc(=O)n1CCCCN1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL20395;75423;None;0;Human;Binding;Ki;=;316,23;6,50;-15;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;466,2;7;1;4;5,99;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCCC3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL204065;75443;None;0;Human;Binding;Ki;=;6,50;8,19;6;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;311,2;2;0;3;3,33;COc1ccc2c(c1)CCN(C)CCc1cc(OC)ccc1C2;https://dx.doi.org/10.1021/jm051237e
CHEMBL20407;75445;None;0;Human;Binding;Ki;=;3162,28;5,50;-3;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;364,1;6;1;5;2,32;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCOCC3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL204098;75449;None;0;Human;Binding;Ki;=;37,30;7,43;-2;3;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;282,2;0;2;3;2,60;CN1CCc2ccccc2Cc2cc(N)c(O)cc2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL204269;75527;None;0;Human;Binding;Ki;=;220,00;6,66;-30;5;Displacement of [3H]spiperone from the cloned human D2 receptor expressed in CHO cells;ChEMBL;385,2;7;0;3;4,90;CC(C)(CCCN1CCCC(c2ccccc2)C1)S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2005.11.067
CHEMBL20444;75572;None;0;Human;Binding;Ki;=;1584,89;5,80;-125;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;379,2;9;1;3;4,18;CCCC(C)(C)C(=O)NCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL2048226;75798;None;0;Human;Binding;Ki;=;158,49;6,80;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;203,2;3;0;1;3,28;CCCN1CCC(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2048226;75798;None;0;Human;Binding;Ki;=;170,00;6,77;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;203,2;3;0;1;3,28;CCCN1CCC(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2048227;75799;None;0;Human;Binding;Ki;=;900,00;6,05;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;237,1;3;0;1;3,93;CCCN1CCC(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2048227;75799;None;0;Human;Binding;Ki;=;1000,00;6,00;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;237,1;3;0;1;3,93;CCCN1CCC(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2048230;75800;None;2;Human;Binding;Ki;=;25118,86;4,60;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;233,2;4;0;2;3,29;CCCN1CCC(c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2048230;75800;None;2;Human;Binding;Ki;=;23000,00;4,64;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;233,2;4;0;2;3,29;CCCN1CCC(c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL20493;75934;None;0;Human;Binding;Ki;=;2511,89;5,60;-199;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;351,2;6;1;3;3,40;CC(C)(C)C(=O)NCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL205238;75983;None;0;Human;Binding;Ki;=;128,00;6,89;-3;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;471,2;6;0;6;4,21;CC(C)(C)c1nc(N2CCN(CCCCn3cc(Cl)ccc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL205264;75990;None;0;Human;Binding;Ki;=;65,80;7,18;-16;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;458,3;6;2;5;3,79;CC(C)(C)NC(=O)NCCCCN1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL205497;76030;None;0;Human;Binding;Ki;=;59,10;7,23;-18;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;478,3;7;2;5;4,52;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)Nc3ccccc3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL205498;76031;None;0;Human;Binding;Ki;=;399,00;6,40;-11;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;505,2;6;0;6;4,58;CC(C)(C)c1nc(N2CCN(CCCCn3cc(C(F)(F)F)ccc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL205733;76077;None;0;Human;Binding;Ki;=;231,00;6,64;-19;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;505,2;6;0;6;4,58;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(C(F)(F)F)cc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL2057451;76096;None;0;Human;Binding;IC50;=;1155,30;5,94;1;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;323,2;2;0;3;3,98;COc1cc2c(cc1OC)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;-
CHEMBL2057451;76096;None;0;Human;Binding;IC50;=;1155,30;5,94;1;2;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;323,2;2;0;3;3,98;COc1cc2c(cc1OC)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
CHEMBL2057451;76096;None;0;Human;Binding;Ki;=;223,61;6,65;1;2;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;323,2;2;0;3;3,98;COc1cc2c(cc1OC)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
CHEMBL2057451;76096;None;0;Human;Binding;Ki;=;223,61;6,65;1;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;323,2;2;0;3;3,98;COc1cc2c(cc1OC)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;-
CHEMBL2057453;76098;None;0;Human;Binding;IC50;=;873,14;6,06;-9;2;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;311,2;2;1;4;3,06;COc1ccc2c(c1)C[C@H]1c3cc(O)c(OC)cc3CCN1C2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
CHEMBL2057453;76098;None;0;Human;Binding;Ki;=;346,76;6,46;-9;2;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;311,2;2;1;4;3,06;COc1ccc2c(c1)C[C@H]1c3cc(O)c(OC)cc3CCN1C2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
CHEMBL2057453;76098;None;0;Human;Binding;Ki;=;347,00;6,46;-9;2;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;311,2;2;1;4;3,06;COc1ccc2c(c1)C[C@H]1c3cc(O)c(OC)cc3CCN1C2;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL2057456;76101;None;0;Human;Binding;IC50;=;514,46;6,29;-8;2;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;371,2;4;2;6;2,57;COc1cc2c(cc1O)[C@@H]1Cc3c(CO)c(OC)cc(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
CHEMBL2057456;76101;None;0;Human;Binding;Ki;=;146,99;6,83;-8;2;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;371,2;4;2;6;2,57;COc1cc2c(cc1O)[C@@H]1Cc3c(CO)c(OC)cc(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
CHEMBL2057456;76101;None;0;Human;Binding;Ki;=;147,00;6,83;-8;2;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;371,2;4;2;6;2,57;COc1cc2c(cc1O)[C@@H]1Cc3c(CO)c(OC)cc(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL2057457;76102;None;0;Human;Binding;IC50;=;456,13;6,34;-5;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;309,2;1;1;3;3,67;COc1cc2c(cc1O)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;-
CHEMBL2057457;76102;None;0;Human;Binding;IC50;=;456,13;6,34;-5;2;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;309,2;1;1;3;3,67;COc1cc2c(cc1O)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
CHEMBL2057457;76102;None;0;Human;Binding;Ki;=;160,90;6,79;-5;2;Radioligand Binding Assay: The affinity of compounds to D1 and D2 dopamine receptors were determined by competition binding assays. Membrane homogenates of HEK293T cells were stably transfected with D1, or D2 receptors. Duplicated tubes were incubated at 30° C. for 50 mins (for D1, and D2) with increasing concentrations of respective compound and with [3H]SCH23390 (for D1 dopamine receptors), or [3H]Spiperone (for dopamine D2 receptor) in a final volume of 200 μL binding buffer containing 50 mM Tris, 4 mM MgCl2, pH 7.4. Nonspecific binding was determined by parallel incubations with either 10 μM SCH23390 for D1, or Spiperone for D2 receptors respectively. The reaction was started by addition of membranes (15 ng/tube) and stopped by rapid filtration through Whatman GF/B glassfiber filter and subsequently washed with cold buffer (50 mM Tris, 5 mM EDTA, pH 7.4) using a Brandel 24-well cell harvester. Scintillation cocktail was added and the radioactivity was determined in a MicroBeta liquid scintillation counter.;ChEMBL;309,2;1;1;3;3,67;COc1cc2c(cc1O)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;-
CHEMBL2057457;76102;None;0;Human;Binding;Ki;=;160,99;6,79;-5;2;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;309,2;1;1;3;3,67;COc1cc2c(cc1O)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.05.057
CHEMBL2057457;76102;None;0;Human;Binding;Ki;=;160,99;6,79;-5;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;309,2;1;1;3;3,67;COc1cc2c(cc1O)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;-
CHEMBL2057457;76102;None;0;Human;Binding;Ki;=;161,00;6,79;-5;2;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;309,2;1;1;3;3,67;COc1cc2c(cc1O)[C@@H]1Cc3cc(C)cc(C)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL2059305;76380;None;0;Human;Binding;Ki;=;42,00;7,38;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;387,2;5;1;2;4,72;O=C1CCc2ccccc2N1CCCN1CCC(c2ccc3[nH]ccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059306;76381;None;0;Human;Binding;Ki;=;9,50;8,02;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;404,2;5;1;4;3,34;O=C1CCc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059307;76382;None;0;Human;Binding;Ki;=;2200,00;5,66;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;405,2;5;1;5;2,73;O=C1CCc2ncccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059308;76383;None;0;Human;Binding;Ki;=;1100,00;5,96;-;1;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;405,2;5;1;5;2,73;O=C1CCc2cnccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059310;76384;None;0;Human;Binding;Ki;=;600,00;6,22;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;405,2;5;1;5;2,73;O=C1CCc2cccnc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059311;76385;None;0;Human;Binding;Ki;=;16,00;7,80;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;406,2;5;1;5;2,78;O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059312;76386;None;0;Human;Binding;Ki;=;55,00;7,26;-;1;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;406,2;5;1;5;2,88;O=C1CCc2ccccc2N1OCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059313;76387;None;0;Human;Binding;Ki;=;1250,00;5,90;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;407,2;5;1;6;2,18;O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cccnc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059315;76389;None;0;Human;Binding;Ki;=;1350,00;5,87;-;1;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;407,2;5;1;6;2,18;O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cnccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059316;76390;None;0;Human;Binding;Ki;=;650,00;6,19;-;1;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;407,2;5;1;6;2,18;O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ncccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059317;76391;None;0;Human;Binding;Ki;=;60,00;7,22;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;422,2;5;1;4;3,48;O=C1CCc2c(F)cccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059318;76392;None;0;Human;Binding;Ki;=;6,50;8,19;-;1;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;422,2;5;1;4;3,48;O=C1CCc2cc(F)ccc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059319;76393;None;0;Human;Binding;Ki;=;90,00;7,05;-;1;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;422,2;5;1;4;3,48;O=C1CCc2ccc(F)cc2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059320;76394;None;0;Human;Binding;Ki;=;95,00;7,02;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;422,2;5;1;4;3,48;O=C1CCc2cccc(F)c2N1CCCN1CCC(n2c(=O)[nH]c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059321;76395;None;0;Human;Binding;Ki;=;41,00;7,39;-;1;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;424,2;5;1;5;2,92;O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cccc(F)c32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059322;76396;None;0;Human;Binding;Ki;=;14,00;7,85;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;424,2;5;1;5;2,92;O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3ccc(F)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059323;76397;None;0;Human;Binding;Ki;=;2,50;8,60;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;424,2;5;1;5;2,92;O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3cc(F)ccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL2059324;76398;None;0;Human;Binding;Ki;=;15,00;7,82;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;424,2;5;1;5;2,92;O=C1COc2ccccc2N1CCCN1CCC(n2c(=O)[nH]c3c(F)cccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
CHEMBL205961;76453;None;0;Human;Binding;Ki;=;936,00;6,03;-64;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;506,2;6;0;7;3,97;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(C(F)(F)F)nc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL2062848;76589;None;0;Human;Binding;Ki;=;12000,00;4,92;1;3;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;364,3;7;1;3;3,81;CCN(CC)[C@@H]1[C@@H](CO)[C@H]2CN(Cc3ccccc3)[C@H](c3ccccc3)[C@H]21;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062849;76590;None;0;Human;Binding;Ki;=;1700,00;5,77;-1;3;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;364,3;7;1;3;3,81;CCN(CC)[C@@H]1[C@@H]2[C@@H](CN(Cc3ccccc3)[C@H]2c2ccccc2)[C@H]1CO;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062850;76591;None;0;Human;Binding;Ki;=;7400,00;5,13;1;3;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;362,2;5;1;3;3,56;OC[C@H]1[C@H]2CN(Cc3ccccc3)[C@H](c3ccccc3)[C@H]2[C@@H]1N1CCCC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062851;76592;None;0;Human;Binding;Ki;=;250,00;6,60;1;3;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;362,2;5;1;3;3,56;OC[C@@H]1[C@@H]2CN(Cc3ccccc3)[C@@H](c3ccccc3)[C@@H]2[C@H]1N1CCCC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062852;76593;None;0;Human;Binding;Ki;=;38000,00;4,42;-1;2;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;302,2;6;1;3;2,46;CCN(CC)[C@@H]1[C@@H](CO)[C@H]2CN(Cc3ccccc3)[C@H](C)[C@H]21;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062853;76594;None;0;Human;Binding;Ki;=;3900,00;5,41;-2;2;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;302,2;6;1;3;2,46;CCN(CC)[C@H]1[C@H](CO)[C@@H]2CN(Cc3ccccc3)[C@@H](C)[C@@H]21;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062854;76595;None;0;Human;Binding;Ki;=;66000,00;4,18;-1;2;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;300,2;4;1;3;2,21;C[C@@H]1[C@@H]2[C@H](CN1Cc1ccccc1)[C@H](CO)[C@H]2N1CCCC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062855;76596;None;0;Human;Binding;Ki;=;16000,00;4,80;-1;2;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;300,2;4;1;3;2,21;C[C@H]1[C@H]2[C@@H](CN1Cc1ccccc1)[C@@H](CO)[C@@H]2N1CCCC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062856;76597;None;0;Human;Binding;Ki;=;5000,00;5,30;1;3;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;442,2;7;1;3;4,57;CCN(CC)[C@@H]1[C@@H](CO)[C@H]2CN(Cc3ccccc3)[C@H](c3ccc(Br)cc3)[C@H]21;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062857;76598;None;0;Human;Binding;Ki;=;2000,00;5,70;1;3;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;442,2;7;1;3;4,57;CCN(CC)[C@@H]1[C@@H]2[C@@H](CN(Cc3ccccc3)[C@H]2c2ccc(Br)cc2)[C@H]1CO;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062858;76599;None;0;Human;Binding;Ki;=;42000,00;4,38;-1;2;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;365,2;7;1;4;3,20;CCN(CC)[C@@H]1[C@@H](CO)[C@H]2CN(Cc3ccccc3)[C@H](c3ccccn3)[C@H]21;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062859;76600;None;0;Human;Binding;Ki;=;12000,00;4,92;-1;2;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;365,2;7;1;4;3,20;CCN(CC)[C@@H]1[C@@H]2[C@@H](CN(Cc3ccccc3)[C@H]2c2ccccn2)[C@H]1CO;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062860;76601;None;0;Human;Binding;Ki;=;7000,00;5,16;-1;3;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;376,3;5;1;3;3,95;OC[C@H]1[C@H]2CN(Cc3ccccc3)[C@H](c3ccccc3)[C@H]2[C@@H]1N1CCCCC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL2062861;76602;None;0;Human;Binding;Ki;=;2000,00;5,70;-1;3;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;376,3;5;1;3;3,95;OC[C@@H]1[C@@H]2CN(Cc3ccccc3)[C@@H](c3ccccc3)[C@@H]2[C@H]1N1CCCCC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
CHEMBL206528;76742;None;0;Human;Binding;Ki;=;409,00;6,39;-43;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;505,2;6;0;6;4,58;CC(C)(C)c1nc(N2CCN(CCCCn3cccc(C(F)(F)F)c3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL20655;76744;None;0;Human;Binding;Ki;=;794,33;6,10;-100;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;363,2;5;1;3;3,55;CC1(C(=O)NCCN2CCN(c3ccc(Cl)cc3)CC2)CCCCC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL2068762;76809;None;6;Human;Binding;Ki;=;22,01;7,66;-16;17;Binding affinity to dopamine D2 receptor;ChEMBL;423,2;7;0;8;1,71;COc1ccc2cccc(N3CCN(CCCCn4ncc(=O)n(C)c4=O)CC3)c2c1;https://dx.doi.org/10.1021/jm050725j
CHEMBL20725;77079;None;0;Human;Binding;Ki;=;2511,89;5,60;-316;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;351,2;7;1;3;3,40;CCCC(C)(C)C(=O)NCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL20729;77086;None;0;Human;Binding;Ki;=;251,19;6,60;-2;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;351,2;6;1;3;3,40;CC(C)(C)C(=O)NCCCCN1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL207488;77123;None;0;Human;Binding;Ki;=;12000,00;4,92;-2754;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;345,1;3;0;5;2,84;Fc1ccc(N2CCN(Cc3cn4nc(Cl)ccc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL207488;77123;None;0;Human;Binding;Ki;=;9900,00;5,00;-2754;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;345,1;3;0;5;2,84;Fc1ccc(N2CCN(Cc3cn4nc(Cl)ccc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL207543;77132;None;0;Human;Binding;Ki;=;1100,00;5,96;-7;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;444,2;4;0;6;4,35;Clc1ccc(N2CCN(Cc3cn4nc(N5CCCCC5)ccc4n3)CC2)cc1Cl;https://dx.doi.org/10.1021/jm060166w
CHEMBL207543;77132;None;0;Human;Binding;Ki;=;710,00;6,15;-7;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;444,2;4;0;6;4,35;Clc1ccc(N2CCN(Cc3cn4nc(N5CCCCC5)ccc4n3)CC2)cc1Cl;https://dx.doi.org/10.1021/jm060166w
CHEMBL20763;77144;None;0;Human;Binding;Ki;=;7,94;8,10;-3;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;376,2;6;1;4;4,03;CCN1CCCCC1c1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL20785;77187;None;0;Human;Binding;Ki;=;316,23;6,50;-31;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;376,2;6;1;4;4,03;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(C(C)N3CCCCC3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL207871;77196;None;0;Human;Binding;Ki;=;244,00;6,61;-154;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;491,3;9;1;5;4,44;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)CCc3ccccc3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL207880;77202;None;0;Human;Binding;Ki;=;527,00;6,28;-66;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;513,3;7;0;6;5,22;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(-c4ccccc4)cc3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL208018;77295;None;0;Human;Binding;Ki;=;43,00;7,37;-54;4;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;332,2;4;0;4;3,50;Cc1nn(-c2ccccc2)cc1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL208018;77295;None;0;Human;Binding;Ki;=;70,79;7,15;-54;4;Binding affinity to dopamine D2;ChEMBL;332,2;4;0;4;3,50;Cc1nn(-c2ccccc2)cc1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL208018;77295;None;0;Human;Binding;Ki;=;71,00;7,15;-54;4;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;332,2;4;0;4;3,50;Cc1nn(-c2ccccc2)cc1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL208228;77327;None;0;Human;Binding;Ki;=;212,00;6,67;-25;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;520,3;9;1;5;4,93;CCN(Cc1ccccc1)C(=O)NCCCCN1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL208274;77339;None;0;Human;Binding;Ki;=;49,00;7,31;-44;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;412,2;5;0;5;4,64;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(-c4ccccc4)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL208274;77339;None;0;Human;Binding;Ki;=;28,00;7,55;-44;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;412,2;5;0;5;4,64;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(-c4ccccc4)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL20854;77391;None;0;Human;Binding;Ki;=;1584,89;5,80;-25;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;365,2;6;1;3;3,79;CC1CN(CCCCNC(=O)C(C)(C)C)CCN1c1ccc(Cl)cc1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL208847;77681;None;0;Human;Binding;Ki;=;84,00;7,08;-7;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;537,3;8;1;5;5,66;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3c4ccc(c3o2)CCc2ccc(cc2)CC4)CC1;https://dx.doi.org/10.1021/jm060138d
CHEMBL208847;77681;None;0;Human;Binding;Ki;=;170,00;6,77;-7;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;537,3;8;1;5;5,66;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3c4ccc(c3o2)CCc2ccc(cc2)CC4)CC1;https://dx.doi.org/10.1021/jm060138d
CHEMBL209034;77776;None;0;Human;Binding;Ki;=;1100,00;5,96;-676;6;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;395;3;0;5;4,01;Clc1ccc2nc(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)cn2n1;https://dx.doi.org/10.1021/jm060166w
CHEMBL209034;77776;None;0;Human;Binding;Ki;=;670,00;6,17;-676;6;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;395;3;0;5;4,01;Clc1ccc2nc(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)cn2n1;https://dx.doi.org/10.1021/jm060166w
CHEMBL2092940;77863;None;0;Human;Binding;Ki;=;6,70;8,17;39;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;323,2;6;1;2;4,51;CCCN(CCc1ccc(C)cc1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL2093000;77881;None;0;Human;Binding;Ki;=;100,00;7,00;-25;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;452,2;7;1;4;5,60;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCC[C@H]3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL2093001;77882;None;0;Human;Binding;Ki;=;1584,89;5,80;-100;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;529,2;8;1;4;6,63;COc1ccc(S(=O)(=O)N(C)c2ccccc2)cc1-c1ccc(CN2CCCCC[C@H]2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL2094011;77921;None;0;Human;Binding;Ki;=;15,00;7,82;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;432,2;4;2;3;4,12;O=C1Cc2c(cccc2N2CCN(CCC3CCc4[nH]c5ccc(F)cc5c4C3)CC2)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL209805;78047;None;0;Human;Binding;Ki;=;338,00;6,47;-5;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;480,1;2;0;5;4,82;Cc1ccc(S(=O)(=O)N2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL209832;78054;None;3;Human;Binding;Ki;=;14000,00;4,85;-29;4;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;320,2;4;0;6;1,98;c1ccc(-n2cc(CN3CCN(c4ncccn4)CC3)cn2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL209832;78054;None;3;Human;Binding;Ki;=;6000,00;5,22;-29;4;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;320,2;4;0;6;1,98;c1ccc(-n2cc(CN3CCN(c4ncccn4)CC3)cn2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL209876;78061;None;0;Human;Binding;Ki;=;28,00;7,55;-75;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;531,3;8;1;4;5,57;COc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2cc3ccc2CCc2ccc(cc2)CC3)CC1;https://dx.doi.org/10.1021/jm060138d
CHEMBL209876;78061;None;0;Human;Binding;Ki;=;42,00;7,38;-75;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;531,3;8;1;4;5,57;COc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2cc3ccc2CCc2ccc(cc2)CC3)CC1;https://dx.doi.org/10.1021/jm060138d
CHEMBL20996;78079;None;0;Human;Binding;Ki;=;1584,89;5,80;-50;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;365,2;8;1;3;3,79;CCCCC(C)(C)C(=O)NCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL210016;78096;None;0;Human;Binding;Ki;=;3772,00;5,42;-15;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;543,3;3;1;7;4,21;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3N3CCN(C)CC3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL21008;78105;None;0;Human;Binding;Ki;=;19,95;7,70;-19;3;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;347,3;7;1;4;2,76;COc1ccccc1N1CCN(CCCCNC(=O)C(C)(C)C)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL210101;78108;None;0;Human;Binding;Ki;=;25,30;7,60;5;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;357,2;6;0;4;4,36;CO/N=C(\CCN1CCC(c2ccccn2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL21011;78110;None;0;Human;Binding;Ki;=;1000,00;6,00;-63;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;365,2;8;1;3;3,79;CCC(C)(C)C(=O)NCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL210232;78129;None;0;Human;Binding;Ki;=;65,00;7,19;-33;4;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;349,2;5;0;6;2,60;COc1ccccc1N1CCN(Cc2cn(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210232;78129;None;0;Human;Binding;Ki;=;120,00;6,92;-33;4;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;349,2;5;0;6;2,60;COc1ccccc1N1CCN(Cc2cn(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210232;78129;None;0;Human;Binding;Ki;=;120,00;6,92;-33;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;349,2;5;0;6;2,60;COc1ccccc1N1CCN(Cc2cn(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL210232;78129;None;0;Human;Binding;Ki;=;65,00;7,19;-33;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;349,2;5;0;6;2,60;COc1ccccc1N1CCN(Cc2cn(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL210283;78140;None;0;Human;Binding;Ki;=;2700,00;5,57;-2630;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;361,2;4;0;6;2,85;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(C#N)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL210283;78140;None;0;Human;Binding;Ki;=;4200,00;5,38;-2630;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;361,2;4;0;6;2,85;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(C#N)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL210318;78152;None;3;Human;Binding;Ki;=;3000,00;5,52;-134;4;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;318,2;4;0;4;3,19;c1ccc(N2CCN(Cc3ccc(-n4cccn4)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210318;78152;None;3;Human;Binding;Ki;=;2400,00;5,62;-134;4;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;318,2;4;0;4;3,19;c1ccc(N2CCN(Cc3ccc(-n4cccn4)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210341;78158;None;0;Human;Binding;Ki;=;3700,00;5,43;-3548;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;438;3;0;4;4,73;Clc1ccc(N2CCN(Cc3cn4cc(Br)ccc4n3)CC2)cc1Cl;https://dx.doi.org/10.1021/jm060166w
CHEMBL210341;78158;None;0;Human;Binding;Ki;=;3500,00;5,46;-3548;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;438;3;0;4;4,73;Clc1ccc(N2CCN(Cc3cn4cc(Br)ccc4n3)CC2)cc1Cl;https://dx.doi.org/10.1021/jm060166w
CHEMBL21035;78164;None;1;Human;Binding;Ki;=;794,33;6,10;-2;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;317,2;6;1;3;2,75;CC(C)(C)C(=O)NCCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL210404;78188;None;0;Human;Binding;Ki;=;31,00;7,51;-79;4;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;349,2;5;0;6;2,60;COc1ccccc1N1CCN(Cc2cnn(-c3ccccn3)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210404;78188;None;0;Human;Binding;Ki;=;40,00;7,40;-79;4;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;349,2;5;0;6;2,60;COc1ccccc1N1CCN(Cc2cnn(-c3ccccn3)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210404;78188;None;0;Human;Binding;Ki;=;39,81;7,40;-79;4;Binding affinity to dopamine D2;ChEMBL;349,2;5;0;6;2,60;COc1ccccc1N1CCN(Cc2cnn(-c3ccccn3)c2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL210405;78189;None;2;Human;Binding;Ki;=;75,00;7,12;-104;6;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;318,2;4;0;4;3,19;c1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210405;78189;None;2;Human;Binding;Ki;=;140,00;6,85;-104;6;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;318,2;4;0;4;3,19;c1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210405;78189;None;2;Human;Binding;Ki;=;141,25;6,85;-104;6;Binding affinity to dopamine D2;ChEMBL;318,2;4;0;4;3,19;c1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL210405;78189;None;2;Human;Binding;Ki;=;140,00;6,85;-104;6;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;318,2;4;0;4;3,19;c1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
CHEMBL210405;78189;None;2;Human;Binding;Ki;=;75,00;7,12;-104;6;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;318,2;4;0;4;3,19;c1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
CHEMBL210461;78206;None;0;Human;Binding;Ki;=;220,00;6,66;-48;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;535,2;7;1;3;6,21;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm060138d
CHEMBL210461;78206;None;0;Human;Binding;Ki;=;140,00;6,85;-48;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;535,2;7;1;3;6,21;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm060138d
CHEMBL210551;78238;None;0;Human;Binding;Ki;=;530,00;6,28;-239;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;402,2;5;0;7;3,16;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(-n4cccn4)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL210551;78238;None;0;Human;Binding;Ki;=;280,00;6,55;-239;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;402,2;5;0;7;3,16;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(-n4cccn4)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL210567;78246;None;0;Human;Binding;Ki;=;13,00;7,89;-19;7;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;497,3;8;1;4;4,91;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccc2CCc2ccc(cc2)CC3)CC1;https://dx.doi.org/10.1021/jm060138d
CHEMBL210567;78246;None;0;Human;Binding;Ki;=;15,00;7,82;-19;7;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;497,3;8;1;4;4,91;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccc2CCc2ccc(cc2)CC3)CC1;https://dx.doi.org/10.1021/jm060138d
CHEMBL210567;78246;None;0;Human;Binding;Ki;=;18,00;7,75;-19;7;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;497,3;8;1;4;4,91;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccc2CCc2ccc(cc2)CC3)CC1;https://dx.doi.org/10.1021/jm100899z
CHEMBL210567;78246;None;0;Human;Binding;Ki;=;24,00;7,62;-19;7;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;497,3;8;1;4;4,91;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccc2CCc2ccc(cc2)CC3)CC1;https://dx.doi.org/10.1021/jm100899z
CHEMBL210567;78246;None;0;Human;Binding;Ki;=;11,00;7,96;-19;7;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;497,3;8;1;4;4,91;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccc2CCc2ccc(cc2)CC3)CC1;https://dx.doi.org/10.1021/jm060138d
CHEMBL210567;78246;None;0;Human;Binding;Ki;=;5,60;8,25;-19;7;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;497,3;8;1;4;4,91;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccc2CCc2ccc(cc2)CC3)CC1;https://dx.doi.org/10.1021/jm060138d
CHEMBL210578;78253;None;0;Human;Binding;Ki;=;1,60;8,80;2;14;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;401,2;6;1;3;4,96;O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL210578;78253;None;0;Human;Binding;Ki;=;0,31;9,51;2;14;Cataleptogenic effect against cloned human Dopamine receptor D2 in male Sprague-Dawley rats in a bar test;ChEMBL;401,2;6;1;3;4,96;O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2003.07.015
CHEMBL210578;78253;None;0;Human;Binding;Ki;=;1,60;8,80;2;14;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;401,2;6;1;3;4,96;O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL210578;78253;None;0;Human;Binding;Ki;=;1,60;8,80;2;14;Binding affinity to human cloned dopamine D2 receptor by radioligand binding assay;ChEMBL;401,2;6;1;3;4,96;O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.03.057
CHEMBL210578;78253;None;0;Human;Binding;Ki;=;0,31;9,51;2;14;In vitro ability to inhibit the binding of [3H]spiperone to cloned human Dopamine receptor D2 using apomorphine induced climbing test in male Swiss mice;ChEMBL;401,2;6;1;3;4,96;O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2003.07.015
CHEMBL210578;78253;None;0;Human;Binding;Ki;=;0,31;9,51;2;14;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;401,2;6;1;3;4,96;O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL210578;78253;UNDEFINED;0;Human;Binding;pKi;=;1,60;8,80;2;14;-;PDSP KiDatabase;401,2;6;1;3;4,96;O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;-
CHEMBL210578;78253;UNDEFINED;0;Human;Binding;pKi;=;1,60;8,80;2;14;-;PDSP KiDatabase;401,2;6;1;3;4,96;O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;-
CHEMBL21059;78257;None;0;Human;Binding;Ki;=;3981,07;5,40;-79;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;385,2;6;1;3;3,77;CC(C)(C)C(=O)NCCCCN1CCN(c2ccc(C(F)(F)F)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL210717;78307;None;1;Human;Binding;Ki;=;63,10;7,20;-69;4;Binding affinity to dopamine D2;ChEMBL;336,2;4;0;4;3,33;Fc1ccccc1N1CCN(Cc2cnn(-c3ccccc3)c2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL210717;78307;None;1;Human;Binding;Ki;=;37,00;7,43;-69;4;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;336,2;4;0;4;3,33;Fc1ccccc1N1CCN(Cc2cnn(-c3ccccc3)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210717;78307;None;1;Human;Binding;Ki;=;63,00;7,20;-69;4;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;336,2;4;0;4;3,33;Fc1ccccc1N1CCN(Cc2cnn(-c3ccccc3)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210955;78352;None;0;Human;Binding;Ki;=;1900,00;5,72;-812;5;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;352,1;4;0;4;3,85;Clc1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210955;78352;None;0;Human;Binding;Ki;=;2900,00;5,54;-812;5;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;352,1;4;0;4;3,85;Clc1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL210955;78352;None;0;Human;Binding;Ki;=;2884,03;5,54;-812;5;Binding affinity to dopamine D2;ChEMBL;352,1;4;0;4;3,85;Clc1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL2109988;78372;None;0;Human;Binding;IC50;=;60,00;7,22;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;320,2;4;0;2;4,23;Cc1ccc(N2CCN(CC3CC3c3ccccc3)CC2)c(C)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL2109988;78372;UNDEFINED;0;Human;Binding;pKi;=;540,00;6,27;-;2;-;PDSP KiDatabase;320,2;4;0;2;4,23;Cc1ccc(N2CCN(CC3CC3c3ccccc3)CC2)c(C)c1;-
CHEMBL2109988;78372;UNDEFINED;0;Human;Binding;pKi;=;935,00;6,03;-;2;-;PDSP KiDatabase;320,2;4;0;2;4,23;Cc1ccc(N2CCN(CC3CC3c3ccccc3)CC2)c(C)c1;-
CHEMBL2109988;78372;UNDEFINED;0;Human;Binding;pKi;=;515,00;6,29;-;2;-;PDSP KiDatabase;320,2;4;0;2;4,23;Cc1ccc(N2CCN(CC3CC3c3ccccc3)CC2)c(C)c1;-
CHEMBL211026;78398;None;8;Human;Binding;Ki;=;860,00;6,07;-112;5;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;319,2;4;0;5;2,59;c1ccc(N2CCN(Cc3cn(-c4ccccc4)nn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL211026;78398;None;8;Human;Binding;Ki;=;1500,00;5,82;-112;5;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;319,2;4;0;5;2,59;c1ccc(N2CCN(Cc3cn(-c4ccccc4)nn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL2110308;78404;None;0;Human;Binding;Ki;=;320,00;6,50;-1;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;337,2;4;1;5;3,02;c1ccc(N2CCN(C3CCC(Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL2110308;78404;None;0;Human;Binding;Ki;=;160,00;6,80;-1;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;337,2;4;1;5;3,02;c1ccc(N2CCN(C3CCC(Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL211118;78443;None;0;Human;Binding;Ki;=;100,00;7,00;-63;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;421,2;5;0;7;2,81;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(N4CCOCC4)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL211118;78443;None;0;Human;Binding;Ki;=;210,00;6,68;-63;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;421,2;5;0;7;2,81;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(N4CCOCC4)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL211135;78449;None;0;Human;Binding;Ki;=;8200,00;5,09;-5011;6;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;361,1;3;0;5;3,36;Clc1ccc(N2CCN(Cc3cn4nc(Cl)ccc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL211135;78449;None;0;Human;Binding;Ki;=;12000,00;4,92;-5011;6;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;361,1;3;0;5;3,36;Clc1ccc(N2CCN(Cc3cn4nc(Cl)ccc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL2111525;78453;None;0;Human;Binding;Ki;=;510,00;6,29;-16;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;455,1;8;1;5;4,72;COc1ccc(Br)cc1-c1nc(CNCC2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL2111525;78453;None;0;Human;Binding;Ki;=;210,00;6,68;-16;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;455,1;8;1;5;4,72;COc1ccc(Br)cc1-c1nc(CNCC2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL2111526;78454;None;0;Human;Binding;Ki;=;8250,00;5,08;-14;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;441,1;7;1;5;4,48;COc1ccc(Br)cc1-c1nc(CNC2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL2111526;78454;None;0;Human;Binding;Ki;=;6600,00;5,18;-14;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;441,1;7;1;5;4,48;COc1ccc(Br)cc1-c1nc(CNC2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL2111527;78455;None;0;Human;Binding;Ki;=;510,00;6,29;-5;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;469,1;9;1;5;5,11;COc1ccc(Br)cc1-c1nc(CNCCC2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL2111527;78455;None;0;Human;Binding;Ki;=;310,00;6,51;-5;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;469,1;9;1;5;5,11;COc1ccc(Br)cc1-c1nc(CNCCC2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL2111528;78456;None;0;Human;Binding;Ki;=;185,00;6,73;1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;471,1;8;1;5;5,19;COc1ccc(Br)cc1-c1nc(CNCC2CCN(Cc3ccccc3)C2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL2111528;78456;None;0;Human;Binding;Ki;=;92,00;7,04;1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;471,1;8;1;5;5,19;COc1ccc(Br)cc1-c1nc(CNCC2CCN(Cc3ccccc3)C2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL2111591;78476;None;0;Human;Binding;Ki;=;501,19;6,30;-63;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;468,3;8;1;3;6,07;COc1cccc2c1CC[C@H]1[C@H]2CCCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL2111592;78477;None;0;Human;Binding;Ki;=;316,23;6,50;-31;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;532,2;9;1;5;5,40;CS(=O)(=O)Oc1cccc2c1CCC1C2CCCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL211164;78481;None;0;Human;Binding;Ki;=;130,00;6,89;-537;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;400,1;4;0;5;3,43;COc1ccccc1N1CCN(Cc2cn3cc(Br)ccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL211164;78481;None;0;Human;Binding;Ki;=;140,00;6,85;-537;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;400,1;4;0;5;3,43;COc1ccccc1N1CCN(Cc2cn3cc(Br)ccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL21118;78510;None;0;Human;Binding;Ki;=;158,49;6,80;-6;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;362,2;6;1;4;3,47;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCC3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL21119;78538;None;0;Human;Binding;Ki;=;630,96;6,20;-31;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;429,3;7;1;3;4,58;O=C(NCCCCN1CCN(c2ccc(Cl)cc2)CC1)C12CC3CC(CC(C3)C1)C2;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL2112210;78607;None;0;Human;Binding;Ki;=;19,95;7,70;-99;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;466,2;7;2;5;4,42;N#Cc1ccc2c(c1)[C@H]1CN(CCCCNC(=O)c3ccc(-c4ccc(N)cc4)cc3)C[C@@H]1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL2112284;78633;None;0;Human;Binding;Ki;=;410,00;6,39;-1;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;369,1;5;1;3;5,11;CC1(C(=O)/C=C(\O)c2ccc(Cl)cc2)CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm970111h
CHEMBL2112285;78634;None;0;Human;Binding;Ki;=;120,00;6,92;-10;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;355,1;5;1;3;4,72;O=C(/C=C(\O)c1ccc(Cl)cc1)C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm970111h
CHEMBL2112882;78899;None;0;Human;Binding;Ki;=;3,16;8,50;-50;7;Binding affinity against human Dopamine receptor D2 in CHO cells using [125I]iodosulpiride;ChEMBL;597,3;6;4;6;2,53;CC(C)C[C@H]1C(=O)N[C@@H](Cc2ccccc2)[C@]2(O)O[C@@](C)(NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)C(=O)N12;https://dx.doi.org/10.1021/jm0341204
CHEMBL2112912;78917;None;0;Human;Binding;Ki;=;21,00;7,68;-2;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;303,2;4;1;2;3,90;C1=C(c2ccccc2)CCN(CCc2c[nH]c3ncccc23)C1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL2112913;78918;None;0;Human;Binding;Ki;=;280,00;6,55;-43;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;329,2;5;1;2;4,45;C1=C(/C=C/c2ccccc2)CCN(CCc2c[nH]c3ncccc23)C1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL2112936;78936;None;0;Human;Binding;Ki;=;3200,00;5,50;-158;5;Binding affinity against dopamine D2 receptor;ChEMBL;482,2;2;4;7;3,99;N[C@H]1CCCC[C@@H]1NC(=O)c1c2c(c3c4c(ncnc14)-c1ccccc1C3=O)N[C@@H]1CCCC[C@H]1N2;https://dx.doi.org/10.1016/s0960-894x(99)00075-x
CHEMBL2113667;79489;None;0;Human;Binding;Ki;=;1000,00;6,00;-831;3;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;406,2;5;1;1;6,79;c1ccc(CCN2[C@H]3CC[C@@H]2CC(c2c(-c4ccccc4)[nH]c4ccccc24)C3)cc1;https://dx.doi.org/10.1021/jm0004998
CHEMBL2113718;79531;None;0;Human;Binding;Ki;=;2400,00;5,62;-245;6;Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;266,2;3;1;3;2,21;N#Cc1cc(CN2CCN(c3ccccc3)CC2)c[nH]1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL2113718;79531;None;0;Human;Binding;Ki;=;3400,00;5,47;-245;6;Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;266,2;3;1;3;2,21;N#Cc1cc(CN2CCN(c3ccccc3)CC2)c[nH]1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL211461;79634;None;0;Human;Binding;Ki;=;1950,00;5,71;-17;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;465,2;4;1;5;5,12;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCC3CCCC3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL211539;79724;None;0;Human;Binding;Ki;=;150,00;6,82;-190;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;414,1;4;0;5;3,74;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(Br)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL211539;79724;None;0;Human;Binding;Ki;=;240,00;6,62;-190;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;414,1;4;0;5;3,74;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(Br)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL211590;79757;None;0;Human;Binding;Ki;=;97,00;7,01;-173;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;462,1;4;0;5;3,58;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(I)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL211590;79757;None;0;Human;Binding;Ki;=;88,00;7,06;-173;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;462,1;4;0;5;3,58;COc1ccccc1N1CCN(Cc2cn3cc(C)cc(I)c3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL21168;79770;None;5;Human;Binding;Ki;=;398,11;6,40;-79;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;401,2;5;1;3;3,79;O=C(NCCN1CCN(c2ccc(Cl)cc2)CC1)C12CC3CC(CC(C3)C1)C2;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL211732;79783;None;0;Human;Binding;Ki;=;132,00;6,88;-1;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;360,2;6;0;5;2,92;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1cc(F)cc(F)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL211836;79803;None;0;Human;Binding;Ki;=;125,00;6,90;-6;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;349,2;6;0;6;2,52;CO/N=C(/CCN1CCN(c2ccccn2)CC1)c1cccc(C#N)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL211910;79816;None;0;Human;Binding;Ki;=;202,00;6,70;-3;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;461,2;4;1;6;4,83;COc1ccccc1CNN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL211915;79817;None;0;Human;Binding;Ki;=;80,00;7,10;7;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;446,2;2;1;6;5,02;Clc1ccc2c(c1)N=C(N1CCN(Cc3cccc4c3OCO4)CC1)c1ccccc1N2;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL21205;79846;None;0;Human;Binding;Ki;=;398,11;6,40;-2;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;371,2;7;1;3;3,67;O=C(NCCCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccccc1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL212077;79852;None;0;Human;Binding;Ki;=;6394,00;5,19;-537;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;513,1;2;1;5;5,77;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc(Cl)c(Cl)c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212160;79870;None;0;Human;Binding;Ki;=;590,00;6,23;-436;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;388,2;5;0;7;2,85;COc1ccccc1N1CCN(Cc2cn3c(-n4cccn4)cccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL212160;79870;None;0;Human;Binding;Ki;=;280,00;6,55;-436;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;388,2;5;0;7;2,85;COc1ccccc1N1CCN(Cc2cn3c(-n4cccn4)cccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL212186;79876;None;0;Human;Binding;Ki;=;3818,00;5,42;-61;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;542,3;4;2;6;6,21;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3NC3CCCCC3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212235;79890;None;0;Human;Binding;Ki;=;63,80;7,20;-1;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;358,2;6;0;5;3,30;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212288;79900;None;0;Human;Binding;Ki;=;164,00;6,79;-1;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;417,2;9;1;7;2,67;CO/N=C(/c1ccc(Cl)cc1)C(CNOC)CN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212291;79902;None;0;Human;Binding;Ki;=;1820,00;5,74;-14;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;325,2;6;0;6;2,04;CO/N=C(/CCN1CCN(c2ccccn2)CC1)c1cccnc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212292;79903;None;0;Human;Binding;Ki;=;76,50;7,12;-1;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;372,2;6;0;5;3,69;CO/N=C(\CCN1CCN(c2ccccn2)CC1C)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212370;79922;None;7;Human;Binding;Ki;=;15000,00;4,82;-2187;6;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cn4ccccc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL212370;79922;None;7;Human;Binding;Ki;=;16000,00;4,80;-2187;6;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cn4ccccc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL212383;79924;None;0;Human;Binding;Ki;=;215,00;6,67;-27;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;528,2;3;1;6;5,45;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3N3CCCCC3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212384;79925;None;0;Human;Binding;Ki;=;3896,00;5,41;-22;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;513,1;1;1;4;6,66;CN1CCN(C2=Nc3cc(Cl)ccc3N(C(=O)Nc3cc(Cl)cc(Cl)c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212402;79928;None;0;Human;Binding;Ki;=;175,00;6,76;-3;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;504,1;2;1;6;4,99;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc(C#N)c3)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212438;79940;None;0;Human;Binding;Ki;=;1280,00;5,89;-40;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;517,1;2;1;5;5,02;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cc(F)c(F)c(F)c3F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212444;79942;None;0;Human;Binding;Ki;=;137,00;6,86;-5;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;352,2;6;0;5;3,26;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccc(C)c(C)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212486;79953;None;1;Human;Binding;Ki;=;1900,00;5,72;-22;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;437,1;1;1;5;3,71;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)C(F)(F)F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL21252;79961;None;0;Human;Binding;Ki;=;1584,89;5,80;-1;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;309,2;6;1;3;2,38;CC(=O)NCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL212597;79979;None;0;Human;Binding;Ki;=;400,00;6,40;-2;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;411,2;3;1;5;3,95;CCCC(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212608;79981;None;0;Human;Binding;Ki;=;1150,00;5,94;-7;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;445,2;2;1;5;4,46;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212608;79981;None;0;Human;Binding;Ki;=;1150,00;5,94;-7;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;445,2;2;1;5;4,46;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212631;79986;None;11;Human;Binding;Ki;=;400,00;6,40;-158;6;Displacement of [3H]7-OH-DPAT from porcine dopamine receptor D2;ChEMBL;322,2;4;0;5;2,67;COc1ccccc1N1CCN(Cc2cn3ccccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL212631;79986;None;11;Human;Binding;Ki;=;930,00;6,03;-158;6;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;322,2;4;0;5;2,67;COc1ccccc1N1CCN(Cc2cn3ccccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL212631;79986;None;11;Human;Binding;Ki;=;110,00;6,96;-158;6;Displacement of [3H]7-OH-DPAT from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;322,2;4;0;5;2,67;COc1ccccc1N1CCN(Cc2cn3ccccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL212631;79986;None;11;Human;Binding;Ki;=;990,00;6,00;-158;6;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;322,2;4;0;5;2,67;COc1ccccc1N1CCN(Cc2cn3ccccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL212700;80010;None;0;Human;Binding;Ki;=;286,00;6,54;-2;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;523,1;2;1;7;4,84;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc4c(c3)OCO4)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212782;80032;None;0;Human;Binding;Ki;=;128,00;6,89;-3;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;338,2;7;0;5;3,03;CCO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212784;80033;None;0;Human;Binding;Ki;=;98,70;7,01;-7;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;358,2;6;0;5;3,30;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL21280;80035;None;0;Human;Binding;Ki;=;251,19;6,60;-3;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;348,2;6;1;4;3,08;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCC3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL212807;80038;None;0;Human;Binding;Ki;=;97,00;7,01;-8;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;539,1;4;1;7;5,13;COc1cccc(OC)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2cc(Cl)ccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212844;80044;None;0;Human;Binding;Ki;=;3000,00;5,52;-34;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;511,2;3;1;7;4,65;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3-n3ccnc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212861;80049;None;0;Human;Binding;Ki;=;68,40;7,17;-8;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;338,2;6;0;5;2,95;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1cccc(C)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212891;80060;None;0;Human;Binding;Ki;=;2530,00;5,60;-1;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;328,2;5;0;5;2,39;CO/N=C(\CN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212896;80061;None;0;Human;Binding;Ki;=;2997,00;5,52;-338;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;451,1;2;1;6;4,52;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccsc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212903;80065;None;0;Human;Binding;Ki;=;68,00;7,17;-2;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;338,2;6;0;5;2,95;CO/N=C(/CCN1CCN(c2ccccn2)CC1)c1cccc(C)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL212905;80066;None;0;Human;Binding;Ki;=;3648,00;5,44;-58;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;470,2;2;1;6;4,33;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc(C#N)c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212912;80067;None;0;Human;Binding;Ki;=;181,00;6,74;-181;6;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;479,1;2;1;5;5,12;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212912;80067;None;0;Human;Binding;Ki;=;181,00;6,74;-181;6;Binding affinity at dopamine D2 receptor;ChEMBL;479,1;2;1;5;5,12;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212912;80067;None;0;Human;Binding;Ki;=;181,00;6,74;-181;6;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;479,1;2;1;5;5,12;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL212936;80073;None;0;Human;Binding;Ki;=;36,00;7,44;-3;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;605;2;1;5;5,72;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3I)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL212969;80082;None;0;Human;Binding;Ki;=;168,00;6,78;-11;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;342,2;6;0;5;2,78;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL213004;80091;None;0;Human;Binding;Ki;=;146,00;6,84;2;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;372,2;6;0;5;3,54;CO/N=C(/c1ccc(Cl)cc1)C(C)CN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1021/jm060279f
CHEMBL213083;80108;None;0;Human;Binding;Ki;=;921,00;6,04;-19;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;463,2;2;1;5;4,60;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc(F)c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213084;80109;None;0;Human;Binding;Ki;=;181,00;6,74;-45;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;479,1;2;1;5;5,12;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc(Cl)c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213110;80117;None;0;Human;Binding;Ki;=;267,00;6,57;-16;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;569,2;5;1;8;5,14;COc1cc(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3cc(Cl)ccc32)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213145;80126;None;0;Human;Binding;Ki;=;759,00;6,12;-4;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;517,1;2;1;5;5,02;CN1CCN(C2=Nc3ccccc3N(NC(=O)c3cc(F)c(F)c(F)c3F)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213164;80132;None;0;Human;Binding;Ki;=;46,60;7,33;-7;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;342,2;6;0;5;2,78;CO/N=C(/CCN1CCN(c2ccccn2)CC1)c1cccc(F)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL213193;80136;None;0;Human;Binding;Ki;=;421,00;6,38;-19;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;531,1;2;1;5;5,62;CN1CCN(C2=Nc3ccccc3N(NC(=O)c3cc(F)ccc3C(F)(F)F)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213200;80138;None;0;Human;Binding;Ki;=;177,00;6,75;4;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;438,1;2;1;4;5,57;Fc1ccc(CN2CCN(C3=Nc4cc(Cl)ccc4Nc4ccccc43)CC2)c(F)c1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213201;80139;None;0;Human;Binding;Ki;=;1969,00;5,71;-30;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;470,2;2;1;6;4,33;CN1CCN(C2=Nc3ccccc3N(NC(=O)c3ccc(C#N)cc3)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213238;80146;None;0;Human;Binding;Ki;=;1186,00;5,93;-11;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;470,2;2;1;6;4,33;CN1CCN(C2=Nc3ccccc3N(NC(=O)c3cccc(C#N)c3)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213239;80147;None;0;Human;Binding;Ki;=;1379,00;5,86;-16;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;475,2;3;1;6;4,47;COc1cccc(C(=O)NN2c3ccccc3N=C(N3CCN(C)CC3)c3cc(Cl)ccc32)c1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213278;80157;None;0;Human;Binding;Ki;=;484,00;6,32;-20;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;496,2;2;1;6;5,01;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3nccc4ccccc34)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213335;80167;None;0;Human;Binding;Ki;=;409,00;6,39;-15;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;507,2;4;1;5;5,90;CCCN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213336;80168;None;0;Human;Binding;Ki;=;287,00;6,54;-131;6;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;473,2;2;1;5;5,08;Cc1cccc(C)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213336;80168;None;0;Human;Binding;Ki;=;287,00;6,54;-131;6;Binding affinity at dopamine D2 receptor;ChEMBL;473,2;2;1;5;5,08;Cc1cccc(C)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213336;80168;None;0;Human;Binding;Ki;=;287,00;6,54;-131;6;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;473,2;2;1;5;5,08;Cc1cccc(C)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213372;80176;None;0;Human;Binding;Ki;=;460,00;6,34;-20;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;436,1;2;1;7;3,45;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccon3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213388;80181;None;0;Human;Binding;Ki;=;1776,00;5,75;-42;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;451,2;2;1;5;4,73;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)C3CCCCC3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213424;80190;None;0;Human;Binding;Ki;=;1015,00;5,99;-354;6;Binding affinity at dopamine D2 receptor;ChEMBL;474,2;2;2;6;4,35;Cc1cccc(N)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213424;80190;None;0;Human;Binding;Ki;=;1015,00;5,99;-354;6;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;474,2;2;2;6;4,35;Cc1cccc(N)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213443;80193;None;0;Human;Binding;Ki;=;931,00;6,03;-93;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;496,2;2;1;6;5,01;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc4ccccc4n3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213466;80198;None;0;Human;Binding;Ki;=;270,00;6,57;-2;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;551,1;2;1;5;5,67;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cc(F)c(F)c(F)c3F)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213472;80201;None;0;Human;Binding;Ki;=;1261,00;5,90;-15;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;489,2;2;1;7;4,19;CN1CCN(C2=Nc3ccccc3N(NC(=O)c3ccc4c(c3)OCO4)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213477;80202;None;0;Human;Binding;Ki;=;374,00;6,43;-30;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;463,2;2;1;5;4,60;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213492;80205;None;0;Human;Binding;Ki;=;383,00;6,42;-316;6;Binding affinity at dopamine D2 receptor;ChEMBL;531,1;2;1;5;5,62;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3c(F)cccc3C(F)(F)F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213492;80205;None;0;Human;Binding;Ki;=;383,00;6,42;-316;6;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;531,1;2;1;5;5,62;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3c(F)cccc3C(F)(F)F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213577;80218;None;0;Human;Binding;Ki;=;29,00;7,54;20;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;460,2;2;1;6;5,06;Clc1ccc2c(c1)N=C(N1CCN(Cc3ccc4c(c3)OCCO4)CC1)c1ccccc1N2;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213668;80238;None;0;Human;Binding;Ki;=;828,00;6,08;-14;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;489,2;2;1;7;4,19;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc4c(c3)OCO4)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL213775;80268;None;0;Human;Binding;Ki;=;2386,00;5,62;-169;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;523,1;2;1;5;5,22;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc(Br)cc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213793;80270;None;0;Human;Binding;Ki;=;517,00;6,29;-169;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;459,2;2;1;5;4,77;Cc1cccc(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)c1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213795;80271;None;0;Human;Binding;Ki;=;1521,00;5,82;-194;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;459,2;2;1;5;4,77;Cc1ccc(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213834;80278;None;0;Human;Binding;Ki;=;458,00;6,34;-457;6;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;495,2;2;1;5;5,62;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc4ccccc34)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213834;80278;None;0;Human;Binding;Ki;=;458,00;6,34;-457;6;Binding affinity at dopamine D2 receptor;ChEMBL;495,2;2;1;5;5,62;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc4ccccc34)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213881;80289;None;0;Human;Binding;Ki;=;390,00;6,41;-97;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;547;2;1;5;6,42;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3c(Cl)cc(Cl)cc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL213882;80290;None;0;Human;Binding;Ki;=;1314,00;5,88;-177;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;495,2;2;1;5;5,62;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc4ccccc4c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL214016;80318;None;0;Human;Binding;Ki;=;1126,00;5,95;-87;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;475,2;3;1;6;4,47;COc1cccc(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)c1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL214142;80340;None;0;Human;Binding;Ki;=;9251,00;5,03;-269;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;479,1;2;1;5;5,12;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc(Cl)cc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL214247;80365;None;0;Human;Binding;Ki;=;995,00;6,00;-8;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;374,2;6;1;6;2,27;CO/N=C(\c1ccc(Cl)cc1)C(O)CN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1021/jm060279f
CHEMBL214314;80379;None;0;Human;Binding;Ki;=;257,00;6,59;-10;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;310,2;5;1;5;2,47;O/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL214407;80401;None;0;Human;Binding;Ki;=;431,00;6,37;-8;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;537,2;4;1;6;6,25;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3Oc3ccccc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL214503;80422;None;0;Human;Binding;Ki;=;231,00;6,64;-32;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;571,1;2;1;5;5,07;CN1CCN(C2=Nc3ccccc3N(NC(=O)c3ccccc3I)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL214739;80529;None;0;Human;Binding;Ki;=;5000,00;5,30;-1;2;Binding affinity to D2 receptor;ChEMBL;318,2;7;0;2;5,06;COc1cccc(CCc2ccccc2OCc2ccccc2)c1;https://dx.doi.org/10.1021/jm060639z
CHEMBL215010;80623;None;0;Human;Binding;Ki;=;5000,00;5,30;-1;2;Binding affinity to D2 receptor;ChEMBL;288,2;6;0;1;5,05;c1ccc(CCc2ccccc2OCc2ccccc2)cc1;https://dx.doi.org/10.1021/jm060639z
CHEMBL215140;80716;None;0;Human;Binding;Ki;=;647,00;6,19;-2;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;341,1;0;1;5;2,99;CN1CCN(C2=Nc3cc(Cl)ccc3N(N)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL215414;81090;None;0;Human;Binding;Ki;=;197,00;6,71;-32;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;505,2;4;1;7;4,48;COc1cccc(OC)c1C(=O)NN1c2ccccc2N=C(N2CCN(C)CC2)c2cc(Cl)ccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL215450;81100;None;0;Human;Binding;Ki;=;60,90;7,21;-5;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;372,2;6;0;5;3,61;CO/N=C(/CCN1CCN(c2ccccn2)CC1)c1ccc(Cl)c(C)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL215581;81132;None;1;Human;Binding;Ki;=;1850,00;5,73;-72;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;467,2;6;1;5;5,37;CCCC(CCC)C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL215611;81138;None;0;Human;Binding;Ki;=;621,00;6,21;-7;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;473,2;4;1;5;4,78;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)CCc3ccccc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL215669;81159;None;0;Human;Binding;Ki;=;3,40;8,47;1122;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;486,1;3;1;5;6,19;FC(F)(F)Oc1cccc(CN2CCN(C3=Nc4cc(Cl)ccc4Nc4ccccc43)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL215705;81173;None;0;Human;Binding;Ki;=;225,00;6,65;-35;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;360,2;6;0;5;2,92;CO/N=C(/CCN1CCN(c2ccccn2)CC1)c1cc(F)cc(F)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL215842;81243;None;0;Human;Binding;Ki;=;709,00;6,15;-13;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;493,1;3;1;5;5,51;CCN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL215885;81345;None;0;Human;Binding;Ki;=;3000,00;5,52;-64;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;475,2;3;1;6;4,47;COc1ccc(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL2159455;81442;None;0;Human;Binding;Ki;=;32,00;7,50;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;490,1;9;1;5;5,14;O=S(=O)(NCC1CCN(CCOc2ccccc2-c2ccccc2)CC1)c1ccc(Cl)s1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159456;81443;None;0;Human;Binding;Ki;=;1059,00;5,97;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;398,1;8;1;5;2,96;O=S(=O)(NCC1CCN(CCOc2cccc(F)c2)CC1)c1cccs1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159457;81444;None;0;Human;Binding;Ki;=;50,00;7,30;1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;434,2;9;1;4;4,02;CC(C)c1ccccc1OCCN1CCC(CNS(=O)(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159458;81445;None;0;Human;Binding;Ki;=;46,00;7,34;-3;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;468,2;9;1;4;4,56;O=S(=O)(NCC1CCN(CCOc2ccccc2-c2ccccc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159459;81446;None;0;Human;Binding;Ki;=;839,00;6,08;1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;410,1;8;1;4;3,03;O=S(=O)(NCC1CCN(CCOc2cccc(F)c2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159460;81448;None;0;Human;Binding;Ki;=;66,00;7,18;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;450,2;9;1;4;4,53;CC(C)c1ccccc1OCCN1CCC(CNS(=O)(=O)c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159461;81449;None;0;Human;Binding;Ki;=;50,00;7,30;-2;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;454,1;9;1;5;4,13;CSc1ccccc1OCCN1CCC(CNS(=O)(=O)c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159462;81450;None;0;Human;Binding;Ki;=;560,00;6,25;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;426,1;8;1;4;3,55;O=S(=O)(NCC1CCN(CCOc2cccc(F)c2)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159463;81451;None;0;Human;Binding;Ki;=;76,00;7,12;6;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;386,2;8;1;4;3,50;CCOc1ccccc1C(=O)NC1CCN(CCOc2cccc(F)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159464;81452;None;1;Human;Binding;Ki;=;84,00;7,08;1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;366,1;7;1;5;2,57;O=S(=O)(NC1CCN(CCOc2ccccc2)CC1)c1cccs1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159465;81453;None;0;Human;Binding;Ki;=;51,00;7,29;-169;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;420,2;8;1;4;3,77;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159466;81454;None;0;Human;Binding;Ki;=;63,00;7,20;-8;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;472,2;8;1;4;4,45;O=S(=O)(NC1CCN(CCOc2ccccc2-c2ccccc2)CC1)c1ccc(F)c(F)c1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159466;81454;None;0;Human;Binding;Ki;=;63,00;7,20;-8;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr by microplate reader based assay;ChEMBL;472,2;8;1;4;4,45;O=S(=O)(NC1CCN(CCOc2ccccc2-c2ccccc2)CC1)c1ccc(F)c(F)c1;https://dx.doi.org/10.1039/C5MD00166H
CHEMBL2159467;81455;None;0;Human;Binding;Ki;=;15,00;7,82;1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;422,2;7;1;3;4,51;O=C(NC1CCN(CCOc2ccccc2-c2ccccc2)C1)c1cccc(F)c1F;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159468;81456;None;0;Human;Binding;Ki;=;79,00;7,10;-2;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;403,2;7;1;4;4,24;CC(C)c1ccccc1OCCN1CCC(NC(=O)c2ccc3ccccc3n2)C1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159469;81457;None;0;Human;Binding;Ki;=;24,00;7,62;1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;437,2;7;1;4;4,79;O=C(NC1CCN(CCOc2ccccc2-c2ccccc2)C1)c1ccc2ccccc2n1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159470;81458;None;0;Human;Binding;Ki;=;16,00;7,80;1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;394,1;8;1;5;3,30;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2cccs2)C1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159471;81459;None;0;Human;Binding;Ki;=;16,00;7,80;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;428,1;8;1;5;3,85;O=S(=O)(NC1CCN(CCOc2ccccc2-c2ccccc2)C1)c1cccs1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159472;81460;None;0;Human;Binding;Ki;=;72,00;7,14;-5;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;406,1;7;1;5;3,06;O=S(=O)(NC1CCN(CCOc2cccc3c2CCCC3)C1)c1cccs1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159473;81461;None;0;Human;Binding;Ki;=;729,00;6,14;-2;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;370,1;7;1;5;2,32;O=S(=O)(NC1CCN(CCOc2cccc(F)c2)C1)c1cccs1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159474;81462;None;0;Human;Binding;Ki;=;67,00;7,17;-4;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;454;7;1;5;4,14;O=S(=O)(NC1CCN(CCOc2cccc(Cl)c2Cl)C1)c1ccc(Cl)s1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159475;81463;None;0;Human;Binding;Ki;=;78,00;7,11;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;454;7;1;5;4,14;O=S(=O)(NC1CCN(CCOc2cc(Cl)ccc2Cl)C1)c1ccc(Cl)s1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159476;81464;None;0;Human;Binding;Ki;=;318,00;6,50;-4;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;386,1;7;1;5;2,83;O=S(=O)(NC1CCN(CCOc2ccccc2)C1)c1ccc(Cl)s1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159477;81465;None;0;Human;Binding;Ki;=;10,00;8,00;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;439,2;8;1;5;3,79;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2cccc3cccnc23)C1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159478;81466;None;0;Human;Binding;Ki;=;41,00;7,39;-4;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;410,1;8;1;5;2,98;CSc1ccccc1OCCN1CCC(NS(=O)(=O)c2ccc(F)cc2)C1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159479;81467;None;0;Human;Binding;Ki;=;11,00;7,96;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;364,1;7;1;4;2,26;O=S(=O)(NC1CCN(CCOc2ccccc2)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159480;81468;None;0;Human;Binding;Ki;=;72,00;7,14;-4;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;418,2;7;1;4;3,14;O=S(=O)(NC1CCN(CCOc2cccc3c2CCCC3)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159481;81469;None;0;Human;Binding;Ki;=;24,00;7,62;-3;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;458,1;8;1;4;4,06;O=S(=O)(NC1CCN(CCOc2ccccc2-c2ccccc2)C1)c1ccc(F)c(F)c1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159482;81470;None;0;Human;Binding;Ki;=;523,00;6,28;-2;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;400,1;7;1;4;2,54;O=S(=O)(NC1CCN(CCOc2cccc(F)c2)C1)c1ccc(F)c(F)c1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159483;81471;None;0;Human;Binding;Ki;=;18,00;7,75;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;458,1;8;1;4;4,06;O=S(=O)(NC1CCN(CCOc2ccccc2-c2ccccc2)C1)c1cc(F)ccc1F;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159484;81472;None;0;Human;Binding;Ki;=;60,00;7,22;-6;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;436,2;7;1;4;3,27;O=S(=O)(NC1CCN(CCOc2cccc3c2CCCC3)C1)c1cc(F)ccc1F;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159485;81473;None;0;Human;Binding;Ki;=;25,00;7,60;-6;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;422,1;8;1;4;3,90;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2cccc(Cl)c2)C1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159486;81474;None;0;Human;Binding;Ki;=;36,00;7,44;-7;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;426,1;8;1;5;3,49;CSc1ccccc1OCCN1CCC(NS(=O)(=O)c2cccc(Cl)c2)C1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159487;81475;None;0;Human;Binding;Ki;=;20,00;7,70;-3;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;428,1;8;1;5;3,96;CC(C)c1ccccc1OCCN1CC[C@@H](NS(=O)(=O)c2ccc(Cl)s2)C1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159488;81476;None;0;Human;Binding;Ki;=;39,00;7,41;-9;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;462,1;8;1;5;4,50;O=S(=O)(N[C@@H]1CCN(CCOc2ccccc2-c2ccccc2)C1)c1ccc(Cl)s1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159489;81477;None;0;Human;Binding;Ki;=;16,00;7,80;-7;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;440,2;8;1;4;3,92;O=S(=O)(N[C@@H]1CCN(CCOc2ccccc2-c2ccccc2)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159490;81478;None;0;Human;Binding;Ki;=;25,00;7,60;1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;428,1;8;1;5;3,96;CC(C)c1ccccc1OCCN1CC[C@H](NS(=O)(=O)c2ccc(Cl)s2)C1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159491;81479;None;0;Human;Binding;Ki;=;8,00;8,10;1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;462,1;8;1;5;4,50;O=S(=O)(N[C@H]1CCN(CCOc2ccccc2-c2ccccc2)C1)c1ccc(Cl)s1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL2159492;81480;None;0;Human;Binding;Ki;=;10,00;8,00;-1;4;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;440,2;8;1;4;3,92;O=S(=O)(N[C@H]1CCN(CCOc2ccccc2-c2ccccc2)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
CHEMBL215950;81482;None;0;Human;Binding;Ki;=;582,00;6,24;-10;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;537,2;5;1;6;5,44;COc1ccc(CCC(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)cc1Cl;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL215997;81506;None;0;Human;Binding;Ki;=;12710,00;4,90;-147;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;446,2;2;1;6;3,86;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccnc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL216198;81599;None;0;Human;Binding;Ki;=;5000,00;5,30;-1;2;Binding affinity to D2 receptor;ChEMBL;289,1;6;0;2;4,45;c1ccc(CCc2ccccc2OCc2ccccn2)cc1;https://dx.doi.org/10.1021/jm060639z
CHEMBL216258;81612;None;0;Human;Binding;Ki;=;13,49;7,87;-5;5;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;304,2;0;1;1;4,18;CN1CCCc2ccccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL216258;81612;None;0;Human;Binding;Ki;=;14,50;7,84;-5;5;Displacement of [3H]spiperone from human D2L dopamine receptor expressed in CHO cells;ChEMBL;304,2;0;1;1;4,18;CN1CCCc2ccccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1021/jm060213k
CHEMBL216439;81864;None;0;Human;Binding;Ki;=;143,00;6,84;-22;6;Displacement of [3H]spiperone from human D2L dopamine receptor expressed in CHO cells;ChEMBL;304,2;0;1;1;4,18;CN1CCCc2c([nH]c3ccccc23)Cc2ccccc2CC1;https://dx.doi.org/10.1021/jm060213k
CHEMBL216439;81864;None;0;Human;Binding;Ki;=;114,82;6,94;-22;6;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;304,2;0;1;1;4,18;CN1CCCc2c([nH]c3ccccc23)Cc2ccccc2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL2164434;81866;None;2;Human;Binding;Ki;=;13570,00;4,87;1;2;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;216,1;4;2;1;2,70;CCCCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/jm300482h
CHEMBL2165114;81993;None;0;Human;Binding;Ki;=;18,00;7,75;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;449,1;7;0;5;5,97;Clc1cccc(N2CCCN(CCCCOc3ccc4scnc4c3)CC2)c1Cl;-
CHEMBL2165114;81993;None;0;Human;Binding;Ki;=;18,00;7,75;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;449,1;7;0;5;5,97;Clc1cccc(N2CCCN(CCCCOc3ccc4scnc4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165115;81994;None;0;Human;Binding;Ki;=;11,00;7,96;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;433,1;7;2;3;5,20;O=c1[nH]c2ccc(OCCCCN3CCC(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165115;81994;None;0;Human;Binding;Ki;=;10,90;7,96;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;433,1;7;2;3;5,20;O=c1[nH]c2ccc(OCCCCN3CCC(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;-
CHEMBL2165116;81995;None;0;Human;Binding;Ki;=;104,00;6,98;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;404,1;6;1;4;4,46;Clc1cccc(N2CCN(CCCOc3ccc4cn[nH]c4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165116;81995;None;0;Human;Binding;Ki;=;104,00;6,98;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;404,1;6;1;4;4,46;Clc1cccc(N2CCN(CCCOc3ccc4cn[nH]c4c3)CC2)c1Cl;-
CHEMBL2165117;81996;None;0;Human;Binding;Ki;=;18,00;7,75;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;433,1;6;1;4;3,87;O=C1NCCc2ccc(OCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165117;81996;None;0;Human;Binding;Ki;=;18,00;7,75;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;433,1;6;1;4;3,87;O=C1NCCc2ccc(OCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21;-
CHEMBL2165118;81997;None;0;Human;Binding;Ki;=;5,70;8,24;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;447,1;6;1;4;4,26;O=C1NCCc2ccc(OCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc21;-
CHEMBL2165118;81997;None;0;Human;Binding;Ki;=;5,70;8,24;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;447,1;6;1;4;4,26;O=C1NCCc2ccc(OCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc21;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165120;81998;None;0;Human;Binding;EC50;=;1,00;9,00;-;1;pERK High-Content Assay: Cell Culture: Chinese Hamster Ovary (CHO) cells stably expressing the hD2L dopamine receptor (Urban et al., Neuropsychopharmacology 32:67 (2007)) were maintained in Ham's F12 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 ug/mL streptomycin, and 0.5 ug/ml G418. On day 1 of the assay, cells were seeded onto black clear-bottom tissue culture-treated 96-well plates (Greiner, BioOne). On day 2 of the assay, cells were washed with serum-free medium (Ham's F-12, penicillin and streptomycin) and incubated in 100 uL serum-free medium overnight.Immunofluorescence: Automatic multichannel pipetters were used for liquid handling and multichannel vacuum manifolds for aspirations. Each tested concentration was typically measured in triplicate or quadruplicate. For concentration curves, half-log-dilutions were used. Drug dilutions were prepared in stimulation medium (serum-free medium, 100 mg/L ascorbic acid).;ChEMBL;459,1;7;1;4;5,21;O=c1ccc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;-
CHEMBL2165120;81998;None;0;Human;Binding;Ki;=;3,40;8,47;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;459,1;7;1;4;5,21;O=c1ccc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165120;81998;None;0;Human;Binding;Ki;=;3,40;8,47;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;459,1;7;1;4;5,21;O=c1ccc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;-
CHEMBL2165121;81999;None;0;Human;Binding;Ki;=;3,10;8,51;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;437,3;9;1;5;4,34;CC(C)Oc1ccccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165122;82000;None;1;Human;Binding;Ki;=;4,20;8,38;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;447,2;7;1;4;4,57;O=C1CCc2ccc(OCCCCN3CCN(c4ccccc4C(F)(F)F)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165123;82001;None;0;Human;Binding;Ki;=;21,00;7,68;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;423,3;9;1;5;3,95;CCOc1cccc(N2CCN(CCCCOc3ccc4c(c3)NC(=O)CC4)CC2)c1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165124;82002;None;0;Human;Binding;Ki;=;53,00;7,28;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;423,3;9;1;5;3,95;CCOc1ccc(N2CCN(CCCCOc3ccc4c(c3)NC(=O)CC4)CC2)cc1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165125;82003;None;0;Human;Binding;Ki;=;11,00;7,96;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;446,2;7;1;3;5,92;O=C1CCc2ccc(OCCCCN3CCC(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165127;82004;None;0;Human;Binding;Ki;=;21,00;7,68;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;433,1;6;1;4;4,47;O=C1CCc2ccc(OCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165128;82005;None;0;Human;Binding;Ki;=;145,00;6,84;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;501,2;6;1;4;5,89;O=C1CCc2ccc(OC[C@H]3CC[C@H](CN4CCN(c5cccc(Cl)c5Cl)CC4)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165129;82006;None;0;Human;Binding;Ki;=;1004,00;6,00;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;443,1;4;1;4;4,08;O=C1CCc2ccc(OCC#CCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165129;82006;None;0;Human;Binding;Ki;=;1004,00;6,00;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;443,1;4;1;4;4,08;O=C1CCc2ccc(OCC#CCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
CHEMBL2165130;82007;None;0;Human;Binding;Ki;=;235,00;6,63;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;459,1;6;1;4;4,61;O=C1CCc2ccc(CO[C@@H]3C[C@H]3CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165131;82008;None;0;Human;Binding;Ki;=;113,00;6,95;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;481,1;5;1;4;5,99;O=C1CCc2ccc(Oc3cccc(CN4CCN(c5cccc(Cl)c5Cl)CC4)c3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165131;82008;None;0;Human;Binding;Ki;=;113,00;6,95;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;481,1;5;1;4;5,99;O=C1CCc2ccc(Oc3cccc(CN4CCN(c5cccc(Cl)c5Cl)CC4)c3)cc2N1;-
CHEMBL2165132;82009;None;0;Human;Binding;Ki;=;108,00;6,97;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;481,1;5;1;4;5,99;O=C1CCc2ccc(Oc3ccc(CN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)cc2N1;-
CHEMBL2165132;82009;None;0;Human;Binding;Ki;=;108,00;6,97;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;481,1;5;1;4;5,99;O=C1CCc2ccc(Oc3ccc(CN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)cc2N1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165133;82010;None;0;Human;Binding;Ki;=;18,00;7,75;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;447,1;7;1;4;4,26;O=C1NCCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21;-
CHEMBL2165133;82010;None;0;Human;Binding;Ki;=;18,00;7,75;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;447,1;7;1;4;4,26;O=C1NCCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165134;82011;None;0;Human;Binding;Ki;=;66,00;7,18;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;418,1;7;1;4;4,85;Clc1cccc(N2CCN(CCCCOc3ccc4cn[nH]c4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165134;82011;None;0;Human;Binding;Ki;=;66,00;7,18;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;418,1;7;1;4;4,85;Clc1cccc(N2CCN(CCCCOc3ccc4cn[nH]c4c3)CC2)c1Cl;-
CHEMBL2165135;82012;None;0;Human;Binding;Ki;=;15,00;7,82;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;434,1;7;2;4;4,14;O=c1[nH]c2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;-
CHEMBL2165135;82012;None;0;Human;Binding;Ki;=;15,00;7,82;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;434,1;7;2;4;4,14;O=c1[nH]c2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165136;82013;None;0;Human;Binding;Ki;=;17,00;7,77;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;435,1;7;0;5;5,58;Clc1cccc(N2CCN(CCCCOc3ccc4scnc4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165136;82013;None;0;Human;Binding;Ki;=;17,00;7,77;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;435,1;7;0;5;5,58;Clc1cccc(N2CCN(CCCCOc3ccc4scnc4c3)CC2)c1Cl;-
CHEMBL2165137;82014;None;0;Human;Binding;Ki;=;42,00;7,38;-69;5;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;434,1;7;0;4;6,64;Clc1cccc(C2CCN(CCCCOc3ccc4scnc4c3)CC2)c1Cl;-
CHEMBL2165137;82014;None;0;Human;Binding;Ki;=;42,00;7,38;-69;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;434,1;7;0;4;6,64;Clc1cccc(C2CCN(CCCCOc3ccc4scnc4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165139;82015;None;10;Human;Binding;Ki;=;30,00;7,52;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;421,1;6;0;5;5,19;Clc1cccc(N2CCN(CCCOc3ccc4scnc4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165139;82015;None;10;Human;Binding;Ki;=;30,00;7,52;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;421,1;6;0;5;5,19;Clc1cccc(N2CCN(CCCOc3ccc4scnc4c3)CC2)c1Cl;-
CHEMBL2165140;82016;None;0;Human;Binding;Ki;=;20,00;7,70;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;435,1;6;0;5;5,58;Clc1cccc(N2CCCN(CCCOc3ccc4scnc4c3)CC2)c1Cl;-
CHEMBL2165140;82016;None;0;Human;Binding;Ki;=;20,00;7,70;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;435,1;6;0;5;5,58;Clc1cccc(N2CCCN(CCCOc3ccc4scnc4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm300603y
CHEMBL2165673;82119;None;1;Human;Binding;Ki;=;45,90;7,34;1;2;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;244,1;1;0;2;2,75;CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL2165674;82120;None;1;Human;Binding;Ki;=;265,00;6,58;2;2;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;206,1;2;0;3;1,45;COc1ccccc1N1CCN(C)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL2165675;82121;None;3;Human;Binding;Ki;=;63,70;7,20;-1;2;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;274,1;3;1;3;2,11;OCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL2165676;82122;None;2;Human;Binding;Ki;=;5,20;8,28;1;2;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;272,1;3;0;2;3,52;CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL2165677;82123;None;0;Human;Binding;Ki;=;3,40;8,47;-1;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;286,1;4;0;2;3,92;CCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL2165677;82123;None;0;Human;Binding;Ki;=;3,40;8,47;-1;2;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;286,1;4;0;2;3,92;CCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL2165678;82124;None;0;Human;Binding;Ki;=;15,60;7,81;-3;2;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;357,1;7;1;3;3,42;CCC(=O)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL2165679;82125;None;0;Human;Binding;Ki;=;84,00;7,08;-2;2;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;319,2;8;1;4;2,12;CCC(=O)NCCCCN1CCN(c2ccccc2OC)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL216794;82176;None;2;Human;Binding;Ki;=;3500,00;5,46;-109;2;Displacement of [125I]7-OH-PIPAT from human D2L receptor expressed in HEK293 cell membrane;ChEMBL;309,2;4;1;3;2,96;Cc1cccc(C(=O)NCN2CCC(c3ccccn3)CC2)c1;https://dx.doi.org/10.1021/jm060662k
CHEMBL216945;82192;None;0;Human;Binding;Ki;=;340,00;6,47;-1;5;Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate;ChEMBL;311,2;2;2;4;3,22;CCCN1Cc2ccccc2C2c3cc(O)c(O)cc3OCC21;https://dx.doi.org/10.1021/jm0604979
CHEMBL217281;82435;None;0;Human;Binding;Ki;=;5000,00;5,30;-1;2;Binding affinity to D2 receptor;ChEMBL;319,2;7;0;3;4,45;COc1cccc(CCc2ccccc2OCc2cccnc2)c1;https://dx.doi.org/10.1021/jm060639z
CHEMBL217425;82458;None;0;Human;Binding;Ki;=;5000,00;5,30;-1;2;Binding affinity to D2 receptor;ChEMBL;289,1;6;0;2;4,45;c1ccc(CCc2ccccc2OCc2cccnc2)cc1;https://dx.doi.org/10.1021/jm060639z
CHEMBL217886;82623;None;0;Human;Binding;Ki;=;5000,00;5,30;-1;2;Binding affinity to D2 receptor;ChEMBL;348,2;8;0;3;5,07;COc1cccc(CCc2ccccc2OCc2cccc(OC)c2)c1;https://dx.doi.org/10.1021/jm060639z
CHEMBL2179217;82653;None;0;Human;Binding;Ki;=;302,60;6,52;1;6;Binding affinity to dopamine D2 receptor;ChEMBL;447,1;5;1;6;4,36;COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1;https://dx.doi.org/10.1021/jm300955x
CHEMBL2179222;82654;None;0;Human;Binding;Ki;=;1812,00;5,74;-3;6;Binding affinity to dopamine D2 receptor;ChEMBL;448,1;5;1;7;3,75;COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)cnc32)cc1NC1CCN(C)CC1;https://dx.doi.org/10.1021/jm300955x
CHEMBL217964;82730;None;0;Human;Binding;Ki;=;16,00;7,80;-54;5;Displacement of [3H]spiperone from human dopamine D2(short) expressed in CHO cell membrane;ChEMBL;462,2;9;1;5;4,23;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3cccc(F)n3)cc2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL217964;82730;None;0;Human;Binding;Ki;=;27,00;7,57;-54;5;Displacement of [3H]spiperone from human dopamine D2(long) expressed in CHO cell membrane;ChEMBL;462,2;9;1;5;4,23;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3cccc(F)n3)cc2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL217981;82804;None;0;Human;Binding;Ki;=;4,90;8,31;9;4;Binding affinity to dopamine D2;ChEMBL;554,2;11;1;7;4,13;COc1ccccc1N1CCN(CCCCCNC(=O)c2nnn(Cc3ccccc3Br)c2C)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL217981;82804;None;0;Human;Binding;Ki;=;0,58;9,24;9;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;554,2;11;1;7;4,13;COc1ccccc1N1CCN(CCCCCNC(=O)c2nnn(Cc3ccccc3Br)c2C)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL2180637;82919;None;0;Human;Binding;Ki;=;1420,00;5,85;-112;6;Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells;ChEMBL;311,2;10;1;2;4,67;CCCCCN(CCc1ccccc1)CCc1cccc(O)c1;https://dx.doi.org/10.1021/jm301258w
CHEMBL2180640;82920;None;0;Human;Binding;Ki;=;1233,00;5,91;-112;5;Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells;ChEMBL;297,2;9;1;2;4,28;CCCCN(CCc1ccccc1)CCc1cccc(O)c1;https://dx.doi.org/10.1021/jm301258w
CHEMBL2180641;82921;None;0;Human;Binding;Ki;=;831,00;6,08;-5;5;Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells;ChEMBL;325,2;11;1;2;5,06;CCCCCCN(CCc1ccccc1)CCc1cccc(O)c1;https://dx.doi.org/10.1021/jm301258w
CHEMBL218150;83060;None;0;Human;Binding;Ki;=;2290,87;5,64;-3090;3;Binding affinity to dopamine D2;ChEMBL;522,1;7;2;3;5,57;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(Br)ccc2[nH]1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218151;83061;None;0;Human;Binding;Ki;=;338,84;6,47;-954;3;Binding affinity to dopamine D2;ChEMBL;469,1;7;2;4;4,68;N#Cc1ccc2cc(C(=O)NCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)[nH]c2c1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218203;83144;None;0;Human;Binding;Ki;=;238,00;6,62;-389;4;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;421,2;7;1;3;4,83;O=C(NCCCCN1CCN(c2ccccc2Cl)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL218203;83144;None;0;Human;Binding;Ki;=;457,09;6,34;-389;4;Binding affinity to dopamine D2;ChEMBL;421,2;7;1;3;4,83;O=C(NCCCCN1CCN(c2ccccc2Cl)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218318;83197;None;0;Human;Binding;Ki;=;67,61;7,17;-147;3;Binding affinity to dopamine D2;ChEMBL;448,2;8;1;6;4,11;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(C#N)ccc3s2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218351;83205;None;0;Human;Binding;Ki;=;7,10;8,15;-1;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;520,3;13;1;8;3,63;CCCc1c(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)nnn1Cc1ccc(OC)cc1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL218351;83205;None;0;Human;Binding;Ki;=;42,66;7,37;-1;4;Binding affinity to dopamine D2;ChEMBL;520,3;13;1;8;3,63;CCCc1c(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)nnn1Cc1ccc(OC)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218368;83209;None;0;Human;Binding;Ki;=;199,53;6,70;-524;3;Binding affinity to dopamine D2;ChEMBL;447,2;8;1;5;4,22;C#Cc1ccc2cc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)sc2c1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218444;83222;None;0;Human;Binding;Ki;=;109,65;6,96;-446;3;Binding affinity to dopamine D2;ChEMBL;484,1;8;2;4;4,27;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(Br)ccc3[nH]2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218607;83258;None;0;Human;Binding;Ki;=;57,54;7,24;-1;4;Binding affinity to dopamine D2;ChEMBL;490,3;12;1;7;3,62;CCCc1c(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)nnn1Cc1ccccc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218607;83258;None;0;Human;Binding;Ki;=;6,40;8,19;-1;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;490,3;12;1;7;3,62;CCCc1c(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)nnn1Cc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL218638;83262;None;0;Human;Binding;Ki;=;158,49;6,80;-630;3;Binding affinity to dopamine D2;ChEMBL;431,2;8;2;5;3,38;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccc(C#N)cc3[nH]2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL218787;83298;None;0;Human;Binding;Ki;=;7585,78;5,12;-1513;3;Binding affinity to dopamine D2;ChEMBL;452;3;0;4;3,91;Clc1ccc(N2CCN(Cc3cnn4c(I)cccc34)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL219274;83384;None;0;Human;Binding;Ki;=;467,74;6,33;-275;3;Binding affinity to dopamine D2;ChEMBL;405,1;7;1;3;4,33;O=C(NCCCCN1CCN(c2ccccc2Cl)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL21967;83456;None;0;Human;Binding;Ki;=;0,79;9,10;-2;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;412,2;9;1;4;4,51;CCN(Cc1ccccc1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL21967;83456;None;0;Human;Binding;Ki;=;0,79;9,10;-2;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;412,2;9;1;4;4,51;CCN(Cc1ccccc1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL220189;83520;None;2;Human;Binding;Ki;=;235,00;6,63;-;1;Displacement of [125I]7-OH-PIPAT from human D2L receptor expressed in HEK293 cell membrane;ChEMBL;308,2;4;1;2;3,56;Cc1cccc(C(=O)NCN2CCC(c3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm060662k
CHEMBL22022;83526;None;0;Human;Binding;Ki;=;79,43;7,10;-3;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;390,2;6;1;4;4,42;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(C(C)N3CCCCCC3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL2204343;83626;None;0;Human;Binding;Ki;=;0,55;9,26;8;5;Inhibition of human dopamine D2 receptor;ChEMBL;391,1;6;1;3;3,60;O=C(CCCN1CC[Si](O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm1013693
CHEMBL2205831;83837;None;0;Human;Binding;Ki;=;2830,00;5,55;-;1;Inhibition of dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;271,2;2;1;2;2,33;OC12C3C4CC5C6C4C1C6C(C53)N2CC1CCCCC1;https://dx.doi.org/10.1016/j.bmc.2013.07.045
CHEMBL2205831;83837;None;0;Human;Binding;Ki;=;2830,00;5,55;-;1;Binding affinity to D2 dopamine receptor;ChEMBL;271,2;2;1;2;2,33;OC12C3C4CC5C6C4C1C6C(C53)N2CC1CCCCC1;https://dx.doi.org/10.1016/j.bmcl.2012.08.046
CHEMBL220700;84004;None;0;Human;Binding;Ki;=;141,25;6,85;-245;3;Binding affinity to dopamine D2;ChEMBL;431,2;8;2;5;3,38;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(C#N)ccc3[nH]2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL2207484;84073;None;2;Human;Binding;Ki;=;43,00;7,37;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;260,2;3;1;1;3,90;CCCN1CCC(c2c[nH]c3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207484;84073;None;2;Human;Binding;Ki;=;27,00;7,57;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;260,2;3;1;1;3,90;CCCN1CCC(c2c[nH]c3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207485;84074;None;0;Human;Binding;Ki;=;275,00;6,56;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;274,2;3;0;2;3,91;CCCN1CCC(c2cn(C)c3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207485;84074;None;0;Human;Binding;Ki;=;157,00;6,80;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;274,2;3;0;2;3,91;CCCN1CCC(c2cn(C)c3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207486;84075;None;0;Human;Binding;Ki;=;32,00;7,50;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;274,2;3;0;2;3,91;CCCN1CCC(c2cn(C)c3ccc(F)cc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207486;84075;None;0;Human;Binding;Ki;=;19,00;7,72;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;274,2;3;0;2;3,91;CCCN1CCC(c2cn(C)c3ccc(F)cc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207487;84076;None;0;Human;Binding;Ki;=;26,00;7,58;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;259,1;3;0;2;4,49;CCCN1CCC(c2csc3ccccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207487;84076;None;0;Human;Binding;Ki;=;121,00;6,92;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;259,1;3;0;2;4,49;CCCN1CCC(c2csc3ccccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207488;84077;None;0;Human;Binding;Ki;=;803,00;6,09;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;243,2;3;0;2;4,02;CCCN1CCC(c2coc3ccccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207488;84077;None;0;Human;Binding;Ki;=;2717,00;5,57;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;243,2;3;0;2;4,02;CCCN1CCC(c2coc3ccccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207489;84078;None;5;Human;Binding;Ki;=;34,00;7,47;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;262,1;3;0;3;3,56;CCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207489;84078;None;5;Human;Binding;Ki;=;194,00;6,71;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;262,1;3;0;3;3,56;CCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207490;84079;None;0;Human;Binding;Ki;=;187,00;6,73;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;243,2;3;1;2;3,15;CCCN1CCC(c2n[nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207490;84079;None;0;Human;Binding;Ki;=;1066,00;5,97;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;243,2;3;1;2;3,15;CCCN1CCC(c2n[nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207491;84080;None;0;Human;Binding;Ki;=;1136,00;5,95;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;242,2;3;0;2;3,69;CCCN1CCC(n2ccc3ccccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207491;84080;None;0;Human;Binding;Ki;=;109,00;6,96;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;242,2;3;0;2;3,69;CCCN1CCC(n2ccc3ccccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207492;84081;None;0;Human;Binding;Ki;=;10820,00;4,97;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;243,2;3;0;3;3,08;CCCN1CCC(n2cnc3ccccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207493;84082;None;0;Human;Binding;Ki;=;456,00;6,34;6;5;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;293,1;3;1;3;3,03;CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207493;84082;None;0;Human;Binding;Ki;=;371,00;6,43;6;5;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;293,1;3;1;3;3,03;CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207494;84083;None;0;Human;Binding;Ki;=;5182,00;5,29;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;307,1;3;0;4;3,04;CCCN1CCC(n2c(=O)n(C)c3cc(Cl)ccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207494;84083;None;0;Human;Binding;Ki;=;2002,00;5,70;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;307,1;3;0;4;3,04;CCCN1CCC(n2c(=O)n(C)c3cc(Cl)ccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207495;84084;None;0;Human;Binding;Ki;=;12830,00;4,89;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;272,2;3;0;3;2,09;CCCN1CCC(N2C(=O)C(=O)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207495;84084;None;0;Human;Binding;Ki;=;12160,00;4,92;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;272,2;3;0;3;2,09;CCCN1CCC(N2C(=O)C(=O)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207496;84085;None;0;Human;Binding;Ki;=;41,00;7,39;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;253,2;3;0;1;4,43;CCCN1CCC(c2cccc3ccccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207496;84085;None;0;Human;Binding;Ki;=;112,00;6,95;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;253,2;3;0;1;4,43;CCCN1CCC(c2cccc3ccccc23)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207497;84086;None;0;Human;Binding;Ki;=;2870,00;5,54;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;253,2;3;0;1;4,43;CCCN1CCC(c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207497;84086;None;0;Human;Binding;Ki;=;1535,00;5,81;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;253,2;3;0;1;4,43;CCCN1CCC(c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207498;84087;None;0;Human;Binding;Ki;=;574,00;6,24;-;1;Displacement of [3H]7-OH-DPAT from human high affinity Dopamine D2S receptor by competition binding assay;ChEMBL;259,1;3;0;2;4,49;CCCN1CCC(c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL2207498;84087;None;0;Human;Binding;Ki;=;2325,00;5,63;-;1;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;259,1;3;0;2;4,49;CCCN1CCC(c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm300975f
CHEMBL220754;84102;None;0;Human;Binding;Ki;=;2,70;8,57;12;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;506,3;12;1;8;3,37;COc1ccc(Cn2nnc(C(=O)NCCCCCN3CCN(c4ccccc4OC)CC3)c2C)cc1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL220754;84102;None;0;Human;Binding;Ki;=;16,98;7,77;12;4;Binding affinity to dopamine D2;ChEMBL;506,3;12;1;8;3,37;COc1ccc(Cn2nnc(C(=O)NCCCCCN3CCN(c4ccccc4OC)CC3)c2C)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL2207632;84104;None;0;Human;Binding;Ki;=;95,00;7,02;-8;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;356,2;4;0;3;4,10;C#Cc1cc(CN2CCN(c3ccccc3OC)CC2)c2cccccc1-2;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207632;84104;None;0;Human;Binding;Ki;=;76,00;7,12;-8;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;356,2;4;0;3;4,10;C#Cc1cc(CN2CCN(c3ccccc3OC)CC2)c2cccccc1-2;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207633;84105;None;0;Human;Binding;Ki;=;65,00;7,19;-4;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;432,2;4;0;3;5,52;COc1ccccc1N1CCN(Cc2cc(C#Cc3ccccc3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207633;84105;None;0;Human;Binding;Ki;=;67,00;7,17;-4;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;432,2;4;0;3;5,52;COc1ccccc1N1CCN(Cc2cc(C#Cc3ccccc3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207634;84106;None;0;Human;Binding;Ki;=;60,00;7,22;-3;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;398,2;5;0;3;5,27;CCCC#Cc1cc(CN2CCN(c3ccccc3OC)CC2)c2cccccc1-2;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207634;84106;None;0;Human;Binding;Ki;=;76,00;7,12;-3;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;398,2;5;0;3;5,27;CCCC#Cc1cc(CN2CCN(c3ccccc3OC)CC2)c2cccccc1-2;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207635;84107;None;0;Human;Binding;Ki;=;150,00;6,82;-141;6;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;362,2;5;1;4;3,61;COc1ccccc1N1CCN(Cc2cc(CO)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207635;84107;None;0;Human;Binding;Ki;=;68,00;7,17;-141;6;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;362,2;5;1;4;3,61;COc1ccccc1N1CCN(Cc2cc(CO)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207636;84108;None;0;Human;Binding;Ki;=;39,00;7,41;-7;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;357,2;4;0;4;3,99;COc1ccccc1N1CCN(Cc2cc(C#N)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207636;84108;None;0;Human;Binding;Ki;=;8,30;8,08;-7;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;357,2;4;0;4;3,99;COc1ccccc1N1CCN(Cc2cc(C#N)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207637;84109;None;0;Human;Binding;Ki;=;210,00;6,68;-114;7;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;389,2;6;0;4;4,18;COc1ccccc1N1CCN(Cc2cc(CN(C)C)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207637;84109;None;0;Human;Binding;Ki;=;140,00;6,85;-114;7;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;389,2;6;0;4;4,18;COc1ccccc1N1CCN(Cc2cc(CN(C)C)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207638;84110;None;0;Human;Binding;Ki;=;51,00;7,29;-22;7;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;429,3;6;0;4;5,11;COc1ccccc1N1CCN(Cc2cc(CN3CCCCC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207638;84110;None;0;Human;Binding;Ki;=;37,00;7,43;-22;7;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;429,3;6;0;4;5,11;COc1ccccc1N1CCN(Cc2cc(CN3CCCCC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207639;84111;None;0;Human;Binding;Ki;=;92,00;7,04;-23;7;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;431,3;6;0;5;3,95;COc1ccccc1N1CCN(Cc2cc(CN3CCOCC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207639;84111;None;0;Human;Binding;Ki;=;130,00;6,89;-23;7;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;431,3;6;0;5;3,95;COc1ccccc1N1CCN(Cc2cc(CN3CCOCC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207640;84112;None;0;Human;Binding;Ki;=;60,00;7,22;-15;7;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;444,3;6;0;5;3,87;COc1ccccc1N1CCN(Cc2cc(CN3CCN(C)CC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207640;84112;None;0;Human;Binding;Ki;=;57,00;7,24;-15;7;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;444,3;6;0;5;3,87;COc1ccccc1N1CCN(Cc2cc(CN3CCN(C)CC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207641;84113;None;0;Human;Binding;Ki;=;34,00;7,47;-30;7;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;536,3;8;0;6;5,45;COc1ccccc1N1CCN(Cc2cc(CN3CCN(c4ccccc4OC)CC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207641;84113;None;0;Human;Binding;Ki;=;17,00;7,77;-30;7;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;536,3;8;0;6;5,45;COc1ccccc1N1CCN(Cc2cc(CN3CCN(c4ccccc4OC)CC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207642;84114;None;0;Human;Binding;Ki;=;95,00;7,02;-20;7;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;540,3;7;0;5;6,10;COc1ccccc1N1CCN(Cc2cc(CN3CCN(c4ccc(Cl)cc4)CC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207642;84114;None;0;Human;Binding;Ki;=;160,00;6,80;-20;7;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;540,3;7;0;5;6,10;COc1ccccc1N1CCN(Cc2cc(CN3CCN(c4ccc(Cl)cc4)CC3)c3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207643;84115;None;12;Human;Binding;Ki;=;24,00;7,62;-70;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;332,2;4;0;3;4,12;COc1ccccc1N1CCN(Cc2ccc3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207643;84115;None;12;Human;Binding;Ki;=;33,00;7,48;-70;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells after 60 mins by scintillation counting analysis;ChEMBL;332,2;4;0;3;4,12;COc1ccccc1N1CCN(Cc2ccc3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.09.064
CHEMBL2207643;84115;None;12;Human;Binding;Ki;=;33,00;7,48;-70;5;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells assessed as inhibition constant;ChEMBL;332,2;4;0;3;4,12;COc1ccccc1N1CCN(Cc2ccc3cccccc2-3)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL221129;84283;None;0;Human;Binding;Ki;=;5,25;8,28;3;4;Binding affinity to dopamine D2;ChEMBL;582,2;13;1;7;4,77;CCCc1c(C(=O)NCCCCCN2CCN(c3ccccc3OC)CC2)nnn1Cc1ccccc1Br;https://dx.doi.org/10.1021/jm0611152
CHEMBL221129;84283;None;0;Human;Binding;Ki;=;0,91;9,04;3;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;582,2;13;1;7;4,77;CCCc1c(C(=O)NCCCCCN2CCN(c3ccccc3OC)CC2)nnn1Cc1ccccc1Br;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL221397;84321;None;0;Human;Binding;Ki;=;407,38;6,39;-1047;3;Binding affinity to dopamine D2;ChEMBL;447,2;8;1;5;4,22;C#Cc1ccc2sc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)cc2c1;https://dx.doi.org/10.1021/jm0611152
CHEMBL221513;84344;None;0;Human;Binding;Ki;=;265,00;6,58;-15;3;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;430,3;8;1;4;4,43;N#Cc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL221513;84344;UNDEFINED;0;Human;Binding;pKi;=;265,00;6,58;-15;3;-;PDSP KiDatabase;430,3;8;1;4;4,43;N#Cc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL221549;84348;None;0;Human;Binding;Ki;=;281,84;6,55;-91;3;Binding affinity to dopamine D2;ChEMBL;431,2;9;1;5;3,69;COc1ccc(C(=O)NCCCCN2CCN(c3ccccc3Cl)CC2)cc1OC;https://dx.doi.org/10.1021/jm0611152
CHEMBL22156;84349;None;0;Human;Binding;Ki;=;39,81;7,40;-31;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;452,2;7;1;4;5,60;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL22156;84349;None;0;Human;Binding;Ki;=;39,81;7,40;-31;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;452,2;7;1;4;5,60;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL22156;84349;None;0;Human;Binding;Ki;=;39,81;7,40;-31;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;452,2;7;1;4;5,60;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL221587;84355;None;0;Human;Binding;Ki;=;2,50;8,60;3;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;476,3;11;1;7;3,37;COc1ccccc1N1CCN(CCCCCNC(=O)c2nnn(Cc3ccccc3)c2C)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL221587;84355;None;0;Human;Binding;Ki;=;9,33;8,03;3;4;Binding affinity to dopamine D2;ChEMBL;476,3;11;1;7;3,37;COc1ccccc1N1CCN(CCCCCNC(=O)c2nnn(Cc3ccccc3)c2C)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL221600;84357;None;0;Human;Binding;Ki;=;38,02;7,42;-64;3;Binding affinity to dopamine D2;ChEMBL;317,2;4;0;3;4,25;c1ccc(C2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL221681;84374;None;0;Human;Binding;Ki;=;95,50;7,02;-138;3;Binding affinity to dopamine D2;ChEMBL;485,1;8;1;5;4,54;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(Br)ccc3o2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL221814;84396;None;0;Human;Binding;Ki;=;218,78;6,66;-67;3;Binding affinity to dopamine D2;ChEMBL;318,2;4;0;4;3,65;c1ccc(C2CCN(Cc3cn(-c4ccccc4)nn3)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL221843;84399;None;0;Human;Binding;Ki;=;229,09;6,64;-1;4;Binding affinity to dopamine D2;ChEMBL;462,3;10;1;7;2,98;COc1ccccc1N1CCN(CCCCNC(=O)c2nnn(Cc3ccccc3)c2C)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL221843;84399;None;0;Human;Binding;Ki;=;35,00;7,46;-1;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;462,3;10;1;7;2,98;COc1ccccc1N1CCN(CCCCNC(=O)c2nnn(Cc3ccccc3)c2C)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL221866;84401;None;0;Human;Binding;Ki;=;9,12;8,04;-1;4;Binding affinity to dopamine D2;ChEMBL;544,2;11;1;7;4,67;COc1ccc(Cn2nnc(C(=O)NCCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c2C)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL221866;84401;None;0;Human;Binding;Ki;=;1,50;8,82;-1;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;544,2;11;1;7;4,67;COc1ccc(Cn2nnc(C(=O)NCCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c2C)cc1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL221897;84407;None;0;Human;Binding;Ki;=;10,00;8,00;-1;3;Binding affinity to dopamine D2;ChEMBL;514,2;10;1;6;4,66;Cc1c(C(=O)NCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nnn1Cc1ccccc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL2219577;84422;None;0;Human;Binding;Ki;=;630,96;6,20;-31;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;535,3;7;1;6;4,66;Cc1cc(C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(OS(C)(=O)=O)cc4CC3)CC2)c2ccccc2n1;https://dx.doi.org/10.1021/jm030817d
CHEMBL2219579;84423;None;0;Human;Binding;Ki;=;158,49;6,80;-125;4;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;413,2;6;1;3;4,70;N#Cc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccccc3)CC1)CC2;https://dx.doi.org/10.1021/jm000090i
CHEMBL2219582;84424;None;0;Human;Binding;Ki;=;31,62;7,50;-31;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;526,3;9;1;6;4,21;COc1ccc(/C=C/C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(OS(C)(=O)=O)cc4CC3)CC2)cc1;https://dx.doi.org/10.1021/jm030817d
CHEMBL2219583;84425;None;0;Human;Binding;Ki;=;794,33;6,10;-251;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;537,2;6;1;5;4,87;Cc1ccc2c(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(S(C)(=O)=O)cc5CC4)CC3)ccc(F)c2n1;https://dx.doi.org/10.1021/jm030817d
CHEMBL2219585;84427;None;0;Human;Binding;Ki;=;398,11;6,40;-50;2;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;437,2;5;1;3;5,45;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cccc4ccccc34)CC1)C2;https://dx.doi.org/10.1021/jm000090i
CHEMBL2219586;84428;None;1;Human;Binding;Ki;=;316,23;6,50;-63;4;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;491,2;7;1;5;4,10;CS(=O)(=O)c1cccc(/C=C/C(=O)N[C@H]2CC[C@H](CCN3CCc4cc(C#N)ccc4C3)CC2)c1;https://dx.doi.org/10.1021/jm000090i
CHEMBL2219587;84429;None;0;Human;Binding;Ki;=;1584,89;5,80;-158;3;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;437,2;5;1;3;5,45;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccc4ccccc4c3)CC1)C2;https://dx.doi.org/10.1021/jm000090i
CHEMBL2219589;84430;None;0;Human;Binding;Ki;=;63,10;7,20;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;514,2;8;1;5;4,34;CS(=O)(=O)Oc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccc(F)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL2219590;84431;None;0;Human;Binding;Ki;=;794,33;6,10;-50;2;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;426,2;5;2;3;4,78;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cc4ccccc4[nH]3)CC1)C2;https://dx.doi.org/10.1021/jm000090i
CHEMBL2219593;84432;None;0;Human;Binding;Ki;=;630,96;6,20;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;535,3;7;1;6;4,83;Cc1cnc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(S(C)(=O)=O)cc5CC4)CC3)c2)o1;https://dx.doi.org/10.1021/jm030817d
CHEMBL2219727;84441;None;0;Human;Binding;Ki;=;125,89;6,90;-39;2;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;452,3;6;2;3;5,18;N#Cc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3c[nH]c4ccccc34)CC1)CC2;https://dx.doi.org/10.1021/jm000090i
CHEMBL2221040;84626;None;0;Human;Binding;Ki;=;490,00;6,31;-9;3;Displacement of [3H]-N-methylspiperone from human dopamine D2long receptor expressed in HEK293 cells after 30 mins by scintillation counting;ChEMBL;311,2;1;4;4;2,98;Oc1ccc([C@H]2CN[C@@H]3CCc4cc(O)c(O)cc4[C@H]3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2012.08.058
CHEMBL2221044;84627;None;0;Human;Binding;Ki;=;160,00;6,80;-144;3;Displacement of [3H]-N-methylspiperone from human dopamine D2long receptor expressed in HEK293 cells after 30 mins by scintillation counting;ChEMBL;353,2;3;3;4;4,10;CCCN1C[C@H](c2ccc(O)cc2)C[C@@H]2c3cc(O)c(O)cc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmc.2012.08.058
CHEMBL222188;84659;None;0;Human;Binding;Ki;=;1000,00;6,00;-15;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;405,3;8;1;3;4,56;O=C(CCCCCN1CCN(c2ccccc2)CC1)NC1CCCc2ccccc21;https://dx.doi.org/10.1021/jm070487n
CHEMBL222188;84659;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;-15;4;-;PDSP KiDatabase;405,3;8;1;3;4,56;O=C(CCCCCN1CCN(c2ccccc2)CC1)NC1CCCc2ccccc21;-
CHEMBL222477;84702;None;0;Human;Binding;Ki;=;51,00;7,29;-1;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;439,2;8;1;3;5,22;O=C(CCCCCN1CCN(c2ccccc2Cl)CC1)NC1CCCc2ccccc21;https://dx.doi.org/10.1021/jm070487n
CHEMBL222477;84702;UNDEFINED;0;Human;Binding;pKi;=;51,00;7,29;-1;4;-;PDSP KiDatabase;439,2;8;1;3;5,22;O=C(CCCCCN1CCN(c2ccccc2Cl)CC1)NC1CCCc2ccccc21;-
CHEMBL222489;84706;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;-4;3;-;PDSP KiDatabase;448,3;9;2;4;3,66;NC(=O)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL222755;84747;None;0;Human;Binding;Ki;=;143,00;6,84;-9;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;419,3;8;1;3;4,87;Cc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL222755;84747;UNDEFINED;0;Human;Binding;pKi;=;143,00;6,84;-9;4;-;PDSP KiDatabase;419,3;8;1;3;4,87;Cc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL224820;85156;None;0;Human;Binding;Ki;=;26,40;7,58;-3;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;435,3;9;1;4;4,57;COc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL224820;85156;UNDEFINED;0;Human;Binding;pKi;=;26,40;7,58;-3;4;-;PDSP KiDatabase;435,3;9;1;4;4,57;COc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL225368;85217;None;0;Human;Binding;Kd;=;2000,00;5,70;-19;2;Displacement of [3H]YM 09151-2 from dopamine D2 receptor in lamb striatum membrane after 2 hrs;ChEMBL;703,3;10;4;7;3,26;CC(C)[C@H](NC(=O)[C@H](Cc1ccc([N+](=O)[O-])cc1)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1)C(=O)N1c2ccccc2C[C@H]1C(N)=O;https://dx.doi.org/10.1021/jm060947x
CHEMBL225512;85244;None;0;Human;Binding;Ki;=;987,00;6,01;-85;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;421,3;8;2;4;4,27;O=C(CCCCCN1CCN(c2ccccc2O)CC1)NC1CCCc2ccccc21;https://dx.doi.org/10.1021/jm070487n
CHEMBL225512;85244;UNDEFINED;0;Human;Binding;pKi;=;987,00;6,01;-85;4;-;PDSP KiDatabase;421,3;8;2;4;4,27;O=C(CCCCCN1CCN(c2ccccc2O)CC1)NC1CCCc2ccccc21;-
CHEMBL225571;85250;None;0;Human;Binding;Ki;=;681,00;6,17;-10;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;450,3;9;1;5;4,47;O=C(CCCCCN1CCN(c2ccccc2[N+](=O)[O-])CC1)NC1CCCc2ccccc21;https://dx.doi.org/10.1021/jm070487n
CHEMBL225571;85250;UNDEFINED;0;Human;Binding;pKi;=;681,00;6,17;-10;4;-;PDSP KiDatabase;450,3;9;1;5;4,47;O=C(CCCCCN1CCN(c2ccccc2[N+](=O)[O-])CC1)NC1CCCc2ccccc21;-
CHEMBL228278;85653;None;0;Human;Binding;Ki;=;133,00;6,88;-12;4;Binding affinity for dopamine D2 receptor;ChEMBL;514,3;9;1;6;4,71;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OC4CC4)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228278;85653;None;0;Human;Binding;Ki;=;133,00;6,88;-12;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;514,3;9;1;6;4,71;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OC4CC4)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL228279;85654;None;0;Human;Binding;Ki;=;154,00;6,81;-34;4;Binding affinity for dopamine D2 receptor;ChEMBL;518,2;8;1;5;5,36;COc1ccc(Cl)cc1S(=O)(=O)N[C@H]1CC[C@H](N2CCC(c3ccccc3OC3CC3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228280;85655;None;0;Human;Binding;Ki;=;187,00;6,73;-102;4;Binding affinity for dopamine D2 receptor;ChEMBL;506,2;7;1;4;5,49;O=S(=O)(N[C@H]1CC[C@@H](N2CCC(c3ccccc3OC3CC3)CC2)CC1)c1cc(Cl)ccc1F;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228332;85660;None;0;Human;Binding;Ki;=;159,00;6,80;-41;4;Binding affinity for dopamine D2 receptor;ChEMBL;506,2;7;1;4;5,49;O=S(=O)(N[C@H]1CC[C@H](N2CCC(c3ccccc3OC3CC3)CC2)CC1)c1cc(Cl)ccc1F;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228333;85661;None;0;Human;Binding;Ki;=;71,00;7,15;-5;4;Binding affinity for dopamine D2 receptor;ChEMBL;498,2;7;1;6;4,43;O=S(=O)(N[C@H]1CC[C@H](N2CCC(c3ccccc3OC3CC3)CC2)CC1)c1ccc2c(c1)OCO2;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228334;85662;None;0;Human;Binding;Ki;=;112,00;6,95;-60;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;556,2;9;1;6;5,11;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OCC(F)(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL228334;85662;None;0;Human;Binding;Ki;=;111,00;6,96;-60;4;Binding affinity for dopamine D2 receptor;ChEMBL;556,2;9;1;6;5,11;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OCC(F)(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228389;85673;None;0;Human;Binding;Ki;=;83,00;7,08;-3;4;Binding affinity for dopamine D2 receptor;ChEMBL;556,2;9;1;6;5,11;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OCC(F)(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228389;85673;None;0;Human;Binding;Ki;=;83,00;7,08;-3;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;556,2;9;1;6;5,11;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OCC(F)(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL228390;85674;None;0;Human;Binding;Ki;=;23,00;7,64;-10;4;Binding affinity for dopamine D2 receptor;ChEMBL;554,2;7;1;6;4,87;O=S(=O)(N[C@H]1CC[C@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1)c1ccc2c(c1)OCCO2;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228445;85684;None;0;Human;Binding;Ki;=;78,00;7,11;-79;4;Binding affinity for dopamine D2 receptor;ChEMBL;548,2;7;1;4;5,89;O=S(=O)(N[C@H]1CC[C@@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1)c1cc(Cl)ccc1F;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228494;85692;None;0;Human;Binding;Ki;=;37,00;7,43;-7;4;Binding affinity for dopamine D2 receptor;ChEMBL;548,2;7;1;4;5,89;O=S(=O)(N[C@H]1CC[C@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1)c1cc(Cl)ccc1F;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228496;85693;None;0;Human;Binding;Ki;=;85,00;7,07;-14;4;Binding affinity for dopamine D2 receptor;ChEMBL;562,2;9;1;5;5,70;O=S(=O)(N[C@H]1CC[C@@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1)c1cccc(OC(F)F)c1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228553;85702;None;0;Human;Binding;Ki;=;129,00;6,89;-10;4;Binding affinity for dopamine D2 receptor;ChEMBL;562,2;9;1;5;5,70;O=S(=O)(N[C@H]1CC[C@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1)c1cccc(OC(F)F)c1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228554;85703;None;0;Human;Binding;Ki;=;104,00;6,98;-2;4;Binding affinity for dopamine D2 receptor;ChEMBL;562,2;9;1;5;5,70;O=S(=O)(N[C@H]1CC[C@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1)c1ccc(OC(F)F)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228606;85710;None;0;Human;Binding;Ki;=;284,00;6,55;-5;4;Binding affinity for dopamine D2 receptor;ChEMBL;520,2;10;1;6;4,52;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OCCF)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228606;85710;None;0;Human;Binding;Ki;=;284,00;6,55;-5;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;520,2;10;1;6;4,52;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OCCF)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL228607;85711;None;0;Human;Binding;Ki;=;88,00;7,06;-2;4;Binding affinity for dopamine D2 receptor;ChEMBL;538,2;10;1;6;4,82;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OCC(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228607;85711;None;0;Human;Binding;Ki;=;88,00;7,06;-2;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;538,2;10;1;6;4,82;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OCC(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL228608;85712;None;0;Human;Binding;Ki;=;106,00;6,97;-8;4;Binding affinity for dopamine D2 receptor;ChEMBL;534,3;9;1;6;5,10;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccc(F)cc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228658;85717;None;0;Human;Binding;Ki;=;104,00;6,98;-4;4;Binding affinity for dopamine D2 receptor;ChEMBL;534,3;9;1;6;5,10;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccc(F)cc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL228659;85718;None;0;Human;Binding;Ki;=;178,00;6,75;-112;4;Binding affinity for dopamine D2 receptor;ChEMBL;534,3;9;1;6;5,10;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4cc(F)ccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL22892;85756;None;0;Human;Binding;Ki;=;556,00;6,25;-181;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;287,2;9;2;4;2,83;Oc1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL22892;85756;None;0;Human;Binding;Ki;=;562,34;6,25;-181;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;287,2;9;2;4;2,83;Oc1ccc(OCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL229084;85782;None;1;Human;Binding;Ki;=;79,00;7,10;-56;4;Binding affinity for dopamine D2 receptor;ChEMBL;492,2;7;1;4;5,22;CC(C)Oc1ccccc1C1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccc(F)c(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL229085;85783;None;0;Human;Binding;Ki;=;144,00;6,84;-158;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;514,3;9;1;6;4,71;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OC4CC4)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL229085;85783;None;0;Human;Binding;Ki;=;144,00;6,84;-158;4;Binding affinity for dopamine D2 receptor;ChEMBL;514,3;9;1;6;4,71;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OC4CC4)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL2298799;85913;None;0;Human;Binding;Ki;=;51,30;7,29;-9;3;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;356,1;6;0;6;2,87;O=[N+]([O-])c1ccc(CCN2CCN(c3ccccc3)CC2)cc1[N+](=O)[O-];https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298801;85915;None;0;Human;Binding;Ki;=;45,50;7,34;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;372,1;5;2;4;2,71;O=c1[nH]c2ccc(OCCN3CCN(c4cccc(Cl)c4)CC3)cc2[nH]1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298805;85916;None;0;Human;Binding;Ki;=;1,51;8,82;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;353,2;6;1;6;2,17;COc1ccccc1N1CCN(CCOc2ccc3nn[nH]c3c2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298806;85917;None;0;Human;Binding;Ki;=;1,66;8,78;9;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;356,2;4;1;3;4,08;c1ccc2c(N3CCN(CCc4ccc5[nH]cnc5c4)CC3)cccc2c1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298807;85918;None;0;Human;Binding;Ki;=;28,18;7,55;3;3;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;418,2;4;2;4;2,60;O=c1[nH]c2ccc(CCN3CCN(c4cccc(C(F)(F)F)c4)CC3)cc2[nH]c1=O;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298813;85924;None;2;Human;Binding;Ki;=;129,00;6,89;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;320,2;5;1;3;3,32;c1ccc(N2CCN(CCCc3ccc4nc[nH]c4c3)CC2)cc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298817;85925;None;0;Human;Binding;Ki;=;97,00;7,01;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;350,2;6;1;4;3,33;COc1ccccc1N1CCN(CCCc2ccc3nc[nH]c3c2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298818;85926;None;0;Human;Binding;Ki;=;3,00;8,52;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;352,2;5;2;3;3,98;S=c1[nH]c2ccc(CCCN3CCN(c4ccccc4)CC3)cc2[nH]1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298819;85927;None;0;Human;Binding;Ki;=;5,80;8,24;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;420,2;5;2;3;5,00;FC(F)(F)c1cccc(N2CCN(CCCc3ccc4[nH]c(=S)[nH]c4c3)CC2)c1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298820;85928;None;0;Human;Binding;Ki;=;20,00;7,70;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;386,1;5;2;3;4,63;S=c1[nH]c2ccc(CCCN3CCN(c4ccc(Cl)cc4)CC3)cc2[nH]1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298821;85929;None;0;Human;Binding;Ki;=;33,00;7,48;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;382,2;6;2;4;3,99;COc1ccc(N2CCN(CCCc3ccc4[nH]c(=S)[nH]c4c3)CC2)cc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298822;85930;None;0;Human;Binding;Ki;=;0,40;9,40;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;382,2;6;2;4;3,99;COc1ccccc1N1CCN(CCCc2ccc3[nH]c(=S)[nH]c3c2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298824;85931;None;0;Human;Binding;Ki;=;12,60;7,90;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;352,2;6;1;5;2,77;COc1ccccc1N1CCN(CCOc2ccc3nc[nH]c3c2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298827;85932;None;0;Human;Binding;Ki;=;0,67;9,17;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;354,2;5;2;4;3,43;S=c1[nH]c2ccc(OCCN3CCN(c4ccccc4)CC3)cc2[nH]1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298828;85933;None;0;Human;Binding;Ki;=;5,94;8,23;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;422,1;5;2;4;4,45;FC(F)(F)c1cccc(N2CCN(CCOc3ccc4[nH]c(=S)[nH]c4c3)CC2)c1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298829;85934;None;0;Human;Binding;Ki;=;0,19;9,72;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;384,2;6;2;5;3,44;COc1ccccc1N1CCN(CCOc2ccc3[nH]c(=S)[nH]c3c2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298830;85935;None;0;Human;Binding;Ki;=;13,20;7,88;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;384,2;6;2;5;3,44;COc1cccc(N2CCN(CCOc3ccc4[nH]c(=S)[nH]c4c3)CC2)c1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298831;85936;None;0;Human;Binding;Ki;=;105,00;6,98;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;384,2;6;2;5;3,44;COc1ccc(N2CCN(CCOc3ccc4[nH]c(=S)[nH]c4c3)CC2)cc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298832;85937;None;0;Human;Binding;Ki;=;2,75;8,56;162;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;388,1;5;2;4;4,08;S=c1[nH]c2ccc(OCCN3CCN(c4ccccc4Cl)CC3)cc2[nH]1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2298833;85938;None;0;Human;Binding;Ki;=;7,06;8,15;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;388,1;5;2;4;4,08;S=c1[nH]c2ccc(OCCN3CCN(c4cccc(Cl)c4)CC3)cc2[nH]1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2299000;85939;None;0;Human;Binding;Ki;=;7,53;8,12;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;338,2;5;2;4;2,06;O=c1[nH]c2ccc(OCCN3CCN(c4ccccc4)CC3)cc2[nH]1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2299001;85940;None;0;Human;Binding;Ki;=;26,10;7,58;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;406,2;5;2;4;3,08;O=c1[nH]c2ccc(OCCN3CCN(c4cccc(C(F)(F)F)c4)CC3)cc2[nH]1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2299002;85941;None;0;Human;Binding;Ki;=;1,30;8,89;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;368,2;6;2;5;2,07;COc1ccccc1N1CCN(CCOc2ccc3[nH]c(=O)[nH]c3c2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL2299003;85942;None;0;Human;Binding;Ki;=;44,80;7,35;-;1;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;368,2;6;2;5;2,07;COc1cccc(N2CCN(CCOc3ccc4[nH]c(=O)[nH]c4c3)CC2)c1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL230069;85979;None;0;Human;Binding;Ki;=;31,62;7,50;-6;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;440,1;4;1;3;5,15;Cc1cc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)ccc1-c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL230070;85980;None;0;Human;Binding;Ki;=;316,23;6,50;-50;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;412,1;4;1;4;4,55;Cc1ccc(-c2ccc(S(=O)(=O)Nc3ccc4c(c3)CCN(C)CC4)cc2)s1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL230218;85999;None;0;Human;Binding;Ki;=;560,00;6,25;-10;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;508,2;8;0;5;6,60;Cc1cccn2cc(-c3ccc(OCCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)nc12;https://dx.doi.org/10.1021/jm070721+
CHEMBL230218;85999;UNDEFINED;0;Human;Binding;pKi;=;560,00;6,25;-10;2;-;PDSP KiDatabase;508,2;8;0;5;6,60;Cc1cccn2cc(-c3ccc(OCCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)nc12;-
CHEMBL2303762;86017;None;0;Human;Binding;IC50;=;2420,00;5,62;-9;2;Inhibitory concentration against binding of [3H]spiperone to human D2 dopaminergic receptor;ChEMBL;433,2;5;7;9;-0,29;OC[C@H]1O[C@H](Oc2ccc(CC3NCCc4cc(O)c(O)cc43)cc2)[C@H](O)[C@H](O)[C@H]1O;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
CHEMBL2303762;86017;None;0;Human;Binding;Ki;=;11400,00;4,94;-9;2;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;433,2;5;7;9;-0,29;OC[C@H]1O[C@H](Oc2ccc(CC3NCCc4cc(O)c(O)cc43)cc2)[C@H](O)[C@H](O)[C@H]1O;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
CHEMBL2308105;86092;None;0;Human;Binding;Ki;=;81,30;7,09;-5;4;Binding affinity at human dopamine receptor D2;ChEMBL;461,3;9;0;2;7,09;Fc1ccc(C(O[C@@H]2C[C@@H]3CC[C@H](C2)N3CCCCc2ccccc2)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/jm010146o
CHEMBL230872;86104;None;0;Human;Binding;Ki;=;49,00;7,31;-30;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;442,2;8;0;6;4,60;COc1ccccc1N1CCN(CCCOc2ccc(-c3cn4ccccc4n3)cc2)CC1;https://dx.doi.org/10.1021/jm070721+
CHEMBL230872;86104;UNDEFINED;0;Human;Binding;pKi;=;49,00;7,31;-30;2;-;PDSP KiDatabase;442,2;8;0;6;4,60;COc1ccccc1N1CCN(CCCOc2ccc(-c3cn4ccccc4n3)cc2)CC1;-
CHEMBL230930;86114;None;0;Human;Binding;Ki;=;100,00;7,00;-10;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;411,2;4;1;5;3,79;Cc1noc(C)c1-c1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL230971;86127;None;0;Human;Binding;Ki;=;44,00;7,36;3;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;480,1;7;0;5;5,90;Clc1cccc(N2CCN(CCCOc3ccc(-c4cn5ccccc5n4)cc3)CC2)c1Cl;https://dx.doi.org/10.1021/jm070721+
CHEMBL230971;86127;UNDEFINED;0;Human;Binding;pKi;=;44,00;7,36;3;2;-;PDSP KiDatabase;480,1;7;0;5;5,90;Clc1cccc(N2CCN(CCCOc3ccc(-c4cn5ccccc5n4)cc3)CC2)c1Cl;-
CHEMBL230972;86128;None;0;Human;Binding;Ki;=;78,00;7,11;2;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;456,3;8;0;6;4,91;COc1ccccc1N1CCN(CCCOc2ccc(-c3cn4cc(C)ccc4n3)cc2)CC1;https://dx.doi.org/10.1021/jm070721+
CHEMBL230972;86128;UNDEFINED;0;Human;Binding;pKi;=;78,00;7,11;2;2;-;PDSP KiDatabase;456,3;8;0;6;4,91;COc1ccccc1N1CCN(CCCOc2ccc(-c3cn4cc(C)ccc4n3)cc2)CC1;-
CHEMBL231055;86140;None;0;Human;Binding;Ki;=;68,40;7,17;-52;2;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;471,3;8;2;5;3,57;COc1ccccc1N1CCN(CCC(O)CNC(=O)c2ccc3c(c2)Cc2ccccc2-3)CC1;https://dx.doi.org/10.1021/jm0704200
CHEMBL231057;86141;None;0;Human;Binding;Ki;=;159,00;6,80;2;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;470,3;9;0;6;5,30;COc1ccccc1N1CCN(CCCCOc2ccc(-c3cn4cccc(C)c4n3)cc2)CC1;https://dx.doi.org/10.1021/jm070721+
CHEMBL231057;86141;UNDEFINED;0;Human;Binding;pKi;=;159,00;6,80;2;2;-;PDSP KiDatabase;470,3;9;0;6;5,30;COc1ccccc1N1CCN(CCCCOc2ccc(-c3cn4cccc(C)c4n3)cc2)CC1;-
CHEMBL231070;86143;None;0;Human;Binding;Ki;=;74,00;7,13;-26;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;281,2;0;1;2;3,40;CN1CCCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1021/jm070388+
CHEMBL231070;86143;None;0;Human;Binding;Ki;=;41,69;7,38;-26;6;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;281,2;0;1;2;3,40;CN1CCCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL231078;86144;None;0;Human;Binding;Ki;=;78,00;7,11;-1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;456,3;8;0;6;4,91;COc1ccccc1N1CCN(CCCOc2ccc(-c3cn4ccc(C)cc4n3)cc2)CC1;https://dx.doi.org/10.1021/jm070721+
CHEMBL231078;86144;UNDEFINED;0;Human;Binding;pKi;=;78,00;7,11;-1;2;-;PDSP KiDatabase;456,3;8;0;6;4,91;COc1ccccc1N1CCN(CCCOc2ccc(-c3cn4ccc(C)cc4n3)cc2)CC1;-
CHEMBL231079;86145;None;0;Human;Binding;Ki;=;83,00;7,08;-10;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;494,2;7;0;5;6,21;Cc1ccn2cc(-c3ccc(OCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)nc2c1;https://dx.doi.org/10.1021/jm070721+
CHEMBL231079;86145;UNDEFINED;0;Human;Binding;pKi;=;83,00;7,08;-10;2;-;PDSP KiDatabase;494,2;7;0;5;6,21;Cc1ccn2cc(-c3ccc(OCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)nc2c1;-
CHEMBL231080;86146;None;0;Human;Binding;Ki;=;125,00;6,90;1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;494,2;7;0;5;6,21;Cc1cccn2cc(-c3ccc(OCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)nc12;https://dx.doi.org/10.1021/jm070721+
CHEMBL231080;86146;UNDEFINED;0;Human;Binding;pKi;=;125,00;6,90;1;2;-;PDSP KiDatabase;494,2;7;0;5;6,21;Cc1cccn2cc(-c3ccc(OCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)nc12;-
CHEMBL231156;86173;None;0;Human;Binding;Ki;=;53,70;7,27;-53;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;494,2;7;1;4;5,24;O=C(NC[C@H]1C[C@@H]1CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL231158;86175;None;0;Human;Binding;Ki;=;52,00;7,28;-1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;470,3;9;0;6;5,30;COc1ccccc1N1CCN(CCCCOc2ccc(-c3cn4ccc(C)cc4n3)cc2)CC1;https://dx.doi.org/10.1021/jm070721+
CHEMBL231158;86175;UNDEFINED;0;Human;Binding;pKi;=;52,00;7,28;-1;2;-;PDSP KiDatabase;470,3;9;0;6;5,30;COc1ccccc1N1CCN(CCCCOc2ccc(-c3cn4ccc(C)cc4n3)cc2)CC1;-
CHEMBL231171;86178;None;0;Human;Binding;Ki;=;172,00;6,76;-7;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;309,2;1;0;2;4,10;COc1ccc2c(c1)CCCN(C)CCCc1ccccc1C2;https://dx.doi.org/10.1021/jm070388+
CHEMBL231181;86187;None;0;Human;Binding;Ki;=;179,00;6,75;-245;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;456,3;9;0;6;4,99;COc1ccccc1N1CCN(CCCCOc2ccc(-c3cn4ccccc4n3)cc2)CC1;https://dx.doi.org/10.1021/jm070721+
CHEMBL231181;86187;UNDEFINED;0;Human;Binding;pKi;=;179,00;6,75;-245;2;-;PDSP KiDatabase;456,3;9;0;6;4,99;COc1ccccc1N1CCN(CCCCOc2ccc(-c3cn4ccccc4n3)cc2)CC1;-
CHEMBL231182;86188;None;0;Human;Binding;Ki;=;47,00;7,33;3;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;470,3;9;0;6;5,30;COc1ccccc1N1CCN(CCCCOc2ccc(-c3cn4cc(C)ccc4n3)cc2)CC1;https://dx.doi.org/10.1021/jm070721+
CHEMBL231182;86188;UNDEFINED;0;Human;Binding;pKi;=;47,00;7,33;3;2;-;PDSP KiDatabase;470,3;9;0;6;5,30;COc1ccccc1N1CCN(CCCCOc2ccc(-c3cn4cc(C)ccc4n3)cc2)CC1;-
CHEMBL231183;86189;None;0;Human;Binding;Ki;=;149,00;6,83;-18;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;508,2;8;0;5;6,60;Cc1ccc2nc(-c3ccc(OCCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)cn2c1;https://dx.doi.org/10.1021/jm070721+
CHEMBL231183;86189;UNDEFINED;0;Human;Binding;pKi;=;149,00;6,83;-18;2;-;PDSP KiDatabase;508,2;8;0;5;6,60;Cc1ccc2nc(-c3ccc(OCCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)cn2c1;-
CHEMBL231249;86265;None;0;Human;Binding;Ki;=;3,98;8,40;-5;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;456,1;5;1;4;4,85;COc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231260;86296;None;0;Human;Binding;Ki;=;111,00;6,96;-1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;508,2;8;0;5;6,60;Cc1ccn2cc(-c3ccc(OCCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)nc2c1;https://dx.doi.org/10.1021/jm070721+
CHEMBL231260;86296;UNDEFINED;0;Human;Binding;pKi;=;111,00;6,95;-1;2;-;PDSP KiDatabase;508,2;8;0;5;6,60;Cc1ccn2cc(-c3ccc(OCCCCN4CCN(c5cccc(Cl)c5Cl)CC4)cc3)nc2c1;-
CHEMBL2312637;86298;None;0;Human;Binding;Ki;=;11,00;7,96;1;5;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 after 1 hr;ChEMBL;492,1;8;1;5;4,42;O=S(=O)(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2cccnc2c1;https://dx.doi.org/10.1016/j.ejmech.2012.11.042
CHEMBL2312639;86300;None;0;Human;Binding;Ki;=;17,00;7,77;1;5;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 after 1 hr;ChEMBL;492,1;8;1;5;4,42;O=S(=O)(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2cn1;https://dx.doi.org/10.1016/j.ejmech.2012.11.042
CHEMBL2312640;86301;None;0;Human;Binding;Ki;=;8,00;8,10;2;5;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 after 1 hr;ChEMBL;492,1;8;1;5;4,42;O=S(=O)(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cncc2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2012.11.042
CHEMBL2312934;86317;None;0;Human;Binding;Ki;=;16,00;7,80;-1;5;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 after 1 hr;ChEMBL;478,1;7;1;5;4,03;O=S(=O)(NCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2cccnc2c1;https://dx.doi.org/10.1016/j.ejmech.2012.11.042
CHEMBL2312935;86318;None;0;Human;Binding;Ki;=;9,00;8,05;2;5;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 after 1 hr;ChEMBL;492,1;8;1;5;4,42;O=S(=O)(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1016/j.ejmech.2012.11.042
CHEMBL231326;86327;None;6;Human;Binding;Ki;=;794,33;6,10;-19;3;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;330,1;6;2;3;3,43;CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CNC3)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231333;86338;None;0;Human;Binding;Ki;=;398,11;6,40;-15;2;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;358,2;6;1;3;3,82;CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CN(C)CC3)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231334;86339;None;0;Human;Binding;Ki;=;31,62;7,50;-25;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;372,2;6;1;3;3,86;CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCN(C)CC3)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231349;86381;None;0;Human;Binding;Ki;=;6,31;8,20;-7;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;484,2;6;1;4;5,63;CC(C)Oc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231350;86384;None;0;Human;Binding;Ki;=;50,12;7,30;-31;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;483,2;6;2;4;5,66;CC(C)Nc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231374;86402;None;0;Human;Binding;Ki;=;1396,00;5,86;-18;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;295,2;1;0;2;3,71;COc1ccc2c(c1)Cc1ccccc1CCCN(C)CC2;https://dx.doi.org/10.1021/jm070388+
CHEMBL231430;86464;None;0;Human;Binding;Ki;=;158,49;6,80;-31;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;426,1;4;1;3;4,84;CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231431;86473;None;0;Human;Binding;Ki;=;50,12;7,30;-12;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;444,1;4;1;3;4,98;CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(F)c(Cl)c4)cc3)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231546;86562;None;0;Human;Binding;Ki;=;63,10;7,20;-12;4;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;504;4;1;3;5,60;CN1CCc2cc(Br)c(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231640;86701;None;0;Human;Binding;Ki;=;501,19;6,30;-31;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;417,2;4;1;4;4,06;CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(C#N)cc4)cc3)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL231648;86712;None;0;Human;Binding;Ki;=;39,81;7,40;-15;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;460,1;4;1;3;5,49;CN1CCc2cc(Cl)c(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)cc3)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL2323579;87003;None;0;Human;Binding;EC50;=;1,40;8,85;-;3;Partial agonist activity at human D2 receptor transfected in HTLA cells measured after overnight incubation by luminescence counter analysis;ChEMBL;439,3;6;1;5;2,65;CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;https://dx.doi.org/10.1021/ml3003814
CHEMBL232592;87080;None;0;Human;Binding;Ki;=;51,00;7,29;-20;4;Binding affinity to human dopamine D2 receptor;ChEMBL;502,2;8;1;7;3,79;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccccc3[N+](=O)[O-])CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL2325926;87081;None;0;Human;Binding;Ki;=;15,00;7,82;-46;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;388,2;3;0;4;4,98;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4ccnn4C)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2325927;87082;None;0;Human;Binding;Ki;=;880,00;6,06;-45;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;371,2;3;0;5;4,24;CN1CCC(c2cn(-c3ccncc3)c3ccc(-c4ccnn4C)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2325928;87083;None;0;Human;Binding;Ki;=;150,00;6,82;-56;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;388,2;3;0;4;4,98;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4cnn(C)c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2325929;87084;None;0;Human;Binding;Ki;=;6400,00;5,19;-169;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;371,2;3;0;5;4,24;CN1CCC(c2cn(-c3ccncc3)c3ccc(-c4cnn(C)c4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL232593;87085;None;0;Human;Binding;Ki;=;86,00;7,07;-85;4;Binding affinity to human dopamine D2 receptor;ChEMBL;502,2;8;1;7;3,79;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccccc3[N+](=O)[O-])CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL2325930;87086;None;0;Human;Binding;Ki;=;27,00;7,57;-2;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;385,2;3;0;3;5,64;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4ccncc4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2325931;87087;None;0;Human;Binding;Ki;=;260,00;6,58;-10;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;368,2;3;0;4;4,90;CN1CCC(c2cn(-c3ccncc3)c3ccc(-c4ccncc4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2325932;87088;None;0;Human;Binding;Ki;=;76,00;7,12;-33;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;385,2;3;0;3;5,64;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4cccnc4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2325933;87089;None;0;Human;Binding;Ki;=;1100,00;5,96;-50;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;368,2;3;0;4;4,90;CN1CCC(c2cn(-c3ccncc3)c3ccc(-c4cccnc4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2325934;87090;None;0;Human;Binding;Ki;=;830,00;6,08;-43;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;369,2;3;0;5;4,29;CN1CCC(c2cn(-c3ccncc3)c3ccc(-c4cncnc4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2325935;87091;None;0;Human;Binding;Ki;=;69,00;7,16;-245;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;390,2;3;0;6;3,77;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4nnn(C)n4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL232607;87100;None;0;Human;Binding;Ki;=;92,00;7,04;-18;4;Binding affinity to human dopamine D2 receptor;ChEMBL;488,2;8;1;7;3,29;COc1ccncc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL232609;87101;None;0;Human;Binding;Ki;=;61,00;7,21;-436;4;Binding affinity to human dopamine D2 receptor;ChEMBL;570,1;7;1;6;4,70;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3cnc(Cl)c(Br)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL2326175;87102;None;0;Human;Binding;Ki;=;220,00;6,66;-1380;4;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;389,2;3;0;5;4,37;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4ncn(C)n4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2326176;87103;None;0;Human;Binding;Ki;=;160,00;6,80;-295;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;388,2;3;0;4;4,98;CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4ccn(C)n4)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL2326468;87156;None;0;Human;Binding;Ki;=;320,00;6,50;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;300,1;2;1;6;2,47;Nc1nc2cc3c(cc2s1)CCN(Cc1cnco1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326469;87157;None;0;Human;Binding;Ki;=;490,00;6,31;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;316,1;2;1;6;2,94;Nc1nc2cc3c(cc2s1)CCN(Cc1cscn1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326470;87158;None;0;Human;Binding;Ki;=;580,00;6,24;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;299,1;2;2;5;2,20;Nc1nc2cc3c(cc2s1)CCN(Cc1cnc[nH]1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326471;87159;None;0;Human;Binding;Ki;=;5000,00;5,30;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;301,1;2;1;7;1,86;Nc1nc2cc3c(cc2s1)CCN(Cc1ncon1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326472;87160;None;1;Human;Binding;Ki;=;15,00;7,82;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;313,1;2;1;6;2,21;Cn1cc(CN2CCc3cc4nc(N)sc4cc3CC2)cn1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326473;87161;None;0;Human;Binding;Ki;=;350,00;6,46;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;313,1;2;1;6;2,21;Cn1ccc(CN2CCc3cc4nc(N)sc4cc3CC2)n1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326474;87162;None;0;Human;Binding;Ki;=;800,00;6,10;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;263,1;2;2;5;1,27;Nc1nc2cc3c(cc2s1)CCN(CCO)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326475;87163;None;0;Human;Binding;Ki;=;4300,00;5,37;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;323,1;1;1;4;3,12;Nc1nc2cc3c(cc2s1)CCN(C(=O)c1ccccc1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326476;87164;None;0;Human;Binding;Ki;=;80,00;7,10;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;309,1;2;1;4;3,48;Nc1nc2cc3c(cc2s1)CCN(Cc1ccccc1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326477;87165;None;0;Human;Binding;Ki;=;75,00;7,12;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;327,1;2;1;4;3,62;Nc1nc2cc3c(cc2s1)CCN(Cc1ccc(F)cc1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326478;87166;None;0;Human;Binding;Ki;=;42,00;7,38;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;327,1;2;1;4;3,62;Nc1nc2cc3c(cc2s1)CCN(Cc1cccc(F)c1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326479;87167;None;0;Human;Binding;Ki;=;92,00;7,04;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;339,1;3;1;5;3,49;COc1ccc(CN2CCc3cc4nc(N)sc4cc3CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326480;87168;None;0;Human;Binding;Ki;=;34,00;7,47;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;339,1;3;1;5;3,49;COc1cccc(CN2CCc3cc4nc(N)sc4cc3CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326481;87169;None;0;Human;Binding;Ki;=;42,00;7,38;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;380,2;3;1;5;3,18;CN(C)C(=O)c1ccc(CN2CCc3cc4nc(N)sc4cc3CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326482;87170;None;0;Human;Binding;Ki;=;42,00;7,38;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;380,2;3;1;5;3,18;CN(C)C(=O)c1cccc(CN2CCc3cc4nc(N)sc4cc3CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326483;87171;None;0;Human;Binding;Ki;=;5000,00;5,30;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;310,1;2;1;5;2,87;Nc1nc2cc3c(cc2s1)CCN(Cc1ccccn1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326484;87172;None;0;Human;Binding;Ki;=;200,00;6,70;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;310,1;2;1;5;2,87;Nc1nc2cc3c(cc2s1)CCN(Cc1cccnc1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326485;87173;None;0;Human;Binding;Ki;=;38,00;7,42;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;310,1;2;1;5;2,87;Nc1nc2cc3c(cc2s1)CCN(Cc1ccncc1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326486;87174;None;2;Human;Binding;Ki;=;150,00;6,82;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;233,1;2;2;4;1,96;CCN[C@@H]1Cc2cc3nc(N)sc3cc2C1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326487;87175;None;0;Human;Binding;Ki;=;3900,00;5,41;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;219,1;0;2;4;1,57;Nc1nc2cc3c(cc2s1)CCNCC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326488;87176;None;0;Human;Binding;Ki;=;1500,00;5,82;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;233,1;0;1;4;1,91;CN1CCc2cc3nc(N)sc3cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326489;87177;None;0;Human;Binding;Ki;=;2500,00;5,60;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;247,1;1;1;4;2,30;CCN1CCc2cc3nc(N)sc3cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326490;87178;None;0;Human;Binding;Ki;=;1100,00;5,96;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;259,1;1;1;4;2,44;Nc1nc2cc3c(cc2s1)CCN(C1CC1)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326491;87179;None;0;Human;Binding;Ki;=;5000,00;5,30;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;301,1;1;1;4;2,84;Nc1nc2cc3c(cc2s1)CCN(CC(F)(F)F)CC3;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL2326492;87180;None;0;Human;Binding;Ki;=;5000,00;5,30;-;1;Displacement of [3H]raclopride from human D2 dopamine receptor expressed in CHO cell membranes;ChEMBL;304,1;2;1;5;1,37;CN(C)C(=O)CN1CCc2cc3nc(N)sc3cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2012.11.023
CHEMBL232779;87244;None;0;Human;Binding;Ki;=;74,00;7,13;-22;4;Binding affinity to human dopamine D2 receptor;ChEMBL;475,2;7;1;5;4,03;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3cccc(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL232780;87245;None;0;Human;Binding;Ki;=;64,00;7,19;-89;4;Binding affinity to human dopamine D2 receptor;ChEMBL;475,2;7;1;5;4,03;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3cccc(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL2331599;87315;None;0;Human;Binding;Ki;=;132,00;6,88;-2;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin) expressed in CHO cell membranes after 60 mins;ChEMBL;343,1;1;2;3;3,94;Cc1cc2c(cc1O)[C@H]1C[C@](O)(c3ccc(Cl)cc3)CCN1CC2;https://dx.doi.org/10.1016/j.bmcl.2012.12.046
CHEMBL233407;87518;None;0;Human;Binding;Ki;=;198,00;6,70;-32;4;Binding affinity to human dopamine D2 receptor;ChEMBL;509,2;7;1;5;4,68;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3cccc(Cl)c3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233410;87519;None;0;Human;Binding;Ki;=;130,00;6,89;-85;4;Binding affinity to human dopamine D2 receptor;ChEMBL;509,2;7;1;5;4,68;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccc(Cl)cc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233416;87520;None;0;Human;Binding;Ki;=;39,00;7,41;-1;4;Binding affinity to human dopamine D2 receptor;ChEMBL;525,2;7;1;5;4,90;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL2334882;87540;None;0;Human;Binding;Ki;=;146,90;6,83;-12;3;Radioligand Binding Assay: The affinity of compounds to D1 and D2 dopamine receptors were determined by competition binding assays. Membrane homogenates of HEK293T cells were stably transfected with D1, or D2 receptors. Duplicated tubes were incubated at 30° C. for 50 mins (for D1, and D2) with increasing concentrations of respective compound and with [3H]SCH23390 (for D1 dopamine receptors), or [3H]Spiperone (for dopamine D2 receptor) in a final volume of 200 μL binding buffer containing 50 mM Tris, 4 mM MgCl2, pH 7.4. Nonspecific binding was determined by parallel incubations with either 10 μM SCH23390 for D1, or Spiperone for D2 receptors respectively. The reaction was started by addition of membranes (15 ng/tube) and stopped by rapid filtration through Whatman GF/B glassfiber filter and subsequently washed with cold buffer (50 mM Tris, 5 mM EDTA, pH 7.4) using a Brandel 24-well cell harvester. Scintillation cocktail was added and the radioactivity was determined in a MicroBeta liquid scintillation counter.;ChEMBL;323,2;1;1;4;2,99;COc1c(O)ccc2c1CN1CCc3cc4c(cc3[C@@H]1C2)OCC4;-
CHEMBL2334885;87541;None;22;Human;Binding;Ki;=;42,40;7,37;5;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor after 1 hr;ChEMBL;341,2;3;1;5;3,07;COc1cc2c(cc1O)CCN1Cc3c(ccc(OC)c3OC)C[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2017.01.090
CHEMBL2334891;87545;None;34;Human;Binding;Ki;=;41,80;7,38;-11;5;Displacement of [3H]SCH23390 from human FLAG-tagged dopamine D2 receptor expressed in HEK293 cells after 1 hr;ChEMBL;341,2;3;1;5;3,07;COc1cc2c(cc1O)[C@@H]1Cc3ccc(OC)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmcl.2017.01.090
CHEMBL2334891;87545;None;34;Human;Binding;Ki;=;91,00;7,04;-11;5;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;341,2;3;1;5;3,07;COc1cc2c(cc1O)[C@@H]1Cc3ccc(OC)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL2334892;87546;None;8;Human;Binding;Ki;=;105,00;6,98;-15;2;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;341,2;3;1;5;3,07;COc1cc2c(cc1O)[C@H]1Cc3ccc(OC)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL2334893;87547;None;0;Human;Binding;IC50;=;91,11;7,04;-7;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;325,1;1;1;5;2,79;COc1cc2c(cc1O)[C@@H]1Cc3cc4c(cc3CN1CC2)OCO4;-
CHEMBL2334893;87547;None;0;Human;Binding;Ki;=;32,00;7,50;-7;2;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;325,1;1;1;5;2,79;COc1cc2c(cc1O)[C@@H]1Cc3cc4c(cc3CN1CC2)OCO4;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL2334893;87547;None;0;Human;Binding;Ki;=;32,16;7,49;-7;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;325,1;1;1;5;2,79;COc1cc2c(cc1O)[C@@H]1Cc3cc4c(cc3CN1CC2)OCO4;-
CHEMBL2335736;87605;None;0;Human;Binding;Ki;=;4,00;8,40;-1;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin) expressed in CHO cell membranes after 60 mins;ChEMBL;409,1;3;2;5;3,88;COc1cc2c(cc1O)[C@H]1C[C@@](O)(c3ccc(OC(F)(F)F)cc3)CCN1CC2;https://dx.doi.org/10.1016/j.bmcl.2012.12.046
CHEMBL2335737;87606;None;0;Human;Binding;Ki;=;12,30;7,91;-2;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin) expressed in CHO cell membranes after 60 mins;ChEMBL;343,1;1;2;3;3,94;Cc1cc2c(cc1O)[C@H]1C[C@@](O)(c3ccc(Cl)cc3)CCN1CC2;https://dx.doi.org/10.1016/j.bmcl.2012.12.046
CHEMBL2335738;87607;None;0;Human;Binding;Ki;=;195,00;6,71;1;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin) expressed in CHO cell membranes after 60 mins;ChEMBL;343,1;2;1;3;3,93;COc1ccc2c(c1)CCN1CC[C@](O)(c3ccc(Cl)cc3)C[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2012.12.046
CHEMBL2335740;87609;None;0;Human;Binding;Ki;=;14,80;7,83;-3;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin) expressed in CHO cell membranes after 60 mins;ChEMBL;359,1;2;2;4;3,63;COc1cc2c(cc1O)[C@H]1C[C@@](O)(c3ccc(Cl)cc3)CCN1CC2;https://dx.doi.org/10.1016/j.bmcl.2012.12.046
CHEMBL2335741;87610;None;0;Human;Binding;Ki;=;101,00;7,00;2;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin) expressed in CHO cell membranes after 60 mins;ChEMBL;359,1;2;2;4;3,63;COc1cc2c(cc1O)[C@H]1C[C@](O)(c3ccc(Cl)cc3)CCN1CC2;https://dx.doi.org/10.1016/j.bmcl.2012.12.046
CHEMBL233582;87615;None;0;Human;Binding;Ki;=;42,00;7,38;-13;4;Binding affinity to human dopamine D2 receptor;ChEMBL;509,2;7;1;5;4,68;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccc(Cl)cc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233584;87616;None;0;Human;Binding;Ki;=;123,00;6,91;-1;4;Binding affinity to human dopamine D2 receptor;ChEMBL;529,3;10;1;7;3,90;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCN(c4ccccc4OCC4CC4)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233592;87618;None;0;Human;Binding;Ki;=;118,00;6,93;-83;4;Binding affinity to human dopamine D2 receptor;ChEMBL;525,2;7;1;5;4,90;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233623;87676;None;0;Human;Binding;Ki;=;50,00;7,30;-56;4;Binding affinity to human dopamine D2 receptor;ChEMBL;501,3;8;1;6;4,20;COc1ccc(C)cc1S(=O)(=O)N[C@H]1CC[C@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL2336280;87686;None;0;Human;Binding;Ki;=;12,00;7,92;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;233,2;4;0;2;3,29;CCCN1CCC(c2ccccc2OC)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336280;87686;None;0;Human;Binding;Ki;=;12,59;7,90;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;233,2;4;0;2;3,29;CCCN1CCC(c2ccccc2OC)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336282;87687;None;0;Human;Binding;Ki;=;580,00;6,24;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;282,1;4;0;4;1,62;CCCN1CCN(c2ccccc2S(C)(=O)=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336282;87687;None;0;Human;Binding;Ki;=;630,96;6,20;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;282,1;4;0;4;1,62;CCCN1CCN(c2ccccc2S(C)(=O)=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336284;87688;None;0;Human;Binding;Ki;=;1500,00;5,82;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;233,2;4;0;2;3,29;CCCN1CCC(c2cccc(OC)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336284;87688;None;0;Human;Binding;Ki;=;1584,89;5,80;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;233,2;4;0;2;3,29;CCCN1CCC(c2cccc(OC)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336285;87689;None;0;Human;Binding;Ki;=;199,53;6,70;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;271,2;3;0;1;4,29;CCCN1CCC(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336285;87689;None;0;Human;Binding;Ki;=;180,00;6,75;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;271,2;3;0;1;4,29;CCCN1CCC(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336289;87690;None;0;Human;Binding;Ki;=;3800,00;5,42;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;335,2;5;0;3;3,99;CCCN1CCC(c2cccc(S(=O)(=O)C3CCCC3)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336289;87690;None;0;Human;Binding;Ki;=;3981,07;5,40;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;335,2;5;0;3;3,99;CCCN1CCC(c2cccc(S(=O)(=O)C3CCCC3)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL2336892;87765;None;0;Human;Binding;Ki;=;240,00;6,62;-32;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;448,3;4;0;4;5,08;c1ccc(N2CCN(Cc3cnn(-c4cc5ccc4CCc4ccc(cc4)CC5)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
CHEMBL2336892;87765;None;0;Human;Binding;Ki;=;55,00;7,26;-32;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;448,3;4;0;4;5,08;c1ccc(N2CCN(Cc3cnn(-c4cc5ccc4CCc4ccc(cc4)CC5)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
CHEMBL2336892;87765;None;0;Human;Binding;Ki;=;350,00;6,46;-32;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;448,3;4;0;4;5,08;c1ccc(N2CCN(Cc3cnn(-c4cc5ccc4CCc4ccc(cc4)CC5)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
CHEMBL2336892;87765;None;0;Human;Binding;Ki;=;33,00;7,48;-32;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;448,3;4;0;4;5,08;c1ccc(N2CCN(Cc3cnn(-c4cc5ccc4CCc4ccc(cc4)CC5)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
CHEMBL2336893;87766;None;0;Human;Binding;Ki;=;28,00;7,55;-1;4;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;448,3;4;0;4;5,08;c1ccc(-n2cc(CN3CCN(c4cc5ccc4CCc4ccc(cc4)CC5)CC3)cn2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
CHEMBL2336893;87766;None;0;Human;Binding;Ki;=;39,00;7,41;-1;4;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;448,3;4;0;4;5,08;c1ccc(-n2cc(CN3CCN(c4cc5ccc4CCc4ccc(cc4)CC5)CC3)cn2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
CHEMBL233790;87832;None;0;Human;Binding;Ki;=;80,00;7,10;-22;4;Binding affinity to human dopamine D2 receptor;ChEMBL;570,1;7;1;6;4,70;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3cnc(Cl)c(Br)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233814;87836;None;0;Human;Binding;Ki;=;173,00;6,76;-34;4;Binding affinity to human dopamine D2 receptor;ChEMBL;505,2;8;1;6;4,03;COc1ccc(F)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233816;87837;None;0;Human;Binding;Ki;=;101,00;7,00;-53;4;Binding affinity to human dopamine D2 receptor;ChEMBL;521,2;8;1;6;4,55;COc1ccc(Cl)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233816;87837;None;0;Human;Binding;Ki;=;259,00;6,59;-53;4;Binding affinity to human dopamine D2 receptor;ChEMBL;521,2;8;1;6;4,55;COc1ccc(Cl)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL233849;87868;None;0;Human;Binding;Ki;=;37,00;7,43;-46;4;Binding affinity to human dopamine D2 receptor;ChEMBL;565,2;8;1;6;4,66;COc1ccc(Br)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234194;88008;None;0;Human;Binding;Ki;=;62,00;7,21;-3;4;Binding affinity to human dopamine D2 receptor;ChEMBL;517,3;9;1;7;3,90;COc1ccc(OC)c(S(=O)(=O)N[C@H]2CC[C@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234231;88013;None;0;Human;Binding;Ki;=;194,00;6,71;-13;4;Binding affinity to human dopamine D2 receptor;ChEMBL;555,2;8;1;6;4,91;COc1ccc(C(F)(F)F)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234232;88014;None;0;Human;Binding;Ki;=;1,90;8,72;7;4;Binding affinity to human dopamine D2 receptor;ChEMBL;555,2;8;1;6;4,91;COc1ccc(C(F)(F)F)cc1S(=O)(=O)N[C@H]1CC[C@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234422;88053;None;0;Human;Binding;Ki;=;18,00;7,75;-17;4;Binding affinity to human dopamine D2 receptor;ChEMBL;532,2;9;1;8;3,80;COc1ccc([N+](=O)[O-])cc1S(=O)(=O)N[C@H]1CC[C@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234423;88054;None;0;Human;Binding;Ki;=;60,00;7,22;-5;4;Binding affinity to human dopamine D2 receptor;ChEMBL;505,2;7;1;5;4,85;Cc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)cc1Cl;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234474;88071;None;0;Human;Binding;Ki;=;588,00;6,23;-30;4;Binding affinity to human dopamine D2 receptor;ChEMBL;533,2;9;1;6;4,55;COc1ccc(Cl)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OCC3CC3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234476;88072;None;0;Human;Binding;Ki;=;425,00;6,37;-11;4;Binding affinity to human dopamine D2 receptor;ChEMBL;521,2;8;1;5;4,68;O=S(=O)(N[C@H]1CC[C@@H](N2CCN(c3ccccc3OCC3CC3)CC2)CC1)c1cc(Cl)ccc1F;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234607;88097;None;0;Human;Binding;Ki;=;78,00;7,11;-20;4;Binding affinity to human dopamine D2 receptor;ChEMBL;521,2;8;1;6;4,55;COc1ccc(Cl)cc1S(=O)(=O)N[C@H]1CC[C@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234609;88098;None;0;Human;Binding;Ki;=;52,00;7,28;-34;4;Binding affinity to human dopamine D2 receptor;ChEMBL;505,2;7;1;5;4,85;Cc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)cc1Cl;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234649;88110;None;0;Human;Binding;Ki;=;24,00;7,62;-19;4;Binding affinity to human dopamine D2 receptor;ChEMBL;471,3;8;1;5;4,03;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)Cc3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234650;88111;None;0;Human;Binding;Ki;=;71,00;7,15;-18;4;Binding affinity to human dopamine D2 receptor;ChEMBL;471,3;8;1;5;4,03;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)Cc3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234669;88115;None;0;Human;Binding;Ki;=;34,00;7,47;-12;4;Binding affinity to human dopamine D2 receptor;ChEMBL;457,2;7;1;5;3,89;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234679;88175;None;0;Human;Binding;Ki;=;55,00;7,26;-8;4;Binding affinity to human dopamine D2 receptor;ChEMBL;482,2;7;1;6;3,76;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccccc3C#N)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234680;88176;None;0;Human;Binding;Ki;=;2,40;8,62;-3;4;Binding affinity to human dopamine D2 receptor;ChEMBL;482,2;7;1;6;3,76;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccccc3C#N)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234681;88177;None;0;Human;Binding;Ki;=;31,00;7,51;-35;4;Binding affinity to human dopamine D2 receptor;ChEMBL;475,2;7;1;5;4,03;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccccc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234854;88376;None;0;Human;Binding;Ki;=;15,00;7,82;-3;4;Binding affinity to human dopamine D2 receptor;ChEMBL;458,2;7;1;6;3,28;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3cccnc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL234874;88377;None;0;Human;Binding;Ki;=;69,00;7,16;-14;4;Binding affinity to human dopamine D2 receptor;ChEMBL;475,2;7;1;5;4,03;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccc(F)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL23537;88597;None;0;Human;Binding;Ki;=;510,00;6,29;-33;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;317,2;4;0;3;4,39;c1ccc(CN2CCC(n3nccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL2365712;89164;None;10;Human;Binding;AC50;=;53,00;7,28;-;13;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;563,3;4;3;6;2,13;CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;https://dx.doi.org/10.1038/s41467-023-40064-9
CHEMBL236617;89196;None;0;Human;Binding;Ki;=;122,00;6,91;-36;4;Binding affinity to human dopamine D2 receptor;ChEMBL;535,2;8;1;7;3,29;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccc(S(C)(=O)=O)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL236618;89197;None;0;Human;Binding;Ki;=;14,00;7,85;-1;4;Binding affinity to human dopamine D2 receptor;ChEMBL;535,2;8;1;7;3,29;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccc(S(C)(=O)=O)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL236621;89198;None;0;Human;Binding;Ki;=;62,00;7,21;-2;4;Binding affinity to human dopamine D2 receptor;ChEMBL;517,3;9;1;7;3,90;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL236621;89198;None;0;Human;Binding;Ki;=;62,00;7,21;-2;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;517,3;9;1;7;3,90;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL2367896;89280;None;0;Human;Binding;Ki;=;158,49;6,80;-1;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;438,2;7;1;4;5,38;CCN1[C@H](c2ccccc2)CC[C@@H]1c1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL236830;89312;None;0;Human;Binding;Ki;=;430,00;6,37;-204;4;Binding affinity to human dopamine D2 receptor;ChEMBL;541,2;8;1;6;4,78;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL236832;89317;None;0;Human;Binding;Ki;=;81,00;7,09;-15;4;Binding affinity to human dopamine D2 receptor;ChEMBL;517,3;9;1;7;3,90;COc1ccc(OC)c(S(=O)(=O)N[C@H]2CC[C@@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL2377443;89852;None;0;Human;Binding;Ki;=;343,00;6,46;-10;4;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;484,2;7;2;4;4,77;COc1ccc2[nH]cc(C3CCN(CCCN4C(=O)CC(c5c[nH]c6ccccc56)C4=O)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2013.02.033
CHEMBL2377445;89854;None;0;Human;Binding;Ki;=;80,00;7,10;-9;4;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;458,2;5;2;3;4,51;O=C1CC(c2c[nH]c3ccccc23)C(=O)N1CCN1CCC(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.02.033
CHEMBL2377590;89878;None;0;Human;Binding;Ki;=;14,00;7,85;-1;5;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;486,2;7;2;3;5,29;O=C1CC(c2c[nH]c3ccccc23)C(=O)N1CCCCN1CCC(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.02.033
CHEMBL2377590;89878;None;0;Human;Binding;Ki;=;14,00;7,85;-1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;486,2;7;2;3;5,29;O=C1CC(c2c[nH]c3ccccc23)C(=O)N1CCCCN1CCC(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
CHEMBL2377591;89879;None;0;Human;Binding;Ki;=;161,00;6,79;-74;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;498,3;8;2;4;5,16;COc1ccc2[nH]cc(C3CCN(CCCCN4C(=O)CC(c5c[nH]c6ccccc56)C4=O)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
CHEMBL2377591;89879;None;0;Human;Binding;Ki;=;161,00;6,79;-74;5;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;498,3;8;2;4;5,16;COc1ccc2[nH]cc(C3CCN(CCCCN4C(=O)CC(c5c[nH]c6ccccc56)C4=O)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2013.02.033
CHEMBL238401;90297;None;0;Human;Binding;Ki;=;2,70;8,57;2;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;545,3;10;0;7;4,63;CCN([C@H]1CC[C@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1)S(=O)(=O)c1ccc(OC)c(OC)c1;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL238402;90298;None;0;Human;Binding;Ki;=;114,00;6,94;-13;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;557,2;9;1;7;4,06;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCN(c4ccccc4OCC(F)(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL238519;90329;None;0;Human;Binding;Ki;=;1258,93;5,90;-501;10;Displacement of [125I]iodosulpiride from human cloned D2 receptor expressed in CHO cells;ChEMBL;483,2;6;1;5;5,00;Cc1ccc2c(OCCN3CCC(Cc4ccc5c(c4F)NC(=O)CO5)CC3)cc(Cl)cc2n1;https://dx.doi.org/10.1016/j.bmcl.2006.11.031
CHEMBL238520;90330;None;0;Human;Binding;Ki;=;1995,26;5,70;-5011;10;Displacement of [125I]iodosulpiride from human cloned D2 receptor expressed in CHO cells;ChEMBL;467,2;6;1;5;4,49;Cc1ccc2c(OCCN3CCC(Cc4cc5c(cc4F)OCC(=O)N5)CC3)cc(F)cc2n1;https://dx.doi.org/10.1016/j.bmcl.2006.11.031
CHEMBL2386603;90424;None;0;Human;Binding;Ki;=;89,00;7,05;-63;2;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;507,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)C(=O)c1ccccc1-2;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386604;90425;None;0;Human;Binding;Ki;=;128,00;6,89;-181;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;463,2;9;1;5;5,15;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(-c3ccsc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386605;90426;None;0;Human;Binding;Ki;=;119,00;6,92;-30;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;424,3;9;1;5;3,48;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(N(C)C)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386606;90427;None;0;Human;Binding;Ki;=;101,00;7,00;-34;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;427,2;9;1;5;4,14;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(SC)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386607;90428;None;0;Human;Binding;Ki;=;125,00;6,90;-22;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;421,2;8;1;5;4,16;COc1ccccc1N1CCCN(CCCCNC(=O)c2cc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386608;90429;None;0;Human;Binding;Ki;=;108,00;6,97;-12;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;427,3;10;1;4;3,93;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(CCF)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386609;90430;None;0;Human;Binding;Ki;=;128,00;6,89;-70;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;407,3;9;1;4;4,06;C=Cc1ccc(C(=O)NCCCCN2CCCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386610;90431;None;0;Human;Binding;Ki;=;111,00;6,96;-29;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;415,2;8;1;4;4,07;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386611;90432;None;0;Human;Binding;Ki;=;95,20;7,02;-10;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;399,2;8;1;4;3,56;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386612;90433;None;0;Human;Binding;Ki;=;56,50;7,25;-7;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;401,2;8;1;5;3,79;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(C)s2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386613;90434;None;0;Human;Binding;Ki;=;138,00;6,86;-54;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;420,3;8;2;4;3,90;COc1ccccc1N1CCCN(CCCCNC(=O)c2cc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386614;90435;None;0;Human;Binding;Ki;=;125,00;6,90;-83;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;437,2;8;1;5;4,63;COc1ccccc1N1CCCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386615;90436;None;0;Human;Binding;Ki;=;107,00;6,97;-12;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;463,2;9;1;5;5,15;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(-c3ccccc3)s2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386616;90437;None;0;Human;Binding;Ki;=;151,00;6,82;-11;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;425,3;10;2;5;2,95;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(CCO)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386617;90438;None;0;Human;Binding;Ki;=;100,00;7,00;-8;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;483,3;8;1;5;4,63;COc1ccccc1N1CCCN(CCCCNC(=O)c2cccc3c2-c2ccccc2C3=O)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386618;90439;None;0;Human;Binding;Ki;=;43,70;7,36;-9;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;465,1;8;1;5;4,24;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(Br)s2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386619;90440;None;0;Human;Binding;Ki;=;280,00;6,55;-35;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;481,2;9;1;5;5,29;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(-c3ccc(F)cc3)s2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386620;90441;None;0;Human;Binding;Ki;=;119,00;6,92;-7;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;416,2;8;1;5;3,47;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(Cl)nc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386621;90442;None;0;Human;Binding;Ki;=;145,00;6,84;-8;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;460,1;8;1;5;3,58;COc1ccccc1N1CCCN(CCCCNC(=O)c2ccc(Br)nc2)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386622;90443;None;0;Human;Binding;Ki;=;152,00;6,82;-3;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;441,3;10;1;6;3,44;COc1ccccc1N1CCCN(CCCCNC(=O)c2cccc(OC)c2OC)CC1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL2386623;90444;None;0;Human;Binding;Ki;=;169,00;6,77;-23;3;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;410,3;9;2;5;3,46;CNc1ccc(C(=O)NCCCCN2CCCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL238717;90480;None;0;Human;Binding;Ki;=;46,00;7,34;11;2;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;362,2;6;0;5;3,00;O=c1c2ccccc2ncn1CCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL238718;90483;None;0;Human;Binding;Ki;=;140,00;6,85;3;3;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;396,2;6;0;5;3,65;O=c1c2ccccc2ncn1CCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL2387229;90509;None;0;Human;Binding;IC50;=;26,30;7,58;-8;13;Antagonist activity at dopamine D2 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 assessed as inhibition of agonist-induced response incubated for 60 mins in incubator followed by 15 mins at room temperature by FLIPR assay;ChEMBL;484,2;7;0;6;6,07;Cc1cc(=O)oc2c(Cl)c(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)ccc12;https://dx.doi.org/10.1021/jm400408r
CHEMBL2387229;90509;None;0;Human;Binding;Ki;=;2,60;8,59;-8;13;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;484,2;7;0;6;6,07;Cc1cc(=O)oc2c(Cl)c(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)ccc12;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL238732;90591;None;0;Human;Binding;Ki;=;2511,89;5,60;-251;10;Displacement of [125I]iodosulpiride from human cloned D2 receptor expressed in CHO cells;ChEMBL;483,2;6;1;5;5,00;Cc1ccc2c(OCCN3CCC(Cc4cc(F)c5c(c4)NC(=O)CO5)CC3)cc(Cl)cc2n1;https://dx.doi.org/10.1016/j.bmcl.2006.11.031
CHEMBL238858;90663;None;0;Human;Binding;Ki;=;808,00;6,09;-1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;451,2;5;0;4;4,53;O=C1c2ccccc2C(=O)N1CCCCN1CCN2c3ccccc3Cc3ccccc3C2C1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL238859;90664;None;0;Human;Binding;Ki;=;1324,00;5,88;-;1;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;475,3;6;1;3;5,82;O=C(NCCCCN1CCN2c3ccccc3Cc3ccccc3C2C1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL238875;90665;None;0;Human;Binding;Ki;=;13350,00;4,88;-5;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;473,3;9;1;4;4,88;COc1ccccc1N(C(C)=O)C1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL238915;90666;None;0;Human;Binding;Ki;=;177,00;6,75;-4;4;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;433,1;6;0;5;3,09;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL238915;90666;None;0;Human;Binding;Ki;=;177,00;6,75;-4;4;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;433,1;6;0;5;3,09;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL238916;90667;None;0;Human;Binding;Ki;=;113,00;6,95;-1;7;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;467,1;6;0;5;3,45;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL238916;90667;None;0;Human;Binding;Ki;=;113,00;6,95;-1;7;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;467,1;6;0;5;3,45;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL238917;90668;None;0;Human;Binding;Ki;=;360,00;6,44;1;4;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;429,2;7;0;6;2,44;COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3S2(=O)=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL238917;90668;None;0;Human;Binding;Ki;=;360,00;6,44;1;4;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;429,2;7;0;6;2,44;COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3S2(=O)=O)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL239065;90691;None;0;Human;Binding;Ki;=;429,00;6,37;-8;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;451,3;7;1;3;5,06;O=C(/C=C/c1ccccc1)NCCCCN1CCN2c3ccccc3Cc3ccccc3C2C1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL239066;90692;None;0;Human;Binding;Ki;=;497,00;6,30;1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;431,2;6;1;4;4,73;O=C(NCCCCN1CCN2c3ccccc3Cc3ccccc3C2C1)c1cccs1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL239067;90693;None;0;Human;Binding;Ki;=;258,00;6,59;-;1;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;431,3;6;1;3;4,93;O=C(NCCCCN1CCN2c3ccccc3Cc3ccccc3C2C1)C1CCCCC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL2392349;90914;None;0;Human;Binding;IC50;=;3,50;8,46;-;6;Inhibition of human recombinant dopamine D2S receptor expressed in HEK293 cells;ChEMBL;443,3;8;0;4;4,80;COc1ccccc1N1CCN(CCCCCN2Cc3ccc4ccccc4c3C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.01.044
CHEMBL239493;90996;None;0;Human;Binding;Ki;=;252,00;6,60;-41;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;535,2;6;1;3;7,09;O=C(NCCCCN1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL239539;90998;None;0;Human;Binding;Ki;=;189,00;6,72;-15;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;467,3;9;1;3;5,52;O=C(NCCCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL2396663;91017;None;0;Human;Binding;EC50;=;16,00;7,80;-15;6;Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm501889t
CHEMBL2396663;91017;None;0;Human;Binding;Ki;=;3,90;8,41;-15;6;Displacement of [3H]spiperone from human dopamine D2S receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm501889t
CHEMBL2396663;91017;None;0;Human;Binding;Ki;=;21,00;7,68;-15;6;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2396663;91017;None;0;Human;Binding;Ki;=;1,20;8,92;-15;6;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2396663;91017;None;0;Human;Binding;Ki;=;14,00;7,85;-15;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2396663;91017;None;0;Human;Binding;Ki;=;9,40;8,03;-15;6;Displacement of [3H]spiperone from human dopamine D2L receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm501889t
CHEMBL239700;91046;None;1;Human;Binding;Ki;=;184,00;6,74;2;3;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;392,2;7;0;6;3,01;COc1ccccc1N1CCN(CCCCn2cnc3ccccc3c2=O)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL239706;91055;None;0;Human;Binding;Ki;=;849,00;6,07;-316;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;541,2;6;1;4;7,16;O=C(NCCCCN1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL239708;91056;None;0;Human;Binding;Ki;=;128,00;6,89;-;1;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;467,3;9;0;4;5,23;O=C1c2ccccc2C(=O)N1CCCCN1CCC(N(Cc2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL239733;91065;None;0;Human;Binding;Ki;=;51,00;7,29;-6;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;443,2;8;1;3;4,70;C#Cc1cccc(C(=O)NCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL239733;91065;None;0;Human;Binding;Ki;=;23,00;7,64;-6;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;443,2;8;1;3;4,70;C#Cc1cccc(C(=O)NCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL2397389;91086;None;0;Human;Binding;EC50;=;140,00;6,85;-9;6;Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm501889t
CHEMBL2397389;91086;None;0;Human;Binding;Ki;=;8,80;8,06;-9;6;Displacement of [3H]spiperone from human dopamine D2S receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm501889t
CHEMBL2397389;91086;None;0;Human;Binding;Ki;=;14,00;7,85;-9;6;Displacement of [3H]spiperone from human dopamine D2L receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm501889t
CHEMBL2397389;91086;None;0;Human;Binding;Ki;=;11,00;7,96;-9;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397389;91086;None;0;Human;Binding;Ki;=;18,00;7,75;-9;6;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397389;91086;None;0;Human;Binding;Ki;=;0,60;9,22;-9;6;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;414,3;10;1;2;5,69;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397390;91087;None;0;Human;Binding;Ki;=;63,00;7,20;-13;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397390;91087;None;0;Human;Binding;Ki;=;5,50;8,26;-13;4;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397390;91087;None;0;Human;Binding;Ki;=;230,00;6,64;-13;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397391;91088;None;0;Human;Binding;Ki;=;280,00;6,55;-4;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397391;91088;None;0;Human;Binding;Ki;=;3,90;8,41;-4;4;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397391;91088;None;0;Human;Binding;Ki;=;66,00;7,18;-4;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397392;91089;None;0;Human;Binding;Ki;=;7,10;8,15;2;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397392;91089;None;0;Human;Binding;Ki;=;0,55;9,26;2;4;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397392;91089;None;0;Human;Binding;Ki;=;9,30;8,03;2;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397476;91091;None;0;Human;Binding;Ki;=;7,80;8,11;2;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397476;91091;None;0;Human;Binding;Ki;=;14,00;7,85;2;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397476;91091;None;0;Human;Binding;Ki;=;1,10;8,96;2;4;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;9;1;4;3,67;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397477;91092;None;0;Human;Binding;Ki;=;4,20;8,38;-1;4;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;549,4;18;1;7;5,43;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cnn(CCCC)n3)c(OC)c2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397477;91092;None;0;Human;Binding;Ki;=;8,80;8,06;-1;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;549,4;18;1;7;5,43;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cnn(CCCC)n3)c(OC)c2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397477;91092;None;0;Human;Binding;Ki;=;8,00;8,10;-1;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;549,4;18;1;7;5,43;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cnn(CCCC)n3)c(OC)c2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397478;91093;None;0;Human;Binding;Ki;=;6,00;8,22;-2;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;549,4;18;1;7;5,43;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cnn(CCCC)n3)c(OC)c2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397478;91093;None;0;Human;Binding;Ki;=;3,90;8,41;-2;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;549,4;18;1;7;5,43;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cnn(CCCC)n3)c(OC)c2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397478;91093;None;0;Human;Binding;Ki;=;0,53;9,28;-2;4;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;549,4;18;1;7;5,43;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cnn(CCCC)n3)c(OC)c2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397479;91094;None;0;Human;Binding;Ki;=;32,00;7,50;-61;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;394,2;9;1;3;5,24;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397479;91094;None;0;Human;Binding;Ki;=;33,00;7,48;-61;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;394,2;9;1;3;5,24;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397479;91094;None;0;Human;Binding;Ki;=;3,10;8,51;-61;4;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;394,2;9;1;3;5,24;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397480;91095;None;0;Human;Binding;Ki;=;22,00;7,66;-20;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;394,2;9;1;3;5,24;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397480;91095;None;0;Human;Binding;Ki;=;2,00;8,70;-20;4;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;394,2;9;1;3;5,24;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL2397480;91095;None;0;Human;Binding;Ki;=;16,00;7,80;-20;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;394,2;9;1;3;5,24;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm400520c
CHEMBL239917;91237;None;0;Human;Binding;Ki;=;1747,00;5,76;-4;3;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;383,2;6;0;3;3,83;O=C1Cc2ccccc2N1CCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL239923;91238;None;0;Human;Binding;Ki;=;703,00;6,15;-2344;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;491,3;10;1;3;6,52;O=C(NCCCCN1CCC(N(Cc2ccccc2)c2ccccc2)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL240021;91246;None;0;Human;Binding;Ki;=;54000,00;4,27;-24;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;437,2;4;0;5;4,72;COc1cc2c(cc1OC)CN(/C=N/c1ccc3c(c1)N(C(=O)OC(C)(C)C)CC3)CC2;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL240022;91247;None;0;Human;Binding;Ki;=;11000,00;4,96;-54;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;408,2;5;0;5;4,36;COc1cc2c(cc1OC)CN(/C=N/c1ccc3c(c1)C(OC(C)=O)CCC3)CC2;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL240023;91248;None;0;Human;Binding;Ki;=;42000,00;4,38;-7;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;408,2;7;0;4;5,23;CCCOC1CCCc2ccc(/N=C/N3CCc4cc(OC)c(OC)cc4C3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL240025;91250;None;0;Human;Binding;Ki;=;1600,00;5,80;-15;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;322,2;5;0;3;4,03;CC(=O)OC1CCc2ccc(/N=C/N(C)Cc3ccccc3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL240106;91268;None;0;Human;Binding;Ki;=;0,85;9,07;-1;4;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;382,1;7;1;4;2,85;C=CCN1CCC[C@H]1CNC(=O)c1cc(Br)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL240106;91268;None;0;Human;Binding;Ki;=;0,88;9,06;-1;4;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;382,1;7;1;4;2,85;C=CCN1CCC[C@H]1CNC(=O)c1cc(Br)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL240377;91542;None;3;Human;Binding;Ki;=;598,00;6,22;-12;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;453,2;8;0;4;4,47;O=C1c2ccccc2C(=O)N1CCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL240378;91543;None;0;Human;Binding;Ki;=;559,00;6,25;-19;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;487,2;8;0;4;5,12;O=C1c2ccccc2C(=O)N1CCCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL240379;91544;None;0;Human;Binding;Ki;=;1180,00;5,93;-8;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;467,3;8;0;4;4,86;O=C1c2ccccc2C(=O)N1CCCCN1CCCN(C(c2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL24051;91584;None;0;Human;Binding;Ki;=;370,00;6,43;-120;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;365,2;4;0;3;5,35;Cc1c(-c2ccccc2)cnn1C1CCN(Cc2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL240564;91590;None;0;Human;Binding;Ki;=;972,00;6,01;-64;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;513,3;12;1;5;5,02;COc1ccccc1C(c1ccccc1OC)N1CCN(CCCCNC(=O)/C=C/c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL240584;91594;None;0;Human;Binding;Ki;=;27,00;7,57;1;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;481,3;9;1;4;4,82;COc1ccccc1N1CCN(CCCCCNC(=O)c2cccc(C#Cc3ccccc3)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL240584;91594;None;0;Human;Binding;Ki;=;31,00;7,51;1;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;481,3;9;1;4;4,82;COc1ccccc1N1CCN(CCCCCNC(=O)c2cccc(C#Cc3ccccc3)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL240587;91595;None;0;Human;Binding;Ki;=;226,00;6,65;-5;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;501,2;8;0;4;5,51;O=C1c2ccccc2C(=O)N1CCCCN1CCCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL240588;91596;None;0;Human;Binding;Ki;=;457,00;6,34;-41;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;477,3;9;1;3;5,76;O=C(NCCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL240589;91597;None;23;Human;Binding;Ki;=;1272,00;5,90;-144;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;334,2;7;1;2;3,65;O=C(/C=C/c1ccccc1)NCCCCN1CCc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL240600;91599;None;0;Human;Binding;Ki;=;626,00;6,20;-173;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;513,2;10;1;5;5,83;COc1ccccc1C(c1ccccc1)N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL240774;91634;None;0;Human;Binding;Ki;=;189,00;6,72;-3;4;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;349,2;6;0;3;3,25;O=C1c2ccccc2CN1CCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL240888;91751;None;0;Human;Binding;Ki;=;31000,00;4,51;-38;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;276,1;2;1;2;3,57;COc1cccc(C2=NCCc3c2[nH]c2ccccc32)c1;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL240995;91792;None;0;Human;Binding;Ki;=;760,00;6,12;-22;3;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;383,2;6;0;3;3,90;O=C1c2ccccc2CN1CCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL240996;91793;None;0;Human;Binding;Ki;=;387,00;6,41;-7;3;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;417,2;6;0;3;4,26;O=C1c2ccccc2CN1CCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL241018;91795;None;0;Human;Binding;Ki;=;4620,00;5,33;-;1;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;535,3;10;1;4;6,17;COc1ccccc1N(C(=O)c1ccccc1)C1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL241026;91796;None;0;Human;Binding;Ki;=;652,00;6,19;-104;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;453,3;10;1;3;5,00;O=C(/C=C/c1ccccc1)NCCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL241027;91797;None;0;Human;Binding;Ki;=;621,00;6,21;-21;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;433,2;9;1;4;4,67;O=C(NCCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1)c1cccs1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL241082;91807;None;0;Human;Binding;Ki;=;25000,00;4,60;-7;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;306,1;3;1;3;3,58;COc1cccc(C2=NCCc3c2[nH]c2ccc(OC)cc32)c1;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL241101;91817;None;0;Human;Binding;Ki;=;14000,00;4,85;-7;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;395,2;4;0;5;3,55;COC(=O)N1CCc2ccc(/N=C/N3CCc4cc(OC)c(OC)cc4C3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL241102;91818;None;0;Human;Binding;Ki;=;12000,00;4,92;-60;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;394,2;5;0;5;3,97;COc1cc2c(cc1OC)CN(/C=N/c1ccc3c(c1)C(OC(C)=O)CC3)CC2;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL241103;91819;None;0;Human;Binding;Ki;=;1700,00;5,77;-16;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;334,2;3;0;3;3,96;CC(=O)OC1CCc2ccc(/N=C/N3CCc4ccccc4C3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL241169;91833;None;0;Human;Binding;Ki;=;0,68;9,17;-1;4;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;430,1;7;1;4;2,69;C=CCN1CCC[C@H]1CNC(=O)c1cc(I)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL241169;91833;None;0;Human;Binding;Ki;=;0,74;9,13;-1;4;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;430,1;7;1;4;2,69;C=CCN1CCC[C@H]1CNC(=O)c1cc(I)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL241210;91834;None;0;Human;Binding;Ki;=;9900,00;5,00;-309;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;477,1;5;1;3;4,95;O=C(NCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(C#Cc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241210;91834;None;0;Human;Binding;Ki;=;4700,00;5,33;-309;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;477,1;5;1;3;4,95;O=C(NCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(C#Cc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241211;91835;None;0;Human;Binding;Ki;=;1200,00;5,92;-109;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;477,1;5;1;3;4,95;O=C(NCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(C#Cc2ccccc2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241211;91835;None;0;Human;Binding;Ki;=;1400,00;5,85;-109;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;477,1;5;1;3;4,95;O=C(NCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(C#Cc2ccccc2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241212;91836;None;0;Human;Binding;Ki;=;160,00;6,80;-199;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;391,2;8;1;4;3,01;C#Cc1ccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241212;91836;None;0;Human;Binding;Ki;=;250,00;6,60;-199;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;391,2;8;1;4;3,01;C#Cc1ccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241225;91837;None;0;Human;Binding;Ki;=;163,00;6,79;-8;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;431,3;9;2;4;4,93;COc1ccccc1NC1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL241281;91845;None;0;Human;Binding;Ki;=;2400,00;5,62;-12;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;348,2;3;0;3;4,34;CC(=O)OC1CCCc2ccc(/N=C/N3CCc4ccccc4C3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL241283;91847;None;0;Human;Binding;Ki;=;8200,00;5,09;1;2;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;422,2;8;0;4;5,85;CCCCSC1=CCc2ccc(/N=C/N3CCc4cc(OC)c(OC)cc4C3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL2413153;91868;None;6;Human;Binding;Ki;=;37,10;7,43;-371;17;Binding affinity to dopamine 2 receptor (unknown origin);ChEMBL;405,2;9;0;8;0,89;Cn1c(=O)cnn(CCCCN2CCN(c3ccccc3OCCF)CC2)c1=O;https://dx.doi.org/10.1016/j.bmc.2013.05.050
CHEMBL241424;91977;None;0;Human;Binding;Ki;=;190,00;6,72;-51;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;467,3;8;1;4;4,43;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(C#Cc3ccccc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241424;91977;None;0;Human;Binding;Ki;=;1400,00;5,85;-51;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;467,3;8;1;4;4,43;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(C#Cc3ccccc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241436;91983;None;0;Human;Binding;Ki;=;240,00;6,62;-29;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;505,2;7;1;3;5,72;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(C#Cc2ccccc2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241436;91983;None;0;Human;Binding;Ki;=;210,00;6,68;-29;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;505,2;7;1;3;5,72;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc(C#Cc2ccccc2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241455;91984;None;0;Human;Binding;Ki;=;963,00;6,02;-398;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;487,2;10;1;3;5,66;O=C(/C=C/c1ccccc1)NCCCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL2414991;92012;None;2;Human;Binding;Ki;=;338,84;6,47;-2;4;Displacement of [3H]spiperone from human D2S receptor expressed in CHO-K1 cells by radioligand competitive binding analysis;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cc(O)c(O)c3c2C1Cc1ccccc1-3;https://dx.doi.org/10.1021/acs.jnatprod.9b00921
CHEMBL2414991;92012;None;2;Human;Binding;Ki;=;38,90;7,41;-2;4;Displacement of [3H] raclopride from D2DR (unknown origin);ChEMBL;267,1;0;2;3;2,85;CN1CCc2cc(O)c(O)c3c2C1Cc1ccccc1-3;https://dx.doi.org/10.1016/j.ejmech.2020.112792
CHEMBL2414991;92012;None;2;Human;Binding;Ki;=;340,00;6,47;-2;4;Displacement of [3H]spiperone from human D2S receptor expressed in CHO-K1 cells by radioligand competitive binding analysis;ChEMBL;267,1;0;2;3;2,85;CN1CCc2cc(O)c(O)c3c2C1Cc1ccccc1-3;https://dx.doi.org/10.1021/acs.jnatprod.9b00921
CHEMBL241631;92030;None;1;Human;Binding;Ki;=;69,00;7,16;-7;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;401,1;5;1;3;3,53;C#Cc1ccc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241631;92030;None;1;Human;Binding;Ki;=;48,00;7,32;-7;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;401,1;5;1;3;3,53;C#Cc1ccc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241641;92031;None;0;Human;Binding;Ki;=;780,00;6,11;-245;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;505,2;7;1;3;5,72;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(C#Cc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241641;92031;None;0;Human;Binding;Ki;=;840,00;6,08;-245;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;505,2;7;1;3;5,72;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(C#Cc2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL241659;92032;None;0;Human;Binding;Ki;=;1000,00;6,00;-56;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;517,2;9;1;4;6,47;O=C(NCCCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL241660;92033;None;0;Human;Binding;Ki;=;160,00;6,80;-4;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;467,2;9;1;4;5,32;O=C(NCCCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1)c1cccs1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL24170;92041;None;0;Human;Binding;Ki;=;460,00;6,34;-14;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;318,2;4;0;4;3,78;c1ccc(CN2CCC(n3cc(-c4ccccc4)nn3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL241973;92157;None;0;Human;Binding;Ki;=;28,30;7,55;-70;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;444,3;9;1;5;4,09;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccccn3)cc2)CC1;https://dx.doi.org/10.1021/jm0704200
CHEMBL242003;92162;None;1;Human;Binding;Ki;=;400,00;6,40;-14;3;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;478,2;7;1;3;7,04;Cc1ccc(C2CCN(Cc3ccc(Oc4ccc(F)c(F)c4)cc3)CC2)cc1NC(=O)C(C)C;https://dx.doi.org/10.1021/jm060383x
CHEMBL242004;92163;None;24;Human;Binding;Ki;=;7400,00;5,13;-3388;3;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;478,2;7;1;3;7,04;Cc1ccc(NC(=O)C(C)C)cc1C1CCN(Cc2ccc(Oc3ccc(F)c(F)c3)cc2)CC1;https://dx.doi.org/10.1021/jm060383x
CHEMBL2420771;92178;None;4;Human;Binding;Ki;=;2179,00;5,66;-41;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;292,1;3;0;3;3,72;Clc1ccccc1N1CCN(Cc2cccs2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420772;92179;None;0;Human;Binding;Ki;=;1545,00;5,81;-34;4;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;326;3;0;3;4,38;Clc1cccc(N2CCN(Cc3cccs3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420773;92180;None;5;Human;Binding;Ki;=;162,00;6,79;-41;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;302,1;5;0;4;3,47;CCOc1ccccc1N1CCN(Cc2cccs2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420777;92184;None;0;Human;Binding;Ki;=;1593,00;5,80;-25;5;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;326;3;0;3;4,38;Clc1ccc(N2CCN(Cc3cccs3)CC2)cc1Cl;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420778;92185;None;0;Human;Binding;Ki;=;2167,00;5,66;-14;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;274,1;3;1;4;2,78;Oc1ccc(N2CCN(Cc3cccs3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420779;92186;None;5;Human;Binding;Ki;=;255,00;6,59;-363;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;297,2;5;0;4;2,80;CCOc1ccccc1N1CCN(Cc2cccnc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420780;92187;None;5;Human;Binding;Ki;=;327,00;6,49;-74;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;321,1;3;0;3;3,71;Clc1cccc(N2CCN(Cc3cccnc3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420781;92188;None;5;Human;Binding;Ki;=;264,00;6,58;-131;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;346,2;5;0;3;4,56;CCOc1ccccc1N1CCN(Cc2cccc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420782;92189;None;0;Human;Binding;Ki;=;351,00;6,46;-11;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;370,1;3;0;2;5,47;Clc1cccc(N2CCN(Cc3cccc4ccccc34)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420890;92190;None;0;Human;Binding;Ki;=;219,00;6,66;-48;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;352,2;5;0;4;4,62;CCOc1ccccc1N1CCN(Cc2csc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420891;92191;None;0;Human;Binding;Ki;=;383,00;6,42;-16;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;376,1;3;0;3;5,53;Clc1cccc(N2CCN(Cc3csc4ccccc34)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420892;92192;None;4;Human;Binding;Ki;=;217,00;6,66;-72;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;296,2;5;0;3;3,41;CCOc1ccccc1N1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420893;92193;None;0;Human;Binding;Ki;=;242,00;6,62;-21;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;320,1;3;0;2;4,32;Clc1cccc(N2CCN(Cc3ccccc3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420894;92194;None;4;Human;Binding;Ki;=;473,00;6,33;-15488;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;335,2;5;1;3;3,89;CCOc1ccccc1N1CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL2420895;92195;None;0;Human;Binding;Ki;=;502,00;6,30;-81;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;359,1;3;1;2;4,80;Clc1cccc(N2CCN(Cc3c[nH]c4ccccc34)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
CHEMBL242218;92201;None;0;Human;Binding;Ki;=;249,00;6,60;-138;3;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;471,3;8;2;5;3,57;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2ccc3c(c2)Cc2ccccc2-3)CC1;https://dx.doi.org/10.1021/jm0704200
CHEMBL24222;92202;None;0;Human;Binding;Ki;=;50,00;7,30;-13;5;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;243,2;3;0;2;2,98;C=CCN1CC[C@@H]2c3cccc(OC)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00043a013
CHEMBL24222;92202;None;0;Human;Binding;Ki;=;50,00;7,30;-13;5;Compound was evaluated for the binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in rat striatum;ChEMBL;243,2;3;0;2;2,98;C=CCN1CC[C@@H]2c3cccc(OC)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL242434;92218;None;0;Human;Binding;Ki;=;134,00;6,87;-11;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;540,2;9;1;6;4,93;CC(=O)OC(CCNC(=O)c1ccc(-c2ccccn2)cc1)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm0704200
CHEMBL242644;92291;None;0;Human;Binding;Ki;=;1090,00;5,96;-128;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;460,2;9;2;6;3,06;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2ccc(-c3ccccn3)cc2)CC1;https://dx.doi.org/10.1021/jm401798r
CHEMBL242644;92291;None;0;Human;Binding;Ki;=;284,00;6,55;-128;6;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;460,2;9;2;6;3,06;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2ccc(-c3ccccn3)cc2)CC1;https://dx.doi.org/10.1021/jm0704200
CHEMBL243012;92380;None;0;Human;Binding;Ki;=;80,00;7,10;-38;3;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cells;ChEMBL;535,3;10;0;6;5,66;COc1ccc(C2=NO[C@H](CCCN3CCN(C(c4ccc(F)cc4)c4ccc(F)cc4)CC3)C2)cc1OC;https://dx.doi.org/10.1016/j.ejmech.2006.12.030
CHEMBL2430438;92407;None;0;Human;Binding;Ki;=;136,60;6,87;1;3;Displacement of [3H]-spiperone from cloned human dopamine D2 receptor;ChEMBL;458,2;9;0;8;4,21;COc1ccccc1N1CCN(CCCCn2cc(-c3ccc(-c4cnco4)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.08.047
CHEMBL2430439;92408;None;0;Human;Binding;Ki;=;181,50;6,74;-1;3;Displacement of [3H]-spiperone from cloned human dopamine D2 receptor;ChEMBL;392,2;8;0;7;2,95;COc1ccccc1N1CCN(CCCCn2cc(-c3cccnc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.08.047
CHEMBL2430440;92409;None;0;Human;Binding;Ki;=;198,80;6,70;-74;3;Displacement of [3H]-spiperone from cloned human dopamine D2 receptor;ChEMBL;406,2;8;1;7;3,14;COc1ccccc1N1CCN(CCCCn2cc(-c3ccc(N)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.08.047
CHEMBL2430441;92410;None;0;Human;Binding;Ki;=;211,70;6,67;-5;3;Displacement of [3H]-spiperone from cloned human dopamine D2 receptor;ChEMBL;421,2;9;0;7;3,56;COc1ccc(-c2cn(CCCCN3CCN(c4ccccc4OC)CC3)nn2)cc1;https://dx.doi.org/10.1016/j.bmcl.2013.08.047
CHEMBL2430442;92411;None;0;Human;Binding;Ki;=;226,60;6,64;-2;3;Displacement of [3H]-spiperone from cloned human dopamine D2 receptor;ChEMBL;469,1;8;0;6;4,32;COc1ccccc1N1CCN(CCCCn2cc(-c3ccc(Br)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.08.047
CHEMBL2430443;92412;None;0;Human;Binding;Ki;=;137,00;6,86;-4;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;391,2;8;0;6;3,56;COc1ccccc1N1CCN(CCCCn2cc(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL2430443;92412;None;0;Human;Binding;Ki;=;228,30;6,64;-4;3;Displacement of [3H]-spiperone from cloned human dopamine D2 receptor;ChEMBL;391,2;8;0;6;3,56;COc1ccccc1N1CCN(CCCCn2cc(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.08.047
CHEMBL2432039;92585;None;0;Human;Binding;Ki;=;5675,00;5,25;-28;13;Inhibition of dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;277,2;3;1;1;2,09;C1C2C3CC4C2C2C1C3[C@H](NCC13C5C6C7C5C1C7C63)C42;https://dx.doi.org/10.1016/j.bmc.2013.07.045
CHEMBL2432049;92594;None;0;Human;Binding;Ki;=;9906,00;5,00;-7;7;Inhibition of dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;266,2;4;1;2;2,36;c1ccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)nc1;https://dx.doi.org/10.1016/j.bmc.2013.07.045
CHEMBL2432058;92600;None;0;Human;Binding;Ki;=;5096,00;5,29;-5;7;Inhibition of dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;279,2;4;0;1;3,31;CN(CCc1ccccc1)[C@H]1C2C3CC4C5C3CC2C5C41;https://dx.doi.org/10.1016/j.bmc.2013.07.045
CHEMBL243224;92609;None;0;Human;Binding;Ki;=;46,00;7,34;-21;3;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cells;ChEMBL;453,3;10;0;7;4,20;CCOc1ccccc1N1CCN(CCC[C@@H]2CC(c3ccc(OC)c(OC)c3)=NO2)CC1;https://dx.doi.org/10.1016/j.ejmech.2006.12.030
CHEMBL243225;92610;None;0;Human;Binding;Ki;=;70,00;7,16;-13;3;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cells;ChEMBL;453,3;10;0;7;4,20;CCOc1ccccc1N1CCN(CCC[C@H]2CC(c3ccc(OC)c(OC)c3)=NO2)CC1;https://dx.doi.org/10.1016/j.ejmech.2006.12.030
CHEMBL243523;92638;None;0;Human;Binding;Ki;=;173,00;6,76;-24;3;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;433,3;9;1;3;5,13;CCc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL243523;92638;UNDEFINED;0;Human;Binding;pKi;=;173,00;6,76;-24;3;-;PDSP KiDatabase;433,3;9;1;3;5,13;CCc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL243742;92881;None;0;Human;Binding;Ki;=;123,00;6,91;-2;3;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;447,3;10;1;3;5,51;CCCc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL243742;92881;UNDEFINED;0;Human;Binding;pKi;=;123,00;6,91;-2;3;-;PDSP KiDatabase;447,3;10;1;3;5,51;CCCc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL243743;92892;None;0;Human;Binding;Ki;=;60,00;7,22;-1;3;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;461,3;11;1;3;5,91;CCCCc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL243743;92892;UNDEFINED;0;Human;Binding;pKi;=;60,00;7,22;-1;3;-;PDSP KiDatabase;461,3;11;1;3;5,91;CCCCc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL243744;92897;None;0;Human;Binding;Ki;=;15,00;7,82;-13;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;447,3;9;1;3;5,69;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL243744;92897;UNDEFINED;0;Human;Binding;pKi;=;15,00;7,82;-13;4;-;PDSP KiDatabase;447,3;9;1;3;5,69;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL243794;92899;None;0;Human;Binding;Ki;=;1400,00;5,85;-20;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;398,2;7;1;3;5,14;CC(=O)Nc1cccc(C2CCN(CCCC(=O)c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm060383x
CHEMBL243953;92916;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;-1;3;-;PDSP KiDatabase;461,3;8;1;3;5,86;CC(C)(C)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL243955;92917;None;0;Human;Binding;Ki;=;32,00;7,50;-35;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;448,3;9;1;4;4,63;CN(C)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL243955;92917;UNDEFINED;0;Human;Binding;pKi;=;32,00;7,49;-35;4;-;PDSP KiDatabase;448,3;9;1;4;4,63;CN(C)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL244004;92920;None;0;Human;Binding;Ki;=;6100,00;5,21;-61;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;392,2;7;1;3;5,10;CC(=O)Nc1cccc(C2CCN(CCCC(=O)c3ccc(C)c(C)c3)CC2)c1;https://dx.doi.org/10.1021/jm060383x
CHEMBL244083;92996;None;5;Human;Binding;Ki;=;398,00;6,40;-354;2;Inhibition of [125I]iodosulpiride binding to human Dopamine D2 receptor expressed in CHO cells;ChEMBL;536,2;7;1;7;4,23;Cc1nc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(S(C)(=O)=O)cc5CC4)CC3)c2)no1;https://dx.doi.org/10.1021/jm040190e
CHEMBL244083;92996;None;5;Human;Binding;Ki;=;398,11;6,40;-354;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;536,2;7;1;7;4,23;Cc1nc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(S(C)(=O)=O)cc5CC4)CC3)c2)no1;https://dx.doi.org/10.1021/jm030817d
CHEMBL244161;93060;None;0;Human;Binding;Ki;=;107,00;6,97;-5;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;434,3;9;2;4;4,60;CNc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL244161;93060;UNDEFINED;0;Human;Binding;pKi;=;107,00;6,97;-5;4;-;PDSP KiDatabase;434,3;9;2;4;4,60;CNc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL2443000;93175;None;0;Human;Binding;Ki;=;3400,00;5,47;-33;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;407,2;12;0;8;1,61;COc1ccccc1N1CCN(Cc2cn(CCOCCOCCF)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443000;93175;None;0;Human;Binding;Ki;=;7700,00;5,11;-33;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;407,2;12;0;8;1,61;COc1ccccc1N1CCN(Cc2cn(CCOCCOCCF)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443001;93176;None;0;Human;Binding;Ki;=;8300,00;5,08;-9;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;451,3;15;0;9;1,63;COc1ccccc1N1CCN(Cc2cn(CCOCCOCCOCCF)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443001;93176;None;0;Human;Binding;Ki;=;4700,00;5,33;-9;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;451,3;15;0;9;1,63;COc1ccccc1N1CCN(Cc2cn(CCOCCOCCOCCF)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443002;93177;None;0;Human;Binding;Ki;=;42000,00;4,38;-63;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;437,2;6;3;10;-0,44;COc1ccccc1N1CCN(Cc2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3F)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443002;93177;None;0;Human;Binding;Ki;=;23000,00;4,64;-63;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;437,2;6;3;10;-0,44;COc1ccccc1N1CCN(Cc2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3F)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443003;93178;None;0;Human;Binding;Ki;=;51000,00;4,29;-102;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;437,2;6;3;10;-0,44;COc1ccccc1N1CCN(Cc2cn([C@@H]3O[C@H](CF)[C@@H](O)[C@H](O)[C@H]3O)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443003;93178;None;0;Human;Binding;Ki;=;24000,00;4,62;-102;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;437,2;6;3;10;-0,44;COc1ccccc1N1CCN(Cc2cn([C@@H]3O[C@H](CF)[C@@H](O)[C@H](O)[C@H]3O)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443004;93179;None;0;Human;Binding;Ki;=;18000,00;4,75;-371;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;411,2;8;0;7;2,95;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCF)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443004;93179;None;0;Human;Binding;Ki;=;1600,00;5,80;-371;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;411,2;8;0;7;2,95;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCF)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443005;93180;None;0;Human;Binding;Ki;=;520,00;6,28;-81;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;425,2;9;0;7;3,34;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCCF)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443005;93180;None;0;Human;Binding;Ki;=;340,00;6,47;-81;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;425,2;9;0;7;3,34;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCCF)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443006;93181;None;0;Human;Binding;Ki;=;2700,00;5,57;-28;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;499,3;14;0;9;2,98;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCOCCOCCF)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443006;93181;None;0;Human;Binding;Ki;=;2900,00;5,54;-28;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;499,3;14;0;9;2,98;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCOCCOCCF)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443007;93182;None;0;Human;Binding;Ki;=;440,00;6,36;-36;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;469,2;12;0;8;3,35;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCCOCCF)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443007;93182;None;0;Human;Binding;Ki;=;770,00;6,11;-36;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;469,2;12;0;8;3,35;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCCOCCF)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443008;93183;None;0;Human;Binding;Ki;=;1500,00;5,82;-77;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;587,3;12;3;12;1,16;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCCOC4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4F)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443008;93183;None;0;Human;Binding;Ki;=;4100,00;5,39;-77;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;587,3;12;3;12;1,16;COc1ccccc1N1CCN(Cc2cn(-c3ccc(OCCCOC4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4F)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443009;93184;None;0;Human;Binding;Ki;=;560,00;6,25;-25;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;375,2;10;0;6;3,14;COc1ccccc1N1CCN(Cc2cn(CCCCCCF)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443009;93184;None;0;Human;Binding;Ki;=;460,00;6,34;-25;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;375,2;10;0;6;3,14;COc1ccccc1N1CCN(Cc2cn(CCCCCCF)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443010;93185;None;0;Human;Binding;Ki;=;1600,00;5,80;-47;5;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;363,2;9;0;7;1,59;COc1ccccc1N1CCN(Cc2cn(CCOCCF)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL2443010;93185;None;0;Human;Binding;Ki;=;750,00;6,12;-47;5;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;363,2;9;0;7;1,59;COc1ccccc1N1CCN(Cc2cn(CCOCCF)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.09.026
CHEMBL244372;93227;None;0;Human;Binding;Ki;=;780,00;6,11;-9;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;474,2;9;1;3;6,36;O=C(Cc1ccccc1)Nc1cccc(C2CCN(CCCC(=O)c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm060383x
CHEMBL244374;93229;None;0;Human;Binding;Ki;=;1300,00;5,89;-41;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;442,3;7;1;3;6,76;Cc1ccc(Oc2cccc(CN3CCC(c4cccc(NC(=O)C(C)C)c4)CC3)c2)cc1;https://dx.doi.org/10.1021/jm060383x
CHEMBL244562;93252;None;0;Human;Binding;IC50;=;41,00;7,39;-38;5;"Functional Assay: To measure D2 and D3 stimulation of mitogenesis (agonist assay) or D2 and D3 inhibition of quinpirole stimulation of mitogenesis (antagonist assay), CHOp-cells (human receptor) were seeded in a 96-well plate at a concentration of 5,000 cells/well. The cells were incubated at 37C. in alpha -MEM with 10% FBS, 0.05% penicillin-streptomycin, and 200 ug/mL of G418. After 48 hours, the cells were rinsed twice with serum-free alpha -MEM and incubated for 24 hours at 37 C. In the functional assay for agonism, the medium was removed and replaced with 90 ul of serum-free alpha -MEM and 10 ul of test compound in sterile water; in the antagonist assay, the test compound was diluted in sterile water plus 30 nM quinpirole. After another 24-hour incubation at 37 C., 0.25 uCi of [3H]thymidine was added to each well and the plates were further incubated for 2 hours at 37 C. The cells were then trypsinized, and the plates were filtered and counted as usual in the art.";ChEMBL;496,1;7;2;4;4,46;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2cccc(=O)[nH]2)cc1;-
CHEMBL244562;93252;None;0;Human;Binding;Ki;=;23,60;7,63;-38;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;496,1;7;2;4;4,46;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2cccc(=O)[nH]2)cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL244577;93255;None;0;Human;Binding;Ki;=;292,00;6,54;-10;3;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;423,3;8;1;3;4,70;O=C(CCCCCN1CCN(c2ccccc2F)CC1)NC1CCCc2ccccc21;https://dx.doi.org/10.1021/jm070487n
CHEMBL244577;93255;UNDEFINED;0;Human;Binding;pKi;=;292,00;6,53;-10;3;-;PDSP KiDatabase;423,3;8;1;3;4,70;O=C(CCCCCN1CCN(c2ccccc2F)CC1)NC1CCCc2ccccc21;-
CHEMBL244773;93275;None;0;Human;Binding;IC50;=;368,00;6,43;-57;5;"Functional Assay: To measure D2 and D3 stimulation of mitogenesis (agonist assay) or D2 and D3 inhibition of quinpirole stimulation of mitogenesis (antagonist assay), CHOp-cells (human receptor) were seeded in a 96-well plate at a concentration of 5,000 cells/well. The cells were incubated at 37C. in alpha -MEM with 10% FBS, 0.05% penicillin-streptomycin, and 200 ug/mL of G418. After 48 hours, the cells were rinsed twice with serum-free alpha -MEM and incubated for 24 hours at 37 C. In the functional assay for agonism, the medium was removed and replaced with 90 ul of serum-free alpha -MEM and 10 ul of test compound in sterile water; in the antagonist assay, the test compound was diluted in sterile water plus 30 nM quinpirole. After another 24-hour incubation at 37 C., 0.25 uCi of [3H]thymidine was added to each well and the plates were further incubated for 2 hours at 37 C. The cells were then trypsinized, and the plates were filtered and counted as usual in the art.";ChEMBL;494,2;7;1;4;5,47;Cc1cccnc1-c1ccc(C(=O)NC/C=C/CN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;-
CHEMBL244773;93275;None;0;Human;Binding;Ki;=;92,00;7,04;-57;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;494,2;7;1;4;5,47;Cc1cccnc1-c1ccc(C(=O)NC/C=C/CN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL244774;93276;None;0;Human;Binding;IC50;=;22,90;7,64;-23;5;"Functional Assay: To measure D2 and D3 stimulation of mitogenesis (agonist assay) or D2 and D3 inhibition of quinpirole stimulation of mitogenesis (antagonist assay), CHOp-cells (human receptor) were seeded in a 96-well plate at a concentration of 5,000 cells/well. The cells were incubated at 37C. in alpha -MEM with 10% FBS, 0.05% penicillin-streptomycin, and 200 ug/mL of G418. After 48 hours, the cells were rinsed twice with serum-free alpha -MEM and incubated for 24 hours at 37 C. In the functional assay for agonism, the medium was removed and replaced with 90 ul of serum-free alpha -MEM and 10 ul of test compound in sterile water; in the antagonist assay, the test compound was diluted in sterile water plus 30 nM quinpirole. After another 24-hour incubation at 37 C., 0.25 uCi of [3H]thymidine was added to each well and the plates were further incubated for 2 hours at 37 C. The cells were then trypsinized, and the plates were filtered and counted as usual in the art.";ChEMBL;496,1;7;1;4;4,40;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2cccc[n+]2[O-])cc1;-
CHEMBL244774;93276;None;0;Human;Binding;Ki;=;25,80;7,59;-23;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;496,1;7;1;4;4,40;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2cccc[n+]2[O-])cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL244775;93277;None;1;Human;Binding;Ki;=;1160,00;5,94;-23;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;496,1;7;1;4;5,18;O=C(NC/C=C/C[N+]1([O-])CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL244946;93321;None;8;Human;Binding;Ki;=;9549,93;5,02;-3801;10;Binding affinity to human recombinant dopamine D2;ChEMBL;537,3;7;0;8;5,63;Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc(-c6cc(C)nn6C)cc5CC4)n3C)cccc2n1;https://dx.doi.org/10.1021/jm0705612
CHEMBL244946;93321;None;8;Human;Binding;Ki;=;316,23;6,50;-3801;10;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;537,3;7;0;8;5,63;Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc(-c6cc(C)nn6C)cc5CC4)n3C)cccc2n1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL244989;93326;None;0;Human;Binding;IC50;=;179,00;6,75;-12;5;"Functional Assay: To measure D2 and D3 stimulation of mitogenesis (agonist assay) or D2 and D3 inhibition of quinpirole stimulation of mitogenesis (antagonist assay), CHOp-cells (human receptor) were seeded in a 96-well plate at a concentration of 5,000 cells/well. The cells were incubated at 37C. in alpha -MEM with 10% FBS, 0.05% penicillin-streptomycin, and 200 ug/mL of G418. After 48 hours, the cells were rinsed twice with serum-free alpha -MEM and incubated for 24 hours at 37 C. In the functional assay for agonism, the medium was removed and replaced with 90 ul of serum-free alpha -MEM and 10 ul of test compound in sterile water; in the antagonist assay, the test compound was diluted in sterile water plus 30 nM quinpirole. After another 24-hour incubation at 37 C., 0.25 uCi of [3H]thymidine was added to each well and the plates were further incubated for 2 hours at 37 C. The cells were then trypsinized, and the plates were filtered and counted as usual in the art.";ChEMBL;453,2;7;1;4;4,38;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2ccc3c(c2)Cc2ccccc2-3)CC1;-
CHEMBL244989;93326;None;0;Human;Binding;Ki;=;48,40;7,32;-12;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;453,2;7;1;4;4,38;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2ccc3c(c2)Cc2ccccc2-3)CC1;https://dx.doi.org/10.1021/jm0704200
CHEMBL244990;93328;None;0;Human;Binding;IC50;=;15,80;7,80;-89;6;"Functional Assay: To measure D2 and D3 stimulation of mitogenesis (agonist assay) or D2 and D3 inhibition of quinpirole stimulation of mitogenesis (antagonist assay), CHOp-cells (human receptor) were seeded in a 96-well plate at a concentration of 5,000 cells/well. The cells were incubated at 37C. in alpha -MEM with 10% FBS, 0.05% penicillin-streptomycin, and 200 ug/mL of G418. After 48 hours, the cells were rinsed twice with serum-free alpha -MEM and incubated for 24 hours at 37 C. In the functional assay for agonism, the medium was removed and replaced with 90 ul of serum-free alpha -MEM and 10 ul of test compound in sterile water; in the antagonist assay, the test compound was diluted in sterile water plus 30 nM quinpirole. After another 24-hour incubation at 37 C., 0.25 uCi of [3H]thymidine was added to each well and the plates were further incubated for 2 hours at 37 C. The cells were then trypsinized, and the plates were filtered and counted as usual in the art.";ChEMBL;498,2;8;2;5;4,36;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;-
CHEMBL244990;93328;None;0;Human;Binding;Ki;=;267,00;6,57;-89;6;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;498,2;8;2;5;4,36;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL245010;93332;None;0;Human;Binding;Ki;=;110,00;6,96;-20;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;462,2;7;1;3;7,11;CC(C)C(=O)Nc1cccc(C2CCN(Cc3ccc(Oc4ccc(Cl)cc4)cc3)CC2)c1;https://dx.doi.org/10.1021/jm060383x
CHEMBL24515;93355;None;7;Human;Binding;Ki;=;19,50;7,71;-38;3;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;401,2;8;1;4;3,68;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL245229;93363;None;0;Human;Binding;Ki;=;1400,00;5,85;-40;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;458,3;8;1;4;6,46;COc1ccc(Oc2ccc(CN3CCC(c4cccc(NC(=O)C(C)C)c4)CC3)cc2)cc1;https://dx.doi.org/10.1021/jm060383x
CHEMBL245231;93365;None;0;Human;Binding;Ki;=;470,00;6,33;-257;3;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;464,2;7;1;3;6,73;CC(C)C(=O)Nc1cccc(C2CCN(Cc3ccc(Oc4ccc(F)c(F)c4)cc3)CC2)c1;https://dx.doi.org/10.1021/jm060383x
CHEMBL24539;93393;None;0;Human;Binding;Ki;=;1100,00;5,96;-40;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;319,2;4;0;5;3,18;c1ccc(CN2CCC(n3nnc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL245570;93419;None;0;Human;Binding;Ki;=;43,65;7,36;-104;4;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;306,2;0;2;2;3,50;CN1CCc2ccccc2Cc2[nH]c3ccc(O)cc3c2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL245570;93419;None;0;Human;Binding;Ki;=;38,40;7,42;-104;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;306,2;0;2;2;3,50;CN1CCc2ccccc2Cc2[nH]c3ccc(O)cc3c2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL245571;93420;None;0;Human;Binding;Ki;=;74,70;7,13;-19;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;306,2;0;2;2;3,50;CN1CCc2cc(O)ccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL245614;93423;None;1;Human;Binding;Ki;=;177,00;6,75;3;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;336,2;4;2;3;3,66;COc1ccc(C2(O)CCN(Cc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL245615;93424;None;1;Human;Binding;Ki;=;98,40;7,01;1;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;382,2;4;2;2;5,32;OC1(c2ccc(-c3ccccc3)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL245764;93454;None;0;Human;Binding;Ki;=;1,70;8,77;-7;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;334,2;1;0;3;3,81;COc1ccc2c(c1)c1c(n2C)Cc2ccccc2CCN(C)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL245815;93462;None;4;Human;Binding;Ki;=;2890,00;5,54;1;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;354,1;4;2;2;4,39;OC1(Cc2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL245816;93463;None;4;Human;Binding;Ki;=;4265,00;5,37;-1;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCCN(Cc2c[nH]c3ccccc23)C1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL24588;93480;None;0;Human;Binding;Ki;=;93,00;7,03;-2;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;231,2;2;1;2;2,91;CCCN1CC[C@@H]2c3cccc(O)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL246020;93502;None;0;Human;Binding;Ki;=;992,00;6,00;2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;338,2;3;1;1;5,38;CC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246021;93503;None;0;Human;Binding;Ki;=;83,10;7,08;2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;381,2;4;2;2;4,45;CC(=O)NC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246230;93544;None;0;Human;Binding;Ki;=;199,00;6,70;3;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;349,1;3;1;2;4,88;N#CC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246231;93545;None;0;Human;Binding;Ki;=;60,00;7,22;9;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;382,1;4;1;3;4,53;COC(=O)C1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246437;93608;None;0;Human;Binding;Ki;=;2370,00;5,62;-22;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;354,1;4;2;2;4,35;OCC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246438;93609;None;0;Human;Binding;Ki;=;68,10;7,17;-1;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;354,1;4;1;2;4,96;COC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246439;93610;None;2;Human;Binding;Ki;=;15,40;7,81;2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;354,1;3;2;2;4,61;Cc1[nH]c2ccccc2c1CN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246484;93624;None;0;Human;Binding;Ki;=;112,20;6,95;-52;7;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;368,2;3;1;5;3,31;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2[nH]ncc21;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL246637;93660;None;1;Human;Binding;Ki;=;6,90;8,16;15;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;374,1;3;2;2;4,96;OC1(c2ccc(Cl)c(Cl)c2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm800532x
CHEMBL246637;93660;None;1;Human;Binding;Ki;=;6,90;8,16;15;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;374,1;3;2;2;4,96;OC1(c2ccc(Cl)c(Cl)c2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246642;93662;None;2;Human;Binding;Ki;=;438,00;6,36;-2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;375,1;3;2;3;4,35;OC1(c2ccc(Cl)c(Cl)c2)CCN(Cc2n[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246643;93663;None;1;Human;Binding;Ki;=;21,00;7,68;1;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;375,1;3;1;3;5,22;OC1(c2ccc(Cl)c(Cl)c2)CCN(Cc2coc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246644;93664;None;1;Human;Binding;Ki;=;21,00;7,68;2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;341,1;3;1;3;4,57;OC1(c2ccc(Cl)cc2)CCN(Cc2coc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246848;93708;None;1;Human;Binding;Ki;=;106,00;6,97;5;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;374,2;3;2;2;4,67;OC1(c2cccc(C(F)(F)F)c2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246849;93709;None;1;Human;Binding;Ki;=;127,00;6,90;3;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;324,2;3;2;2;3,79;OC1(c2ccc(F)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246854;93711;None;1;Human;Binding;Ki;=;54,00;7,27;2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;353,1;4;1;4;4,64;CSc1ccc(C2(O)CCN(Cc3coc4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL246855;93712;None;1;Human;Binding;Ki;=;188,00;6,73;2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;424,2;8;1;3;6,36;CCCCCCn1cc(CN2CCC(O)(c3ccc(Cl)cc3)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL247058;93753;None;8;Human;Binding;Ki;=;5,50;8,26;102;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;382,2;5;2;4;4,38;COc1ccc2[nH]cc(CN3CCC(O)(c4ccc(SC)cc4)CC3)c2c1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL24809;93946;None;0;Human;Binding;Ki;=;310,00;6,51;-2;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;331,2;4;0;3;4,70;Cc1cc(-c2ccccc2)n(C2CCN(Cc3ccccc3)CC2)n1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL249854;94269;None;0;Human;Binding;IC50;=;640,00;6,19;-;4;Inhibition of dopamine D2 receptor;ChEMBL;529,3;7;2;6;4,11;CC(=O)c1sc(NC(=O)N[C@@H]2CN(C(C)=O)CC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)nc1C;https://dx.doi.org/10.1016/j.bmcl.2007.03.065
CHEMBL250552;94367;None;0;Human;Binding;Ki;=;26,00;7,58;-31;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL250552;94367;None;0;Human;Binding;Ki;=;238,00;6,62;-31;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL250552;94367;None;0;Human;Binding;Ki;=;58,60;7,23;-31;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL250689;94398;None;2;Human;Binding;IC50;=;1000,00;6,00;-;4;Inhibition of dopamine D2 receptor;ChEMBL;465,3;7;2;3;5,66;CC(=O)c1cccc(NC(=O)N[C@@H]2CCCC[C@H]2CN2CCC[C@@H](Cc3ccc(F)cc3)C2)c1;https://dx.doi.org/10.1016/j.bmcl.2007.03.065
CHEMBL251834;94602;None;0;Human;Binding;Ki;=;3,00;8,52;-38;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;473,2;6;1;7;4,07;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccno1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL251834;94602;UNDEFINED;0;Human;Binding;pKi;=;3,00;8,52;-38;4;-;PDSP KiDatabase;473,2;6;1;7;4,07;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccno1;-
CHEMBL251835;94603;None;0;Human;Binding;Kd;=;125,89;6,90;-338;10;Binding affinity to human dopamine D2 receptor;ChEMBL;534,1;2;1;6;3,77;CN1C[C@H](C(=O)N2CCN(c3ccc4nonc4c3)CC2)C[C@@H]2c3cccc4[nH]c(Br)c(c34)C[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2007.12.030
CHEMBL252030;94636;None;0;Human;Binding;Ki;=;15,00;7,82;-45;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;420,2;5;1;5;3,78;CC(=O)NC1CCc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc21;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL252030;94636;UNDEFINED;0;Human;Binding;pKi;=;15,00;7,82;-45;4;-;PDSP KiDatabase;420,2;5;1;5;3,78;CC(=O)NC1CCc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc21;-
CHEMBL252201;94660;None;0;Human;Binding;Ki;=;33,00;7,48;-34;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;510,2;8;1;5;5,40;O=C(CCc1ccccc1)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL252201;94660;UNDEFINED;0;Human;Binding;pKi;=;33,00;7,48;-34;4;-;PDSP KiDatabase;510,2;8;1;5;5,40;O=C(CCc1ccccc1)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;-
CHEMBL252342;94692;None;0;Human;Binding;Ki;=;638,00;6,20;-28;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;392,3;7;1;4;3,66;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2ccc(N)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL252343;94693;None;0;Human;Binding;Ki;=;90,60;7,04;-8;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;432,3;7;1;4;3,57;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2ccc3c(c2C1)CC(=O)N3;https://dx.doi.org/10.1021/jm070860r
CHEMBL252429;94698;None;0;Human;Binding;Ki;=;10,00;8,00;-6;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;500,2;6;1;5;5,22;O=C(NC1CCc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc21)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL252429;94698;UNDEFINED;0;Human;Binding;pKi;=;10,00;8,00;-6;4;-;PDSP KiDatabase;500,2;6;1;5;5,22;O=C(NC1CCc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc21)c1ccc(F)cc1;-
CHEMBL252430;94699;None;0;Human;Binding;Ki;=;5,00;8,30;-7;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;483,2;6;1;6;4,47;O=C(NC1CCc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc21)c1cccnc1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL252430;94699;UNDEFINED;0;Human;Binding;pKi;=;5,00;8,30;-7;4;-;PDSP KiDatabase;483,2;6;1;6;4,47;O=C(NC1CCc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc21)c1cccnc1;-
CHEMBL252539;94716;None;0;Human;Binding;Ki;=;14,60;7,84;-32;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;461,2;7;1;4;5,09;CCCN(CCN1CCN(c2cccc(Cl)c2Cl)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL252816;94750;None;0;Human;Binding;Ki;=;10,00;8,00;-5;3;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;474,2;5;1;5;4,33;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)C(F)(F)F;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL252816;94750;UNDEFINED;0;Human;Binding;pKi;=;10,00;8,00;-5;3;-;PDSP KiDatabase;474,2;5;1;5;4,33;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)C(F)(F)F;-
CHEMBL252818;94751;None;0;Human;Binding;Ki;=;22,00;7,66;-2187;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;420,2;5;1;5;3,78;CC(=O)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL252818;94751;UNDEFINED;0;Human;Binding;pKi;=;22,00;7,66;-2187;4;-;PDSP KiDatabase;420,2;5;1;5;3,78;CC(=O)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;-
CHEMBL253022;94778;None;0;Human;Binding;Ki;=;34,00;7,47;-3388;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;434,2;6;1;5;4,17;CCC(=O)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL253022;94778;UNDEFINED;0;Human;Binding;pKi;=;34,00;7,47;-3388;4;-;PDSP KiDatabase;434,2;6;1;5;4,17;CCC(=O)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;-
CHEMBL253024;94779;None;0;Human;Binding;Ki;=;21,00;7,68;-69;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;446,2;6;1;5;4,17;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)C1CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL253024;94779;UNDEFINED;0;Human;Binding;pKi;=;21,00;7,68;-69;4;-;PDSP KiDatabase;446,2;6;1;5;4,17;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)C1CC1;-
CHEMBL253233;94820;None;0;Human;Binding;Ki;=;22,00;7,66;-4;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;482,2;6;1;5;5,08;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL253233;94820;UNDEFINED;0;Human;Binding;pKi;=;22,00;7,66;-4;4;-;PDSP KiDatabase;482,2;6;1;5;5,08;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccccc1;-
CHEMBL253318;94838;None;0;Human;Binding;Ki;=;6110,00;5,21;-112;6;In vitro binding affinity towards cloned human Dopamine receptor D2A using [3H]- Raclopride as radioligand.;ChEMBL;276,1;0;1;2;2,77;CN1CCc2ccc3[nH]c(=O)c4cccc5c4c3c2[C@H]1C5;https://dx.doi.org/10.1016/s0960-894x(00)00655-7
CHEMBL253319;94839;None;0;Human;Binding;Ki;=;54,60;7,26;1;5;In vitro binding affinity towards cloned human Dopamine receptor D2A using [3H]- Raclopride as radioligand.;ChEMBL;276,1;0;1;2;2,77;CN1CCc2ccc3c(=O)[nH]c4cccc5c4c3c2[C@H]1C5;https://dx.doi.org/10.1016/s0960-894x(00)00655-7
CHEMBL253439;94852;None;0;Human;Binding;Ki;=;5,00;8,30;-50;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;516,2;6;1;5;5,73;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL253439;94852;UNDEFINED;0;Human;Binding;pKi;=;5,00;8,30;-50;4;-;PDSP KiDatabase;516,2;6;1;5;5,73;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccc(Cl)cc1;-
CHEMBL253878;94917;None;0;Human;Binding;Ki;=;26,00;7,58;-660;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;496,2;7;1;5;5,01;O=C(Cc1ccccc1)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL253878;94917;UNDEFINED;0;Human;Binding;pKi;=;26,00;7,59;-660;4;-;PDSP KiDatabase;496,2;7;1;5;5,01;O=C(Cc1ccccc1)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;-
CHEMBL253992;94934;None;0;Human;Binding;Ki;=;649,00;6,19;-57;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2cc(O)ccc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL254198;94960;None;0;Human;Binding;Ki;=;167,00;6,78;-16;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;407,3;8;1;4;4,17;CCCN(CCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL254199;94961;None;0;Human;Binding;Ki;=;24,60;7,61;-1;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;461,3;8;1;5;4,68;Oc1ccc2c(c1)CC(N(CCc1cccs1)CCN1CCN(c3ccccc3)CC1)CC2;https://dx.doi.org/10.1021/jm070860r
CHEMBL254202;94962;None;0;Human;Binding;Ki;=;70,30;7,15;-51;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;409,3;7;2;5;3,49;CCCN(CCN1CCN(c2ccccc2)CC1)C1CCc2cc(O)c(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL254203;94963;None;0;Human;Binding;Ki;=;21,70;7,66;-7;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;437,3;9;2;5;4,27;CCCN(CCCCN1CCN(c2ccccc2)CC1)C1CCc2cc(O)c(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL25483;95053;None;0;Human;Binding;Ki;=;4,10;8,39;3;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;229,1;2;1;2;2,68;C=CCN1CC[C@@H]2c3cccc(O)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL255163;95106;None;0;Human;Binding;Ki;=;590,00;6,23;-7;5;Binding affinity to human dopamine D2 long receptor;ChEMBL;348,1;6;0;3;4,01;FCCOc1cccc(CN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
CHEMBL256040;95273;None;0;Human;Binding;Ki;=;103,00;6,99;-2;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;538,2;6;2;4;6,69;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(Cl)cc(Cl)cc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256040;95273;None;0;Human;Binding;Ki;=;6,50;8,19;-2;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;538,2;6;2;4;6,69;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(Cl)cc(Cl)cc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256040;95273;UNDEFINED;0;Human;Binding;pKi;=;103,00;6,99;-2;4;-;PDSP KiDatabase;538,2;6;2;4;6,69;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(Cl)cc(Cl)cc3Cl)CC2)CC1;-
CHEMBL256040;95273;UNDEFINED;0;Human;Binding;pKi;=;6,50;8,19;-2;4;-;PDSP KiDatabase;538,2;6;2;4;6,69;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(Cl)cc(Cl)cc3Cl)CC2)CC1;-
CHEMBL256041;95274;None;0;Human;Binding;Ki;=;183,00;6,74;-5;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;468,3;7;2;4;4,55;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)NCc3cccc(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256041;95274;None;0;Human;Binding;Ki;=;120,00;6,92;-5;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;468,3;7;2;4;4,55;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)NCc3cccc(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256041;95274;UNDEFINED;0;Human;Binding;pKi;=;183,00;6,74;-5;4;-;PDSP KiDatabase;468,3;7;2;4;4,55;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)NCc3cccc(F)c3)CC2)CC1;-
CHEMBL256041;95274;UNDEFINED;0;Human;Binding;pKi;=;120,00;6,92;-5;4;-;PDSP KiDatabase;468,3;7;2;4;4,55;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)NCc3cccc(F)c3)CC2)CC1;-
CHEMBL256492;95370;None;0;Human;Binding;Ki;=;310,00;6,51;-169;5;Binding affinity to human dopamine D2 long receptor;ChEMBL;374,2;8;0;5;3,37;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCCF;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
CHEMBL256597;95390;None;0;Human;Binding;Ki;=;4,70;8,33;-1;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;504,2;6;2;4;6,04;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(Cl)cccc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256597;95390;None;0;Human;Binding;Ki;=;55,00;7,26;-1;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;504,2;6;2;4;6,04;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(Cl)cccc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256597;95390;UNDEFINED;0;Human;Binding;pKi;=;55,00;7,26;-1;4;-;PDSP KiDatabase;504,2;6;2;4;6,04;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(Cl)cccc3Cl)CC2)CC1;-
CHEMBL256597;95390;UNDEFINED;0;Human;Binding;pKi;=;4,70;8,33;-1;4;-;PDSP KiDatabase;504,2;6;2;4;6,04;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(Cl)cccc3Cl)CC2)CC1;-
CHEMBL256637;95394;None;0;Human;Binding;Ki;=;760,00;6,12;-446;5;Binding affinity to human dopamine D2 long receptor;ChEMBL;408,2;8;0;5;4,03;COc1cc(CN2CCN(c3ccc(Cl)cc3)CC2)c(OCCF)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
CHEMBL256804;95433;None;0;Human;Binding;Ki;=;54,00;7,27;-7;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccc(F)c(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256804;95433;None;0;Human;Binding;Ki;=;127,00;6,90;-7;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccc(F)c(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256804;95433;UNDEFINED;0;Human;Binding;pKi;=;54,00;7,27;-7;4;-;PDSP KiDatabase;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccc(F)c(F)c3)CC2)CC1;-
CHEMBL256804;95433;UNDEFINED;0;Human;Binding;pKi;=;127,00;6,90;-7;4;-;PDSP KiDatabase;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccc(F)c(F)c3)CC2)CC1;-
CHEMBL256853;95446;None;0;Human;Binding;Ki;=;288,00;6,54;-9;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;496,3;8;2;6;4,75;COc1ccc(NC(=O)NC2CCC(N3CCN(c4ccccc4OC(C)C)CC3)CC2)c(OC)c1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256853;95446;None;0;Human;Binding;Ki;=;892,00;6,05;-9;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;496,3;8;2;6;4,75;COc1ccc(NC(=O)NC2CCC(N3CCN(c4ccccc4OC(C)C)CC3)CC2)c(OC)c1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL256853;95446;UNDEFINED;0;Human;Binding;pKi;=;892,00;6,05;-9;4;-;PDSP KiDatabase;496,3;8;2;6;4,75;COc1ccc(NC(=O)NC2CCC(N3CCN(c4ccccc4OC(C)C)CC3)CC2)c(OC)c1;-
CHEMBL256853;95446;UNDEFINED;0;Human;Binding;pKi;=;288,00;6,54;-9;4;-;PDSP KiDatabase;496,3;8;2;6;4,75;COc1ccc(NC(=O)NC2CCC(N3CCN(c4ccccc4OC(C)C)CC3)CC2)c(OC)c1;-
CHEMBL257077;95496;None;0;Human;Binding;Ki;=;108,00;6,97;-12;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;470,2;6;2;4;5,38;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3cccc(Cl)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL257077;95496;None;0;Human;Binding;Ki;=;84,00;7,08;-12;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;470,2;6;2;4;5,38;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3cccc(Cl)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL257077;95496;UNDEFINED;0;Human;Binding;pKi;=;108,00;6,97;-12;4;-;PDSP KiDatabase;470,2;6;2;4;5,38;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3cccc(Cl)c3)CC2)CC1;-
CHEMBL257077;95496;UNDEFINED;0;Human;Binding;pKi;=;84,00;7,08;-12;4;-;PDSP KiDatabase;470,2;6;2;4;5,38;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3cccc(Cl)c3)CC2)CC1;-
CHEMBL257097;95499;None;0;Human;Binding;Ki;=;199,00;6,70;-1;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3cc(F)ccc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL257097;95499;None;0;Human;Binding;Ki;=;0,46;9,34;-1;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3cc(F)ccc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL257097;95499;UNDEFINED;0;Human;Binding;pKi;=;199,00;6,70;-1;4;-;PDSP KiDatabase;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3cc(F)ccc3F)CC2)CC1;-
CHEMBL257097;95499;UNDEFINED;0;Human;Binding;pKi;=;0,46;9,34;-1;4;-;PDSP KiDatabase;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3cc(F)ccc3F)CC2)CC1;-
CHEMBL257098;95500;None;0;Human;Binding;Ki;=;33,00;7,48;-11;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;470,2;6;2;4;5,38;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccccc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL257098;95500;None;0;Human;Binding;Ki;=;878,00;6,06;-11;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;470,2;6;2;4;5,38;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccccc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL257098;95500;UNDEFINED;0;Human;Binding;pKi;=;878,00;6,06;-11;4;-;PDSP KiDatabase;470,2;6;2;4;5,38;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccccc3Cl)CC2)CC1;-
CHEMBL257098;95500;UNDEFINED;0;Human;Binding;pKi;=;33,00;7,48;-11;4;-;PDSP KiDatabase;470,2;6;2;4;5,38;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccccc3Cl)CC2)CC1;-
CHEMBL25772;95637;None;0;Human;Binding;Ki;=;140,00;6,85;-56;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;331,2;4;0;3;4,70;Cc1c(-c2ccccc2)cnn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL25815;95736;None;0;Human;Binding;Ki;=;105,00;6,98;-48;4;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;386,2;6;1;2;5,17;O=C1Nc2cccc3c2[C@]1(CCCCN1CC=C(c2ccccc2)CC1)CCC3;https://dx.doi.org/10.1021/jm0108505
CHEMBL25887;95879;None;0;Human;Binding;Ki;=;1200,00;5,92;-67;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;332,2;4;0;4;4,09;Cc1nnn(C2CCN(Cc3ccccc3)CC2)c1-c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL259199;95951;None;0;Human;Binding;IC50;=;1500,00;5,82;-;5;Binding affinity at dopamine D2 receptor;ChEMBL;573,3;11;1;8;4,15;CCOc1ccccc1N1CCN(CCCC(=O)NCc2nc3cc(F)ccc3c(=O)n2-c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.11.049
CHEMBL25924;95960;None;0;Human;Binding;Ki;=;233,00;6,63;-128;6;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;311,2;1;0;1;5,11;CN1CCc2cccc3c2[C@H]1Cc1cccc(-c2ccccc2)c1-3;https://dx.doi.org/10.1021/jm0108505
CHEMBL25924;95960;None;0;Human;Binding;Ki;=;233,00;6,63;-128;6;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;311,2;1;0;1;5,11;CN1CCc2cccc3c2[C@H]1Cc1cccc(-c2ccccc2)c1-3;https://dx.doi.org/10.1021/jm960189i
CHEMBL25938;95994;None;0;Human;Binding;Ki;=;66,00;7,18;-6;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;317,2;4;1;2;4,46;c1ccc(CN2CCC(c3cc(-c4ccccc4)[nH]n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL25938;95994;None;0;Human;Binding;Ki;=;66,00;7,18;-6;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;317,2;4;1;2;4,46;c1ccc(CN2CCC(c3cc(-c4ccccc4)[nH]n3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL259415;96002;None;0;Human;Binding;IC50;=;6900,00;5,16;-;5;Binding affinity at dopamine D2 receptor;ChEMBL;509,3;8;1;6;4,22;Cc1cccc(N2CCN(CCCC(=O)NCc3nc4ccccc4c(=O)n3-c3ccccc3)CC2)c1C;https://dx.doi.org/10.1016/j.bmc.2007.11.049
CHEMBL259776;96080;None;0;Human;Binding;IC50;=;5300,00;5,28;-;4;Binding affinity at dopamine D2 receptor;ChEMBL;529,2;9;1;7;3,75;COc1ccccc1N1CCN(CCCC(=O)NCc2nc3ccc(F)cc3c(=O)n2-c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.11.049
CHEMBL260907;96292;None;0;Human;Binding;IC50;=;1000,00;6,00;-;4;Binding affinity at dopamine D2 receptor;ChEMBL;543,3;10;1;7;4,14;CCOc1ccccc1N1CCN(CCCC(=O)NCc2nc3ccc(F)cc3c(=O)n2-c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.11.049
CHEMBL260994;96300;None;0;Human;Binding;Ki;=;960,00;6,02;-588;8;Inhibition of dopamine D2 receptor;ChEMBL;383,2;6;1;3;4,37;O=C1Nc2ccccc2C1CCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm070279v
CHEMBL261019;96306;None;0;Human;Binding;IC50;=;6600,00;5,18;-;5;Binding affinity at dopamine D2 receptor;ChEMBL;567,2;8;1;6;4,76;O=C(CCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)NCc1nc2cc(F)ccc2c(=O)n1-c1ccccc1;https://dx.doi.org/10.1016/j.bmc.2007.11.049
CHEMBL261102;96325;None;0;Human;Binding;IC50;=;1500,00;5,82;-;5;Binding affinity at dopamine D2 receptor;ChEMBL;527,3;8;1;6;4,36;Cc1cccc(N2CCN(CCCC(=O)NCc3nc4cc(F)ccc4c(=O)n3-c3ccccc3)CC2)c1C;https://dx.doi.org/10.1016/j.bmc.2007.11.049
CHEMBL26120;96344;None;0;Human;Binding;Ki;=;15,00;7,82;-12;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;356,2;4;0;4;4,57;Cc1nn(C2CCN(Cc3cccc(C#N)c3)CC2)cc1-c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL261434;96378;None;0;Human;Binding;IC50;=;4000,00;5,40;-;5;Binding affinity at dopamine D2 receptor;ChEMBL;527,3;8;1;6;4,36;Cc1cccc(N2CCN(CCCC(=O)NCc3nc4ccc(F)cc4c(=O)n3-c3ccccc3)CC2)c1C;https://dx.doi.org/10.1016/j.bmc.2007.11.049
CHEMBL26181;96442;None;4;Human;Binding;EC50;=;2,53;8,60;4;4;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;273,2;5;1;4;2,79;CCCN(CCC)[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL26181;96442;None;4;Human;Binding;Ki;=;11,40;7,94;4;4;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;273,2;5;1;4;2,79;CCCN(CCC)[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL26188;96454;None;0;Human;Binding;Ki;=;90,00;7,05;-53;4;Binding affinity to D2 short receptor;ChEMBL;367,2;8;1;4;3,03;COc1ccccc1N1CCN(CCCCNC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL26188;96454;None;0;Human;Binding;Ki;=;130,00;6,89;-53;4;Binding affinity to D2 long receptor;ChEMBL;367,2;8;1;4;3,03;COc1ccccc1N1CCN(CCCCNC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2011.10.063
CHEMBL262469;96544;None;0;Human;Binding;Ki;=;11,00;7,96;-8;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;570,3;8;0;7;5,76;COc1cccc(OC)c1CC(=O)N1CCC(C)c2cccc(CCN3CCN(c4nsc5ccccc45)CC3)c21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL262724;96573;None;0;Human;Binding;Ki;=;29,60;7,53;-21;4;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;457,1;7;1;5;4,27;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2n1;https://dx.doi.org/10.1021/jm040190e
CHEMBL262724;96573;None;0;Human;Binding;Ki;=;29,60;7,53;-21;4;Binding affinity for human dopamine D2 receptor;ChEMBL;457,1;7;1;5;4,27;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2n1;https://dx.doi.org/10.1021/jm049465g
CHEMBL262724;96573;None;0;Human;Binding;Ki;=;58,30;7,23;-21;4;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;457,1;7;1;5;4,27;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2n1;https://dx.doi.org/10.1021/jm040190e
CHEMBL263162;96642;None;0;Human;Binding;Ki;=;52,00;7,28;-47;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;361,2;4;1;4;4,71;Cc1ccc(-c2nc(O)n(C3CCN(Cc4ccccc4)CC3)c2C)cc1;https://dx.doi.org/10.1021/jm991029k
CHEMBL263282;96653;None;0;Human;Binding;Ki;=;3,60;8,44;-34;3;Tested for the inhibitory activity against D2H (high-affinity states) receptor in infected HEK 293 cells.;ChEMBL;371,1;5;1;2;3,91;CCCN(C/C=C/I)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00050a021
CHEMBL263282;96653;None;0;Human;Binding;Ki;=;324,00;6,49;-34;3;Tested for the inhibitory activity against Dopamine D2 receptor in infected Sf9 cells;ChEMBL;371,1;5;1;2;3,91;CCCN(C/C=C/I)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00050a021
CHEMBL263329;96660;None;0;Human;Binding;Ki;=;9,10;8,04;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;405,2;7;1;4;4,47;c1cc2c(c(N3CCN(CCCCCc4c[nH]c5ccccc45)CC3)c1)OCCO2;https://dx.doi.org/10.1021/jm050148z
CHEMBL26365;96701;None;0;Human;Binding;Ki;=;890,00;6,05;-2;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;286,1;0;3;4;2,18;Oc1cc2c(cc1O)[C@H]1c3cncc(F)c3CN[C@@H]1CC2;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL264394;96790;None;0;Human;Binding;Ki;=;310,00;6,51;-;1;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;446,1;6;0;6;6,39;Cc1noc(-c2ccc(CSc3nc4ccccc4n3Cc3ccc(Cl)cc3)cc2)n1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL26471;96826;None;0;Human;Binding;Ki;=;317,00;6,50;-2;3;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;261,1;0;0;2;2,98;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)C3=O;https://dx.doi.org/10.1021/jm9911433
CHEMBL26560;96933;None;0;Human;Binding;Ki;=;218,00;6,66;4;2;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;231,2;2;1;2;2,91;CCCN1CC[C@H]2c3cccc(O)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL266018;96983;None;0;Human;Binding;Ki;=;158,49;6,80;-79;6;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;358,2;6;2;3;3,52;CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CCNCC3)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL266723;97073;None;0;Human;Binding;Ki;=;1100,00;5,96;-14;4;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;340,1;0;0;4;3,75;CN1CCN(C2=Nc3cc(Cl)ccc3N(C)c3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL26677;97079;None;0;Human;Binding;IC50;=;13,00;7,89;-;5;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;368,2;8;0;5;3,49;COc1cccc(C(=O)CCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm981041x
CHEMBL26751;97156;None;0;Human;Binding;Ki;=;23,80;7,62;-1;4;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;263,1;0;1;2;2,83;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@H]3O;https://dx.doi.org/10.1021/jm9911433
CHEMBL267557;97162;None;0;Human;Binding;Ki;=;235,00;6,63;-5;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;229,1;2;1;2;2,37;C=CCN1CC[C@H]2Cc3c(O)cccc3C[C@@H]21;https://dx.doi.org/10.1021/jm00060a015
CHEMBL267562;97164;None;0;Human;Binding;Ki;=;625,00;6,20;-2;4;Binding affinity at human dopamine receptor D2;ChEMBL;487,1;6;0;2;7,57;Fc1ccc(C(OC2CC3CCC(C2)N3Cc2ccc(Cl)c(Cl)c2)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/jm010146o
CHEMBL26789;97200;None;1;Human;Binding;Ki;=;20,60;7,69;1;3;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;248,2;5;0;3;2,62;CCCCN1CCN(c2ccccc2OC)CC1;https://dx.doi.org/10.1021/jm300482h
CHEMBL268371;97253;None;0;Human;Binding;Ki;=;323,00;6,49;-1;3;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;417,2;6;0;3;4,20;O=C1Cc2ccccc2N1CCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL26853;97274;None;2;Human;Binding;Ki;=;300,00;6,52;-15;3;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;379,2;6;0;5;2,50;COc1ccccc1N1CCN(CCCN2C(=O)c3ccccc3C2=O)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL268799;97305;None;5;Human;Binding;Ki;=;71,00;7,15;-53;5;Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand;ChEMBL;325,1;3;1;2;4,14;Clc1ccc(N2CCN(Cc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm9600712
CHEMBL269004;97337;None;1;Human;Binding;EC50;=;41,00;7,39;-15;6;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmc.2022.117131
CHEMBL269004;97337;None;1;Human;Binding;Ki;=;7,10;8,15;-15;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL269004;97337;None;1;Human;Binding;Ki;=;14,00;7,85;-15;6;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL269004;97337;None;1;Human;Binding;Ki;=;6,00;8,22;-15;6;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL26907;97348;None;0;Human;Binding;Ki;=;3380,00;5,47;-100;4;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;341,2;1;1;2;5,12;Cc1cccc(O)c1-c1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm0108505
CHEMBL26907;97348;None;0;Human;Binding;Ki;=;2500,00;5,60;-100;4;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;341,2;1;1;2;5,12;Cc1cccc(O)c1-c1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm0108505
CHEMBL26929;97384;None;0;Human;Binding;IC50;=;20,00;7,70;-;4;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;394,3;7;0;4;4,73;COc1ccccc1N1CCN(CCCC2CCCc3c(OC)cccc32)CC1;https://dx.doi.org/10.1021/jm981041x
CHEMBL269396;97396;None;0;Human;Binding;Ki;=;1400,00;5,85;-1;2;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;323,1;1;0;1;5,47;CC1CCN(C2=Cc3cc(Cl)ccc3Cc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL26962;97422;None;0;Human;Binding;Ki;=;168,00;6,78;-275;4;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;373,3;8;1;4;3,29;COc1ccccc1N1CCN(CCCCNC(=O)C2CCCCC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL26965;97429;None;0;Human;Binding;Ki;=;450,00;6,35;-10;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;310,2;2;3;4;3,00;CCCc1ccc2c(n1)CN[C@@H]1CCc3cc(O)c(O)cc3[C@@H]21;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL26998;97482;None;12;Human;Binding;Ki;=;90,00;7,05;-380;11;In vitro binding affinity towards Dopamine receptor D2 by using [3H]U-86170 as radioligand;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2cccc(O)c2C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL26998;97482;None;12;Human;Binding;Ki;=;93,00;7,03;-380;11;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2cccc(O)c2C1;https://dx.doi.org/10.1021/jm00067a003
CHEMBL26998;97482;None;12;Human;Binding;Ki;=;819,00;6,09;-380;11;Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2cccc(O)c2C1;https://dx.doi.org/10.1021/jm9911433
CHEMBL270056;97500;None;0;Human;Binding;Ki;=;330,00;6,48;2;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;311,2;3;0;5;2,19;Fc1cccc(N2CCN(Cc3cnn4ccccc34)CC2)n1;https://dx.doi.org/10.1021/jm701375u
CHEMBL270056;97500;None;0;Human;Binding;Ki;=;220,00;6,66;2;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;311,2;3;0;5;2,19;Fc1cccc(N2CCN(Cc3cnn4ccccc34)CC2)n1;https://dx.doi.org/10.1021/jm701375u
CHEMBL270406;97571;None;0;Human;Binding;Ki;=;94,00;7,03;-72;5;Binding affinity to human dopamine D2 long receptor;ChEMBL;404,2;9;0;6;3,38;COc1cc(CN2CCN(c3ccccc3OC)CC2)c(OCCF)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
CHEMBL270408;97572;None;0;Human;Binding;Ki;=;57,00;7,24;-36;5;Binding affinity to human dopamine D2 long receptor;ChEMBL;344,2;7;0;4;3,37;COc1ccccc1N1CCN(Cc2cccc(OCCF)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
CHEMBL270426;97577;None;0;Human;Binding;Ki;=;235,00;6,63;-5;5;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting;ChEMBL;281,1;1;1;3;3,15;COc1cc2c3c(c1)-c1c(O)cccc1C[C@H]3N(C)CC2;https://dx.doi.org/10.1021/jm9015763
CHEMBL270589;97600;None;0;Human;Binding;Ki;=;22,00;7,66;2;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(F)cccc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL270589;97600;None;0;Human;Binding;Ki;=;2,40;8,62;2;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(F)cccc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL270589;97600;UNDEFINED;0;Human;Binding;pKi;=;2,40;8,62;2;4;-;PDSP KiDatabase;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(F)cccc3F)CC2)CC1;-
CHEMBL270589;97600;UNDEFINED;0;Human;Binding;pKi;=;22,00;7,66;2;4;-;PDSP KiDatabase;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3c(F)cccc3F)CC2)CC1;-
CHEMBL27101;97681;None;0;Human;Binding;Ki;=;2200,00;5,66;-12;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;286,1;0;3;4;2,18;Oc1cc2c(cc1O)[C@H]1c3ccc(F)nc3CN[C@@H]1CC2;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL27117;97718;None;0;Human;Binding;Ki;=;1400,00;5,85;-10;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;282,1;0;3;4;2,35;Cc1ccc2c(n1)CN[C@@H]1CCc3cc(O)c(O)cc3[C@@H]21;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL27132;97749;None;0;Human;Binding;Ki;=;39,20;7,41;-6;5;Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride;ChEMBL;261,2;0;0;1;3,90;C[C@H]1c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm9911433
CHEMBL271513;97780;None;0;Human;Binding;Ki;=;120,00;6,92;-32;5;Binding affinity to human dopamine D2 long receptor;ChEMBL;344,2;7;0;4;3,37;COc1ccccc1N1CCN(Cc2ccc(OCCF)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
CHEMBL27162;97802;None;55;Human;Binding;Ki;=;11400,00;4,94;-7;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;158,1;0;1;2;1,20;N#Cc1ccc2c(c1)CNCC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL271913;97861;None;0;Human;Binding;Ki;=;99,00;7,00;1;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;500,3;7;2;5;5,39;COc1ccc(Cl)cc1NC(=O)NC1CCC(N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL271913;97861;None;0;Human;Binding;Ki;=;1,20;8,92;1;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;500,3;7;2;5;5,39;COc1ccc(Cl)cc1NC(=O)NC1CCC(N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL271913;97861;UNDEFINED;0;Human;Binding;pKi;=;99,00;7,00;1;4;-;PDSP KiDatabase;500,3;7;2;5;5,39;COc1ccc(Cl)cc1NC(=O)NC1CCC(N2CCN(c3ccccc3OC(C)C)CC2)CC1;-
CHEMBL271913;97861;UNDEFINED;0;Human;Binding;pKi;=;1,20;8,92;1;4;-;PDSP KiDatabase;500,3;7;2;5;5,39;COc1ccc(Cl)cc1NC(=O)NC1CCC(N2CCN(c3ccccc3OC(C)C)CC2)CC1;-
CHEMBL271989;97871;None;0;Human;Binding;Ki;=;5,60;8,25;1;4;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK293 cells;ChEMBL;390,2;8;1;5;4,26;COc1ccccc1N1CCN(CCCCNc2ccc3ccccc3n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.096
CHEMBL272073;97884;None;0;Human;Binding;Ki;=;1100,00;5,96;-21;5;Binding affinity to human dopamine D2 long receptor;ChEMBL;348,1;6;0;3;4,01;FCCOc1ccc(CN2CCN(c3ccc(Cl)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
CHEMBL272340;97936;None;0;Human;Binding;Ki;=;921,00;6,04;-16;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;466,3;7;2;5;4,74;COc1ccccc1NC(=O)NC1CCC(N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL272340;97936;None;0;Human;Binding;Ki;=;390,00;6,41;-16;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;466,3;7;2;5;4,74;COc1ccccc1NC(=O)NC1CCC(N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL272340;97936;UNDEFINED;0;Human;Binding;pKi;=;390,00;6,41;-16;4;-;PDSP KiDatabase;466,3;7;2;5;4,74;COc1ccccc1NC(=O)NC1CCC(N2CCN(c3ccccc3OC(C)C)CC2)CC1;-
CHEMBL272340;97936;UNDEFINED;0;Human;Binding;pKi;=;921,00;6,04;-16;4;-;PDSP KiDatabase;466,3;7;2;5;4,74;COc1ccccc1NC(=O)NC1CCC(N2CCN(c3ccccc3OC(C)C)CC2)CC1;-
CHEMBL272395;97949;None;0;Human;Binding;Ki;=;210,00;6,68;2;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;371,1;3;0;5;2,81;Brc1cccc(N2CCN(Cc3cnn4ccccc34)CC2)n1;https://dx.doi.org/10.1021/jm701375u
CHEMBL272395;97949;None;0;Human;Binding;Ki;=;150,00;6,82;2;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;371,1;3;0;5;2,81;Brc1cccc(N2CCN(Cc3cnn4ccccc34)CC2)n1;https://dx.doi.org/10.1021/jm701375u
CHEMBL272396;97950;None;0;Human;Binding;Ki;=;880,00;6,06;1;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;371,1;3;0;5;2,81;Brc1cccc(N2CCN(Cc3cc4ccccn4n3)CC2)n1;https://dx.doi.org/10.1021/jm701375u
CHEMBL272396;97950;None;0;Human;Binding;Ki;=;550,00;6,26;1;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;371,1;3;0;5;2,81;Brc1cccc(N2CCN(Cc3cc4ccccn4n3)CC2)n1;https://dx.doi.org/10.1021/jm701375u
CHEMBL27247;97957;None;0;Human;Binding;Ki;=;7980,00;5,10;-10;5;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;304,2;1;1;2;2,98;CC(=O)N[C@H]1c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm9911433
CHEMBL27251;97969;None;0;Human;Binding;Ki;=;2250,00;5,65;-125;9;Binding affinity towards Dopamine receptor D2;ChEMBL;262,1;0;1;2;2,80;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@@H]3N;https://dx.doi.org/10.1021/jm030030n
CHEMBL27251;97969;None;0;Human;Binding;Ki;=;2250,00;5,65;-125;9;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;262,1;0;1;2;2,80;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@@H]3N;https://dx.doi.org/10.1021/jm0108505
CHEMBL27251;97969;None;0;Human;Binding;Ki;=;2250,00;5,65;-125;9;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;262,1;0;1;2;2,80;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@@H]3N;https://dx.doi.org/10.1021/jm9911433
CHEMBL27254;97980;None;0;Human;Binding;Ki;=;146,00;6,84;-37;4;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;493,1;8;1;4;3,63;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(I)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL272602;98004;None;0;Human;Binding;Ki;=;4700,00;5,33;-3;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;308,2;3;1;5;2,36;Oc1ccccc1N1CCN(Cc2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm701375u
CHEMBL272602;98004;None;0;Human;Binding;Ki;=;4500,00;5,35;-3;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;308,2;3;1;5;2,36;Oc1ccccc1N1CCN(Cc2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm701375u
CHEMBL272853;98054;None;7;Human;Binding;Ki;=;50000,00;4,30;-7;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;354,2;6;0;5;3,00;FCCOc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
CHEMBL272853;98054;None;7;Human;Binding;Ki;=;30000,00;4,52;-7;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;354,2;6;0;5;3,00;FCCOc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
CHEMBL272873;98057;None;0;Human;Binding;Ki;=;79000,00;4,10;-8;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;354,2;6;0;5;3,00;FCCOc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
CHEMBL272873;98057;None;0;Human;Binding;Ki;=;66000,00;4,18;-8;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;354,2;6;0;5;3,00;FCCOc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
CHEMBL27309;98097;None;0;Human;Binding;Ki;=;182,00;6,74;-6;4;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;277,1;0;1;2;3,01;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@@]3(C)O;https://dx.doi.org/10.1021/jm9911433
CHEMBL273921;98224;None;0;Human;Binding;Ki;=;234,42;6,63;-104;13;Binding affinity towards cloned human dopamine D2 receptor was determined;ChEMBL;422,2;4;1;5;3,61;O=C1c2ccccc2CCCN1CCN1CCC(n2c(O)nc3cc(F)ccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(03)00077-5
CHEMBL275379;98442;None;0;Human;Binding;Ki;=;12000,00;4,92;-50;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;282,1;0;3;4;2,35;Cc1cnc2c(c1)[C@@H]1c3cc(O)c(O)cc3CC[C@H]1NC2;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL275543;98475;None;0;Human;Binding;Ki;=;59,00;7,23;4;2;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;229,1;2;1;2;2,68;C=CCN1CCC2c3cccc(O)c3CC[C@@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL27559;98484;None;0;Human;Binding;Ki;=;114,00;6,94;-2;8;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting;ChEMBL;279,2;2;1;2;3,92;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(O)c1-3;https://dx.doi.org/10.1021/jm9015763
CHEMBL27559;98484;None;0;Human;Binding;Ki;=;12,70;7,90;-2;8;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;279,2;2;1;2;3,92;CCCN1CCc2cccc3c2[C@H]1Cc1cccc(O)c1-3;https://dx.doi.org/10.1021/jm960189i
CHEMBL275696;98498;None;0;Human;Binding;Ki;=;520,00;6,28;-74;4;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;324,1;1;0;2;3,99;CN1CCN(C2=Cc3cc(Cl)ccc3Cc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL276042;98552;None;0;Human;Binding;Kd;=;19,90;7,70;-12;2;Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as high affinity state;ChEMBL;282,1;0;3;4;2,43;CN1CCc2cc(N)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
CHEMBL276042;98552;None;0;Human;Binding;Kd;=;3300,00;5,48;-12;2;Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as low affinity state;ChEMBL;282,1;0;3;4;2,43;CN1CCc2cc(N)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
CHEMBL276326;98587;None;0;Human;Binding;Kd;=;6,75;8,17;-3;3;Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as high affinity state;ChEMBL;345;0;2;3;3,61;CN1CCc2cc(Br)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
CHEMBL276326;98587;None;0;Human;Binding;Kd;=;728,00;6,14;-3;3;Compound was evaluated for the ability to displace [3H]spiperone at Dopamine receptor D2 in porcine anterior pituitary gland as low affinity state;ChEMBL;345;0;2;3;3,61;CN1CCc2cc(Br)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1021/jm00126a009
CHEMBL276778;98637;None;0;Human;Binding;Ki;=;86,70;7,06;-25;6;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;295,2;1;0;2;3,71;COc1ccc2c(c1)CCN(C)CCCc1ccccc1C2;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL276778;98637;None;0;Human;Binding;Ki;=;87,00;7,06;-25;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;295,2;1;0;2;3,71;COc1ccc2c(c1)CCN(C)CCCc1ccccc1C2;https://dx.doi.org/10.1021/jm070388+
CHEMBL277631;98757;None;2;Human;Binding;Ki;=;25,12;7,60;-5;3;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;362,2;6;1;4;3,64;CCN1CCCC1c1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL277669;98762;None;0;Human;Binding;Ki;=;1584,89;5,80;-50;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;395,2;6;1;3;3,51;CC(C)(C)C(=O)NCCCCN1CCN(c2ccc(Br)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL277684;98764;None;0;Human;Binding;Ki;=;316,23;6,50;-7;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;350,2;8;1;4;3,33;CCN(CC)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL277790;98774;None;0;Human;Binding;Ki;=;79,43;7,10;-100;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;451,2;7;1;4;4,84;N#Cc1ccc2c(c1)C1CN(CCCCNC(=O)c3ccc(-c4ccccc4)cc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL277937;98788;None;0;Human;Binding;Ki;=;1995,26;5,70;-15;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;335,2;6;1;3;2,89;CC(C)(C)C(=O)NCCCCN1CCN(c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL27811;98820;None;45;Human;Binding;Ki;=;200,00;6,70;-1;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;198,1;1;2;1;2,54;C1=C(c2c[nH]c3ccccc23)CCNC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL278288;98842;None;0;Human;Binding;Ki;=;398,11;6,40;-3;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;365,2;7;1;3;3,79;CC(C)(C)C(=O)NCCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL278751;98885;None;17;Human;Binding;Ki;=;63,10;7,20;-3;8;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;275,2;6;0;2;4,24;CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL278751;98885;None;17;Human;Binding;Ki;=;15,00;7,82;-3;8;Binding affinity was measured at cloned mammalian dopamine D2 receptor expressed in CHO-K1 cells (using [3H]U-86170);ChEMBL;275,2;6;0;2;4,24;CCCN(CCC)[C@@H]1CCc2c(OC)cccc2[C@@H]1C;https://dx.doi.org/10.1016/S0960-894X(01)80181-5
CHEMBL279039;98927;None;0;Human;Binding;Ki;=;158,49;6,80;-10;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;376,2;6;1;4;3,86;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL279247;98954;None;0;Human;Binding;Ki;=;6,10;8,21;-15;3;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;331,2;4;0;3;4,70;Cc1nn(C2CCN(Cc3ccccc3)CC2)cc1-c1ccccc1;https://dx.doi.org/10.1021/jm030836n
CHEMBL279247;98954;None;0;Human;Binding;Ki;=;6,10;8,21;-15;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;331,2;4;0;3;4,70;Cc1nn(C2CCN(Cc3ccccc3)CC2)cc1-c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL27940;98973;None;0;Human;Binding;Ki;=;201,00;6,70;-13;5;Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride;ChEMBL;249,2;0;0;1;3,75;Cc1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm9911433
CHEMBL27940;98973;None;0;Human;Binding;Ki;=;201,00;6,70;-13;5;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;249,2;0;0;1;3,75;Cc1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960189i
CHEMBL279729;99014;None;0;Human;Binding;Ki;=;630,00;6,20;-1;3;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;365,2;6;1;4;3,16;CCCCN1CCC[C@@H]1CNC(=O)c1cc(Cl)cc2c1OCCN2C;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
CHEMBL279925;99043;None;0;Human;Binding;Ki;=;100,00;7,00;-50;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;614,2;10;1;8;5,51;Cc1nnc(-c2ccc(-c3ccc(C(=O)NCCCCN4CCc5ccc(OS(=O)(=O)C(F)(F)F)cc5C4)cc3)cc2)o1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL279937;99045;None;0;Human;Binding;Ki;=;57,00;7,24;-1;3;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;413,2;6;1;4;3,61;CN1CCOc2c(C(=O)NC[C@H]3CCCN3CCc3ccccc3)cc(Cl)cc21;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
CHEMBL280177;99076;None;0;Human;Binding;Ki;=;7,94;8,10;-3;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;390,2;6;1;4;4,42;CCN1CCCCCC1c1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL280490;99123;None;0;Human;Binding;Ki;=;100,00;7,00;-50;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;467,2;7;1;4;5,06;COc1ccc(S(=O)(=O)N(C)C)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL28054;99132;None;0;Human;Binding;Ki;=;1300,00;5,89;-1;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;268,1;0;3;4;2,04;Oc1cc2c(cc1O)[C@H]1c3cnccc3CN[C@@H]1CC2;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL28056;99134;None;0;Human;Binding;Ki;=;498,00;6,30;-257;6;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;350,2;1;0;2;5,29;Cc1cccc(C#N)c1-c1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm0108505
CHEMBL28056;99134;None;0;Human;Binding;Ki;=;2470,00;5,61;-257;6;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;350,2;1;0;2;5,29;Cc1cccc(C#N)c1-c1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm0108505
CHEMBL280804;99158;None;0;Human;Binding;Ki;=;24,50;7,61;-8;3;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;319,2;3;0;2;4,44;CCO[C@@]1(CC)c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm9911433
CHEMBL280955;99176;None;0;Human;Binding;Ki;=;18,00;7,75;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;243,2;3;0;2;2,98;C=CCN1CC[C@H]2c3cccc(OC)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00043a013
CHEMBL280955;99176;None;0;Human;Binding;Ki;=;18,00;7,75;1;4;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;243,2;3;0;2;2,98;C=CCN1CC[C@H]2c3cccc(OC)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL280961;99178;None;0;Human;Binding;Ki;=;15,85;7,80;-15;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;424,2;7;1;4;4,82;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCC3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL281048;99187;None;0;Human;Binding;Ki;=;261,00;6,58;-19;6;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;262,1;0;1;2;2,80;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@H]3N;https://dx.doi.org/10.1021/jm9911433
CHEMBL281048;99187;None;0;Human;Binding;Ki;=;261,00;6,58;-19;6;Binding affinity towards Dopamine receptor D2;ChEMBL;262,1;0;1;2;2,80;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@H]3N;https://dx.doi.org/10.1021/jm030030n
CHEMBL281177;99209;None;0;Human;Binding;Ki;=;12,59;7,90;-10;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;438,2;7;1;4;5,21;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCC3c3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL281195;99213;None;0;Human;Binding;Ki;=;90,00;7,05;-19;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;331,2;4;1;2;4,76;Cc1c(C2CCN(Cc3ccccc3)CC2)n[nH]c1-c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL281357;99237;None;0;Human;Binding;Ki;=;527,00;6,28;-6;5;Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride;ChEMBL;235,1;0;0;1;3,44;CN1CCc2cccc3c2[C@H]1Cc1ccccc1-3;https://dx.doi.org/10.1021/jm9911433
CHEMBL281357;99237;None;0;Human;Binding;Ki;=;527,00;6,28;-6;5;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;235,1;0;0;1;3,44;CN1CCc2cccc3c2[C@H]1Cc1ccccc1-3;https://dx.doi.org/10.1021/jm0108505
CHEMBL281357;99237;None;0;Human;Binding;Ki;=;527,00;6,28;-6;5;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;235,1;0;0;1;3,44;CN1CCc2cccc3c2[C@H]1Cc1ccccc1-3;https://dx.doi.org/10.1021/jm960189i
CHEMBL281363;99239;None;0;Human;Binding;Ki;=;800,00;6,10;-79;3;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;413,2;6;1;4;3,61;CN1CCOc2c(C(=O)NC[C@@H]3CCCN3CCc3ccccc3)cc(Cl)cc21;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
CHEMBL281554;99270;None;0;Human;Binding;Ki;=;70,80;7,15;-38;3;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;319,2;3;0;2;4,44;CCO[C@]1(CC)c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm9911433
CHEMBL281923;99329;None;0;Human;Binding;Ki;=;71,00;7,15;-64;6;Binding affinity towards Dopamine receptor D2;ChEMBL;291,2;1;0;2;3,66;CO[C@@]1(C)c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm030030n
CHEMBL281923;99329;None;0;Human;Binding;Ki;=;71,00;7,15;-64;6;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;291,2;1;0;2;3,66;CO[C@@]1(C)c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm9911433
CHEMBL281924;99330;None;0;Human;Binding;Ki;=;7,10;8,15;-6;6;Binding affinity towards Dopamine receptor D2;ChEMBL;291,2;1;0;2;3,66;CO[C@]1(C)c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm030030n
CHEMBL281924;99330;None;0;Human;Binding;Ki;=;7,10;8,15;-6;6;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;291,2;1;0;2;3,66;CO[C@]1(C)c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm9911433
CHEMBL281932;99331;None;0;Human;Binding;Ki;=;2500,00;5,60;-38;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;268,1;0;3;4;2,04;Oc1cc2c(cc1O)[C@H]1c3cccnc3CN[C@@H]1CC2;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL282008;99349;None;8;Human;Binding;Ki;=;2511,89;5,60;-100;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;323,2;4;1;3;2,62;CC(C)(C)C(=O)NCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL282083;99362;None;0;Human;Binding;Ki;=;71,00;7,15;1;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;414,2;6;1;5;3,27;COc1c(C(=O)NCCN2CCN(c3ccccc3)CC2)cc(C#N)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL282136;99370;None;0;Human;Binding;Ki;=;400,00;6,40;2;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;282,1;0;3;4;2,35;Cc1cncc2c1CN[C@@H]1CCc3cc(O)c(O)cc3[C@@H]21;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL282287;99391;None;0;Human;Binding;Ki;=;398,11;6,40;-19;2;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;362,2;6;1;4;3,64;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(C(C)N3CCCC3)[nH]2)c1;https://dx.doi.org/10.1016/0960-894X(96)00202-8
CHEMBL282323;99396;None;0;Human;Binding;Ki;=;709,00;6,15;-61;3;Binding affinity against cloned human D2 receptor transfected in CHO-K1 cells using [3H]- spiperone as radioligand.;ChEMBL;327,2;7;1;4;2,97;O[C@H](COc1ccccc1)CN1CCC(Oc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00233-3
CHEMBL282375;99402;None;0;Human;Binding;Ki;=;3650,00;5,44;-18;5;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;304,2;1;1;2;2,98;CC(=O)N[C@@H]1c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm9911433
CHEMBL282413;99408;None;0;Human;Binding;Ki;=;2260,00;5,65;-3;2;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;607,1;5;0;7;5,56;CN1CCc2cccc3c2[C@H]1Cc1cccc(-c2c(OS(=O)(=O)C(F)(F)F)cccc2OS(=O)(=O)C(F)(F)F)c1-3;https://dx.doi.org/10.1021/jm0108505
CHEMBL282863;99478;None;0;Human;Binding;Ki;=;19,40;7,71;-5;5;Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride;ChEMBL;261,2;0;0;1;3,90;C[C@@H]1c2cccc3c2-c2c1ccc1c2[C@@H](C3)N(C)CC1;https://dx.doi.org/10.1021/jm9911433
CHEMBL282927;99492;None;0;Human;Binding;Ki;=;100,00;7,00;1;2;In vitro binding affinity for Dopamine receptor D2;ChEMBL;394,2;5;1;3;3,76;NC(=O)C1CCC(CN2CCC(=C(c3ccccc3)c3ccc(F)cc3)CC2)O1;https://dx.doi.org/10.1016/s0960-894x(01)00200-1
CHEMBL282971;99496;None;0;Human;Binding;Ki;=;1995,26;5,70;-2511;14;The compound was tested for the binding affinity towards human cloned Dopamine receptor D2 in CHO cells, using [125I]iodosulpride as radioligand;ChEMBL;491,1;5;1;6;4,96;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN2CCC[C@@H]2C1;https://dx.doi.org/10.1016/s0960-894x(02)00172-5
CHEMBL283034;99506;None;0;Human;Binding;Ki;=;1207,00;5,92;-3;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;481,1;6;1;4;4,47;COc1c(C(=O)NCCN2CCN(c3cccc(C)c3)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL283065;99513;None;0;Human;Binding;Ki;=;2030,00;5,69;-158;3;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;371,2;3;0;3;5,12;COc1cccc(OC)c1-c1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm0108505
CHEMBL28313;99526;None;0;Human;Binding;Ki;=;108,00;6,97;-38;6;In vitro binding affinity towards Dopamine receptor D2 by using [3H]U-86170 as radioligand;ChEMBL;337,1;5;1;4;2,77;CCCNC1CCc2cccc(OS(=O)(=O)C(F)(F)F)c2C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL283142;99528;None;0;Human;Binding;Ki;=;63,10;7,20;1;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;351,2;6;1;3;3,40;CC(C)(C)C(=O)NCCCCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL28321;99545;None;0;Human;Binding;Ki;=;1,30;8,89;-1;4;In vitro binding affinity was measured at the cloned human Dopamine receptor D2 using [3H]spiroperidol as radioligand.;ChEMBL;347,2;5;0;4;3,81;COc1ccccc1N1CCN(Cc2ccn(-c3ccccc3)c2)CC1;https://dx.doi.org/10.1021/jm981041x
CHEMBL283247;99548;None;0;Human;Binding;Ki;=;1900,00;5,72;-2;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;324,2;3;3;4;3,38;CCCCc1cnc2c(c1)[C@@H]1c3cc(O)c(O)cc3CC[C@H]1NC2;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL283353;99568;None;0;Human;Binding;Ki;=;2511,89;5,60;-316;2;Binding affinity at cloned human Dopamine receptor D2 expressed in CHO cells, using [125I]iodosulpiride as radioligand;ChEMBL;337,2;6;1;3;3,01;CCC(C)(C)C(=O)NCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(96)00198-9
CHEMBL283353;99568;None;0;Human;Binding;Ki;=;2519,00;5,60;-316;2;In vitro binding affinity was measured at the cloned human Dopamine receptor D2 using [3H]spiroperidol as radioligand.;ChEMBL;337,2;6;1;3;3,01;CCC(C)(C)C(=O)NCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm981041x
CHEMBL283528;99601;None;0;Human;Binding;Ki;=;12,00;7,92;1;3;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;365,2;6;1;4;3,16;CCCCN1CCC[C@H]1CNC(=O)c1cc(Cl)cc2c1OCCN2C;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
CHEMBL283738;99624;None;0;Human;Binding;Ki;=;25,00;7,60;-5;2;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;229,1;2;1;2;2,68;C=CCN1CC[C@@H]2c3c(O)cccc3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL284346;99707;None;0;Human;Binding;Ki;=;1600,00;5,80;-93;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;332,2;4;0;4;4,09;Cc1c(-c2ccccc2)nnn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL28437;99710;None;0;Human;Binding;Ki;=;62,00;7,21;-77;6;In vitro binding affinity towards Dopamine receptor D2 by using [3H]U-86170 as radioligand;ChEMBL;379,1;7;0;4;3,89;CCCN(CCC)C1CCc2cccc(OS(=O)(=O)C(F)(F)F)c2C1;https://dx.doi.org/10.1021/jm00008a010
CHEMBL284586;99746;None;0;Human;Binding;Ki;=;83,20;7,08;-15;3;Binding affinity was measured on cloned Human D2A Receptor which is labeled by [3H]raclopride;ChEMBL;247,1;0;0;1;3,34;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)C3;https://dx.doi.org/10.1021/jm9911433
CHEMBL284586;99746;None;0;Human;Binding;Ki;=;83,20;7,08;-15;3;In vitro binding affinity towards cloned human Dopamine receptor D2A using [3H]- Raclopride as radioligand.;ChEMBL;247,1;0;0;1;3,34;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)C3;https://dx.doi.org/10.1016/s0960-894x(00)00655-7
CHEMBL284644;99756;None;0;Human;Binding;Ki;=;4400,00;5,36;-30;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;268,1;0;3;4;2,04;Oc1cc2c(cc1O)[C@H]1c3ccncc3CN[C@@H]1CC2;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL284716;99763;None;15;Human;Binding;Ki;=;1072,00;5,97;-2290;3;Inhibitory activity against [125I]- NCQ298 binding to dopamine receptor D2 in Sf 9 cells;ChEMBL;371,1;5;1;2;3,91;CCCN(C/C=C/I)C1CCc2cccc(O)c2C1;https://dx.doi.org/10.1021/jm00073a016
CHEMBL284896;99788;None;0;Human;Binding;Ki;=;7000,00;5,16;-25;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;389,2;6;1;4;3,40;COc1c(C(=O)NCCN2CCN(c3ccccc3)CC2)ccc2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL284959;99794;None;0;Human;Binding;Ki;=;9100,00;5,04;-32;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;296,2;0;3;4;2,66;Cc1cc2c(nc1C)CN[C@@H]1CCc3cc(O)c(O)cc3[C@@H]21;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL285157;99828;None;39;Human;Binding;Ki;=;25,80;7,59;4;4;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;288,2;3;1;1;4,46;C1=C(c2c[nH]c3ccccc23)CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL285352;99854;None;0;Human;Binding;Ki;=;215,00;6,67;-2;4;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;263,1;0;1;2;2,83;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@@H]3O;https://dx.doi.org/10.1021/jm9911433
CHEMBL285873;99924;None;0;Human;Binding;Ki;=;75,00;7,12;1;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;229,1;2;1;2;2,68;C=CCN1CC[C@H]2c3cccc(O)c3CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL285924;99934;None;0;Human;Binding;Ki;=;520,00;6,28;-10;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;298,1;1;3;5;2,05;COc1ccc2c(n1)CN[C@@H]1CCc3cc(O)c(O)cc3[C@@H]21;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL286177;99971;None;0;Human;Binding;Ki;=;2336,00;5,63;-131;2;Binding affinity against cloned human D2 receptor transfected in CHO-K1 cells using [3H]- spiperone as radioligand.;ChEMBL;377,2;7;1;4;4,12;OC(COc1cccc2ccccc12)CN1CCC(Oc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00233-3
CHEMBL286205;99975;None;0;Human;Binding;Ki;=;8,50;8,07;-1;3;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;243,2;3;0;2;2,98;C=CCN1CC[C@@H]2c3c(cccc3OC)CC[C@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL286725;100056;None;8;Human;Binding;IC50;=;700,00;6,16;-7762;5;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;369,2;7;1;5;2,26;COc1cccc(C(=O)NCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm981041x
CHEMBL286725;100056;None;8;Human;Binding;Ki;=;467,00;6,33;-7762;5;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;369,2;7;1;5;2,26;COc1cccc(C(=O)NCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL287217;100126;None;0;Human;Binding;Ki;=;450,00;6,35;-11;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;317,2;4;0;3;4,39;c1ccc(CN2CCC(n3cnc(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL287412;100148;None;0;Human;Binding;Ki;=;15,00;7,82;-4;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;365,2;4;0;3;5,35;Cc1nn(C2CCN(Cc3cccc(Cl)c3)CC2)cc1-c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
CHEMBL287443;100151;None;0;Human;Binding;Ki;=;5692,00;5,25;-7;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;512,1;7;1;6;4,07;COc1c(C(=O)NCCN2CCN(c3ccc([N+](=O)[O-])cc3)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL287513;100163;None;0;Human;Binding;Ki;=;3600,00;5,44;-6;2;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;322,2;0;3;4;2,92;Oc1cc2c(cc1O)[C@H]1c3cc4c(nc3CN[C@@H]1CC2)CCCC4;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
CHEMBL287770;100201;None;0;Human;Binding;Ki;=;1050,00;5,98;-3;2;In vitro binding affinity towards human Dopamine receptor D2A was determined in mouse fibroblast LtK cells using [3H]raclopride;ChEMBL;275,2;6;0;2;4,24;CCCN(CCC)[C@H]1CCc2cccc(OC)c2[C@H]1C;https://dx.doi.org/10.1021/jm00001a020
CHEMBL288090;100233;3H-YM 09151-2;16;Human;Binding;pKi;=;580,00;6,24;-57;7;-;PDSP KiDatabase;295,2;3;2;3;3,27;C=CCN1CCc2cc(O)c(O)cc2C(c2ccccc2)C1;-
CHEMBL288721;100302;None;0;Human;Binding;Ki;=;614,00;6,21;-7;2;In vitro binding affinity towards human Dopamine receptor D2A was determined in mouse fibroblast LtK cells using [3H]raclopride;ChEMBL;261,2;4;1;2;3,93;CCCN(C(C)C)[C@@H]1CCc2cccc(O)c2[C@@H]1C;https://dx.doi.org/10.1021/jm00001a020
CHEMBL28964;100411;None;0;Human;Binding;Ki;=;484,00;6,32;-7;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;481,1;6;1;4;4,47;COc1c(C(=O)NCCN2CCN(c3ccccc3C)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL290091;100454;None;0;Human;Binding;Ki;=;40,00;7,40;-70;2;In vitro binding affinity towards human Dopamine receptor D2A was determined in mouse fibroblast LtK cells using [3H]raclopride;ChEMBL;287,2;6;0;2;4,43;CCCN(CCC)[C@@H]1CCc2cccc(C(C)=O)c2[C@@H]1C;https://dx.doi.org/10.1021/jm00001a020
CHEMBL290446;100489;None;0;Human;Binding;Ki;=;33,90;7,47;-5;2;In vitro binding affinity towards human Dopamine receptor D2A was determined in mouse fibroblast LtK cells using [3H]raclopride;ChEMBL;275,2;6;0;2;4,24;CCCN(CCC)[C@@H]1CCc2cccc(OC)c2[C@@H]1C;https://dx.doi.org/10.1021/jm00001a020
CHEMBL290546;100496;None;0;Human;Binding;Ki;=;124,00;6,91;-18;2;In vitro binding affinity towards human Dopamine receptor D2A was determined in mouse fibroblast LtK cells using [3H]raclopride;ChEMBL;393,2;7;0;4;4,46;CCCN(CCC)[C@@H]1CCc2cccc(OS(=O)(=O)C(F)(F)F)c2[C@@H]1C;https://dx.doi.org/10.1021/jm00001a020
CHEMBL291380;100597;None;0;Human;Binding;IC50;=;250,00;6,60;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;348,2;4;0;4;3,60;Fc1ccccc1-c1cccc(CN2CCN(c3ncccn3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL291417;100602;None;0;Human;Binding;Ki;=;31,62;7,50;-1;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;299,1;2;0;2;3,95;Clc1ccc2c(c1)C1CN(Cc3ccccc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL291439;100605;None;0;Human;Binding;Ki;=;2200,00;5,66;-3;4;Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay;ChEMBL;506,1;10;1;6;4,05;COc1cc2c(cc1OC)CN(CCCCNC(=O)c1cc(Br)cc(OC)c1OC)CC2;https://dx.doi.org/10.1021/jm301545c
CHEMBL291545;100619;None;0;Human;Binding;Ki;=;199,53;6,70;-99;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;521,2;9;2;5;4,36;O=C(/C=C/c1ccc2[nH]ccc2c1)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL291801;100651;None;0;Human;Binding;Ki;=;251,19;6,60;-199;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;534,3;12;1;5;5,47;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(cccc2OS(C)(=O)=O)C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL29182;100655;None;0;Human;Binding;Ki;=;1173,00;5,93;-23;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;495,2;6;1;4;4,78;COc1c(C(=O)NCCN2CCN(c3cccc(C)c3C)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL291824;100657;None;0;Human;Binding;IC50;=;70,00;7,16;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;365,2;4;0;3;4,35;Fc1ccc(-c2cncc(CN3CCN(c4ccc(F)cc4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL292186;100705;None;0;Human;Binding;Ki;=;398,11;6,40;-12;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;387,2;7;0;3;5,72;COc1cc2ccccc2cc1C(=O)CCC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm960017l
CHEMBL292418;100752;None;5;Human;Binding;Ki;=;1374,00;5,86;-588;4;In vitro ability to inhibit [3H]spiperone binding to Dopamine receptor D2 from pig anterior pituitary tissue;ChEMBL;273,1;1;2;2;3,32;Oc1cc2c(cc1Cl)CCNCC2c1ccccc1;https://dx.doi.org/10.1021/jm00079a008
CHEMBL292485;100760;None;0;Human;Binding;Ki;=;501,19;6,30;-19;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;290,1;2;0;3;3,17;N#Cc1ccc2c(c1)OCC1CN(Cc3ccccc3)CC21;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL292577;100772;None;0;Human;Binding;Ki;=;316,23;6,50;-31;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;563,2;9;1;7;3,73;Cn1c(=O)ccc2cc(/C=C/C(=O)NCCCCN3CCc4ccc(OS(=O)(=O)C(F)(F)F)cc4C3)ccc21;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL292759;100800;None;0;Human;Binding;Ki;=;3981,07;5,40;-794;14;Compound was tested for its binding affinity against Dopamine receptor D2 in human cloned receptors in CHO cells using [125 I]iodosulpride;ChEMBL;439,1;5;1;5;3,01;COc1ccc(NS(=O)(=O)c2ccc(Br)cc2)cc1N1CCN(C)CC1;https://dx.doi.org/10.1021/jm980532e
CHEMBL292943;100831;None;0;Human;Binding;IC50;=;50,00;7,30;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;360,2;5;0;5;3,47;COc1ccc(-c2cccc(CN3CCN(c4ncccn4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL293158;100855;None;0;Human;Binding;Ki;=;19054,61;4,72;-47;4;Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone;ChEMBL;273,1;1;1;2;3,62;CN1CCc2cc(Cl)c(O)cc2[C@H]1c1ccccc1;https://dx.doi.org/10.1021/jm00129a006
CHEMBL293159;100856;None;0;Human;Binding;Ki;=;19,95;7,70;-7;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;290,1;2;0;3;3,17;N#Cc1ccc2c(c1)[C@H]1CN(Cc3ccccc3)C[C@@H]1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL293225;100866;None;0;Human;Binding;Ki;=;630,00;6,20;-1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;455,1;7;1;5;4,87;COc1ccc(Br)cc1-c1nc(CNC2CCN(Cc3ccccc3)CC2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL293225;100866;None;0;Human;Binding;Ki;=;940,00;6,03;-1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;455,1;7;1;5;4,87;COc1ccc(Br)cc1-c1nc(CNC2CCN(Cc3ccccc3)CC2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL293347;100882;None;0;Human;Binding;Ki;=;251,19;6,60;-63;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;524,2;10;1;6;4,09;CC(=O)c1ccc(/C=C/C(=O)NCCCCN2CCc3ccc(OS(=O)(=O)C(F)(F)F)cc3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL29336;100885;None;0;Human;Binding;Ki;=;5692,00;5,25;-7;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;497,1;7;1;5;4,17;COc1ccc(N2CCN(CCNC(=O)c3cc(Br)c4ccccc4c3OC)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL293645;100928;None;0;Human;Binding;Ki;=;85,00;7,07;2;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;457,1;6;0;5;4,90;COc1ccc(Br)cc1-c1nc(CN2CCN(Cc3ccccc3)CC2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL293645;100928;None;0;Human;Binding;Ki;=;210,00;6,68;2;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;457,1;6;0;5;4,90;COc1ccc(Br)cc1-c1nc(CN2CCN(Cc3ccccc3)CC2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL293828;100955;None;0;Human;Binding;Ki;=;1905,46;5,72;-10;4;Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone;ChEMBL;301,1;3;1;2;4,40;CCCN1CCc2cc(Cl)c(O)cc2[C@@H]1c1ccccc1;https://dx.doi.org/10.1021/jm00129a006
CHEMBL29410;101004;None;0;Human;Binding;Ki;=;398,11;6,40;-79;9;The compound was tested for the binding affinity towards human cloned Dopamine receptor D2 in CHO cells, using [125I]iodosulpride as radioligand;ChEMBL;505,1;5;1;6;5,35;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN2CCCCC2C1;https://dx.doi.org/10.1016/s0960-894x(02)00172-5
CHEMBL294275;101037;None;0;Human;Binding;Ki;=;199,53;6,70;-2;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;295,2;3;0;3;3,30;COc1ccc2c(c1)C1CN(Cc3ccccc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL29433;101046;None;0;Human;Binding;Ki;=;1584,89;5,80;-1995;14;The compound was tested for the binding affinity towards human cloned Dopamine receptor D2 in CHO cells, using [125I]iodosulpride as radioligand;ChEMBL;491,1;5;1;6;4,96;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN2CCC[C@H]2C1;https://dx.doi.org/10.1016/s0960-894x(02)00172-5
CHEMBL29435;101051;None;0;Human;Binding;Ki;=;1288,00;5,89;-1;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;512,1;7;1;6;4,07;COc1c(C(=O)NCCN2CCN(c3cccc([N+](=O)[O-])c3)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL29436;101054;None;0;Human;Binding;Ki;=;151,00;6,82;-6;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;512,1;7;1;6;4,07;COc1c(C(=O)NCCN2CCN(c3ccccc3[N+](=O)[O-])CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL294394;101058;None;3;Human;Binding;Ki;=;3100,00;5,51;-30;4;Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;241,2;3;1;2;2,34;c1ccc(N2CCN(Cc3ccc[nH]3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL294394;101058;None;3;Human;Binding;Ki;=;3000,00;5,52;-30;4;Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;241,2;3;1;2;2,34;c1ccc(N2CCN(Cc3ccc[nH]3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL294458;101061;None;0;Human;Binding;Ki;=;7350,00;5,13;-1513;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2L stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;351,1;4;1;4;3,42;N#CC(C#N)=Cc1cc(CN2CCN(c3ccc(Cl)cc3)CC2)c[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL294458;101061;None;0;Human;Binding;Ki;=;10300,00;4,99;-1513;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2S stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;351,1;4;1;4;3,42;N#CC(C#N)=Cc1cc(CN2CCN(c3ccc(Cl)cc3)CC2)c[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL294459;101062;None;1;Human;Binding;Ki;=;1850,00;5,73;-346;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2L stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;317,2;4;1;4;2,77;N#CC(C#N)=Cc1cc(CN2CCN(c3ccccc3)CC2)c[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL294459;101062;None;1;Human;Binding;Ki;=;975,00;6,01;-346;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2S stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;317,2;4;1;4;2,77;N#CC(C#N)=Cc1cc(CN2CCN(c3ccccc3)CC2)c[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL294515;101075;None;0;Human;Binding;Ki;=;31,62;7,50;-5;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;290,1;2;0;3;3,17;N#Cc1ccc2c(c1)[C@@H]1CN(Cc3ccccc3)C[C@H]1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL294747;101115;None;44;Human;Binding;Ki;=;39,81;7,40;-125;6;Binding affinity towards mouse LtK- cells transfected with human D2 receptor using [3H]spiperone;ChEMBL;485,3;10;1;5;4,90;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(C(C)=O)cc3)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(95)00011-H
CHEMBL294747;101115;None;44;Human;Binding;Ki;=;39,81;7,40;-125;6;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;485,3;10;1;5;4,90;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(C(C)=O)cc3)cc2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL294780;101119;None;3;Human;Binding;Ki;=;3000,00;5,52;-9;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;319,2;4;0;4;3,66;c1ccc(-c2nc(CN3CCN(c4ccccc4)CC3)co2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL294780;101119;None;3;Human;Binding;Ki;=;1750,00;5,76;-9;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;319,2;4;0;4;3,66;c1ccc(-c2nc(CN3CCN(c4ccccc4)CC3)co2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL295094;101161;None;0;Human;Binding;Ki;=;2420,00;5,62;-22;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;363,1;4;1;3;3,50;O=C(NCN1CCN(c2ccccc2Cl)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1021/jm970021c
CHEMBL295094;101161;None;0;Human;Binding;Ki;=;363,08;6,44;-22;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;363,1;4;1;3;3,50;O=C(NCN1CCN(c2ccccc2Cl)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL29610;101294;None;0;Human;Binding;Ki;=;996,00;6,00;-3;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;481,1;6;1;4;4,47;COc1c(C(=O)NCCN2CCN(c3ccc(C)cc3)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL296506;101352;None;0;Human;Binding;Ki;=;2454,71;5,61;-151;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;339,2;5;1;4;2,51;COc1ccccc1N1CCN(CNC(=O)c2cccc(C)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL296506;101352;None;0;Human;Binding;Ki;=;835,00;6,08;-151;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;339,2;5;1;4;2,51;COc1ccccc1N1CCN(CNC(=O)c2cccc(C)c2)CC1;https://dx.doi.org/10.1021/jm970021c
CHEMBL296512;101353;None;0;Human;Binding;Ki;=;28,00;7,55;-316;3;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;312,1;2;2;1;4,58;Fc1ccc(-c2[nH]c3cc(F)ccc3c2C2CCCNC2)cc1;https://dx.doi.org/10.1021/jm0004998
CHEMBL296953;101408;None;0;Human;Binding;Ki;=;66,07;7,18;-27;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;363,1;4;1;3;3,50;O=C(NCN1CCN(c2ccccc2Cl)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL296953;101408;None;0;Human;Binding;Ki;=;495,00;6,30;-27;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;363,1;4;1;3;3,50;O=C(NCN1CCN(c2ccccc2Cl)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm970021c
CHEMBL297960;101559;None;0;Human;Binding;Ki;=;125,89;6,90;-50;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;615,2;10;1;6;5,28;O=C(NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1)c1ccc(-c2ccc(N3CCCC3=O)cc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL298166;101580;None;0;Human;Binding;Ki;=;1330,00;5,88;-38;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;343,1;4;1;3;3,16;Cc1cccc(C(=O)NCN2CCN(c3ccccc3Cl)CC2)c1;https://dx.doi.org/10.1021/jm970021c
CHEMBL298166;101580;None;0;Human;Binding;Ki;=;467,74;6,33;-38;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;343,1;4;1;3;3,16;Cc1cccc(C(=O)NCN2CCN(c3ccccc3Cl)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL29846;101614;None;0;Human;Binding;Ki;=;794,33;6,10;-1288;14;Compound was tested for its binding affinity against Dopamine receptor D2 in human cloned receptors in CHO cells using [125 I]iodosulpride;ChEMBL;465,1;5;1;6;4,42;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN(C)CC1;https://dx.doi.org/10.1021/jm980532e
CHEMBL29846;101614;None;0;Human;Binding;Ki;=;794,33;6,10;-1288;14;The compound was tested for the binding affinity towards human cloned Dopamine receptor D2 in CHO cells, using [125I]iodosulpride as radioligand;ChEMBL;465,1;5;1;6;4,42;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCN(C)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00172-5
CHEMBL29849;101621;None;0;Human;Binding;Ki;=;1288,00;5,89;-1;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;497,1;7;1;5;4,17;COc1cccc(N2CCN(CCNC(=O)c3cc(Br)c4ccccc4c3OC)CC2)c1;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL298763;101659;None;0;Human;Binding;Ki;=;1500,00;5,82;-10;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;329,1;4;1;3;2,85;O=C(NCN1CCN(c2ccccc2Cl)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm970021c
CHEMBL298763;101659;None;0;Human;Binding;Ki;=;177,83;6,75;-10;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;329,1;4;1;3;2,85;O=C(NCN1CCN(c2ccccc2Cl)CC1)c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL298875;101672;None;0;Human;Binding;Ki;=;180,00;6,75;-95;6;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;438,1;5;1;3;4,62;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL298875;101672;None;0;Human;Binding;Ki;=;130,00;6,89;-95;6;Ability to displace [3H]spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human cloned dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;438,1;5;1;3;4,62;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL298875;101672;None;0;Human;Binding;Ki;=;150,00;6,82;-95;6;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;438,1;5;1;3;4,62;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL298875;101672;None;0;Human;Binding;Ki;=;150,00;6,82;-95;6;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;438,1;5;1;3;4,62;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL299038;101694;None;0;Human;Binding;Ki;=;501,19;6,30;-63;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;532,2;9;1;5;5,15;O=C(NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL299479;101761;None;0;Human;Binding;Ki;=;1995,26;5,70;-79;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;343,1;5;0;3;4,41;O=C(OCC1CCN(Cc2ccccc2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm960017l
CHEMBL299691;101793;None;1;Human;Binding;Ki;=;140,00;6,85;-169;6;Binding affinity for human Dopamine receptor D2;ChEMBL;373,2;4;0;4;2,66;O=C1CC2(CCCC2)CC(=O)N1CCN1CCN(c2ccccc2F)CC1;https://dx.doi.org/10.1021/jm0491391
CHEMBL299879;101819;None;5;Human;Binding;Ki;=;63,00;7,20;-7;7;Binding affinity against cloned human Dopamine receptor D2 was evaluated;ChEMBL;471,2;9;2;5;4,07;O=[N+]([O-])c1ccccc1S(=O)(=O)NC[C@H]1CC[C@H](CNCC2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00287-1
CHEMBL300553;101909;None;0;Human;Binding;Ki;=;15000,00;4,82;-91;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2S stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;351,1;4;1;4;3,42;N#CC(C#N)=Cc1[nH]ccc1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL300553;101909;None;0;Human;Binding;Ki;=;8950,00;5,05;-91;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2L stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;351,1;4;1;4;3,42;N#CC(C#N)=Cc1[nH]ccc1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL300571;101912;None;0;Human;Binding;Ki;=;7,20;8,14;-6;5;Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone;ChEMBL;271,1;4;2;4;2,32;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CO2;https://dx.doi.org/10.1016/s0960-894x(98)00014-6
CHEMBL300571;101912;None;0;Human;Binding;Ki;=;7,20;8,14;-6;5;Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.;ChEMBL;271,1;4;2;4;2,32;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CO2;https://dx.doi.org/10.1021/jm9703653
CHEMBL300647;101920;None;7;Human;Binding;Ki;=;0,66;9,18;-2;3;The compound was tested for binding affinity against dopamine receptor D2 using raclopride as radioligand;ChEMBL;335,1;1;0;1;5,39;CN(C)C1C=CC2(CC1)c1ccccc1C=Cc1ccc(Cl)cc12;https://dx.doi.org/10.1021/jm00109a026
CHEMBL300647;101920;None;7;Human;Binding;Ki;=;6,50;8,19;-2;3;The compound was tested for binding affinity against Dopamine receptor D2 using raclopride as radioligand;ChEMBL;335,1;1;0;1;5,39;CN(C)C1C=CC2(CC1)c1ccccc1C=Cc1ccc(Cl)cc12;https://dx.doi.org/10.1021/jm00109a026
CHEMBL300956;101968;None;2;Human;Binding;Ki;=;380,19;6,42;-234;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;334,2;4;1;4;2,38;Cc1ccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL300956;101968;None;2;Human;Binding;Ki;=;1150,00;5,94;-234;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;334,2;4;1;4;2,38;Cc1ccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)cc1;https://dx.doi.org/10.1021/jm970021c
CHEMBL301242;102007;None;0;Human;Binding;Ki;=;70,10;7,15;-33;5;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;507,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc2c1-c1ccccc1C2=O;https://dx.doi.org/10.1021/jm040190e
CHEMBL301242;102007;None;0;Human;Binding;Ki;=;89,00;7,05;-33;5;Binding affinity at human dopamine receptor D2;ChEMBL;507,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc2c1-c1ccccc1C2=O;https://dx.doi.org/10.1021/jm010146o
CHEMBL301242;102007;None;0;Human;Binding;Ki;=;19,40;7,71;-33;5;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;507,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc2c1-c1ccccc1C2=O;https://dx.doi.org/10.1021/jm040190e
CHEMBL30146;102032;None;0;Human;Binding;Ki;=;303,00;6,52;-3;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;497,1;7;1;5;4,17;COc1ccccc1N1CCN(CCNC(=O)c2cc(Br)c3ccccc3c2OC)CC1;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL301475;102035;None;0;Human;Binding;Ki;=;630,96;6,20;-158;4;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;521,2;9;2;5;4,36;O=C(/C=C/c1c[nH]c2ccccc12)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1021/jm000090i
CHEMBL301475;102035;None;0;Human;Binding;Ki;=;630,96;6,20;-158;4;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;521,2;9;2;5;4,36;O=C(/C=C/c1c[nH]c2ccccc12)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL301559;102049;None;13;Human;Binding;Ki;=;202,00;6,70;-12;8;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL301559;102049;None;13;Human;Binding;Ki;=;0,50;9,30;-12;8;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL301559;102049;None;13;Human;Binding;Ki;=;56,00;7,25;-12;8;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL301559;102049;None;13;Human;Binding;Ki;=;34,00;7,47;-12;8;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm001015a
CHEMBL301559;102049;None;13;Human;Binding;Ki;=;202,00;6,70;-12;8;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL301559;102049;None;13;Human;Binding;Ki;=;34,00;7,47;-12;8;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL301559;102049;None;13;Human;Binding;Ki;=;40,00;7,40;-12;8;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL30206;102121;None;0;Human;Binding;Ki;=;517,00;6,29;-13;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;501,1;6;1;4;4,82;COc1c(C(=O)NCCN2CCN(c3ccccc3Cl)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL302075;102124;None;0;Human;Binding;IC50;=;65,00;7,19;-12;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;360,1;4;0;2;4,92;Clc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c(Cl)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL302075;102124;None;0;Human;Binding;IC50;=;93,00;7,03;-12;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;360,1;4;0;2;4,92;Clc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c(Cl)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL302075;102124;None;0;Human;Binding;Ki;=;93,00;7,03;-12;2;Binding affinity at human Dopamine receptor D2 by [3H]- YM 09151 displacement.;ChEMBL;360,1;4;0;2;4,92;Clc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c(Cl)c1;https://dx.doi.org/10.1016/s0960-894x(00)00421-2
CHEMBL30208;102126;None;0;Human;Binding;Ki;=;1892,00;5,72;-77;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;467,1;6;1;4;4,16;COc1c(C(=O)NCCN2CCN(c3ccccc3)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL302183;102144;None;0;Human;Binding;IC50;=;120,00;6,92;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;349,2;4;0;5;3,00;Fc1ccc(-c2cncc(CN3CCN(c4ncccn4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL302186;102145;None;0;Human;Binding;Ki;=;13500,00;4,87;-338;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;363,2;6;1;4;4,56;c1ccc(CN2CCC(NCc3csc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL302186;102145;None;0;Human;Binding;Ki;=;23000,00;4,64;-338;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;363,2;6;1;4;4,56;c1ccc(CN2CCC(NCc3csc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL302374;102177;None;0;Human;Binding;Ki;=;39,30;7,41;-31;4;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;531;7;1;3;4,93;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(I)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL302374;102177;None;0;Human;Binding;Ki;=;39,30;7,41;-31;4;Binding affinity for human dopamine D2 receptor;ChEMBL;531;7;1;3;4,93;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(I)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL302374;102177;None;0;Human;Binding;Ki;=;51,40;7,29;-31;4;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;531;7;1;3;4,93;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(I)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL302393;102179;None;0;Human;Binding;Ki;=;263,03;6,58;-3;2;Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone;ChEMBL;273,1;1;1;2;3,62;CN1Cc2cc(Cl)c(O)cc2[C@H](c2ccccc2)C1;https://dx.doi.org/10.1021/jm00129a006
CHEMBL302416;102182;None;0;Human;Binding;Ki;=;316,23;6,50;-4;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;290,1;2;0;3;3,17;N#Cc1ccc2c(c1)C1CN(Cc3ccccc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL302416;102182;None;0;Human;Binding;Ki;=;25,12;7,60;-4;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;290,1;2;0;3;3,17;N#Cc1ccc2c(c1)C1CN(Cc3ccccc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL302796;102241;None;0;Human;Binding;Ki;=;606,00;6,22;-7;5;Binding affinity at human dopamine receptor D2;ChEMBL;411,2;6;1;3;4,13;O=C(NCCCN1CCN(c2ccccc2)CC1)C1c2ccccc2-c2ccccc21;https://dx.doi.org/10.1021/jm010146o
CHEMBL302904;102267;None;0;Human;Binding;IC50;=;23,00;7,64;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;347,2;4;0;3;4,21;Fc1ccc(-c2cncc(CN3CCN(c4ccccc4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL303313;102335;None;2;Human;Binding;Ki;=;1,10;8,96;-5;9;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;344,1;1;0;3;4,34;CN1CCN([C@H]2Cc3ccccc3Sc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL303336;102337;None;18;Human;Binding;Ki;=;640,00;6,19;-;4;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;291,2;2;0;1;4,56;c1ccc(CN2CCC3(CCCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL303502;102365;None;0;Human;Binding;Ki;=;118,00;6,93;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;299,2;6;0;3;4,06;CCCN(Cc1ccco1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL303502;102365;None;0;Human;Binding;Ki;=;125,00;6,90;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;299,2;6;0;3;4,06;CCCN(Cc1ccco1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL303519;102369;None;0;Human;Binding;IC50;=;9800,00;5,01;-;3;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;342,2;3;0;4;3,37;c1cnc(N2CCN(Cc3cccc4c3Cc3ccccc3-4)CC2)nc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL303538;102373;None;0;Human;Binding;Ki;=;59000,00;4,23;-4897;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2S stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;351,1;4;1;4;3,42;N#CC(C#N)=Cc1ccc(CN2CCN(c3ccc(Cl)cc3)CC2)[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL303538;102373;None;0;Human;Binding;Ki;=;48500,00;4,31;-4897;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2L stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;351,1;4;1;4;3,42;N#CC(C#N)=Cc1ccc(CN2CCN(c3ccc(Cl)cc3)CC2)[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL303556;102376;None;0;Human;Binding;Ki;=;9,30;8,03;-10;5;Affinity for the Dopamine receptor D2S was determined using membranes from CHO cells labeled with [3H]spiperone;ChEMBL;308,2;4;2;3;2,67;O=C1Cc2c(ccc3c2O[C@@H](CNCc2ccccc2)CC3)N1;https://dx.doi.org/10.1016/s0960-894x(01)00778-8
CHEMBL303979;102465;None;0;Human;Binding;Ki;=;25,12;7,60;-3;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;283,1;2;0;2;3,43;Fc1ccc2c(c1)C1CN(Cc3ccccc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL3039867;102476;None;0;Human;Binding;Ki;=;63,10;7,20;-31;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;526,3;9;1;6;4,21;COc1cccc(/C=C/C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(OS(C)(=O)=O)cc4CC3)CC2)c1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3039868;102477;None;0;Human;Binding;Ki;=;398,11;6,40;-158;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;516,2;7;1;4;4,55;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3c(F)cccc3F)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3039869;102478;None;0;Human;Binding;Ki;=;79,43;7,10;-63;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;514,2;8;1;5;4,34;CS(=O)(=O)Oc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3cccc(F)c3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3039921;102487;None;0;Human;Binding;Ki;=;125,89;6,90;-63;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;505,2;7;1;5;4,14;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccc(C#N)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3039922;102488;None;0;Human;Binding;Ki;=;158,49;6,80;-100;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;505,2;7;1;5;4,14;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccccc3C#N)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL303993;102489;None;0;Human;Binding;Ki;=;1862,09;5,73;-281;4;Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone;ChEMBL;273,1;1;1;2;3,62;CN1CCc2cc(Cl)c(O)cc2[C@@H]1c1ccccc1;https://dx.doi.org/10.1021/jm00129a006
CHEMBL3039930;102490;None;0;Human;Binding;Ki;=;125,89;6,90;-100;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;498,2;7;1;4;4,41;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccccc3F)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3039993;102504;None;0;Human;Binding;Ki;=;199,53;6,70;-63;3;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;431,2;6;1;3;4,83;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccc(F)cc3)CC1)C2;https://dx.doi.org/10.1021/jm000090i
CHEMBL3040059;102515;None;0;Human;Binding;Ki;=;170,00;6,77;-1;3;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis;ChEMBL;423,2;2;3;4;5,30;CN1CCc2ccc(Cc3ccc(O)c4ccccc34)c3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2013.05.014
CHEMBL3040086;102519;None;0;Human;Binding;Ki;=;79,43;7,10;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;498,2;7;1;4;4,41;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccc(F)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3040088;102520;None;0;Human;Binding;Ki;=;100,00;7,00;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;526,3;9;1;6;4,21;COc1ccccc1/C=C/C(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(OS(C)(=O)=O)cc3CC2)CC1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3040115;102522;None;0;Human;Binding;Ki;=;77,00;7,11;-1;3;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis;ChEMBL;357,2;2;2;3;4,44;CN1CCc2ccc(Cc3ccccc3)c3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2013.05.014
CHEMBL3040156;102527;None;0;Human;Binding;Ki;=;43,00;7,37;-2;3;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis;ChEMBL;297,1;1;3;4;2,34;CN1CCc2ccc(CO)c3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2013.05.014
CHEMBL3040157;102528;None;0;Human;Binding;Ki;=;79,00;7,10;-1;3;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis;ChEMBL;400,2;3;2;4;4,51;CN(C)c1ccc(Cc2ccc3c4c2-c2c(ccc(O)c2O)C[C@H]4N(C)CC3)cc1;https://dx.doi.org/10.1016/j.bmc.2013.05.014
CHEMBL3040164;102530;None;0;Human;Binding;Ki;=;54,00;7,27;-2;3;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis;ChEMBL;281,1;0;2;3;3,16;Cc1ccc2c3c1-c1c(ccc(O)c1O)C[C@H]3N(C)CC2;https://dx.doi.org/10.1016/j.bmc.2013.05.014
CHEMBL3040217;102535;None;0;Human;Binding;Ki;=;47,00;7,33;-1;3;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis;ChEMBL;373,2;2;3;4;4,15;CN1CCc2ccc(Cc3ccc(O)cc3)c3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2013.05.014
CHEMBL3040263;102537;None;0;Human;Binding;Ki;=;199,53;6,70;-63;4;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;413,2;6;1;3;4,70;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccccc3)CC1)C2;https://dx.doi.org/10.1021/jm000090i
CHEMBL3040265;102538;None;0;Human;Binding;Ki;=;158,49;6,80;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;505,2;7;1;5;4,14;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3cccc(C#N)c3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3040266;102539;None;0;Human;Binding;Ki;=;251,19;6,60;-125;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;516,2;7;1;4;4,55;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3cc(F)cc(F)c3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3040288;102544;None;0;Human;Binding;IC50;=;63,30;7,20;-;7;Displacement of [3H]-methylspiperone from dopamine D2L receptor (unknown origin) after 60 mins;ChEMBL;348,2;4;2;4;3,64;Fc1cccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)c1;https://dx.doi.org/10.1016/j.ejmech.2013.02.020
CHEMBL3040324;102549;None;0;Human;Binding;IC50;=;146,70;6,83;-;9;Displacement of [3H]-methylspiperone from dopamine D2L receptor (unknown origin) after 60 mins;ChEMBL;330,2;4;2;4;3,50;c1ccc(Cc2nc3c(c(Nc4ccccc4)n2)CCNCC3)cc1;https://dx.doi.org/10.1016/j.ejmech.2013.02.020
CHEMBL3040325;102550;None;0;Human;Binding;IC50;=;162,80;6,79;-;7;Displacement of [3H]-methylspiperone from dopamine D2L receptor (unknown origin) after 60 mins;ChEMBL;360,2;5;2;5;3,51;COc1cccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)c1;https://dx.doi.org/10.1016/j.ejmech.2013.02.020
CHEMBL3040339;102551;None;0;Human;Binding;Ki;=;125,89;6,90;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;498,2;7;1;4;4,41;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3cccc(F)c3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3040340;102552;None;0;Human;Binding;Ki;=;79,43;7,10;-63;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;514,2;8;1;5;4,34;CS(=O)(=O)Oc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccccc3F)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3040361;102558;None;0;Human;Binding;IC50;=;85,80;7,07;-;8;Displacement of [3H]-methylspiperone from dopamine D2L receptor (unknown origin) after 60 mins;ChEMBL;364,1;4;2;4;4,15;Clc1cccc(Nc2nc(Cc3ccccc3)nc3c2CCNCC3)c1;https://dx.doi.org/10.1016/j.ejmech.2013.02.020
CHEMBL304605;102733;None;0;Human;Binding;Ki;=;168,00;6,78;-51;8;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;491,2;6;1;3;5,67;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm0704200
CHEMBL304605;102733;None;0;Human;Binding;Ki;=;168,00;6,78;-51;8;Binding affinity for human dopamine D2 receptor;ChEMBL;491,2;6;1;3;5,67;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm049465g
CHEMBL304605;102733;None;0;Human;Binding;Ki;=;198,00;6,70;-51;8;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;491,2;6;1;3;5,67;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL304605;102733;None;0;Human;Binding;Ki;=;168,00;6,78;-51;8;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;491,2;6;1;3;5,67;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm040190e
CHEMBL304692;102747;None;0;Human;Binding;IC50;=;2300,00;5,64;-;3;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;342,2;3;0;4;3,37;c1cnc(N2CCN(Cc3cccc4c3-c3ccccc3C4)CC2)nc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL304856;102771;None;0;Human;Binding;Ki;=;316,23;6,50;-2;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;265,1;2;0;2;3,29;c1ccc(CN2CC3COc4ccccc4C3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL305276;102845;None;0;Human;Binding;Ki;=;133,00;6,88;-33;2;Inhibition of human dopamine D2 receptor;ChEMBL;369,2;3;0;3;3,04;CN1C(=O)C(N2CCN(Cc3ccc(Cl)cc3)CC2)Cc2ccccc21;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL305276;102845;None;0;Human;Binding;Ki;=;133,00;6,88;-33;2;Binding affinity at human Dopamine receptor D2 by [3H]- YM 09151 displacement.;ChEMBL;369,2;3;0;3;3,04;CN1C(=O)C(N2CCN(Cc3ccc(Cl)cc3)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(00)00421-2
CHEMBL305276;102845;None;0;Human;Binding;Ki;=;133,00;6,88;-33;2;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;369,2;3;0;3;3,04;CN1C(=O)C(N2CCN(Cc3ccc(Cl)cc3)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL305392;102870;None;0;Human;Binding;Ki;=;10,00;8,00;-1;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;288,2;2;0;2;3,72;N#Cc1ccc2c(c1)C1CN(Cc3ccccc3)CC1CC2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL305481;102880;None;2;Human;Binding;Ki;=;670,00;6,17;-10;3;Displacement of [3H]spiperone from human dopamine D2 receptor in CHO cells;ChEMBL;323,1;3;1;2;4,51;Clc1ccc(CN2CC=C(c3nc4ccccc4[nH]3)CC2)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00402-2
CHEMBL30560;102903;None;43;Human;Binding;Ki;=;334,00;6,48;2;2;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;177,1;1;1;2;1,51;COc1cccc2c1CCC(N)C2;https://dx.doi.org/10.1021/jm960345l
CHEMBL305706;102919;None;2;Human;Binding;Ki;=;4777,00;5,32;-19;2;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL305706;102919;None;2;Human;Binding;Ki;=;275,00;6,56;-19;2;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;247,2;5;1;2;3,37;CCCN(CCC)[C@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL305834;102932;None;0;Human;Binding;Ki;=;9,30;8,03;3;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;399,2;4;1;5;4,83;Cc1cccc(-c2cccc(CN3CCN(c4cccc5nc(O)oc45)CC3)c2)c1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL305920;102946;None;0;Human;Binding;Ki;=;1,00;9,00;48;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;399,2;4;1;4;4,01;O=C1COc2c(cccc2N2CCN(Cc3cccc(-c4ccccc4)c3)CC2)N1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL306634;103038;None;0;Human;Binding;Ki;=;10,00;8,00;12;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;399,2;4;0;5;4,12;Cn1c(=O)oc2c(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)cccc21;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL306672;103043;None;0;Human;Binding;Ki;=;11,00;7,96;-1;5;Binding affinity at human dopamine receptor D2;ChEMBL;445,1;7;0;4;4,58;O=C1c2ccccc2C(=O)N1CCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm010146o
CHEMBL306830;103058;None;0;Human;Binding;Ki;=;8,10;8,09;1;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;403,2;4;1;5;4,66;Oc1nc2cccc(N3CCN(Cc4cccc(-c5ccc(F)cc5)c4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL307800;103181;None;0;Human;Binding;Ki;=;10,00;8,00;1;5;Binding affinity at human dopamine receptor D2;ChEMBL;493,2;7;1;3;5,82;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)C1c2ccccc2-c2ccccc21;https://dx.doi.org/10.1021/jm010146o
CHEMBL307869;103190;None;0;Human;Binding;Ki;=;340,00;6,47;-41;3;Displacement of [3H]spiperone from human dopamine D2 receptor in CHO cells;ChEMBL;340,1;3;0;3;5,24;Clc1cccc(CN2CC=C(c3nc4ccccc4s3)CC2)c1;https://dx.doi.org/10.1016/S0960-894X(97)00402-2
CHEMBL307956;103205;None;0;Human;Binding;Ki;=;5000,00;5,30;-1258;3;Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;235,1;0;1;1;2,87;c1ccc2c(c1)Cc1ccccc1C21CCNC1;https://dx.doi.org/10.1016/j.bmcl.2004.02.014
CHEMBL308098;103220;None;0;Human;Binding;Ki;=;1062,00;5,97;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;365,2;7;0;2;4,54;Fc1ccc(C#CCOCCC2CCN(CCc3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL308345;103253;None;0;Human;Binding;Ki;=;0,47;9,33;33;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;404,2;4;1;6;4,06;Oc1nc2cccc(N3CCN(Cc4cc(-c5ccc(F)cc5)ccn4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL3084502;103349;None;0;Human;Binding;Ki;=;33,40;7,48;-3;5;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;366,1;3;2;2;4,84;O[C@@]1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2Cc1c[nH]c2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084502;103349;None;0;Human;Binding;Ki;=;160,30;6,79;-3;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;366,1;3;2;2;4,84;O[C@@]1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2Cc1c[nH]c2ccccc12;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL3084503;103350;None;0;Human;Binding;Ki;=;35,30;7,45;-5;6;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;400,1;3;2;2;5,49;O[C@]1(c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H](C1)N2Cc1c[nH]c2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084504;103351;None;0;Human;Binding;Ki;=;545,00;6,26;-1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;400,1;3;2;2;5,49;O[C@]1(c2cccc(Cl)c2Cl)C[C@@H]2CC[C@H](C1)N2Cc1c[nH]c2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084505;103352;None;0;Human;Binding;Ki;=;41,40;7,38;-1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;350,2;3;2;2;4,32;O[C@]1(c2ccc(F)cc2)C[C@@H]2CC[C@H](C1)N2Cc1c[nH]c2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084506;103353;None;0;Human;Binding;Ki;=;196,00;6,71;1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;382,2;3;2;2;5,34;O[C@]1(c2ccc3ccccc3c2)C[C@@H]2CC[C@H](C1)N2Cc1c[nH]c2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084507;103354;None;0;Human;Binding;Ki;=;2070,00;5,68;3;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;362,2;4;2;3;4,19;COc1ccccc1[C@@]1(O)C[C@@H]2CC[C@H](C1)N2Cc1c[nH]c2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084508;103355;None;0;Human;Binding;Ki;=;565,00;6,25;-1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;378,2;4;2;3;4,90;CSc1ccc([C@@]2(O)C[C@@H]3CC[C@H](C2)N3Cc2c[nH]c3ccccc23)cc1;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084509;103356;None;0;Human;Binding;Ki;=;225,00;6,65;-2;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;367,1;3;2;3;4,23;O[C@]1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2Cc1n[nH]c2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084510;103357;None;0;Human;Binding;Ki;=;39,40;7,41;-1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;396,2;4;2;3;4,84;COc1ccc2[nH]cc(CN3[C@H]4CC[C@@H]3C[C@@](O)(c3ccc(Cl)cc3)C4)c2c1;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084511;103358;None;0;Human;Binding;Ki;=;554,00;6,26;2;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;408,2;5;2;4;4,91;COc1ccc2[nH]cc(CN3[C@H]4CC[C@@H]3C[C@@](O)(c3ccc(SC)cc3)C4)c2c1;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084512;103359;None;0;Human;Binding;Ki;=;12,90;7,89;-3;6;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;383,1;3;1;3;5,57;O[C@]1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2Cc1csc2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084513;103360;None;0;Human;Binding;Ki;=;29,80;7,53;-1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;417,1;3;1;3;6,22;O[C@]1(c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H](C1)N2Cc1csc2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084514;103361;None;0;Human;Binding;Ki;=;280,00;6,55;1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;417,1;3;1;3;6,22;O[C@]1(c2cccc(Cl)c2Cl)C[C@@H]2CC[C@H](C1)N2Cc1csc2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084515;103362;None;0;Human;Binding;Ki;=;1,06;8,97;-1;6;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;367,1;3;1;3;5,10;O[C@]1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2Cc1coc2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084516;103363;None;0;Human;Binding;Ki;=;1,70;8,77;-5;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;401,1;3;1;3;5,75;O[C@@]1(c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H](C1)N2Cc1coc2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084517;103364;None;0;Human;Binding;Ki;=;40,10;7,40;-1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;401,1;3;1;3;5,75;O[C@]1(c2cccc(Cl)c2Cl)C[C@@H]2CC[C@H](C1)N2Cc1coc2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084518;103365;None;0;Human;Binding;Ki;=;4,90;8,31;-4;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;351,2;3;1;3;4,59;O[C@]1(c2ccc(F)cc2)C[C@@H]2CC[C@H](C1)N2Cc1coc2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084519;103366;None;0;Human;Binding;Ki;=;1,50;8,82;-1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;411,1;3;1;3;5,21;O[C@]1(c2ccc(Br)cc2)C[C@@H]2CC[C@H](C1)N2Cc1coc2ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084520;103367;None;0;Human;Binding;Ki;=;1,50;8,82;1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;397,1;4;1;4;5,11;COc1ccc2occ(CN3[C@H]4CC[C@@H]3C[C@@](O)(c3ccc(Cl)cc3)C4)c2c1;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084521;103368;None;0;Human;Binding;Ki;=;1,20;8,92;-3;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;385,1;3;1;3;5,24;O[C@]1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2Cc1coc2ccc(F)cc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084522;103369;None;0;Human;Binding;Ki;=;11,70;7,93;-1;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;417,1;3;1;3;6,25;O[C@]1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2Cc1coc2ccc3ccccc3c12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084523;103370;None;0;Human;Binding;Ki;=;5,60;8,25;-2;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;417,1;3;1;3;6,25;O[C@]1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2Cc1coc2c1ccc1ccccc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL3084524;103371;None;0;Human;Binding;Ki;=;1,40;8,85;-2;2;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;419,1;3;1;3;5,89;O[C@]1(c2ccc(Cl)c(Cl)c2)C[C@@H]2CC[C@H](C1)N2Cc1coc2ccc(F)cc12;https://dx.doi.org/10.1021/jm800532x
CHEMBL308476;103464;None;0;Human;Binding;Ki;=;4,00;8,40;21;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;383,2;4;1;3;5,03;c1ccc(-c2cccc(CN3CCN(c4cccc5c4CCCN5)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL308480;103465;None;0;Human;Binding;Ki;=;338,84;6,47;-37;6;Binding affinity towards dopamine receptor D2;ChEMBL;365,2;4;0;3;4,17;O=C1CC(CN2CCC(C(=O)c3ccc(F)cc3)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL308480;103465;None;0;Human;Binding;Ki;=;104,71;6,98;-37;6;Binding affinity towards dopamine receptor D2;ChEMBL;365,2;4;0;3;4,17;O=C1CC(CN2CCC(C(=O)c3ccc(F)cc3)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL308480;103465;None;0;Human;Binding;Ki;=;223,87;6,65;-37;6;Binding affinity towards dopamine receptor D2;ChEMBL;365,2;4;0;3;4,17;O=C1CC(CN2CCC(C(=O)c3ccc(F)cc3)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL3084971;103518;None;5;Human;Binding;Ki;=;28,00;7,55;-14;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;365,3;6;1;5;3,66;c1ccc(N2CCN(CC[C@H]3CC[C@@H](Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL3085215;103573;None;0;Human;Binding;Ki;=;30100,00;4,52;-2511;2;In vitro binding affinity at human cloned Dopamine receptor D2A by measuring its ability to displace [3H]raclopride from D2A receptor expressed in mouse fibroblast (LtK-) cells;ChEMBL;275,2;5;0;3;3,31;CCCN(C(C)C)[C@@H]1COc2cccc(C(C)=O)c2C1;https://dx.doi.org/10.1021/jm990956o
CHEMBL3085802;103612;None;0;Human;Binding;Ki;=;1000,00;6,00;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;329,2;4;1;2;3,27;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085812;103613;None;0;Human;Binding;Ki;=;354,81;6,45;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;344,2;3;1;3;4,13;CC(C)(C)OC(=O)N[C@H]1CC[C@H](CN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085813;103614;None;0;Human;Binding;Ki;=;1148,15;5,94;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;358,3;4;1;3;4,38;CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085814;103615;None;0;Human;Binding;Ki;=;1071,52;5,97;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;358,3;4;1;3;4,52;CC(C)(C)OC(=O)N[C@H]1CC[C@@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085815;103616;None;0;Human;Binding;Ki;=;549,54;6,26;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;352,2;4;1;3;4,63;CC(C)(C)OC(=O)Nc1ccc(CCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085816;103617;None;0;Human;Binding;Ki;=;13489,63;4,87;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;329,2;4;1;2;3,27;CN(C)C(=O)N[C@H]1CC[C@@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085817;103618;None;0;Human;Binding;Ki;=;380,19;6,42;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;403,2;5;1;5;4,43;CC(C)(C)OC(=O)N[C@H]1CC[C@H](CCN2CCc3ccc([N+](=O)[O-])cc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085818;103619;None;0;Human;Binding;Ki;=;2238,72;5,65;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;383,3;4;1;4;4,39;CC(C)(C)OC(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(C#N)cc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085819;103620;None;0;Human;Binding;Ki;=;23,44;7,63;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;325,2;4;1;3;3,00;CC(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(C#N)cc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085820;103621;None;0;Human;Binding;Ki;=;10,47;7,98;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;469,2;5;1;4;5,98;CC(C)(C)OC(=O)N[C@H]1CC[C@H](CCN2CCCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085821;103622;None;22;Human;Binding;Ki;=;8,20;8,09;-8;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;455,2;5;1;4;5,59;CC(C)(C)OC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL3085821;103622;None;22;Human;Binding;Ki;=;39,81;7,40;-8;2;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;455,2;5;1;4;5,59;CC(C)(C)OC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085822;103623;None;0;Human;Binding;Ki;=;309,03;6,51;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;441,2;4;1;4;5,20;CC(C)(C)OC(=O)N[C@H]1CC[C@H](CN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085823;103624;None;0;Human;Binding;Ki;=;147,91;6,83;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;455,2;5;1;4;5,45;CC(C)(C)OC(=O)NC[C@H]1CC[C@H](CN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085824;103625;None;22;Human;Binding;Ki;=;33,11;7,48;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;455,2;5;1;4;5,59;CC(C)(C)OC(=O)N[C@H]1CC[C@@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3085825;103626;None;0;Human;Binding;Ki;=;42,66;7,37;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;426,2;5;1;3;4,19;CN(C)C(=O)NC[C@H]1CC[C@H](CN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3088209;103803;None;0;Human;Binding;Ki;=;741,31;6,13;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;358,3;4;1;3;4,52;CC(C)(C)OC(=O)N[C@H]1CC[C@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3088210;103804;None;0;Human;Binding;Ki;=;6025,60;5,22;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;300,2;4;1;2;3,13;CC(=O)N[C@H]1CC[C@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3088211;103805;None;0;Human;Binding;Ki;=;2691,53;5,57;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;330,2;5;1;3;3,74;CCOC(=O)N[C@H]1CC[C@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3088212;103806;None;0;Human;Binding;Ki;=;1479,11;5,83;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;344,2;5;1;3;4,13;CC(C)OC(=O)N[C@H]1CC[C@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3088213;103807;None;0;Human;Binding;Ki;=;5248,07;5,28;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;358,3;6;1;3;4,38;CC(C)COC(=O)N[C@H]1CC[C@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3088214;103808;None;0;Human;Binding;Ki;=;912,01;6,04;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;378,2;5;1;3;4,78;O=C(N[C@H]1CC[C@H](CCN2CCc3ccccc3C2)CC1)Oc1ccccc1;https://dx.doi.org/10.1021/jm401318w
CHEMBL3088215;103809;None;0;Human;Binding;Ki;=;245,47;6,61;-;1;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO cell membranes after 3 hrs by liquid scintillation counting analysis;ChEMBL;357,3;4;2;2;4,09;CC(C)(C)NC(=O)N[C@H]1CC[C@H](CCN2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm401318w
CHEMBL308875;103833;None;0;Human;Binding;Ki;=;8,10;8,09;4;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;368,2;4;0;3;5,42;c1ccc(-c2cccc(CN3CCN(c4cccc5ccoc45)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL308980;103850;None;0;Human;Binding;Ki;=;948,00;6,02;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;349,2;9;0;2;5,06;C(=C/c1ccccc1)\COCC1CCN(CCCc2ccccc2)CC1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL309106;103868;None;1;Human;Binding;Ki;=;23,00;7,64;-72;8;Binding affinity towards recombinant human Dopamine receptor D2L was determined using [3H]spiperone as radioligand;ChEMBL;585,3;10;2;8;3,25;CC(C)Oc1ccccc1N1CCN(C[C@@H](O)CNC(=O)c2ccc3c(c2)C(=O)N(c2ccc(N(C)C)cc2)C3=O)CC1;https://dx.doi.org/10.1021/jm9905918
CHEMBL309106;103868;None;1;Human;Binding;Ki;=;25,00;7,60;-72;8;Binding affinity towards recombinant human Dopamine receptor D2S was determined using [3H]spiperone as radioligand;ChEMBL;585,3;10;2;8;3,25;CC(C)Oc1ccccc1N1CCN(C[C@@H](O)CNC(=O)c2ccc3c(c2)C(=O)N(c2ccc(N(C)C)cc2)C3=O)CC1;https://dx.doi.org/10.1021/jm9905918
CHEMBL309118;103869;None;0;Human;Binding;Ki;=;512,00;6,29;-14;5;Binding affinity at human dopamine receptor D2;ChEMBL;493,1;6;1;4;5,15;O=C(NCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc2c1-c1ccccc1C2=O;https://dx.doi.org/10.1021/jm010146o
CHEMBL309215;103950;None;0;Human;Binding;Ki;=;10,00;8,00;2;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;415,2;5;1;6;4,53;COc1cccc(-c2cccc(CN3CCN(c4cccc5nc(O)oc45)CC3)c2)c1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL3092753;104012;None;0;Human;Binding;Ki;=;1400,00;5,85;-776;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;251,1;1;2;1;1,67;NC(N)=NC(=O)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1016/j.bmc.2013.10.010
CHEMBL309336;104095;None;0;Human;Binding;Ki;=;11,40;7,94;1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;479,2;6;1;4;5,86;Cc1ccsc1C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL309372;104159;None;3;Human;Binding;EC50;=;12,00;7,92;-;2;Agonist activity at human D2R expressed in HEK293 cells incubated for 3 mins by FLIPR analysis;ChEMBL;322,2;4;1;4;2,89;COc1ccccc1N1CCN(Cc2nc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL309459;104198;None;0;Human;Binding;Ki;=;34,00;7,47;-4;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;431,2;6;1;4;4,90;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccc(Cl)cc3)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL309460;104200;None;0;Human;Binding;Ki;=;900,00;6,05;-38;2;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;332,2;5;1;3;3,89;c1ccc(CCN2CCC(c3cc(-c4cccnc4)[nH]n3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL309501;104204;None;0;Human;Binding;Ki;=;5,00;8,30;-1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;411,2;6;1;4;4,56;Cc1ccccc1N1CCN(CC[C@H]2CC[C@H](NC(=O)c3cccs3)CC2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL309623;104221;None;0;Human;Binding;Ki;=;38,00;7,42;-269;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;397,3;6;1;3;4,45;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccccc3)CC2)CC1)C1CCCCC1;https://dx.doi.org/10.1021/jm9707378
CHEMBL309623;104221;None;0;Human;Binding;Ki;=;38,00;7,42;-269;3;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;397,3;6;1;3;4,45;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccccc3)CC2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL309727;104236;None;0;Human;Binding;Ki;=;5,00;8,30;-1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;465,1;6;1;4;5,56;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1ccsc1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL309901;104277;None;0;Human;Binding;Ki;=;200,00;6,70;-125;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;365,2;4;1;2;5,42;Cc1c(C2CCN(Cc3ccccc3)CC2)n[nH]c1-c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL309979;104353;None;0;Human;Binding;Ki;=;7,40;8,13;-1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;465,2;6;1;3;5,76;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL310045;104410;None;0;Human;Binding;Ki;=;1,30;8,89;13;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;391,1;4;1;6;4,58;Oc1nc2cccc(N3CCN(Cc4cccc(-c5ccsc5)c4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL310048;104411;None;0;Human;Binding;Ki;=;0,93;9,03;28;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;385,2;4;1;4;4,48;c1ccc(-c2cccc(CN3CCN(c4cccc5c4OCCN5)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL310153;104424;None;0;Human;Binding;Ki;=;204,17;6,69;-31;5;Binding affinity towards dopamine receptor D2;ChEMBL;350,2;4;0;4;3,26;COc1ccccc1N1CCN(CC2CC(=O)c3ccccc3C2)CC1;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL310158;104425;None;0;Human;Binding;Ki;=;41,50;7,38;-2;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;459,2;6;1;3;5,49;O=C(NC1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1ccccc1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL310204;104430;None;0;Human;Binding;Ki;=;15,00;7,82;-3;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;431,3;6;1;3;5,11;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccccc3Cl)CC2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL3102875;104442;None;0;Human;Binding;Ki;=;32,36;7,49;1;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;407,2;5;0;4;4,37;CC(=O)c1ccc2c(c1)CC(CN1CCC(C(=O)c3ccc(F)cc3)CC1)CC2=O;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL310310;104464;None;15;Human;Binding;Ki;=;1740,00;5,76;-478;6;Binding affinity at human dopamine receptor D2;ChEMBL;341,2;4;0;2;5,07;CN1C2CCC1CC(OC(c1ccccc1)c1ccc(Cl)cc1)C2;https://dx.doi.org/10.1021/jm010146o
CHEMBL310401;104512;None;0;Human;Binding;Ki;=;37,50;7,43;-6;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;431,3;6;1;3;5,11;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3)CC2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL3104091;104514;None;0;Human;Binding;Ki;=;831,76;6,08;-81;24;Displacement of [3H]N-Methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;288,2;0;0;2;3,72;CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1;https://dx.doi.org/10.1016/j.bmcl.2013.12.024
CHEMBL3104091;104514;None;0;Human;Binding;Ki;=;835,00;6,08;-81;24;Displacement of [3H]N-Methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;288,2;0;0;2;3,72;CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1;https://dx.doi.org/10.1016/j.bmcl.2013.12.024
CHEMBL3104515;104605;None;0;Human;Binding;Ki;=;112,20;6,95;-4;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;410,2;5;2;5;3,84;Nc1ccc2c(c1)C(=O)C(CCN1CCC(C(=O)c3ccc(F)cc3O)CC1)CC2;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104516;104606;None;0;Human;Binding;Ki;=;50,12;7,30;-1;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;420,2;4;0;5;4,79;CC(=O)c1ccc2c(c1)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104517;104607;None;0;Human;Binding;Ki;=;17,38;7,76;-1;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;454,2;4;0;4;6,26;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2cc(-c3ccccc3)ccc21;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104519;104609;None;0;Human;Binding;Ki;=;120,23;6,92;-10;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;439,2;5;1;6;4,74;O=[N+]([O-])c1ccc2c(c1)C(O)C(CCN1CCC(c3noc4cc(F)ccc34)CC1)CC2;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104520;104610;None;0;Human;Binding;Ki;=;19,05;7,72;26;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;411,2;6;1;6;3,41;COc1ccccc1N1CCN(CCC2CCc3ccc([N+](=O)[O-])cc3C2O)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104521;104611;None;0;Human;Binding;Ki;=;177,83;6,75;-1;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;381,2;5;2;5;3,09;COc1ccccc1N1CCN(CCC2CCc3ccc(N)cc3C2O)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104522;104612;None;0;Human;Binding;Ki;=;87,10;7,06;-13;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;409,2;4;2;5;4,42;Nc1ccc2c(c1)C(O)C(CCN1CCC(c3noc4cc(F)ccc34)CC1)CC2;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104523;104613;None;0;Human;Binding;Ki;=;645,65;6,19;-144;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;412,2;5;3;5;3,69;Nc1ccc2c(c1)C(O)C(CCN1CCC(C(=O)c3ccc(F)cc3O)CC1)CC2;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104524;104614;None;0;Human;Binding;Ki;=;37,15;7,43;-1;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;437,2;5;0;6;4,89;O=C1c2cc([N+](=O)[O-])ccc2CCC1CCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104646;104630;None;0;Human;Binding;Ki;=;41,69;7,38;19;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;409,2;6;0;6;3,56;COc1ccccc1N1CCN(CCC2CCc3ccc([N+](=O)[O-])cc3C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104647;104631;None;0;Human;Binding;Ki;=;46,77;7,33;-9;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;407,2;4;1;5;4,56;Nc1ccc2c(c1)C(=O)C(CCN1CCC(c3noc4cc(F)ccc34)CC1)CC2;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL3104648;104632;None;0;Human;Binding;Ki;=;50,12;7,30;-1;2;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;379,2;5;1;5;3,23;COc1ccccc1N1CCN(CCC2CCc3ccc(N)cc3C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
CHEMBL310577;104783;None;0;Human;Binding;Ki;=;12,00;7,92;-8;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;427,2;7;1;5;4,26;COc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)c4cccs4)CC3)CC2)c1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL310680;104803;None;0;Human;Binding;Ki;=;81,00;7,09;-5;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;431,3;6;1;3;5,11;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccc(Cl)cc3)CC2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL310819;104825;None;0;Human;Binding;Ki;=;860,00;6,07;-38;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;332,2;5;1;3;3,89;c1ccc(CCN2CCC(c3cc(-c4ccccn4)[nH]n3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL310867;104834;None;3;Human;Binding;Ki;=;85,00;7,07;-100;7;Binding affinity of compound measured using [3H]spiperone for the cloned human Dopamine receptor D2L (high/low affinity is given as 85/6400);ChEMBL;271,2;5;0;3;3,31;CCCN(CCC)[C@H]1CCc2nn3ccccc3c2C1;https://dx.doi.org/10.1016/s0960-894x(02)00390-6
CHEMBL310867;104834;None;3;Human;Binding;Ki;=;35,00;7,46;-100;7;Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D2 short (high/low affinity is given as 35/3700);ChEMBL;271,2;5;0;3;3,31;CCCN(CCC)[C@H]1CCc2nn3ccccc3c2C1;https://dx.doi.org/10.1016/s0960-894x(02)00390-6
CHEMBL3113644;105088;None;0;Human;Binding;IC50;=;16280,00;4,79;-;1;Antagonist activity at dopamine D2 receptor (unknown origin) expressed in HEK cells co-expressing Gqi5 assessed as inhibition of dopamine-induced effect by FLIPR assay;ChEMBL;244,1;2;1;4;1,97;Nc1ccc2oc(=O)c(CN3CCCC3)cc2c1;https://dx.doi.org/10.1016/j.ejmech.2013.11.035
CHEMBL311508;105276;None;0;Human;Binding;Ki;=;1356,00;5,87;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;319,2;5;0;2;3,76;C(#Cc1ccccc1)COC1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL311539;105339;None;0;Human;Binding;Ki;=;81,30;7,09;-47;4;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;325,1;3;1;2;4,14;Clc1ccc2[nH]ccc2c1N1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL311575;105355;None;0;Human;Binding;Ki;=;16,50;7,78;-3;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;411,2;6;1;4;4,56;Cc1ccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)c4cccs4)CC3)CC2)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL311730;105457;None;30;Human;Binding;Ki;=;755,00;6,12;1;4;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;281,1;4;0;3;2,68;CCCN1CCC[C@@H](c2cccc(S(C)(=O)=O)c2)C1;https://dx.doi.org/10.1021/jm901689v
CHEMBL311730;105457;None;30;Human;Binding;Ki;=;447,00;6,35;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;281,1;4;0;3;2,68;CCCN1CCC[C@@H](c2cccc(S(C)(=O)=O)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL311730;105457;None;30;Human;Binding;Ki;=;3884,00;5,41;1;4;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;281,1;4;0;3;2,68;CCCN1CCC[C@@H](c2cccc(S(C)(=O)=O)c2)C1;https://dx.doi.org/10.1021/jm901689v
CHEMBL311772;105461;None;0;Human;Binding;Ki;=;40,00;7,40;-1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;397,2;6;1;4;4,25;O=C(NC1CCC(CCN2CCN(c3ccccc3)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL311832;105468;None;0;Human;Binding;Ki;=;690,00;6,16;-1;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;357,2;4;1;2;4,60;c1ccc(CCN2CCC3(CCc4c3n[nH]c4-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL312255;105666;None;0;Human;Binding;Ki;=;700,00;6,16;-34;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;385,1;4;1;2;5,76;Clc1ccc(-c2cc(C3CCN(Cc4ccccc4Cl)CC3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL312430;105691;None;0;Human;Binding;Ki;=;3,00;8,52;-2;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;449,2;6;1;4;5,09;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1ccco1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL3126735;105850;None;2;Human;Binding;IC50;=;2000,00;5,70;-8;3;Antagonist activity at DRD2 (unknown origin) expressed in HEK293T cells transfected with Galphai1-RLuc8 and gamma2-GFP10 assessed as inhibition of quinpirole-induced Gi1 activation pre-incubated with quinpirole for 10 mins before compound incubation for 10 mins by BRET assay;ChEMBL;397,2;10;1;2;6,01;Fc1ccc(C(SCCNCCCc2ccccc2)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b01373
CHEMBL3126735;105850;None;2;Human;Binding;Ki;=;228,00;6,64;-8;3;Displacement of [3H]N-methylspiperone from human D2R expressed in HEK293 cell membranes incubated for 1 hr by radioligand binding assay;ChEMBL;397,2;10;1;2;6,01;Fc1ccc(C(SCCNCCCc2ccccc2)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b01373
CHEMBL312752;105914;None;0;Human;Binding;Ki;=;19,00;7,72;1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;479,2;6;1;4;5,86;Cc1csc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc(Cl)c4Cl)CC3)CC2)c1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL312803;105959;None;0;Human;Binding;Ki;=;177,00;6,75;-14;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;427,2;7;1;5;4,26;COc1ccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)c4cccs4)CC3)CC2)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL312877;105999;None;0;Human;Binding;Ki;=;293,00;6,53;-2;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;442,2;8;1;5;4,83;COc1ccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)cc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL312877;105999;None;0;Human;Binding;Ki;=;293,00;6,53;-2;2;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;442,2;8;1;5;4,83;COc1ccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL313147;106044;None;1;Human;Binding;Ki;=;1495,00;5,83;-52;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;700,4;21;0;8;9,42;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2CCCCn2c(-c3ccc(OCCCN(CC)CC)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL313189;106051;None;0;Human;Binding;IC50;=;9549,93;5,02;-;5;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;308,2;3;0;3;3,79;CN(C)CCC1CC2c3ccccc3Cc3ccccc3N2O1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
CHEMBL313255;106061;None;0;Human;Binding;Ki;=;501,19;6,30;-158;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;484,3;7;2;4;4,70;CC(=O)Nc1cccc(/C=C/C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(C#N)cc4CC3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL313257;106062;None;0;Human;Binding;Ki;=;1750,00;5,76;-13;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;728,5;23;0;8;10,20;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2CCCCCCn2c(-c3ccc(OCCCN(CC)CC)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL313320;106120;None;0;Human;Binding;Ki;=;110,00;6,96;1;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;429,1;5;0;5;3,42;COc1ccc(Br)cc1C1=N[C@@H](CN2CCN(c3ccccc3)CC2)CO1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL313320;106120;None;0;Human;Binding;Ki;=;400,00;6,40;1;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;429,1;5;0;5;3,42;COc1ccc(Br)cc1C1=N[C@@H](CN2CCN(c3ccccc3)CC2)CO1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL313320;106120;None;0;Human;Binding;Ki;=;2200,00;5,66;1;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;429,1;5;0;5;3,42;COc1ccc(Br)cc1C1=N[C@@H](CN2CCN(c3ccccc3)CC2)CO1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL313320;106120;None;0;Human;Binding;Ki;=;900,00;6,05;1;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;429,1;5;0;5;3,42;COc1ccc(Br)cc1C1=N[C@@H](CN2CCN(c3ccccc3)CC2)CO1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL3134061;106162;None;0;Human;Binding;EC50;=;10,00;8,00;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;324,2;4;2;4;2,87;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCN)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134062;106163;None;0;Human;Binding;EC50;=;132,00;6,88;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;366,2;5;2;4;3,05;CC(=O)NCCCOc1ccc2c(c1O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134063;106164;None;0;Human;Binding;EC50;=;266,00;6,58;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;537,3;11;3;6;5,11;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCNC(=O)OC(C)(C)C)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134063;106164;None;0;Human;Binding;IC50;=;6540,00;5,18;-;1;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;537,3;11;3;6;5,11;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCNC(=O)OC(C)(C)C)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134064;106165;None;0;Human;Binding;EC50;=;396,00;6,40;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;730,4;13;4;8;5,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134064;106165;None;0;Human;Binding;IC50;=;4360,00;5,36;-;1;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;730,4;13;4;8;5,85;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134065;106166;None;0;Human;Binding;EC50;=;149,00;6,83;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;758,4;15;4;8;6,63;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134065;106166;None;0;Human;Binding;IC50;=;5320,00;5,27;-;1;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;758,4;15;4;8;6,63;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134066;106167;None;0;Human;Binding;EC50;=;419,00;6,38;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;786,4;17;4;8;7,41;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134066;106167;None;0;Human;Binding;IC50;=;3600,00;5,44;-;1;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;786,4;17;4;8;7,41;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134067;106168;None;0;Human;Binding;EC50;=;79,00;7,10;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;814,5;19;4;8;8,19;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134067;106168;None;0;Human;Binding;IC50;=;1350,00;5,87;-;1;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;814,5;19;4;8;8,19;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134068;106169;None;0;Human;Binding;EC50;=;110,00;6,96;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;842,5;21;4;8;8,97;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134068;106169;None;0;Human;Binding;IC50;=;183,00;6,74;-;1;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;842,5;21;4;8;8,97;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134069;106170;None;0;Human;Binding;EC50;=;224,00;6,65;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;870,5;23;4;8;9,75;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134070;106171;None;0;Human;Binding;EC50;=;385,00;6,42;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;926,6;27;4;8;11,31;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCCCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134070;106171;None;0;Human;Binding;IC50;=;2680,00;5,57;-;1;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;926,6;27;4;8;11,31;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCCCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134071;106172;None;0;Human;Binding;EC50;=;248,00;6,61;-;1;Agonist activity at human recombinant dopamine D2L receptor expressed in CHOFlpIn cells assessed as ERK1/2 phosphorylation by alphascreen assay;ChEMBL;954,6;29;4;8;12,09;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL3134071;106172;None;0;Human;Binding;IC50;=;1550,00;5,81;-;1;Displacement of [3H]spiperone from human recombinant dopamine D2L receptor expressed in CHOFlpIn cells after 3 hrs by liquid scintillation counting;ChEMBL;954,6;29;4;8;12,09;CN1CCc2cccc3c2[C@H]1Cc1ccc(OCCCNC(=O)CCCCCCCCCCCCCCCCCCC(=O)NCCCOc2ccc4c(c2O)-c2cccc5c2[C@@H](C4)N(C)CC5)c(O)c1-3;https://dx.doi.org/10.1039/C3MD00154G
CHEMBL313620;106210;None;0;Human;Binding;Ki;=;8,80;8,06;-5;4;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;442,2;8;1;5;4,83;COc1ccccc1N1CCN(CCCOc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL313620;106210;None;0;Human;Binding;Ki;=;8,80;8,06;-5;4;Binding affinity to dopaminergic D2 receptor (unknown origin);ChEMBL;442,2;8;1;5;4,83;COc1ccccc1N1CCN(CCCOc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.09.045
CHEMBL313620;106210;None;0;Human;Binding;Ki;=;8,80;8,06;-5;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;442,2;8;1;5;4,83;COc1ccccc1N1CCN(CCCOc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL313692;106218;None;0;Human;Binding;Ki;=;3438,00;5,46;-19;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;748,4;20;0;8;10,04;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2Cc2ccc(Cn3c(-c4ccc(OCCCN(CC)CC)cc4)nc4ccccc43)cc2)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL313851;106250;None;0;Human;Binding;Ki;=;132,00;6,88;-6;4;Affinity for the Dopamine receptor D2S was determined using membranes from CHO cells labeled with [3H]spiperone;ChEMBL;361,1;4;2;3;4,07;FC(F)(F)c1nc2c3c(ccc2[nH]1)CCC(CNCc1ccccc1)O3;https://dx.doi.org/10.1016/s0960-894x(01)00778-8
CHEMBL3139045;106343;None;0;Human;Binding;Ki;=;60,00;7,22;-16;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;466,2;10;2;5;3,63;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2cc3cc(OCCF)ccc3[nH]2)CC1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139046;106344;None;0;Human;Binding;Ki;=;42,40;7,37;-28;3;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;556,3;17;2;7;3,89;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(OCCOCCOCCF)ccc3[nH]2)CC1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139049;106345;None;0;Human;Binding;Ki;=;15,70;7,80;-87;3;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;422,2;8;3;5;3,21;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(O)ccc3[nH]2)CC1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139050;106346;None;0;Human;Binding;Ki;=;7,50;8,12;-2;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;466,2;10;2;5;3,63;COc1ccc2[nH]cc(C(=O)NC/C=C/CN3CCN(c4ccccc4OCCF)CC3)c2c1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139051;106347;None;0;Human;Binding;Ki;=;155,00;6,81;-18;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;554,3;16;2;7;3,67;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2cc3cc(OCCOCCOCCF)ccc3[nH]2)CC1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139052;106348;None;0;Human;Binding;Ki;=;40,40;7,39;-20;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;436,2;9;2;4;3,62;O=C(NC/C=C/CN1CCN(c2ccccc2OCCF)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139053;106349;None;0;Human;Binding;Ki;=;23,90;7,62;-56;3;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;468,3;11;2;5;3,86;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(OCCF)ccc3[nH]2)CC1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139054;106350;None;0;Human;Binding;Ki;=;120,00;6,92;-31;3;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;510,3;13;2;6;3,65;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2cc3cc(OCCOCCF)ccc3[nH]2)CC1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139057;106351;None;0;Human;Binding;Ki;=;5,10;8,29;-5;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;438,2;10;2;4;3,85;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1c[nH]c2ccccc12;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139059;106352;None;0;Human;Binding;Ki;=;21,80;7,66;-19;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;512,3;14;2;6;3,87;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(OCCOCCF)ccc3[nH]2)CC1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139060;106353;None;0;Human;Binding;Ki;=;2,00;8,70;-5;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;468,3;11;2;5;3,86;COc1ccc2[nH]cc(C(=O)NCCCCN3CCN(c4ccccc4OCCF)CC3)c2c1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139061;106354;None;0;Human;Binding;Ki;=;11,70;7,93;-3;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;434,2;8;2;5;3,29;COc1ccc2[nH]cc(C(=O)NC/C=C/CN3CCN(c4ccccc4OC)CC3)c2c1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139063;106355;None;0;Human;Binding;Ki;=;66,30;7,18;-21;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;466,2;10;2;5;3,63;COc1ccc2[nH]c(C(=O)NC/C=C/CN3CCN(c4ccccc4OCCF)CC3)cc2c1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139064;106356;None;0;Human;Binding;Ki;=;119,00;6,92;-27;3;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;434,2;8;2;5;3,29;COc1ccc2[nH]c(C(=O)NC/C=C/CN3CCN(c4ccccc4OC)CC3)cc2c1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139065;106357;None;0;Human;Binding;Ki;=;33,60;7,47;-8;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;452,2;9;3;5;3,33;O=C(NC/C=C/CN1CCN(c2ccccc2OCCF)CC1)c1cc2cc(O)ccc2[nH]1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139068;106358;None;0;Human;Binding;Ki;=;5,90;8,23;-1;2;Displacement of [125I]ABN from human D2 receptor transfected in HEK-293 cell membrane after 60 mins by filtration binding assay;ChEMBL;466,2;10;2;5;3,63;COc1ccc2c(C(=O)NC/C=C/CN3CCN(c4ccccc4OCCF)CC3)c[nH]c2c1;https://dx.doi.org/10.1039/c3md00098b
CHEMBL3139201;106407;None;0;Human;Binding;Ki;=;251,19;6,60;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;535,3;8;1;6;4,59;CS(=O)(=O)Oc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cccc(-n4cccc4)c3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139204;106408;None;0;Human;Binding;Ki;=;501,19;6,30;-125;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;535,3;7;1;6;4,83;Cc1cc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(S(C)(=O)=O)cc5CC4)CC3)c2)on1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139214;106413;None;0;Human;Binding;Ki;=;316,23;6,50;-125;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;520,2;7;1;5;4,96;CS(=O)(=O)Oc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cccc4ccccc34)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139215;106414;None;0;Human;Binding;Ki;=;158,49;6,80;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;551,2;8;1;7;4,77;Cc1cc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(OS(C)(=O)=O)cc5CC4)CC3)c2)on1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139216;106415;None;0;Human;Binding;Ki;=;316,23;6,50;-100;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;551,2;8;1;7;4,77;Cc1cnc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(OS(C)(=O)=O)cc5CC4)CC3)c2)o1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139221;106416;None;0;Human;Binding;Ki;=;316,23;6,50;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;519,3;6;1;5;4,73;Cc1ccc2c(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(S(C)(=O)=O)cc5CC4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139222;106417;None;0;Human;Binding;Ki;=;316,23;6,50;-158;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;548,2;8;1;7;4,26;CS(=O)(=O)Oc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cccc(-c4ncccn4)c3)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139223;106418;None;0;Human;Binding;Ki;=;630,96;6,20;-99;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;535,3;7;1;6;4,83;Cc1ncc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(S(C)(=O)=O)cc5CC4)CC3)c2)o1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139262;106427;None;0;Human;Binding;Ki;=;92,70;7,03;-3;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(OCCCCF)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139262;106427;None;0;Human;Binding;Ki;=;5,50;8,26;-3;5;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(OCCCCF)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139262;106427;None;0;Human;Binding;Ki;=;80,50;7,09;-3;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(OCCCCF)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139262;106427;None;0;Human;Binding;Ki;=;5,60;8,25;-3;5;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(OCCCCF)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139262;106427;None;0;Human;Binding;Ki;=;91,20;7,04;-3;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(OCCCCF)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139262;106427;None;0;Human;Binding;Ki;=;61,66;7,21;-3;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(OCCCCF)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139265;106428;None;0;Human;Binding;Ki;=;5,01;8,30;-5;4;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;429,2;9;2;6;2,85;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(OCCF)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139265;106428;None;0;Human;Binding;Ki;=;252,00;6,60;-5;4;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;429,2;9;2;6;2,85;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(OCCF)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139265;106428;None;0;Human;Binding;Ki;=;235,00;6,63;-5;4;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;429,2;9;2;6;2,85;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(OCCF)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139265;106428;None;0;Human;Binding;Ki;=;218,78;6,66;-5;4;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;429,2;9;2;6;2,85;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(OCCF)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139265;106428;None;0;Human;Binding;Ki;=;234,42;6,63;-5;4;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;429,2;9;2;6;2,85;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(OCCF)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139265;106428;None;0;Human;Binding;Ki;=;6,67;8,18;-5;4;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;429,2;9;2;6;2,85;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(OCCF)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139302;106433;None;0;Human;Binding;Ki;=;131,00;6,88;-9;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;493,1;6;2;5;3,10;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(I)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139302;106433;None;0;Human;Binding;Ki;=;95,50;7,02;-9;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;493,1;6;2;5;3,10;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(I)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139302;106433;None;0;Human;Binding;Ki;=;66,07;7,18;-9;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;493,1;6;2;5;3,10;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(I)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139302;106433;None;0;Human;Binding;Ki;=;80,50;7,09;-9;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;493,1;6;2;5;3,10;Oc1ccc2c(c1)O[C@@H](CNCCN1CCN(c3ccc(I)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139327;106440;None;0;Human;Binding;Ki;=;199,53;6,70;-79;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;552,2;8;1;8;4,16;Cc1nc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(OS(C)(=O)=O)cc5CC4)CC3)c2)no1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139341;106442;None;0;Human;Binding;Ki;=;199,53;6,70;-99;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;521,2;7;1;6;4,35;CS(=O)(=O)Oc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cccc4ncccc34)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139393;106446;None;0;Human;Binding;Ki;=;151,36;6,82;-93;6;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;263,2;7;2;3;3,26;CCCCCCNC[C@H]1CCc2ccc(O)cc2O1;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139393;106446;None;0;Human;Binding;Ki;=;260,00;6,58;-93;6;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;263,2;7;2;3;3,26;CCCCCCNC[C@H]1CCc2ccc(O)cc2O1;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139393;106446;None;0;Human;Binding;Ki;=;168,00;6,78;-93;6;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;263,2;7;2;3;3,26;CCCCCCNC[C@H]1CCc2ccc(O)cc2O1;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139393;106446;None;0;Human;Binding;Ki;=;6,31;8,20;-93;6;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;263,2;7;2;3;3,26;CCCCCCNC[C@H]1CCc2ccc(O)cc2O1;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139393;106446;None;0;Human;Binding;Ki;=;257,04;6,59;-93;6;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;263,2;7;2;3;3,26;CCCCCCNC[C@H]1CCc2ccc(O)cc2O1;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139393;106446;None;0;Human;Binding;Ki;=;8,19;8,09;-93;6;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;263,2;7;2;3;3,26;CCCCCCNC[C@H]1CCc2ccc(O)cc2O1;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139422;106448;None;0;Human;Binding;Ki;=;199,53;6,70;-158;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;551,2;8;1;7;4,77;Cc1ncc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(OS(C)(=O)=O)cc5CC4)CC3)c2)o1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139450;106459;None;0;Human;Binding;Ki;=;3,79;8,42;-14;5;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(I)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139450;106459;None;0;Human;Binding;Ki;=;51,80;7,29;-14;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(I)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139450;106459;None;0;Human;Binding;Ki;=;35,48;7,45;-14;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(I)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139450;106459;None;0;Human;Binding;Ki;=;2,04;8,69;-14;5;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(I)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139450;106459;None;0;Human;Binding;Ki;=;81,28;7,09;-14;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(I)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139450;106459;None;0;Human;Binding;Ki;=;140,00;6,85;-14;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccc(I)cc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139455;106460;None;0;Human;Binding;Ki;=;0,16;9,79;-6;3;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1I)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139455;106460;None;0;Human;Binding;Ki;=;51,20;7,29;-6;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1I)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139455;106460;None;0;Human;Binding;Ki;=;166,00;6,78;-6;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1I)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139455;106460;None;0;Human;Binding;Ki;=;0,68;9,17;-6;3;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1I)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139455;106460;None;0;Human;Binding;Ki;=;83,18;7,08;-6;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1I)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139455;106460;None;0;Human;Binding;Ki;=;29,51;7,53;-6;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1I)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139475;106462;None;0;Human;Binding;Ki;=;452,00;6,34;-7;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1OCCCCF)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139475;106462;None;0;Human;Binding;Ki;=;354,81;6,45;-7;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1OCCCCF)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139475;106462;None;0;Human;Binding;Ki;=;156,00;6,81;-7;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1OCCCCF)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139475;106462;None;0;Human;Binding;Ki;=;144,54;6,84;-7;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;359,2;9;2;4;4,00;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1OCCCCF)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139483;106465;None;0;Human;Binding;Ki;=;501,19;6,30;-158;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;534,3;7;1;6;4,27;Cn1nccc1-c1cccc(C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(S(C)(=O)=O)cc4CC3)CC2)c1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139486;106466;None;0;Human;Binding;Ki;=;199,53;6,70;-63;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;551,2;8;1;7;4,77;Cc1coc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(OS(C)(=O)=O)cc5CC4)CC3)c2)n1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139554;106478;None;0;Human;Binding;Ki;=;28,84;7,54;-13;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1cccc(I)c1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139554;106478;None;0;Human;Binding;Ki;=;72,90;7,14;-13;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1cccc(I)c1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139554;106478;None;0;Human;Binding;Ki;=;33,88;7,47;-13;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1cccc(I)c1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139554;106478;None;0;Human;Binding;Ki;=;30,80;7,51;-13;5;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1cccc(I)c1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139554;106478;None;0;Human;Binding;Ki;=;2,06;8,69;-13;5;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1cccc(I)c1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139554;106478;None;0;Human;Binding;Ki;=;1,02;8,99;-13;5;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;395;4;2;3;3,48;Oc1ccc2c(c1)O[C@@H](CNCc1cccc(I)c1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL3139574;106482;None;0;Human;Binding;Ki;=;199,53;6,70;-158;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;535,3;7;1;6;4,66;Cc1ccc2c(C(=O)N[C@H]3CC[C@H](CCN4CCc5ccc(OS(C)(=O)=O)cc5CC4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm030817d
CHEMBL3139580;106485;None;0;Human;Binding;Ki;=;630,96;6,20;-99;2;Binding affinity against human Dopamine receptor D2 expressed in CHO cells by using [125I]iodosulpiride as radioligand;ChEMBL;504,2;6;1;4;5,02;CS(=O)(=O)c1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cccc4ccccc34)CC1)CC2;https://dx.doi.org/10.1021/jm030817d
CHEMBL314050;106590;None;0;Human;Binding;Ki;=;398,11;6,40;-63;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;445,3;6;1;3;4,88;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccc(F)cc3)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL314095;106596;None;0;Human;Binding;Ki;=;2780,00;5,56;-1148;3;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;341,1;2;1;4;3,71;O=c1oc2cc(O)ccc2c2c1CN(Cc1ccc(Cl)cc1)CC2;https://dx.doi.org/10.1021/jm970170v
CHEMBL314095;106596;None;0;Human;Binding;Ki;=;2780,00;5,56;-1148;3;Binding affinity to human D2 receptor assessed as inhibition constant;ChEMBL;341,1;2;1;4;3,71;O=c1oc2cc(O)ccc2c2c1CN(Cc1ccc(Cl)cc1)CC2;https://dx.doi.org/10.1016/j.ejmech.2020.113034
CHEMBL314107;106600;None;0;Human;Binding;IC50;=;446,68;6,35;-;5;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;330,2;2;0;3;3,68;CN(C)CC1CC2c3cc(F)ccc3Cc3ccc(F)cc3N2O1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
CHEMBL314174;106611;None;0;Human;Binding;Ki;=;3,90;8,41;-4;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;283,1;6;3;4;2,44;Oc1nc2c(OCCNCc3ccccc3)cccc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL314536;106946;None;0;Human;Binding;Ki;=;134,00;6,87;-1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;285,2;4;0;2;5,00;CCCN1CCC[C@@H](c2cccc(-c3ccsc3)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL314663;106965;None;0;Human;Binding;Ki;=;56,00;7,25;-6;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;694,4;16;0;8;8,71;C(=C/Cn1c(-c2ccc(OCCCN3CCCC3)cc2)nc2ccccc21)\Cn1c(-c2ccc(OCCCN3CCCC3)cc2)nc2ccccc21;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL314937;107003;None;0;Human;Binding;Ki;=;1518,00;5,82;-17;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;698,4;20;0;8;9,20;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2C/C=C\Cn2c(-c3ccc(OCCCN(CC)CC)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL314952;107006;None;0;Human;Binding;Ki;=;8,00;8,10;-2;4;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;307,2;3;1;3;2,50;O=C1Cc2c(cccc2N2CCN(Cc3ccccc3)CC2)N1;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL314983;107015;None;0;Human;Binding;Ki;=;70,00;7,16;-8;2;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;413,2;7;1;5;4,22;c1ccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)nc1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL314983;107015;None;0;Human;Binding;Ki;=;70,00;7,16;-8;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;413,2;7;1;5;4,22;c1ccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)nc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL315137;107036;None;0;Human;Binding;Ki;=;343,00;6,46;-69;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;754,5;24;0;8;10,76;CCCN(CCC)CCCOc1ccc(-c2nc3ccccc3n2C/C=C/Cn2c(-c3ccc(OCCCN(CCC)CCC)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL315209;107046;None;0;Human;Binding;Ki;=;630,96;6,20;-63;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;445,3;6;1;3;4,88;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3ccccc3F)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL315560;107101;None;0;Human;Binding;Ki;=;1414,00;5,85;-53;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;599,3;14;0;7;8,10;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2C/C=C/Cn2c(-c3ccc(OC)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL315564;107103;None;0;Human;Binding;Ki;=;2400,00;5,62;-7;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;443,1;5;0;5;3,81;COc1ccc(Br)cc1C1=N[C@@H](CN2CCN(c3ccccc3)CC2)[C@@H](C)O1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL315564;107103;None;0;Human;Binding;Ki;=;3700,00;5,43;-7;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;443,1;5;0;5;3,81;COc1ccc(Br)cc1C1=N[C@@H](CN2CCN(c3ccccc3)CC2)[C@@H](C)O1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL315564;107103;None;0;Human;Binding;Ki;=;18000,00;4,75;-7;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;443,1;5;0;5;3,81;COc1ccc(Br)cc1C1=N[C@@H](CN2CCN(c3ccccc3)CC2)[C@@H](C)O1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL315564;107103;None;0;Human;Binding;Ki;=;21000,00;4,68;-7;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;443,1;5;0;5;3,81;COc1ccc(Br)cc1C1=N[C@@H](CN2CCN(c3ccccc3)CC2)[C@@H](C)O1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL315772;107125;None;0;Human;Binding;IC50;=;8,71;8,06;-;13;Binding affinity against Dopamine receptor D2L;ChEMBL;328,1;2;0;3;4,06;CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1;https://dx.doi.org/10.1016/s0960-894x(02)00796-5
CHEMBL315772;107125;None;0;Human;Binding;IC50;=;8,71;8,06;-;13;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;328,1;2;0;3;4,06;CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
CHEMBL315864;107142;None;0;Human;Binding;Ki;=;87,30;7,06;-6;4;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;308,2;3;2;4;2,59;Oc1nc2c(N3CCN(Cc4ccccc4)CC3)cccc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL315879;107145;None;0;Human;Binding;Ki;=;2350,00;5,63;-5754;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;401,2;8;1;4;3,68;COc1cccc(C(=O)NCCCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL315879;107145;None;0;Human;Binding;Ki;=;2350,00;5,63;-5754;4;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;401,2;8;1;4;3,68;COc1cccc(C(=O)NCCCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm991138z
CHEMBL316014;107165;None;0;Human;Binding;Ki;=;1027,00;5,99;-26;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;709,4;18;0;7;10,83;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2C/C=C/Cn2c(-c3ccc(OCCCC4CCCCC4)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL316125;107190;None;0;Human;Binding;Ki;=;83,00;7,08;-41;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;353,2;4;1;4;4,78;Cc1c(-c2ccccc2)nc(O)n1C1CCN(CC2CCCCC2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL316222;107206;None;0;Human;Binding;Ki;=;2345,00;5,63;-67;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;698,4;20;0;8;9,20;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2C/C=C/Cn2c(-c3ccc(OCCCN(CC)CC)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL316727;107285;None;0;Human;Binding;Ki;=;176,00;6,75;-89;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;232,1;0;0;3;3,25;Cc1sc(C)c2c1CCCc1cnn(C)c1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL316983;107327;None;0;Human;Binding;Ki;=;52,00;7,28;-26;6;High inhibition constant against [3H]spiperone binding to human Dopamine receptor D2L expressed in CHO cells;ChEMBL;248,2;6;0;3;2,74;CCCN(CCC)[C@H]1CCn2c(C=O)ccc2C1;https://dx.doi.org/10.1021/jm049269+
CHEMBL316983;107327;None;0;Human;Binding;Ki;=;3000,00;5,52;-26;6;Binding affinity (low) towards human dopamine receptor 2 short against radioligand [3H]spiperone, expressed in Chinese hamster ovary cells;ChEMBL;248,2;6;0;3;2,74;CCCN(CCC)[C@H]1CCn2c(C=O)ccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL316983;107327;None;0;Human;Binding;Ki;=;41,00;7,39;-26;6;High inhibition constant against [3H]spiperone binding to human Dopamine receptor D2S expressed in CHO cells;ChEMBL;248,2;6;0;3;2,74;CCCN(CCC)[C@H]1CCn2c(C=O)ccc2C1;https://dx.doi.org/10.1021/jm049269+
CHEMBL316983;107327;None;0;Human;Binding;Ki;=;3000,00;5,52;-26;6;Low inhibition constant against [3H]spiperone binding to human Dopamine receptor D2S expressed in CHO cells;ChEMBL;248,2;6;0;3;2,74;CCCN(CCC)[C@H]1CCn2c(C=O)ccc2C1;https://dx.doi.org/10.1021/jm049269+
CHEMBL316983;107327;None;0;Human;Binding;Ki;=;52,00;7,28;-26;6;High binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;248,2;6;0;3;2,74;CCCN(CCC)[C@H]1CCn2c(C=O)ccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL316983;107327;None;0;Human;Binding;Ki;=;41,00;7,39;-26;6;High binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;248,2;6;0;3;2,74;CCCN(CCC)[C@H]1CCn2c(C=O)ccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL316983;107327;None;0;Human;Binding;Ki;=;6900,00;5,16;-26;6;Binding affinity (low) towards human dopamine receptor 2 long against radioligand [3H]spiperone, expressed in Chinese hamster ovary cells;ChEMBL;248,2;6;0;3;2,74;CCCN(CCC)[C@H]1CCn2c(C=O)ccc2C1;https://dx.doi.org/10.1021/jm0503805
CHEMBL316983;107327;None;0;Human;Binding;Ki;=;6900,00;5,16;-26;6;Low inhibition constant against [3H]spiperone binding to human Dopamine receptor D2L expressed in CHO cells;ChEMBL;248,2;6;0;3;2,74;CCCN(CCC)[C@H]1CCn2c(C=O)ccc2C1;https://dx.doi.org/10.1021/jm049269+
CHEMBL317078;107337;None;0;Human;Binding;Ki;=;641,00;6,19;-2;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;232,1;0;0;3;3,25;Cc1sc(C)c2c1CCCc1cn(C)nc1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL317266;107359;None;0;Human;Binding;Ki;=;2552,00;5,59;-50;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;387,2;4;0;3;3,19;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2ccc(F)cc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL317433;107380;None;0;Human;Binding;Ki;=;0,20;9,70;1;2;Compound was evaluated for the binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;418,2;3;2;5;2,74;O=C1NCN(c2ccccc2)C12CCN(CC1COc3ccc4[nH]ccc4c3O1)CC2;https://dx.doi.org/10.1021/jm00094a021
CHEMBL317488;213663;None;37;Human;Binding;Ki;=;60,10;7,22;1;2;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;-;-;-;-;-;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(N)=O;https://dx.doi.org/10.1021/jm980525q
CHEMBL317488;213663;None;37;Human;Binding;Ki;=;0,06;10,22;1;2;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;-;-;-;-;-;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(N)=O;https://dx.doi.org/10.1021/jm980525q
CHEMBL317488;213663;None;37;Human;Binding;Ki;=;0,09;10,05;1;2;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p;ChEMBL;-;-;-;-;-;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(N)=O;https://dx.doi.org/10.1021/jm980525q
CHEMBL317488;213663;None;37;Human;Binding;Ki;=;73,20;7,13;1;2;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p;ChEMBL;-;-;-;-;-;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(N)=O;https://dx.doi.org/10.1021/jm980525q
CHEMBL317488;213663;None;37;Human;Binding;Ki;=;0,13;9,89;1;2;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;-;-;-;-;-;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(N)=O;https://dx.doi.org/10.1021/jm980525q
CHEMBL317488;213663;None;37;Human;Binding;Ki;=;60,00;7,22;1;2;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;-;-;-;-;-;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(N)=O;https://dx.doi.org/10.1021/jm980525q
CHEMBL317488;213663;None;37;Human;Binding;Ki;=;0,04;10,40;1;2;Inhibitor constant of compound for high affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in absence of Gpp(NH)p (pretreatment with 100 nM of compound);ChEMBL;-;-;-;-;-;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(N)=O;https://dx.doi.org/10.1021/jm980525q
CHEMBL317488;213663;None;37;Human;Binding;Ki;=;78,00;7,11;1;2;Inhibitor constant of compound for low affinity component of [3H]spiroperidol/N-propylnorapomorphine binding to Dopamine receptor D2 in presence of Gpp(NH)p;ChEMBL;-;-;-;-;-;CC(C)C[C@H](NC(=O)[C@@H]1CCCN1)C(=O)NCC(N)=O;https://dx.doi.org/10.1021/jm980525q
CHEMBL317535;107388;None;0;Human;Binding;Ki;=;59,00;7,23;-2;10;Binding affinity against dopamine receptor D2 using [3H]spiperone radioligand in CHO cells;ChEMBL;260,2;5;1;3;2,45;CCOC(=O)c1[nH]c2ccccc2c1CCN(C)C;https://dx.doi.org/10.1021/jm010943m
CHEMBL317670;107410;None;0;Human;Binding;Ki;=;713,00;6,15;-354;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;381,2;4;0;3;3,23;Cc1ccc(CN2CCN(CC(=O)N3c4ccccc4C[C@H]3C)CC2)cc1F;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL317741;107422;None;0;Human;Binding;Ki;=;510,00;6,29;-25;4;Affinity towards Dopamine receptor D2;ChEMBL;329,1;3;2;3;3,93;C=CCN1CCc2c(cc(O)c(O)c2Cl)[C@@H](c2ccccc2)C1;https://dx.doi.org/10.1021/jm9800292
CHEMBL317770;107430;None;0;Human;Binding;Ki;=;534,00;6,27;-3;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;258;0;1;2;3,93;Clc1sc(Cl)c2c1CCCc1c[nH]nc1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL317879;107445;None;0;Human;Binding;Ki;=;117,00;6,93;-27;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;397,2;4;0;3;3,83;CC1(C)Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL317996;107459;None;0;Human;Binding;Ki;=;398,11;6,40;-1;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;532,2;9;1;5;5,40;CS(=O)(=O)Oc1cccc2c1CC[C@H]1[C@@H]2CCCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL318166;107487;None;0;Human;Binding;Ki;=;5,80;8,24;-5;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;552,2;6;2;7;4,09;O=C(OCc1ccccc1)c1cc2c3c(ccc2[nH]1)OCC(CN1CCC2(CC1)C(=O)NCN2c1ccccc1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL318374;107523;None;0;Human;Binding;Ki;=;15,90;7,80;-79;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;380,2;7;2;5;3,32;COC(=O)c1cc2c3c(ccc2[nH]1)OCC(CNCCCc1ccccc1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL318739;107589;None;0;Human;Binding;Ki;=;607,00;6,22;1;2;Binding affinity toward Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as the competitive ligand;ChEMBL;403,1;4;0;3;3,70;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL318740;107590;None;0;Human;Binding;Ki;=;523,00;6,28;-14;2;In vitro binding affinity is the ability to displace [3H]N-0437 from human Dopamine receptor D2 expressed in CHO-K1 cells;ChEMBL;221,2;5;1;2;2,39;CCCN(CCC)C1CCc2n[nH]cc2C1;https://dx.doi.org/10.1021/jm00016a016
CHEMBL318747;107592;None;0;Human;Binding;Ki;=;2740,00;5,56;-13;3;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;358,2;7;0;3;4,49;COc1cccc(CCCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm991138z
CHEMBL318760;107595;None;1;Human;Binding;Ki;=;3780,00;5,42;-16;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;415,1;5;0;4;3,77;CSc1ccc2c(c1)CCN2C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL318925;107630;None;0;Human;Binding;Ki;=;251,19;6,60;-39;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;532,2;9;1;5;5,40;CS(=O)(=O)Oc1cccc2c1CC[C@H]1[C@H]2CCCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL318949;107644;None;0;Human;Binding;Ki;=;885,00;6,05;-9;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;260,1;2;0;3;4,13;CCCn1ncc2c1-c1c(C)sc(C)c1CCC2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL319005;107685;None;4;Human;Binding;Ki;=;1600,00;5,80;-60;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;292,2;3;2;2;3,61;COc1cccc(CC2NCCc3c2[nH]c2ccccc32)c1;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL319023;107706;None;0;Human;Binding;Ki;=;255,00;6,59;-213;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;402,2;5;1;7;2,37;CCOC(=O)C1CCN(CC2COc3ccc4[nH]c(C(=O)OC)cc4c3O2)CC1;https://dx.doi.org/10.1021/jm00094a021
CHEMBL319043;107724;None;0;Human;Binding;Ki;=;59,00;7,23;-2;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;409,2;6;0;5;2,80;COc1ccc(OC)c(CN2CCN(CC(=O)N3c4ccccc4C[C@H]3C)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL319116;107783;None;0;Human;Binding;Ki;=;63,10;7,20;-31;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;440,2;7;2;3;5,37;O=C(NCCCCN1CC[C@H]2c3cccc(O)c3CC[C@@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL319352;107993;None;0;Human;Binding;Ki;=;140,00;6,85;-616;11;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;488,2;6;1;7;3,17;Cn1nnc(-c2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)n1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL319352;107993;None;0;Human;Binding;Ki;=;140,00;6,85;-616;11;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;488,2;6;1;7;3,17;Cn1nnc(-c2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)n1;https://dx.doi.org/10.1021/jm100652h
CHEMBL319355;107997;None;1;Human;Binding;Ki;=;1258,93;5,90;1;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;532,2;9;1;5;5,40;CS(=O)(=O)Oc1cccc2c1CC[C@@H]1[C@@H]2CCCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL319650;108253;None;0;Human;Binding;Ki;=;487,00;6,31;13;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;399,2;5;0;4;3,06;COc1cccc2c1CCN2C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL319707;108305;None;0;Human;Binding;Ki;=;302,00;6,52;-34;2;Binding affinity to dopamine D2 receptor;ChEMBL;281,1;0;3;3;2,96;Cc1ccc2c(c1)[C@@H]1c3cc(O)c(O)cc3CC[C@H]1NC2;https://dx.doi.org/10.1016/j.ejmech.2011.11.039
CHEMBL31991;108508;None;0;Human;Binding;Ki;=;244,00;6,61;-123;3;Binding affinity against cloned human D2 receptor transfected in CHO-K1 cells using [3H]- spiperone as radioligand.;ChEMBL;327,2;7;1;4;2,97;O[C@@H](COc1ccccc1)CN1CCC(Oc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00233-3
CHEMBL319923;108520;None;0;Human;Binding;Ki;=;219,00;6,66;-54;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;397,2;5;0;3;3,83;CC[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL319927;108525;None;0;Human;Binding;Ki;=;183,00;6,74;1;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;397,2;4;0;3;4,00;C[C@H]1c2ccccc2N(C(=O)CN2CCN(Cc3ccc(Cl)cc3)CC2)[C@@H]1C;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL320067;108589;None;0;Human;Binding;Ki;=;4375,00;5,36;-45;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;383,2;4;0;3;3,61;CC1CN(C(=O)CN2CCN(Cc3ccc(Cl)cc3)CC2)c2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL320114;108594;None;0;Human;Binding;Ki;=;672,00;6,17;-3;3;Binding affinity at human dopamine receptor D2;ChEMBL;319,2;2;0;2;4,32;CN1C2CCC1CC(OC1c3ccccc3Cc3ccccc31)C2;https://dx.doi.org/10.1021/jm010146o
CHEMBL320173;108604;None;0;Human;Binding;Ki;=;3,10;8,51;-3;2;Compound was evaluated for the binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using [3H]U-86170 as radioligand;ChEMBL;476,2;4;2;7;2,52;COC(=O)c1cc2c3c(ccc2[nH]1)OCC(CN1CCC2(CC1)C(=O)NCN2c1ccccc1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL320397;108643;None;0;Human;Binding;Ki;=;113,00;6,95;-4;5;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)CCN1Cc3c(ccc(O)c3OC)C[C@@H]21;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL320440;108652;None;0;Human;Binding;Ki;=;1784,00;5,75;-147;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;391,3;5;0;3;3,90;CC(C)c1ccc(CN2CCN(CC(=O)N3c4ccccc4CC3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL320515;108661;None;0;Human;Binding;Ki;=;199,00;6,70;-16;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;419,2;4;0;3;3,71;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(F)c(F)c2Cl)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL320526;108662;None;0;Human;Binding;Ki;=;7,00;8,15;47;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;713,3;8;5;8;8,21;CCCN(CCc1ccc(N/C(S)=N/c2ccc3c(c2)C(=O)OC32c3ccc(O)cc3Oc3cc(O)ccc32)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL320597;108677;None;0;Human;Binding;IC50;=;113,00;6,95;-56;3;Inhibitory concentration against dopamine receptor D2;ChEMBL;363,2;4;0;3;3,09;Cc1ccc(CN2CCN(CC(=O)N3c4ccccc4C[C@H]3C)CC2)cc1;https://dx.doi.org/10.1021/jm058225d
CHEMBL320597;108677;None;0;Human;Binding;Ki;=;113,00;6,95;-56;3;Inhibition of human dopamine D2 receptor;ChEMBL;363,2;4;0;3;3,09;Cc1ccc(CN2CCN(CC(=O)N3c4ccccc4C[C@H]3C)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL320597;108677;None;0;Human;Binding;Ki;=;113,00;6,95;-56;3;Binding affinity towards Dopamine receptor D2 was determined via standard competitive displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;363,2;4;0;3;3,09;Cc1ccc(CN2CCN(CC(=O)N3c4ccccc4C[C@H]3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL320597;108677;None;0;Human;Binding;Ki;=;113,00;6,95;-56;3;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;363,2;4;0;3;3,09;Cc1ccc(CN2CCN(CC(=O)N3c4ccccc4C[C@H]3C)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL320721;108693;None;0;Human;Binding;Ki;=;1096,00;5,96;-52;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;401,2;5;0;3;3,38;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1c2ccccc2C[C@H]1CF;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL320734;108696;None;0;Human;Binding;Ki;=;6200,00;5,21;-1;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;390,1;5;0;4;5,12;COC(=O)c1ccc(Cc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL320779;108736;None;0;Human;Binding;Ki;=;110,00;6,96;218;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;713,3;8;5;8;8,21;CCCN(CCc1ccc(N/C(S)=N/c2ccc3c(c2)C(=O)OC32c3ccc(O)cc3Oc3cc(O)ccc32)cc1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL320880;108806;None;0;Human;Binding;Ki;=;1,80;8,74;-6;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;461,2;4;3;6;1,83;NC(=O)c1cc2c3c(ccc2[nH]1)OCC(CN1CCC2(CC1)C(=O)NCN2c1ccccc1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL321042;108925;None;1;Human;Binding;Ki;=;1600,00;5,80;-691;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;346,1;1;2;3;3,36;CN1CCc2cc(Br)c(O)cc2C(c2ccc(N)cc2)C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL321058;108932;None;0;Human;Binding;Ki;=;3431,00;5,46;-7;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;383,2;4;0;3;3,35;Cc1cccc2c1CCN2C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL321121;108984;None;0;Human;Binding;Ki;=;96,00;7,02;-31;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;377,2;5;0;3;3,48;CC[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(C)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL321201;109044;None;0;Human;Binding;Ki;=;1149,00;5,94;-288;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;383,2;4;0;3;3,44;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccccc2Cl)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL321244;109081;None;0;Human;Binding;Ki;=;25,12;7,60;-10;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;426,2;9;1;4;5,07;CCN(Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1)[C@@H](C)c1ccccc1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL321405;109197;None;0;Human;Binding;Ki;=;1100,00;5,96;1;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;442,1;6;0;5;5,43;CS(=O)(=O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL32145;109225;None;2;Human;Binding;Ki;=;19,00;7,72;-125;4;The compound was evaluated for the binding affinity towards dopamine receptor D2 at high affinity state.;ChEMBL;373,1;3;2;3;4,04;C=CCN1CCc2c(cc(O)c(O)c2Br)C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
CHEMBL32145;109225;None;2;Human;Binding;Ki;=;21000,00;4,68;-125;4;The compound was evaluated for the binding affinity towards dopamine receptor D2 at low affinity state.;ChEMBL;373,1;3;2;3;4,04;C=CCN1CCc2c(cc(O)c(O)c2Br)C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
CHEMBL321492;109240;None;0;Human;Binding;Ki;=;135,00;6,87;-22;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;452,1;5;1;3;4,86;COc1c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL321492;109240;None;0;Human;Binding;Ki;=;290,00;6,54;-22;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;452,1;5;1;3;4,86;COc1c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL321492;109240;None;0;Human;Binding;Ki;=;170,00;6,77;-22;4;Ability to displace [3H]spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human cloned dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;452,1;5;1;3;4,86;COc1c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL321492;109240;None;0;Human;Binding;Ki;=;200,00;6,70;-22;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;452,1;5;1;3;4,86;COc1c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL321513;109244;None;0;Human;Binding;Ki;=;296,00;6,53;-4;3;Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151;ChEMBL;319,2;4;1;4;2,79;c1ccc(-c2nc(CN3CCN(c4cccnc4)CC3)c[nH]2)cc1;https://dx.doi.org/10.1021/jm960637m
CHEMBL321538;109249;None;0;Human;Binding;Ki;=;753,00;6,12;-125;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;377,2;5;0;3;3,34;CCc1ccc(CN2CCN(CC(=O)N3c4ccccc4CC3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL321557;109252;None;0;Human;Binding;Ki;=;3400,00;5,47;-32;3;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;398,2;6;0;3;5,37;COc1cccc2c1CCCC2CCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm991138z
CHEMBL321698;109270;None;0;Human;Binding;Ki;=;747,00;6,13;-120;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;383,2;4;0;3;3,44;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL321734;109277;None;0;Human;Binding;Ki;=;225,00;6,65;-8;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;379,2;5;0;4;2,79;COc1ccccc1CN1CCN(CC(=O)N2c3ccccc3CC2C)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL3217984;109310;None;0;Human;Binding;Ki;=;125,89;6,90;-63;23;Binding affinity to dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;308,1;0;0;3;4,23;CN1CCC2C(C1)c1cccc3c1N2c1ccccc1CS3;https://dx.doi.org/10.1039/C2MD00311B
CHEMBL321871;109337;None;0;Human;Binding;Ki;=;2524,00;5,60;-4;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;411,2;5;0;3;4,07;CC(C)C1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL3220212;109498;None;0;Human;Binding;Ki;=;63,10;7,20;-6;2;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;381,2;3;1;4;4,23;Cc1noc2c1C(=O)CC(CN1CCC(c3c[nH]c4cc(F)ccc34)CC1)C2;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL3220214;109500;None;0;Human;Binding;Ki;=;32,36;7,49;-1;2;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;383,2;3;0;6;3,89;Cc1nc2c(o1)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL3220215;109501;None;0;Human;Binding;Ki;=;199,53;6,70;-39;7;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;381,2;3;1;4;4,23;Cc1nc2c(o1)CC(CN1CCC(c3c[nH]c4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL3220216;109502;None;0;Human;Binding;Ki;=;173,78;6,76;-2;2;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;379,2;3;1;4;4,14;Cc1nc2c(o1)CC(CN1CC=C(c3c[nH]c4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL3220218;109504;None;0;Human;Binding;Ki;=;199,53;6,70;-10;2;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;454,2;4;0;7;4,65;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2nc(N3CCCC3)sc21;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL3220219;109505;None;0;Human;Binding;Ki;=;158,49;6,80;-19;7;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;452,2;4;1;5;4,99;O=C1CC(CN2CCC(c3c[nH]c4cc(F)ccc34)CC2)Cc2nc(N3CCCC3)sc21;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL3220220;109506;None;0;Human;Binding;Ki;=;54,95;7,26;-1;2;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;450,2;4;1;5;4,90;O=C1CC(CN2CC=C(c3c[nH]c4cc(F)ccc34)CC2)Cc2nc(N3CCCC3)sc21;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL322070;109537;None;0;Human;Binding;Ki;=;1,00;9,00;-2;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;446,1;9;1;4;5,16;CCN(Cc1ccc(Cl)cc1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL3221299;109580;None;0;Human;Binding;Ki;=;3,90;8,41;-;1;Antagonist activity at dopamine D2 receptor (unknown origin);ChEMBL;316,2;6;1;6;2,54;CCN1CCCC1CNc1nncc2ccc(OC)c(OC)c12;https://dx.doi.org/10.1039/C1MD00074H
CHEMBL322179;109590;None;0;Human;Binding;Ki;=;777,00;6,11;-1;3;Binding affinity at human dopamine receptor D2;ChEMBL;425,2;6;1;4;3,84;O=C(NCCCN1CCN(c2ccccc2)CC1)c1cccc2c1-c1ccccc1C2=O;https://dx.doi.org/10.1021/jm010146o
CHEMBL322222;109677;None;0;Human;Binding;Ki;=;1434,00;5,84;-478;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;393,2;4;0;5;2,51;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc3c(c2)OCO3)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL322326;109697;None;0;Human;Binding;Ki;=;1642,00;5,79;-204;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;369,2;5;0;3;3,05;O=C1Cc2ccccc2N1CCN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL322567;109727;None;0;Human;Binding;Ki;=;1225,00;5,91;-4;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;383,1;5;0;4;2,69;O=C1C(=O)N(CCN2CCN(Cc3ccc(Cl)cc3)CC2)c2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL322638;109733;None;0;Human;Binding;Ki;=;375,00;6,43;-30;2;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;323,2;3;1;3;4,23;CCCN1CC(c2ccccc2)OC2c3cc(O)ccc3CCC21;https://dx.doi.org/10.1021/jm001015a
CHEMBL322760;109746;None;0;Human;Binding;Ki;=;710,00;6,15;-134;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;509,1;4;2;8;4,96;CN1CCc2cc(Br)c(O)cc2C(c2ccc(Nc3ccc([N+](=O)[O-])c4nonc34)cc2)C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL322802;109756;None;0;Human;Binding;Ki;=;7,40;8,13;-3;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;5;2;4;3,57;COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(Cc2ccccc2)C[C@@H]1C;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL322802;109756;None;0;Human;Binding;Ki;=;340,00;6,47;-3;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;5;2;4;3,57;COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(Cc2ccccc2)C[C@@H]1C;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL322802;109756;None;0;Human;Binding;Ki;=;470,00;6,33;-3;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;5;2;4;3,57;COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(Cc2ccccc2)C[C@@H]1C;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL322802;109756;None;0;Human;Binding;Ki;=;8,60;8,07;-3;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;5;2;4;3,57;COc1cc(N)c(Cl)cc1C(=O)N[C@H]1CCN(Cc2ccccc2)C[C@@H]1C;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL323022;109803;None;0;Human;Binding;Ki;=;5247,00;5,28;-38;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;397,2;5;0;3;3,48;CC1Cc2ccccc2N1C(=O)CN1CCN(CCc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL323088;109817;None;0;Human;Binding;Ki;=;2,00;8,70;-3;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;448,2;4;3;6;2,23;O=C1NCN(c2ccccc2)C12CCN(CC1COc3ccc4[nH]c(CO)cc4c3O1)CC2;https://dx.doi.org/10.1021/jm00094a021
CHEMBL323213;109832;None;0;Human;Binding;Ki;=;377,00;6,42;1;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;423,2;4;0;3;4,53;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1c2ccccc2[C@H]2CCCC[C@H]21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL3234522;109972;None;0;Human;Binding;AC50;=;913,00;6,04;47;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;410,1;4;1;4;3,48;CN1C(=O)c2ccccc2[S+]([O-])c2ccc(C(=O)NCCc3cccs3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234522;109972;None;0;Human;Binding;Ki;=;190,00;6,72;47;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;410,1;4;1;4;3,48;CN1C(=O)c2ccccc2[S+]([O-])c2ccc(C(=O)NCCc3cccs3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234527;109977;None;0;Human;Binding;AC50;=;1150,00;5,94;-;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;434,1;5;1;4;3,77;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3ccc(OC)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234536;109981;None;0;Human;Binding;AC50;=;576,00;6,24;2;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;422,1;4;1;3;3,90;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3ccc(F)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234536;109981;None;0;Human;Binding;Ki;=;90,00;7,05;2;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;422,1;4;1;3;3,90;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3ccc(F)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234537;109982;None;0;Human;Binding;AC50;=;257,00;6,59;5;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;429,1;4;1;4;3,63;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3ccc(C#N)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234537;109982;None;0;Human;Binding;Ki;=;23,00;7,64;5;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;429,1;4;1;4;3,63;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3ccc(C#N)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234538;109983;None;0;Human;Binding;AC50;=;1290,00;5,89;1;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;496;4;1;3;5,09;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)N[C@H](C)c3ccc(Br)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234538;109983;None;0;Human;Binding;Ki;=;530,00;6,28;1;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;496;4;1;3;5,09;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)N[C@H](C)c3ccc(Br)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234539;109984;None;0;Human;Binding;AC50;=;2890,00;5,54;11;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;468,2;4;1;3;5,48;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)N[C@H](C)c3ccc4ccccc4c3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234539;109984;None;0;Human;Binding;Ki;=;290,00;6,54;11;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;468,2;4;1;3;5,48;CCN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)N[C@H](C)c3ccc4ccccc4c3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234540;109986;None;0;Human;Binding;AC50;=;2890,00;5,54;-;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;424,1;3;1;3;4,03;CN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3ccc(Cl)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234541;109987;None;0;Human;Binding;AC50;=;1020,00;5,99;1;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;468;3;1;3;4,14;CN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3ccc(Br)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234541;109987;None;0;Human;Binding;Ki;=;240,00;6,62;1;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;468;3;1;3;4,14;CN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3ccc(Br)cc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234542;109988;None;0;Human;Binding;AC50;=;2890,00;5,54;67;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;391,1;3;1;4;2,77;CN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3cccnc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234542;109988;None;0;Human;Binding;Ki;=;310,00;6,51;67;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;391,1;3;1;4;2,77;CN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCc3cccnc3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234543;109989;None;0;Human;Binding;AC50;=;363,00;6,44;1;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;397,1;4;1;4;2,27;CN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCCN3CCCC3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL3234543;109989;None;0;Human;Binding;Ki;=;210,00;6,68;1;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;397,1;4;1;4;2,27;CN1C(=O)c2ccccc2[S@+]([O-])c2ccc(C(=O)NCCN3CCCC3)cc21;https://dx.doi.org/10.1021/jm500126s
CHEMBL323525;110103;None;0;Human;Binding;Ki;=;2094,00;5,68;-138;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;379,2;5;0;4;2,79;COc1ccc(CN2CCN(CC(=O)N3c4ccccc4CC3C)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL323537;110121;None;0;Human;Binding;Ki;=;2629,00;5,58;-56;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;383,2;4;0;3;3,44;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL323817;110331;None;0;Human;Binding;Ki;=;0,79;9,10;1;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;438,2;8;1;4;4,99;CCN(Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1)C1CCc2ccccc21;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL323997;110393;None;0;Human;Binding;Ki;=;927,00;6,03;-4;3;Binding affinity at human dopamine receptor D2;ChEMBL;575,2;10;0;3;8,15;Fc1ccc(C(OCCN2C3CCC2CC(OC(c2ccc(F)cc2)c2ccc(F)cc2)C3)c2ccc(F)cc2)cc1;https://dx.doi.org/10.1021/jm010146o
CHEMBL32402;110394;None;0;Human;Binding;Ki;=;911,00;6,04;-251;3;Binding affinity against cloned human D2 receptor transfected in CHO-K1 cells using [3H]- spiperone as radioligand.;ChEMBL;327,2;7;1;4;2,97;OC(COc1ccccc1)CN1CCC(Oc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00233-3
CHEMBL324044;110401;None;0;Human;Binding;Ki;=;31,62;7,50;-2;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;472,2;11;1;6;4,52;CCN(Cc1ccc(OC)c(OC)c1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL324372;110456;None;0;Human;Binding;Ki;=;2980,00;5,53;-19;3;In vitro affinity at human cloned Dopamine receptor D2A by [3H]raclopride displacement.;ChEMBL;307,2;2;0;3;3,65;COc1c(C(C)=O)ccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL324619;110501;None;0;Human;Binding;Ki;=;297,00;6,53;61;2;Binding affinity against human recombinant dopamine receptor D2 in presence of 0.5% human serum albumin;ChEMBL;422,1;6;0;5;5,82;COC(=O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL324619;110501;None;0;Human;Binding;Ki;=;73,00;7,14;61;2;Binding affinity against human recombinant dopamine receptor D2 was determined using radioligand competition binding assay;ChEMBL;422,1;6;0;5;5,82;COC(=O)c1ccc(CSc2nc3ccccc3n2Cc2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.04.005
CHEMBL325060;110583;None;0;Human;Binding;Ki;=;1258,93;5,90;-12;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;466,2;7;1;4;5,91;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3c3ccccc3C)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL325104;110590;None;0;Human;Binding;Ki;=;6300,00;5,20;-6;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;264,2;3;0;2;3,31;C#Cc1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL325104;110590;None;0;Human;Binding;Ki;=;6600,00;5,18;-6;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;264,2;3;0;2;3,31;C#Cc1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL325516;110656;None;0;Human;Binding;IC50;=;2620,00;5,58;-;14;Inhibition of human dopamine receptor D2;ChEMBL;496,2;9;0;3;6,01;O=C(OCCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/jm010878g
CHEMBL325658;110679;None;0;Human;Binding;Ki;=;794,33;6,10;-15;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;482,2;8;1;5;5,61;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3c3cccc(OC)c3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL325710;110691;None;3;Human;Binding;Ki;=;27,00;7,57;-19;4;in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]NPA as radioligand.;ChEMBL;289,2;5;1;4;3,47;CCCN(CCC)C1Cc2cc3nc(N)sc3cc2C1;https://dx.doi.org/10.1021/jm000087z
CHEMBL325750;110701;None;0;Human;Binding;IC50;=;123,00;6,91;-;7;Inhibition of human dopamine receptor D2;ChEMBL;379,1;3;1;6;2,62;O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3nsnc3c1)CC2;https://dx.doi.org/10.1021/jm010878g
CHEMBL325772;110704;None;0;Human;Binding;Ki;=;190,00;6,72;-33;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;486,1;5;1;3;4,46;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(I)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL325772;110704;None;0;Human;Binding;Ki;=;70,00;7,16;-33;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;486,1;5;1;3;4,46;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(I)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL325772;110704;None;0;Human;Binding;Ki;=;60,00;7,22;-33;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;486,1;5;1;3;4,46;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(I)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL325772;110704;None;0;Human;Binding;Ki;=;23,00;7,64;-33;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;486,1;5;1;3;4,46;COc1c(C(=O)N[C@@H]2CCN(Cc3ccccc3)C2)cc(I)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL325818;110709;None;0;Human;Binding;Ki;=;420,00;6,38;-7;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;452,1;6;1;3;4,86;COc1c(C(=O)NC[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL325818;110709;None;0;Human;Binding;Ki;=;870,00;6,06;-7;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;452,1;6;1;3;4,86;COc1c(C(=O)NC[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL325818;110709;None;0;Human;Binding;Ki;=;640,00;6,19;-7;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;452,1;6;1;3;4,86;COc1c(C(=O)NC[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL325818;110709;None;0;Human;Binding;Ki;=;1300,00;5,89;-7;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;452,1;6;1;3;4,86;COc1c(C(=O)NC[C@@H]2CCN(Cc3ccccc3)C2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL325859;110718;None;0;Human;Binding;Ki;=;25,12;7,60;-15;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;482,2;8;1;5;5,61;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCCCCC3c3ccc(OC)cc3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL326010;110751;None;0;Human;Binding;Ki;=;271,00;6,57;-38;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;417,1;4;0;3;4,09;C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2cc(Cl)cc(Cl)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL326159;110985;None;0;Human;Binding;Ki;=;2760,00;5,56;-1;3;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;293,1;1;1;3;3,35;CC(=O)c1ccc2c(c1O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL326202;111013;None;0;Human;Binding;Ki;=;518,00;6,29;-24;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;400,2;4;0;2;5,06;CC1Cc2ccccc2N1C(=O)CC1CCN(Cc2ccc(F)cc2Cl)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL326250;111063;None;0;Human;Binding;Ki;=;129,00;6,89;-4;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;425,2;6;0;3;4,61;CCC1(CC)Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL326263;111079;None;0;Human;Binding;IC50;=;2240,00;5,65;-;14;Inhibition of human dopamine receptor D2;ChEMBL;503,2;9;0;4;5,75;N#Cc1ccc(CCOC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1021/jm010878g
CHEMBL326454;111254;None;1;Human;Binding;Ki;=;2,30;8,64;-6;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;6;2;4;3,64;CNc1cc(OC)c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL326454;111254;None;1;Human;Binding;Ki;=;3,70;8,43;-6;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;6;2;4;3,64;CNc1cc(OC)c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL326454;111254;None;1;Human;Binding;Ki;=;2,00;8,70;-6;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;6;2;4;3,64;CNc1cc(OC)c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL326454;111254;None;1;Human;Binding;Ki;=;3,00;8,52;-6;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;6;2;4;3,64;CNc1cc(OC)c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL3265038;111282;None;0;Human;Binding;Ki;=;21,47;7,67;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;2289,3;80;35;31;-8,16;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCC(N)=O)C(=O)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265039;111283;None;0;Human;Binding;Ki;=;9,69;8,01;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1910,1;71;32;26;-6,01;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265040;111285;None;0;Human;Binding;Ki;=;10,32;7,99;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1463,7;43;14;19;1,63;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265041;111286;None;0;Human;Binding;Ki;=;27,32;7,56;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;2061;54;18;25;1,82;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)N[C@H](C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N3CCC[C@H]3C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CO)C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N3CCC[C@H]3C(=O)O)C(C)C)[C@@H](C)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265042;111287;None;0;Human;Binding;Ki;=;12,27;7,91;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;3412,9;116;39;44;-1,47;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCC(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265043;111288;None;0;Human;Binding;Ki;=;8,14;8,09;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;2816,6;99;36;35;-1,47;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc3c[nH]c4ccccc34)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265044;111289;None;0;Human;Binding;Ki;=;12,96;7,89;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1854;65;21;25;-1,35;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N3CCC[C@H]3C(=O)O)C(C)C)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265045;111290;None;0;Human;Binding;Ki;=;8,01;8,10;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;3257,5;104;41;47;-10,10;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)N[C@H](C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CN3CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H](C)O)[C@@H](C)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265046;111291;None;0;Human;Binding;Ki;=;28,43;7,55;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1548,8;47;15;20;1,53;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265047;111292;None;0;Human;Binding;Ki;=;30,33;7,52;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1608,8;51;15;22;0,78;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265048;111293;None;0;Human;Binding;Ki;=;23,78;7,62;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1680,9;56;15;23;1,58;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCCOCCOCCOCCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265049;111294;None;0;Human;Binding;Ki;=;1,47;8,83;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1710,9;58;15;24;1,20;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265063;111299;None;0;Human;Binding;Ki;=;667,00;6,18;-251;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;476,2;9;2;3;5,78;CCCN(CC[C@]1(O)C[C@@H](NC(=O)c2ccc3ccccc3c2)C1)C1CC1c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm401798r
CHEMBL3265064;111300;None;0;Human;Binding;Ki;=;923,00;6,04;-47;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;476,2;9;2;3;5,78;CCCN(CC[C@]1(O)C[C@@H](NC(=O)c2ccc3ccccc3c2)C1)[C@H]1C[C@@H]1c1ccccc1Cl;https://dx.doi.org/10.1021/jm401798r
CHEMBL3265065;111301;None;0;Human;Binding;Ki;=;1220,00;5,91;-43;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;476,2;9;2;3;5,78;CCCN(CC[C@]1(O)C[C@@H](NC(=O)c2ccc3ccccc3c2)C1)[C@H]1C[C@@H]1c1cccc(Cl)c1;https://dx.doi.org/10.1021/jm401798r
CHEMBL3265067;111303;None;1;Human;Binding;Ki;=;623,00;6,21;-229;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;476,2;9;2;3;5,78;CCCN(CC[C@]1(O)C[C@@H](NC(=O)c2ccc3ccccc3c2)C1)[C@@H]1C[C@H]1c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm401798r
CHEMBL3265314;111339;None;0;Human;Binding;Ki;=;27,39;7,56;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1798,9;64;15;26;1,24;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCOCCOCCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265315;111340;None;0;Human;Binding;Ki;=;53,92;7,27;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;1887;70;15;28;1,27;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265316;111341;None;0;Human;Binding;Ki;=;25,27;7,60;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;2063,1;82;15;32;1,34;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265317;111342;None;0;Human;Binding;Ki;=;26,13;7,58;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;3504,7;119;42;52;-10,52;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCC(=O)N[C@H](C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CN3CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H](C)O)[C@@H](C)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265318;111343;None;0;Human;Binding;Ki;=;35,77;7,45;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;3592,7;125;42;54;-10,49;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCOCCOCCC(=O)N[C@H](C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CN3CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H](C)O)[C@@H](C)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265319;111344;None;0;Human;Binding;Ki;=;42,80;7,37;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;3680,8;131;42;56;-10,46;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)N[C@H](C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CN3CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H](C)O)[C@@H](C)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265320;111345;None;0;Human;Binding;Ki;=;44,67;7,35;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;3768,8;137;42;58;-10,42;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)N[C@H](C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CN3CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H](C)O)[C@@H](C)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265321;111346;None;0;Human;Binding;Ki;=;5,98;8,22;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;2146,1;68;17;28;5,34;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCC(=O)N[C@@H](CCCCNC(=O)O/N=C/c3ccc([Si](F)(C(C)(C)C)C(C)(C)C)cc3)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265322;111347;None;0;Human;Binding;Ki;=;52,03;7,28;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;2225,2;73;20;33;-1,55;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCC(=O)N[C@@H](CCCCNC(=O)CN3CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC3)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)O)[C@@H](C)CC)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265323;111348;None;0;Human;Binding;Ki;=;64,16;7,19;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;3519,7;109;40;47;-5,66;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)N[C@H](C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCCNC(=O)CN3CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC3)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CCCC[n+]3c(C)cc(/C=C/C=C/c4ccc(N(C)C)cc4)cc3C)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)O)[C@@H](C)O)[C@@H](C)O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265324;111349;None;0;Human;Binding;Ki;=;7,31;8,14;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;835,4;33;3;13;2,50;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCSC2CC(=O)N(CCCCCC(=O)NCCOCCOCCOCCOCCC(N)=O)C2=O)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
CHEMBL3265329;111350;None;0;Human;Binding;Ki;=;0,63;9,20;-;1;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;304,2;8;1;2;2,97;C=CCN1CCC[C@H]1CNC(=O)c1cccc(CCCF)c1;https://dx.doi.org/10.1021/jm5004123
CHEMBL326662;111367;None;0;Human;Binding;Ki;=;39,81;7,40;-3;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;424,2;7;1;4;4,82;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(C3CCCN3Cc3ccccc3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL326670;111369;None;0;Human;Binding;Ki;=;120,00;6,92;-16;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;397,2;4;0;3;4,00;C[C@@H]1c2ccccc2N(C(=O)CN2CCN(Cc3ccc(Cl)cc3)CC2)[C@@H]1C;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL326863;111402;None;0;Human;Binding;Ki;=;134,00;6,87;-12;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;427,2;6;0;4;3,83;CCOc1ccc(Cl)cc1CN1CCN(CC(=O)N2c3ccccc3C[C@H]2C)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL326864;111403;None;1;Human;Binding;Ki;=;7800,00;5,11;-32;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;316,2;4;0;4;3,76;N#CC(C#N)=Cc1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL326864;111403;None;1;Human;Binding;Ki;=;11000,00;4,96;-32;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;316,2;4;0;4;3,76;N#CC(C#N)=Cc1cccn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL326877;111405;None;30;Human;Binding;Ki;=;8500,00;5,07;-8;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;240,2;3;0;2;3,33;c1ccc(CN2CCC(n3cccc3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL326877;111405;None;30;Human;Binding;Ki;=;9800,00;5,01;-8;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;240,2;3;0;2;3,33;c1ccc(CN2CCC(n3cccc3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL326962;111418;None;0;Human;Binding;IC50;=;557,00;6,25;-;7;Inhibition of human dopamine receptor D2;ChEMBL;365,2;3;1;5;2,34;O=C1NCN(c2ccccc2)C12CCN(Cc1ccc3c(c1)OCO3)CC2;https://dx.doi.org/10.1021/jm010878g
CHEMBL327176;111455;None;0;Human;Binding;Ki;=;330,00;6,48;-60;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;375,2;6;1;4;4,83;Cc1c(-c2ccccc2)nc(O)n1C1CCN(CCCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL327245;111469;None;0;Human;Binding;Ki;=;2550,00;5,59;-645;3;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;372,2;7;0;4;4,13;COc1cccc(C(=O)CCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm991138z
CHEMBL3276140;111531;None;2;Human;Binding;EC50;=;111,20;6,95;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;351,1;2;0;5;3,29;CC(=O)Oc1ccc2c(c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL3276140;111531;None;2;Human;Binding;EC50;=;100,00;7,00;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;351,1;2;0;5;3,29;CC(=O)Oc1ccc2c(c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL327713;111547;None;0;Human;Binding;Ki;=;250,00;6,60;-7;3;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;299,2;1;0;1;4,86;C=C1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL327782;111560;None;0;Human;Binding;Ki;=;3,00;8,52;-4;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;299,1;6;3;4;3,02;Sc1nc2c(OCCNCc3ccccc3)cccc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL328002;111610;None;0;Human;Binding;Ki;=;1258,93;5,90;-79;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;488,3;11;1;5;5,64;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2nc(SC)ncc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL328051;111617;None;1;Human;Binding;Ki;=;53,00;7,28;-6;4;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;291,2;3;1;2;3,49;c1ccc(CN2CCN(c3cccc4[nH]ccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL328054;111618;None;0;Human;Binding;Ki;=;436,00;6,36;-288;3;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;321,1;3;0;4;3,36;COc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccccc1)CC3;https://dx.doi.org/10.1021/jm970170v
CHEMBL328054;111618;None;0;Human;Binding;Ki;=;436,00;6,36;-288;3;Binding affinity to human D2 receptor assessed as inhibition constant;ChEMBL;321,1;3;0;4;3,36;COc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccccc1)CC3;https://dx.doi.org/10.1016/j.ejmech.2020.113034
CHEMBL328114;111631;None;0;Human;Binding;Ki;=;959,00;6,02;-281;5;Inhibition of [3H]spiperone binding to Dopamine receptor D2;ChEMBL;449,2;7;0;7;3,15;COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2;https://dx.doi.org/10.1021/jm049619s
CHEMBL328119;111633;None;0;Human;Binding;Ki;=;73,00;7,14;-3;3;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;413,1;6;0;4;4,34;O=S(=O)(Oc1cccc([C@@H]2CCCN(CCc3ccccc3)C2)c1)C(F)(F)F;https://dx.doi.org/10.1021/jm00043a013
CHEMBL328187;111643;None;0;Human;Binding;Ki;=;310,00;6,51;-102;9;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;487,3;6;1;6;3,77;Cn1cc(-c2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)nn1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
CHEMBL328187;111643;None;0;Human;Binding;Ki;=;310,00;6,51;-102;9;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;487,3;6;1;6;3,77;Cn1cc(-c2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)nn1;https://dx.doi.org/10.1021/jm100652h
CHEMBL328246;111654;None;0;Human;Binding;Ki;=;690,00;6,16;-7;5;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;364,2;1;0;2;5,24;CC(C)=C1c2ccc(Cl)cc2C=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL328283;111660;None;0;Human;Binding;Ki;=;262,00;6,58;-5;2;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;399,2;6;1;4;4,14;COc1ccc2c(c1)C(NCCN1CCN(c3ccc(Cl)cc3)CC1)CCC2;https://dx.doi.org/10.1021/jm991138z
CHEMBL328459;111689;None;0;Human;Binding;Ki;=;17,00;7,77;-39;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;296,2;5;1;1;4,47;CCN(C)CCc1c(-c2ccc(F)cc2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL328476;111692;None;0;Human;Binding;Ki;=;4600,00;5,34;-512;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;306,1;2;2;3;3,33;c1ccc2c3c([nH]c2c1)C(Cc1ccc2c(c1)OCO2)NCC3;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL328595;111713;None;0;Human;Binding;Ki;=;68,00;7,17;-851;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;296,2;5;1;1;4,47;CCN(C)CCc1c(-c2cccc(F)c2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL3286429;111724;None;0;Human;Binding;Ki;=;3962,00;5,40;-27;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;355,1;5;0;4;4,24;Clc1ccc(N2CCN(CCCc3nc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3286432;111725;None;0;Human;Binding;Ki;=;39,00;7,41;-7;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;482,1;8;1;6;3,97;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3286567;111736;None;1;Human;Binding;Ki;=;2100,00;5,68;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;213,1;0;2;2;1,50;c1cc2c3c(c[nH]c3c1)CC1CNCCN21;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286567;111736;None;1;Human;Binding;Ki;=;2089,30;5,68;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;213,1;0;2;2;1,50;c1cc2c3c(c[nH]c3c1)CC1CNCCN21;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286568;111737;None;0;Human;Binding;Ki;=;660,69;6,18;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;227,1;0;1;2;1,84;CN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286568;111737;None;0;Human;Binding;Ki;=;660,00;6,18;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;227,1;0;1;2;1,84;CN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286569;111738;None;0;Human;Binding;Ki;=;141,25;6,85;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;241,2;1;1;2;2,23;CCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286569;111738;None;0;Human;Binding;Ki;=;140,00;6,85;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;241,2;1;1;2;2,23;CCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286570;111740;None;0;Human;Binding;Ki;=;575,44;6,24;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;255,2;2;1;2;2,63;CCCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286570;111740;None;0;Human;Binding;Ki;=;570,00;6,24;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;255,2;2;1;2;2,63;CCCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286571;111741;None;0;Human;Binding;Ki;=;110,00;6,96;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;269,2;3;1;2;3,02;CCCCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286571;111741;None;0;Human;Binding;Ki;=;109,65;6,96;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;269,2;3;1;2;3,02;CCCCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286572;111742;None;0;Human;Binding;Ki;=;310,00;6,51;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;269,2;2;1;2;2,87;CC(C)CN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286572;111742;None;0;Human;Binding;Ki;=;309,03;6,51;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;269,2;2;1;2;2,87;CC(C)CN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286573;111743;None;0;Human;Binding;Ki;=;97,72;7,01;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;283,2;4;1;2;3,40;CCCCCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286573;111743;None;0;Human;Binding;Ki;=;98,00;7,01;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;283,2;4;1;2;3,40;CCCCCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286574;111744;None;0;Human;Binding;Ki;=;24,00;7,62;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;283,2;3;1;2;3,26;CC(C)CCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286574;111744;None;0;Human;Binding;Ki;=;23,99;7,62;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;283,2;3;1;2;3,26;CC(C)CCN1CCN2c3cccc4[nH]cc(c34)CC2C1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286575;111745;None;0;Human;Binding;Ki;=;53,70;7,27;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;309,2;2;1;2;3,79;c1cc2c3c(c[nH]c3c1)CC1CN(CC3CCCCC3)CCN21;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286575;111745;None;0;Human;Binding;Ki;=;54,00;7,27;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;309,2;2;1;2;3,79;c1cc2c3c(c[nH]c3c1)CC1CN(CC3CCCCC3)CCN21;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286576;111746;None;0;Human;Binding;Ki;=;128,82;6,89;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;303,2;2;1;2;3,42;c1ccc(CN2CCN3c4cccc5[nH]cc(c45)CC3C2)cc1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286576;111746;None;0;Human;Binding;Ki;=;130,00;6,89;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;303,2;2;1;2;3,42;c1ccc(CN2CCN3c4cccc5[nH]cc(c45)CC3C2)cc1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286577;111747;None;0;Human;Binding;Ki;=;450,00;6,35;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;379,2;3;1;2;5,08;c1ccc(-c2ccccc2CN2CCN3c4cccc5[nH]cc(c45)CC3C2)cc1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286577;111747;None;0;Human;Binding;Ki;=;199,53;6,70;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;379,2;3;1;2;5,08;c1ccc(-c2ccccc2CN2CCN3c4cccc5[nH]cc(c45)CC3C2)cc1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286578;111748;None;0;Human;Binding;Ki;=;0,65;9,19;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;379,2;3;1;2;5,08;c1ccc(-c2cccc(CN3CCN4c5cccc6[nH]cc(c56)CC4C3)c2)cc1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286578;111748;None;0;Human;Binding;Ki;=;0,23;9,64;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;379,2;3;1;2;5,08;c1ccc(-c2cccc(CN3CCN4c5cccc6[nH]cc(c56)CC4C3)c2)cc1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286579;111749;None;0;Human;Binding;Ki;=;120,23;6,92;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;379,2;3;1;2;5,08;c1ccc(-c2ccc(CN3CCN4c5cccc6[nH]cc(c56)CC4C3)cc2)cc1;https://dx.doi.org/10.1021/jm5003759
CHEMBL3286579;111749;None;0;Human;Binding;Ki;=;140,00;6,85;-;1;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in CHOK1a cell membrane after 180 mins by scintillation counting analysis;ChEMBL;379,2;3;1;2;5,08;c1ccc(-c2ccc(CN3CCN4c5cccc6[nH]cc(c56)CC4C3)cc2)cc1;https://dx.doi.org/10.1021/jm5003759
CHEMBL328667;111765;None;0;Human;Binding;Ki;=;150,00;6,82;-27;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;360,2;4;2;3;4,02;O=C(Nc1nccc2ccccc12)NC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL328681;111766;None;0;Human;Binding;Ki;=;3180,00;5,50;-100;3;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;399,2;6;1;4;4,14;COc1cccc2c1CCCC2NCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm991138z
CHEMBL3287279;111802;None;0;Human;Binding;Ki;=;800,00;6,10;-114;2;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in human HEK293 cell membrane for 1 hr by liquid scintillation counting analysis;ChEMBL;463,1;7;1;4;5,02;O=C(NCC[C@@H](F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/ml500006v
CHEMBL3287280;111803;None;0;Human;Binding;Ki;=;2500,00;5,60;-87;2;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in human HEK293 cell membrane for 1 hr by liquid scintillation counting analysis;ChEMBL;463,1;7;1;4;5,02;O=C(NCC[C@H](F)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/ml500006v
CHEMBL3287281;111804;None;0;Human;Binding;Ki;=;7400,00;5,13;-13;2;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in human HEK293 cell membrane for 1 hr by liquid scintillation counting analysis;ChEMBL;463,1;7;1;4;5,02;O=C(NCCC(CF)N1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/ml500006v
CHEMBL328739;111836;None;0;Human;Binding;Ki;=;15,00;7,82;-19;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;361,2;4;0;4;4,00;Cc1c(-c2ccccc2)n(C)c(=O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL3287390;111837;None;0;Human;Binding;Ki;=;39,00;7,41;-5;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3ccn4nccc4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287390;111837;None;0;Human;Binding;Ki;=;34,00;7,47;-5;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3ccn4nccc4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287391;111838;None;0;Human;Binding;Ki;=;30,00;7,52;-2;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3cccn4nccc34)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287391;111838;None;0;Human;Binding;Ki;=;25,00;7,60;-2;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3cccn4nccc34)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287392;111839;None;0;Human;Binding;Ki;=;4,20;8,38;-1;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3ccc4ccnn4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287392;111839;None;0;Human;Binding;Ki;=;2,10;8,68;-1;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3ccc4ccnn4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287393;111840;None;0;Human;Binding;Ki;=;64,00;7,19;-4;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3cccc4ccnn34)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287393;111840;None;0;Human;Binding;Ki;=;16,00;7,80;-4;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3cccc4ccnn34)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287394;111841;None;0;Human;Binding;Ki;=;10,00;8,00;-2;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3cc4ccccn4n3)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287394;111841;None;0;Human;Binding;Ki;=;9,40;8,03;-2;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;418,1;7;0;5;4,62;Clc1cccc(N2CCN(CCCCOc3cc4ccccn4n3)CC2)c1Cl;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287395;111842;None;0;Human;Binding;Ki;=;6,70;8,17;-3;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;490,2;9;0;7;4,80;CCOC(=O)c1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287395;111842;None;0;Human;Binding;Ki;=;7,40;8,13;-3;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;490,2;9;0;7;4,80;CCOC(=O)c1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287396;111843;None;0;Human;Binding;Ki;=;2,30;8,64;-2;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;448,1;8;1;6;4,12;OCc1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287396;111843;None;0;Human;Binding;Ki;=;3,10;8,51;-2;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;448,1;8;1;6;4,12;OCc1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287397;111844;None;0;Human;Binding;IC50;=;363,08;6,44;1;5;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287397;111844;None;0;Human;Binding;IC50;=;360,00;6,44;1;5;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287397;111844;None;0;Human;Binding;Ki;=;4,60;8,34;1;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287397;111844;None;0;Human;Binding;Ki;=;3,20;8,49;1;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287398;111845;None;0;Human;Binding;Ki;=;29,00;7,54;-1;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2cccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287398;111845;None;0;Human;Binding;Ki;=;24,00;7,62;-1;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2cccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287399;111846;None;0;Human;Binding;Ki;=;8,10;8,09;-3;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287399;111846;None;0;Human;Binding;Ki;=;6,20;8,21;-3;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287400;111847;None;0;Human;Binding;Ki;=;15,00;7,82;-4;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2c(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cccc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287400;111847;None;0;Human;Binding;Ki;=;51,00;7,29;-4;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cnn2c(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cccc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287401;111848;None;0;Human;Binding;Ki;=;10,00;8,00;-2;3;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1c(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nn2ccccc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287401;111848;None;0;Human;Binding;Ki;=;14,00;7,85;-2;3;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1c(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nn2ccccc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287402;111849;None;0;Human;Binding;IC50;=;28,84;7,54;-2;5;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287402;111849;None;0;Human;Binding;IC50;=;22,00;7,66;-2;5;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287402;111849;None;0;Human;Binding;Ki;=;14,00;7,85;-2;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287402;111849;None;0;Human;Binding;Ki;=;14,00;7,85;-2;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;446,1;8;0;6;4,43;O=Cc1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287403;111850;None;0;Human;Binding;IC50;=;3,80;8,42;2;5;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;461,1;8;1;7;4,43;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287403;111850;None;0;Human;Binding;IC50;=;3,80;8,42;2;5;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;461,1;8;1;7;4,43;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287403;111850;None;0;Human;Binding;Ki;=;0,25;9,60;2;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;461,1;8;1;7;4,43;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287403;111850;None;0;Human;Binding;Ki;=;1,80;8,74;2;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;461,1;8;1;7;4,43;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287403;111850;None;0;Human;Binding;Ki;=;0,17;9,77;2;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;461,1;8;1;7;4,43;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287403;111850;None;0;Human;Binding;Ki;=;1,70;8,77;2;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;461,1;8;1;7;4,43;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287404;111851;None;0;Human;Binding;Ki;=;2,30;8,64;-3;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;461,1;8;1;7;4,43;O/N=C/c1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287404;111851;None;0;Human;Binding;Ki;=;3,30;8,48;-3;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;461,1;8;1;7;4,43;O/N=C/c1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287405;111852;None;0;Human;Binding;Ki;=;0,32;9,49;3;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;443,1;7;0;6;4,49;N#Cc1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287405;111852;None;0;Human;Binding;Ki;=;0,58;9,24;3;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;443,1;7;0;6;4,49;N#Cc1cnn2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287406;111853;None;0;Human;Binding;Ki;=;8,90;8,05;-4;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;443,1;7;0;6;4,49;N#Cc1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL3287406;111853;None;0;Human;Binding;Ki;=;6,70;8,17;-4;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;443,1;7;0;6;4,49;N#Cc1cc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccn2n1;https://dx.doi.org/10.1021/jm5004039
CHEMBL328894;112072;None;0;Human;Binding;Ki;=;519,00;6,29;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;240,2;3;0;2;3,15;N#Cc1cccc([C@@H]2CCCN(CC3CC3)C2)c1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL328925;112081;None;0;Human;Binding;Ki;=;53000,00;4,28;-12;4;Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone;ChEMBL;356,1;4;1;5;2,80;OCc1cnn2cccc(CN3CCN(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1021/jm015522j
CHEMBL328925;112081;None;0;Human;Binding;Ki;=;39000,00;4,41;-12;4;Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone;ChEMBL;356,1;4;1;5;2,80;OCc1cnn2cccc(CN3CCN(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1021/jm015522j
CHEMBL3289383;112083;None;0;Human;Binding;Ki;=;635,00;6,20;-48;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;380,1;6;0;3;3,80;[O-][S+](CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289383;112083;None;0;Human;Binding;Ki;=;630,96;6,20;-48;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;380,1;6;0;3;3,80;[O-][S+](CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289642;112092;None;0;Human;Binding;Ki;=;1543,00;5,81;-251;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;372,1;4;0;3;4,05;O=C1c2ccc(F)cc2CC1CCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289642;112092;None;0;Human;Binding;Ki;=;1548,82;5,81;-251;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;372,1;4;0;3;4,05;O=C1c2ccc(F)cc2CC1CCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289644;112094;None;0;Human;Binding;Ki;=;1417,00;5,85;-109;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;358,2;4;0;2;4,41;Fc1ccc2c(c1)CC(CCN1CCN(c3ccc(Cl)cc3)CC1)C2;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289645;112095;None;0;Human;Binding;Ki;=;1096,48;5,96;-89;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;365,2;6;0;4;3,69;FC(F)(F)c1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289645;112095;None;0;Human;Binding;Ki;=;1092,00;5,96;-89;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;365,2;6;0;4;3,69;FC(F)(F)c1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289646;112096;None;0;Human;Binding;Ki;=;1046,00;5,98;-954;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;329,2;6;0;4;3,12;Cc1ccc(N2CCN(CCCOc3ccc(F)cc3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289646;112096;None;0;Human;Binding;Ki;=;1047,13;5,98;-954;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;329,2;6;0;4;3,12;Cc1ccc(N2CCN(CCCOc3ccc(F)cc3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289647;112097;None;0;Human;Binding;Ki;=;1000,00;6,00;-53;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;345,2;6;0;4;3,83;Cc1ccc(N2CCN(CCCSc3ccc(F)cc3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289647;112097;None;0;Human;Binding;Ki;=;1106,00;5,96;-53;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;345,2;6;0;4;3,83;Cc1ccc(N2CCN(CCCSc3ccc(F)cc3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289648;112098;None;0;Human;Binding;Ki;=;1995,26;5,70;-85;10;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;327,2;6;0;3;3,67;Cc1ccc(N2CCN(CCCCc3ccc(F)cc3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL3289648;112098;None;0;Human;Binding;Ki;=;1861,00;5,73;-85;10;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;327,2;6;0;3;3,67;Cc1ccc(N2CCN(CCCCc3ccc(F)cc3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL3289648;112098;None;0;Human;Binding;Ki;=;1995,26;5,70;-85;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;327,2;6;0;3;3,67;Cc1ccc(N2CCN(CCCCc3ccc(F)cc3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289648;112098;None;0;Human;Binding;Ki;=;1861,00;5,73;-85;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;327,2;6;0;3;3,67;Cc1ccc(N2CCN(CCCCc3ccc(F)cc3)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289649;112099;None;0;Human;Binding;Ki;=;3108,00;5,51;-25;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;383,2;7;0;4;5,02;Clc1ccc(N2CCN(CCCCCc3nc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289653;112103;None;0;Human;Binding;Ki;=;1979,00;5,70;-25;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;354,1;5;0;3;4,84;Clc1ccc(N2CCN(CCCc3cc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289655;112105;None;0;Human;Binding;Ki;=;2507,00;5,60;-13;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;368,2;5;0;3;5,23;Clc1ccc(N2CCCN(CCCc3cc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL3289656;112106;None;1;Human;Binding;Ki;=;6370,00;5,20;-1621;12;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;339,2;5;0;6;2,84;c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL3289708;112108;None;0;Human;Binding;Ki;=;43,00;7,37;-11;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;416,1;6;1;6;2,71;Cc1cccc(S(=O)(=O)NCCN2CCN(c3nsc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289709;112109;None;0;Human;Binding;Ki;=;13,00;7,89;-10;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;430,1;7;1;6;3,10;Cc1cccc(S(=O)(=O)NCCCN2CCN(c3nsc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289944;112112;None;0;Human;Binding;Ki;=;8,70;8,06;-21;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;444,2;8;1;6;3,48;Cc1cccc(S(=O)(=O)NCCCCN2CCN(c3nsc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289945;112113;None;0;Human;Binding;Ki;=;7,80;8,11;1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;484,1;7;1;6;4,09;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc(Cl)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289946;112114;None;0;Human;Binding;Ki;=;27,00;7,57;-3;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;498,1;8;1;6;4,48;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc(Cl)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289947;112115;None;0;Human;Binding;Ki;=;37,00;7,43;-7;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;468,1;7;1;6;3,58;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289948;112116;None;0;Human;Binding;Ki;=;27,00;7,57;-2;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;500,1;8;1;7;3,69;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc(OC(F)(F)F)cc1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289949;112117;None;0;Human;Binding;Ki;=;48,00;7,32;-21;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;514,1;9;1;7;4,08;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc(OC(F)(F)F)cc1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289950;112118;None;0;Human;Binding;Ki;=;56,00;7,25;-6;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;422,1;7;1;7;2,85;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1cccs1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289951;112119;None;0;Human;Binding;Ki;=;3,20;8,49;-1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;436,1;8;1;7;3,24;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1cccs1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289952;112120;None;0;Human;Binding;Ki;=;18,00;7,75;-19;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;452,1;6;1;6;3,55;O=S(=O)(NCCN1CCN(c2nsc3ccccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289953;112121;None;0;Human;Binding;Ki;=;2,20;8,66;-1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;466,1;7;1;6;3,94;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289954;112122;None;0;Human;Binding;Ki;=;0,90;9,05;1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;480,2;8;1;6;4,33;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289955;112123;None;0;Human;Binding;Ki;=;6,00;8,22;2;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;500,1;7;1;6;4,59;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc2cc(Cl)ccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289956;112124;None;0;Human;Binding;Ki;=;49,00;7,31;-6;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;514,1;8;1;6;4,98;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc2cc(Cl)ccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289957;112125;None;0;Human;Binding;Ki;=;48,00;7,32;-4;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;472,1;7;1;7;4,00;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289958;112126;None;0;Human;Binding;Ki;=;15,00;7,82;-2;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;486,1;8;1;7;4,39;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289960;112128;None;0;Human;Binding;Ki;=;45,00;7,35;-6;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;520,1;8;1;7;5,04;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1cc2ccc(Cl)cc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289961;112129;None;0;Human;Binding;Ki;=;8,30;8,08;1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;504,1;7;1;7;4,45;Cc1c(S(=O)(=O)NCCCN2CCN(c3nsc4ccccc34)CC2)sc2ccc(F)cc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289962;112130;None;0;Human;Binding;Ki;=;44,00;7,36;-9;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;518,1;8;1;7;4,84;Cc1c(S(=O)(=O)NCCCCN2CCN(c3nsc4ccccc34)CC2)sc2ccc(F)cc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289963;112131;None;0;Human;Binding;Ki;=;26,00;7,58;-4;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;456,1;7;1;8;2,44;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1cnc2ccccn12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289964;112132;None;0;Human;Binding;Ki;=;46,00;7,34;-11;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;470,2;8;1;8;2,83;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1cnc2ccccn12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289965;112133;None;0;Human;Binding;Ki;=;27,00;7,57;-13;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;473,1;7;1;8;3,40;O=S(=O)(NCCCN1CCN(c2nsc3ccccc23)CC1)c1cccc2scnc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289966;112134;None;0;Human;Binding;Ki;=;16,00;7,80;-4;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;487,1;8;1;8;3,79;O=S(=O)(NCCCCN1CCN(c2nsc3ccccc23)CC1)c1cccc2scnc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289967;112135;None;0;Human;Binding;Ki;=;2000,00;5,70;-199;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;414,2;7;1;6;2,63;Cc1cccc(S(=O)(=O)NCCCN2CCN(c3noc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289968;112136;None;0;Human;Binding;Ki;=;44,00;7,36;-39;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;428,2;8;1;6;3,02;Cc1cccc(S(=O)(=O)NCCCCN2CCN(c3noc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289970;112139;None;0;Human;Binding;Ki;=;57,00;7,24;-81;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;482,1;8;1;6;4,01;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1ccc(Cl)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289972;112141;None;0;Human;Binding;Ki;=;77,00;7,11;-776;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;466,1;8;1;6;3,50;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289973;112142;None;0;Human;Binding;Ki;=;63,00;7,20;6;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;484,1;8;1;7;3,22;O=S(=O)(NCCCN1CCN(c2noc3ccccc23)CC1)c1ccc(OC(F)(F)F)cc1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289974;112143;None;0;Human;Binding;Ki;=;400,00;6,40;-1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;498,2;9;1;7;3,61;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1ccc(OC(F)(F)F)cc1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289975;112144;None;0;Human;Binding;Ki;=;55,00;7,26;1;3;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;406,1;7;1;7;2,38;O=S(=O)(NCCCN1CCN(c2noc3ccccc23)CC1)c1cccs1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289976;112145;None;0;Human;Binding;Ki;=;5,30;8,28;12;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;420,1;8;1;7;2,77;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1cccs1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289977;112146;None;0;Human;Binding;Ki;=;7200,00;5,14;-66;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;450,2;7;1;6;3,47;O=S(=O)(NCCCN1CCN(c2noc3ccccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289978;112147;None;0;Human;Binding;Ki;=;15,00;7,82;-21;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;464,2;8;1;6;3,86;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289980;112149;None;0;Human;Binding;Ki;=;51,00;7,29;-7;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;498,1;8;1;6;4,51;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1ccc2cc(Cl)ccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289981;112150;None;0;Human;Binding;Ki;=;15,00;7,82;2;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;456,1;7;1;7;3,53;O=S(=O)(NCCCN1CCN(c2noc3ccccc23)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289982;112151;None;0;Human;Binding;Ki;=;1300,00;5,89;-7;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;470,1;8;1;7;3,92;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289983;112152;None;0;Human;Binding;Ki;=;30,00;7,52;2;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;490,1;7;1;7;4,19;O=S(=O)(NCCCN1CCN(c2noc3ccccc23)CC1)c1cc2ccc(Cl)cc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289984;112153;None;0;Human;Binding;Ki;=;54,00;7,27;-10;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;504,1;8;1;7;4,58;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1cc2ccc(Cl)cc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289986;112155;None;0;Human;Binding;Ki;=;46,00;7,34;-17;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;502,2;8;1;7;4,37;Cc1c(S(=O)(=O)NCCCCN2CCN(c3noc4ccccc34)CC2)sc2ccc(F)cc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289987;112156;None;0;Human;Binding;Ki;=;100,00;7,00;-16;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;454,2;8;1;8;2,36;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1cnc2ccccn12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289989;112158;None;0;Human;Binding;Ki;=;170,00;6,77;-2;3;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;471,1;8;1;8;3,32;O=S(=O)(NCCCCN1CCN(c2noc3ccccc23)CC1)c1cccc2scnc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289990;112159;None;0;Human;Binding;Ki;=;20,00;7,70;-18;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;417,2;6;1;5;3,43;Cc1cccc(S(=O)(=O)NCCN2CCC(c3noc4cc(F)ccc34)CC2)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289991;112160;None;0;Human;Binding;Ki;=;16,00;7,80;-26;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;431,2;7;1;5;3,82;Cc1cccc(S(=O)(=O)NCCCN2CCC(c3noc4cc(F)ccc34)CC2)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289992;112161;None;0;Human;Binding;Ki;=;17,00;7,77;-11;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;445,2;8;1;5;4,21;Cc1cccc(S(=O)(=O)NCCCCN2CCC(c3noc4cc(F)ccc34)CC2)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289993;112162;None;0;Human;Binding;Ki;=;14,00;7,85;-11;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;485,1;7;1;5;4,82;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc(Cl)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289994;112163;None;0;Human;Binding;Ki;=;15,00;7,82;-3;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;499,1;8;1;5;5,21;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc(Cl)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289995;112164;None;0;Human;Binding;Ki;=;3,70;8,43;-4;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;469,1;7;1;5;4,31;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289996;112165;None;0;Human;Binding;Ki;=;26,00;7,58;-6;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;483,1;8;1;5;4,70;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289997;112166;None;0;Human;Binding;Ki;=;33,00;7,48;-8;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;501,1;8;1;6;4,41;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc(OC(F)(F)F)cc1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289998;112167;None;0;Human;Binding;Ki;=;64,00;7,19;-17;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;515,1;9;1;6;4,80;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc(OC(F)(F)F)cc1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3289999;112168;None;0;Human;Binding;Ki;=;8,70;8,06;-9;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;423,1;7;1;6;3,58;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cccs1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290001;112171;None;0;Human;Binding;Ki;=;9,10;8,04;-12;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;453,2;6;1;5;4,28;O=S(=O)(NCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cccc2ccccc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290002;112172;None;0;Human;Binding;Ki;=;4,00;8,40;-7;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;467,2;7;1;5;4,67;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cccc2ccccc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290003;112173;None;0;Human;Binding;Ki;=;3,00;8,52;-5;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;481,2;8;1;5;5,06;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cccc2ccccc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290004;112174;None;0;Human;Binding;Ki;=;5,20;8,28;-13;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;453,2;6;1;5;4,28;O=S(=O)(NCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290005;112175;None;0;Human;Binding;Ki;=;1,00;9,00;-1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;467,2;7;1;5;4,67;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290006;112176;None;0;Human;Binding;Ki;=;1,10;8,96;1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;481,2;8;1;5;5,06;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290007;112177;None;0;Human;Binding;Ki;=;23,00;7,64;-7;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;501,1;7;1;5;5,32;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc2cc(Cl)ccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290008;112178;None;0;Human;Binding;Ki;=;1,00;9,00;-1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;515,1;8;1;5;5,71;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1ccc2cc(Cl)ccc2c1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290009;112179;None;0;Human;Binding;Ki;=;36,00;7,44;-40;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;473,1;7;1;6;4,73;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1csc2ccccc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290010;112180;None;0;Human;Binding;Ki;=;22,00;7,66;-5;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;487,1;8;1;6;5,12;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1csc2ccccc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290011;112181;None;0;Human;Binding;Ki;=;11,00;7,96;-12;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;473,1;7;1;6;4,73;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290012;112182;None;0;Human;Binding;Ki;=;2,00;8,70;-3;12;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;487,1;8;1;6;5,12;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290012;112182;None;0;Human;Binding;Ki;=;1,80;8,74;-3;12;Displacement of [3H]methylspiperone from human recombinant D2S receptor expressed in HEK293 cells;ChEMBL;487,1;8;1;6;5,12;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290013;112183;None;0;Human;Binding;Ki;=;27,00;7,57;-10;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;507,1;7;1;6;5,38;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccc(Cl)cc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290014;112184;None;0;Human;Binding;Ki;=;1,20;8,92;-1;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;521,1;8;1;6;5,77;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccc(Cl)cc2s1;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290015;112185;None;0;Human;Binding;Ki;=;8,00;8,10;-3;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;505,1;7;1;6;5,18;Cc1c(S(=O)(=O)NCCCN2CCC(c3noc4cc(F)ccc34)CC2)sc2ccc(F)cc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290016;112186;None;0;Human;Binding;Ki;=;1,90;8,72;-9;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;519,1;8;1;6;5,57;Cc1c(S(=O)(=O)NCCCCN2CCC(c3noc4cc(F)ccc34)CC2)sc2ccc(F)cc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290017;112187;None;0;Human;Binding;Ki;=;1,50;8,82;-2;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;535,1;8;1;6;6,08;Cc1c(S(=O)(=O)NCCCCN2CCC(c3noc4cc(F)ccc34)CC2)sc2ccc(Cl)cc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290018;112188;None;0;Human;Binding;Ki;=;15,00;7,82;-4;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;457,2;7;1;7;3,16;O=S(=O)(NCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cnc2ccccn12;https://dx.doi.org/10.1021/jm401895u
CHEMBL3290021;112191;None;0;Human;Binding;Ki;=;25,00;7,60;-2;4;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;488,1;8;1;7;4,51;O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cccc2scnc12;https://dx.doi.org/10.1021/jm401895u
CHEMBL329126;112352;None;0;Human;Binding;Ki;=;1170,00;5,93;-457;3;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;335,2;3;0;4;3,67;COc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccc(C)cc1)CC3;https://dx.doi.org/10.1021/jm970170v
CHEMBL329126;112352;None;0;Human;Binding;Ki;=;1170,00;5,93;-457;3;Binding affinity to human D2 receptor assessed as inhibition constant;ChEMBL;335,2;3;0;4;3,67;COc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccc(C)cc1)CC3;https://dx.doi.org/10.1016/j.ejmech.2020.113034
CHEMBL329228;112380;None;0;Human;Binding;Ki;=;282,00;6,55;-6;3;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;373,2;6;1;4;3,50;COc1cccc(NC(=O)CCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm991138z
CHEMBL329276;112389;None;0;Human;Binding;Ki;=;4166,00;5,38;-24;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;204,1;0;1;2;2,85;Cc1sc(C)c2c1CCc1c[nH]nc1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL329398;112408;None;0;Human;Binding;Ki;=;2,60;8,59;-3;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;317,1;6;3;4;3,09;Oc1nc2c(OCCNCc3ccccc3)cc(Cl)cc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL329443;112418;None;0;Human;Binding;Ki;=;91,00;7,04;1;4;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;310,2;5;0;3;2,53;CCCN1CCC[C@@H](c2cccc(S(=O)(=O)N(C)C)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL329443;112418;None;0;Human;Binding;Ki;=;227,00;6,64;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;310,2;5;0;3;2,53;CCCN1CCC[C@@H](c2cccc(S(=O)(=O)N(C)C)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL329566;112442;None;0;Human;Binding;Ki;=;61,00;7,21;-128;9;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;293,2;2;0;2;3,77;CN(C)C[C@H]1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL329702;112459;None;0;Human;Binding;Ki;=;1000,00;6,00;-19;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;518,2;9;1;5;5,01;CS(=O)(=O)Oc1ccc2c(c1)CC[C@H]1[C@H]2CCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL3298200;112506;None;0;Human;Binding;Ki;=;2238,72;5,65;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;486,2;7;3;6;4,64;Cc1cc(C)c2c(N)c(C(=O)NCCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298200;112506;None;0;Human;Binding;Ki;=;2250,00;5,65;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;486,2;7;3;6;4,64;Cc1cc(C)c2c(N)c(C(=O)NCCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298685;112539;None;0;Human;Binding;Ki;=;1995,26;5,70;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;500,2;8;3;6;5,03;Cc1cc(C)c2c(N)c(C(=O)NCCCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298685;112539;None;0;Human;Binding;Ki;=;1980,00;5,70;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;500,2;8;3;6;5,03;Cc1cc(C)c2c(N)c(C(=O)NCCCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298686;112540;None;0;Human;Binding;Ki;=;975,00;6,01;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;514,2;9;3;6;5,42;Cc1cc(C)c2c(N)c(C(=O)NCCCCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298686;112540;None;0;Human;Binding;Ki;=;977,24;6,01;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;514,2;9;3;6;5,42;Cc1cc(C)c2c(N)c(C(=O)NCCCCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298755;112553;None;70;Human;Binding;Ki;=;9090,00;5,04;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;211,1;1;2;2;1,91;OC1(c2ccc(Cl)cc2)CCNCC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298755;112553;None;70;Human;Binding;Ki;=;9120,11;5,04;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;211,1;1;2;2;1,91;OC1(c2ccc(Cl)cc2)CCNCC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298756;112554;None;0;Human;Binding;Ki;=;2754,23;5,56;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;354,2;4;2;4;3,15;CC(C)(C)OC(=O)NCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298756;112554;None;0;Human;Binding;Ki;=;2750,00;5,56;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;354,2;4;2;4;3,15;CC(C)(C)OC(=O)NCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298757;112555;None;0;Human;Binding;Ki;=;1350,00;5,87;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;368,2;5;2;4;3,54;CC(C)(C)OC(=O)NCCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298757;112555;None;0;Human;Binding;Ki;=;1348,96;5,87;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;368,2;5;2;4;3,54;CC(C)(C)OC(=O)NCCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298758;112556;None;0;Human;Binding;Ki;=;48,30;7,32;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;489,2;7;2;8;3,41;COc1ccccc1N1CCN(CCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298758;112556;None;0;Human;Binding;Ki;=;47,86;7,32;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;489,2;7;2;8;3,41;COc1ccccc1N1CCN(CCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298759;112557;None;0;Human;Binding;Ki;=;19,50;7,71;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;503,2;8;2;8;3,80;COc1ccccc1N1CCN(CCCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298759;112557;None;0;Human;Binding;Ki;=;19,50;7,71;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;503,2;8;2;8;3,80;COc1ccccc1N1CCN(CCCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298825;112560;None;0;Human;Binding;Ki;=;2089,30;5,68;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;382,2;6;2;4;3,93;CC(C)(C)OC(=O)NCCCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298825;112560;None;0;Human;Binding;Ki;=;2110,00;5,68;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;382,2;6;2;4;3,93;CC(C)(C)OC(=O)NCCCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298826;112561;None;0;Human;Binding;Ki;=;6,30;8,20;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;517,2;9;2;8;4,19;COc1ccccc1N1CCN(CCCCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298826;112561;None;0;Human;Binding;Ki;=;6,31;8,20;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;517,2;9;2;8;4,19;COc1ccccc1N1CCN(CCCCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298827;112562;None;0;Human;Binding;EC50;=;2,69;8,57;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;531,2;10;2;8;4,58;COc1ccccc1N1CCN(CCCCCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298827;112562;None;0;Human;Binding;EC50;=;2,69;8,57;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;531,2;10;2;8;4,58;COc1ccccc1N1CCN(CCCCCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298827;112562;None;0;Human;Binding;Ki;=;3,50;8,46;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;531,2;10;2;8;4,58;COc1ccccc1N1CCN(CCCCCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298827;112562;None;0;Human;Binding;Ki;=;3,55;8,45;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;531,2;10;2;8;4,58;COc1ccccc1N1CCN(CCCCCNC(=O)c2sc3nc(OC)c(Cl)c(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298828;112563;None;0;Human;Binding;EC50;=;5,50;8,26;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;548,2;10;2;6;6,67;COc1nc2sc(C(=O)NCCCCCCN3CCC(c4ccc(Cl)cc4)CC3)c(N)c2c(C)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298828;112563;None;0;Human;Binding;EC50;=;5,49;8,26;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;548,2;10;2;6;6,67;COc1nc2sc(C(=O)NCCCCCCN3CCC(c4ccc(Cl)cc4)CC3)c(N)c2c(C)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298828;112563;None;0;Human;Binding;Ki;=;0,60;9,22;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;548,2;10;2;6;6,67;COc1nc2sc(C(=O)NCCCCCCN3CCC(c4ccc(Cl)cc4)CC3)c(N)c2c(C)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298828;112563;None;0;Human;Binding;Ki;=;0,62;9,21;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;548,2;10;2;6;6,67;COc1nc2sc(C(=O)NCCCCCCN3CCC(c4ccc(Cl)cc4)CC3)c(N)c2c(C)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298829;112564;None;0;Human;Binding;Ki;=;42,60;7,37;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;415,2;7;1;4;4,81;CC(C)(C)OC(=O)NCCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298829;112564;None;0;Human;Binding;Ki;=;42,66;7,37;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;415,2;7;1;4;4,81;CC(C)(C)OC(=O)NCCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298830;112565;None;0;Human;Binding;EC50;=;87,60;7,06;-;1;Agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;569,1;9;2;7;5,88;COc1nc2sc(C(=O)NCCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c(N)c2c(C)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298830;112565;None;0;Human;Binding;Ki;=;15,49;7,81;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;569,1;9;2;7;5,88;COc1nc2sc(C(=O)NCCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c(N)c2c(C)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298830;112565;None;0;Human;Binding;Ki;=;15,50;7,81;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;569,1;9;2;7;5,88;COc1nc2sc(C(=O)NCCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)c(N)c2c(C)c1Cl;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298895;112569;None;11;Human;Binding;EC50;=;13,20;7,88;-;1;Agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;519,2;8;2;6;5,52;Cc1cc(C)c2c(N)c(C(=O)NCCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298895;112569;None;11;Human;Binding;Ki;=;11,20;7,95;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;519,2;8;2;6;5,52;Cc1cc(C)c2c(N)c(C(=O)NCCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298895;112569;None;11;Human;Binding;Ki;=;11,22;7,95;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;519,2;8;2;6;5,52;Cc1cc(C)c2c(N)c(C(=O)NCCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298896;112570;None;0;Human;Binding;Ki;=;9,12;8,04;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;481,3;9;2;7;4,23;COc1ccccc1N1CCN(CCCCCNC(=O)c2sc3nc(C)cc(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3298896;112570;None;0;Human;Binding;Ki;=;9,10;8,04;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;481,3;9;2;7;4,23;COc1ccccc1N1CCN(CCCCCNC(=O)c2sc3nc(C)cc(C)c3c2N)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL329904;112584;None;2;Human;Binding;Ki;=;854,00;6,07;-7;5;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;279,2;2;1;2;3,92;CCCN1CCc2cccc3c2C1Cc1cccc(O)c1-3;https://dx.doi.org/10.1021/jm200347t
CHEMBL329904;112584;UNDEFINED;2;Human;Binding;pKi;=;114,00;6,94;-7;5;-;PDSP KiDatabase;279,2;2;1;2;3,92;CCCN1CCc2cccc3c2C1Cc1cccc(O)c1-3;-
CHEMBL3299091;112586;None;0;Human;Binding;Ki;=;2050,00;5,69;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;396,2;7;2;4;4,32;CC(C)(C)OC(=O)NCCCCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299091;112586;None;0;Human;Binding;Ki;=;2041,74;5,69;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;396,2;7;2;4;4,32;CC(C)(C)OC(=O)NCCCCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299092;112587;None;0;Human;Binding;Ki;=;902,00;6,04;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;410,2;8;2;4;4,71;CC(C)(C)OC(=O)NCCCCCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299092;112587;None;0;Human;Binding;Ki;=;891,25;6,05;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;410,2;8;2;4;4,71;CC(C)(C)OC(=O)NCCCCCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299093;112588;None;0;Human;Binding;IC50;=;93,33;7,03;-;1;Antagonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of dopamine-induced ERK1/2 phosphorylation treated for 30 mins prior to dopamine stimulation for 5 mins by AlphaScreen assay;ChEMBL;335,2;5;1;5;2,34;COc1ccccc1N1CCN(CCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299093;112588;None;0;Human;Binding;IC50;=;93,30;7,03;-;1;Antagonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of dopamine-induced ERK1/2 phosphorylation treated for 30 mins prior to dopamine stimulation for 5 mins by AlphaScreen assay;ChEMBL;335,2;5;1;5;2,34;COc1ccccc1N1CCN(CCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299093;112588;None;0;Human;Binding;Ki;=;169,82;6,77;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;335,2;5;1;5;2,34;COc1ccccc1N1CCN(CCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299093;112588;None;0;Human;Binding;Ki;=;171,00;6,77;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;335,2;5;1;5;2,34;COc1ccccc1N1CCN(CCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299094;112589;None;0;Human;Binding;EC50;=;0,39;9,41;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;349,2;6;1;5;2,73;COc1ccccc1N1CCN(CCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299094;112589;None;0;Human;Binding;EC50;=;0,39;9,41;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;349,2;6;1;5;2,73;COc1ccccc1N1CCN(CCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299094;112589;None;0;Human;Binding;Ki;=;15,85;7,80;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;349,2;6;1;5;2,73;COc1ccccc1N1CCN(CCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299094;112589;None;0;Human;Binding;Ki;=;16,10;7,79;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;349,2;6;1;5;2,73;COc1ccccc1N1CCN(CCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299095;112590;None;0;Human;Binding;EC50;=;0,60;9,22;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;363,3;7;1;5;3,12;COc1ccccc1N1CCN(CCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299095;112590;None;0;Human;Binding;EC50;=;0,60;9,22;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;363,3;7;1;5;3,12;COc1ccccc1N1CCN(CCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299095;112590;None;0;Human;Binding;Ki;=;19,05;7,72;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;363,3;7;1;5;3,12;COc1ccccc1N1CCN(CCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299095;112590;None;0;Human;Binding;Ki;=;18,90;7,72;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;363,3;7;1;5;3,12;COc1ccccc1N1CCN(CCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299096;112591;None;0;Human;Binding;EC50;=;1,45;8,84;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;377,3;8;1;5;3,51;COc1ccccc1N1CCN(CCCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299096;112591;None;0;Human;Binding;EC50;=;1,43;8,85;-;1;Partial agonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as induction of ERK1/2 phosphorylation by AlphaScreen assay;ChEMBL;377,3;8;1;5;3,51;COc1ccccc1N1CCN(CCCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299096;112591;None;0;Human;Binding;Ki;=;12,10;7,92;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;377,3;8;1;5;3,51;COc1ccccc1N1CCN(CCCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299096;112591;None;0;Human;Binding;Ki;=;12,02;7,92;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;377,3;8;1;5;3,51;COc1ccccc1N1CCN(CCCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299097;112592;None;0;Human;Binding;IC50;=;3,98;8,40;-;1;Antagonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of dopamine-induced ERK1/2 phosphorylation treated for 30 mins prior to dopamine stimulation for 5 mins by AlphaScreen assay;ChEMBL;391,3;9;1;5;3,90;COc1ccccc1N1CCN(CCCCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299097;112592;None;0;Human;Binding;IC50;=;3,98;8,40;-;1;Antagonist activity at human D2L receptor expressed in FlpIn CHO cells assessed as inhibition of dopamine-induced ERK1/2 phosphorylation treated for 30 mins prior to dopamine stimulation for 5 mins by AlphaScreen assay;ChEMBL;391,3;9;1;5;3,90;COc1ccccc1N1CCN(CCCCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299097;112592;None;0;Human;Binding;Ki;=;74,13;7,13;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;391,3;9;1;5;3,90;COc1ccccc1N1CCN(CCCCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299097;112592;None;0;Human;Binding;Ki;=;74,80;7,13;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;391,3;9;1;5;3,90;COc1ccccc1N1CCN(CCCCCCNC(=O)OC(C)(C)C)CC1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299098;112593;None;0;Human;Binding;Ki;=;910,00;6,04;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;458,2;5;3;6;3,86;Cc1cc(C)c2c(N)c(C(=O)NCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299098;112593;None;0;Human;Binding;Ki;=;912,01;6,04;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;458,2;5;3;6;3,86;Cc1cc(C)c2c(N)c(C(=O)NCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299099;112594;None;0;Human;Binding;Ki;=;1700,00;5,77;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;472,2;6;3;6;4,25;Cc1cc(C)c2c(N)c(C(=O)NCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL3299099;112594;None;0;Human;Binding;Ki;=;1698,24;5,77;-;1;Displacement of [3H]spiperone from human D2L receptor expressed in FlpIn CHO cell membrane after 3 hrs by liquid scintillation counting analysis;ChEMBL;472,2;6;3;6;4,25;Cc1cc(C)c2c(N)c(C(=O)NCCCN3CCC(O)(c4ccc(Cl)cc4)CC3)sc2n1;https://dx.doi.org/10.1021/jm500457x
CHEMBL330100;112635;None;0;Human;Binding;Ki;=;659,00;6,18;-41;3;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;351,1;4;0;5;3,37;COc1ccc2c3c(c(=O)oc2c1OC)CN(Cc1ccccc1)CC3;https://dx.doi.org/10.1021/jm970170v
CHEMBL330108;112638;None;0;Human;Binding;Ki;=;540,00;6,27;-61;4;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;341,1;3;1;3;3,16;O=C1Cc2c(ccc(Cl)c2N2CCN(Cc3ccccc3)CC2)N1;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL330216;112667;None;0;Human;Binding;Ki;=;533,00;6,27;-346;3;Tested for antagonist binding affinity by measuring displacement of [3H]spiperone from Human Dopamine receptor D2L expressed in CHO K-1 cells;ChEMBL;265,1;2;1;4;2,65;CCCN1CCOC2c3cc(O)ccc3SCC21;https://dx.doi.org/10.1021/jm0000113
CHEMBL3302600;112689;None;0;Human;Binding;Ki;=;715,00;6,15;-234;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;456,2;7;2;6;1,78;COc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3ccc(F)cc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL330303;112713;None;0;Human;Binding;Ki;=;187,00;6,73;-977;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;414,2;5;1;1;6,37;CCN(C)CCc1c(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL330470;112794;None;0;Human;Binding;Ki;=;3960,00;5,40;-363;3;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;399,2;5;0;4;3,17;COc1ccc2c(c1)C(=O)N(CCN1CCN(c3ccc(Cl)cc3)CC1)CC2;https://dx.doi.org/10.1021/jm991138z
CHEMBL330865;112906;None;0;Human;Binding;Ki;=;219,00;6,66;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;363,2;5;0;3;4,39;COc1ccc2c(c1)CCC(C1CCN(CCc3ccccc3)CC1)C2=O;https://dx.doi.org/10.1021/jm00029a008
CHEMBL331005;112947;None;0;Human;Binding;Ki;=;411,00;6,39;-23;3;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;293,2;2;0;2;4,01;CCc1ccc2c(c1OC)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL331077;113007;None;0;Human;Binding;IC50;=;1905,46;5,72;-;6;Binding affinity against Dopamine receptor D2L;ChEMBL;295,2;2;0;4;2,80;CN(C)CC1CC2c3ccccc3Cc3ccncc3N2O1;https://dx.doi.org/10.1016/s0960-894x(02)00796-5
CHEMBL331100;113054;None;0;Human;Binding;Ki;=;1750,00;5,76;-16;3;In vitro affinity at human cloned Dopamine receptor D2A by [3H]raclopride displacement.;ChEMBL;291,2;2;0;2;4,09;C=Cc1ccc2c(c1OC)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL331470;113245;None;0;Human;Binding;Ki;=;344,00;6,46;-;1;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;351,2;4;0;2;4,53;O=C1c2ccc(F)cc2CCC1C1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL3317465;113411;None;0;Human;Binding;Ki;=;1,00;9,00;5;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1154,5;32;0;17;9,46;O=C(CCc1cn(CCOCCOCCOCCn2cc(CCC(=O)OC3(c4ccc(Cl)cc4)CCN(CCCC(=O)c4ccc(F)cc4)CC3)nn2)nn1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3317465;113411;None;0;Human;Binding;Ki;=;3,00;8,52;5;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1154,5;32;0;17;9,46;O=C(CCc1cn(CCOCCOCCOCCn2cc(CCC(=O)OC3(c4ccc(Cl)cc4)CCN(CCCC(=O)c4ccc(F)cc4)CC3)nn2)nn1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318824;113466;None;0;Human;Binding;Ki;=;1,60;8,80;1;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;431,2;8;0;4;5,39;CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318824;113466;None;0;Human;Binding;Ki;=;3,90;8,41;1;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;431,2;8;0;4;5,39;CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318831;113468;None;0;Human;Binding;Ki;=;5,40;8,27;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;832,3;17;0;8;9,75;O=C(CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318831;113468;None;0;Human;Binding;Ki;=;6,70;8,17;2;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;832,3;17;0;8;9,75;O=C(CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318832;113469;None;0;Human;Binding;Ki;=;12,00;7,92;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;846,3;18;0;8;10,14;O=C(CCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318832;113469;None;0;Human;Binding;Ki;=;12,00;7,92;2;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;846,3;18;0;8;10,14;O=C(CCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318833;113470;None;0;Human;Binding;Ki;=;3,00;8,52;4;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;860,3;19;0;8;10,53;O=C(CCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318833;113470;None;0;Human;Binding;Ki;=;2,30;8,64;4;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;860,3;19;0;8;10,53;O=C(CCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318834;113471;None;0;Human;Binding;Ki;=;2,60;8,59;3;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;874,3;20;0;8;10,92;O=C(CCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318834;113471;None;0;Human;Binding;Ki;=;3,30;8,48;3;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;874,3;20;0;8;10,92;O=C(CCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318835;113472;None;0;Human;Binding;Ki;=;2,50;8,60;2;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;888,3;21;0;8;11,31;O=C(CCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318835;113472;None;0;Human;Binding;Ki;=;2,90;8,54;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;888,3;21;0;8;11,31;O=C(CCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318836;113473;None;0;Human;Binding;Ki;=;6,50;8,19;1;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;902,4;22;0;8;11,70;O=C(CCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318836;113473;None;0;Human;Binding;Ki;=;5,60;8,25;1;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;902,4;22;0;8;11,70;O=C(CCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318837;113474;None;0;Human;Binding;Ki;=;15,00;7,82;1;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;916,4;23;0;8;12,09;O=C(CCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318837;113474;None;0;Human;Binding;Ki;=;31,00;7,51;1;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;916,4;23;0;8;12,09;O=C(CCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318838;113475;None;0;Human;Binding;Ki;=;66,00;7,18;3;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;944,4;25;0;8;12,87;O=C(CCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318838;113475;None;0;Human;Binding;Ki;=;46,00;7,34;3;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;944,4;25;0;8;12,87;O=C(CCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318839;113476;None;0;Human;Binding;Ki;=;62,00;7,21;1;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;972,4;27;0;8;13,65;O=C(CCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318839;113476;None;0;Human;Binding;Ki;=;120,00;6,92;1;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;972,4;27;0;8;13,65;O=C(CCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318840;113478;None;0;Human;Binding;Ki;=;280,00;6,55;1;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1000,5;29;0;8;14,43;O=C(CCCCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318840;113478;None;0;Human;Binding;Ki;=;140,00;6,85;1;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1000,5;29;0;8;14,43;O=C(CCCCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318841;113479;None;0;Human;Binding;Ki;=;160,00;6,80;2;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1028,5;31;0;8;15,21;O=C(CCCCCCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318841;113479;None;0;Human;Binding;Ki;=;150,00;6,82;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1028,5;31;0;8;15,21;O=C(CCCCCCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318842;113480;None;0;Human;Binding;Ki;=;25,00;7,60;3;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1056,5;33;0;8;15,99;O=C(CCCCCCCCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318842;113480;None;0;Human;Binding;Ki;=;27,00;7,57;3;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1056,5;33;0;8;15,99;O=C(CCCCCCCCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318843;113481;None;0;Human;Binding;Ki;=;280,00;6,55;1;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1084,6;35;0;8;16,77;O=C(CCCCCCCCCCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318843;113481;None;0;Human;Binding;Ki;=;310,00;6,51;1;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1084,6;35;0;8;16,77;O=C(CCCCCCCCCCCCCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318844;113482;None;0;Human;Binding;Ki;=;47,00;7,33;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;493,2;8;0;4;6,60;Cc1ccc(C(=O)OC2(c3ccc(Cl)cc3)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318844;113482;None;0;Human;Binding;Ki;=;56,00;7,25;2;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;493,2;8;0;4;6,60;Cc1ccc(C(=O)OC2(c3ccc(Cl)cc3)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318845;113483;None;0;Human;Binding;Ki;=;4,50;8,35;2;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;417,2;7;0;4;5,00;CC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318845;113483;None;0;Human;Binding;Ki;=;4,50;8,35;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;417,2;7;0;4;5,00;CC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318846;113484;None;0;Human;Binding;Ki;=;1,10;8,96;5;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;944,4;20;0;10;9,36;O=C(CCN1CCN(CCC(=O)OC2(c3ccc(Cl)cc3)CCN(CCCC(=O)c3ccc(F)cc3)CC2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318846;113484;None;0;Human;Binding;Ki;=;2,50;8,60;5;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;944,4;20;0;10;9,36;O=C(CCN1CCN(CCC(=O)OC2(c3ccc(Cl)cc3)CCN(CCCC(=O)c3ccc(F)cc3)CC2)CC1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318847;113485;None;0;Human;Binding;Ki;=;2,20;8,66;10;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;946,4;23;0;10;9,61;CN(CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)CCN(C)CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318847;113485;None;0;Human;Binding;Ki;=;3,20;8,49;10;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;946,4;23;0;10;9,61;CN(CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1)CCN(C)CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318848;113486;None;0;Human;Binding;Ki;=;1,90;8,72;4;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;474,2;10;0;5;4,93;CN(C)CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318848;113486;None;0;Human;Binding;Ki;=;1,80;8,74;4;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;474,2;10;0;5;4,93;CN(C)CCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318849;113487;None;0;Human;Binding;Ki;=;1,60;8,80;1;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1106,5;29;0;14;11,76;O=C(CCc1cn(CCCCCCCCn2cc(CCC(=O)OC3(c4ccc(Cl)cc4)CCN(CCCC(=O)c4ccc(F)cc4)CC3)nn2)nn1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318849;113487;None;0;Human;Binding;Ki;=;1,30;8,89;1;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1106,5;29;0;14;11,76;O=C(CCc1cn(CCCCCCCCn2cc(CCC(=O)OC3(c4ccc(Cl)cc4)CCN(CCCC(=O)c4ccc(F)cc4)CC3)nn2)nn1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318850;113488;None;0;Human;Binding;Ki;=;4,90;8,31;1;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1134,5;31;0;14;12,54;O=C(CCc1cn(CCCCCCCCCCn2cc(CCC(=O)OC3(c4ccc(Cl)cc4)CCN(CCCC(=O)c4ccc(F)cc4)CC3)nn2)nn1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318850;113488;None;0;Human;Binding;Ki;=;5,40;8,27;1;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1134,5;31;0;14;12,54;O=C(CCc1cn(CCCCCCCCCCn2cc(CCC(=O)OC3(c4ccc(Cl)cc4)CCN(CCCC(=O)c4ccc(F)cc4)CC3)nn2)nn1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318851;113489;None;0;Human;Binding;Ki;=;1,60;8,80;7;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1198,5;35;0;18;9,48;O=C(CCc1cn(CCOCCOCCOCCOCCn2cc(CCC(=O)OC3(c4ccc(Cl)cc4)CCN(CCCC(=O)c4ccc(F)cc4)CC3)nn2)nn1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318851;113489;None;0;Human;Binding;Ki;=;3,80;8,42;7;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;1198,5;35;0;18;9,48;O=C(CCc1cn(CCOCCOCCOCCOCCn2cc(CCC(=O)OC3(c4ccc(Cl)cc4)CCN(CCCC(=O)c4ccc(F)cc4)CC3)nn2)nn1)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318852;113490;None;3;Human;Binding;Ki;=;860,00;6,07;2;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;389,1;5;1;3;3,95;O=C(CCC(=O)N1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL3318852;113490;None;3;Human;Binding;Ki;=;470,00;6,33;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;389,1;5;1;3;3,95;O=C(CCC(=O)N1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
CHEMBL332178;113598;None;0;Human;Binding;Ki;=;248,00;6,61;-32;3;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;279,2;1;0;2;3,76;COc1c(C)ccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL3321788;113601;None;0;Human;Binding;Ki;=;33,00;7,48;-3;9;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;387,2;6;1;2;5,32;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL3321789;113602;None;0;Human;Binding;Ki;=;22,00;7,66;-5;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;389,2;6;1;3;4,76;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCOc1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL3321790;113603;None;0;Human;Binding;Ki;=;2,90;8,54;-4;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;405,1;6;1;3;5,48;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL3321791;113604;None;0;Human;Binding;Ki;=;27,00;7,57;-2;9;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;405,1;6;1;3;5,48;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1cccc(F)c1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL3321792;113605;None;0;Human;Binding;Ki;=;4,80;8,32;-3;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;405,1;6;1;3;5,48;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1ccccc1F;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
CHEMBL332270;113722;None;0;Human;Binding;Ki;=;10,00;8,00;-3;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;446,1;9;1;4;5,16;CCN(Cc1cccc(Cl)c1)Cc1ccc(-c2cc(S(=O)(=O)CC)ccc2OC)[nH]1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL3322992;113726;None;0;Human;Binding;Ki;=;178,00;6,75;-17;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;377,2;7;1;5;2,67;O=C(NCCCCN1CCN(c2ccccc2)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322993;113727;None;0;Human;Binding;IC50;=;26,00;7,58;-5;2;Antagonist activity against human D2R expressed in CHO cells assessed as inhibition of quinpirole-induced mitogenesis after 24 hrs by [3H]thymidine uptake assay;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cn3ccccc3n2)CC1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322993;113727;None;0;Human;Binding;IC50;=;6,60;8,18;-5;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cn3ccccc3n2)CC1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322993;113727;None;0;Human;Binding;Ki;=;19,00;7,72;-5;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cn3ccccc3n2)CC1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322994;113728;None;0;Human;Binding;IC50;=;55,00;7,26;-39;2;Antagonist activity against human D2R expressed in CHO cells assessed as inhibition of quinpirole-induced mitogenesis after 24 hrs by [3H]thymidine uptake assay;ChEMBL;445,1;7;1;5;3,97;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322994;113728;None;0;Human;Binding;IC50;=;91,00;7,04;-39;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;445,1;7;1;5;3,97;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322994;113728;None;0;Human;Binding;Ki;=;12,00;7,92;-39;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;445,1;7;1;5;3,97;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322995;113729;None;0;Human;Binding;IC50;=;60,00;7,22;-56;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;445,2;7;1;5;3,69;O=C(NCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322995;113729;None;0;Human;Binding;Ki;=;162,00;6,79;-56;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;445,2;7;1;5;3,69;O=C(NCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322996;113730;None;0;Human;Binding;Ki;=;191,00;6,72;-29;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;470,2;7;1;6;3,56;N#Cc1cc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(F)(F)F)c1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322997;113731;None;0;Human;Binding;Ki;=;1303,00;5,88;-10;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;489,3;7;1;5;5,26;CC(C)(C)c1cc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(C)(C)C)c1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322998;113732;None;0;Human;Binding;IC50;=;161,00;6,79;-28;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;428,2;7;1;6;3,21;O=C(NCCCCN1CCN(c2ccnc3ccccc23)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322998;113732;None;0;Human;Binding;Ki;=;572,00;6,24;-28;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;428,2;7;1;6;3,21;O=C(NCCCCN1CCN(c2ccnc3ccccc23)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3322999;113733;None;0;Human;Binding;Ki;=;13567,00;4,87;-25;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;496,2;7;1;6;4,23;O=C(NCCCCN1CCN(c2cc(C(F)(F)F)nc3ccccc23)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323000;113734;None;0;Human;Binding;Ki;=;4983,00;5,30;-50;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;496,2;7;1;6;4,23;O=C(NCCCCN1CCN(c2ccnc3cc(C(F)(F)F)ccc23)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323001;113735;None;0;Human;Binding;Ki;=;1883,00;5,72;-66;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;462,2;7;1;6;3,87;O=C(NCCCCN1CCN(c2ccnc3cc(Cl)ccc23)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323002;113736;None;0;Human;Binding;Ki;=;1563,00;5,81;-19;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;428,2;7;1;6;3,21;O=C(NCCCCN1CCN(c2ccc3ccccc3n2)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323003;113737;None;0;Human;Binding;IC50;=;248,00;6,61;-4;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;429,2;7;1;7;2,61;O=C(NCCCCN1CCN(c2ncnc3ccccc23)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323003;113737;None;0;Human;Binding;Ki;=;1133,00;5,95;-4;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;429,2;7;1;7;2,61;O=C(NCCCCN1CCN(c2ncnc3ccccc23)CC1)c1cn2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323004;113738;None;0;Human;Binding;Ki;=;1452,00;5,84;-18;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;485,3;7;1;7;3,91;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)c2ccccc2n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323005;113739;None;0;Human;Binding;Ki;=;24938,00;4,60;-12;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;461,2;7;1;7;2,78;Cc1nc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323006;113740;None;0;Human;Binding;Ki;=;3646,00;5,44;-24;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;461,2;7;1;7;2,78;Cc1cc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)nc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323007;113741;None;0;Human;Binding;Ki;=;4604,00;5,34;-33;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;449,3;7;1;7;3,06;Cc1nc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(C)(C)C)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323008;113742;None;0;Human;Binding;Ki;=;366,00;6,44;-38;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;449,3;7;1;7;3,06;Cc1cc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)nc(C(C)(C)C)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323009;113743;None;0;Human;Binding;Ki;=;361,00;6,44;-19;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;491,3;7;1;7;4,05;CC(C)(C)c1cc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)nc(C(C)(C)C)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323010;113744;None;0;Human;Binding;Ki;=;191,00;6,72;-22;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;475,3;8;1;7;3,63;CC(C)(C)c1nc(C2CC2)cc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323011;113745;None;0;Human;Binding;IC50;=;261,00;6,58;-30;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;503,3;7;1;7;3,77;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323011;113745;None;0;Human;Binding;IC50;=;2300,00;5,64;-30;2;Antagonist activity against human D2R expressed in CHO cells assessed as inhibition of quinpirole-induced mitogenesis after 24 hrs by [3H]thymidine uptake assay;ChEMBL;503,3;7;1;7;3,77;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323011;113745;None;0;Human;Binding;Ki;=;148,00;6,83;-30;2;Displacement of [125I]IABN from chimeric human D2 receptor possessing extracellular loop II of D3 receptor expressed in HEK293 cell membranes by gamma counting method;ChEMBL;503,3;7;1;7;3,77;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323011;113745;None;0;Human;Binding;Ki;=;702,00;6,15;-30;2;Displacement of [125I]IABN from wild type human D2R expressed in HEK293 cell membranes by gamma counting method;ChEMBL;503,3;7;1;7;3,77;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323011;113745;None;0;Human;Binding;Ki;=;511,00;6,29;-30;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;503,3;7;1;7;3,77;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323012;113746;None;0;Human;Binding;IC50;=;418,00;6,38;-83;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;502,3;7;2;5;4,61;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cc4ccccc4[nH]3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323012;113746;None;0;Human;Binding;Ki;=;913,00;6,04;-83;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;502,3;7;2;5;4,61;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cc4ccccc4[nH]3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323013;113747;None;0;Human;Binding;IC50;=;301,00;6,52;-79;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;503,3;7;2;6;4,00;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3nc4ccccc4[nH]3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323013;113747;None;0;Human;Binding;IC50;=;490,00;6,31;-79;2;Antagonist activity against human D2R expressed in CHO cells assessed as inhibition of quinpirole-induced mitogenesis after 24 hrs by [3H]thymidine uptake assay;ChEMBL;503,3;7;2;6;4,00;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3nc4ccccc4[nH]3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323013;113747;None;0;Human;Binding;Ki;=;336,00;6,47;-79;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;503,3;7;2;6;4,00;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3nc4ccccc4[nH]3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323014;113748;None;0;Human;Binding;Ki;=;683,00;6,17;-21;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;520,2;7;1;7;4,74;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cc4cccnc4s3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323015;113749;None;0;Human;Binding;IC50;=;37,00;7,43;-36;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;504,3;7;1;8;3,17;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4cccnc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323015;113749;None;0;Human;Binding;IC50;=;205,00;6,69;-36;2;Antagonist activity against human D2R expressed in CHO cells assessed as inhibition of quinpirole-induced mitogenesis after 24 hrs by [3H]thymidine uptake assay;ChEMBL;504,3;7;1;8;3,17;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4cccnc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323015;113749;None;0;Human;Binding;Ki;=;436,00;6,36;-36;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;504,3;7;1;8;3,17;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4cccnc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323016;113750;None;0;Human;Binding;IC50;=;420,00;6,38;-56;2;Antagonist activity against human D2R expressed in CHO cells assessed as inhibition of quinpirole-induced mitogenesis after 24 hrs by [3H]thymidine uptake assay;ChEMBL;504,3;7;1;8;3,17;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccncc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323016;113750;None;0;Human;Binding;IC50;=;49,00;7,31;-56;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;504,3;7;1;8;3,17;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccncc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323016;113750;None;0;Human;Binding;Ki;=;450,00;6,35;-56;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;504,3;7;1;8;3,17;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4ccncc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323017;113751;None;0;Human;Binding;IC50;=;1160,00;5,94;-66;2;Antagonist activity against human D2R expressed in CHO cells assessed as inhibition of quinpirole-induced mitogenesis after 24 hrs by [3H]thymidine uptake assay;ChEMBL;538,2;7;1;8;3,82;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4nc(Cl)ccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323017;113751;None;0;Human;Binding;IC50;=;22,00;7,66;-66;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;538,2;7;1;8;3,82;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4nc(Cl)ccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323017;113751;None;0;Human;Binding;Ki;=;655,00;6,18;-66;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;538,2;7;1;8;3,82;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4nc(Cl)ccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323018;113752;None;0;Human;Binding;Ki;=;481,00;6,32;-13;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;535,2;7;2;8;4,32;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3sc4ncccc4c3N)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323019;113753;None;0;Human;Binding;IC50;=;311,00;6,51;-20;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;559,3;9;2;6;4,67;CN(C)Cc1c(C(=O)NCCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)[nH]c2ccccc12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323019;113753;None;0;Human;Binding;Ki;=;527,00;6,28;-20;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;559,3;9;2;6;4,67;CN(C)Cc1c(C(=O)NCCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)[nH]c2ccccc12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323112;113774;None;0;Human;Binding;IC50;=;217,00;6,66;-8;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;560,3;9;1;8;3,83;CN(C)Cc1c(C(=O)NCCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)nc2ccccn12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323112;113774;None;0;Human;Binding;Ki;=;191,00;6,72;-8;2;Displacement of [125I]IABN from wild type human D2R expressed in HEK293 cell membranes by gamma counting method;ChEMBL;560,3;9;1;8;3,83;CN(C)Cc1c(C(=O)NCCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)nc2ccccn12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323112;113774;None;0;Human;Binding;Ki;=;301,00;6,52;-8;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;560,3;9;1;8;3,83;CN(C)Cc1c(C(=O)NCCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)nc2ccccn12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323112;113774;None;0;Human;Binding;Ki;=;72,00;7,14;-8;2;Displacement of [125I]IABN from chimeric human D2 receptor possessing extracellular loop II of D3 receptor expressed in HEK293 cell membranes by gamma counting method;ChEMBL;560,3;9;1;8;3,83;CN(C)Cc1c(C(=O)NCCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)nc2ccccn12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323113;113775;None;0;Human;Binding;Ki;=;934,00;6,03;-20;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;533,3;8;2;8;3,27;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cn4c(CO)cccc4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323114;113776;None;0;Human;Binding;IC50;=;281,00;6,55;-10;2;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;560,3;9;1;8;3,83;CN(C)Cc1cccc2nc(C(=O)NCCCCN3CCN(c4cc(C(F)(F)F)nc(C(C)(C)C)n4)CC3)cn12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323114;113776;None;0;Human;Binding;Ki;=;245,00;6,61;-10;2;Displacement of [125I]IABN from wild type human D2R expressed in HEK293 cell membranes by gamma counting method;ChEMBL;560,3;9;1;8;3,83;CN(C)Cc1cccc2nc(C(=O)NCCCCN3CCN(c4cc(C(F)(F)F)nc(C(C)(C)C)n4)CC3)cn12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323114;113776;None;0;Human;Binding;Ki;=;176,00;6,75;-10;2;Displacement of [125I]IABN from chimeric human D2 receptor possessing extracellular loop II of D3 receptor expressed in HEK293 cell membranes by gamma counting method;ChEMBL;560,3;9;1;8;3,83;CN(C)Cc1cccc2nc(C(=O)NCCCCN3CCN(c4cc(C(F)(F)F)nc(C(C)(C)C)n4)CC3)cn12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323114;113776;None;0;Human;Binding;Ki;=;298,00;6,53;-10;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;560,3;9;1;8;3,83;CN(C)Cc1cccc2nc(C(=O)NCCCCN3CCN(c4cc(C(F)(F)F)nc(C(C)(C)C)n4)CC3)cn12;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323115;113777;None;0;Human;Binding;Ki;=;809,00;6,09;-25;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;546,3;8;1;6;4,73;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)C3CCN(c4ccccc4)CC3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323116;113778;None;0;Human;Binding;Ki;=;337,00;6,47;-9;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;560,3;9;1;6;4,72;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)C3CCN(Cc4ccccc4)CC3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL3323117;113779;None;0;Human;Binding;Ki;=;1510,00;5,82;-162;2;Displacement of [125I]IABN from human D2LR expressed in HEK293 cell membranes by gamma counting method;ChEMBL;545,3;8;1;5;5,79;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)[C@H]3CC[C@H](c4ccccc4)CC3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1021/jm500801r
CHEMBL332677;114116;None;0;Human;Binding;Ki;=;536,00;6,27;1;2;in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]-0437 as radioligand.;ChEMBL;305,2;5;1;5;3,30;CCCN(CCC)C1COc2c(ccc3sc(N)nc23)C1;https://dx.doi.org/10.1021/jm000087z
CHEMBL332677;114116;None;0;Human;Binding;Ki;=;3510,00;5,46;1;2;in vitro binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]spiperone as radioligand.;ChEMBL;305,2;5;1;5;3,30;CCCN(CCC)C1COc2c(ccc3sc(N)nc23)C1;https://dx.doi.org/10.1021/jm000087z
CHEMBL333085;114414;None;0;Human;Binding;Ki;=;1330,00;5,88;-48;2;Displacement of [3H]-raclopride fromd human Dopamine receptor D2A expressed in LtK- cells;ChEMBL;341,2;2;0;2;5,11;COc1ccccc1-c1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960189i
CHEMBL333134;114446;None;0;Human;Binding;Ki;=;311,00;6,51;-5;3;Displacement of [3H]-raclopride fromd human Dopamine receptor D2A expressed in LtK- cells;ChEMBL;277,1;1;0;2;3,64;CC(=O)c1cccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960189i
CHEMBL3335470;114567;None;0;Human;Binding;Ki;=;30,00;7,52;-39;2;Displacement of [3H]-raclopride from human D2long receptor expressed in HEK293Galpha15 cells after 120 mins by scintillation counting analysis;ChEMBL;423,2;5;2;4;3,32;N#Cc1cc(N2CCN(CC[C@H]3CC[C@H](NC(N)=O)CC3)CC2)cc(C(F)(F)F)c1;https://dx.doi.org/10.1021/ml500201u
CHEMBL3335471;114568;None;0;Human;Binding;Ki;=;5,40;8,27;-8;2;Displacement of [3H]-raclopride from human D2long receptor expressed in HEK293Galpha15 cells after 120 mins by scintillation counting analysis;ChEMBL;437,2;6;2;5;2,72;N#Cc1cc(N2CCN(CC[C@H]3CC[C@H](NC(=O)CN)CC3)CC2)cc(C(F)(F)F)c1;https://dx.doi.org/10.1021/ml500201u
CHEMBL3335472;114569;None;0;Human;Binding;Ki;=;37,00;7,43;-54;2;Displacement of [3H]-raclopride from human D2long receptor expressed in HEK293Galpha15 cells after 120 mins by scintillation counting analysis;ChEMBL;459,2;6;2;5;2,44;N#Cc1cc(N2CCN(CC[C@H]3CC[C@H](NS(N)(=O)=O)CC3)CC2)cc(C(F)(F)F)c1;https://dx.doi.org/10.1021/ml500201u
CHEMBL3335538;114582;None;0;Human;Binding;Ki;=;5500,00;5,26;-128;3;Inhibition of human dopamine D2L receptor;ChEMBL;365,2;6;0;3;4,42;FC(F)(F)Oc1ccc(CN2CCOC(CCc3ccccc3)C2)cc1;https://dx.doi.org/10.1021/ml500267c
CHEMBL3335539;114583;None;0;Human;Binding;IC50;=;16500,00;4,78;-;3;Inhibition of human dopamine D2L receptor;ChEMBL;311,2;6;0;3;3,53;COc1ccc(CN2CCOC(CCc3ccccc3)C2)cc1;https://dx.doi.org/10.1021/ml500267c
CHEMBL3335554;114590;None;0;Human;Binding;Ki;=;5500,00;5,26;-85;3;Inhibition of human dopamine D2L receptor;ChEMBL;365,2;6;0;3;4,42;FC(F)(F)Oc1ccc(CN2CCO[C@H](CCc3ccccc3)C2)cc1;https://dx.doi.org/10.1021/ml500267c
CHEMBL3335555;114591;None;0;Human;Binding;IC50;=;16500,00;4,78;-;3;Inhibition of human dopamine D2L receptor;ChEMBL;297,2;5;1;3;3,23;Oc1ccc(CN2CCO[C@H](CCc3ccccc3)C2)cc1;https://dx.doi.org/10.1021/ml500267c
CHEMBL333725;114612;None;0;Human;Binding;Ki;=;1010,00;6,00;-2;2;Displacement of [3H]-raclopride fromd human Dopamine receptor D2A expressed in LtK- cells;ChEMBL;279,2;1;1;2;3,92;CC(C)N1CCc2cccc3c2[C@H]1Cc1cccc(O)c1-3;https://dx.doi.org/10.1021/jm960189i
CHEMBL333784;114652;None;0;Human;Binding;Ki;=;1000,00;6,00;-251;8;Binding affinity towards Dopamine receptor D2 (human cloned receptor) in CHO cells using [125I]iodosulpiride radioligand.;ChEMBL;404,1;5;0;3;4,27;CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2ccc(Cl)c(Cl)c2)CC1;https://dx.doi.org/10.1021/jm991151j
CHEMBL333836;114796;None;0;Human;Binding;Ki;=;195,00;6,71;-25;3;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;383,1;2;0;4;3,67;CN1CCc2cccc3c2[C@H]1Cc1cccc(OS(=O)(=O)C(F)(F)F)c1-3;https://dx.doi.org/10.1021/jm960189i
CHEMBL334116;114881;None;0;Human;Binding;Ki;=;1040,00;5,98;1;2;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;413,1;3;0;5;3,68;COc1c(OS(=O)(=O)C(F)(F)F)ccc2c1-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL3344356;115220;None;0;Human;Binding;Ki;=;88,02;7,05;-1;2;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;287,1;1;1;4;3,12;COc1cc2c(cc1O)[C@@H]1Cc3sccc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344456;115250;None;0;Human;Binding;Ki;=;40,83;7,39;-1;3;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;315,1;2;1;4;3,68;CCc1cc2c(s1)C[C@H]1c3cc(O)c(OC)cc3CCN1C2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344457;115251;None;0;Human;Binding;Ki;=;38,63;7,41;1;2;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;329,1;3;1;4;4,07;CCCc1cc2c(s1)C[C@H]1c3cc(O)c(OC)cc3CCN1C2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344458;115252;None;0;Human;Binding;Ki;=;17,61;7,75;2;4;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;343,2;4;1;4;4,46;CCCCc1cc2c(s1)C[C@H]1c3cc(O)c(OC)cc3CCN1C2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344459;115253;None;0;Human;Binding;Ki;=;7,54;8,12;2;4;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;343,2;3;1;4;4,32;COc1cc2c(cc1O)[C@@H]1Cc3sc(CC(C)C)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344460;115254;None;0;Human;Binding;Ki;=;46,70;7,33;2;2;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;357,2;5;1;4;4,85;CCCCCc1cc2c(s1)C[C@H]1c3cc(O)c(OC)cc3CCN1C2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344461;115255;None;0;Human;Binding;Ki;=;79,54;7,10;-;1;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;357,2;4;1;4;4,71;COc1cc2c(cc1O)[C@@H]1Cc3sc(CCC(C)C)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344462;115256;None;0;Human;Binding;Ki;=;29,10;7,54;14;2;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;357,2;4;1;4;4,71;CCC(C)Cc1cc2c(s1)C[C@H]1c3cc(O)c(OC)cc3CCN1C2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344463;115257;None;0;Human;Binding;Ki;=;189,99;6,72;3;2;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;357,2;2;1;4;4,71;COc1cc2c(cc1O)[C@@H]1Cc3sc(CC(C)(C)C)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344465;115258;None;0;Human;Binding;Ki;=;34,23;7,47;11;3;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;355,2;3;1;4;4,46;COc1cc2c(cc1O)[C@@H]1Cc3sc(CC4CCC4)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344466;115259;None;0;Human;Binding;Ki;=;11,51;7,94;5;3;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;341,1;3;1;4;4,07;COc1cc2c(cc1O)[C@@H]1Cc3sc(CC4CC4)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344467;115260;None;0;Human;Binding;Ki;=;34,36;7,46;-2;3;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;349,1;3;1;4;3,90;COc1cc2c(cc1O)[C@@H]1Cc3sc(CCCl)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344468;115261;None;0;Human;Binding;Ki;=;18,38;7,74;4;3;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;363,1;4;1;4;4,29;COc1cc2c(cc1O)[C@@H]1Cc3sc(CCCCl)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344469;115262;None;0;Human;Binding;Ki;=;16,49;7,78;2;3;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;363,1;3;1;4;4,29;COc1cc2c(cc1O)[C@@H]1Cc3sc(CC(C)Cl)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL3344470;115263;None;0;Human;Binding;Ki;=;12,02;7,92;54;3;Displacement of [3H]Spiperone from D2 receptor (unknown origin) transfected in HEK293T cells after 50 mins by liquid scintillation counting analysis;ChEMBL;377,1;5;1;4;4,68;COc1cc2c(cc1O)[C@@H]1Cc3sc(CCCCCl)cc3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2014.09.024
CHEMBL334472;115267;None;32;Human;Binding;Ki;=;285,00;6,54;-15;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;205,1;3;2;2;2,25;CCCNC1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL334472;115267;None;32;Human;Binding;Ki;=;0,50;9,30;-15;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;205,1;3;2;2;2,25;CCCNC1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL334529;115277;None;5;Human;Binding;Ki;=;630,96;6,20;-131;15;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;415,2;9;0;4;4,65;CCCN(CCC)C1CCc2cc(CS(=O)(=O)c3ccc(OC)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL334529;115277;3H-SPIPERONE;5;Human;Binding;pKi;=;138,04;6,86;-131;15;-;PDSP KiDatabase;415,2;9;0;4;4,65;CCCN(CCC)C1CCc2cc(CS(=O)(=O)c3ccc(OC)cc3)ccc2C1;-
CHEMBL334529;115277;125I-IODOSULPRIDE;5;Human;Binding;pKi;=;63,10;7,20;-131;15;-;PDSP KiDatabase;415,2;9;0;4;4,65;CCCN(CCC)C1CCc2cc(CS(=O)(=O)c3ccc(OC)cc3)ccc2C1;-
CHEMBL334545;115281;None;0;Human;Binding;Ki;=;295,12;6,53;-269;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;299,2;9;1;3;3,74;Cc1ccc(OCCNCCCOc2ccccc2C)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL334545;115281;None;0;Human;Binding;Ki;=;296,00;6,53;-269;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;299,2;9;1;3;3,74;Cc1ccc(OCCNCCCOc2ccccc2C)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL334956;115419;None;0;Human;Binding;Ki;=;20,00;7,70;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;403,2;5;1;3;4,08;O=C1c2ccccc2C(=O)N1CCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL334989;115433;None;0;Human;Binding;Ki;=;364,00;6,44;-77;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;283,2;9;1;2;3,99;Cc1ccc(CCCNCCCOc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL335259;115574;None;0;Human;Binding;Ki;=;25,00;7,60;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;445,2;7;1;3;5,17;Cc1cccc2c1C(=O)N(CCCCCN1CC=C(c3c[nH]c4ccc(F)cc34)CC1)C2=O;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL3353894;115782;None;0;Human;Binding;Ki;=;64,00;7,19;-2;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;377,2;7;0;6;3,03;COc1ccccc1N1CCN(CCCc2cn(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353895;115783;None;0;Human;Binding;Ki;=;53,60;7,27;-8;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;391,2;8;0;6;3,42;COc1ccccc1N1CCN(CCCCc2cn(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3353895;115783;None;0;Human;Binding;Ki;=;30,90;7,51;-8;3;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;391,2;8;0;6;3,42;COc1ccccc1N1CCN(CCCCc2cn(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353896;115784;None;0;Human;Binding;Ki;=;19,40;7,71;-6;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;405,3;9;0;6;3,81;COc1ccccc1N1CCN(CCCCCc2cn(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353897;115785;None;0;Human;Binding;Ki;=;79,30;7,10;-2;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;428,2;7;0;7;3,58;COc1ccccc1N1CCN(CCCc2cn(-c3cccc4cnccc34)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353898;115786;None;0;Human;Binding;Ki;=;42,30;7,37;-11;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;442,2;8;0;7;3,97;COc1ccccc1N1CCN(CCCCc2cn(-c3cccc4cnccc34)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353899;115787;None;0;Human;Binding;Ki;=;17,70;7,75;-9;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;456,3;9;0;7;4,36;COc1ccccc1N1CCN(CCCCCc2cn(-c3cccc4cnccc34)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353900;115788;None;0;Human;Binding;Ki;=;158,00;6,80;-21;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;459,2;8;0;7;4,76;COc1ccccc1N1CCN(CCCc2cn(-c3ccc(-c4ccsc4)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353901;115789;None;0;Human;Binding;Ki;=;94,30;7,03;-72;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;473,2;9;0;7;5,15;COc1ccccc1N1CCN(CCCCc2cn(-c3ccc(-c4ccsc4)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353902;115790;None;0;Human;Binding;Ki;=;109,00;6,96;-17;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;487,2;10;0;7;5,54;COc1ccccc1N1CCN(CCCCCc2cn(-c3ccc(-c4ccsc4)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353903;115791;None;0;Human;Binding;Ki;=;73,50;7,13;-2;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;395,2;7;0;6;3,17;COc1ccccc1N1CCN(CCCc2cn(-c3ccc(F)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353904;115792;None;0;Human;Binding;Ki;=;46,70;7,33;-7;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;409,2;8;0;6;3,56;COc1ccccc1N1CCN(CCCCc2cn(-c3ccc(F)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353905;115793;None;0;Human;Binding;Ki;=;23,70;7,62;-7;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;423,2;9;0;6;3,95;COc1ccccc1N1CCN(CCCCCc2cn(-c3ccc(F)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353906;115794;None;0;Human;Binding;Ki;=;272,00;6,57;-2;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;407,2;8;0;7;3,04;COc1ccccc1N1CCN(CCCc2cn(-c3ccccc3OC)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353907;115795;None;0;Human;Binding;Ki;=;139,00;6,86;-5;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;421,2;9;0;7;3,43;COc1ccccc1N1CCN(CCCCc2cn(-c3ccccc3OC)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353908;115796;None;0;Human;Binding;Ki;=;62,70;7,20;-3;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;435,3;10;0;7;3,82;COc1ccccc1N1CCN(CCCCCc2cn(-c3ccccc3OC)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353909;115797;None;0;Human;Binding;Ki;=;162,00;6,79;-5;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;420,3;8;0;7;3,10;COc1ccccc1N1CCN(CCCc2cn(-c3ccc(N(C)C)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353910;115798;None;0;Human;Binding;Ki;=;171,00;6,77;-18;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;434,3;9;0;7;3,49;COc1ccccc1N1CCN(CCCCc2cn(-c3ccc(N(C)C)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353911;115799;None;0;Human;Binding;Ki;=;62,60;7,20;-9;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;448,3;10;0;7;3,88;COc1ccccc1N1CCN(CCCCCc2cn(-c3ccc(N(C)C)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353912;115800;None;0;Human;Binding;Ki;=;44,10;7,36;-4;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;423,2;8;0;7;3,75;COc1ccccc1N1CCN(CCCc2cn(-c3ccc(SC)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353913;115801;None;0;Human;Binding;Ki;=;37,70;7,42;-18;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;437,2;9;0;7;4,14;COc1ccccc1N1CCN(CCCCc2cn(-c3ccc(SC)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353914;115802;None;0;Human;Binding;Ki;=;26,60;7,58;-11;4;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;451,2;10;0;7;4,53;COc1ccccc1N1CCN(CCCCCc2cn(-c3ccc(SC)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353915;115803;None;0;Human;Binding;Ki;=;12,80;7,89;-1;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;393,2;7;1;7;2,74;COc1ccccc1N1CCN(CCCc2cn(-c3ccccc3O)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL3353916;115804;None;0;Human;Binding;Ki;=;9,40;8,03;-3;2;Displacement of of [125I]-IABN from human D2 long receptor expressed in HEK293 cell membranes after 60 mins by filtration binding assay;ChEMBL;407,2;8;1;7;3,13;COc1ccccc1N1CCN(CCCCc2cn(-c3ccccc3O)nn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.12.023
CHEMBL335392;115805;None;0;Human;Binding;Ki;=;190,00;6,72;-15;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;219,2;3;1;2;2,59;CCCN(C)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL335392;115805;None;0;Human;Binding;Ki;=;0,67;9,17;-15;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;219,2;3;1;2;2,59;CCCN(C)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL3354065;115836;None;3;Human;Binding;Ki;=;676,08;6,17;-691;13;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;328,3;7;0;2;4,26;CCCCC1CCN(CCCN2C(=O)CCc3ccccc32)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL3358098;116238;None;0;Human;Binding;Ki;=;5596,00;5,25;-354;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;389,2;7;1;5;2,96;O=C(NCCCCN1CCN(c2ccccn2)CC1)c1cc2ccccc2cn1;https://dx.doi.org/10.1021/jm501119j
CHEMBL3358100;116240;None;0;Human;Binding;Ki;=;286,00;6,54;-57;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;402,2;7;1;4;3,88;Cc1cccc(N2CCN(CCCCNC(=O)c3cc4ccccc4cn3)CC2)c1;https://dx.doi.org/10.1021/jm501119j
CHEMBL3358102;116242;None;0;Human;Binding;Ki;=;219,00;6,66;-128;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;420,3;8;1;5;3,52;COc1cccc(N2CCN(CCCCNC(=O)c3cc4ccccc4n3C)CC2)c1;https://dx.doi.org/10.1021/jm501119j
CHEMBL3358104;116244;None;0;Human;Binding;Ki;=;53,00;7,28;-263;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;444,2;7;2;3;4,52;O=C(NCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/jm501119j
CHEMBL3358105;116245;None;0;Human;Binding;Ki;=;76,00;7,12;-251;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;395,2;7;1;4;3,90;O=C(NCCCCN1CCN(c2ccccc2F)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm501119j
CHEMBL335844;116259;None;0;Human;Binding;Ki;=;12,00;7,92;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;449,2;7;1;3;5,00;O=C1c2cccc(F)c2C(=O)N1CCCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL3358493;116265;None;0;Human;Binding;Ki;=;85,00;7,07;-213;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;405,2;7;1;4;4,38;Cc1cccc(N2CCN(CCCCNC(=O)c3cc4ccccc4o3)CC2)c1C;https://dx.doi.org/10.1021/jm501119j
CHEMBL3358498;116270;None;0;Human;Binding;Ki;=;160,00;6,80;-52;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;406,2;7;1;4;3,71;O=C(NCCCCN1CCN(c2cccc(F)c2)CC1)c1cc2ccccc2cn1;https://dx.doi.org/10.1021/jm501119j
CHEMBL3358506;116278;None;0;Human;Binding;Ki;=;3412,00;5,47;-43;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;406,3;7;2;4;3,44;Cc1cccc(N2CCN(CCCCNC(=O)[C@H]3CCc4ccccc4N3)CC2)c1;https://dx.doi.org/10.1021/jm501119j
CHEMBL3358512;116284;None;0;Human;Binding;Ki;=;58,00;7,24;-81;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;387,2;7;1;3;4,17;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm501119j
CHEMBL3358513;116285;None;0;Human;Binding;Ki;=;1,00;9,00;39;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;388,2;7;1;4;3,57;O=C(NCCCCN1CCN(c2cnc3ccccc3c2)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm501119j
CHEMBL335971;116421;None;1;Human;Binding;Ki;=;58882,00;4,23;-42;2;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;219,2;4;1;2;2,55;CCCN[C@@H]1CCc2ccc(OC)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL336295;116610;None;0;Human;Binding;Ki;=;550,00;6,26;-23;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;329,2;7;0;3;4,57;CCCN(CCc1cccs1)[C@@H]1CCc2ccc(OC)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL336652;116658;None;0;Human;Binding;Ki;=;836,00;6,08;-85;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;205,1;3;2;2;2,25;CCCNC1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL336652;116658;None;0;Human;Binding;Ki;=;3,80;8,42;-85;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;205,1;3;2;2;2,25;CCCNC1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL336771;116677;None;0;Human;Binding;Ki;=;10,00;8,00;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;449,2;7;1;3;5,00;O=C1c2ccc(F)cc2C(=O)N1CCCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL336851;116690;None;0;Human;Binding;Ki;=;547,00;6,26;-33;3;Tested for the inhibitory activity against Dopamine D2 receptor in infected Sf9 cells;ChEMBL;371,1;5;1;2;3,91;CCCN(C/C=C/I)C1CCc2cc(O)ccc2C1;https://dx.doi.org/10.1021/jm00050a021
CHEMBL336851;116690;None;0;Human;Binding;Ki;=;9,70;8,01;-33;3;Tested for the inhibitory activity against D2H (high-affinity states) receptor in infected HEK 293 cells.;ChEMBL;371,1;5;1;2;3,91;CCCN(C/C=C/I)C1CCc2cc(O)ccc2C1;https://dx.doi.org/10.1021/jm00050a021
CHEMBL336930;116697;None;0;Human;Binding;Ki;=;140,00;6,85;-25;5;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL336930;116697;None;0;Human;Binding;Ki;=;84,00;7,08;-25;5;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL336962;116701;None;2;Human;Binding;Ki;=;3206,00;5,49;-1;2;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;219,2;4;1;2;2,55;CCCN[C@H]1CCc2ccc(OC)cc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL336971;116706;None;0;Human;Binding;Ki;=;316,23;6,50;-316;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;392,3;9;1;3;5,65;CCCN(CCC)[C@@H]1CCc2cc(CCc3ccc(/C(C)=N\O)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL337531;116810;None;0;Human;Binding;Ki;=;48,00;7,32;-120;5;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;559;7;1;3;4,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[te]1;https://dx.doi.org/10.1021/jm025558r
CHEMBL337531;116810;None;0;Human;Binding;Ki;=;91,00;7,04;-120;5;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;559;7;1;3;4,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[te]1;https://dx.doi.org/10.1021/jm025558r
CHEMBL337627;116827;None;0;Human;Binding;Ki;=;227,00;6,64;-162;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;321,1;9;1;3;4,49;Clc1ccc(OCCNCCCSc2ccccc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL337951;116890;None;0;Human;Binding;IC50;=;228,00;6,64;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;390,1;5;0;3;4,93;COc1c(Cl)cc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)cc1Cl;https://dx.doi.org/10.1021/jm990562x
CHEMBL337983;116894;None;0;Human;Binding;IC50;=;752,00;6,12;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;322,2;5;0;3;3,62;COc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL338183;116931;None;0;Human;Binding;IC50;=;128,00;6,89;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;340,2;4;0;2;4,57;Cc1cc(Cl)ccc1N1CCN(C[C@H]2C[C@@H]2c2ccccc2)CC1;https://dx.doi.org/10.1021/jm990562x
CHEMBL338270;116941;None;0;Human;Binding;Ki;=;25,00;7,60;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;459,2;9;1;3;5,64;O=C1c2ccccc2C(=O)N1CCCCCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL338337;116957;None;0;Human;Binding;IC50;=;45,00;7,35;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;320,2;4;0;2;4,23;Cc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c(C)c1;https://dx.doi.org/10.1021/jm990562x
CHEMBL338337;116957;None;0;Human;Binding;Ki;=;540,00;6,27;-;2;Displacement of [3H]YM-09151-2 from human dopamine D2S receptor in membrane suspensions by liquid scintillation counter;ChEMBL;320,2;4;0;2;4,23;Cc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c(C)c1;https://dx.doi.org/10.1016/j.bmc.2008.08.061
CHEMBL338496;116989;None;0;Human;Binding;Ki;=;630,96;6,20;-79;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;408,3;9;0;3;5,23;CCCN(CCC)C1CCc2cc(CN(C(C)=O)c3ccc(OC)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL338606;117015;None;0;Human;Binding;Ki;=;27,00;7,57;-50;5;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;411,2;9;1;4;3,57;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.09.142
CHEMBL338606;117015;None;0;Human;Binding;Ki;=;20,70;7,68;-50;5;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;411,2;9;1;4;3,57;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL338606;117015;None;0;Human;Binding;Ki;=;21,00;7,68;-50;5;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;411,2;9;1;4;3,57;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.09.142
CHEMBL338841;117068;None;0;Human;Binding;Ki;=;161,00;6,79;-134;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;519,1;9;1;4;4,03;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2cccc(I)c2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL338938;117082;None;0;Human;Binding;Ki;=;6309,57;5,20;-251;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;409,3;9;1;3;4,76;CCCN(CCC)C1CCc2cc(CN(C(N)=O)c3ccc(OC)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL339033;117097;None;0;Human;Binding;Ki;=;403,00;6,39;-1;2;Displacement of [3H]spiperone from CHO-K1 cell membranes expressing human dopamine receptor D2;ChEMBL;329,2;6;1;4;2,86;O[C@H](CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00076a022
CHEMBL339098;117110;None;0;Human;Binding;Ki;=;25,00;7,60;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;431,2;7;1;3;4,86;O=C1c2cccc(F)c2C(=O)N1CCCCCN1CC=C(c2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL339674;117369;None;1;Human;Binding;IC50;=;68,00;7,17;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;324,2;4;0;2;4,06;Cc1cc(F)ccc1N1CCN(C[C@H]2C[C@@H]2c2ccccc2)CC1;https://dx.doi.org/10.1021/jm990562x
CHEMBL339963;117547;None;0;Human;Binding;Ki;=;101,00;7,00;1;2;Displacement of [3H]spiperone from CHO-K1 cell membranes expressing human dopamine receptor D2;ChEMBL;329,2;6;1;4;2,86;O[C@@H](CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00076a022
CHEMBL340220;117876;None;0;Human;Binding;Ki;=;20,00;7,70;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;445,2;7;1;3;5,17;Cc1ccc2c(c1)C(=O)N(CCCCCN1CC=C(c3c[nH]c4ccc(F)cc34)CC1)C2=O;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL340608;118149;None;0;Human;Binding;Ki;=;63,00;7,20;-83;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;519,1;9;1;4;4,03;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccccc2I)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL340712;118169;None;0;Human;Binding;Ki;=;76,40;7,12;-151;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;519,1;9;1;4;4,03;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(I)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL3407518;118177;None;0;Human;Binding;Ki;=;14,00;7,85;10;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;557,2;9;1;6;5,80;O=C1CCc2ccc(OCCCCN3CCC(c4cn(S(=O)(=O)c5ccccc5)c5ccccc45)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL340816;118213;None;0;Human;Binding;Ki;=;124,40;6,91;-1;6;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;351,2;6;0;2;5,20;O=C(CCCN1C2CCC1CC(c1ccccc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL340816;118213;None;0;Human;Binding;Ki;=;124,40;6,91;-1;6;Binding affinity for dopamine D2 receptor;ChEMBL;351,2;6;0;2;5,20;O=C(CCCN1C2CCC1CC(c1ccccc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.09.046
CHEMBL340816;118213;UNDEFINED;0;Human;Binding;pKi;=;124,40;6,91;-1;6;-;PDSP KiDatabase;351,2;6;0;2;5,20;O=C(CCCN1C2CCC1CC(c1ccccc1)C2)c1ccc(F)cc1;-
CHEMBL340851;118219;None;0;Human;Binding;Ki;=;32,00;7,50;-1;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;499,3;12;1;5;5,01;COc1ccccc1N1CCN(CCCCNC(=O)/C=C/c2ccc(OCc3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL3409232;118298;None;0;Human;Binding;Ki;=;73,00;7,14;-3;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;505,3;9;1;4;6,52;O=C1CCc2ccc(OCCCCN3CC=C(c4cn(Cc5ccccc5)c5ccccc45)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409233;118299;None;0;Human;Binding;Ki;=;40,00;7,40;1;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;555,2;9;1;6;5,71;O=C1CCc2ccc(OCCCCN3CC=C(c4cn(S(=O)(=O)c5ccccc5)c5ccccc45)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409234;118300;None;0;Human;Binding;Ki;=;4,80;8,32;31;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;507,3;9;1;4;6,61;O=C1CCc2ccc(OCCCCN3CCC(c4cn(Cc5ccccc5)c5ccccc45)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409235;118301;None;0;Human;Binding;Ki;=;70,00;7,16;2;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;467,3;11;2;4;5,57;O=C1CCc2ccc(OCCCCNCCc3cn(Cc4ccccc4)c4ccccc34)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409236;118302;None;0;Human;Binding;Ki;=;120,00;6,92;-2;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;517,2;11;2;6;4,75;O=C1CCc2ccc(OCCCCNCCc3cn(S(=O)(=O)c4ccccc4)c4ccccc34)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409237;118303;None;0;Human;Binding;Ki;=;20,00;7,70;-1;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;508,3;9;1;5;5,56;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4ccn5Cc4ccccc4)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409238;118304;None;0;Human;Binding;Ki;=;1,30;8,89;-3;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;558,2;9;1;7;4,74;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4ccn5S(=O)(=O)c4ccccc4)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409239;118305;None;0;Human;Binding;Ki;=;11,00;7,96;4;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;526,3;9;1;5;5,70;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4ccn5Cc4ccccc4F)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409240;118306;None;0;Human;Binding;Ki;=;6,10;8,21;3;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;526,3;9;1;5;5,70;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4ccn5Cc4cccc(F)c4)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409241;118307;None;0;Human;Binding;Ki;=;12,00;7,92;8;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;526,3;9;1;5;5,70;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4ccn5Cc4ccc(F)cc4)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409242;118308;None;0;Human;Binding;Ki;=;1,30;8,89;5;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;542,2;9;1;5;6,21;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4ccn5Cc4cccc(Cl)c4)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409243;118309;None;0;Human;Binding;Ki;=;31,00;7,51;19;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;465,2;9;1;4;5,35;NC(=O)c1ccccc1OCCCN1CC=C(c2cn(Cc3ccccc3)c3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409244;118310;None;0;Human;Binding;Ki;=;160,00;6,80;-4;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;515,2;9;1;6;4,54;NC(=O)c1ccccc1OCCCN1CC=C(c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409245;118311;None;0;Human;Binding;Ki;=;29,00;7,54;16;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;467,3;9;1;4;5,44;NC(=O)c1ccccc1OCCCN1CCC(c2cn(Cc3ccccc3)c3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409246;118312;None;0;Human;Binding;Ki;=;62,00;7,21;-1;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;517,2;9;1;6;4,63;NC(=O)c1ccccc1OCCCN1CCC(c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409247;118313;None;0;Human;Binding;Ki;=;270,00;6,57;2;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;427,2;11;2;4;4,39;NC(=O)c1ccccc1OCCCNCCc1cn(Cc2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409248;118314;None;0;Human;Binding;Ki;=;180,00;6,75;-2;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;477,2;11;2;6;3,58;NC(=O)c1ccccc1OCCCNCCc1cn(S(=O)(=O)c2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409249;118315;None;0;Human;Binding;Ki;=;95,00;7,02;-3;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;468,3;9;1;5;4,38;NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3Cc2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409250;118316;None;0;Human;Binding;Ki;=;21,00;7,68;1;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;486,2;9;1;5;4,52;NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3Cc2ccccc2F)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409251;118317;None;0;Human;Binding;Ki;=;45,00;7,35;-4;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;486,2;9;1;5;4,52;NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3Cc2cccc(F)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409252;118318;None;0;Human;Binding;Ki;=;44,00;7,36;1;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;486,2;9;1;5;4,52;NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409253;118319;None;0;Human;Binding;Ki;=;76,00;7,12;-6;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;502,2;9;1;5;5,03;NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3Cc2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409254;118320;None;0;Human;Binding;Ki;=;23,00;7,64;-10;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;544,2;8;1;7;4,35;O=C1CCc2ccc(OCCCN3CCN(c4cccc5c4ccn5S(=O)(=O)c4ccccc4)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409255;118321;None;0;Human;Binding;Ki;=;220,00;6,66;-57;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;515,2;8;0;7;5,22;O=S(=O)(c1ccccc1)n1ccc2c(N3CCN(CCCOc4ccc5ccoc5c4)CC3)cccc21;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409256;118322;None;0;Human;Binding;Ki;=;6,30;8,20;-63;10;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;518,2;9;1;7;3,57;NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409256;118322;None;0;Human;Binding;Ki;=;6,30;8,20;-63;10;Displacement of [3H]methylspiperone from human D2S receptor expressed in HEK293 cells;ChEMBL;518,2;9;1;7;3,57;NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409257;118323;None;0;Human;Binding;Ki;=;78,00;7,11;-27;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;532,2;10;1;7;3,96;NC(=O)c1ccccc1OCCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409258;118324;None;0;Human;Binding;Ki;=;110,00;6,96;-64;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;533,2;10;0;7;5,26;CC(C)Oc1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409259;118325;None;0;Human;Binding;Ki;=;120,00;6,92;-10;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;547,3;11;0;7;5,65;CC(C)Oc1ccccc1OCCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409260;118326;None;0;Human;Binding;Ki;=;290,00;6,54;-38;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;475,2;8;0;6;4,47;O=S(=O)(c1ccccc1)n1ccc2c(N3CCN(CCCOc4ccccc4)CC3)cccc21;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409261;118327;None;0;Human;Binding;Ki;=;62,00;7,21;-3;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;489,2;9;0;6;4,86;O=S(=O)(c1ccccc1)n1ccc2c(N3CCN(CCCCOc4ccccc4)CC3)cccc21;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409262;118328;None;0;Human;Binding;Ki;=;67,00;7,17;-12;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;493,2;8;0;6;4,61;O=S(=O)(c1ccccc1)n1ccc2c(N3CCN(CCCOc4ccc(F)cc4)CC3)cccc21;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL3409263;118329;None;0;Human;Binding;Ki;=;47,00;7,33;-6;2;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;507,2;9;0;6;5,00;O=S(=O)(c1ccccc1)n1ccc2c(N3CCN(CCCCOc4ccc(F)cc4)CC3)cccc21;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
CHEMBL34095;118339;None;2;Human;Binding;Ki;=;350,00;6,46;-10;4;Affinity towards Dopamine receptor D2;ChEMBL;373,1;3;2;3;4,04;C=CCN1CCc2c(cc(O)c(O)c2Br)[C@@H](c2ccccc2)C1;https://dx.doi.org/10.1021/jm9800292
CHEMBL341225;118523;None;0;Human;Binding;Ki;=;5754,40;5,24;-213;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;363,1;9;1;3;4,20;Cc1ccc(OCCNCCCOc2ccc(Br)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL341225;118523;None;0;Human;Binding;Ki;=;5730,00;5,24;-213;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;363,1;9;1;3;4,20;Cc1ccc(OCCNCCCOc2ccc(Br)cc2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL341310;118534;None;0;Human;Binding;IC50;=;2,00;8,70;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;360,1;4;0;2;4,92;Clc1cccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)c1Cl;https://dx.doi.org/10.1021/jm990562x
CHEMBL341497;118589;None;0;Human;Binding;IC50;=;37,00;7,43;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;292,2;4;0;2;3,61;c1ccc([C@H]2C[C@@H]2CN2CCN(c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL342001;118844;None;0;Human;Binding;Ki;=;4300,00;5,37;-117;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2[nH]cc(CN3CCN(c4ccc(Cl)cc4)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL342001;118844;None;0;Human;Binding;Ki;=;2600,00;5,58;-117;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;350,1;3;1;3;4,01;N#Cc1ccc2[nH]cc(CN3CCN(c4ccc(Cl)cc4)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL342060;118850;None;0;Human;Binding;Ki;=;120,00;6,92;-38;6;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2ccn3nccc3c2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL342060;118850;None;0;Human;Binding;Ki;=;190,55;6,72;-38;6;Binding affinity to dopamine D2;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2ccn3nccc3c2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL342060;118850;None;0;Human;Binding;Ki;=;58,00;7,24;-38;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2ccn3nccc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL342060;118850;None;0;Human;Binding;Ki;=;190,00;6,72;-38;6;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2ccn3nccc3c2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL3423328;119000;None;0;Human;Binding;Ki;=;700,00;6,16;-346;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;451,2;6;1;10;0,99;Cn1c(=O)c2c(nc3n(CCCCN4CCN(c5ccccc5O)CC4)ccn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423329;119001;None;0;Human;Binding;Ki;=;265,00;6,58;-37;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;465,2;7;1;10;1,38;Cn1c(=O)c2c(nc3n(CCCCCN4CCN(c5ccccc5O)CC4)ccn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423330;119002;None;0;Human;Binding;Ki;=;430,00;6,37;-213;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;465,2;6;1;10;1,30;Cc1cn2c3c(=O)n(C)c(=O)n(C)c3nc2n1CCCCN1CCN(c2ccccc2O)CC1;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423331;119003;None;0;Human;Binding;Ki;=;468,00;6,33;-38;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;479,3;7;1;10;1,69;Cc1cn2c3c(=O)n(C)c(=O)n(C)c3nc2n1CCCCCN1CCN(c2ccccc2O)CC1;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423332;119004;None;0;Human;Binding;Ki;=;4,00;8,40;1;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;527,3;7;1;10;2,66;Cn1c(=O)c2c(nc3n(CCCCN4CCN(c5ccccc5O)CC4)c(-c4ccccc4)cn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423333;119005;None;0;Human;Binding;Ki;=;24,00;7,62;-2;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;541,3;8;1;10;3,05;Cn1c(=O)c2c(nc3n(CCCCCN4CCN(c5ccccc5O)CC4)c(-c4ccccc4)cn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423334;119006;None;0;Human;Binding;Ki;=;259,00;6,59;-3;4;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;483,2;7;0;9;2,33;Cn1c(=O)c2c(nc3n(CCCCCN4CCN(c5ccc(Cl)cc5)CC4)ccn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423335;119007;None;0;Human;Binding;Ki;=;123,00;6,91;-3;4;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;483,2;6;0;9;2,25;Cc1cn2c3c(=O)n(C)c(=O)n(C)c3nc2n1CCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423336;119008;None;0;Human;Binding;Ki;=;106,00;6,97;-1;4;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;497,2;7;0;9;2,64;Cc1cn2c3c(=O)n(C)c(=O)n(C)c3nc2n1CCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423337;119009;None;0;Human;Binding;Ki;=;23,00;7,64;1;4;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;545,2;7;0;9;3,61;Cn1c(=O)c2c(nc3n(CCCCN4CCN(c5ccc(Cl)cc5)CC4)c(-c4ccccc4)cn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423338;119010;None;0;Human;Binding;Ki;=;9,00;8,05;5;4;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;559,2;8;0;9;4,00;Cn1c(=O)c2c(nc3n(CCCCCN4CCN(c5ccc(Cl)cc5)CC4)c(-c4ccccc4)cn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423339;119011;None;0;Human;Binding;Ki;=;27,00;7,57;14;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;477,3;6;0;9;2,21;Cc1cccc(N2CCN(CCCCn3c(C)cn4c5c(=O)n(C)c(=O)n(C)c5nc34)CC2)c1C;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423340;119012;None;0;Human;Binding;Ki;=;59,00;7,23;-2;4;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;531,2;7;0;9;3,29;Cc1cn2c3c(=O)n(C)c(=O)n(C)c3nc2n1CCCCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423377;119013;None;0;Human;Binding;Ki;=;340,00;6,47;-169;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;493,2;7;1;11;0,74;Cn1c(=O)c2c(nc3n(CCCCCN4CCN(c5ccccc5O)CC4)c(=O)ccn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423378;119014;None;0;Human;Binding;Ki;=;68,00;7,17;-1;4;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;497,2;6;0;10;1,30;Cn1c(=O)c2c(nc3n(CCCCN4CCN(c5ccc(Cl)cc5)CC4)c(=O)ccn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423379;119015;None;0;Human;Binding;Ki;=;215,00;6,67;-2;3;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by microbeta plate reader based method;ChEMBL;511,2;7;0;10;1,69;Cn1c(=O)c2c(nc3n(CCCCCN4CCN(c5ccc(Cl)cc5)CC4)c(=O)ccn23)n(C)c1=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.046
CHEMBL3423400;119016;None;0;Human;Binding;Kd;=;5000,00;5,30;2;4;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;659,4;11;5;6;2,43;CCCC[C@H](NC(=O)[C@H]1CC[C@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1C[C@@H](N)C[C@H]1C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423401;119017;None;0;Human;Binding;Kd;=;6300,00;5,20;2;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;786,5;22;8;8;3,36;CCCC[C@H](NC(=O)CCCCCNC(=O)[C@H]1CC[C@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423402;119018;None;0;Human;Binding;Kd;=;7000,00;5,16;2;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as low affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;793,5;18;7;7;3,45;NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423402;119018;None;0;Human;Binding;Kd;=;240,00;6,62;2;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;793,5;18;7;7;3,45;NCCCC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H]1CCCN1C(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423403;119019;None;0;Human;Binding;Kd;=;280,00;6,55;9;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;790,4;18;6;7;3,25;NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)[C@@H]1CCCN1C(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423403;119019;None;0;Human;Binding;Kd;=;9000,00;5,05;9;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as low affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;790,4;18;6;7;3,25;NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)[C@@H]1CCCN1C(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423404;119020;None;0;Human;Binding;Kd;=;4700,00;5,33;-3;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;673,4;16;7;7;2,68;CCCC[C@H](NC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423405;119021;None;0;Human;Binding;Kd;=;20000,00;4,70;-1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as low affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;793,5;17;7;7;3,45;CCCC[C@H](NC(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1C[C@@H](N)C[C@H]1C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423405;119021;None;0;Human;Binding;Kd;=;600,00;6,22;-1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;793,5;17;7;7;3,45;CCCC[C@H](NC(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N1C[C@@H](N)C[C@H]1C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423406;119022;None;0;Human;Binding;Kd;=;16000,00;4,80;-1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as low affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;696,4;16;7;6;3,46;CCCC[C@H](NC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423406;119022;None;0;Human;Binding;Kd;=;900,00;6,05;-1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;696,4;16;7;6;3,46;CCCC[C@H](NC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423407;119023;None;0;Human;Binding;Kd;=;8000,00;5,10;1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as low affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;693,4;16;6;6;3,26;CCCC[C@H](NC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1ccc(F)c(F)c1)C(=O)N[C@@H](CCCCN)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423407;119023;None;0;Human;Binding;Kd;=;190,00;6,72;1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;693,4;16;6;6;3,26;CCCC[C@H](NC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1ccc(F)c(F)c1)C(=O)N[C@@H](CCCCN)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423408;119024;None;0;Human;Binding;Kd;=;13000,00;4,89;1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as low affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;772,4;17;6;7;3,11;CCCC[C@H](NC(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1C[C@@H](N)C[C@H]1C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423408;119024;None;0;Human;Binding;Kd;=;500,00;6,30;1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;772,4;17;6;7;3,11;CCCC[C@H](NC(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1C[C@@H](N)C[C@H]1C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423409;119025;None;0;Human;Binding;Kd;=;2000,00;5,70;1;3;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;788,5;22;7;7;3,79;CCCC[C@H](NC(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N[C@@H](CCCCN)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423410;119027;None;0;Human;Binding;Kd;=;200,00;6,70;6;2;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;790,4;18;6;7;3,25;NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)[C@H]1CCCN1C(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423410;119027;None;0;Human;Binding;Kd;=;4000,00;5,40;6;2;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as low affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;790,4;18;6;7;3,25;NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)[C@H]1CCCN1C(=O)CCCCCNC(=O)[C@H]1CC[C@@H]2c3[nH]c4ccccc4c3CCN2C1)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423411;119028;None;0;Human;Binding;Kd;=;14000,00;4,85;2;2;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as low affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;790,4;18;6;7;3,25;NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)[C@H]1CCCN1C(=O)CCCCCNC(=O)[C@@H]1CC[C@H]2c3[nH]c4ccccc4c3CCN2C1)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL3423411;119028;None;0;Human;Binding;Kd;=;400,00;6,40;2;2;Displacement of [3H]-YM09151-2 from dopamine D2 receptor (unknown origin) expressed in sheep striatum membranes assessed as high affinity constant after 2 hrs by scintillation counting analysis;ChEMBL;790,4;18;6;7;3,25;NCCCC[C@H](NC(=O)[C@H](Cc1ccc(F)c(F)c1)NC(=O)[C@H]1CCCN1C(=O)CCCCCNC(=O)[C@@H]1CC[C@H]2c3[nH]c4ccccc4c3CCN2C1)C(N)=O;https://dx.doi.org/10.1016/j.ejmech.2015.04.052
CHEMBL342536;119056;None;0;Human;Binding;Ki;=;183,00;6,74;-2;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;417,2;3;2;5;5,12;Clc1ccc2c(c1)C(NC1CCN(Cc3ccccc3)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL342630;119104;None;0;Human;Binding;Ki;=;5940,00;5,23;-6;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;207,1;2;1;1;2,68;CC(C)N[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL342630;119104;None;0;Human;Binding;Ki;=;2450,00;5,61;-6;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;207,1;2;1;1;2,68;CC(C)N[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL343411;119291;None;0;Human;Binding;Ki;=;1100,00;5,96;-72;2;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;389,1;7;0;4;3,73;O=C(CCCN1CCC(S(=O)(=O)c2ccccc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm011030v
CHEMBL343755;119341;None;0;Human;Binding;Ki;=;110,00;6,96;-245;16;Binding affinity towards Dopamine receptor D2;ChEMBL;335,2;1;1;2;3,05;C[C@H]1C[C@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1;https://dx.doi.org/10.1021/jm020153s
CHEMBL343880;119357;None;0;Human;Binding;Ki;=;5600,00;5,25;-1047;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2cc(CN3CCN(c4ccccc4)CC3)[nH]c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL343880;119357;None;0;Human;Binding;Ki;=;2500,00;5,60;-1047;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;316,2;3;1;3;3,36;N#Cc1ccc2cc(CN3CCN(c4ccccc4)CC3)[nH]c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL344270;119408;None;0;Human;Binding;Ki;=;790,00;6,10;-28;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;384,1;3;1;3;4,67;N#Cc1ccc2[nH]cc(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL344270;119408;None;0;Human;Binding;Ki;=;480,00;6,32;-28;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;384,1;3;1;3;4,67;N#Cc1ccc2[nH]cc(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL344531;119450;None;0;Human;Binding;Ki;=;199,53;6,70;-39;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;466,2;7;1;4;5,99;COc1ccc(S(=O)(=O)C(C)C)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL344602;119459;None;0;Human;Binding;Ki;=;1400,00;5,85;-186;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;384,1;3;1;3;4,67;N#Cc1ccc2cc(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)[nH]c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL344602;119459;None;0;Human;Binding;Ki;=;2000,00;5,70;-186;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;384,1;3;1;3;4,67;N#Cc1ccc2cc(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)[nH]c2c1;https://dx.doi.org/10.1021/jm0009989
CHEMBL344677;119468;None;0;Human;Binding;Ki;=;98,00;7,01;-8;6;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc3ccnn23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL344677;119468;None;0;Human;Binding;Ki;=;150,00;6,82;-8;6;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc3ccnn23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL344677;119468;None;0;Human;Binding;Ki;=;151,36;6,82;-8;6;Binding affinity to dopamine D2;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc3ccnn23)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL344677;119468;None;0;Human;Binding;Ki;=;34,00;7,47;-8;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc3ccnn23)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL345087;119518;None;0;Human;Binding;Ki;=;4720,00;5,33;-13;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;249,2;4;0;1;3,80;CCCN(C(C)C)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL345087;119518;None;0;Human;Binding;Ki;=;1530,00;5,82;-13;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;249,2;4;0;1;3,80;CCCN(C(C)C)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL345357;119551;None;0;Human;Binding;Ki;=;27542,29;4,56;-1318;4;Binding affinity to dopamine D2;ChEMBL;356,1;4;1;5;2,80;OCc1ccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn2c1;https://dx.doi.org/10.1021/jm0611152
CHEMBL345357;119551;None;0;Human;Binding;Ki;=;28000,00;4,55;-1318;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;356,1;4;1;5;2,80;OCc1ccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn2c1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL345357;119551;None;0;Human;Binding;Ki;=;22000,00;4,66;-1318;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;356,1;4;1;5;2,80;OCc1ccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn2c1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL345438;119561;None;0;Human;Binding;Ki;=;26,00;7,58;-2;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;389,2;3;0;3;3,40;Cc1ccc(CN2CCN(C3CCc4cccc5c4N(C3=O)C(C)C5)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL345458;119562;None;0;Human;Binding;Ki;=;1281,00;5,89;2;2;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;201,1;1;0;3;1,52;CN(C)[C@@H]1Cc2cccc3ncn(c23)C1;https://dx.doi.org/10.1021/jm960360q
CHEMBL345552;119575;None;0;Human;Binding;Ki;=;493,00;6,31;-114;3;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;337,2;3;1;4;2,65;Cc1ccc(N2CCN(Cc3ccc4c(c3)NC(=O)CO4)CC2)cc1;https://dx.doi.org/10.1021/jm990277d
CHEMBL345820;119603;None;0;Human;Binding;Ki;=;830,00;6,08;-1380;8;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;485,2;8;1;4;5,49;COc1c(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)ccc2ccccc12;https://dx.doi.org/10.1021/jm020952a
CHEMBL346129;119635;None;0;Human;Binding;Ki;=;5,90;8,23;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;393,2;7;1;4;3,86;Cc1ccccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1021/jm300603y
CHEMBL3461530;119639;None;2;Human;Binding;Ki;=;1606,00;5,79;-48;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;341,2;6;2;4;1,97;Cc1cccc(N2CCN(CCCNC(=O)c3cn[nH]c3C)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL346389;119668;None;3;Human;Binding;Ki;=;413,00;6,38;-97;12;Inhibition of human dopamine D2 receptor;ChEMBL;357,1;3;1;4;2,99;O=C1COc2cc(CN3CCN(c4ccc(Cl)cc4)CC3)ccc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL346389;119668;None;3;Human;Binding;Ki;=;413,00;6,38;-97;12;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;357,1;3;1;4;2,99;O=C1COc2cc(CN3CCN(c4ccc(Cl)cc4)CC3)ccc2N1;https://dx.doi.org/10.1021/jm990277d
CHEMBL346389;119668;None;3;Human;Binding;Ki;=;413,00;6,38;-97;12;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;357,1;3;1;4;2,99;O=C1COc2cc(CN3CCN(c4ccc(Cl)cc4)CC3)ccc2N1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL346398;119670;None;0;Human;Binding;Ki;=;52,50;7,28;-18;2;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;336,2;3;1;3;3,71;Cc1ccc(C2CCN(Cc3ccc4c(c3)NC(=O)CO4)CC2)cc1;https://dx.doi.org/10.1021/jm990277d
CHEMBL346512;119679;None;0;Human;Binding;Ki;=;622,00;6,21;-12;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;432,3;9;1;5;4,07;N#CCCCN(CCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL346692;119697;None;0;Human;Binding;Ki;=;135,00;6,87;-588;6;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;444,1;7;2;3;4,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/jm020952a
CHEMBL346692;119697;None;0;Human;Binding;Ki;=;202,30;6,69;-588;6;Displacement of [3H]-sulpiride from human D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting method;ChEMBL;444,1;7;2;3;4,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1039/C8MD00237A
CHEMBL346692;119697;None;0;Human;Binding;Ki;=;103,00;6,99;-588;6;Displacement of [125I]IABN from human D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;444,1;7;2;3;4,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/jm300482h
CHEMBL346692;119697;None;0;Human;Binding;Ki;=;103,00;6,99;-588;6;Displacement of [125I]-IABN from D2 receptor;ChEMBL;444,1;7;2;3;4,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/jm301017v
CHEMBL346692;119697;None;0;Human;Binding;Ki;=;103,00;6,99;-588;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;444,1;7;2;3;4,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL346692;119697;None;0;Human;Binding;Ki;=;3090,30;5,51;-588;6;Binding affinity to dopamine D2;ChEMBL;444,1;7;2;3;4,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/jm0611152
CHEMBL346692;119697;None;0;Human;Binding;Ki;=;760,00;6,12;-588;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;444,1;7;2;3;4,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL346805;119712;None;0;Human;Binding;Ki;=;9200,00;5,04;-3630;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;354,1;4;0;5;3,12;O=Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL346805;119712;None;0;Human;Binding;Ki;=;9500,00;5,02;-3630;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;354,1;4;0;5;3,12;O=Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL346898;119719;None;8;Human;Binding;Ki;=;17900,00;4,75;-4;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;264,2;5;0;2;3,45;CN(C)CCC(C#N)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL347155;119740;None;0;Human;Binding;Ki;=;800,00;6,10;-67;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;340,1;4;1;3;3,53;Clc1ccc(N2CCN(CCc3cc4ccc[nH]c-4n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL347290;119757;None;0;Human;Binding;Ki;=;1560,00;5,81;-512;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;449,2;9;1;4;4,72;COc1cccc(C(=O)NCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL347291;119758;None;0;Human;Binding;Ki;=;900,00;6,05;-33;3;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;336,2;5;1;4;2,94;COc1ccc(N2CCN(CCc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
CHEMBL347959;119830;None;0;Human;Binding;Ki;=;2596,00;5,59;-5;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;321,2;1;2;5;3,21;Cc1ccc2c(c1)C(NC1CCN(C)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL348285;119866;None;3;Human;Binding;Ki;=;355,00;6,45;6;2;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;187,1;1;1;3;1,18;CN[C@@H]1Cc2cccc3ncn(c23)C1;https://dx.doi.org/10.1021/jm960360q
CHEMBL348435;119886;None;0;Human;Binding;Ki;=;5590,00;5,25;-457;2;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;353,2;4;1;5;2,35;COc1ccc(N2CCN(Cc3ccc4c(c3)NC(=O)CO4)CC2)cc1;https://dx.doi.org/10.1021/jm990277d
CHEMBL348977;119943;None;0;Human;Binding;Ki;=;68,00;7,17;-85;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;375,2;5;1;4;3,86;Nc1ccccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCC3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL349034;119950;None;0;Human;Binding;IC50;=;79,00;7,10;-1;3;The in vitro intrinsic activity was measured at DA D2 receptor by measuring its ability to increase [3H]thymidine uptake in CHO-K1 cells transfected with the Dopamine receptor D2;ChEMBL;383,2;6;1;5;3,80;Fc1ccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL349034;119950;None;0;Human;Binding;Ki;=;8,50;8,07;-1;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;383,2;6;1;5;3,80;Fc1ccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL349057;119954;None;0;Human;Binding;Ki;=;16,00;7,80;-5;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;395,2;5;1;5;3,44;Nc1cc(F)ccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCO3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL349151;119966;None;0;Human;Binding;Ki;=;4,70;8,33;-1;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;425,2;5;1;5;4,54;Nc1cc(F)ccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL349426;119987;None;0;Human;Binding;Ki;=;3,20;8,49;-162;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;415,3;6;1;5;4,81;c1ccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncnc5ccccc45)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL349683;120017;None;0;Human;Binding;Ki;=;3,50;8,46;-5;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;407,2;5;1;4;4,38;Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCC3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL349699;120020;None;3;Human;Binding;Ki;=;980,00;6,01;-25;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;360,2;4;0;5;2,73;Fc1ccc(OC[C@@H]2CC[C@@H]3CN(c4ncc(F)cn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL349833;120034;None;0;Human;Binding;Ki;=;139,00;6,86;-15;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;409,2;3;0;3;3,75;CC1Cc2cccc3c2N1C(=O)C(N1CCN(Cc2ccc(Cl)cc2)CC1)CC3;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL349843;120036;None;0;Human;Binding;Ki;=;2557,00;5,59;-15;4;Binding affinity was measured at cloned mammalian dopamine D2 receptor expressed in CHO-K1 cells (using [3H]U-86170);ChEMBL;351,1;5;1;4;3,33;CCCN[C@@H]1CCc2c(OS(=O)(=O)C(F)(F)F)cccc2[C@@H]1C;https://dx.doi.org/10.1016/S0960-894X(01)80181-5
CHEMBL349904;120051;None;0;Human;Binding;Ki;=;1720,00;5,76;-87;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;380,3;4;0;5;3,75;CC(C)(C)c1ccc(OC[C@@H]2CC[C@H]3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL349980;120058;None;0;Human;Binding;Ki;=;240,00;6,62;-28;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;367,2;6;1;7;2,45;c1cnc(N[C@H]2CC[C@H](CCN3CCN(c4ncccn4)CC3)CC2)nc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL350160;120076;None;0;Human;Binding;Ki;=;187,00;6,73;-109;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;323,2;4;0;4;3,06;c1ccc(OC[C@@H]2CC[C@H]3CN(c4ccccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL350166;120078;None;3;Human;Binding;Ki;=;130,00;6,89;-4;3;Binding affinity towards human dopamine receptor D2 by the displacement of [3H]spiperone radioligand from the cloned receptor expressed in CHO cells;ChEMBL;265,1;5;0;5;2,86;CN(C)CCSc1nc(-c2ccncc2)cs1;https://dx.doi.org/10.1016/j.bmcl.2003.11.050
CHEMBL350352;120095;None;0;Human;Binding;Ki;=;11,00;7,96;-2;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;433,2;6;1;5;4,97;Clc1cccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)c1Cl;https://dx.doi.org/10.1021/jm9707378
CHEMBL350567;120120;None;0;Human;Binding;Ki;=;17,00;7,77;-6;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;392,2;5;0;4;4,82;O=C(CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3)c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL35093;120161;None;1;Human;Binding;Ki;=;2748,00;5,56;-75;6;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;349,2;4;1;3;3,30;Cc1ccc(N2CCN(CC[C@H]3NC(=O)c4ccccc43)CC2)cc1C;https://dx.doi.org/10.1016/s0960-894x(98)00252-2
CHEMBL351098;120179;None;0;Human;Binding;Ki;=;918,00;6,04;-51;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;354,2;5;0;6;2,46;COc1ccc(OC[C@@H]2CC[C@H]3CN(c4ncccn4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL351247;120200;None;0;Human;Binding;Ki;=;14,00;7,85;-9;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;411,2;5;1;5;4,16;Nc1cc(F)ccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL351300;120205;None;0;Human;Binding;Ki;=;100,00;7,00;-31;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;470,1;6;1;2;5,68;O=C(/C=C/c1ccc(F)cc1)N[C@H]1CC[C@H](CCN2Cc3ccc(Br)cc3C2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
CHEMBL351459;120217;None;0;Human;Binding;Ki;=;19,00;7,72;-2;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;393,2;5;1;5;4,02;Nc1ccccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL351550;120228;None;0;Human;Binding;Ki;=;24000,00;4,62;-707;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;416,2;4;0;4;5,29;Cc1nn2c(-c3ccccc3)cccc2c1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL351550;120228;None;0;Human;Binding;Ki;=;28000,00;4,55;-707;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;416,2;4;0;4;5,29;Cc1nn2c(-c3ccccc3)cccc2c1CN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL351592;120234;None;0;Human;Binding;Ki;=;5,20;8,28;-10;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;393,2;5;1;4;4,00;Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCC3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL351611;120236;None;0;Human;Binding;Ki;=;44,00;7,36;-27;2;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;322,2;4;0;3;3,67;c1ccc(OC[C@@H]2CC[C@H]3CN(c4ccccc4)CCN3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
CHEMBL351612;120237;None;0;Human;Binding;Ki;=;313,00;6,50;-4;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;433,3;4;0;4;3,80;COc1ccc(C)cc1CN1CCN(C2CCc3cccc4c3N(C2=O)C(C)(C)C4)CC1;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL351617;120238;None;0;Human;Binding;Ki;=;6,00;8,22;2;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;395,3;7;1;6;3,67;COc1ccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)cc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL351708;120247;None;0;Human;Binding;Ki;=;23,00;7,64;-14;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;377,2;5;1;5;3,30;Nc1ccccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCO3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL351722;120248;None;0;Human;Binding;Ki;=;2511,89;5,60;-39;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;424,2;5;1;4;4,80;N#Cc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
CHEMBL351963;120268;None;0;Human;Binding;Ki;=;209,00;6,68;-52;2;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;375,2;3;0;3;3,02;Cc1ccc(CN2CCN(C3CCc4cccc5c4N(CC5)C3=O)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL351963;120268;None;0;Human;Binding;Ki;=;209,00;6,68;-52;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;375,2;3;0;3;3,02;Cc1ccc(CN2CCN(C3CCc4cccc5c4N(CC5)C3=O)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL351989;120271;None;0;Human;Binding;Ki;=;165,00;6,78;-13;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;403,3;3;0;3;3,79;Cc1ccc(CN2CCN(C3CCc4cccc5c4N(C3=O)C(C)(C)C5)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL352182;120294;None;0;Human;Binding;Ki;=;4,70;8,33;16;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;485,1;5;1;5;5,17;Nc1cc(Br)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL352194;120297;None;0;Human;Binding;Ki;=;11,00;7,96;-15;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;389,2;5;1;4;4,25;Nc1ccccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCC3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL352207;120299;None;0;Human;Binding;Ki;=;116,00;6,94;-21;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;395,2;3;0;3;3,36;O=C1C(N2CCN(Cc3ccc(Cl)cc3)CC2)CCc2cccc3c2N1CC3;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL35226;120309;None;0;Human;Binding;IC50;=;3400,00;5,47;-;8;Ability to displace [3H]YM-0915 from Dopamine receptor D2;ChEMBL;339,2;5;1;4;4,09;CCCN1CCC(COc2nc3ccccc3c3c2CCCN3)CC1;https://dx.doi.org/10.1021/jm020954v
CHEMBL3526391;120355;None;58;Human;Binding;Ki;=;37,00;7,43;-;1;Binding Assay: The ability of test compounds to displace 3H-raclopride at the D2s receptor can be determined on membranes from D2s-transfected CHO cells (Bmax 13 pmol/mg protein). An assay can use a standard 96-well glass-fiber filter plate to retain radioligand bound by the receptor. Retained 3H can be determined in a TopCount scintillation plate counter following the addition of a liquid scintillant to each well. Compounds can be evaluated for their potency using competition curve analysis, resulting in calculated Ki values.;ChEMBL;295,1;0;1;4;3,13;c1ccc2c(c1)N=C(N1CCNCC1)c1ccccc1S2;-
CHEMBL352648;120356;None;0;Human;Binding;Ki;=;8,80;8,06;-3;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;410,2;5;0;4;4,96;O=C(CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL352686;120361;None;0;Human;Binding;Ki;=;63,00;7,20;-16;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;375,2;5;1;4;3,86;Nc1ccccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCC3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL352925;120396;None;0;Human;Binding;Ki;=;32000,00;4,50;-18620;4;In vitro ability to displace [3H]spiperone from the cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;334,2;4;1;4;2,62;c1ccc(C2=NCC[C@H](CN3CCN(c4ccccc4)CC3)N2)cc1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL352925;120396;None;0;Human;Binding;Ki;=;25000,00;4,60;-18620;4;In vitro ability to displace [3H]spiperone from the cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;334,2;4;1;4;2,62;c1ccc(C2=NCC[C@H](CN3CCN(c4ccccc4)CC3)N2)cc1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL353087;120413;None;0;Human;Binding;Ki;=;21000,00;4,68;-79;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;415,2;7;2;4;3,56;COc1cc(NC(C)=O)c(Cl)cc1C(=O)NC[C@@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL353087;120413;None;0;Human;Binding;Ki;=;19000,00;4,72;-79;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;415,2;7;2;4;3,56;COc1cc(NC(C)=O)c(Cl)cc1C(=O)NC[C@@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL353090;120415;None;0;Human;Binding;Ki;=;1600,00;5,80;-46;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;402,1;6;1;3;3,71;COc1ccc(Br)cc1C(=O)NC[C@@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL353090;120415;None;0;Human;Binding;Ki;=;3100,00;5,51;-46;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;402,1;6;1;3;3,71;COc1ccc(Br)cc1C(=O)NC[C@@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL353220;120431;None;0;Human;Binding;Ki;=;14000,00;4,85;-7;4;In vitro binding affinity to displace [3H]-spiperone from the cloned human dopamine receptor D2 short in CHO cells;ChEMBL;442,1;5;1;5;3,39;COc1ccc(Br)cc1C1=NCC[C@@H](CN2CCN(c3ccccc3)CC2)N1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL353220;120431;None;0;Human;Binding;Ki;=;16000,00;4,80;-7;4;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 long in CHO cells;ChEMBL;442,1;5;1;5;3,39;COc1ccc(Br)cc1C1=NCC[C@@H](CN2CCN(c3ccccc3)CC2)N1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL354005;120522;None;0;Human;Binding;Ki;=;4,00;8,40;-13;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;411,2;5;1;5;4,16;Nc1cc(F)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL354180;120539;None;0;Human;Binding;Ki;=;10,00;8,00;12;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;401,2;7;2;4;3,89;CNc1cc(OC)c(C(=O)NC[C@@H]2CN(Cc3ccccc3)C[C@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL354180;120539;None;0;Human;Binding;Ki;=;28,00;7,55;12;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;401,2;7;2;4;3,89;CNc1cc(OC)c(C(=O)NC[C@@H]2CN(Cc3ccccc3)C[C@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL35426;120544;None;0;Human;Binding;EC50;=;100,00;7,00;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;279,1;0;0;3;3,17;CN1CCc2cccc3c2[C@H]1Cc1ccc2c(c1-3)OCO2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL35426;120544;None;0;Human;Binding;EC50;=;102,00;6,99;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;279,1;0;0;3;3,17;CN1CCc2cccc3c2[C@H]1Cc1ccc2c(c1-3)OCO2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL3544895;120570;None;12;Human;Binding;Kd;=;10,00;8,00;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;357,1;6;0;2;5,23;O=C(CCCN1CC=C(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL3544895;120570;None;12;Human;Binding;Ki;=;10,00;8,00;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;357,1;6;0;2;5,23;O=C(CCCN1CC=C(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL354699;120738;None;0;Human;Binding;Ki;=;220,00;6,66;-7;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;453,2;4;0;4;4,15;COc1ccc(Cl)cc1CN1CCN(C2CCc3cccc4c3N(C2=O)C(C)(C)C4)CC1;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL354748;120782;None;0;Human;Binding;Ki;=;19000,00;4,72;-4;4;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 long in CHO cells;ChEMBL;334,2;3;1;4;2,62;c1ccc(C2=NC[C@@H](N3CCN(c4ccccc4)CC3)CCN2)cc1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL354748;120782;None;0;Human;Binding;Ki;=;14000,00;4,85;-4;4;In vitro binding affinity to displace [3H]-spiperone from the cloned human dopamine receptor D2 short in CHO cells;ChEMBL;334,2;3;1;4;2,62;c1ccc(C2=NC[C@@H](N3CCN(c4ccccc4)CC3)CCN2)cc1;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
CHEMBL355371;120837;None;0;Human;Binding;EC50;=;28,00;7,55;-5;3;The in vitro intrinsic activity was measured at DA D2 receptor by measuring its ability to increase [3H]thymidine uptake in CHO-K1 cells transfected with the Dopamine receptor D2;ChEMBL;366,3;6;1;6;3,06;c1ccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)nc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL355371;120837;None;0;Human;Binding;Ki;=;12,00;7,92;-5;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;366,3;6;1;6;3,06;c1ccc(N2CCN(CC[C@H]3CC[C@H](Nc4ncccn4)CC3)CC2)nc1;https://dx.doi.org/10.1021/jm9707378
CHEMBL355566;120867;None;0;Human;Binding;Ki;=;21,00;7,68;7;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;401,2;7;2;4;3,89;CNc1cc(OC)c(C(=O)NC[C@@H]2CN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL355566;120867;None;0;Human;Binding;Ki;=;51,00;7,29;7;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;401,2;7;2;4;3,89;CNc1cc(OC)c(C(=O)NC[C@@H]2CN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL356149;121022;None;0;Human;Binding;Ki;=;1099,00;5,96;-2;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;341,1;1;2;5;3,55;CN1CCC(NC2=Nc3cccnc3Nc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm0104825
CHEMBL356269;121048;None;0;Human;Binding;Ki;=;5,70;8,24;2;2;Binding affinity towards human Dopamine receptor D2L evaluated using [3H]N-0437;ChEMBL;345,2;4;1;2;5,37;Oc1ccc(C2=CCN(C[C@@H]3CCC=C(c4ccccc4)C3)CC2)cc1;https://dx.doi.org/10.1021/jm00026a007
CHEMBL356269;121048;None;0;Human;Binding;Ki;=;94,00;7,03;2;2;Binding affinity towards human Dopamine receptor D2L evaluated using [3H]spiperone;ChEMBL;345,2;4;1;2;5,37;Oc1ccc(C2=CCN(C[C@@H]3CCC=C(c4ccccc4)C3)CC2)cc1;https://dx.doi.org/10.1021/jm00026a007
CHEMBL356358;121058;None;6;Human;Binding;IC50;=;810,00;6,09;-;2;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;369,2;7;1;5;2,26;COc1ccccc1C(=O)NCCN1CCN(c2ccccc2OC)CC1;https://dx.doi.org/10.1021/jm981041x
CHEMBL356526;121079;None;0;Human;Binding;Ki;=;199,53;6,70;-99;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;555,3;7;1;4;6,55;COc1ccc(S(=O)(=O)N2CCc3ccccc3C2)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL356945;121129;None;0;Human;Binding;Ki;=;460,00;6,34;-19;2;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;384,2;8;1;4;3,85;COc1ccc(SC)cc1C(=O)NC[C@@H]1CCCN1CCc1ccccc1;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
CHEMBL357416;121181;None;3;Human;Binding;Ki;=;0,20;9,70;-1;3;Binding affinity towards human Dopamine receptor D2L evaluated using [3H]N-0437;ChEMBL;345,2;4;1;2;5,37;Oc1ccc(C2=CCC[C@@H](CN3CC=C(c4ccccc4)CC3)C2)cc1;https://dx.doi.org/10.1021/jm00026a007
CHEMBL357416;121181;None;3;Human;Binding;Ki;=;3,50;8,46;-1;3;Binding affinity towards human Dopamine receptor D2L evaluated using [3H]spiperone;ChEMBL;345,2;4;1;2;5,37;Oc1ccc(C2=CCC[C@@H](CN3CC=C(c4ccccc4)CC3)C2)cc1;https://dx.doi.org/10.1021/jm00026a007
CHEMBL357448;121187;None;0;Human;Binding;Ki;=;2990,00;5,52;-1659;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;383,2;8;1;5;2,65;COc1cccc(C(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL357684;121211;None;0;Human;Binding;Ki;=;830,00;6,08;-12;5;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL357684;121211;None;0;Human;Binding;Ki;=;970,00;6,01;-12;5;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL357684;121211;None;0;Human;Binding;Ki;=;150,00;6,82;-12;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL357684;121211;None;0;Human;Binding;Ki;=;831,76;6,08;-12;5;Binding affinity to dopamine D2;ChEMBL;393,2;7;1;6;2,29;COc1ccccc1N1CCN(CCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL3577342;121273;None;0;Human;Binding;EC50;=;380,00;6,42;-3;6;Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay;ChEMBL;551,3;18;1;8;4,63;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cn(CCCC)nn3)c(OC)c2)CO1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577342;121273;None;0;Human;Binding;Ki;=;2,90;8,54;-3;6;Displacement of [3H]spiperone from human dopamine D2S receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;551,3;18;1;8;4,63;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cn(CCCC)nn3)c(OC)c2)CO1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577342;121273;None;0;Human;Binding;Ki;=;1,60;8,80;-3;6;Displacement of [3H]spiperone from human dopamine D2L receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;551,3;18;1;8;4,63;C#CC1=CC[C@@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cn(CCCC)nn3)c(OC)c2)CO1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577343;121274;None;0;Human;Binding;EC50;=;480,00;6,32;-3;6;Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay;ChEMBL;551,3;18;1;8;4,63;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cn(CCCC)nn3)c(OC)c2)CO1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577343;121274;None;0;Human;Binding;Ki;=;10,00;8,00;-3;6;Displacement of [3H]spiperone from human dopamine D2S receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;551,3;18;1;8;4,63;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cn(CCCC)nn3)c(OC)c2)CO1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577343;121274;None;0;Human;Binding;Ki;=;4,90;8,31;-3;6;Displacement of [3H]spiperone from human dopamine D2L receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;551,3;18;1;8;4,63;C#CC1=CC[C@H](N(CCC)CCCCNC(=O)c2ccc(OCCCc3cn(CCCC)nn3)c(OC)c2)CO1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577344;121275;None;0;Human;Binding;EC50;=;140,00;6,85;-22;6;Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay;ChEMBL;632,4;20;3;9;5,11;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)CCc3ccc(O)c4[nH]c(=O)ccc34)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577344;121275;None;0;Human;Binding;Ki;=;24,00;7,62;-22;6;Displacement of [3H]spiperone from human dopamine D2L receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;632,4;20;3;9;5,11;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)CCc3ccc(O)c4[nH]c(=O)ccc34)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577344;121275;None;0;Human;Binding;Ki;=;53,00;7,28;-22;6;Displacement of [3H]spiperone from human dopamine D2S receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;632,4;20;3;9;5,11;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)CCc3ccc(O)c4[nH]c(=O)ccc34)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577345;121276;None;0;Human;Binding;EC50;=;30,00;7,52;-19;6;Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay;ChEMBL;591,4;18;2;8;5,58;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)[C@@H]3CCc4c(O)cccc4C3)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577345;121276;None;0;Human;Binding;Ki;=;18,00;7,75;-19;6;Displacement of [3H]spiperone from human dopamine D2L receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;591,4;18;2;8;5,58;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)[C@@H]3CCc4c(O)cccc4C3)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577345;121276;None;0;Human;Binding;Ki;=;30,00;7,52;-19;6;Displacement of [3H]spiperone from human dopamine D2S receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;591,4;18;2;8;5,58;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)[C@@H]3CCc4c(O)cccc4C3)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577346;121277;None;0;Human;Binding;EC50;=;1,40;8,85;-2;6;Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay;ChEMBL;591,4;18;2;8;5,58;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)[C@H]3CCc4c(O)cccc4C3)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577346;121277;None;0;Human;Binding;Ki;=;0,47;9,33;-2;6;Displacement of [3H]spiperone from human dopamine D2L receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;591,4;18;2;8;5,58;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)[C@H]3CCc4c(O)cccc4C3)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL3577346;121277;None;0;Human;Binding;Ki;=;0,54;9,27;-2;6;Displacement of [3H]spiperone from human dopamine D2S receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;591,4;18;2;8;5,58;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN(CCC)[C@H]3CCc4c(O)cccc4C3)cc2OC)nn1;https://dx.doi.org/10.1021/jm501889t
CHEMBL357807;121330;None;0;Human;Binding;Ki;=;2,00;8,70;-5;3;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;397,2;6;0;4;4,66;COc1ccc2c(c1)CCC1(CCN(CCCC(=O)c3ccc(F)cc3)CC1)O2;https://dx.doi.org/10.1021/jm011030v
CHEMBL358657;121747;None;0;Human;Binding;Ki;=;183,00;6,74;-3;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;397,2;3;2;5;4,78;Cc1ccc2c(c1)C(NC1CCN(Cc3ccccc3)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL3588913;121785;None;0;Human;Binding;Ki;=;31,50;7,50;-10;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;441,3;8;0;6;4,57;COc1ccccc1N1CCN(CCCCc2cn(-c3ccc4ccccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588914;121786;None;0;Human;Binding;Ki;=;57,20;7,24;-36;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;479,3;8;0;6;4,99;COc1ccccc1N1CCN(CCCCc2cn(-c3ccc4c(c3)Cc3ccccc3-4)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588915;121787;None;0;Human;Binding;Ki;=;51,80;7,29;-16;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;430,2;8;1;6;3,90;COc1ccccc1N1CCN(CCCCc2cn(-c3ccc4[nH]ccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588916;121788;None;0;Human;Binding;Ki;=;83,40;7,08;-6;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;442,2;8;0;7;3,97;COc1ccccc1N1CCN(CCCCc2cn(-c3ccc4cnccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588917;121789;None;0;Human;Binding;Ki;=;80,80;7,09;-21;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;479,2;7;0;5;5,87;Clc1cccc(N2CCN(CCCCc3cn(-c4ccc5ccccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588918;121790;None;0;Human;Binding;Ki;=;424,00;6,37;-85;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;517,2;7;0;5;6,29;Clc1cccc(N2CCN(CCCCc3cn(-c4ccc5c(c4)Cc4ccccc4-5)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588919;121791;None;0;Human;Binding;Ki;=;46,60;7,33;-46;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;468,2;7;1;5;5,20;Clc1cccc(N2CCN(CCCCc3cn(-c4ccc5[nH]ccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588920;121792;None;0;Human;Binding;Ki;=;23,30;7,63;-2;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;441,3;8;0;6;4,71;COc1ccccc1N1CCN(CCCCn2cc(-c3ccc4ccccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588921;121793;None;0;Human;Binding;Ki;=;50,10;7,30;-9;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;479,3;8;0;6;5,13;COc1ccccc1N1CCN(CCCCn2cc(-c3ccc4c(c3)Cc3ccccc3-4)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588981;121803;None;0;Human;Binding;Ki;=;43,70;7,36;-7;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;430,2;8;1;6;4,04;COc1ccccc1N1CCN(CCCCn2cc(-c3ccc4[nH]ccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588982;121804;None;0;Human;Binding;Ki;=;42,50;7,37;-6;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;442,2;8;0;7;4,10;COc1ccccc1N1CCN(CCCCn2cc(-c3ccc4ncccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588983;121805;None;0;Human;Binding;Ki;=;69,00;7,16;-11;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;467,3;9;0;6;5,22;COc1ccccc1N1CCN(CCCCn2cc(-c3ccc(-c4ccccc4)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588984;121806;None;0;Human;Binding;Ki;=;103,00;6,99;-13;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;479,2;7;0;5;6,01;Clc1cccc(N2CCN(CCCCn3cc(-c4ccc5ccccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588985;121807;None;0;Human;Binding;Ki;=;885,00;6,05;-63;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;517,2;7;0;5;6,43;Clc1cccc(N2CCN(CCCCn3cc(-c4ccc5c(c4)Cc4ccccc4-5)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588986;121808;None;0;Human;Binding;Ki;=;56,10;7,25;-38;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;468,2;7;1;5;5,34;Clc1cccc(N2CCN(CCCCn3cc(-c4ccc5[nH]ccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588987;121809;None;0;Human;Binding;Ki;=;53,90;7,27;-39;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;480,2;7;0;6;5,40;Clc1cccc(N2CCN(CCCCn3cc(-c4ccc5ncccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588988;121810;None;0;Human;Binding;Ki;=;2590,00;5,59;-309;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;505,2;8;0;5;6,52;Clc1cccc(N2CCN(CCCCn3cc(-c4ccc(-c5ccccc5)cc4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588989;121811;None;0;Human;Binding;Ki;=;189,00;6,72;-4;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;457,2;8;1;7;3,68;COc1ccccc1N1CCN(CC(O)CCn2cc(-c3ccc4ccccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588990;121812;None;0;Human;Binding;Ki;=;819,00;6,09;-26;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;483,3;9;1;7;4,19;COc1ccccc1N1CCN(CC(O)CCn2cc(-c3ccc(-c4ccccc4)cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588991;121813;None;0;Human;Binding;Ki;=;1210,00;5,92;-6;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;407,2;8;1;7;2,53;COc1ccccc1N1CCN(CC(O)CCn2cc(-c3ccccc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588992;121814;None;0;Human;Binding;Ki;=;1020,00;5,99;-2;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;437,2;9;1;8;2,54;COc1ccccc1-c1cn(CCC(O)CN2CCN(c3ccccc3OC)CC2)nn1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588993;121815;None;0;Human;Binding;Ki;=;607,00;6,22;-32;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;495,3;8;1;7;4,10;COc1ccccc1N1CCN(CC(O)CCn2cc(-c3ccc4c(c3)Cc3ccccc3-4)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588994;121816;None;0;Human;Binding;Ki;=;424,00;6,37;-6;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;458,2;8;1;8;3,08;COc1ccccc1N1CCN(CC(O)CCn2cc(-c3ccc4ncccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588995;121817;None;0;Human;Binding;Ki;=;18800,00;4,73;-741;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;495,2;7;1;6;4,98;OC(CCn1cc(-c2ccc3ccccc3c2)nn1)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588996;121818;None;0;Human;Binding;Ki;=;15100,00;4,82;-269;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;521,2;8;1;6;5,49;OC(CCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588997;121819;None;0;Human;Binding;Ki;=;789,00;6,10;-23;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;446,2;8;2;7;3,01;COc1ccccc1N1CCN(CC(O)CCn2cc(-c3ccc4[nH]ccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3588998;121820;None;0;Human;Binding;Ki;=;963,00;6,02;-162;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;484,2;7;2;6;4,31;OC(CCn1cc(-c2ccc3[nH]ccc3c2)nn1)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3589575;121834;None;0;Human;Binding;Ki;=;5,00;8,30;-4;3;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;368,2;7;1;3;4,50;CCCN(CCNC(=O)/N=N/c1ccc(F)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3589575;121834;None;0;Human;Binding;Ki;=;4,00;8,40;-4;3;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;368,2;7;1;3;4,50;CCCN(CCNC(=O)/N=N/c1ccc(F)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3589576;121835;None;0;Human;Binding;Ki;=;3,90;8,41;-2;3;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;386,2;7;1;3;4,64;CCCN(CCNC(=O)/N=N/c1ccc(F)c(F)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3589576;121835;None;0;Human;Binding;Ki;=;8,50;8,07;-2;3;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;386,2;7;1;3;4,64;CCCN(CCNC(=O)/N=N/c1ccc(F)c(F)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3589577;121836;None;0;Human;Binding;Ki;=;73,00;7,14;-8;6;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;404,2;7;1;3;4,78;CCCN(CCNC(=O)/N=N/c1cc(F)c(F)c(F)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3589577;121836;None;0;Human;Binding;Ki;=;110,00;6,96;-8;6;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;404,2;7;1;3;4,78;CCCN(CCNC(=O)/N=N/c1cc(F)c(F)c(F)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3589650;121859;None;0;Human;Binding;Ki;=;244,00;6,61;-13;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;496,2;7;1;7;4,37;OC(CCn1cc(-c2ccc3ncccc3c2)nn1)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3589651;121860;None;0;Human;Binding;Ki;=;268,00;6,57;-83;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;472,1;7;2;5;3,85;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL3589651;121860;None;0;Human;Binding;Ki;=;321,00;6,49;-83;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;472,1;7;2;5;3,85;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL3589652;121861;None;0;Human;Binding;Ki;=;54,70;7,26;-234;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;509,2;7;2;4;4,87;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)-c1ccccc1C2;https://dx.doi.org/10.1016/j.bmc.2015.01.017
CHEMBL359002;121925;None;0;Human;Binding;IC50;=;761,00;6,12;-;2;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;423,3;7;1;5;2,89;COc1ccccc1N1CCN(CCC(=O)NC2CCc3c(cccc3OC)C2)CC1;https://dx.doi.org/10.1021/jm981041x
CHEMBL3590077;121933;None;0;Human;Binding;Ki;=;34,00;7,47;-11;6;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;413,2;8;1;5;4,23;COc1ccccc1N1CCN(CCCCNC(=O)/N=N/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590077;121933;None;0;Human;Binding;Ki;=;38,00;7,42;-11;6;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;413,2;8;1;5;4,23;COc1ccccc1N1CCN(CCCCNC(=O)/N=N/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL3590077;121933;None;0;Human;Binding;Ki;=;34,00;7,47;-11;6;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;413,2;8;1;5;4,23;COc1ccccc1N1CCN(CCCCNC(=O)/N=N/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL3590077;121933;None;0;Human;Binding;Ki;=;38,00;7,42;-11;6;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;413,2;8;1;5;4,23;COc1ccccc1N1CCN(CCCCNC(=O)/N=N/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590078;121934;None;0;Human;Binding;Ki;=;7,50;8,12;-13;3;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;431,2;8;1;5;4,37;COc1ccccc1N1CCN(CCCCNC(=O)/N=N/c2ccc(F)c(F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590078;121934;None;0;Human;Binding;Ki;=;12,00;7,92;-13;3;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;431,2;8;1;5;4,37;COc1ccccc1N1CCN(CCCCNC(=O)/N=N/c2ccc(F)c(F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590079;121935;None;0;Human;Binding;Ki;=;6,60;8,18;-5;3;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;449,2;8;1;5;4,51;COc1ccccc1N1CCN(CCCCNC(=O)/N=N/c2cc(F)c(F)c(F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590079;121935;None;0;Human;Binding;Ki;=;9,50;8,02;-5;3;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;449,2;8;1;5;4,51;COc1ccccc1N1CCN(CCCCNC(=O)/N=N/c2cc(F)c(F)c(F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590080;121936;None;0;Human;Binding;Ki;=;2,90;8,54;-23;6;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;394,2;10;1;2;4,62;CCCN(CCCCNC(=O)/C=C/c1ccc(F)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590080;121936;None;0;Human;Binding;Ki;=;19,00;7,72;-23;6;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;394,2;10;1;2;4,62;CCCN(CCCCNC(=O)/C=C/c1ccc(F)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590081;121937;None;0;Human;Binding;Ki;=;36,00;7,44;-33;6;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;396,2;9;1;3;5,28;CCCN(CCCCNC(=O)/N=N/c1ccc(F)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590081;121937;None;0;Human;Binding;Ki;=;23,00;7,64;-33;6;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;396,2;9;1;3;5,28;CCCN(CCCCNC(=O)/N=N/c1ccc(F)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590082;121938;None;0;Human;Binding;Ki;=;13,00;7,89;-9;3;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;414,2;9;1;3;5,42;CCCN(CCCCNC(=O)/N=N/c1ccc(F)c(F)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590082;121938;None;0;Human;Binding;Ki;=;25,00;7,60;-9;3;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;414,2;9;1;3;5,42;CCCN(CCCCNC(=O)/N=N/c1ccc(F)c(F)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590083;121939;None;0;Human;Binding;Ki;=;12,00;7,92;-4;3;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;432,2;9;1;3;5,56;CCCN(CCCCNC(=O)/N=N/c1cc(F)c(F)c(F)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590083;121939;None;0;Human;Binding;Ki;=;40,00;7,40;-4;3;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;432,2;9;1;3;5,56;CCCN(CCCCNC(=O)/N=N/c1cc(F)c(F)c(F)c1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590084;121940;None;0;Human;Binding;Ki;=;13,00;7,89;-16;6;Displacement of [3H]spiperone from human dopamine D2 short receptor expressed in CHO cell membranes;ChEMBL;366,2;8;1;2;3,83;CCCN(CCNC(=O)/C=C/c1ccc(F)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590084;121940;None;0;Human;Binding;Ki;=;43,00;7,37;-16;6;Displacement of [3H]spiperone from human dopamine D2 long receptor expressed in CHO cell membranes;ChEMBL;366,2;8;1;2;3,83;CCCN(CCNC(=O)/C=C/c1ccc(F)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2014.12.012
CHEMBL3590085;121941;None;24;Human;Binding;Ki;=;2110,00;5,68;-660;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;481,2;7;0;7;4,69;Cc1ncoc1-c1nnc(SCCCN2C[C@@H]3C[C@]3(c3ccc(C(F)(F)F)cc3F)C2)n1C;https://dx.doi.org/10.1021/jm501512b
CHEMBL3590086;121942;None;0;Human;Binding;Ki;=;46,90;7,33;-50;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;442,2;7;2;5;3,42;Cc1ccc(Cl)c(N2CCN(CCCCNC(=O)c3ccc4oc(=O)[nH]c4c3)CC2)c1;https://dx.doi.org/10.1021/jm501512b
CHEMBL3590086;121942;None;0;Human;Binding;Ki;=;335,00;6,47;-50;3;Binding affinity to human dopamine D2 receptor;ChEMBL;442,2;7;2;5;3,42;Cc1ccc(Cl)c(N2CCN(CCCCNC(=O)c3ccc4oc(=O)[nH]c4c3)CC2)c1;https://dx.doi.org/10.1021/jm501512b
CHEMBL359270;122057;None;0;Human;Binding;Ki;=;650,00;6,19;-40;2;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;359,1;3;0;2;4,59;Fc1ccc(CCN2CCC3(C=Cc4cc(F)ccc4O3)CC2)c(F)c1;https://dx.doi.org/10.1021/jm011030v
CHEMBL3596212;122121;None;0;Human;Binding;Ki;=;14,80;7,83;-60;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;427,2;7;1;4;4,92;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597635;122298;None;0;Human;Binding;EC50;=;170,00;6,77;-47;5;Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of quinpirole-stimulated mitogenesis;ChEMBL;438,2;7;1;4;4,72;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597635;122298;None;0;Human;Binding;IC50;=;29,00;7,54;-47;5;Antagonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of quinpirole-stimulated mitogenesis;ChEMBL;438,2;7;1;4;4,72;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597635;122298;None;0;Human;Binding;Ki;=;15,80;7,80;-47;5;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;438,2;7;1;4;4,72;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597636;122299;None;0;Human;Binding;EC50;=;200,00;6,70;-107;5;Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of quinpirole-stimulated mitogenesis;ChEMBL;454,2;7;2;5;3,69;O=C(NCCC(O)CN1CCN(c2cccc3ccccc23)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597636;122299;None;0;Human;Binding;IC50;=;720,00;6,14;-107;5;Antagonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of quinpirole-stimulated mitogenesis;ChEMBL;454,2;7;2;5;3,69;O=C(NCCC(O)CN1CCN(c2cccc3ccccc23)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597636;122299;None;0;Human;Binding;Ki;=;258,00;6,59;-107;5;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;454,2;7;2;5;3,69;O=C(NCCC(O)CN1CCN(c2cccc3ccccc23)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597637;122300;None;0;Human;Binding;EC50;=;10000,00;5,00;-25;5;Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of quinpirole-stimulated mitogenesis;ChEMBL;452,2;8;1;5;4,23;COc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2cnc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597637;122300;None;0;Human;Binding;IC50;=;63,00;7,20;-25;5;Antagonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of quinpirole-stimulated mitogenesis;ChEMBL;452,2;8;1;5;4,23;COc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2cnc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597637;122300;None;0;Human;Binding;Ki;=;43,10;7,37;-25;5;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;452,2;8;1;5;4,23;COc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2cnc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597638;122301;None;0;Human;Binding;Ki;=;885,00;6,05;-28;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;468,2;8;2;6;3,20;COc1c(Cl)cccc1N1CCN(CC(O)CCNC(=O)c2cnc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597639;122302;None;0;Human;Binding;Ki;=;39,20;7,41;-67;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;474,1;7;1;4;5,01;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccc(F)cc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597640;122303;None;0;Human;Binding;Ki;=;827,00;6,08;-102;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;490,1;7;2;5;3,98;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccc(F)cc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597641;122304;None;0;Human;Binding;Ki;=;53,00;7,28;-134;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;440,2;8;2;4;4,16;COc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2cc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597642;122305;None;0;Human;Binding;Ki;=;72,30;7,14;-79;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;441,2;8;1;5;4,43;COc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2cc3ccccc3o2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597643;122306;None;0;Human;Binding;EC50;=;76,00;7,12;-109;5;Agonist activity at human dopamine D2 receptor expressed in CHO cells assessed as stimulation of quinpirole-stimulated mitogenesis;ChEMBL;426,2;7;2;3;4,65;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597643;122306;None;0;Human;Binding;IC50;=;87,00;7,06;-109;5;Antagonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of quinpirole-stimulated mitogenesis;ChEMBL;426,2;7;2;3;4,65;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597643;122306;None;0;Human;Binding;Ki;=;12,90;7,89;-109;5;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;426,2;7;2;3;4,65;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597644;122307;None;0;Human;Binding;Ki;=;13,80;7,86;-79;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;456,3;8;2;4;4,66;COc1ccc2[nH]c(C(=O)NCCCCN3CCN(c4cccc5ccccc45)CC3)cc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597645;122308;None;0;Human;Binding;Ki;=;8,37;8,08;-64;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;443,2;7;1;4;5,39;O=C(NCCCCN1CCN(c2cccc3ccccc23)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597646;122309;None;0;Human;Binding;Ki;=;929,00;6,03;-9;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;434,2;8;2;6;2,55;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2ccc3ccccc3n2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597647;122310;None;0;Human;Binding;Ki;=;68,20;7,17;-26;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;436,2;8;1;5;3,71;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3cc(F)ccc3n2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597648;122311;None;0;Human;Binding;Ki;=;1000,00;6,00;-19;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;452,2;8;2;6;2,69;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2ccc3cc(F)ccc3n2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597649;122312;None;0;Human;Binding;Ki;=;915,00;6,04;-26;5;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;434,2;8;2;6;2,55;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2cnc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597650;122313;None;0;Human;Binding;Ki;=;34,10;7,47;-15;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;436,2;8;1;5;3,71;COc1ccccc1N1CCN(CCCCNC(=O)c2cnc3ccc(F)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597651;122314;None;0;Human;Binding;Ki;=;682,00;6,17;-15;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;452,2;8;2;6;2,69;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2cnc3ccc(F)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597652;122315;None;0;Human;Binding;Ki;=;707,00;6,15;-13;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;448,2;8;2;6;2,85;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2cnc3ccc(C)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597653;122316;None;0;Human;Binding;Ki;=;774,00;6,11;-11;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;464,2;9;2;7;2,56;COc1ccc2ncc(C(=O)NCCC(O)CN3CCN(c4ccccc4OC)CC3)cc2c1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL3597654;122317;None;0;Human;Binding;Ki;=;1030,00;5,99;-26;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;434,2;8;2;6;2,55;COc1ccccc1N1CCN(CC(O)CCNC(=O)c2ccc3cccnc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL360394;122725;None;0;Human;Binding;Ki;=;150,00;6,82;-38;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;356,2;5;1;2;4,36;O=C(NC1CCN(Cc2ccccc2)C1)c1cccc(-c2ccccc2)c1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL360424;122773;None;0;Human;Binding;Ki;=;980,00;6,01;-537;3;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@H]1CCN(Cc2ccccc2)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL360424;122773;None;0;Human;Binding;Ki;=;980,00;6,01;-537;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@H]1CCN(Cc2ccccc2)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL360457;122817;None;0;Human;Binding;Ki;=;3,60;8,44;2;2;In vitro binding affinity against recombinant human dopamine receptor D2L in human liver microsomes;ChEMBL;383,2;3;1;4;3,66;CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CC[C@H](O)CCC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.12.028
CHEMBL3605326;122880;None;0;Human;Binding;Ki;=;5586,00;5,25;-64;2;Displacement of [3H]-sulpiride from human dopamine D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting;ChEMBL;462,1;7;1;5;5,53;O=C(CCCCN1CCN(c2ccc(Cl)cc2Cl)CC1)Nc1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2015.07.072
CHEMBL3605326;122880;None;0;Human;Binding;Ki;=;5586,00;5,25;-64;2;Displacement of [3H]-sulpiride from human D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting method;ChEMBL;462,1;7;1;5;5,53;O=C(CCCCN1CCN(c2ccc(Cl)cc2Cl)CC1)Nc1nc2ccccc2s1;https://dx.doi.org/10.1039/C8MD00237A
CHEMBL3605331;122881;None;0;Human;Binding;Ki;=;175,00;6,76;-44;2;Displacement of [3H]-sulpiride from human dopamine D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting;ChEMBL;412,2;7;1;5;4,37;O=C(CCCCN1CCN(c2ccccc2F)CC1)Nc1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2015.07.072
CHEMBL3605331;122881;None;0;Human;Binding;Ki;=;175,00;6,76;-44;2;Displacement of [3H]-sulpiride from human D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting method;ChEMBL;412,2;7;1;5;4,37;O=C(CCCCN1CCN(c2ccccc2F)CC1)Nc1nc2ccccc2s1;https://dx.doi.org/10.1039/C8MD00237A
CHEMBL3605344;122882;None;0;Human;Binding;Ki;=;197,00;6,71;-20;2;Displacement of [3H]-sulpiride from human dopamine D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting;ChEMBL;458,2;8;1;6;4,89;COc1ccc2nc(NC(=O)CCCCN3CCN(c4ccc(Cl)cc4)CC3)sc2c1;https://dx.doi.org/10.1016/j.bmc.2015.07.072
CHEMBL361035;123168;None;0;Human;Binding;Ki;=;60,00;7,22;-39;3;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@H]1CCN(Cc2ccccc2)C1)c1cccc(-c2cccs2)c1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL361035;123168;None;0;Human;Binding;Ki;=;60,00;7,22;-39;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@H]1CCN(Cc2ccccc2)C1)c1cccc(-c2cccs2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL3613873;123309;None;0;Human;Binding;Ki;=;81,00;7,09;-2;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;417,2;7;0;8;2,68;COc1ccccc1N1CCN(CCCc2cn(-c3ccn4nccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613873;123309;None;0;Human;Binding;Ki;=;140,00;6,85;-2;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;417,2;7;0;8;2,68;COc1ccccc1N1CCN(CCCc2cn(-c3ccn4nccc4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613874;123310;None;0;Human;Binding;Ki;=;6,70;8,17;1;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;483,1;7;0;8;3,79;O=Cc1cnn2ccc(-n3cc(CCCN4CCN(c5cccc(Cl)c5Cl)CC4)nn3)cc12;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613874;123310;None;0;Human;Binding;Ki;=;3,80;8,42;1;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;483,1;7;0;8;3,79;O=Cc1cnn2ccc(-n3cc(CCCN4CCN(c5cccc(Cl)c5Cl)CC4)nn3)cc12;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613875;123311;None;0;Human;Binding;Ki;=;110,00;6,96;-17;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;497,1;8;0;8;4,18;O=Cc1cnn2ccc(-n3cc(CCCCN4CCN(c5cccc(Cl)c5Cl)CC4)nn3)cc12;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613875;123311;None;0;Human;Binding;Ki;=;51,00;7,29;-17;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;497,1;8;0;8;4,18;O=Cc1cnn2ccc(-n3cc(CCCCN4CCN(c5cccc(Cl)c5Cl)CC4)nn3)cc12;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613876;123312;None;0;Human;Binding;Ki;=;11,00;7,96;3;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;469,1;6;0;8;3,40;O=Cc1cnn2ccc(-n3cc(CCN4CCN(c5cccc(Cl)c5Cl)CC4)nn3)cc12;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613876;123312;None;0;Human;Binding;Ki;=;8,00;8,10;3;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;469,1;6;0;8;3,40;O=Cc1cnn2ccc(-n3cc(CCN4CCN(c5cccc(Cl)c5Cl)CC4)nn3)cc12;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613877;123313;None;0;Human;Binding;Ki;=;9,40;8,03;-1;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;431,2;7;0;9;2,10;COc1ccccc1N1CCN(CCc2cn(-c3ccn4ncc(C=O)c4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613877;123313;None;0;Human;Binding;Ki;=;18,00;7,75;-1;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;431,2;7;0;9;2,10;COc1ccccc1N1CCN(CCc2cn(-c3ccn4ncc(C=O)c4c3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613878;123314;None;0;Human;Binding;Ki;=;22,00;7,66;-6;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;441,1;5;0;7;3,59;Clc1cccc(N2CCN(CCc3cn(-c4ccn5nccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613878;123314;None;0;Human;Binding;Ki;=;10,00;8,00;-6;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;441,1;5;0;7;3,59;Clc1cccc(N2CCN(CCc3cn(-c4ccn5nccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613879;123315;None;0;Human;Binding;Ki;=;130,00;6,89;-15;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;455,1;6;0;7;3,98;Clc1cccc(N2CCN(CCCc3cn(-c4ccn5nccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613879;123315;None;0;Human;Binding;Ki;=;54,00;7,27;-15;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;455,1;6;0;7;3,98;Clc1cccc(N2CCN(CCCc3cn(-c4ccn5nccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613880;123316;None;0;Human;Binding;Ki;=;7,30;8,14;-41;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;469,2;7;0;7;4,37;Clc1cccc(N2CCN(CCCCc3cn(-c4ccn5nccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL3613880;123316;None;0;Human;Binding;Ki;=;23,00;7,64;-41;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;469,2;7;0;7;4,37;Clc1cccc(N2CCN(CCCCc3cn(-c4ccn5nccc5c4)nn3)CC2)c1Cl;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL361875;123697;None;0;Human;Binding;Ki;=;1210,00;5,92;-151;5;Inhibition of [3H]raclopride binding to human dopamine D2A receptor expressed in Ltk cells;ChEMBL;367,3;8;0;3;5,35;CCCN(CCC)[C@H]1CCc2c(cccc2-c2c(OC)cccc2OC)C1;https://dx.doi.org/10.1021/jm0498102
CHEMBL362101;123740;None;0;Human;Binding;Ki;=;89,00;7,05;-37;5;Binding affinity towards human D2 long receptor using [3H]spiperone expressed in CHO cells;ChEMBL;537;7;1;4;4,99;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(I)s1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL362101;123740;None;0;Human;Binding;Ki;=;32,00;7,50;-37;5;Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells;ChEMBL;537;7;1;4;4,99;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(I)s1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL3622092;123782;None;0;Human;Binding;Ki;=;7500,00;5,12;2;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;364,2;7;2;4;3,41;COc1ccc(NCCN2CCN(Cc3cc4ccccc4[nH]3)CC2)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622093;123783;None;0;Human;Binding;Ki;=;920,00;6,04;2;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;412,1;6;2;3;4,16;Brc1ccc(NCCN2CCN(Cc3cc4ccccc4[nH]3)CC2)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622094;123784;None;0;Human;Binding;Ki;=;520,00;6,28;2;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;406,3;9;1;4;4,21;CCCN(CCN1CCN(Cc2cc3ccccc3[nH]2)CC1)c1ccc(OC)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622095;123785;None;0;Human;Binding;Ki;=;220,00;6,66;2;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;454,2;8;1;3;4,96;CCCN(CCN1CCN(Cc2cc3ccccc3[nH]2)CC1)c1ccc(Br)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622096;123786;None;0;Human;Binding;Ki;=;430,00;6,37;1;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;8;2;4;3,45;COc1ccc(NCCN2CCN(CCc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622097;123787;None;0;Human;Binding;Ki;=;48,00;7,32;-2;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;426,1;7;2;3;4,20;Brc1ccc(NCCN2CCN(CCc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622097;123787;None;0;Human;Binding;Ki;=;53,00;7,28;-2;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;426,1;7;2;3;4,20;Brc1ccc(NCCN2CCN(CCc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622098;123788;None;0;Human;Binding;Ki;=;120,00;6,92;2;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;420,3;10;1;4;4,25;CCCN(CCN1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccc(OC)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622099;123789;None;0;Human;Binding;Ki;=;58,00;7,24;-74;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;468,2;9;1;3;5,01;CCCN(CCN1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccc(Br)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622099;123789;None;0;Human;Binding;Ki;=;51,00;7,29;-74;5;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;468,2;9;1;3;5,01;CCCN(CCN1CCN(CCc2c[nH]c3ccccc23)CC1)c1ccc(Br)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622100;123790;None;0;Human;Binding;Ki;=;4000,00;5,40;1;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;378,2;8;2;4;3,08;COc1ccc(CNCCN2CCN(Cc3cc4ccccc4[nH]3)CC2)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622101;123791;None;0;Human;Binding;Ki;=;5200,00;5,28;-2;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;426,1;7;2;3;3,84;Brc1ccc(CNCCN2CCN(Cc3cc4ccccc4[nH]3)CC2)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622102;123792;None;0;Human;Binding;Ki;=;4100,00;5,39;1;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;420,3;10;1;4;4,21;CCCN(CCN1CCN(Cc2cc3ccccc3[nH]2)CC1)Cc1ccc(OC)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL3622103;123793;None;0;Human;Binding;Ki;=;920,00;6,04;1;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;468,2;9;1;3;4,96;CCCN(CCN1CCN(Cc2cc3ccccc3[nH]2)CC1)Cc1ccc(Br)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
CHEMBL362285;123858;None;0;Human;Binding;Ki;=;21,20;7,67;-1;2;In vitro binding affinity against recombinant human dopamine receptor D2L in human liver microsomes;ChEMBL;383,2;3;1;4;3,66;CCN1CCN(c2cc(-c3ccc(F)cc3)c3c(n2)CCC[C@H](O)CC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.12.028
CHEMBL363124;124116;None;0;Human;Binding;Ki;=;23,99;7,62;-2;5;Binding affinity against Dopamine receptor D2;ChEMBL;357,2;4;1;4;3,48;c1ccc2c(N3CCN(CCc4ccc5[nH]nnc5c4)CC3)cccc2c1;https://dx.doi.org/10.1016/j.bmcl.2004.06.005
CHEMBL363124;124116;None;0;Human;Binding;Ki;=;23,99;7,62;-2;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;357,2;4;1;4;3,48;c1ccc2c(N3CCN(CCc4ccc5[nH]nnc5c4)CC3)cccc2c1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL363452;124332;None;0;Human;Binding;Ki;=;370,00;6,43;-1862;3;Binding affinity against D2L receptor;ChEMBL;351,2;8;2;4;4,88;C[C@H](Nc1ccnc(NCCOc2ccc(F)cc2)c1)c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2004.06.007
CHEMBL363466;124336;None;0;Human;Binding;Ki;=;241,00;6,62;-93;5;Inhibition of [3H]raclopride binding to human dopamine D2A receptor expressed in Ltk cells;ChEMBL;311,2;4;0;3;3,79;COc1cccc(OC)c1-c1cccc2c1CC[C@H](N(C)C)C2;https://dx.doi.org/10.1021/jm0498102
CHEMBL363581;124394;None;0;Human;Binding;Ki;=;12,00;7,92;-18;9;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;329,1;2;0;3;4,47;CN(C)C[C@@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL363829;124441;None;0;Human;Binding;Ki;=;55,00;7,26;-194;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;424,2;4;1;5;4,89;CC1(C)CCNc2c(CCN3CCN(c4nsc5ccccc45)CC3)cc(F)cc21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL3639415;124463;None;0;Human;Binding;Ki;=;486,00;6,31;-53;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;370,2;5;1;5;3,04;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3639416;124464;None;0;Human;Binding;Ki;=;1935,00;5,71;-104;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;7;1;6;3,33;Cc1cc2c(c(N3CCN(CC[C@H]4CC[C@H](NC(=O)CC5CCOCC5)CC4)CC3)n1)CCO2;-
CHEMBL3639637;124493;None;0;Human;Binding;Ki;=;408,24;6,39;-52;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;7;1;5;4,48;O=C(C[C@H]1CCCOC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3639943;124532;None;0;Human;Binding;Ki;=;721,30;6,14;-199;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;490,3;7;1;5;4,84;O=C(Cc1ccc2c(c1)OCO2)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3639968;124538;None;0;Human;Binding;Ki;=;241,28;6,62;-120;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;476,3;5;1;5;4,26;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)N1CCc2ccccc21;-
CHEMBL3642680;124876;None;0;Human;Binding;Ki;=;802,00;6,10;-123;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;468,3;8;1;6;4,22;CO[C@@H]1CC[C@@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5occc45)CC3)CC2)C1;-
CHEMBL3642681;124877;None;0;Human;Binding;Ki;=;1538,00;5,81;-177;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;468,3;7;2;6;3,96;O=C(C[C@H]1CC[C@H](O)CC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642682;124878;None;0;Human;Binding;Ki;=;780,00;6,11;-120;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;384,3;6;1;5;3,42;CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642683;124879;None;0;Human;Binding;Ki;=;1347,00;5,87;-165;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;8;1;6;3,05;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642684;124880;None;0;Human;Binding;Ki;=;959,00;6,02;-93;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;400,2;7;2;6;2,40;O=C(CCO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642685;124881;None;0;Human;Binding;Ki;=;1360,00;5,87;-239;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;386,2;6;2;6;2,01;O=C(CO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642686;124882;None;0;Human;Binding;Ki;=;1158,00;5,94;-263;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;400,2;7;1;6;2,66;COCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642687;124883;None;0;Human;Binding;Ki;=;1463,00;5,83;-263;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;482,3;8;1;6;4,61;CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5occc45)CC3)CC2)CC1;-
CHEMBL3642688;124884;None;0;Human;Binding;Ki;=;683,00;6,17;-109;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;454,3;7;1;6;3,83;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642689;124885;None;0;Human;Binding;Ki;=;515,00;6,29;-177;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;440,3;6;1;6;3,44;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1)C1CCOCC1;-
CHEMBL3642690;124886;None;0;Human;Binding;Ki;=;996,00;6,00;-134;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;8;1;6;3,05;CCOCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642691;124887;None;0;Human;Binding;Ki;=;261,00;6,58;-60;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;396,3;6;1;5;3,42;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1)C1CC1;-
CHEMBL3642692;124888;None;0;Human;Binding;Ki;=;866,00;6,06;-128;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;406,2;6;1;6;2,45;CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642693;124889;None;0;Human;Binding;Ki;=;119,00;6,92;-63;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;386,2;5;1;5;3,50;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642694;124890;None;0;Human;Binding;Ki;=;780,00;6,11;-91;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;420,2;7;1;6;2,84;CCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642695;124891;None;0;Human;Binding;Ki;=;539,00;6,27;-102;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;435,2;7;1;6;2,29;CN(C)S(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1;-
CHEMBL3642696;124892;None;0;Human;Binding;Ki;=;163,00;6,79;-102;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;400,2;6;1;5;3,89;CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642697;124893;None;0;Human;Binding;Ki;=;305,00;6,52;-158;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,2;8;1;6;3,52;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642698;124894;None;0;Human;Binding;Ki;=;302,00;6,52;-120;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;498,3;8;1;6;5,08;CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5sccc45)CC3)CC2)CC1;-
CHEMBL3642699;124895;None;0;Human;Binding;Ki;=;271,00;6,57;-79;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;484,3;8;1;6;4,69;CO[C@@H]1CC[C@@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5sccc45)CC3)CC2)C1;-
CHEMBL3642699;124895;None;0;Human;Binding;Ki;=;234,00;6,63;-79;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;484,3;8;1;6;4,69;CO[C@@H]1CC[C@@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5sccc45)CC3)CC2)C1;-
CHEMBL364270;124896;None;0;Human;Binding;Ki;=;68,00;7,17;-18;9;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;329,1;2;0;3;4,62;CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL3642700;124897;None;0;Human;Binding;Ki;=;220,00;6,66;-100;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,2;7;1;6;3,13;COCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642701;124898;None;0;Human;Binding;Ki;=;144,00;6,84;-53;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;7;1;6;4,30;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642702;124899;None;0;Human;Binding;Ki;=;992,00;6,00;-588;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;6;1;6;3,91;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1)C1CCOCC1;-
CHEMBL3642703;124900;None;0;Human;Binding;Ki;=;246,00;6,61;-81;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;484,3;8;1;6;4,69;CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5sccc45)CC3)CC2)C1;-
CHEMBL3642704;124901;None;0;Human;Binding;Ki;=;218,00;6,66;-154;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;402,2;6;2;6;2,48;O=C(CO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642705;124902;None;0;Human;Binding;Ki;=;392,00;6,41;-97;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;484,3;7;2;6;4,42;O=C(C[C@H]1CC[C@H](O)CC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642706;124903;None;0;Human;Binding;Ki;=;461,00;6,34;-87;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;483,3;6;1;6;4,88;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4occc34)CC2)CC1)c1ccnc2ccccc12;-
CHEMBL3642707;124904;None;0;Human;Binding;Ki;=;265,00;6,58;-91;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;422,2;6;1;6;2,92;CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642708;124905;None;0;Human;Binding;Ki;=;217,00;6,66;-75;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;436,2;7;1;6;3,31;CCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4sccc34)CC2)CC1;-
CHEMBL3642709;124906;None;0;Human;Binding;Ki;=;770,10;6,11;-61;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;372,3;5;1;5;2,22;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642710;124908;None;0;Human;Binding;Ki;=;503,50;6,30;-85;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;6;1;6;2,63;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCOCC1;-
CHEMBL3642711;124909;None;0;Human;Binding;Ki;=;869,00;6,06;-43;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;7;1;6;3,02;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642712;124910;None;0;Human;Binding;Ki;=;1488,00;5,83;-85;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,3;8;1;6;2,24;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642713;124911;None;0;Human;Binding;Ki;=;812,70;6,09;-83;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;386,3;6;1;5;2,61;CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642714;124912;None;0;Human;Binding;Ki;=;1471,40;5,83;-151;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;458,3;7;1;7;2,01;O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642715;124913;None;0;Human;Binding;Ki;=;1545,40;5,81;-141;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;402,3;7;1;6;1,85;COCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642716;124914;None;0;Human;Binding;Ki;=;1018,30;5,99;-104;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;450,2;7;1;7;1,25;CS(=O)(=O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642717;124915;None;0;Human;Binding;Ki;=;1568,00;5,80;-128;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;388,2;6;2;6;1,20;O=C(CO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642718;124916;None;0;Human;Binding;Ki;=;733,50;6,13;-64;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;402,3;7;2;6;1,59;O=C(CCO)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642719;124917;None;0;Human;Binding;Ki;=;609,50;6,21;-61;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;6;1;6;2,24;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCOC1;-
CHEMBL3642720;124918;None;0;Human;Binding;Ki;=;1044,00;5,98;-165;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;6;1;6;2,38;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCCO1;-
CHEMBL3642721;124919;None;0;Human;Binding;Ki;=;481,20;6,32;-63;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;434,3;6;1;5;3,52;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccccc1;-
CHEMBL3642722;124920;None;0;Human;Binding;Ki;=;341,90;6,47;-31;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;452,3;6;1;5;3,66;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3642723;124921;None;0;Human;Binding;Ki;=;289,20;6,54;-21;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;468,2;6;1;5;4,17;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(Cl)cc1;-
CHEMBL3642724;124922;None;0;Human;Binding;Ki;=;871,20;6,06;-46;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;502,3;6;1;5;4,54;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(C(F)(F)F)cc1;-
CHEMBL3642725;124923;None;0;Human;Binding;Ki;=;1269,50;5,90;-57;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;408,2;6;1;6;1,64;CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642726;124924;None;0;Human;Binding;Ki;=;1093,50;5,96;-61;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;422,2;7;1;6;2,03;CCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642727;124925;None;0;Human;Binding;Ki;=;240,00;6,62;-35;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;488,2;7;1;6;3,21;O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3642728;124926;None;0;Human;Binding;Ki;=;586,80;6,23;-114;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;412,3;7;1;5;3,00;O=C(CC1CC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642729;124927;None;0;Human;Binding;Ki;=;555,00;6,26;-54;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;412,3;6;1;5;3,00;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCC1;-
CHEMBL3642730;124928;None;0;Human;Binding;Ki;=;766,80;6,12;-120;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;6;1;6;2,63;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CCCOC1;-
CHEMBL3642731;124929;None;0;Human;Binding;Ki;=;506,50;6,29;-40;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;6;2;6;3,15;C[C@]1(O)CC[C@H](C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)CC1;-
CHEMBL3642732;124930;None;0;Human;Binding;Ki;=;475,00;6,32;-77;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;6;2;6;3,15;C[C@]1(O)CC[C@@H](C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)CC1;-
CHEMBL3642733;124931;None;0;Human;Binding;Ki;=;5340,00;5,27;-281;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;517,3;7;1;6;4,51;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(N2CCCCC2)cc1;-
CHEMBL3642734;124932;None;0;Human;Binding;Ki;=;867,10;6,06;-194;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;519,3;7;1;7;3,35;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(N2CCOCC2)cc1;-
CHEMBL3642735;124933;None;0;Human;Binding;Ki;=;592,90;6,23;-100;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;6;2;6;1,73;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1(O)CC1;-
CHEMBL3642736;124934;None;0;Human;Binding;Ki;=;702,50;6,15;-91;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;397,2;6;1;6;2,12;N#CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642737;124935;None;0;Human;Binding;Ki;=;687,50;6,16;-104;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;440,2;6;1;5;3,16;O=C(CC(F)(F)F)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642738;124936;None;0;Human;Binding;Ki;=;1124,00;5,95;-95;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;458,3;7;1;7;2,01;O=C(C[C@@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642739;124937;None;0;Human;Binding;Ki;=;547,50;6,26;-151;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;485,3;6;1;6;4,07;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccnc2ccccc12;-
CHEMBL3642740;124938;None;0;Human;Binding;Ki;=;485,60;6,31;-44;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;398,3;6;1;5;2,61;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CC1;-
CHEMBL3642741;124939;None;0;Human;Binding;Ki;=;1262,80;5,90;-75;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;7;1;6;2,77;O=C(CC1CCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642742;124940;None;0;Human;Binding;Ki;=;2451,90;5,61;-165;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;484,3;8;1;6;3,80;CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)CC1;-
CHEMBL3642743;124941;None;0;Human;Binding;Ki;=;781,50;6,11;-67;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;437,2;7;1;6;1,48;CN(C)S(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642744;124942;None;0;Human;Binding;Ki;=;1461,00;5,83;-181;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;458,3;7;1;7;2,01;O=C(C[C@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642745;124943;None;0;Human;Binding;Ki;=;914,70;6,04;-63;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;7;1;6;2,77;O=C(C[C@H]1CCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642746;124944;None;0;Human;Binding;Ki;=;857,90;6,07;-46;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;7;1;6;2,77;O=C(C[C@@H]1CCCO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642747;124945;None;0;Human;Binding;Ki;=;523,90;6,28;-56;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;5;1;5;3,25;CC(C)(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642748;124946;None;0;Human;Binding;Ki;=;654,80;6,18;-60;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;7;1;5;3,25;CC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642749;124947;None;0;Human;Binding;Ki;=;444,20;6,35;-27;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;6;1;5;3,64;CC(C)(C)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642750;124948;None;0;Human;Binding;Ki;=;602,70;6,22;-67;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;426,3;7;1;5;3,39;O=C(CC1CCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642751;124949;None;0;Human;Binding;Ki;=;438,30;6,36;-25;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;434,2;6;1;5;2,86;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1CC1(F)F;-
CHEMBL3642752;124950;None;0;Human;Binding;Ki;=;705,10;6,15;-69;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;400,3;6;1;5;2,86;CC(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642753;124951;None;0;Human;Binding;Ki;=;709,40;6,15;-53;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;7;1;5;3,25;CCC(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642754;124952;None;0;Human;Binding;Ki;=;754,60;6,12;-69;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;7;1;6;2,24;O=C(CC1COC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642755;124953;None;0;Human;Binding;Ki;=;322,50;6,49;-11;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;401,3;5;1;5;2,36;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642756;124954;None;0;Human;Binding;Ki;=;773,30;6,11;-40;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;426,2;5;1;5;2,77;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C(F)(F)F;-
CHEMBL3642757;124955;None;0;Human;Binding;Ki;=;198,40;6,70;-12;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;412,3;6;1;5;3,17;CC(C)=CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642758;124956;None;0;Human;Binding;Ki;=;945,40;6,02;-74;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;412,3;7;1;5;3,17;C/C=C/CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642759;124957;None;0;Human;Binding;Ki;=;425,60;6,37;-34;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;396,3;5;1;5;2,23;CC#CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642760;124958;None;0;Human;Binding;Ki;=;837,20;6,08;-35;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;358,2;6;1;5;1,83;O=CN[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642761;124959;None;0;Human;Binding;Ki;=;1304,60;5,88;-331;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;453,3;7;1;7;2,74;Cc1cc(CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)on1;-
CHEMBL3642762;124960;None;0;Human;Binding;Ki;=;396,80;6,40;-25;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;439,3;6;1;7;2,81;Cc1cc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)on1;-
CHEMBL3642763;124961;None;0;Human;Binding;Ki;=;2562,70;5,59;-107;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;457,3;8;1;6;2,07;CN(C)C(=O)CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642764;124962;None;0;Human;Binding;Ki;=;999,70;6,00;-46;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;7;2;6;2,37;CC(C)(O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642765;124963;None;0;Human;Binding;Ki;=;731,80;6,14;-37;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;7;2;6;2,52;O=C(C[C@@H](O)C(F)(F)F)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642766;124964;None;0;Human;Binding;Ki;=;887,40;6,05;-44;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;8;2;6;2,37;CC[C@H](O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642767;124965;None;0;Human;Binding;Ki;=;1291,70;5,89;-66;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;8;1;6;3,41;CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)C1;-
CHEMBL3642768;124966;None;0;Human;Binding;Ki;=;926,50;6,03;-66;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;458,3;7;2;7;1,74;O=C(CC1C[C@H](O)CO1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642769;124967;None;0;Human;Binding;Ki;=;828,30;6,08;-53;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;400,3;7;1;5;3,00;CCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642770;124968;None;0;Human;Binding;Ki;=;1277,10;5,89;-56;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;8;1;5;3,64;CC(C)CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642771;124969;None;0;Human;Binding;Ki;=;1143,60;5,94;-60;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;8;1;5;3,39;CCCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642772;124970;None;0;Human;Binding;Ki;=;1253,70;5,90;-63;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;454,3;7;1;5;3,55;O=C(CCC(F)(F)F)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642773;124971;None;0;Human;Binding;Ki;=;248,80;6,60;-53;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;384,3;5;1;5;3,34;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nc(C)cc4occc34)CC2)CC1;-
CHEMBL3642774;124972;None;0;Human;Binding;Ki;=;274,60;6,56;-19;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;454,3;6;1;6;3,75;Cc1cc2occc2c(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4CCOCC4)CC3)CC2)n1;-
CHEMBL3642775;124973;None;0;Human;Binding;Ki;=;640,60;6,19;-69;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;468,3;7;1;6;4,14;Cc1cc2occc2c(N2CCN(CC[C@H]3CC[C@H](NC(=O)CC4CCOCC4)CC3)CC2)n1;-
CHEMBL3642776;124974;None;0;Human;Binding;Ki;=;429,70;6,37;-89;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;8;1;6;3,36;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nc(C)cc4occc34)CC2)CC1;-
CHEMBL3642777;124975;None;0;Human;Binding;Ki;=;915,00;6,04;-120;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;386,3;5;1;5;2,53;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nc(C)cc4c3CCO4)CC2)CC1;-
CHEMBL3642778;124976;None;0;Human;Binding;Ki;=;1950,00;5,71;-56;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;6;1;6;2,94;Cc1cc2c(c(N3CCN(CC[C@H]4CC[C@H](NC(=O)C5CCOCC5)CC4)CC3)n1)CCO2;-
CHEMBL3642779;124977;None;0;Human;Binding;Ki;=;1486,00;5,83;-125;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;8;1;6;2,55;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nc(C)cc4c3CCO4)CC2)CC1;-
CHEMBL3642780;124978;None;0;Human;Binding;Ki;=;1461,00;5,83;-107;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;384,3;5;1;5;3,34;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ncc(C)c4occc34)CC2)CC1;-
CHEMBL3642781;124979;None;0;Human;Binding;Ki;=;1126,00;5,95;-199;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;454,3;6;1;6;3,75;Cc1cnc(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4CCOCC4)CC3)CC2)c2ccoc12;-
CHEMBL3642782;124980;None;0;Human;Binding;Ki;=;2718,00;5,57;-229;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;468,3;7;1;6;4,14;Cc1cnc(N2CCN(CC[C@H]3CC[C@H](NC(=O)CC4CCOCC4)CC3)CC2)c2ccoc12;-
CHEMBL3642783;124981;None;0;Human;Binding;Ki;=;2471,00;5,61;-204;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;8;1;6;3,36;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ncc(C)c4occc34)CC2)CC1;-
CHEMBL3642784;124982;None;0;Human;Binding;Ki;=;2308,00;5,64;-47;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;386,3;5;1;5;2,53;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ncc(C)c4c3CCO4)CC2)CC1;-
CHEMBL3642785;124983;None;0;Human;Binding;Ki;=;4510,00;5,35;-229;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;6;1;6;2,94;Cc1cnc(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4CCOCC4)CC3)CC2)c2c1OCC2;-
CHEMBL3642786;124984;None;0;Human;Binding;Ki;=;2951,00;5,53;-67;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;7;1;6;3,33;Cc1cnc(N2CCN(CC[C@H]3CC[C@H](NC(=O)CC4CCOCC4)CC3)CC2)c2c1OCC2;-
CHEMBL3642787;124985;None;0;Human;Binding;Ki;=;3564,00;5,45;-95;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;8;1;6;2,55;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ncc(C)c4c3CCO4)CC2)CC1;-
CHEMBL3642788;124986;None;0;Human;Binding;Ki;=;842,60;6,07;-74;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,2;6;2;6;2,13;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C(O)C(F)(F)F;-
CHEMBL3642789;124987;None;0;Human;Binding;Ki;=;1384,90;5,86;-87;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;446,3;9;1;7;2,21;COC(CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)OC;-
CHEMBL3642790;124988;None;0;Human;Binding;Ki;=;2365,40;5,63;-128;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;460,3;10;1;7;2,60;COC(CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)OC;-
CHEMBL3642791;124989;None;0;Human;Binding;Ki;=;516,00;6,29;-53;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;518,2;7;1;8;2,98;CS(=O)(=O)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)s1;-
CHEMBL3642792;124990;None;0;Human;Binding;Ki;=;312,60;6,50;-20;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;449,3;6;1;6;3,22;Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)cn1;-
CHEMBL3642793;124991;None;0;Human;Binding;Ki;=;381,20;6,42;-29;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;459,3;6;1;6;3,39;N#Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)cc1;-
CHEMBL3642794;124992;None;0;Human;Binding;Ki;=;179,50;6,75;-39;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;532,4;7;1;7;3,27;CN1CCN(c2ccc(C(=O)N[C@H]3CC[C@H](CCN4CCN(c5nccc6c5CCO6)CC4)CC3)cc2)CC1;-
CHEMBL3642795;124993;None;0;Human;Binding;Ki;=;998,40;6,00;-64;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;520,3;7;1;8;2,75;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(N2CCOCC2)nc1;-
CHEMBL3642796;124994;None;0;Human;Binding;Ki;=;222,90;6,65;-18;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;511,3;7;1;6;4,58;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(-c2cccnc2)cc1;-
CHEMBL3642797;124995;None;0;Human;Binding;Ki;=;3372,00;5,47;-190;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;478,3;6;1;7;3,25;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc2c(c1)OCO2;-
CHEMBL3642798;124996;None;0;Human;Binding;Ki;=;3042,00;5,52;-162;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;492,3;7;1;7;3,17;O=C(Cc1ccc2c(c1)OCO2)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642799;124997;None;0;Human;Binding;Ki;=;958,60;6,02;-97;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;6;2;6;2,12;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)C1(O)CCC1;-
CHEMBL3642800;124998;None;0;Human;Binding;Ki;=;1265,00;5,90;-162;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,3;6;2;6;1,97;CC(C)(O)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642801;124999;None;0;Human;Binding;Ki;=;116,60;6,93;-8;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;567,3;7;1;8;2,75;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(N2CCS(=O)(=O)CC2)cc1;-
CHEMBL3642802;125000;None;0;Human;Binding;Ki;=;478,00;6,32;-13;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;500,3;7;1;7;3,70;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(-n2cccn2)cc1;-
CHEMBL3642803;125001;None;0;Human;Binding;Ki;=;2147,00;5,67;-109;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;516,3;7;1;8;3,88;Cc1nc(-c2cccc(C(=O)N[C@H]3CC[C@H](CCN4CCN(c5nccc6c5CCO6)CC4)CC3)c2)no1;-
CHEMBL3642804;125002;None;0;Human;Binding;Ki;=;500,60;6,30;-24;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;485,3;6;1;6;4,07;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc2ncccc2c1;-
CHEMBL3642805;125003;None;0;Human;Binding;Ki;=;1308,90;5,88;-89;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;489,3;7;1;7;3,59;O=C(Cc1noc2ccccc12)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642806;125004;None;0;Human;Binding;Ki;=;506,00;6,30;-27;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;521,3;7;1;9;2,14;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1cnc(N2CCOCC2)cn1;-
CHEMBL3642807;125005;None;0;Human;Binding;Ki;=;1663,00;5,78;-25;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;490,3;6;1;5;4,82;CC(C)(C)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)cc1;-
CHEMBL3642808;125006;None;0;Human;Binding;Ki;=;518,30;6,29;-23;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;502,2;6;1;5;4,82;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(Cl)cc1Cl;-
CHEMBL3642809;125007;None;0;Human;Binding;Ki;=;163,30;6,79;-6;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;499,3;7;1;6;4,31;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(-n2cccc2)cc1;-
CHEMBL3642810;125008;None;0;Human;Binding;Ki;=;1132,00;5,95;-60;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;510,3;7;1;5;5,18;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccc(-c2ccccc2)cc1;-
CHEMBL3642811;125009;None;0;Human;Binding;Ki;=;680,50;6,17;-95;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,3;7;1;6;2,24;CO[C@H](C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642812;125010;None;0;Human;Binding;Ki;=;3161,00;5,50;-75;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;506,3;7;1;6;4,70;CC(C)(C)Oc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4nccc5c4CCO5)CC3)CC2)cc1;-
CHEMBL3642813;125011;None;0;Human;Binding;Ki;=;788,50;6,10;-39;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,3;7;1;6;2,24;CO[C@@H](C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642814;125012;None;0;Human;Binding;Ki;=;242,60;6,62;-15;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,2;7;1;6;3,07;O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1)c1ccccc1;-
CHEMBL3642815;125013;None;0;Human;Binding;Ki;=;801,30;6,10;-26;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;8;1;6;2,63;COC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642816;125014;None;0;Human;Binding;Ki;=;842,70;6,07;-20;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;8;2;6;2,37;CC[C@@H](O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL3642817;125015;None;0;Human;Binding;Ki;=;408,60;6,39;-18;3;Radioligand Binding Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;7;2;6;2,51;O=C(CC1(O)CCC1)N[C@H]1CC[C@H](CCN2CCN(c3nccc4c3CCO4)CC2)CC1;-
CHEMBL364565;125490;None;0;Human;Binding;Ki;=;1015,00;5,99;-40;6;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;295,2;6;0;2;4,14;c1ccc(Cc2ccccc2OCCN2CCCCC2)cc1;https://dx.doi.org/10.1021/jm049720x
CHEMBL364586;125494;None;0;Human;Binding;Ki;=;5317,00;5,27;-3;3;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;295,2;6;0;3;3,39;O=C(c1ccccc1)c1ccccc1OCCN1CCCC1;https://dx.doi.org/10.1021/jm049720x
CHEMBL3646149;125522;None;0;Human;Binding;Ki;=;11,00;7,96;-;1;Binding Assay: The ability of test compounds to displace 3H-raclopride at the D2s receptor can be determined on membranes from D2s-transfected CHO cells (Bmax 13 pmol/mg protein). An assay can use a standard 96-well glass-fiber filter plate to retain radioligand bound by the receptor. Retained 3H can be determined in a TopCount scintillation plate counter following the addition of a liquid scintillant to each well. Compounds can be evaluated for their potency using competition curve analysis, resulting in calculated Ki values.;ChEMBL;313,1;0;1;4;3,27;Fc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1S2;-
CHEMBL3646150;125523;None;5;Human;Binding;Ki;=;0,70;9,15;-;1;Binding Assay: The ability of test compounds to displace 3H-raclopride at the D2s receptor can be determined on membranes from D2s-transfected CHO cells (Bmax 13 pmol/mg protein). An assay can use a standard 96-well glass-fiber filter plate to retain radioligand bound by the receptor. Retained 3H can be determined in a TopCount scintillation plate counter following the addition of a liquid scintillant to each well. Compounds can be evaluated for their potency using competition curve analysis, resulting in calculated Ki values.;ChEMBL;329,1;0;1;4;3,79;Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1S2;-
CHEMBL3646151;125524;None;0;Human;Binding;Ki;=;1,10;8,96;-;1;Binding Assay: The ability of test compounds to displace 3H-raclopride at the D2s receptor can be determined on membranes from D2s-transfected CHO cells (Bmax 13 pmol/mg protein). An assay can use a standard 96-well glass-fiber filter plate to retain radioligand bound by the receptor. Retained 3H can be determined in a TopCount scintillation plate counter following the addition of a liquid scintillant to each well. Compounds can be evaluated for their potency using competition curve analysis, resulting in calculated Ki values.;ChEMBL;327,1;0;0;4;3,62;CN1CCN(C2=Nc3ccccc3Sc3ccc(F)cc32)CC1;-
CHEMBL364759;125815;None;0;Human;Binding;Ki;=;21,90;7,66;-9;2;Binding affinity for human dopamine D2 receptor;ChEMBL;448,1;7;1;5;4,01;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc([N+](=O)[O-])c1;https://dx.doi.org/10.1021/jm049465g
CHEMBL3647673;125816;None;0;Human;Binding;Ki;=;10,80;7,97;-269;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1424,8;22;16;13;3,92;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647674;125817;None;0;Human;Binding;Ki;=;6,90;8,16;-8;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1438,8;23;16;13;4,31;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCCC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647675;125818;None;0;Human;Binding;Ki;=;45,20;7,34;-63;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1452,8;24;16;13;4,70;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCCCC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647676;125819;None;0;Human;Binding;Ki;=;182,50;6,74;-1513;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1602,8;27;18;17;3,57;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647677;125820;None;0;Human;Binding;Ki;=;28,50;7,54;-85;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1619,8;27;18;16;4,31;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647678;125821;None;0;Human;Binding;Ki;=;100,90;7,00;-331;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1456,8;23;16;14;3,88;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647679;125822;None;0;Human;Binding;Ki;=;16,90;7,77;-48;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1474,8;23;16;14;4,02;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)c(F)c2)NC1=O;-
CHEMBL3647680;125823;None;0;Human;Binding;Ki;=;25,40;7,59;-102;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1474,8;23;16;14;4,02;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2cc(F)cc(F)c2)NC1=O;-
CHEMBL3647681;125824;None;0;Human;Binding;Ki;=;30,30;7,52;-199;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1456,8;23;16;14;3,88;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2cccc(F)c2)NC1=O;-
CHEMBL3647682;125825;None;0;Human;Binding;Ki;=;31,80;7,50;-58;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1456,8;23;16;14;3,88;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2F)NC1=O;-
CHEMBL3647683;125826;None;0;Human;Binding;Ki;=;40,40;7,39;-7;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1528,7;23;16;14;4,43;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2c(F)c(F)c(F)c(F)c2F)NC1=O;-
CHEMBL3647684;125827;None;0;Human;Binding;Ki;=;34,30;7,46;-436;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1455,8;23;17;16;2,84;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647685;125828;None;0;Human;Binding;Ki;=;112,80;6,95;-537;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1896;34;20;20;5,49;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](CCCCNC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647686;125829;None;0;Human;Binding;Ki;=;39,20;7,41;-301;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1880;34;19;19;5,78;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](CCCCNC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647687;125830;None;0;Human;Binding;Ki;=;56,40;7,25;-354;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1488,8;23;16;15;2,56;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCS(=O)(=O)C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647688;125831;None;0;Human;Binding;Ki;=;31,60;7,50;-512;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1471,8;23;17;16;1,85;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCC[S@@+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647688;125831;None;0;Human;Binding;Ki;=;255,10;6,59;-512;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1471,8;23;17;16;1,85;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCC[S@@+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647689;125832;None;0;Human;Binding;Ki;=;32,50;7,49;-812;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1635,8;27;18;16;3,33;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)C[S+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647690;125833;None;0;Human;Binding;Ki;=;76,50;7,12;-1513;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1472,8;23;16;14;2,89;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCC[S+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647691;125834;None;0;Human;Binding;Ki;=;149,30;6,83;-7413;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1618,8;27;18;17;2,58;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)C[S+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647692;125835;None;0;Human;Binding;Ki;=;22,50;7,65;-562;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1928;34;20;20;3,52;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](CCCCNC(=O)C[S+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)NC(=O)C[S+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647693;125836;None;0;Human;Binding;Ki;=;67,60;7,17;-851;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1912;34;19;19;3,81;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](CCCCNC(=O)C[S+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)NC(=O)C[S+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647695;125838;None;0;Human;Binding;Ki;=;114,60;6,94;-5754;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1487,8;23;17;17;1,52;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCS(=O)(=O)C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647697;125840;None;0;Human;Binding;Ki;=;199,50;6,70;-575;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1495,8;24;16;14;3,38;CC(=O)N(CCCNC[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1)[C@@H]1CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC1=O;-
CHEMBL3647698;125841;None;0;Human;Binding;Ki;=;328,30;6,48;-3715;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1439,8;23;16;15;3,13;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647699;125842;None;0;Human;Binding;Ki;=;175,30;6,76;-2187;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1453,7;22;16;15;2,66;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647700;125843;None;0;Human;Binding;Ki;=;272,40;6,57;-5370;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1469,7;22;17;16;2,37;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647701;125844;None;0;Human;Binding;Ki;=;309,00;6,51;-138;3;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1438,8;23;16;14;3,74;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647702;125845;None;0;Human;Binding;Ki;=;276,80;6,56;-851;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1658,9;28;18;16;3,82;CC(=O)N(CCC(=O)N[C@@H](CN[C@@H]1CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC1=O)Cc1ccc(O)cc1)C[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
CHEMBL3647703;125846;None;0;Human;Binding;Ki;=;39,90;7,40;-52;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1537,8;24;15;14;3,64;CC(=O)N(CCCN(C(C)=O)[C@@H]1CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC1=O)C[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
CHEMBL3647704;125847;None;0;Human;Binding;Ki;=;14,00;7,85;-354;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1644,9;29;18;16;4,29;CC(=O)N(CCCN[C@@H](CN[C@@H]1CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC1=O)Cc1ccc(O)cc1)C[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
CHEMBL3647705;125848;None;0;Human;Binding;Ki;=;135,20;6,87;-954;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1737,9;28;16;17;6,72;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N(CCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647706;125849;None;0;Human;Binding;Ki;=;46,80;7,33;-363;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1495,8;24;16;14;3,38;CC(=O)N(CCCN[C@@H]1CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC1=O)C[C@@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
CHEMBL3647707;125850;None;0;Human;Binding;Ki;=;44,00;7,36;-97;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1601,8;27;18;16;4,17;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647707;125850;None;0;Human;Binding;Ki;=;24,20;7,62;-97;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1601,8;27;18;16;4,17;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647708;125851;None;0;Human;Binding;Ki;=;38,60;7,41;-52;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1601,8;27;18;16;4,17;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647709;125852;None;0;Human;Binding;Ki;=;15,00;7,82;-63;4;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1617,8;27;19;17;3,88;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647710;125853;None;0;Human;Binding;Ki;=;298,90;6,52;-66;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1470,7;22;16;14;3,40;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3647711;125854;None;0;Human;Binding;Ki;=;345,20;6,46;-2041;3;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1753,9;28;17;18;6,43;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N(CCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL3647712;125855;None;0;Human;Binding;Ki;=;25,30;7,60;-18;3;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1615,8;26;18;16;3,70;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647713;125856;None;0;Human;Binding;Ki;=;179,40;6,75;-234;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1602,8;27;18;17;3,57;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2cccnc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3647714;125857;None;0;Human;Binding;Ki;=;329,70;6,48;-89;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1754,9;28;16;16;7,46;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N(CCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL364782;125859;None;0;Human;Binding;Ki;=;1000,00;6,00;-501;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@H]1CCN(Cc2ccccc2)C1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL3650452;126442;None;0;Human;Binding;Ki;=;444,90;6,35;-141;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1736,9;28;16;16;7,33;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N(CCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3650453;126443;None;0;Human;Binding;Ki;=;8,50;8,07;-22;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1601,8;27;18;16;4,17;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@@H](Cc2ccc(O)cc2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3650454;126444;None;0;Human;Binding;Ki;=;285,30;6,54;-416;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1694,9;29;18;17;3,23;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](Cc2ccc(O)cc2)NC(=O)CCN(C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)S(C)(=O)=O)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3650455;126445;None;0;Human;Binding;Ki;=;199,60;6,70;-144;3;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1452,8;22;16;14;3,27;C[C@@H](O)C1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccccc2)NC1=O;-
CHEMBL3650456;126446;None;0;Human;Binding;Ki;=;84,20;7,08;-144;3;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1897;34;19;18;6,52;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NC[C@H](CCCCNC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)NC(=O)CSC[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL3650457;126447;None;0;Human;Binding;Ki;=;19,40;7,71;-77;2;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1502,8;24;16;15;2,95;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCCCS(=O)(=O)C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(F)cc2)NC1=O;-
CHEMBL365605;127126;None;0;Human;Binding;Ki;=;24,00;7,62;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;411,2;5;1;4;4,35;Clc1cccc2[nH]cc(CCCN3CCN(c4cccc5c4OCCO5)CC3)c12;https://dx.doi.org/10.1021/jm050148z
CHEMBL366043;127533;None;0;Human;Binding;Ki;=;2600,00;5,58;-524;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;390,1;5;1;2;5,01;O=C(NC1CCN(Cc2ccccc2)C1)c1ccc(-c2ccc(Cl)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL366081;127547;None;2;Human;Binding;Ki;=;62,70;7,20;2;3;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;318,2;4;1;2;4,47;COc1ccc2[nH]cc(C3=CCN(Cc4ccccc4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL366164;127578;None;0;Human;Binding;Ki;=;12,00;7,92;-8;9;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;329,1;2;0;3;4,47;CN(C)C[C@H]1C[C@@H]2c3ccccc3Sc3ccc(F)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL366304;127616;None;0;Human;Binding;Ki;=;900,00;6,05;-50;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@@H]1CCN(Cc2ccccc2)C1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL3664814;128044;None;0;Human;Binding;Ki;=;253,68;6,60;-50;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;372,2;5;1;4;3,68;CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664815;128045;None;0;Human;Binding;Ki;=;426,60;6,37;-72;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,3;8;1;5;3,70;COCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664816;128046;None;0;Human;Binding;Ki;=;529,67;6,28;-58;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;458,3;7;1;6;3,46;O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664817;128047;None;0;Human;Binding;Ki;=;467,56;6,33;-47;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;458,3;7;1;6;3,46;O=C(C[C@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664818;128048;None;0;Human;Binding;Ki;=;332,35;6,48;-34;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;458,3;7;1;6;3,46;O=C(C[C@@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664819;128049;None;0;Human;Binding;Ki;=;389,06;6,41;-42;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;7;1;5;4,23;O=C(CC1CCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664820;128050;None;0;Human;Binding;Ki;=;203,61;6,69;-48;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;386,3;6;1;4;4,07;CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664821;128051;None;0;Human;Binding;Ki;=;302,84;6,52;-120;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;412,3;7;1;4;4,46;O=C(CC1CC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664822;128052;None;0;Human;Binding;Ki;=;120,38;6,92;-33;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;434,3;6;1;4;4,97;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)c1ccccc1;-
CHEMBL3664823;128053;None;0;Human;Binding;Ki;=;209,41;6,68;-52;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;440,2;6;1;4;4,61;O=C(CC(F)(F)F)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664824;128054;None;0;Human;Binding;Ki;=;410,40;6,39;-52;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;454,2;7;1;4;5,00;O=C(CCC(F)(F)F)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664825;128055;None;0;Human;Binding;Ki;=;235,50;6,63;-27;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,2;6;2;5;3,58;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C(O)C(F)(F)F;-
CHEMBL3664826;128056;None;0;Human;Binding;Ki;=;507,18;6,29;-34;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;402,3;7;1;5;3,31;COCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664827;128057;None;0;Human;Binding;Ki;=;152,76;6,82;-19;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;459,3;6;1;5;4,84;N#Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)cc1;-
CHEMBL3664828;128058;None;0;Human;Binding;Ki;=;133,46;6,88;-11;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;449,3;6;1;5;4,68;Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)cn1;-
CHEMBL3664829;128059;None;0;Human;Binding;Ki;=;227,84;6,64;-21;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;7;1;5;4,23;O=C(C[C@H]1CCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664830;128060;None;0;Human;Binding;Ki;=;531,19;6,28;-81;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;7;1;5;4,23;O=C(C[C@@H]1CCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664831;128061;None;0;Human;Binding;Ki;=;133,11;6,88;-40;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;388,2;5;1;5;3,90;COC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664832;128062;None;0;Human;Binding;Ki;=;515,70;6,29;-426;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;453,3;7;1;6;4,20;Cc1cc(CC(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)on1;-
CHEMBL3664833;128063;None;0;Human;Binding;Ki;=;202,82;6,69;-66;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;397,2;6;1;5;3,57;N#CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664834;128064;None;0;Human;Binding;Ki;=;361,06;6,44;-35;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;7;2;5;4,75;O=C(CC1(O)CCCCC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664835;128065;None;0;Human;Binding;Ki;=;523,08;6,28;-56;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;7;1;5;4,62;O=C(CC1CCCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664836;128066;None;0;Human;Binding;Ki;=;397,43;6,40;-47;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;400,3;6;1;4;4,32;CC(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664837;128067;None;0;Human;Binding;Ki;=;238,80;6,62;-47;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;7;1;4;4,71;CC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664838;128068;None;0;Human;Binding;Ki;=;277,39;6,56;-47;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;400,3;7;1;4;4,46;CCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664839;128069;None;0;Human;Binding;Ki;=;194,24;6,71;-25;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;434,2;6;1;4;4,32;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1CC1(F)F;-
CHEMBL3664840;128070;None;0;Human;Binding;Ki;=;402,37;6,39;-53;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;8;1;5;4,08;COC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664841;128071;None;0;Human;Binding;Ki;=;305,12;6,52;-47;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;446,2;6;1;4;4,68;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1CC(Cl)C1;-
CHEMBL3664842;128072;None;0;Human;Binding;Ki;=;258,19;6,59;-50;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;7;1;5;3,70;O=C(CC1COC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664843;128073;None;0;Human;Binding;Ki;=;330,53;6,48;-63;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;8;1;5;4,87;CO[C@@H]1CC[C@@H](CC(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)C1;-
CHEMBL3664844;128074;None;0;Human;Binding;Ki;=;305,62;6,51;-43;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;472,3;7;2;6;3,59;O=C(CC1(O)CCOCC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664845;128075;None;0;Human;Binding;Ki;=;406,70;6,39;-85;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,3;6;2;5;3,43;CC(C)(O)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664846;128076;None;0;Human;Binding;Ki;=;463,94;6,33;-16;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,3;7;1;5;3,69;CO[C@@H](C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664847;128077;None;0;Human;Binding;Ki;=;503,95;6,30;-52;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;416,3;7;1;5;3,69;CO[C@H](C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664848;128078;None;0;Human;Binding;Ki;=;281,84;6,55;-47;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;7;2;5;3,82;CC(C)(O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664849;128079;None;0;Human;Binding;Ki;=;146,90;6,83;-23;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;468,2;6;1;4;5,63;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)c1ccc(Cl)cc1;-
CHEMBL3664850;128080;None;0;Human;Binding;Ki;=;233,95;6,63;-47;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;452,2;6;1;4;5,11;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3664851;128081;None;0;Human;Binding;Ki;=;208,99;6,68;-27;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,2;6;2;5;3,58;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)[C@H](O)C(F)(F)F;-
CHEMBL3664852;128082;None;0;Human;Binding;Ki;=;283,73;6,55;-14;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,2;6;2;5;3,58;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)[C@@H](O)C(F)(F)F;-
CHEMBL3664853;128083;None;0;Human;Binding;Ki;=;422,11;6,38;-46;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;7;1;5;4,62;O=C(C[C@@H]1CCCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664854;128084;None;0;Human;Binding;Ki;=;491,09;6,31;-64;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;7;1;5;4,62;O=C(C[C@H]1CCCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664855;128085;None;0;Human;Binding;Ki;=;321,69;6,49;-27;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;7;1;5;4,48;O=C(C[C@@H]1CCCOC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664856;128086;None;0;Human;Binding;Ki;=;393,12;6,41;-52;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;430,3;9;1;5;4,09;CCOCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664857;128087;None;0;Human;Binding;Ki;=;262,23;6,58;-40;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;7;2;5;3,96;O=C(CC1(O)CCC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664858;128088;None;0;Human;Binding;Ki;=;463,70;6,33;-32;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;6;1;5;3,84;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1CCCO1;-
CHEMBL3664859;128089;None;0;Human;Binding;Ki;=;165,40;6,78;-21;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;6;1;5;3,70;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1CCOC1;-
CHEMBL3664860;128090;None;0;Human;Binding;Ki;=;183,74;6,74;-19;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;442,3;6;1;5;4,09;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1CCOCC1;-
CHEMBL3664861;128091;None;0;Human;Binding;Ki;=;245,32;6,61;-39;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;6;2;5;3,19;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1(O)CC1;-
CHEMBL3664862;128092;None;0;Human;Binding;Ki;=;245,54;6,61;-12;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;466,2;6;1;4;5,00;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1(C(F)(F)F)CC1;-
CHEMBL3664863;128093;None;0;Human;Binding;Ki;=;351,61;6,45;-25;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;414,3;7;1;4;4,71;CCC(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664864;128094;None;0;Human;Binding;Ki;=;130,00;6,89;-28;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;476,2;6;1;6;3,09;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1CCS(=O)(=O)C1;-
CHEMBL3664865;128095;None;0;Human;Binding;Ki;=;351,77;6,45;-39;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;7;1;5;4,48;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664866;128096;None;0;Human;Binding;Ki;=;100,30;7,00;-12;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;412,3;6;1;4;4,46;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1CCC1;-
CHEMBL3664867;128097;None;0;Human;Binding;Ki;=;164,90;6,78;-35;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;450,2;7;1;6;2,70;CS(=O)(=O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664868;128098;None;0;Human;Binding;Ki;=;593,34;6,23;-58;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;519,3;7;1;6;4,81;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)c1ccc(N2CCOCC2)cc1;-
CHEMBL3664869;128099;None;0;Human;Binding;Ki;=;370,18;6,43;-60;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;485,3;6;1;5;5,52;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)c1ccnc2ccccc12;-
CHEMBL3664870;128100;None;0;Human;Binding;Ki;=;345,34;6,46;-93;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;492,3;6;1;6;4,75;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)c1ccc2c(c1)OCCO2;-
CHEMBL3664871;128101;None;0;Human;Binding;Ki;=;324,88;6,49;-81;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;492,3;7;1;6;4,63;O=C(Cc1ccc2c(c1)OCO2)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664872;128102;None;0;Human;Binding;Ki;=;1047,58;5,98;-154;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;490,3;6;1;5;4,91;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1COc2ccccc2C1;-
CHEMBL3664873;128103;None;0;Human;Binding;Ki;=;149,51;6,83;-25;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;455,3;6;1;5;4,00;CN1CCC(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)CC1;-
CHEMBL3664874;128104;None;0;Human;Binding;Ki;=;225,02;6,65;-10;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;428,3;6;1;5;3,70;CC1(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)COC1;-
CHEMBL3664875;128105;None;0;Human;Binding;Ki;=;360,81;6,44;-44;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;484,3;8;1;5;5,25;CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)CC1;-
CHEMBL3664876;128106;None;0;Human;Binding;Ki;=;268,44;6,57;-25;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;402,3;6;2;5;3,04;C[C@@H](O)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664877;128107;None;0;Human;Binding;Ki;=;297,86;6,53;-32;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;388,2;6;2;5;2,65;O=C(CO)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664878;128108;None;0;Human;Binding;Ki;=;218,85;6,66;-56;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;456,3;6;2;5;4,36;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C1(O)CCCCC1;-
CHEMBL3664879;128109;None;0;Human;Binding;Ki;=;196,50;6,71;-16;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;7;1;5;5,01;COC1(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)CCCCC1;-
CHEMBL3664880;128110;None;0;Human;Binding;Ki;=;103,73;6,98;-5;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,3;7;1;6;2,91;CN1CCN(CC(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)CC1;-
CHEMBL3664881;128111;None;0;Human;Binding;Ki;=;413,56;6,38;-39;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;408,2;6;1;5;3,09;CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664882;128112;None;0;Human;Binding;Ki;=;63,45;7,20;-17;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;470,2;7;1;5;4,52;O=S(=O)(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)c1ccccc1;-
CHEMBL3664883;128113;None;0;Human;Binding;Ki;=;104,22;6,98;-39;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;488,2;7;1;5;4,66;O=S(=O)(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3664884;128114;None;0;Human;Binding;Ki;=;114,29;6,94;-9;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;474,2;7;1;7;3,26;Cn1cnc(S(=O)(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4OCO5)CC3)CC2)c1;-
CHEMBL3664885;128115;None;0;Human;Binding;Ki;=;346,12;6,46;-16;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;426,2;5;1;4;4,22;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)C(F)(F)F;-
CHEMBL3664886;128116;None;0;Human;Binding;Ki;=;229,19;6,64;-44;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;475,3;5;1;4;5,32;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)N1CCc2ccccc21;-
CHEMBL3664887;128117;None;0;Human;Binding;Ki;=;52,74;7,28;-1;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;401,3;5;1;4;3,81;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664888;128118;None;0;Human;Binding;Ki;=;229,70;6,64;-18;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;390,2;6;1;4;3,63;O=C(CF)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664889;128119;None;0;Human;Binding;Ki;=;2707,02;5,57;-114;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;483,2;6;2;4;6,02;O=C(Nc1ccc(Cl)cc1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664890;128120;None;0;Human;Binding;Ki;=;229,21;6,64;-19;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;437,2;7;1;5;2,94;CN(C)S(=O)(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3664891;128121;None;0;Human;Binding;Ki;=;229,43;6,64;-37;3;Biochemical Assay: The ability of the compounds to bind to the 5-HT2A, D3 and D2 receptors was determined using radioligand binding to cloned receptors selectively expressed in HEK-293 EBNA cells.;ChEMBL;479,2;7;1;6;2,71;O=S(=O)(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3OCO4)CC2)CC1)N1CCOCC1;-
CHEMBL366900;128754;None;0;Human;Binding;Ki;=;6,10;8,21;-6;2;Binding affinity for human dopamine D2 receptor;ChEMBL;421,1;6;1;3;4,24;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL366904;128788;None;0;Human;Binding;Ki;=;76,50;7,12;-25;5;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;443,1;6;1;4;4,85;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm040190e
CHEMBL366904;128788;None;0;Human;Binding;Ki;=;76,50;7,12;-25;5;Binding affinity for human dopamine D2 receptor;ChEMBL;443,1;6;1;4;4,85;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm049465g
CHEMBL366904;128788;None;0;Human;Binding;Ki;=;131,00;6,88;-25;5;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;443,1;6;1;4;4,85;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2o1;https://dx.doi.org/10.1021/jm040190e
CHEMBL367045;129116;None;0;Human;Binding;Ki;=;13,00;7,89;-11;8;In vitro binding affinity towards Dopamine receptor D2 in human using [3H]-spiperone as radioligand;ChEMBL;297,1;1;0;4;3,16;CN1CCN(C2=Cn3cccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1021/jm0309811
CHEMBL367129;129501;None;0;Human;Binding;Ki;=;199,53;6,70;-79;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;574,2;10;1;6;5,35;CC(=O)c1ccc(-c2ccc(C(=O)NCCCCN3CCc4ccc(OS(=O)(=O)C(F)(F)F)cc4C3)cc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL3676846;130062;None;0;Human;Binding;Ki;=;50,40;7,30;-46;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;368,2;5;1;3;4,70;CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676847;130063;None;0;Human;Binding;Ki;=;71,18;7,15;-57;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;412,3;8;1;4;4,71;COCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676848;130064;None;0;Human;Binding;Ki;=;37,32;7,43;-15;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;438,3;6;1;4;5,10;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1CCOCC1;-
CHEMBL3676849;130065;None;0;Human;Binding;Ki;=;77,56;7,11;-24;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;452,3;7;1;4;5,49;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676850;130066;None;0;Human;Binding;Ki;=;48,10;7,32;-38;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;382,3;6;1;3;5,09;CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676851;130067;None;0;Human;Binding;Ki;=;80,10;7,10;-23;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;398,3;7;1;4;4,32;COCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676852;130068;None;0;Human;Binding;Ki;=;50,80;7,29;-35;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;446,2;7;1;5;3,72;CS(=O)(=O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676853;130069;None;0;Human;Binding;Ki;=;85,90;7,07;-42;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;454,3;7;1;5;4,48;O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676854;130070;None;0;Human;Binding;Ki;=;32,32;7,49;-23;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;430,3;6;1;3;5,99;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccccc1;-
CHEMBL3676855;130071;None;0;Human;Binding;Ki;=;83,59;7,08;-123;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;449,3;7;1;5;5,22;Cc1cc(CC(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)on1;-
CHEMBL3676856;130072;None;0;Human;Binding;Ki;=;46,52;7,33;-31;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;384,2;6;2;4;3,67;O=C(CO)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676857;130073;None;0;Human;Binding;Ki;=;42,66;7,37;-42;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;436,2;6;1;3;5,63;O=C(CC(F)(F)F)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676858;130074;None;0;Human;Binding;Ki;=;406,32;6,39;-54;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;515,3;7;1;5;5,83;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(N2CCOCC2)cc1;-
CHEMBL3676859;130075;None;0;Human;Binding;Ki;=;39,54;7,40;-22;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;396,3;6;1;3;5,33;CC(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676860;130077;None;0;Human;Binding;Ki;=;43,49;7,36;-22;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;7;1;3;5,72;CC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676861;130078;None;0;Human;Binding;Ki;=;53,71;7,27;-23;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;412,3;6;2;4;4,45;CC(C)(O)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676862;130079;None;0;Human;Binding;Ki;=;52,97;7,28;-23;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;424,3;6;1;4;4,71;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1CCOC1;-
CHEMBL3676863;130080;None;0;Human;Binding;Ki;=;81,48;7,09;-28;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;424,3;6;1;4;4,86;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1CCCO1;-
CHEMBL3676864;130081;None;0;Human;Binding;Ki;=;96,68;7,01;-28;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;481,3;6;1;4;6,54;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccnc2ccccc12;-
CHEMBL3676865;130082;None;0;Human;Binding;Ki;=;38,05;7,42;-20;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;408,3;6;1;3;5,48;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1CCC1;-
CHEMBL3676866;130083;None;0;Human;Binding;Ki;=;62,94;7,20;-50;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;398,3;7;2;4;4,06;O=C(CCO)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676867;130084;None;0;Human;Binding;Ki;=;47,49;7,32;-32;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;6;2;4;4,20;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1(O)CC1;-
CHEMBL3676868;130085;None;0;Human;Binding;Ki;=;41,51;7,38;-50;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;393,2;6;1;4;4,59;N#CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676869;130086;None;0;Human;Binding;Ki;=;68,89;7,16;-22;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;448,3;6;1;3;6,13;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3676870;130087;None;0;Human;Binding;Ki;=;33,71;7,47;-15;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;408,3;7;1;3;5,48;O=C(CC1CC1)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676871;130088;None;0;Human;Binding;Ki;=;37,09;7,43;-7;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;438,3;6;1;4;5,10;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1CCCOC1;-
CHEMBL3676872;130089;None;0;Human;Binding;Ki;=;22,68;7,64;-8;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;394,3;6;1;3;5,09;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1CC1;-
CHEMBL3676873;130090;None;0;Human;Binding;Ki;=;37,96;7,42;-6;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;5;1;3;5,72;CC(C)(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676874;130091;None;0;Human;Binding;Ki;=;52,86;7,28;-19;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;438,3;7;1;4;5,25;O=C(CC1CCCO1)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676875;130092;None;0;Human;Binding;Ki;=;28,11;7,55;-7;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;430,2;6;1;3;5,33;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1CC1(F)F;-
CHEMBL3676876;130093;None;0;Human;Binding;Ki;=;46,02;7,34;-9;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;7;1;3;5,72;CCC(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676877;130094;None;0;Human;Binding;Ki;=;46,39;7,33;-11;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;452,2;6;2;4;4,60;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C(O)C(F)(F)F;-
CHEMBL3676878;130095;None;0;Human;Binding;Ki;=;45,27;7,34;-26;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;396,3;7;1;3;5,48;CCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676879;130096;None;0;Human;Binding;Ki;=;41,33;7,38;-18;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;7;2;4;4,84;CC(C)(O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676880;130097;None;0;Human;Binding;Ki;=;50,42;7,30;-21;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;466,2;7;2;4;4,99;O=C(C[C@@H](O)C(F)(F)F)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676881;130098;None;0;Human;Binding;Ki;=;47,35;7,33;-16;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;404,2;6;1;4;4,11;CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676882;130099;None;0;Human;Binding;Ki;=;47,99;7,32;-16;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;418,2;7;1;4;4,50;CCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676883;130100;None;0;Human;Binding;Ki;=;58,62;7,23;-9;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;480,2;7;1;4;5,85;Cc1ccc(S(=O)(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL3676884;130101;None;0;Human;Binding;Ki;=;37,47;7,43;-9;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;422,2;5;1;3;5,24;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C(F)(F)F;-
CHEMBL3676885;130102;None;0;Human;Binding;Ki;=;53,03;7,28;-12;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;424,3;6;1;3;6,11;CC(C)(C)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676886;130103;None;0;Human;Binding;Ki;=;36,41;7,44;-8;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;435,3;6;1;5;5,29;Cc1cc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)on1;-
CHEMBL3676887;130104;None;0;Human;Binding;Ki;=;92,30;7,04;-37;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;453,3;8;1;4;4,55;CN(C)C(=O)CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676888;130105;None;0;Human;Binding;Ki;=;47,02;7,33;-15;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;433,2;7;1;4;3,96;CN(C)S(=O)(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676889;130106;None;0;Human;Binding;Ki;=;61,16;7,21;-20;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;450,2;7;1;3;6,02;O=C(CCC(F)(F)F)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676890;130107;None;0;Human;Binding;Ki;=;65,98;7,18;-22;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;424,3;8;1;3;6,11;CC(C)CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676891;130108;None;0;Human;Binding;Ki;=;55,43;7,26;-21;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;8;2;4;4,84;CC[C@@H](O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676892;130109;None;0;Human;Binding;Ki;=;33,75;7,47;-15;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;8;2;4;4,84;CC[C@H](O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676893;130110;None;0;Human;Binding;Ki;=;58,22;7,24;-28;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;422,3;7;1;3;5,87;O=C(CC1CCC1)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676894;130111;None;0;Human;Binding;Ki;=;25,80;7,59;-7;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;464,2;6;1;3;6,64;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(Cl)cc1;-
CHEMBL3676895;130112;None;0;Human;Binding;Ki;=;151,81;6,82;-69;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;498,2;6;1;3;7,01;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(C(F)(F)F)cc1;-
CHEMBL3676896;130113;None;0;Human;Binding;Ki;=;345,18;6,46;-79;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;513,3;7;1;4;6,98;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(N2CCCCC2)cc1;-
CHEMBL3676897;130114;None;0;Human;Binding;Ki;=;48,85;7,31;-33;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;442,3;9;1;5;4,69;COC(CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)OC;-
CHEMBL3676898;130115;None;0;Human;Binding;Ki;=;18,01;7,74;-6;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;408,3;6;1;3;5,64;CC(C)=CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676899;130116;None;0;Human;Binding;Ki;=;57,95;7,24;-31;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;408,3;7;1;3;5,64;C/C=C/CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676900;130117;None;0;Human;Binding;Ki;=;25,62;7,59;-12;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;392,2;5;1;3;4,70;CC#CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676901;130118;None;0;Human;Binding;Ki;=;38,76;7,41;-14;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;354,2;6;1;3;4,31;O=CN[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676902;130119;None;0;Human;Binding;Ki;=;65,71;7,18;-30;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;8;1;3;5,87;CCCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676903;130120;None;0;Human;Binding;Ki;=;28,63;7,54;-10;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;474,3;6;1;5;5,72;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc2c(c1)OCO2;-
CHEMBL3676904;130121;None;0;Human;Binding;Ki;=;46,90;7,33;-8;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;496,3;7;1;5;6,18;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(-n2cccn2)cc1;-
CHEMBL3676905;130122;None;0;Human;Binding;Ki;=;1111,22;5,95;-295;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;486,3;6;1;3;7,29;CC(C)(C)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL3676906;130123;None;0;Human;Binding;Ki;=;226,91;6,64;-79;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;512,3;7;1;6;6,35;Cc1nc(-c2ccc(C(=O)N[C@H]3CC[C@H](CCN4CCC(c5coc6ccccc56)CC4)CC3)cc2)no1;-
CHEMBL3676907;130124;None;0;Human;Binding;Ki;=;50,09;7,30;-8;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;528,3;7;1;5;5,74;CN1CCN(c2ccc(C(=O)N[C@H]3CC[C@H](CCN4CCC(c5coc6ccccc56)CC4)CC3)cc2)CC1;-
CHEMBL3676908;130125;None;0;Human;Binding;Ki;=;22,11;7,66;-6;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;506,3;7;1;3;7,66;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(-c2ccccc2)cc1;-
CHEMBL3676909;130126;None;0;Human;Binding;Ki;=;16,72;7,78;-3;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;507,3;7;1;4;7,05;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(-c2cccnc2)cc1;-
CHEMBL3676910;130127;None;0;Human;Binding;Ki;=;51,80;7,29;-14;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;516,3;7;1;6;5,22;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(N2CCOCC2)nc1;-
CHEMBL3676911;130128;None;0;Human;Binding;Ki;=;19,22;7,72;-5;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;563,3;7;1;6;5,23;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(N2CCS(=O)(=O)CC2)cc1;-
CHEMBL3676912;130129;None;0;Human;Binding;Ki;=;105,59;6,98;-13;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;517,3;7;1;7;4,62;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1cnc(N2CCOCC2)cn1;-
CHEMBL3676913;130130;None;0;Human;Binding;Ki;=;34,26;7,46;-7;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;495,3;7;1;4;6,78;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(-n2cccc2)cc1;-
CHEMBL3676914;130131;None;0;Human;Binding;Ki;=;28,13;7,55;-11;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;445,3;6;1;4;5,70;Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cn1;-
CHEMBL3676915;130132;None;0;Human;Binding;Ki;=;15,19;7,82;-5;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;455,3;6;1;4;5,86;N#Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL3676916;130133;None;0;Human;Binding;Ki;=;168,26;6,77;-79;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;502,3;7;1;4;7,17;CC(C)(C)Oc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL3676917;130134;None;0;Human;Binding;Ki;=;67,41;7,17;-21;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;480,3;8;1;4;6,27;CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)CC1;-
CHEMBL3676919;130135;None;0;Human;Binding;Ki;=;92,47;7,03;-56;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;488,3;7;1;5;5,65;O=C(Cc1ccc2c(c1)OCO2)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676920;130136;None;0;Human;Binding;Ki;=;60,84;7,22;-15;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;514,2;7;1;6;5,46;CS(=O)(=O)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)s1;-
CHEMBL3676921;130137;None;0;Human;Binding;Ki;=;34,19;7,47;-20;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;424,3;7;1;4;4,71;O=C(CC1COC1)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676922;130138;None;0;Human;Binding;Ki;=;344,55;6,46;-57;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;492,4;6;1;3;7,53;CC(C)(C)C1CCC(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)CC1;-
CHEMBL3676923;130139;None;0;Human;Binding;Ki;=;129,19;6,89;-10;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;488,3;6;1;3;6,89;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C12CC3CC(CC(C3)C1)C2;-
CHEMBL3676924;130140;None;0;Human;Binding;Ki;=;72,97;7,14;-10;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;504,3;6;1;3;7,05;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)C1CCC(C(F)(F)F)CC1;-
CHEMBL3676925;130141;None;0;Human;Binding;Ki;=;291,61;6,54;-107;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;486,3;8;1;3;7,19;CC(C)Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL3676926;130142;None;0;Human;Binding;Ki;=;204,42;6,69;-154;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;458,3;7;1;3;6,55;CCc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL3676928;130144;None;0;Human;Binding;Ki;=;401,84;6,40;-154;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;472,3;7;1;3;7,11;CC(C)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL3676929;130145;None;0;Human;Binding;Ki;=;355,25;6,45;-165;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;470,3;7;1;3;6,87;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(C2CC2)cc1;-
CHEMBL3676930;130146;None;0;Human;Binding;Ki;=;244,83;6,61;-30;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;485,3;7;1;5;6,06;O=C(Cc1noc2ccccc12)N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1;-
CHEMBL3676931;130147;None;0;Human;Binding;Ki;=;79,51;7,10;-13;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;508,2;7;1;5;5,39;CS(=O)(=O)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL3676932;130148;None;0;Human;Binding;Ki;=;38,17;7,42;-8;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;498,2;6;1;3;7,30;O=C(N[C@H]1CC[C@H](CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc(Cl)cc1Cl;-
CHEMBL3676933;130149;None;0;Human;Binding;Ki;=;70,03;7,16;-5;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;522,3;7;1;4;6,84;CC(C)(C)c1ccc(S(=O)(=O)N[C@H]2CC[C@H](CCN3CCC(c4coc5ccccc45)CC3)CC2)cc1;-
CHEMBL367720;130157;None;0;Human;Binding;Ki;=;31,20;7,51;-15;2;Binding affinity for human dopamine D2 receptor;ChEMBL;404,1;6;1;4;3,50;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccncc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL368816;131424;None;0;Human;Binding;Ki;=;863,00;6,06;-323;3;Binding affinity against human Dopamine receptor D2;ChEMBL;408,1;5;0;4;3,61;N#Cc1ccc(S(=O)(=O)C2(F)CCN(CCc3ccc(F)cc3F)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.05.104
CHEMBL368961;131449;None;0;Human;Binding;Ki;=;45,70;7,34;-35;2;Binding affinity for human dopamine D2 receptor;ChEMBL;481,1;7;1;5;4,56;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ncccn2)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL3695354;132061;None;0;Human;Binding;Ki;=;186,60;6,73;-64;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;368,2;5;1;3;4,70;CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1;-
CHEMBL3695355;132062;None;0;Human;Binding;Ki;=;287,60;6,54;-93;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;412,3;8;1;4;4,71;COCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1;-
CHEMBL3695356;132063;None;0;Human;Binding;Ki;=;305,00;6,52;-138;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;438,3;6;1;4;5,10;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1)C1CCOCC1;-
CHEMBL3695357;132064;None;0;Human;Binding;Ki;=;218,80;6,66;-38;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;452,3;7;1;4;5,49;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1;-
CHEMBL3695358;132065;None;0;Human;Binding;Ki;=;297,70;6,53;-48;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;370,3;5;1;3;3,89;CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695359;132066;None;0;Human;Binding;Ki;=;509,40;6,29;-77;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;414,3;8;1;4;3,90;COCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695360;132067;None;0;Human;Binding;Ki;=;716,30;6,14;-56;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;440,3;6;1;4;4,29;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1CCOCC1;-
CHEMBL3695361;132068;None;0;Human;Binding;Ki;=;650,00;6,19;-61;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;454,3;7;1;4;4,68;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695362;132069;None;0;Human;Binding;Ki;=;91,90;7,04;-41;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;382,3;6;1;3;5,09;CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1;-
CHEMBL3695363;132070;None;0;Human;Binding;Ki;=;256,30;6,59;-61;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;398,3;7;1;4;4,32;COCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1;-
CHEMBL3695364;132071;None;0;Human;Binding;Ki;=;153,90;6,81;-67;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;446,2;7;1;5;3,72;CS(=O)(=O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1;-
CHEMBL3695365;132072;None;0;Human;Binding;Ki;=;219,00;6,66;-53;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;454,3;7;1;5;4,48;O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4occc34)CC2)CC1;-
CHEMBL3695366;132073;None;0;Human;Binding;Ki;=;345,70;6,46;-75;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;384,3;6;1;3;4,28;CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695367;132074;None;0;Human;Binding;Ki;=;671,20;6,17;-29;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;400,3;7;1;4;3,51;COCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695368;132075;None;0;Human;Binding;Ki;=;418,70;6,38;-85;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;448,2;7;1;5;2,91;CS(=O)(=O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695369;132076;None;0;Human;Binding;Ki;=;729,00;6,14;-61;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;456,3;7;1;5;3,67;O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695370;132077;None;0;Human;Binding;Ki;=;318,70;6,50;-75;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;432,3;6;1;3;5,18;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccccc1;-
CHEMBL3695371;132078;None;0;Human;Binding;Ki;=;344,60;6,46;-79;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;438,2;6;1;3;4,82;O=C(CC(F)(F)F)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695372;132079;None;0;Human;Binding;Ki;=;540,00;6,27;-269;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;451,3;7;1;5;4,41;Cc1cc(CC(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4CCO5)CC3)CC2)on1;-
CHEMBL3695373;132080;None;0;Human;Binding;Ki;=;570,90;6,24;-57;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;386,3;6;2;4;2,86;O=C(CO)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695374;132081;None;0;Human;Binding;Ki;=;420,30;6,38;-46;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;456,3;7;1;5;3,67;O=C(C[C@@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695375;132082;None;0;Human;Binding;Ki;=;687,40;6,16;-64;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;456,3;7;1;5;3,67;O=C(C[C@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695376;132083;None;0;Human;Binding;Ki;=;285,00;6,54;-36;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;398,3;6;1;3;4,52;CC(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695377;132084;None;0;Human;Binding;Ki;=;212,60;6,67;-40;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;412,3;7;1;3;4,91;CC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695378;132085;None;0;Human;Binding;Ki;=;379,20;6,42;-42;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;440,3;7;1;4;4,43;O=C(CC1CCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695379;132086;None;0;Human;Binding;Ki;=;144,80;6,84;-17;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;6;1;3;4,67;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1CCC1;-
CHEMBL3695380;132087;None;0;Human;Binding;Ki;=;344,30;6,46;-53;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;400,3;7;2;4;3,25;O=C(CCO)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695381;132088;None;0;Human;Binding;Ki;=;298,60;6,53;-35;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;412,3;6;2;4;3,39;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1(O)CC1;-
CHEMBL3695382;132089;None;0;Human;Binding;Ki;=;151,40;6,82;-16;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;396,3;6;1;3;4,28;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1CC1;-
CHEMBL3695383;132090;None;0;Human;Binding;Ki;=;267,50;6,57;-93;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;7;1;3;4,67;O=C(CC1CC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695384;132091;None;0;Human;Binding;Ki;=;514,10;6,29;-70;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;440,3;7;1;4;4,43;O=C(C[C@H]1CCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695385;132092;None;0;Human;Binding;Ki;=;557,40;6,25;-47;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;440,3;7;1;4;4,43;O=C(C[C@@H]1CCCO1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695386;132093;None;0;Human;Binding;Ki;=;128,10;6,89;-12;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;517,3;7;1;5;5,02;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(N2CCOCC2)cc1;-
CHEMBL3695387;132094;None;0;Human;Binding;Ki;=;71,90;7,14;-14;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;466,2;6;1;3;5,83;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(Cl)cc1;-
CHEMBL3695388;132095;None;0;Human;Binding;Ki;=;73,70;7,13;-15;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;450,3;6;1;3;5,32;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3695389;132096;None;0;Human;Binding;Ki;=;239,40;6,62;-37;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;468,3;7;2;4;4,18;O=C(C[C@@H](O)C(F)(F)F)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695390;132097;None;0;Human;Binding;Ki;=;240,50;6,62;-26;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;454,2;6;2;4;3,79;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C(O)C(F)(F)F;-
CHEMBL3695391;132098;None;0;Human;Binding;Ki;=;495,10;6,30;-63;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;414,3;6;2;4;3,64;CC(C)(O)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695392;132099;None;0;Human;Binding;Ki;=;305,50;6,51;-25;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;6;2;4;3,78;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1(O)CCC1;-
CHEMBL3695393;132100;None;0;Human;Binding;Ki;=;563,00;6,25;-91;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;483,3;6;1;4;5,73;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccnc2ccccc12;-
CHEMBL3695394;132101;None;0;Human;Binding;Ki;=;124,10;6,91;-11;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;437,3;6;1;5;4,48;Cc1cc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4CCO5)CC3)CC2)on1;-
CHEMBL3695395;132102;None;0;Human;Binding;Ki;=;151,00;6,82;-14;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;447,3;6;1;4;4,88;Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4CCO5)CC3)CC2)cn1;-
CHEMBL3695396;132103;None;0;Human;Binding;Ki;=;288,70;6,54;-13;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;424,2;5;1;3;4,43;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C(F)(F)F;-
CHEMBL3695397;132104;None;0;Human;Binding;Ki;=;147,10;6,83;-24;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;530,4;7;1;5;4,93;CN1CCN(c2ccc(C(=O)N[C@H]3CC[C@H](CCN4CCC(c5cccc6c5CCO6)CC4)CC3)cc2)CC1;-
CHEMBL3695398;132105;None;0;Human;Binding;Ki;=;191,80;6,72;-23;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;457,3;6;1;4;5,05;N#Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4CCO5)CC3)CC2)cc1;-
CHEMBL3695399;132106;None;0;Human;Binding;Ki;=;919,50;6,04;-56;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;518,3;7;1;6;4,41;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(N2CCOCC2)nc1;-
CHEMBL3695400;132108;None;0;Human;Binding;Ki;=;328,20;6,48;-33;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;406,2;6;1;4;3,30;CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695401;132109;None;0;Human;Binding;Ki;=;333,00;6,48;-29;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;420,2;7;1;4;3,69;CCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695402;132110;None;0;Human;Binding;Ki;=;137,70;6,86;-26;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;468,2;7;1;4;4,73;O=S(=O)(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccccc1;-
CHEMBL3695403;132111;None;0;Human;Binding;Ki;=;104,80;6,98;-25;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;486,2;7;1;4;4,87;O=S(=O)(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3695404;132112;None;0;Human;Binding;Ki;=;250,90;6,60;-25;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;435,3;7;1;4;3,15;CN(C)S(=O)(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695405;132113;None;0;Human;Binding;Ki;=;135,00;6,87;-24;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;6;1;4;3,90;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1CCOC1;-
CHEMBL3695406;132114;None;0;Human;Binding;Ki;=;372,60;6,43;-28;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;6;1;4;4,04;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1CCCO1;-
CHEMBL3695407;132115;None;0;Human;Binding;Ki;=;633,00;6,20;-37;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;440,3;6;1;4;4,29;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1CCCOC1;-
CHEMBL3695408;132116;None;0;Human;Binding;Ki;=;139,60;6,86;-38;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;395,3;6;1;4;3,78;N#CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695409;132117;None;0;Human;Binding;Ki;=;2272,30;5,64;-31;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;515,4;7;1;4;6,17;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(N2CCCCC2)cc1;-
CHEMBL3695410;132118;None;0;Human;Binding;Ki;=;1461,20;5,83;-22;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;500,3;6;1;3;6,20;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(C(F)(F)F)cc1;-
CHEMBL3695411;132119;None;0;Human;Binding;Ki;=;377,70;6,42;-7;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;412,3;5;1;3;4,91;CC(C)(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695412;132120;None;0;Human;Binding;Ki;=;394,40;6,40;-66;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;6;1;3;5,30;CC(C)(C)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695413;132121;None;0;Human;Binding;Ki;=;301,20;6,52;-48;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;424,3;7;1;3;5,06;O=C(CC1CCC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695414;132122;None;0;Human;Binding;Ki;=;235,80;6,63;-24;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;432,3;6;1;3;4,52;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)C1CC1(F)F;-
CHEMBL3695415;132123;None;0;Human;Binding;Ki;=;1201,30;5,92;-72;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;412,3;7;1;3;4,91;CCC(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695416;132124;None;0;Human;Binding;Ki;=;1063,30;5,97;-69;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;455,3;8;1;4;3,73;CN(C)C(=O)CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695417;132125;None;0;Human;Binding;Ki;=;403,70;6,39;-41;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;386,2;5;1;3;4,84;CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3ccc(F)c4occc34)CC2)CC1;-
CHEMBL3695418;132126;None;0;Human;Binding;Ki;=;361,30;6,44;-31;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;456,3;6;1;4;5,24;O=C(N[C@H]1CC[C@H](CCN2CCC(c3ccc(F)c4occc34)CC2)CC1)C1CCOCC1;-
CHEMBL3695419;132127;None;0;Human;Binding;Ki;=;615,90;6,21;-30;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;470,3;7;1;4;5,63;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCC(c3ccc(F)c4occc34)CC2)CC1;-
CHEMBL3695420;132128;None;0;Human;Binding;Ki;=;612,90;6,21;-66;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;430,3;8;1;4;4,85;COCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3ccc(F)c4occc34)CC2)CC1;-
CHEMBL3695421;132129;None;0;Human;Binding;Ki;=;1700,00;5,77;-194;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;498,3;7;1;5;5,37;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(-n2cccn2)cc1;-
CHEMBL3695422;132130;None;0;Human;Binding;Ki;=;3728,00;5,43;-251;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;514,3;7;1;6;5,54;Cc1nc(-c2ccc(C(=O)N[C@H]3CC[C@H](CCN4CCC(c5cccc6c5CCO6)CC4)CC3)cc2)no1;-
CHEMBL3695423;132131;None;0;Human;Binding;Ki;=;194,80;6,71;-29;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;516,2;7;1;6;4,64;CS(=O)(=O)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4CCO5)CC3)CC2)s1;-
CHEMBL3695425;132133;None;0;Human;Binding;Ki;=;175,51;6,76;-27;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;428,3;7;2;4;4,03;CC(C)(O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695426;132134;None;0;Human;Binding;Ki;=;196,80;6,71;-38;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;398,3;7;1;3;4,67;CCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695427;132135;None;0;Human;Binding;Ki;=;253,00;6,60;-33;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;452,3;7;1;3;5,21;O=C(CCC(F)(F)F)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695428;132136;None;0;Human;Binding;Ki;=;1067,60;5,97;-107;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;8;1;3;5,30;CC(C)CCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695429;132137;None;0;Human;Binding;Ki;=;411,00;6,39;-89;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;412,3;8;1;3;5,06;CCCCC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695430;132138;None;0;Human;Binding;Ki;=;329,10;6,48;-58;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;565,3;7;1;6;4,42;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(N2CCS(=O)(=O)CC2)cc1;-
CHEMBL3695432;132139;None;0;Human;Binding;Ki;=;808,80;6,09;-234;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;476,3;6;1;5;4,91;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc2c(c1)OCO2;-
CHEMBL3695433;132140;None;0;Human;Binding;Ki;=;196,50;6,71;-45;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;426,3;7;1;4;3,90;O=C(CC1COC1)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695434;132141;None;0;Human;Binding;Ki;=;355,80;6,45;-35;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;428,3;8;2;4;4,03;CC[C@@H](O)CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695435;132142;None;0;Human;Binding;Ki;=;366,10;6,44;-75;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;444,3;9;1;5;3,88;COC(CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)OC;-
CHEMBL3695436;132143;None;0;Human;Binding;Ki;=;69,90;7,16;-1;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;399,3;5;1;3;4,02;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695437;132144;None;0;Human;Binding;Ki;=;73,90;7,13;-11;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;6;1;3;4,83;CC(C)=CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695438;132145;None;0;Human;Binding;Ki;=;437,70;6,36;-75;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;410,3;7;1;3;4,83;C/C=C/CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695439;132146;None;0;Human;Binding;Ki;=;118,40;6,93;-16;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;394,3;5;1;3;3,89;CC#CC(=O)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695440;132147;None;0;Human;Binding;Ki;=;167,20;6,78;-14;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;356,2;6;1;3;3,50;O=CN[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695442;132149;None;0;Human;Binding;Ki;=;233,50;6,63;-28;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;500,2;6;1;3;6,49;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(Cl)cc1Cl;-
CHEMBL3695443;132150;None;0;Human;Binding;Ki;=;85,10;7,07;-8;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;497,3;7;1;4;5,97;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(-n2cccc2)cc1;-
CHEMBL3695444;132151;None;0;Human;Binding;Ki;=;501,40;6,30;-64;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;508,3;7;1;3;6,85;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(-c2ccccc2)cc1;-
CHEMBL3695445;132152;None;0;Human;Binding;Ki;=;99,80;7,00;-18;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;509,3;7;1;4;6,24;O=C(N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc(-c2cccnc2)cc1;-
CHEMBL3695446;132153;None;0;Human;Binding;Ki;=;243,60;6,61;-75;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;487,3;7;1;5;5,25;O=C(Cc1noc2ccccc12)N[C@H]1CC[C@H](CCN2CCC(c3cccc4c3CCO4)CC2)CC1;-
CHEMBL3695447;132154;None;0;Human;Binding;Ki;=;161,50;6,79;-11;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;510,3;7;1;5;4,58;CS(=O)(=O)c1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCC(c4cccc5c4CCO5)CC3)CC2)cc1;-
CHEMBL3697951;132559;None;0;Human;Binding;Ki;=;67,35;7,17;-58;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;373,2;5;1;5;2,62;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697952;132560;None;0;Human;Binding;Ki;=;173,34;6,76;-93;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;417,3;8;1;6;2,64;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697953;132561;None;0;Human;Binding;Ki;=;197,58;6,70;-77;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;459,3;7;1;7;2,41;O=C(CC1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697954;132562;None;0;Human;Binding;Ki;=;301,03;6,52;-104;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;459,3;7;1;7;2,41;O=C(C[C@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697955;132563;None;0;Human;Binding;Ki;=;172,17;6,76;-69;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;459,3;7;1;7;2,41;O=C(C[C@@H]1COCCO1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697956;132564;None;0;Human;Binding;Ki;=;188,71;6,72;-61;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;443,3;7;1;6;3,17;O=C(CC1CCCO1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697957;132565;None;0;Human;Binding;Ki;=;74,48;7,13;-57;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;387,3;6;1;5;3,01;CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697958;132566;None;0;Human;Binding;Ki;=;141,87;6,85;-114;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;413,3;7;1;5;3,40;O=C(CC1CC1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697959;132567;None;0;Human;Binding;Ki;=;238,22;6,62;-54;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;403,2;7;1;6;2,25;COCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697960;132568;None;0;Human;Binding;Ki;=;183,57;6,74;-107;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;389,2;6;2;6;1,59;O=C(CO)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697961;132569;None;0;Human;Binding;Ki;=;269,17;6,57;-26;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;435,3;6;1;5;3,92;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)c1ccccc1;-
CHEMBL3697962;132570;None;0;Human;Binding;Ki;=;68,55;7,16;-53;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;389,2;5;1;6;2,84;COC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697963;132571;None;0;Human;Binding;Ki;=;314,12;6,50;-234;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;454,3;7;1;7;3,14;Cc1cc(CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)on1;-
CHEMBL3697964;132572;None;0;Human;Binding;Ki;=;75,98;7,12;-83;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;398,2;6;1;6;2,52;N#CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697965;132573;None;0;Human;Binding;Ki;=;159,74;6,80;-45;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;471,3;7;2;6;3,69;O=C(CC1(O)CCCCC1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697966;132574;None;0;Human;Binding;Ki;=;91,22;7,04;-57;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;441,2;6;1;5;3,56;O=C(CC(F)(F)F)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697967;132575;None;0;Human;Binding;Ki;=;136,57;6,87;-74;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;401,3;6;1;5;3,26;CC(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697968;132576;None;0;Human;Binding;Ki;=;132,77;6,88;-57;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;415,3;7;1;5;3,65;CC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697969;132577;None;0;Human;Binding;Ki;=;143,65;6,84;-91;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;401,3;7;1;5;3,40;CCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697970;132579;None;0;Human;Binding;Ki;=;143,98;6,84;-56;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;435,2;6;1;5;3,26;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1CC1(F)F;-
CHEMBL3697971;132580;None;0;Human;Binding;Ki;=;181,28;6,74;-66;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;431,3;8;1;6;3,03;COC(C)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697972;132581;None;0;Human;Binding;Ki;=;105,93;6,97;-52;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;429,3;7;1;6;2,64;O=C(CC1COC1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697973;132582;None;0;Human;Binding;Ki;=;182,55;6,74;-72;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;471,3;8;1;6;3,81;CO[C@@H]1CC[C@@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)C1;-
CHEMBL3697974;132583;None;0;Human;Binding;Ki;=;181,01;6,74;-31;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;417,3;6;2;6;2,37;CC(C)(O)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697975;132584;None;0;Human;Binding;Ki;=;250,30;6,60;-11;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;417,3;7;1;6;2,64;CO[C@H](C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697976;132585;None;0;Human;Binding;Ki;=;150,42;6,82;-30;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;417,3;7;1;6;2,64;CO[C@@H](C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697977;132586;None;0;Human;Binding;Ki;=;76,78;7,12;-48;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;431,3;7;2;6;2,76;CC(C)(O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697978;132587;None;0;Human;Binding;Ki;=;94,57;7,02;-67;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;443,3;7;2;6;2,91;O=C(CC1(O)CCC1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697979;132588;None;0;Human;Binding;Ki;=;61,45;7,21;-33;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;415,2;6;2;6;2,13;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1(O)CC1;-
CHEMBL3697980;132590;None;0;Human;Binding;Ki;=;219,64;6,66;-63;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;457,3;7;1;6;3,56;O=C(C[C@@H]1CCCCO1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697981;132591;None;0;Human;Binding;Ki;=;310,25;6,51;-89;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;457,3;7;1;6;3,56;O=C(C[C@H]1CCCCO1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697982;132592;None;0;Human;Binding;Ki;=;136,98;6,86;-45;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;457,3;7;1;6;3,42;O=C(C[C@@H]1CCCOC1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697983;132593;None;0;Human;Binding;Ki;=;183,73;6,74;-46;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;457,3;7;1;6;3,42;O=C(C[C@H]1CCCOC1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697984;132594;None;0;Human;Binding;Ki;=;145,23;6,84;-46;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;409,2;6;1;6;2,04;CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697985;132595;None;0;Human;Binding;Ki;=;84,94;7,07;-14;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;429,3;6;2;6;2,52;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1(O)CCC1;-
CHEMBL3697986;132596;None;0;Human;Binding;Ki;=;123,97;6,91;-33;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;443,3;6;2;6;2,91;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1(O)CCCC1;-
CHEMBL3697987;132597;None;0;Human;Binding;Ki;=;175,40;6,76;-37;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;457,3;6;2;6;3,30;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1(O)CCCCC1;-
CHEMBL3697988;132598;None;0;Human;Binding;Ki;=;122,13;6,91;-9;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;417,3;7;2;6;2,37;CCC(O)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697989;132599;None;0;Human;Binding;Ki;=;90,15;7,04;-15;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;431,3;7;2;6;2,62;CC(C)[C@@H](O)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697990;132600;None;0;Human;Binding;Ki;=;73,41;7,13;-5;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;431,3;7;2;6;2,62;CC(C)[C@H](O)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697991;132601;None;0;Human;Binding;Ki;=;250,97;6,60;-19;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;471,3;7;1;6;3,95;COC1(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)CCCCC1;-
CHEMBL3697992;132602;None;0;Human;Binding;Ki;=;89,81;7,05;-40;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;403,2;6;2;6;1,98;C[C@@H](O)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3697993;132603;None;0;Human;Binding;Ki;=;218,89;6,66;-48;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;443,3;6;1;6;3,03;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1CCOCC1;-
CHEMBL3697994;132604;None;0;Human;Binding;Ki;=;116,64;6,93;-9;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;429,3;6;1;6;2,78;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1CCCO1;-
CHEMBL3697995;132605;None;0;Human;Binding;Ki;=;1510,24;5,82;-43;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;520,3;7;1;7;3,75;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)c1ccc(N2CCOCC2)cc1;-
CHEMBL3697996;132606;None;0;Human;Binding;Ki;=;82,51;7,08;-21;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;453,2;6;1;5;4,05;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3697997;132607;None;0;Human;Binding;Ki;=;509,13;6,29;-213;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;486,3;6;1;6;4,46;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)c1ccnc2ccccc12;-
CHEMBL3697998;132608;None;0;Human;Binding;Ki;=;88,19;7,05;-50;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;436,2;6;1;6;3,31;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)c1cccnc1;-
CHEMBL3697999;132609;None;0;Human;Binding;Ki;=;4818,65;5,32;-1047;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;493,3;6;1;7;3,69;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)c1ccc2c(c1)OCCO2;-
CHEMBL3698000;132610;None;0;Human;Binding;Ki;=;572,43;6,24;-660;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;491,3;6;1;6;3,85;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1COc2ccccc2C1;-
CHEMBL3698001;132611;None;0;Human;Binding;Ki;=;680,96;6,17;-323;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;493,3;7;1;7;3,57;O=C(Cc1ccc2c(c1)OCO2)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698002;132612;None;0;Human;Binding;Ki;=;58,95;7,23;-16;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;477,2;6;1;7;2,04;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1CCS(=O)(=O)C1;-
CHEMBL3698003;132613;None;0;Human;Binding;Ki;=;138,86;6,86;-66;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;457,3;7;1;6;3,42;O=C(CC1CCOCC1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698004;132614;None;0;Human;Binding;Ki;=;91,14;7,04;-46;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;413,3;6;1;5;3,40;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1CCC1;-
CHEMBL3698005;132615;None;0;Human;Binding;Ki;=;95,38;7,02;-66;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;451,2;7;1;7;1,65;CS(=O)(=O)CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698006;132616;None;0;Human;Binding;Ki;=;752,51;6,12;-223;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;485,3;8;1;6;4,20;CO[C@H]1CC[C@H](CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)CC1;-
CHEMBL3698007;132617;None;0;Human;Binding;Ki;=;62,94;7,20;-4;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;456,3;6;1;6;2,94;CN1CCC(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)CC1;-
CHEMBL3698008;132618;None;0;Human;Binding;Ki;=;81,08;7,09;-12;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;429,3;6;1;6;2,64;CC1(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)COC1;-
CHEMBL3698009;132619;None;0;Human;Binding;Ki;=;101,02;7,00;-28;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;460,2;6;1;6;3,79;N#Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)cc1;-
CHEMBL3698010;132620;None;0;Human;Binding;Ki;=;81,06;7,09;-27;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;447,2;6;1;5;3,62;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C1CC(Cl)C1;-
CHEMBL3698011;132621;None;0;Human;Binding;Ki;=;38,06;7,42;-8;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;471,3;7;1;7;1,85;CN1CCN(CC(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)CC1;-
CHEMBL3698012;132622;None;0;Human;Binding;Ki;=;86,54;7,06;-13;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;429,3;7;1;6;2,78;COC1(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)CC1;-
CHEMBL3698013;132623;None;0;Human;Binding;Ki;=;116,62;6,93;-10;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;431,3;7;1;6;3,03;COC(C)(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698014;132624;None;0;Human;Binding;Ki;=;89,50;7,05;-6;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;445,3;8;1;6;3,27;CO[C@@H](C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C(C)C;-
CHEMBL3698015;132625;None;0;Human;Binding;Ki;=;111,52;6,95;-5;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;445,3;8;1;6;3,27;CO[C@H](C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C(C)C;-
CHEMBL3698016;132626;None;0;Human;Binding;Ki;=;73,84;7,13;-39;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;477,2;7;1;6;2,97;O=S(=O)(CC(F)(F)F)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698017;132627;None;0;Human;Binding;Ki;=;72,43;7,14;-25;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;471,2;7;1;6;3,46;O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)c1ccccc1;-
CHEMBL3698018;132628;None;0;Human;Binding;Ki;=;46,18;7,34;-20;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;489,2;7;1;6;3,60;O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)c1ccc(F)cc1;-
CHEMBL3698019;132629;None;0;Human;Binding;Ki;=;55,32;7,26;-24;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;475,2;7;1;8;2,20;Cn1cnc(S(=O)(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc5c4OCO5)CC3)CC2)c1;-
CHEMBL3698020;132630;None;0;Human;Binding;Ki;=;113,43;6,95;-22;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;427,2;5;1;5;3,17;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)C(F)(F)F;-
CHEMBL3698021;132631;None;0;Human;Binding;Ki;=;30,42;7,52;-2;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;402,3;5;1;5;2,76;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698022;132632;None;0;Human;Binding;Ki;=;123,11;6,91;-67;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;391,2;6;1;5;2,57;O=C(CF)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698023;132633;None;0;Human;Binding;Ki;=;116,67;6,93;-47;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;457,3;8;2;6;3,01;O=C(C[C@H]1C[C@H](CO)C1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698024;132634;None;0;Human;Binding;Ki;=;157,94;6,80;-151;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;484,2;6;2;5;4,96;O=C(Nc1ccc(Cl)cc1)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698025;132635;None;0;Human;Binding;Ki;=;127,71;6,89;-38;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;438,2;7;1;6;1,88;CN(C)S(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1;-
CHEMBL3698026;132636;None;0;Human;Binding;Ki;=;62,99;7,20;-48;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 μg protein/well (D2, D3) and 15 μg protein/well (5-HT2A), respectively. The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 μl with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 μM-0.1 nM for 1 h at RT.";ChEMBL;480,2;7;1;7;1,65;O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3cccc4c3OCO4)CC2)CC1)N1CCOCC1;-
CHEMBL369913;132796;None;0;Human;Binding;Ki;=;17,00;7,77;-56;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;434,2;4;0;5;4,52;CC(=O)N1CCC(C)c2cccc(CCN3CCN(c4nsc5ccccc45)CC3)c21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL369984;132818;None;0;Human;Binding;Ki;=;14,60;7,84;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;395,2;5;1;4;3,83;Fc1ccc2c(CCCN3CCN(c4cccc5c4OCCO5)CC3)c[nH]c2c1;https://dx.doi.org/10.1021/jm050148z
CHEMBL370110;132866;None;0;Human;Binding;Ki;=;1,20;8,92;-1;8;Inhibitory activity against dopamine D2(long) receptor;ChEMBL;460,2;4;0;8;2,82;CN1CCc2c(sc3ncn(CCN4CCN(c5cncc6ccccc56)CC4)c(=O)c23)C1;https://dx.doi.org/10.1016/j.bmcl.2005.04.077
CHEMBL370136;132886;None;0;Human;Binding;Ki;=;164,60;6,78;1;3;Binding affinity to dopamine D2 receptor;ChEMBL;479,2;6;2;6;3,17;COc1ccc(-c2cc3c(=O)n(CCN4CCN(c5ccccc5Cl)CC4)c(=O)[nH]c3[nH]2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.09.027
CHEMBL370191;132955;None;0;Human;Binding;Ki;=;83,00;7,08;-8;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;521,2;6;0;6;5,22;CC(C)(C)c1nc(N2CCN(CCCCN3C(=O)CCSc4ccccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL370359;133215;None;0;Human;Binding;Ki;=;31,60;7,50;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;411,2;5;1;4;4,35;Clc1ccc2[nH]cc(CCCN3CCN(c4cccc5c4OCCO5)CC3)c2c1;https://dx.doi.org/10.1021/jm050148z
CHEMBL370364;133226;None;0;Human;Binding;Ki;=;1720,00;5,76;-4;3;Binding affinity to dopamine D2 receptor;ChEMBL;463,2;5;2;5;3,47;Cc1ccc(-c2cc3c(=O)n(CCN4CCN(c5ccccc5Cl)CC4)c(=O)[nH]c3[nH]2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.09.027
CHEMBL370457;133388;None;0;Human;Binding;Ki;=;4,70;8,33;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;422,2;5;2;4;3,78;C[C@@H]1Oc2c(cccc2N2CCN(CCCc3c[nH]c4ccc(F)cc34)CC2)NC1=O;https://dx.doi.org/10.1021/jm050148z
CHEMBL370652;133518;None;0;Human;Binding;Ki;=;1300,00;5,89;-61;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;430,1;5;1;3;5,44;O=C(N[C@H]1CCN(Cc2ccc(C(F)(F)F)cc2)C1)c1cccc(-c2cccs2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL370659;133520;None;0;Human;Binding;Ki;=;29,00;7,54;-99;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;436,2;4;0;5;4,19;CC(=O)N1CCC(C)c2cc(F)cc(CCN3CCN(c4noc5ccccc45)CC3)c21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL370713;133573;None;0;Human;Binding;Ki;=;96,50;7,01;-14;2;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;433,1;7;1;4;4,11;COc1ccc(C(=O)NC/C=C/CN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL370713;133573;None;0;Human;Binding;Ki;=;30,40;7,52;-14;2;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;433,1;7;1;4;4,11;COc1ccc(C(=O)NC/C=C/CN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL370713;133573;None;0;Human;Binding;Ki;=;30,40;7,52;-14;2;Binding affinity for human dopamine D2 receptor;ChEMBL;433,1;7;1;4;4,11;COc1ccc(C(=O)NC/C=C/CN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL370823;133596;None;0;Human;Binding;Ki;=;1500,00;5,82;-301;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;380,1;5;1;3;4,56;O=C(N[C@H]1CCN(Cc2ccc(F)cc2)C1)c1ccc(-c2cccs2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL371289;133669;None;0;Human;Binding;Ki;=;21,00;7,68;-95;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;406,2;4;1;5;4,11;CC1CC(=O)Nc2c(CCN3CCN(c4nsc5ccccc45)CC3)cccc21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL37170;134347;None;0;Human;Binding;Ki;=;5882,00;5,23;-758;6;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;349,2;4;1;3;3,30;Cc1ccc(N2CCN(CC[C@@H]3NC(=O)c4ccccc43)CC2)cc1C;https://dx.doi.org/10.1016/s0960-894x(98)00252-2
CHEMBL372020;135256;None;0;Human;Binding;Ki;=;5100,00;5,29;-30;4;Low inhibition constant against [3H]spiperone binding to human Dopamine receptor D2S expressed in CHO cells;ChEMBL;245,2;5;0;3;2,80;CCCN(CCC)[C@H]1CCn2c(C#N)ccc2C1;https://dx.doi.org/10.1021/jm049269+
CHEMBL372020;135256;None;0;Human;Binding;Ki;=;190,00;6,72;-30;4;High inhibition constant against [3H]spiperone binding to human Dopamine receptor D2L expressed in CHO cells;ChEMBL;245,2;5;0;3;2,80;CCCN(CCC)[C@H]1CCn2c(C#N)ccc2C1;https://dx.doi.org/10.1021/jm049269+
CHEMBL372020;135256;None;0;Human;Binding;Ki;=;6500,00;5,19;-30;4;Low inhibition constant against [3H]spiperone binding to human Dopamine receptor D2L expressed in CHO cells;ChEMBL;245,2;5;0;3;2,80;CCCN(CCC)[C@H]1CCn2c(C#N)ccc2C1;https://dx.doi.org/10.1021/jm049269+
CHEMBL372020;135256;None;0;Human;Binding;Ki;=;130,00;6,89;-30;4;High inhibition constant against [3H]spiperone binding to human Dopamine receptor D2S expressed in CHO cells;ChEMBL;245,2;5;0;3;2,80;CCCN(CCC)[C@H]1CCn2c(C#N)ccc2C1;https://dx.doi.org/10.1021/jm049269+
CHEMBL372022;135257;None;0;Human;Binding;Ki;=;6,60;8,18;-8;2;Binding affinity for human dopamine D2 receptor;ChEMBL;419,1;6;2;4;3,81;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1O;https://dx.doi.org/10.1021/jm049465g
CHEMBL372541;135321;None;0;Human;Binding;Ki;=;81,00;7,09;-478;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;420,2;4;0;5;4,13;CC1CC(=O)N(C)c2c(CCN3CCN(c4nsc5ccccc45)CC3)cccc21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL372735;135363;None;0;Human;Binding;Ki;=;15,90;7,80;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;391,2;5;1;4;4,00;Cc1cccc2c(CCCN3CCN(c4cccc5c4OCCO5)CC3)c[nH]c12;https://dx.doi.org/10.1021/jm050148z
CHEMBL372811;135486;None;0;Human;Binding;Ki;=;18,00;7,75;-40;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;452,2;4;0;5;4,66;CC(=O)N1CCC(C)c2cc(F)cc(CCN3CCN(c4nsc5ccccc45)CC3)c21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL373032;135853;None;0;Human;Binding;Ki;=;500,00;6,30;-9;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;446,1;6;1;4;5,32;O=C(N[C@H]1CCN(Cc2ccc(OC(F)(F)F)cc2)C1)c1cccc(-c2cccs2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL37333;136353;None;0;Human;Binding;IC50;=;3900,00;5,41;-;2;Binding affinity to dopamine receptor D2;ChEMBL;323,1;4;2;4;2,15;COc1cc(N)c(Cl)cc1C(=O)NC[C@H]1CCN2CCC[C@H]12;https://dx.doi.org/10.1021/jm0509501
CHEMBL3735756;136538;None;0;Human;Binding;Ki;=;1729,00;5,76;-60;19;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in stable fibroblast after 90 mins by scintillation counting method;ChEMBL;447,2;12;0;5;5,15;COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC;https://dx.doi.org/10.1039/C4MD00418C
CHEMBL373873;136650;None;0;Human;Binding;Ki;=;14,00;7,85;-5;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;500,2;9;1;6;4,27;Cc1c(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nnn1Cc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL373873;136650;None;0;Human;Binding;Ki;=;38,90;7,41;-5;4;Binding affinity to dopamine D2;ChEMBL;500,2;9;1;6;4,27;Cc1c(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nnn1Cc1ccccc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL3739680;136693;None;0;Human;Binding;Ki;=;104,00;6,98;-14;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr by microplate reader based assay;ChEMBL;453,2;8;1;5;4,18;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2cccc3ncccc23)CC1;https://dx.doi.org/10.1039/C5MD00166H
CHEMBL3739745;136701;None;0;Human;Binding;Ki;=;140,00;6,85;-7;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr by microplate reader based assay;ChEMBL;406,2;8;1;6;2,37;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2cnn(C)c2)CC1;https://dx.doi.org/10.1039/C5MD00166H
CHEMBL3740054;136739;None;0;Human;Binding;Ki;=;102,00;6,99;-11;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr by microplate reader based assay;ChEMBL;420,2;8;1;4;3,77;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2cccc(F)c2)CC1;https://dx.doi.org/10.1039/C5MD00166H
CHEMBL3740054;136739;None;0;Human;Binding;Ki;=;102,00;6,99;-11;5;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;420,2;8;1;4;3,77;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2cccc(F)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2015.11.040
CHEMBL3740055;136740;None;0;Human;Binding;Ki;=;85,00;7,07;-14;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr by microplate reader based assay;ChEMBL;470,1;8;1;4;4,83;O=S(=O)(NC1CCN(CCOc2ccccc2-c2ccccc2)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1039/C5MD00166H
CHEMBL3740235;136762;None;0;Human;Binding;Ki;=;147,00;6,83;-18;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr by microplate reader based assay;ChEMBL;438,2;8;1;4;3,91;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2cc(F)ccc2F)CC1;https://dx.doi.org/10.1039/C5MD00166H
CHEMBL3740360;136775;None;0;Human;Binding;Ki;=;6230,00;5,21;-5;2;Displacement of [3H]-sulpiride from human dopamine D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting;ChEMBL;445,1;8;1;6;5,06;Clc1ccc(N2CCN(CCCCNc3noc(-c4ccccc4)n3)CC2)c(Cl)c1;https://dx.doi.org/10.1016/j.bmc.2015.12.002
CHEMBL3740360;136775;None;0;Human;Binding;Ki;=;1290,00;5,89;-5;2;Displacement of [3H]-sulpiride from human dopamine D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting;ChEMBL;445,1;8;1;6;5,06;Clc1ccc(N2CCN(CCCCNc3noc(-c4ccccc4)n3)CC2)c(Cl)c1;https://dx.doi.org/10.1016/j.bmc.2015.12.002
CHEMBL3742076;136954;None;0;Human;Binding;Ki;=;51,00;7,29;4;2;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells after 1 hr by microplate reader based assay;ChEMBL;420,2;8;1;4;3,77;CC(C)c1ccccc1OCCN1CCC(NS(=O)(=O)c2ccccc2F)CC1;https://dx.doi.org/10.1039/C5MD00166H
CHEMBL3742207;136972;None;0;Human;Binding;Ki;=;79630,00;4,10;-295;2;Displacement of [3H]-sulpiride from human dopamine D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting;ChEMBL;411,2;8;1;6;4,40;Clc1ccc(N2CCN(CCCCNc3noc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2015.12.002
CHEMBL3745815;137069;None;0;Human;Binding;Ki;=;54,00;7,27;-10;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;468,2;8;0;4;4,66;CN(C1CCN(CCOc2ccccc2-c2ccccc2)CC1)S(=O)(=O)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3745853;137074;None;0;Human;Binding;Ki;=;37,00;7,43;-2;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;508,2;10;0;4;5,44;O=S(=O)(c1ccc(F)cc1)N(CC1CC1)C1CCN(CCOc2ccccc2-c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3745882;137077;None;0;Human;Binding;Ki;=;18,00;7,75;3;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;460,3;10;0;6;3,49;CC(C)c1ccccc1OCCN1CCC(N(CC2CC2)S(=O)(=O)c2cnn(C)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3745975;137085;None;0;Human;Binding;Ki;=;290,00;6,54;-4;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;448,2;7;0;4;4,29;CN(C1CCN(CCOc2ccccc2C(C)(C)C)CC1)S(=O)(=O)c1cccc(F)c1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3746079;137091;None;0;Human;Binding;Ki;=;324,00;6,49;-5;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;448,2;7;0;4;4,29;CN(C1CCN(CCOc2ccccc2C(C)(C)C)CC1)S(=O)(=O)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3746083;137092;None;0;Human;Binding;Ki;=;160,00;6,80;-3;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;488,3;9;0;4;5,07;CC(C)(C)c1ccccc1OCCN1CCC(N(CC2CC2)S(=O)(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3746493;137118;None;0;Human;Binding;Ki;=;230,00;6,64;-4;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;474,3;9;0;6;3,66;Cn1cc(S(=O)(=O)N(CC2CC2)C2CCN(CCOc3ccccc3C(C)(C)C)CC2)cn1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3746713;137134;None;0;Human;Binding;Ki;=;52,00;7,28;-1;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;450,2;8;0;4;4,52;CN(C1CCN(CCOc2ccccc2-c2ccccc2)CC1)S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3746771;137138;None;0;Human;Binding;Ki;=;280,00;6,55;-4;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;434,2;7;0;6;2,88;CN(C1CCN(CCOc2ccccc2C(C)(C)C)CC1)S(=O)(=O)c1cnn(C)c1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3746806;137143;None;0;Human;Binding;Ki;=;360,00;6,44;-5;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;430,2;7;0;4;4,15;CN(C1CCN(CCOc2ccccc2C(C)(C)C)CC1)S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3747003;137154;None;0;Human;Binding;Ki;=;35,00;7,46;-4;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;454,2;8;0;6;3,25;CN(C1CCN(CCOc2ccccc2-c2ccccc2)CC1)S(=O)(=O)c1cnn(C)c1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3747052;137159;None;0;Human;Binding;Ki;=;60,00;7,22;-6;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;416,2;8;0;4;3,97;CC(C)c1ccccc1OCCN1CCC(N(C)S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3747071;137160;None;0;Human;Binding;Ki;=;50,00;7,30;-3;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;434,2;8;0;4;4,11;CC(C)c1ccccc1OCCN1CCC(N(C)S(=O)(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3747114;137167;None;0;Human;Binding;Ki;=;45,00;7,35;-2;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;434,2;8;0;4;4,11;CC(C)c1ccccc1OCCN1CCC(N(C)S(=O)(=O)c2cccc(F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3747148;137171;None;0;Human;Binding;Ki;=;15,00;7,82;3;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;474,2;10;0;4;4,89;CC(C)c1ccccc1OCCN1CCC(N(CC2CC2)S(=O)(=O)c2cccc(F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3747240;137174;None;0;Human;Binding;Ki;=;16,00;7,80;-1;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;494,2;10;0;6;4,03;Cn1cc(S(=O)(=O)N(CC2CC2)C2CCN(CCOc3ccccc3-c3ccccc3)CC2)cn1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3747459;137185;None;0;Human;Binding;Ki;=;46,00;7,34;-4;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;420,2;8;0;6;2,71;CC(C)c1ccccc1OCCN1CCC(N(C)S(=O)(=O)c2cnn(C)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL374749;137190;None;0;Human;Binding;Ki;=;128,82;6,89;-457;3;Binding affinity to dopamine D2;ChEMBL;447,2;8;1;3;5,34;O=C(NCCCCN1CCN(c2ccccc2Cl)CC1)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL3747744;137210;None;0;Human;Binding;Ki;=;20,00;7,70;1;4;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr;ChEMBL;474,2;10;0;4;4,89;CC(C)c1ccccc1OCCN1CCC(N(CC2CC2)S(=O)(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.11.041
CHEMBL3752512;137398;None;0;Human;Binding;Ki;=;45,00;7,35;-14;5;Displacement of [3H]spiperone from human cloned D2 dopamine receptor incubated for 90 mins by radioligand binding assay;ChEMBL;257,1;0;0;2;3,37;CN1CCc2ccccc2Cc2sccc2CC1;https://dx.doi.org/10.1039/C5MD00258C
CHEMBL3752900;137435;None;0;Human;Binding;Ki;=;1862,09;5,73;-61;22;Binding affinity to D2 dopamine receptor (unknown origin) by competition binding assay;ChEMBL;274,1;7;1;1;4,04;C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12;https://dx.doi.org/10.1016/j.bmcl.2015.12.053
CHEMBL3753266;137487;None;0;Human;Binding;Ki;=;1,50;8,82;1;5;Displacement of [3H]spiperone from human cloned D2 dopamine receptor incubated for 90 mins by radioligand binding assay;ChEMBL;307,1;0;0;2;4,52;CN1CCc2ccccc2Cc2sc3ccccc3c2CC1;https://dx.doi.org/10.1039/C5MD00258C
CHEMBL3753318;137501;None;0;Human;Binding;Ki;=;5128,61;5,29;-162;19;Binding affinity to D2 dopamine receptor (unknown origin) by competition binding assay;ChEMBL;254,2;7;1;1;3,69;C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12;https://dx.doi.org/10.1016/j.bmcl.2015.12.053
CHEMBL3754166;137602;None;0;Human;Binding;Ki;=;4365,16;5,36;-436;22;Binding affinity to D2 dopamine receptor (unknown origin) by competition binding assay;ChEMBL;318,1;7;1;1;4,15;C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12;https://dx.doi.org/10.1016/j.bmcl.2015.12.053
CHEMBL3754496;137640;None;0;Human;Binding;Ki;=;2454,71;5,61;-147;19;Binding affinity to D2 dopamine receptor (unknown origin) by competition binding assay;ChEMBL;258,2;7;1;1;3,52;C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12;https://dx.doi.org/10.1016/j.bmcl.2015.12.053
CHEMBL3758330;137732;None;0;Human;Binding;Ki;=;5031,00;5,30;-398;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;403,2;7;2;4;3,88;O=C(NCCCCN1CCN(c2ccccc2O)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758368;137737;None;0;Human;Binding;Ki;=;34,00;7,47;-3;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;404,2;9;0;4;5,22;COc1ccccc1N1CCN(CCCCCOc2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758591;137764;None;0;Human;Binding;Ki;=;322,00;6,49;-16;5;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;446,2;8;1;4;4,30;O=S(=O)(NC1CCN(CCOc2ccccc2C2CCCC2)CC1)c1cccc(F)c1;https://dx.doi.org/10.1016/j.ejmech.2015.11.040
CHEMBL3758610;137765;None;0;Human;Binding;Ki;=;55,00;7,26;-34;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;480,2;9;2;5;3,54;CS(=O)(=O)Nc1cccc(N2CCN(CCCCNC(=O)c3ccc4ccccc4c3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758665;137769;None;0;Human;Binding;Ki;=;911,00;6,04;-234;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;474,3;9;2;5;4,74;CCOC(=O)Nc1cccc(N2CCN(CCCCNC(=O)c3ccc4ccccc4c3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758711;137774;None;0;Human;Binding;Ki;=;1553,00;5,81;-1412;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;455,2;7;1;3;5,19;O=C(NCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758741;137781;None;0;Human;Binding;Ki;=;302,00;6,52;-229;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;415,3;7;1;3;4,79;Cc1cccc(N2CCN(CCCCNC(=O)c3ccc4ccccc4c3)CC2)c1C;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758881;137798;None;0;Human;Binding;Ki;=;404,00;6,39;-562;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;401,2;7;1;3;4,48;Cc1ccccc1N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758913;137801;None;0;Human;Binding;Ki;=;322,00;6,49;-162;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;387,3;9;1;4;3,68;COc1ccccc1N1CCN(CCCCNC(=O)CC2CCCCC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758920;137803;None;0;Human;Binding;Ki;=;12143,00;4,92;-1148;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;421,2;7;1;3;4,83;O=C(NCCCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3758991;137814;None;0;Human;Binding;Ki;=;13,00;7,89;-10;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;416,2;8;2;4;4,07;COc1ccccc1N1CCN(CCCCNC(=O)Nc2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3759205;137830;None;0;Human;Binding;Ki;=;60,00;7,22;-60;5;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;446,2;8;1;4;4,30;CC(C)c1cccc(OCCN2C3CCC2CC(NS(=O)(=O)c2ccc(F)cc2)C3)c1;https://dx.doi.org/10.1016/j.ejmech.2015.11.040
CHEMBL3759312;137848;None;0;Human;Binding;Ki;=;1549,00;5,81;-128;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;396,3;8;1;4;3,44;COc1ccccc1N1CCN(CCCCNC(=O)N(C)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3759441;137863;None;0;Human;Binding;Ki;=;52,00;7,28;-104;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;442,2;7;2;4;3,67;O=C1Cc2c(cccc2N2CCN(CCCCNC(=O)c3ccc4ccccc4c3)CC2)N1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3759491;137867;None;0;Human;Binding;Ki;=;373,00;6,43;-1862;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;403,2;7;2;4;3,88;O=C(NCCCCN1CCN(c2cccc(O)c2)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3759513;137869;None;0;Human;Binding;Ki;=;3323,00;5,48;-707;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;421,2;7;1;3;4,83;O=C(NCCCCN1CCN(c2cccc(Cl)c2)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3759607;137888;None;0;Human;Binding;Ki;=;310,00;6,51;-251;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;405,2;7;1;3;4,31;O=C(NCCCCN1CCN(c2ccccc2F)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3759617;137889;None;0;Human;Binding;Ki;=;199,00;6,70;-99;5;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;446,2;8;1;4;4,30;CC(C)c1cccc(OCCN2C3CCC2CC(NS(=O)(=O)c2cccc(F)c2)C3)c1;https://dx.doi.org/10.1016/j.ejmech.2015.11.040
CHEMBL3759819;137908;None;0;Human;Binding;Ki;=;94,00;7,03;-6;5;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;496,2;8;1;4;5,36;O=S(=O)(NC1CC2CCC(C1)N2CCOc1cccc(-c2ccccc2)c1)c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.ejmech.2015.11.040
CHEMBL3759865;137914;None;0;Human;Binding;Ki;=;95,00;7,02;-74;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;426,2;7;2;3;4,65;O=C(NCCCCN1CCN(c2cccc3[nH]ccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3760063;137938;None;0;Human;Binding;Ki;=;482,00;6,32;-263;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;376,2;7;1;5;1,64;COc1ccccc1N1CCN(CCCCNC(=O)N2CCOCC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL3760110;137940;None;0;Human;Binding;Ki;=;131,00;6,88;-38;3;Displacement of [3H]-spiperone from human dopamine D2S receptor expressed in HEK293 cell membranes;ChEMBL;443,2;7;3;4;3,34;O=C(NCCCCN1CCN(c2cccc3[nH]c(=O)[nH]c23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.068
CHEMBL376020;137944;None;0;Human;Binding;Ki;=;128,82;6,89;-30;3;Binding affinity to dopamine D2;ChEMBL;432,2;8;1;6;3,65;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3cc(C#N)ccc3o2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL37604;137949;None;0;Human;Binding;Ki;=;1209,00;5,92;-128;2;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;348,2;4;1;2;4,36;Cc1ccc(C2CCN(CCC3NC(=O)c4ccccc43)CC2)cc1C;https://dx.doi.org/10.1016/s0960-894x(98)00252-2
CHEMBL376092;137955;None;3;Human;Binding;Ki;=;27,00;7,57;-20;2;Displacement of [125I]7-OH-PIPAT from human D2L receptor expressed in HEK293 cell membrane;ChEMBL;338,2;5;1;3;3,57;COc1ccccc1C1CCN(CNC(=O)c2cccc(C)c2)CC1;https://dx.doi.org/10.1021/jm060662k
CHEMBL3763200;137977;None;0;Human;Binding;Ki;=;12589,25;4,90;-125;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;463,2;7;0;7;4,45;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccncc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3763633;138007;None;2;Human;Binding;Ki;=;2300,00;5,64;-213;3;Displacement of [3H]methyl-spiperone from human recombinant dopamine D2 receptor expressed in HEK293 cells;ChEMBL;344,1;5;1;4;2,29;O=C(NCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccncc1;https://dx.doi.org/10.1016/j.bmc.2017.09.018
CHEMBL3764143;138051;None;0;Human;Binding;Ki;=;5011,87;5,30;-891;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;529,2;8;0;8;5,71;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764143;138051;None;0;Human;Binding;Ki;=;1584,89;5,80;-891;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;529,2;8;0;8;5,71;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764143;138051;None;0;Human;Binding;Ki;=;15848,93;4,80;-891;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;529,2;8;0;8;5,71;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764191;138055;None;0;Human;Binding;Ki;=;7943,28;5,10;-79;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;468,1;7;0;7;5,12;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccsc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764212;138056;None;0;Human;Binding;Ki;=;15848,93;4,80;-50;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;505,2;8;1;7;4,16;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccc(C(N)=O)c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764245;138059;None;0;Human;Binding;Ki;=;7943,28;5,10;-398;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;468,2;7;0;6;5,44;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCCCC1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764246;138060;None;0;Human;Binding;Ki;=;25118,86;4,60;-1584;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;490,2;8;0;9;4,71;Cc1ccc(C2CN(CCCSc3nnc(-c4ccc(-c5noc(C)n5)cc4)n3C)CCO2)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764306;138066;None;0;Human;Binding;Ki;=;25118,86;4,60;-1584;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;506,2;8;1;8;3,55;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)nc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL376445;138077;None;0;Human;Binding;Ki;=;10000,00;5,00;-2884;3;Binding affinity to dopamine D2;ChEMBL;523;7;1;4;5,83;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(Br)ccc2o1;https://dx.doi.org/10.1021/jm0611152
CHEMBL3764557;138087;None;0;Human;Binding;Ki;=;12589,25;4,90;-501;5;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;467,2;7;0;8;4,35;Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764586;138091;None;0;Human;Binding;Ki;=;10000,00;5,00;-50;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;485,2;7;0;8;4,49;Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3F)C2)n1C;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764597;138093;None;0;Human;Binding;Ki;=;15848,93;4,80;-398;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;523,2;8;1;7;4,29;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3F)C2)nnc1-c1ccc(C(N)=O)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764612;138095;None;0;Human;Binding;Ki;=;15848,93;4,80;-63;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;463,2;7;0;7;4,45;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764639;138097;None;0;Human;Binding;Ki;=;10000,00;5,00;-100;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;487,2;7;0;7;4,93;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C#N)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764739;138105;None;0;Human;Binding;Ki;=;6309,57;5,20;-50;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;465,2;7;0;7;4,39;Cn1cccc1-c1nnc(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764833;138112;None;0;Human;Binding;Ki;=;15848,93;4,80;-79;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;477,1;7;0;8;4,10;Cc1ncoc1-c1nnc(SCCCN2CCOC(c3ccc(Br)cc3)C2)n1C;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3764884;138116;None;0;Human;Binding;Ki;=;7943,28;5,10;-31;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;469,1;7;0;8;4,51;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1nccs1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3765072;138122;None;0;Human;Binding;Ki;=;10000,00;5,00;-79;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;529,2;8;0;9;4,64;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-n2cnnc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3765169;138127;None;0;Human;Binding;Ki;=;10000,00;5,00;-63;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;464,2;7;0;8;3,85;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3765267;138133;None;0;Human;Binding;Ki;=;19952,62;4,70;-1000;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;504,2;8;0;7;5,26;CC(=O)c1ccc(-c2nnc(SCCCN3CCOC(c4ccc(C(F)(F)F)cc4)C3)n2C)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3765285;138136;None;0;Human;Binding;Ki;=;12589,25;4,90;-1000;3;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;530,2;8;0;9;5,11;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2nnco2)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3765422;138152;None;0;Human;Binding;Ki;=;15848,93;4,80;-158;2;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;506,2;8;1;8;3,55;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cncc(C(N)=O)c1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3765426;138154;None;0;Human;Binding;Ki;=;10000,00;5,00;-1000;4;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;505,2;8;1;7;4,16;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3765426;138154;None;0;Human;Binding;Ki;=;12589,25;4,90;-1000;4;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;505,2;8;1;7;4,16;Cn1c(SCCCN2CCOC(c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
CHEMBL3769441;138250;None;0;Human;Binding;Ki;=;5187,00;5,29;-57;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;456,2;7;2;6;1,78;COc1cccc(N2CCN(CC(O)CN3C(=O)NC(C)(c4ccc(F)cc4)C3=O)CC2)c1;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3769534;138258;None;0;Human;Binding;Ki;=;127,00;6,90;-12;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;470,2;8;2;6;2,17;CCOc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3ccc(F)cc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3769536;138259;None;0;Human;Binding;Ki;=;6790,00;5,17;-5;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;462,2;6;2;5;2,05;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3ccc(F)cc3F)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL376955;138261;None;0;Human;Binding;Ki;=;140,00;6,85;-1;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;349,2;7;0;6;2,54;N#CCO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL3769606;138268;None;0;Human;Binding;Ki;=;839,00;6,08;-17;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;460,2;6;2;5;2,43;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3ccccc3Cl)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3769612;138271;None;0;Human;Binding;Ki;=;1814,00;5,74;-32;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;454,2;6;2;5;2,39;Cc1ccc(C)c(N2CCN(CC(O)CN3C(=O)NC(C)(c4ccc(F)cc4)C3=O)CC2)c1;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3769836;138292;None;0;Human;Binding;Ki;=;2906,00;5,54;-12;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;426,2;6;2;5;1,78;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3ccccc3)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3770110;138308;None;0;Human;Binding;Ki;=;2261,00;5,65;-12;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;454,2;6;2;5;2,39;Cc1ccc(N2CCN(CC(O)CN3C(=O)NC(C)(c4ccc(F)cc4)C3=O)CC2)cc1C;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3770293;138325;None;0;Human;Binding;Ki;=;5641,00;5,25;-6;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;444,2;6;2;5;1,92;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3ccc(F)cc3)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3770473;138344;None;0;Human;Binding;Ki;=;1709,00;5,77;-7;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;444,2;6;2;5;1,92;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3ccccc3F)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL377050;138346;None;0;Human;Binding;Ki;=;172,00;6,76;-7;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;324,2;6;0;5;2,64;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL3770522;138349;None;0;Human;Binding;Ki;=;4255,00;5,37;-4;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;460,2;6;2;5;2,43;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3ccc(Cl)cc3)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3770581;138353;None;0;Human;Binding;Ki;=;1976,00;5,70;-14;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;494,1;6;2;5;3,08;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3ccc(Cl)c(Cl)c3)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3770639;138360;None;0;Human;Binding;Ki;=;931,00;6,03;-66;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;451,2;6;2;6;1,65;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3ccccc3C#N)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3771222;138415;None;0;Human;Binding;Ki;=;261,00;6,58;-3;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;516,3;8;2;5;3,36;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3771222;138415;None;0;Human;Binding;Ki;=;261,00;6,58;-3;3;Displacement of [3H]-raclopride from D2 receptor (unknown origin);ChEMBL;516,3;8;2;5;3,36;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O;https://dx.doi.org/10.1039/C8MD00168E
CHEMBL3771309;138420;None;0;Human;Binding;Ki;=;302,00;6,52;-17;3;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;494,1;6;2;5;3,08;CC1(c2ccc(F)cc2)NC(=O)N(CC(O)CN2CCN(c3cccc(Cl)c3Cl)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
CHEMBL3771384;138435;None;0;Human;Binding;Ki;=;4897,79;5,31;-173;15;Binding affinity to human dopamine D2 receptor by radioligand binding assay;ChEMBL;239,1;5;1;2;2,59;C=CCOc1cc(F)c(F)cc1C1CC1CN;https://dx.doi.org/10.1021/acs.jmedchem.5b01153
CHEMBL3771384;138435;None;0;Human;Binding;Ki;=;4898,00;5,31;-173;15;Binding affinity to human dopamine D2 receptor by radioligand binding assay;ChEMBL;239,1;5;1;2;2,59;C=CCOc1cc(F)c(F)cc1C1CC1CN;https://dx.doi.org/10.1021/acs.jmedchem.5b01153
CHEMBL377200;138462;None;0;Human;Binding;Ki;=;630,96;6,20;-75;5;Binding affinity to dopamine D2;ChEMBL;332,2;4;0;4;3,50;Cc1c(CN2CCN(c3ccccc3)CC2)cnn1-c1ccccc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL377200;138462;None;0;Human;Binding;Ki;=;630,00;6,20;-75;5;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;332,2;4;0;4;3,50;Cc1c(CN2CCN(c3ccccc3)CC2)cnn1-c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL377200;138462;None;0;Human;Binding;Ki;=;250,00;6,60;-75;5;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;332,2;4;0;4;3,50;Cc1c(CN2CCN(c3ccccc3)CC2)cnn1-c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL377299;138485;None;0;Human;Binding;Ki;=;234,00;6,63;-32;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;506,3;9;2;5;4,24;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)NCCc3ccccc3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL377388;138502;None;0;Human;Binding;Ki;=;257,00;6,59;-1;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;344,2;7;0;6;3,10;CCO/N=C(\CCN1CCN(c2nccs2)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL377420;138511;None;0;Human;Binding;Ki;=;3230,00;5,49;-162;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;535,2;5;1;8;4,49;COc1cc(C(=O)NN2c3ccccc3N=C(N3CCN(C)CC3)c3cc(Cl)ccc32)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL3774411;138519;None;0;Human;Binding;Ki;=;630,96;6,20;-100;5;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;504,2;7;1;7;3,88;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774411;138519;None;0;Human;Binding;Ki;=;1995,26;5,70;-100;5;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;504,2;7;1;7;3,88;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774411;138519;None;0;Human;Binding;Ki;=;630,96;6,20;-100;5;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;504,2;7;1;7;3,88;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774412;138520;None;0;Human;Binding;Ki;=;398,11;6,40;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;451,2;8;0;9;2,97;COc1cccc(N2CCC3CN(CCCSc4nnc(-c5cnccn5)n4C)CC32)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774425;138523;None;0;Human;Binding;Ki;=;31,62;7,50;-158;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4cccc(C(F)(F)F)c4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774431;138524;None;0;Human;Binding;Ki;=;39,81;7,40;-186;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;443,3;7;0;6;4,70;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1C1CCCCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774431;138524;None;0;Human;Binding;Ki;=;794,33;6,10;-186;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;443,3;7;0;6;4,70;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1C1CCCCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774431;138524;None;0;Human;Binding;Ki;=;398,11;6,40;-186;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;443,3;7;0;6;4,70;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1C1CCCCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774462;138528;None;0;Human;Binding;Ki;=;158,49;6,80;-630;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;479,2;7;0;6;5,18;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1C1CCCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774462;138528;None;0;Human;Binding;Ki;=;199,53;6,70;-630;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;479,2;7;0;6;5,18;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1C1CCCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774462;138528;None;0;Human;Binding;Ki;=;501,19;6,30;-630;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;479,2;7;0;6;5,18;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1C1CCCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774463;138529;None;0;Human;Binding;Ki;=;6309,57;5,20;-251;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;493,2;7;0;6;5,57;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1C1CCCCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774490;138534;None;0;Human;Binding;Ki;=;398,11;6,40;-199;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;488,2;7;0;7;4,59;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccncc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774519;138537;None;0;Human;Binding;Ki;=;630,96;6,20;-630;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;475,2;7;0;8;3,38;Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL377452;138538;None;0;Human;Binding;Ki;=;63,00;7,20;1;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;480,1;2;0;5;4,82;Cc1ccccc1S(=O)(=O)N1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL3774534;138539;None;0;Human;Binding;Ki;=;630,96;6,20;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccnnc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774540;138541;None;0;Human;Binding;Ki;=;100,00;7,00;-93;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;492,2;7;0;8;4,49;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774540;138541;None;0;Human;Binding;Ki;=;630,96;6,20;-93;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;492,2;7;0;8;4,49;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774540;138541;None;0;Human;Binding;Ki;=;125,89;6,90;-93;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;492,2;7;0;8;4,49;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774569;138545;None;0;Human;Binding;Ki;=;398,11;6,40;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;468,2;7;0;8;3,01;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1-c1ccn(C)c(=O)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774588;138547;None;0;Human;Binding;Ki;=;199,53;6,70;-85;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;442,2;7;0;8;3,61;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774588;138547;None;0;Human;Binding;Ki;=;125,89;6,90;-85;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;442,2;7;0;8;3,61;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774588;138547;None;0;Human;Binding;Ki;=;199,53;6,70;-85;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;442,2;7;0;8;3,61;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774591;138549;None;0;Human;Binding;Ki;=;1000,00;6,00;-79;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;457,2;7;0;8;3,24;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774591;138549;None;0;Human;Binding;Ki;=;316,23;6,50;-79;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;457,2;7;0;8;3,24;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774591;138549;None;0;Human;Binding;Ki;=;398,11;6,40;-79;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;457,2;7;0;8;3,24;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774621;138552;None;0;Human;Binding;Ki;=;31,62;7,50;-39;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;505,2;8;0;9;3,86;Cn1c(SCCCN2CC3CCN(c4ccccc4OC(F)(F)F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774649;138555;None;0;Human;Binding;Ki;=;251,19;6,60;-26;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;427,2;7;0;7;3,40;Cn1c(SCCCN2CC3CCN(c4ccccc4)C3C2)nnc1C1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774649;138555;None;0;Human;Binding;Ki;=;199,53;6,70;-26;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;427,2;7;0;7;3,40;Cn1c(SCCCN2CC3CCN(c4ccccc4)C3C2)nnc1C1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774649;138555;None;0;Human;Binding;Ki;=;794,33;6,10;-26;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;427,2;7;0;7;3,40;Cn1c(SCCCN2CC3CCN(c4ccccc4)C3C2)nnc1C1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774683;138559;None;0;Human;Binding;Ki;=;501,19;6,30;-114;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774683;138559;None;0;Human;Binding;Ki;=;158,49;6,80;-114;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774683;138559;None;0;Human;Binding;Ki;=;251,19;6,60;-114;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774769;138566;None;0;Human;Binding;Ki;=;630,96;6,20;-141;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;518,2;7;0;8;3,89;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774769;138566;None;0;Human;Binding;Ki;=;501,19;6,30;-141;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;518,2;7;0;8;3,89;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774769;138566;None;0;Human;Binding;Ki;=;1584,89;5,80;-141;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;518,2;7;0;8;3,89;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)n(C)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774783;138568;None;0;Human;Binding;Ki;=;251,19;6,60;-63;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774783;138568;None;0;Human;Binding;Ki;=;630,96;6,20;-63;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774783;138568;None;0;Human;Binding;Ki;=;316,23;6,50;-63;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774869;138584;None;0;Human;Binding;Ki;=;251,19;6,60;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;439,2;7;0;8;3,10;Cn1c(SCCCN2CC3CCN(c4cccc(F)c4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774895;138586;None;0;Human;Binding;Ki;=;100,00;7,00;-316;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;505,2;8;0;9;3,86;Cn1c(SCCCN2CC3CCN(c4cccc(OC(F)(F)F)c4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774911;138591;None;0;Human;Binding;Ki;=;1258,93;5,90;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;507,2;7;0;8;4,12;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4C(F)(F)F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774927;138593;None;0;Human;Binding;Ki;=;3162,28;5,50;-25;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;435,2;7;0;8;3,27;Cc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3774996;138598;None;0;Human;Binding;Ki;=;199,53;6,70;-99;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;439,2;7;0;8;3,10;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775005;138600;None;0;Human;Binding;Ki;=;158,49;6,80;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;442,2;7;0;8;3,61;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4cccc(F)c4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775023;138602;None;0;Human;Binding;Ki;=;1584,89;5,80;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;451,2;8;0;9;2,97;COc1ccc(N2CCC3CN(CCCSc4nnc(-c5cnccn5)n4C)CC32)cc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775033;138606;None;0;Human;Binding;Ki;=;630,96;6,20;-63;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;454,2;7;1;7;3,00;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1-c1cc[nH]c(=O)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775036;138607;None;0;Human;Binding;Ki;=;199,53;6,70;-63;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;491,2;7;0;8;3,93;Cn1cc(-c2nnc(SCCCN3CC4CCN(c5ccc(C(F)(F)F)cc5)C4C3)n2C)cn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775071;138614;None;0;Human;Binding;Ki;=;630,96;6,20;-79;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;435,2;7;0;8;3,27;Cc1ccc(N2CCC3CN(CCCSc4nnc(-c5cnccn5)n4C)CC32)cc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775097;138617;None;0;Human;Binding;Ki;=;6309,57;5,20;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;446,2;7;0;9;2,84;Cn1c(SCCCN2CC3CCN(c4ccc(C#N)cc4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775197;138628;None;0;Human;Binding;Ki;=;398,11;6,40;-58;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;488,2;7;0;7;4,59;Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775197;138628;None;0;Human;Binding;Ki;=;794,33;6,10;-58;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;488,2;7;0;7;4,59;Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775197;138628;None;0;Human;Binding;Ki;=;1258,93;5,90;-58;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;488,2;7;0;7;4,59;Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1cccnc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775214;138631;None;0;Human;Binding;Ki;=;251,19;6,60;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;488,2;7;0;7;4,59;Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1ccncc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775226;138633;None;0;Human;Binding;Ki;=;100,00;7,00;-70;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;510,2;7;0;8;4,63;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775226;138633;None;0;Human;Binding;Ki;=;50,12;7,30;-70;4;Antagonist activity at human dopamine D2L receptor expressed in CHO cells assessed as inhibition of dopamine-mediated Ca+2 stimulation pretreated for 10 mins followed by addition of dopamine by fluo-4 AM dye-based FLIPR assay;ChEMBL;510,2;7;0;8;4,63;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775226;138633;None;0;Human;Binding;Ki;=;63,10;7,20;-70;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;510,2;7;0;8;4,63;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775226;138633;None;0;Human;Binding;Ki;=;1584,89;5,80;-70;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;510,2;7;0;8;4,63;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4F)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775243;138636;None;0;Human;Binding;Ki;=;501,19;6,30;-107;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;496,2;7;0;8;3,36;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1N1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775243;138636;None;0;Human;Binding;Ki;=;199,53;6,70;-107;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;496,2;7;0;8;3,36;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1N1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775243;138636;None;0;Human;Binding;Ki;=;199,53;6,70;-107;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;496,2;7;0;8;3,36;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1N1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775256;138637;None;0;Human;Binding;Ki;=;158,49;6,80;-79;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;494,2;7;0;8;4,65;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1nccs1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775294;138643;None;0;Human;Binding;Ki;=;398,11;6,40;-31;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;439,2;7;0;8;3,10;Cn1c(SCCCN2CC3CCN(c4ccccc4F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775301;138645;None;0;Human;Binding;Ki;=;501,19;6,30;-100;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;492,1;7;0;8;4,78;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(Cl)cc4Cl)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775338;138649;None;0;Human;Binding;Ki;=;10,00;8,00;-25;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;492,1;7;0;8;4,78;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4cc(Cl)cc(Cl)c4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775350;138650;None;0;Human;Binding;Ki;=;3981,07;5,40;-91;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;504,2;7;0;8;3,29;Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1ccn(C)c(=O)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775350;138650;None;0;Human;Binding;Ki;=;1258,93;5,90;-91;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;504,2;7;0;8;3,29;Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1ccn(C)c(=O)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775350;138650;None;0;Human;Binding;Ki;=;1000,00;6,00;-91;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;504,2;7;0;8;3,29;Cn1c(SCCCN2CC3CCN(c4c(F)cc(F)cc4F)C3C2)nnc1-c1ccn(C)c(=O)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775386;138652;None;0;Human;Binding;Ki;=;316,23;6,50;-25;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;505,2;8;0;9;3,86;Cn1c(SCCCN2CC3CCN(c4ccc(OC(F)(F)F)cc4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775395;138654;None;0;Human;Binding;Ki;=;630,96;6,20;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;508,2;8;0;9;4,37;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccc(OC(F)(F)F)cc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775408;138657;None;0;Human;Binding;Ki;=;316,23;6,50;-63;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;488,2;7;0;7;4,59;Cn1c(SCCCN2CC3CCN(c4ccccc4C(F)(F)F)C3C2)nnc1-c1ccccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL377542;138661;None;0;Human;Binding;Ki;=;64000,00;4,19;-131;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;311,2;3;0;5;2,19;Fc1ccc(N2CCN(Cc3cn4ccncc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL377542;138661;None;0;Human;Binding;Ki;=;68000,00;4,17;-131;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;311,2;3;0;5;2,19;Fc1ccc(N2CCN(Cc3cn4ccncc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL3775482;138668;None;0;Human;Binding;Ki;=;158,49;6,80;-63;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;492,2;7;0;8;4,49;Cc1cc(-c2nnc(SCCCN3CC4CCN(c5ccc(C(F)(F)F)cc5)C4C3)n2C)on1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775534;138671;None;0;Human;Binding;Ki;=;630,96;6,20;-56;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;449,2;7;0;9;3,34;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4cccc(C#N)c4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775534;138671;None;0;Human;Binding;Ki;=;50,12;7,30;-56;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;449,2;7;0;9;3,34;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4cccc(C#N)c4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775534;138671;None;0;Human;Binding;Ki;=;31,62;7,50;-56;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;449,2;7;0;9;3,34;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4cccc(C#N)c4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775554;138673;None;0;Human;Binding;Ki;=;398,11;6,40;-251;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;488,2;7;0;7;4,59;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775572;138676;None;0;Human;Binding;Ki;=;1258,93;5,90;-25;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cncnc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775583;138679;None;0;Human;Binding;Ki;=;316,23;6,50;-6;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cccnn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775589;138680;None;0;Human;Binding;Ki;=;251,19;6,60;-74;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;424,2;7;0;8;3,47;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775589;138680;None;0;Human;Binding;Ki;=;158,49;6,80;-74;4;Antagonist activity at human dopamine D2L receptor expressed in CHO cells assessed as inhibition of dopamine-mediated Ca+2 stimulation pretreated for 10 mins followed by addition of dopamine by fluo-4 AM dye-based FLIPR assay;ChEMBL;424,2;7;0;8;3,47;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775589;138680;None;0;Human;Binding;Ki;=;251,19;6,60;-74;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;424,2;7;0;8;3,47;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775589;138680;None;0;Human;Binding;Ki;=;398,11;6,40;-74;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;424,2;7;0;8;3,47;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775598;138682;None;0;Human;Binding;Ki;=;251,19;6,60;-66;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;479,2;9;0;9;3,75;CC(C)Oc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775598;138682;None;0;Human;Binding;Ki;=;5011,87;5,30;-66;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;479,2;9;0;9;3,75;CC(C)Oc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775598;138682;None;0;Human;Binding;Ki;=;251,19;6,60;-66;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;479,2;9;0;9;3,75;CC(C)Oc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775604;138683;None;0;Human;Binding;Ki;=;794,33;6,10;-251;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;488,2;7;0;7;4,59;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1cccnc1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775618;138684;None;0;Human;Binding;Ki;=;316,23;6,50;-19;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;451,2;8;0;9;2,97;COc1ccccc1N1CCC2CN(CCCSc3nnc(-c4cnccn4)n3C)CC21;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775631;138689;None;0;Human;Binding;Ki;=;199,53;6,70;-31;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;446,2;7;0;9;2,84;Cn1c(SCCCN2CC3CCN(c4ccccc4C#N)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775667;138692;None;0;Human;Binding;Ki;=;100,00;7,00;-50;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;446,2;7;0;9;2,84;Cn1c(SCCCN2CC3CCN(c4cccc(C#N)c4)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775718;138697;None;0;Human;Binding;Ki;=;398,11;6,40;-100;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;504,2;7;1;7;3,88;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccc(=O)[nH]c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775737;138701;None;0;Human;Binding;Ki;=;251,19;6,60;-1122;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;445,2;7;0;7;3,54;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1C1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775737;138701;None;0;Human;Binding;Ki;=;630,96;6,20;-1122;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;445,2;7;0;7;3,54;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1C1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775737;138701;None;0;Human;Binding;Ki;=;251,19;6,60;-1122;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;445,2;7;0;7;3,54;Cn1c(SCCCN2CC3CCN(c4ccc(F)cc4)C3C2)nnc1C1CCOCC1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775753;138702;None;0;Human;Binding;Ki;=;501,19;6,30;-158;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;469,2;8;0;9;3,11;COc1cc(N2CCC3CN(CCCSc4nnc(-c5cnccn5)n4C)CC32)ccc1F;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775771;138706;None;0;Human;Binding;Ki;=;630,96;6,20;-251;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;457,2;7;0;8;3,24;Cn1c(SCCCN2CC3CCN(c4c(F)cccc4F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775810;138711;None;0;Human;Binding;Ki;=;158,49;6,80;-125;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;489,2;7;0;8;3,98;Cn1c(SCCCN2CC3CCN(c4ccc(C(F)(F)F)cc4)C3C2)nnc1-c1ccncn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775836;138716;None;0;Human;Binding;Ki;=;316,23;6,50;-79;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;435,2;7;0;8;3,27;Cc1cccc(N2CCC3CN(CCCSc4nnc(-c5cnccn5)n4C)CC32)c1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL377584;138717;None;0;Human;Binding;Ki;=;350,00;6,46;-95;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;571,1;2;1;5;5,07;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc(I)c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL3775872;138721;None;0;Human;Binding;Ki;=;19,95;7,70;-19;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;508,2;8;0;9;4,37;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4ccccc4OC(F)(F)F)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775946;138728;None;0;Human;Binding;Ki;=;398,11;6,40;-100;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;507,2;7;0;8;4,12;Cn1c(SCCCN2CC3CCN(c4c(F)cccc4C(F)(F)F)C3C2)nnc1-c1cnccn1;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL3775967;138731;None;0;Human;Binding;Ki;=;501,19;6,30;-199;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;460,2;7;0;8;3,75;Cc1ncoc1-c1nnc(SCCCN2CC3CCN(c4c(F)cccc4F)C3C2)n1C;https://dx.doi.org/10.1016/j.bmc.2016.02.031
CHEMBL377756;138753;None;0;Human;Binding;Ki;=;92,00;7,04;-12;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;528,2;2;2;6;5,06;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3c(N)cccc3C(F)(F)F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL377877;138781;None;0;Human;Binding;Ki;=;792,00;6,10;-50;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;523,1;2;1;5;5,22;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3Br)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL3779928;138805;None;0;Human;Binding;Ki;=;159,00;6,80;-12;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;355,2;4;1;5;3,46;CCOc1ccc2c(c1OC)CN1CCc3cc(OC)c(O)cc3C1C2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL3780140;138817;None;0;Human;Binding;Ki;=;283,00;6,55;-14;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;397,2;7;1;5;4,63;CCCCCOc1ccc2c(c1OC)CN1CCc3cc(OC)c(O)cc3C1C2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL3780184;138821;None;0;Human;Binding;Ki;=;54,00;7,27;-4;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;381,2;5;1;5;3,85;COc1cc2c(cc1O)C1Cc3ccc(OCC4CC4)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL3780268;138829;None;0;Human;Binding;Ki;=;211,00;6,68;-30;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;385,2;6;2;6;2,83;COc1cc2c(cc1O)C1Cc3ccc(OCCCO)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL3780481;138847;None;11;Human;Binding;Ki;=;102,00;6,99;-6;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;341,2;3;1;5;3,07;COc1cc2c(cc1O)C1Cc3ccc(OC)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL3780506;138849;None;0;Human;Binding;Ki;=;99,00;7,00;-12;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;369,2;5;1;5;3,85;CCCOc1ccc2c(c1OC)CN1CCc3cc(OC)c(O)cc3C1C2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL3780975;138889;None;0;Human;Binding;Ki;=;1095,00;5,96;-1;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;329,2;4;2;5;3,23;COc1cc2c(cc1O)C(C)N(Cc1cccc(O)c1OC)CC2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL3781840;138956;None;0;Human;Binding;Ki;=;121,00;6,92;-10;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;383,2;6;1;5;4,24;CCCCOc1ccc2c(c1OC)CN1CCc3cc(OC)c(O)cc3C1C2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL378301;138992;None;0;Human;Binding;Ki;=;65,00;7,19;7;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;430,2;2;1;4;5,91;Cc1ccc(CN2CCN(C3=Nc4cc(Cl)ccc4Nc4ccccc43)CC2)c(C)c1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL378324;138998;None;0;Human;Binding;Ki;=;64,50;7,19;-9;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;392,1;6;0;5;3,95;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccc(Cl)c(Cl)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL378341;139003;None;0;Human;Binding;Ki;=;69,00;7,16;-2;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;565,1;2;1;5;6,27;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cc(F)ccc3C(F)(F)F)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL378455;139030;None;0;Human;Binding;Ki;=;38,00;7,42;-56;6;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;315,2;4;0;3;4,16;C1=C(c2ccccc2)CCN(Cc2cnn(-c3ccccc3)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL378455;139030;None;0;Human;Binding;Ki;=;28,00;7,55;-56;6;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;315,2;4;0;3;4,16;C1=C(c2ccccc2)CCN(Cc2cnn(-c3ccccc3)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL378512;139042;None;0;Human;Binding;Ki;=;274,00;6,56;-4;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;539,2;4;1;6;6,01;CCOc1ccc2ccccc2c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL378515;139045;None;0;Human;Binding;Ki;=;79,00;7,10;-54;6;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;357,1;4;0;6;2,71;COc1ccccc1N1CCN(Cc2cn3nc(Cl)ccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL378515;139045;None;0;Human;Binding;Ki;=;96,00;7,02;-54;6;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;357,1;4;0;6;2,71;COc1ccccc1N1CCN(Cc2cn3nc(Cl)ccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL378543;139077;None;0;Human;Binding;Ki;=;4927,00;5,31;-3;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;444,2;1;0;4;5,27;Cc1ccccc1C(=O)N1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL378576;139105;None;0;Human;Binding;Ki;=;171,00;6,77;-2;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;376,1;6;0;5;3,44;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL378648;139167;None;0;Human;Binding;Ki;=;194,00;6,71;-3;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;504,1;2;1;6;4,99;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc(C#N)cc3)c3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL378669;139196;None;0;Human;Binding;Ki;=;496,00;6,30;-562;6;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;494,1;2;2;6;4,70;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3c(N)cccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL378669;139196;None;0;Human;Binding;Ki;=;496,00;6,30;-562;6;Binding affinity at dopamine D2 receptor;ChEMBL;494,1;2;2;6;4,70;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3c(N)cccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL378680;139205;None;2;Human;Binding;Ki;=;3200,00;5,50;-2454;6;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;360,1;3;0;4;3,96;Clc1ccc(N2CCN(Cc3cn4ccccc4n3)CC2)cc1Cl;https://dx.doi.org/10.1021/jm060166w
CHEMBL378680;139205;None;2;Human;Binding;Ki;=;2700,00;5,57;-2454;6;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;360,1;3;0;4;3,96;Clc1ccc(N2CCN(Cc3cn4ccccc4n3)CC2)cc1Cl;https://dx.doi.org/10.1021/jm060166w
CHEMBL378914;139331;None;0;Human;Binding;Ki;=;196,00;6,71;-6;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;545,2;4;1;7;6,08;CCOc1c(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)sc2ccccc12;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL379125;139369;None;0;Human;Binding;Ki;=;72,00;7,14;-218;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;448,1;4;0;5;3,27;COc1ccccc1N1CCN(Cc2cn3cc(I)ccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL379125;139369;None;0;Human;Binding;Ki;=;73,00;7,14;-218;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;448,1;4;0;5;3,27;COc1ccccc1N1CCN(Cc2cn3cc(I)ccc3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL379177;139381;None;3;Human;Binding;Ki;=;220,00;6,66;-47;4;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;316,2;4;0;4;3,56;C1=C(c2ccccc2)CCN(Cc2cn(-c3ccccc3)nn2)C1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL379177;139381;None;3;Human;Binding;Ki;=;110,00;6,96;-47;4;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;316,2;4;0;4;3,56;C1=C(c2ccccc2)CCN(Cc2cn(-c3ccccc3)nn2)C1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL379238;139395;None;0;Human;Binding;Ki;=;1500,00;5,82;-100;2;Displacement of [3H]spiperone from the cloned human D2 receptor expressed in CHO cells;ChEMBL;376,2;7;0;5;3,89;CC(C)(CCCN1CCCC(c2cnco2)C1)S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2005.11.067
CHEMBL379560;139622;None;0;Human;Binding;Ki;=;1126,00;5,95;-87;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;475,2;3;1;6;4,47;COc1ccccc1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL379593;139626;None;0;Human;Binding;Ki;=;998,00;6,00;-5;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;507,2;3;1;5;5,89;CC(C)N1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL379602;139629;None;9;Human;Binding;Ki;=;8,00;8,10;-33;6;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;348,2;5;0;5;3,20;COc1ccccc1N1CCN(Cc2cnn(-c3ccccc3)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL379602;139629;None;9;Human;Binding;Ki;=;11,00;7,96;-33;6;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;348,2;5;0;5;3,20;COc1ccccc1N1CCN(Cc2cnn(-c3ccccc3)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL379662;139642;None;0;Human;Binding;Ki;=;164,00;6,79;-4;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;281,2;1;0;2;3,32;COc1cccc2c1Cc1ccccc1CCN(C)CC2;https://dx.doi.org/10.1021/jm051237e
CHEMBL3797205;139651;None;0;Human;Binding;EC50;=;8800,00;5,06;-13;6;Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay;ChEMBL;492,2;12;4;7;3,61;COc1cc(CCNC[C@@H](O)c2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3797205;139651;None;0;Human;Binding;Ki;=;310,00;6,51;-13;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;492,2;12;4;7;3,61;COc1cc(CCNC[C@@H](O)c2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3797205;139651;None;0;Human;Binding;Ki;=;96,00;7,02;-13;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;492,2;12;4;7;3,61;COc1cc(CCNC[C@@H](O)c2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3797209;139652;None;0;Human;Binding;EC50;=;16,80;7,78;-4;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3797209;139652;None;0;Human;Binding;EC50;=;20,50;7,69;-4;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3797209;139652;None;0;Human;Binding;EC50;=;33,90;7,47;-4;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3797209;139652;None;0;Human;Binding;EC50;=;13,70;7,86;-4;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3797209;139652;None;0;Human;Binding;EC50;=;0,90;9,05;-4;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3797209;139652;None;0;Human;Binding;IC50;=;98,90;7,00;-4;2;Antagonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced GalphaoA activation by BRET assay;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3797209;139652;None;0;Human;Binding;IC50;=;931,10;6,03;-4;2;Antagonist activity at human dopamine D2 receptor expressed in forskolin stimulated-HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced Galphai1 activation by BRET assay;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3797209;139652;None;0;Human;Binding;IC50;=;157,80;6,80;-4;2;Antagonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as reduction in quinpirole-mediated beta-arrestin 2 recruitment preincubated for 15 mins followed by quinpirole addition measured for 1 sec by BRET assay;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3797209;139652;None;0;Human;Binding;Ki;=;146,00;6,84;-4;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3797209;139652;None;0;Human;Binding;Ki;=;2,59;8,59;-4;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;315,2;7;0;4;3,26;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3797435;139686;None;0;Human;Binding;Ki;=;205,00;6,69;-28;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;437,2;5;0;7;3,16;CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C#N)cc3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3797651;139720;None;0;Human;Binding;Ki;=;22,00;7,66;-10;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;442,2;6;0;7;3,30;COc1ccc(-c2cc(N3CCN(C)CC3)nc3c2ccn3S(=O)(=O)CC(C)C)cc1;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3797717;139727;None;0;Human;Binding;Ki;=;367,00;6,43;-93;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;480,2;5;0;6;4,31;CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3797740;139729;None;0;Human;Binding;EC50;=;29,00;7,54;1;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;245,2;3;1;3;1,60;CCCN(C)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3797740;139729;None;0;Human;Binding;EC50;=;18,10;7,74;1;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;245,2;3;1;3;1,60;CCCN(C)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3797740;139729;None;0;Human;Binding;Ki;=;12,50;7,90;1;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;245,2;3;1;3;1,60;CCCN(C)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3797740;139729;None;0;Human;Binding;Ki;=;1180,00;5,93;1;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;245,2;3;1;3;1,60;CCCN(C)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3797758;139733;None;0;Human;Binding;Ki;=;85,00;7,07;-14;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;303,1;8;3;5;2,32;COc1ccccc1OCCNCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3797758;139733;None;0;Human;Binding;Ki;=;48,00;7,32;-14;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;303,1;8;3;5;2,32;COc1ccccc1OCCNCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3797876;139751;None;0;Human;Binding;Ki;=;430,00;6,37;-5;7;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;319,1;8;4;6;1,81;COc1ccccc1OCCNC[C@H](O)c1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3797876;139751;None;0;Human;Binding;Ki;=;640,00;6,19;-5;7;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;319,1;8;4;6;1,81;COc1ccccc1OCCNC[C@H](O)c1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3798018;139776;None;0;Human;Binding;Ki;=;5120,00;5,29;5;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;228,1;1;2;4;0,34;CN[C@@H]1Cc2cc(C#N)cc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798179;139799;None;0;Human;Binding;EC50;=;22,70;7,64;1;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;417,2;7;3;4;2,88;CN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798179;139799;None;0;Human;Binding;EC50;=;1,10;8,96;1;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;417,2;7;3;4;2,88;CN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3798179;139799;None;0;Human;Binding;EC50;=;154,50;6,81;1;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;417,2;7;3;4;2,88;CN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3798179;139799;None;0;Human;Binding;EC50;=;154,00;6,81;1;2;Agonist activity at dopamine D2 receptor (unknown origin) assessed as increase in beta-arrestin-2 recruitment;ChEMBL;417,2;7;3;4;2,88;CN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
CHEMBL3798179;139799;None;0;Human;Binding;EC50;=;27,70;7,56;1;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;417,2;7;3;4;2,88;CN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798179;139799;None;0;Human;Binding;EC50;=;124,70;6,90;1;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;417,2;7;3;4;2,88;CN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3798179;139799;None;0;Human;Binding;Ki;=;5,78;8,24;1;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;417,2;7;3;4;2,88;CN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798179;139799;None;0;Human;Binding;Ki;=;4230,00;5,37;1;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;417,2;7;3;4;2,88;CN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798334;139822;None;0;Human;Binding;EC50;=;4100,00;5,39;-;3;Agonist activity at human dopamine D2 receptor short isoform transfected in HEK293 cells measured for 10 mins by spectroscopic analysis;ChEMBL;419,2;7;1;5;4,15;COc1ccccc1N1CCN(CCCNC(=O)Oc2cccc3ccccc23)CC1;https://dx.doi.org/10.1039/C5MD00590F
CHEMBL3798478;139839;None;0;Human;Binding;Ki;=;382,00;6,42;-75;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;451,2;5;1;6;3,77;CC(C)CS(=O)(=O)n1ccc2c(-c3ccc4[nH]ccc4c3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3798490;139842;None;0;Human;Binding;Ki;=;52,00;7,28;-6;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;482,2;6;0;7;3,30;COCCS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL379874;139879;None;0;Human;Binding;Ki;=;1474,00;5,83;-104;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;451,1;2;1;6;4,52;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccs3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL3798748;139880;None;0;Human;Binding;EC50;=;13000,00;4,89;-363;6;Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay;ChEMBL;492,2;12;4;7;3,61;COc1cc(CCNC[C@H](O)c2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3798748;139880;None;0;Human;Binding;Ki;=;65,00;7,19;-363;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;492,2;12;4;7;3,61;COc1cc(CCNC[C@H](O)c2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3798748;139880;None;0;Human;Binding;Ki;=;130,00;6,89;-363;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;492,2;12;4;7;3,61;COc1cc(CCNC[C@H](O)c2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL379875;139881;None;0;Human;Binding;Ki;=;5561,00;5,25;-181;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;535,2;5;1;8;4,49;COc1cc(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL3798803;139893;None;0;Human;Binding;EC50;=;30,50;7,52;-1;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;259,2;4;1;4;1,75;CCCCn1c(=O)n2c3c(cccc31)C[C@@H](NC)C2;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798803;139893;None;0;Human;Binding;EC50;=;83,00;7,08;-1;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;259,2;4;1;4;1,75;CCCCn1c(=O)n2c3c(cccc31)C[C@@H](NC)C2;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798803;139893;None;0;Human;Binding;Ki;=;361,00;6,44;-1;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;259,2;4;1;4;1,75;CCCCn1c(=O)n2c3c(cccc31)C[C@@H](NC)C2;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798803;139893;None;0;Human;Binding;Ki;=;12,80;7,89;-1;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;259,2;4;1;4;1,75;CCCCn1c(=O)n2c3c(cccc31)C[C@@H](NC)C2;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3798840;139898;None;0;Human;Binding;Ki;=;630,00;6,20;-13;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;480,2;5;0;6;4,31;CC(C)CS(=O)(=O)n1ccc2c(-c3cccc(C(F)(F)F)c3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3798953;139910;None;0;Human;Binding;Ki;=;614,00;6,21;-56;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;440,2;6;0;6;3,85;CCc1ccc(-c2cc(N3CCN(C)CC3)nc3c2ccn3S(=O)(=O)CC(C)C)cc1;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3799120;139932;None;0;Human;Binding;Ki;=;25,00;7,60;-4;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;466,2;4;0;6;4,06;CC(C)S(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3799125;139933;None;37;Human;Binding;Ki;=;49,00;7,31;-1548;3;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;406,2;10;3;5;3,74;COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3799157;139938;None;0;Human;Binding;EC50;=;549,00;6,26;1;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;245,2;3;1;4;1,36;CCCn1c(=O)n2c3c(cccc31)C[C@@H](NC)C2;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799157;139938;None;0;Human;Binding;EC50;=;38,70;7,41;1;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;245,2;3;1;4;1,36;CCCn1c(=O)n2c3c(cccc31)C[C@@H](NC)C2;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799157;139938;None;0;Human;Binding;Ki;=;751,00;6,12;1;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;245,2;3;1;4;1,36;CCCn1c(=O)n2c3c(cccc31)C[C@@H](NC)C2;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799157;139938;None;0;Human;Binding;Ki;=;13,20;7,88;1;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;245,2;3;1;4;1,36;CCCn1c(=O)n2c3c(cccc31)C[C@@H](NC)C2;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799271;139958;None;4;Human;Binding;EC50;=;697,00;6,16;5;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;189,1;0;2;3;0,21;N[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799271;139958;None;4;Human;Binding;EC50;=;684,00;6,17;5;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;189,1;0;2;3;0,21;N[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799271;139958;None;4;Human;Binding;Ki;=;12100,00;4,92;5;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;189,1;0;2;3;0,21;N[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799271;139958;None;4;Human;Binding;Ki;=;114,00;6,94;5;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;189,1;0;2;3;0,21;N[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL379942;139986;None;0;Human;Binding;Ki;=;175,00;6,76;-87;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;493,1;2;1;5;5,42;Cc1ccccc1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2cc(Cl)ccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL3799427;139989;None;0;Human;Binding;Ki;=;1700,00;5,77;-38;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;437,2;12;4;6;3,98;COc1cc(CCNC[C@@H](O)c2ccc(O)c(O)c2)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3799427;139989;None;0;Human;Binding;Ki;=;1900,00;5,72;-38;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;437,2;12;4;6;3,98;COc1cc(CCNC[C@@H](O)c2ccc(O)c(O)c2)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3799455;139996;None;0;Human;Binding;EC50;=;240,00;6,62;-15;6;Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay;ChEMBL;472,2;12;3;5;4,63;COc1cc(CCNCCc2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3799455;139996;None;0;Human;Binding;Ki;=;64,00;7,19;-15;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;472,2;12;3;5;4,63;COc1cc(CCNCCc2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3799455;139996;None;0;Human;Binding;Ki;=;160,00;6,80;-15;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;472,2;12;3;5;4,63;COc1cc(CCNCCc2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3799529;140004;None;0;Human;Binding;Ki;=;1700,00;5,77;-562;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;466,2;5;1;6;3,97;CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(C(F)(F)F)cc3)cc(N3CCNCC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3799547;140007;None;0;Human;Binding;Ki;=;113,00;6,95;-4;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;480,2;5;0;6;4,31;CC(C)CS(=O)(=O)n1ccc2c(-c3ccccc3C(F)(F)F)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3799593;140017;None;0;Human;Binding;Ki;=;350,00;6,46;-1;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;319,1;8;4;6;1,81;COc1ccccc1OCCNC[C@@H](O)c1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3799593;140017;None;0;Human;Binding;Ki;=;200,00;6,70;-1;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;319,1;8;4;6;1,81;COc1ccccc1OCCNC[C@@H](O)c1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3799603;140019;None;0;Human;Binding;EC50;=;37,60;7,42;-;3;Agonist activity at human dopamine D2 receptor short isoform transfected in HEK293 cells measured for 10 mins by spectroscopic analysis;ChEMBL;421,1;7;1;4;4,68;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)Oc1ccccc1;https://dx.doi.org/10.1039/C5MD00590F
CHEMBL3799626;140021;None;0;Human;Binding;EC50;=;102,00;6,99;-1;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;466,2;7;2;4;3,97;CN(CCCCNC(=O)c1ccc2c(c1)Cc1ccccc1-2)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799626;140021;None;0;Human;Binding;EC50;=;109,00;6,96;-1;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;466,2;7;2;4;3,97;CN(CCCCNC(=O)c1ccc2c(c1)Cc1ccccc1-2)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799626;140021;None;0;Human;Binding;Ki;=;5,47;8,26;-1;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;466,2;7;2;4;3,97;CN(CCCCNC(=O)c1ccc2c(c1)Cc1ccccc1-2)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799626;140021;None;0;Human;Binding;Ki;=;3700,00;5,43;-1;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;466,2;7;2;4;3,97;CN(CCCCNC(=O)c1ccc2c(c1)Cc1ccccc1-2)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3799638;140022;None;0;Human;Binding;Ki;=;547,00;6,26;-34;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;412,2;5;0;6;3,29;CC(C)CS(=O)(=O)n1ccc2c(-c3ccccc3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3800150;140110;None;0;Human;Binding;Ki;=;86,00;7,07;3;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;518,2;8;0;7;4,87;CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(OCc4ccccc4)cc3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3800153;140111;None;0;Human;Binding;Ki;=;1231,00;5,91;-22;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;438,1;3;0;6;3,28;CN1CCN(c2cc(-c3ccc(C(F)(F)F)cc3)c3ccn(S(C)(=O)=O)c3n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3800165;140113;None;0;Human;Binding;EC50;=;13,00;7,89;-2;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;273,2;5;1;4;2,14;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3800165;140113;None;0;Human;Binding;EC50;=;68,00;7,17;-2;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;273,2;5;1;4;2,14;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3800165;140113;None;0;Human;Binding;Ki;=;868,00;6,06;-2;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;273,2;5;1;4;2,14;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3800165;140113;None;0;Human;Binding;Ki;=;8,08;8,09;-2;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;273,2;5;1;4;2,14;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3800251;140125;None;0;Human;Binding;Ki;=;640,00;6,19;-53;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;446,2;5;0;7;3,97;Cc1cc(-c2cc(N3CCN(C)CC3)nc3c2ccn3S(=O)(=O)CC(C)C)c(C)s1;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL3800303;140132;None;0;Human;Binding;Ki;=;110,00;6,96;-4;7;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;437,2;12;4;6;3,98;COc1cc(CCNC[C@H](O)c2ccc(O)c(O)c2)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800303;140132;None;0;Human;Binding;Ki;=;67,00;7,17;-4;7;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;437,2;12;4;6;3,98;COc1cc(CCNC[C@H](O)c2ccc(O)c(O)c2)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800341;140138;None;0;Human;Binding;EC50;=;1100,00;5,96;-5;6;Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay;ChEMBL;476,2;12;3;6;4,12;COc1cc(CCNCCc2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800341;140138;None;0;Human;Binding;Ki;=;17,00;7,77;-5;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;476,2;12;3;6;4,12;COc1cc(CCNCCc2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800341;140138;None;0;Human;Binding;Ki;=;12,00;7,92;-5;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;476,2;12;3;6;4,12;COc1cc(CCNCCc2ccc(O)c3c2OCC(=O)N3)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800400;140146;None;0;Human;Binding;Ki;=;5700,00;5,24;-8912;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;488,2;12;4;6;4,12;COc1cc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800400;140146;None;0;Human;Binding;Ki;=;3200,00;5,50;-8912;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;488,2;12;4;6;4,12;COc1cc(CCNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800468;140157;None;0;Human;Binding;Ki;=;2900,00;5,54;-112;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;488,2;12;4;6;4,12;COc1cc(CCNC[C@@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800468;140157;None;0;Human;Binding;Ki;=;2300,00;5,64;-112;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;488,2;12;4;6;4,12;COc1cc(CCNC[C@@H](O)c2ccc(O)c3[nH]c(=O)ccc23)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800539;140172;None;0;Human;Binding;Ki;=;108,00;6,97;-4;2;Displacement of [3H]NMSP from human dopamine D2S receptor expressed in CHO cell membrane incubated for 1 hr by scintillation counting method;ChEMBL;428,2;5;1;7;3,00;CC(C)CS(=O)(=O)n1ccc2c(-c3ccc(O)cc3)cc(N3CCN(C)CC3)nc21;https://dx.doi.org/10.1016/j.bmcl.2016.04.024
CHEMBL380054;140173;None;12;Human;Binding;Ki;=;19000,00;4,72;-457;6;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;310,2;3;0;4;2,80;Fc1ccc(N2CCN(Cc3cn4ccccc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL380054;140173;None;12;Human;Binding;Ki;=;21000,00;4,68;-457;6;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;310,2;3;0;4;2,80;Fc1ccc(N2CCN(Cc3cn4ccccc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL3800633;140187;None;0;Human;Binding;EC50;=;78,20;7,11;1;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;418,2;7;2;5;3,14;CN(CCCCNC(=O)c1cc2ccccc2o1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3800633;140187;None;0;Human;Binding;EC50;=;43,30;7,36;1;2;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;418,2;7;2;5;3,14;CN(CCCCNC(=O)c1cc2ccccc2o1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3800633;140187;None;0;Human;Binding;EC50;=;19,50;7,71;1;2;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;418,2;7;2;5;3,14;CN(CCCCNC(=O)c1cc2ccccc2o1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3800633;140187;None;0;Human;Binding;EC50;=;209,90;6,68;1;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;418,2;7;2;5;3,14;CN(CCCCNC(=O)c1cc2ccccc2o1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3800633;140187;None;0;Human;Binding;EC50;=;163,30;6,79;1;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;418,2;7;2;5;3,14;CN(CCCCNC(=O)c1cc2ccccc2o1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL3800633;140187;None;0;Human;Binding;Ki;=;14700,00;4,83;1;2;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;418,2;7;2;5;3,14;CN(CCCCNC(=O)c1cc2ccccc2o1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3800633;140187;None;0;Human;Binding;Ki;=;15,50;7,81;1;2;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;418,2;7;2;5;3,14;CN(CCCCNC(=O)c1cc2ccccc2o1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL3800636;140188;None;0;Human;Binding;EC50;=;2600,00;5,58;-7;6;Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay;ChEMBL;421,2;12;3;5;4,49;COc1cc(CCNCCc2ccc(O)c(O)c2)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800636;140188;None;0;Human;Binding;Ki;=;63,00;7,20;-7;6;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;421,2;12;3;5;4,49;COc1cc(CCNCCc2ccc(O)c(O)c2)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800636;140188;None;0;Human;Binding;Ki;=;120,00;6,92;-7;6;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;421,2;12;3;5;4,49;COc1cc(CCNCCc2ccc(O)c(O)c2)ccc1OCCCc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
CHEMBL3800675;140191;None;0;Human;Binding;EC50;=;5300,00;5,28;-;3;Agonist activity at human dopamine D2 receptor short isoform transfected in HEK293 cells measured for 10 mins by spectroscopic analysis;ChEMBL;417,2;7;1;4;4,84;Cc1ccccc1N1CCN(CCCCNC(=O)Oc2cccc3ccccc23)CC1;https://dx.doi.org/10.1039/C5MD00590F
CHEMBL3800677;140192;None;0;Human;Binding;EC50;=;14000,00;4,85;-;3;Agonist activity at human dopamine D2 receptor short isoform transfected in HEK293 cells measured for 10 mins by spectroscopic analysis;ChEMBL;403,2;6;1;4;4,45;Cc1ccccc1N1CCN(CCCNC(=O)Oc2cccc3ccccc23)CC1;https://dx.doi.org/10.1039/C5MD00590F
CHEMBL3800682;140197;None;0;Human;Binding;EC50;=;2600,00;5,58;-;3;Agonist activity at human dopamine D2 receptor short isoform transfected in HEK293 cells measured for 10 mins by spectroscopic analysis;ChEMBL;514,2;8;2;5;4,94;NC(=O)c1ccc(OC(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c2ccccc12;https://dx.doi.org/10.1039/C5MD00590F
CHEMBL3800683;140198;None;0;Human;Binding;EC50;=;3500,00;5,46;-;3;Agonist activity at human dopamine D2 receptor short isoform transfected in HEK293 cells measured for 10 mins by spectroscopic analysis;ChEMBL;479,1;7;1;6;4,46;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)Oc1cccc2c1OCCO2;https://dx.doi.org/10.1039/C5MD00590F
CHEMBL3800685;140200;None;0;Human;Binding;EC50;=;9900,00;5,00;-;3;Agonist activity at human dopamine D2 receptor short isoform transfected in HEK293 cells measured for 10 mins by spectroscopic analysis;ChEMBL;461,1;7;2;5;4,56;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)Oc1cccc2[nH]cnc12;https://dx.doi.org/10.1039/C5MD00590F
CHEMBL380171;140217;None;0;Human;Binding;Ki;=;168,00;6,78;-75;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;467,3;7;0;7;3,57;COc1cccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c1=O;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL380236;140230;None;0;Human;Binding;Ki;=;1362,00;5,87;-9;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;513,2;2;1;5;5,48;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc(C(F)(F)F)c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL380287;140246;None;0;Human;Binding;Ki;=;7800,00;5,11;-8;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;459,2;4;0;7;3,11;CN1CCN(c2ccc3nc(CN4CCN(c5ccc(Cl)c(Cl)c5)CC4)cn3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL380287;140246;None;0;Human;Binding;Ki;=;8000,00;5,10;-8;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;459,2;4;0;7;3,11;CN1CCN(c2ccc3nc(CN4CCN(c5ccc(Cl)c(Cl)c5)CC4)cn3n2)CC1;https://dx.doi.org/10.1021/jm060166w
CHEMBL380330;140252;None;0;Human;Binding;Ki;=;12,88;7,89;-1;6;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;281,2;1;0;2;3,32;COc1ccc2c(c1)CCN(C)CCc1ccccc1C2;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL380330;140252;None;0;Human;Binding;Ki;=;13,00;7,89;-1;6;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;281,2;1;0;2;3,32;COc1ccc2c(c1)CCN(C)CCc1ccccc1C2;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL380330;140252;None;0;Human;Binding;Ki;=;13,00;7,89;-1;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting;ChEMBL;281,2;1;0;2;3,32;COc1ccc2c(c1)CCN(C)CCc1ccccc1C2;https://dx.doi.org/10.1016/j.bmc.2009.08.028
CHEMBL380330;140252;None;0;Human;Binding;Ki;=;13,00;7,89;-1;6;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;281,2;1;0;2;3,32;COc1ccc2c(c1)CCN(C)CCc1ccccc1C2;https://dx.doi.org/10.1021/jm051237e
CHEMBL380464;140275;None;0;Human;Binding;Ki;=;0,99;9,00;3;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;301,1;0;1;2;3,67;CN1CCc2ccccc2Cc2c(ccc(O)c2Cl)CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL380597;140379;None;0;Human;Binding;Ki;=;118,00;6,93;-7;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;503,3;6;0;5;5,07;CC(C)(C)c1nc(N2CCN(CCCCN3C(=O)CCCc4ccccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL381019;140609;None;0;Human;Binding;Ki;=;60,00;7,22;-15;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;376,2;5;1;3;4,73;Cc1ccc(CN2CC[C@H](NC(=O)c3cccc(-c4cccs4)c3)C2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL381514;140768;None;0;Human;Binding;Ki;=;91,30;7,04;-16;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;472,3;7;2;5;4,04;CC(C)(C)CNC(=O)NCCCCN1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL3817898;140816;None;0;Human;Binding;Ki;=;249,00;6,60;-14;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;309,2;6;0;3;3,72;COc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3817898;140816;None;0;Human;Binding;Ki;=;251,19;6,60;-14;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;309,2;6;0;3;3,72;COc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818047;140825;None;0;Human;Binding;Ki;=;126,00;6,90;-35;8;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;313,1;5;0;2;4,36;O=C(CCCN1CCc2ccccc2C1)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818047;140825;None;0;Human;Binding;Ki;=;125,89;6,90;-35;8;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;313,1;5;0;2;4,36;O=C(CCCN1CCc2ccccc2C1)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818056;140827;None;0;Human;Binding;Ki;=;366,00;6,44;-36;7;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;295,2;5;1;3;3,41;O=C(CCCN1CCc2ccccc2C1)c1ccc(O)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818056;140827;None;0;Human;Binding;Ki;=;363,08;6,44;-36;7;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;295,2;5;1;3;3,41;O=C(CCCN1CCc2ccccc2C1)c1ccc(O)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818124;140830;None;0;Human;Binding;Ki;=;18,00;7,75;2;9;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;454,2;6;1;5;4,70;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3cc(Cl)ccc3s1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818124;140830;None;0;Human;Binding;Ki;=;18,20;7,74;2;9;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;454,2;6;1;5;4,70;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3cc(Cl)ccc3s1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818200;140838;None;0;Human;Binding;Ki;=;1445,44;5,84;-63;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;304,2;5;0;3;3,58;N#Cc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818200;140838;None;0;Human;Binding;Ki;=;1456,00;5,84;-63;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;304,2;5;0;3;3,58;N#Cc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818398;140854;None;0;Human;Binding;Ki;=;215,00;6,67;-1;5;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;440,1;6;1;5;5,25;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818398;140854;None;0;Human;Binding;Ki;=;213,80;6,67;-1;5;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;440,1;6;1;5;5,25;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818478;140862;None;0;Human;Binding;Ki;=;22,39;7,65;-13;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;402,2;6;2;3;3,92;O=C1NCN(c2ccccc2)C12CCN(CCCCc1c[nH]c3ccccc13)CC2;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818478;140862;None;0;Human;Binding;Ki;=;22,00;7,66;-13;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;402,2;6;2;3;3,92;O=C1NCN(c2ccccc2)C12CCN(CCCCc1c[nH]c3ccccc13)CC2;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818799;140886;None;0;Human;Binding;Ki;=;195,00;6,71;-6;5;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;477,2;8;0;4;6,30;Fc1ccc(C(c2ccc(F)cc2)N2CCN(CCCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818799;140886;None;0;Human;Binding;Ki;=;194,98;6,71;-6;5;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;477,2;8;0;4;6,30;Fc1ccc(C(c2ccc(F)cc2)N2CCN(CCCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818805;140887;None;0;Human;Binding;Ki;=;134,00;6,87;-8;6;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;422,2;6;2;3;5,12;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818805;140887;None;0;Human;Binding;Ki;=;134,90;6,87;-8;6;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;422,2;6;2;3;5,12;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818935;140900;None;0;Human;Binding;Ki;=;10,23;7,99;2;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;404,2;6;1;5;3,58;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3o1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818935;140900;None;0;Human;Binding;Ki;=;10,00;8,00;2;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;404,2;6;1;5;3,58;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3o1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818940;140901;None;0;Human;Binding;Ki;=;438,00;6,36;-1;5;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;384,2;6;1;4;4,79;OC1(c2ccc(Cl)cc2)CCN(CCCCc2nc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3818989;140904;None;1;Human;Binding;Ki;=;645,65;6,19;-165;8;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;279,2;5;0;2;3,71;O=C(CCCN1CCc2ccccc2C1)c1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818989;140904;None;1;Human;Binding;Ki;=;646,00;6,19;-165;8;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;279,2;5;0;2;3,71;O=C(CCCN1CCc2ccccc2C1)c1ccccc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3818994;140905;None;8;Human;Binding;Ki;=;49,00;7,31;-21;8;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;297,2;5;0;2;3,85;O=C(CCCN1CCc2ccccc2C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819153;140910;None;0;Human;Binding;Ki;=;95,00;7,02;1;8;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;424,2;6;1;5;4,78;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2nc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819153;140910;None;0;Human;Binding;Ki;=;95,50;7,02;1;8;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;424,2;6;1;5;4,78;O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2nc3ccccc3o2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL381936;140929;None;0;Human;Binding;Ki;=;58,70;7,23;-35;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;283,2;0;2;3;2,72;CN1CCc2cc(O)ccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL3819403;140932;None;0;Human;Binding;Ki;=;159,00;6,80;1;5;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;505,2;9;0;5;6,33;O=C(CCCCN1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819403;140932;None;0;Human;Binding;Ki;=;158,49;6,80;1;5;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;505,2;9;0;5;6,33;O=C(CCCCN1CCN(C(c2ccc(F)cc2)c2ccc(F)cc2)CC1)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819427;140934;None;0;Human;Binding;Ki;=;218,00;6,66;-18;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;322,2;6;1;3;2,81;NC(=O)c1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819427;140934;None;0;Human;Binding;Ki;=;218,78;6,66;-18;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;322,2;6;1;3;2,81;NC(=O)c1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL381946;140935;None;0;Human;Binding;Ki;=;62,00;7,21;4;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;281,2;1;0;2;3,32;COc1ccc2c(c1)Cc1ccccc1CCN(C)CC2;https://dx.doi.org/10.1021/jm051237e
CHEMBL3819494;140938;None;0;Human;Binding;Ki;=;158,49;6,80;-4;7;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;304,2;5;1;1;4,55;c1ccc2c(c1)CCN(CCCCc1c[nH]c3ccccc13)C2;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819494;140938;None;0;Human;Binding;Ki;=;170,00;6,77;-4;7;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;304,2;5;1;1;4,55;c1ccc2c(c1)CCN(CCCCc1c[nH]c3ccccc13)C2;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819567;140944;None;0;Human;Binding;Ki;=;24,00;7,62;1;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;420,2;6;1;5;4,05;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3s1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819567;140944;None;0;Human;Binding;Ki;=;23,99;7,62;1;7;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;420,2;6;1;5;4,05;O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3s1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819713;140956;None;0;Human;Binding;Ki;=;44,00;7,36;-3;8;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;426,2;6;1;4;5,79;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819713;140956;None;0;Human;Binding;Ki;=;44,67;7,35;-3;8;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;426,2;6;1;4;5,79;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819714;140957;None;0;Human;Binding;Ki;=;181,97;6,74;-10;6;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;454,1;7;1;5;5,82;O=C(CCCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819714;140957;None;0;Human;Binding;Ki;=;180,00;6,75;-10;6;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;454,1;7;1;5;5,82;O=C(CCCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1nc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819726;140959;None;0;Human;Binding;Ki;=;1150,00;5,94;-13;7;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;295,2;3;0;1;3,99;Fc1ccc2c(c1)CC(CCN1CCc3ccccc3C1)C2;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819731;140961;None;0;Human;Binding;Ki;=;319,00;6,50;-11;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;283,2;5;0;1;4,21;Fc1ccc(CCCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819731;140961;None;0;Human;Binding;Ki;=;316,23;6,50;-11;9;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;283,2;5;0;1;4,21;Fc1ccc(CCCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819732;140962;None;0;Human;Binding;Ki;=;123,00;6,91;-2;8;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;301,1;5;0;2;4,37;Fc1ccc(SCCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819732;140962;None;0;Human;Binding;Ki;=;123,03;6,91;-2;8;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;301,1;5;0;2;4,37;Fc1ccc(SCCCN2CCc3ccccc3C2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819734;140963;None;0;Human;Binding;Ki;=;758,58;6,12;-26;6;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;386,1;5;1;4;4,87;OC1(c2ccc(Cl)cc2)CCN(CCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819734;140963;None;0;Human;Binding;Ki;=;763,00;6,12;-26;6;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor incubated for 1.5 hrs by microbeta scintillation counting method;ChEMBL;386,1;5;1;4;4,87;OC1(c2ccc(Cl)cc2)CCN(CCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
CHEMBL3819742;140965;None;0;Human;Binding;Ki;=;422,00;6,38;-18;7;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;317,1;5;0;2;3,38;[O-][S+](CCCN1CCc2ccccc2C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL3819742;140965;None;0;Human;Binding;Ki;=;426,58;6,37;-18;7;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in cell membranes after 1 hr by liquid scintillation counting;ChEMBL;317,1;5;0;2;3,38;[O-][S+](CCCN1CCc2ccccc2C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
CHEMBL382010;140969;None;0;Human;Binding;Ki;=;36,90;7,43;-5;4;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;267,2;0;1;2;3,01;CN1CCc2ccccc2Cc2cc(O)ccc2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL382568;141164;None;0;Human;Binding;Ki;=;646,00;6,19;-120;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;522,2;6;1;7;3,26;CC(C)(C)c1nc(N2CCN(CCCCn3cc(C(F)(F)F)c(=O)[nH]c3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL382591;141168;None;0;Human;Binding;Ki;=;354,00;6,45;-29;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;491,3;6;0;6;4,12;CC(C)(C)c1nc(N2CCN(CCCCN3C(=O)COc4ccccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL38262;141172;None;9;Human;Binding;Ki;=;1842,00;5,74;-208;3;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;349,2;4;1;3;3,30;Cc1ccc(N2CCN(CCC3NC(=O)c4ccccc43)CC2)cc1C;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL38262;141172;None;9;Human;Binding;Ki;=;1842,00;5,74;-208;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;349,2;4;1;3;3,30;Cc1ccc(N2CCN(CCC3NC(=O)c4ccccc43)CC2)cc1C;https://dx.doi.org/10.1016/s0960-894x(98)00252-2
CHEMBL382773;141247;None;0;Human;Binding;Ki;=;62,60;7,20;-79;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;451,3;6;0;6;3,87;Cc1ccn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)c1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL382850;141302;None;0;Human;Binding;Ki;=;253,00;6,60;-7;4;Inhibition of binding to human D2L receptor expressed in HEK 293 cells by radioligand binding assay;ChEMBL;304,2;1;1;1;4,18;CCN1CCc2ccccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1021/jm050846j
CHEMBL383188;141363;None;0;Human;Binding;Ki;=;196,00;6,71;-102;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;454,2;6;1;7;2,25;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(=O)[nH]c3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL383188;141363;None;0;Human;Binding;Ki;=;196,00;6,71;-102;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;454,2;6;1;7;2,25;CC(C)(C)c1nc(N2CCN(CCCCn3ccc(=O)[nH]c3=O)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL383205;141366;None;0;Human;Binding;Ki;=;126,00;6,90;-37;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;489,3;6;0;5;4,67;CC(C)(C)c1nc(N2CCN(CCCCN3C(=O)CCc4ccccc43)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL383396;141405;None;0;Human;Binding;Ki;=;11,40;7,94;-;1;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;388,2;5;2;3;3,81;O=C1CCc2c(cccc2N2CCN(CCCc3c[nH]c4ccccc34)CC2)N1;https://dx.doi.org/10.1021/jm050148z
CHEMBL383451;141410;None;0;Human;Binding;Ki;=;88,00;7,06;-47;3;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;335,1;0;1;2;4,32;CN1CCc2ccccc2Cc2cc(Cl)c(O)c(Cl)c2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL384046;141498;None;0;Human;Binding;Ki;=;6800,00;5,17;-25;4;Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate;ChEMBL;269,1;0;3;4;2,09;Oc1cc2c(cc1O)[C@@H]1c3ccccc3CN[C@H]1CO2;https://dx.doi.org/10.1021/jm0604979
CHEMBL384069;141500;None;0;Human;Binding;Ki;=;139,00;6,86;-3;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;509,1;3;1;6;5,12;COc1cccc(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3cc(Cl)ccc32)c1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL38409;141505;None;0;Human;Binding;Ki;=;10,00;8,00;1;7;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;448,2;8;0;6;4,28;O=C1c2ccccc2C(=O)N1CCCCCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL384248;141544;None;0;Human;Binding;Ki;=;28425,00;4,55;-331;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;446,2;2;1;6;3,86;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccncc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL384269;141548;None;0;Human;Binding;Ki;=;533,00;6,27;-33;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;481,1;2;1;5;4,74;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccc(F)c3F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL38428;141551;None;9;Human;Binding;Ki;=;128,00;6,89;-;2;In vitro ability to inhibit [3H]raclopride binding to cloned human D2A receptors expressed in mouse fibroblast (LtK-) cells;ChEMBL;249,2;5;1;3;2,82;CCCN(CCC)C1COc2c(O)cccc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00232-2
CHEMBL384500;141590;None;0;Human;Binding;Ki;=;630,00;6,20;-57;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;480,1;2;1;6;4,51;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cccnc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL384538;141595;None;0;Human;Binding;Ki;=;5000,00;5,30;-1;2;Binding affinity to D2 receptor;ChEMBL;496,4;7;2;4;6,69;C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)C[C@@H]2OC(=O)C(=C)[C@H]2CCCC)C[C@@H](O)[C@H](C)[C@@H]1O;https://dx.doi.org/10.1021/jm060639z
CHEMBL384634;141615;None;0;Human;Binding;Ki;=;8,00;8,10;389;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;482,1;2;1;6;5,62;FC1(F)Oc2cccc(CN3CCN(C4=Nc5cc(Cl)ccc5Nc5ccccc54)CC3)c2O1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL384916;141659;None;0;Human;Binding;Ki;=;78,00;7,11;-1;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;527,2;3;1;6;6,19;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3sccc3-c3ccccc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL385289;141721;None;0;Human;Binding;Ki;=;61,66;7,21;1;4;Binding affinity to dopamine D2;ChEMBL;540,2;10;1;7;3,74;COc1ccccc1N1CCN(CCCCNC(=O)c2nnn(Cc3ccccc3Br)c2C)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL385289;141721;None;0;Human;Binding;Ki;=;17,00;7,77;1;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;540,2;10;1;7;3,74;COc1ccccc1N1CCN(CCCCNC(=O)c2nnn(Cc3ccccc3Br)c2C)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL385295;141723;None;0;Human;Binding;Ki;=;1571,00;5,80;-33;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;459,2;2;1;5;4,77;Cc1ccccc1C(=O)NN1c2ccccc2N=C(N2CCN(C)CC2)c2cc(Cl)ccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL38580;141819;None;0;Human;Binding;Ki;=;47,50;7,32;-8;2;In vitro ability to inhibit [3H]raclopride binding to cloned human D2A receptors expressed in mouse fibroblast (LtK-) cells;ChEMBL;299,2;6;0;3;4,37;CCCN(CCC)C1COc2c(cccc2-c2ccoc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00232-2
CHEMBL386122;141867;None;0;Human;Binding;Ki;=;240,00;6,62;-70;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;513,1;2;1;5;5,77;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3c(Cl)cccc3Cl)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL386424;141920;None;0;Human;Binding;Ki;=;1600,00;5,80;-15;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;471,2;3;1;5;4,86;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)/C=C/c3ccccc3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL38656;141949;None;0;Human;Binding;Ki;=;1360,00;5,87;-83;2;In vitro ability to inhibit [3H]raclopride binding to cloned human D2A receptors expressed in mouse fibroblast (LtK-) cells;ChEMBL;327,2;7;0;4;3,94;CCCN(CCC)C1COc2c(cccc2C(=O)c2ccoc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00232-2
CHEMBL386986;142004;None;0;Human;Binding;Ki;=;21,88;7,66;-2;4;Binding affinity to dopamine D2;ChEMBL;568,2;12;1;7;4,38;CCCc1c(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)nnn1Cc1ccccc1Br;https://dx.doi.org/10.1021/jm0611152
CHEMBL386986;142004;None;0;Human;Binding;Ki;=;3,00;8,52;-2;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;568,2;12;1;7;4,38;CCCc1c(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)nnn1Cc1ccccc1Br;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL387052;142018;None;0;Human;Binding;Ki;=;5000,00;5,30;-1;2;Binding affinity to D2 receptor;ChEMBL;319,2;7;0;3;4,45;COc1cccc(CCc2ccccc2OCc2ccccn2)c1;https://dx.doi.org/10.1021/jm060639z
CHEMBL387250;142045;None;1;Human;Binding;Ki;=;2500,00;5,60;-316;4;Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate;ChEMBL;269,1;0;3;4;2,09;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CO2;https://dx.doi.org/10.1021/jm0604979
CHEMBL387569;142101;None;0;Human;Binding;Ki;=;49,00;7,31;1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;456,3;8;0;6;4,91;COc1ccccc1N1CCN(CCCOc2ccc(-c3cn4cccc(C)c4n3)cc2)CC1;https://dx.doi.org/10.1021/jm070721+
CHEMBL387569;142101;UNDEFINED;0;Human;Binding;pKi;=;49,00;7,31;1;2;-;PDSP KiDatabase;456,3;8;0;6;4,91;COc1ccccc1N1CCN(CCCOc2ccc(-c3cn4cccc(C)c4n3)cc2)CC1;-
CHEMBL387738;142127;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;-3;3;-;PDSP KiDatabase;483,3;9;1;5;3,97;CS(=O)(=O)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL387784;142134;None;0;Human;Binding;Ki;=;68,00;7,17;-1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;494,2;8;0;5;6,29;Clc1cccc(N2CCN(CCCCOc3ccc(-c4cn5ccccc5n4)cc3)CC2)c1Cl;https://dx.doi.org/10.1021/jm070721+
CHEMBL387784;142134;UNDEFINED;0;Human;Binding;pKi;=;68,00;7,17;-1;2;-;PDSP KiDatabase;494,2;8;0;5;6,29;Clc1cccc(N2CCN(CCCCOc3ccc(-c4cn5ccccc5n4)cc3)CC2)c1Cl;-
CHEMBL387832;142140;None;0;Human;Binding;Ki;=;154,00;6,81;-57;4;Binding affinity for dopamine D2 receptor;ChEMBL;562,2;9;1;5;5,70;O=S(=O)(N[C@H]1CC[C@@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1)c1ccc(OC(F)F)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL387833;142141;None;0;Human;Binding;Ki;=;228,00;6,64;-42;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;538,2;10;1;6;4,82;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OCC(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL387833;142141;None;0;Human;Binding;Ki;=;276,00;6,56;-42;4;Binding affinity for dopamine D2 receptor;ChEMBL;538,2;10;1;6;4,82;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OCC(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL388247;142192;None;4;Human;Binding;Ki;=;1000,00;6,00;-79;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;344,2;6;2;3;3,48;CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CNCC3)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL388247;142192;None;4;Human;Binding;Ki;=;794,33;6,10;-79;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;344,2;6;2;3;3,48;CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CNCC3)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL388361;142242;None;0;Human;Binding;Ki;=;55,00;7,26;-1;4;Binding affinity for dopamine D2 receptor;ChEMBL;516,3;9;1;6;4,96;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL388361;142242;None;0;Human;Binding;Ki;=;55,00;7,26;-1;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;516,3;9;1;6;4,96;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL3883955;142265;None;0;Human;Binding;Ki;=;5,00;8,30;-16;12;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;484,2;7;0;7;4,44;O=c1ccc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)nn1-c1c(F)cccc1F;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL388509;142369;None;0;Human;Binding;Kd;=;16000,00;4,80;-26;2;Displacement of [3H]YM 09151-2 from dopamine D2 receptor in lamb striatum membrane after 2 hrs;ChEMBL;628,3;9;4;5;2,52;CC(C)[C@H](NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1)C(=O)N[C@@H](Cc1ccc(F)cc1)C(=O)N1CCC[C@H]1C(N)=O;https://dx.doi.org/10.1021/jm060947x
CHEMBL3885419;142406;None;0;Human;Binding;IC50;=;1,10;8,96;-;2;Displacement of [3H]methyl-spiperone from human recombinant dopamine D2S receptor expressed in HEK293 cells measured after 60 mins by scintillation counting method;ChEMBL;361,2;0;1;2;4,84;CC(C)(C)[C@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1;https://dx.doi.org/10.1016/j.bmc.2016.11.014
CHEMBL388674;142432;None;0;Human;Binding;Ki;=;398,11;6,40;-100;4;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;432,1;4;1;4;4,90;CN1CCc2ccc(NS(=O)(=O)c3ccc(-c4ccc(Cl)cc4)s3)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL388897;142450;None;0;Human;Binding;Ki;=;129,00;6,89;-100;4;Binding affinity for dopamine D2 receptor;ChEMBL;518,2;8;1;5;5,36;COc1ccc(Cl)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCC(c3ccccc3OC3CC3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL3889852;142501;None;0;Human;Binding;Ki;=;794,33;6,10;-15;3;Displacement of [3H]-methyl-spiperone from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by radioligand binding assay;ChEMBL;352,1;2;1;4;3,44;O=S(=O)(c1ccccc1)n1ccc2c3c(ccc21)[C@H]1CCNCC[C@@H]31;https://dx.doi.org/10.1016/j.bmc.2016.10.010
CHEMBL3890178;142540;None;0;Human;Binding;Ki;=;39,81;7,40;-2;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;515,2;8;1;6;4,96;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccccc1C(N)=O;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3890882;142628;None;0;Human;Binding;Ki;=;15848,93;4,80;-3981;3;Displacement of [3H]-methyl-spiperone from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by radioligand binding assay;ChEMBL;356,1;5;2;5;2,62;CN[C@@H]1c2cc3ccn(S(=O)(=O)c4ccccc4)c3cc2[C@H]1CCO;https://dx.doi.org/10.1016/j.bmc.2016.10.010
CHEMBL389104;142653;None;0;Human;Binding;Ki;=;66,00;7,18;-5;4;Binding affinity for dopamine D2 receptor;ChEMBL;498,2;7;1;6;4,43;O=S(=O)(N[C@H]1CC[C@@H](N2CCC(c3ccccc3OC3CC3)CC2)CC1)c1ccc2c(c1)OCO2;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL389110;142663;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;-2;3;-;PDSP KiDatabase;462,3;9;2;4;4,52;CC(=O)Nc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL389128;142676;None;0;Human;Binding;Ki;=;120,00;6,92;-12;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;428,2;7;1;3;6,45;CC(C)C(=O)Nc1cccc(C2CCN(Cc3ccc(Oc4ccccc4)cc3)CC2)c1;https://dx.doi.org/10.1021/jm060383x
CHEMBL389129;142678;None;0;Human;Binding;Ki;=;2900,00;5,54;-354;3;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;496,2;7;1;3;7,76;CC(C)C(=O)Nc1cccc(C2CCN(Cc3ccc(Oc4ccc(Cl)c(Cl)c4)cc3)CC2)c1;https://dx.doi.org/10.1021/jm060383x
CHEMBL3891542;142710;None;0;Human;Binding;Ki;=;4,10;8,39;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;437,3;9;1;5;4,34;CCOc1ccccc1N1CCCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;-
CHEMBL3891773;142740;None;0;Human;Binding;Ki;=;4,60;8,34;-21;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;344,2;4;1;5;3,33;N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3892201;142792;None;0;Human;Binding;Ki;=;177,00;6,75;-11;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;485,3;11;1;4;5,92;COc1ccc(-c2ccccc2N2CCN(CCCCCC(=O)N[C@@H](C)c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3892440;142828;None;0;Human;Binding;Ki;=;8,90;8,05;-93;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;422,2;6;1;6;2,92;CS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL389356;142971;None;0;Human;Binding;Ki;=;518,00;6,29;-37;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;281,2;0;1;2;3,40;CN1CCCc2cc(O)ccc2Cc2ccccc2CC1;https://dx.doi.org/10.1021/jm070388+
CHEMBL389357;142972;None;0;Human;Binding;Ki;=;25,00;7,60;-4;6;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;295,2;1;0;2;3,71;COc1ccc2c(c1)CCCN(C)CCc1ccccc1C2;https://dx.doi.org/10.1021/jm070388+
CHEMBL389357;142972;None;0;Human;Binding;Ki;=;24,55;7,61;-4;6;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;295,2;1;0;2;3,71;COc1ccc2c(c1)CCCN(C)CCc1ccccc1C2;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL3894257;143047;None;0;Human;Binding;Ki;=;1230,27;5,91;-81;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;493,2;7;0;7;5,63;Cc1ncsc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3894679;143095;None;0;Human;Binding;Ki;=;393,00;6,41;-12;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;530,2;10;1;5;4,75;O=C(CCOCCN1CCN(c2ncccc2-c2ccc(F)cc2)CC1)NCc1ccc(C(F)(F)F)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3894853;143120;None;0;Human;Binding;Ki;=;2238,72;5,65;-416;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;503,2;7;0;7;4,56;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccn(C)c(=O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3895172;143151;None;0;Human;Binding;Ki;=;345,00;6,46;-10;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;511,2;10;1;4;5,22;O=C(CCOCCN1CCN(c2ccccc2-c2ccccc2)CC1)NCc1ccc(C(F)(F)F)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3895540;143199;None;0;Human;Binding;Ki;=;0,30;9,52;-6;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;504,2;7;0;7;4,75;CN([C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)S(=O)(=O)c1cccs1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3895585;143204;None;0;Human;Binding;Ki;=;467,74;6,33;-46;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;479,1;7;0;7;5,32;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1nccs1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL389559;143205;None;0;Human;Binding;Ki;=;382,00;6,42;-4;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;295,2;0;1;2;3,79;CN1CCCc2ccccc2Cc2ccc(O)cc2CCC1;https://dx.doi.org/10.1021/jm070388+
CHEMBL3896355;143296;None;0;Human;Binding;Ki;=;260,00;6,58;-14;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;614,4;16;1;7;5,46;COc1ccc(-c2ccccc2N2CCN(CCCCCC(=O)NCc3ccc(OCCCN4CCOCC4)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3896638;143338;None;0;Human;Binding;Ki;=;331,13;6,48;-575;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;478,1;7;0;6;5,92;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccsc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3896746;143354;None;0;Human;Binding;Ki;=;15,00;7,82;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;445,1;6;1;4;4,63;O=C1CCc2ccc(OC/C=C/CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
CHEMBL3896937;143370;None;0;Human;Binding;Ki;=;0,51;9,29;-9;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;464,2;6;2;6;4,58;O=C(Nc1cccnc1)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3897134;143394;None;0;Human;Binding;Ki;=;660,69;6,18;-331;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;423,2;7;0;6;4,38;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(F)cc3)C2)nnc1-c1cccnc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL389718;143402;None;0;Human;Binding;Ki;=;68,00;7,17;-17;4;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;447,3;9;1;4;4,76;CC(=O)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
CHEMBL389718;143402;UNDEFINED;0;Human;Binding;pKi;=;68,00;7,17;-17;4;-;PDSP KiDatabase;447,3;9;1;4;4,76;CC(=O)c1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL3897426;143431;None;0;Human;Binding;Ki;=;522,00;6,28;-20;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;514,3;11;1;5;5,37;COc1ccc(-c2cc(F)ccc2N2CCN(CCCCCC(=O)NCc3ccc(C#N)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3897772;143461;None;0;Human;Binding;Ki;=;1445,44;5,84;-316;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;489,2;7;0;6;4,58;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1=CC=NC(=O)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3897805;143466;None;0;Human;Binding;IC50;=;2508,05;5,60;-6;3;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;339,1;2;0;5;3,09;COc1ccc(OC)c2c1C[C@H]1c3cc4c(cc3CCN1C2)OCO4;-
CHEMBL3897805;143466;None;0;Human;Binding;Ki;=;485,43;6,31;-6;3;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;339,1;2;0;5;3,09;COc1ccc(OC)c2c1C[C@H]1c3cc4c(cc3CCN1C2)OCO4;-
CHEMBL3898054;143498;None;0;Human;Binding;Ki;=;20,00;7,70;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;446,2;7;1;3;5,32;O=C1NCCc2ccc(OCCCCN3CCC(c4cccc(Cl)c4Cl)CC3)cc21;-
CHEMBL3899117;143638;None;0;Human;Binding;Ki;=;72,00;7,14;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;449,2;8;1;4;5,24;CC(=O)Nc1cc(OCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)ccc1C;-
CHEMBL3899125;143641;None;0;Human;Binding;Ki;=;354,81;6,45;-1584;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;515,2;8;1;6;4,96;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3899169;143649;None;0;Human;Binding;Ki;=;2780,00;5,56;-562;6;Binding Assay or Functional Activity Assay: Further, the compounds of the invention may be tested in binding assays and functional activity assays by well known methods for other physiologically important receptors such as, but not limited to, the hERG channel, other serotonin receptors (specifically 5-HT1B, 5-HT1D, receptors, lack of agonist activity at 5-HT2B receptors, 5-HT2C, 5-HT5, 5-HT6, and 5-HT7 receptors), dopaminergic receptors (specifically D1, D2, and D3), GABAA receptors, adrenergic receptors and monoamine transporters.;ChEMBL;433,1;3;1;6;4,62;Cc1ccc2c(c1)Oc1sc(Cl)cc1C(N1CCN(CC(C)(C)C(=O)O)CC1)=N2;-
CHEMBL3899336;143670;None;0;Human;Binding;Ki;=;61,66;7,21;-63;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,1;7;0;7;5,45;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3cc(Cl)cc(Cl)c3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL390015;143767;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;4;2;-;PDSP KiDatabase;498,3;10;2;5;3,93;CS(=O)(=O)Nc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
CHEMBL3900752;143834;None;0;Human;Binding;Ki;=;0,72;9,14;-1;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;471,3;7;1;5;5,20;CC(C)N(C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)C(C)C;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3901211;143890;None;0;Human;Binding;Ki;=;707,95;6,15;-16;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;409,2;7;0;7;4,14;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccccc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL390129;143897;None;0;Human;Binding;Ki;=;165,00;6,78;-134;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;516,3;9;1;6;4,96;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL390129;143897;None;0;Human;Binding;Ki;=;144,00;6,84;-134;4;Binding affinity for dopamine D2 receptor;ChEMBL;516,3;9;1;6;4,96;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL3901587;143931;None;0;Human;Binding;Ki;=;977,24;6,01;-141;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL390181;143965;None;0;Human;Binding;Ki;=;400,00;6,40;-19;3;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cells;ChEMBL;535,3;10;0;6;5,66;COc1ccc(C2=NO[C@@H](CCCN3CCN(C(c4ccc(F)cc4)c4ccc(F)cc4)CC3)C2)cc1OC;https://dx.doi.org/10.1016/j.ejmech.2006.12.030
CHEMBL390184;143971;None;1;Human;Binding;Ki;=;79,00;7,10;-26;4;Binding affinity for dopamine D2 receptor;ChEMBL;492,2;7;1;4;5,22;CC(C)Oc1ccccc1C1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccc(F)c(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL390192;143990;None;0;Human;Binding;Ki;=;82,00;7,09;-8;4;Binding affinity for dopamine D2 receptor;ChEMBL;560,2;8;1;5;5,76;COc1ccc(Cl)cc1S(=O)(=O)N[C@H]1CC[C@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL390212;144007;None;0;Human;Binding;Ki;=;1000,00;6,00;-23;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;458,3;8;1;4;6,46;COc1ccc(Oc2cccc(CN3CCC(c4cccc(NC(=O)C(C)C)c4)CC3)c2)cc1;https://dx.doi.org/10.1021/jm060383x
CHEMBL390213;144008;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;-27;3;-;PDSP KiDatabase;406,3;8;1;4;3,96;O=C(CCCCCN1CCN(c2ccccn2)CC1)NC1CCCc2ccccc21;-
CHEMBL3902496;144046;None;0;Human;Binding;Ki;=;18,00;7,75;-338;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;400,2;6;1;5;3,89;CCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL390253;144048;None;0;Human;Binding;IC50;=;88,30;7,05;-56;5;"Functional Assay: To measure D2 and D3 stimulation of mitogenesis (agonist assay) or D2 and D3 inhibition of quinpirole stimulation of mitogenesis (antagonist assay), CHOp-cells (human receptor) were seeded in a 96-well plate at a concentration of 5,000 cells/well. The cells were incubated at 37C. in alpha -MEM with 10% FBS, 0.05% penicillin-streptomycin, and 200 ug/mL of G418. After 48 hours, the cells were rinsed twice with serum-free alpha -MEM and incubated for 24 hours at 37 C. In the functional assay for agonism, the medium was removed and replaced with 90 ul of serum-free alpha -MEM and 10 ul of test compound in sterile water; in the antagonist assay, the test compound was diluted in sterile water plus 30 nM quinpirole. After another 24-hour incubation at 37 C., 0.25 uCi of [3H]thymidine was added to each well and the plates were further incubated for 2 hours at 37 C. The cells were then trypsinized, and the plates were filtered and counted as usual in the art.";ChEMBL;498,2;8;2;5;4,36;O=C(NCC(O)CCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;-
CHEMBL390253;144048;None;0;Human;Binding;Ki;=;28,40;7,55;-56;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;498,2;8;2;5;4,36;O=C(NCC(O)CCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL390297;144114;None;0;Human;Binding;Kd;=;300,00;6,52;-;1;Displacement of [3H]YM 09151-2 from dopamine D2 receptor in lamb striatum membrane after 2 hrs;ChEMBL;737,4;12;4;7;4,24;CN1C[C@H](C(=O)N[C@@H](Cc2ccc([N+](=O)[O-])cc2)C(=O)N[C@@H](CCC2CCCCC2)C(=O)N2CCCC(C(N)=O)C2)C=C2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1021/jm060947x
CHEMBL390299;144118;None;0;Human;Binding;Kd;=;20,00;7,70;34;2;Displacement of [3H]YM 09151-2 from dopamine D2 receptor in lamb striatum membrane after 2 hrs;ChEMBL;735,3;11;4;7;3,26;CN1C[C@H](C(=O)N[C@@H](Cc2ccc([N+](=O)[O-])cc2)C(=O)N[C@@H](Cc2ccc(F)cc2)C(=O)N2CCCC(C(N)=O)C2)C=C2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1021/jm060947x
CHEMBL3903297;144159;None;0;Human;Binding;IC50;=;1239,40;5,91;-1;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;323,1;0;0;5;2,80;c1c2c(cc3c1OCO3)CN1CCc3cc4c(cc3[C@@H]1C2)OCO4;-
CHEMBL3903297;144159;None;0;Human;Binding;Ki;=;239,90;6,62;-1;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;323,1;0;0;5;2,80;c1c2c(cc3c1OCO3)CN1CCc3cc4c(cc3[C@@H]1C2)OCO4;-
CHEMBL3903492;144182;None;36;Human;Binding;IC50;=;8500,00;5,07;-;1;Selectivity interaction (CEREP panel (binding assay, receptors and ion channels)) EUB0001623a DRD2;ChEMBL;340,1;2;1;3;3,90;Cc1n[nH]c2ncc(C(=O)N3CCC[C@H]3c3ccc(Cl)cc3)cc12;https://dx.doi.org/10.6019/CHEMBL5465560
CHEMBL3903542;144187;None;0;Human;Binding;Ki;=;145,00;6,84;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;501,2;6;1;4;5,89;O=C1CCc2ccc(OCC3CCC(CN4CCN(c5cccc(Cl)c5Cl)CC4)CC3)cc2N1;-
CHEMBL3903560;144190;None;0;Human;Binding;Ki;=;9,60;8,02;-39;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;416,2;7;1;6;3,13;COCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3903779;144219;None;0;Human;Binding;Ki;=;741,31;6,13;-245;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;506,2;7;0;6;5,62;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CC2CCC(C1)O2;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3904094;144261;None;0;Human;Binding;Ki;=;537,00;6,27;-7;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;469,2;10;1;6;3,46;N#Cc1ccc(CNC(=O)CCOCCN2CCN(c3ncccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL390473;144337;None;0;Human;Binding;Ki;=;94,00;7,03;-2;4;Binding affinity for dopamine D2 receptor;ChEMBL;534,3;9;1;6;5,10;COc1ccc(S(=O)(=O)N[C@H]2CC[C@H](N3CCC(c4cc(F)ccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL3905196;144383;None;0;Human;Binding;Ki;=;1584,89;5,80;-60;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccccc3C(F)(F)F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3905247;144388;None;0;Human;Binding;Ki;=;0,43;9,37;-14;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;487,2;6;2;5;5,28;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3905582;144432;None;0;Human;Binding;Ki;=;128,82;6,89;-131;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;480,1;7;0;8;4,71;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1csnn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3906408;144525;None;0;Human;Binding;Ki;=;64,00;7,19;-6;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;584,4;15;1;6;5,45;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NCc1ccc(OCCCN2CCOCC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3908174;144738;None;0;Human;Binding;Ki;=;851,14;6,07;-489;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;476,2;7;0;7;4,60;Cn1nccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3908548;144785;None;0;Human;Binding;Ki;=;537,03;6,27;-20;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;445,2;7;0;7;4,42;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3908548;144785;None;0;Human;Binding;Ki;=;676,08;6,17;-20;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;445,2;7;0;7;4,42;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3908862;144820;None;0;Human;Binding;Ki;=;977,24;6,01;-36;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;491,2;8;0;7;5,55;Cc1ncoc1-c1nnc(SCCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3908870;144823;None;0;Human;Binding;Ki;=;2933,00;5,53;-42;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;314,2;5;0;3;2,96;CC1(C)CC(=O)N(CCCCN2Cc3ccccc3C2)C(=O)C1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3908870;144823;None;0;Human;Binding;Ki;=;2951,21;5,53;-42;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;314,2;5;0;3;2,96;CC1(C)CC(=O)N(CCCCN2Cc3ccccc3C2)C(=O)C1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3909821;144949;None;0;Human;Binding;Ki;=;2,20;8,66;-1;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;457,3;5;1;6;3,41;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)N1CCOCC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL391016;144989;None;0;Human;Binding;Ki;=;55,00;7,26;-10;4;Binding affinity to human dopamine D2 receptor;ChEMBL;458,2;7;1;6;3,28;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3cccnc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL391017;144992;None;0;Human;Binding;Ki;=;43,00;7,37;-3;4;Binding affinity to human dopamine D2 receptor;ChEMBL;488,2;8;1;7;3,29;COc1ccncc1S(=O)(=O)N[C@H]1CC[C@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL3910287;145015;None;0;Human;Binding;Ki;=;251,19;6,60;-3;3;Displacement of [3H]-methyl-spiperone from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by radioligand binding assay;ChEMBL;487,2;8;1;5;4,65;CC(=O)Nc1ccc(CCN(C)CC2Cc3ccc4c(ccn4S(=O)(=O)c4ccccc4)c32)cc1;https://dx.doi.org/10.1016/j.bmc.2016.10.010
CHEMBL391035;145029;None;0;Human;Binding;Ki;=;42,00;7,38;-64;4;Binding affinity to human dopamine D2 receptor;ChEMBL;525,2;7;1;5;5,19;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccc(Cl)cc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL391057;145053;None;0;Human;Binding;Ki;=;590,00;6,23;-19;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;483,2;9;1;4;5,82;O=C(NCCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL3910730;145063;None;0;Human;Binding;Ki;=;1385,00;5,86;-51;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;509,3;10;1;5;5,24;N#Cc1ccc(CNC(=O)CCCCCN2CCN(c3ccc(F)cc3-c3ccc(C#N)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL391107;145108;None;0;Human;Binding;Ki;=;191,00;6,72;-36;4;Binding affinity to human dopamine D2 receptor;ChEMBL;457,2;7;1;5;3,89;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL391120;145124;None;0;Human;Binding;Ki;=;619,00;6,21;-26;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;543,3;11;1;6;5,84;COc1ccccc1C(c1ccccc1OC)N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL391190;145207;None;0;Human;Binding;Ki;=;1900,00;5,72;-52;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;336,1;3;2;4;3,33;COc1ccc2[nH]c3c(c2c1)CCNC3Cc1ccc2c(c1)OCO2;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL3912029;145224;None;0;Human;Binding;Ki;=;794,33;6,10;-27;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;427,2;7;0;7;4,28;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccc(F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3912435;145285;None;0;Human;Binding;Ki;=;0,45;9,35;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;438,2;7;1;7;2,72;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4OCCO5)CC3)nc2N1;-
CHEMBL391256;145301;None;0;Human;Binding;Ki;=;140,00;6,85;-16;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;391,2;8;1;4;3,01;C#Cc1cccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL391256;145301;None;0;Human;Binding;Ki;=;78,00;7,11;-16;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;391,2;8;1;4;3,01;C#Cc1cccc(C(=O)NCCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL391257;145304;None;0;Human;Binding;Ki;=;280,00;6,55;-26;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;467,3;8;1;4;4,43;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(C#Cc3ccccc3)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL391257;145304;None;0;Human;Binding;Ki;=;1200,00;5,92;-26;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;467,3;8;1;4;4,43;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(C#Cc3ccccc3)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL3912801;145334;None;0;Human;Binding;Ki;=;457,09;6,34;-165;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;535,3;8;1;6;5,36;CC(=O)NC1CCC(c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3912897;145353;None;0;Human;Binding;Ki;=;3311,31;5,48;-112;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;405,2;7;0;6;4,24;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccccc3)C2)nnc1-c1cccnc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3913062;145379;None;0;Human;Binding;Ki;=;16982,44;4,77;-33;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;409,2;7;0;7;4,14;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccccc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3913062;145379;None;0;Human;Binding;Ki;=;933,25;6,03;-33;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;409,2;7;0;7;4,14;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccccc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3913100;145387;None;0;Human;Binding;Ki;=;4346,00;5,36;-50;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;469,2;10;1;6;3,46;N#Cc1ccc(CNC(=O)CCOCCN2CCN(c3cccnc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3913542;145440;None;0;Human;Binding;Ki;=;1230,27;5,91;-371;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;501,2;7;0;6;5,88;Cc1ccc(-c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)c(C)n1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3913607;145446;None;0;Human;Binding;Ki;=;660,69;6,18;-125;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3913607;145446;None;0;Human;Binding;Ki;=;891,25;6,05;-125;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3913691;145453;None;0;Human;Binding;Ki;=;1,70;8,77;-6;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;440,2;5;1;5;4,05;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)C(F)(F)F;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3913849;145473;None;0;Human;Binding;Ki;=;1348,96;5,87;-144;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;493,2;7;1;6;4,19;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCNC(=O)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3914155;145516;None;0;Human;Binding;Ki;=;631,00;6,20;-39;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;468,3;10;1;5;4,07;N#Cc1ccc(CNC(=O)CCOCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3914195;145522;None;0;Human;Binding;Ki;=;123,03;6,91;-25;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccccc3C(F)(F)F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3914195;145522;None;0;Human;Binding;Ki;=;724,44;6,14;-25;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccccc3C(F)(F)F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3914241;145532;None;0;Human;Binding;Ki;=;10,00;8,00;-7;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;402,2;5;0;6;3,68;CCOC(=O)N1CCC(CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3914556;145569;None;0;Human;Binding;Ki;=;426,58;6,37;-309;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;479,1;7;0;7;5,32;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1nccs1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL391530;145666;None;0;Human;Binding;Ki;=;810,00;6,09;-93;4;Binding affinity to human dopamine D2 receptor;ChEMBL;517,3;9;1;7;3,90;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL391530;145666;None;0;Human;Binding;Ki;=;94,00;7,03;-93;4;Binding affinity to human dopamine D2 receptor;ChEMBL;517,3;9;1;7;3,90;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL391530;145666;None;0;Human;Binding;Ki;=;136,00;6,87;-93;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;517,3;9;1;7;3,90;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCN(c4ccccc4OC(C)C)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL3915863;145742;None;0;Human;Binding;Ki;=;4,50;8,35;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;434,1;6;2;4;4,14;O=c1[nH]c2ccc(OCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;-
CHEMBL3916047;145764;None;0;Human;Binding;Ki;=;3,40;8,47;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;445,1;6;1;4;4,82;O=c1ccc2ccc(OCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;-
CHEMBL3916231;145787;None;3;Human;Binding;Ki;=;693,00;6,16;-1;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;406,2;8;1;4;3,79;CC(O)CN1CCN(CCSC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL3916231;145787;None;3;Human;Binding;Ki;=;693,00;6,16;-1;3;Displacement of [3H]N-methylspiperone from human D2R expressed in HEK293 cell membranes incubated for 1 hr by radioligand binding assay;ChEMBL;406,2;8;1;4;3,79;CC(O)CN1CCN(CCSC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01373
CHEMBL391661;145841;None;0;Human;Binding;Ki;=;3162,28;5,50;-1258;8;Displacement of [125I]iodosulpiride from human cloned D2 receptor expressed in CHO cells;ChEMBL;483,2;6;1;5;5,00;Cc1ccc2c(OCCN3CCC(Cc4cc5c(cc4F)OCC(=O)N5)CC3)cc(Cl)cc2n1;https://dx.doi.org/10.1016/j.bmcl.2006.11.031
CHEMBL3917887;146002;None;0;Human;Binding;Ki;=;295,12;6,53;-13;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;445,2;7;0;7;4,42;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3918282;146058;None;4;Human;Binding;Ki;=;78,60;7,11;8;3;Displacement of [3H]N-methylspiperone from human D2R expressed in HEK293 cell membranes incubated for 1 hr by radioligand binding assay;ChEMBL;498,2;10;1;4;4,02;[O-][S+](CCN1CCN(CC(O)Cc2ccccc2)CC1)C(c1ccc(F)cc1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b01373
CHEMBL3918282;146058;None;4;Human;Binding;Ki;=;78,60;7,11;8;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;498,2;10;1;4;4,02;[O-][S+](CCN1CCN(CC(O)Cc2ccccc2)CC1)C(c1ccc(F)cc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL3918755;146122;None;0;Human;Binding;Ki;=;0,63;9,20;-14;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;463,2;6;2;5;5,19;O=C(Nc1ccccc1)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3918805;146129;None;0;Human;Binding;EC50;=;6,00;8,22;-;1;pERK High-Content Assay: Cell Culture: Chinese Hamster Ovary (CHO) cells stably expressing the hD2L dopamine receptor (Urban et al., Neuropsychopharmacology 32:67 (2007)) were maintained in Ham's F12 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 ug/mL streptomycin, and 0.5 ug/ml G418. On day 1 of the assay, cells were seeded onto black clear-bottom tissue culture-treated 96-well plates (Greiner, BioOne). On day 2 of the assay, cells were washed with serum-free medium (Ham's F-12, penicillin and streptomycin) and incubated in 100 uL serum-free medium overnight.Immunofluorescence: Automatic multichannel pipetters were used for liquid handling and multichannel vacuum manifolds for aspirations. Each tested concentration was typically measured in triplicate or quadruplicate. For concentration curves, half-log-dilutions were used. Drug dilutions were prepared in stimulation medium (serum-free medium, 100 mg/L ascorbic acid).;ChEMBL;447,1;6;1;4;4,86;O=C1CCc2ccc(OCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
CHEMBL3918805;146129;None;0;Human;Binding;Ki;=;8,30;8,08;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;447,1;6;1;4;4,86;O=C1CCc2ccc(OCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
CHEMBL391895;146139;None;0;Human;Binding;Ki;=;313,00;6,50;-20;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;537,3;11;1;5;5,77;COc1ccccc1C(c1ccccc1OC)N1CCN(CCCCNC(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL391985;146251;None;0;Human;Binding;Ki;=;120,23;6,92;-6;3;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;383,2;3;0;6;3,89;Cc1noc2c1C(=O)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)C2;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL3920167;146298;None;0;Human;Binding;Ki;=;501,19;6,30;-2951;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;539,2;8;0;7;6,52;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccc(-c2ncco2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3920252;146309;None;0;Human;Binding;Ki;=;0,33;9,48;-7;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;448,2;6;1;5;4,80;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3920432;146327;None;0;Human;Binding;Ki;=;1,90;8,72;-8;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;450,2;8;1;6;3,70;CCCS(=O)(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL392066;146358;None;0;Human;Binding;Ki;=;139,00;6,86;-12;4;Binding affinity to human dopamine D2 receptor;ChEMBL;505,2;8;1;6;4,03;COc1ccc(F)cc1S(=O)(=O)N[C@H]1CC[C@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL3921885;146512;None;0;Human;Binding;Ki;=;524,81;6,28;-323;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;441,2;7;0;6;4,52;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(F)cc3F)C2)nnc1-c1cccnc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3921903;146516;None;0;Human;Binding;Ki;=;0,93;9,03;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;449,3;9;1;5;4,69;CC(C)Oc1ccccc1N1CCCN(CCCCOc2ccc3ccc(=O)[nH]c3c2)CC1;-
CHEMBL3922143;146547;None;0;Human;Binding;Ki;=;8128,31;5,09;-61;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;427,2;7;0;7;4,28;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3922143;146547;None;0;Human;Binding;Ki;=;426,58;6,37;-61;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;427,2;7;0;7;4,28;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3922535;146601;None;0;Human;Binding;Ki;=;691,83;6,16;-478;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;498,2;7;0;7;5,13;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C#N)nc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3922670;146620;None;0;Human;Binding;Ki;=;685,00;6,16;-12;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;487,2;10;1;6;3,60;N#Cc1ccc(CNC(=O)CCOCCN2CCN(c3ncccc3-c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3922838;146646;None;0;Human;Binding;Ki;=;870,96;6,06;-501;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;503,2;7;0;7;4,56;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(=O)n(C)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL39230;146666;None;0;Human;Binding;Ki;=;4020,00;5,40;-37;5;Binding affinity against cloned human Dopamine receptor D2 using [3H]spiperone as radioligand transfected in HEK cells;ChEMBL;315,1;2;3;4;3,66;CCCc1cc2c(s1)CN[C@H]1CCc3cc(O)c(O)cc3[C@H]21;https://dx.doi.org/10.1021/jm00018a002
CHEMBL3923145;146685;None;0;Human;Binding;Ki;=;2450,00;5,61;-46;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;444,3;10;1;5;3,59;O=C(CCOCCN1CCN(c2ccccc2-c2ccccc2)CC1)NCc1ccncc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3923240;146699;None;0;Human;Binding;Ki;=;4,00;8,40;-21;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;416,2;6;1;6;4,11;CCOC(=O)N[C@H]1CC[C@@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3923578;146734;None;0;Human;Binding;Ki;=;1621,81;5,79;-446;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;493,2;7;0;7;5,63;Cc1ncsc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL392377;146760;None;0;Human;Binding;Ki;=;58,00;7,24;1;4;Binding affinity to human dopamine D2 receptor;ChEMBL;541,2;8;1;6;4,78;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccc(OC(F)(F)F)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL392401;146791;None;6;Human;Binding;Ki;=;88000,00;4,06;-79;2;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;264,1;1;3;2;3,11;Oc1cccc(C2NCCc3c2[nH]c2ccccc32)c1;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL392437;146844;None;0;Human;Binding;Ki;=;15,00;7,82;-22;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;429,1;7;1;3;4,31;C#Cc1cccc(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL392437;146844;None;0;Human;Binding;Ki;=;24,00;7,62;-22;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;429,1;7;1;3;4,31;C#Cc1cccc(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL3924375;146845;None;0;Human;Binding;Ki;=;293,00;6,53;-37;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;496,3;11;1;5;5,23;COc1ccc(-c2ccccc2N2CCN(CCCCCC(=O)NCc3ccc(C#N)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL392579;147013;None;0;Human;Binding;Ki;=;1570,00;5,80;-51;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;497,3;10;1;4;6,58;O=C(NCCCCN1CCC(N(Cc2ccccc2)c2ccccc2)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL3926847;147128;None;0;Human;Binding;Ki;=;257,04;6,59;-257;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;445,2;7;0;7;4,42;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3927895;147259;None;0;Human;Binding;Ki;=;331,13;6,48;-138;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3927895;147259;None;0;Human;Binding;Ki;=;4365,16;5,36;-138;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL392791;147261;None;0;Human;Binding;Ki;=;2288,00;5,64;-;1;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;407,2;8;1;5;3,65;COc1ccccc1NC1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL392822;147296;None;2;Human;Binding;Ki;=;382,00;6,42;4;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccccc2Cl)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL392823;147297;None;2;Human;Binding;Ki;=;5360,00;5,27;-3;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;322,2;3;3;3;3,36;Oc1ccc(C2(O)CCN(Cc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL392887;147373;None;0;Human;Binding;Ki;=;1700,00;5,77;-5;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;380,2;4;1;4;4,18;COc1cc2c(cc1OC)CN(/C=N/c1ccc3c(c1)C(O)CCCC3)CC2;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL392888;147377;None;0;Human;Binding;Ki;=;59000,00;4,23;-16;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;280,2;4;1;2;3,46;CN(/C=N/c1ccc2c(c1)C(O)CC2)Cc1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL3929083;147404;None;0;Human;Binding;Ki;=;616,60;6,21;-562;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;473,2;7;0;6;5,26;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccncc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3929168;147413;None;0;Human;Binding;Ki;=;0,94;9,03;-4;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;454,3;6;1;5;5,06;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL392970;147480;None;0;Human;Binding;Ki;=;14000,00;4,85;-70;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;422,2;5;0;5;4,75;COc1cc2c(cc1OC)CN(/C=N/c1ccc3c(c1)C(OC(C)=O)CCCC3)CC2;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL3929710;147483;None;0;Human;Binding;Ki;=;5,70;8,24;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;424,2;8;1;6;3,35;COc1ccccc1N1CCCN(CCCCOc2ccc3c(n2)NC(=O)CC3)CC1;-
CHEMBL3929918;147510;None;0;Human;Binding;Ki;=;1995,26;5,70;-1258;3;Displacement of [3H]-methyl-spiperone from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by radioligand binding assay;ChEMBL;326,1;4;1;4;2,74;CNCC1Cc2ccc3c(ccn3S(=O)(=O)c3ccccc3)c21;https://dx.doi.org/10.1016/j.bmc.2016.10.010
CHEMBL393027;147550;None;1;Human;Binding;Ki;=;201,00;6,70;10;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;354,1;3;2;2;4,70;OC1(c2ccc(Cl)cc2)CCCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL3930825;147645;None;0;Human;Binding;Ki;=;1778,28;5,75;-18;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;474,2;7;0;7;4,65;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL393104;147682;None;0;Human;Binding;Ki;=;76,00;7,12;-47;4;Binding affinity to human dopamine D2 receptor;ChEMBL;525,2;7;1;5;5,19;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccc(Cl)cc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL393105;147683;None;0;Human;Binding;Ki;=;271,00;6,57;-478;4;Binding affinity to human dopamine D2 receptor;ChEMBL;509,2;7;1;5;4,68;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3cccc(Cl)c3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL3931765;147762;None;4;Human;Binding;Ki;=;298,00;6,53;1;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;422,2;8;1;4;2,80;CC(O)CN1CCN(CC[S+]([O-])C(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL3931765;147762;None;4;Human;Binding;Ki;=;298,00;6,53;1;3;Displacement of [3H]N-methylspiperone from human D2R expressed in HEK293 cell membranes incubated for 1 hr by radioligand binding assay;ChEMBL;422,2;8;1;4;2,80;CC(O)CN1CCN(CC[S+]([O-])C(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01373
CHEMBL3932186;147815;None;0;Human;Binding;Ki;=;2,10;8,68;-40;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;472,2;6;1;6;4,90;O=C(NC[C@H]1CC[C@H](CN2CCN(c3nsc4cc(Cl)ccc34)CC2)CC1)c1ccco1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3932551;147857;None;0;Human;Binding;Ki;=;295,00;6,53;-25;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;485,3;11;1;4;5,92;COc1ccc(-c2ccccc2N2CCN(CCCCCC(=O)N[C@H](C)c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL393275;147892;None;0;Human;Binding;Ki;=;1500,00;5,82;-33;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;322,2;4;2;3;3,62;COc1cccc(CC2NCCc3c2[nH]c2ccc(OC)cc32)c1;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL3933256;147959;None;0;Human;Binding;Ki;=;0,35;9,46;-6;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;485,2;7;1;7;3,74;O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1cccnc1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL393365;148011;None;0;Human;Binding;Ki;=;23,00;7,64;-10;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;443,2;8;1;3;4,70;C#Cc1ccc(C(=O)NCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL393365;148011;None;0;Human;Binding;Ki;=;11,00;7,96;-10;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;443,2;8;1;3;4,70;C#Cc1ccc(C(=O)NCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL3934712;148145;None;0;Human;Binding;Ki;=;25,00;7,60;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;420,1;6;2;4;3,75;O=c1[nH]c2ccc(OCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2[nH]1;-
CHEMBL393492;148167;None;0;Human;Binding;Ki;=;319,00;6,50;-3;4;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;379,2;7;0;4;3,25;COc1ccccc1N1CCN(CCCCN2Cc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL3935170;148190;None;0;Human;Binding;Ki;=;4,40;8,36;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;438,3;9;1;6;3,74;CCOc1ccccc1N1CCCN(CCCCOc2ccc3c(n2)NC(=O)CC3)CC1;-
CHEMBL393539;148214;None;0;Human;Binding;Ki;=;1258,93;5,90;-794;9;Displacement of [125I]iodosulpiride from human cloned D2 receptor expressed in CHO cells;ChEMBL;467,2;6;1;5;4,49;Cc1ccc2c(OCCN3CCC(Cc4ccc5c(c4F)NC(=O)CO5)CC3)cc(F)cc2n1;https://dx.doi.org/10.1016/j.bmcl.2006.11.031
CHEMBL3935692;148263;None;0;Human;Binding;Ki;=;213,80;6,67;-181;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3935692;148263;None;0;Human;Binding;Ki;=;295,12;6,53;-181;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3935776;148272;None;0;Human;Binding;Ki;=;316,23;6,50;-57;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3935776;148272;None;0;Human;Binding;Ki;=;309,03;6,51;-57;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3936812;148389;None;0;Human;Binding;Ki;=;524,81;6,28;-7;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;463,2;6;0;7;4,77;Cc1ncoc1-c1nnc(SCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL393725;148447;None;0;Human;Binding;Ki;=;110,00;6,96;-15;4;Binding affinity to human dopamine D2 receptor;ChEMBL;501,3;8;1;6;4,20;COc1ccc(C)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL3937643;148498;None;0;Human;Binding;Ki;=;1,70;8,77;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;410,2;8;1;6;2,96;COc1ccccc1N1CCN(CCCCOc2ccc3c(n2)NC(=O)CC3)CC1;-
CHEMBL393774;148510;None;0;Human;Binding;Ki;=;4925,00;5,31;-;1;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;481,2;6;1;4;5,88;O=C(NCCCCN1CCN2c3ccccc3Cc3ccccc3C2C1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL393775;148513;None;0;Human;Binding;Ki;=;1149,00;5,94;-11;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;496,2;5;0;5;5,46;O=C1Cc2ccccc2C(=C2CCN(CCCCN3C(=O)c4ccccc4C3=O)CC2)c2ccsc21;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL3938107;148563;None;0;Human;Binding;Ki;=;891,25;6,05;-489;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;473,2;7;0;6;5,26;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3938210;148580;None;0;Human;Binding;Ki;=;0,21;9,68;1;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;437,2;6;2;5;4,13;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1ccc[nH]1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3939830;148768;None;0;Human;Binding;Ki;=;2570,40;5,59;-72;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;474,2;7;0;7;4,65;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccnnc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL394019;148811;None;0;Human;Binding;Ki;=;587,00;6,23;-208;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;511,2;9;1;3;6,41;O=C(NCCCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL394065;148867;None;0;Human;Binding;Ki;=;120,00;6,92;1;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;342,1;3;1;1;5,28;FC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL394066;148869;None;2;Human;Binding;Ki;=;548,00;6,26;-1;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;341,1;3;2;3;3,70;OC1(c2ccc(Cl)cc2)CCN(Cc2n[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL3940712;148876;None;0;Human;Binding;Ki;=;1,40;8,85;-7;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;477,3;7;2;5;4,87;O=C(NCc1ccccc1)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL394080;148886;None;0;Human;Binding;Ki;=;405,00;6,39;-10;4;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;379,2;7;0;4;3,19;COc1ccccc1N1CCN(CCCCN2C(=O)Cc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL3940897;148895;None;0;Human;Binding;Ki;=;1548,82;5,81;-389;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;474,2;7;0;7;4,65;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccnnc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL394110;148924;None;0;Human;Binding;Ki;=;38,00;7,42;5;4;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;399,2;6;0;5;2,43;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL394110;148924;None;0;Human;Binding;Ki;=;38,00;7,42;5;4;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;399,2;6;0;5;2,43;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL3941102;148925;None;0;Human;Binding;Ki;=;2766,00;5,56;-63;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;512,2;10;1;5;4,61;O=C(CCOCCN1CCN(c2cccnc2-c2ccccc2)CC1)NCc1ccc(C(F)(F)F)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3941190;148933;None;0;Human;Binding;Ki;=;14,00;7,85;-12;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;453,2;6;2;7;3,97;Nc1ccc2c(N3CCN(CC[C@H]4CC[C@H](NC(=O)c5ccco5)CC4)CC3)nsc2c1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL394139;148952;None;0;Human;Binding;Ki;=;356,00;6,45;-23;4;Binding affinity to human dopamine D2 receptor;ChEMBL;509,2;7;1;5;4,68;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3cc(Cl)ccc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL3941520;148965;None;0;Human;Binding;Ki;=;1148,15;5,94;-1698;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;530,2;8;1;7;4,67;Cc1nc(C(N)=O)ccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3941529;148966;None;0;Human;Binding;Ki;=;53,00;7,28;-5;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;455,3;10;1;3;5,91;C[C@H](NC(=O)CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3941818;149006;None;0;Human;Binding;Ki;=;363,08;6,44;-5128;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;539,2;8;0;7;6,52;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(-c2ncco2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL394189;149020;None;0;Human;Binding;Ki;=;136,00;6,87;-4;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;491,3;9;1;3;6,15;O=C(NCCCCN1CCCN(C(c2ccccc2)c2ccccc2)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL3942236;149071;None;0;Human;Binding;Ki;=;15,00;7,82;-20;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;424,2;5;0;6;3,95;O=C(c1ccco1)N1CCC(CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL394292;149151;None;0;Human;Binding;Ki;=;27,00;7,57;-64;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;429,1;7;1;3;4,31;C#Cc1ccc(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL394292;149151;None;0;Human;Binding;Ki;=;15,00;7,82;-64;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;429,1;7;1;3;4,31;C#Cc1ccc(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL3943838;149282;None;0;Human;Binding;Ki;=;4,60;8,34;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;461,2;7;1;4;4,65;O=C1NCCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc21;-
CHEMBL3944009;149296;None;0;Human;Binding;Ki;=;3,60;8,44;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;435,3;9;1;5;4,30;CCOc1ccccc1N1CCCN(CCCCOc2ccc3ccc(=O)[nH]c3c2)CC1;-
CHEMBL3944642;149372;None;0;Human;Binding;Ki;=;630,96;6,20;-51;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL394473;149383;None;0;Human;Binding;Ki;=;83,00;7,08;-223;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 short expressed in CHO cell membranes;ChEMBL;401,1;5;1;3;3,53;C#Cc1cccc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL394473;149383;None;0;Human;Binding;Ki;=;120,00;6,92;-223;4;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cell membranes;ChEMBL;401,1;5;1;3;3,53;C#Cc1cccc(C(=O)NCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2007.08.038
CHEMBL394541;149466;None;0;Human;Binding;IC50;=;175,00;6,76;-23;5;"Functional Assay: To measure D2 and D3 stimulation of mitogenesis (agonist assay) or D2 and D3 inhibition of quinpirole stimulation of mitogenesis (antagonist assay), CHOp-cells (human receptor) were seeded in a 96-well plate at a concentration of 5,000 cells/well. The cells were incubated at 37C. in alpha -MEM with 10% FBS, 0.05% penicillin-streptomycin, and 200 ug/mL of G418. After 48 hours, the cells were rinsed twice with serum-free alpha -MEM and incubated for 24 hours at 37 C. In the functional assay for agonism, the medium was removed and replaced with 90 ul of serum-free alpha -MEM and 10 ul of test compound in sterile water; in the antagonist assay, the test compound was diluted in sterile water plus 30 nM quinpirole. After another 24-hour incubation at 37 C., 0.25 uCi of [3H]thymidine was added to each well and the plates were further incubated for 2 hours at 37 C. The cells were then trypsinized, and the plates were filtered and counted as usual in the art.";ChEMBL;442,2;8;1;5;3,87;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2ccc(-c3ccccn3)cc2)CC1;-
CHEMBL394541;149466;None;0;Human;Binding;Ki;=;69,00;7,16;-23;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;442,2;8;1;5;3,87;COc1ccccc1N1CCN(C/C=C/CNC(=O)c2ccc(-c3ccccn3)cc2)CC1;https://dx.doi.org/10.1021/jm0704200
CHEMBL394569;149496;None;0;Human;Binding;Ki;=;610,00;6,21;-123;2;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;426,2;8;1;3;5,78;CC(C)C(=O)Nc1cccc(C2CCN(CCCC(=O)c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm060383x
CHEMBL3945775;149505;None;0;Human;Binding;Ki;=;954,99;6,02;-47;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;445,2;7;0;7;4,42;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccc(F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3945776;149506;None;0;Human;Binding;Ki;=;3801,89;5,42;-42;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(F)cc3C(F)(F)F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3946313;149570;None;0;Human;Binding;Ki;=;954,99;6,02;-134;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;541,2;7;0;6;6,28;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnc1C(F)(F)F;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3946901;149673;None;0;Human;Binding;Ki;=;524,81;6,28;-301;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;473,2;7;0;6;5,26;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccccn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3946995;149686;None;0;Human;Binding;Ki;=;2,90;8,54;-22;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;438,2;6;1;6;4,39;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1ccco1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3947670;149777;None;0;Human;Binding;Ki;=;1959,00;5,71;-18;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;487,2;10;1;6;3,60;N#Cc1ccc(CNC(=O)CCOCCN2CCN(c3cccnc3-c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL394779;149792;None;0;Human;Binding;Ki;=;63,00;7,20;1;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;281,2;0;1;2;3,40;CN1CCCc2ccccc2Cc2cc(O)ccc2CC1;https://dx.doi.org/10.1021/jm070388+
CHEMBL3947961;149811;None;0;Human;Binding;Ki;=;870,96;6,06;-109;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;473,2;7;0;6;5,26;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccncc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3948056;149826;None;0;Human;Binding;Ki;=;0,42;9,38;-6;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;498,2;7;1;6;4,65;Cc1ccc(S(=O)(=O)N[C@H]2CC[C@H](CCN3CCN(c4nsc5ccccc45)CC3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3948167;149842;None;0;Human;Binding;Ki;=;812,83;6,09;-478;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;480,2;7;0;6;5,09;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCOCC1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL394862;149895;None;0;Human;Binding;Ki;=;84,00;7,08;-33;2;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;509,2;7;2;4;4,87;O=C(NCC(O)CCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm0704200
CHEMBL394863;149896;None;0;Human;Binding;Ki;=;1050,00;5,98;-6;6;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;494,2;7;1;4;5,24;O=C(NC[C@H]1C[C@H]1CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL3948819;149915;None;0;Human;Binding;Ki;=;1000,00;6,00;-1000;3;Displacement of [3H]-methyl-spiperone from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by radioligand binding assay;ChEMBL;376,1;4;1;4;3,89;CNCC1Cc2ccc3c(ccn3S(=O)(=O)c3cccc4ccccc34)c21;https://dx.doi.org/10.1016/j.bmc.2016.10.010
CHEMBL3949662;150025;None;0;Human;Binding;Ki;=;724,44;6,14;-616;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;491,2;7;0;6;5,40;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3F)C2)nnc1-c1cccnc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3950020;150068;None;0;Human;Binding;Ki;=;268,00;6,57;-5;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;512,2;10;1;5;4,61;O=C(CCOCCN1CCN(c2ncccc2-c2ccccc2)CC1)NCc1ccc(C(F)(F)F)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3950254;150093;None;0;Human;Binding;Ki;=;549,54;6,26;-1230;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;516,2;8;1;7;4,36;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C(N)=O)nc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3950264;150095;None;0;Human;Binding;Ki;=;977,24;6,01;-32;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;427,2;7;0;7;4,28;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3950264;150095;None;0;Human;Binding;Ki;=;1096,48;5,96;-32;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;427,2;7;0;7;4,28;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3950540;150128;None;0;Human;Binding;Ki;=;346,74;6,46;-1318;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;497,2;7;0;6;5,73;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(C#N)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3950977;150187;None;0;Human;Binding;Ki;=;6,30;8,20;-33;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;438,2;6;1;6;4,39;O=C(N[C@H]1CC[C@@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1ccco1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3952761;150382;None;0;Human;Binding;Ki;=;0,87;9,06;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;451,3;9;1;5;4,73;CC(C)Oc1ccccc1N1CCCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;-
CHEMBL3953365;150467;None;0;Human;Binding;Ki;=;794,33;6,10;-35;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;463,2;6;0;7;4,77;Cc1ncoc1-c1nnc(SCCN2CC[C@@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3953773;150500;None;0;Human;Binding;Ki;=;2,40;8,62;-6;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;477,3;6;1;5;5,21;CN(C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3953892;150516;None;0;Human;Binding;Ki;=;102,85;6,99;-42;3;"Radioligand Binding Assay: liquots of membrane preparations were thawed at RT, resuspended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KC1, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein / well (D2, D3) and 15 ug protein / well (5-HT2A), respectively.The binding affinity (IQ) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ulÂ with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H] -spiperone for D2, 0.5 nM [3H] -spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10uM - 0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;481,3;6;1;4;6,54;O=C(NC1CCC(CCN2CCC(c3coc4ccccc34)CC2)CC1)c1ccc2ncccc2c1;-
CHEMBL3954123;150539;None;21;Human;Binding;Ki;=;14,00;7,85;10;2;Radioligand Binding Assay: The pharmacological profile of metopimazine, metopimazine acid (MPZA), domperidone, and metoclopramide were assessed by radioligand binding and by a functional antagonist assay. For the radioligand binding assay, cell membranes of dopamine D2 receptor expressing cells were incubated with [3H]spiperone and competing drugs in buffer. The assay was terminated by rapid filtration, and the bound radioactive signal was determined by liquid scintillation counting.;ChEMBL;446,1;6;1;6;3,88;CS(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(C(=O)O)CC1)c1ccccc1S2;-
CHEMBL3954490;150592;None;0;Human;Binding;Ki;=;1737,80;5,76;-87;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;493,2;7;1;8;4,13;Cc1ncoc1-c1nnc(SCC(O)CN2CC[C@@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3954568;150606;None;0;Human;Binding;Ki;=;512,86;6,29;-15;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;463,2;6;0;7;4,77;Cc1ncoc1-c1nnc(SCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3954568;150606;None;0;Human;Binding;Ki;=;977,24;6,01;-15;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;463,2;6;0;7;4,77;Cc1ncoc1-c1nnc(SCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL395501;150656;None;6;Human;Binding;Ki;=;199,53;6,70;-39;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;344,2;6;1;3;3,77;CCCCc1ccc(S(=O)(=O)Nc2ccc3c(c2)CN(C)C3)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL395525;150696;None;0;Human;Binding;Ki;=;15,85;7,80;-10;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;440,1;4;1;3;5,15;Cc1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL3955505;150733;None;0;Human;Binding;Ki;=;223,87;6,65;-154;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(C(F)(F)F)cc3F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3955608;150742;None;0;Human;Binding;Ki;=;467,74;6,33;-371;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;474,2;7;0;7;4,65;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cnccn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3955917;150776;None;0;Human;Binding;Ki;=;375,00;6,43;-14;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;600,4;15;1;7;5,07;COc1ccc(-c2ccccc2N2CCN(CCCCCC(=O)NCc3ccc(OCCN4CCOCC4)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3956612;150870;None;0;Human;Binding;Ki;=;1348,96;5,87;-67;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;473,2;7;0;6;5,26;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3956720;150884;None;0;Human;Binding;Ki;=;0,85;9,07;-4;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;412,2;6;1;5;3,89;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)C1CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3956758;150891;None;0;Human;Binding;Ki;=;537,03;6,27;-223;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;476,2;7;0;7;4,60;Cn1cc(-c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)cn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3957278;150955;None;0;Human;Binding;Ki;=;2,10;8,68;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;421,2;8;1;5;3,91;COc1ccccc1N1CCCN(CCCCOc2ccc3ccc(=O)[nH]c3c2)CC1;-
CHEMBL3958201;151055;None;0;Human;Binding;Ki;=;588,84;6,23;-851;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;478,2;7;0;5;6,24;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCCCC1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3958215;151057;None;0;Human;Binding;Ki;=;758,58;6,12;-478;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;309,2;3;0;2;3,63;O=C1c2ccc(F)cc2CC1CCN1CCc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3958215;151057;None;0;Human;Binding;Ki;=;750,00;6,12;-478;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;309,2;3;0;2;3,63;O=C1c2ccc(F)cc2CC1CCN1CCc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3958309;151072;None;0;Human;Binding;Ki;=;295,12;6,53;-288;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;474,2;7;0;7;4,65;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccncn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3958494;151108;None;0;Human;Binding;Ki;=;1000,00;6,00;-26;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;409,2;7;0;7;4,14;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccccc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3958494;151108;None;0;Human;Binding;Ki;=;512,86;6,29;-26;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;409,2;7;0;7;4,14;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccccc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3958949;151159;None;0;Human;Binding;Ki;=;1148,15;5,94;-446;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;503,2;8;0;7;5,27;COc1ncccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3958956;151162;None;0;Human;Binding;Ki;=;178,00;6,75;-12;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;455,3;10;1;3;5,74;C[C@@H]1CN(c2ccccc2-c2ccccc2)CCN1CCCCCC(=O)NCc1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3959240;151206;None;0;Human;Binding;Ki;=;218,78;6,66;-691;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;551,2;8;1;7;4,51;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(S(N)(=O)=O)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL395933;151214;None;0;Human;Binding;Ki;=;162,00;6,79;-2;5;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;349,2;6;0;3;3,18;O=C1Cc2ccccc2N1CCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL3959698;151261;None;0;Human;Binding;Ki;=;8,90;8,05;-8;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;438,2;6;1;6;4,25;O=C(NC[C@H]1CC[C@H](CN2CCN(c3nsc4ccccc34)CC2)CC1)c1ccco1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3960056;151314;None;0;Human;Binding;Ki;=;116,00;6,94;-10;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;455,3;10;1;3;5,91;C[C@@H](NC(=O)CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL396024;151342;None;0;Human;Binding;Ki;=;319,00;6,50;-173;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;509,2;7;2;4;4,87;O=C(NCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm0704200
CHEMBL3960785;151401;None;0;Human;Binding;Ki;=;0,53;9,28;-1;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;415,2;5;1;5;3,64;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL396092;151408;None;2;Human;Binding;Ki;=;129,00;6,89;3;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;340,1;3;2;2;4,30;OC1(c2cccc(Cl)c2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL3961596;151482;None;0;Human;Binding;Ki;=;2511,89;5,60;-2511;3;Displacement of [3H]-methyl-spiperone from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by radioligand binding assay;ChEMBL;376,1;4;1;4;3,89;CNCC1Cc2cc3ccn(S(=O)(=O)c4cccc5ccccc45)c3cc21;https://dx.doi.org/10.1016/j.bmc.2016.10.010
CHEMBL3962525;151590;None;0;Human;Binding;Ki;=;2,80;8,55;-19;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;414,2;7;1;5;4,28;CCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3963243;151654;None;0;Human;Binding;Ki;=;1000,00;6,00;-251;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;522,2;7;1;6;4,45;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1CCN(C(N)=O)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3963688;151712;None;0;Human;Binding;Ki;=;6309,57;5,20;-39;3;Displacement of [3H]-methyl-spiperone from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by radioligand binding assay;ChEMBL;356,1;5;2;5;2,62;CN[C@H]1c2cc3c(ccn3S(=O)(=O)c3ccccc3)cc2[C@@H]1CCO;https://dx.doi.org/10.1016/j.bmc.2016.10.010
CHEMBL3963783;151721;None;0;Human;Binding;Ki;=;239,88;6,62;-169;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;427,2;7;0;7;4,28;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3964512;151818;None;0;Human;Binding;Ki;=;758,58;6,12;-151;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;489,2;7;0;6;4,58;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1=CCC(=O)N=C1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3964512;151818;None;0;Human;Binding;Ki;=;338,84;6,47;-151;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;489,2;7;0;6;4,58;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1C1=CCC(=O)N=C1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3964649;151834;None;0;Human;Binding;Ki;=;7585,78;5,12;-208;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;531,2;8;1;7;5,26;Cc1nc(C(=O)O)ccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL396560;151954;None;0;Human;Binding;Ki;=;11,90;7,92;-14;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;320,2;1;1;2;3,80;COc1ccc2[nH]c3c(c2c1)CCN(C)CCc1ccccc1C3;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL396561;151958;None;0;Human;Binding;Ki;=;22,80;7,64;-1;4;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;320,2;1;1;2;3,80;COc1ccc2c(c1)CCN(C)CCc1c([nH]c3ccccc13)C2;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL3966484;152040;None;0;Human;Binding;Ki;=;15848,93;4,80;-79;3;Displacement of [3H]-methyl-spiperone from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by radioligand binding assay;ChEMBL;356,1;5;2;5;2,62;CN[C@H]1c2c(ccc3c2ccn3S(=O)(=O)c2ccccc2)[C@@H]1CCO;https://dx.doi.org/10.1016/j.bmc.2016.10.010
CHEMBL3966647;152060;None;0;Human;Binding;Ki;=;2187,76;5,66;-28;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccc(F)cc3C(F)(F)F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3966842;152091;None;0;Human;Binding;Ki;=;0,43;9,37;-10;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;490,2;7;1;7;4,41;O=S(=O)(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3966956;152105;None;0;Human;Binding;Ki;=;0,40;9,40;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;435,2;7;1;6;3,28;O=c1ccc2ccc(OCCCCN3CCN(c4cccc5c4OCCO5)CC3)cc2[nH]1;-
CHEMBL3967683;152186;None;0;Human;Binding;Ki;=;630,96;6,20;-81;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;473,2;7;0;6;5,26;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccccn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3967779;152202;None;0;Human;Binding;Ki;=;0,85;9,07;-9;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;449,2;6;1;6;4,19;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1cccnc1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3967806;152205;None;0;Human;Binding;Ki;=;478,63;6,32;-346;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;462,2;7;0;6;5,46;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccco1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3968272;152260;None;0;Human;Binding;Ki;=;1479,11;5,83;-446;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;487,2;7;0;6;5,57;Cc1ncccc1-c1nnc(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3968569;152290;None;0;Human;Binding;Ki;=;75,00;7,12;-3;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;498,3;12;1;4;5,41;CN(C)Cc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3969386;152376;None;0;Human;Binding;Ki;=;1380,38;5,86;-83;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;474,2;7;0;7;4,65;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccnn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL396950;152387;None;0;Human;Binding;Ki;=;857,00;6,07;-2;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;267,2;0;2;2;3,06;Oc1ccc2c(c1)CCCNCCc1ccccc1C2;https://dx.doi.org/10.1021/jm070388+
CHEMBL3970323;152473;None;0;Human;Binding;Ki;=;630,96;6,20;-912;5;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;515,2;8;1;6;4,96;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccc(C(N)=O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3970746;152525;None;0;Human;Binding;Ki;=;26,00;7,58;-109;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;483,2;7;1;8;4,30;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4cc([N+](=O)[O-])ccc34)CC2)CC1)c1ccco1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3970994;152549;None;0;Human;Binding;Ki;=;5623,41;5,25;-87;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;289,2;3;0;1;4,46;C1=C(CCN2CCc3ccccc3C2)CCc2ccccc21;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3970994;152549;None;0;Human;Binding;Ki;=;5647,00;5,25;-87;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;289,2;3;0;1;4,46;C1=C(CCN2CCc3ccccc3C2)CCc2ccccc21;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL397103;152557;None;0;Human;Binding;Ki;=;14,00;7,85;-1;4;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;400,1;6;1;3;2,68;C=CCN1CCC[C@H]1CNC(=O)c1cc(I)ccc1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL397103;152557;None;0;Human;Binding;Ki;=;15,00;7,82;-1;4;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;400,1;6;1;3;2,68;C=CCN1CCC[C@H]1CNC(=O)c1cc(I)ccc1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL3971125;152573;None;0;Human;Binding;Ki;=;243,00;6,61;-20;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;510,3;11;1;5;5,79;COc1ccc(-c2ccccc2N2CCN(CCCCCC(=O)N[C@H](C)c3ccc(C#N)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3971907;152684;None;0;Human;Binding;Ki;=;0,51;9,29;-1;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;429,3;6;1;5;4,03;CCN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL397207;152699;None;0;Human;Binding;Ki;=;1028,00;5,99;-1;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;325,2;2;0;3;3,71;COc1cc2c(cc1OC)Cc1ccccc1CCCN(C)CC2;https://dx.doi.org/10.1021/jm070388+
CHEMBL3973357;152844;None;0;Human;Binding;Ki;=;4,00;8,40;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;423,3;8;1;5;3,95;COc1ccccc1N1CCCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;-
CHEMBL3973487;152854;None;0;Human;Binding;Ki;=;25,00;7,60;-158;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;386,2;5;1;5;3,50;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL397476;153000;None;0;Human;Binding;Ki;=;100,00;7,00;-25;5;Displacement of [125I]iodosulpiride from human recombinant dopamine D2 receptor expressed in CHO cells;ChEMBL;468,2;5;1;3;5,96;CC(C)c1cc2c(cc1NS(=O)(=O)c1ccc(-c3ccc(Cl)cc3)cc1)CCN(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2006.10.036
CHEMBL3975147;153050;None;0;Human;Binding;Ki;=;1288,25;5,89;-190;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccc(F)cc3C(F)(F)F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL397543;153092;None;0;Human;Binding;Ki;=;398,11;6,40;-9;2;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;355,2;4;1;4;2,89;O=C1CC(CN2CCC(C(=O)c3ccc(F)cc3)CC2)Cc2[nH]ncc21;https://dx.doi.org/10.1039/C1MD00202C
CHEMBL397592;153142;None;0;Human;Binding;Ki;=;23,00;7,64;-1;4;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;352,1;6;1;3;2,84;C=CCN1CCC[C@H]1CNC(=O)c1cc(Br)ccc1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL397592;153142;None;0;Human;Binding;Ki;=;27,00;7,57;-1;4;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;352,1;6;1;3;2,84;C=CCN1CCC[C@H]1CNC(=O)c1cc(Br)ccc1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL3975989;153155;None;0;Human;Binding;Ki;=;63,10;7,20;-114;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@@H]3c3ccccc3C(F)(F)F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3976192;153183;None;0;Human;Binding;Ki;=;1445,44;5,84;-134;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;474,2;7;0;7;4,65;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cnccn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3976282;153191;None;0;Human;Binding;Ki;=;0,19;9,72;-3;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;454,2;6;1;6;4,86;O=C(N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3976319;153197;None;0;Human;Binding;Ki;=;346,74;6,46;-426;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;478,1;7;0;6;5,92;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1cccs1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3976948;153266;None;0;Human;Binding;Ki;=;3460,00;5,46;-13;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;530,2;10;1;5;4,75;O=C(CCOCCN1CCN(c2cccnc2-c2ccc(F)cc2)CC1)NCc1ccc(C(F)(F)F)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3976966;153268;None;0;Human;Binding;Ki;=;3248,00;5,49;-741;3;"Radioligand Binding Assay: Aliquots of membrane preparations were thawed at RT, resupended in assay buffer (D2, D3: 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 5 mM KCl, 1.5 mM CaCl2, pH=7.4; 5-HT2A: 50 mM Tris-HCl, 10 mM MgCl2, 1 mM EGTA, pH=7.4), homogenized with a Polytron for 20-30 sec at 12.000 rpm and adjusted to a final concentration of approximately 7.5 ug protein/well (D2, D3) and 15 ug protein/well (5-HT2A), respectively.The binding affinity (Ki) of the compounds was determined using radioligand binding. Membranes were incubated in a total volume of 200 ul with a fixed concentration of radioligand (final concentration approximately 0.7 nM [3H]-spiperone for D2, 0.5 nM [3H]-spiperone for D3, and 1.1 nM [3H]-ketanserin for 5-HT2A) and ten concentrations of test compound in ranging between 10 uM-0.1 nM for 1 h at RT. At the end of the incubation, the reaction mixtures were filtered on to unifilter 96-well white microplates with bonded GF/C filters.";ChEMBL;483,3;6;1;4;5,73;O=C(NC1CCC(CCN2CCC(c3cccc4c3CCO4)CC2)CC1)c1ccc2ncccc2c1;-
CHEMBL3977072;153279;None;0;Human;Binding;Ki;=;136,00;6,87;-8;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;570,4;14;1;6;5,06;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NCc1ccc(OCCN2CCOCC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL397770;153361;None;1;Human;Binding;Ki;=;26,10;7,58;10;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;374,1;3;2;2;4,96;OC1(c2cccc(Cl)c2Cl)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL3978288;153422;None;0;Human;Binding;Ki;=;1,29;8,89;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;452,3;9;1;6;4,13;CC(C)Oc1ccccc1N1CCCN(CCCCOc2ccc3c(n2)NC(=O)CC3)CC1;-
CHEMBL3978613;153460;None;0;Human;Binding;Ki;=;524,81;6,28;-194;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,2;7;0;7;5,16;Cc1cc(-c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)on1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3979307;153534;None;0;Human;Binding;Ki;=;243,00;6,61;-6;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;455,3;10;1;3;5,74;C[C@H]1CN(c2ccccc2-c2ccccc2)CCN1CCCCCC(=O)NCc1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3979523;153558;None;0;Human;Binding;Ki;=;446,68;6,35;-2137;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;514,2;8;0;6;6,07;CC(=O)c1ccc(-c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL398175;153822;None;0;Human;Binding;IC50;=;1300,00;5,89;-74;5;"Functional Assay: To measure D2 and D3 stimulation of mitogenesis (agonist assay) or D2 and D3 inhibition of quinpirole stimulation of mitogenesis (antagonist assay), CHOp-cells (human receptor) were seeded in a 96-well plate at a concentration of 5,000 cells/well. The cells were incubated at 37C. in alpha -MEM with 10% FBS, 0.05% penicillin-streptomycin, and 200 ug/mL of G418. After 48 hours, the cells were rinsed twice with serum-free alpha -MEM and incubated for 24 hours at 37 C. In the functional assay for agonism, the medium was removed and replaced with 90 ul of serum-free alpha -MEM and 10 ul of test compound in sterile water; in the antagonist assay, the test compound was diluted in sterile water plus 30 nM quinpirole. After another 24-hour incubation at 37 C., 0.25 uCi of [3H]thymidine was added to each well and the plates were further incubated for 2 hours at 37 C. The cells were then trypsinized, and the plates were filtered and counted as usual in the art.";ChEMBL;494,2;7;1;4;5,47;Cc1cccc(-c2ccc(C(=O)NC/C=C/CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2)n1;-
CHEMBL398175;153822;None;0;Human;Binding;Ki;=;105,00;6,98;-74;5;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;494,2;7;1;4;5,47;Cc1cccc(-c2ccc(C(=O)NC/C=C/CN3CCN(c4cccc(Cl)c4Cl)CC3)cc2)n1;https://dx.doi.org/10.1021/jm0704200
CHEMBL3981856;153838;None;0;Human;Binding;Ki;=;467,74;6,33;-549;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;529,2;9;1;6;4,89;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccc(CC(N)=O)cc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3982119;153864;None;0;Human;Binding;IC50;=;1727,60;5,76;-6;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;355,2;4;0;5;3,38;COc1cc2c(cc1OC)[C@@H]1Cc3c(OC)ccc(OC)c3CN1CC2;-
CHEMBL3982119;153864;None;0;Human;Binding;Ki;=;334,38;6,48;-6;2;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;355,2;4;0;5;3,38;COc1cc2c(cc1OC)[C@@H]1Cc3c(OC)ccc(OC)c3CN1CC2;-
CHEMBL3982360;153896;None;0;Human;Binding;Ki;=;0,30;9,52;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;437,2;7;1;6;3,32;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4OCCO5)CC3)cc2N1;-
CHEMBL3982486;153909;None;0;Human;Binding;Ki;=;0,71;9,15;-12;4;Displacement of [3H]spiperone from recombinant human D2L receptor expressed in CHO cell membranes after 60 mins by scintillation counting method;ChEMBL;416,2;6;1;6;4,11;CCOC(=O)N[C@H]1CC[C@H](CCN2CCN(c3nsc4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
CHEMBL3983121;153985;None;0;Human;Binding;Ki;=;66,07;7,18;-158;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;477,1;7;0;7;5,45;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3cc(Cl)cc(Cl)c3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3983496;154027;None;0;Human;Binding;Ki;=;321,00;6,49;-50;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;531,3;14;1;6;5,34;COCOc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccc(OC)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3983588;154040;None;0;Human;Binding;Ki;=;0,47;9,33;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;450,2;7;2;6;2,88;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5c4OCC(=O)N5)CC3)cc2N1;-
CHEMBL398368;154051;None;0;Human;Binding;Ki;=;159,00;6,80;9;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;406,3;9;2;3;5,61;CCCCCCOc1ccc(C2(O)CCN(Cc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL3983684;154052;None;0;Human;Binding;Ki;=;1698,24;5,77;-158;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;507,2;7;0;6;4,53;CN1CCC(c2nnc(SCCCN3CC[C@]4(C[C@@H]4c4ccc(C(F)(F)F)cc4)C3)n2C)CC1=O;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3983937;154078;None;0;Human;Binding;Ki;=;794,33;6,10;-123;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;409,2;7;0;7;4,14;Cc1ncoc1-c1nnc(SCCCN2CC[C@@]3(C[C@H]3c3ccccc3)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3984236;154113;None;0;Human;Binding;Ki;=;436,52;6,36;-85;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;474,2;7;0;7;4,65;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccncn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3984387;154133;None;0;Human;Binding;Ki;=;117,49;6,93;-42;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;480,1;7;0;8;4,71;Cn1c(SCCCN2CC[C@]3(C[C@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1csnn1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3984541;154148;None;0;Human;Binding;Ki;=;419,00;6,38;-28;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;531,3;14;2;6;4,73;COc1ccc(-c2ccccc2N2CCN(CCCCCC(=O)NCc3ccc(OCCO)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL39847;154158;None;0;Human;Binding;Ki;=;398,00;6,40;-363;2;In vitro ability to inhibit [3H]raclopride binding to cloned human D2A receptors expressed in mouse fibroblast (LtK-) cells;ChEMBL;315,2;6;0;3;4,84;CCCN(CCC)C1COc2c(cccc2-c2ccsc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00232-2
CHEMBL3985152;154204;None;0;Human;Binding;Ki;=;36,00;7,44;-8;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;501,3;13;1;5;5,33;COCOc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3985419;154229;None;0;Human;Binding;Ki;=;501,19;6,30;-301;2;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;462,2;7;0;6;5,46;Cn1c(SCCCN2CC[C@]3(C[C@@H]3c3ccc(C(F)(F)F)cc3)C2)nnc1-c1ccoc1;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL3985877;154288;None;0;Human;Binding;Ki;=;165,96;6,78;-158;4;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;495,2;7;0;7;5,30;Cc1ncoc1-c1nnc(SCCCN2CC[C@]3(C[C@H]3c3ccc(F)cc3C(F)(F)F)C2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
CHEMBL398618;154329;None;0;Human;Binding;Ki;=;15,00;7,82;-5;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;496,2;6;1;5;5,39;Cc1ccc(C(=O)NC2CCc3ccc(CCN4CCN(c5nsc6ccccc56)CC4)cc32)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL398618;154329;UNDEFINED;0;Human;Binding;pKi;=;15,00;7,82;-5;4;-;PDSP KiDatabase;496,2;6;1;5;5,39;Cc1ccc(C(=O)NC2CCc3ccc(CCN4CCN(c5nsc6ccccc56)CC4)cc32)cc1;-
CHEMBL398619;154330;None;0;Human;Binding;Ki;=;6,00;8,22;-6;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;483,2;6;1;6;4,47;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1cccnc1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL398619;154330;UNDEFINED;0;Human;Binding;pKi;=;6,00;8,22;-6;4;-;PDSP KiDatabase;483,2;6;1;6;4,47;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1cccnc1;-
CHEMBL3986254;154338;None;0;Human;Binding;Ki;=;308,00;6,51;-16;4;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting analysis;ChEMBL;510,3;11;1;5;5,79;COc1ccc(-c2ccccc2N2CCN(CCCCCC(=O)N[C@@H](C)c3ccc(C#N)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
CHEMBL3986927;154440;None;0;Human;Binding;Ki;=;5399,00;5,27;-81;8;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;334,2;5;1;3;3,20;O=C1Cc2cc(C(=O)CCCN3CCc4ccccc4C3)ccc2N1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3986927;154440;None;0;Human;Binding;Ki;=;5370,32;5,27;-81;8;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;334,2;5;1;3;3,20;O=C1Cc2cc(C(=O)CCCN3CCc4ccccc4C3)ccc2N1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL398711;154457;None;0;Human;Binding;Ki;=;8,00;8,10;-52;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;474,2;5;1;5;4,33;O=C(NC1CCc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc21)C(F)(F)F;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL398711;154457;UNDEFINED;0;Human;Binding;pKi;=;8,00;8,10;-52;4;-;PDSP KiDatabase;474,2;5;1;5;4,33;O=C(NC1CCc2cc(CCN3CCN(c4nsc5ccccc45)CC3)ccc21)C(F)(F)F;-
CHEMBL398744;154475;None;0;Human;Binding;Ki;=;5,00;8,30;-9;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;472,2;6;1;6;4,67;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccco1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL398744;154475;UNDEFINED;0;Human;Binding;pKi;=;5,00;8,30;-9;4;-;PDSP KiDatabase;472,2;6;1;6;4,67;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccco1;-
CHEMBL398813;154493;None;0;Human;Binding;Ki;=;73,00;7,14;1;3;Displacement of [3H]Spiperone from human Dopamine receptor D2 isoform long expressed in HEK293 cells;ChEMBL;430,2;6;0;5;4,02;O=c1c2ccccc2ncn1CCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.06.002
CHEMBL3990113;154537;None;0;Human;Binding;Ki;=;138,00;6,86;-9;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;356,1;5;0;3;5,33;Clc1ccc2sc(CCCCN3CCc4ccccc4C3)nc2c1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990113;154537;None;0;Human;Binding;Ki;=;138,04;6,86;-9;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;356,1;5;0;3;5,33;Clc1ccc2sc(CCCCN3CCc4ccccc4C3)nc2c1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990475;154577;None;0;Human;Binding;Ki;=;915,00;6,04;-13;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;291,2;4;1;2;3,55;c1ccc2c(c1)CCN(CCCc1nc3ccccc3[nH]1)C2;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990475;154577;None;0;Human;Binding;Ki;=;812,83;6,09;-13;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;291,2;4;1;2;3,55;c1ccc2c(c1)CCN(CCCc1nc3ccccc3[nH]1)C2;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990525;154583;None;0;Human;Binding;Ki;=;1174,90;5,93;-14;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;327,1;5;0;2;4,40;O=C(CCCN1CCc2ccccc2CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990525;154583;None;0;Human;Binding;Ki;=;1170,00;5,93;-14;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;327,1;5;0;2;4,40;O=C(CCCN1CCc2ccccc2CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990611;154595;None;0;Human;Binding;Ki;=;851,14;6,07;-20;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;390,1;5;0;3;5,98;Clc1ccc2sc(CCCCN3CCc4c(Cl)cccc4C3)nc2c1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990611;154595;None;0;Human;Binding;Ki;=;853,00;6,07;-20;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;390,1;5;0;3;5,98;Clc1ccc2sc(CCCCN3CCc4c(Cl)cccc4C3)nc2c1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990801;154613;None;0;Human;Binding;Ki;=;269,15;6,57;-9;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;356,1;5;0;3;5,33;Clc1cccc2c1CN(CCCCc1nc3ccccc3s1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3990801;154613;None;0;Human;Binding;Ki;=;272,00;6,57;-9;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;356,1;5;0;3;5,33;Clc1cccc2c1CN(CCCCc1nc3ccccc3s1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991094;154642;None;0;Human;Binding;Ki;=;2583,50;5,59;-104;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;291,2;3;0;2;3,49;O=C1c2ccccc2CC1CCN1CCc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991133;154648;None;0;Human;Binding;Ki;=;946,00;6,02;-1995;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;325,1;3;0;2;4,14;O=C1c2ccc(Cl)cc2CC1CCN1CCc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991133;154648;None;0;Human;Binding;Ki;=;954,99;6,02;-1995;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;325,1;3;0;2;4,14;O=C1c2ccc(Cl)cc2CC1CCN1CCc2ccccc2C1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991166;154652;None;0;Human;Binding;Ki;=;416,87;6,38;-58;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;416,1;7;0;5;5,35;COc1cc2c(cc1OC)CN(CCCCc1nc3cc(Cl)ccc3s1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991166;154652;None;0;Human;Binding;Ki;=;418,00;6,38;-58;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;416,1;7;0;5;5,35;COc1cc2c(cc1OC)CN(CCCCc1nc3cc(Cl)ccc3s1)CC2;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991357;154675;None;0;Human;Binding;Ki;=;3548,13;5,45;-29;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;327,1;5;0;2;4,75;O=C(CCCN1CCCc2ccccc2C1)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991357;154675;None;0;Human;Binding;Ki;=;3578,00;5,45;-29;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;327,1;5;0;2;4,75;O=C(CCCN1CCCc2ccccc2C1)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991399;154681;None;0;Human;Binding;Ki;=;1087,00;5,96;-97;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;362,2;5;0;3;5,78;Clc1ccc2sc(CCCCN3CCC4CCCCC4C3)nc2c1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL3991399;154681;None;0;Human;Binding;Ki;=;1096,48;5,96;-97;9;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting method;ChEMBL;362,2;5;0;3;5,78;Clc1ccc2sc(CCCCN3CCC4CCCCC4C3)nc2c1;https://dx.doi.org/10.1016/j.bmc.2016.09.019
CHEMBL399164;154690;None;0;Human;Binding;Ki;=;88,70;7,05;-10;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;423,3;8;1;5;3,79;CCCN(CCN1CCN(c2ccccc2OC)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL399164;154690;None;0;Human;Binding;Ki;=;9,56;8,02;-10;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;423,3;8;1;5;3,79;CCCN(CCN1CCN(c2ccccc2OC)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL399164;154690;None;0;Human;Binding;Ki;=;35,80;7,45;-10;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;423,3;8;1;5;3,79;CCCN(CCN1CCN(c2ccccc2OC)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm070860r
CHEMBL399195;154694;None;0;Human;Binding;Ki;=;149,00;6,83;-61;4;Binding affinity to human dopamine D2 receptor;ChEMBL;475,2;7;1;5;4,03;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@@H](NS(=O)(=O)c3ccccc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL399396;154726;None;0;Human;Binding;Ki;=;58,80;7,23;12;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;396,2;5;1;3;4,92;CCOC(=O)C1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL399601;154753;None;0;Human;Binding;Ki;=;2000,00;5,70;2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;395,2;5;2;2;4,49;CC(=O)NCC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL400235;154886;None;0;Human;Binding;Ki;=;27,00;7,57;-60;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;448,2;7;1;5;4,57;CCCC(=O)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL400235;154886;UNDEFINED;0;Human;Binding;pKi;=;27,00;7,57;-60;4;-;PDSP KiDatabase;448,2;7;1;5;4,57;CCCC(=O)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;-
CHEMBL400236;154887;None;0;Human;Binding;Ki;=;67,00;7,17;-89;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;448,2;6;1;5;4,42;CC(C)C(=O)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL400236;154887;UNDEFINED;0;Human;Binding;pKi;=;67,00;7,17;-89;4;-;PDSP KiDatabase;448,2;6;1;5;4,42;CC(C)C(=O)NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;-
CHEMBL400826;154989;None;0;Human;Binding;Ki;=;165,00;6,78;4;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;380,2;6;1;2;5,51;C=CCOC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL400827;154990;None;1;Human;Binding;Ki;=;29,60;7,53;8;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;354,1;3;1;3;4,32;Cn1cc(CN2CCC(O)(c3ccc(Cl)cc3)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL401031;155024;None;1;Human;Binding;Ki;=;23,90;7,62;13;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;352,2;4;2;3;4,37;CSc1ccc(C2(O)CCN(Cc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL401223;155060;None;0;Human;Binding;Ki;=;161,00;6,79;-3;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;467,3;10;1;3;5,39;O=C(/C=C/c1ccccc1)NCCCCN1CCCN(C(c2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL401224;155061;None;0;Human;Binding;Ki;=;633,00;6,20;-16;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;497,3;9;1;4;6,21;O=C(NCCCCN1CCCN(C(c2ccccc2)c2ccccc2)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL40284;155361;None;0;Human;Binding;Ki;=;1600,00;5,80;-89;2;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;278,1;2;2;2;3,50;c1ccc(-c2[nH]c3ccccc3c2C2CNCCO2)cc1;https://dx.doi.org/10.1021/jm0004998
CHEMBL403280;155440;None;0;Human;Binding;Ki;=;35,50;7,45;1;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccc(F)cc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL403280;155440;None;0;Human;Binding;Ki;=;0,69;9,16;1;4;Displacement of [125I]spiperone from human recombinant dopamine D2 receptor;ChEMBL;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccc(F)cc3F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.068
CHEMBL403280;155440;UNDEFINED;0;Human;Binding;pKi;=;0,69;9,16;1;4;-;PDSP KiDatabase;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccc(F)cc3F)CC2)CC1;-
CHEMBL403280;155440;UNDEFINED;0;Human;Binding;pKi;=;35,50;7,45;1;4;-;PDSP KiDatabase;472,3;6;2;4;5,01;CC(C)Oc1ccccc1N1CCN(C2CCC(NC(=O)Nc3ccc(F)cc3F)CC2)CC1;-
CHEMBL404000;155563;None;0;Human;Binding;Ki;=;21,00;7,68;-234;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;378,2;4;1;5;3,61;NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL404000;155563;UNDEFINED;0;Human;Binding;pKi;=;21,00;7,68;-234;4;-;PDSP KiDatabase;378,2;4;1;5;3,61;NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21;-
CHEMBL404888;155756;None;0;Human;Binding;Ki;=;21000,00;4,68;-1737;5;Binding affinity to human dopamine D2 long receptor;ChEMBL;378,2;7;0;4;4,02;COc1cc(CN2CCN(c3ccc(Cl)cc3)CC2)ccc1OCCF;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
CHEMBL405260;155802;None;0;Human;Binding;Ki;=;79,00;7,10;15;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;354,2;6;0;5;3,00;FCCOc1ccccc1N1CCN(Cc2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm701375u
CHEMBL405260;155802;None;0;Human;Binding;Ki;=;46,00;7,34;15;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;354,2;6;0;5;3,00;FCCOc1ccccc1N1CCN(Cc2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm701375u
CHEMBL405292;155805;None;0;Human;Binding;Ki;=;3400,00;5,47;1;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;311,2;3;0;5;2,19;Fc1cccc(N2CCN(Cc3cc4ccccn4n3)CC2)n1;https://dx.doi.org/10.1021/jm701375u
CHEMBL405292;155805;None;0;Human;Binding;Ki;=;1700,00;5,77;1;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;311,2;3;0;5;2,19;Fc1cccc(N2CCN(Cc3cc4ccccn4n3)CC2)n1;https://dx.doi.org/10.1021/jm701375u
CHEMBL405751;155846;None;0;Human;Binding;Ki;=;2084,00;5,68;-69;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;579,2;3;1;7;5,67;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cnn(-c4ccccc4)c3C(F)(F)F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL40584;155859;None;0;Human;Binding;Ki;=;350,00;6,46;-707;3;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;380,2;5;1;1;6,26;c1ccc(CCN2CCC(c3c(-c4ccccc4)[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm0004998
CHEMBL4059581;155882;None;0;Human;Binding;EC50;=;194,50;6,71;2;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;435,3;13;1;5;4,55;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4059581;155882;None;0;Human;Binding;EC50;=;196,80;6,71;2;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;435,3;13;1;5;4,55;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4059581;155882;None;0;Human;Binding;EC50;=;24,60;7,61;2;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;435,3;13;1;5;4,55;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4059581;155882;None;0;Human;Binding;Ki;=;37,20;7,43;2;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;435,3;13;1;5;4,55;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4060194;155947;None;0;Human;Binding;Ki;=;4351,00;5,36;-154;3;Displacement of [3H]-Raclopride from D2L receptor (unknown origin);ChEMBL;382,1;6;0;5;3,95;CCN(CC)CC1=Cc2cn(S(=O)(=O)c3ccccc3)c3cccc(c23)O1;https://dx.doi.org/10.1021/acsmedchemlett.6b00482
CHEMBL4060403;155963;None;0;Human;Binding;Ki;=;0,30;9,52;4;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;459,1;7;1;6;3,99;O=Cc1cnn2ccc(NC(=O)CCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060403;155963;None;0;Human;Binding;Ki;=;0,41;9,39;4;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;459,1;7;1;6;3,99;O=Cc1cnn2ccc(NC(=O)CCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;5,70;8,24;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;5,00;8,30;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;2,10;8,68;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;2,00;8,70;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;1,80;8,74;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;5,80;8,24;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;2,50;8,60;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;6,20;8,21;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;5,70;8,24;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;EC50;=;3,70;8,43;3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;Ki;=;0,16;9,80;3;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;Ki;=;1,20;8,92;3;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;Ki;=;0,72;9,14;3;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060461;155970;None;0;Human;Binding;Ki;=;0,09;10,03;3;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(/C=N/O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4060603;155987;None;0;Human;Binding;Ki;=;121,00;6,92;3;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;407,3;11;1;5;3,77;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4060649;155990;None;0;Human;Binding;Ki;=;17,00;7,77;3;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;427,2;7;2;3;4,07;Cc1cccc(S(=O)(=O)NCCCN2CC=C(c3c[nH]c4ccc(F)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4061131;156032;None;0;Human;Binding;Ki;=;1011,00;6,00;-7;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;482,2;6;0;5;3,99;O=S(=O)(c1cncc2ccccc12)N1CCC(CCN2CCN(c3cccc(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4061189;156041;None;0;Human;Binding;Ki;=;6698,00;5,17;-1348;4;Displacement of [3H]-Raclopride from D2L receptor (unknown origin);ChEMBL;356,1;4;0;4;2,49;CN(C)CC1=CC2=CN(S(=O)(=O)c3ccccc3)C3=CC=CC(O1)C23;https://dx.doi.org/10.1021/acsmedchemlett.6b00482
CHEMBL4061986;156096;None;0;Human;Binding;Ki;=;33,00;7,48;1;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;417,2;7;1;7;3,57;Oc1ccc(N2CCN(CCCCOc3ccn4nccc4c3)CC2)c2cccnc12;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4061986;156096;None;0;Human;Binding;Ki;=;25,00;7,60;1;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;417,2;7;1;7;3,57;Oc1ccc(N2CCN(CCCCOc3ccn4nccc4c3)CC2)c2cccnc12;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4062165;156109;None;0;Human;Binding;Ki;=;8300,00;5,08;-7;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;214,1;3;0;2;2,72;CCCCN1CCc2cc(C#N)ccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL406221;156112;None;0;Human;Binding;IC50;=;140,00;6,85;-;4;Binding affinity at dopamine D2 receptor;ChEMBL;573,3;11;1;8;4,15;CCOc1ccccc1N1CCN(CCCC(=O)NCc2nc3ccc(F)cc3c(=O)n2-c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2007.11.049
CHEMBL4062553;156143;None;0;Human;Binding;Ki;=;6168,00;5,21;-316;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;477,3;8;0;7;4,96;COc1ccccc1N1CCC2(CCN(CCCSc3nnc(-c4ccccc4)n3C)CC2)C1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4062602;156147;None;0;Human;Binding;Ki;=;3,24;8,49;-1;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;409,2;5;0;5;3,96;O=C1COc2ccccc2N1CCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4062602;156147;None;0;Human;Binding;Ki;=;3,20;8,49;-1;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;409,2;5;0;5;3,96;O=C1COc2ccccc2N1CCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4062817;156168;None;0;Human;Binding;Ki;=;0,30;9,52;33;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;477,2;8;2;3;5,31;O=S(=O)(NCCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4063145;156196;None;0;Human;Binding;EC50;=;110,00;6,96;-2;5;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;480,2;8;3;10;2,16;O=C1COc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4063145;156196;None;0;Human;Binding;EC50;=;110,00;6,96;-2;5;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;480,2;8;3;10;2,16;O=C1COc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4063145;156196;None;0;Human;Binding;Ki;=;0,98;9,01;-2;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;480,2;8;3;10;2,16;O=C1COc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4063145;156196;None;0;Human;Binding;Ki;=;0,95;9,02;-2;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;480,2;8;3;10;2,16;O=C1COc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4063145;156196;None;0;Human;Binding;Ki;=;0,67;9,17;-2;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;480,2;8;3;10;2,16;O=C1COc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4063145;156196;None;0;Human;Binding;Ki;=;0,91;9,04;-2;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;480,2;8;3;10;2,16;O=C1COc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4063235;156205;None;0;Human;Binding;Ki;=;0,16;9,80;6;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;405,2;8;0;7;3,20;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(C#N)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4063235;156205;None;0;Human;Binding;Ki;=;0,25;9,60;6;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;405,2;8;0;7;3,20;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(C#N)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4063282;156211;None;0;Human;Binding;Ki;=;46,00;7,34;-2;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;7;1;6;2,88;COc1ccccc1N1CCN(CCCC(=O)Nc2ccn3nccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4063282;156211;None;0;Human;Binding;Ki;=;36,00;7,44;-2;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;7;1;6;2,88;COc1ccccc1N1CCN(CCCC(=O)Nc2ccn3nccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL40634;156219;None;0;Human;Binding;Ki;=;58,80;7,23;-3;2;In vitro binding affinity towards human Dopamine receptor D2A was determined in mouse fibroblast LtK cells using [3H]raclopride;ChEMBL;303,2;6;0;3;4,01;CCCN(CCC)[C@@H]1CCc2cccc(C(=O)OC)c2[C@@H]1C;https://dx.doi.org/10.1021/jm00001a020
CHEMBL4063564;156230;None;0;Human;Binding;Ki;=;1400,00;5,85;-3;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;288,1;3;1;3;2,50;C[C@@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL4064186;156287;None;0;Human;Binding;Ki;=;1,50;8,82;11;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;446,2;7;2;6;3,81;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5ncccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4064186;156287;None;0;Human;Binding;Ki;=;3,40;8,47;11;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;446,2;7;2;6;3,81;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5ncccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4064191;156289;None;0;Human;Binding;Ki;=;1200,00;5,92;-1;3;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;245,1;1;3;4;0,64;O=c1ccc2c(N3CCNCC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4064191;156289;None;0;Human;Binding;Ki;=;5300,00;5,28;-1;3;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;245,1;1;3;4;0,64;O=c1ccc2c(N3CCNCC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4064742;156324;None;0;Human;Binding;EC50;=;630,00;6,20;1;6;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;480,2;7;3;7;2,98;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4064742;156324;None;0;Human;Binding;EC50;=;470,00;6,33;1;6;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;480,2;7;3;7;2,98;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4064742;156324;None;0;Human;Binding;Ki;=;1,60;8,80;1;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;480,2;7;3;7;2,98;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4064742;156324;None;0;Human;Binding;Ki;=;1,60;8,80;1;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;480,2;7;3;7;2,98;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4064759;156327;None;0;Human;Binding;Ki;=;1500,00;5,82;-2;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;250,1;1;1;5;0,92;CN1CCN(c2ccc(O)c3c2OCCO3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4064759;156327;None;0;Human;Binding;Ki;=;3200,00;5,50;-2;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;250,1;1;1;5;0,92;CN1CCN(c2ccc(O)c3c2OCCO3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4064919;156344;None;0;Human;Binding;Ki;=;13400,00;4,87;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;258,2;6;2;1;3,87;CCCC(CCC)NC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4064974;156351;None;0;Human;Binding;Ki;=;39,00;7,41;-93;6;Displacement of [3H]spiperone from human D2-long receptor expressed in CHO cell membranes;ChEMBL;439,2;10;1;6;3,02;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1cc2ccccn2n1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL4064974;156351;None;0;Human;Binding;Ki;=;21,00;7,68;-93;6;Displacement of [3H]spiperone from human D2-short receptor expressed in CHO cell membranes;ChEMBL;439,2;10;1;6;3,02;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1cc2ccccn2n1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL40650;156356;None;2;Human;Binding;Ki;=;19,70;7,71;-41;15;Binding affinity against Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;448,2;4;1;7;2,97;COc1cccc2c1CC[C@H]1CN(CCn3c(=O)[nH]c4c(sc5cccnc54)c3=O)C[C@@H]21;https://dx.doi.org/10.1021/jm970364a
CHEMBL4065353;156384;None;0;Human;Binding;Ki;=;18,50;7,73;6;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;445,2;9;3;5;3,42;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4065568;156407;None;0;Human;Binding;EC50;=;56,00;7,25;-5;4;Agonist activity at human recombinant D2S receptor expressed in HEK-293 cells by cellular dielectric spectroscopy;ChEMBL;429,1;6;2;3;4,20;Cc1cccc(S(=O)(=O)NCCN2CC=C(c3c[nH]c4ccc(Cl)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4065568;156407;None;0;Human;Binding;Ki;=;3,30;8,48;-5;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;429,1;6;2;3;4,20;Cc1cccc(S(=O)(=O)NCCN2CC=C(c3c[nH]c4ccc(Cl)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4065797;156430;None;0;Human;Binding;EC50;=;1100,00;5,96;-38;5;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;305,2;3;2;5;1,65;CCCN1CCCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4065797;156430;None;0;Human;Binding;Ki;=;56,00;7,25;-38;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;305,2;3;2;5;1,65;CCCN1CCCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4065797;156430;None;0;Human;Binding;Ki;=;360,00;6,44;-38;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;305,2;3;2;5;1,65;CCCN1CCCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4066426;156476;None;0;Human;Binding;Ki;=;121,00;6,92;-2;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;532,1;6;0;5;5,16;O=S(=O)(c1cccc2ncccc12)N1CCC(CCN2CCN(c3ccc(Cl)c(Cl)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4066435;156480;None;0;Human;Binding;Ki;=;42,66;7,37;6;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;381,2;6;0;5;2,63;COc1ccccc1N1CCN(CCCN2C(=O)COc3ccccc32)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4066435;156480;None;0;Human;Binding;Ki;=;42,70;7,37;6;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;381,2;6;0;5;2,63;COc1ccccc1N1CCN(CCCN2C(=O)COc3ccccc32)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4066532;156496;None;0;Human;Binding;Ki;=;23,00;7,64;-3;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;449,1;6;2;3;4,54;O=S(=O)(NCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4066916;156523;None;0;Human;Binding;Ki;=;6900,00;5,16;-58;4;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;236,1;1;2;5;0,57;Oc1ccc(N2CCNCC2)c2c1OCCO2;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4066916;156523;None;0;Human;Binding;Ki;=;6000,00;5,22;-58;4;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;236,1;1;2;5;0,57;Oc1ccc(N2CCNCC2)c2c1OCCO2;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4066971;156530;None;0;Human;Binding;Ki;=;2,50;8,60;3;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;459,1;8;3;4;4,38;O=S(=O)(NCCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4067439;156565;None;0;Human;Binding;EC50;=;2,60;8,59;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccc3c(C=O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4067439;156565;None;0;Human;Binding;EC50;=;4,20;8,38;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccc3c(C=O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4067439;156565;None;0;Human;Binding;EC50;=;10,10;8,00;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccc3c(C=O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4067439;156565;None;0;Human;Binding;EC50;=;2,60;8,59;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccc3c(C=O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4067439;156565;None;0;Human;Binding;EC50;=;7,70;8,11;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccc3c(C=O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4067439;156565;None;0;Human;Binding;Ki;=;7,70;8,11;-1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccc3c(C=O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4067439;156565;None;0;Human;Binding;Ki;=;7,80;8,11;-1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccc3c(C=O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4067700;156593;None;0;Human;Binding;Ki;=;180,00;6,75;-1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;479,1;6;2;3;5,35;Cc1[nH]c2ccc(Cl)cc2c1C1=CCN(CCNS(=O)(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4067792;156601;None;0;Human;Binding;Ki;=;1440,00;5,84;-5;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;396,2;5;1;4;3,53;N#Cc1ccc2c(c1)CN(C[C@@H]1C[C@H]1CNC(=O)c1ccnc3ccccc13)CC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4068455;156655;None;0;Human;Binding;EC50;=;56,90;7,25;-1;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4068455;156655;None;0;Human;Binding;EC50;=;269,80;6,57;-1;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4068455;156655;None;0;Human;Binding;EC50;=;184,90;6,73;-1;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4068455;156655;None;0;Human;Binding;IC50;=;3647,50;5,44;-1;2;Antagonist activity at human dopamine D2 receptor expressed in forskolin stimulated-HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced Galphai1 activation by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4068455;156655;None;0;Human;Binding;IC50;=;712,90;6,15;-1;2;Antagonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as reduction in quinpirole-mediated beta-arrestin 2 recruitment preincubated for 15 mins followed by quinpirole addition measured for 1 sec by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4068455;156655;None;0;Human;Binding;IC50;=;2013,70;5,70;-1;2;Antagonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced GalphaoA activation by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4068455;156655;None;0;Human;Binding;Ki;=;86,80;7,06;-1;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;487,3;11;2;5;4,54;CCCN(CCC)[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4068561;156665;None;0;Human;Binding;EC50;=;46,00;7,34;2;4;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;476,2;8;3;9;2,67;O=c1ccc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4068561;156665;None;0;Human;Binding;EC50;=;70,00;7,16;2;4;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;476,2;8;3;9;2,67;O=c1ccc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4068561;156665;None;0;Human;Binding;Ki;=;1,60;8,80;2;4;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;476,2;8;3;9;2,67;O=c1ccc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4068561;156665;None;0;Human;Binding;Ki;=;1,30;8,89;2;4;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;476,2;8;3;9;2,67;O=c1ccc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4068561;156665;None;0;Human;Binding;Ki;=;3,40;8,47;2;4;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;476,2;8;3;9;2,67;O=c1ccc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4068561;156665;None;0;Human;Binding;Ki;=;0,54;9,27;2;4;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;476,2;8;3;9;2,67;O=c1ccc2c(N3CCN(CCCCOc4ccn5ncc(/C=N/O)c5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4068702;156682;None;0;Human;Binding;EC50;=;1600,00;5,80;-64;5;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;645,4;16;3;10;4,37;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4068702;156682;None;0;Human;Binding;Ki;=;220,00;6,66;-64;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;645,4;16;3;10;4,37;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4068702;156682;None;0;Human;Binding;Ki;=;200,00;6,70;-64;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;645,4;16;3;10;4,37;CCCCn1cc(CCCOc2ccc(C(=O)NCCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4068843;156692;None;0;Human;Binding;Ki;=;14,40;7,84;-5;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;399,2;6;2;4;3,25;N#Cc1ccc2c(c1)CN(C[C@@H]1C[C@H]1CCNC(=O)c1cc3cccnc3[nH]1)CC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4068850;156694;None;0;Human;Binding;Ki;=;4287,00;5,37;-1071;2;Displacement of [3H]-Raclopride from D2L receptor (unknown origin);ChEMBL;377,1;3;1;5;3,76;O=S(=O)(c1cccc2ccccc12)n1cc2c3c(cccc31)OC(CO)=C2;https://dx.doi.org/10.1021/acsmedchemlett.6b00482
CHEMBL4069091;156709;None;0;Human;Binding;Ki;=;0,50;9,30;4;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;474,1;7;2;7;3,99;O=C(CCCN1CCN(c2cccc(Cl)c2Cl)CC1)Nc1ccn2ncc(/C=N\O)c2c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069091;156709;None;0;Human;Binding;Ki;=;0,57;9,24;4;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;474,1;7;2;7;3,99;O=C(CCCN1CCN(c2cccc(Cl)c2Cl)CC1)Nc1ccn2ncc(/C=N\O)c2c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069145;156716;None;0;Human;Binding;EC50;=;6,80;8,17;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccc3c(/C=N/O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069145;156716;None;0;Human;Binding;EC50;=;4,30;8,37;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccc3c(/C=N/O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069145;156716;None;0;Human;Binding;EC50;=;13,10;7,88;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccc3c(/C=N/O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069145;156716;None;0;Human;Binding;EC50;=;10,70;7,97;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccc3c(/C=N/O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069145;156716;None;0;Human;Binding;EC50;=;2,90;8,54;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccc3c(/C=N/O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069145;156716;None;0;Human;Binding;Ki;=;1,70;8,77;-1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccc3c(/C=N/O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069145;156716;None;0;Human;Binding;Ki;=;4,20;8,38;-1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccc3c(/C=N/O)cnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4069237;156728;None;0;Human;Binding;Ki;=;2,80;8,55;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;479,1;7;2;3;5,43;O=S(=O)(NCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc2ccccc12;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4069306;156737;None;0;Human;Binding;Ki;=;1300,00;5,89;-208;3;Inhibition of human dopamine D2 receptor;ChEMBL;320,2;5;1;2;4,00;c1ccc(CCC2CN(Cc3c[nH]c4ccccc34)CCO2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL4070091;156797;None;0;Human;Binding;Ki;=;1,10;8,96;21;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;418,2;7;1;7;2,75;COc1ccccc1N1CCN(CCCC(=O)Nc2ccn3ncc(C#N)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4070091;156797;None;0;Human;Binding;Ki;=;0,55;9,26;21;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;418,2;7;1;7;2,75;COc1ccccc1N1CCN(CCCC(=O)Nc2ccn3ncc(C#N)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4070254;156811;None;0;Human;Binding;Ki;=;1,00;9,00;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;477,1;8;2;3;5,32;O=S(=O)(NCCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4070604;156845;None;0;Human;Binding;EC50;=;680,00;6,17;-245;5;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;631,3;15;3;10;3,98;CCCCn1cc(CCCOc2ccc(C(=O)NCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4070604;156845;None;0;Human;Binding;Ki;=;440,00;6,36;-245;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;631,3;15;3;10;3,98;CCCCn1cc(CCCOc2ccc(C(=O)NCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4070604;156845;None;0;Human;Binding;Ki;=;350,00;6,46;-245;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;631,3;15;3;10;3,98;CCCCn1cc(CCCOc2ccc(C(=O)NCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2OC)nn1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4070715;156860;None;0;Human;Binding;Ki;=;4,50;8,35;2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;477,1;8;2;3;5,32;O=S(=O)(NCCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4071185;156906;None;0;Human;Binding;EC50;=;17,70;7,75;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;EC50;=;0,54;9,27;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;EC50;=;0,72;9,14;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;EC50;=;3,00;8,52;1;5;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;EC50;=;0,12;9,92;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;EC50;=;13,40;7,87;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;EC50;=;0,31;9,51;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;EC50;=;0,13;9,89;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;Ki;=;0,94;9,03;1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071185;156906;None;0;Human;Binding;Ki;=;2,40;8,62;1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccc2c(C=O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071189;156907;None;0;Human;Binding;Ki;=;37579,00;4,42;-162;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;463,2;8;0;7;4,58;COc1ccccc1N1CC2(CCN(CCCSc3nnc(-c4ccccc4)n3C)CC2)C1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4071243;156916;None;0;Human;Binding;Ki;=;60,60;7,22;2;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;435,3;13;1;5;4,55;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4071451;156935;None;0;Human;Binding;Ki;=;14,00;7,85;2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;449,2;6;2;3;4,53;O=S(=O)(NCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4071868;156966;None;0;Human;Binding;EC50;=;0,60;9,22;-3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;EC50;=;0,39;9,41;-3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;EC50;=;0,16;9,80;-3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;EC50;=;0,19;9,72;-3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;EC50;=;13,10;7,88;-3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;EC50;=;12,10;7,92;-3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;EC50;=;1,50;8,82;-3;5;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;EC50;=;0,94;9,03;-3;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;Ki;=;2,50;8,60;-3;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4071868;156966;None;0;Human;Binding;Ki;=;0,84;9,08;-3;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccc2c(/C=N/O)cnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4072171;156991;None;0;Human;Binding;Ki;=;588,00;6,23;-4;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;302,1;4;1;3;2,89;CC[C@@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL4072780;157045;None;0;Human;Binding;EC50;=;92,00;7,04;1;6;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;466,2;7;3;7;2,59;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4072780;157045;None;0;Human;Binding;Ki;=;0,87;9,06;1;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;466,2;7;3;7;2,59;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4072780;157045;None;0;Human;Binding;Ki;=;0,67;9,17;1;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;466,2;7;3;7;2,59;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4072785;157048;None;0;Human;Binding;Ki;=;14000,00;4,85;-21;2;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;263,1;1;3;5;0,52;O=C1COc2c(N3CCCNCC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4072785;157048;None;0;Human;Binding;Ki;=;8900,00;5,05;-21;2;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;263,1;1;3;5;0,52;O=C1COc2c(N3CCCNCC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4072821;157054;None;0;Human;Binding;Ki;=;7,40;8,13;-1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;452,2;10;0;8;3,50;CCOC(=O)c1cc2cc(OCCCCN3CCN(c4ccccc4OC)CC3)ccn2n1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4072821;157054;None;0;Human;Binding;Ki;=;8,10;8,09;-1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;452,2;10;0;8;3,50;CCOC(=O)c1cc2cc(OCCCCN3CCN(c4ccccc4OC)CC3)ccn2n1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4073330;157098;None;0;Human;Binding;Ki;=;19,00;7,72;-3;4;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;434,2;7;1;8;3,13;O=c1ccc2c(N3CCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2o1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4073330;157098;None;0;Human;Binding;Ki;=;40,00;7,40;-3;4;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;434,2;7;1;8;3,13;O=c1ccc2c(N3CCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2o1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4073927;157141;None;0;Human;Binding;Ki;=;9792,00;5,01;-380;3;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;479,3;7;0;6;5,49;Cn1c(SCCCN2CCC3(CC2)CCN(c2ccc(F)cc2)CC3)nnc1-c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4074195;157166;None;0;Human;Binding;Ki;=;2,60;8,59;2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;493,2;8;2;3;5,82;O=S(=O)(NCCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4075144;157233;None;0;Human;Binding;Ki;=;1,70;8,77;5;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;447,1;7;2;3;4,42;O=S(=O)(NCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4075422;157259;None;0;Human;Binding;Ki;=;1218,00;5,91;-7;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;464,2;6;0;5;3,85;O=S(=O)(c1cncc2ccccc12)N1CCC(CCN2CCN(c3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4075673;157278;None;0;Human;Binding;Ki;=;3,00;8,52;31;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;441,2;8;2;3;4,46;Cc1cccc(S(=O)(=O)NCCCCN2CC=C(c3c[nH]c4ccc(F)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4076086;157306;None;0;Human;Binding;Ki;=;57101,00;4,24;-131;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;486,3;7;0;7;5,22;Cn1c(SCCCN2CCC3(CC2)CCN(c2cccc(C#N)c2)CC3)nnc1-c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4076129;157309;None;0;Human;Binding;EC50;=;2529,30;5,60;4;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;491,4;17;1;5;6,11;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4076129;157309;None;0;Human;Binding;IC50;=;801,70;6,10;4;2;Antagonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced GalphaoA activation by BRET assay;ChEMBL;491,4;17;1;5;6,11;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4076129;157309;None;0;Human;Binding;IC50;=;4487,50;5,35;4;2;Antagonist activity at human dopamine D2 receptor expressed in forskolin stimulated-HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced Galphai1 activation by BRET assay;ChEMBL;491,4;17;1;5;6,11;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4076129;157309;None;0;Human;Binding;Ki;=;23,80;7,62;4;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;491,4;17;1;5;6,11;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4076408;157326;None;0;Human;Binding;Ki;=;76,00;7,12;-2;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;498,2;6;0;5;4,50;O=S(=O)(c1cccc2ncccc12)N1CCC(CCN2CCN(c3cccc(Cl)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4076516;157339;None;0;Human;Binding;Ki;=;6370,00;5,20;-263;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;463,2;8;0;7;4,58;COc1ccccc1N1CCC2(CCN(CCCSc3nnc(-c4ccccc4)n3C)C2)C1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4076525;157342;None;0;Human;Binding;Ki;=;223,00;6,65;-7;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;482,2;6;0;5;3,99;O=S(=O)(c1cccc2ncccc12)N1CCC(CCN2CCN(c3ccc(F)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4076527;157343;None;0;Human;Binding;Ki;=;83671,00;4,08;-95;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;462,3;7;0;7;4,74;Cn1c(SCCCN2CCC3(CC2)CCN(c2ccccn2)CC3)nnc1-c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4076796;157367;None;43;Human;Binding;Ki;=;53800,00;4,27;-9;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;158,1;0;1;2;1,20;N#Cc1ccc2c(c1)CCNC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4076903;157381;None;0;Human;Binding;Ki;=;1237,00;5,91;-5;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;464,2;6;0;5;3,85;O=S(=O)(c1cccc2ncccc12)N1CCC(CCN2CCN(c3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4077040;157391;None;0;Human;Binding;Ki;=;5,50;8,26;-1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;443,1;7;2;3;4,59;Cc1cccc(S(=O)(=O)NCCCN2CC=C(c3c[nH]c4ccc(Cl)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4077251;157410;None;0;Human;Binding;Ki;=;21216,00;4,67;-25;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;435,2;8;0;7;3,79;COc1ccccc1N1CC2(CN(CCCSc3nnc(-c4ccccc4)n3C)C2)C1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4077430;157418;None;0;Human;Binding;EC50;=;1499,70;5,82;3;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;420,2;7;2;6;2,69;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4077430;157418;None;0;Human;Binding;EC50;=;104,50;6,98;3;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;420,2;7;2;6;2,69;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4077430;157418;None;0;Human;Binding;EC50;=;712,90;6,15;3;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;420,2;7;2;6;2,69;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4077430;157418;None;0;Human;Binding;IC50;=;4102,00;5,39;3;2;Antagonist activity at human dopamine D2 receptor expressed in forskolin stimulated-HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced Galphai1 activation by BRET assay;ChEMBL;420,2;7;2;6;2,69;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4077430;157418;None;0;Human;Binding;Ki;=;338,00;6,47;3;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;420,2;7;2;6;2,69;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4077536;157424;None;0;Human;Binding;Ki;=;8,41;8,07;-19;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;456,1;6;2;3;4,66;O=C(NC[C@@H]1C[C@H]1CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4077538;157425;None;0;Human;Binding;Ki;=;1821,00;5,74;-10;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;482,2;6;0;5;3,99;O=S(=O)(c1cccc2ncccc12)N1CCC(CCN2CCN(c3cccc(F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4077937;157459;None;0;Human;Binding;Ki;=;3,50;8,46;2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;447,1;7;2;3;4,42;O=S(=O)(NCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL407818;157472;None;0;Human;Binding;Ki;=;6100,00;5,21;-6;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;308,2;3;1;5;2,36;Oc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
CHEMBL407818;157472;None;0;Human;Binding;Ki;=;87000,00;4,06;-6;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;308,2;3;1;5;2,36;Oc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
CHEMBL4078348;157484;None;0;Human;Binding;EC50;=;0,30;9,52;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;EC50;=;0,80;9,10;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;EC50;=;0,12;9,92;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;EC50;=;0,12;9,92;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;EC50;=;14,50;7,84;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;EC50;=;10,50;7,98;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;EC50;=;1,30;8,89;-1;5;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;EC50;=;0,65;9,19;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;Ki;=;0,70;9,15;-1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078348;157484;None;0;Human;Binding;Ki;=;2,10;8,68;-1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4078379;157489;None;0;Human;Binding;Ki;=;21,80;7,66;-8;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;459,3;9;2;5;3,76;CCCn1c(=O)n2c3c(cccc31)C[C@@H](N(C)CCCCNC(=O)c1cc3ccccc3[nH]1)C2;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4078873;157530;None;0;Human;Binding;Ki;=;20,00;7,70;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;413,2;6;2;3;3,68;Cc1cccc(S(=O)(=O)NCCN2CC=C(c3c[nH]c4ccc(F)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4079301;157560;None;0;Human;Binding;Ki;=;12,00;7,92;-2;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;405,2;8;0;7;3,20;COc1ccccc1N1CCN(CCCCOc2ccn3nc(C#N)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4079301;157560;None;0;Human;Binding;Ki;=;12,00;7,92;-2;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;405,2;8;0;7;3,20;COc1ccccc1N1CCN(CCCCOc2ccn3nc(C#N)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4079375;157567;None;0;Human;Binding;EC50;=;68,00;7,17;1;6;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;465,2;8;2;9;2,16;O=Cc1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4079375;157567;None;0;Human;Binding;Ki;=;0,73;9,14;1;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;465,2;8;2;9;2,16;O=Cc1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4079375;157567;None;0;Human;Binding;Ki;=;1,10;8,96;1;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;465,2;8;2;9;2,16;O=Cc1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCC(=O)N5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4079631;157588;None;0;Human;Binding;Ki;=;5162,00;5,29;-19;2;Displacement of [3H]-Raclopride from D2L receptor (unknown origin);ChEMBL;375,1;3;0;5;3,96;O=CC1=Cc2cn(S(=O)(=O)c3cccc4ccccc34)c3cccc(c23)O1;https://dx.doi.org/10.1021/acsmedchemlett.6b00482
CHEMBL4079637;157590;None;0;Human;Binding;Ki;=;190,00;6,72;-8;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;399,2;6;2;4;3,25;N#Cc1ccc2c(c1)CN(CC[C@@H]1C[C@H]1CNC(=O)c1cc3cccnc3[nH]1)CC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4079972;157620;None;0;Human;Binding;Ki;=;99,00;7,00;2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;507,2;8;2;3;6,13;Cc1[nH]c2ccc(Cl)cc2c1C1=CCN(CCCCNS(=O)(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4080034;157625;None;0;Human;Binding;Ki;=;133,00;6,88;-46;2;Inhibition of human dopamine D2 receptor;ChEMBL;381,1;6;0;4;4,28;COc1ccc(Cl)cc1OC[C@@H]1CN(Cc2ccc(Cl)cc2)CCO1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL4080369;157652;None;0;Human;Binding;Ki;=;2,50;8,60;2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;457,2;8;2;3;4,98;Cc1cccc(S(=O)(=O)NCCCCN2CC=C(c3c[nH]c4ccc(Cl)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4080398;157657;None;0;Human;Binding;Ki;=;141,00;6,85;-3;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;498,2;6;0;5;4,50;O=S(=O)(c1cccc2ncccc12)N1CCC(CCN2CCN(c3ccc(Cl)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4080399;157658;None;0;Human;Binding;Ki;=;2,60;8,59;-1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;445,1;7;3;4;3,98;O=S(=O)(NCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4080762;157681;None;0;Human;Binding;Ki;=;14,00;7,85;-1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccn3nccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4080762;157681;None;0;Human;Binding;Ki;=;18,00;7,75;-1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccn3nccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4081383;157737;None;0;Human;Binding;Ki;=;149,00;6,83;-3;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;532,2;6;0;5;4,87;O=S(=O)(c1cccc2ncccc12)N1CCC(CCN2CCN(c3cccc(C(F)(F)F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4081424;157741;None;0;Human;Binding;Ki;=;202,00;6,70;-47;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;472,1;7;2;5;3,85;O=C(NCC[C@@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL4081987;157806;None;0;Human;Binding;Ki;=;67,00;7,17;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;457,2;7;2;3;4,90;Cc1cccc(S(=O)(=O)NCCCN2CC=C(c3c(C)[nH]c4ccc(Cl)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4082456;157842;None;0;Human;Binding;Ki;=;36,00;7,44;1;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;532,1;6;0;5;5,16;O=S(=O)(c1cccc2ncccc12)N1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4083059;157881;None;0;Human;Binding;Ki;=;1489,00;5,83;-1479;5;Displacement of [3H]-Raclopride from D2L receptor (unknown origin);ChEMBL;404,1;4;0;5;4,33;CN(C)CC1=Cc2cn(S(=O)(=O)c3cccc4ccccc34)c3cccc(c23)O1;https://dx.doi.org/10.1021/acsmedchemlett.6b00482
CHEMBL4083239;157895;None;0;Human;Binding;EC50;=;93,00;7,03;12;6;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;462,2;7;3;6;3,10;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4083239;157895;None;0;Human;Binding;Ki;=;1,00;9,00;12;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;462,2;7;3;6;3,10;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4083239;157895;None;0;Human;Binding;Ki;=;0,89;9,05;12;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;462,2;7;3;6;3,10;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4083252;157898;None;0;Human;Binding;Ki;=;260,00;6,58;-891;17;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;423,2;8;0;7;3,79;COc1ccccc1N1CCN(CCCSc2nnc(-c3ccccc3)n2C)CC1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4083727;157944;None;0;Human;Binding;Ki;=;110,00;6,96;-2;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;424,2;7;1;8;2,79;Oc1ccc(N2CCN(CCCCOc3ccn4nccc4c3)CC2)c2c1OCCO2;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4083727;157944;None;0;Human;Binding;Ki;=;68,00;7,17;-2;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;424,2;7;1;8;2,79;Oc1ccc(N2CCN(CCCCOc3ccn4nccc4c3)CC2)c2c1OCCO2;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4083890;157960;None;0;Human;Binding;Ki;=;832,00;6,08;-5;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;214,1;3;0;2;2,72;CCCCN1CCc2ccc(C#N)cc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4083903;157961;None;0;Human;Binding;Ki;=;19,90;7,70;-13;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;468,1;6;1;4;4,73;O=C(NC[C@@H]1C[C@H]1CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccnc2ccccc12;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4084262;157994;None;0;Human;Binding;Ki;=;10895,00;4,96;-1380;13;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;491,3;8;0;7;5,36;COc1ccccc1N1CCC2(CCN(CCCSc3nnc(-c4ccccc4)n3C)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4084492;158024;None;0;Human;Binding;Ki;=;44,00;7,36;-2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;465,1;6;2;3;5,04;O=S(=O)(NCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4084690;158045;None;0;Human;Binding;EC50;=;220,00;6,66;3;4;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;477,2;7;2;7;3,75;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5oc(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4084690;158045;None;0;Human;Binding;EC50;=;130,00;6,89;3;4;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;477,2;7;2;7;3,75;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5oc(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4084690;158045;None;0;Human;Binding;Ki;=;37,00;7,43;3;4;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;477,2;7;2;7;3,75;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5oc(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4084690;158045;None;0;Human;Binding;Ki;=;100,00;7,00;3;4;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;477,2;7;2;7;3,75;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5oc(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4084712;158050;None;0;Human;Binding;Ki;=;3400,00;5,47;-112;4;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;277,1;1;2;5;0,86;CN1CCCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4084712;158050;None;0;Human;Binding;Ki;=;6400,00;5,19;-112;4;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;277,1;1;2;5;0,86;CN1CCCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4085184;158082;None;0;Human;Binding;Ki;=;317,00;6,50;-4;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;288,1;3;1;3;2,50;C[C@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL4085282;158087;None;0;Human;Binding;EC50;=;88,70;7,05;16;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;467,3;15;1;7;3,02;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4085282;158087;None;0;Human;Binding;EC50;=;139,00;6,86;16;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;467,3;15;1;7;3,02;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4085282;158087;None;0;Human;Binding;EC50;=;677,60;6,17;16;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;467,3;15;1;7;3,02;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4085282;158087;None;0;Human;Binding;Ki;=;34,70;7,46;16;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;467,3;15;1;7;3,02;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4085752;158127;None;0;Human;Binding;EC50;=;170,00;6,77;6;4;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;467,2;8;2;10;2,60;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4085752;158127;None;0;Human;Binding;Ki;=;16,00;7,80;6;4;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;467,2;8;2;10;2,60;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4085752;158127;None;0;Human;Binding;Ki;=;1,70;8,77;6;4;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;467,2;8;2;10;2,60;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4085752;158127;None;0;Human;Binding;Ki;=;29,00;7,54;6;4;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;467,2;8;2;10;2,60;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4085752;158127;None;0;Human;Binding;Ki;=;1,10;8,96;6;4;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;467,2;8;2;10;2,60;O/N=C/c1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4085780;158130;None;3;Human;Binding;Ki;=;1096,48;5,96;-380;13;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;349,2;5;0;3;3,18;O=C1CCc2ccccc2N1CCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL4085802;158133;None;0;Human;Binding;Ki;=;11,00;7,96;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;449,1;6;2;3;4,54;O=S(=O)(NCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4085920;158142;None;0;Human;Binding;Ki;=;430,00;6,37;-239;6;Displacement of [3H]spiperone from human D2-long receptor expressed in CHO cell membranes;ChEMBL;503,3;7;1;7;3,77;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cc4ccccn4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL4085920;158142;None;0;Human;Binding;Ki;=;200,00;6,70;-239;6;Displacement of [3H]spiperone from human D2-short receptor expressed in CHO cell membranes;ChEMBL;503,3;7;1;7;3,77;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cc4ccccn4n3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL4086211;158160;None;0;Human;Binding;Ki;=;145,00;6,84;-3;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;532,1;6;0;5;5,16;O=S(=O)(c1cncc2ccccc12)N1CCC(CCN2CCN(c3ccc(Cl)c(Cl)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4086515;158183;None;0;Human;Binding;Ki;=;1950,00;5,71;-89;5;Displacement of [3H]-Raclopride from human dopamine D2 receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;323,2;3;2;6;1,28;CN1CCN(c2nc(N)nc(Cc3c[nH]c4ccccc34)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114645
CHEMBL4086613;158192;None;0;Human;Binding;Ki;=;493,00;6,31;-14;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;243,2;4;0;3;2,48;CCCCN1CCN(c2cccc(C#N)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4086953;158214;None;0;Human;Binding;Ki;=;124,00;6,91;1;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;519,4;19;1;5;6,89;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCCCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4087187;158231;None;0;Human;Binding;Ki;=;5,10;8,29;1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccn3nc(C=O)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4087187;158231;None;0;Human;Binding;Ki;=;5,50;8,26;1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccn3nc(C=O)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4087217;158236;None;0;Human;Binding;EC50;=;130,00;6,89;-10;3;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;291,2;3;2;5;1,25;CCCN1CCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4087217;158236;None;0;Human;Binding;Ki;=;35,00;7,46;-10;3;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;291,2;3;2;5;1,25;CCCN1CCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4087217;158236;None;0;Human;Binding;Ki;=;120,00;6,92;-10;3;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;291,2;3;2;5;1,25;CCCN1CCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4087513;158261;None;0;Human;Binding;Ki;=;9500,00;5,02;-9;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;396,2;5;1;4;3,53;N#Cc1ccc2c(c1)CCN(C[C@@H]1C[C@H]1CNC(=O)c1ccnc3ccccc13)C2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4087852;158286;None;0;Human;Binding;Ki;=;1,80;8,74;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;461,1;8;2;3;4,81;O=S(=O)(NCCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4088249;158325;None;0;Human;Binding;Ki;=;10,00;8,00;-10;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;433,1;6;2;3;4,03;O=S(=O)(NCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4088639;158351;None;0;Human;Binding;Ki;=;1,50;8,82;23;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;421,2;8;1;7;2,70;COc1ccccc1N1CCN(CCCC(=O)Nc2ccn3ncc(C=O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4088639;158351;None;0;Human;Binding;Ki;=;1,40;8,85;23;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;421,2;8;1;7;2,70;COc1ccccc1N1CCN(CCCC(=O)Nc2ccn3ncc(C=O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4088925;158377;None;0;Human;Binding;Ki;=;100,00;7,00;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;493,2;7;2;3;5,74;Cc1[nH]c2ccc(Cl)cc2c1C1=CCN(CCCNS(=O)(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4089290;158419;None;0;Human;Binding;Ki;=;60152,00;4,22;-316;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;449,2;8;0;7;4,18;COc1ccccc1N1CCC2(CN(CCCSc3nnc(-c4ccccc4)n3C)C2)C1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4089427;158433;None;0;Human;Binding;Ki;=;418,00;6,38;-29;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;482,2;6;0;5;3,99;O=S(=O)(c1cncc2ccccc12)N1CCC(CCN2CCN(c3ccc(F)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4089939;158479;None;0;Human;Binding;Ki;=;182,00;6,74;-204;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;398,2;6;2;3;3,85;N#Cc1ccc2c(c1)CN(C[C@@H]1C[C@H]1CCNC(=O)c1cc3ccccc3[nH]1)CC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4090208;158507;None;0;Human;Binding;EC50;=;2,90;8,54;-1;5;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;EC50;=;0,39;9,41;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;EC50;=;0,11;9,96;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;EC50;=;0,71;9,15;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;EC50;=;12,40;7,91;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;EC50;=;12,50;7,90;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;EC50;=;0,11;9,96;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;EC50;=;0,74;9,13;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;Ki;=;2,30;8,64;-1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090208;158507;None;0;Human;Binding;Ki;=;0,90;9,05;-1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;421,2;10;1;6;4,28;CCCN(CCCCOc1ccn2ncc(C=O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4090568;158541;None;0;Human;Binding;Ki;=;17,78;7,75;-3;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;408,2;5;0;6;3,23;O=C1COc2ccccc2N1CCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4090568;158541;None;0;Human;Binding;Ki;=;17,70;7,75;-3;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;408,2;5;0;6;3,23;O=C1COc2ccccc2N1CCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4091064;158586;None;0;Human;Binding;Ki;=;0,91;9,04;3;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;456,1;6;1;6;4,05;N#Cc1cnn2ccc(NC(=O)CCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4091064;158586;None;0;Human;Binding;Ki;=;0,52;9,28;3;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;456,1;6;1;6;4,05;N#Cc1cnn2ccc(NC(=O)CCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc12;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4091155;158599;None;0;Human;Binding;Ki;=;7,80;8,11;-1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;431,1;6;1;5;4,18;O=C(CCCN1CCN(c2cccc(Cl)c2Cl)CC1)Nc1ccn2nccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4091155;158599;None;0;Human;Binding;Ki;=;8,10;8,09;-1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;431,1;6;1;5;4,18;O=C(CCCN1CCN(c2cccc(Cl)c2Cl)CC1)Nc1ccn2nccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4091193;158603;None;0;Human;Binding;Ki;=;5,60;8,25;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;463,1;7;2;3;4,93;O=S(=O)(NCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4091507;158631;None;0;Human;Binding;EC50;=;370,00;6,43;-17;5;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;447,2;7;2;7;3,25;O=c1ccc2c(N3CCCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4091507;158631;None;0;Human;Binding;EC50;=;250,00;6,60;-17;5;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;447,2;7;2;7;3,25;O=c1ccc2c(N3CCCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4091507;158631;None;0;Human;Binding;Ki;=;78,00;7,11;-17;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;447,2;7;2;7;3,25;O=c1ccc2c(N3CCCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4091507;158631;None;0;Human;Binding;Ki;=;46,00;7,34;-17;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;447,2;7;2;7;3,25;O=c1ccc2c(N3CCCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4091933;158674;None;0;Human;Binding;Ki;=;2,20;8,66;15;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;453,2;7;2;7;3,03;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4091933;158674;None;0;Human;Binding;Ki;=;2,90;8,54;15;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;453,2;7;2;7;3,03;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4092015;158678;None;0;Human;Binding;Ki;=;29300,00;4,53;-173;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;463,2;8;0;7;4,72;COc1ccccc1N1CCC12CCN(CCCSc1nnc(-c3ccccc3)n1C)CC2;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4092243;158708;None;0;Human;Binding;Ki;=;0,70;9,15;38;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;463,2;7;2;3;4,92;O=S(=O)(NCCCN1CC=C(c2c[nH]c3ccc(F)cc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4092441;158726;None;0;Human;Binding;EC50;=;240,00;6,62;-1;6;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;433,2;7;2;7;2,86;O=c1ccc2c(N3CCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4092441;158726;None;0;Human;Binding;Ki;=;3,70;8,43;-1;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;433,2;7;2;7;2,86;O=c1ccc2c(N3CCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4092441;158726;None;0;Human;Binding;Ki;=;8,30;8,08;-1;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;433,2;7;2;7;2,86;O=c1ccc2c(N3CCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4092462;158732;None;0;Human;Binding;Ki;=;1900,00;5,72;-2;3;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;287,2;3;2;4;1,77;CCCN1CCN(c2ccc(O)c3[nH]c(=O)ccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4092462;158732;None;0;Human;Binding;Ki;=;480,00;6,32;-2;3;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;287,2;3;2;4;1,77;CCCN1CCN(c2ccc(O)c3[nH]c(=O)ccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4092928;158765;None;0;Human;Binding;Ki;=;93,10;7,03;-2;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;302,1;4;1;3;2,89;CC[C@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL4093223;158791;None;0;Human;Binding;Ki;=;54,80;7,26;1;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;463,3;15;1;5;5,33;CCCN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4093477;158816;None;0;Human;Binding;EC50;=;944,00;6,03;-12;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4093477;158816;None;0;Human;Binding;EC50;=;1153,50;5,94;-12;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4093477;158816;None;0;Human;Binding;EC50;=;458,10;6,34;-12;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4093477;158816;None;0;Human;Binding;IC50;=;2971,70;5,53;-12;2;Antagonist activity at human dopamine D2 receptor expressed in forskolin stimulated-HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced Galphai1 activation by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4093477;158816;None;0;Human;Binding;IC50;=;4529,00;5,34;-12;2;Antagonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 assessed as inhibition of quinpirole-induced GalphaoA activation by BRET assay;ChEMBL;487,3;11;2;5;4,54;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4093477;158816;None;0;Human;Binding;Ki;=;8,43;8,07;-12;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;487,3;11;2;5;4,54;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3c2n(c(=O)n3CCC)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4093493;158822;None;0;Human;Binding;Ki;=;8300,00;5,08;-23;3;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;249,1;1;3;5;0,13;O=C1COc2c(N3CCNCC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4093493;158822;None;0;Human;Binding;Ki;=;1800,00;5,75;-23;3;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;249,1;1;3;5;0,13;O=C1COc2c(N3CCNCC3)ccc(O)c2N1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4093656;158835;None;0;Human;Binding;Ki;=;10,00;8,00;-57;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;456,1;7;1;4;4,87;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL4093971;158848;None;0;Human;Binding;Ki;=;30,00;7,52;-1;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;532,1;6;0;5;5,16;O=S(=O)(c1cncc2ccccc12)N1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4093980;158850;None;0;Human;Binding;Ki;=;275,42;6,56;-3;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;419,1;5;0;4;3,93;O=C1COc2ccccc2N1CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4093980;158850;None;0;Human;Binding;Ki;=;273,00;6,56;-3;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;419,1;5;0;4;3,93;O=C1COc2ccccc2N1CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4094407;158895;None;0;Human;Binding;Ki;=;780,00;6,11;-1;3;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;259,1;1;2;4;0,99;CN1CCN(c2ccc(O)c3[nH]c(=O)ccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4094407;158895;None;0;Human;Binding;Ki;=;250,00;6,60;-1;3;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;259,1;1;2;4;0,99;CN1CCN(c2ccc(O)c3[nH]c(=O)ccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4094869;158945;None;0;Human;Binding;EC50;=;9,80;8,01;-4;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;EC50;=;8,40;8,08;-4;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;EC50;=;1,50;8,82;-4;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;EC50;=;161,00;6,79;-4;5;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;EC50;=;1,70;8,77;-4;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;EC50;=;5,20;8,28;-4;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;EC50;=;48,00;7,32;-4;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;EC50;=;54,00;7,27;-4;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;Ki;=;96,00;7,02;-4;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094869;158945;None;0;Human;Binding;Ki;=;39,00;7,41;-4;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccn2nccc2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4094900;158949;None;0;Human;Binding;Ki;=;5700,00;5,24;-2;2;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;278,2;3;1;5;1,70;CCCN1CCN(c2ccc(O)c3c2OCCO3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4095082;158965;None;0;Human;Binding;Ki;=;1842,00;5,74;-208;3;Inhibition of human dopamine D2 receptor;ChEMBL;349,2;4;1;3;3,55;Cc1ccc(N2CCN(CCC3C(=O)Nc4ccccc43)CC2)cc1C;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL4095216;158978;None;0;Human;Binding;Ki;=;695,00;6,16;-21;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;384,2;5;2;3;3,46;N#Cc1ccc2c(c1)CN(C[C@@H]1C[C@H]1CNC(=O)c1cc3ccccc3[nH]1)CC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4095452;159000;None;0;Human;Binding;EC50;=;1064,10;5,97;2;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;524,3;14;2;9;1,96;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCOCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4095452;159000;None;0;Human;Binding;EC50;=;1870,70;5,73;2;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;524,3;14;2;9;1,96;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCOCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4095452;159000;None;0;Human;Binding;EC50;=;3981,10;5,40;2;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;524,3;14;2;9;1,96;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCOCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4095452;159000;None;0;Human;Binding;Ki;=;306,00;6,51;2;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;524,3;14;2;9;1,96;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCOCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4095555;159011;None;0;Human;Binding;Ki;=;2,40;8,62;-2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;433,1;6;2;3;4,03;O=S(=O)(NCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4095881;159038;None;0;Human;Binding;Ki;=;2,90;8,54;5;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;452,2;8;1;9;2,60;O=Cc1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4095881;159038;None;0;Human;Binding;Ki;=;5,70;8,24;5;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;452,2;8;1;9;2,60;O=Cc1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5c4OCCO5)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4095979;159050;None;0;Human;Binding;Ki;=;4,40;8,36;4;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;461,1;8;2;3;4,81;O=S(=O)(NCCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4096353;159084;None;0;Human;Binding;Ki;=;0,52;9,28;11;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;436,2;8;2;8;2,69;COc1ccccc1N1CCN(CCCC(=O)Nc2ccn3ncc(/C=N\O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4096353;159084;None;0;Human;Binding;Ki;=;0,97;9,01;11;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;436,2;8;2;8;2,69;COc1ccccc1N1CCN(CCCC(=O)Nc2ccn3ncc(/C=N\O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4096422;159094;None;0;Human;Binding;EC50;=;74,00;7,13;9;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;420,2;7;2;5;2,93;CN(CCCCOc1ccc2c(c1)NC(=O)CC2)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4096422;159094;None;0;Human;Binding;EC50;=;188,80;6,72;9;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;420,2;7;2;5;2,93;CN(CCCCOc1ccc2c(c1)NC(=O)CC2)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4096422;159094;None;0;Human;Binding;EC50;=;157,80;6,80;9;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;420,2;7;2;5;2,93;CN(CCCCOc1ccc2c(c1)NC(=O)CC2)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4096422;159094;None;0;Human;Binding;Ki;=;40,10;7,40;9;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;420,2;7;2;5;2,93;CN(CCCCOc1ccc2c(c1)NC(=O)CC2)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4096479;159099;None;0;Human;Binding;Ki;=;2,30;8,64;1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;493,2;8;2;3;5,82;O=S(=O)(NCCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc2ccccc12;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL409662;159113;None;0;Human;Binding;Ki;=;950,00;6,02;-1202;9;Inhibition of dopamine D2 receptor;ChEMBL;429,2;7;1;3;5,07;CCC1(CCCCN2CCN(c3ccc(Cl)cc3)CC2)C(=O)Nc2cc(F)ccc21;https://dx.doi.org/10.1021/jm070279v
CHEMBL4096858;159136;None;0;Human;Binding;Ki;=;4000,00;5,40;-1348;3;Displacement of [3H]spiperone from human D2-long receptor expressed in CHO cell membranes;ChEMBL;519,2;7;1;6;5,34;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cc4ccccc4s3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL4096858;159136;None;0;Human;Binding;Ki;=;2700,00;5,57;-1348;3;Displacement of [3H]spiperone from human D2-short receptor expressed in CHO cell membranes;ChEMBL;519,2;7;1;6;5,34;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)c3cc4ccccc4s3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL4096866;159138;None;0;Human;Binding;Ki;=;37,00;7,43;-2;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;498,2;6;0;5;4,50;O=S(=O)(c1cncc2ccccc12)N1CCC(CCN2CCN(c3cccc(Cl)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4097330;159173;None;0;Human;Binding;EC50;=;0,30;9,52;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;EC50;=;13,70;7,86;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;EC50;=;0,13;9,89;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;EC50;=;15,90;7,80;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;EC50;=;0,81;9,09;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;EC50;=;0,11;9,96;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;EC50;=;0,61;9,21;1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;EC50;=;3,00;8,52;1;5;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;Ki;=;0,63;9,20;1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097330;159173;None;0;Human;Binding;Ki;=;0,75;9,12;1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4097572;159201;None;0;Human;Binding;Ki;=;38,70;7,41;1;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;463,3;15;1;5;5,33;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4097669;159207;None;0;Human;Binding;Ki;=;476,00;6,32;-48;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;398,2;6;2;3;3,85;N#Cc1ccc2c(c1)CN(CC[C@@H]1C[C@H]1CNC(=O)c1cc3ccccc3[nH]1)CC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4098236;159250;None;0;Human;Binding;Ki;=;1,80;8,74;3;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(C=O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098236;159250;None;0;Human;Binding;Ki;=;2,30;8,64;3;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;408,2;9;0;7;3,14;COc1ccccc1N1CCN(CCCCOc2ccn3ncc(C=O)c3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098803;159314;None;0;Human;Binding;EC50;=;4,40;8,36;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098803;159314;None;0;Human;Binding;EC50;=;1,50;8,82;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098803;159314;None;0;Human;Binding;EC50;=;5,00;8,30;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098803;159314;None;0;Human;Binding;EC50;=;2,10;8,68;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098803;159314;None;0;Human;Binding;EC50;=;1,90;8,72;-1;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098803;159314;None;0;Human;Binding;Ki;=;0,74;9,13;-1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098803;159314;None;0;Human;Binding;Ki;=;1,80;8,74;-1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;380,2;8;0;6;3,32;COc1ccccc1N1CCN(CCCCOc2ccc3ccnn3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;EC50;=;0,67;9,17;-2;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;EC50;=;0,21;9,68;-2;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;EC50;=;0,17;9,77;-2;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;EC50;=;0,49;9,31;-2;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;EC50;=;0,96;9,02;-2;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;EC50;=;1,70;8,77;-2;5;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;EC50;=;11,90;7,92;-2;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;EC50;=;13,20;7,88;-2;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;Ki;=;0,87;9,06;-2;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4098859;159323;None;0;Human;Binding;Ki;=;2,20;8,66;-2;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;436,2;10;2;7;4,28;CCCN(CCCCOc1ccn2ncc(/C=N\O)c2c1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4099491;159381;None;51;Human;Binding;Ki;=;4890,00;5,31;-8;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;187,1;1;1;3;0,97;N#Cc1cccc(N2CCNCC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4099666;159393;None;0;Human;Binding;Ki;=;4,80;8,32;2;3;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;463,2;7;2;7;3,36;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5oc(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4099666;159393;None;0;Human;Binding;Ki;=;2,00;8,70;2;3;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;463,2;7;2;7;3,36;O=C1CCc2ccc(OCCCCN3CCN(c4ccc(O)c5oc(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4099711;159398;None;0;Human;Binding;Ki;=;6,00;8,22;2;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;410,2;9;1;7;2,82;COc1ccccc1N1CCN(CCCCOc2ccn3nc(CO)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4099711;159398;None;0;Human;Binding;Ki;=;5,80;8,24;2;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;410,2;9;1;7;2,82;COc1ccccc1N1CCN(CCCCOc2ccn3nc(CO)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4099997;159423;None;0;Human;Binding;Ki;=;56,00;7,25;3;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;471,2;8;2;3;5,29;Cc1cccc(S(=O)(=O)NCCCCN2CC=C(c3c(C)[nH]c4ccc(Cl)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4100183;159437;None;0;Human;Binding;EC50;=;62,00;7,21;-1;6;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;437,2;7;2;8;2,35;O=C1COc2c(N3CCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4100183;159437;None;0;Human;Binding;Ki;=;0,86;9,07;-1;6;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;437,2;7;2;8;2,35;O=C1COc2c(N3CCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4100183;159437;None;0;Human;Binding;Ki;=;2,00;8,70;-1;6;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;437,2;7;2;8;2,35;O=C1COc2c(N3CCN(CCCCOc4ccn5nccc5c4)CC3)ccc(O)c2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4100322;159450;None;0;Human;Binding;EC50;=;1853,50;5,73;2;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;423,3;12;1;6;3,00;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4100322;159450;None;0;Human;Binding;EC50;=;350,80;6,46;2;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;423,3;12;1;6;3,00;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4100322;159450;None;0;Human;Binding;EC50;=;2471,70;5,61;2;2;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;423,3;12;1;6;3,00;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4100322;159450;None;0;Human;Binding;Ki;=;111,00;6,96;2;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;423,3;12;1;6;3,00;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCOCCOCCCCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4100470;159463;None;0;Human;Binding;Ki;=;148,00;6,83;-4;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;532,2;6;0;5;4,87;O=S(=O)(c1cncc2ccccc12)N1CCC(CCN2CCN(c3cccc(C(F)(F)F)c3)CC2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.04.046
CHEMBL4100734;159490;None;0;Human;Binding;EC50;=;570,20;6,24;2;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;532,3;15;2;6;5,81;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCCCCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4100734;159490;None;0;Human;Binding;EC50;=;666,80;6,18;2;2;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;532,3;15;2;6;5,81;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCCCCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4100734;159490;None;0;Human;Binding;Ki;=;284,00;6,55;2;2;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;532,3;15;2;6;5,81;CN[C@@H]1Cc2cccc3c2n(c(=O)n3CCCCCCCCCCCCOc2ccc3c(c2)NC(=O)CC3)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL4100951;159516;None;0;Human;Binding;Ki;=;3,70;8,43;4;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;479,1;7;2;3;5,43;O=S(=O)(NCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4101993;159603;None;0;Human;Binding;Ki;=;7501,00;5,12;-91;2;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;529,2;7;0;6;6,65;Cn1c(SCCCN2CCC3(CC2)CCN(c2cccc(Cl)c2Cl)CC3)nnc1-c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
CHEMBL4102616;159651;None;0;Human;Binding;EC50;=;1,70;8,77;-6;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;EC50;=;98,00;7,01;-6;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;EC50;=;5,50;8,26;-6;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;EC50;=;8,70;8,06;-6;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;EC50;=;9,60;8,02;-6;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;EC50;=;2,20;8,66;-6;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;EC50;=;61,00;7,21;-6;5;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;EC50;=;218,00;6,66;-6;5;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;Ki;=;48,00;7,32;-6;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102616;159651;None;0;Human;Binding;Ki;=;120,00;6,92;-6;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;393,2;9;1;5;4,47;CCCN(CCCCOc1ccc2ccnn2c1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4102628;159653;None;0;Human;Binding;EC50;=;190,00;6,72;1;5;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;476,2;7;3;6;3,49;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4102628;159653;None;0;Human;Binding;EC50;=;200,00;6,70;1;5;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;476,2;7;3;6;3,49;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4102628;159653;None;0;Human;Binding;Ki;=;0,81;9,09;1;5;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;476,2;7;3;6;3,49;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4102628;159653;None;0;Human;Binding;Ki;=;1,60;8,80;1;5;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;476,2;7;3;6;3,49;O=C1CCc2ccc(OCCCCN3CCCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
CHEMBL4102646;159658;None;0;Human;Binding;EC50;=;300,00;6,52;-7;3;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;263,1;1;2;5;0,47;CN1CCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4102646;159658;None;0;Human;Binding;Ki;=;630,00;6,20;-7;3;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;263,1;1;2;5;0,47;CN1CCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4102646;159658;None;0;Human;Binding;Ki;=;200,00;6,70;-7;3;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;263,1;1;2;5;0,47;CN1CCN(c2ccc(O)c3c2OCC(=O)N3)CC1;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4103639;159737;None;0;Human;Binding;EC50;=;51,00;7,29;3;3;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;461,2;8;2;8;2,67;O=Cc1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4103639;159737;None;0;Human;Binding;Ki;=;0,58;9,24;3;3;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes;ChEMBL;461,2;8;2;8;2,67;O=Cc1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4103639;159737;None;0;Human;Binding;Ki;=;1,00;9,00;3;3;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes;ChEMBL;461,2;8;2;8;2,67;O=Cc1cnn2ccc(OCCCCN3CCN(c4ccc(O)c5[nH]c(=O)ccc45)CC3)cc12;https://dx.doi.org/10.1016/j.bmc.2017.08.037
CHEMBL4103725;159748;None;0;Human;Binding;Ki;=;2,70;8,57;2;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;463,1;7;2;3;4,93;O=S(=O)(NCCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4104013;159768;None;0;Human;Binding;EC50;=;0,63;9,20;331;3;Agonist activity at human dopamine D2L receptor expressed in F1pIn CHO cells assessed as induction of ERK1/2 phosphorylation incubated for 5 mins by AlphaScreen assay;ChEMBL;408,2;5;1;6;2,06;O=C1COc2ccccc2N1CCCN1CCN(c2cccc3[nH]c(=O)oc23)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4104013;159768;None;0;Human;Binding;EC50;=;0,64;9,19;331;3;Agonist activity at human dopamine D2L receptor expressed in F1pIn CHO cells assessed as induction of ERK1/2 phosphorylation incubated for 5 mins by AlphaScreen assay;ChEMBL;408,2;5;1;6;2,06;O=C1COc2ccccc2N1CCCN1CCN(c2cccc3[nH]c(=O)oc23)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4104013;159768;None;0;Human;Binding;Ki;=;1,74;8,76;331;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;408,2;5;1;6;2,06;O=C1COc2ccccc2N1CCCN1CCN(c2cccc3[nH]c(=O)oc23)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4104013;159768;None;0;Human;Binding;Ki;=;1,70;8,77;331;3;Displacement of [3H]-raclopride from human dopamine D2L receptor expressed in F1pIn CHO cells after 60 mins by scintillation counting analysis;ChEMBL;408,2;5;1;6;2,06;O=C1COc2ccccc2N1CCCN1CCN(c2cccc3[nH]c(=O)oc23)CC1;https://dx.doi.org/10.1021/jm5013243
CHEMBL4104216;159785;None;0;Human;Binding;Ki;=;37,00;7,43;-9;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;465,1;6;2;3;5,04;O=S(=O)(NCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc2ccccc12;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4104272;159792;None;0;Human;Binding;Ki;=;400,00;6,40;-70;3;Inhibition of human dopamine D2 receptor;ChEMBL;322,2;5;1;3;3,45;c1ccc(OCC2CN(Cc3c[nH]c4ccccc34)CCO2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL4104596;159821;None;0;Human;Binding;Ki;=;350,00;6,46;-14;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;443,1;6;2;3;4,51;Cc1cccc(S(=O)(=O)NCCN2CC=C(c3c(C)[nH]c4ccc(Cl)cc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4104622;159822;None;0;Human;Binding;Ki;=;1,50;8,82;-1;4;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;431,1;6;3;4;3,59;O=S(=O)(NCCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1)c1cccc(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
CHEMBL4105030;159849;None;0;Human;Binding;Ki;=;1,90;8,72;1;5;Displacement of [3H]spiperone from human Dopamine D2S receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3nc(/C=N/O)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4105030;159849;None;0;Human;Binding;Ki;=;3,30;8,48;1;5;Displacement of [3H]spiperone from human Dopamine D2L receptor expressed in CHO cell membranes after 2 hrs by scintillation counting analysis;ChEMBL;423,2;9;1;8;3,13;COc1ccccc1N1CCN(CCCCOc2ccn3nc(/C=N/O)cc3c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
CHEMBL4105375;159881;None;0;Human;Binding;Ki;=;2290,00;5,64;-44;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;425,2;6;1;5;3,29;N#Cc1cccc(N2CCN(C[C@@H]3C[C@H]3CNC(=O)c3ccnc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
CHEMBL4105681;159905;None;0;Human;Binding;Ki;=;316,00;6,50;-13;2;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by MicroBeta microplate counting method;ChEMBL;472,1;7;2;5;3,85;O=C(NCC[C@H](O)CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cnc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01148
CHEMBL4110066;160352;None;0;Human;Binding;Ki;=;79,70;7,10;-1584;6;Radioligand Binding Assay: The affinity of a test compound for the human dopamine receptor subtype hDRD2 was determined by radioligand binding assays in CHO-K1 cells stably transfected with hDRD2 receptor, as follows. The cDNA coding sequence of hDRD2 (GenBank accession No. X51362) was subcloned into the mammalian expression vector pcDNA3.1/GS (Life Technologies). Clonal cell lines stably expressing hDRD2 were obtained by transfection into CHO-K1 cells and subsequently selected with culture medium containing 0.3 mg/mL of zeocin (Life Technologies).Membranes for in vitro receptor binding assays were obtained by the following procedures. CHO-K1 cells expressing hDRD2 were homogenized in ice-cold buffer with 10 mM Tris-HCl, 5 mM EDTA, 3 mM EGTA, 1 mM phenylmethylsuphonyl fluoride, pH 7.6 using Polytron PT10-35GT (Kinematica) at 18,000 rpm for 30 seconds and centrifuged at 500xg for 10 minutes. The supernatant containing the plasma membranes was centrifuged at 100,000xg for 30 minutes and the pellet was resuspended.;ChEMBL;1471,8;23;17;16;1,85;C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccncc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](NCC[S@+]([O-])C[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)CCCCNC(=O)[C@H](Cc2ccc(O)cc2)NC1=O;-
CHEMBL41134;160762;None;0;Human;Binding;Ki;=;590,00;6,23;-537;2;In vitro ability to inhibit [3H]raclopride binding to cloned human D2A receptors expressed in mouse fibroblast (LtK-) cells;ChEMBL;309,2;6;0;2;4,78;CCCN(CCC)C1COc2c(cccc2-c2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00232-2
CHEMBL411437;160887;None;0;Human;Binding;Ki;=;180,00;6,75;1;4;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;354,2;6;0;5;3,00;FCCOc1ccccc1N1CCN(Cc2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm701375u
CHEMBL411437;160887;None;0;Human;Binding;Ki;=;150,00;6,82;1;4;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;354,2;6;0;5;3,00;FCCOc1ccccc1N1CCN(Cc2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm701375u
CHEMBL4116172;161091;None;0;Human;Binding;Ki;=;140,00;6,85;1;2;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;509,1;13;1;9;4,57;[N-]=[N+]=NCCSSCCn1cc(C(=O)CCCN2CCC(O)(c3ccc(Cl)cc3)CC2)nn1;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL4116172;161091;None;0;Human;Binding;Ki;=;260,00;6,58;1;2;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;509,1;13;1;9;4,57;[N-]=[N+]=NCCSSCCn1cc(C(=O)CCCN2CCC(O)(c3ccc(Cl)cc3)CC2)nn1;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL411663;161155;None;0;Human;Binding;Ki;=;330,00;6,48;-16;8;Inhibition of dopamine D2 receptor;ChEMBL;367,2;6;1;3;3,85;O=C1Nc2ccc(F)cc2C1CCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1021/jm070279v
CHEMBL4117243;161230;None;0;Human;Binding;Ki;=;73,00;7,14;1;2;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;509,1;13;2;7;5,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(OCCSSCCO)cc1;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL4117243;161230;None;0;Human;Binding;Ki;=;240,00;6,62;1;2;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;509,1;13;2;7;5,04;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(OCCSSCCO)cc1;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL4117325;161245;None;0;Human;Binding;Ki;=;4500,00;5,35;-26;3;Displacement of [3H]spiperone from human D2-short receptor expressed in CHO cell membranes;ChEMBL;420,2;6;1;5;2,56;O=C(NCCCCN1CC[N+]2(CCOc3ccccc32)CC1)c1cc2ccccn2n1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL4117325;161245;None;0;Human;Binding;Ki;=;6300,00;5,20;-26;3;Displacement of [3H]spiperone from human D2-long receptor expressed in CHO cell membranes;ChEMBL;420,2;6;1;5;2,56;O=C(NCCCCN1CC[N+]2(CCOc3ccccc32)CC1)c1cc2ccccn2n1;https://dx.doi.org/10.1016/j.bmc.2017.04.036
CHEMBL4117866;161306;None;0;Human;Binding;Ki;=;940,00;6,03;-1;2;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;510,2;13;2;7;4,98;COc1cc(CCN2CCC(O)(c3ccc(Cl)cc3)CC2)ccc1OCCCSSCCN;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL4117866;161306;None;0;Human;Binding;Ki;=;1000,00;6,00;-1;2;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;510,2;13;2;7;4,98;COc1cc(CCN2CCC(O)(c3ccc(Cl)cc3)CC2)ccc1OCCCSSCCN;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL4117923;161310;None;0;Human;Binding;Ki;=;1500,00;5,82;-3;2;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;496,2;12;2;7;4,59;COc1cc(CCN2CCC(O)(c3ccc(Cl)cc3)CC2)ccc1OCCSSCCN;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL4117923;161310;None;0;Human;Binding;Ki;=;1500,00;5,82;-3;2;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;496,2;12;2;7;4,59;COc1cc(CCN2CCC(O)(c3ccc(Cl)cc3)CC2)ccc1OCCSSCCN;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL4117924;161311;None;0;Human;Binding;Ki;=;1500,00;5,82;-2;2;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;420,2;7;3;5;0,85;O=C(NCCN1CCC(O)(c2ccc(Cl)cc2)CC1)NCCN1C(=O)C=CC1=O;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL4117924;161311;None;0;Human;Binding;Ki;=;2200,00;5,66;-2;2;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;420,2;7;3;5;0,85;O=C(NCCN1CCC(O)(c2ccc(Cl)cc2)CC1)NCCN1C(=O)C=CC1=O;https://dx.doi.org/10.1016/j.bmc.2017.06.034
CHEMBL41200;161353;None;0;Human;Binding;Ki;=;1090,00;5,96;-851;2;In vitro ability to inhibit [3H]raclopride binding to cloned human D2A receptors expressed in mouse fibroblast (LtK-) cells;ChEMBL;339,2;7;0;3;4,79;CCCN(CCC)C1COc2c(cccc2-c2ccc(OC)cc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00232-2
CHEMBL4128926;161661;None;0;Human;Binding;IC50;=;1,80;8,74;-;38;Displacement of [3H]7-OH-DPAT from human recombinant dopamine D2S receptor after 60 mins by scintillation counting analysis;ChEMBL;583,2;8;3;6;5,76;CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12;https://dx.doi.org/10.1016/j.bmcl.2018.03.093
CHEMBL413275;161782;None;0;Human;Binding;Ki;=;31,62;7,50;-1;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;347,2;3;1;4;3,13;CC(=O)Nc1ccc(CN2C[C@H]3COc4ccc(C#N)cc4[C@@H]3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL413343;161785;None;0;Human;Binding;Ki;=;330,00;6,48;-1;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;401,2;7;2;4;3,89;CNc1cc(OC)c(C(=O)NC[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL413343;161785;None;0;Human;Binding;Ki;=;120,00;6,92;-1;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;401,2;7;2;4;3,89;CNc1cc(OC)c(C(=O)NC[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL413483;161796;None;0;Human;Binding;Ki;=;187,00;6,73;-1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;242,2;3;0;2;3,54;CCC(C)N1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL413483;161796;None;0;Human;Binding;Ki;=;98,00;7,01;-1;4;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;242,2;3;0;2;3,54;CCC(C)N1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL414433;161913;None;0;Human;Binding;Ki;=;25,00;7,60;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;413,2;7;1;3;4,72;O=C1c2ccccc2C(=O)N1CCCCCN1CC=C(c2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL414628;161935;None;0;Human;Binding;Ki;=;2511,89;5,60;-7943;11;Compound was evaluated for binding affinity against Dopamine receptor D2 in CHO cells using [125I]iodosulpiride as the radioligand;ChEMBL;499;4;1;5;2,46;COc1ccc(S(=O)(=O)N2CCc3ccc(I)cc32)cc1N1CCNCC1;https://dx.doi.org/10.1016/s0960-894x(00)00597-7
CHEMBL414838;161952;None;1;Human;Binding;Ki;=;54,50;7,26;-61;3;Binding affinity for human dopamine D2 receptor;ChEMBL;480,1;7;1;4;5,16;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2cccnc2)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL414839;161953;None;0;Human;Binding;Ki;=;3,70;8,43;-6;2;Binding affinity for human dopamine D2 receptor;ChEMBL;433,1;7;1;4;4,11;COc1ccccc1C(=O)NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm049465g
CHEMBL415014;161970;None;0;Human;Binding;Ki;=;1440,00;5,84;-239;3;Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151;ChEMBL;334,2;4;1;5;2,50;Cc1[nH]c(-c2ccccc2)nc1CN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/jm960637m
CHEMBL4159893;162124;None;0;Human;Binding;Ki;=;3129,00;5,50;-11;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;286,1;4;0;3;4,26;CC(C)c1nc(CN2CC[C@H](c3ccccc3)C2)cs1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4160967;162185;None;0;Human;Binding;Ki;=;1522,00;5,82;-1;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;351,2;5;1;5;3,35;Cc1oc(-c2ccc3ccccc3c2)nc1CN1CCO[C@H](CCN)C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4161308;162208;None;0;Human;Binding;Ki;=;2941,00;5,53;-147;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting method;ChEMBL;369,2;4;1;5;3,67;CC(C)c1nc2c(N3CCNCC3)ccnc2n1Cc1cccc(Cl)c1;https://dx.doi.org/10.1016/j.ejmech.2017.12.053
CHEMBL4161436;162212;None;3;Human;Binding;Ki;=;3231,00;5,49;-169;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;340,1;4;0;6;3,51;c1ccc(-c2nc(CN3CCCN(c4nccs4)CC3)co2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4161676;162232;None;0;Human;Binding;Ki;=;1996,00;5,70;-2;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;344,2;6;1;4;3,08;CCOc1ccc([C@H](O)CN2CCN(c3ccccc3F)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4161837;162238;None;2;Human;Binding;Ki;=;2233,00;5,65;-7;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;301,2;5;0;3;3,29;Cc1ccn(CCN2CCC(Cc3ccccc3F)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL416266;162293;None;5;Human;Binding;Ki;=;22,00;7,66;1;4;In vitro binding affinity towards D2 receptor was determined;ChEMBL;463,2;9;1;6;1,78;CCS(=O)(=O)Nc1cccc(N2CCN(CCCCN3C(=O)C4CCCN4C3=O)CC2)c1;https://dx.doi.org/10.1021/jm000929u
CHEMBL4163265;162323;None;2;Human;Binding;Ki;=;37,00;7,43;2;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;349,1;6;1;5;2,89;Fc1ccccc1N1CCN(CCCNc2cncc(Cl)n2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4164541;162408;None;0;Human;Binding;Ki;=;6100,00;5,21;-870;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting method;ChEMBL;355,2;4;1;5;3,10;CCc1nc2c(N3CCNCC3)ccnc2n1Cc1cccc(Cl)c1;https://dx.doi.org/10.1016/j.ejmech.2017.12.053
CHEMBL4164695;162422;None;0;Human;Binding;Ki;=;6787,00;5,17;-;1;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;378,2;6;0;5;4,40;COc1ccc(-c2nc(CN(C)C[C@@H]3Cc4ccccc4O3)c(C)o2)cc1C;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4164849;162434;None;0;Human;Binding;Ki;=;5698,00;5,24;-3;2;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;324,1;5;0;5;3,68;Cc1oc(-c2ccco2)nc1CN(C)C[C@@H]1Cc2ccccc2O1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL416508;162454;None;0;Human;Binding;Ki;=;100,00;7,00;-199;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;465,3;10;1;3;6,00;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(C#N)cccc2C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL416523;162466;None;0;Human;Binding;IC50;=;29,51;7,53;-;5;Binding affinity towards Dopamine receptor D2 by displacement of [3H]-Raclopride.;ChEMBL;414,3;8;1;5;3,33;COc1cccc2c1CC(CNCCCCN1C(=O)CC3(CCCC3)CC1=O)CO2;https://dx.doi.org/10.1016/0960-894X(96)00174-6
CHEMBL4165273;162468;None;2;Human;Binding;Ki;=;5947,00;5,23;-7;2;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;315,2;7;0;4;4,26;CCN(CCc1ccccn1)Cc1csc(C2CCCC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4166178;162518;None;0;Human;Binding;Ki;=;4918,00;5,31;-1;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;331,1;6;2;5;1,74;O=C(CO)NC[C@H]1CCN(Cc2csc(-c3ccccc3)n2)C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4166411;162533;None;1;Human;Binding;Ki;=;3683,00;5,43;-;1;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;328,2;5;2;4;0,90;CN1CCN(CCCNC(=O)c2cc(=O)c3ccccc3[nH]2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL416732;162585;None;16;Human;Binding;Ki;=;5400,00;5,27;1;2;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;179,1;0;3;3;1,30;CC1NCCc2cc(O)c(O)cc21;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
CHEMBL4167807;162621;None;0;Human;Binding;Ki;=;5044,00;5,30;-16;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;286,1;5;0;3;4,08;CCCc1nc(CN2CC[C@H](c3ccccc3)C2)cs1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL416842;162656;None;0;Human;Binding;Ki;=;316,23;6,50;-100;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;512,2;10;1;6;3,89;COc1cccc(/C=C/C(=O)NCCCCN2CCc3ccc(OS(=O)(=O)C(F)(F)F)cc3C2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL4168691;162673;None;4;Human;Binding;Ki;=;1821,00;5,74;-52;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;344,2;5;0;4;3,17;N#Cc1c(CN2CCN(CCc3ccccc3)CC2)cn2ccccc12;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4169236;162705;None;0;Human;Binding;Ki;=;3436,00;5,46;-269;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting method;ChEMBL;353,2;4;1;5;3,15;CC(C)c1nc2c(N3CCNCC3)ccnc2n1Cc1cccc(F)c1;https://dx.doi.org/10.1016/j.ejmech.2017.12.053
CHEMBL416939;162713;None;0;Human;Binding;Ki;=;2529,00;5,60;-47;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;423,2;6;1;4;4,05;COc1c(C(=O)NCCN2CCN(c3ccccc3)CC2)cc(Cl)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL4169603;162730;None;3;Human;Binding;Ki;=;5596,00;5,25;-2;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;337,2;6;0;6;3,04;Cc1cc(C)n(C2CN(CCCc3nc(-c4ccccc4)no3)C2)n1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4169755;162740;None;0;Human;Binding;Ki;=;3195,00;5,50;1;2;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;345,2;6;1;4;1,66;C[C@H]1CN(CCCNC(=O)CN2CCc3ccccc3C2)C[C@@H](C)O1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4171171;162825;None;4;Human;Binding;Ki;=;53,00;7,28;-1;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;345,2;7;1;5;3,14;Clc1cncc(NCCCCN2CCN(c3ccccc3)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4173176;162960;None;0;Human;Binding;Ki;=;334,00;6,48;-6;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;331,2;5;1;5;2,75;C[C@H](CNc1cncc(Cl)n1)N1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4173442;162977;None;0;Human;Binding;Ki;=;6912,00;5,16;-6;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;277,2;4;0;4;1,85;COC[C@@H](C)N1CCN(c2cccc(F)c2C#N)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4174330;163033;None;3;Human;Binding;Ki;=;3420,00;5,47;-33;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;335,1;5;1;5;2,50;Fc1ccc(N2CCN(CCNc3cncc(Cl)n3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL417473;163048;None;0;Human;Binding;Ki;=;26,00;7,58;-4;5;Displacement of [3H]raclopride from human Dopamine receptor D2A;ChEMBL;277,1;0;1;2;3,01;CN1CCc2ccc3c4c2[C@H]1Cc1cccc(c1-4)[C@]3(C)O;https://dx.doi.org/10.1021/jm9911433
CHEMBL4175018;163067;None;0;Human;Binding;Ki;=;1245,00;5,91;-23;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;377,2;4;0;5;3,92;Cc1oc(-c2ccco2)nc1CN1CCN([C@@H]2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4175829;163121;None;0;Human;Binding;Ki;=;3482,00;5,46;-575;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting method;ChEMBL;339,2;4;1;5;2,59;CCc1nc2c(N3CCNCC3)ccnc2n1Cc1cccc(F)c1;https://dx.doi.org/10.1016/j.ejmech.2017.12.053
CHEMBL417608;163137;None;0;Human;Binding;IC50;=;1778,28;5,75;-;5;Binding affinity towards Dopamine receptor D2 by displacement of [3H]-Raclopride.;ChEMBL;456,3;10;0;5;4,45;CCCN(CCCCN1C(=O)CC2(CCCC2)CC1=O)CC1COc2cccc(OC)c2C1;https://dx.doi.org/10.1016/0960-894X(96)00174-6
CHEMBL4176490;163167;None;4;Human;Binding;Ki;=;2187,00;5,66;-75;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;331,2;6;1;5;2,75;Clc1cncc(NCCCN2CCN(c3ccccc3)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4176546;163173;None;4;Human;Binding;Ki;=;7881,00;5,10;-3;2;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;335,2;5;2;4;2,15;CN(C)Cc1cccc(CN/C=C2/C(=O)NC(=O)c3ccccc32)c1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL4176800;163184;None;0;Human;Binding;Ki;=;7745,00;5,11;-5;3;Displacement of [3H]N-methylspiperone from human DRD2 after 90 mins by scintillation counting method;ChEMBL;338,2;7;1;5;1,50;O[C@@H](COC[C@@H]1CCCO1)CN1CCN(c2ccccc2F)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00718
CHEMBL41802;163260;None;0;Human;Binding;Ki;=;87,00;7,06;-1;2;In vitro binding affinity towards human Dopamine receptor D2A was determined in mouse fibroblast LtK cells using [3H]raclopride;ChEMBL;245,2;5;0;1;4,23;CCCN(CCC)[C@@H]1CCc2ccccc2[C@@H]1C;https://dx.doi.org/10.1021/jm00001a020
CHEMBL41830;163304;None;0;Human;Binding;Ki;=;3506,00;5,46;-1;3;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;305,2;2;0;2;4,10;O=C1c2ccccc2CCC12CCN(Cc1ccccc1)CC2;https://dx.doi.org/10.1021/jm00029a008
CHEMBL418321;163310;None;0;Human;Binding;Ki;=;50,12;7,30;-3;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;343,1;2;0;2;4,06;Brc1ccc2c(c1)C1CN(Cc3ccccc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL418321;163310;None;0;Human;Binding;Ki;=;501,19;6,30;-3;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;343,1;2;0;2;4,06;Brc1ccc2c(c1)C1CN(Cc3ccccc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL418671;163371;None;13;Human;Binding;Ki;=;31,62;7,50;-22;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;361,2;4;1;4;3,17;CC(=O)Nc1ccc(CCN2C[C@@H]3c4cc(C#N)ccc4OC[C@H]3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL418705;163379;None;0;Human;Binding;Ki;=;77,00;7,11;-1;4;Binding affinity against [3H]U-86,170-labeled dopamine receptor D2 in cloned CHO cells;ChEMBL;243,2;3;0;2;2,98;C=CCN1CCC2c3c(cccc3OC)CC[C@@H]21;https://dx.doi.org/10.1021/jm00060a014
CHEMBL418758;163386;None;0;Human;Binding;Ki;=;1438,00;5,84;-54;2;Binding affinity against cloned human D2 receptor transfected in CHO-K1 cells using [3H]- spiperone as radioligand.;ChEMBL;375,2;7;1;3;4,53;OC(COc1cccc2ccccc12)CN1CCC(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00233-3
CHEMBL418802;163394;None;0;Human;Binding;Ki;=;6,70;8,17;-11;2;Binding affinity towards Dopamine receptor D2 from mammalian clones expressed in CHO cell membranes using 2 (86.1 Ci/mmol,1.7nanoM)as radioligand;ChEMBL;462,2;4;2;8;3,49;COC(=O)c1cc2c3c(ccc2[nH]1)OCC(CN1CCC(n2c(O)nc4ccccc42)CC1)O3;https://dx.doi.org/10.1021/jm00094a021
CHEMBL418854;163400;None;0;Human;Binding;Ki;=;13,20;7,88;-8;8;The compound was tested for binding affinity against human Dopamine receptor D2L;ChEMBL;402,2;6;1;5;4,00;COc1ccccc1N1CCC(CNCC2COc3ccc(Cl)cc3O2)CC1;https://dx.doi.org/10.1021/jm9910122
CHEMBL419275;163460;None;0;Human;Binding;Ki;=;3,00;8,52;66;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;404,2;4;1;6;4,06;Oc1nc2cccc(N3CCN(Cc4cccc(-c5ccc(F)cc5)n4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL419356;163472;None;0;Human;Binding;Ki;=;71,00;7,15;-11;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;366,2;4;0;2;4,41;CC1Cc2ccccc2N1C(=O)CC1CCN(Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL419487;163493;None;0;Human;Binding;Ki;=;199,53;6,70;-50;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;469,3;7;1;4;4,94;CC(=O)c1cccc(/C=C/C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(C#N)cc4CC3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL419505;163497;None;1;Human;Binding;Ki;=;262,00;6,58;-295;2;Binding affinity at human dopamine receptor D2;ChEMBL;479,2;7;1;3;5,97;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)-c1ccccc1-2;https://dx.doi.org/10.1021/jm010146o
CHEMBL419505;163497;None;1;Human;Binding;Ki;=;262,00;6,58;-295;2;Compound was evaluated for binding affinity against Dopamine receptor D2 subtype from primate;ChEMBL;479,2;7;1;3;5,97;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)-c1ccccc1-2;https://dx.doi.org/10.1016/s0960-894x(98)00469-7
CHEMBL419610;163511;None;0;Human;Binding;IC50;=;246,00;6,61;-;2;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;326,2;4;0;2;4,27;Clc1ccc(N2CCN(C[C@H]3C[C@@H]3c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm990562x
CHEMBL419706;163522;None;0;Human;Binding;Ki;=;630,96;6,20;1;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;454,3;7;2;3;5,76;O=C(NCCCCN1CCC[C@@H]2c3cccc(O)c3CC[C@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL419760;163528;None;0;Human;Binding;Ki;=;100,00;7,00;-3;2;Binding affinity, displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;410,2;6;1;4;4,04;CCS(=O)(=O)c1ccc(OC)c(-c2ccc(CN3CCc4ccccc4C3)[nH]2)c1;https://dx.doi.org/10.1016/S0960-894X(96)00621-X
CHEMBL419908;163549;None;0;Human;Binding;Ki;=;620,00;6,21;-102;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;433,2;5;0;4;3,68;CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2cccc(OC(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL419916;163552;None;0;Human;Binding;Ki;=;1918,00;5,72;-158;2;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;405,3;4;0;3;4,08;CC1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(C(C)(C)C)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL420016;163570;None;0;Human;Binding;Ki;=;2,00;8,70;15;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;410,2;4;1;6;4,39;N#Cc1ccccc1-c1cccc(CN2CCN(c3cccc4nc(O)oc34)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL420067;163577;None;0;Human;Binding;Ki;=;980,00;6,01;-2;3;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;398,2;6;0;3;5,37;COc1ccc2c(c1)C(CCCN1CCN(c3ccc(Cl)cc3)CC1)CCC2;https://dx.doi.org/10.1021/jm991138z
CHEMBL4204059;163740;None;0;Human;Binding;Ki;=;37,00;7,43;-23;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hR;ChEMBL;300,2;5;0;5;2,83;CCCCc1cc(-c2ccoc2)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.7b01898
CHEMBL420789;164064;None;0;Human;Binding;Ki;=;398,11;6,40;-63;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;445,3;6;1;3;4,88;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)/C=C/c3cccc(F)c3)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL4208744;164128;None;0;Human;Binding;Ki;=;250,00;6,60;-1380;3;Displacement of [3H]methyl-spiperone from human recombinant dopamine D2 receptor expressed in HEK293 cells;ChEMBL;378,1;5;1;4;2,94;O=C(NCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1)c1ccccn1;https://dx.doi.org/10.1016/j.bmc.2017.09.018
CHEMBL4208934;164144;None;0;Human;Binding;Ki;=;466,00;6,33;-66;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hR;ChEMBL;272,2;3;0;5;2,05;CCc1cc(-c2ccoc2)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.7b01898
CHEMBL420954;164184;None;4;Human;Binding;Ki;=;120,00;6,92;-9;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;357,2;4;1;2;5,49;Clc1ccc(-c2cc(C3CCN(CC4CCCCC4)CC3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL420986;164213;None;0;Human;Binding;Ki;=;3,00;8,52;-7;4;Affinity for the Dopamine receptor D2S was determined using membranes from CHO cells labeled with [3H]spiperone;ChEMBL;309,1;4;3;4;2,75;Oc1nc2c3c(ccc2[nH]1)CC[C@H](CNCc1ccccc1)O3;https://dx.doi.org/10.1016/s0960-894x(01)00778-8
CHEMBL4212199;164398;None;0;Human;Binding;Ki;=;343,00;6,46;-10;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 or CHO-K1 cells after 1 hr by microbeta counting analysis;ChEMBL;500,2;9;2;5;4,19;O=S(=O)(NC1CCN(CC(O)COc2ccccc2-c2ccccc2)CC1)c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmc.2017.03.057
CHEMBL4216126;164721;None;0;Human;Binding;Ki;=;328,00;6,48;-10;5;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 or CHO-K1 cells after 1 hr by microbeta counting analysis;ChEMBL;434,2;9;1;4;4,16;CC(C)c1ccccc1OCCCN1CCC(NS(=O)(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2017.03.057
CHEMBL4216263;164731;None;2;Human;Binding;Ki;=;4847,00;5,32;-812;4;Displacement of [3H]-raclopride from recombinant human D2LR receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;337;2;1;2;3,66;CCn1cncc1-c1c[nH]c2ccc(I)cc12;https://dx.doi.org/10.1039/C8MD00313K
CHEMBL4216263;164731;None;2;Human;Binding;Ki;=;4898,00;5,31;-812;4;Displacement of [3H] raclopride from human recombinant D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method;ChEMBL;337;2;1;2;3,66;CCn1cncc1-c1c[nH]c2ccc(I)cc12;https://dx.doi.org/10.1016/j.ejmech.2019.03.017
CHEMBL421667;164753;None;0;Human;Binding;Ki;=;117,00;6,93;3;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;479,1;7;1;4;3,24;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(I)cc2)CC1;https://dx.doi.org/10.1021/jm030836n
CHEMBL4216870;164770;None;0;Human;Binding;Ki;=;8210,00;5,09;-288;13;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293T cell membranes after 90 mins by scintillation counting method;ChEMBL;697,4;15;2;6;9,20;NCCCCCCn1cc(CCCCN2CCC(c3ccc(-c4cc(C(=O)O)cc5cc(-c6ccc(C(F)(F)F)cc6)ccc45)cc3)CC2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00168
CHEMBL421801;164866;None;0;Human;Binding;Ki;=;501,19;6,30;-38;3;Binding affinity towards dopamine receptor D2;ChEMBL;408,2;4;0;5;4,60;COc1ccc2c(c1)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL421801;164866;None;0;Human;Binding;Ki;=;457,09;6,34;-38;3;Binding affinity towards dopamine receptor D2;ChEMBL;408,2;4;0;5;4,60;COc1ccc2c(c1)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL421801;164866;None;0;Human;Binding;Ki;=;436,52;6,36;-38;3;Binding affinity towards dopamine receptor D2;ChEMBL;408,2;4;0;5;4,60;COc1ccc2c(c1)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
CHEMBL421902;164949;None;0;Human;Binding;Ki;=;40,00;7,40;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;431,2;7;1;3;4,86;O=C1c2ccc(F)cc2C(=O)N1CCCCCN1CC=C(c2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL422274;165001;None;40;Human;Binding;Ki;=;5825,00;5,24;-2;2;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;177,1;1;1;2;1,51;COc1ccc2c(c1)CC(N)CC2;https://dx.doi.org/10.1021/jm960345l
CHEMBL42228;165002;None;4;Human;Binding;Ki;=;1630,00;5,79;-;4;Binding affinity for dopamine D2 receptor using [3H]spiperone in guinea pig striatum;ChEMBL;275,2;5;0;2;3,52;O=C(CC1CCN(CC2CC2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00029a008
CHEMBL422310;165008;None;0;Human;Binding;Ki;=;635,00;6,20;-16;2;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;397,2;3;1;5;4,39;Cc1ccc2c(c1)C(N1CCN(CCc3ccccc3)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL422334;165012;None;0;Human;Binding;Kd;=;1,86;8,73;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;389,2;7;0;3;5,08;COC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL422334;165012;None;0;Human;Binding;Ki;=;1,91;8,72;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;389,2;7;0;3;5,08;COC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL422344;165013;None;0;Human;Binding;Ki;=;12,00;7,92;7;3;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;217,1;1;1;4;1,23;CN(C)[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/jm960360q
CHEMBL4224763;165028;None;0;Human;Binding;Ki;=;368,00;6,43;-72;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;275,2;8;1;2;4,54;CCCCCCCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL4225278;165060;None;0;Human;Binding;Ki;=;98,00;7,01;-10;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;289,2;9;1;2;4,93;CCCCCCCCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL4225278;165060;None;0;Human;Binding;Ki;=;62,00;7,21;-10;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;289,2;9;1;2;4,93;CCCCCCCCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL4225278;165060;None;0;Human;Binding;Ki;=;42,00;7,38;-10;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;289,2;9;1;2;4,93;CCCCCCCCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL4225830;165098;None;0;Human;Binding;Ki;=;2877,00;5,54;-8;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;219,2;4;1;2;2,98;CCCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL422618;165127;None;0;Human;Binding;Ki;=;40,00;7,40;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;427,2;7;1;3;5,03;Cc1cccc2c(C3=CCN(CCCCCN4C(=O)c5ccccc5C4=O)CC3)c[nH]c12;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL4226226;165133;None;0;Human;Binding;Ki;=;345,00;6,46;-21;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;381,2;8;2;4;3,46;CN(C)c1ccc(C(=O)NCCCCN2CCC(c3cccc(O)c3)C2)cc1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL4226226;165133;None;0;Human;Binding;Ki;=;343,00;6,46;-21;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;381,2;8;2;4;3,46;CN(C)c1ccc(C(=O)NCCCCN2CCC(c3cccc(O)c3)C2)cc1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL4226226;165133;None;0;Human;Binding;Ki;=;360,00;6,44;-21;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;381,2;8;2;4;3,46;CN(C)c1ccc(C(=O)NCCCCN2CCC(c3cccc(O)c3)C2)cc1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL4226336;165140;None;0;Human;Binding;Ki;=;369,00;6,43;-33;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;261,2;7;1;2;4,15;CCCCCCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL4227192;165192;None;0;Human;Binding;Ki;=;3555,00;5,45;-30;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;247,2;6;1;2;3,76;CCCCCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL422788;165237;None;0;Human;Binding;Ki;=;10,80;7,97;-13;3;Compound was measured for the binding affinity in homogenated mouse fibroblast (LTK) cells transfected with human Dopamine receptor D2A using [3H]raclopride as radioligand.;ChEMBL;378,2;6;0;5;3,69;Cc1cc2ccc(OCCCN3CCN(c4ccccc4)CC3)cc2oc1=O;https://dx.doi.org/10.1016/s0960-894x(98)00646-5
CHEMBL422883;165299;None;0;Human;Binding;Ki;=;354,00;6,45;-6;2;Tested for the binding constant against cloned human Dopamine receptor D2L in HEK cells by displacing [3H]spiperone;ChEMBL;512,3;10;2;5;4,19;O=C(NCCN(CCCN1CCN(c2ccccc2)CC1)C1CCc2ccc(O)cc2C1)c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(01)00820-4
CHEMBL4229178;165326;None;0;Human;Binding;Ki;=;464,00;6,33;-38;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblasts membranes by radioligand binding assay;ChEMBL;303,3;10;1;2;5,32;CCCCCCCCCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL422959;165344;None;0;Human;Binding;Ki;=;49000,00;4,31;-58;4;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;268,2;4;0;3;3,14;O=Cc1ccn(C2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL422959;165344;None;0;Human;Binding;Ki;=;65000,00;4,19;-58;4;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;268,2;4;0;3;3,14;O=Cc1ccn(C2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
CHEMBL423040;165361;None;0;Human;Binding;Ki;=;210,00;6,68;-27;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;408,2;8;1;6;3,17;COc1cccc(C(=O)NCCCCN2CCN(c3noc4ccccc34)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL423198;165375;None;0;Human;Binding;Ki;=;100,00;7,00;-63;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;509,2;7;1;5;4,83;COc1ccc(S(=O)(=O)N2CCOCC2)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL423206;165376;None;0;Human;Binding;Ki;=;1800,00;5,75;-18;2;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;351,2;1;0;2;4,54;Fc1ccc2c(c1)CCC1(CCN(C3CCc4ccccc4C3)CC1)O2;https://dx.doi.org/10.1021/jm011030v
CHEMBL423247;165383;None;0;Human;Binding;Ki;=;4900,00;5,31;-1862;4;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;340,1;3;0;4;3,62;Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL423247;165383;None;0;Human;Binding;Ki;=;5000,00;5,30;-1862;4;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;340,1;3;0;4;3,62;Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
CHEMBL423247;165383;None;0;Human;Binding;Ki;=;4897,79;5,31;-1862;4;Binding affinity to dopamine D2;ChEMBL;340,1;3;0;4;3,62;Cc1cccc2c(CN3CCN(c4ccc(Cl)cc4)CC3)cnn12;https://dx.doi.org/10.1021/jm0611152
CHEMBL423440;165416;None;0;Human;Binding;Ki;=;2000,00;5,70;-38;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;402,1;6;1;3;3,71;COc1ccc(Br)cc1C(=O)NC[C@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL423440;165416;None;0;Human;Binding;Ki;=;1500,00;5,82;-38;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;402,1;6;1;3;3,71;COc1ccc(Br)cc1C(=O)NC[C@H]1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL423632;165446;None;0;Human;Binding;Ki;=;374,00;6,43;-28;2;Compound was measured in vivo for its binding affinity at Dopamine receptor D2 using [3H]spiperone as radioligand.;ChEMBL;373,2;3;1;2;4,35;O=C(c1cccc(CN2CCc3c([nH]c4ccccc34)C2)c1)N1CCCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00074-7
CHEMBL423659;165449;None;0;Human;Binding;Ki;=;3019,95;5,52;-141;2;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;320,2;4;1;4;2,07;N#Cc1ccccc1N1CCN(CNC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL423659;165449;None;0;Human;Binding;Ki;=;4180,00;5,38;-141;2;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;320,2;4;1;4;2,07;N#Cc1ccccc1N1CCN(CNC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1021/jm970021c
CHEMBL423671;165452;None;0;Human;Binding;Ki;=;25,12;7,60;-79;4;Binding affinity towards mouse LtK- cells transfected with human D2 receptor using [3H]spiperone;ChEMBL;521,2;10;1;6;4,10;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(S(C)(=O)=O)cc3)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(95)00011-H
CHEMBL423706;165455;None;0;Human;Binding;Ki;=;40,00;7,40;-;1;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;392,2;8;1;2;5,62;O=C(CCCN1CCC(CCc2c[nH]c3ccccc23)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
CHEMBL423735;165464;None;0;Human;Binding;Ki;=;65,00;7,19;-5;5;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL423735;165464;None;0;Human;Binding;Ki;=;110,00;6,96;-5;5;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;407,2;8;1;6;2,67;COc1ccccc1N1CCN(CCCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL4238029;165490;None;0;Human;Binding;Ki;=;42,00;7,38;-2;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;489,2;6;1;5;4,08;O=S(=O)(c1cccc2ncccc12)N1CCC[C@H]1CCN1CCN(c2cccc3[nH]ccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4238124;165496;None;0;Human;Binding;Ki;=;12,00;7,92;-2;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;508,2;6;0;7;3,37;O=S(=O)(c1cccc2ncccc12)N1CCC[C@@H]1CCN1CCN(c2cccc3c2OCCO3)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4238479;165515;None;0;Human;Binding;Ki;=;5,00;8,30;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;506,2;6;0;6;4,82;O=S(=O)(c1cccc2cnccc12)N1CCC[C@@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4238679;165520;None;0;Human;Binding;Ki;=;0,90;9,05;3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;0;7;4,21;O=S(=O)(c1cncc2ccccc12)N1CCC[C@@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4238897;165531;None;0;Human;Binding;Ki;=;11,00;7,96;2;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;493,2;6;0;7;3,82;O=S(=O)(c1cccc2ncccc12)N1CC[C@@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4239091;165539;None;0;Human;Binding;Ki;=;0,30;9,52;3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;0;7;4,21;O=S(=O)(c1cccc2cnccc12)N1CCC[C@@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4239573;165556;None;0;Human;Binding;Ki;=;186,00;6,73;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;928,4;29;1;18;4,03;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCOCCOCCOCCOCCOCCNC(=O)COc2cncc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4239573;165556;None;0;Human;Binding;Ki;=;352,00;6,45;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;928,4;29;1;18;4,03;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCOCCOCCOCCOCCOCCNC(=O)COc2cncc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4239705;165564;None;0;Human;Binding;Ki;=;29,00;7,54;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;492,2;6;0;6;4,42;O=S(=O)(c1cncc2ccccc12)N1CC[C@@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4239823;165568;None;3;Human;Binding;Ki;=;11,00;7,96;-1;5;Displacement of [3H]methyl-spiperone from recombinant human dopamine D2 receptor after 60 mins by scintillation counting method;ChEMBL;506,2;6;0;6;4,82;O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4239823;165568;None;3;Human;Binding;Ki;=;11,00;7,96;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;506,2;6;0;6;4,82;O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4239987;165573;None;0;Human;Binding;Ki;=;295,00;6,53;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;802,4;20;3;11;6,68;CCCN(CCc1ccc(NC(=O)CCc2cn(CCCCCCNC(=O)COc3cncc(C#Cc4csc(C)n4)c3)nn2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4239987;165573;None;0;Human;Binding;Ki;=;142,00;6,85;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;802,4;20;3;11;6,68;CCCN(CCc1ccc(NC(=O)CCc2cn(CCCCCCNC(=O)COc3cncc(C#Cc4csc(C)n4)c3)nn2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4240162;165583;None;0;Human;Binding;Ki;=;4,00;8,40;4;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;535,2;6;0;7;4,99;O=S(=O)(c1cccc2ncccc12)N1CCCCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4240642;165600;None;0;Human;Binding;Ki;=;5,00;8,30;4;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;521,2;6;0;7;4,60;O=S(=O)(c1ccnc2ccccc12)N1CCCC[C@@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4240910;165612;None;0;Human;Binding;Ki;=;9,00;8,05;2;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;1;7;3,04;O=c1[nH]c2c(N3CCN(CC[C@@H]4CCCN4S(=O)(=O)c4cccc5ncccc45)CC3)cccc2o1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4240954;165613;None;0;Human;Binding;Ki;=;16,00;7,80;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;506,2;6;0;6;4,82;O=S(=O)(c1cccc2ncccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4241050;165618;None;0;Human;Binding;Ki;=;1,70;8,77;7;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;508,2;6;0;6;4,94;O=S(=O)(c1cccc2ncccc12)N1CCC[C@H]1CCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4241081;165620;None;0;Human;Binding;Ki;=;7,00;8,15;3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;521,2;6;0;7;4,60;O=S(=O)(c1cccc2ncccc12)N1CCCC[C@@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4241180;165624;None;0;Human;Binding;Ki;=;94,00;7,03;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;890,5;26;1;13;8,00;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCN(C)CCCCCNC(=O)COc2cccc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4241180;165624;None;0;Human;Binding;Ki;=;147,00;6,83;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;890,5;26;1;13;8,00;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCN(C)CCCCCNC(=O)COc2cccc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL424125;165627;None;0;Human;Binding;IC50;=;150,00;6,82;-;4;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;394,3;7;0;4;4,73;COc1ccc2c(c1)C(CCCN1CCN(c3ccccc3OC)CC1)CCC2;https://dx.doi.org/10.1021/jm981041x
CHEMBL4241497;165635;None;0;Human;Binding;Ki;=;10,00;8,00;1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;534,2;6;0;6;5,59;O=S(=O)(c1cccc2ncccc12)N1CCCCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4241776;165645;None;0;Human;Binding;Ki;=;252,00;6,60;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;918,5;28;1;13;8,78;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCCCN(C)CCCCCNC(=O)COc2cccc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4241776;165645;None;0;Human;Binding;Ki;=;398,00;6,40;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;918,5;28;1;13;8,78;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCCCN(C)CCCCCNC(=O)COc2cccc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4241830;165648;None;0;Human;Binding;Ki;=;13,00;7,89;-2;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;508,2;6;0;7;3,37;O=S(=O)(c1cccc2ncccc12)N1CCC[C@H]1CCN1CCN(c2cccc3c2OCCO3)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4241844;165649;None;0;Human;Binding;Ki;=;13,00;7,89;61;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;929,5;28;3;12;8,56;CCCN(CCc1ccc(NC(=O)CCc2cn(CCCCCCCCN(C)CCCCCNC(=O)COc3cncc(C#Cc4csc(C)n4)c3)nn2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4241844;165649;None;0;Human;Binding;Ki;=;50,00;7,30;61;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;929,5;28;3;12;8,56;CCCN(CCc1ccc(NC(=O)CCc2cn(CCCCCCCCN(C)CCCCCNC(=O)COc3cncc(C#Cc4csc(C)n4)c3)nn2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4242170;165665;None;0;Human;Binding;Ki;=;37,00;7,43;-4;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;489,2;6;1;5;4,08;O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3[nH]ccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4242192;165667;None;0;Human;Binding;Ki;=;17,00;7,77;-;1;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;404,2;9;2;3;4,56;C#CCCC(=O)Nc1ccc(CCN(CCC)C2CCc3c(O)cccc3C2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4242192;165667;None;0;Human;Binding;Ki;=;19,00;7,72;-;1;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;404,2;9;2;3;4,56;C#CCCC(=O)Nc1ccc(CCN(CCC)C2CCc3c(O)cccc3C2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4242268;165670;None;0;Human;Binding;Ki;=;22,00;7,66;-3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;508,2;6;0;7;3,37;O=S(=O)(c1cncc2ccccc12)N1CCC[C@@H]1CCN1CCN(c2cccc3c2OCCO3)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4242392;165674;None;0;Human;Binding;Ki;=;0,50;9,30;23;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;0;7;4,21;O=S(=O)(c1cccc2cnccc12)N1CCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4242453;165676;None;0;Human;Binding;Ki;=;303,00;6,52;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;919,5;28;1;14;8,17;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCCCN(C)CCCCCNC(=O)COc2cncc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4242453;165676;None;0;Human;Binding;Ki;=;115,00;6,94;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;919,5;28;1;14;8,17;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCCCN(C)CCCCCNC(=O)COc2cncc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4242858;165694;None;0;Human;Binding;Ki;=;0,70;9,15;1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;0;7;4,21;O=S(=O)(c1cccc2ncccc12)N1CCC[C@@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL424294;165699;None;19;Human;Binding;Ki;=;95,00;7,02;-263;8;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;423,2;8;1;5;4,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm100899z
CHEMBL424294;165699;None;19;Human;Binding;Ki;=;87,00;7,06;-263;8;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;423,2;8;1;5;4,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL424294;165699;None;19;Human;Binding;Ki;=;87,10;7,06;-263;8;Binding affinity to dopamine D2;ChEMBL;423,2;8;1;5;4,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm0611152
CHEMBL424294;165699;None;19;Human;Binding;Ki;=;52,00;7,28;-263;8;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;423,2;8;1;5;4,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm025558r
CHEMBL424294;165699;None;19;Human;Binding;Ki;=;25,00;7,60;-263;8;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;423,2;8;1;5;4,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL424294;165699;None;19;Human;Binding;Ki;=;72,00;7,14;-263;8;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;423,2;8;1;5;4,24;COc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccc3s2)CC1;https://dx.doi.org/10.1021/jm100899z
CHEMBL4243036;165705;None;0;Human;Binding;Ki;=;12,00;7,92;3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;1;7;3,04;O=c1[nH]c2c(N3CCN(CC[C@H]4CCCN4S(=O)(=O)c4cncc5ccccc45)CC3)cccc2o1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4243497;165719;None;0;Human;Binding;Ki;=;10,00;8,00;2;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;493,2;6;0;7;3,82;O=S(=O)(c1cncc2ccccc12)N1CC[C@@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4243579;165720;None;0;Human;Binding;Ki;=;3,00;8,52;3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;491,2;6;0;7;3,74;O=S(=O)(c1cccc2cnccc12)N1CCC[C@H]1CCN1CCN(c2noc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL424384;165735;None;0;Human;Binding;Ki;=;2,30;8,64;30;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;441,2;5;1;5;5,06;Nc1cc(Cl)ccc1C(=O)CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL4243848;165737;None;0;Human;Binding;Ki;=;4,00;8,40;-3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;506,2;6;0;6;4,82;O=S(=O)(c1cccc2ncccc12)N1CCC[C@@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4243932;165740;None;0;Human;Binding;Ki;=;24,00;7,62;-3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;492,2;6;0;6;4,42;O=S(=O)(c1cccc2ncccc12)N1CC[C@@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4244280;165749;None;0;Human;Binding;Ki;=;23,00;7,64;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;520,2;6;0;6;5,21;O=S(=O)(c1cncc2ccccc12)N1CCCC[C@@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL424458;165757;None;0;Human;Binding;Ki;=;100,00;7,00;-15;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;433,3;9;0;2;6,48;CCCN(CCC)[C@@H]1CCc2c(ccc(CCc3ccc(C(F)(F)F)cc3)c2OC)C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL4244691;165763;None;0;Human;Binding;Ki;=;5,00;8,30;1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;506,2;6;0;6;4,82;O=S(=O)(c1cccc2cnccc12)N1CCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4245263;165785;None;0;Human;Binding;Ki;=;0,10;10,00;3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;508,2;6;0;6;4,94;O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4245607;165802;None;0;Human;Binding;Ki;=;6,00;8,22;1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;534,2;6;0;6;5,59;O=S(=O)(c1cncc2ccccc12)N1CCCCC[C@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4245622;165804;None;0;Human;Binding;Ki;=;15,00;7,82;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;520,2;6;1;4;5,70;O=S(=O)(c1cccc2ncccc12)N1CCC[C@@H]1CCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL424575;165807;None;0;Human;Binding;Ki;=;190,00;6,72;-6;4;Binding affinity towards human Dopamine receptor D2 (long) by [3H]-spiperone displacement.;ChEMBL;429,2;9;2;4;4,67;CCC[C@@H]1CN(Cc2ccccc2)C[C@@H]1CNC(=O)c1cc(Cl)c(NC)cc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL424575;165807;None;0;Human;Binding;Ki;=;190,00;6,72;-6;4;Binding affinity towards human Dopamine receptor D2 (short) by [3H]-spiperone displacement.;ChEMBL;429,2;9;2;4;4,67;CCC[C@@H]1CN(Cc2ccccc2)C[C@@H]1CNC(=O)c1cc(Cl)c(NC)cc1OC;https://dx.doi.org/10.1016/s0960-894x(99)00086-4
CHEMBL4245997;165819;None;0;Human;Binding;Ki;=;3,00;8,52;1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;489,2;6;1;5;4,08;O=S(=O)(c1cncc2ccccc12)N1CCC[C@@H]1CCN1CCN(c2cccc3[nH]ccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4246185;165826;None;0;Human;Binding;Ki;=;79,00;7,10;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;957,6;30;3;12;9,35;CCCN(CCc1ccc(NC(=O)CCc2cn(CCCCCCCCCCN(C)CCCCCNC(=O)COc3cncc(C#Cc4csc(C)n4)c3)nn2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4246185;165826;None;0;Human;Binding;Ki;=;171,00;6,77;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;957,6;30;3;12;9,35;CCCN(CCc1ccc(NC(=O)CCc2cn(CCCCCCCCCCN(C)CCCCCNC(=O)COc3cncc(C#Cc4csc(C)n4)c3)nn2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4246202;165827;None;0;Human;Binding;Ki;=;1,00;9,00;7;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;0;7;4,21;O=S(=O)(c1cccc2ncccc12)N1CCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4246630;165846;None;0;Human;Binding;Ki;=;12,00;7,92;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;520,2;6;1;4;5,70;O=S(=O)(c1cncc2ccccc12)N1CCC[C@@H]1CCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4246655;165847;None;0;Human;Binding;Ki;=;0,14;9,85;63;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;0;7;4,21;O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL424667;165848;None;0;Human;Binding;Ki;=;31,00;7,51;-2;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;409,2;8;1;7;2,56;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3nonc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL424667;165848;UNDEFINED;0;Human;Binding;pKi;=;31,00;7,51;-2;2;-;PDSP KiDatabase;409,2;8;1;7;2,56;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc3nonc3c2)CC1;-
CHEMBL424678;165851;None;0;Human;Binding;Ki;=;137,00;6,86;-51;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;492,3;8;2;5;4,19;CC(C)(C)c1nc(N2CCN(CCCCNC(=O)NCc3ccccc3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL4246881;165853;None;0;Human;Binding;Ki;=;45,00;7,35;14;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;891,5;26;1;14;7,39;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCN(C)CCCCCNC(=O)COc2cncc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4246881;165853;None;0;Human;Binding;Ki;=;132,00;6,88;14;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;891,5;26;1;14;7,39;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCCCCCCCN(C)CCCCCNC(=O)COc2cncc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL424690;165855;None;0;Human;Binding;Ki;=;174,00;6,76;-28;2;Binding affinity to cloned human dopamine D2 receptor;ChEMBL;491,3;9;1;5;4,79;CC(C)(C)c1nc(N2CCN(CCCCCC(=O)NCc3ccccc3)CC2)cc(C(F)(F)F)n1;https://dx.doi.org/10.1016/j.bmcl.2005.12.079
CHEMBL4247275;165871;None;0;Human;Binding;Ki;=;5,00;8,30;5;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;507,2;6;1;7;3,04;O=c1[nH]c2c(N3CCN(CC[C@@H]4CCCN4S(=O)(=O)c4cncc5ccccc45)CC3)cccc2o1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4247770;165884;None;0;Human;Binding;Ki;=;19,00;7,72;-3;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;508,2;6;0;7;3,37;O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2cccc3c2OCCO3)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL424808;165895;None;0;Human;Binding;Ki;=;5000,00;5,30;-208;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;371,2;5;2;3;3,94;Nc1cccc(-c2ccc(C(=O)NC3CCN(Cc4ccccc4)C3)cc2)c1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL4248491;165915;None;0;Human;Binding;Ki;=;6,00;8,22;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;506,2;6;0;6;4,82;O=S(=O)(c1cncc2ccccc12)N1CCC[C@@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4248544;165917;None;0;Human;Binding;Ki;=;21,00;7,68;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;520,2;6;0;6;5,21;O=S(=O)(c1cccc2ncccc12)N1CCCC[C@@H]1CCN1CCN(c2cccc3sccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4248597;165920;None;0;Human;Binding;Ki;=;8,00;8,10;-1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;489,2;6;1;5;4,08;O=S(=O)(c1cccc2ncccc12)N1CCC[C@@H]1CCN1CCN(c2cccc3[nH]ccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4249179;165959;None;0;Human;Binding;Ki;=;4,00;8,40;1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;491,2;6;0;7;3,74;O=S(=O)(c1cccc2ncccc12)N1CCC[C@H]1CCN1CCN(c2noc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4249426;165975;None;0;Human;Binding;Ki;=;11,00;7,96;5;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;520,2;6;1;4;5,70;O=S(=O)(c1cccc2ncccc12)N1CCC[C@H]1CCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4249547;165979;None;0;Human;Binding;Ki;=;251,00;6,60;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;840,4;23;1;16;4,00;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCOCCOCCOCCNC(=O)COc2cncc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4249547;165979;None;0;Human;Binding;Ki;=;438,00;6,36;-;2;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;840,4;23;1;16;4,00;COc1cc(CN2CCN(c3ccccc3OC)CC2)ccc1OCc1cn(CCOCCOCCOCCNC(=O)COc2cncc(C#Cc3csc(C)n3)c2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4249640;165984;None;0;Human;Binding;Ki;=;3,00;8,52;1;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;491,2;6;0;7;3,74;O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CCN(c2noc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4250062;165998;None;0;Human;Binding;Ki;=;69,00;7,16;-;1;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes co-expressing mGluR5a (unknown origin) after 1 hr by liquid scintillation counting;ChEMBL;366,2;7;0;5;3,04;C#CCOc1ccc(CN2CCN(c3ccccc3OC)CC2)cc1OC;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4250062;165998;None;0;Human;Binding;Ki;=;77,00;7,11;-;1;Displacement of [3H]-Raclopride from recombinant human dopamine D2 receptor expressed in HEK293T cell membranes after 1 hr by liquid scintillation counting;ChEMBL;366,2;7;0;5;3,04;C#CCOc1ccc(CN2CCN(c3ccccc3OC)CC2)cc1OC;https://dx.doi.org/10.1021/acs.jmedchem.8b00671
CHEMBL4250244;166013;None;0;Human;Binding;Ki;=;13,00;7,89;4;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;520,2;6;1;4;5,70;O=S(=O)(c1cncc2ccccc12)N1CCC[C@H]1CCN1CC=C(c2c[nH]c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4250274;166014;None;0;Human;Binding;Ki;=;3,00;8,52;6;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;535,2;6;0;7;4,99;O=S(=O)(c1ccnc2ccccc12)N1CCCCC[C@H]1CCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL4250475;166019;None;0;Human;Binding;Ki;=;2,00;8,70;2;5;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;508,2;6;0;6;4,94;O=S(=O)(c1cccc2ncccc12)N1CCC[C@@H]1CCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
CHEMBL425057;166025;None;0;Human;Binding;Ki;=;338,84;6,47;-100;4;Binding affinity to dopamine D2;ChEMBL;319,2;4;0;5;2,59;c1ccc(N2CCN(Cc3cnn(-c4ccccn4)c3)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL425057;166025;None;0;Human;Binding;Ki;=;190,00;6,72;-100;4;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;319,2;4;0;5;2,59;c1ccc(N2CCN(Cc3cnn(-c4ccccn4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL425057;166025;None;0;Human;Binding;Ki;=;340,00;6,47;-100;4;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;319,2;4;0;5;2,59;c1ccc(N2CCN(Cc3cnn(-c4ccccn4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL425064;166027;None;0;Human;Binding;Ki;=;55000,00;4,26;-18;4;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;311,2;3;0;5;2,19;Fc1ccc(N2CCN(Cc3cn4cccnc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL425064;166027;None;0;Human;Binding;Ki;=;49000,00;4,31;-18;4;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;311,2;3;0;5;2,19;Fc1ccc(N2CCN(Cc3cn4cccnc4n3)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
CHEMBL425069;166029;None;0;Human;Binding;Ki;=;340,00;6,47;-213;6;Binding affinity at dopamine D2 receptor;ChEMBL;505,2;4;1;7;4,48;COc1cccc(OC)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL425069;166029;None;0;Human;Binding;Ki;=;340,00;6,47;-213;6;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;505,2;4;1;7;4,48;COc1cccc(OC)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL425069;166029;None;0;Human;Binding;Ki;=;340,00;6,47;-213;6;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;505,2;4;1;7;4,48;COc1cccc(OC)c1C(=O)NN1c2ccc(Cl)cc2N=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL425143;166049;None;0;Human;Binding;Ki;=;43,70;7,36;-48;2;Binding affinity for human dopamine D2 receptor;ChEMBL;480,1;7;1;4;5,16;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccncc2)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL425208;166061;None;0;Human;Binding;Ki;=;92,00;7,04;-40;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;440,2;4;1;5;3,91;CC1CC(=O)Nc2c(CCN3CCN(c4n[s+]([O-])c5ccccc45)CC3)cc(F)cc21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL425285;166077;None;0;Human;Binding;Ki;=;14,13;7,85;-3;4;Binding affinity to dopamine D2;ChEMBL;528,2;11;1;6;4,92;CCCc1c(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nnn1Cc1ccccc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL425285;166077;None;0;Human;Binding;Ki;=;6,40;8,19;-3;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;528,2;11;1;6;4,92;CCCc1c(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nnn1Cc1ccccc1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL426062;166216;None;0;Human;Binding;Ki;=;70,00;7,16;-34;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;362,1;5;1;3;4,42;O=C(N[C@H]1CCN(Cc2ccccc2)C1)c1cccc(-c2ccsc2)c1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL426111;166226;None;0;Human;Binding;Ki;=;261,00;6,58;-4;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;503,3;6;0;5;4,92;C[C@H](CCN1CCN(c2cc(C(F)(F)F)nc(C(C)(C)C)n2)CC1)CN1C(=O)CCc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2005.10.035
CHEMBL426317;166262;None;0;Human;Binding;Ki;=;2575,00;5,59;-6309;13;Binding affinity to D2 dopamine receptor by radioligand binding assay;ChEMBL;373,2;7;0;8;0,55;COc1cccc(N2CCN(CCCCn3ncc(=O)n(C)c3=O)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2006.01.052
CHEMBL426473;166286;None;0;Human;Binding;Ki;=;356,00;6,45;-33;2;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;482,3;6;0;8;2,56;Cc1cn(CCCCN2CCN(c3cc(C(F)(F)F)nc(C(C)(C)C)n3)CC2)c(=O)n(C)c1=O;https://dx.doi.org/10.1016/j.bmcl.2005.10.068
CHEMBL426510;166291;None;0;Human;Binding;Ki;=;101,00;7,00;-7;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;342,2;6;0;5;2,78;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1cccc(F)c1;https://dx.doi.org/10.1021/jm060279f
CHEMBL426863;166353;None;0;Human;Binding;Ki;=;120,00;6,92;-33;5;Displacement of [3H]spiperone from human D2 long receptor expressed in CHO cells;ChEMBL;503,3;7;1;3;5,18;O=C(NCCCCN1CCN(c2cccc(F)c2F)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm060138d
CHEMBL426863;166353;None;0;Human;Binding;Ki;=;35,00;7,46;-33;5;Displacement of [3H]spiperone from human D2 short receptor expressed in CHO cells;ChEMBL;503,3;7;1;3;5,18;O=C(NCCCCN1CCN(c2cccc(F)c2F)CC1)c1cc2ccc1CCc1ccc(cc1)CC2;https://dx.doi.org/10.1021/jm060138d
CHEMBL426868;166354;None;0;Human;Binding;Ki;=;837,00;6,08;-54;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;435,1;2;1;6;4,05;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccco3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL426994;166373;None;0;Human;Binding;Ki;=;18,20;7,74;-8;2;Binding affinity for human dopamine D2 receptor;ChEMBL;418,1;6;2;4;3,68;Nc1ccccc1C(=O)NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm049465g
CHEMBL427048;166382;None;0;Human;Binding;Ki;=;221,00;6,66;-4;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;342,2;6;0;5;2,78;CO/N=C(/CCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL427230;166417;None;0;Human;Binding;Ki;=;608,00;6,22;-25;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;513,1;2;1;5;5,77;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3cc(Cl)cc(Cl)c3)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL427522;166467;None;0;Human;Binding;Ki;=;3700,00;5,43;-53;2;Ability to displace [3H]spiperone from human Dopamine receptor D2S stably transfected in GH4C1 (rat pituitary) cells;ChEMBL;384,2;6;1;3;4,17;O=Cc1ccc(-c2ccc(C(=O)NC3CCN(Cc4ccccc4)C3)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.07.045
CHEMBL427555;166475;None;0;Human;Binding;Ki;=;4460,00;5,35;-316;3;Displacement of [3H]spiperone from human dopamine D2(short) receptor in rat pituitary GH4C1 cells;ChEMBL;392,2;6;1;4;4,43;COc1cccc(CN2CC[C@H](NC(=O)c3ccc(-c4cccs4)cc3)C2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.08.051
CHEMBL4277264;166520;None;21;Human;Binding;Ki;=;8300,00;5,08;-616;26;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cells measured after 90 mins by microbeta scintillation counting method;ChEMBL;356,1;3;0;6;4,95;Cc1cc(Oc2nccc3occc23)ccc1-c1c(C)ncc2nccn12;https://dx.doi.org/10.1021/acs.jmedchem.9b00351
CHEMBL4278465;166587;None;0;Human;Binding;Ki;=;550,00;6,26;-1;16;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;ChEMBL;538,2;8;1;3;7,54;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCN(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.10.036
CHEMBL428197;166773;None;0;Human;Binding;Ki;=;27,00;7,57;-20;4;Binding affinity to human dopamine D2 receptor;ChEMBL;475,2;7;1;5;4,03;CC(C)Oc1ccccc1N1CCN([C@H]2CC[C@H](NS(=O)(=O)c3ccc(F)cc3)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL4282702;166803;None;0;Human;Binding;Ki;=;460,00;6,34;-3;11;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;ChEMBL;443,2;7;1;2;6,19;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.10.036
CHEMBL4282887;166814;None;0;Human;Binding;Ki;=;860,00;6,07;-30;2;Displacement of [3H]N-Methylspiperone from human dopamine D2 receptor expressed in fibroblasts;ChEMBL;397,2;8;3;5;2,07;COc1cc2c(cc1O)CN(CCCCNC(=O)c1ccc(C(N)=O)cc1)CC2;https://dx.doi.org/10.1021/acsmedchemlett.8b00229
CHEMBL4283982;166875;None;0;Human;Binding;Ki;=;1100,00;5,96;-524;4;Displacement of [3H]N-Methylspiperone from human dopamine D2 receptor expressed in fibroblasts;ChEMBL;388,2;7;2;4;3,62;COc1cc2c(cc1O)CN(CCCCNC(=O)c1ccc(Cl)cc1)CC2;https://dx.doi.org/10.1021/acsmedchemlett.8b00229
CHEMBL428561;166957;None;8;Human;Binding;Ki;=;30,00;7,52;1;4;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;334,2;9;1;3;2,98;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCF)ccc1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL428561;166957;None;8;Human;Binding;Ki;=;30,00;7,52;1;4;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;334,2;9;1;3;2,98;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCF)ccc1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL4287062;167041;None;0;Human;Binding;Ki;=;700,00;6,16;-257;4;Displacement of [3H]N-Methylspiperone from human dopamine D2 receptor expressed in fibroblasts;ChEMBL;404,2;7;2;4;4,12;COc1cc2c(cc1O)CN(CCCCNC(=O)c1ccc3ccccc3c1)CC2;https://dx.doi.org/10.1021/acsmedchemlett.8b00229
CHEMBL4287471;167064;None;0;Human;Binding;Ki;=;800,00;6,10;-295;4;Displacement of [3H]N-Methylspiperone from human dopamine D2 receptor expressed in fibroblasts;ChEMBL;430,2;8;2;4;4,64;COc1cc2c(cc1O)CN(CCCCNC(=O)c1ccc(-c3ccccc3)cc1)CC2;https://dx.doi.org/10.1021/acsmedchemlett.8b00229
CHEMBL4287623;167073;None;0;Human;Binding;Ki;=;317,00;6,50;1;12;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;ChEMBL;535,2;7;1;2;7,83;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.10.036
CHEMBL4289498;167166;None;0;Human;Binding;Ki;=;2,90;8,54;-4;13;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;461,2;6;0;5;4,64;O=C(CCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2c3c(c1)CCN3C(=O)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL429076;167248;None;0;Human;Binding;Ki;=;36,00;7,44;-3;4;Binding affinity to human dopamine D2 receptor;ChEMBL;565,2;8;1;6;4,66;COc1ccc(Br)cc1S(=O)(=O)N[C@H]1CC[C@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL4291048;167262;None;0;Human;Binding;Ki;=;148,00;6,83;-5;17;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;ChEMBL;524,2;7;1;3;7,15;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCN(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.10.036
CHEMBL4293307;167372;None;0;Human;Binding;Ki;=;417,00;6,38;1;17;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;ChEMBL;562,2;10;1;5;7,28;COc1ccc(N(CCCCN2CCC(O)(c3ccc(Cl)c(C(F)(F)F)c3)CC2)c2ccc(OC)cc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2018.10.036
CHEMBL4293999;167410;None;0;Human;Binding;Ki;=;2,90;8,54;-3;15;Binding affinity to D2 receptor (unknown origin);ChEMBL;475,2;7;0;5;5,04;O=C(CCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2c3c(c1)CCN3C(=O)CC2;https://dx.doi.org/10.1016/j.ejmech.2020.112709
CHEMBL429453;167445;None;0;Human;Binding;Ki;=;113,00;6,95;-7;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;545,3;10;0;7;4,63;CCN([C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1)S(=O)(=O)c1ccc(OC)c(OC)c1;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL429462;167455;None;0;Human;Binding;Ki;=;435,00;6,36;-14;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;433,3;9;1;3;4,87;O=C(NCCCCN1CCN(C(c2ccccc2)c2ccccc2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL4294744;167466;None;0;Human;Binding;Ki;=;2163,10;5,67;-109;2;Displacement of [3H]-sulpiride from human D2 receptor expressed in HEK293 cells after 150 mins by liquid scintillation counting method;ChEMBL;399,2;6;0;4;3,16;O=C1c2ccccc2C(=O)N1CCCCN1CCN(c2cccc(F)c2F)CC1;https://dx.doi.org/10.1039/C8MD00237A
CHEMBL429623;167506;None;0;Human;Binding;Ki;=;45,00;7,35;-20;4;Binding affinity to human dopamine D2 receptor;ChEMBL;532,2;9;1;8;3,80;COc1ccc([N+](=O)[O-])cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCN(c3ccccc3OC(C)C)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.008
CHEMBL429644;167511;None;0;Human;Binding;Ki;=;3100,00;5,51;1;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;424,2;8;0;4;5,94;CCCCSC1CCc2ccc(/N=C/N3CCc4cc(OC)c(OC)cc4C3)cc21;https://dx.doi.org/10.1016/j.bmcl.2007.01.093
CHEMBL4299919;167615;None;0;Human;Binding;Ki;=;534,00;6,27;-1;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;495,2;7;2;6;2,54;N#Cc1ccccc1N1CCN(CC(O)CN2C(=O)NC(c3ccccc3)(c3ccccc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4300388;167655;None;0;Human;Binding;Ki;=;269,00;6,57;-3;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;456,2;7;2;6;1,78;COc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3cccc(F)c3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4300399;167657;None;0;Human;Binding;Ki;=;162,00;6,79;-11;6;Displacement of [3H]methylspiperonee from recombinant human D2 receptor expressed in HEK293 cells cell membranes after 60 mins by liquid scintillation counting method;ChEMBL;398,3;9;0;5;3,84;COc1ccccc1N1CCN(CCOCCOc2cc(C)cc(C)c2C)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
CHEMBL4300609;167669;None;0;Human;Binding;Ki;=;1206,00;5,92;-33;5;Displacement of [3H]methylspiperonee from recombinant human D2 receptor expressed in HEK293 cells cell membranes after 60 mins by liquid scintillation counting method;ChEMBL;382,3;10;0;4;3,56;Cc1cccc(OCCOCCN2CCN(CCc3ccccc3)CC2)c1C;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
CHEMBL4300710;167679;None;0;Human;Binding;Ki;=;4963,00;5,30;-34;5;Displacement of [3H]methylspiperonee from recombinant human D2 receptor expressed in HEK293 cells cell membranes after 60 mins by liquid scintillation counting method;ChEMBL;368,2;7;0;4;4,21;COc1ccc(N2CCN(CCCOc3c(C)cc(C)cc3C)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
CHEMBL4300745;167685;None;0;Human;Binding;Ki;=;876,00;6,06;-17;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;452,2;7;2;6;1,95;COc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3ccc(C)cc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4300883;167695;None;0;Human;Binding;Ki;=;601,00;6,22;-75;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;532,2;8;2;5;3,88;CC1(c2ccc(Cl)cc2)NC(=O)N(CC(O)CN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4300899;167697;None;0;Human;Binding;Ki;=;97,00;7,01;-48;5;Displacement of [3H]methylspiperonee from recombinant human D2 receptor expressed in HEK293 cells cell membranes after 60 mins by liquid scintillation counting method;ChEMBL;354,2;7;0;4;3,90;COc1ccccc1N1CCN(CCCOc2ccc(C)cc2C)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
CHEMBL4300976;167702;None;0;Human;Binding;Ki;=;303,00;6,52;-50;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;452,2;8;2;6;2,04;CCOc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3ccccc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4301717;167750;None;0;Human;Binding;Ki;=;1285,00;5,89;-144;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;467,2;6;2;6;2,16;CC1(c2ccc(Cl)cc2)NC(=O)N(CC(O)CN2CCN(c3ccccc3C#N)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4301757;167755;None;0;Human;Binding;Ki;=;782,00;6,11;-33;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;463,2;7;2;7;1,52;COc1ccc(C2(C)NC(=O)N(CC(O)CN3CCN(c4ccccc4C#N)CC3)C2=O)cc1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4301924;167763;None;0;Human;Binding;Ki;=;506,00;6,30;-70;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;511,1;6;2;6;2,27;CC1(c2ccc(Br)cc2)NC(=O)N(CC(O)CN2CCN(c3ccccc3C#N)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4301925;167764;None;0;Human;Binding;Ki;=;301,00;6,52;-1;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;456,2;7;2;6;1,78;COc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3ccccc3F)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4301967;167770;None;0;Human;Binding;Ki;=;1165,00;5,93;-194;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;468,2;8;2;7;1,65;COc1ccc(C2(C)NC(=O)N(CC(O)CN3CCN(c4ccccc4OC)CC3)C2=O)cc1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4301968;167771;None;0;Human;Binding;Ki;=;366,00;6,44;-18;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;472,2;7;2;6;2,30;COc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3ccc(Cl)cc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL430198;167773;None;0;Human;Binding;Ki;=;184,00;6,74;2;3;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;339,1;3;2;2;4,27;NC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
CHEMBL4302240;167791;None;0;Human;Binding;Ki;=;931,00;6,03;-10;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;528,3;9;2;6;3,23;COc1ccc(C2(C)NC(=O)N(CC(O)CN3CCN(C(c4ccccc4)c4ccccc4)CC3)C2=O)cc1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4302327;167798;None;0;Human;Binding;Ki;=;497,00;6,30;-2;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;500,2;8;2;6;2,67;COc1ccccc1N1CCN(CC(O)CN2C(=O)NC(c3ccccc3)(c3ccccc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL430242;167804;None;0;Human;Binding;Ki;=;6530,00;5,18;-50;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;569,3;13;0;6;8,09;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2C/C=C/Cn2c(-c3ccccc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL4302436;167805;None;0;Human;Binding;Ki;=;267,00;6,57;-26;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;516,1;7;2;6;2,41;COc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3ccc(Br)cc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4302457;167809;None;0;Human;Binding;Ki;=;299,00;6,52;-15;5;Displacement of [3H]methylspiperonee from recombinant human D2 receptor expressed in HEK293 cells cell membranes after 60 mins by liquid scintillation counting method;ChEMBL;344,2;6;0;3;4,24;Cc1cc(OCCCN2CCN(c3ccccc3)CC2)ccc1Cl;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
CHEMBL4302539;167816;None;0;Human;Binding;Ki;=;1033,00;5,99;-102;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;438,2;7;2;6;1,65;COc1ccccc1N1CCN(CC(O)CN2C(=O)NC(C)(c3ccccc3)C2=O)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4302540;167817;None;0;Human;Binding;Ki;=;1690,00;5,77;-141;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;433,2;6;2;6;1,51;CC1(c2ccccc2)NC(=O)N(CC(O)CN2CCN(c3ccccc3C#N)CC2)C1=O;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
CHEMBL4302655;167825;None;0;Human;Binding;Ki;=;189,00;6,72;-38;6;Displacement of [3H]methylspiperonee from recombinant human D2 receptor expressed in HEK293 cells cell membranes after 60 mins by liquid scintillation counting method;ChEMBL;398,3;9;0;5;3,84;COc1ccccc1N1CCN(CCOCCOc2c(C)cc(C)cc2C)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
CHEMBL4302724;167831;None;0;Human;Binding;Ki;=;219,00;6,66;1;2;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHOK1 cell membranes after 60 mins by liquid scintillation counting method;ChEMBL;384,2;9;0;5;3,53;COc1ccccc1N1CCN(CCOCCOc2c(C)cccc2C)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
CHEMBL430439;167885;None;0;Human;Binding;Ki;=;4,50;8,35;1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;459,2;6;1;3;5,49;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1ccccc1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL430444;167888;None;0;Human;Binding;Ki;=;4324,00;5,36;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;389,2;7;0;2;5,65;FC(F)(F)c1ccc(/C=C/COCC2CCN(Cc3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL430522;167900;None;0;Human;Binding;Ki;=;700,00;6,16;-17;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;452,1;5;1;3;4,86;COc1c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL430522;167900;None;0;Human;Binding;Ki;=;1000,00;6,00;-17;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;452,1;5;1;3;4,86;COc1c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL430522;167900;None;0;Human;Binding;Ki;=;260,00;6,58;-17;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;452,1;5;1;3;4,86;COc1c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL430522;167900;None;0;Human;Binding;Ki;=;490,00;6,31;-17;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;452,1;5;1;3;4,86;COc1c(C(=O)N[C@H]2CN(Cc3ccccc3)C[C@@H]2C)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL43073;167928;None;0;Human;Binding;Ki;=;763,00;6,12;-12;2;In vitro ability to inhibit [3H]raclopride binding to cloned human D2A receptors expressed in mouse fibroblast (LtK-) cells;ChEMBL;377,2;6;0;2;5,80;CCCN(CCC)C1COc2c(cccc2-c2ccc(C(F)(F)F)cc2)C1;https://dx.doi.org/10.1016/s0960-894x(99)00232-2
CHEMBL430798;167937;None;16;Human;Binding;IC50;=;52,00;7,28;-;8;Binding affinity towards human Dopamine receptor D2;ChEMBL;441,1;2;0;7;3,35;CN1CCN(C2=Nc3ccccc3Oc3ccc(OS(=O)(=O)C(F)(F)F)cc32)CC1;https://dx.doi.org/10.1021/jm991005d
CHEMBL431640;168052;None;0;Human;Binding;Ki;=;271,00;6,57;-53;2;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;395,2;5;0;3;3,60;C=C[C@@H]1Cc2ccccc2N1C(=O)CN1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
CHEMBL432059;168111;None;0;Human;Binding;Ki;=;13000,00;4,89;-4466;4;Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3ccc4ccnn4c3)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
CHEMBL432059;168111;None;0;Human;Binding;Ki;=;15000,00;4,82;-4466;4;Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3ccc4ccnn4c3)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
CHEMBL432579;168183;None;1;Human;Binding;Ki;=;2066,00;5,68;-173;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;218,1;0;1;2;3,24;Cc1sc(C)c2c1CCCc1c[nH]nc1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL432762;168203;None;1;Human;Binding;Ki;=;94,00;7,03;-7;4;Ability to inhibit the binding of [3H]spiperone to the D2L dopamine receptor in COS7 cells;ChEMBL;304,2;1;0;2;3,90;CC1c2ccccc2C=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00004a016
CHEMBL432762;168203;None;1;Human;Binding;Ki;=;94,00;7,03;-7;4;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;304,2;1;0;2;3,90;CC1c2ccccc2C=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL433121;168263;None;0;Human;Binding;Ki;=;59,20;7,23;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;354,2;7;0;4;4,37;CCCN(Cc1ccc([N+](=O)[O-])cc1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL433121;168263;None;0;Human;Binding;Ki;=;215,00;6,67;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;354,2;7;0;4;4,37;CCCN(Cc1ccc([N+](=O)[O-])cc1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL433255;168287;None;0;Human;Binding;Ki;=;7943,28;5,10;-1258;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;389,2;6;0;4;5,06;COc1cc2ccccc2cc1OC(=O)CC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm960017l
CHEMBL433376;168302;None;0;Human;Binding;Ki;=;28,00;7,55;-2;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;216,1;0;0;3;2,79;Cc1oc(C)c2c1CCCc1cnn(C)c1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL433552;168320;None;0;Human;Binding;Ki;=;1000,00;6,00;-100;2;Ability to displace [125I]sulpiride from human Dopamine receptor D2, expressed in CHO cells;ChEMBL;516,2;8;1;5;6,58;COc1ccc(S(=O)(=O)Oc2ccccc2)cc1-c1ccc(CN2CCCCCC2c2ccccc2)[nH]1;https://dx.doi.org/10.1016/S0960-894X(97)00045-0
CHEMBL433741;168350;None;0;Human;Binding;Ki;=;77,00;7,11;-457;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;395,3;8;1;4;3,64;COc1cccc(C(=O)NCCCCN2CCN(c3cccc(C)c3C)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL434403;168458;None;0;Human;Binding;Ki;=;19,95;7,70;-25;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;465,2;6;1;5;4,66;CC(=O)c1ccc(C(=O)Nc2ccc(CCN3CC4COc5ccc(C#N)cc5C4C3)cc2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL434665;168497;None;14;Human;Binding;EC50;=;111,20;6,95;2;3;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;231,1;3;2;4;1,67;CCCN[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL434665;168497;None;14;Human;Binding;EC50;=;1,00;9,00;2;3;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;231,1;3;2;4;1,67;CCCN[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL434665;168497;None;14;Human;Binding;EC50;=;17,10;7,77;2;3;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;231,1;3;2;4;1,67;CCCN[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL434665;168497;None;14;Human;Binding;EC50;=;121,90;6,91;2;3;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;231,1;3;2;4;1,67;CCCN[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
CHEMBL434665;168497;None;14;Human;Binding;EC50;=;16,00;7,80;2;3;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;231,1;3;2;4;1,67;CCCN[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL434665;168497;None;14;Human;Binding;Ki;=;2,50;8,60;2;3;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;231,1;3;2;4;1,67;CCCN[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/jm960360q
CHEMBL434665;168497;None;14;Human;Binding;Ki;=;2,78;8,56;2;3;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;231,1;3;2;4;1,67;CCCN[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL434665;168497;None;14;Human;Binding;Ki;=;2430,00;5,61;2;3;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;231,1;3;2;4;1,67;CCCN[C@@H]1Cc2cccc3nc(O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
CHEMBL43475;168505;None;9;Human;Binding;Ki;=;30,00;7,52;-12;2;In vitro binding affinity towards human Dopamine receptor D2A was determined in mouse fibroblast LtK cells using [3H]raclopride;ChEMBL;261,2;5;1;2;3,93;CCCN(CCC)[C@@H]1CCc2cccc(O)c2[C@@H]1C;https://dx.doi.org/10.1021/jm00001a020
CHEMBL435301;168597;None;0;Human;Binding;Ki;=;5,90;8,23;-2;9;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;329,1;2;0;3;4,62;CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1;https://dx.doi.org/10.1021/jm049632c
CHEMBL435598;168652;None;0;Human;Binding;Ki;=;292,00;6,54;-239;3;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;299,2;9;1;3;3,74;Cc1ccc(OCCNCCCOc2cccc(C)c2)cc1;https://dx.doi.org/10.1021/jm970422s
CHEMBL435598;168652;None;0;Human;Binding;Ki;=;295,12;6,53;-239;3;Binding affinity to displace [3H]spiperone from cloned human dopamine receptor D2 was determined;ChEMBL;299,2;9;1;3;3,74;Cc1ccc(OCCNCCCOc2cccc(C)c2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL436157;168729;None;0;Human;Binding;Ki;=;125,89;6,90;-7;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;242,1;2;0;3;2,38;CCCN1CC2COc3ccc(C#N)cc3C2C1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL436274;168748;None;0;Human;Binding;Ki;=;892,00;6,05;-22;3;Displacement of [3H]-methylspiperone from human D2 receptor transfected in Sf9 cells assessed as inhibition constant measured after 60 mins;ChEMBL;417,2;3;1;5;4,73;Clc1ccc2c(c1)C(N1CCN(CCc3ccccc3)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL436274;168748;None;0;Human;Binding;Ki;=;892,00;6,05;-22;3;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;417,2;3;1;5;4,73;Clc1ccc2c(c1)C(N1CCN(CCc3ccccc3)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL436998;168832;None;0;Human;Binding;Ki;=;663,00;6,18;-1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in HEK cells;ChEMBL;447,2;9;1;4;5,05;O=C(NCCCCN1CCCN(C(c2ccccc2)c2ccccc2)CC1)c1cccs1;https://dx.doi.org/10.1016/j.bmc.2007.08.034
CHEMBL437112;168844;None;0;Human;Binding;Ki;=;180,00;6,75;-17;2;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;495,1;4;1;7;4,92;CCOc1csc(C(=O)NN2c3ccc(Cl)cc3N=C(N3CCN(C)CC3)c3ccccc32)c1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
CHEMBL437490;168887;None;5;Human;Binding;Ki;=;400,00;6,40;-144;5;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;336,2;4;0;4;3,33;Fc1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL437490;168887;None;5;Human;Binding;Ki;=;450,00;6,35;-144;5;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;336,2;4;0;4;3,33;Fc1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL437490;168887;None;5;Human;Binding;Ki;=;446,68;6,35;-144;5;Binding affinity to dopamine D2;ChEMBL;336,2;4;0;4;3,33;Fc1ccc(N2CCN(Cc3cnn(-c4ccccc4)c3)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL437525;168898;None;0;Human;Binding;Ki;=;13,00;7,89;1;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;492,3;11;1;8;2,98;COc1ccc(Cn2nnc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)c2C)cc1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL437525;168898;None;0;Human;Binding;Ki;=;54,95;7,26;1;4;Binding affinity to dopamine D2;ChEMBL;492,3;11;1;8;2,98;COc1ccc(Cn2nnc(C(=O)NCCCCN3CCN(c4ccccc4OC)CC3)c2C)cc1;https://dx.doi.org/10.1021/jm0611152
CHEMBL437532;168900;None;0;Human;Binding;Ki;=;19,40;7,71;4;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;357,2;6;0;4;4,36;CO/N=C(/CCN1CCC(c2ccccn2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm060279f
CHEMBL437687;168919;None;0;Human;Binding;Ki;=;112,00;6,95;-9;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;338,2;6;0;5;2,95;CO/N=C(\CCN1CCN(c2ccccn2)CC1)c1ccccc1C;https://dx.doi.org/10.1021/jm060279f
CHEMBL437917;168945;None;0;Human;Binding;Ki;=;1616,00;5,79;-33;2;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;531,1;2;1;5;5,62;CN1CCN(C2=Nc3cc(Cl)ccc3N(NC(=O)c3ccc(F)cc3C(F)(F)F)c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
CHEMBL43819;168969;None;0;Human;Binding;Ki;=;28,00;7,55;-6;3;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;290,2;2;1;1;4,64;CN1CCCC(c2c(-c3ccccc3)[nH]c3ccccc23)C1;https://dx.doi.org/10.1021/jm0004998
CHEMBL438673;169026;None;0;Human;Binding;Ki;=;192,00;6,72;-549;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;557,2;9;1;7;4,06;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCN(c4ccccc4OCC(F)(F)F)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL438980;169067;None;0;Human;Binding;Ki;=;15,00;7,82;-83;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;468,2;5;1;5;5,13;O=C1CC(c2ccccc2)c2cccc(CCN3CCN(c4nsc5ccccc45)CC3)c2N1;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL439197;169100;None;0;Human;Binding;Ki;=;57,00;7,24;-19;4;Binding affinity for dopamine D2 receptor;ChEMBL;554,2;7;1;6;4,87;O=S(=O)(N[C@H]1CC[C@@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1)c1ccc2c(c1)OCCO2;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL439646;169162;None;0;Human;Binding;Ki;=;201,00;6,70;-10;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;423,2;3;0;3;4,14;CC1(C)Cc2cccc3c2N1C(=O)C(N1CCN(Cc2ccc(Cl)cc2)CC1)CC3;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL439680;169168;None;0;Human;Binding;Ki;=;12,00;7,92;-5;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;496,2;5;0;5;5,55;CC(=O)N1CCC(c2ccccc2)c2cccc(CCN3CCN(c4nsc5ccccc45)CC3)c21;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL440120;169213;None;0;Human;Binding;Ki;=;12750,00;4,89;-45;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2S stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;317,2;4;1;4;2,77;N#CC(C#N)=Cc1[nH]ccc1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL440120;169213;None;0;Human;Binding;Ki;=;4000,00;5,40;-45;4;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2L stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;317,2;4;1;4;2,77;N#CC(C#N)=Cc1[nH]ccc1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
CHEMBL440389;169252;None;0;Human;Binding;Ki;=;11,00;7,96;-85;2;Binding affinity against Dopamine receptor D2 expressed in CHO cells;ChEMBL;420,2;4;1;5;4,42;Cc1ccc(CCN2CCN(c3nsc4ccccc34)CC2)c2c1C(C)CC(=O)N2;https://dx.doi.org/10.1016/j.bmcl.2005.06.097
CHEMBL440512;169273;None;40;Human;Binding;Ki;=;119,00;6,92;-1;3;In vitro binding affinity of compound against neuronal Dopamine receptor D2;ChEMBL;328,1;0;1;5;3,45;Cc1cc2c(s1)Nc1ccccc1N=C2N1CC[N+](C)([O-])CC1;https://dx.doi.org/10.1016/S0960-894X(96)00567-7
CHEMBL441089;169343;None;0;Human;Binding;Ki;=;251,19;6,60;-79;2;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;365,3;9;0;2;5,46;CCCN(CCC)C1CCc2cc(CCc3ccc(OC)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
CHEMBL441092;169344;None;20;Human;Binding;Ki;=;1492,00;5,83;-4;2;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;163,1;0;2;2;1,21;NC1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL441274;169371;None;0;Human;Binding;Ki;=;187,00;6,73;-5;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;423,2;4;0;3;4,36;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1c2ccccc2CC12CCCC2;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL441529;169403;None;0;Human;Binding;Ki;=;368,00;6,43;-2;2;Displacement of [3H]PIPAT from human recombinant D2L receptor expressed in HEK293 cells;ChEMBL;374,2;6;1;6;2,27;CO/N=C(/c1ccc(Cl)cc1)C(O)CN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1021/jm060279f
CHEMBL441618;169416;None;30;Human;Binding;Ki;=;41,69;7,38;-416;8;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;290,2;0;1;1;3,79;CN1CCc2ccccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL441618;169416;None;30;Human;Binding;Ki;=;44,70;7,35;-416;8;Displacement of [3H]spiperone from D2L dopamine receptor;ChEMBL;290,2;0;1;1;3,79;CN1CCc2ccccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1021/jm051237e
CHEMBL441618;169416;None;30;Human;Binding;Ki;=;44,50;7,35;-416;8;Displacement of [3H]spiperone from human cloned D2 dopamine receptor incubated for 90 mins by radioligand binding assay;ChEMBL;290,2;0;1;1;3,79;CN1CCc2ccccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1039/C5MD00258C
CHEMBL441618;169416;None;30;Human;Binding;Ki;=;44,50;7,35;-416;8;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;290,2;0;1;1;3,79;CN1CCc2ccccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1016/j.bmcl.2006.11.093
CHEMBL441618;169416;None;30;Human;Binding;Ki;=;44,50;7,35;-416;8;Displacement of [3H]spiperone from human D2L dopamine receptor expressed in CHO cells;ChEMBL;290,2;0;1;1;3,79;CN1CCc2ccccc2Cc2[nH]c3ccccc3c2CC1;https://dx.doi.org/10.1021/jm060213k
CHEMBL442059;169472;None;0;Human;Binding;Ki;=;69,00;7,16;-43;4;Binding affinity for dopamine D2 receptor;ChEMBL;560,2;8;1;5;5,76;COc1ccc(Cl)cc1S(=O)(=O)N[C@H]1CC[C@@H](N2CCC(c3ccccc3OCC(F)(F)F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL442290;169506;None;0;Human;Binding;Ki;=;6,00;8,22;-2;4;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;500,2;6;1;5;5,22;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
CHEMBL442290;169506;UNDEFINED;0;Human;Binding;pKi;=;6,00;8,22;-2;4;-;PDSP KiDatabase;500,2;6;1;5;5,22;O=C(NC1CCc2ccc(CCN3CCN(c4nsc5ccccc45)CC3)cc21)c1ccc(F)cc1;-
CHEMBL442535;169534;None;0;Human;Binding;Ki;=;703,00;6,15;-17;2;Binding affinity at Dopamine D2 receptors in rat striatum by [3H]spiperone displacement.;ChEMBL;501,1;6;1;4;4,82;COc1c(C(=O)NCCN2CCN(c3cccc(Cl)c3)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/0960-894X(96)00231-4
CHEMBL443006;169581;None;0;Human;Binding;Ki;=;25,12;7,60;-15;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;397,1;5;1;5;2,58;CS(=O)(=O)Nc1ccc(CCN2CC3COc4ccc(C#N)cc4C3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL443034;169585;None;0;Human;Binding;Ki;=;2,80;8,55;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;423,3;9;1;5;3,95;CCOc1ccccc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1021/jm300603y
CHEMBL44310;169589;None;0;Human;Binding;Ki;=;500,00;6,30;-8;3;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;380,2;5;1;1;6,26;c1ccc(CCN2CCCC(c3c(-c4ccccc4)[nH]c4ccccc34)C2)cc1;https://dx.doi.org/10.1021/jm0004998
CHEMBL4434714;169615;None;0;Human;Binding;Ki;=;42,00;7,38;-10;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,3;11;2;6;4,28;COc1ccc(N(Cc2ccccc2F)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4434714;169615;None;0;Human;Binding;Ki;=;19,00;7,72;-10;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,3;11;2;6;4,28;COc1ccc(N(Cc2ccccc2F)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4434735;169616;None;0;Human;Binding;Ki;=;15,00;7,82;-3;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;478,2;8;0;6;3,76;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2cccc3cccnc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4434865;216384;None;1;Human;Binding;Ki;=;6300,00;5,20;-23;2;Displacement of [3H]methyl-spiperone from recombinant human D2S receptor measured after 60 mins by scintillation counting analysis;ChEMBL;-;-;-;-;-;c1ccc(Cc2cn(C3CCN(Cc4ccccc4)CC3)nn2)cc1;https://dx.doi.org/10.1016/j.bmc.2022.116851
CHEMBL4435367;169641;None;0;Human;Binding;Ki;=;2754,23;5,56;1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;387,2;6;1;8;1,52;Nc1nc2c(s1)CCN(CCCCN1CCN(c3ncccn3)CC1)CC2;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4435528;169647;None;0;Human;Binding;Ki;=;391,00;6,41;-13;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;362,2;7;3;4;4,47;COc1ccc2[nH]cc(CCNCc3ccc(-c4cccc(O)c4)o3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL443567;169663;None;0;Human;Binding;Ki;=;356,10;6,45;-5;3;Binding affinity to dopamine D2 receptor;ChEMBL;483,1;5;2;5;3,81;O=c1[nH]c2[nH]c(-c3ccccc3Cl)cc2c(=O)n1CCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.09.027
CHEMBL4436025;169687;None;0;Human;Binding;Ki;=;1620,00;5,79;-44;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;485,2;9;2;6;3,96;CCc1cc(Cl)c(OC)c(N2CCN(CC(O)CCNC(=O)c3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4436241;169699;None;0;Human;Binding;Kd;=;0,54;9,27;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2cc(Cl)cc(Cl)c2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4436241;169699;None;0;Human;Binding;Ki;=;0,45;9,35;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2cc(Cl)cc(Cl)c2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4436317;169701;None;0;Human;Binding;Ki;=;21400,00;4,67;-1659;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;486,2;9;2;4;4,67;CCc1cc(Cl)c(OC)c(N2CCN(C[C@H](F)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4436610;169717;None;0;Human;Binding;Kd;=;0,46;9,34;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,2;6;1;3;4,79;O=C(CCCN1CCC(O)(c2ccc(C(F)(F)F)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4436610;169717;None;0;Human;Binding;Ki;=;0,32;9,49;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,2;6;1;3;4,79;O=C(CCCN1CCC(O)(c2ccc(C(F)(F)F)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4437202;169741;None;0;Human;Binding;Ki;=;41686,94;4,38;-3;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;370,2;4;0;5;2,00;O=C(c1ccccc1)N1CCN(CCN2CCc3ncsc3CC2)CC1;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4437233;169751;None;0;Human;Binding;Ki;=;46,00;7,34;-15;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;509,3;10;2;5;4,41;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2cccc(F)c2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4437233;169751;None;0;Human;Binding;Ki;=;73,00;7,14;-15;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;509,3;10;2;5;4,41;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2cccc(F)c2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4437341;169758;None;2;Human;Binding;Ki;=;743,00;6,13;-1479;3;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;444,2;8;1;5;4,62;N#Cc1cccc(N2CCN(CCCCNC(=O)c3ccc(-c4ccsc4)cc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4437523;169772;None;3;Human;Binding;Ki;=;376,00;6,42;-190;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;350,1;6;3;3;4,61;Oc1ccc(-c2ccc(CNCCc3c[nH]c4ccc(F)cc34)o2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4437552;169774;None;0;Human;Binding;EC50;=;1636,00;5,79;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;379,2;3;0;5;3,85;CCc1cc2c(c(OC(C)=O)c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4437552;169774;None;0;Human;Binding;EC50;=;1621,81;5,79;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;379,2;3;0;5;3,85;CCc1cc2c(c(OC(C)=O)c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4437740;169790;None;0;Human;Binding;Ki;=;70600,00;4,15;-8;3;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;433,2;7;3;5;3,36;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1C[C@@H]1C[C@H]1CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL4437740;169790;None;0;Human;Binding;Ki;=;831,00;6,08;-8;3;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;433,2;7;3;5;3,36;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1C[C@@H]1C[C@H]1CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL4438037;169810;None;0;Human;Binding;Ki;=;757,00;6,12;-199;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;487,1;8;1;4;6,05;O=C(NCCCCN1CCN(c2ccc(Cl)cc2Cl)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4438361;169823;None;0;Human;Binding;Ki;=;14,70;7,83;1;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;280,2;7;0;3;2,96;CCCCN1CCN(c2ccccc2OCCF)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4438630;169851;None;0;Human;Binding;Ki;=;16318,00;4,79;-741;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;433,2;8;1;4;5,06;Cc1cccc(N2CCN(CCCCNC(=O)c3ccc(-c4ccsc4)cc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4438800;169865;None;0;Human;Binding;EC50;=;1258,93;5,90;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;429,1;2;0;5;4,05;CC(=O)Oc1c(Br)cc2c(c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4438800;169865;None;0;Human;Binding;EC50;=;1412,00;5,85;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;429,1;2;0;5;4,05;CC(=O)Oc1c(Br)cc2c(c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4438968;169877;None;0;Human;Binding;Ki;=;2511,89;5,60;1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;372,2;6;0;7;1,94;c1cnc(N2CCN(CCCCN3CCc4ncsc4CC3)CC2)nc1;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4439029;169882;None;0;Human;Binding;IC50;=;28,18;7,55;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;323,2;3;0;3;4,02;CCc1ccc2c3c1CCN(C)[C@@H]3Cc1ccc(OC)c(OC)c1-2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4439029;169882;None;0;Human;Binding;IC50;=;28,20;7,55;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;323,2;3;0;3;4,02;CCc1ccc2c3c1CCN(C)[C@@H]3Cc1ccc(OC)c(OC)c1-2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4439144;169887;None;0;Human;Binding;Ki;=;950,00;6,02;-2;2;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;457,2;9;0;6;3,22;COc1ccc(N2CCN(CCCCCCN3C(=O)c4ccccc4S3(=O)=O)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4439577;169921;None;0;Human;Binding;Ki;=;18,20;7,74;1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;438,1;6;0;5;4,45;Clc1cccc(N2CCN(CCCCN3CCc4ncsc4CC3)CC2)c1Cl;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4439644;169927;None;0;Human;Binding;Ki;=;55,00;7,26;-12;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;551,2;10;2;5;4,89;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccc(Br)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4439644;169927;None;0;Human;Binding;Ki;=;34,00;7,47;-12;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;551,2;10;2;5;4,89;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccc(Br)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4439728;169931;None;0;Human;Binding;Ki;=;790,00;6,10;-15;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;539,2;9;2;4;5,02;O=C(NCCCN1CCN(c2ccc(Br)cc2)CC1)NN(Cc1ccc(F)cc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4439728;169931;None;0;Human;Binding;Ki;=;620,00;6,21;-15;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;539,2;9;2;4;5,02;O=C(NCCCN1CCN(c2ccc(Br)cc2)CC1)NN(Cc1ccc(F)cc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4439795;169935;None;0;Human;Binding;Ki;=;28,00;7,55;2;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;461,2;8;0;5;3,87;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4440130;169953;None;0;Human;Binding;Ki;=;302,00;6,52;-75;5;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells by microbeta liquid scintillation counting;ChEMBL;419,1;4;1;6;3,81;COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1cccc2ncccc12;https://dx.doi.org/10.1021/acsmedchemlett.6b00056
CHEMBL4440301;169967;None;0;Human;Binding;Ki;=;29,80;7,53;-1;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;310,2;6;0;3;3,83;CCCCN1CCN(c2cc(CC)cc(Cl)c2OC)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4440695;169995;None;0;Human;Binding;Ki;=;9,00;8,05;2;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;484,2;8;0;7;3,82;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4440708;169997;None;0;Human;Binding;Kd;=;32,36;7,49;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;359,1;5;1;2;4,87;OC1(c2ccc(Cl)cc2)CCN(CC/C=C\c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4440708;169997;None;0;Human;Binding;Ki;=;29,51;7,53;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;359,1;5;1;2;4,87;OC1(c2ccc(Cl)cc2)CCN(CC/C=C\c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL444128;170031;None;0;Human;Binding;Ki;=;21000,00;4,68;-2;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;310,2;9;2;2;3,86;CCCNCCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1021/jm800895v
CHEMBL444128;170031;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-2;4;-;PDSP KiDatabase;310,2;9;2;2;3,86;CCCNCCCCNC(=O)c1ccc(-c2ccccc2)cc1;-
CHEMBL444128;170031;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-2;4;-;PDSP KiDatabase;310,2;9;2;2;3,86;CCCNCCCCNC(=O)c1ccc(-c2ccccc2)cc1;-
CHEMBL4441358;170035;None;0;Human;Binding;Ki;=;139,00;6,86;-25;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;224,1;2;1;2;2,31;CCc1cccc(N2CCNCC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4441655;170058;None;0;Human;Binding;Ki;=;50140,00;4,30;-14;4;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;382,1;4;1;8;0,83;CN1CCN(c2nc(N)nc(CS(=O)(=O)c3ccccc3Cl)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4441888;170070;None;0;Human;Binding;Ki;=;2187,76;5,66;-181;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting;ChEMBL;444,2;6;0;5;4,18;COc1ccccc1N1CCN(C[C@H]2OCCOC2(c2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.02.056
CHEMBL4442011;170081;None;0;Human;Binding;EC50;=;613,50;6,21;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;323,2;3;0;3;4,02;CCc1ccc2c3c1CCN(C)[C@H]3Cc1ccc(OC)c(OC)c1-2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4442011;170081;None;0;Human;Binding;EC50;=;616,60;6,21;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;323,2;3;0;3;4,02;CCc1ccc2c3c1CCN(C)[C@H]3Cc1ccc(OC)c(OC)c1-2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4442011;170081;None;0;Human;Binding;IC50;=;40,74;7,39;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;323,2;3;0;3;4,02;CCc1ccc2c3c1CCN(C)[C@H]3Cc1ccc(OC)c(OC)c1-2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4442011;170081;None;0;Human;Binding;IC50;=;40,77;7,39;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;323,2;3;0;3;4,02;CCc1ccc2c3c1CCN(C)[C@H]3Cc1ccc(OC)c(OC)c1-2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4442260;170096;None;0;Human;Binding;EC50;=;0,71;9,15;-;1;Agonist activity at dopamine D2 receptor (unknown origin) assessed as increase in beta-arrestin-2 recruitment after 20 mins measured for 1 sec by BRET-based luciferase reporter gene assay;ChEMBL;418,2;7;2;4;4,03;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5[nH]ccc45)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
CHEMBL4442321;170098;None;0;Human;Binding;Ki;=;27359,00;4,56;-851;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;453,2;8;1;4;5,40;O=C(NCCCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4442385;170105;None;0;Human;Binding;Ki;=;867,00;6,06;-27;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;414,2;8;0;4;4,58;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4442419;170108;None;0;Human;Binding;Ki;=;150,00;6,82;-3;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;533,3;12;2;7;4,15;COc1ccc(N(Cc2cccc(OC)c2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4442419;170108;None;0;Human;Binding;Ki;=;110,00;6,96;-3;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;533,3;12;2;7;4,15;COc1ccc(N(Cc2cccc(OC)c2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4442456;170112;None;0;Human;Binding;Ki;=;1410,00;5,85;-70;5;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells by microbeta liquid scintillation counting;ChEMBL;389,1;3;1;5;3,80;O=S(=O)(c1ccc2ncccc2c1)n1cc(C2=CCNCC2)c2ccccc21;https://dx.doi.org/10.1021/acsmedchemlett.6b00056
CHEMBL4442460;170113;None;0;Human;Binding;Ki;=;73,00;7,14;-301;17;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;473,3;10;2;5;4,13;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4442460;170113;None;0;Human;Binding;Ki;=;77,00;7,11;-301;17;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;473,3;10;2;5;4,13;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4442470;170114;None;0;Human;Binding;Ki;=;47,00;7,33;-17;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;509,3;10;2;5;4,41;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2F)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4442470;170114;None;0;Human;Binding;Ki;=;92,00;7,04;-17;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;509,3;10;2;5;4,41;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2F)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4442855;170142;None;3;Human;Binding;Ki;=;505,00;6,30;-19;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;351,1;6;3;4;4,00;Oc1ccc(-c2ccc(CNCCc3c[nH]c4ncc(F)cc34)o2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4443185;170172;None;0;Human;Binding;Ki;=;180,00;6,75;1;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;443,3;9;0;4;5,19;COc1ccc(N2CCN(CCCCCCN3C(=O)c4cccc5cccc3c45)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL444342;170193;None;0;Human;Binding;Ki;=;5,90;8,23;1;3;Binding affinity towards DA D2 receptor using [3H]N-methyl-spiperone as radioligand.;ChEMBL;407,2;5;1;5;4,41;Nc1ccccc1C(=O)CCCN1CC[C@@H]2[C@H](C1)c1cccc3c1N2CCCS3;https://dx.doi.org/10.1016/s0960-894x(02)01028-4
CHEMBL4443944;170231;None;0;Human;Binding;Ki;=;440,00;6,36;-28;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;445,3;9;2;6;2,91;O=C(NCCCN1CCN(c2ncccn2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4443944;170231;None;0;Human;Binding;Ki;=;580,00;6,24;-28;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;445,3;9;2;6;2,91;O=C(NCCCN1CCN(c2ncccn2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4444351;170259;None;0;Human;Binding;Ki;=;141,00;6,85;1;3;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;324,1;4;1;3;4,53;COc1ccc2[nH]cc(C3=CCN(Cc4cccs4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4444768;170285;None;0;Human;Binding;Kd;=;2,40;8,62;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4444768;170285;None;0;Human;Binding;Ki;=;2,63;8,58;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4445706;170340;None;0;Human;Binding;Ki;=;250,00;6,60;-10;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;528,3;11;2;7;4,01;COc1ccc(N(Cc2ccc(C#N)cc2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4445706;170340;None;0;Human;Binding;Ki;=;110,00;6,96;-10;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;528,3;11;2;7;4,01;COc1ccc(N(Cc2ccc(C#N)cc2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4445841;170354;None;0;Human;Binding;EC50;=;6,30;8,20;6;3;Partial agonist activity at D2 receptor (unknown origin) assessed as beta arrestin-2 recruitment;ChEMBL;432,3;7;1;5;4,04;Cn1ccc2c(N3CCN(CCCCOc4ccc5c(c4)NC(=O)CC5)CC3)cccc21;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL4445841;170354;None;0;Human;Binding;EC50;=;6,30;8,20;6;3;Agonist activity at human dopamine D2long receptor (unknown origin) expressed in HEK293T cells co-expressing TEV fused-beta-Arrestin2 and GRK2 assessed as increase in beta-arrestin-2 recruitment after overnight incubation by Tango assay;ChEMBL;432,3;7;1;5;4,04;Cn1ccc2c(N3CCN(CCCCOc4ccc5c(c4)NC(=O)CC5)CC3)cccc21;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
CHEMBL4445841;170354;None;0;Human;Binding;Ki;=;12,00;7,92;6;3;Partial agonist activity at human D2 receptor assessed as inhibition constant;ChEMBL;432,3;7;1;5;4,04;Cn1ccc2c(N3CCN(CCCCOc4ccc5c(c4)NC(=O)CC5)CC3)cccc21;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL4446350;170390;None;0;Human;Binding;Ki;=;12046,00;4,92;-1445;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;453,2;8;1;4;5,40;O=C(NCCCCN1CCN(c2cccc(Cl)c2)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4446597;170406;None;3;Human;Binding;Kd;=;30,90;7,51;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;323,2;6;1;3;3,63;O=C(CCCN1CCC(O)(c2ccccc2)CC1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4446597;170406;None;3;Human;Binding;Ki;=;32,36;7,49;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;323,2;6;1;3;3,63;O=C(CCCN1CCC(O)(c2ccccc2)CC1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4446609;170407;None;0;Human;Binding;Ki;=;891,00;6,05;-1071;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;456,2;8;2;3;4,66;CCc1cccc(N2CCN(C[C@@H](F)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4447330;170453;None;0;Human;Binding;Ki;=;40040,00;4,40;-11;4;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;471,3;9;0;5;4,83;COc1ccc(N2CCN(CCCCCCN3C(=O)c4cccc5cccc(c45)C3=O)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4447416;170458;None;0;Human;Binding;Ki;=;1000,00;6,00;-9;5;Displacement of [3H]-Raclopride from human dopamine D2 receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;348,1;4;1;7;2,00;CC(Oc1ccccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2022.114645
CHEMBL4447416;170458;None;0;Human;Binding;Ki;=;1001,00;6,00;-9;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;348,1;4;1;7;2,00;CC(Oc1ccccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4447416;170458;None;0;Human;Binding;Ki;=;1001,00;6,00;-9;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;348,1;4;1;7;2,00;CC(Oc1ccccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4447846;170484;None;0;Human;Binding;Ki;=;240,00;6,62;-120;6;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells by microbeta liquid scintillation counting;ChEMBL;419,1;4;1;6;3,81;COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1ccc2cccnc2c1;https://dx.doi.org/10.1021/acsmedchemlett.6b00056
CHEMBL4448120;170510;None;0;Human;Binding;Ki;=;3,24;8,49;2;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;397,2;8;0;6;4,29;COc1ccccc1N1CCN(CCCCOc2ccc3scnc3c2)CC1;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4448166;170514;None;0;Human;Binding;Ki;=;94,00;7,03;-27;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;505,3;11;2;5;4,66;COc1ccccc1N1CCN(CCCCNC(=O)NN(Cc2ccccc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4448166;170514;None;0;Human;Binding;Ki;=;160,00;6,80;-27;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;505,3;11;2;5;4,66;COc1ccccc1N1CCN(CCCCNC(=O)NN(Cc2ccccc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4448285;170522;None;0;Human;Binding;Ki;=;1025,00;5,99;-10;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;397,2;7;2;4;5,32;COc1ccc2[nH]cc(CCNCc3ccc(-c4cnc5ccccc5c4)o3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4449148;170587;None;0;Human;Binding;Ki;=;264,00;6,58;1;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;494,2;9;0;6;4,64;O=[N+]([O-])c1ccccc1N1CCN(CCCCCCN2c3cccc4cccc(c34)S2(=O)=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4449936;170649;None;0;Human;Binding;Ki;=;148,00;6,83;-1;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;348,2;5;1;3;4,47;COc1ccc(CN2CC=C(c3c[nH]c4ccc(OC)cc34)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4450047;170656;None;2;Human;Binding;Kd;=;12,88;7,89;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;389,2;7;1;3;4,82;O=C(CCCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4450047;170656;None;2;Human;Binding;Ki;=;12,02;7,92;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;389,2;7;1;3;4,82;O=C(CCCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4450777;170710;None;0;Human;Binding;Ki;=;169,00;6,77;-309;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;453,2;8;1;4;5,40;O=C(NCCCCN1CCN(c2ccccc2Cl)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL445111;170732;None;0;Human;Binding;Ki;=;1258,93;5,90;-50;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;452,3;5;1;4;4,89;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL4451231;170740;None;0;Human;Binding;Ki;=;17670,00;4,75;-812;5;Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis;ChEMBL;492,3;7;1;5;5,27;O=c1c(-c2ccccc2)c2ccccn2c(=O)n1CCCCN1CCCC(c2c[nH]c3ccccc23)C1;https://dx.doi.org/10.1016/j.ejmech.2019.01.031
CHEMBL4451351;170754;None;0;Human;Binding;Ki;=;151,36;6,82;1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;372,2;5;0;6;2,37;COc1ccccc1N1CCN(CCN2CCc3ncsc3CC2)CC1;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4451384;170756;None;0;Human;Binding;Kd;=;0,05;10,26;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;401,2;6;1;3;4,96;O=C(CCCN1[C@H]2CC[C@@H]1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4451384;170756;None;0;Human;Binding;Ki;=;0,05;10,28;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;401,2;6;1;3;4,96;O=C(CCCN1[C@H]2CC[C@@H]1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4451683;170784;None;0;Human;Binding;Ki;=;151,00;6,82;-354;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;454,2;8;3;4;3,69;CCc1cccc(N2CCN(CC(O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4451683;170784;None;0;Human;Binding;Ki;=;132,00;6,88;-354;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;454,2;8;3;4;3,69;CCc1cccc(N2CCN(CC(O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4451797;170793;None;0;Human;Binding;EC50;=;0,40;9,40;-;1;Partial agonist activity at human D2L receptor expressed in HEK293T cells co-expressing Galpahi1/Gbeta1/GFP2-Ggamma2 assessed as Galphai1 dissociation after 15 mins in presence of coelenterazine 400a by luciferase reporter gene assay;ChEMBL;363,2;4;1;2;3,92;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCc3cccc(Cl)c3C2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00508
CHEMBL4451797;170793;None;0;Human;Binding;IC50;=;71,00;7,15;-;1;Antagonist activity at D2L receptor (unknown origin) expressed in human HTLA cells assessed as inhibition of dopamine-stimulated beta-arrestin2 recruitment measured after 20 to 22 hrs by brightglo-luciferase reporter gene assay;ChEMBL;363,2;4;1;2;3,92;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCc3cccc(Cl)c3C2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00508
CHEMBL4452569;170860;None;3;Human;Binding;Ki;=;7080,00;5,15;-1778;4;Displacement of [3H] raclopride from human recombinant D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method;ChEMBL;355;2;1;2;3,79;CCn1cncc1-c1c[nH]c2ccc(I)c(F)c12;https://dx.doi.org/10.1016/j.ejmech.2019.03.017
CHEMBL4453290;170909;None;0;Human;Binding;Kd;=;2,09;8,68;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2c(Cl)cccc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4453290;170909;None;0;Human;Binding;Ki;=;1,48;8,83;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2c(Cl)cccc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4453733;170943;None;0;Human;Binding;Ki;=;3981,00;5,40;-190;3;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;446,1;7;2;6;4,26;COc1ccc2c(c1)c(-c1[nH]c(NCC(F)F)nc1C)cn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4454000;170958;None;0;Human;Binding;Ki;=;151,00;6,82;1;3;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;332,2;5;1;2;4,86;CCOc1ccc2[nH]cc(C3=CCN(Cc4ccccc4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4454096;170968;None;0;Human;Binding;Ki;=;42,00;7,38;-12;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;567,3;11;2;5;5,93;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(-c3ccccc3)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4454096;170968;None;0;Human;Binding;Ki;=;140,00;6,85;-12;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;567,3;11;2;5;5,93;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(-c3ccccc3)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4454105;170970;None;0;Human;Binding;Ki;=;8,00;8,10;1;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;477,2;8;0;5;4,37;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2cccc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4454176;170978;None;0;Human;Binding;Ki;=;20,00;7,70;-6;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;516,3;8;2;4;5,30;COc1ccc2[nH]cc(C3CCN(CCCCN4C(=O)CC(c5c[nH]c6ccc(F)cc56)C4=O)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
CHEMBL4455658;171059;None;0;Human;Binding;Ki;=;896,00;6,05;-112;5;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;530,2;7;1;5;5,81;O=c1c(-c2ccccc2Cl)c2n(c(=O)n1CCCCN1CCCC(c3c[nH]c4ccccc34)C1)CCCC2;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
CHEMBL4455788;171065;None;0;Human;Binding;Kd;=;1,00;9,00;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2cccc(Cl)c2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4455788;171065;None;0;Human;Binding;Ki;=;1,00;9,00;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2cccc(Cl)c2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4456046;171075;None;0;Human;Binding;Ki;=;113,00;6,95;-5;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;457,2;9;0;6;3,22;COc1cccc(N2CCN(CCCCCCN3C(=O)c4ccccc4S3(=O)=O)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4457109;171169;None;0;Human;Binding;Ki;=;45,00;7,35;-1;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;461,2;8;0;5;3,87;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4457881;171212;None;0;Human;Binding;Ki;=;321,00;6,49;-1;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;346,2;5;1;2;5,24;CC(C)Oc1ccc2[nH]cc(C3=CCN(Cc4ccccc4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4458938;171277;None;0;Human;Binding;Ki;=;82,00;7,09;-3;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;464,3;8;0;4;5,73;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2cccc3cccnc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4459381;171309;None;0;Human;Binding;Ki;=;3449,00;5,46;-208;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;435,2;8;2;5;4,45;O=C(NCCCCN1CCN(c2ccccc2O)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4459533;171320;None;0;Human;Binding;Ki;=;137,00;6,86;-43;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;469,2;9;1;5;4,99;CCc1cc(Cl)c(OC)c(N2CCN(CCCCNC(=O)c3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL445977;171337;None;0;Human;Binding;Ki;=;266,00;6,58;-;1;Binding affinity at dopamine D2 receptor;ChEMBL;330,2;8;0;3;3,54;CCN(CCc1ccccc1OC(F)(F)F)CCN1CCCC1;https://dx.doi.org/10.1021/jm7013666
CHEMBL4460564;171384;None;0;Human;Binding;Ki;=;112,00;6,95;1;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;348,2;5;1;3;4,47;COc1cccc(CN2CC=C(c3c[nH]c4ccc(OC)cc34)CC2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4460592;171389;None;0;Human;Binding;Ki;=;5495,41;5,26;-12;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;387,2;6;1;4;3,66;O=C(NCCCCN1CCc2ncsc2CC1)C12CC3CC(CC(C3)C1)C2;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4460743;171399;None;0;Human;Binding;Ki;=;19,00;7,72;-16;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;503,3;11;2;6;4,14;COc1ccc(N(Cc2ccccc2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4460743;171399;None;0;Human;Binding;Ki;=;45,00;7,35;-16;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;503,3;11;2;6;4,14;COc1ccc(N(Cc2ccccc2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4460839;171404;None;0;Human;Binding;Ki;=;299,00;6,52;-1;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;376,2;6;1;3;5,25;COc1cccc(CN2CC=C(c3c[nH]c4ccc(OC(C)C)cc34)CC2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4461461;171448;None;0;Human;Binding;Ki;=;12,20;7,91;-19;3;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;403,2;8;2;4;3,27;CCc1cccc(N2CCN(CCCCNC(=O)c3nc(C)c[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4461948;171481;None;2;Human;Binding;Kd;=;3,02;8,52;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;359,2;6;1;3;3,91;O=C(CCCN1CCC(O)(c2ccc(F)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4461948;171481;None;2;Human;Binding;Ki;=;3,31;8,48;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;359,2;6;1;3;3,91;O=C(CCCN1CCC(O)(c2ccc(F)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4462108;171492;None;0;Human;Binding;Ki;=;193,00;6,71;-40;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;347,2;6;0;3;4,02;Fc1ccc(CCCCN2CCN(c3ccc(Cl)cn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4462108;171492;None;0;Human;Binding;Ki;=;194,98;6,71;-40;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;347,2;6;0;3;4,02;Fc1ccc(CCCCN2CCN(c3ccc(Cl)cn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4462139;171495;None;0;Human;Binding;Ki;=;963,00;6,02;-20;5;Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis;ChEMBL;510,2;7;1;5;5,41;O=c1c(-c2ccc(F)cc2)c2ccccn2c(=O)n1CCCCN1CCCC(c2c[nH]c3ccccc23)C1;https://dx.doi.org/10.1016/j.ejmech.2019.01.031
CHEMBL4462404;171504;None;0;Human;Binding;Ki;=;656,00;6,18;-6;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;378,1;4;1;6;0,30;CC([Se]c1ccccc1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4462814;171526;None;11;Human;Binding;Ki;=;676,00;6,17;-7;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;316,2;6;2;2;4,76;c1ccc(-c2ccc(CNCCc3c[nH]c4ccccc34)o2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4462839;171529;None;0;Human;Binding;Ki;=;27,00;7,57;5;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;495,2;8;0;5;4,23;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ccccc2C(F)(F)F)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4462915;171533;None;0;Human;Binding;Ki;=;2,82;8,55;1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;412,2;8;1;7;3,87;COc1ccccc1N1CCN(CCCCOc2ccc3sc(N)nc3c2)CC1;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4463030;171540;None;0;Human;Binding;Ki;=;7,00;8,15;3;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;495,2;8;0;5;4,23;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4463034;171541;None;0;Human;Binding;Ki;=;58,00;7,24;2;5;Displacement of [3H]Spiperone from human D2S receptor expressed in CHO cell membranes;ChEMBL;385,2;4;2;3;4,31;COc1ccc2[nH]cc(C3=CCN(Cc4cc(=O)[nH]c5ccccc45)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4463187;171549;None;0;Human;Binding;Kd;=;7,41;8,13;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)c(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4463187;171549;None;0;Human;Binding;Ki;=;7,76;8,11;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)c(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4463200;171550;None;0;Human;Binding;Ki;=;77,00;7,11;-10;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;509,3;10;2;5;4,41;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4463200;171550;None;0;Human;Binding;Ki;=;30,00;7,52;-10;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;509,3;10;2;5;4,41;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4463276;171556;None;0;Human;Binding;Ki;=;140,00;6,85;-5;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;385,2;6;1;5;3,45;COc1ccccc1N1CCN(CCNC(=O)/N=N/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4463276;171556;None;0;Human;Binding;Ki;=;270,00;6,57;-5;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;385,2;6;1;5;3,45;COc1ccccc1N1CCN(CCNC(=O)/N=N/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4463620;171583;None;0;Human;Binding;Ki;=;537,00;6,27;-125;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;464,2;8;3;6;2,76;CCc1cc2c(cc1N1CCN(CC(O)CCNC(=O)c3cc4ccccc4[nH]3)CC1)OCO2;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4463737;171594;None;0;Human;Binding;Ki;=;3802,00;5,42;-23;3;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;446,1;6;1;7;3,91;COc1ccc2c(c1)c(-c1c(C)nc(N)n1CC(F)F)cn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4464060;171615;None;0;Human;Binding;Ki;=;1740,00;5,76;-9;3;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;235,2;3;1;4;1,84;CCCN1CC(c2ccc(N)nc2)OC[C@@H]1C;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL4464512;171649;None;0;Human;Binding;Ki;=;39,00;7,41;-1;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;461,2;8;0;5;3,87;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4464971;171680;None;0;Human;Binding;Ki;=;364,00;6,44;-14;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;489,2;9;2;7;2,94;CCc1cc(Cl)c(OC)c(N2CCN(CC(O)CCNC(=O)c3ccc4c(c3)OCO4)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4465002;171682;None;0;Human;Binding;Ki;=;100,00;7,00;-9;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;477,3;9;2;5;3,88;COc1ccccc1N1CCN(CCNC(=O)NN(Cc2ccccc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4465002;171682;None;0;Human;Binding;Ki;=;71,00;7,15;-9;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;477,3;9;2;5;3,88;COc1ccccc1N1CCN(CCNC(=O)NN(Cc2ccccc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4465127;171692;None;0;Human;Binding;Ki;=;2,40;8,62;-;1;Binding affinity to human D2R;ChEMBL;1369,6;42;9;14;8,88;CCCN(CCc1ccc(NC(=O)CCC(=O)NCCOCCOCC(=O)NCCCC[C@H](NC(C)=O)C(=O)NCCCC[C@H](NC(C)=O)C(=O)NCCCCCCNC(=O)c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)c2C)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmcl.2019.126644
CHEMBL4465147;171695;None;0;Human;Binding;EC50;=;120,00;6,92;-;1;Agonist activity at dopamine D2long receptor (unknown origin) assessed as increase in beta-arrestin recruitment;ChEMBL;345,1;6;0;3;4,65;CC1(Oc2ccc(Cl)cc2)CCN(CCOc2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
CHEMBL4465181;171697;None;0;Human;Binding;Ki;=;105,00;6,98;-1;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;495,1;8;0;5;4,52;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4465318;171702;None;0;Human;Binding;Kd;=;213,80;6,67;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cc(F)cc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4465318;171702;None;0;Human;Binding;Ki;=;169,82;6,77;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cc(F)cc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4465414;171716;None;0;Human;Binding;Ki;=;757,00;6,12;-107;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;332,2;6;3;3;4,47;Oc1ccc(-c2ccc(CNCCc3c[nH]c4ccccc34)o2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4465596;171728;None;0;Human;Binding;Ki;=;1440,00;5,84;-61;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;465,2;8;2;7;3,03;CCc1cc2c(cc1N1CCN(CC(O)CCNC(=O)c3cc4ccccc4o3)CC1)OCO2;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4465929;171748;None;0;Human;Binding;Ki;=;1348,00;5,87;-2;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;300,2;4;1;7;0,79;CN1CCN(c2nc(N)nc(COc3ccccc3)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4466114;171760;None;0;Human;Binding;Ki;=;490,00;6,31;-11;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;555,1;8;2;4;4,33;O=C(NCCN1CCN(c2ccc(I)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4466114;171760;None;0;Human;Binding;Ki;=;510,00;6,29;-11;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;555,1;8;2;4;4,33;O=C(NCCN1CCN(c2ccc(I)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4466356;171780;None;0;Human;Binding;Ki;=;132,00;6,88;1;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;362,2;6;1;3;4,86;CCOc1ccc2[nH]cc(C3=CCN(Cc4ccc(OC)cc4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4466483;171788;None;0;Human;Binding;Ki;=;8700,00;5,06;-323;27;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cells measured after 90 mins by microbeta scintillation counting method;ChEMBL;411,1;3;0;5;6,42;FC(F)(F)c1cc(Oc2nccc3ccsc23)ccc1-c1cccc2nccn12;https://dx.doi.org/10.1021/acs.jmedchem.9b00351
CHEMBL4466677;171804;None;0;Human;Binding;Ki;=;112,20;6,95;-64;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting;ChEMBL;444,2;6;0;5;4,18;COc1ccccc1N1CCN(CC2COCC(c3ccccc3)(c3ccccc3)O2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.02.056
CHEMBL4467404;171859;None;0;Human;Binding;EC50;=;2,90;8,54;-;1;Agonist activity at human dopamine D2long receptor (unknown origin) expressed in HEK293T cells co-expressing TEV fused-beta-Arrestin2 and GRK2 assessed as increase in beta-arrestin-2 recruitment after overnight incubation by Tango assay;ChEMBL;446,3;7;1;5;4,35;Cc1cc2c(N3CCN(CCCCOc4ccc5c(c4)NC(=O)CC5)CC3)cccc2n1C;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
CHEMBL4467437;171861;None;0;Human;Binding;Ki;=;22,00;7,66;-9;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;569,2;10;2;5;5,03;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2F)c2ccc(Br)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4467437;171861;None;0;Human;Binding;Ki;=;45,00;7,35;-9;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;569,2;10;2;5;5,03;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2F)c2ccc(Br)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4467483;171864;None;0;Human;Binding;EC50;=;54,95;7,26;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1c(Br)ccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4467483;171864;None;0;Human;Binding;EC50;=;55,37;7,26;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1c(Br)ccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4467483;171864;None;0;Human;Binding;IC50;=;30,20;7,52;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1c(Br)ccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4467483;171864;None;0;Human;Binding;IC50;=;30,35;7,52;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1c(Br)ccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4467883;171889;None;4;Human;Binding;EC50;=;540,00;6,27;-;1;Antagonist activity at dopamine D2long receptor (unknown origin) assessed as inhibition of agonist-induced beta-arrestin recruitment;ChEMBL;413,1;6;0;3;5,67;CC1(Oc2ccc(Cl)cc2)CCN(CCOc2ccccc2C(F)(F)F)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
CHEMBL4467883;171889;None;4;Human;Binding;EC50;=;600,00;6,22;-;1;Agonist activity at dopamine D2long receptor (unknown origin) assessed as increase in beta-arrestin recruitment;ChEMBL;413,1;6;0;3;5,67;CC1(Oc2ccc(Cl)cc2)CCN(CCOc2ccccc2C(F)(F)F)CC1;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
CHEMBL4467984;171896;None;0;Human;Binding;Ki;=;0,84;9,08;-;1;Binding affinity to human D2R;ChEMBL;1224,5;34;8;11;9,73;CCCN(CCc1ccc(NC(=O)CCC(=O)NCCCC[C@H](NC(C)=O)C(=O)NCCCC[C@H](NC(C)=O)C(=O)NCCCCCCNC(=O)c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)c2C)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmcl.2019.126644
CHEMBL4468036;171899;None;0;Human;Binding;Ki;=;431,00;6,37;1;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;458,2;9;0;5;5,09;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccccc2[N+](=O)[O-])CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4468396;171916;None;0;Human;Binding;Ki;=;5129,00;5,29;-51;2;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;369,1;3;1;6;3,89;Cc1sc(N)nc1-c1cn(S(=O)(=O)c2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4468416;171918;None;0;Human;Binding;Kd;=;120,23;6,92;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4468416;171918;None;0;Human;Binding;Ki;=;83,18;7,08;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4469147;171970;None;0;Human;Binding;Ki;=;5248,00;5,28;-346;2;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;394,1;4;2;5;3,54;CC(=O)Nc1nc(C)c(-c2ccc3ccn(S(=O)(=O)c4ccccc4)c3c2)[nH]1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4469309;171977;None;0;Human;Binding;Ki;=;3319,00;5,48;-1096;6;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells by microbeta liquid scintillation counting;ChEMBL;419,1;4;1;6;3,81;COc1ccc2c(c1)c(C1=CCNCC1)cn2S(=O)(=O)c1cncc2ccccc12;https://dx.doi.org/10.1021/acsmedchemlett.6b00056
CHEMBL4469537;171987;None;0;Human;Binding;Ki;=;1977,00;5,70;-154;5;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;514,3;7;1;5;5,29;O=c1c(-c2ccc(F)cc2)c2n(c(=O)n1CCCCN1CCCC(c3c[nH]c4ccccc34)C1)CCCC2;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
CHEMBL4469539;171988;None;0;Human;Binding;Ki;=;141,00;6,85;2;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;486,2;9;0;6;4,73;O=C1c2cccc3cccc(c23)C(=O)N1CCCCCCN1CCN(c2ccccc2[N+](=O)[O-])CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4469633;171995;None;0;Human;Binding;Ki;=;1651,00;5,78;-54;5;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;530,2;7;1;5;5,81;O=c1c(-c2ccc(Cl)cc2)c2n(c(=O)n1CCCCN1CCCC(c3c[nH]c4ccccc34)C1)CCCC2;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
CHEMBL4469777;172001;None;0;Human;Binding;Ki;=;58,10;7,24;-17;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;238,1;2;0;2;2,65;CCc1cccc(N2CCN(C)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4469813;172007;None;0;Human;Binding;Ki;=;1129,00;5,95;-53;5;Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis;ChEMBL;522,3;8;1;6;5,28;COc1ccc(-c2c(=O)n(CCCCN3CCCC(c4c[nH]c5ccccc45)C3)c(=O)n3ccccc23)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.01.031
CHEMBL4469848;172011;None;0;Human;Binding;Ki;=;7600,00;5,12;-162;24;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cells measured after 90 mins by microbeta scintillation counting method;ChEMBL;395,1;3;0;5;5,95;FC(F)(F)c1cc(Oc2nccc3occc23)ccc1-c1cccc2nccn12;https://dx.doi.org/10.1021/acs.jmedchem.9b00351
CHEMBL4470231;172034;None;0;Human;Binding;Ki;=;32,00;7,50;-9;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;507,2;10;2;5;4,78;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4470231;172034;None;0;Human;Binding;Ki;=;23,00;7,64;-9;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;507,2;10;2;5;4,78;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4470304;172038;None;0;Human;Binding;Ki;=;188,00;6,73;-4;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;415,2;8;0;5;3,97;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4470321;172039;None;0;Human;Binding;Kd;=;17,78;7,75;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;371,1;4;1;2;4,59;OC1(c2ccc(Cl)cc2)CCN(CCCC#Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4470321;172039;None;0;Human;Binding;Ki;=;19,05;7,72;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;371,1;4;1;2;4,59;OC1(c2ccc(Cl)cc2)CCN(CCCC#Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4470487;172049;None;0;Human;Binding;Ki;=;51,00;7,29;-2;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;429,2;8;0;7;2,00;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4470487;172049;None;0;Human;Binding;Ki;=;51,00;7,29;-2;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;429,2;8;0;7;2,00;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4470553;172054;None;7;Human;Binding;EC50;=;520,00;6,28;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;307,2;2;0;3;3,95;CCCN1CCc2cccc3c2[C@H]1Cc1ccc2c(c1-3)OCO2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4470553;172054;None;7;Human;Binding;EC50;=;501,19;6,30;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;307,2;2;0;3;3,95;CCCN1CCc2cccc3c2[C@H]1Cc1ccc2c(c1-3)OCO2;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4471658;172131;None;0;Human;Binding;Ki;=;138,04;6,86;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;448,2;7;2;6;3,27;Cc1cc(C(N)=O)c(-c2cccc(OC(=O)NCCN3CCN(c4ccccc4)CC3)c2)o1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4471658;172131;None;0;Human;Binding;Ki;=;138,00;6,86;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;448,2;7;2;6;3,27;Cc1cc(C(N)=O)c(-c2cccc(OC(=O)NCCN3CCN(c4ccccc4)CC3)c2)o1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4471669;172134;None;0;Human;Binding;Ki;=;2,93;8,53;-8;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;280,2;5;0;2;3,82;CCCCN1CCN(c2cccc(CC)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4471755;172145;None;0;Human;Binding;Ki;=;1802,00;5,74;-34;5;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;556,3;9;1;7;5,17;COc1ccc(-c2c3n(c(=O)n(CCCCN4CCCC(c5c[nH]c6ccc(OC)cc56)C4)c2=O)CCCC3)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
CHEMBL4472043;172164;None;0;Human;Binding;Ki;=;6309,57;5,20;-1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;362,2;5;0;6;2,88;c1nc2c(s1)CCN(CCCCN1CCc3ncsc3CC1)CC2;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4472206;172176;None;0;Human;Binding;Kd;=;2,69;8,57;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;451,2;7;1;3;6,09;O=C(CCCN1CCC(O)(c2ccccc2-c2ccccc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4472206;172176;None;0;Human;Binding;Ki;=;2,46;8,61;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;451,2;7;1;3;6,09;O=C(CCCN1CCC(O)(c2ccccc2-c2ccccc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4472382;172189;None;0;Human;Binding;Kd;=;1,51;8,82;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;373,2;5;1;2;4,96;OC1(c2ccc(Cl)cc2)CCN(CC[C@H]2C[C@@H]2c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4472382;172189;None;0;Human;Binding;Ki;=;1,51;8,82;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;373,2;5;1;2;4,96;OC1(c2ccc(Cl)cc2)CCN(CC[C@H]2C[C@@H]2c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4472580;172206;None;0;Human;Binding;Ki;=;210,00;6,68;-3;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;467,3;11;2;6;3,51;C=C(C)CN(NC(=O)NCCCN1CCN(c2ccccc2OC)CC1)c1ccc(OC)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4472580;172206;None;0;Human;Binding;Ki;=;300,00;6,52;-3;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;467,3;11;2;6;3,51;C=C(C)CN(NC(=O)NCCCN1CCN(c2ccccc2OC)CC1)c1ccc(OC)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4472585;172207;None;0;Human;Binding;Kd;=;3,39;8,47;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;391,1;6;1;3;4,94;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccccc1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4472585;172207;None;0;Human;Binding;Ki;=;3,55;8,45;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;391,1;6;1;3;4,94;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccccc1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4473026;172237;None;0;Human;Binding;Ki;=;24,00;7,62;-1;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;445,2;8;0;5;3,35;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ccccc2F)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4473083;172242;None;0;Human;Binding;Ki;=;1234,00;5,91;-9;4;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;368,1;4;1;7;2,09;CN1CCN(c2nc(N)nc(COc3ccc(Cl)cc3Cl)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4473519;172280;None;0;Human;Binding;Ki;=;186,21;6,73;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;433,2;7;2;6;2,49;NC(=O)c1ccn(-c2cccc(OC(=O)NCCN3CCN(c4ccccc4)CC3)c2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4473519;172280;None;0;Human;Binding;Ki;=;186,00;6,73;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;433,2;7;2;6;2,49;NC(=O)c1ccn(-c2cccc(OC(=O)NCCN3CCN(c4ccccc4)CC3)c2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4474014;172323;None;0;Human;Binding;Ki;=;602,56;6,22;-14;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;339,2;4;0;3;3,54;Fc1ccc2c(c1)CC(CCN1CCCN(c3ccccn3)CC1)C2;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4474014;172323;None;0;Human;Binding;Ki;=;599,00;6,22;-14;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;339,2;4;0;3;3,54;Fc1ccc2c(c1)CC(CCN1CCCN(c3ccccn3)CC1)C2;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4474020;172324;None;0;Human;Binding;Kd;=;11,48;7,94;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;359,1;5;1;2;4,87;OC1(c2ccc(Cl)cc2)CCN(CC/C=C/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4474020;172324;None;0;Human;Binding;Ki;=;11,22;7,95;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;359,1;5;1;2;4,87;OC1(c2ccc(Cl)cc2)CCN(CC/C=C/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4474618;172373;None;0;Human;Binding;Ki;=;178,00;6,75;-12;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;362,2;7;3;4;4,47;COc1cccc2[nH]cc(CCNCc3ccc(-c4ccc(O)cc4)o3)c12;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL447476;172385;None;0;Human;Binding;Ki;=;130,00;6,89;-4;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;6;2;4;3,79;CNc1cc(OC)c(C(=O)N[C@H]2CCCN(Cc3ccccc3)C2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL447476;172385;None;0;Human;Binding;Ki;=;210,00;6,68;-4;4;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;387,2;6;2;4;3,79;CNc1cc(OC)c(C(=O)N[C@H]2CCCN(Cc3ccccc3)C2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL447476;172385;None;0;Human;Binding;Ki;=;250,00;6,60;-4;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;6;2;4;3,79;CNc1cc(OC)c(C(=O)N[C@H]2CCCN(Cc3ccccc3)C2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL447476;172385;None;0;Human;Binding;Ki;=;170,00;6,77;-4;4;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;387,2;6;2;4;3,79;CNc1cc(OC)c(C(=O)N[C@H]2CCCN(Cc3ccccc3)C2)cc1Cl;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CHEMBL4474827;172388;None;0;Human;Binding;Ki;=;5561,00;5,25;-933;4;Displacement of [3H]-raclopride from recombinant human D2LR receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;240,1;2;2;3;1,67;Cn1cncc1-c1c[nH]c2ccc(C(N)=O)cc12;https://dx.doi.org/10.1039/C8MD00313K
CHEMBL4475042;172401;None;0;Human;Binding;Ki;=;24,00;7,62;-1;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;541,2;10;2;5;5,43;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccc(Cl)cc2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4475042;172401;None;0;Human;Binding;Ki;=;35,00;7,46;-1;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;541,2;10;2;5;5,43;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccc(Cl)cc2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4475262;172416;None;0;Human;Binding;Ki;=;177,83;6,75;1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;386,2;6;0;6;3,11;COc1ccccc1N1CCN(CCCN2CCCc3ncsc3C2)CC1;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4475451;172429;None;0;Human;Binding;Kd;=;70,79;7,15;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;357,1;3;1;2;4,20;OC1(c2ccc(Cl)cc2)CCN(CCC#Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4475451;172429;None;0;Human;Binding;Ki;=;74,13;7,13;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;357,1;3;1;2;4,20;OC1(c2ccc(Cl)cc2)CCN(CCC#Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4475608;172443;None;0;Human;Binding;Kd;=;1,95;8,71;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;371,2;6;1;3;4,59;Cc1ccccc1C(=O)CCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4475608;172443;None;0;Human;Binding;Ki;=;3,55;8,45;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;371,2;6;1;3;4,59;Cc1ccccc1C(=O)CCCN1CCC(O)(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4475978;172462;None;0;Human;Binding;Ki;=;180,00;6,75;-3;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;453,3;11;2;6;3,12;C=CCN(NC(=O)NCCCN1CCN(c2ccccc2OC)CC1)c1ccc(OC)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4475978;172462;None;0;Human;Binding;Ki;=;340,00;6,47;-3;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;453,3;11;2;6;3,12;C=CCN(NC(=O)NCCCN1CCN(c2ccccc2OC)CC1)c1ccc(OC)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4476164;172474;None;0;Human;Binding;Ki;=;2349,00;5,63;-87;5;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;496,3;7;1;5;5,15;O=c1c(-c2ccccc2)c2n(c(=O)n1CCCCN1CCCC(c3c[nH]c4ccccc34)C1)CCCC2;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
CHEMBL4476278;172479;None;0;Human;Binding;Ki;=;730,00;6,14;-43;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,2;9;2;4;4,88;O=C(NCCCN1CCN(c2ccc(Br)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4476278;172479;None;0;Human;Binding;Ki;=;520,00;6,28;-43;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,2;9;2;4;4,88;O=C(NCCCN1CCN(c2ccc(Br)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4476372;172484;None;0;Human;Binding;Ki;=;9333,00;5,03;-177;4;Displacement of [3H] raclopride from human recombinant D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method;ChEMBL;263,1;2;1;2;3,84;CCn1cncc1-c1c[nH]c2ccc(Cl)c(F)c12;https://dx.doi.org/10.1016/j.ejmech.2019.03.017
CHEMBL4476394;172486;None;2;Human;Binding;Ki;=;11400,00;4,94;-1698;5;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;484,2;9;3;5;3,69;CCc1cc(Cl)c(OC)c(N2CCN(CC(O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4476394;172486;None;2;Human;Binding;Ki;=;13200,00;4,88;-1698;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;484,2;9;3;5;3,69;CCc1cc(Cl)c(OC)c(N2CCN(CC(O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4476432;172490;None;0;Human;Binding;Ki;=;27,00;7,57;1;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;485,3;10;0;5;5,22;CCOc1ccccc1N1CCN(CCCCCCN2C(=O)c3cccc4cccc(c34)C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4476605;172507;None;0;Human;Binding;Ki;=;261,00;6,58;-173;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;487,2;8;1;4;5,77;O=C(NCCCCN1CCN(c2ccccc2C(F)(F)F)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4476699;172515;None;0;Human;Binding;Ki;=;6,34;8,20;-40;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;439,2;8;1;4;4,98;CCc1cccc(N2CCN(CCCCNC(=O)c3cc4ccccc4o3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL447809;172538;None;0;Human;Binding;Ki;=;721,00;6,14;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;220,2;3;1;3;1,92;CCCN1CCN(c2cccc(O)c2)CC1;https://dx.doi.org/10.1021/jm901689v
CHEMBL447809;172538;None;0;Human;Binding;Ki;=;69,00;7,16;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;220,2;3;1;3;1,92;CCCN1CCN(c2cccc(O)c2)CC1;https://dx.doi.org/10.1021/jm901689v
CHEMBL447809;172538;UNDEFINED;0;Human;Binding;pKi;=;721,00;6,14;-;1;-;PDSP KiDatabase;220,2;3;1;3;1,92;CCCN1CCN(c2cccc(O)c2)CC1;-
CHEMBL447809;172538;UNDEFINED;0;Human;Binding;pKi;=;69,00;7,16;-;1;-;PDSP KiDatabase;220,2;3;1;3;1,92;CCCN1CCN(c2cccc(O)c2)CC1;-
CHEMBL447907;172548;UNDEFINED;0;Human;Binding;pKi;=;100,00;7,00;61;2;-;PDSP KiDatabase;409,2;8;1;7;2,56;COc1ccc(N2CCN(CCCCNC(=O)c3ccc4nonc4c3)CC2)cc1;-
CHEMBL4482896;172582;None;0;Human;Binding;Kd;=;141,25;6,85;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cc(F)ccc1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4482896;172582;None;0;Human;Binding;Ki;=;112,20;6,95;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cc(F)ccc1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4483304;172596;None;0;Human;Binding;Ki;=;3631,00;5,44;-213;3;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;408,1;5;2;5;3,92;CCC(=O)Nc1nc(C)c(-c2ccc3ccn(S(=O)(=O)c4ccccc4)c3c2)[nH]1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4483496;172615;None;0;Human;Binding;Ki;=;411,00;6,39;-2;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;397,2;4;0;4;3,11;O=S(=O)(c1ccccc1)N1CCc2ccc(N3CCN(C4CCC4)CC3)cc21;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4483554;172619;None;0;Human;Binding;Ki;=;16,00;7,80;-2;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;498,3;8;2;4;5,16;COc1ccc2[nH]cc(C3CC(=O)N(CCCCN4CCC(c5c[nH]c6ccccc56)CC4)C3=O)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
CHEMBL4483569;172623;None;0;Human;Binding;Ki;=;219,00;6,66;-245;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;454,2;8;3;4;3,69;CCc1cccc(N2CCN(C[C@@H](O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL448891;172688;None;26;Human;Binding;Ki;=;305,00;6,52;-5;5;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;341,2;3;1;5;3,07;COc1cc2c(cc1OC)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.12.016
CHEMBL448891;172688;None;26;Human;Binding;Ki;=;533,00;6,27;-5;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor after 1 hr;ChEMBL;341,2;3;1;5;3,07;COc1cc2c(cc1OC)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmcl.2017.01.090
CHEMBL449250;172721;None;0;Human;Binding;Ki;=;758,58;6,12;-38;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;274,2;3;1;3;1,88;CCCN1CCOC2c3cc(C(N)=O)ccc3CCC21;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL449920;172772;None;3;Human;Binding;Ki;=;6400,00;5,19;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;234,2;4;0;3;2,23;CCCN1CCN(c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL449920;172772;None;3;Human;Binding;Ki;=;6309,57;5,20;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;234,2;4;0;3;2,23;CCCN1CCN(c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL450021;172783;None;0;Human;Binding;Ki;=;110,00;6,96;-9;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;377,2;5;1;5;4,41;COc1ccc(-c2nc(O)n(C3CCN(Cc4ccccc4)CC3)c2C)cc1;https://dx.doi.org/10.1021/jm991029k
CHEMBL451149;172867;None;3;Human;Binding;Ki;=;300,00;6,52;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;234,2;4;0;3;2,23;CCCN1CCN(c2cccc(OC)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL451149;172867;None;3;Human;Binding;Ki;=;316,23;6,50;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;234,2;4;0;3;2,23;CCCN1CCN(c2cccc(OC)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL4513262;172882;None;0;Human;Binding;IC50;=;1949,84;5,71;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1ccc(Br)c3c1[C@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4513262;172882;None;0;Human;Binding;IC50;=;1957,00;5,71;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1ccc(Br)c3c1[C@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4514517;172944;None;20;Human;Binding;Kd;=;10,23;7,99;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccccc1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4514517;172944;None;20;Human;Binding;Ki;=;7,94;8,10;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccccc1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4515075;172962;None;0;Human;Binding;Ki;=;520,00;6,28;-27;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;364,1;4;1;7;2,71;CC(Sc1ccccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4515160;172965;None;0;Human;Binding;Ki;=;19,00;7,72;-2;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;504,2;7;2;3;5,43;O=C1CC(c2c[nH]c3ccc(F)cc23)C(=O)N1CCCCN1CCC(c2c[nH]c3ccc(F)cc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
CHEMBL4515234;172970;None;0;Human;Binding;Ki;=;247,00;6,61;-323;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;456,2;8;2;3;4,66;CCc1cccc(N2CCN(CC(F)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4515776;172995;None;0;Human;Binding;IC50;=;15,00;7,82;-;1;Antagonist activity at human dopamine D2 receptor expressed in CHO cells co-expressing A2A receptor assessed as reduction in sumanirole-induced response after 90 mins by DMR analysis;ChEMBL;1657,8;50;6;21;6,80;COC(=O)CN(CC(=O)NCCOCCOCCNC(=O)CCC(=O)Nc1ccc(CCN2CN(c3ccccc3)C3(CCN(CCCC(=O)c4ccc(F)cc4)CC3)C2=O)cc1)CC(=O)NCCOCCOCCNC(=O)CCC(=O)Nc1ccc(CCN2CN(c3ccccc3)C3(CCN(CCCC(=O)c4ccc(F)cc4)CC3)C2=O)cc1;https://dx.doi.org/10.1021/acs.jmedchem.8b01249
CHEMBL4516799;173040;None;0;Human;Binding;Ki;=;150,00;6,82;-13;3;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;419,2;8;3;5;2,24;CCc1cccc(N2CCN(CC(O)CCNC(=O)c3nc(C)c[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4517102;173053;None;0;Human;Binding;Ki;=;164,00;6,79;-165;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;455,2;8;2;5;3,95;CCc1cccc(N2CCN(CC(O)CCNC(=O)c3cc4ccccc4o3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4517296;173057;None;0;Human;Binding;Ki;=;56,00;7,25;1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;447,2;7;2;6;2,70;Cn1c(C(N)=O)ccc1-c1cccc(OC(=O)NCCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4517296;173057;None;0;Human;Binding;Ki;=;56,23;7,25;1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;447,2;7;2;6;2,70;Cn1c(C(N)=O)ccc1-c1cccc(OC(=O)NCCN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4517898;173084;None;0;Human;Binding;Ki;=;193,00;6,71;-45;2;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;455,2;8;2;6;2,85;CCc1cccc(N2CCN(CC(O)CCNC(=O)c3cn4ccccc4n3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4518618;173126;None;0;Human;Binding;Ki;=;424,00;6,37;-141;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;459,2;8;2;6;2,93;CCc1cccc(N2CCN(CC(O)CCNC(=O)c3ccc4c(c3)OCO4)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4519004;173141;None;0;Human;Binding;Ki;=;2138,00;5,67;-25;3;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;486,2;8;2;6;5,24;COc1ccc2c(c1)c(-c1[nH]c(NCCc3ccccc3)nc1C)cn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4519136;173147;None;0;Human;Binding;EC50;=;330,00;6,48;-;2;Agonist activity at D2 receptor (unknown origin);ChEMBL;502,1;4;0;4;5,46;Clc1ccc(Br)c(CN2CCN([C@@H]3CC[C@@]4(c5ccc6c(c5)OCO6)C[C@H]4C3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.8b01767
CHEMBL4519266;173152;None;0;Human;Binding;Ki;=;1365,00;5,87;-38;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;376,2;8;2;4;4,78;COc1ccc(-c2ccc(CNCCc3c[nH]c4ccc(OC)cc34)o2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4519420;173161;None;0;Human;Binding;Kd;=;21,88;7,66;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,2;7;1;2;5,18;OC1(c2ccc(Cl)cc2)CCN(CCCCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4519420;173161;None;0;Human;Binding;Ki;=;21,88;7,66;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,2;7;1;2;5,18;OC1(c2ccc(Cl)cc2)CCN(CCCCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4519916;173186;None;0;Human;Binding;Ki;=;245,00;6,61;-10;2;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;385,2;5;0;4;2,97;CCCN1CCN(c2ccc3c(c2)CCN3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4520003;173193;None;0;Human;Binding;Ki;=;1175,00;5,93;-56;3;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;472,2;7;2;6;5,20;COc1ccc2c(c1)c(-c1[nH]c(NCc3ccccc3)nc1C)cn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4520460;173212;None;0;Human;Binding;Ki;=;120,00;6,92;-10;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;516,3;10;2;6;4,14;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(C#N)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4520460;173212;None;0;Human;Binding;Ki;=;210,00;6,68;-10;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;516,3;10;2;6;4,14;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(C#N)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4520580;173217;None;0;Human;Binding;Ki;=;1592,00;5,80;-331;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;397,2;4;0;4;3,07;O=S(=O)(c1ccccc1)N1Cc2cccc(N3CCN(C4CCC4)CC3)c2C1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4520796;173228;None;0;Human;Binding;Ki;=;1094,00;5,96;-100;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;356,2;5;1;7;2,22;Cc1ccc(C(C)C)c(OCc2nc(N)nc(N3CCN(C)CC3)n2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4520796;173228;None;0;Human;Binding;Ki;=;1090,00;5,96;-100;5;Displacement of [3H]-Raclopride from human dopamine D2 receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;356,2;5;1;7;2,22;Cc1ccc(C(C)C)c(OCc2nc(N)nc(N3CCN(C)CC3)n2)c1;https://dx.doi.org/10.1016/j.ejmech.2022.114645
CHEMBL4521477;173255;None;0;Human;Binding;Ki;=;257,00;6,59;-1;3;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;278,1;3;1;2;4,05;C1=C(c2c[nH]c3ccccc23)CCN(Cc2ccco2)C1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4521947;173274;None;0;Human;Binding;Ki;=;27,80;7,56;-81;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;468,2;9;2;4;4,72;CCc1cc(Cl)c(OC)c(N2CCN(CCCCNC(=O)c3cc4ccccc4[nH]3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4522568;173298;None;0;Human;Binding;Ki;=;566,00;6,25;-4;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;348,1;4;1;7;2,00;CC(Oc1cccc(Cl)c1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4523054;173325;None;0;Human;Binding;EC50;=;1819,70;5,74;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;365,2;2;0;5;3,60;CC(=O)Oc1c(C)cc2c(c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4523054;173325;None;0;Human;Binding;EC50;=;1812,00;5,74;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;365,2;2;0;5;3,60;CC(=O)Oc1c(C)cc2c(c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4524981;173367;None;0;Human;Binding;Ki;=;674,00;6,17;-4;4;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;334,1;4;1;7;1,44;CN1CCN(c2nc(N)nc(COc3cccc(Cl)c3)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4525992;173402;None;0;Human;Binding;Ki;=;355,00;6,45;-1;4;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;397,2;4;0;4;3,11;O=S(=O)(c1ccccc1)N1CCc2c(N3CCN(C4CCC4)CC3)cccc21;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4526012;173403;None;0;Human;Binding;Ki;=;1862,00;5,73;-64;5;Displacement of [3H] raclopride from human recombinant D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method;ChEMBL;275;1;1;2;3,33;Cn1cncc1-c1c[nH]c2ccc(Br)cc12;https://dx.doi.org/10.1016/j.ejmech.2019.03.017
CHEMBL4527078;173453;None;0;Human;Binding;Ki;=;18900,00;4,72;-537;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;486,2;9;2;4;4,67;CCc1cc(Cl)c(OC)c(N2CCN(C[C@@H](F)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4527124;173457;None;0;Human;Binding;Ki;=;1224,00;5,91;-6;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;348,1;4;1;7;1,75;Cc1cc(OCc2nc(N)nc(N3CCN(C)CC3)n2)ccc1Cl;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4527257;173463;None;0;Human;Binding;Ki;=;166,00;6,78;-1;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;338,1;5;1;3;4,92;CCOc1ccc2[nH]cc(C3=CCN(Cc4cccs4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4528835;173536;None;0;Human;Binding;Kd;=;0,14;9,84;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;371,1;6;0;2;5,11;O=C(CCCN1CCC2(c3ccc(Cl)cc3)CC2C1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4528835;173536;None;0;Human;Binding;Ki;=;0,16;9,80;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;371,1;6;0;2;5,11;O=C(CCCN1CCC2(c3ccc(Cl)cc3)CC2C1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4529368;173556;None;0;Human;Binding;Kd;=;1,05;8,98;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2cc(Cl)ccc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4529368;173556;None;0;Human;Binding;Ki;=;1,02;8,99;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2cc(Cl)ccc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4532712;173675;None;0;Human;Binding;Ki;=;740,00;6,13;-3;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;314,2;4;1;7;1,09;Cc1cccc(OCc2nc(N)nc(N3CCN(C)CC3)n2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4532741;173676;None;0;Human;Binding;Ki;=;271,00;6,57;-5;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;471,3;9;0;5;4,83;COc1cccc(N2CCN(CCCCCCN3C(=O)c4cccc5cccc(c45)C3=O)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4533305;173699;None;0;Human;Binding;Ki;=;199,53;6,70;-154;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;341,2;6;0;4;3,40;O=C(CCCN1CCCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4533305;173699;None;0;Human;Binding;Ki;=;181,00;6,74;-154;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;341,2;6;0;4;3,40;O=C(CCCN1CCCN(c2ccccn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4534566;173761;None;0;Human;Binding;Ki;=;20800,00;4,68;-741;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;486,2;9;2;4;4,67;CCc1cc(Cl)c(OC)c(N2CCN(CC(F)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4534703;173765;None;0;Human;Binding;Ki;=;110,00;6,96;-3;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;399,2;7;1;5;3,84;COc1ccccc1N1CCN(CCCNC(=O)/N=N/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4534703;173765;None;0;Human;Binding;Ki;=;51,00;7,29;-3;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;399,2;7;1;5;3,84;COc1ccccc1N1CCN(CCCNC(=O)/N=N/c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4534733;173767;None;0;Human;Binding;Ki;=;211,00;6,68;-25;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;357,2;3;0;4;2,19;CN1CCN(c2cccc3c2CCN3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4535174;173788;None;0;Human;Binding;Ki;=;63,10;7,20;-70;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;487,1;8;1;4;6,05;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4536315;173832;None;0;Human;Binding;Ki;=;167,00;6,78;-7;4;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;376,2;7;3;4;4,78;COc1ccc2[nH]c(C)c(CCNCc3ccc(-c4ccc(O)cc4)o3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4536530;173844;None;0;Human;Binding;Ki;=;430,00;6,37;-14;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;507,2;8;2;4;4,49;O=C(NCCN1CCN(c2ccc(Br)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4536530;173844;None;0;Human;Binding;Ki;=;390,00;6,41;-14;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;507,2;8;2;4;4,49;O=C(NCCN1CCN(c2ccc(Br)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4536834;173854;None;0;Human;Binding;Ki;=;324,00;6,49;-12;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;384,2;5;0;3;4,03;CCCN1CCC(c2ccc3c(c2)N(S(=O)(=O)c2ccccc2)CC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4537230;173876;None;0;Human;Binding;Kd;=;30,90;7,51;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;373,2;5;1;2;4,96;OC1(c2ccc(Cl)cc2)CCN(CC[C@H]2C[C@H]2c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4537230;173876;None;0;Human;Binding;Ki;=;29,51;7,53;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;373,2;5;1;2;4,96;OC1(c2ccc(Cl)cc2)CCN(CC[C@H]2C[C@H]2c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4537294;173879;None;0;Human;Binding;Ki;=;180,00;6,75;-38;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;385,2;5;0;4;2,92;CCCN1CCN(c2cccc3c2CN(S(=O)(=O)c2ccccc2)C3)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4538667;173933;None;0;Human;Binding;Ki;=;2,00;8,70;9;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;448,3;9;0;6;4,14;COc1ccccc1N1CCN(CCCCCCn2c(=O)n3c4c(cccc42)CCC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4540218;174008;None;0;Human;Binding;Ki;=;29,00;7,54;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;462,2;8;2;6;3,65;Cc1cc(C(N)=O)c(-c2cccc(OC(=O)NCCCN3CCN(c4ccccc4)CC3)c2)o1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4540218;174008;None;0;Human;Binding;Ki;=;29,51;7,53;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;462,2;8;2;6;3,65;Cc1cc(C(N)=O)c(-c2cccc(OC(=O)NCCCN3CCN(c4ccccc4)CC3)c2)o1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4540404;174017;None;0;Human;Binding;Ki;=;48,00;7,32;-2;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;427,2;8;0;5;3,21;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4540679;174025;None;0;Human;Binding;Kd;=;3,24;8,49;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccccc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4540679;174025;None;0;Human;Binding;Ki;=;2,14;8,67;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccccc2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4541515;174064;None;0;Human;Binding;Ki;=;2,20;8,66;-;1;Binding affinity to human D2R;ChEMBL;1243,6;35;7;10;12,43;CCCN(CCc1ccc(NC(=O)CCC(=O)NCCCCCC(=O)NCc2ccc(C(=O)NCCCCCC(=O)NCCCCCCNC(=O)c3nn(-c4ccc(Cl)cc4Cl)c(-c4ccc(Cl)cc4)c3C)cc2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmcl.2019.126644
CHEMBL4542754;174115;None;0;Human;Binding;Ki;=;114,00;6,94;-2;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;443,3;9;0;4;5,19;COc1cccc(N2CCN(CCCCCCN3C(=O)c4cccc5cccc3c45)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4542935;174122;None;0;Human;Binding;IC50;=;280,00;6,55;-;1;Antagonist activity at human dopamine D2 receptor expressed in CHO cells co-expressing A2A receptor assessed as reduction in sumanirole-induced response after 90 mins by DMR analysis;ChEMBL;1103,6;37;5;16;1,92;COC(=O)CN(CC(=O)NCCOCCOCCNC(C)=O)CC(=O)NCCOCCOCCNC(=O)CCC(=O)Nc1ccc(CCN2CN(c3ccccc3)C3(CCN(CCCC(=O)c4ccc(F)cc4)CC3)C2=O)cc1;https://dx.doi.org/10.1021/acs.jmedchem.8b01249
CHEMBL4543263;174131;None;0;Human;Binding;Ki;=;142,00;6,85;1;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;308,2;4;1;3;4,06;COc1ccc2[nH]cc(C3=CCN(Cc4ccco4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4543524;174139;None;0;Human;Binding;Ki;=;12,50;7,90;-10;3;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;417,2;9;2;4;3,52;CCc1c[nH]c(C(=O)NCCCCN2CCN(c3cccc(CC)c3Cl)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4543685;174148;None;0;Human;Binding;Ki;=;233,00;6,63;-13;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;268,1;3;0;3;2,66;CCc1cc(Cl)c(OC)c(N2CCN(C)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4544086;174165;None;0;Human;Binding;Ki;=;140,00;6,85;-229;16;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;491,3;10;2;5;4,27;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(F)cc2)c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4544086;174165;None;0;Human;Binding;Ki;=;110,00;6,96;-229;16;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;491,3;10;2;5;4,27;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(F)cc2)c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4544491;174186;None;0;Human;Binding;Kd;=;0,14;9,84;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2ccc(Cl)c(Cl)c2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4544491;174186;None;0;Human;Binding;Ki;=;0,15;9,81;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2ccc(Cl)c(Cl)c2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4544583;174191;None;0;Human;Binding;Ki;=;5,50;8,26;-38;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;438,2;8;2;3;4,72;CCc1cccc(N2CCN(CCCCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4545775;174224;None;0;Human;Binding;Ki;=;24994,00;4,60;-691;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;433,2;8;1;4;5,06;Cc1ccc(N2CCN(CCCCNC(=O)c3ccc(-c4ccsc4)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4546210;174239;None;0;Human;Binding;Ki;=;10800,00;4,97;-107;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;487,2;9;1;5;4,94;CCc1cc(Cl)c(OC)c(N2CCN(CC(F)CCNC(=O)c3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4546839;174264;None;0;Human;Binding;Ki;=;1,10;8,96;-;1;Binding affinity to human D2R;ChEMBL;1514,7;50;10;17;8,03;CCCN(CCc1ccc(NC(=O)CCC(=O)NCCOCCOCC(=O)NCCOCCOCC(=O)NCCCC[C@H](NC(C)=O)C(=O)NCCCC[C@H](NC(C)=O)C(=O)NCCCCCCNC(=O)c2nn(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)c2C)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmcl.2019.126644
CHEMBL4548041;174305;None;0;Human;Binding;Ki;=;2362,00;5,63;-18;4;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;334,1;4;1;7;1,44;CN1CCN(c2nc(N)nc(COc3ccccc3Cl)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4548632;174327;None;0;Human;Binding;Ki;=;165,00;6,78;2;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;376,2;6;1;3;5,25;COc1ccc(CN2CC=C(c3c[nH]c4ccc(OC(C)C)cc34)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL45491;174361;None;9;Human;Binding;Ki;=;200,00;6,70;-4;3;The compound was tested for binding affinity against dopamine receptor D2 using raclopride as radioligand;ChEMBL;337,2;1;0;1;5,00;CN(C)C1C=CC2(CC1)c1ccccc1CCc1ccc(Cl)cc12;https://dx.doi.org/10.1021/jm00109a026
CHEMBL45491;174361;None;9;Human;Binding;Ki;=;2,00;8,70;-4;3;The compound was tested for binding affinity against dopamine receptor D2 using raclopride as radioligand;ChEMBL;337,2;1;0;1;5,00;CN(C)C1C=CC2(CC1)c1ccccc1CCc1ccc(Cl)cc12;https://dx.doi.org/10.1021/jm00109a026
CHEMBL4549734;174386;None;0;Human;Binding;Ki;=;310,00;6,51;-10;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;371,2;4;0;4;2,53;CCN1CCN(c2cccc3c2CN(S(=O)(=O)c2ccccc2)C3)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4550561;174424;None;0;Human;Binding;Ki;=;1826,00;5,74;-43;2;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;396,2;4;0;3;4,12;O=S(=O)(c1ccccc1)N1Cc2cccc(C3CCN(C4CCC4)CC3)c2C1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4550633;174429;None;0;Human;Binding;Ki;=;62,00;7,21;-14;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,3;11;2;6;4,28;COc1cccc(CN(NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c2ccc(F)cc2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4550633;174429;None;0;Human;Binding;Ki;=;110,00;6,96;-14;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,3;11;2;6;4,28;COc1cccc(CN(NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c2ccc(F)cc2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4550815;174436;None;0;Human;Binding;EC50;=;2140,00;5,67;-;1;Antagonist activity at dopamine D2long receptor (unknown origin) assessed as inhibition of agonist-induced beta-arrestin recruitment;ChEMBL;331,1;6;0;3;4,26;CC1(Oc2ccc(Cl)cc2)CCN(CCOc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.8b00435
CHEMBL4551160;174451;None;0;Human;Binding;Ki;=;1610,00;5,79;-120;5;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;433,2;7;3;5;3,36;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1C[C@H]1C[C@@H]1CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL4551160;174451;None;0;Human;Binding;Ki;=;87,80;7,06;-120;5;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;433,2;7;3;5;3,36;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1C[C@H]1C[C@@H]1CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL4551220;174453;None;0;Human;Binding;Ki;=;136,00;6,87;-8;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;371,2;4;0;4;2,58;CCN1CCN(c2ccc3c(c2)N(S(=O)(=O)c2ccccc2)CC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4552041;174486;None;0;Human;Binding;Ki;=;368,00;6,43;-6;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;330,2;6;1;2;5,10;CN(CCc1c[nH]c2ccccc12)Cc1ccc(-c2ccccc2)o1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4552542;174511;None;0;Human;Binding;Ki;=;26,90;7,57;7;3;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;318,2;4;1;2;4,47;COc1cccc(CN2CC=C(c3c[nH]c4ccccc34)CC2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL455288;174525;None;0;Human;Binding;Ki;=;47,00;7,33;-1122;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;682,3;13;0;8;7,43;O=C(OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1)c1ccc(OCCCN2CCCCC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
CHEMBL455288;174525;UNDEFINED;0;Human;Binding;pKi;=;47,00;7,33;-1122;6;-;PDSP KiDatabase;682,3;13;0;8;7,43;O=C(OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1)c1ccc(OCCCN2CCCCC2)cc1;-
CHEMBL4552939;174530;None;0;Human;Binding;Ki;=;6,83;8,17;-33;3;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;454,2;8;3;4;3,69;CCc1cccc(N2CCN(CCC(O)CNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4553059;174532;None;0;Human;Binding;Ki;=;328,00;6,48;-134;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;457,2;8;1;4;4,93;CCc1cccc(N2CCN(CC(F)CCNC(=O)c3cc4ccccc4o3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4554053;174567;None;0;Human;Binding;Ki;=;66,00;7,18;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;447,2;8;2;6;2,88;NC(=O)c1ccn(-c2cccc(OC(=O)NCCCN3CCN(c4ccccc4)CC3)c2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4554053;174567;None;0;Human;Binding;Ki;=;66,07;7,18;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;447,2;8;2;6;2,88;NC(=O)c1ccn(-c2cccc(OC(=O)NCCCN3CCN(c4ccccc4)CC3)c2)c1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4554558;174593;None;0;Human;Binding;Ki;=;71,90;7,14;2;3;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;294,1;3;1;2;4,52;C1=C(c2c[nH]c3ccccc23)CCN(Cc2cccs2)C1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4555307;174620;None;0;Human;Binding;Ki;=;5,64;8,25;-16;3;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;439,2;8;1;5;3,88;CCc1cccc(N2CCN(CCCCNC(=O)c3cn4ccccc4n3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4555349;174623;None;0;Human;Binding;Ki;=;3020,00;5,52;-83;5;Displacement of [3H] raclopride from human recombinant D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method;ChEMBL;355;2;1;2;3,79;CCn1cncc1-c1c[nH]c2c(F)cc(I)cc12;https://dx.doi.org/10.1016/j.ejmech.2019.03.017
CHEMBL4555547;174631;None;2;Human;Binding;EC50;=;6,31;8,20;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;379,2;4;0;5;4,07;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(OC(C)=O)c(OC(C)=O)c1-3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4555547;174631;None;2;Human;Binding;EC50;=;6,34;8,20;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;379,2;4;0;5;4,07;CCCN1CCc2cccc3c2[C@H]1Cc1ccc(OC(C)=O)c(OC(C)=O)c1-3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4555827;174636;None;1;Human;Binding;Ki;=;10800,00;4,97;-1445;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;484,2;9;3;5;3,69;CCc1cc(Cl)c(OC)c(N2CCN(C[C@H](O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4555890;174641;None;0;Human;Binding;Ki;=;30,00;7,52;1;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;493,2;10;0;5;5,13;CCOc1ccccc1N1CCN(CCCCCCN2c3cccc4cccc(c34)S2(=O)=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4556173;174653;None;0;Human;Binding;Kd;=;18,62;7,73;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(F)cc2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4556173;174653;None;0;Human;Binding;Ki;=;17,78;7,75;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(F)cc2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4557247;174705;None;0;Human;Binding;Ki;=;734,00;6,13;-28;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;316,1;4;1;7;1,50;CN1CCN(c2nc(N)nc(CSc3ccccc3)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4558031;174740;None;0;Human;Binding;Ki;=;363,08;6,44;-27;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;387,2;4;0;4;3,83;O=C1c2ccc(F)cc2CC1CCN1CCCN(c2ccc(Cl)cn2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4558031;174740;None;0;Human;Binding;Ki;=;364,00;6,44;-27;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;387,2;4;0;4;3,83;O=C1c2ccc(F)cc2CC1CCN1CCCN(c2ccc(Cl)cn2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4558444;174756;None;0;Human;Binding;Ki;=;465,00;6,33;-2;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;352,2;5;1;3;5,31;CC(C)Oc1ccc2[nH]cc(C3=CCN(Cc4cccs4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4559278;174789;None;0;Human;Binding;Ki;=;323,59;6,49;-81;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting;ChEMBL;419,2;9;1;5;4,02;COc1ccccc1OCCNCC1OCCOC1(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2019.02.056
CHEMBL4560883;174859;None;0;Human;Binding;Ki;=;4369,00;5,36;-4;4;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;348,1;4;1;7;1,75;Cc1cc(Cl)ccc1OCc1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL456232;174914;None;0;Human;Binding;Ki;=;89,40;7,05;11;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;395,2;7;1;7;2,17;COc1ccccc1N1CCN(CCCNC(=O)c2ccc3nonc3c2)CC1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL456232;174914;UNDEFINED;0;Human;Binding;pKi;=;89,40;7,05;11;2;-;PDSP KiDatabase;395,2;7;1;7;2,17;COc1ccccc1N1CCN(CCCNC(=O)c2ccc3nonc3c2)CC1;-
CHEMBL456233;174915;None;0;Human;Binding;Ki;=;5,92;8,23;-1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;465,3;11;1;6;3,55;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc(-n2ccnc2)cc1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL456233;174915;UNDEFINED;0;Human;Binding;pKi;=;5,92;8,23;-1;2;-;PDSP KiDatabase;465,3;11;1;6;3,55;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc(-n2ccnc2)cc1;-
CHEMBL4562787;174942;None;0;Human;Binding;Ki;=;438,00;6,36;-9;4;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;371,2;4;0;4;2,58;CCN1CCN(c2ccc3c(c2)CCN3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4563944;174988;None;0;Human;Binding;Ki;=;4,30;8,37;-9;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;491,3;10;2;5;4,27;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4563944;174988;None;0;Human;Binding;Ki;=;6,60;8,18;-9;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;491,3;10;2;5;4,27;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4564093;174993;None;0;Human;Binding;Ki;=;1302,00;5,88;-7;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;442,2;8;0;5;4,21;O=C1c2cccc3cccc(c23)C(=O)N1CCCCCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4564103;174995;None;0;Human;Binding;IC50;=;337,50;6,47;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1c(Br)ccc3c1[C@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4564103;174995;None;0;Human;Binding;IC50;=;316,23;6,50;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1c(Br)ccc3c1[C@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL456429;175002;None;0;Human;Binding;Ki;=;1231,00;5,91;-1;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;373,1;4;1;3;4,18;O=C(CN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL456429;175002;None;0;Human;Binding;Ki;=;1231,00;5,91;-1;3;Binding affinity for dopamine D2 receptor;ChEMBL;373,1;4;1;3;4,18;O=C(CN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.09.046
CHEMBL456429;175002;UNDEFINED;0;Human;Binding;pKi;=;1231,00;5,91;-1;3;-;PDSP KiDatabase;373,1;4;1;3;4,18;O=C(CN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;-
CHEMBL456430;175003;None;0;Human;Binding;Ki;=;1050,00;5,98;-6;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;345,1;3;1;2;4,49;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2Cc1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL456430;175003;None;0;Human;Binding;Ki;=;1050,00;5,98;-6;3;Binding affinity for dopamine D2 receptor;ChEMBL;345,1;3;1;2;4,49;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2Cc1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.09.046
CHEMBL456430;175003;UNDEFINED;0;Human;Binding;pKi;=;1050,00;5,98;-6;3;-;PDSP KiDatabase;345,1;3;1;2;4,49;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2Cc1ccc(F)cc1;-
CHEMBL4564507;175012;None;0;Human;Binding;Ki;=;16,10;7,79;-12;3;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;401,2;7;2;4;3,04;CCc1cccc(N2CCN(C/C=C/CNC(=O)c3nc(C)c[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4565126;175030;None;15;Human;Binding;Ki;=;87,30;7,06;2;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;318,2;4;1;2;4,47;COc1ccc(CN2CC=C(c3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4565200;175036;None;0;Human;Binding;Ki;=;214,00;6,67;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;464,2;7;2;6;3,73;Cc1cc(C(N)=O)c(-c2cccc(OC(=O)NCCN3CCN(c4ccccc4)CC3)c2)s1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4565200;175036;None;0;Human;Binding;Ki;=;213,80;6,67;-1;2;Displacement of [3H]-spiperone from human D2 receptor expressed in CHO cells co-expressing Galpha16 incubated for 120 mins by liquid scintillation counting method;ChEMBL;464,2;7;2;6;3,73;Cc1cc(C(N)=O)c(-c2cccc(OC(=O)NCCN3CCN(c4ccccc4)CC3)c2)s1;https://dx.doi.org/10.1016/j.ejmech.2019.111674
CHEMBL4565558;175052;None;0;Human;Binding;Ki;=;61,00;7,21;3;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;457,2;9;0;6;3,22;COc1ccccc1N1CCN(CCCCCCN2C(=O)c3ccccc3S2(=O)=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4565558;175052;None;0;Human;Binding;Ki;=;1,00;9,00;3;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;457,2;9;0;6;3,22;COc1ccccc1N1CCN(CCCCCCN2C(=O)c3ccccc3S2(=O)=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4565997;175070;None;0;Human;Binding;Ki;=;4753,00;5,32;-354;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;435,2;8;2;5;4,45;O=C(NCCCCN1CCN(c2ccc(O)cc2)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4566363;175084;None;0;Human;Binding;Ki;=;1042,00;5,98;-4;2;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;396,2;4;0;3;4,17;O=S(=O)(c1ccccc1)N1CCc2c(C3CCN(C4CCC4)CC3)cccc21;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL456647;175089;None;0;Human;Binding;Ki;=;6300,00;5,20;1;2;Displacement of [3H]spiroperidol from human cloned dopaminergic D2 receptor expressed in rat C6 cells;ChEMBL;460,3;11;0;5;5,08;COc1cccc(CCc2ccccc2OCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm800928j
CHEMBL456647;175089;UNDEFINED;0;Human;Binding;pKi;=;6300,00;5,20;1;2;-;PDSP KiDatabase;460,3;11;0;5;5,08;COc1cccc(CCc2ccccc2OCCCN2CCN(c3ccccc3OC)CC2)c1;-
CHEMBL456675;175105;None;0;Human;Binding;Ki;=;20000,00;4,70;-1;2;Displacement of [3H]spiroperidol from human cloned dopaminergic D2 receptor expressed in rat C6 cells;ChEMBL;432,3;10;0;6;3,86;COc1cccc(CCc2ccccc2OCCCN2CCN(c3ncccn3)CC2)c1;https://dx.doi.org/10.1021/jm800928j
CHEMBL456675;175105;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1;2;-;PDSP KiDatabase;432,3;10;0;6;3,86;COc1cccc(CCc2ccccc2OCCCN2CCN(c3ncccn3)CC2)c1;-
CHEMBL4566992;175114;None;0;Human;Binding;Ki;=;84,00;7,08;-2;4;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;371,2;4;0;4;2,58;CCN1CCN(c2cccc3c2CCN3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4567758;175151;None;0;Human;Binding;Ki;=;310,00;6,51;-19;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;463,3;9;2;6;3,05;O=C(NCCCN1CCN(c2ncccn2)CC1)NN(Cc1ccc(F)cc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4567758;175151;None;0;Human;Binding;Ki;=;430,00;6,37;-19;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;463,3;9;2;6;3,05;O=C(NCCCN1CCN(c2ncccn2)CC1)NN(Cc1ccc(F)cc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4567895;175159;None;0;Human;Binding;Ki;=;38,60;7,41;-194;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;449,2;9;1;5;4,76;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccsc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL456825;175175;None;0;Human;Binding;Ki;=;40,60;7,39;-22;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)[C@@H]1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL4568709;175193;None;0;Human;Binding;Kd;=;7,59;8,12;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;384,2;7;1;4;3,84;CN(C)c1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4568709;175193;None;0;Human;Binding;Ki;=;5,25;8,28;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;384,2;7;1;4;3,84;CN(C)c1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4569757;175236;None;0;Human;Binding;Ki;=;132,00;6,88;-2;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;495,1;8;0;5;4,52;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL4570073;175257;None;0;Human;Binding;Ki;=;26,00;7,58;-12;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;525,2;10;2;5;4,92;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2F)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4570073;175257;None;0;Human;Binding;Ki;=;41,00;7,39;-12;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;525,2;10;2;5;4,92;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccccc2F)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4570209;175265;None;0;Human;Binding;Ki;=;11160,00;4,95;-181;5;Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis;ChEMBL;552,3;9;1;7;5,29;COc1ccc(-c2c(=O)n(CCCCN3CCCC(c4c[nH]c5ccc(OC)cc45)C3)c(=O)n3ccccc23)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.01.031
CHEMBL457024;175266;None;0;Human;Binding;Ki;=;26,00;7,58;-31;4;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL457025;175267;None;0;Human;Binding;Ki;=;26,00;7,58;-31;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;393,3;7;1;4;3,78;CCCN(CCN1CCN(c2ccccc2)CC1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL4570273;175271;None;0;Human;Binding;Kd;=;0,14;9,84;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2cccc(Cl)c2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4570273;175271;None;0;Human;Binding;Ki;=;0,12;9,92;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;409,1;6;1;3;5,08;O=C(CCCN1CCC(O)(c2cccc(Cl)c2Cl)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4570411;175276;None;0;Human;Binding;Ki;=;649,00;6,19;-11;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;353,2;4;0;4;3,18;O=C1c2ccc(F)cc2CC1CCN1CCCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4570411;175276;None;0;Human;Binding;Ki;=;645,65;6,19;-11;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;353,2;4;0;4;3,18;O=C1c2ccc(F)cc2CC1CCN1CCCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4570430;175278;None;0;Human;Binding;Ki;=;1832,00;5,74;-102;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;449,2;9;1;5;4,76;COc1cccc(N2CCN(CCCCNC(=O)c3ccc(-c4ccsc4)cc3)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4570554;175285;None;0;Human;Binding;Ki;=;13500,00;4,87;-354;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;484,2;9;3;5;3,69;CCc1cc(Cl)c(OC)c(N2CCN(C[C@@H](O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4570584;175287;None;0;Human;Binding;Ki;=;4247,00;5,37;-48;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;314,2;4;1;7;1,09;Cc1ccccc1OCc1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4570930;175299;None;0;Human;Binding;Ki;=;64,57;7,19;2;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;386,2;6;0;6;2,77;COc1ccccc1N1CCN(CCCN2CCc3ncsc3CC2)CC1;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4571077;175310;None;0;Human;Binding;Ki;=;118,00;6,93;-3;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;450,2;8;0;5;4,13;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4571321;175316;None;0;Human;Binding;Ki;=;62,00;7,21;-12;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;516,3;8;2;4;5,30;COc1ccc2[nH]cc(C3CC(=O)N(CCCCN4CCC(c5c[nH]c6ccc(F)cc56)CC4)C3=O)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
CHEMBL4571568;175331;None;0;Human;Binding;Ki;=;92,90;7,03;-371;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;444,2;8;1;5;4,62;N#Cc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccsc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4571862;175341;None;0;Human;Binding;Ki;=;190,00;6,72;-14;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;486,2;7;2;3;5,29;O=C1CC(c2c[nH]c3ccc(F)cc23)C(=O)N1CCCCN1CCC(c2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
CHEMBL4572158;175350;None;0;Human;Binding;Ki;=;1168,00;5,93;-131;5;Displacement of [3H]-Raclopride from human D2L receptor expressed in HEK293 cells by microbeta liquid scintillation counting;ChEMBL;423,1;3;1;5;4,46;O=S(=O)(c1ccc2cccnc2c1)n1cc(C2=CCNCC2)c2cc(Cl)ccc21;https://dx.doi.org/10.1021/acsmedchemlett.6b00056
CHEMBL4572614;175374;None;0;Human;Binding;Ki;=;9600,00;5,02;-117;24;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cells measured after 90 mins by microbeta scintillation counting method;ChEMBL;410,1;3;0;6;5,66;Cc1ncc2nccn2c1-c1ccc(Oc2nccc3occc23)cc1C(F)(F)F;https://dx.doi.org/10.1021/acs.jmedchem.9b00351
CHEMBL4572646;175377;None;0;Human;Binding;Ki;=;690,00;6,16;-32;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;569,2;9;2;4;4,72;O=C(NCCCN1CCN(c2ccc(I)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4572646;175377;None;0;Human;Binding;Ki;=;670,00;6,17;-32;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;569,2;9;2;4;4,72;O=C(NCCCN1CCN(c2ccc(I)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4572887;175387;None;0;Human;Binding;Ki;=;22,39;7,65;1;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;453,2;6;1;6;4,04;Nc1nc2c(s1)CCN(CCCCN1CCN(c3cccc(Cl)c3Cl)CC1)CC2;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4573441;175413;None;0;Human;Binding;Ki;=;287,00;6,54;-56;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;361,1;6;0;4;3,66;O=C(CCCN1CCN(c2ccc(Cl)cn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4573441;175413;None;0;Human;Binding;Ki;=;288,40;6,54;-56;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;361,1;6;0;4;3,66;O=C(CCCN1CCN(c2ccc(Cl)cn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4574793;175473;None;0;Human;Binding;Ki;=;40,74;7,39;-4;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;375,2;6;0;4;4,05;O=C(CCCN1CCCN(c2ccc(Cl)cn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4574793;175473;None;0;Human;Binding;Ki;=;41,00;7,39;-4;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;375,2;6;0;4;4,05;O=C(CCCN1CCCN(c2ccc(Cl)cn2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4576998;175563;None;0;Human;Binding;Kd;=;60,26;7,22;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1c(F)cccc1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4576998;175563;None;0;Human;Binding;Ki;=;63,10;7,20;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1c(F)cccc1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4577414;175585;None;0;Human;Binding;Ki;=;4,65;8,33;-5;3;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;459,2;8;1;6;4,25;CCc1cccc(N2CCN(CCCCNC(=O)c3nc4sccn4c3C)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4578143;175626;None;0;Human;Binding;Ki;=;108,00;6,97;1;2;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;362,2;6;1;3;4,86;CCOc1ccc2[nH]cc(C3=CCN(Cc4cccc(OC)c4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
CHEMBL4579251;175673;None;0;Human;Binding;Ki;=;140,00;6,85;-301;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;435,2;8;2;5;4,45;O=C(NCCCCN1CCN(c2cccc(O)c2)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL457957;175684;None;0;Human;Binding;Ki;=;904,00;6,04;-186;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;522,3;10;0;3;6,56;CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)Cc1ccc(OCCCN2CCCCC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
CHEMBL457957;175684;UNDEFINED;0;Human;Binding;pKi;=;904,00;6,04;-186;6;-;PDSP KiDatabase;522,3;10;0;3;6,56;CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)Cc1ccc(OCCCN2CCCCC2)cc1;-
CHEMBL4579585;175685;None;0;Human;Binding;Ki;=;4,20;8,38;-;1;Binding affinity to human D2R;ChEMBL;1602,8;50;10;13;14,72;CCCN(CCc1ccc(NC(=O)CCC(=O)NCCCCCC(=O)NCc2ccc(C(=O)NCCCCCC(=O)NCCCCCC(=O)NCc3ccc(C(=O)NCCCCCC(=O)NCCCCCCNC(=O)c4nn(-c5ccc(Cl)cc5Cl)c(-c5ccc(Cl)cc5)c4C)cc3)cc2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmcl.2019.126644
CHEMBL4579687;175691;None;0;Human;Binding;IC50;=;44,67;7,35;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1ccc(Br)c3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4579687;175691;None;0;Human;Binding;IC50;=;45,07;7,35;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;373,1;2;0;3;4,22;COc1ccc2c(c1OC)-c1ccc(Br)c3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL457974;175692;UNDEFINED;0;Human;Binding;pKi;=;100,00;7,00;2;2;-;PDSP KiDatabase;433,2;9;1;6;3,21;COc1ccc(N2CCN(CCCCNC(=O)c3ccc(-n4ccnc4)cc3)CC2)cc1;-
CHEMBL4579883;175698;None;0;Human;Binding;Ki;=;42,00;7,38;-2;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;385,2;5;0;4;2,97;CCCN1CCN(c2cccc3c2CCN3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4579971;175702;None;0;Human;Binding;Kd;=;66,07;7,18;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;347,1;5;1;2;4,39;OC1(c2ccc(Cl)cc2)CCN(CCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4579971;175702;None;0;Human;Binding;Ki;=;61,66;7,21;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;347,1;5;1;2;4,39;OC1(c2ccc(Cl)cc2)CCN(CCCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL458001;175704;None;0;Human;Binding;Ki;=;5248,07;5,28;-173;11;Displacement of [125I]iodosulpiride from dopamine D2 receptor expressed in CHO cells;ChEMBL;499,2;6;2;6;4,27;O=C(Nc1cccc(Cn2ncc(N3CCNCC3)c(Cl)c2=O)c1)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1021/jm800962k
CHEMBL458002;175705;None;0;Human;Binding;Ki;=;4897,79;5,31;-2290;11;Displacement of [125I]iodosulpiride from dopamine D2 receptor expressed in CHO cells;ChEMBL;513,2;6;2;6;4,58;Cc1ccc(Cn2ncc(N3CCNCC3)c(Cl)c2=O)cc1NC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1021/jm800962k
CHEMBL4580959;175744;None;0;Human;Binding;Ki;=;506,00;6,30;-2;5;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;364,1;4;1;6;-0,27;CN1CCN(c2nc(N)nc(C[Se]c3ccccc3)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4581262;175756;None;0;Human;Binding;EC50;=;602,56;6,22;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;385,1;2;0;5;3,94;CC(=O)Oc1c(Cl)cc2c(c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4581262;175756;None;0;Human;Binding;EC50;=;604,00;6,22;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;385,1;2;0;5;3,94;CC(=O)Oc1c(Cl)cc2c(c1OC(C)=O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4582096;175804;None;0;Human;Binding;Ki;=;160,00;6,80;-45;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,3;11;2;6;4,28;COc1ccc(N(Cc2ccc(F)cc2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4582096;175804;None;0;Human;Binding;Ki;=;110,00;6,96;-45;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,3;11;2;6;4,28;COc1ccc(N(Cc2ccc(F)cc2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL458220;175808;None;0;Human;Binding;Ki;=;5128,61;5,29;-97;10;Displacement of [125I]iodosulpiride from dopamine D2 receptor expressed in CHO cells;ChEMBL;513,2;6;2;6;4,58;Cc1c(Cn2ncc(N3CCNCC3)c(Cl)c2=O)cccc1NC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1021/jm800962k
CHEMBL4582567;175826;None;0;Human;Binding;Ki;=;1047,00;5,98;-33;5;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;532,3;7;1;5;5,43;O=c1c(-c2ccc(F)cc2)c2n(c(=O)n1CCCCN1CCCC(c3c[nH]c4ccc(F)cc34)C1)CCCC2;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
CHEMBL4582714;175834;None;0;Human;Binding;Ki;=;85,11;7,07;3;2;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO-K1 cell membrane incubated for 2 hrs by MicroBeta Trilux scintillation counting method;ChEMBL;400,2;7;0;6;3,15;COc1ccccc1N1CCN(CCCCN2CCc3ncsc3CC2)CC1;https://dx.doi.org/10.1039/C9MD00379G
CHEMBL4583082;175843;None;0;Human;Binding;Ki;=;220,00;6,66;-72;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;362,2;7;3;4;4,47;COc1ccc2[nH]cc(CCNCc3ccc(-c4ccc(O)cc4)o3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL458342;175854;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-29;3;-;PDSP KiDatabase;366,2;3;1;3;4,46;Clc1ccc(N2CCC3CCC(C2)N3Cc2c[nH]c3ncccc23)cc1;-
CHEMBL458354;175866;None;0;Human;Binding;Ki;=;1341,00;5,87;-2;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;427,2;8;1;7;2,70;COc1cc(F)cc(N2CCN(CCCCNC(=O)c3ccc4nonc4c3)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL458354;175866;UNDEFINED;0;Human;Binding;pKi;=;1341,00;5,87;-2;2;-;PDSP KiDatabase;427,2;8;1;7;2,70;COc1cc(F)cc(N2CCN(CCCCNC(=O)c3ccc4nonc4c3)CC2)c1;-
CHEMBL4583596;175869;None;0;Human;Binding;Ki;=;94,00;7,03;-9;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;566,2;10;2;6;5,31;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(C#N)cc2)c2ccc(Cl)cc2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4583596;175869;None;0;Human;Binding;Ki;=;150,00;6,82;-9;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;566,2;10;2;6;5,31;COc1ccccc1N1CCN(CCCNC(=O)NN(Cc2ccc(C#N)cc2)c2ccc(Cl)cc2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4583609;175871;None;0;Human;Binding;Ki;=;2049,00;5,69;-4677;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;487,1;8;1;4;6,05;O=C(NCCCCN1CCN(c2cc(Cl)cc(Cl)c2)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4584060;175888;None;0;Human;Binding;Kd;=;288,40;6,54;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;343,1;2;1;2;3,81;OC1(c2ccc(Cl)cc2)CCN(CC#Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4584060;175888;None;0;Human;Binding;Ki;=;281,84;6,55;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;343,1;2;1;2;3,81;OC1(c2ccc(Cl)cc2)CCN(CC#Cc2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4584325;175902;None;0;Human;Binding;Ki;=;2916,00;5,54;-12;4;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;314,2;4;1;7;1,09;Cc1ccc(OCc2nc(N)nc(N3CCN(C)CC3)n2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4584497;175911;None;0;Human;Binding;Ki;=;80,20;7,10;-213;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;456,2;8;2;3;4,66;CCc1cccc(N2CCN(C[C@H](F)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
CHEMBL4584504;175912;None;0;Human;Binding;Ki;=;446,00;6,35;-223;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;350,1;6;3;3;4,61;Oc1ccc(-c2ccc(CNCCc3c[nH]c4cc(F)ccc34)o2)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4584719;175922;None;0;Human;Binding;Ki;=;10,00;8,00;1;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;471,3;9;0;5;4,83;COc1ccccc1N1CCN(CCCCCCN2C(=O)c3cccc4cccc(c34)C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4585384;175947;None;0;Human;Binding;Ki;=;59,00;7,23;-7;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,3;11;2;6;4,28;COc1ccc(N(Cc2cccc(F)c2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4585384;175947;None;0;Human;Binding;Ki;=;35,00;7,46;-7;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;521,3;11;2;6;4,28;COc1ccc(N(Cc2cccc(F)c2)NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL458554;175952;UNDEFINED;0;Human;Binding;pKi;=;100,00;7,00;1;2;-;PDSP KiDatabase;409,2;8;1;7;2,56;COc1cccc(N2CCN(CCCCNC(=O)c3ccc4nonc4c3)CC2)c1;-
CHEMBL4586276;175986;None;0;Human;Binding;Ki;=;458,00;6,34;-18;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;357,2;3;0;4;2,19;CN1CCN(c2ccc3c(c2)N(S(=O)(=O)c2ccccc2)CC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4586327;175988;None;0;Human;Binding;Ki;=;619,00;6,21;-27;6;Displacement of [3H]N-methylspiperone from human dopamine D2L receptor expressed in HEK293 cell membranes incubated for 1 hr by liquid scintillation counting analysis;ChEMBL;254,1;3;1;3;2,32;CCc1cc(Cl)c(OC)c(N2CCNCC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
CHEMBL4586531;175996;None;0;Human;Binding;Ki;=;8434,00;5,07;-1071;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;419,2;8;1;4;4,75;O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL458758;176035;None;0;Human;Binding;Ki;=;196,00;6,71;-4;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;465,3;11;1;6;3,55;O=C(NCCCCN1CCN(c2cccc(OCCF)c2)CC1)c1ccc(-n2ccnc2)cc1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL458758;176035;UNDEFINED;0;Human;Binding;pKi;=;196,00;6,71;-4;2;-;PDSP KiDatabase;465,3;11;1;6;3,55;O=C(NCCCCN1CCN(c2cccc(OCCF)c2)CC1)c1ccc(-n2ccnc2)cc1;-
CHEMBL458759;176036;UNDEFINED;0;Human;Binding;pKi;=;100,00;7,00;2;2;-;PDSP KiDatabase;441,2;10;1;7;2,90;O=C(NCCCCN1CCN(c2cccc(OCCF)c2)CC1)c1ccc2nonc2c1;-
CHEMBL4587635;176039;None;0;Human;Binding;Ki;=;190,00;6,72;-281;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;433,2;8;1;4;5,06;Cc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccsc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4587645;176040;None;0;Human;Binding;Ki;=;640,00;6,19;-52;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;477,2;9;2;4;4,77;O=C(NCCCN1CCN(c2ccc(Cl)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4587645;176040;None;0;Human;Binding;Ki;=;410,00;6,39;-52;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;477,2;9;2;4;4,77;O=C(NCCCN1CCN(c2ccc(Cl)cc2)CC1)NN(Cc1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4587772;176046;None;0;Human;Binding;Ki;=;11,00;7,96;1;5;Displacement of [3H]-raclopride from recombinant human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;457,3;10;0;4;5,58;CCOc1ccccc1N1CCN(CCCCCCN2C(=O)c3cccc4cccc2c34)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.06.029
CHEMBL4589737;176121;None;0;Human;Binding;EC50;=;2561,00;5,59;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;309,2;2;0;3;3,76;COc1ccc2c(c1OC)-c1ccc(C)c3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4589737;176121;None;0;Human;Binding;EC50;=;2570,40;5,59;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;309,2;2;0;3;3,76;COc1ccc2c(c1OC)-c1ccc(C)c3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4589737;176121;None;0;Human;Binding;IC50;=;3630,78;5,44;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;309,2;2;0;3;3,76;COc1ccc2c(c1OC)-c1ccc(C)c3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4589737;176121;None;0;Human;Binding;IC50;=;3629,00;5,44;-;2;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;309,2;2;0;3;3,76;COc1ccc2c(c1OC)-c1ccc(C)c3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4589982;176125;None;0;Human;Binding;Ki;=;500,00;6,30;-25;3;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;495,2;9;2;4;4,91;O=C(NCCCN1CCN(c2ccc(Cl)cc2)CC1)NN(Cc1ccc(F)cc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4589982;176125;None;0;Human;Binding;Ki;=;380,00;6,42;-25;3;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;495,2;9;2;4;4,91;O=C(NCCCN1CCN(c2ccc(Cl)cc2)CC1)NN(Cc1ccc(F)cc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
CHEMBL4590085;176133;None;0;Human;Binding;Kd;=;52,48;7,28;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cccc(F)c1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4590085;176133;None;0;Human;Binding;Ki;=;46,77;7,33;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;393,1;6;1;3;4,57;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cccc(F)c1F;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL4590192;176136;None;0;Human;Binding;Ki;=;99,70;7,00;-245;2;Displacement of 2,3-dimethoxy-5-[125I]-iodo-N-[9-benzyl-9-azabicyclo[3.3.1]nonan-3beta-yl]benzamide from human dopamine D2L receptor expressed in HEK293 cells measured after 60 mins by gamma counting analysis;ChEMBL;487,2;8;1;4;5,77;O=C(NCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1ccc(-c2ccsc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2019.07.020
CHEMBL4591021;176179;None;0;Human;Binding;EC50;=;0,30;9,52;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;355,2;6;0;5;3,40;COCOc1ccc2c(c1OCOC)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4591021;176179;None;0;Human;Binding;EC50;=;0,32;9,50;-;2;Agonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;355,2;6;0;5;3,40;COCOc1ccc2c(c1OCOC)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
CHEMBL4591250;176193;None;0;Human;Binding;Ki;=;95,00;7,02;-16;3;Displacement of [3H]raclopride from human recombinant dopamine D2 long receptor expressed in CHO-K1 cells incubated for 120 mins by scintillation counting analysis;ChEMBL;385,2;5;0;4;2,97;CCCN1CCN(c2ccc3c(c2)N(S(=O)(=O)c2ccccc2)CC3)CC1;https://dx.doi.org/10.1016/j.bmcl.2016.07.055
CHEMBL4591410;176202;None;0;Human;Binding;Ki;=;1730,00;5,76;-61;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;336,2;7;3;4;3,49;COc1ccc2[nH]cc(CCNCc3ccc(-c4cn[nH]c4)o3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL4591440;176204;None;0;Human;Binding;Ki;=;217,00;6,66;-95;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;528,3;9;2;5;5,17;COc1ccc2[nH]cc(C3CCN(CCCCN4C(=O)CC(c5c[nH]c6ccc(OC)cc56)C4=O)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
CHEMBL4591554;176210;None;0;Human;Binding;Ki;=;286,00;6,54;-1;2;Displacement of [3H]spiperone from human D2S receptor expressed in CHO-K1 cells by radioligand competitive binding analysis;ChEMBL;347,1;2;2;3;3,63;CN1CCc2cc(O)c(O)cc2C1Cc1ccccc1Br;https://dx.doi.org/10.1021/acs.jnatprod.9b00921
CHEMBL4591554;176210;None;0;Human;Binding;Ki;=;288,40;6,54;-1;2;Displacement of [3H]spiperone from human D2S receptor expressed in CHO-K1 cells by radioligand competitive binding analysis;ChEMBL;347,1;2;2;3;3,63;CN1CCc2cc(O)c(O)cc2C1Cc1ccccc1Br;https://dx.doi.org/10.1021/acs.jnatprod.9b00921
CHEMBL4591878;176225;None;0;Human;Binding;Ki;=;329,00;6,48;-2;4;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;350,1;4;1;7;2,15;CN1CCN(c2nc(N)nc(CSc3ccccc3Cl)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
CHEMBL4592256;176242;None;0;Human;Binding;Ki;=;8710,00;5,06;-63;4;Displacement of [3H] raclopride from human recombinant D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method;ChEMBL;279,1;2;1;2;4,07;CCn1cncc1-c1c[nH]c2ccc(C(F)(F)F)cc12;https://dx.doi.org/10.1016/j.ejmech.2019.03.017
CHEMBL4592941;176267;None;0;Human;Binding;Ki;=;239,00;6,62;-18;5;Displacement of [3H]raclopride from full length human cloned D2L receptor expressed in HEK293 cells incubated for 1 hr by radioligand displacement assay;ChEMBL;428,2;8;0;6;2,61;O=C1c2ccccc2S(=O)(=O)N1CCCCCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
CHEMBL459350;176294;None;0;Human;Binding;Ki;=;101,00;7,00;-371;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;494,3;10;0;3;6,99;CN(CCC=C1c2ccccc2CCc2ccccc21)Cc1ccc(OCCCN2CCCCC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
CHEMBL459350;176294;UNDEFINED;0;Human;Binding;pKi;=;101,00;7,00;-371;6;-;PDSP KiDatabase;494,3;10;0;3;6,99;CN(CCC=C1c2ccccc2CCc2ccccc21)Cc1ccc(OCCCN2CCCCC2)cc1;-
CHEMBL4593671;176298;None;0;Human;Binding;Ki;=;571,00;6,24;-8;5;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;380,1;7;2;3;5,42;COc1ccc2[nH]cc(CCNCc3ccc(-c4ccc(Cl)cc4)o3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
CHEMBL459373;176304;None;0;Human;Binding;Ki;=;41,00;7,39;-33;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;535,2;11;0;5;7,72;CN(CCCN1c2ccccc2Sc2ccc(Cl)cc21)Cc1ccc(OCCCN2CCCCC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
CHEMBL459373;176304;UNDEFINED;0;Human;Binding;pKi;=;41,00;7,39;-33;6;-;PDSP KiDatabase;535,2;11;0;5;7,72;CN(CCCN1c2ccccc2Sc2ccc(Cl)cc21)Cc1ccc(OCCCN2CCCCC2)cc1;-
CHEMBL4594629;176326;None;0;Human;Binding;Ki;=;3162,00;5,50;-40;2;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;418,1;4;1;4;3,93;COc1ccc2c(c1)c(-c1[nH]c3cccc[n+]3c1C)cn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4594691;176337;None;1;Human;Binding;Ki;=;5623,00;5,25;-100;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;432,3;11;1;2;6,00;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4594692;176338;None;1;Human;Binding;Ki;=;275,40;6,56;-9;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;454,2;11;0;6;5,24;CCN(CCCSc1nnc(-c2ccccc2)n1C)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4594758;176347;None;0;Human;Binding;Ki;=;794,00;6,10;-56;4;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;352,1;3;2;5;3,16;Cc1nc(N)[nH]c1-c1cn(S(=O)(=O)c2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4594878;176355;None;0;Human;Binding;Ki;=;1585,00;5,80;-54;4;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;366,1;4;2;5;3,41;CCc1nc(N)[nH]c1-c1cn(S(=O)(=O)c2ccccc2)c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4594879;176356;None;0;Human;Binding;Ki;=;1175,00;5,93;-147;4;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;402,1;3;2;5;4,31;Cc1nc(N)[nH]c1-c1cn(S(=O)(=O)c2cccc3ccccc23)c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4594959;176365;None;1;Human;Binding;Ki;=;407,40;6,39;-26;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;448,3;11;1;3;5,62;CCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595069;176382;None;0;Human;Binding;Ki;=;336,00;6,47;-2;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;483,2;8;0;4;5,38;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4595115;176389;None;0;Human;Binding;Ki;=;927,00;6,03;-1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;517,2;8;0;4;5,75;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccc(C(F)(F)F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4595145;176393;None;1;Human;Binding;Ki;=;1230,00;5,91;-154;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;489,3;13;1;4;5,92;CCCN(CCCCNC(=O)c1ccc(-c2ccccn2)cc1)C[C@H]1C[C@@H]1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595146;176394;None;1;Human;Binding;Ki;=;2105,00;5,68;-1047;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;482,2;11;1;2;7,17;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595147;176395;None;1;Human;Binding;Ki;=;1116,00;5,95;-41;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;478,2;12;1;3;6,53;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595148;176396;None;1;Human;Binding;Ki;=;1083,90;5,96;-75;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;462,3;12;1;3;6,01;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595149;176397;None;1;Human;Binding;Ki;=;2435,90;5,61;-4;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;472,2;12;0;6;5,19;CN(CCCSc1nnc(-c2ccccc2)n1C)CC1CC1c1cc(F)ccc1OCCF;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595150;176398;None;0;Human;Binding;Ki;=;550,00;6,26;-363;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;509,2;12;1;3;7,08;CCCN(CCCCNC(=O)c1ccc(-c2ccccn2)cc1)C[C@@H]1C[C@H]1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595195;176404;None;1;Human;Binding;Ki;=;408,00;6,39;-17;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;464,2;11;1;3;6,14;CCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595236;176410;None;0;Human;Binding;Ki;=;945,00;6,03;-1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;481,2;8;0;3;6,20;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccc(C(F)(F)F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4595264;176414;None;1;Human;Binding;Ki;=;3494,00;5,46;-186;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;421,3;11;2;2;5,33;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)CC1CC1c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595265;176415;None;1;Human;Binding;Ki;=;2105,00;5,68;-53;4;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;505,3;13;1;4;6,44;CCCN(CCCCNC(=O)c1ccc(-c2ccccn2)cc1)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595266;176416;None;1;Human;Binding;Ki;=;3144,00;5,50;-794;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;489,3;13;1;4;5,92;CCCN(CCCCNC(=O)c1ccc(-c2ccccn2)cc1)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595274;176418;None;0;Human;Binding;Ki;=;496,00;6,30;-9;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;481,2;8;0;3;6,20;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4595382;176428;None;1;Human;Binding;Ki;=;1421,00;5,85;-123;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;467,2;12;2;3;5,86;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595409;176430;None;1;Human;Binding;Ki;=;660,70;6,18;-3;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;440,2;11;1;6;4,89;CCOc1ccc(F)cc1C1CC1CNCCCSc1nnc(-c2ccccc2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595453;176437;None;0;Human;Binding;Ki;=;204,00;6,69;3;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;491,2;8;0;3;5,95;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccc(Br)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4595569;176450;None;0;Human;Binding;Ki;=;142,00;6,85;-1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;483,2;8;0;4;5,38;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4595674;176461;None;0;Human;Binding;Ki;=;1622,00;5,79;-85;3;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;396,1;5;2;6;3,42;CCc1nc(N)[nH]c1-c1cn(S(=O)(=O)c2ccccc2)c2ccc(OC)cc12;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4595675;176462;None;0;Human;Binding;Ki;=;3981,00;5,40;-117;3;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;338,1;3;2;5;2,85;Nc1ncc(-c2cccc3c2ccn3S(=O)(=O)c2ccccc2)[nH]1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4595677;176463;None;0;Human;Binding;Ki;=;304,00;6,52;-2;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;517,2;8;0;4;5,75;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4595726;176468;None;1;Human;Binding;Ki;=;4606,00;5,34;-141;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;448,2;11;1;2;6,52;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595727;176469;None;1;Human;Binding;Ki;=;253,10;6,60;-2;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;426,2;10;1;6;4,50;COc1ccc(F)cc1C1CC1CNCCCSc1nnc(-c2ccccc2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595728;176470;None;1;Human;Binding;Ki;=;380,20;6,42;-6;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;468,2;12;0;6;5,63;CCOc1ccc(F)cc1C1CC1CN(CC)CCCSc1nnc(-c2ccccc2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4595815;176479;None;0;Human;Binding;Ki;=;7079,00;5,15;-794;2;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;386,1;4;2;6;3,00;COc1ccc2c(c1)c(-c1cnc(N)[nH]1)cn2S(=O)(=O)c1cccc(F)c1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4595859;176486;None;1;Human;Binding;Ki;=;216,00;6,67;-8;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;496,2;12;0;6;6,14;COc1ccc(Cl)cc1C1CC1CN(CCCSc1nnc(-c2ccccc2)n1C)CC1CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4596220;176537;None;1;Human;Binding;Ki;=;3162,00;5,50;-123;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;437,2;11;2;2;5,85;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)CC1CC1c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4596221;176538;None;1;Human;Binding;Ki;=;844,60;6,07;-7;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;486,2;13;0;6;5,58;CCN(CCCSc1nnc(-c2ccccc2)n1C)CC1CC1c1cc(F)ccc1OCCF;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4596261;176541;None;0;Human;Binding;Ki;=;246,00;6,61;-1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;481,2;8;0;3;6,49;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4596298;176545;None;0;Human;Binding;Ki;=;1230,00;5,91;-13;3;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;422,1;4;1;7;3,87;COc1ccc2c(c1)c(-c1nc3n(c1C)CCCN3)cn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4596341;176553;None;1;Human;Binding;Ki;=;992,00;6,00;-77;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;471,2;11;2;2;6,50;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)C[C@H]1C[C@@H]1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4596514;176570;None;1;Human;Binding;Ki;=;537,00;6,27;-245;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;471,2;11;2;2;6,50;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)C[C@@H]1C[C@H]1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4596543;176574;None;0;Human;Binding;Ki;=;1202,00;5,92;-602;4;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;368,1;4;2;6;2,86;COc1ccc2c(c1)c(-c1cnc(N)[nH]1)cn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4596544;176575;None;0;Human;Binding;Ki;=;161,00;6,79;3;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;481,2;8;0;3;6,20;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccccc2C(F)(F)F)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4596571;176576;None;1;Human;Binding;Ki;=;5934,00;5,23;-128;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;421,3;11;2;2;5,33;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)CC1CC1c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4596654;176590;None;0;Human;Binding;Ki;=;90,00;7,05;-1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;467,2;8;0;4;4,87;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccccc2F)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4596888;176614;None;0;Human;Binding;Ki;=;220,00;6,66;-1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;517,1;8;0;4;6,04;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4596929;176619;None;1;Human;Binding;Ki;=;676,00;6,17;-154;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;482,2;11;1;2;7,17;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)C[C@@H]1C[C@H]1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4596930;176620;None;1;Human;Binding;Ki;=;4823,00;5,32;-177;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;432,3;11;1;2;6,00;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597000;176626;None;0;Human;Binding;Ki;=;197,00;6,71;-1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;447,2;8;0;3;5,84;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4597048;176632;None;1;Human;Binding;Ki;=;1023,00;5,99;-194;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;509,2;12;1;3;7,08;CCCN(CCCCNC(=O)c1ccc(-c2ccccn2)cc1)C[C@H]1C[C@@H]1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597157;176646;None;1;Human;Binding;Ki;=;1161,40;5,93;-13;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;468,2;12;0;6;5,63;CCCN(CCCSc1nnc(-c2ccccc2)n1C)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597188;176650;None;1;Human;Binding;Ki;=;1148,00;5,94;-54;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;482,2;11;1;2;7,17;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)C[C@H]1C[C@@H]1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597227;176655;None;0;Human;Binding;Ki;=;87,00;7,06;-8;5;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;338,1;3;2;5;2,85;Nc1ncc(-c2cn(S(=O)(=O)c3ccccc3)c3ccccc23)[nH]1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4597228;176656;None;0;Human;Binding;Ki;=;58,00;7,24;1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;447,2;8;0;3;5,84;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4597530;176689;None;1;Human;Binding;Ki;=;1349,00;5,87;-331;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;489,3;13;1;4;5,92;CCCN(CCCCNC(=O)c1ccc(-c2ccccn2)cc1)C[C@@H]1C[C@H]1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597531;176690;None;1;Human;Binding;Ki;=;507,00;6,29;-45;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;451,3;12;2;3;5,34;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597533;176692;None;1;Human;Binding;Ki;=;1502,00;5,82;-4;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;458,2;12;1;6;4,84;Cn1c(SCCCNCC2CC2c2cc(F)ccc2OCCF)nnc1-c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597600;176700;None;0;Human;Binding;Ki;=;2344,00;5,63;-263;4;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;432,1;4;2;6;4,32;COc1ccc2c(c1)c(-c1[nH]c(N)nc1C)cn2S(=O)(=O)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4597637;176704;None;1;Human;Binding;Ki;=;323,60;6,49;-3;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;440,2;10;0;6;4,85;COc1ccc(F)cc1C1CC1CN(C)CCCSc1nnc(-c2ccccc2)n1C;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597876;176731;None;1;Human;Binding;Ki;=;1502,00;5,82;-588;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;471,2;11;2;2;6,50;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)CC1CC1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4597877;176732;None;1;Human;Binding;Ki;=;238,00;6,62;-7;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;470,2;11;0;6;5,75;CCN(CCCSc1nnc(-c2ccccc2)n1C)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4598000;176750;None;1;Human;Binding;Ki;=;2362,00;5,63;-1949;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;509,2;12;1;3;7,08;CCCN(CCCCNC(=O)c1ccc(-c2ccccn2)cc1)CC1CC1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4598002;176752;None;1;Human;Binding;Ki;=;4012,00;5,40;-257;6;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;448,2;11;1;2;6,52;CCCN(CCCCNC(=O)c1ccc2ccccc2c1)CC1CC1c1cccc(Cl)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4598003;176753;None;1;Human;Binding;Ki;=;512,90;6,29;-4;4;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;468,2;11;0;6;5,63;COc1ccc(F)cc1C1CC1CN(CCCSc1nnc(-c2ccccc2)n1C)C(C)C;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4598088;176761;None;0;Human;Binding;Ki;=;121,00;6,92;-2;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;483,2;8;0;4;5,38;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4598089;176762;None;0;Human;Binding;Ki;=;254,00;6,59;-3;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;517,1;8;0;4;6,04;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4598090;176763;None;0;Human;Binding;Ki;=;94,00;7,03;1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;481,2;8;0;3;6,49;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4598209;176774;None;0;Human;Binding;Ki;=;708,00;6,15;-177;4;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;352,1;3;2;5;3,16;Cc1nc(N)[nH]c1-c1ccc2ccn(S(=O)(=O)c3ccccc3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4598210;176775;None;0;Human;Binding;Ki;=;320,00;6,50;-4;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;431,2;8;0;3;5,32;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2ccccc2F)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4598299;176784;None;1;Human;Binding;Ki;=;380,00;6,42;-16;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;437,2;11;2;3;4,95;CCN(CCCCNC(=O)c1cc2ccccc2[nH]1)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4598348;176789;None;0;Human;Binding;Ki;=;1318,00;5,88;-131;4;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;432,1;4;2;6;4,32;COc1ccc2c(c1)c(-c1[nH]c(N)nc1C)cn2S(=O)(=O)c1cccc2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
CHEMBL4598357;176790;None;0;Human;Binding;Ki;=;75,00;7,12;-1;5;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader method;ChEMBL;447,2;8;0;3;5,84;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2019.06.028
CHEMBL4598388;176793;None;1;Human;Binding;Ki;=;3494,00;5,46;-316;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;437,2;11;2;2;5,85;CCCN(CCCCNC(=O)c1cc2ccccc2[nH]1)CC1CC1c1cccc(Cl)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL4598389;176794;None;1;Human;Binding;Ki;=;233,00;6,63;-6;5;Displacement of [3H]-N-methylspiperone from recombinant human D2 receptor stably expressed in fibroblast cell membranes measured after 90 mins by microbeta scintillation counting method;ChEMBL;484,2;12;0;6;6,14;CCCN(CCCSc1nnc(-c2ccccc2)n1C)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.9b01835
CHEMBL459871;176803;None;0;Human;Binding;Ki;=;389,05;6,41;-6;3;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;253,1;0;2;2;2,67;Oc1ccc2c(c1)CCNCCc1ccccc1C2;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL459930;176808;None;0;Human;Binding;Ki;=;213,80;6,67;-25;2;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;454,2;5;0;7;4,67;CCOC(=O)c1oc2c(c1C)C(=O)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)C2;https://dx.doi.org/10.1021/jm800602w
CHEMBL460223;176842;None;0;Human;Binding;Ki;=;970,00;6,01;-52;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;340,1;3;1;3;3,93;Clc1ccc(N2CCCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL460223;176842;UNDEFINED;0;Human;Binding;pKi;=;970,00;6,01;-52;3;-;PDSP KiDatabase;340,1;3;1;3;3,93;Clc1ccc(N2CCCN(Cc3c[nH]c4ncccc34)CC2)cc1;-
CHEMBL460402;176867;UNDEFINED;0;Human;Binding;pKi;=;1000,00;6,00;-288;6;-;PDSP KiDatabase;508,3;9;0;3;6,63;CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)c1ccc(OCCCN2CCCCC2)cc1;-
CHEMBL460542;176880;None;0;Human;Binding;Kd;=;489,78;6,31;-630;9;Binding affinity to dopamine D2 receptor;ChEMBL;491,2;7;0;4;5,26;CN(CCC(=O)N1CCN(c2ccc(F)c(F)c2)CC1)CCC1c2ccccc2Oc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2009.01.072
CHEMBL460644;176901;None;0;Human;Binding;Ki;=;1170,00;5,93;-20;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;294,2;3;1;5;1,68;c1cnc(N2CCN(Cc3c[nH]c4ncccc34)CC2)nc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL460644;176901;UNDEFINED;0;Human;Binding;pKi;=;1170,00;5,93;-20;3;-;PDSP KiDatabase;294,2;3;1;5;1,68;c1cnc(N2CCN(Cc3c[nH]c4ncccc34)CC2)nc1;-
CHEMBL460854;176916;None;0;Human;Binding;Ki;=;53,00;7,28;-2;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;380,2;4;2;2;4,88;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCc1c[nH]c2ccccc12;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL460854;176916;UNDEFINED;0;Human;Binding;pKi;=;53,00;7,28;-2;3;-;PDSP KiDatabase;380,2;4;2;2;4,88;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCc1c[nH]c2ccccc12;-
CHEMBL461571;176985;None;0;Human;Binding;IC50;=;3550,00;5,45;-;20;Displacement of radioligand from dopamine D2S receptor;ChEMBL;531,1;8;1;5;6,63;Cc1c(C(=O)c2ccc(Cl)cc2)c2ccc(OC(F)(F)F)cc2n1Cc1cccc(O[C@H](C)C(=O)O)c1;https://dx.doi.org/10.1016/j.bmcl.2008.07.103
CHEMBL461627;176990;None;0;Human;Binding;Ki;=;85,11;7,07;-54;2;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;426,2;4;0;7;3,97;COC(=O)c1coc2c1C(=O)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)C2;https://dx.doi.org/10.1021/jm800602w
CHEMBL4632519;177147;None;0;Human;Binding;Ki;=;370,00;6,43;-6;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;443,2;8;0;4;4,05;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4633772;177233;None;0;Human;Binding;Ki;=;854,00;6,07;-14;3;Binding affinity to human D2 receptor;ChEMBL;376,2;4;1;4;3,42;C#CCOc1c(OC)cc2c3c1-c1cc(NC(C)=O)ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4634039;177257;None;0;Human;Binding;Ki;=;679,00;6,17;-2;3;Binding affinity to human D2 receptor;ChEMBL;250,1;0;1;2;3,02;CN1CCc2cccc3c2C1Cc1ccc(N)cc1-3;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4635363;177313;None;0;Human;Binding;Ki;=;225,00;6,65;-12;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;443,2;8;0;4;4,05;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCCCN1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4635603;177333;None;0;Human;Binding;Ki;=;33,00;7,48;-3;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;452,2;9;0;7;5,91;c1ccc2oc(SCCCCCCN3CCN(c4nsc5ccccc45)CC3)nc2c1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4636031;177361;None;0;Human;Binding;Ki;=;31,00;7,51;-1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;508,2;10;1;6;5,11;O=S(=O)(NCCCCCCN1CCN(c2nsc3ccccc23)CC1)c1cccc2ccccc12;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4636318;177384;None;0;Human;Binding;Ki;=;963,00;6,02;-8;3;Binding affinity to human D2 receptor;ChEMBL;336,2;3;1;4;3,57;COc1cc2c3c(c1OC1CC1)-c1cc(N)ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4636435;177392;None;0;Human;Binding;Ki;=;168,00;6,78;-7;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;477,3;8;0;4;4,42;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4636589;177404;None;0;Human;Binding;Ki;=;431,00;6,37;-1;4;Binding affinity to human D2 receptor;ChEMBL;334,2;3;1;4;3,04;C#CCOc1c(OC)cc2c3c1-c1cc(N)ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4636778;177412;None;4;Human;Binding;Ki;=;11900,00;4,92;-8;2;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;434,2;8;1;4;4,56;CC(O)CN1[C@@H](C)CN(CCSC(c2ccc(F)cc2)c2ccc(F)cc2)C[C@H]1C;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4636948;177419;None;0;Human;Binding;Ki;=;320,00;6,50;-1;4;Binding affinity to human D2 receptor;ChEMBL;326,1;2;1;5;3,06;COc1cc2c3c(c1O)-c1cc([N+](=O)[O-])ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4637246;177437;None;0;Human;Binding;Ki;=;231,00;6,64;1;4;Binding affinity to human D2 receptor;ChEMBL;296,2;1;2;4;2,73;COc1cc2c3c(c1O)-c1cc(N)ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4637294;177442;None;0;Human;Binding;Ki;=;56,00;7,25;-1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;470,2;8;0;5;5,79;O=C1c2cccc3cccc(c23)N1CCCCCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4637673;177467;None;0;Human;Binding;Ki;=;978,00;6,01;-1;2;Binding affinity to human D2 receptor;ChEMBL;352,2;3;1;4;3,41;COc1cc2c3c(c1OC)-c1cc(NC(C)=O)ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4638308;177507;None;0;Human;Binding;Ki;=;16,00;7,80;-2;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;435,2;8;1;6;4,32;O=c1[nH]c2ccccc2n1CCCCCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4638388;177515;None;0;Human;Binding;Ki;=;106,00;6,97;-4;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;548,2;11;0;6;6,18;Cc1ccc(S(=O)(=O)N(CCCCCCN2CCN(c3nsc4ccccc34)CC2)c2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4638599;177532;None;0;Human;Binding;EC50;=;13,60;7,87;-;5;Agonist activity at D2 receptor (unknown origin);ChEMBL;407,2;6;0;7;3,31;O=c1n(CCCCN2CCN(c3cccc4sccc34)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.bmcl.2020.127027
CHEMBL4638749;177547;None;0;Human;Binding;Ki;=;2048,00;5,69;-10;3;Binding affinity to human D2 receptor;ChEMBL;364,1;4;0;5;3,37;C#CCOc1c(OC)cc2c3c1-c1cc([N+](=O)[O-])ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4639203;177587;None;0;Human;Binding;Ki;=;55,00;7,26;-1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;477,2;8;0;4;4,71;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4639398;177598;None;0;Human;Binding;Ki;=;260,00;6,58;-1;4;Binding affinity to human D2 receptor;ChEMBL;310,2;2;1;4;3,04;COc1cc2c3c(c1OC)-c1cc(N)ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL4641296;177744;None;0;Human;Binding;Ki;=;31,00;7,51;-3;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;458,2;10;1;6;3,96;O=S(=O)(NCCCCCCN1CCN(c2nsc3ccccc23)CC1)c1ccccc1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4641502;177759;None;0;Human;Binding;Ki;=;1740,00;5,76;-173;7;Displacement of [3H]-N-Methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells incubated for 90 mins by microbeta counting method;ChEMBL;307,1;0;1;4;3,63;CN1CCc2cccc3c2C1Cc1ccc2nc(N)sc2c1-3;https://dx.doi.org/10.1016/j.bmc.2020.115578
CHEMBL4641609;177770;None;0;Human;Binding;Ki;=;1,00;9,00;3;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;466,2;8;0;6;4,01;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4642594;177853;None;0;Human;Binding;Ki;=;18,00;7,75;1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;506,2;8;0;6;5,34;O=S1(=O)c2cccc3cccc(c23)N1CCCCCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4642981;177878;None;0;Human;Binding;Ki;=;1,00;9,00;12;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;475,2;8;0;7;4,74;O=c1n(CCCCCCN2CCN(c3nsc4ccccc34)CC2)c2cccc3c2n1CCC3;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4643450;177901;None;0;Human;Binding;Ki;=;16,00;7,80;-3;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;436,2;8;0;7;4,59;O=c1oc2ccccc2n1CCCCCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4644391;177972;None;0;Human;Binding;EC50;=;27,30;7,56;-;6;Agonist activity at D2 receptor (unknown origin);ChEMBL;432,2;6;0;8;3,19;N#Cc1ccc2nn(CCCCN3CCN(c4cccc5sccc45)CC3)c(=O)n2c1;https://dx.doi.org/10.1016/j.bmcl.2020.127027
CHEMBL4644906;178006;None;0;Human;Binding;Ki;=;39,00;7,41;-1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;464,2;9;1;6;4,94;O=C1CCc2cc(OCCCCCCN3CCN(c4nsc5ccccc45)CC3)ccc2N1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4645139;178017;None;0;Human;Binding;Ki;=;1507,80;5,82;-3;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;377,1;4;1;3;4,88;C=CCN1CCc2cc(OC)c(O)cc2C(c2c(Cl)cccc2Cl)C1;https://dx.doi.org/10.1016/j.bmcl.2020.127305
CHEMBL4645292;178026;None;0;Human;Binding;Ki;=;41,00;7,39;-10;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;439,3;9;0;5;3,41;COc1ccccc1N1CCN(CCCCCCN2C(=O)[C@H]3[C@@H]4CC[C@@H](C4)[C@H]3C2=O)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4645308;178028;None;0;Human;Binding;Ki;=;35,00;7,46;-2;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;443,2;8;0;4;4,05;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCCCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4645525;178041;None;0;Human;Binding;Ki;=;27,00;7,57;1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;508,2;10;1;6;5,11;O=S(=O)(NCCCCCCN1CCN(c2nsc3ccccc23)CC1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4645677;178050;None;0;Human;Binding;EC50;=;16,00;7,80;-;1;Agonist activity at D2S (unknown origin);ChEMBL;560,2;7;1;6;3,63;O=C1CCC(N2Cc3c(OCc4ccc(CN5CCN(c6ccc(F)cc6F)CC5)cc4)cccc3C2=O)C(=O)N1;https://dx.doi.org/10.1021/acs.jmedchem.9b01928
CHEMBL4645793;178062;None;0;Human;Binding;Ki;=;14,00;7,85;-3;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;422,2;9;1;5;4,41;O=C(NCCCCCCN1CCN(c2nsc3ccccc23)CC1)c1ccccc1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4646868;178136;None;0;Human;Binding;Ki;=;59,00;7,23;-1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;498,2;8;0;6;5,43;O=C1c2cccc3cccc(c23)C(=O)N1CCCCCCN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4646927;178138;None;0;Human;Binding;Ki;=;478,00;6,32;-1;4;Binding affinity to human D2 receptor;ChEMBL;340,1;3;0;5;3,36;COc1cc2c3c(c1OC)-c1cc([N+](=O)[O-])ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL464811;178220;None;0;Human;Binding;Ki;=;285,00;6,54;-87;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;543,3;7;1;6;6,55;Clc1ccc2c(c1)N=C(N1CCN(Cc3ccc(OCCCN4CCCCC4)cc3)CC1)c1ccccc1N2;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
CHEMBL4648390;178234;None;0;Human;Binding;Ki;=;164,00;6,79;-3;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;602,2;11;0;6;6,89;O=S(=O)(c1ccccc1)N(CCCCCCN1CCN(c2nsc3ccccc23)CC1)c1cccc(C(F)(F)F)c1;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4648581;178242;None;0;Human;Binding;Ki;=;9,00;8,05;-1;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;436,2;8;0;8;3,49;O=c1n(CCCCCCN2CCN(c3nsc4ccccc34)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.bmc.2020.115459
CHEMBL4649785;178322;None;0;Human;Binding;Ki;=;759,00;6,12;-3;3;Binding affinity to human D2 receptor;ChEMBL;336,2;4;1;4;3,59;C=CCOc1c(OC)cc2c3c1-c1cc(N)ccc1CC3N(C)CC2;https://dx.doi.org/10.1016/j.bmcl.2020.127053
CHEMBL465014;178332;None;0;Human;Binding;Ki;=;121,00;6,92;-1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;419,2;8;1;6;2,82;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(-n3ccnc3)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL465014;178332;UNDEFINED;0;Human;Binding;pKi;=;121,00;6,92;-1;2;-;PDSP KiDatabase;419,2;8;1;6;2,82;COc1ccccc1N1CCN(CCCNC(=O)c2ccc(-n3ccnc3)cc2)CC1;-
CHEMBL465054;178337;None;0;Human;Binding;Ki;=;88,00;7,06;-11;4;Displacement of [3H]raclopride from human cloned dopamine D2 receptor expressed in CHO cell membrane;ChEMBL;343,2;1;2;3;4,52;CN1CCc2cc(-c3ccccc3)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2008.02.038
CHEMBL46523;178464;None;0;Human;Binding;Ki;=;1600,00;5,80;-79;3;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;366,2;4;1;1;6,21;c1ccc(CN2CCCC(c3c(-c4ccccc4)[nH]c4ccccc34)C2)cc1;https://dx.doi.org/10.1021/jm0004998
CHEMBL4740785;179572;None;0;Human;Binding;Ki;=;59,00;7,23;-;1;Displacement of [3H]raclopride from human D2R isoform 2 stably expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method;ChEMBL;1292,7;44;2;17;10,92;CCCN(CCCCNC(=O)c1ccc(-c2ccc(OCc3cn(CCOCCOCCOCCOCCOCCn4cc(COc5ccc(-c6ccc(C(=O)NCCCCN(CCC)C7Cc8ccccc8C7)cc6)cc5)nn4)nn3)cc2)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.ejmech.2020.113151
CHEMBL4740880;179582;None;0;Human;Binding;Ki;=;124,00;6,91;-77;2;Binding affinity to human dopamine D2 receptor;ChEMBL;337,1;1;1;3;5,17;C[C@H]1C=C(C2=Nc3ccccc3Nc3ccc(Cl)cc32)CCN1C;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4741142;179608;None;0;Human;Binding;Ki;=;100,00;7,00;-64;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;419,1;7;1;5;3,47;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4741279;179627;None;0;Human;Binding;Ki;=;8830,00;5,05;-1;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;484,2;8;1;3;5,82;O=C(c1ccc(F)cc1)N1CCC(NCCSC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4741673;179655;None;0;Human;Binding;Ki;=;25,30;7,60;-2;3;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;417,3;5;2;3;4,12;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)[C@@H]3CCCN3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4741702;179660;None;0;Human;Binding;Ki;=;2,90;8,54;-1;2;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;433,3;4;1;3;4,29;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)N3CCOCC3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4741978;179683;None;1;Human;Binding;Ki;=;813,00;6,09;-21;5;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta plate reader analysis;ChEMBL;584,3;13;0;7;5,32;C#CCN(C)Cc1ccc(OCCCCCN2CCN(c3cccc4c3ccn4S(=O)(=O)c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112765
CHEMBL4742056;179689;None;0;Human;Binding;Ki;=;135,00;6,87;-123;2;Binding affinity to human dopamine D2 receptor;ChEMBL;362,1;1;1;4;5,04;C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccc(C#N)cc32)CCN1C;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4742201;179705;None;3;Human;Binding;Ki;=;65300,00;4,18;-1;2;Binding affinity to D2 receptor (unknown origin);ChEMBL;323,2;3;0;3;2,48;CN(C)CCN1C(=O)c2ccccc2N(C)C(=O)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2020.127493
CHEMBL4742856;179737;None;0;Human;Binding;Ki;=;9,12;8,04;-1;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;438,2;7;1;6;3,31;Cn1ccc2c(S(=O)(=O)N[C@@H]3CCN(CCCc4noc5ccccc45)C3)cccc21;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4743651;179797;None;0;Human;Binding;Ki;=;91,10;7,04;-6;2;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;419,3;6;1;2;5,30;CCN(CC)C(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(Cl)cc3[C@@H](C)C2)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4744007;179825;None;0;Human;Binding;Ki;=;3,09;8,51;-3;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;465,2;8;1;6;3,98;COc1ccc2cc(S(=O)(=O)N[C@@H]3CCN(CCCc4noc5ccccc45)C3)ccc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4744811;179901;None;0;Human;Binding;Ki;=;86,20;7,06;-4;3;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;461,3;6;3;5;4,29;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC[C@H]1CC[C@H](NC(=O)c2cc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL4744811;179901;None;0;Human;Binding;Ki;=;104,00;6,98;-4;3;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cells after 90 mins by microbeta counting based assay;ChEMBL;461,3;6;3;5;4,29;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC[C@H]1CC[C@H](NC(=O)c2cc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1021/acsmedchemlett.9b00660
CHEMBL4744824;179902;None;0;Human;Binding;Ki;=;2900,00;5,54;-1;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;466,2;8;1;3;5,68;O=C(c1ccccc1)N1CCC(NCCSC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4745124;179945;None;0;Human;Binding;Ki;=;63,00;7,20;-676;3;Binding affinity to human dopamine D2 receptor;ChEMBL;351,1;1;1;3;5,48;Cc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1cc(Cl)ccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4745489;179971;None;0;Human;Binding;Ki;=;110,00;6,96;-776;3;Binding affinity to human dopamine D2 receptor;ChEMBL;421,1;2;1;4;6,07;C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccc(OC(F)(F)F)cc32)CCN1C;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4745809;179996;None;0;Human;Binding;Ki;=;20,60;7,69;3;3;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;418,2;5;1;3;4,55;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)[C@@H]3CCCO3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4746800;180076;None;0;Human;Binding;Ki;=;11600,00;4,94;-95;6;Binding affinity to D2 receptor (unknown origin);ChEMBL;292,2;3;0;2;3,38;CN(C)CCN1C(=O)c2ccccc2/C=C\c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2020.127493
CHEMBL4747225;180119;None;0;Human;Binding;Ki;=;0,20;9,70;1;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;435,2;7;1;5;3,97;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4747978;180180;None;0;Human;Binding;Ki;=;0,63;9,20;1;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;473,1;7;1;6;4,47;Cc1c(S(=O)(=O)N[C@@H]2CCN(CCCc3noc4ccccc34)C2)sc2ccc(F)cc12;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4748107;180191;None;0;Human;Binding;Ki;=;102,33;6,99;-5;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;469,1;7;1;5;4,62;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1ccc2cc(Cl)ccc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL47482;180197;UNDEFINED;3;Human;Binding;pKi;=;10000,00;5,00;-354;5;-;PDSP KiDatabase;209,1;1;1;1;2,68;NCC1c2ccccc2Cc2ccccc21;-
CHEMBL4748201;180198;None;0;Human;Binding;Ki;=;270,00;6,57;-;1;Displacement of [3H]raclopride from human D2R isoform 2 stably expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method;ChEMBL;1204,7;38;2;15;10,89;CCCN(CCCCNC(=O)c1ccc(-c2ccc(OCc3cn(CCOCCOCCOCCn4cc(COc5ccc(-c6ccc(C(=O)NCCCCN(CCC)C7Cc8ccccc8C7)cc6)cc5)nn4)nn3)cc2)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.ejmech.2020.113151
CHEMBL4748379;180212;None;0;Human;Binding;Ki;=;1,74;8,76;-2;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;455,1;7;1;6;4,34;Cc1ccc2sc(S(=O)(=O)N[C@@H]3CCN(CCCc4noc5ccccc45)C3)cc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4748915;180259;None;0;Human;Binding;Ki;=;1380,00;5,86;-3;4;Binding affinity to human dopamine D2 receptor;ChEMBL;323,1;1;1;3;4,78;CN1CC=C(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4749824;180328;None;0;Human;Binding;Ki;=;38,02;7,42;-29;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;438,2;7;1;6;3,31;Cn1ccc2c(S(=O)(=O)N[C@H]3CCN(CCCc4noc5ccccc45)C3)cccc21;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4750587;180375;None;0;Human;Binding;Ki;=;169,82;6,77;-26;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;437,1;7;1;5;3,61;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4750607;180376;None;0;Human;Binding;Ki;=;4020,00;5,40;-5;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;496,2;11;2;4;5,45;OC(Cc1ccccc1)CN1CCC(NCCSC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4750660;180380;None;0;Human;Binding;Ki;=;12400,00;4,91;1;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;486,2;9;1;3;5,20;[O-][S+](CCNC1CCN(Cc2ccc(F)cc2)CC1)C(c1ccc(F)cc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4750664;180381;None;0;Human;Binding;Ki;=;31,62;7,50;-18;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;399,2;7;1;5;3,12;Cc1cccc(S(=O)(=O)N[C@@H]2CCN(CCCc3noc4ccccc34)C2)c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4750939;180405;None;0;Human;Binding;Ki;=;23,90;7,62;-3;3;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;405,3;5;1;2;4,91;CCN(C)C(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(Cl)cc3[C@@H](C)C2)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4751063;180417;None;0;Human;Binding;Ki;=;8,32;8,08;-10;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;475,1;7;1;6;4,68;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1cc2ccc(Cl)cc2s1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4752414;180538;None;0;Human;Binding;Ki;=;5,80;8,24;-;1;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;450,2;4;0;3;5,55;C[C@H]1CN(CC[C@H]2CC[C@H](N3C(=O)c4ccccc4C3=O)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4753094;180596;None;0;Human;Binding;Ki;=;5,62;8,25;-22;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;425,1;7;1;6;3,56;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1cc2ccccc2o1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4753808;180653;None;0;Human;Binding;Ki;=;12,10;7,92;-10;5;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;470,3;4;0;3;5,96;C[C@H]1CN(CC[C@H]2CC[C@H](N3C(=O)CC4(CCCC4)CC3=O)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4754138;180685;None;0;Human;Binding;Ki;=;20,42;7,69;-45;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;435,2;7;1;5;3,97;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1cccc2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4754193;180686;None;0;Human;Binding;Ki;=;1,41;8,85;-3;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;459,1;7;1;6;4,17;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1cc2ccc(F)cc2s1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4755336;180782;None;0;Human;Binding;Ki;=;48,00;7,32;-;1;Displacement of [3H]raclopride from human D2R isoform 2 stably expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method;ChEMBL;842,6;34;0;13;6,06;CCCN(CCCCc1cn(CCOCCOCCOCCOCCOCCn2cc(CCCCN(CCC)C3Cc4ccccc4C3)nn2)nn1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.ejmech.2020.113151
CHEMBL4755563;180805;None;0;Human;Binding;Ki;=;188,70;6,72;-10;2;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;453,3;5;1;2;6,10;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)N(C)c3ccccc3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4756254;180879;None;0;Human;Binding;Ki;=;98,00;7,01;-204;2;Binding affinity to human dopamine D2 receptor;ChEMBL;351,1;1;1;3;5,48;Cc1ccc2c(c1)N=C(C1=C[C@H](C)N(C)CC1)c1cc(Cl)ccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4756446;180902;None;0;Human;Binding;Ki;=;9000,00;5,05;-20;5;Binding affinity to D2 receptor (unknown origin);ChEMBL;306,2;4;0;2;3,77;CN(C)CCCN1C(=O)c2ccccc2/C=C\c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2020.127493
CHEMBL4756826;180923;None;0;Human;Binding;Ki;=;9,80;8,01;-1;3;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;388,2;5;1;2;4,78;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)C3CC3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4756987;180939;None;0;Human;Binding;Ki;=;167,50;6,78;-41;2;Binding affinity to human dopamine D2 receptor;ChEMBL;331,2;2;1;3;5,08;CCc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1ccccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4757297;180965;None;0;Human;Binding;Ki;=;69,00;7,16;-34;2;Binding affinity to human dopamine D2 receptor;ChEMBL;367,1;2;1;4;5,18;COc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1cc(Cl)ccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4758402;181064;None;0;Human;Binding;Ki;=;95,50;7,02;-23;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;403,1;7;1;5;2,95;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4758723;181090;None;0;Human;Binding;Ki;=;127,00;6,90;-630;2;Binding affinity to human dopamine D2 receptor;ChEMBL;355,1;1;1;3;5,31;C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccc(F)cc32)CCN1C;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4758774;181095;None;0;Human;Binding;Ki;=;6610,00;5,18;-1;2;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;512,2;11;2;4;4,46;[O-][S+](CCNC1CCN(CC(O)Cc2ccccc2)CC1)C(c1ccc(F)cc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4758966;181109;None;0;Human;Binding;Ki;=;47,00;7,33;-512;3;Binding affinity to human dopamine D2 receptor;ChEMBL;381,2;3;1;4;5,57;CCOc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1cc(Cl)ccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4759208;181129;None;0;Human;Binding;Ki;=;241,00;6,62;-26;3;Displacement of [3H]-Raclopride from dopamine D2 receptor (unknown origin) incubated for 1 hr by microbeta counting method;ChEMBL;355,1;3;0;5;2,63;CN1CCN(c2ccc3ccn(S(=O)(=O)c4ccccc4)c3c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112916
CHEMBL4759492;181154;None;0;Human;Binding;Ki;=;0,93;9,03;-3;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;438,2;7;1;6;3,31;Cn1ccc2cc(S(=O)(=O)N[C@@H]3CCN(CCCc4noc5ccccc45)C3)ccc21;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4759730;181171;None;0;Human;Binding;Ki;=;31,00;7,51;-30;4;Displacement of [3H]-Raclopride from dopamine D2 receptor (unknown origin) incubated for 1 hr by microbeta counting method;ChEMBL;355,1;3;0;5;2,63;CN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112916
CHEMBL4759975;181188;None;0;Human;Binding;Ki;=;2,80;8,55;-1;2;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;439,2;5;2;2;6,07;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)Nc3ccccc3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4760655;181243;None;0;Human;Binding;Ki;=;2,57;8,59;2;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;469,1;7;1;5;4,62;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1ccc2cc(Cl)ccc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4760689;181250;None;0;Human;Binding;Ki;=;150,30;6,82;-1;2;Binding affinity to D2 receptor (unknown origin);ChEMBL;425,2;7;1;5;4,88;CC(=O)Nc1ccc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1C;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4760903;181270;None;0;Human;Binding;Ki;=;28,00;7,55;-199;3;Binding affinity to human dopamine D2 receptor;ChEMBL;365,2;2;1;3;5,73;CCc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1cc(Cl)ccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL476108;181297;None;0;Human;Binding;Ki;=;43,30;7,36;-6;11;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;374,2;6;0;3;4,65;O=C(CCCN1CCCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL476108;181297;UNDEFINED;0;Human;Binding;pKi;=;43,30;7,36;-6;11;-;PDSP KiDatabase;374,2;6;0;3;4,65;O=C(CCCN1CCCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
CHEMBL476109;181300;None;0;Human;Binding;Ki;=;178,40;6,75;-4;7;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;400,2;6;0;3;5,18;O=C(CCCN1C2CCC1CN(c1ccc(Cl)cc1)CC2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL476109;181300;UNDEFINED;0;Human;Binding;pKi;=;178,40;6,75;-4;7;-;PDSP KiDatabase;400,2;6;0;3;5,18;O=C(CCCN1C2CCC1CN(c1ccc(Cl)cc1)CC2)c1ccc(F)cc1;-
CHEMBL4761274;181319;None;0;Human;Binding;Ki;=;84,00;7,08;-10;2;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;390,2;6;1;2;5,17;CCCC(=O)N[C@H]1CC[C@H](CCN2CCc3ccc(Cl)cc3[C@@H](C)C2)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL476185;181365;None;0;Human;Binding;Ki;=;229,09;6,64;1;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;378,2;6;0;4;3,07;O=C1c2ccccc2CCCN1CCCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL4762024;181376;None;0;Human;Binding;Ki;=;14,10;7,85;-2;3;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;456,3;4;0;3;5,43;C[C@H]1CN(CC[C@H]2CC[C@H](N3C(=O)[C@H]4CCCC[C@H]4C3=O)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4762226;181395;None;0;Human;Binding;Ki;=;17,78;7,75;-16;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;459,1;7;1;6;4,17;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1cc2ccc(F)cc2s1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4762918;181445;None;0;Human;Binding;Ki;=;99,30;7,00;-5;2;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;430,3;5;1;2;5,95;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)C3CCCCC3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4763085;181460;None;0;Human;Binding;Ki;=;14,13;7,85;-42;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;435,2;7;1;5;3,97;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4763106;181464;None;0;Human;Binding;Ki;=;34,67;7,46;-3;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;475,1;7;1;6;4,68;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1cc2ccc(Cl)cc2s1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL476393;181531;None;0;Human;Binding;Ki;=;151,36;6,82;4;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;379,2;6;0;5;2,47;O=C1c2ccccc2CCCN1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL476394;181532;None;0;Human;Binding;Ki;=;36,31;7,44;-3;4;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;445,2;6;0;3;4,98;O=C1c2ccccc2CCCN1CCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL4764006;181534;None;0;Human;Binding;Ki;=;1,23;8,91;-3;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;425,1;7;1;6;3,56;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1cc2ccccc2o1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4764468;181567;None;0;Human;Binding;Ki;=;16,22;7,79;-21;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;441,1;7;1;6;4,03;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4764557;181578;None;0;Human;Binding;Ki;=;56,23;7,25;-9;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;465,2;8;1;6;3,98;COc1ccc2cc(S(=O)(=O)N[C@H]3CCN(CCCc4noc5ccccc45)C3)ccc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4764639;181584;None;0;Human;Binding;Ki;=;1589,00;5,80;-11;3;Binding affinity to D2 receptor (unknown origin);ChEMBL;425,2;8;1;5;4,25;CC(=O)NCc1ccc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4764692;181591;None;0;Human;Binding;Ki;=;16,30;7,79;6;3;Binding affinity to D2 receptor (unknown origin);ChEMBL;409,2;7;1;5;4,45;CC(=O)Nc1ccc(OCCCN2CCN(c3cccc4ccsc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4764883;181607;None;0;Human;Binding;Ki;=;1010,00;6,00;-2;3;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;423,2;7;4;6;2,09;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC(O)CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL4764883;181607;None;0;Human;Binding;Ki;=;1010,00;6,00;-2;3;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cells after 90 mins by microbeta counting based assay;ChEMBL;423,2;7;4;6;2,09;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC(O)CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acsmedchemlett.9b00660
CHEMBL4765081;181628;None;0;Human;Binding;Ki;=;6070,00;5,22;-1;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;446,2;7;1;3;5,41;CC(C)(C)C(=O)N1CCC(NCCSC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL476641;181661;None;0;Human;Binding;Ki;=;794,33;6,10;-3;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;393,2;6;0;4;3,30;COc1ccccc1N1CCN(CCCN2CCCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL476808;181676;None;0;Human;Binding;Ki;=;20,42;7,69;1;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;407,3;8;0;4;3,69;COc1ccccc1N1CCN(CCCCCN2CCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL476933;181685;None;0;Human;Binding;Ki;=;155,00;6,81;3;3;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;352,2;6;0;3;4,14;O=C(CCCN1CC2CCC(C1)N2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL476933;181685;UNDEFINED;0;Human;Binding;pKi;=;155,00;6,81;3;3;-;PDSP KiDatabase;352,2;6;0;3;4,14;O=C(CCCN1CC2CCC(C1)N2c1ccccc1)c1ccc(F)cc1;-
CHEMBL476934;181686;None;0;Human;Binding;Ki;=;170,00;6,77;1;3;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;372,1;6;0;3;4,41;O=C(CCCN1CC2CC1CN2c1ccc(Cl)cc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL476934;181686;UNDEFINED;0;Human;Binding;pKi;=;170,00;6,77;1;3;-;PDSP KiDatabase;372,1;6;0;3;4,41;O=C(CCCN1CC2CC1CN2c1ccc(Cl)cc1)c1ccc(F)cc1;-
CHEMBL476935;181687;None;0;Human;Binding;Kd;=;28,18;7,55;-6;10;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL476935;181687;None;0;Human;Binding;Ki;=;253,50;6,60;-6;10;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL476935;181687;None;0;Human;Binding;Ki;=;29,51;7,53;-6;10;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL476935;181687;None;0;Human;Binding;Ki;=;63,00;7,20;-6;10;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100899z
CHEMBL476935;181687;None;0;Human;Binding;Ki;=;254,00;6,59;-6;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL476935;181687;None;0;Human;Binding;Ki;=;253,30;6,60;-6;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
CHEMBL476935;181687;None;0;Human;Binding;Ki;=;253,50;6,60;-6;10;Binding affinity for dopamine D2 receptor;ChEMBL;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.09.046
CHEMBL476935;181687;None;0;Human;Binding;Ki;=;61,00;7,21;-6;10;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100899z
CHEMBL476935;181687;UNDEFINED;0;Human;Binding;pKi;=;254,00;6,60;-6;10;-;PDSP KiDatabase;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
CHEMBL476935;181687;UNDEFINED;0;Human;Binding;pKi;=;253,50;6,60;-6;10;-;PDSP KiDatabase;360,1;6;0;3;4,26;O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
CHEMBL477055;181699;None;0;Human;Binding;Ki;=;218,78;6,66;1;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;431,2;5;0;3;4,59;O=C1c2ccccc2CCCN1CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL477206;181714;None;0;Human;Binding;Ki;=;3,63;8,44;-4;6;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;407,3;7;0;4;3,69;COc1ccccc1N1CCN(CCCCN2CCCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL477206;181714;None;0;Human;Binding;Ki;=;1,50;8,82;-4;6;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;407,3;7;0;4;3,69;COc1ccccc1N1CCN(CCCCN2CCCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL477206;181714;None;0;Human;Binding;Ki;=;3,90;8,41;-4;6;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;407,3;7;0;4;3,69;COc1ccccc1N1CCN(CCCCN2CCCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL477250;181718;None;0;Human;Binding;Ki;=;12,30;7,91;-6;5;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;393,2;7;0;4;3,30;COc1ccccc1N1CCN(CCCCN2CCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL477250;181718;None;0;Human;Binding;Ki;=;21,00;7,68;-6;5;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;393,2;7;0;4;3,30;COc1ccccc1N1CCN(CCCCN2CCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL477250;181718;None;0;Human;Binding;Ki;=;7,00;8,15;-6;5;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;393,2;7;0;4;3,30;COc1ccccc1N1CCN(CCCCN2CCc3ccccc3C2=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.12.083
CHEMBL4775997;181755;None;0;Human;Binding;Ki;=;56,23;7,25;-38;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;437,1;7;1;5;3,61;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4776090;181762;None;0;Human;Binding;Ki;=;453,00;6,34;-83;2;Binding affinity to human dopamine D2 receptor;ChEMBL;335,2;1;1;3;4,96;Cc1ccc2c(c1)N=C(C1=C[C@H](C)N(C)CC1)c1cc(F)ccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4776225;181769;None;0;Human;Binding;Ki;=;32,36;7,49;-29;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;435,2;7;1;5;3,97;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1cccc2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL477646;181781;None;0;Human;Binding;Ki;=;11,48;7,94;14;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;431,2;6;0;3;4,59;O=C1c2ccccc2CCN1CCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL4777055;181831;None;0;Human;Binding;Ki;=;79,10;7,10;-1;3;Binding affinity to D2 receptor (unknown origin);ChEMBL;410,2;7;1;6;3,85;CC(=O)Nc1ccc(OCCCN2CCN(c3nsc4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4778076;181912;None;0;Human;Binding;Ki;=;19100,00;4,72;2;3;Binding affinity to D2 receptor (unknown origin);ChEMBL;348,2;4;0;3;3,54;O=C1c2ccccc2/C=C\c2ccccc2N1CCCN1CCOCC1;https://dx.doi.org/10.1016/j.bmcl.2020.127493
CHEMBL477821;181928;None;1;Human;Binding;IC50;=;2060,00;5,69;-;2;Inhibition of dopamine D2 receptor;ChEMBL;424,2;4;1;4;4,28;O=c1[nH]c2ccccc2n1C1CCN(C2CCN(Cc3ccccc3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2008.09.023
CHEMBL4778398;181943;None;0;Human;Binding;Ki;=;5880,00;5,23;-1;3;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cells after 90 mins by microbeta counting based assay;ChEMBL;421,2;6;3;5;3,22;O=C(NCCCCN1CCO[C@H]2c3cc(O)ccc3OC[C@@H]21)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acsmedchemlett.9b00660
CHEMBL4778418;181945;None;0;Human;Binding;Ki;=;15,14;7,82;-3;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;473,1;7;1;6;4,47;Cc1c(S(=O)(=O)N[C@H]2CCN(CCCc3noc4ccccc34)C2)sc2ccc(F)cc12;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4779001;181989;None;0;Human;Binding;Ki;=;479,00;6,32;-9;2;Binding affinity to human dopamine D2 receptor;ChEMBL;337,1;1;1;3;5,17;C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CCN1C;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4779364;182014;None;0;Human;Binding;Ki;=;167,20;6,78;1;2;Binding affinity to D2 receptor (unknown origin);ChEMBL;421,1;7;1;4;4,54;CC(=O)Nc1ccc(OCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4779739;182035;None;0;Human;Binding;Ki;=;104,71;6,98;-102;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;399,2;7;1;5;3,12;Cc1cccc(S(=O)(=O)N[C@H]2CCN(CCCc3noc4ccccc34)C2)c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4779912;182054;None;0;Human;Binding;Ki;=;290,50;6,54;-1;2;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;391,2;4;1;2;4,52;C[C@@H]1CN(CC[C@H]2CC[C@H](NC(=O)N(C)C)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4780335;182085;None;0;Human;Binding;Ki;=;93,90;7,03;-1;5;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;414,2;5;1;3;5,27;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)c3ccco3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL478034;182086;None;0;Human;Binding;IC50;=;1130,00;5,95;-;2;Inhibition of dopamine D2 receptor;ChEMBL;435,2;5;1;6;3,54;O=c1[nH]c2ccccc2n1C1CCN(C2CCN(Cc3ccccc3[N+](=O)[O-])CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2008.09.023
CHEMBL4780470;182100;None;0;Human;Binding;Ki;=;8,91;8,05;-3;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;489,1;7;1;6;4,99;Cc1c(S(=O)(=O)N[C@@H]2CCN(CCCc3noc4ccccc34)C2)sc2ccc(Cl)cc12;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4781480;182180;None;0;Human;Binding;Ki;=;189,00;6,72;-;1;Displacement of [3H]raclopride from human D2R isoform 2 stably expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method;ChEMBL;255,2;7;0;1;3,67;C#CCCCCN(CCC)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.ejmech.2020.113151
CHEMBL4782149;182234;None;0;Human;Binding;Ki;=;43,65;7,36;-39;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;441,1;7;1;6;4,03;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1csc2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4782694;182288;None;0;Human;Binding;Ki;=;1180,00;5,93;-21;2;Binding affinity to human dopamine D2 receptor;ChEMBL;351,1;1;1;3;5,56;CN1CCC(C2=Nc3cc(Cl)ccc3Nc3ccccc32)=CC1(C)C;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4784228;182417;None;0;Human;Binding;Ki;=;56,23;7,25;-20;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;419,1;7;1;5;3,47;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4784373;182436;None;0;Human;Binding;Ki;=;2,10;8,68;1;7;Binding affinity to D2 receptor (unknown origin);ChEMBL;411,2;7;1;5;4,57;CC(=O)Nc1ccc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4784414;182439;None;0;Human;Binding;Ki;=;23,99;7,62;-17;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;455,1;7;1;6;4,34;Cc1ccc2sc(S(=O)(=O)N[C@H]3CCN(CCCc4noc5ccccc45)C3)cc2c1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4784751;182463;None;0;Human;Binding;Ki;=;31,60;7,50;-9;4;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;468,3;4;0;3;5,28;C[C@H]1CN(CC[C@H]2CC[C@H](N3C(=O)[C@H]4[C@H]5CC[C@H](C5)[C@H]4C3=O)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4785434;182502;None;0;Human;Binding;Ki;=;12,30;7,91;-27;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;438,2;7;1;6;3,31;Cn1ccc2cc(S(=O)(=O)N[C@H]3CCN(CCCc4noc5ccccc45)C3)ccc21;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL478617;182544;None;0;Human;Binding;Ki;=;2,30;8,64;5;6;Binding affinity for dopamine D2 receptor;ChEMBL;367,2;6;1;3;4,30;O=C(CCCN1C2CCC1CC(O)(c1ccccc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.09.046
CHEMBL478617;182544;None;0;Human;Binding;Ki;=;2,30;8,64;5;6;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;367,2;6;1;3;4,30;O=C(CCCN1C2CCC1CC(O)(c1ccccc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
CHEMBL478617;182544;UNDEFINED;0;Human;Binding;pKi;=;2,30;8,64;5;6;-;PDSP KiDatabase;367,2;6;1;3;4,30;O=C(CCCN1C2CCC1CC(O)(c1ccccc1)C2)c1ccc(F)cc1;-
CHEMBL4786420;182571;None;0;Human;Binding;Ki;=;66,00;7,18;-;1;Displacement of [3H]raclopride from human D2R isoform 2 stably expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method;ChEMBL;798,6;31;0;12;6,04;CCCN(CCCCc1cn(CCOCCOCCOCCOCCn2cc(CCCCN(CCC)C3Cc4ccccc4C3)nn2)nn1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.ejmech.2020.113151
CHEMBL478671;182587;None;0;Human;Binding;Ki;=;55,50;7,26;-4;4;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells after 50 mins by beta liquid scintillation counter;ChEMBL;349,2;5;0;3;4,92;CCCC(=O)Oc1cccc2c1-c1cccc3c1[C@@H](C2)N(CCC)CC3;https://dx.doi.org/10.1021/jm200347t
CHEMBL478688;182604;None;0;Human;Binding;Ki;=;158,49;6,80;-3;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;393,2;7;0;4;3,30;COc1cccc(N2CCN(CCCCN3CCc4ccccc4C3=O)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL4788140;182701;None;0;Human;Binding;Ki;=;43,70;7,36;-6;4;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;466,2;4;0;3;5,06;C[C@H]1CN(CC[C@H]2CC[C@H](N3C(=O)[C@H]4[C@H]5C=C[C@H](C5)[C@H]4C3=O)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4789422;182805;None;1;Human;Binding;Ki;=;467,30;6,33;-;1;Binding affinity to D2 receptor (unknown origin);ChEMBL;383,2;8;1;5;3,25;COc1ccccc1N1CCN(CCCOc2ccc(NC(C)=O)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4789472;182808;None;0;Human;Binding;Ki;=;1258,93;5,90;-24;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;387,2;6;0;4;4,19;O=C(CCCN1C2CCC1CN(c1ccc(Cl)cn1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4789472;182808;None;0;Human;Binding;Ki;=;1249,00;5,90;-24;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;387,2;6;0;4;4,19;O=C(CCCN1C2CCC1CN(c1ccc(Cl)cn1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4790018;182849;None;0;Human;Binding;Ki;=;73,00;7,14;-;1;Displacement of [3H]raclopride from human D2R isoform 2 stably expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method;ChEMBL;754,5;28;0;11;6,02;CCCN(CCCCc1cn(CCOCCOCCOCCn2cc(CCCCN(CCC)C3Cc4ccccc4C3)nn2)nn1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.ejmech.2020.113151
CHEMBL4790020;182850;None;0;Human;Binding;Ki;=;38,90;7,41;-4;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;489,1;7;1;6;4,99;Cc1c(S(=O)(=O)N[C@H]2CCN(CCCc3noc4ccccc34)C2)sc2ccc(Cl)cc12;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4790699;182907;None;0;Human;Binding;Ki;=;148,30;6,83;-3;3;Binding affinity to D2 receptor (unknown origin);ChEMBL;429,2;7;1;5;4,71;CC(=O)Nc1ccc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1F;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4791063;182930;None;0;Human;Binding;Ki;=;7440,00;5,13;-2;2;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;502,2;8;1;3;5,96;O=C(c1ccc(F)cc1F)N1CCC(NCCSC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4791884;182986;None;0;Human;Binding;Ki;=;9420,00;5,03;1;3;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cells after 90 mins by microbeta counting based assay;ChEMBL;421,2;6;3;5;3,22;O=C(NCCCCN1CCO[C@@H]2c3cc(O)ccc3OC[C@@H]21)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acsmedchemlett.9b00660
CHEMBL4792709;183047;None;0;Human;Binding;Ki;=;20,60;7,69;-1;3;Binding affinity to D2 receptor (unknown origin);ChEMBL;425,2;7;0;5;4,60;CC(=O)N(C)c1ccc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4792999;183071;None;0;Human;Binding;Ki;=;250,00;6,60;-;1;Displacement of [3H]raclopride from human D2R isoform 2 stably expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method;ChEMBL;1248,7;41;2;16;10,91;CCCN(CCCCNC(=O)c1ccc(-c2ccc(OCc3cn(CCOCCOCCOCCOCCn4cc(COc5ccc(-c6ccc(C(=O)NCCCCN(CCC)C7Cc8ccccc8C7)cc6)cc5)nn4)nn3)cc2)cc1)C1Cc2ccccc2C1;https://dx.doi.org/10.1016/j.ejmech.2020.113151
CHEMBL4793608;183109;None;0;Human;Binding;Ki;=;19,95;7,70;-47;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;441,1;7;1;6;4,03;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1csc2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4793813;183125;None;0;Human;Binding;Ki;=;819,00;6,09;-102;2;Binding affinity to human dopamine D2 receptor;ChEMBL;317,2;1;1;3;4,82;Cc1ccc2c(c1)C(C1=C[C@H](C)N(C)CC1)=Nc1ccccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4794406;183188;None;0;Human;Binding;Ki;=;2920,00;5,54;-3;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;470,2;9;1;3;6,18;Fc1ccc(CN2CCC(NCCSC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4794870;183223;None;0;Human;Binding;Ki;=;970,00;6,01;-;1;Displacement of [3H]raclopride from human D2R isoform 2 stably expressed in HEK293 cell membranes measured after 1 hr by liquid scintillation counting method;ChEMBL;480,3;12;1;3;5,75;C#CCOc1ccc(-c2ccc(C(=O)NCCCCN(CCC)C3Cc4ccccc4C3)cc2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.113151
CHEMBL4794963;183228;None;0;Human;Binding;Ki;=;1143,00;5,94;-21;7;Binding affinity to D2 receptor (unknown origin);ChEMBL;425,2;8;1;5;4,96;CC(=O)Nc1ccc(OCCCCN2CCC(c3noc4cc(F)ccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4795230;183254;None;0;Human;Binding;Ki;=;106,00;6,97;-120;2;Binding affinity to human dopamine D2 receptor;ChEMBL;371,1;1;1;3;5,82;C[C@H]1C=C(C2=Nc3cc(Cl)ccc3Nc3ccc(Cl)cc32)CCN1C;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4795995;183319;None;0;Human;Binding;Ki;=;0,45;9,35;7;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;441,1;7;1;6;4,03;O=S(=O)(N[C@@H]1CCN(CCCc2noc3ccccc23)C1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4796647;183377;None;0;Human;Binding;Ki;=;323,59;6,49;-20;4;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;403,1;7;1;5;2,95;O=S(=O)(N[C@H]1CCN(CCCc2noc3ccccc23)C1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
CHEMBL4796968;183401;None;0;Human;Binding;Ki;=;7500,00;5,12;2;4;Binding affinity to D2 receptor (unknown origin);ChEMBL;361,2;4;0;3;3,46;CN1CCN(CCCN2C(=O)c3ccccc3/C=C\c3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127493
CHEMBL4797375;183430;None;0;Human;Binding;Ki;=;1218,00;5,91;-512;2;Binding affinity to human dopamine D2 receptor;ChEMBL;401,2;2;1;4;5,72;Cc1ccc2c(c1)N=C(C1=C[C@H](C)N(C)CC1)c1cc(OC(F)(F)F)ccc1N2;https://dx.doi.org/10.1016/j.bmcl.2020.127563
CHEMBL4797996;183494;None;0;Human;Binding;Ki;=;6,30;8,20;-5;3;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;417,3;4;1;2;5,06;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)N3CCCC3)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4798631;183531;None;0;Human;Binding;Ki;=;498,20;6,30;-;1;Binding affinity to D2 receptor (unknown origin);ChEMBL;355,2;7;1;6;2,03;CC(=O)Nc1ccc(OCCCN2CCN(c3ncccn3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4798638;183532;None;0;Human;Binding;Ki;=;2270,00;5,64;-3;3;Displacement of [3H]-N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by microbeta scintillation counting method;ChEMBL;496,2;11;2;4;5,45;OC(CNC1CCN(CCSC(c2ccc(F)cc2)c2ccc(F)cc2)CC1)Cc1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2020.112674
CHEMBL4799863;183630;None;0;Human;Binding;Ki;=;5,90;8,23;-11;4;Displacement of [3H]-spiperone from recombinant human D2L receptor expressed in CHO cells;ChEMBL;391,2;4;1;2;4,52;C[C@H]1CN(CC[C@H]2CC[C@H](NC(=O)N(C)C)CC2)CCc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2020.127681
CHEMBL4799934;183639;None;0;Human;Binding;Ki;=;119,20;6,92;-1;3;Binding affinity to D2 receptor (unknown origin);ChEMBL;427,2;7;2;6;3,54;CC(=O)Nc1ccc(OCC(O)CN2CCC(c3noc4cc(F)ccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127506
CHEMBL4802393;183731;None;0;Human;Binding;Ki;=;645,65;6,19;-10;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;389,2;7;0;3;5,03;Fc1ccc(CCCCN2CCN(c3cccc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4802393;183731;None;0;Human;Binding;Ki;=;641,00;6,19;-10;7;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;389,2;7;0;3;5,03;Fc1ccc(CCCCN2CCN(c3cccc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4803797;183861;None;0;Human;Binding;Ki;=;1174,90;5,93;-39;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;327,2;6;0;4;3,01;O=C(CCCN1CCN(c2cccnc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL4803797;183861;None;0;Human;Binding;Ki;=;1168,00;5,93;-39;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;327,2;6;0;4;3,01;O=C(CCCN1CCN(c2cccnc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115943
CHEMBL480434;183903;None;0;Human;Binding;Ki;=;251,19;6,60;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;229,2;3;0;3;2,09;CCCN1CCN(c2cccc(C#N)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL480434;183903;None;0;Human;Binding;Ki;=;270,00;6,57;-;1;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;229,2;3;0;3;2,09;CCCN1CCN(c2cccc(C#N)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL482556;184205;None;0;Human;Binding;Ki;=;1202,26;5,92;-63;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;298,2;2;1;3;2,63;CCCN1CCO[C@@H]2c3cc4c(=O)[nH]ccc4cc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL482978;184266;None;0;Human;Binding;Ki;=;3090,30;5,51;-32;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;273,2;3;0;3;2,99;CCCN1CCO[C@@H]2c3cc(C(C)=O)ccc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL483593;184351;None;0;Human;Binding;Ki;=;220,00;6,66;-64;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;486,3;10;1;2;6,93;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CC=C(C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL483593;184351;None;0;Human;Binding;Ki;=;360,00;6,44;-64;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;486,3;10;1;2;6,93;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CC=C(C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL483593;184351;UNDEFINED;0;Human;Binding;pKi;=;220,00;6,66;-64;4;-;PDSP KiDatabase;486,3;10;1;2;6,93;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CC=C(C#C[Si](C)(C)C)CC1;-
CHEMBL483593;184351;UNDEFINED;0;Human;Binding;pKi;=;360,00;6,44;-64;4;-;PDSP KiDatabase;486,3;10;1;2;6,93;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CC=C(C#C[Si](C)(C)C)CC1;-
CHEMBL484170;184416;None;0;Human;Binding;Ki;=;7943,28;5,10;-;1;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;288,2;3;1;3;2,14;CCCN1CCO[C@@H]2c3cc(C(=O)NC)ccc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL484202;184423;None;0;Human;Binding;Ki;=;610,00;6,21;-36;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;438,3;10;0;4;6,22;C#CC1=CCC(N(CCC)CCCCn2cc(-c3ccc(-c4ccccc4)cc3)nn2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484202;184423;None;0;Human;Binding;Ki;=;170,00;6,77;-36;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;438,3;10;0;4;6,22;C#CC1=CCC(N(CCC)CCCCn2cc(-c3ccc(-c4ccccc4)cc3)nn2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484202;184423;UNDEFINED;0;Human;Binding;pKi;=;610,00;6,21;-36;4;-;PDSP KiDatabase;438,3;10;0;4;6,22;C#CC1=CCC(N(CCC)CCCCn2cc(-c3ccc(-c4ccccc4)cc3)nn2)CC1;-
CHEMBL484202;184423;UNDEFINED;0;Human;Binding;pKi;=;170,00;6,77;-36;4;-;PDSP KiDatabase;438,3;10;0;4;6,22;C#CC1=CCC(N(CCC)CCCCn2cc(-c3ccc(-c4ccccc4)cc3)nn2)CC1;-
CHEMBL484203;184424;None;0;Human;Binding;Ki;=;2100,00;5,68;-28;3;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;314,2;8;0;4;3,58;CC#CC1=CCC(N(CCC)CCCCn2cc(C)nn2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484203;184424;None;0;Human;Binding;Ki;=;4100,00;5,39;-28;3;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;314,2;8;0;4;3,58;CC#CC1=CCC(N(CCC)CCCCn2cc(C)nn2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484203;184424;UNDEFINED;0;Human;Binding;pKi;=;4100,00;5,39;-28;3;-;PDSP KiDatabase;314,2;8;0;4;3,58;CC#CC1=CCC(N(CCC)CCCCn2cc(C)nn2)CC1;-
CHEMBL484203;184424;UNDEFINED;0;Human;Binding;pKi;=;2100,00;5,68;-28;3;-;PDSP KiDatabase;314,2;8;0;4;3,58;CC#CC1=CCC(N(CCC)CCCCn2cc(C)nn2)CC1;-
CHEMBL484204;184425;None;0;Human;Binding;Ki;=;8800,00;5,06;-9;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;352,3;11;1;2;4,99;CCCN(CCC)CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484204;184425;None;0;Human;Binding;Ki;=;9700,00;5,01;-9;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;352,3;11;1;2;4,99;CCCN(CCC)CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484204;184425;UNDEFINED;0;Human;Binding;pKi;=;8800,00;5,06;-9;4;-;PDSP KiDatabase;352,3;11;1;2;4,99;CCCN(CCC)CCCCNC(=O)c1ccc(-c2ccccc2)cc1;-
CHEMBL484204;184425;UNDEFINED;0;Human;Binding;pKi;=;9700,00;5,01;-9;4;-;PDSP KiDatabase;352,3;11;1;2;4,99;CCCN(CCC)CCCCNC(=O)c1ccc(-c2ccccc2)cc1;-
CHEMBL484357;184447;None;0;Human;Binding;Ki;=;4700,00;5,33;-16;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;490,3;10;1;2;7,11;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CC=C(C#Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484357;184447;None;0;Human;Binding;Ki;=;5500,00;5,26;-16;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;490,3;10;1;2;7,11;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CC=C(C#Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484357;184447;UNDEFINED;0;Human;Binding;pKi;=;5500,00;5,26;-16;4;-;PDSP KiDatabase;490,3;10;1;2;7,11;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CC=C(C#Cc2ccccc2)CC1;-
CHEMBL484357;184447;UNDEFINED;0;Human;Binding;pKi;=;4700,00;5,33;-16;4;-;PDSP KiDatabase;490,3;10;1;2;7,11;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CC=C(C#Cc2ccccc2)CC1;-
CHEMBL484358;184448;None;0;Human;Binding;Ki;=;43,00;7,37;-21;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;414,3;10;1;2;5,69;C#CC1=CCC(N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484358;184448;None;0;Human;Binding;Ki;=;40,00;7,40;-21;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;414,3;10;1;2;5,69;C#CC1=CCC(N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL484358;184448;UNDEFINED;0;Human;Binding;pKi;=;43,00;7,37;-21;4;-;PDSP KiDatabase;414,3;10;1;2;5,69;C#CC1=CCC(N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;-
CHEMBL484358;184448;UNDEFINED;0;Human;Binding;pKi;=;40,00;7,40;-21;4;-;PDSP KiDatabase;414,3;10;1;2;5,69;C#CC1=CCC(N(CCC)CCCCNC(=O)c2ccc(-c3ccccc3)cc2)CC1;-
CHEMBL4845711;184487;None;0;Human;Binding;Ki;=;1825,00;5,74;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;373,3;8;2;3;3,61;COc1ccccc1C1CC1CNCC[C@H]1CC[C@H](NC(=O)N(C)C)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4845711;184487;None;0;Human;Binding;Ki;=;1819,70;5,74;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;373,3;8;2;3;3,61;COc1ccccc1C1CC1CNCC[C@H]1CC[C@H](NC(=O)N(C)C)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4845741;184490;None;0;Human;Binding;Ki;=;676,08;6,17;-51;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;310,2;6;1;4;2,81;Nc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4845741;184490;None;0;Human;Binding;Ki;=;674,00;6,17;-51;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;310,2;6;1;4;2,81;Nc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4845838;184501;None;0;Human;Binding;Ki;=;897,00;6,05;-66;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;444,1;6;1;4;3,79;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1ccc(Br)cc1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL484598;184514;None;0;Human;Binding;Ki;=;831,76;6,08;-199;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;286,2;2;1;3;2,03;CCCN1CCO[C@@H]2c3cc4c(cc3CC[C@H]21)CNC4=O;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL484599;184515;None;0;Human;Binding;Ki;=;1202,26;5,92;-81;4;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;274,2;3;1;3;1,88;CCCN1CCO[C@@H]2c3cc(C(N)=O)ccc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL4846101;184522;None;0;Human;Binding;Ki;=;426,60;6,37;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;472,2;11;1;3;6,51;CCCN(CCCCOc1ccc2ccc(=O)[nH]c2c1)CC1CC1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4846101;184522;None;0;Human;Binding;Ki;=;426,58;6,37;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;472,2;11;1;3;6,51;CCCN(CCCCOc1ccc2ccc(=O)[nH]c2c1)CC1CC1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4846146;184526;None;0;Human;Binding;Ki;=;375,00;6,43;-5;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;382,1;4;1;7;2,65;CC(Oc1cc(Cl)ccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4846153;184528;None;0;Human;Binding;Ki;=;1345,00;5,87;-446;5;Displacement of [3H]-haloperidol from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;426,1;3;1;6;3,49;O=S(=O)(c1cccc(Cl)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21;https://dx.doi.org/10.1021/acs.jmedchem.1c00224
CHEMBL4846201;184531;None;0;Human;Binding;Ki;=;588,84;6,23;-10;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;416,2;10;4;4;3,24;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)NCC(C)CCCc1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4846380;184542;None;0;Human;Binding;Ki;=;1698,24;5,77;-97;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;350,2;6;4;5;1,93;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)NC(C)c1ccco1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4846472;184548;None;0;Human;Binding;Ki;=;32,90;7,48;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;9;2;4;4,35;COc1ccc(Cl)cc1C1CC1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4846472;184548;None;0;Human;Binding;Ki;=;33,11;7,48;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;9;2;4;4,35;COc1ccc(Cl)cc1C1CC1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4846561;184556;None;0;Human;Binding;Ki;=;0,95;9,02;-1;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;571,2;13;3;7;4,78;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCNC(=O)c3cc4ccccc4o3)CN2CC)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4846574;184557;None;0;Human;Binding;Ki;=;46,00;7,34;-38;5;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;441,2;7;1;5;4,06;COc1cc2c(cc1OC)CN(Cc1ccccc1CNC(=O)c1cccc(C#N)c1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4846638;184560;None;0;Human;Binding;Ki;=;263,03;6,58;-6;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;380,2;7;4;4;2,80;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)NCC(C)C1CCCCC1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4846823;184570;None;0;Human;Binding;Ki;=;1096,48;5,96;-1479;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;383,2;5;0;4;4,08;CC1(CCCN2CCN(c3ccccn3)CC2)Cc2cc(Cl)ccc2C1=O;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4846823;184570;None;0;Human;Binding;Ki;=;1096,00;5,96;-1479;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;383,2;5;0;4;4,08;CC1(CCCN2CCN(c3ccccn3)CC2)Cc2cc(Cl)ccc2C1=O;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4846866;184572;None;0;Human;Binding;Ki;=;1,90;8,72;2;9;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;480,3;9;0;6;4,75;CN1CCN(Cc2ccc(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL484732;184601;None;0;Human;Binding;Ki;=;776,25;6,11;-20;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;300,2;2;1;3;2,07;CCCN1CCO[C@@H]2c3cc4c(cc3CC[C@H]21)CCNC4=O;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL4847379;184606;None;0;Human;Binding;Ki;=;1506,00;5,82;-4;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;328,2;5;1;7;1,74;CCC(Oc1ccccc1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4847432;184614;None;0;Human;Binding;Ki;=;1,90;8,72;-2;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;400,2;10;4;6;1,87;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCO)CN2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4848199;184657;None;0;Human;Binding;Ki;=;776,00;6,11;-10;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;366,2;6;1;4;3,03;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1ccccc1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4848451;184672;None;0;Human;Binding;Ki;=;98,30;7,01;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;9;2;3;5,23;O=c1ccc2ccc(OCCCCNCC3CC3c3cccc4ccccc34)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4848451;184672;None;0;Human;Binding;Ki;=;97,72;7,01;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;9;2;3;5,23;O=c1ccc2ccc(OCCCCNCC3CC3c3cccc4ccccc34)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4848710;184691;None;0;Human;Binding;Ki;=;568,00;6,25;-40;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;396,2;7;1;5;3,04;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3ccccc3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4848815;184696;None;0;Human;Binding;Ki;=;524,81;6,28;-8;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;388,2;8;4;4;2,77;CCC(CNC(=O)/N=C(\N)NCCCc1sc(N)nc1C)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4848907;184706;None;0;Human;Binding;Ki;=;853,00;6,07;-72;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;356,2;6;1;5;2,62;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1ccco1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4848910;184707;None;0;Human;Binding;Ki;=;76,00;7,12;2;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;480,1;6;2;4;4,65;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccc(Br)cc1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4849077;184719;None;0;Human;Binding;Ki;=;270,00;6,57;-1;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;424,2;7;1;7;3,82;CCCCC(Oc1cc(Cl)cc(Cl)c1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4849107;184721;None;0;Human;Binding;Ki;=;25,30;7,60;-3;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;529,2;11;3;6;4,55;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCCCOc2ccc3c(c2)NC(=O)CC3)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4849230;184723;None;0;Human;Binding;Ki;=;413,00;6,38;1;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;396,1;6;1;7;2,52;CN1CCN(c2nc(N)nc(CCCOc3cc(Cl)ccc3Cl)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4849499;184741;None;0;Human;Binding;Ki;=;900,00;6,05;-2;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;413,2;5;3;5;3,46;N#Cc1cccc(C(=O)NCc2ccccc2CN2CCc3cc(O)c(O)cc3C2)c1;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4849734;184767;None;0;Human;Binding;Ki;=;863,00;6,06;-67;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;396,2;7;1;5;3,04;COc1ccccc1C(=O)NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4849780;184772;None;0;Human;Binding;Ki;=;263,03;6,58;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;456,2;11;1;4;5,52;CCN(CCCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4849780;184772;None;0;Human;Binding;Ki;=;263,30;6,58;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;456,2;11;1;4;5,52;CCN(CCCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL485027;184812;None;0;Human;Binding;Ki;=;3388,44;5,47;-;1;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;394,2;6;1;4;3,72;CCCN1CCO[C@@H]2c3cc(C(=O)NCc4ccc(OC)cc4)ccc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL485029;184815;None;0;Human;Binding;Ki;=;1862,09;5,73;-;1;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;302,2;3;0;3;2,49;CCCN1CCO[C@@H]2c3cc(C(=O)N(C)C)ccc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL4850300;184817;None;0;Human;Binding;Ki;=;2,29;8,64;-4;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;543,2;12;4;7;4,05;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCNC(=O)c3cc4ccccc4o3)CN2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4850635;184836;None;0;Human;Binding;Ki;=;155,70;6,81;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;378,2;9;2;4;3,70;COc1ccccc1C1CC1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4850635;184836;None;0;Human;Binding;Ki;=;154,88;6,81;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;378,2;9;2;4;3,70;COc1ccccc1C1CC1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4851121;184873;None;0;Human;Binding;Ki;=;1330,00;5,88;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;411,2;7;2;2;4,91;CN(C)C(=O)N[C@H]1CC[C@H](CCNCC2CC2c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4851121;184873;None;0;Human;Binding;Ki;=;1122,02;5,95;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;411,2;7;2;2;4,91;CN(C)C(=O)N[C@H]1CC[C@H](CCNCC2CC2c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL485127;184879;None;0;Human;Binding;Ki;=;501,19;6,30;1;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;286,2;2;1;3;2,03;CCCN1CCO[C@H]2c3cc4c(cc3CC[C@@H]21)CNC4=O;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL485128;184880;None;0;Human;Binding;Ki;=;2041,74;5,69;-269;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;287,2;2;0;4;2,46;CCCN1CCO[C@@H]2c3cc4c(cc3CC[C@H]21)COC4=O;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL485227;184946;None;0;Human;Binding;Ki;=;4700,00;5,33;-38;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;392,3;10;1;2;5,91;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCCCC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL485227;184946;None;0;Human;Binding;Ki;=;6300,00;5,20;-38;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;392,3;10;1;2;5,91;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCCCC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL485227;184946;UNDEFINED;0;Human;Binding;pKi;=;6300,00;5,20;-38;4;-;PDSP KiDatabase;392,3;10;1;2;5,91;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCCCC1;-
CHEMBL485227;184946;UNDEFINED;0;Human;Binding;pKi;=;4700,00;5,33;-38;4;-;PDSP KiDatabase;392,3;10;1;2;5,91;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCCCC1;-
CHEMBL4852472;184966;None;0;Human;Binding;Ki;=;803,00;6,09;-123;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;402,2;7;1;6;3,10;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3cccs3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4852524;184969;None;0;Human;Binding;Ki;=;43,80;7,36;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;410,2;10;2;4;4,23;COc1ccc(F)cc1[C@@H]1C[C@H]1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4852524;184969;None;0;Human;Binding;Ki;=;43,65;7,36;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;410,2;10;2;4;4,23;COc1ccc(F)cc1[C@@H]1C[C@H]1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4852663;184980;None;0;Human;Binding;Ki;=;12,20;7,91;-1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;437,2;8;0;5;5,21;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCCC5)cc4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4852808;184990;None;0;Human;Binding;Ki;=;32,20;7,49;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;414,2;9;2;4;4,40;COc1ccc(Cl)cc1C1CC1CNCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4852808;184990;None;0;Human;Binding;Ki;=;32,36;7,49;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;414,2;9;2;4;4,40;COc1ccc(Cl)cc1C1CC1CNCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4852835;184992;None;0;Human;Binding;Ki;=;6,58;8,18;-;1;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;396,2;9;2;4;3,84;COc1ccc(F)cc1[C@@H]1C[C@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1016/j.bmcl.2024.129654
CHEMBL4852835;184992;None;0;Human;Binding;Ki;=;362,50;6,44;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;396,2;9;2;4;3,84;COc1ccc(F)cc1[C@@H]1C[C@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4852835;184992;None;0;Human;Binding;Ki;=;363,08;6,44;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;396,2;9;2;4;3,84;COc1ccc(F)cc1[C@@H]1C[C@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4853107;185009;None;0;Human;Binding;Ki;=;501,19;6,30;-6;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;402,2;8;4;4;2,77;Cc1ccc(CC(C)CNC(=O)/N=C(\N)NCCCc2sc(N)nc2C)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL485325;185014;None;0;Human;Binding;Ki;=;1479,11;5,83;-12;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;301,2;2;0;4;2,50;CCCN1CCO[C@@H]2c3cc4c(cc3CC[C@H]21)CCOC4=O;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL4853342;185027;None;0;Human;Binding;Ki;=;2,50;8,60;2;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;487,2;8;0;6;5,10;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCOCC5)cc4Cl)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4853503;185036;None;0;Human;Binding;Ki;=;958,00;6,02;-112;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;474,1;7;1;5;3,80;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3ccc(Br)cc3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL485352;185037;None;0;Human;Binding;Ki;=;794,33;6,10;-19;2;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;256,2;2;0;3;2,66;CCCN1CCO[C@@H]2c3cc(C#N)ccc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL4853568;185044;None;0;Human;Binding;Ki;=;1,86;8,73;-1;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;570,3;13;4;6;4,52;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCNC(=O)c3cc4ccccc4[nH]3)CN2CC)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4853668;185049;None;0;Human;Binding;Ki;=;562,34;6,25;-39;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;340,2;9;4;4;2,16;CCCCCCNC(=O)/N=C(\N)NCCCc1sc(N)nc1C;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4853700;185053;None;0;Human;Binding;Ki;=;92,00;7,04;-7;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;414,2;7;0;6;2,22;O=C1c2ccccc2S(=O)(=O)N1CCCCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4853772;185056;None;0;Human;Binding;Ki;=;1174,90;5,93;-19;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;376,1;6;4;4;2,51;Cc1nc(N)sc1CCCN/C(N)=N/C(=S)N[C@H](C)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL485384;185062;None;0;Human;Binding;Ki;=;670,00;6,17;-52;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;510,3;10;0;4;7,46;CCCN(CCCCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)C1CC=C(C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL485384;185062;None;0;Human;Binding;Ki;=;690,00;6,16;-52;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;510,3;10;0;4;7,46;CCCN(CCCCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)C1CC=C(C#C[Si](C)(C)C)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL485384;185062;UNDEFINED;0;Human;Binding;pKi;=;670,00;6,17;-52;4;-;PDSP KiDatabase;510,3;10;0;4;7,46;CCCN(CCCCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)C1CC=C(C#C[Si](C)(C)C)CC1;-
CHEMBL485384;185062;UNDEFINED;0;Human;Binding;pKi;=;690,00;6,16;-52;4;-;PDSP KiDatabase;510,3;10;0;4;7,46;CCCN(CCCCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)C1CC=C(C#C[Si](C)(C)C)CC1;-
CHEMBL4853938;185067;None;0;Human;Binding;Ki;=;27,60;7,56;-1;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;527,2;11;3;6;4,77;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCCCNC(=O)c2cc3ccccc3o2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4853993;185074;None;0;Human;Binding;Ki;=;785,00;6,11;-29;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;430,2;7;1;5;3,69;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3cccc(Cl)c3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4854126;185081;None;0;Human;Binding;Ki;=;1025,00;5,99;-23;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;442,2;7;1;4;4,70;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4854351;185099;None;0;Human;Binding;Ki;=;732,00;6,13;-758;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;435,2;7;2;5;3,52;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3cc4ccccc4[nH]3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4854391;185100;None;0;Human;Binding;Ki;=;380,19;6,42;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;422,2;9;2;5;3,90;O=C1CCc2ccc(OCCCCNCC3CC3c3cccc4c3OCCO4)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4854391;185100;None;0;Human;Binding;Ki;=;384,30;6,42;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;422,2;9;2;5;3,90;O=C1CCc2ccc(OCCCCNCC3CC3c3cccc4c3OCCO4)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4854456;185103;None;0;Human;Binding;Ki;=;3090,30;5,51;-134;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;389,1;4;0;4;3,96;O=C1c2cc(Cl)c(Cl)cc2CC1CCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4854456;185103;None;0;Human;Binding;Ki;=;3071,00;5,51;-134;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;389,1;4;0;4;3,96;O=C1c2cc(Cl)c(Cl)cc2CC1CCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4854512;185106;None;0;Human;Binding;Ki;=;100,00;7,00;1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;436,2;6;2;4;4,54;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1cccc(Cl)c1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4854935;185125;None;0;Human;Binding;Ki;=;47,00;7,33;1;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;436,2;6;2;4;4,54;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccc(Cl)cc1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4855019;185130;None;0;Human;Binding;Ki;=;310,00;6,51;2;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;452,2;6;2;4;5,04;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccc3ccccc3c1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4855361;185155;None;0;Human;Binding;Ki;=;84,00;7,08;-;1;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;528,1;6;2;4;4,49;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccc(I)cc1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4855393;185161;None;0;Human;Binding;Ki;=;432,00;6,37;-6;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;382,1;4;1;7;2,65;CC(Oc1cccc(Cl)c1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4855583;185173;None;0;Human;Binding;Ki;=;213,80;6,67;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;442,2;10;1;4;5,13;CCN(CCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4855583;185173;None;0;Human;Binding;Ki;=;214,00;6,67;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;442,2;10;1;4;5,13;CCN(CCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cc(Cl)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4855711;185179;None;0;Human;Binding;Ki;=;417,00;6,38;-22;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;372,2;6;1;5;3,09;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1cccs1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4855775;185182;None;0;Human;Binding;Ki;=;453,90;6,34;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;392,2;9;2;4;3,91;COc1ccccc1C1CC1CNC/C=C/COc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4855775;185182;None;0;Human;Binding;Ki;=;457,09;6,34;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;392,2;9;2;4;3,91;COc1ccccc1C1CC1CNC/C=C/COc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4855879;185188;None;0;Human;Binding;Ki;=;962,00;6,02;-776;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;486,2;10;1;8;3,07;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3cc(OC)c(OC)c(OC)c3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4855891;185189;None;0;Human;Binding;Ki;=;27,00;7,57;-1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;558,1;7;2;5;4,50;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccc(I)c(OC)c1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4856005;185194;None;0;Human;Binding;Ki;=;602,56;6,22;-13;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;346,2;6;4;4;1,78;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)NCc1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4856059;185204;None;0;Human;Binding;Ki;=;154,88;6,81;-25;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;360,2;6;4;4;2,34;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)N[C@H](C)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4856161;185213;None;0;Human;Binding;Ki;=;420,00;6,38;1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;480,1;6;2;4;4,65;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccccc1Br)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4856753;185248;None;0;Human;Binding;Ki;=;2,00;8,70;2;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;467,3;9;0;6;4,84;Fc1ccc2c(C3CCN(CCCCOc4ccc(CN5CCOCC5)cc4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4856983;185257;None;0;Human;Binding;Ki;=;7,24;8,14;-7;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;490,2;13;3;6;4,09;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCOCc3ccccc3)CN2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4857166;185269;None;0;Human;Binding;Ki;=;74,00;7,13;2;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;432,2;7;2;5;3,90;COc1ccc(C(=O)NCc2ccccc2CN2CCc3cc(OC)c(O)cc3C2)cc1;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4857350;185286;None;0;Human;Binding;Ki;=;12,60;7,90;-1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;451,3;8;0;5;5,52;Cc1cc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)ccc1CN1CCCC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4857560;185304;None;0;Human;Binding;Ki;=;478,63;6,32;-6;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;394,3;8;4;4;3,19;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)NCC(C)CC1CCCCC1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4857597;185308;None;0;Human;Binding;Ki;=;526,50;6,28;-120;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;364,2;6;1;4;3,11;O=C1CCc2cc(CCCCN3CCN(c4ccccn4)CC3)ccc2N1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4857597;185308;None;0;Human;Binding;Ki;=;501,19;6,30;-120;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;364,2;6;1;4;3,11;O=C1CCc2cc(CCCCN3CCN(c4ccccn4)CC3)ccc2N1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4857665;185315;None;0;Human;Binding;Ki;=;1047,13;5,98;-251;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;383,2;6;0;4;4,08;O=C1c2ccc(Cl)cc2CC1CCCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4857665;185315;None;0;Human;Binding;Ki;=;1056,00;5,98;-251;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;383,2;6;0;4;4,08;O=C1c2ccc(Cl)cc2CC1CCCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4857676;185316;None;0;Human;Binding;Ki;=;580,00;6,24;-2;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;396,1;5;1;7;3,04;CCC(Oc1ccc(Cl)c(Cl)c1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4857759;185320;None;0;Human;Binding;Ki;=;15,60;7,81;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;426,2;10;2;4;4,74;COc1ccc(Cl)cc1C1CC1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4857759;185320;None;0;Human;Binding;Ki;=;15,49;7,81;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;426,2;10;2;4;4,74;COc1ccc(Cl)cc1C1CC1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4857918;185328;None;0;Human;Binding;Ki;=;13,40;7,87;-1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;480,3;9;0;6;4,41;CN1CCN(CCc2ccc(OCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4858771;185375;None;0;Human;Binding;Ki;=;229,00;6,64;-3;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;410,1;6;1;7;3,43;CCCC(Oc1cc(Cl)ccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4858824;185378;None;0;Human;Binding;Ki;=;205,00;6,69;-7;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;402,2;7;2;4;4,01;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2Cc2ccccc2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4858961;185385;None;0;Human;Binding;Ki;=;66,40;7,18;-4;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;354,2;7;2;4;3,08;CCCN1CCC(CNC(=O)c2c(O)c(CC)cc(Cl)c2OC)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4859080;185392;None;0;Human;Binding;Ki;=;128,82;6,89;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;430,1;9;2;3;5,39;O=c1ccc2ccc(OCCCCNCC3CC3c3cccc(Cl)c3Cl)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4859080;185392;None;0;Human;Binding;Ki;=;128,10;6,89;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;430,1;9;2;3;5,39;O=c1ccc2ccc(OCCCCNCC3CC3c3cccc(Cl)c3Cl)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4859348;185409;None;0;Human;Binding;Ki;=;10,30;7,99;-1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;469,3;8;0;5;5,74;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCCCC5)cc4F)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4859394;185414;None;0;Human;Binding;Ki;=;259,20;6,59;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;408,2;11;2;4;4,52;COc1ccccc1C1CC1CNCCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4859394;185414;None;0;Human;Binding;Ki;=;257,04;6,59;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;408,2;11;2;4;4,52;COc1ccccc1C1CC1CNCCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4859410;185418;None;0;Human;Binding;Ki;=;38,00;7,42;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;428,2;10;2;4;4,79;COc1ccc(Cl)cc1C1CC1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4859410;185418;None;0;Human;Binding;Ki;=;38,02;7,42;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;428,2;10;2;4;4,79;COc1ccc(Cl)cc1C1CC1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4859567;185428;None;0;Human;Binding;Ki;=;178,00;6,75;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;420,2;9;2;5;3,85;O=c1ccc2ccc(OCCCCNCC3CC3c3cccc4c3OCCO4)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4859567;185428;None;0;Human;Binding;Ki;=;177,83;6,75;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;420,2;9;2;5;3,85;O=c1ccc2ccc(OCCCCNCC3CC3c3cccc4c3OCCO4)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4859988;185449;None;0;Human;Binding;Ki;=;1930,00;5,71;-134;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;352,2;7;1;4;3,19;CC(=O)Nc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4859988;185449;None;0;Human;Binding;Ki;=;1949,84;5,71;-134;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;352,2;7;1;4;3,19;CC(=O)Nc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4860006;185450;None;0;Human;Binding;Ki;=;157,00;6,80;-1;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;382,1;4;1;7;2,65;CC(Oc1cc(Cl)cc(Cl)c1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4860225;185463;None;0;Human;Binding;Ki;=;83,00;7,08;-2;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;413,2;5;3;5;3,46;N#Cc1ccc(C(=O)NCc2ccccc2CN2CCc3cc(O)c(O)cc3C2)cc1;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4860275;185466;None;0;Human;Binding;Ki;=;320,00;6,50;-5;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;396,1;5;1;7;3,04;CCC(Oc1cc(Cl)ccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4860275;185466;None;0;Human;Binding;Ki;=;320,00;6,50;-5;5;Displacement of [3H]-Raclopride from human dopamine D2 receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;396,1;5;1;7;3,04;CCC(Oc1cc(Cl)ccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2022.114645
CHEMBL4860478;185477;None;0;Human;Binding;Ki;=;2,54;8,60;-3;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;542,2;12;5;6;3,79;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCNC(=O)c3cc4ccccc4[nH]3)CN2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4860528;185483;None;0;Human;Binding;Ki;=;446,68;6,35;-8511;20;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;326,2;8;4;4;1,77;CCCCCNC(=O)/N=C(\N)NCCCc1sc(N)nc1C;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4860626;185491;None;0;Human;Binding;Ki;=;26,00;7,58;-26;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;467,1;6;0;5;3,74;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4860687;185496;None;0;Human;Binding;Ki;=;967,00;6,01;-75;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;430,2;7;1;5;3,69;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3ccc(Cl)cc3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4860719;185500;None;0;Human;Binding;Ki;=;206,00;6,69;2;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;396,1;6;1;7;2,52;CN1CCN(c2nc(N)nc(CCCOc3cccc(Cl)c3Cl)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4860754;185502;None;0;Human;Binding;Ki;=;20,00;7,70;-6;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;443,2;8;0;6;2,83;COc1ccccc1N1CCN(CCCCCN2C(=O)c3ccccc3S2(=O)=O)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4860828;185504;None;0;Human;Binding;Ki;=;1,90;8,72;2;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;471,2;8;0;6;4,59;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCOCC5)cc4F)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4861193;185520;None;0;Human;Binding;Ki;=;7,40;8,13;1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;479,3;9;0;5;5,89;CC1CCN(CCc2ccc(OCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4861311;185526;None;0;Human;Binding;Ki;=;9,70;8,01;-1;9;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;465,3;9;0;5;5,64;Fc1ccc2c(C3CCN(CCCOc4ccc(CCN5CCCCC5)cc4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4861431;185535;None;0;Human;Binding;Ki;=;754,00;6,12;-3;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;382,1;4;1;7;2,65;CC(Oc1ccc(Cl)c(Cl)c1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4861553;185548;None;0;Human;Binding;Ki;=;365,60;6,44;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;410,2;10;2;4;4,85;CSc1ccccc1C1CC1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4861553;185548;None;0;Human;Binding;Ki;=;363,08;6,44;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;410,2;10;2;4;4,85;CSc1ccccc1C1CC1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4861643;185554;None;0;Human;Binding;Ki;=;2,70;8,57;1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;493,3;10;0;5;6,28;CC1CCN(CCc2ccc(OCCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4861794;185566;None;0;Human;Binding;Ki;=;1095,00;5,96;-40;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;324,2;6;1;5;2,45;Nc1ccc(C(=O)CCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4861794;185566;None;0;Human;Binding;Ki;=;1096,48;5,96;-40;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;324,2;6;1;5;2,45;Nc1ccc(C(=O)CCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4862275;185593;None;0;Human;Binding;Ki;=;688,00;6,16;-20;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;402,3;7;1;5;3,31;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)C3CCCCC3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4862301;185596;None;0;Human;Binding;Ki;=;61,90;7,21;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;394,2;10;2;4;4,13;COc1ccccc1C1CC1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4862301;185596;None;0;Human;Binding;Ki;=;61,66;7,21;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;394,2;10;2;4;4,13;COc1ccccc1C1CC1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4862320;185599;None;0;Human;Binding;Ki;=;568,00;6,25;-74;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;396,2;7;1;5;3,04;COc1ccc(C(=O)NCCCCN2CCO[C@@H]3c4ccccc4OC[C@H]32)cc1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4862399;185603;None;0;Human;Binding;Ki;=;563,00;6,25;-35;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;416,2;6;1;4;4,18;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1cccc2ccccc12;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4862405;185604;None;0;Human;Binding;Ki;=;1310,00;5,88;-4;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;540,3;11;4;5;4,75;CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN(CCCCNC(=O)c3cc4ccccc4[nH]3)C2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4862439;185608;None;0;Human;Binding;Ki;=;48,98;7,31;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;10;2;4;4,27;COc1ccc(F)cc1C1CC1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4862439;185608;None;0;Human;Binding;Ki;=;49,30;7,31;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;10;2;4;4,27;COc1ccc(F)cc1C1CC1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4862770;185631;None;0;Human;Binding;Ki;=;11,48;7,94;2;6;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;428,2;10;2;4;4,79;COc1ccc(Cl)cc1[C@H]1C[C@@H]1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4862770;185631;None;0;Human;Binding;Ki;=;11,50;7,94;2;6;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;428,2;10;2;4;4,79;COc1ccc(Cl)cc1[C@H]1C[C@@H]1CNCCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4862790;185637;None;0;Human;Binding;Ki;=;744,00;6,13;-81;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;397,2;7;1;6;2,44;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3cccnc3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4862839;185642;None;0;Human;Binding;Ki;=;280,00;6,55;1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;470,1;6;2;4;5,20;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1cccc(Cl)c1Cl)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4862890;185643;None;0;Human;Binding;Ki;=;20,80;7,68;1;6;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;410,2;10;2;4;4,23;COc1ccc(F)cc1[C@H]1C[C@@H]1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4862890;185643;None;0;Human;Binding;Ki;=;20,89;7,68;1;6;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;410,2;10;2;4;4,23;COc1ccc(F)cc1[C@H]1C[C@@H]1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4863032;185650;None;0;Human;Binding;Ki;=;708,00;6,15;-104;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;456,2;9;1;7;3,06;COc1cc(C(=O)NCCCCN2CCO[C@@H]3c4ccccc4OC[C@H]32)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4863636;185695;None;0;Human;Binding;Ki;=;302,00;6,52;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;414,2;9;2;3;5,28;O=C1CCc2ccc(OCCCCNCC3CC3c3cccc4ccccc34)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4863636;185695;None;0;Human;Binding;Ki;=;299,90;6,52;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;414,2;9;2;3;5,28;O=C1CCc2ccc(OCCCCNCC3CC3c3cccc4ccccc34)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4863748;185702;None;0;Human;Binding;Ki;=;190,00;6,72;1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;436,2;6;2;4;4,54;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccccc1Cl)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4863832;185707;None;0;Human;Binding;Ki;=;6,58;8,18;2;6;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;396,2;9;2;4;3,84;COc1ccc(F)cc1[C@H]1C[C@@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4863832;185707;None;0;Human;Binding;Ki;=;6,61;8,18;2;6;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;396,2;9;2;4;3,84;COc1ccc(F)cc1[C@H]1C[C@@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4863920;185712;None;0;Human;Binding;Ki;=;832,40;6,08;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;393,3;7;2;2;4,75;CN(C)C(=O)N[C@H]1CC[C@H](CCNCC2CC2c2cccc3ccccc23)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4863920;185712;None;0;Human;Binding;Ki;=;831,76;6,08;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;393,3;7;2;2;4,75;CN(C)C(=O)N[C@H]1CC[C@H](CCNCC2CC2c2cccc3ccccc23)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4863980;185716;None;0;Human;Binding;Ki;=;5,40;8,27;1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;487,2;8;0;6;5,10;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCOCC5)c(Cl)c4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4863992;185718;None;0;Human;Binding;Ki;=;125,89;6,90;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;380,2;9;2;4;3,74;COc1ccccc1C1CC1CNCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4863992;185718;None;0;Human;Binding;Ki;=;125,70;6,90;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;380,2;9;2;4;3,74;COc1ccccc1C1CC1CNCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4864074;185723;None;0;Human;Binding;Ki;=;1065,00;5,97;-58;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;472,2;8;1;5;4,71;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3ccc(-c4ccccc4)cc3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4864112;185728;None;0;Human;Binding;Ki;=;697,00;6,16;-645;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;426,2;8;1;6;3,05;COc1ccc(C(=O)NCCCCN2CCO[C@@H]3c4cc(OC)ccc4OC[C@H]32)cc1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4864320;185736;None;0;Human;Binding;Ki;=;2,57;8,59;-5;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;587,3;14;3;7;4,96;CCCN1C[C@H](OCCCCOc2ccc3c(c2)NC(=O)CC3)C[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4864366;185740;None;0;Human;Binding;Ki;=;162,00;6,79;-7;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;430,2;9;2;4;4,44;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCCc2ccccc2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4864369;185741;None;0;Human;Binding;Ki;=;977,20;6,01;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;442,2;10;2;4;4,32;COc1ccccc1C1CC1CNCC[C@H]1CC[C@H](NS(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4864369;185741;None;0;Human;Binding;Ki;=;977,24;6,01;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;442,2;10;2;4;4,32;COc1ccccc1C1CC1CNCC[C@H]1CC[C@H](NS(=O)(=O)c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4864436;185746;None;0;Human;Binding;Ki;=;27,40;7,56;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;398,2;9;2;4;3,88;COc1ccc(F)cc1C1CC1CNCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4864436;185746;None;0;Human;Binding;Ki;=;27,54;7,56;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;398,2;9;2;4;3,88;COc1ccc(F)cc1C1CC1CNCCCOc1ccc2c(c1)NC(=O)CC2;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4864448;185748;None;0;Human;Binding;Ki;=;377,00;6,42;-3;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;410,1;6;1;7;3,43;CCCC(Oc1cc(Cl)cc(Cl)c1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4864813;185767;None;0;Human;Binding;Ki;=;589,00;6,23;-42;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;441,2;8;1;7;2,95;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3ccc([N+](=O)[O-])cc3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4864863;185770;None;0;Human;Binding;Ki;=;103,00;6,99;-1;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;424,2;7;1;7;3,82;CCCCC(Oc1cc(Cl)ccc1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4864969;185777;None;0;Human;Binding;Ki;=;642,00;6,19;-32;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;446,2;7;1;5;4,19;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3ccc4ccccc4c3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4865118;185786;None;0;Human;Binding;Ki;=;159,00;6,80;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;426,2;10;1;4;4,61;CCN(CCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4865118;185786;None;0;Human;Binding;Ki;=;158,49;6,80;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;426,2;10;1;4;4,61;CCN(CCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4865389;185800;None;0;Human;Binding;Ki;=;323,59;6,49;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;440,2;11;1;4;5,00;CCN(CCCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4865389;185800;None;0;Human;Binding;Ki;=;322,50;6,49;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;440,2;11;1;4;5,00;CCN(CCCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cc(F)ccc1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4865434;185803;None;0;Human;Binding;Ki;=;0,69;9,16;-2;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;354,2;7;2;4;3,22;CCCN1CCC[C@H]1CNC(=O)c1c(O)c(CC)cc(Cl)c1OC;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4865591;185815;None;0;Human;Binding;Ki;=;2691,53;5,57;-138;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;366,2;6;1;5;2,56;O=C1CCc2cc(OCCCN3CCN(c4ccccn4)CC3)ccc2N1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4865591;185815;None;0;Human;Binding;Ki;=;2667,00;5,57;-138;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;366,2;6;1;5;2,56;O=C1CCc2cc(OCCCN3CCN(c4ccccn4)CC3)ccc2N1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4865735;185827;None;0;Human;Binding;Ki;=;10,80;7,97;-2;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;451,3;8;0;5;5,60;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCCCC5)cc4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4865765;185828;None;0;Human;Binding;Ki;=;354,81;6,45;-7;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;402,2;9;4;4;2,85;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)NCC(C)CCc1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4865907;185833;None;0;Human;Binding;Ki;=;1,70;8,77;2;9;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;466,3;8;0;6;4,36;CN1CCN(Cc2ccc(OCCCN3CCC(c4noc5cc(F)ccc45)CC3)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4866053;185841;None;0;Human;Binding;Ki;=;510,00;6,29;-64;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;341,2;4;1;4;2,64;OC1c2ccc(F)cc2CC1CCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4866058;185842;None;0;Human;Binding;Ki;=;1230,27;5,91;-199;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;341,2;4;0;3;3,66;Clc1ccc2c(c1)CC(CCN1CCN(c3ccccn3)CC1)C2;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4866058;185842;None;0;Human;Binding;Ki;=;1234,00;5,91;-199;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;341,2;4;0;3;3,66;Clc1ccc2c(c1)CC(CCN1CCN(c3ccccn3)CC1)C2;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4866981;185911;None;0;Human;Binding;Ki;=;20,00;7,70;-1;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;463,2;7;0;5;3,98;O=C1c2ccccc2S(=O)(=O)N1CCCCCN1CCN(c2cccc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4867109;185918;None;0;Human;Binding;Ki;=;254,00;6,59;-2;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;447,1;7;0;5;3,48;O=C1c2ccccc2S(=O)(=O)N1CCCCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4867331;185929;None;0;Human;Binding;Ki;=;140,00;6,85;1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;432,2;7;2;5;3,90;COc1cccc(C(=O)NCc2ccccc2CN2CCc3cc(OC)c(O)cc3C2)c1;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4867565;185948;None;5;Human;Binding;Ki;=;4392,00;5,36;-1445;17;Displacement of [3H]-haloperidol from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;410,1;3;1;6;2,98;O=S(=O)(c1cccc(F)c1)n1ccc2c(N3CCNCC3)nc3ccccc3c21;https://dx.doi.org/10.1021/acs.jmedchem.1c00224
CHEMBL4867794;185962;None;0;Human;Binding;Ki;=;316,23;6,50;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;9;2;4;4,35;COc1ccc(Cl)cc1[C@@H]1C[C@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4867794;185962;None;0;Human;Binding;Ki;=;12,80;7,89;-;1;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;412,2;9;2;4;4,35;COc1ccc(Cl)cc1[C@@H]1C[C@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1016/j.bmcl.2024.129654
CHEMBL4867794;185962;None;0;Human;Binding;Ki;=;317,00;6,50;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;9;2;4;4,35;COc1ccc(Cl)cc1[C@@H]1C[C@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4867962;185968;None;0;Human;Binding;Ki;=;794,33;6,10;-32;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;360,2;6;4;4;2,34;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)N[C@@H](C)c1ccccc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4867978;185969;None;0;Human;Binding;Ki;=;10,50;7,98;-1;9;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;467,3;9;0;6;4,49;Fc1ccc2c(C3CCN(CCCOc4ccc(CCN5CCOCC5)cc4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4868275;185989;None;0;Human;Binding;Ki;=;2590,00;5,59;-6;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;492,2;10;1;4;5,88;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2Cc2ccccc2)c1OCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4868595;186003;None;0;Human;Binding;Ki;=;7,42;8,13;-2;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;446,2;10;3;5;3,73;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCc3ccccc3)CN2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4868911;186021;None;0;Human;Binding;Ki;=;356,00;6,45;2;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;396,1;6;1;7;2,52;CN1CCN(c2nc(N)nc(CCCOc3ccc(Cl)c(Cl)c3)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4869122;186031;None;0;Human;Binding;Ki;=;962,00;6,02;-28;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;411,2;7;1;6;2,94;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1ccc([N+](=O)[O-])cc1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4869151;186034;None;0;Human;Binding;Ki;=;1760,00;5,75;-5;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;541,2;11;3;6;5,01;CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN(CCCCNC(=O)c3cc4ccccc4o3)C2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4869198;186039;None;0;Human;Binding;Ki;=;17,00;7,77;1;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;481,1;7;0;5;4,13;O=C1c2ccccc2S(=O)(=O)N1CCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4869411;186049;None;0;Human;Binding;Ki;=;495,00;6,30;-5;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;410,1;6;1;7;3,43;CCCC(Oc1cccc(Cl)c1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4869668;186072;None;0;Human;Binding;Ki;=;728,00;6,14;-11;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;372,2;6;1;4;3,30;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)C1CCCCC1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4870140;186098;None;0;Human;Binding;Ki;=;321,60;6,49;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;446,2;9;1;3;5,77;CN(CCCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4870140;186098;None;0;Human;Binding;Ki;=;323,59;6,49;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;446,2;9;1;3;5,77;CN(CCCCOc1ccc2c(c1)NC(=O)CC2)CC1CC1c1cccc(Cl)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4870307;186109;None;0;Human;Binding;Ki;=;9,50;8,02;-1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;481,3;9;0;6;5,61;COc1cc(CN2CCCCC2)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4870374;186114;None;0;Human;Binding;Ki;=;2156,00;5,67;-707;5;Displacement of [3H]-haloperidol from human D2L receptor expressed in HEK293 cell membranes measured after 1 hr by microbeta counting method;ChEMBL;406,1;3;1;6;3,15;Cc1cccc(S(=O)(=O)n2ccc3c(N4CCNCC4)nc4ccccc4c32)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00224
CHEMBL4870716;186143;None;0;Human;Binding;Ki;=;1,50;8,82;2;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;453,2;8;0;6;4,45;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCOCC5)cc4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4870901;186156;None;0;Human;Binding;Ki;=;2290,87;5,64;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;401,3;7;2;4;3,37;CN(C)C(=O)N[C@H]1CC[C@H](CCNCC2CC2c2cccc3c2OCCO3)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4870901;186156;None;0;Human;Binding;Ki;=;2309,00;5,64;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;401,3;7;2;4;3,37;CN(C)C(=O)N[C@H]1CC[C@H](CCNCC2CC2c2cccc3c2OCCO3)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4871669;186205;None;0;Human;Binding;Ki;=;38,20;7,42;-1;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;340,2;6;2;4;2,69;CCc1cc(Cl)c(OC)c(C(=O)NCC2CCN(CC)C2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4871762;186217;None;0;Human;Binding;Ki;=;126,70;6,90;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;390,2;9;2;4;3,87;COc1ccccc1C1CC1CNC/C=C/COc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4871762;186217;None;0;Human;Binding;Ki;=;125,89;6,90;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;390,2;9;2;4;3,87;COc1ccccc1C1CC1CNC/C=C/COc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4871774;186219;None;0;Human;Binding;Ki;=;217,80;6,66;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;406,2;11;2;4;4,48;COc1ccccc1C1CC1CNCCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4871774;186219;None;0;Human;Binding;Ki;=;218,78;6,66;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;406,2;11;2;4;4,48;COc1ccccc1C1CC1CNCCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4871811;186223;None;0;Human;Binding;Ki;=;173,00;6,76;-2;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;526,2;11;4;5;4,50;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCCCNC(=O)c2cc3ccccc3[nH]2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4871833;186226;None;0;Human;Binding;Ki;=;244,30;6,61;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;432,1;9;2;3;5,43;O=C1CCc2ccc(OCCCCNCC3CC3c3cccc(Cl)c3Cl)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4871833;186226;None;0;Human;Binding;Ki;=;245,47;6,61;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;432,1;9;2;3;5,43;O=C1CCc2ccc(OCCCCNCC3CC3c3cccc(Cl)c3Cl)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4871868;186229;None;0;Human;Binding;Ki;=;3235,94;5,49;-1318;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;397,2;6;0;4;4,47;CC1(CCCCN2CCN(c3ccccn3)CC2)Cc2cc(Cl)ccc2C1=O;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4871868;186229;None;0;Human;Binding;Ki;=;3260,00;5,49;-1318;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;397,2;6;0;4;4,47;CC1(CCCCN2CCN(c3ccccn3)CC2)Cc2cc(Cl)ccc2C1=O;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4872375;186262;None;0;Human;Binding;Ki;=;2511,89;5,60;-3;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;360,2;7;4;4;3,41;CCCCCCNC(=O)/N=C(\N)Nc1cccc(-c2csc(N)n2)c1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4872467;186270;None;0;Human;Binding;Ki;=;42,66;7,37;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;410,2;10;2;4;4,23;COc1ccc(F)cc1C1CC1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4872467;186270;None;0;Human;Binding;Ki;=;42,70;7,37;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;410,2;10;2;4;4,23;COc1ccc(F)cc1C1CC1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4872548;186274;None;0;Human;Binding;Ki;=;60,26;7,22;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;392,2;10;2;4;4,09;COc1ccccc1C1CC1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4872548;186274;None;0;Human;Binding;Ki;=;59,90;7,22;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;392,2;10;2;4;4,09;COc1ccccc1C1CC1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4872713;186289;None;0;Human;Binding;Ki;=;165,00;6,78;-10;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;413,2;7;0;5;2,82;O=C1c2ccccc2S(=O)(=O)N1CCCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4873100;186315;None;0;Human;Binding;Ki;=;954,00;6,02;-158;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;415,2;7;0;7;1,61;O=C1c2ccccc2S(=O)(=O)N1CCCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4873127;186318;None;0;Human;Binding;Ki;=;506,00;6,30;-2;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;424,2;7;1;7;3,82;CCCCC(Oc1cccc(Cl)c1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4873313;186327;None;0;Human;Binding;Ki;=;1,77;8,75;-4;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;545,2;12;4;7;3,84;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCOc3ccc4c(c3)NC(=O)CC4)CN2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4873319;186328;None;0;Human;Binding;Ki;=;2,60;8,59;1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;483,3;9;0;7;4,46;COc1cc(CN2CCOCC2)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4873623;186351;None;0;Human;Binding;Ki;=;421,00;6,38;-11;5;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;396,1;5;1;7;3,04;CCC(Oc1cccc(Cl)c1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4873623;186351;None;0;Human;Binding;Ki;=;420,00;6,38;-11;5;Displacement of [3H]-Raclopride from human dopamine D2 receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;396,1;5;1;7;3,04;CCC(Oc1cccc(Cl)c1Cl)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2022.114645
CHEMBL4874021;186379;None;0;Human;Binding;Ki;=;25,80;7,59;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;396,2;9;2;4;3,84;COc1ccc(F)cc1C1CC1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4874021;186379;None;0;Human;Binding;Ki;=;25,70;7,59;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;396,2;9;2;4;3,84;COc1ccc(F)cc1C1CC1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4874069;186383;None;0;Human;Binding;Ki;=;691,83;6,16;-131;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;349,2;6;0;4;3,35;O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc2c(c1)CCC2;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4874069;186383;None;0;Human;Binding;Ki;=;699,00;6,16;-131;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;349,2;6;0;4;3,35;O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc2c(c1)CCC2;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4874131;186388;None;0;Human;Binding;Ki;=;2187,76;5,66;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;399,3;8;2;3;4,14;COc1ccccc1C1CC1CNCC[C@H]1CC[C@H](NC(=O)N2CCCC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4874131;186388;None;0;Human;Binding;Ki;=;2188,00;5,66;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;399,3;8;2;3;4,14;COc1ccccc1C1CC1CNCC[C@H]1CC[C@H](NC(=O)N2CCCC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4874914;186438;None;0;Human;Binding;Ki;=;34,00;7,47;-1;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;481,2;7;0;5;3,84;O=C1c2ccccc2S(=O)(=O)N1CCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4875008;186447;None;0;Human;Binding;Ki;=;785,00;6,11;-74;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;405,2;6;2;4;3,51;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4875081;186453;None;0;Human;Binding;Ki;=;12,88;7,89;2;6;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;9;2;4;4,35;COc1ccc(Cl)cc1[C@H]1C[C@@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4875081;186453;None;0;Human;Binding;Ki;=;12,80;7,89;2;6;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;412,2;9;2;4;4,35;COc1ccc(Cl)cc1[C@H]1C[C@@H]1CNCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4875181;186460;None;0;Human;Binding;Ki;=;923,00;6,04;-173;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;386,2;7;1;6;2,63;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3ccco3)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4875195;186462;None;0;Human;Binding;Ki;=;217,00;6,66;-2;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;326,1;5;2;4;2,30;CCc1cc(Cl)c(OC)c(C(=O)NCC2CCN(C)C2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4875600;186484;None;0;Human;Binding;Ki;=;316,23;6,50;-154;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;378,2;6;4;4;2,48;Cc1nc(N)sc1CCCN/C(N)=N/C(=O)NC(C)c1cccc(F)c1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4876116;186524;None;0;Human;Binding;Ki;=;30,20;7,52;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;426,2;10;2;4;4,74;COc1ccc(Cl)cc1[C@@H]1C[C@H]1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4876116;186524;None;0;Human;Binding;Ki;=;30,10;7,52;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;426,2;10;2;4;4,74;COc1ccc(Cl)cc1[C@@H]1C[C@H]1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4876207;186529;None;0;Human;Binding;Ki;=;52,00;7,28;2;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;420,2;6;2;4;4,03;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccc(F)cc1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4876260;186533;None;0;Human;Binding;Ki;=;56,00;7,25;-28;4;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;466,1;5;3;4;4,35;O=C(NCc1ccccc1CN1CCc2cc(O)c(O)cc2C1)c1cccc(Br)c1;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4876297;186539;None;0;Human;Binding;Ki;=;4513,00;5,35;-870;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;355,1;4;0;4;3,30;O=C1c2cc(Cl)ccc2CC1CCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4876297;186539;None;0;Human;Binding;Ki;=;4466,84;5,35;-870;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;355,1;4;0;4;3,30;O=C1c2cc(Cl)ccc2CC1CCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL4876353;186545;None;0;Human;Binding;Ki;=;74,40;7,13;-1;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;502,2;8;2;7;3,25;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCc2c(C)nc3n(c2=O)CCCC3)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL4876545;186556;None;0;Human;Binding;Ki;=;2,00;8,70;38;5;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;477,2;6;0;6;3,36;COc1ccccc1N1CCN(Cc2ccc(CN3C(=O)c4ccccc4S3(=O)=O)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
CHEMBL4876546;186557;None;0;Human;Binding;Ki;=;190,00;6,72;1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;427,2;6;2;5;3,76;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccc(C#N)cc1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4876611;186562;None;0;Human;Binding;Ki;=;1047,13;5,98;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;406,3;9;2;3;4,77;COc1ccccc1C1CC1CNCC[C@H]1CC[C@H](NC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4876611;186562;None;0;Human;Binding;Ki;=;1040,00;5,98;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;406,3;9;2;3;4,77;COc1ccccc1C1CC1CNCC[C@H]1CC[C@H](NC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4876719;186569;None;0;Human;Binding;Ki;=;11,60;7,94;-1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;469,3;8;0;5;5,74;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCCCC5)c(F)c4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4876727;186570;None;0;Human;Binding;Ki;=;368,00;6,43;-5;3;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;396,1;5;1;7;3,04;CCC(Oc1cc(Cl)cc(Cl)c1)c1nc(N)nc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
CHEMBL4876799;186579;None;0;Human;Binding;Ki;=;1258,93;5,90;-1;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;338,2;6;4;4;1,78;CCCCCCNC(=O)/N=C(\N)NC1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4876926;186584;None;0;Human;Binding;Ki;=;150,00;6,82;1;2;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;480,1;6;2;4;4,65;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1cccc(Br)c1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4877460;186611;None;0;Human;Binding;Ki;=;39,00;7,41;-1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;427,2;6;2;5;3,76;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1cccc(C#N)c1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4877715;186636;None;0;Human;Binding;Ki;=;861,00;6,07;-42;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;446,2;7;1;5;4,19;COc1ccc2c(c1)[C@H]1OCCN(CCCCNC(=O)c3cccc4ccccc34)[C@@H]1CO2;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4877827;186645;None;0;Human;Binding;Ki;=;95,20;7,02;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;408,2;10;2;4;4,80;CSc1ccccc1C1CC1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4877827;186645;None;0;Human;Binding;Ki;=;95,50;7,02;-;1;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;408,2;10;2;4;4,80;CSc1ccccc1C1CC1CNCCCCOc1ccc2ccc(=O)[nH]c2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
CHEMBL4877940;186651;None;0;Human;Binding;Ki;=;6,20;8,21;1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;467,3;9;0;6;5,22;COc1cc(CN2CCCC2)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4877973;186653;None;0;Human;Binding;Ki;=;3,10;8,51;1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;467,3;8;0;6;4,76;Cc1cc(OCCCN2CCC(c3noc4cc(F)ccc34)CC2)ccc1CN1CCOCC1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4878121;186664;None;0;Human;Binding;Ki;=;78,00;7,11;1;3;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;432,2;7;2;5;3,90;COc1cc2c(cc1O)CN(Cc1ccccc1CNC(=O)c1ccccc1OC)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4878215;186671;None;0;Human;Binding;Ki;=;549,54;6,26;-1;6;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;344,1;3;4;4;1,40;N/C(=N\C(=O)NCc1ccccc1)NC1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
CHEMBL4878271;186678;None;0;Human;Binding;Ki;=;2,00;8,70;2;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;471,2;8;0;6;4,59;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCOCC5)c(F)c4)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL4878501;186691;None;0;Human;Binding;Ki;=;723,00;6,14;-52;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;416,2;6;1;4;4,18;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1ccc2ccccc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4878577;186698;None;0;Human;Binding;Ki;=;663,00;6,18;-28;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;400,2;6;1;4;3,68;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4878587;186699;None;0;Human;Binding;Ki;=;50,00;7,30;-14;5;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;441,2;7;1;5;4,06;COc1cc2c(cc1OC)CN(Cc1ccccc1CNC(=O)c1ccc(C#N)cc1)CC2;https://dx.doi.org/10.1016/j.bmcl.2021.128047
CHEMBL4878826;186708;None;0;Human;Binding;Ki;=;473,00;6,33;-26;2;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;400,2;6;1;4;3,68;O=C(NCCCCN1CCO[C@@H]2c3ccccc3OC[C@H]21)c1ccc(Cl)cc1;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL4879054;186719;None;0;Human;Binding;Ki;=;14,10;7,85;-1;4;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;471,2;8;0;5;5,87;Fc1ccc2c(C3CCN(CCCOc4ccc(CN5CCCC5)cc4Cl)CC3)noc2c1;https://dx.doi.org/10.1016/j.bmcl.2021.127909
CHEMBL48807;186752;None;2;Human;Binding;Ki;=;2454,71;5,61;-81;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;325,2;5;1;4;2,21;COc1ccccc1N1CCN(CNC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL48807;186752;None;2;Human;Binding;Ki;=;1880,00;5,73;-81;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;325,2;5;1;4;2,21;COc1ccccc1N1CCN(CNC(=O)c2ccccc2)CC1;https://dx.doi.org/10.1021/jm970021c
CHEMBL48819;186765;None;0;Human;Binding;Ki;=;1445,44;5,84;-53;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;359,1;5;1;4;2,86;COc1ccccc1N1CCN(CNC(=O)c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL48819;186765;None;0;Human;Binding;Ki;=;451,00;6,35;-53;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;359,1;5;1;4;2,86;COc1ccccc1N1CCN(CNC(=O)c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1021/jm970021c
CHEMBL489576;186968;None;0;Human;Binding;IC50;=;2690,00;5,57;-;2;Inhibition of dopamine D2 receptor;ChEMBL;476,2;4;1;4;4,79;O=c1[nH]c2cc(F)ccc2n1C1CCN(C2CCN(Cc3ccccc3C(F)(F)F)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2008.09.023
CHEMBL490417;187074;None;0;Human;Binding;Ki;=;316,23;6,50;-2511;7;Binding affinity at dopamine D2 receptor;ChEMBL;402,2;4;1;5;3,24;Cc1ccc2c(N3CCN(CCc4ccc5c(c4)NC(=O)CO5)CC3)cccc2n1;https://dx.doi.org/10.1016/j.bmcl.2008.08.110
CHEMBL491466;187209;None;0;Human;Binding;Ki;=;180,00;6,75;-1;4;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;514,3;10;0;4;7,63;CCCN(CCCCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)C1CC=C(C#Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL491466;187209;None;0;Human;Binding;Ki;=;210,00;6,68;-1;4;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;514,3;10;0;4;7,63;CCCN(CCCCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)C1CC=C(C#Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm800895v
CHEMBL491466;187209;UNDEFINED;0;Human;Binding;pKi;=;210,00;6,68;-1;4;-;PDSP KiDatabase;514,3;10;0;4;7,63;CCCN(CCCCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)C1CC=C(C#Cc2ccccc2)CC1;-
CHEMBL491466;187209;UNDEFINED;0;Human;Binding;pKi;=;180,00;6,74;-1;4;-;PDSP KiDatabase;514,3;10;0;4;7,63;CCCN(CCCCn1cc(-c2ccc(-c3ccccc3)cc2)nn1)C1CC=C(C#Cc2ccccc2)CC1;-
CHEMBL492033;187270;None;0;Human;Binding;Ki;=;515,00;6,29;-;1;Displacement of [3H]YM-09151-2 from human dopamine D2S receptor in membrane suspensions by liquid scintillation counter;ChEMBL;320,2;4;0;2;4,23;Cc1ccc(N2CCN(C[C@@H]3C[C@@H]3c3ccccc3)CC2)c(C)c1;https://dx.doi.org/10.1016/j.bmc.2008.08.061
CHEMBL492282;187291;None;0;Human;Binding;Ki;=;1,30;8,89;2;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;433,3;8;0;3;5,08;CC(C)c1ccccc1N1CCN(CCCCCC(=O)N2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL492282;187291;UNDEFINED;0;Human;Binding;pKi;=;1,30;8,89;2;3;-;PDSP KiDatabase;433,3;8;0;3;5,08;CC(C)c1ccccc1N1CCN(CCCCCC(=O)N2CCc3ccccc3C2)CC1;-
CHEMBL49231;187299;None;2;Human;Binding;Ki;=;349,00;6,46;-43;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;359,1;5;1;4;2,86;COc1ccccc1N1CCN(CNC(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm970021c
CHEMBL49231;187299;None;2;Human;Binding;Ki;=;269,15;6,57;-43;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;359,1;5;1;4;2,86;COc1ccccc1N1CCN(CNC(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL492480;187329;None;0;Human;Binding;Ki;=;362,00;6,44;-95;4;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;467,3;8;0;3;5,62;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)N1CCc2ccccc2C1;https://dx.doi.org/10.1021/jm800615e
CHEMBL492480;187329;UNDEFINED;0;Human;Binding;pKi;=;362,00;6,44;-95;4;-;PDSP KiDatabase;467,3;8;0;3;5,62;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)N1CCc2ccccc2C1;-
CHEMBL492690;187362;None;0;Human;Binding;Ki;=;22,00;7,66;1;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;421,3;8;0;4;3,96;COc1ccccc1N1CCN(CCCCCC(=O)N2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL492690;187362;UNDEFINED;0;Human;Binding;pKi;=;22,00;7,66;1;3;-;PDSP KiDatabase;421,3;8;0;4;3,96;COc1ccccc1N1CCN(CCCCCC(=O)N2CCc3ccccc3C2)CC1;-
CHEMBL492691;187363;None;0;Human;Binding;Ki;=;33,00;7,48;-2;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;411,2;10;1;4;4,41;CSc1ccccc1N1CCN(CCCCCC(=O)NCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL492691;187363;UNDEFINED;0;Human;Binding;pKi;=;33,00;7,48;-2;3;-;PDSP KiDatabase;411,2;10;1;4;4,41;CSc1ccccc1N1CCN(CCCCCC(=O)NCc2ccccc2)CC1;-
CHEMBL492871;187390;None;0;Human;Binding;Ki;=;503,00;6,30;-630;4;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;441,3;10;1;3;5,35;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NCc1ccccc1;https://dx.doi.org/10.1021/jm800615e
CHEMBL492871;187390;UNDEFINED;0;Human;Binding;pKi;=;503,00;6,30;-630;4;-;PDSP KiDatabase;441,3;10;1;3;5,35;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NCc1ccccc1;-
CHEMBL492872;187391;None;0;Human;Binding;Ki;=;9,20;8,04;15;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;407,3;10;1;3;4,81;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL492872;187391;UNDEFINED;0;Human;Binding;pKi;=;9,20;8,04;15;3;-;PDSP KiDatabase;407,3;10;1;3;4,81;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NCc2ccccc2)CC1;-
CHEMBL493305;187466;None;0;Human;Binding;Ki;=;40,00;7,40;-19;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;437,3;8;0;4;4,68;CSc1ccccc1N1CCN(CCCCCC(=O)N2CCc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL493305;187466;UNDEFINED;0;Human;Binding;pKi;=;40,00;7,40;-19;3;-;PDSP KiDatabase;437,3;8;0;4;4,68;CSc1ccccc1N1CCN(CCCCCC(=O)N2CCc3ccccc3C2)CC1;-
CHEMBL493709;187518;None;0;Human;Binding;Ki;=;501,00;6,30;-26;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;396,3;10;1;5;3,09;COc1ccccc1N1CCN(CCCCCC(=O)NCc2ccncc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL493709;187518;UNDEFINED;0;Human;Binding;pKi;=;501,00;6,30;-26;3;-;PDSP KiDatabase;396,3;10;1;5;3,09;COc1ccccc1N1CCN(CCCCCC(=O)NCc2ccncc2)CC1;-
CHEMBL493909;187548;None;0;Human;Binding;Ki;=;5,30;8,28;1;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;436,2;10;1;5;4,28;CSc1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(C#N)cc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL493909;187548;UNDEFINED;0;Human;Binding;pKi;=;5,30;8,28;1;3;-;PDSP KiDatabase;436,2;10;1;5;4,28;CSc1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(C#N)cc2)CC1;-
CHEMBL494118;187590;None;0;Human;Binding;Ki;=;93,00;7,03;-11;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;453,3;8;0;3;5,58;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)N1Cc2ccccc2C1;https://dx.doi.org/10.1021/jm800615e
CHEMBL494118;187590;UNDEFINED;0;Human;Binding;pKi;=;93,00;7,03;-11;3;-;PDSP KiDatabase;453,3;8;0;3;5,58;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)N1Cc2ccccc2C1;-
CHEMBL494119;187591;None;0;Human;Binding;Ki;=;65,00;7,19;-2;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;419,3;8;0;3;5,04;CC(C)c1ccccc1N1CCN(CCCCCC(=O)N2Cc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL494119;187591;UNDEFINED;0;Human;Binding;pKi;=;65,00;7,19;-2;3;-;PDSP KiDatabase;419,3;8;0;3;5,04;CC(C)c1ccccc1N1CCN(CCCCCC(=O)N2Cc3ccccc3C2)CC1;-
CHEMBL494312;187619;None;0;Human;Binding;Ki;=;20,00;7,70;-2;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;432,3;10;1;4;4,68;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(C#N)cc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL494312;187619;UNDEFINED;0;Human;Binding;pKi;=;20,00;7,70;-2;3;-;PDSP KiDatabase;432,3;10;1;4;4,68;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(C#N)cc2)CC1;-
CHEMBL494316;187620;None;0;Human;Binding;Ki;=;730,00;6,14;-223;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;407,3;8;0;4;3,92;COc1ccccc1N1CCN(CCCCCC(=O)N2Cc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL494316;187620;UNDEFINED;0;Human;Binding;pKi;=;730,00;6,14;-223;3;-;PDSP KiDatabase;407,3;8;0;4;3,92;COc1ccccc1N1CCN(CCCCCC(=O)N2Cc3ccccc3C2)CC1;-
CHEMBL494458;187644;None;0;Human;Binding;Ki;=;723,00;6,14;-125;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;535,3;12;1;6;4,69;CS(=O)(=O)Oc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm800615e
CHEMBL494458;187644;UNDEFINED;0;Human;Binding;pKi;=;723,00;6,14;-125;3;-;PDSP KiDatabase;535,3;12;1;6;4,69;CS(=O)(=O)Oc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;-
CHEMBL494512;187656;None;1;Human;Binding;Ki;=;311,00;6,51;-7;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;420,3;10;1;5;3,57;COc1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(C#N)cc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL494512;187656;UNDEFINED;1;Human;Binding;pKi;=;311,00;6,51;-7;3;-;PDSP KiDatabase;420,3;10;1;5;3,57;COc1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(C#N)cc2)CC1;-
CHEMBL494661;187690;None;0;Human;Binding;Ki;=;7,80;8,11;7;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;501,3;12;1;6;4,15;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(OS(C)(=O)=O)cc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL494661;187690;UNDEFINED;0;Human;Binding;pKi;=;7,80;8,11;7;3;-;PDSP KiDatabase;501,3;12;1;6;4,15;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(OS(C)(=O)=O)cc2)CC1;-
CHEMBL494709;187699;None;0;Human;Binding;Ki;=;185,00;6,73;-190;4;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;442,3;10;1;4;4,75;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NCc1ccncc1;https://dx.doi.org/10.1021/jm800615e
CHEMBL494709;187699;UNDEFINED;0;Human;Binding;pKi;=;185,00;6,73;-190;4;-;PDSP KiDatabase;442,3;10;1;4;4,75;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NCc1ccncc1;-
CHEMBL49502;187757;None;0;Human;Binding;Ki;=;2290,87;5,64;-109;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;354,1;4;1;4;2,72;N#Cc1ccccc1N1CCN(CNC(=O)c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL49502;187757;None;0;Human;Binding;Ki;=;897,00;6,05;-109;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;354,1;4;1;4;2,72;N#Cc1ccccc1N1CCN(CNC(=O)c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1021/jm970021c
CHEMBL495120;187775;None;0;Human;Binding;Ki;=;226,00;6,65;-17;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;395,3;10;1;4;3,69;COc1ccccc1N1CCN(CCCCCC(=O)NCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL495120;187775;UNDEFINED;0;Human;Binding;pKi;=;226,00;6,65;-17;3;-;PDSP KiDatabase;395,3;10;1;4;3,69;COc1ccccc1N1CCN(CCCCCC(=O)NCc2ccccc2)CC1;-
CHEMBL495321;187816;None;0;Human;Binding;Ki;=;64,00;7,19;-7;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;412,2;10;1;5;3,80;CSc1ccccc1N1CCN(CCCCCC(=O)NCc2ccncc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL495321;187816;UNDEFINED;0;Human;Binding;pKi;=;64,00;7,19;-7;3;-;PDSP KiDatabase;412,2;10;1;5;3,80;CSc1ccccc1N1CCN(CCCCCC(=O)NCc2ccncc2)CC1;-
CHEMBL496687;188021;None;0;Human;Binding;Ki;=;1400,00;5,85;-4168;2;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;362,2;2;2;1;5,54;Fc1ccc2c([C@@H]3CNCC[C@H]3F)c(-c3cccc4ccccc34)[nH]c2c1;https://dx.doi.org/10.1021/jm0004998
CHEMBL496739;188024;None;9;Human;Binding;Ki;=;263,00;6,58;-58;9;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;391,2;7;1;4;4,07;Cc1cccc(N2CCN(CCCCNC(=O)c3cc4ccccc4o3)CC2)c1;https://dx.doi.org/10.1021/jm501119j
CHEMBL496860;188036;None;0;Human;Binding;Ki;=;500,00;6,30;-2187;2;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;362,2;2;2;1;5,54;Fc1ccc2c([C@@H]3CNCC[C@H]3F)c(-c3ccc4ccccc4c3)[nH]c2c1;https://dx.doi.org/10.1021/jm0004998
CHEMBL497054;188062;None;0;Human;Binding;Ki;=;1600,00;5,80;-14454;3;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;318,1;2;2;2;4,45;Fc1ccc2c([C@@H]3CNCC[C@H]3F)c(-c3ccsc3)[nH]c2c1;https://dx.doi.org/10.1021/jm0004998
CHEMBL497338;188103;None;0;Human;Binding;Ki;=;146,00;6,84;-;1;Binding affinity at dopamine D2 receptor;ChEMBL;330,2;7;0;3;3,54;CN(CCc1ccccc1OC(F)(F)F)CCN1CCCCC1;https://dx.doi.org/10.1021/jm7013666
CHEMBL497749;188160;None;0;Human;Binding;Ki;=;132,00;6,88;-28;9;Displacement of [3H]spiperone from human D2L receptor after 60 mins;ChEMBL;439,2;8;1;5;3,34;COc1ccccc1N1CCN(CCCNS(=O)(=O)c2ccc3ccccc3c2)CC1;https://dx.doi.org/10.1016/j.bmcl.2010.07.002
CHEMBL497963;188190;None;0;Human;Binding;Ki;=;63,10;7,20;-125;12;Displacement of radioligand from human cloned dopamine D2 receptor;ChEMBL;453,2;8;1;5;4,25;Cc1ccc2c(OCCN3CCC(Cc4cccc(NS(C)(=O)=O)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm8001444
CHEMBL498565;188264;None;0;Human;Binding;Ki;=;516,00;6,29;-;1;Binding affinity at dopamine D2 receptor;ChEMBL;316,2;7;0;3;3,15;CN(CCc1ccccc1OC(F)(F)F)CCN1CCCC1;https://dx.doi.org/10.1021/jm7013666
CHEMBL49876;188282;None;0;Human;Binding;Ki;=;602,56;6,22;-165;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;354,1;4;1;4;2,72;N#Cc1ccccc1N1CCN(CNC(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL49876;188282;None;0;Human;Binding;Ki;=;929,00;6,03;-165;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;354,1;4;1;4;2,72;N#Cc1ccccc1N1CCN(CNC(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm970021c
CHEMBL498774;188287;None;0;Human;Binding;Ki;=;213,00;6,67;-;1;Binding affinity at dopamine D2 receptor;ChEMBL;344,2;8;0;3;3,94;CCN(CCc1ccccc1OC(F)(F)F)CCN1CCCCC1;https://dx.doi.org/10.1021/jm7013666
CHEMBL5028204;188595;None;0;Human;Binding;Ki;=;2,26;8,65;-5;2;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;312,1;5;3;4;2,10;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
CHEMBL5028215;188597;None;0;Human;Binding;Ki;=;2818,38;5,55;-6;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;380,2;6;1;5;2,95;O=C1CCc2cc(OCCCN3CCCN(c4ccccn4)CC3)ccc2N1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL5028215;188597;None;0;Human;Binding;Ki;=;2798,00;5,55;-6;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;380,2;6;1;5;2,95;O=C1CCc2cc(OCCCN3CCCN(c4ccccn4)CC3)ccc2N1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL5029038;188718;None;0;Human;Binding;Ki;=;1092,00;5,96;-11;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;366,2;7;1;5;2,83;CC(=O)Nc1ccc(C(=O)CCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL5029038;188718;None;0;Human;Binding;Ki;=;1096,48;5,96;-11;7;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor incubated for 1 hr by liquid scintillation counting method;ChEMBL;366,2;7;1;5;2,83;CC(=O)Nc1ccc(C(=O)CCCN2CCN(c3ccccn3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113243
CHEMBL503468;188756;None;0;Human;Binding;IC50;=;700,00;6,16;-;4;Binding affinity to human dopamine D2 receptor;ChEMBL;770,4;14;4;4;10,44;O=C(Nc1ccc2[nH]cc(C3CCN(CCCCCCCN4CCC(c5c[nH]c6ccc(NC(=O)c7ccc(F)cc7)cc56)CC4)CC3)c2c1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm7011722
CHEMBL5070377;216723;None;0;Human;Binding;Ki;=;3650,00;5,44;-72;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCNCCc1ccccc1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5070958;216737;None;3;Human;Binding;IC50;=;9400,00;5,03;-;5;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;-;-;-;-;-;NCCCCN(C[C@H]1Cc2ncccc2CN1)[C@H]1CCCc2cccnc21;https://dx.doi.org/10.1021/acs.jmedchem.1c01564
CHEMBL5071238;216741;None;0;Human;Binding;Ki;=;114,00;6,94;-1;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CC(O)CCNCCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5071238;216741;None;0;Human;Binding;Ki;=;457,00;6,34;-1;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CC(O)CCNCCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5072449;216769;None;0;Human;Binding;Ki;=;1310,00;5,88;-2;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;O=C(NCCCCN1CC[C@]2(c3cccc(O)c3)CCC[C@H]1[C@H]2O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5073337;216780;None;0;Human;Binding;Ki;=;112,20;6,95;-26;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2cc3ccc(Cl)cc3s2)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5073754;216793;None;0;Human;Binding;Ki;=;23,10;7,64;-1;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCNCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5073754;216793;None;0;Human;Binding;Ki;=;43,90;7,36;-1;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCNCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5073904;216795;None;0;Human;Binding;Ki;=;903,00;6,04;-14;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;N#CC(CCNCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5074399;216804;None;0;Human;Binding;Ki;=;44,20;7,36;-1;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CCCCNCCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5074399;216804;None;0;Human;Binding;Ki;=;62,10;7,21;-1;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CCCCNCCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5075014;216842;None;0;Human;Binding;Ki;=;4530,00;5,34;-4;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;O=C(NCCCCN1CC[C@]2(c3cccc(O)c3)CCC[C@H]1[C@@H]2O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5075726;216883;None;0;Human;Binding;Ki;=;51,60;7,29;1;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5075990;216895;None;0;Human;Binding;Ki;=;93,70;7,03;-1;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN2CCCCNCCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5075990;216895;None;0;Human;Binding;Ki;=;502,00;6,30;-1;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN2CCCCNCCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5076359;216920;None;0;Human;Binding;Ki;=;5240,00;5,28;-15;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;COc1cccc(C(=CCNCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c2cccc(OC)c2)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5076569;216937;None;0;Human;Binding;IC50;=;10000,00;5,00;-;5;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;-;-;-;-;-;NCCCCN(C[C@H]1Cc2cccnc2CN1)[C@H]1CCCc2cccnc21;https://dx.doi.org/10.1021/acs.jmedchem.1c01564
CHEMBL5076846;216952;None;0;Human;Binding;Ki;=;53,70;7,27;-83;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2cc3ccc(F)cc3s2)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5076882;216954;None;0;Human;Binding;Ki;=;154,88;6,81;-39;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2cccc(Cl)c2)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5077104;216969;None;0;Human;Binding;Ki;=;1940,00;5,71;-32;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;N#CC(CCNCCCCC(=O)N1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5077114;216970;None;0;Human;Binding;Ki;=;2860,00;5,54;-213;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2C[C@H]1C[C@@H]1CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5077178;216975;None;0;Human;Binding;Ki;=;257,04;6,59;-19;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5077645;216997;None;0;Human;Binding;Ki;=;2790,00;5,55;-12022;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;Oc1cccc([C@@]23CCC[C@@H]([C@H]2O)N(C/C=C/c2ccccc2)CC3)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5077645;216997;None;0;Human;Binding;Ki;=;7380,00;5,13;-12022;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;Oc1cccc([C@@]23CCC[C@@H]([C@H]2O)N(C/C=C/c2ccccc2)CC3)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5077755;217001;None;0;Human;Binding;Ki;=;50,12;7,30;-29;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1ccc(Cl)c(Cl)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5079053;217089;None;0;Human;Binding;Ki;=;2380,00;5,62;-8;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN2CC(=O)N2CCC(c3ccccc3)(c3ccccc3)C2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5079536;217110;None;0;Human;Binding;Ki;=;53,70;7,27;-7;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;Cc1c(S(=O)(=O)N[C@H]2C[C@H](C)N(CCCc3noc4cc(F)ccc34)C2)sc2ccc(Cl)cc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5079903;217139;None;0;Human;Binding;Ki;=;2630,00;5,58;-10;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;N#CC(CCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5080305;217165;None;0;Human;Binding;Ki;=;93,33;7,03;-15;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;Cc1cccc(S(=O)(=O)CC2CCN(CCCc3noc4cc(F)ccc34)C2)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5080654;217186;None;0;Human;Binding;Ki;=;636,00;6,20;-549;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5080654;217186;None;0;Human;Binding;Ki;=;186,00;6,73;-549;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5080719;217190;None;0;Human;Binding;Ki;=;30,20;7,52;-10;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2cc3ccccc3o2)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5080955;217200;None;0;Human;Binding;Ki;=;134,90;6,87;-21;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1ccc(F)c(Cl)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5081136;217213;None;0;Human;Binding;Ki;=;9,41;8,03;-4;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2C[C@@H](OCCCCNCCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CN2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5081505;217237;None;0;Human;Binding;IC50;=;9800,00;5,01;-;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;-;-;-;-;-;c1cnc2c(c1)CN[C@@H](CN(CCCC1CCNCC1)[C@H]1CCCc3cccnc31)C2;https://dx.doi.org/10.1021/acs.jmedchem.1c01564
CHEMBL5082182;217281;None;2;Human;Binding;Ki;=;162,18;6,79;-37;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1cccc(Cl)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5082267;217284;None;0;Human;Binding;Ki;=;302,00;6,52;-102;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1cccc(C(F)(F)F)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5082465;217293;None;0;Human;Binding;Ki;=;2950,00;5,53;-51;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CCCCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5082650;217304;None;0;Human;Binding;Ki;=;1586,00;5,80;-398;7;Displacement of [3H]spiperone from human recombinant dopamine D2S receptor expressed in CHO cells by liquid scintillation counting analysis;ChEMBL;-;-;-;-;-;Nc1nc(-c2ccccc2)c2c(n1)-c1cc(OCCCN3CCCCC3)ccc1C2=O;https://dx.doi.org/10.1021/acs.jmedchem.0c00914
CHEMBL5083186;217339;None;0;Human;Binding;Ki;=;3890,00;5,41;-199;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2CC1CC1CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5083441;217348;None;0;Human;Binding;Ki;=;187,00;6,73;-9;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CCC(c3cccc(O)c3)c3cccc(O)c3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5083473;217354;None;0;Human;Binding;Ki;=;190,00;6,72;-5;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CCC(c3cccc(O)c3)c3cccc(OC)c3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5083505;217355;None;0;Human;Binding;Ki;=;645,65;6,19;-16;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL508399;189082;None;0;Human;Binding;Ki;=;77,62;7,11;-20;3;Displacement of [3H]SCH23390 from human cloned dopamine D2L receptor;ChEMBL;281,2;1;1;2;3,40;CCN1CCc2ccccc2Cc2ccc(O)cc2CC1;https://dx.doi.org/10.1016/j.bmcl.2008.04.081
CHEMBL5084145;217387;None;0;Human;Binding;Ki;=;2270,00;5,64;-125;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCN1CCc2ccc(C#N)cc2C1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5084167;217388;None;0;Human;Binding;Ki;=;5,25;8,28;-21;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1ccc2ccccc2c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5085390;217453;None;0;Human;Binding;Ki;=;154,88;6,81;-12;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2ccc3cc(Cl)ccc3c2)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5085974;217493;None;0;Human;Binding;Ki;=;74,70;7,13;-58;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5085974;217493;None;0;Human;Binding;Ki;=;31,30;7,50;-58;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5086564;217524;None;0;Human;Binding;Ki;=;4860,00;5,31;-87;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCOC(=O)/C=C1\[C@@H]2CCC[C@@]1(c1cccc(O)c1)CCN2C[C@@H]1C[C@H]1CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5087504;217594;None;0;Human;Binding;Ki;=;987,00;6,01;-4;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;Oc1cccc(C(CCNCCCCN2CCN(c3ccccc3)CC2)c2cccc(O)c2)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5087543;217597;None;0;Human;Binding;Ki;=;167,00;6,78;-5;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCNCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5087543;217597;None;0;Human;Binding;Ki;=;700,00;6,16;-5;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCNCCC(O)CN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5087742;217606;None;0;Human;Binding;Ki;=;53,70;7,27;-12;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2csc3ccccc23)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5088070;217626;None;0;Human;Binding;Ki;=;43,00;7,37;-34;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5088070;217626;None;0;Human;Binding;Ki;=;20,30;7,69;-34;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5088232;217636;None;0;Human;Binding;Ki;=;46,77;7,33;-30;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2ccc3ccccc3c2)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5088622;217655;None;0;Human;Binding;Ki;=;1246,00;5,90;-173;7;Displacement of [3H]spiperone from human recombinant dopamine D2S receptor expressed in CHO cells by liquid scintillation counting analysis;ChEMBL;-;-;-;-;-;Nc1nc(-c2ccccc2)c2c(n1)-c1cc(OCCCN3CCCC3)ccc1C2;https://dx.doi.org/10.1021/acs.jmedchem.0c00914
CHEMBL5089348;217693;None;0;Human;Binding;Ki;=;95,50;7,02;-48;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1ccc(C(F)(F)F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5089655;217710;None;0;Human;Binding;Ki;=;36,30;7,44;-2;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;N#CC(CCNCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5089655;217710;None;0;Human;Binding;Ki;=;149,00;6,83;-2;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;N#CC(CCNCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5089932;217723;None;0;Human;Binding;Ki;=;1730,00;5,76;-6;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCCCNCCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5090215;217739;None;0;Human;Binding;Ki;=;1240,00;5,91;-8;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)C(=O)C(CCNCCCCN1CCc2ccc(C#N)cc2C1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5090346;217747;None;0;Human;Binding;Ki;=;17600,00;4,75;-15;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;N#CC(CCNCCc1ccccc1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5090557;217760;None;0;Human;Binding;Ki;=;54,95;7,26;-79;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2cc3ccccc3s2)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5091656;217808;None;0;Human;Binding;Ki;=;12400,00;4,91;-7;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CCC(C#N)(c2ccccc2)c2ccccc2)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5092243;217844;None;0;Human;Binding;Ki;=;170,00;6,77;-2;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CCc1cccc(N2CCN(CCC(c3cccc(OC)c3)c3cccc(OC)c3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5092755;217877;None;0;Human;Binding;Ki;=;19,95;7,70;-11;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;Cc1ccc(S(=O)(=O)CC2CCN(CCCc3noc4cc(F)ccc34)C2)cc1C;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5093017;217891;None;0;Human;Binding;Ki;=;128,82;6,89;-36;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;C[C@H]1C[C@H](NS(=O)(=O)c2ccc(F)c(Cl)c2)CN1CCCc1noc2cc(F)ccc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL5093200;217906;None;0;Human;Binding;Ki;=;42,70;7,37;-3;4;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;-;-;-;-;-;CN(C)CCC(C(=O)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
CHEMBL5093250;217910;None;0;Human;Binding;Ki;=;426,58;6,37;-33;4;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;-;-;-;-;-;O=S(=O)(CC1CCN(CCCc2noc3cc(F)ccc23)C1)c1ccc(F)c(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
CHEMBL51023;189217;None;1;Human;Binding;Ki;=;173,78;6,76;-43;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;339,2;5;1;4;2,51;COc1ccccc1N1CCN(CNC(=O)c2ccc(C)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL51023;189217;None;1;Human;Binding;Ki;=;291,00;6,54;-43;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;339,2;5;1;4;2,51;COc1ccccc1N1CCN(CNC(=O)c2ccc(C)cc2)CC1;https://dx.doi.org/10.1021/jm970021c
CHEMBL51433;189658;None;2;Human;Binding;Ki;=;32,00;7,50;-128;8;Compound is evaluated for binding affinity towards Dopamine receptor D2 using [3H]spiperone in CHO cells at 10 uM;ChEMBL;380,2;5;1;6;1,52;COc1ccccc1N1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1;https://dx.doi.org/10.1021/jm970159v
CHEMBL51433;189658;None;2;Human;Binding;Ki;=;132,00;6,88;-128;8;Compound is evaluated for binding affinity towards recombinant human Dopamine receptor D2 using [3H]spiperone in CHO cells;ChEMBL;380,2;5;1;6;1,52;COc1ccccc1N1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1;https://dx.doi.org/10.1021/jm970159v
CHEMBL514382;189663;None;0;Human;Binding;Ki;=;35,48;7,45;-5;3;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;397,2;6;0;3;3,94;O=C1c2ccccc2CCN1CCCCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.01.067
CHEMBL514562;189684;None;0;Human;Binding;Ki;=;243,00;6,61;-12;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;433,2;9;1;6;3,21;COc1cccc(N2CCN(CCCCNC(=O)c3ccc(-n4ccnc4)cc3)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL514562;189684;UNDEFINED;0;Human;Binding;pKi;=;243,00;6,61;-12;2;-;PDSP KiDatabase;433,2;9;1;6;3,21;COc1cccc(N2CCN(CCCCNC(=O)c3ccc(-n4ccnc4)cc3)CC2)c1;-
CHEMBL514590;189690;None;0;Human;Binding;Ki;=;588,00;6,23;-4;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;367,1;3;2;3;4,23;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2Cc1c[nH]c2ncccc12;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL514590;189690;UNDEFINED;0;Human;Binding;pKi;=;588,00;6,23;-4;3;-;PDSP KiDatabase;367,1;3;2;3;4,23;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2Cc1c[nH]c2ncccc12;-
CHEMBL514591;189691;None;0;Human;Binding;Ki;=;170,00;6,77;1;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;372,1;6;0;3;4,61;O=C(CCCN1CC2CC1N(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL514591;189691;UNDEFINED;0;Human;Binding;pKi;=;170,00;6,77;1;3;-;PDSP KiDatabase;372,1;6;0;3;4,61;O=C(CCCN1CC2CC1N(c1ccc(Cl)cc1)C2)c1ccc(F)cc1;-
CHEMBL514747;189709;None;0;Human;Binding;Ki;=;62,00;7,21;-5;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;338,1;3;1;3;3,68;Clc1ccc(N2CC3CC2CN3Cc2c[nH]c3ncccc23)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
CHEMBL514747;189709;UNDEFINED;0;Human;Binding;pKi;=;62,00;7,21;-5;3;-;PDSP KiDatabase;338,1;3;1;3;3,68;Clc1ccc(N2CC3CC2CN3Cc2c[nH]c3ncccc23)cc1;-
CHEMBL514885;189730;None;0;Human;Binding;Ki;=;264,00;6,58;-288;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;475,3;8;1;6;4,78;CCCN(CCN1CCN(c2ccc(-c3ccccc3)cc2)CC1)[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL514908;189735;None;0;Human;Binding;Ki;=;133,00;6,88;-4;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;451,2;9;1;6;3,35;COc1cc(F)cc(N2CCN(CCCCNC(=O)c3ccc(-n4ccnc4)cc3)CC2)c1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL514908;189735;UNDEFINED;0;Human;Binding;pKi;=;133,00;6,88;-4;2;-;PDSP KiDatabase;451,2;9;1;6;3,35;COc1cc(F)cc(N2CCN(CCCCNC(=O)c3ccc(-n4ccnc4)cc3)CC2)c1;-
CHEMBL51536;189795;None;0;Human;Binding;Ki;=;48,98;7,31;-3;3;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;343,1;4;1;3;3,16;Cc1ccc(C(=O)NCN2CCN(c3ccccc3Cl)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
CHEMBL51536;189795;None;0;Human;Binding;Ki;=;466,00;6,33;-3;3;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;343,1;4;1;3;3,16;Cc1ccc(C(=O)NCN2CCN(c3ccccc3Cl)CC2)cc1;https://dx.doi.org/10.1021/jm970021c
CHEMBL515472;189810;None;0;Human;Binding;Ki;=;2686,00;5,57;-45;15;Inhibition of human cloned dopamine D2 receptor by competitive binding experiment;ChEMBL;405,2;9;1;4;4,17;COc1c(OCCF)cccc1[C@H](O)C1CCN(CCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.03.021
CHEMBL515535;189818;None;0;Human;Binding;Ki;=;17,80;7,75;1;2;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;441,2;10;1;7;2,90;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc2nonc2c1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
CHEMBL515535;189818;UNDEFINED;0;Human;Binding;pKi;=;17,80;7,75;1;2;-;PDSP KiDatabase;441,2;10;1;7;2,90;O=C(NCCCCN1CCN(c2ccccc2OCCF)CC1)c1ccc2nonc2c1;-
CHEMBL516088;189888;None;0;Human;Binding;Ki;=;3828,00;5,42;-29;17;Inhibition of human cloned dopamine D2 receptor by competitive binding experiment;ChEMBL;403,2;9;0;4;4,32;COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.03.021
CHEMBL516334;189914;None;0;Human;Binding;Ki;=;67000,00;4,17;-2;2;Displacement of [3H]spiroperidol from human cloned dopaminergic D2 receptor expressed in rat C6 cells;ChEMBL;474,3;12;0;5;5,47;COc1cccc(CCc2ccccc2OCCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/jm800928j
CHEMBL516334;189914;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-2;2;-;PDSP KiDatabase;474,3;12;0;5;5,47;COc1cccc(CCc2ccccc2OCCCCN2CCN(c3ccccc3OC)CC2)c1;-
CHEMBL516809;189975;None;0;Human;Binding;Ki;=;12,02;7,92;-1;3;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;444,2;4;0;5;5,85;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2oc(-c3ccccc3)cc21;https://dx.doi.org/10.1021/jm800602w
CHEMBL517028;190051;None;0;Human;Binding;Ki;=;3,80;8,42;-2;4;Displacement of [3H]raclopride from human cloned dopamine D2 receptor expressed in CHO cell membrane;ChEMBL;359,2;1;3;4;4,22;CN1CCc2cc(-c3ccc(O)cc3)cc3c2[C@H]1Cc1ccc(O)c(O)c1-3;https://dx.doi.org/10.1016/j.bmc.2008.02.038
CHEMBL5170808;190080;None;0;Human;Binding;Ki;=;7,00;8,15;-1;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;410,1;7;3;8;2,36;Nc1nc(N)nc(NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5170927;190089;None;0;Human;Binding;Ki;=;81,00;7,09;64;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;391,2;6;1;6;2,43;N#Cc1cccnc1N1CCN(CCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5171456;190120;None;0;Human;Binding;Ki;=;13460,00;4,87;-4;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;444,2;7;3;8;2,92;COc1ccccc1N1CCN(c2nc(N)nc(NCCc3c[nH]c4ccccc34)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5171734;190139;None;0;Human;Binding;Ki;=;5003,00;5,30;-10;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;456,1;9;5;7;4,42;Nc1nc(NCCNc2cccc(Cl)c2Cl)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5171776;190143;None;0;Human;Binding;Ki;=;328,00;6,48;-14;2;Binding affinity to dopamine D2S receptor (unknown origin) by radioligand displacement assay;ChEMBL;609,2;7;1;5;4,70;Cc1cc(C)n2c1C=[N+]1[N+](=C3C=CC=C(NCCCCN4CCN(c5cccc(Cl)c5Cl)CC4)N3[B-]1(F)F)[B-]2(F)F;https://dx.doi.org/10.1016/j.bmcl.2022.128573
CHEMBL517244;190175;None;0;Human;Binding;Ki;=;146,00;6,84;-407;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;508,3;11;0;3;7,38;CN(CCCC12CCC(c3ccccc31)c1ccccc12)Cc1ccc(OCCCN2CCCCC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
CHEMBL517244;190175;UNDEFINED;0;Human;Binding;pKi;=;146,00;6,84;-407;6;-;PDSP KiDatabase;508,3;11;0;3;7,38;CN(CCCC12CCC(c3ccccc31)c1ccccc12)Cc1ccc(OCCCN2CCCCC2)cc1;-
CHEMBL5172673;190189;None;0;Human;Binding;Ki;=;143,00;6,84;-47;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;430,2;8;0;7;3,43;O=c1n(CCCCCCN2CCN(c3cccc4cccnc34)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5172819;190202;None;0;Human;Binding;Ki;=;9,00;8,05;776;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;408,2;7;1;5;2,58;O=C1CCc2ccc(OCCCCN3CCN(C(=O)c4ccccn4)CC3)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5173564;190253;None;0;Human;Binding;Ki;=;2100,00;5,68;3;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;392,3;6;0;4;2,66;O=C(c1ccccc1)N1CCN(CCCN2CCN(c3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5173624;190257;None;0;Human;Binding;Ki;=;5500,00;5,26;5;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;422,3;7;0;5;2,67;COc1ccc(N2CCN(CCCN3CCN(C(=O)c4ccccc4)CC3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL517407;190286;None;0;Human;Binding;Ki;=;52,00;7,28;-33;6;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;532,2;10;0;4;8,01;CN(CC/C=C1\c2ccccc2Sc2ccc(Cl)cc21)Cc1ccc(OCCCN2CCCCC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
CHEMBL5174637;190321;None;0;Human;Binding;Ki;=;13300,00;4,88;-67;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;403,2;9;4;7;3,25;COc1ccccc1CCNc1nc(N)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5176374;190432;None;0;Human;Binding;Ki;=;770,00;6,11;16;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;390,3;6;0;6;2,29;N#Cc1cccnc1N1CCN(CCCN2CCN(c3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL51767;190451;None;0;Human;Binding;Ki;=;11,75;7,93;-13;5;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;408,2;7;0;6;3,70;COc1ccccc1N1CCN(CCCOc2ccc3c(C)cc(=O)oc3c2)CC1;https://dx.doi.org/10.1021/jm400408r
CHEMBL5177023;190467;None;3;Human;Binding;IC50;=;1000,00;6,00;-;3;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;681,3;8;2;9;6,20;Cc1c(C#Cc2ccc(CN3CCC(CO)CC3)cc2)cc(C(F)F)c2cn(C(C(=O)Nc3nccs3)c3ncn4c3CCC43CC3)nc12;https://dx.doi.org/10.1021/acs.jmedchem.2c00893
CHEMBL5177186;190478;None;0;Human;Binding;Ki;=;3077,00;5,51;-50;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;441,1;8;4;6;4,55;Nc1nc(NCCc2cccc(Cl)c2Cl)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5177716;190515;None;0;Human;Binding;Ki;=;1390,00;5,86;-2;4;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;433,2;5;0;6;3,52;O=c1n(Cc2ccc(CN3CCN(c4ccc(Cl)cc4)CC3)cc2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5178499;190560;None;0;Human;Binding;Ki;=;8749,00;5,06;-489;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;388,2;9;5;7;3,11;Nc1nc(NCCNc2ccccc2)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5178688;190567;None;0;Human;Binding;Ki;=;590,00;6,23;-;1;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;423,3;7;0;6;2,06;COc1ccccc1N1CCN(CCCN2CCN(C(=O)c3ccccn3)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5178994;190592;None;0;Human;Binding;Ki;=;260,00;6,58;114;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;422,3;7;0;5;2,67;COc1ccccc1N1CCN(CCCN2CCN(C(=O)c3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5181868;190792;None;0;Human;Binding;Ki;=;229,00;6,64;-10;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;374,2;9;2;4;1,82;NS(=O)(=O)NCCCCCCN1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5182383;190824;None;0;Human;Binding;Ki;=;85,00;7,07;1;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;468,2;8;0;5;6,15;S=c1n(CCCCCCN2CCN(c3cccc(Cl)c3)CC2)c2cccc3c2n1CCC3;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5182877;190856;None;0;Human;Binding;Ki;=;110,00;6,96;-6;4;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;420,3;7;0;7;2,30;COc1ccccc1N1CCN(CCCN2CCN(c3ncccc3C#N)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5183389;190885;3H-RACLOPRIDE;6;Human;Binding;pKi;=;1000,00;6,00;-1698;11;-;PDSP KiDatabase;318,2;4;1;3;2,63;NC(=O)c1ccc(F)c2c1CC(N(C1CCC1)C1CCC1)CO2;-
CHEMBL5184538;190965;None;0;Human;Binding;Ki;=;13,00;7,89;-1;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;515,3;12;4;9;3,61;COc1ccccc1N1CCN(CCCCNc2nc(N)nc(NCCc3c[nH]c4ccccc34)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5185787;191056;None;0;Human;Binding;Ki;=;32,00;7,50;-5;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;429,3;8;0;6;4,03;O=c1n(CCCCCCN2CCN(c3cccc4ccccc34)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5186688;191116;None;0;Human;Binding;Ki;=;148,00;6,83;-2;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;433,2;5;0;6;3,52;O=c1n(Cc2ccc(CN3CCN(c4cccc(Cl)c4)CC3)cc2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5186821;191131;None;0;Human;Binding;Ki;=;366,00;6,44;-6;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;342,2;7;3;8;1,05;Nc1nc(N)nc(NCCCCN2CCN(c3ccccc3)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5187317;191168;None;0;Human;Binding;Ki;=;38,00;7,42;-3;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;386,3;9;3;9;1,45;COc1ccccc1N1CCN(CCCCCNc2nc(N)nc(N)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5187578;191193;None;0;Human;Binding;Ki;=;5,50;8,26;1;5;Competitive binding affinity to human D2R in transfected cells;ChEMBL;230,1;4;0;2;3,47;O=Cc1ccc(-c2ccccc2OCF)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00949
CHEMBL5188923;191282;None;0;Human;Binding;Ki;=;82,00;7,09;28;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;461,2;6;0;5;3,36;O=C(c1ccccn1)N1CCN(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5189101;191294;None;0;Human;Binding;Ki;=;60,00;7,22;-60;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;437,2;8;0;8;2,65;O=c1n(CCCCCCN2CCN(c3cccc4c3OCCO4)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5189520;191319;None;0;Human;Binding;Ki;=;4402,00;5,36;-10;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;419,2;10;4;8;3,09;COc1ccccc1OCCNc1nc(N)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5189648;191324;None;0;Human;Binding;Ki;=;52,00;7,28;-6;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;485,3;11;4;8;3,60;Nc1nc(NCCCCN2CCN(c3ccccc3)CC2)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5190020;191346;None;0;Human;Binding;Ki;=;3907,00;5,41;-1;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;418,2;10;5;8;3,12;COc1ccccc1NCCNc1nc(N)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5190788;191398;None;0;Human;Binding;Ki;=;10,00;8,00;1;4;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;458,2;6;0;6;3,59;N#Cc1cccnc1N1CCN(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5190996;191405;None;0;Human;Binding;Ki;=;559,00;6,25;-18;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;439,2;5;0;6;3,78;O=c1n(CC2CCC(CN3CCN(c4cccc(Cl)c4)CC3)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5191557;191443;None;0;Human;Binding;Ki;=;8,00;8,10;-1;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;424,2;8;3;8;2,75;Nc1nc(N)nc(NCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5193103;191557;None;0;Human;Binding;Ki;=;62,00;7,21;-3;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;447,2;8;0;6;3,90;O=c1n(CCCCCCN2CCN(c3cccc(C(F)(F)F)c3)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5193798;191611;None;0;Human;Binding;Ki;=;1500,00;5,82;26;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;420,3;7;0;7;2,30;COc1ccc(N2CCN(CCCN3CCN(c4ncccc4C#N)CC3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5194270;191640;None;0;Human;Binding;Ki;=;5,00;8,30;-1;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;438,2;9;3;8;3,14;Nc1nc(N)nc(NCCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5194614;191663;None;0;Human;Binding;Ki;=;39,00;7,41;1;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;553,2;11;4;8;4,91;Nc1nc(NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5194826;191674;None;0;Human;Binding;Ki;=;8333,00;5,08;-10;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;414,2;6;3;7;2,92;Nc1nc(NCCc2c[nH]c3ccccc23)nc(N2CCN(c3ccccc3)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5195091;191687;None;0;Human;Binding;Ki;=;120,00;6,92;14;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;460,2;6;0;4;3,96;O=C(c1ccccc1)N1CCN(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5196828;191807;None;0;Human;Binding;Ki;=;130,00;6,89;-;1;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;406,2;6;0;7;1,91;COc1ccccc1N1CCN(CCN2CCN(c3ncccc3C#N)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL519688;191810;None;0;Human;Binding;Ki;=;4570,88;5,34;-;1;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;330,2;6;1;3;3,31;CCCCNC(=O)c1ccc2c(c1)[C@H]1OCCN(CCC)[C@@H]1CC2;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
CHEMBL5197266;191846;None;0;Human;Binding;Ki;=;4402,00;5,36;-9;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;457,1;9;4;7;4,39;Nc1nc(NCCOc2cccc(Cl)c2Cl)nc(NCCc2c[nH]c3ccccc23)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL51977;191869;None;0;Human;Binding;Ki;=;398,11;6,40;-251;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;474,2;10;1;2;6,79;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(Cl)cccc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL51977;191869;None;0;Human;Binding;Ki;=;398,11;6,40;-251;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;474,2;10;1;2;6,79;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(Cl)cccc2C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL5197737;191872;None;0;Human;Binding;Ki;=;46,00;7,34;1;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;372,2;8;3;9;1,06;COc1ccccc1N1CCN(CCCCNc2nc(N)nc(N)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5197911;191882;None;0;Human;Binding;Ki;=;20,00;7,70;-5;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;400,3;10;3;9;1,84;COc1ccccc1N1CCN(CCCCCCNc2nc(N)nc(N)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5197956;191884;None;0;Human;Binding;Ki;=;309,00;6,51;-8;2;Binding affinity to dopamine D2S receptor (unknown origin) by radioligand displacement assay;ChEMBL;599,3;9;1;6;3,96;CCc1c(C)c2n(c1C)[B-](F)(F)[N+]1=C3C=CC=C(NCCCCN4CCN(c5ccccc5OC)CC4)N3[B-](F)(F)[N+]1=C2;https://dx.doi.org/10.1016/j.bmcl.2022.128573
CHEMBL5199228;191969;None;0;Human;Binding;Ki;=;9,00;8,05;-1;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;447,2;8;0;6;4,18;O=c1n(CCCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5199820;191999;None;0;Human;Binding;Ki;=;418,00;6,38;-52;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;457,3;9;4;8;2,82;Nc1nc(NCCc2c[nH]c3ccccc23)nc(NCCN2CCN(c3ccccc3)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5200023;192014;None;0;Human;Binding;Ki;=;130,00;6,89;13;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;500,2;5;0;6;3,46;Cn1nc(C(=O)N2CCN(CCN3CCN(c4cccc(Cl)c4Cl)CC3)CC2)c2ccccc21;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5201464;192103;None;0;Human;Binding;Ki;=;235,00;6,63;-6;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;338,2;8;2;3;2,69;NC(=O)NCCCCCCN1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5201719;192122;None;0;Human;Binding;Ki;=;3207,00;5,49;-1;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;482,1;6;3;7;4,22;Nc1nc(NCCc2c[nH]c3ccccc23)nc(N2CCN(c3cccc(Cl)c3Cl)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5201798;192128;None;0;Human;Binding;Ki;=;2100,00;5,68;3;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;405,2;7;1;6;2,82;N#Cc1cccnc1N1CCN(CCCCOc2ccc3c(c2)NC(=O)CC3)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5201984;192139;None;0;Human;Binding;Ki;=;18,00;7,75;3;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;452,2;8;0;5;4,79;O=c1n(CCCCCCN2CCN(c3cccc(Cl)c3)CC2)c2cccc3c2n1CCC3;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5202003;192140;None;0;Human;Binding;Ki;=;860,00;6,07;41;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;355,2;7;1;6;1,43;COc1ccccc1N1CCN(CCCNC(=O)c2cnccn2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL5202054;192144;None;0;Human;Binding;Ki;=;137,00;6,86;-8;5;Binding affinity to D2L receptor (unknown origin) assessed as inhibition constant;ChEMBL;413,2;8;0;6;3,53;O=c1n(CCCCCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5202120;192147;None;0;Human;Binding;Ki;=;1039,00;5,98;-14;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;356,2;8;3;8;1,44;Nc1nc(N)nc(NCCCCCN2CCN(c3ccccc3)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5202417;192164;None;0;Human;Binding;Ki;=;81,10;7,09;-3;2;Binding affinity to dopamine D2S receptor (unknown origin) by radioligand displacement assay;ChEMBL;571,3;8;1;6;3,40;COc1ccccc1N1CCN(CCCCNC2=CC=CC3=[N+]4[N+](=Cc5c(C)cc(C)n5[B-]4(F)F)[B-](F)(F)N23)CC1;https://dx.doi.org/10.1016/j.bmcl.2022.128573
CHEMBL5204088;192289;None;0;Human;Binding;Ki;=;253,00;6,60;-3;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;488,2;8;0;4;4,54;O=S1(=O)N(CCCCCCN2CCN(c3cccc(Cl)c3)CC2)c2cccc3c2N1CCC3;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5204274;192298;None;3;Human;Binding;Ki;=;1940,00;5,71;-56;5;Displacement of [3H]-raclopride from human full length D2L receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;456,2;8;1;6;3,24;O=C(NCCCCCCn1nc2ccccn2c1=O)N1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114319
CHEMBL5204696;192319;None;0;Human;Binding;Ki;=;182,00;6,74;-10;2;Binding affinity to dopamine D2S receptor (unknown origin) by radioligand displacement assay;ChEMBL;593,3;8;1;6;3,94;COc1ccccc1N1CCN(CCCCNC2=CC=CC3=[N+]4[N+](=Cc5cc6ccccc6n5[B-]4(F)F)[B-](F)(F)N23)CC1;https://dx.doi.org/10.1016/j.bmcl.2022.128573
CHEMBL5205324;192354;None;0;Human;Binding;Ki;=;1009,00;6,00;-12;5;Binding affinity to human D2 receptor expressed in HEK293 cells incubated for 1 hr by microbeta plate reader analysis;ChEMBL;370,3;9;3;8;1,83;Nc1nc(N)nc(NCCCCCCN2CCN(c3ccccc3)CC2)n1;https://dx.doi.org/10.1016/j.ejmech.2021.113931
CHEMBL5205697;192382;None;0;Human;Binding;Ki;=;210,00;6,68;6;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;444,2;5;0;6;3,20;N#Cc1cccnc1N1CCN(CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL520610;192406;None;0;Human;Binding;Ki;=;328,00;6,48;7;2;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;339,1;0;3;6;3,04;CN1CCc2c3c(cc4nc(N)sc24)-c2c(ccc(O)c2O)C[C@H]31;https://dx.doi.org/10.1016/j.bmc.2008.05.077
CHEMBL5207676;192502;None;0;Human;Binding;Ki;=;497,30;6,30;-9;2;Binding affinity to dopamine D2S receptor (unknown origin) by radioligand displacement assay;ChEMBL;637,2;8;1;5;5,26;CCc1c(C)c2n(c1C)[B-](F)(F)[N+]1=C3C=CC=C(NCCCCN4CCN(c5cccc(Cl)c5Cl)CC4)N3[B-](F)(F)[N+]1=C2;https://dx.doi.org/10.1016/j.bmcl.2022.128573
CHEMBL5209381;192628;None;0;Human;Binding;Ki;=;630,00;6,20;13;2;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;462,3;6;0;7;2,16;COc1ccccc1N1CCN(CCN2CCN(C(=O)c3nn(C)c4ccccc34)CC2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
CHEMBL52096;192638;None;0;Human;Binding;Ki;=;10,80;7,97;-15;6;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;378,2;6;0;5;3,69;Cc1cc(=O)oc2cc(OCCCN3CCN(c4ccccc4)CC3)ccc12;https://dx.doi.org/10.1021/jm400408r
CHEMBL52096;192638;None;0;Human;Binding;Ki;=;13,70;7,86;-15;6;Compound was measured for the binding affinity in homogenated mouse fibroblast (LTK) cells transfected with human Dopamine receptor D2A using [3H]raclopride as radioligand.;ChEMBL;378,2;6;0;5;3,69;Cc1cc(=O)oc2cc(OCCCN3CCN(c4ccccc4)CC3)ccc12;https://dx.doi.org/10.1016/s0960-894x(98)00646-5
CHEMBL52135;192682;None;0;Human;Binding;Ki;=;398,11;6,40;-100;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;524,2;10;1;6;4,09;CC(=O)c1cccc(/C=C/C(=O)NCCCCN2CCc3ccc(OS(=O)(=O)C(F)(F)F)cc3C2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL521687;192740;None;0;Human;Binding;Ki;=;30,00;7,52;-2;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;505,2;12;1;7;3,75;CSc1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(OS(C)(=O)=O)cc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL521687;192740;UNDEFINED;0;Human;Binding;pKi;=;30,00;7,52;-2;3;-;PDSP KiDatabase;505,2;12;1;7;3,75;CSc1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(OS(C)(=O)=O)cc2)CC1;-
CHEMBL5219240;192800;None;3;Human;Binding;Ki;=;300,00;6,52;-27;5;Displacement of [3H]-Raclopride from human dopamine D2 receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;394,2;4;1;7;3,39;CN1CCN(c2nc(N)nc(C(C)(C)Sc3ccc4ccccc4c3)n2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114645
CHEMBL5219924;192825;None;16;Human;Binding;Ki;=;1,70;8,77;1;3;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;492,3;5;0;6;4,26;O=C1C2C3CCC(C3)C2C(=O)N1CC1CCCCC1CN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128275
CHEMBL5221187;192873;None;0;Human;Binding;Ki;=;5128,61;5,29;-5248;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;363,2;5;0;3;3,49;Cc1ccc(N2CCN(CCCN3C(=O)CCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221189;192874;None;0;Human;Binding;Ki;=;138,04;6,86;-245;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;383,2;5;0;3;3,83;O=C1CCc2ccccc2N1CCCN1CCN(c2ccccc2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221227;192878;None;0;Human;Binding;Ki;=;12882,50;4,89;-204;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;335,2;4;0;3;2,79;O=C1CCc2ccccc2N1CCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221238;192881;None;0;Human;Binding;Ki;=;707,95;6,15;-269;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;335,2;5;0;3;3,65;c1ccc(N2CCN(CCCN3CCCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221253;192883;None;0;Human;Binding;Ki;=;1445,44;5,84;-812;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;363,2;5;0;3;3,49;Cc1cccc(N2CCN(CCCN3C(=O)CCc4ccccc43)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221334;192890;None;0;Human;Binding;Ki;=;54,95;7,26;-79;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;417,1;5;0;3;4,49;O=C1CCc2ccccc2N1CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221350;192893;None;0;Human;Binding;Ki;=;549,54;6,26;-812;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;417,1;5;0;3;4,49;O=C1CCc2ccccc2N1CCCN1CCN(c2ccc(Cl)cc2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221353;192894;None;0;Human;Binding;Kd;=;0,01;10,83;1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;389,2;8;4;5;1,85;Cc1ccc(CC(C)CNC(=O)/N=C(\N)NCCCc2nnc(N)s2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221353;192894;None;0;Human;Binding;Kd;=;0,01;10,83;1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;389,2;8;4;5;1,85;Cc1ccc(CC(C)CNC(=O)/N=C(\N)NCCCc2nnc(N)s2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221353;192894;None;0;Human;Binding;Ki;=;1071,52;5,97;1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;389,2;8;4;5;1,85;Cc1ccc(CC(C)CNC(=O)/N=C(\N)NCCCc2nnc(N)s2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221357;192895;None;0;Human;Binding;Ki;=;3981,07;5,40;-891;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;351,2;5;0;5;1,97;O=C1CCc2ccccc2N1CCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221414;192905;None;0;Human;Binding;Ki;=;23988,33;4,62;-3630;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;394,2;6;0;5;3,09;O=C1CCc2ccccc2N1CCCN1CCN(c2ccc([N+](=O)[O-])cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221444;192914;None;0;Human;Binding;Kd;=;0,01;10,83;-2;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;568,3;15;8;10;-0,09;N/C(=N\C(=O)NCCCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221444;192914;None;0;Human;Binding;Kd;=;0,01;10,83;-2;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;568,3;15;8;10;-0,09;N/C(=N\C(=O)NCCCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221444;192914;None;0;Human;Binding;Ki;=;954,99;6,02;-2;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;568,3;15;8;10;-0,09;N/C(=N\C(=O)NCCCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221451;192917;None;0;Human;Binding;Kd;=;0,01;10,83;-5;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;332,1;6;4;4;1,47;N/C(=N\C(=O)NCc1ccccc1)NCCCc1cnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221451;192917;None;0;Human;Binding;Kd;=;0,01;10,83;-5;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;332,1;6;4;4;1,47;N/C(=N\C(=O)NCc1ccccc1)NCCCc1cnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221451;192917;None;0;Human;Binding;Ki;=;4570,88;5,34;-5;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;332,1;6;4;4;1,47;N/C(=N\C(=O)NCc1ccccc1)NCCCc1cnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221490;192921;None;0;Human;Binding;Ki;=;954,99;6,02;-1096;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;417,1;5;0;3;4,49;O=C1CCc2ccccc2N1CCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221531;192931;None;0;Human;Binding;Ki;=;1698,24;5,77;-45;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;321,2;5;0;4;3,58;c1ccc(N2CCN(CCCc3nc4ccccc4o3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221583;192936;None;0;Human;Binding;Ki;=;2511,89;5,60;-707;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;394,2;6;0;5;3,09;O=C1CCc2ccccc2N1CCCN1CCN(c2cccc([N+](=O)[O-])c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221670;192947;None;0;Human;Binding;Ki;=;20892,96;4,68;-3019;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;379,2;6;0;4;3,19;COc1ccc(N2CCN(CCCN3C(=O)CCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221749;192956;None;0;Human;Binding;Ki;=;281,84;6,55;-12;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;377,2;7;0;3;3,96;O=C1CCc2ccccc2N1CCCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5221757;192957;None;0;Human;Binding;Kd;=;0,01;10,83;-7;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;312,2;8;4;4;1,46;CCCCCNC(=O)/N=C(\N)NCCCc1cnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221757;192957;None;0;Human;Binding;Kd;=;0,01;10,83;-7;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;312,2;8;4;4;1,46;CCCCCNC(=O)/N=C(\N)NCCCc1cnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221757;192957;None;0;Human;Binding;Ki;=;3467,37;5,46;-7;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;312,2;8;4;4;1,46;CCCCCNC(=O)/N=C(\N)NCCCc1cnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL522194;192986;None;0;Human;Binding;Ki;=;91,00;7,04;-3;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;489,2;12;1;7;3,03;COc1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(OS(C)(=O)=O)cc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL522194;192986;UNDEFINED;0;Human;Binding;pKi;=;91,00;7,04;-3;3;-;PDSP KiDatabase;489,2;12;1;7;3,03;COc1ccccc1N1CCN(CCCCCC(=O)NCc2ccc(OS(C)(=O)=O)cc2)CC1;-
CHEMBL5221974;192991;None;0;Human;Binding;Kd;=;0,01;10,83;204;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;365,1;6;4;5;1,57;CC(NC(=O)/N=C(\N)NCCCc1nnc(N)s1)c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5221974;192991;None;0;Human;Binding;Kd;=;0,01;10,83;204;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;365,1;6;4;5;1,57;CC(NC(=O)/N=C(\N)NCCCc1nnc(N)s1)c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222031;193000;None;0;Human;Binding;Ki;=;81,28;7,09;-131;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;379,2;6;0;4;3,19;COc1ccccc1N1CCN(CCCN2C(=O)CCc3ccccc32)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222200;193026;None;0;Human;Binding;Ki;=;5495,41;5,26;-5495;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;383,2;5;0;3;3,83;O=C1CCc2ccccc2N1CCCN1CCN(c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222201;193027;None;0;Human;Binding;Ki;=;2754,23;5,56;-1230;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;350,2;5;0;4;2,57;O=C1CCc2ccccc2N1CCCN1CCN(c2ccccn2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222229;193031;None;0;Human;Binding;Ki;=;3090,30;5,51;-741;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;379,2;6;0;4;3,19;COc1cccc(N2CCN(CCCN3C(=O)CCc4ccccc43)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222241;193035;None;0;Human;Binding;Kd;=;0,01;10,83;1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;403,2;10;4;5;2,33;CC(CCCc1ccccc1)CNC(=O)/N=C(\N)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222241;193035;None;0;Human;Binding;Kd;=;0,01;10,83;1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;403,2;10;4;5;2,33;CC(CCCc1ccccc1)CNC(=O)/N=C(\N)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222241;193035;None;0;Human;Binding;Ki;=;446,68;6,35;1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;403,2;10;4;5;2,33;CC(CCCc1ccccc1)CNC(=O)/N=C(\N)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222300;193044;None;0;Human;Binding;Ki;=;131,83;6,88;-323;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;394,2;6;0;5;3,09;O=C1CCc2ccccc2N1CCCN1CCN(c2ccccc2[N+](=O)[O-])CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222419;193060;None;0;Human;Binding;Ki;=;354,81;6,45;-331;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;374,2;5;0;4;3,05;N#Cc1ccccc1N1CCN(CCCN2C(=O)CCc3ccccc32)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222491;193077;None;0;Human;Binding;Kd;=;0,01;10,83;1;20;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;315,2;6;4;3;1,11;C[C@@H](NC(=O)/N=C(\N)NCCCc1ncn[nH]1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222491;193077;None;0;Human;Binding;Kd;=;0,01;10,83;1;20;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;315,2;6;4;3;1,11;C[C@@H](NC(=O)/N=C(\N)NCCCc1ncn[nH]1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222506;193078;None;0;Human;Binding;Ki;=;1778,28;5,75;-173;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;337,2;5;0;4;4,05;c1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222529;193082;None;0;Human;Binding;Kd;=;0,01;10,83;204;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;327,2;9;4;5;1,25;CCCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222529;193082;None;0;Human;Binding;Kd;=;0,01;10,83;204;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;327,2;9;4;5;1,25;CCCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222597;193095;None;0;Human;Binding;Ki;=;11,00;7,96;-28;19;Displacement of [3H]7-OH-DPAT from recombinant human D2S receptor measured after 60 mins by scintillation counting analysis;ChEMBL;340,2;2;1;2;4,60;CC1(C)CN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CCN1;https://dx.doi.org/10.1016/j.bmcl.2022.128879
CHEMBL5222630;193102;None;0;Human;Binding;Ki;=;1122,02;5,95;-263;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;363,2;6;0;3;3,57;O=C1CCc2ccccc2N1CCCCN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222660;193106;None;0;Human;Binding;Kd;=;0,01;10,83;-1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;388,2;8;4;4;2,46;Cc1ccc(CC(C)CNC(=O)/N=C(\N)NCCCc2cnc(N)s2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222660;193106;None;0;Human;Binding;Kd;=;0,01;10,83;-1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;388,2;8;4;4;2,46;Cc1ccc(CC(C)CNC(=O)/N=C(\N)NCCCc2cnc(N)s2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222660;193106;None;0;Human;Binding;Ki;=;489,78;6,31;-1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;388,2;8;4;4;2,46;Cc1ccc(CC(C)CNC(=O)/N=C(\N)NCCCc2cnc(N)s2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222691;193108;None;0;Human;Binding;Ki;=;758,58;6,12;-831;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;383,2;5;0;3;3,83;O=C1CCc2ccccc2N1CCCN1CCN(c2cccc(Cl)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222695;193109;None;0;Human;Binding;Ki;=;6165,95;5,21;-204;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;320,2;5;1;3;3,32;c1ccc(N2CCN(CCCc3nc4ccccc4[nH]3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222747;193117;None;0;Human;Binding;Ki;=;724,44;6,14;-380;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;319,2;5;0;3;3,85;c1ccc(N2CCN(CCCn3ccc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222773;193121;None;0;Human;Binding;Ki;=;398,11;6,40;-295;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;363,2;5;0;3;3,49;Cc1ccccc1N1CCN(CCCN2C(=O)CCc3ccccc32)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222793;193127;None;0;Human;Binding;Kd;=;0,01;10,83;-1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;367,2;7;4;5;1,88;CC(CNC(=O)/N=C(\N)NCCCc1nnc(N)s1)C1CCCCC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222793;193127;None;0;Human;Binding;Kd;=;0,01;10,83;-1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;367,2;7;4;5;1,88;CC(CNC(=O)/N=C(\N)NCCCc1nnc(N)s1)C1CCCCC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222793;193127;None;0;Human;Binding;Ki;=;1621,81;5,79;-1;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;367,2;7;4;5;1,88;CC(CNC(=O)/N=C(\N)NCCCc1nnc(N)s1)C1CCCCC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222802;193128;None;0;Human;Binding;Kd;=;0,01;10,83;-229;20;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;313,2;8;4;5;0,86;CCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222802;193128;None;0;Human;Binding;Kd;=;0,01;10,83;-229;20;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;313,2;8;4;5;0,86;CCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222802;193128;None;0;Human;Binding;Ki;=;9549,93;5,02;-229;20;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;313,2;8;4;5;0,86;CCCCCNC(=O)/N=C(\N)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222872;193140;None;0;Human;Binding;Kd;=;0,01;10,83;-181;20;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;333,1;6;4;5;0,87;N/C(=N\C(=O)NCc1ccccc1)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222872;193140;None;0;Human;Binding;Kd;=;0,01;10,83;-181;20;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;333,1;6;4;5;0,87;N/C(=N\C(=O)NCc1ccccc1)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222872;193140;None;0;Human;Binding;Ki;=;6309,57;5,20;-181;20;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;333,1;6;4;5;0,87;N/C(=N\C(=O)NCc1ccccc1)NCCCc1nnc(N)s1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222877;193142;None;0;Human;Binding;Ki;=;12022,64;4,92;-977;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;320,2;5;0;4;3,25;c1ccc(N2CCN(CCCn3cnc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
CHEMBL5222926;193149;None;0;Human;Binding;Kd;=;0,01;10,83;204;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;347,2;6;4;5;1,43;C[C@@H](NC(=O)/N=C(\N)NCCCc1nnc(N)s1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL5222926;193149;None;0;Human;Binding;Kd;=;0,01;10,83;204;6;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;347,2;6;4;5;1,43;C[C@@H](NC(=O)/N=C(\N)NCCCc1nnc(N)s1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
CHEMBL522343;193165;None;0;Human;Binding;Ki;=;21,00;7,68;-4;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;408,3;10;1;4;4,20;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NCc2ccncc2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL522343;193165;UNDEFINED;0;Human;Binding;pKi;=;21,00;7,68;-4;3;-;PDSP KiDatabase;408,3;10;1;4;4,20;CC(C)c1ccccc1N1CCN(CCCCCC(=O)NCc2ccncc2)CC1;-
CHEMBL522460;193182;None;43;Human;Binding;IC50;=;2650,00;5,58;-;15;Inhibition of dopamine D2 receptor;ChEMBL;404,3;4;1;4;3,94;Cc1ccccc1CN1CCC(N2CCC(n3c(=O)[nH]c4ccccc43)CC2)CC1;https://dx.doi.org/10.1016/j.bmcl.2008.09.023
CHEMBL522708;193222;None;0;Human;Binding;Ki;=;501,19;6,30;-316;11;Displacement of radioligand from human cloned dopamine D2 receptor;ChEMBL;479,2;7;0;5;4,42;Cc1ccc2c(OCCN3CCC(Cc4cccc(N5CCCS5(=O)=O)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm8001444
CHEMBL523245;193290;None;0;Human;Binding;Ki;=;900,00;6,05;-7413;3;Ability to displace [3H]spiperone binding to CHO cells stably expressing dopamine receptor D2;ChEMBL;330,1;2;2;1;4,53;Fc1ccc(-c2[nH]c3cc(F)ccc3c2[C@@H]2CNCC[C@H]2F)cc1;https://dx.doi.org/10.1021/jm0004998
CHEMBL523381;193309;None;0;Human;Binding;Ki;=;96,00;7,02;-89;3;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;423,2;8;0;4;4,63;CSc1ccccc1N1CCN(CCCCCC(=O)N2Cc3ccccc3C2)CC1;https://dx.doi.org/10.1021/jm800615e
CHEMBL523381;193309;UNDEFINED;0;Human;Binding;pKi;=;96,00;7,02;-89;3;-;PDSP KiDatabase;423,2;8;0;4;4,63;CSc1ccccc1N1CCN(CCCCCC(=O)N2Cc3ccccc3C2)CC1;-
CHEMBL523993;193393;None;0;Human;Binding;Ki;=;935,00;6,03;-;1;Displacement of [3H]YM-09151-2 from human dopamine D2S receptor in membrane suspensions by liquid scintillation counter;ChEMBL;320,2;4;0;2;4,23;Cc1ccc(N2CCN(C[C@H]3C[C@H]3c3ccccc3)CC2)c(C)c1;https://dx.doi.org/10.1016/j.bmc.2008.08.061
CHEMBL52466;193449;None;0;Human;Binding;Ki;=;158,49;6,80;-63;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;549,2;9;2;7;4,14;O=C(/C=C/c1ccc2nc(O)ccc2c1)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL52468;193452;None;0;Human;Binding;Ki;=;251,19;6,60;-79;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;533,2;9;1;6;4,43;O=C(/C=C/c1ccc2ncccc2c1)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL5266134;193578;None;0;Human;Binding;EC50;=;34,37;7,46;-;4;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;584,3;12;4;10;4,80;CCCN(CCc1cc(O)c(CCN(CCC)[C@H]2CCc3nc(N)sc3C2)cc1O)[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/j.bmc.2022.117131
CHEMBL5266180;193580;None;0;Human;Binding;Ki;=;32300,00;4,49;-4;2;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;460,2;7;3;8;2,13;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CCn1cc(CNC(=O)c2cc3ccccc3[nH]2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5266180;193580;None;0;Human;Binding;Ki;=;13500,00;4,87;-4;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;460,2;7;3;8;2,13;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CCn1cc(CNC(=O)c2cc3ccccc3[nH]2)nn1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5266395;193587;None;0;Human;Binding;IC50;=;1380,38;5,86;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;486,2;7;0;4;4,24;O=C(CCCN1CCN(c2cccc(Cl)c2Cl)CC1)N1C=CN(Cc2ccccc2)C(=O)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5266508;193593;None;0;Human;Binding;EC50;=;0,37;9,43;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;497,2;6;2;5;2,14;CC(C)(C)NC(=O)C1C(=O)NCCN1C(=O)CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5266508;193593;None;0;Human;Binding;IC50;=;3,80;8,42;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;497,2;6;2;5;2,14;CC(C)(C)NC(=O)C1C(=O)NCCN1C(=O)CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5266559;193595;None;0;Human;Binding;EC50;=;260,00;6,58;-;1;Partial agonist activity at human D2 receptor expressed in CHO-K1 cells assessed as forskolin-stimulated cAMP production incubated for 60 mins;ChEMBL;354,1;3;1;5;3,31;Oc1cc(CN2CCN(c3ccccn3)CC2)c(Cl)c2cccnc12;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5267221;193621;None;0;Human;Binding;EC50;=;13,40;7,87;-;4;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;546,3;12;2;6;6,05;CCCN(CCc1ccc(CCN(CCC)[C@H]2CCc3nc(N)sc3C2)cc1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmc.2022.117131
CHEMBL5267958;193652;None;0;Human;Binding;Ki;=;80,80;7,09;-60;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;461,3;7;3;5;4,14;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC[C@@H]1CC[C@H](CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5267958;193652;None;0;Human;Binding;Ki;=;22600,00;4,65;-60;2;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;461,3;7;3;5;4,14;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC[C@@H]1CC[C@H](CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5268231;193662;None;0;Human;Binding;EC50;=;2,34;8,63;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;468,2;8;1;4;3,80;CN(CC(=O)NC1CCCCC1)C(=O)CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5268231;193662;None;0;Human;Binding;IC50;=;2,88;8,54;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;468,2;8;1;4;3,80;CN(CC(=O)NC1CCCCC1)C(=O)CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5269858;193720;None;0;Human;Binding;IC50;=;3311,31;5,48;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;523,2;7;2;5;2,67;O=C1NCCN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C1C(=O)NC1CCCCC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5270832;193763;None;0;Human;Binding;EC50;=;3,63;8,44;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;523,2;7;1;5;3,49;CN1CCN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C(C(=O)NC2CCCCC2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5270832;193763;None;0;Human;Binding;IC50;=;1,66;8,78;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;523,2;7;1;5;3,49;CN1CCN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C(C(=O)NC2CCCCC2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5272162;193819;None;0;Human;Binding;Ki;=;2100,00;5,68;-3162;3;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;321,2;4;2;3;2,98;OCc1[nH]c2ccccc2c1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL52724;193826;None;0;Human;Binding;Ki;=;125,89;6,90;-63;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;589,2;10;2;6;4,51;CNC(=O)c1cccc(-c2ccc(C(=O)NCCCCN3CCc4ccc(OS(=O)(=O)C(F)(F)F)cc4C3)cc2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL5272965;193850;None;0;Human;Binding;EC50;=;839,50;6,08;5;2;Partial agonist activity at human D2 receptor assessed as beta arrestin-2 recruitment;ChEMBL;433,2;6;2;4;3,13;CC1Cc2ccccc2N1C(=O)NCCCCN(C)[C@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5272965;193850;None;0;Human;Binding;EC50;=;61,70;7,21;5;2;Partial agonist activity at human D2 receptor assessed as increase in cAMP accumulation;ChEMBL;433,2;6;2;4;3,13;CC1Cc2ccccc2N1C(=O)NCCCCN(C)[C@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5272965;193850;None;0;Human;Binding;Ki;=;26,90;7,57;5;2;Partial agonist activity at human D2 receptor assessed as inhibition constant;ChEMBL;433,2;6;2;4;3,13;CC1Cc2ccccc2N1C(=O)NCCCCN(C)[C@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5273118;193859;None;0;Human;Binding;Ki;=;853,00;6,07;1;2;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;471,3;7;3;4;3,90;CN(CC[C@@H]1CC[C@H](CNC(=O)c2cc3ccccc3[nH]2)C1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5273118;193859;None;0;Human;Binding;Ki;=;2,03;8,69;1;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;471,3;7;3;4;3,90;CN(CC[C@@H]1CC[C@H](CNC(=O)c2cc3ccccc3[nH]2)C1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5273430;193871;None;0;Human;Binding;EC50;=;0,21;9,67;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;531,2;8;1;5;3,35;CN1CCN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C(C(=O)NCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5273430;193871;None;0;Human;Binding;IC50;=;1,10;8,96;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;531,2;8;1;5;3,35;CN1CCN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C(C(=O)NCc2ccccc2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5273758;193883;None;0;Human;Binding;Ki;=;12,88;7,89;-;1;Displacement of [3H] raclopride from D2DR (unknown origin);ChEMBL;283,2;1;2;3;3,38;CN1CCC2C=C(O)C(O)=C3C(c4ccccc4)CC1C32;https://dx.doi.org/10.1016/j.ejmech.2020.112792
CHEMBL5273776;193885;None;0;Human;Binding;Ki;=;1320,00;5,88;2;2;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;471,3;7;3;4;3,90;CN(CC[C@@H]1CC[C@@H](CNC(=O)c2cc3ccccc3[nH]2)C1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5273776;193885;None;0;Human;Binding;Ki;=;4,58;8,34;2;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;471,3;7;3;4;3,90;CN(CC[C@@H]1CC[C@@H](CNC(=O)c2cc3ccccc3[nH]2)C1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5273880;193891;None;0;Human;Binding;IC50;=;371,54;6,43;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;501,2;7;1;5;5,01;CC(C)(C)NC(=O)Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc2ccccc21;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5274482;193927;None;0;Human;Binding;IC50;=;1548,82;5,81;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;442,2;7;1;4;3,27;CN(CC(=O)NC(C)(C)C)C(=O)CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5274609;193931;None;0;Human;Binding;Ki;=;110,00;6,96;-3;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;461,3;6;3;5;4,29;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC[C@H]1CC[C@@H](NC(=O)c2cc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5274672;193934;None;0;Human;Binding;IC50;=;162,18;6,79;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;527,2;7;1;5;5,68;Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)c1C(=O)NC(C)(C)C;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5275212;193954;None;0;Human;Binding;EC50;=;1,70;8,77;-;2;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;534,4;16;2;4;7,67;CCCN(CCCCCCCCCN(CCC)[C@@H]1CCc2c(O)cccc2C1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmc.2022.117131
CHEMBL5275349;193959;None;0;Human;Binding;IC50;=;3801,89;5,42;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;683;8;1;5;7,07;O=C(Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc2cc(Br)c(Br)cc21)NC1CCCCC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5276671;194019;None;0;Human;Binding;EC50;=;0,44;9,36;-;4;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;548,4;17;2;4;8,06;CCCN(CCCCCCCCCCN(CCC)[C@@H]1CCc2c(O)cccc2C1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmc.2022.117131
CHEMBL52770;194029;None;0;Human;Binding;Ki;=;501,19;6,30;-3;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;532,2;9;1;5;5,15;O=C(NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1)c1cccc(-c2ccccc2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL5277640;194049;None;0;Human;Binding;Ki;=;1320,00;5,88;-2;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;235,2;3;1;4;1,84;CCCN1C[C@H](c2ccc(N)nc2)OC[C@@H]1C;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5277859;194064;None;0;Human;Binding;Ki;=;10200,00;4,99;-38;2;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;348,1;4;0;5;2,80;CCOC(=O)N1CCN(Cc2cnn(-c3ccc(Cl)cc3)c2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL5278239;194079;None;0;Human;Binding;EC50;=;3,24;8,49;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;476,2;9;1;4;3,67;CN(CC(=O)NCc1ccccc1)C(=O)CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5278239;194079;None;0;Human;Binding;IC50;=;4,57;8,34;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;476,2;9;1;4;3,67;CN(CC(=O)NCc1ccccc1)C(=O)CCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5278254;194080;None;0;Human;Binding;IC50;=;1479,11;5,83;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;497,2;6;1;5;2,95;CN1CCN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C(C(=O)NC(C)(C)C)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5278601;194096;None;0;Human;Binding;EC50;=;3162,28;5,50;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;691;9;1;5;6,94;O=C(Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc2cc(Br)c(Br)cc21)NCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5278601;194096;None;0;Human;Binding;IC50;=;2,19;8,66;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;691;9;1;5;6,94;O=C(Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc2cc(Br)c(Br)cc21)NCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5278853;194109;None;0;Human;Binding;Ki;=;4900,00;5,31;-6456;3;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;316,2;3;1;3;3,36;N#Cc1[nH]c2ccccc2c1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL5279818;194148;None;0;Human;Binding;Ki;=;316,23;6,50;-;1;Displacement of [3H] raclopride from D2DR (unknown origin);ChEMBL;311,2;5;0;3;3,57;COc1cc(CCN(C)C)c2c(c1OC)-c1ccccc1CC2;https://dx.doi.org/10.1016/j.ejmech.2020.112792
CHEMBL5280364;194174;None;0;Human;Binding;Ki;=;22000,00;4,66;-14454;3;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;381,2;5;1;4;3,81;CCOC(=O)c1[nH]c2ccc(F)cc2c1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL5280481;194178;None;0;Human;Binding;Ki;=;115,00;6,94;-18;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;461,3;7;3;5;4,14;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC[C@@H]1CC[C@@H](CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5280481;194178;None;0;Human;Binding;Ki;=;25400,00;4,59;-18;2;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;461,3;7;3;5;4,14;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC[C@@H]1CC[C@@H](CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5280677;194185;None;0;Human;Binding;IC50;=;109,65;6,96;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;478,2;6;0;4;4,37;O=C(CCCN1CCN(c2cccc(Cl)c2Cl)CC1)N1C=CN(C2CCCCC2)C(=O)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5280797;194194;None;0;Human;Binding;Ki;=;7930,00;5,10;-2;2;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;476,3;6;3;6;2,19;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC(=O)N1CCC(CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5280797;194194;None;0;Human;Binding;Ki;=;1870,00;5,73;-2;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;476,3;6;3;6;2,19;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CC(=O)N1CCC(CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5280979;194200;None;0;Human;Binding;IC50;=;9120,11;5,04;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;527,2;8;1;5;5,55;O=C(Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc2ccccc21)NC1CCCCC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5281787;194236;None;0;Human;Binding;IC50;=;1737,80;5,76;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;553,2;8;1;5;6,21;Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)c1C(=O)NC1CCCCC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5281830;194240;None;0;Human;Binding;EC50;=;5011,87;5,30;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;561,2;9;1;5;6,08;Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)c1C(=O)NCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5281830;194240;None;0;Human;Binding;IC50;=;5,01;8,30;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;561,2;9;1;5;6,08;Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc(-c2ccccc2)c1C(=O)NCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5282604;194273;None;0;Human;Binding;IC50;=;446,68;6,35;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;657;7;1;5;6,54;CC(C)(C)NC(=O)Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc2cc(Br)c(Br)cc21;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5283457;194318;None;0;Human;Binding;Ki;=;38,90;7,41;-;1;Displacement of [3H] raclopride from D2DR (unknown origin);ChEMBL;283,2;3;2;3;2,97;CN(C)CCc1cc(O)c(O)c2c1CCc1ccccc1-2;https://dx.doi.org/10.1016/j.ejmech.2020.112792
CHEMBL5283620;194329;None;0;Human;Binding;EC50;=;5,29;8,28;-;4;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;556,4;12;3;5;6,43;CCCN(CCc1ccc(CCN(CCC)[C@@H]2CCc3cc(O)c(O)cc3C2)cc1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmc.2022.117131
CHEMBL5283891;194341;None;0;Human;Binding;EC50;=;7,59;8,12;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;531,2;8;2;5;2,54;O=C1NCCN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C1C(=O)NCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5283891;194341;None;0;Human;Binding;IC50;=;1,15;8,94;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;531,2;8;2;5;2,54;O=C1NCCN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C1C(=O)NCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5285185;194392;None;0;Human;Binding;Ki;=;15,85;7,80;-;1;Displacement of [3H] raclopride from D2DR (unknown origin);ChEMBL;309,2;3;2;3;3,93;C=CCN1CCC2C=C(O)C(O)=C3C(c4ccccc4)CC1C32;https://dx.doi.org/10.1016/j.ejmech.2020.112792
CHEMBL5285358;194402;None;0;Human;Binding;Ki;=;8800,00;5,06;-17378;3;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;334,2;4;2;4;3,30;O/N=C/c1c(CN2CCN(c3ccccc3)CC2)[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL5286161;194444;None;0;Human;Binding;Ki;=;49,10;7,31;-2;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;443,2;7;3;4;3,12;CN(C[C@H]1C[C@@H]1CCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5286175;194445;None;0;Human;Binding;Ki;=;4700,00;5,33;-151;3;Displacement of [3H]-spiperone from human D2 receptor assessed as inhibition constant;ChEMBL;340,1;1;1;4;4,01;Clc1ccc2c(c1)N=C(N1CCN(c3ccccc3)CC1)CCN2;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL5286231;194448;None;0;Human;Binding;Ki;=;3801,89;5,42;-;1;Displacement of [3H] raclopride from D2DR (unknown origin);ChEMBL;311,2;3;0;3;3,56;COC1=CC2CCN(C)C3CC(c4ccccc4)C(=C1OC)C23;https://dx.doi.org/10.1016/j.ejmech.2020.112792
CHEMBL5286603;194460;None;0;Human;Binding;Ki;=;371,00;6,43;-2;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;433,2;7;3;5;3,36;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1C[C@H]1C[C@H]1CCNC(=O)c1cc2ccccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5287555;194494;None;0;Human;Binding;Ki;=;9,56;8,02;11;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;443,2;7;3;4;3,12;CN(C[C@@H]1C[C@H]1CCNC(=O)c1cc2ccccc2[nH]1)[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5288557;194539;None;0;Human;Binding;IC50;=;13489,63;4,87;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;535,2;9;1;5;5,41;O=C(Cn1c(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)nc2ccccc21)NCc1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5288831;194552;None;0;Human;Binding;Ki;=;7920,00;5,10;-24;2;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;459,3;6;3;5;4,06;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1C/C=C1\CCC(CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5288831;194552;None;0;Human;Binding;Ki;=;55,90;7,25;-24;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;459,3;6;3;5;4,06;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1C/C=C1\CCC(CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5289063;194563;None;0;Human;Binding;EC50;=;90,00;7,05;-;3;Partial agonist activity at human D2 receptor assessed as increase in cAMP accumulation;ChEMBL;447,2;7;2;7;3,25;O=c1ccc2c(N3CCCN(CCCCOc4ccc5ccnn5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5289063;194563;None;0;Human;Binding;EC50;=;250,00;6,60;-;3;Partial agonist activity at human D2 receptor assessed as beta arrestin-2 recruitment;ChEMBL;447,2;7;2;7;3,25;O=c1ccc2c(N3CCCN(CCCCOc4ccc5ccnn5c4)CC3)ccc(O)c2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL52901;194600;None;0;Human;Binding;Ki;=;316,23;6,50;-79;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;533,2;9;1;6;4,43;O=C(/C=C/c1cnc2ccccc2c1)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL5290330;194604;None;0;Human;Binding;IC50;=;1737,80;5,76;-;3;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;452,2;5;0;4;3,84;CC(C)(C)N1C=CN(C(=O)CCCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1=O;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
CHEMBL5291065;194628;None;0;Human;Binding;Ki;=;15000,00;4,82;-38;2;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;461,3;7;3;5;4,14;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CCC1CCC(CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL5291065;194628;None;0;Human;Binding;Ki;=;86,70;7,06;-38;2;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;461,3;7;3;5;4,14;C[C@H]1CO[C@@H](c2ccc(N)nc2)CN1CCC1CCC(CNC(=O)c2cc3ccccc3[nH]2)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
CHEMBL52987;194666;None;0;Human;Binding;Ki;=;316,23;6,50;-79;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;512,2;10;1;6;3,89;COc1ccc(/C=C/C(=O)NCCCCN2CCc3ccc(OS(=O)(=O)C(F)(F)F)cc3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL5315307;194725;None;0;Human;Binding;EC50;=;7,69;8,11;-;4;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;572,4;12;4;6;6,13;CCCN(CCc1cc(O)c(CCN(CCC)[C@H]2CCc3c(O)cccc3C2)cc1O)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/j.bmc.2022.117131
CHEMBL53351;194808;None;0;Human;Binding;Ki;=;501,19;6,30;-125;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;525,2;10;1;6;3,95;CN(C)c1ccc(/C=C/C(=O)NCCCCN2CCc3ccc(OS(=O)(=O)C(F)(F)F)cc3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL53510;194840;None;4;Human;Binding;Ki;=;1070,00;5,97;-109;4;Ability to displace [3H]raclopride binding to cloned human Dopamine receptor D2A;ChEMBL;265,1;0;1;2;3,45;Cc1ccc2c(c1O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm00004a011
CHEMBL53510;194840;None;4;Human;Binding;Ki;=;1070,00;5,97;-109;4;In vitro affinity at human cloned Dopamine receptor D2A by [3H]-raclopride displacement.;ChEMBL;265,1;0;1;2;3,45;Cc1ccc2c(c1O)-c1cccc3c1[C@@H](C2)N(C)CC3;https://dx.doi.org/10.1021/jm960188q
CHEMBL53833;194889;None;0;Human;Binding;Ki;=;501,19;6,30;-19;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;384,2;7;1;2;4,92;O=C(NCCCCN1CCc2ccccc2C1)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL538397;194892;None;0;Human;Binding;Ki;=;201,00;6,70;-37;4;Binding affinity for dopamine D2 receptor;ChEMBL;520,2;10;1;6;4,52;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OCCF)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.04.098
CHEMBL538397;194892;None;0;Human;Binding;Ki;=;330,00;6,48;-37;4;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;520,2;10;1;6;4,52;COc1ccc(S(=O)(=O)N[C@H]2CC[C@@H](N3CCC(c4ccccc4OCCF)CC3)CC2)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2007.09.051
CHEMBL5393856;194946;None;0;Human;Binding;Ki;=;295,12;6,53;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;419,2;7;0;6;4,76;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)oc2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5393856;194946;None;0;Human;Binding;Ki;=;292,00;6,54;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;419,2;7;0;6;4,76;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)oc2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5394229;194964;None;2;Human;Binding;Ki;=;36,00;7,44;-27;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;520,3;9;2;4;6,36;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5394229;194964;None;2;Human;Binding;Ki;=;52,00;7,28;-27;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;520,3;9;2;4;6,36;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5394387;194980;None;0;Human;Binding;Ki;=;13300,00;4,88;-501;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;351,2;5;0;4;4,81;Cc1cccnc1C1CCN(CCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5394431;194985;None;0;Human;Binding;Ki;=;140,00;6,85;-13;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;462,2;8;2;4;4,83;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccc(F)cc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5394431;194985;None;0;Human;Binding;Ki;=;31,00;7,51;-13;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;462,2;8;2;4;4,83;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccc(F)cc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5394961;195013;None;0;Human;Binding;Ki;=;0,20;9,70;9;2;Displacement of [3H]-NMSP from D2 receptor (unknown origin) assessed as inhibition constant by radioligand binding assay;ChEMBL;315,2;5;0;4;3,90;CCCCc1cc(-c2ccsc2)cc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.bmcl.2023.129497
CHEMBL5395187;195029;None;0;Human;Binding;Ki;=;210,00;6,68;-23;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5395187;195029;None;0;Human;Binding;Ki;=;75,00;7,12;-23;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5395417;195041;None;0;Human;Binding;Ki;=;2277,00;5,64;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;432,2;7;0;6;4,51;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)n(C)c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5395417;195041;None;0;Human;Binding;Ki;=;2290,87;5,64;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;432,2;7;0;6;4,51;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)n(C)c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5395539;195050;None;0;Human;Binding;Ki;=;322,00;6,49;-6;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;670,3;13;1;7;5,19;CN(C)C(=O)C(CCN1C[C@H](F)C[C@H]1C(=O)NCCCCN1CCN(c2nsc3ccccc23)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5395668;195055;None;0;Human;Binding;Ki;=;239,00;6,62;-6;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;378,2;7;2;5;2,29;O=C(NCCCCN1CCN(c2ccccn2)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5395965;195067;None;0;Human;Binding;Ki;=;6,50;8,19;-20;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;500,2;6;2;4;4,78;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)C1=CC2C=CC=CC2N1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5396317;195076;None;0;Human;Binding;Ki;=;170,00;6,77;-7;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;500,3;10;2;4;5,50;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccc(C(C)C)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5396317;195076;None;0;Human;Binding;Ki;=;400,00;6,40;-7;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;500,3;10;2;4;5,50;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccc(C(C)C)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5396600;195092;None;0;Human;Binding;Ki;=;83,40;7,08;-165;2;Displacement of [3H]-NMSP from D2 receptor (unknown origin) assessed as inhibition constant by radioligand binding assay;ChEMBL;355,2;4;0;4;4,68;CN1CCN(c2cc(-c3ccsc3)cc(CC3CCCCC3)n2)CC1;https://dx.doi.org/10.1016/j.bmcl.2023.129497
CHEMBL5396612;195094;None;0;Human;Binding;Ki;=;707,00;6,15;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;408,2;9;2;5;4,70;COc1cccc2cc(CNCCCCOc3ccc4ccc(=O)[nH]c4c3)sc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5396612;195094;None;0;Human;Binding;Ki;=;707,95;6,15;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;408,2;9;2;5;4,70;COc1cccc2cc(CNCCCCOc3ccc4ccc(=O)[nH]c4c3)sc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5396616;195095;None;0;Human;Binding;Ki;=;616,00;6,21;-3;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;413,2;8;2;6;3,96;CCCOc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OCCOCC)c3CN1CC2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5397609;195152;None;0;Human;Binding;Ki;=;978,00;6,01;-31;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;474,2;10;0;2;6,37;CCCN(CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1)[C@@H]1C[C@H]1c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5398100;195174;None;0;Human;Binding;Ki;=;1,86;8,73;-5;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;515,2;5;1;4;5,23;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)N1CCc2ncccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5398291;195182;None;2;Human;Binding;Ki;=;69,70;7,16;1;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;377,2;7;2;4;2,90;O=C(NCCCCN1CCN(c2ccccc2)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5398747;195206;None;0;Human;Binding;Ki;=;4660,00;5,33;-6;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;595,3;9;1;6;4,12;CN(C)C(=O)C(CCN1C[C@H](O)C[C@H]1CN1CCN(c2cccc(C(F)(F)F)n2)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5398913;195208;None;0;Human;Binding;Ki;=;851,00;6,07;-69;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;432,2;8;1;2;5,25;CN(C)C(=O)C(CCN[C@@H]1C[C@H]1c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5399129;195223;None;0;Human;Binding;Ki;=;175,00;6,76;-9;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;443,2;8;1;5;2,90;COCCC(=O)N1CCC(O)(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5399166;195227;None;0;Human;Binding;Ki;=;2739,00;5,56;-53;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;369,2;5;2;5;3,94;CCCCOc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5399270;195235;None;2;Human;Binding;Ki;=;121,00;6,92;-2;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;419,2;5;0;4;4,65;Clc1cccc(N2CCN(CCC3(c4ccccn4)CCOCC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5399568;195260;None;0;Human;Binding;Ki;=;1433,00;5,84;-46;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;383,2;6;2;5;4,33;CCCCCOc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5399689;195263;None;0;Human;Binding;Ki;=;6890,00;5,16;-151;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;351,2;5;0;4;4,81;Cc1ccc2nc(CCCN3CCC(c4ccccn4)CC3)sc2c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5399720;195264;None;0;Human;Binding;Ki;=;427,00;6,37;-69;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;367,2;6;0;5;4,51;COc1ccc2nc(CCCN3CCC(c4ccccn4)CC3)sc2c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5399833;195272;None;0;Human;Binding;Ki;=;86,00;7,07;-17;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;498,3;10;2;5;4,71;C#CCOc1ccc(NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c(-c2ccccc2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5399833;195272;None;0;Human;Binding;Ki;=;46,00;7,34;-17;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;498,3;10;2;5;4,71;C#CCOc1ccc(NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c(-c2ccccc2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5400232;195292;None;0;Human;Binding;Ki;=;100,00;7,00;-25;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;444,3;8;2;4;4,70;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5400232;195292;None;0;Human;Binding;Ki;=;210,00;6,68;-25;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;444,3;8;2;4;4,70;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5400356;195303;None;0;Human;Binding;Ki;=;1690,00;5,77;-5;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;450,2;7;0;6;3,73;FC(F)(F)c1cccc(N2CCN(CCCOC3(c4ccccn4)CCOCC3)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5400528;195309;None;0;Human;Binding;Ki;=;20,50;7,69;-19;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;412,2;4;0;3;3,90;CN(C)C(=O)N1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5400876;195320;None;4;Human;Binding;Ki;=;2930,00;5,53;-645;21;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;338,2;5;0;5;3,45;c1ccc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5400983;195324;None;0;Human;Binding;Ki;=;14000,00;4,85;-1230;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;372,1;5;0;5;4,10;Clc1ccc2sc(CCCN3CCN(c4ccccn4)CC3)nc2c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5401818;195350;None;0;Human;Binding;Ki;=;109,00;6,96;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,2;9;2;5;4,28;CCOc1cccc2cc(CNCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5401818;195350;None;0;Human;Binding;Ki;=;109,65;6,96;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,2;9;2;5;4,28;CCOc1cccc2cc(CNCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5402212;195371;None;0;Human;Binding;Ki;=;26,70;7,57;-11;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;427,3;5;1;4;3,44;CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(C(F)(F)F)n3)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5402456;195382;None;0;Human;Binding;Ki;=;1344,00;5,87;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;402,2;7;0;5;5,21;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2cccnc2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5402456;195382;None;0;Human;Binding;Ki;=;1348,96;5,87;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;402,2;7;0;5;5,21;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2cccnc2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5403204;195411;None;0;Human;Binding;Ki;=;78,00;7,11;-63;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;488,3;10;2;5;4,38;COc1ccc(-c2ccccc2)c(CNC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5403204;195411;None;0;Human;Binding;Ki;=;130,00;6,89;-63;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;488,3;10;2;5;4,38;COc1ccc(-c2ccccc2)c(CNC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5403268;195417;None;0;Human;Binding;Ki;=;479,00;6,32;-363;5;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;421,3;9;1;5;3,06;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(OC)c3F)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5403504;195429;None;0;Human;Binding;Ki;=;519,00;6,29;-301;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;368,2;6;0;6;3,46;COc1cccnc1N1CCN(CCCc2nc3ccccc3s2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5403610;195433;None;0;Human;Binding;Ki;=;49800,00;4,30;-851;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;352,2;5;0;5;3,75;Cc1ccc2nc(CCCN3CCN(c4ccccn4)CC3)sc2c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5403986;195445;None;0;Human;Binding;Ki;=;2420,00;5,62;-89;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;372,1;5;0;5;4,10;Clc1ccc2nc(CCCN3CCN(c4ccccn4)CC3)sc2c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5404031;195448;None;0;Human;Binding;Ki;=;9,93;8,00;-2;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;423,2;8;2;5;3,62;CSc1ccccc1N1CCN(CCCCNC(=O)c2n[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5404054;195452;None;0;Human;Binding;Ki;=;7,80;8,11;-22;8;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;504,3;7;1;4;5,95;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)c4ccnc5ccccc45)CC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5404724;195492;None;0;Human;Binding;Ki;=;2220,00;5,65;-10;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;680,4;13;2;7;4,02;CN(C)C(=O)C(CCN1C[C@H](O)C[C@H]1C(=O)NCCCCN1CCN(c2cccc(C(F)(F)F)n2)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5404807;195494;None;0;Human;Binding;Ki;=;0,87;9,06;-3;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;509,3;6;1;4;5,14;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)N4CCc5ncccc5C4)CC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5405086;195511;None;0;Human;Binding;Ki;=;67,00;7,17;-24;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2cccc(F)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5405086;195511;None;0;Human;Binding;Ki;=;86,00;7,07;-24;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2cccc(F)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5405133;195514;None;0;Human;Binding;Ki;=;181,97;6,74;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,1;8;2;5;4,31;COc1cccc2cc(CNCCCOc3ccc4ccc(=O)[nH]c4c3)sc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5405133;195514;None;0;Human;Binding;Ki;=;181,00;6,74;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,1;8;2;5;4,31;COc1cccc2cc(CNCCCOc3ccc4ccc(=O)[nH]c4c3)sc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5405333;195523;None;0;Human;Binding;Ki;=;460,00;6,34;-23;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;534,3;10;2;4;6,04;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5405333;195523;None;0;Human;Binding;Ki;=;290,00;6,54;-23;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;534,3;10;2;4;6,04;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5406129;195563;None;0;Human;Binding;Ki;=;1400,00;5,85;-58;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;592,2;8;1;5;5,49;CN(C)C(=O)C(CCN1C[C@H](O)C/C1=C\N1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5406300;195571;None;0;Human;Binding;Ki;=;669,00;6,17;-31;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;367,2;6;0;5;4,51;COc1cccc2nc(CCCN3CCC(c4ccccn4)CC3)sc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5406355;195574;None;0;Human;Binding;Ki;=;439,00;6,36;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;422,2;11;2;5;5,05;CCOc1cccc2cc(CNCCCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5406355;195574;None;0;Human;Binding;Ki;=;446,68;6,35;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;422,2;11;2;5;5,05;CCOc1cccc2cc(CNCCCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5406501;195584;None;2;Human;Binding;Ki;=;2130,00;5,67;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;317,2;6;2;4;4,18;CCOc1cccc2cc(C(C)NCC3(O)CCCCC3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5407131;195616;None;0;Human;Binding;Ki;=;1440,00;5,84;-1;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;600,3;11;0;7;5,29;CCc1cc(Cl)c(OC)c(N2CCN(Cc3cn(CCC(C(=O)N(C)C)(c4ccccc4)c4ccccc4)nn3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5407341;195623;None;0;Human;Binding;Ki;=;89,00;7,05;-11;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;492,3;9;2;5;4,84;COc1ccc(NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1-c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5407341;195623;None;0;Human;Binding;Ki;=;53,00;7,28;-11;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;492,3;9;2;5;4,84;COc1ccc(NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)cc1-c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5407747;195633;None;0;Human;Binding;Ki;=;963,00;6,02;-9;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;490,2;10;1;5;5,02;Clc1cccc(N2CCN(CCCCNCCC3(c4ccccn4)CCOCC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5407845;195639;None;0;Human;Binding;Ki;=;13400,00;4,87;-25;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;450,2;10;1;4;6,15;CCC1(CC)CC(OCCCNCc2cccc(Cl)c2Cl)(c2ccccn2)CCO1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5408223;195657;None;0;Human;Binding;Ki;=;1,78;8,75;-7;8;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;421,3;8;1;4;3,74;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)COC)CC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5408427;195663;None;0;Human;Binding;Ki;=;1,32;8,88;3;2;Displacement of [3H]-NMSP from D2 receptor (unknown origin) assessed as inhibition constant by radioligand binding assay;ChEMBL;301,2;3;0;4;3,69;CC(C)c1cc(-c2ccsc2)cc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.bmcl.2023.129497
CHEMBL5409134;195686;None;0;Human;Binding;Ki;=;4,12;8,38;-2;7;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;450,3;7;1;4;4,25;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(=O)N(C)C)CC3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5409227;195693;None;0;Human;Binding;Ki;=;108,00;6,97;-5;5;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;407,2;8;2;5;2,90;COc1cccc(N2CCN(CCCCNC(=O)c3n[nH]c4ccccc34)CC2)c1;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5409322;195703;None;0;Human;Binding;Ki;=;465,00;6,33;-1288;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;484,2;7;0;5;4,88;CN(C)C(=O)C(CCN1CCN(c2nsc3ccccc23)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5409419;195711;None;0;Human;Binding;Ki;=;39,30;7,41;-12;8;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;420,2;7;1;5;4,54;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2c(c1)NC(=O)CC2)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5409419;195711;None;0;Human;Binding;Ki;=;39,81;7,40;-12;8;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;420,2;7;1;5;4,54;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2c(c1)NC(=O)CC2)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5409755;195731;None;0;Human;Binding;Ki;=;5,30;8,28;-6;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;422,2;7;2;4;3,65;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(N)=O)CC3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5410159;195755;None;0;Human;Binding;Ki;=;7330,00;5,13;-275;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;476,2;10;1;3;4,96;CN(C)C(=O)C(CCN(CCO)[C@@H]1C[C@H]1c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5410179;195756;None;0;Human;Binding;Ki;=;150,00;6,82;-22;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;486,3;9;2;4;5,82;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2ccc(C(C)C)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5410179;195756;None;0;Human;Binding;Ki;=;90,00;7,05;-22;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;486,3;9;2;4;5,82;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2ccc(C(C)C)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5410217;195758;None;0;Human;Binding;Ki;=;26302,68;4,58;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;408,2;7;0;6;5,27;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2scnc2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5410217;195758;None;0;Human;Binding;Ki;=;25852,00;4,59;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;408,2;7;0;6;5,27;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2scnc2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5410387;195769;None;0;Human;Binding;Ki;=;2682,00;5,57;-177;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;355,2;4;2;5;3,55;CCCOc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5410716;195781;None;0;Human;Binding;Ki;=;1491,00;5,83;-56;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;397,2;7;2;5;4,72;CCCCCCOc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5411002;195801;None;0;Human;Binding;Ki;=;76,40;7,12;3;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;395,2;7;2;4;3,03;O=C(NCCCCN1CCN(c2cccc(F)c2)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5411404;195820;None;0;Human;Binding;Ki;=;120,00;6,92;-11;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;474,3;9;2;5;4,71;COc1cccc(-c2ccccc2NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5411404;195820;None;0;Human;Binding;Ki;=;110,00;6,96;-11;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;474,3;9;2;5;4,71;COc1cccc(-c2ccccc2NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5411545;195826;None;0;Human;Binding;Ki;=;1288,25;5,89;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;450,3;12;1;5;5,79;CCCN(CCCCOc1ccc2c(c1)NC(=O)CC2)Cc1cc2cccc(OCC)c2o1;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5411545;195826;None;0;Human;Binding;Ki;=;1274,00;5,89;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;450,3;12;1;5;5,79;CCCN(CCCCOc1ccc2c(c1)NC(=O)CC2)Cc1cc2cccc(OCC)c2o1;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5412359;195871;None;0;Human;Binding;Ki;=;63,10;7,20;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;384,2;9;2;4;4,40;CCOc1cccc2cc(CNCC[C@H]3CC[C@H](NC(=O)C4CC4)CC3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5412359;195871;None;0;Human;Binding;Ki;=;62,80;7,20;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;384,2;9;2;4;4,40;CCOc1cccc2cc(CNCC[C@H]3CC[C@H](NC(=O)C4CC4)CC3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5412606;195885;None;0;Human;Binding;Ki;=;2010,00;5,70;-22;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;682,4;13;1;6;5,00;CN(C)C(=O)C(CCN1C[C@H](F)C[C@H]1C(=O)NCCCCN1CCN(c2cccc(C(F)(F)F)n2)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5412718;195889;None;0;Human;Binding;Ki;=;26,00;7,58;-16;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2cccc(F)c2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5412718;195889;None;0;Human;Binding;Ki;=;13,00;7,89;-16;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2cccc(F)c2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5412886;195898;None;0;Human;Binding;Ki;=;9,86;8,01;-1;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;421,2;9;2;5;3,29;CCOc1ccccc1N1CCN(CCCCNC(=O)c2n[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5412995;195904;None;2;Human;Binding;Ki;=;1550,00;5,81;-28;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;428,2;9;1;3;4,61;COc1ccccc1[C@@H]1C[C@H]1NCCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5413807;195943;None;0;Human;Binding;Ki;=;5430,00;5,26;-33;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;474,3;5;0;5;5,07;FC(F)(F)c1cccc(N2CCN(CCC3(c4ccccn4)CCOC4(CCCC4)C3)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5414097;195954;None;0;Human;Binding;Ki;=;139,00;6,86;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;416,2;6;1;5;4,28;COc1cccc2c3c(oc12)CN(C/C=C/COc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5414097;195954;None;0;Human;Binding;Ki;=;141,25;6,85;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;416,2;6;1;5;4,28;COc1cccc2c3c(oc12)CN(C/C=C/COc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5414152;195955;None;0;Human;Binding;Ki;=;758,58;6,12;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;420,2;11;2;5;5,01;CCOc1cccc2cc(CNCCCCCOc3ccc4ccc(=O)[nH]c4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5414152;195955;None;0;Human;Binding;Ki;=;745,00;6,13;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;420,2;11;2;5;5,01;CCOc1cccc2cc(CNCCCCCOc3ccc4ccc(=O)[nH]c4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL541435;195965;None;0;Human;Binding;Ki;=;316,23;6,50;-1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;377,2;6;0;3;3,19;COCC1[C@@H]2CC[C@H]1CN(CCN1CCN(c3cccc(Cl)c3)C1=O)C2;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL5414422;195971;None;0;Human;Binding;Ki;=;954,99;6,02;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,2;10;1;6;5,23;CCOc1cccc2cc(CNCCCCOc3ccc4oc(C)nc4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5414422;195971;None;0;Human;Binding;Ki;=;935,00;6,03;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,2;10;1;6;5,23;CCOc1cccc2cc(CNCCCCOc3ccc4oc(C)nc4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5414796;195989;None;2;Human;Binding;Ki;=;141,00;6,85;-19;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;679,3;13;2;6;4,91;CN(C)C(=O)C(CCN1C[C@H](O)C[C@H]1C(=O)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5414943;196003;None;0;Human;Binding;Ki;=;588,84;6,23;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;364,2;8;2;4;4,27;O=C1CCc2ccc(OCCCCNCc3cc4ccccc4o3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5414943;196003;None;0;Human;Binding;Ki;=;582,00;6,24;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;364,2;8;2;4;4,27;O=C1CCc2ccc(OCCCCNCc3cc4ccccc4o3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5415178;196020;None;0;Human;Binding;Ki;=;3235,94;5,49;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;406,2;7;1;5;4,15;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2c(c1)NC(=O)C2)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5415178;196020;None;0;Human;Binding;Ki;=;3189,00;5,50;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;406,2;7;1;5;4,15;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2c(c1)NC(=O)C2)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5415335;196029;None;0;Human;Binding;Ki;=;340,00;6,47;-9;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;444,3;8;2;4;4,70;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5415335;196029;None;0;Human;Binding;Ki;=;130,00;6,89;-9;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;444,3;8;2;4;4,70;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccc(-c3ccccc3)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5415412;196032;None;0;Human;Binding;Ki;=;8,71;8,06;-1;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;407,2;8;2;5;2,90;COc1ccccc1N1CCN(CCCCNC(=O)c2n[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5415451;196034;None;0;Human;Binding;Ki;=;286,00;6,54;-3;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;642,3;14;0;7;6,11;CCc1cc(Cl)c(OC)c(N2CCN(CCCCc3cn(CCC(C(=O)N(C)C)(c4ccccc4)c4ccccc4)nn3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5415691;196043;None;0;Human;Binding;Ki;=;122,00;6,91;-5;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;505,2;9;0;5;6,18;CCC1(CC)CC(OCCCN2CCN(c3cccc(Cl)c3Cl)CC2)(c2ccccn2)CCO1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5415842;196051;None;0;Human;Binding;Ki;=;1240,00;5,91;-12;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;506,3;9;0;6;5,29;CCC1(CC)CC(OCCCN2CCN(c3cccc(C(F)(F)F)n3)CC2)(c2ccccn2)CCO1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5415846;196052;None;0;Human;Binding;Ki;=;0,75;9,12;-2;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;420,3;6;1;3;4,24;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)N(C)C)CC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5416644;196087;None;0;Human;Binding;Ki;=;220,00;6,66;-10;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;488,3;10;2;5;4,38;COc1cccc(-c2ccccc2CNC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5416644;196087;None;0;Human;Binding;Ki;=;88,00;7,06;-10;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;488,3;10;2;5;4,38;COc1cccc(-c2ccccc2CNC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5416728;196092;None;0;Human;Binding;Ki;=;120,00;6,92;-3;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;500,3;8;2;4;5,99;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2ccc(C(C)(C)C)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5416728;196092;None;0;Human;Binding;Ki;=;78,00;7,11;-3;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;500,3;8;2;4;5,99;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2ccc(C(C)(C)C)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5417227;196115;None;0;Human;Binding;Ki;=;30,90;7,51;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;396,2;10;1;6;5,39;CCOc1cccc2cc(CNCCCCOc3ccc4scnc4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5417227;196115;None;0;Human;Binding;Ki;=;30,20;7,52;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;396,2;10;1;6;5,39;CCOc1cccc2cc(CNCCCCOc3ccc4scnc4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5417253;196118;None;0;Human;Binding;Ki;=;1480,00;5,83;-1202;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;496,2;7;0;4;4,69;CN(C)C(=O)C(CCN1CCN(c2cccc(C(F)(F)F)n2)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5417351;196129;None;22;Human;Binding;Ki;=;1,49;8,83;-5;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;398,2;5;2;3;3,73;NC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5417643;196147;None;0;Human;Binding;Ki;=;8640,00;5,06;-107;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;428,2;9;1;3;4,61;COc1ccc([C@@H]2C[C@H]2NCCC(C(=O)N(C)C)(c2ccccc2)c2ccccc2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5417857;196159;None;0;Human;Binding;Ki;=;4,07;8,39;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;392,2;9;2;5;4,23;COc1cccc2cc(CNCCCCOc3ccc4ccc(=O)[nH]c4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5417857;196159;None;0;Human;Binding;Ki;=;4,01;8,40;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;392,2;9;2;5;4,23;COc1cccc2cc(CNCCCCOc3ccc4ccc(=O)[nH]c4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5418730;196200;None;0;Human;Binding;Ki;=;4070,00;5,39;-15;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;356,2;6;1;3;4,32;Clc1ccc([C@@H]2C[C@H]2NCCC2(c3ccccn3)CCOCC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5418748;196201;None;0;Human;Binding;Ki;=;6,61;8,18;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;407,2;10;1;6;4,89;CCOc1cccc2cc(CNCCCCOc3ccc4ccc(=O)oc4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5418748;196201;None;0;Human;Binding;Ki;=;6,48;8,19;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;407,2;10;1;6;4,89;CCOc1cccc2cc(CNCCCCOc3ccc4ccc(=O)oc4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5418819;196206;None;0;Human;Binding;Ki;=;117,00;6,93;-5;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;592,3;10;0;4;6,29;CN(C)C(=O)C(CCN1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)C1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5418890;196210;None;0;Human;Binding;Ki;=;2089,30;5,68;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,2;10;1;6;5,23;CCOc1cccc2cc(CNCCCCOc3ccc4c(C)noc4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5418890;196210;None;0;Human;Binding;Ki;=;2077,00;5,68;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,2;10;1;6;5,23;CCOc1cccc2cc(CNCCCCOc3ccc4c(C)noc4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5420183;196268;None;0;Human;Binding;Ki;=;7,34;8,13;-5;2;Displacement of [3H]-NMSP from D2 receptor (unknown origin) assessed as inhibition constant by radioligand binding assay;ChEMBL;273,1;2;0;4;2,87;Cc1cc(-c2ccsc2)cc(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/j.bmcl.2023.129497
CHEMBL5420316;196276;None;0;Human;Binding;Ki;=;89,80;7,05;-3;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;428,2;5;1;4;3,01;CN(C)C(=O)N1CCC(O)(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)C1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL54206;196291;None;25;Human;Binding;Kd;=;8,51;8,07;-;3;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;341,2;6;1;3;3,77;O=C(CCCN1CCC(O)(c2ccccc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL54206;196291;None;25;Human;Binding;Ki;=;7,59;8,12;-;3;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;341,2;6;1;3;3,77;O=C(CCCN1CCC(O)(c2ccccc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL5420627;196294;None;0;Human;Binding;Ki;=;557,00;6,25;-1;2;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;378,2;7;2;5;2,29;O=C(NCCCCN1CCN(c2cccnc2)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5421272;196316;None;0;Human;Binding;Ki;=;210,00;6,68;-177;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2c(F)cccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5421272;196316;None;0;Human;Binding;Ki;=;140,00;6,85;-177;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2c(F)cccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5421574;196332;None;0;Human;Binding;Ki;=;446,68;6,35;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;383,2;10;1;6;4,51;CCOc1cccc2cc(CNCCCCOc3ccc4c(c3)OCO4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5421574;196332;None;0;Human;Binding;Ki;=;438,00;6,36;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;383,2;10;1;6;4,51;CCOc1cccc2cc(CNCCCCOc3ccc4c(c3)OCO4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5421714;196337;None;0;Human;Binding;Ki;=;272,00;6,57;-21;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;681,3;13;1;5;5,89;CN(C)C(=O)C(CCN1C[C@H](F)C[C@H]1C(=O)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5421827;196342;None;0;Human;Binding;Ki;=;125,00;6,90;-4;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;457,2;8;1;5;3,29;COCCC(=O)N1CCC(O)(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5421925;196346;None;0;Human;Binding;Ki;=;5,76;8,24;-4;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;494,3;7;2;4;4,69;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4=CC5C=CC=CC5N4)CC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5422150;196356;None;0;Human;Binding;Ki;=;6500,00;5,19;-173;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;372,1;5;0;5;4,10;Clc1cccc2sc(CCCN3CCN(c4ccccn4)CC3)nc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5422196;196357;None;0;Human;Binding;Ki;=;11,80;7,93;1;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;411,2;7;2;4;3,55;O=C(NCCCCN1CCN(c2ccccc2Cl)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5422870;196394;None;0;Human;Binding;Ki;=;74,00;7,13;-46;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;562,3;15;2;7;4,74;COCCOCCOc1ccc(NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c(-c2ccccc2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5422870;196394;None;0;Human;Binding;Ki;=;130,00;6,89;-46;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;562,3;15;2;7;4,74;COCCOCCOc1ccc(NC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c(-c2ccccc2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5423250;196408;None;0;Human;Binding;Ki;=;1310,00;5,88;-4;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;504,3;7;0;6;5,04;FC(F)(F)c1cccc(N2CCN(CCCOC3(c4ccccn4)CCOC4(CCCC4)C3)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5424038;196444;None;0;Human;Binding;Ki;=;7,04;8,15;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;408,2;10;2;5;4,67;CCOc1cccc2cc(CNCCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5424038;196444;None;0;Human;Binding;Ki;=;7,08;8,15;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;408,2;10;2;5;4,67;CCOc1cccc2cc(CNCCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5424052;196445;None;0;Human;Binding;Ki;=;8,57;8,07;13;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;445,2;7;2;4;3,91;O=C(NCCCCN1CCN(c2ccccc2C(F)(F)F)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5424241;196453;None;0;Human;Binding;Ki;=;68,10;7,17;-1;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;479,3;7;1;5;5,51;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(=O)OC(C)(C)C)CC3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5424897;196485;None;0;Human;Binding;Ki;=;15,20;7,82;-20;7;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;465,3;10;1;5;4,13;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(=O)CCOC)CC3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5425134;196490;None;0;Human;Binding;Ki;=;0,48;9,32;-2;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;406,3;6;2;3;3,90;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)NC)CC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5425252;196494;None;0;Human;Binding;Ki;=;120,00;6,92;-281;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;458,3;9;2;4;4,37;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5425252;196494;None;0;Human;Binding;Ki;=;190,00;6,72;-281;9;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;458,3;9;2;4;4,37;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5425375;196499;None;0;Human;Binding;Ki;=;591,00;6,23;-8;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;397,2;7;2;5;4,72;CCCCOc1c(O)ccc2c1CN1CCc3cc(OCCC)c(O)cc3[C@@H]1C2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5425434;196501;None;0;Human;Binding;Ki;=;33,30;7,48;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,2;9;2;5;4,28;COc1cccc2cc(CNCCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5425434;196501;None;0;Human;Binding;Ki;=;33,88;7,47;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;394,2;9;2;5;4,28;COc1cccc2cc(CNCCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5425920;196526;None;0;Human;Binding;Ki;=;1050,00;5,98;-48;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;366,2;6;0;5;4,14;Cc1ccc(N2CCN(CCCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5425944;196529;None;0;Human;Binding;Ki;=;58,80;7,23;3;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;449,2;7;0;5;4,62;Clc1cccc(N2CCN(CCCOC3(c4ccccn4)CCOCC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5426242;196538;None;0;Human;Binding;Ki;=;84,30;7,07;-7;8;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;418,2;7;1;5;4,50;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5426242;196538;None;0;Human;Binding;Ki;=;85,11;7,07;-7;8;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;418,2;7;1;5;4,50;COc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5426286;196539;None;0;Human;Binding;Ki;=;423,00;6,37;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;392,2;9;2;5;4,23;CCOc1cccc2cc(CNCCCOc3ccc4ccc(=O)[nH]c4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5426286;196539;None;0;Human;Binding;Ki;=;426,58;6,37;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;392,2;9;2;5;4,23;CCOc1cccc2cc(CNCCCOc3ccc4ccc(=O)[nH]c4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5426481;196550;None;0;Human;Binding;Ki;=;830,00;6,08;-169;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;386,1;6;0;5;4,49;Clc1ccc(N2CCN(CCCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5426620;196560;None;0;Human;Binding;Ki;=;38,40;7,42;1;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;442,2;5;1;4;3,40;CN(C)C(=O)N1CCC(O)(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5427065;196574;None;0;Human;Binding;Ki;=;114,00;6,94;-112;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;524,3;8;2;5;4,70;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4=CC5C=CC=CC5N4)CC3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5427288;196585;None;0;Human;Binding;Ki;=;151,36;6,82;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;404,2;6;1;5;4,11;COc1cccc2c3c(oc12)CN(CCCOc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5427288;196585;None;0;Human;Binding;Ki;=;149,00;6,83;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;404,2;6;1;5;4,11;COc1cccc2c3c(oc12)CN(CCCOc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5427695;196607;None;0;Human;Binding;Ki;=;134,00;6,87;-14;5;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;406,3;6;1;4;3,18;COc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)N(C)C)CC3)CC2)c1F;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5427937;196616;None;0;Human;Binding;Ki;=;110,00;6,96;-19;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;472,3;9;2;4;4,68;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccc(C)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5427937;196616;None;0;Human;Binding;Ki;=;62,00;7,21;-19;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;472,3;9;2;4;4,68;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccccc2-c2ccc(C)cc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5428803;196644;None;0;Human;Binding;Ki;=;5045,00;5,30;-147;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;359,2;4;2;5;3,11;COc1c(O)ccc2c1CN1CCc3cc(OCCF)c(O)cc3[C@@H]1C2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5429048;196654;None;0;Human;Binding;Ki;=;3,75;8,43;-6;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;536,2;7;1;4;6,56;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1ccc(-c2cccnc2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5429207;196661;None;0;Human;Binding;Ki;=;7460,00;5,13;-8;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;420,2;5;0;5;3,76;FC(F)(F)c1cccc(N2CCN(CCC3(c4ccccn4)CCOCC3)CC2)n1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5429491;196672;None;0;Human;Binding;Ki;=;26,40;7,58;1;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;395,2;7;2;4;3,03;O=C(NCCCCN1CCN(c2ccccc2F)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5429826;196683;None;0;Human;Binding;Ki;=;29,00;7,54;-43;7;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;510,2;6;1;4;6,04;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1ccnc2ccccc12;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5430494;196712;None;0;Human;Binding;Ki;=;16,50;7,78;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;432,2;8;1;5;4,89;CCOc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5430494;196712;None;0;Human;Binding;Ki;=;16,60;7,78;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;432,2;8;1;5;4,89;CCOc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5431103;196730;None;6;Human;Binding;Ki;=;2,85;8,54;-20;8;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;441,2;8;1;4;4,22;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5431474;196751;None;0;Human;Binding;Ki;=;46,00;7,34;-1;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;444,3;8;2;4;4,70;COc1ccccc1N1CCN(CCCNC(=O)Nc2cccc(-c3ccccc3)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5431474;196751;None;0;Human;Binding;Ki;=;18,00;7,75;-1;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;444,3;8;2;4;4,70;COc1ccccc1N1CCN(CCCNC(=O)Nc2cccc(-c3ccccc3)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5431642;196760;None;2;Human;Binding;Ki;=;596,00;6,22;-10;5;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;395,2;7;2;4;3,03;O=C(NCCCCN1CCN(c2ccc(F)cc2)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5432478;196802;None;3;Human;Binding;Ki;=;115,00;6,94;-2;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;431,2;6;2;4;3,52;O=C(NCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5432993;196832;None;0;Human;Binding;Ki;=;1180,00;5,93;-4;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;594,3;9;1;5;5,01;CN(C)C(=O)C(CCN1C[C@H](O)C[C@H]1CN1CCN(c2cccc(Cl)c2Cl)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5433001;196833;None;0;Human;Binding;Ki;=;2089,00;5,68;-123;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;341,2;3;2;5;3,16;CCOc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5433201;196841;None;0;Human;Binding;Ki;=;204,00;6,69;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;406,2;6;1;5;4,15;COc1cccc2c3c(oc12)CN(CCCOc1ccc2c(c1)NC(=O)CC2)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5433201;196841;None;0;Human;Binding;Ki;=;204,17;6,69;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;406,2;6;1;5;4,15;COc1cccc2c3c(oc12)CN(CCCOc1ccc2c(c1)NC(=O)CC2)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5433284;196846;None;22;Human;Binding;Ki;=;1,21;8,92;-5;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;412,2;5;2;3;3,99;CNC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5433458;196855;None;2;Human;Binding;Ki;=;5520,00;5,26;-64;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;410,2;6;1;3;5,63;Clc1ccc([C@@H]2C[C@H]2NCCC2(c3ccccn3)CCOC3(CCCC3)C2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5433509;196857;None;0;Human;Binding;Ki;=;38,00;7,42;-12;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2cc(F)ccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5433509;196857;None;0;Human;Binding;Ki;=;88,00;7,06;-12;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2cc(F)ccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5434229;196886;None;0;Human;Binding;Ki;=;127,00;6,90;-117;7;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;442,3;8;1;5;3,32;COCCC(=O)N[C@H]1CC[C@H](CCN2CCN(c3cccc(C(F)(F)F)n3)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5434650;196909;None;0;Human;Binding;Ki;=;870,00;6,06;-7;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;618,3;11;1;6;4,93;CCc1cc(Cl)c(OC)c(N2CCN(C[C@@H]3C[C@@H](O)CN3CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5434856;196922;None;0;Human;Binding;Ki;=;17400,00;4,76;-707;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;367,2;6;0;5;4,51;COc1ccc(C2CCN(CCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5435054;196931;None;0;Human;Binding;Ki;=;99,30;7,00;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;387,3;8;2;4;4,14;CCOc1cccc2cc(CNCC[C@H]3CC[C@H](NC(=O)N(C)C)CC3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5435054;196931;None;0;Human;Binding;Ki;=;100,00;7,00;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;387,3;8;2;4;4,14;CCOc1cccc2cc(CNCC[C@H]3CC[C@H](NC(=O)N(C)C)CC3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5435235;196939;None;0;Human;Binding;Ki;=;146,00;6,84;2;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;606,3;9;0;4;6,68;CC1CCC(CN2CCN(c3cccc(Cl)c3Cl)CC2)CN1CCC(C(=O)N(C)C)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5435325;196942;None;0;Human;Binding;Ki;=;89,13;7,05;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;446,2;8;1;5;5,28;CC(C)Oc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5435325;196942;None;0;Human;Binding;Ki;=;88,80;7,05;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;446,2;8;1;5;5,28;CC(C)Oc1cccc2c3c(oc12)CN(CCCCOc1ccc2ccc(=O)[nH]c2c1)CC3;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5435580;196957;None;0;Human;Binding;Ki;=;109,00;6,96;-7;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;445,2;7;2;4;3,91;O=C(NCCCCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5435745;196969;None;0;Human;Binding;Ki;=;86,00;7,07;-24;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;427,2;7;0;4;3,78;COCCC(=O)N1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5436551;197005;None;0;Human;Binding;Ki;=;8010,00;5,10;-169;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;416,2;8;1;2;4,74;CN(C)C(=O)C(CCN[C@@H]1C[C@H]1c1ccc(F)cc1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
CHEMBL5436641;197008;None;0;Human;Binding;Ki;=;162,00;6,79;-162;7;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;511,3;6;1;5;5,15;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(C(F)(F)F)n3)CC2)CC1)c1ccnc2ccccc12;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5436702;197010;None;0;Human;Binding;Ki;=;408,00;6,39;-40;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;352,2;6;0;5;3,84;c1ccc(N2CCN(CCCCc3nc4ccccc4s3)CC2)nc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5436809;197015;None;0;Human;Binding;Ki;=;110,00;6,96;-33;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;462,2;8;2;4;4,83;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2cccc(F)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5436809;197015;None;0;Human;Binding;Ki;=;170,00;6,77;-33;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;462,2;8;2;4;4,83;COc1ccccc1N1CCN(CCCNC(=O)Nc2ccccc2-c2cccc(F)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5436957;197018;None;0;Human;Binding;Ki;=;7,20;8,14;-3;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;426,2;5;0;3;4,29;CN(C)C(=O)N1CCC(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5437265;197036;None;0;Human;Binding;Ki;=;1580,00;5,80;-549;3;Displacement of [3H]N-methylspiperone from human D2 receptor stably expressed in HEK293 cell membrane assessed as inhibition constant incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;352,2;5;0;5;3,75;Cc1ccnc(N2CCN(CCCc3nc4ccccc4s3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00734
CHEMBL5437660;197053;None;0;Human;Binding;Ki;=;5,80;8,24;-8;8;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;436,3;7;2;4;3,91;CCc1cc(Cl)c(OC)c(N2CCN(CC[C@H]3CC[C@H](NC(=O)NC)CC3)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5438081;197072;None;0;Human;Binding;Ki;=;19,40;7,71;-20;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;441,2;8;0;4;4,17;COCCC(=O)N1CCC(CCCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5438205;197080;None;0;Human;Binding;Ki;=;73,00;7,14;-19;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccc(F)cc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5438205;197080;None;0;Human;Binding;Ki;=;40,00;7,40;-19;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;476,3;9;2;4;4,51;COc1ccccc1N1CCN(CCCNC(=O)NCc2ccc(F)cc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5438433;197088;None;0;Human;Binding;Ki;=;69,18;7,16;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;413,3;8;2;4;4,67;CCOc1cccc2cc(CNCC[C@H]3CC[C@H](NC(=O)N4CCCC4)CC3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5438433;197088;None;0;Human;Binding;Ki;=;67,90;7,17;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;413,3;8;2;4;4,67;CCOc1cccc2cc(CNCC[C@H]3CC[C@H](NC(=O)N4CCCC4)CC3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5438487;197090;None;0;Human;Binding;Ki;=;811,00;6,09;-14;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;383,2;6;2;5;4,33;CCCOc1cc2c(cc1O)[C@@H]1Cc3ccc(O)c(OCCC)c3CN1CC2;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
CHEMBL5438499;197091;None;0;Human;Binding;Ki;=;239,00;6,62;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;362,2;8;2;4;4,22;O=c1ccc2ccc(OCCCCNCc3cc4ccccc4o3)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5438499;197091;None;0;Human;Binding;Ki;=;239,88;6,62;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;362,2;8;2;4;4,22;O=c1ccc2ccc(OCCCCNCc3cc4ccccc4o3)cc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5439203;197119;None;0;Human;Binding;Ki;=;264,00;6,58;-1;3;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;379,2;7;2;6;1,69;O=C(NCCCCN1CCN(c2ncccn2)CC1)c1n[nH]c2ccccc12;https://dx.doi.org/10.1016/j.ejmech.2023.115285
CHEMBL5439853;197147;None;0;Human;Binding;Ki;=;160,00;6,80;-24;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2L receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;488,3;10;2;5;4,38;COc1ccc(CNC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c(-c2ccccc2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5439853;197147;None;0;Human;Binding;Ki;=;37,00;7,43;-24;3;Displacement of [3H]-N-methylspiperone from human dopmaine D2S receptor expressed in CHO cell membrane assessed as inhibition constant by competition binding assay;ChEMBL;488,3;10;2;5;4,38;COc1ccc(CNC(=O)NCCCN2CCN(c3ccccc3OC)CC2)c(-c2ccccc2)c1;https://dx.doi.org/10.1021/acs.jmedchem.3c00537
CHEMBL5440422;197175;None;0;Human;Binding;Ki;=;1,80;8,74;-3;2;Displacement of [3H]N-methylspiperone from human D2 receptor in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;530,3;8;1;4;6,46;CCc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)c4ccc(-c5cccnc5)cc4)CC3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.2c01624
CHEMBL5440936;197192;None;0;Human;Binding;Ki;=;549,54;6,26;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;422,2;10;1;5;5,01;CCOc1cccc2cc(CN(C)CCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5440936;197192;None;0;Human;Binding;Ki;=;539,00;6,27;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;422,2;10;1;5;5,01;CCOc1cccc2cc(CN(C)CCCCOc3ccc4c(c3)NC(=O)CC4)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5441140;197200;None;0;Human;Binding;Ki;=;0,12;9,92;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;406,2;10;2;5;4,62;CCOc1cccc2cc(CNCCCCOc3ccc4ccc(=O)[nH]c4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL5441140;197200;None;0;Human;Binding;Ki;=;0,13;9,89;-;1;Displacement of [3H]N-methylspiperone from Dopamine D2 receptor (unknown origin) expressed in HEK293T cell membrane incubated for 2 hrs by radioligand competitive binding based MicroBeta TriLux reader method;ChEMBL;406,2;10;2;5;4,62;CCOc1cccc2cc(CNCCCCOc3ccc4ccc(=O)[nH]c4c3)oc12;https://dx.doi.org/10.1021/acs.jmedchem.3c00098
CHEMBL54715;197232;None;0;Human;Binding;Ki;=;1584,89;5,80;-31;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;546,2;9;1;5;5,46;Cc1ccccc1-c1ccc(C(=O)NCCCCN2CCc3ccc(OS(=O)(=O)C(F)(F)F)cc3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL54777;197245;None;0;Human;Binding;Ki;=;100,00;7,00;-39;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;589,2;10;2;6;4,51;CNC(=O)c1ccc(-c2ccc(C(=O)NCCCCN3CCc4ccc(OS(=O)(=O)C(F)(F)F)cc4C3)cc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL54786;197247;None;0;Human;Binding;IC50;=;44,00;7,36;-;5;Inhibitory concentration against dopamine receptor D2;ChEMBL;371,2;4;1;3;3,70;O=C1Cc2cc(CCN3CCN(c4cccc5ccccc45)CC3)ccc2N1;https://dx.doi.org/10.1021/jm058225d
CHEMBL549438;197289;None;0;Human;Binding;Ki;=;158,49;6,80;-1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;348,1;6;0;4;3,01;Cc1cc(CN(C)CCN2CCN(c3cccc(Cl)c3)C2=O)on1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL54948;197296;None;0;Human;Binding;Ki;=;1000,00;6,00;-19;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;546,2;9;1;5;5,46;Cc1cc(C(=O)NCCCCN2CCc3ccc(OS(=O)(=O)C(F)(F)F)cc3C2)ccc1-c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL549638;197327;None;0;Human;Binding;Ki;=;4700,00;5,33;-11;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;353,2;3;0;5;3,12;Cc1cc2nc(C)c(CN3CCN(c4ccc(F)cc4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL549638;197327;None;0;Human;Binding;Ki;=;3500,00;5,46;-11;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;353,2;3;0;5;3,12;Cc1cc2nc(C)c(CN3CCN(c4ccc(F)cc4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL549638;197327;UNDEFINED;0;Human;Binding;pKi;=;3500,00;5,46;-11;4;-;PDSP KiDatabase;353,2;3;0;5;3,12;Cc1cc2nc(C)c(CN3CCN(c4ccc(F)cc4)CC3)n2c(C)n1;-
CHEMBL549638;197327;UNDEFINED;0;Human;Binding;pKi;=;4700,00;5,33;-11;4;-;PDSP KiDatabase;353,2;3;0;5;3,12;Cc1cc2nc(C)c(CN3CCN(c4ccc(F)cc4)CC3)n2c(C)n1;-
CHEMBL5498852;197388;None;0;Human;Binding;IC50;=;1400,00;5,85;-;5;Bayer Inhouse kinase panel (DRD2);ChEMBL;391,2;6;2;6;2,37;CNc1cc[n+](CCNC(=O)c2ccn3c(-c4c(C)noc4C)cnc3c2)cc1;https://dx.doi.org/10.6019/CHEMBL5463728
CHEMBL550222;197604;None;0;Human;Binding;Ki;=;16,00;7,80;-3;3;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;423,2;8;1;6;3,39;CSc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL550222;197604;None;0;Human;Binding;Ki;=;26,00;7,58;-3;3;Displacement of [3H]spiperone from human cloned dopamine D2L receptor E181V/I183S mutant expressed in HEK293 cells;ChEMBL;423,2;8;1;6;3,39;CSc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL550222;197604;None;0;Human;Binding;Ki;=;37,00;7,43;-3;3;Displacement of [3H]spiperone from wild type human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;423,2;8;1;6;3,39;CSc1ccccc1N1CCN(CCCCNC(=O)c2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL550392;197620;None;0;Human;Binding;Ki;=;8600,00;5,07;-134;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;335,2;3;0;5;2,98;Cc1cc2nc(C)c(CN3CCN(c4ccccc4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL550392;197620;None;0;Human;Binding;Ki;=;11000,00;4,96;-134;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;335,2;3;0;5;2,98;Cc1cc2nc(C)c(CN3CCN(c4ccccc4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL550392;197620;UNDEFINED;0;Human;Binding;pKi;=;8600,00;5,07;-134;4;-;PDSP KiDatabase;335,2;3;0;5;2,98;Cc1cc2nc(C)c(CN3CCN(c4ccccc4)CC3)n2c(C)n1;-
CHEMBL550392;197620;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-134;4;-;PDSP KiDatabase;335,2;3;0;5;2,98;Cc1cc2nc(C)c(CN3CCN(c4ccccc4)CC3)n2c(C)n1;-
CHEMBL55090;197688;None;0;Human;Binding;Ki;=;398,11;6,40;-100;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;533,2;9;1;6;4,43;O=C(/C=C/c1ccc2ccccc2n1)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL550920;197691;None;0;Human;Binding;Ki;=;13000,00;4,89;-851;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;351,2;4;0;6;2,68;COc1ccc(N2CCN(Cc3c(C)nc4cc(C)ncn34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL550920;197691;None;0;Human;Binding;Ki;=;9100,00;5,04;-851;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;351,2;4;0;6;2,68;COc1ccc(N2CCN(Cc3c(C)nc4cc(C)ncn34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL550920;197691;UNDEFINED;0;Human;Binding;pKi;=;9100,00;5,04;-851;4;-;PDSP KiDatabase;351,2;4;0;6;2,68;COc1ccc(N2CCN(Cc3c(C)nc4cc(C)ncn34)CC2)cc1;-
CHEMBL550920;197691;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-851;4;-;PDSP KiDatabase;351,2;4;0;6;2,68;COc1ccc(N2CCN(Cc3c(C)nc4cc(C)ncn34)CC2)cc1;-
CHEMBL551199;197720;None;0;Human;Binding;Ki;=;150,00;6,82;-70;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;393,2;4;1;7;1,58;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccccn4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL551199;197720;None;0;Human;Binding;Ki;=;270,00;6,57;-70;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;393,2;4;1;7;1,58;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccccn4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL551199;197720;UNDEFINED;0;Human;Binding;pKi;=;270,00;6,57;-70;4;-;PDSP KiDatabase;393,2;4;1;7;1,58;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccccn4)CC3)c[nH]c2c1=O;-
CHEMBL551199;197720;UNDEFINED;0;Human;Binding;pKi;=;150,00;6,82;-70;4;-;PDSP KiDatabase;393,2;4;1;7;1,58;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccccn4)CC3)c[nH]c2c1=O;-
CHEMBL551927;197831;None;0;Human;Binding;Ki;=;15,85;7,80;1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;423,2;5;0;2;5,24;C[C@@]12CC(c3ccccc3)C[C@@H](C1)N(CCN1CCN(c3cccc(Cl)c3)C1=O)C2;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL551964;197845;None;1;Human;Binding;Ki;=;1306,00;5,88;-354;4;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;451,2;3;0;7;3,92;Cc1ccc2c3c(ccc2n1)OC[C@H](CN1CCN(c2ccc4cc(C#N)ccc4n2)CC1)O3;https://dx.doi.org/10.1021/jm900374r
CHEMBL552268;197882;None;0;Human;Binding;Ki;=;130,00;6,89;-61;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;382,2;5;2;6;1,65;COc1ccccc1N1CCN(Cc2cc3c(=O)[nH]c(N(C)C)nc3[nH]2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL552268;197882;None;0;Human;Binding;Ki;=;170,00;6,77;-61;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;382,2;5;2;6;1,65;COc1ccccc1N1CCN(Cc2cc3c(=O)[nH]c(N(C)C)nc3[nH]2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL552268;197882;UNDEFINED;0;Human;Binding;pKi;=;170,00;6,77;-61;4;-;PDSP KiDatabase;382,2;5;2;6;1,65;COc1ccccc1N1CCN(Cc2cc3c(=O)[nH]c(N(C)C)nc3[nH]2)CC1;-
CHEMBL552268;197882;UNDEFINED;0;Human;Binding;pKi;=;130,00;6,89;-61;4;-;PDSP KiDatabase;382,2;5;2;6;1,65;COc1ccccc1N1CCN(Cc2cc3c(=O)[nH]c(N(C)C)nc3[nH]2)CC1;-
CHEMBL552373;197899;None;1;Human;Binding;Ki;=;120,00;6,92;-125;6;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;366,2;4;0;3;3,08;N#Cc1cccc(N2CCN(CCN3CCC(C(F)(F)F)CC3)C2=O)c1;https://dx.doi.org/10.1016/j.bmcl.2010.09.142
CHEMBL552373;197899;None;1;Human;Binding;Ki;=;158,49;6,80;-125;6;Antagonistic activity at human DRD2 receptor by filtration binding assay;ChEMBL;366,2;4;0;3;3,08;N#Cc1cccc(N2CCN(CCN3CCC(C(F)(F)F)CC3)C2=O)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL552373;197899;None;1;Human;Binding;Ki;=;158,49;6,80;-125;6;Binding affinity to human dopamine D2 receptor by filtration binding assay;ChEMBL;366,2;4;0;3;3,08;N#Cc1cccc(N2CCN(CCN3CCC(C(F)(F)F)CC3)C2=O)c1;https://dx.doi.org/10.1016/j.bmcl.2009.06.028
CHEMBL552373;197899;None;1;Human;Binding;Ki;=;42,00;7,38;-125;6;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;366,2;4;0;3;3,08;N#Cc1cccc(N2CCN(CCN3CCC(C(F)(F)F)CC3)C2=O)c1;https://dx.doi.org/10.1016/j.bmcl.2010.09.142
CHEMBL55276;197930;None;0;Human;Binding;Ki;=;316,23;6,50;-63;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;482,1;9;1;5;3,88;O=C(/C=C/c1ccccc1)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL554692;198009;None;0;Human;Binding;Ki;=;26000,00;4,58;-371;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;369,2;3;0;5;3,63;Cc1cc2nc(C)c(CN3CCN(c4ccc(Cl)cc4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL554692;198009;None;0;Human;Binding;Ki;=;57000,00;4,24;-371;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;369,2;3;0;5;3,63;Cc1cc2nc(C)c(CN3CCN(c4ccc(Cl)cc4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL554692;198009;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-371;4;-;PDSP KiDatabase;369,2;3;0;5;3,63;Cc1cc2nc(C)c(CN3CCN(c4ccc(Cl)cc4)CC3)n2c(C)n1;-
CHEMBL554692;198009;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-371;4;-;PDSP KiDatabase;369,2;3;0;5;3,63;Cc1cc2nc(C)c(CN3CCN(c4ccc(Cl)cc4)CC3)n2c(C)n1;-
CHEMBL554693;198010;None;0;Human;Binding;Ki;=;100,00;7,00;1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;417,2;9;0;4;3,77;COc1ccc(CCN(C)CCN2CCN(c3cccc(Cl)c3)C2=O)cc1OC;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL554738;198016;None;0;Human;Binding;Ki;=;50,12;7,30;-1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;399,1;6;0;3;4,93;CN(CCN1CCN(c2cccc(Cl)c2)C1=O)Cc1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL55524;198039;None;0;Human;Binding;Ki;=;316,23;6,50;-7;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;482,1;9;1;5;3,88;O=C(/C=C\c1ccccc1)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL555744;198056;None;0;Human;Binding;Ki;=;79,43;7,10;1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;309,1;4;0;3;2,61;COC[C@@H]1CCCN1N1CCN(c2cccc(Cl)c2)C1=O;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL556288;198087;None;0;Human;Binding;Ki;=;390,00;6,41;-69;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;392,2;4;1;6;2,18;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccccc4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL556288;198087;None;0;Human;Binding;Ki;=;180,00;6,75;-69;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;392,2;4;1;6;2,18;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccccc4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL556288;198087;UNDEFINED;0;Human;Binding;pKi;=;180,00;6,74;-69;4;-;PDSP KiDatabase;392,2;4;1;6;2,18;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccccc4)CC3)c[nH]c2c1=O;-
CHEMBL556288;198087;UNDEFINED;0;Human;Binding;pKi;=;390,00;6,41;-69;4;-;PDSP KiDatabase;392,2;4;1;6;2,18;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccccc4)CC3)c[nH]c2c1=O;-
CHEMBL556313;198092;None;1;Human;Binding;Ki;=;120,00;6,92;-125;7;Binding affinity for human Dopamine receptor D2;ChEMBL;391,2;4;0;4;2,80;O=C1CC2(CCCC2)CC(=O)N1CCN1CCN(c2cc(F)ccc2F)CC1;https://dx.doi.org/10.1021/jm0491391
CHEMBL556496;198122;None;0;Human;Binding;Ki;=;25,12;7,60;25;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;413,2;6;0;3;4,47;COc1cccc(C2CCCN(CCN3CCN(c4cccc(Cl)c4)C3=O)C2)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL557110;198179;None;0;Human;Binding;Ki;=;79,43;7,10;1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;413,2;7;0;3;4,26;O=C1N(CCN2CCCC(OCc3ccccc3)C2)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL558058;198263;None;0;Human;Binding;Ki;=;19,95;7,70;-12;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;423,3;6;0;2;5,10;CN(CCN1CCN(c2cccc(C(F)(F)F)c2)C1=O)C[C@]12CC[C@H](CC1)C2(C)C;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL55840;198294;None;0;Human;Binding;Ki;=;1000,00;6,00;-199;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;532,2;9;1;5;5,04;O=C(/C=C/c1ccc2ccccc2c1)NCCCCN1CCc2ccc(OS(=O)(=O)C(F)(F)F)cc2C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL558838;198331;None;0;Human;Binding;Ki;=;2600,00;5,58;-426;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;380,2;5;1;6;2,66;COc1ccccc1N1CCN(Cc2c(C)[nH]c3nc(N(C)C)ncc23)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL558838;198331;None;0;Human;Binding;Ki;=;2900,00;5,54;-426;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;380,2;5;1;6;2,66;COc1ccccc1N1CCN(Cc2c(C)[nH]c3nc(N(C)C)ncc23)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL558838;198331;UNDEFINED;0;Human;Binding;pKi;=;2900,00;5,54;-426;4;-;PDSP KiDatabase;380,2;5;1;6;2,66;COc1ccccc1N1CCN(Cc2c(C)[nH]c3nc(N(C)C)ncc23)CC1;-
CHEMBL558838;198331;UNDEFINED;0;Human;Binding;pKi;=;2600,00;5,59;-426;4;-;PDSP KiDatabase;380,2;5;1;6;2,66;COc1ccccc1N1CCN(Cc2c(C)[nH]c3nc(N(C)C)ncc23)CC1;-
CHEMBL559399;198386;None;0;Human;Binding;Ki;=;840,00;6,08;-36;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;410,2;4;1;6;2,32;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccc(F)cc4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL559399;198386;None;0;Human;Binding;Ki;=;400,00;6,40;-36;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;410,2;4;1;6;2,32;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccc(F)cc4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL559399;198386;UNDEFINED;0;Human;Binding;pKi;=;840,00;6,08;-36;4;-;PDSP KiDatabase;410,2;4;1;6;2,32;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccc(F)cc4)CC3)c[nH]c2c1=O;-
CHEMBL559399;198386;UNDEFINED;0;Human;Binding;pKi;=;400,00;6,40;-36;4;-;PDSP KiDatabase;410,2;4;1;6;2,32;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccc(F)cc4)CC3)c[nH]c2c1=O;-
CHEMBL559868;198447;None;0;Human;Binding;Ki;=;2900,00;5,54;-426;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;326,1;3;1;3;3,54;Clc1nccc2c(CN3CCN(c4ccccc4)CC3)c[nH]c12;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL559868;198447;None;0;Human;Binding;Ki;=;2600,00;5,58;-426;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;326,1;3;1;3;3,54;Clc1nccc2c(CN3CCN(c4ccccc4)CC3)c[nH]c12;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL559868;198447;UNDEFINED;0;Human;Binding;pKi;=;2600,00;5,59;-426;4;-;PDSP KiDatabase;326,1;3;1;3;3,54;Clc1nccc2c(CN3CCN(c4ccccc4)CC3)c[nH]c12;-
CHEMBL559868;198447;UNDEFINED;0;Human;Binding;pKi;=;2900,00;5,54;-426;4;-;PDSP KiDatabase;326,1;3;1;3;3,54;Clc1nccc2c(CN3CCN(c4ccccc4)CC3)c[nH]c12;-
CHEMBL559873;198448;None;0;Human;Binding;Ki;=;3,16;8,50;-5;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;375,1;4;0;3;4,09;O=C1N(CCN2CCCc3sccc3C2)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL560177;198478;None;0;Human;Binding;Ki;=;100,00;7,00;-39;4;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;341,1;4;0;2;3,60;O=C1N(CCN2Cc3ccccc3C2)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL560270;198488;None;0;Human;Binding;Ki;=;251,19;6,60;-12;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;369,3;6;0;2;4,38;Cc1cccc(N2CCN(CCN(C)C[C@]34CC[C@H](CC3)C4(C)C)C2=O)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL561123;198591;None;0;Human;Binding;Ki;=;730,00;6,14;-35;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;408,2;4;1;7;1,42;Cn1c(N2CCOCC2)nc2c(CN3CCN(c4ccccc4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL561123;198591;None;0;Human;Binding;Ki;=;1100,00;5,96;-35;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;408,2;4;1;7;1,42;Cn1c(N2CCOCC2)nc2c(CN3CCN(c4ccccc4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL561123;198591;UNDEFINED;0;Human;Binding;pKi;=;1100,00;5,96;-35;4;-;PDSP KiDatabase;408,2;4;1;7;1,42;Cn1c(N2CCOCC2)nc2c(CN3CCN(c4ccccc4)CC3)c[nH]c2c1=O;-
CHEMBL561123;198591;UNDEFINED;0;Human;Binding;pKi;=;730,00;6,14;-35;4;-;PDSP KiDatabase;408,2;4;1;7;1,42;Cn1c(N2CCOCC2)nc2c(CN3CCN(c4ccccc4)CC3)c[nH]c2c1=O;-
CHEMBL561128;198592;None;0;Human;Binding;Ki;=;251,19;6,60;-5;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;417,1;5;0;2;5,12;O=C1N(CCN2CCC(c3ccc(Cl)cc3)CC2)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL56118;198604;None;0;Human;Binding;Ki;=;8000,00;5,10;-263;6;Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;266,2;3;1;3;2,21;N#Cc1c[nH]c(CN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL56118;198604;None;0;Human;Binding;Ki;=;3700,00;5,43;-263;6;Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;266,2;3;1;3;2,21;N#Cc1c[nH]c(CN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL561262;198617;None;0;Human;Binding;Ki;=;40000,00;4,40;-707;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;351,2;4;0;6;2,68;COc1ccccc1N1CCN(Cc2c(C)nc3cc(C)ncn23)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL561262;198617;None;0;Human;Binding;Ki;=;53000,00;4,28;-707;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;351,2;4;0;6;2,68;COc1ccccc1N1CCN(Cc2c(C)nc3cc(C)ncn23)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL561262;198617;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-707;4;-;PDSP KiDatabase;351,2;4;0;6;2,68;COc1ccccc1N1CCN(Cc2c(C)nc3cc(C)ncn23)CC1;-
CHEMBL561262;198617;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-707;4;-;PDSP KiDatabase;351,2;4;0;6;2,68;COc1ccccc1N1CCN(Cc2c(C)nc3cc(C)ncn23)CC1;-
CHEMBL561326;198628;None;0;Human;Binding;Ki;=;501,19;6,30;-3;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;451,2;6;0;5;4,51;O=C1N(CCN2CCC(c3nnc(-c4ccccc4)o3)CC2)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL561622;198682;None;0;Human;Binding;Ki;=;160,00;6,80;-4;3;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;382,2;7;0;4;4,52;Clc1ccc(N2CCN(CCCCCc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm900690y
CHEMBL561622;198682;None;0;Human;Binding;Ki;=;220,00;6,66;-4;3;Displacement of [3H]spiperone from wild type human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;382,2;7;0;4;4,52;Clc1ccc(N2CCN(CCCCCc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm900690y
CHEMBL561763;198707;None;0;Human;Binding;Ki;=;20,00;7,70;2;3;Displacement of [3H]spiperone from human cloned dopamine D2L receptor E181V/I183S mutant expressed in HEK293 cells;ChEMBL;409,2;7;1;6;3,00;CSc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL561763;198707;None;0;Human;Binding;Ki;=;2,20;8,66;2;3;Displacement of [3H]spiperone from wild type human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;409,2;7;1;6;3,00;CSc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL561763;198707;None;0;Human;Binding;Ki;=;1,40;8,85;2;3;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;409,2;7;1;6;3,00;CSc1ccccc1N1CCN(CCCNC(=O)c2cnn3ccccc23)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL562384;198791;None;0;Human;Binding;Ki;=;10000,00;5,00;-100;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;336,2;3;0;6;2,37;Cc1cc2nc(C)c(CN3CCN(c4ccccn4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL562384;198791;None;0;Human;Binding;Ki;=;17000,00;4,77;-100;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;336,2;3;0;6;2,37;Cc1cc2nc(C)c(CN3CCN(c4ccccn4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL562384;198791;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-100;4;-;PDSP KiDatabase;336,2;3;0;6;2,37;Cc1cc2nc(C)c(CN3CCN(c4ccccn4)CC3)n2c(C)n1;-
CHEMBL562384;198791;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-100;4;-;PDSP KiDatabase;336,2;3;0;6;2,37;Cc1cc2nc(C)c(CN3CCN(c4ccccn4)CC3)n2c(C)n1;-
CHEMBL562464;198804;None;0;Human;Binding;Ki;=;25,12;7,60;-10;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;409,2;4;0;2;4,46;O=C1N(CCN2C[C@@H]3CC[C@H]2Cc2ccccc2C3)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL562620;198832;None;0;Human;Binding;Ki;=;3600,00;5,44;-426;3;Displacement of [3H]spiperone from human cloned dopamine D2L receptor E181V/I183S mutant expressed in HEK293 cells;ChEMBL;322,2;4;0;5;2,67;COc1ccccc1N1CCN(Cc2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL562620;198832;None;0;Human;Binding;Ki;=;280,00;6,55;-426;3;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;322,2;4;0;5;2,67;COc1ccccc1N1CCN(Cc2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL562620;198832;None;0;Human;Binding;Ki;=;350,00;6,46;-426;3;Displacement of [3H]spiperone from wild type human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;322,2;4;0;5;2,67;COc1ccccc1N1CCN(Cc2cc3ccccn3n2)CC1;https://dx.doi.org/10.1021/jm900690y
CHEMBL562833;198863;None;0;Human;Binding;Ki;=;316,23;6,50;-12;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;387,2;4;0;2;4,48;CC1(C)[C@@H]2CC[C@]13CCN(CCN1CCN(c4cccc(Cl)c4)C1=O)C3C2;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL562836;198865;None;0;Human;Binding;Ki;=;630,96;6,20;-15;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;373,3;6;0;2;4,22;CN(CCN1CCN(c2ccc(F)cc2)C1=O)C[C@]12CC[C@H](CC1)C2(C)C;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL562948;198886;None;0;Human;Binding;Ki;=;199,53;6,70;-19;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;355,3;6;0;2;4,08;CN(CCN1CCN(c2ccccc2)C1=O)C[C@]12CC[C@H](CC1)C2(C)C;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL563078;198907;None;0;Human;Binding;Ki;=;3300,00;5,48;-204;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;403,1;3;0;5;4,28;Cc1cc2nc(C)c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL563078;198907;None;0;Human;Binding;Ki;=;5500,00;5,26;-204;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;403,1;3;0;5;4,28;Cc1cc2nc(C)c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)n2c(C)n1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL563078;198907;UNDEFINED;0;Human;Binding;pKi;=;5500,00;5,26;-204;4;-;PDSP KiDatabase;403,1;3;0;5;4,28;Cc1cc2nc(C)c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)n2c(C)n1;-
CHEMBL563078;198907;UNDEFINED;0;Human;Binding;pKi;=;3300,00;5,48;-204;4;-;PDSP KiDatabase;403,1;3;0;5;4,28;Cc1cc2nc(C)c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)n2c(C)n1;-
CHEMBL563109;198912;None;0;Human;Binding;Ki;=;1300,00;5,89;-13;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;351,2;4;0;6;2,68;COc1ccccc1N1CCN(Cc2cnc3cc(C)nc(C)n23)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL563109;198912;None;0;Human;Binding;Ki;=;570,00;6,24;-13;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;351,2;4;0;6;2,68;COc1ccccc1N1CCN(Cc2cnc3cc(C)nc(C)n23)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL563109;198912;UNDEFINED;0;Human;Binding;pKi;=;1300,00;5,89;-13;4;-;PDSP KiDatabase;351,2;4;0;6;2,68;COc1ccccc1N1CCN(Cc2cnc3cc(C)nc(C)n23)CC1;-
CHEMBL563109;198912;UNDEFINED;0;Human;Binding;pKi;=;570,00;6,24;-13;4;-;PDSP KiDatabase;351,2;4;0;6;2,68;COc1ccccc1N1CCN(Cc2cnc3cc(C)nc(C)n23)CC1;-
CHEMBL563274;198930;None;0;Human;Binding;Ki;=;125,89;6,90;-19;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;389,2;6;0;2;4,73;CN(CCN1CCN(c2cccc(Cl)c2)C1=O)C[C@]12CC[C@H](CC1)C2(C)C;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL563435;198956;None;0;Human;Binding;Ki;=;125,89;6,90;-25;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;385,3;7;0;3;4,08;COc1cccc(N2CCN(CCN(C)C[C@]34CC[C@H](CC3)C4(C)C)C2=O)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL563563;198974;None;0;Human;Binding;Ki;=;100,00;7,00;-7;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;375,2;4;0;2;4,48;CC1(C)C[C@@H]2C[C@@](C)(CN2CCN2CCN(c3cccc(Cl)c3)C2=O)C1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL563580;198978;None;0;Human;Binding;Ki;=;5,01;8,30;-3;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;333,2;4;0;2;3,60;O=C1N(CCN2[C@H]3CCC[C@@H]2CC3)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL563614;198982;None;0;Human;Binding;Ki;=;2900,00;5,54;-181;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;365,2;4;0;6;2,98;COc1ccccc1N1CCN(Cc2c(C)nc3cc(C)nc(C)n23)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL563614;198982;None;0;Human;Binding;Ki;=;2300,00;5,64;-181;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;365,2;4;0;6;2,98;COc1ccccc1N1CCN(Cc2c(C)nc3cc(C)nc(C)n23)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL563614;198982;UNDEFINED;0;Human;Binding;pKi;=;2900,00;5,54;-181;4;-;PDSP KiDatabase;365,2;4;0;6;2,98;COc1ccccc1N1CCN(Cc2c(C)nc3cc(C)nc(C)n23)CC1;-
CHEMBL563614;198982;UNDEFINED;0;Human;Binding;pKi;=;2300,00;5,64;-181;4;-;PDSP KiDatabase;365,2;4;0;6;2,98;COc1ccccc1N1CCN(Cc2c(C)nc3cc(C)nc(C)n23)CC1;-
CHEMBL563635;198985;None;0;Human;Binding;Ki;=;25,12;7,60;-10;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;295,1;6;0;2;2,92;CCN(CC)CCN1CCN(c2cccc(Cl)c2)C1=O;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL563860;199021;None;0;Human;Binding;Ki;=;3,98;8,40;-1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;319,1;4;0;2;3,07;O=C1N(CCN2C[C@H]3CC[C@@H]2C3)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL563926;199034;None;0;Human;Binding;Ki;=;50,12;7,30;2;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;387,2;8;0;3;3,77;COc1cccc(CCN(C)CCN2CCN(c3cccc(Cl)c3)C2=O)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL564688;199143;None;0;Human;Binding;Ki;=;570,00;6,24;-138;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;460,2;4;1;6;3,49;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL564688;199143;None;0;Human;Binding;Ki;=;380,00;6,42;-138;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;460,2;4;1;6;3,49;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)c[nH]c2c1=O;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL564688;199143;UNDEFINED;0;Human;Binding;pKi;=;570,00;6,24;-138;4;-;PDSP KiDatabase;460,2;4;1;6;3,49;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)c[nH]c2c1=O;-
CHEMBL564688;199143;UNDEFINED;0;Human;Binding;pKi;=;380,00;6,42;-138;4;-;PDSP KiDatabase;460,2;4;1;6;3,49;Cn1c(N2CCCC2)nc2c(CN3CCN(c4ccc(Cl)c(Cl)c4)CC3)c[nH]c2c1=O;-
CHEMBL564709;199145;None;0;Human;Binding;Ki;=;160,00;6,80;-23;4;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;365,2;4;0;6;2,98;COc1ccc(N2CCN(Cc3c(C)nc4cc(C)nc(C)n34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL564709;199145;None;0;Human;Binding;Ki;=;260,00;6,58;-23;4;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;365,2;4;0;6;2,98;COc1ccc(N2CCN(Cc3c(C)nc4cc(C)nc(C)n34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
CHEMBL564709;199145;UNDEFINED;0;Human;Binding;pKi;=;260,00;6,59;-23;4;-;PDSP KiDatabase;365,2;4;0;6;2,98;COc1ccc(N2CCN(Cc3c(C)nc4cc(C)nc(C)n34)CC2)cc1;-
CHEMBL564709;199145;UNDEFINED;0;Human;Binding;pKi;=;160,00;6,80;-23;4;-;PDSP KiDatabase;365,2;4;0;6;2,98;COc1ccc(N2CCN(Cc3c(C)nc4cc(C)nc(C)n34)CC2)cc1;-
CHEMBL564930;199171;None;0;Human;Binding;Ki;=;31,62;7,50;-1;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;375,2;4;0;2;4,34;CC1(C)[C@H]2CC[C@]1(C)CN(CCN1CCN(c3cccc(Cl)c3)C1=O)C2;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL564948;199174;None;0;Human;Binding;Ki;=;1000,00;6,00;-39;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;369,3;6;0;2;4,38;Cc1ccc(N2CCN(CCN(C)C[C@]34CC[C@H](CC3)C4(C)C)C2=O)cc1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL565075;199190;None;0;Human;Binding;Ki;=;25,12;7,60;-7;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;347,2;4;0;2;3,70;O=C1N(CCN2C[C@H]3CC[C@H](CC3)C2)CCN1c1cccc(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL565553;199250;None;0;Human;Binding;Ki;=;310,00;6,51;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;449,2;5;2;4;4,78;O=c1[nH]c2cccc(OC3CCN(CCC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL565553;199250;UNDEFINED;0;Human;Binding;pKi;=;310,00;6,51;-;1;-;PDSP KiDatabase;449,2;5;2;4;4,78;O=c1[nH]c2cccc(OC3CCN(CCC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;-
CHEMBL565935;199312;None;0;Human;Binding;Ki;=;100,00;7,00;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;421,2;4;3;4;3,34;O=C1Cc2c(ccc3c2OC[C@H](CNCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566155;199352;None;0;Human;Binding;Ki;=;36,00;7,44;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;435,2;5;3;4;3,73;O=C1Cc2c(ccc3c2OC[C@H](CNCCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566172;199356;None;0;Human;Binding;Ki;=;120,00;6,92;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;434,2;4;2;4;3,66;O=c1[nH]c2cccc(CN3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566172;199356;UNDEFINED;0;Human;Binding;pKi;=;120,00;6,92;-;1;-;PDSP KiDatabase;434,2;4;2;4;3,66;O=c1[nH]c2cccc(CN3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;-
CHEMBL566356;199390;None;0;Human;Binding;Ki;=;12,00;7,92;12;3;Displacement of [3H]spiperone from D2 receptor;ChEMBL;432,2;3;2;4;3,81;O=c1[nH]c2cccc(N3C[C@H]4C[C@@H]3CN4CC3CCc4[nH]c5ccc(F)cc5c4C3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566356;199390;None;0;Human;Binding;Ki;=;14,00;7,85;12;3;Displacement of [3H]spiperone from D2 receptor;ChEMBL;432,2;3;2;4;3,81;O=c1[nH]c2cccc(N3C[C@H]4C[C@@H]3CN4CC3CCc4[nH]c5ccc(F)cc5c4C3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566379;199396;None;0;Human;Binding;Ki;=;45,00;7,35;-7;3;Displacement of [3H]spiperone from D2 receptor;ChEMBL;449,2;6;3;4;4,12;O=C1Cc2c(ccc3c2OC[C@H](CNCCCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566379;199396;None;0;Human;Binding;Ki;=;50,00;7,30;-7;3;Displacement of [3H]spiperone from D2 receptor;ChEMBL;449,2;6;3;4;4,12;O=C1Cc2c(ccc3c2OC[C@H](CNCCCC2CCc4c([nH]c5ccc(F)cc45)C2)O3)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566380;199397;None;0;Human;Binding;Ki;=;220,00;6,66;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;420,2;3;2;4;3,67;O=c1[nH]c2cccc(N3CCN(CC4CCc5c([nH]c6ccc(F)cc56)C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566380;199397;UNDEFINED;0;Human;Binding;pKi;=;220,00;6,66;-;1;-;PDSP KiDatabase;420,2;3;2;4;3,67;O=c1[nH]c2cccc(N3CCN(CC4CCc5c([nH]c6ccc(F)cc56)C4)CC3)c2o1;-
CHEMBL566396;199402;None;0;Human;Binding;Ki;=;28,00;7,55;3;2;Displacement of [3H]spiperone from D2 receptor;ChEMBL;449,2;5;2;4;4,64;O=c1[nH]c2cccc(OCC3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL566396;199402;UNDEFINED;0;Human;Binding;pKi;=;28,00;7,55;3;2;-;PDSP KiDatabase;449,2;5;2;4;4,64;O=c1[nH]c2cccc(OCC3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;-
CHEMBL566508;199415;None;0;Human;Binding;Ki;=;32,36;7,49;-7;4;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;426,2;4;0;7;4,10;CSc1ncc2c(n1)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
CHEMBL567454;199530;None;0;Human;Binding;Ki;=;140,00;6,85;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;435,2;4;2;4;4,39;O=c1[nH]c2cccc(OC3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL567454;199530;UNDEFINED;0;Human;Binding;pKi;=;140,00;6,85;-;1;-;PDSP KiDatabase;435,2;4;2;4;4,39;O=c1[nH]c2cccc(OC3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;-
CHEMBL567919;199615;None;0;Human;Binding;Ki;=;1584,89;5,80;-31;2;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;351,3;6;0;4;2,20;CN(CCN1CCN(C2COOC2)C1=O)C[C@]12CC[C@H](CC1)C2(C)C;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
CHEMBL568103;199640;None;0;Human;Binding;Ki;=;50,00;7,30;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;448,2;5;2;4;4,45;O=c1[nH]c2cccc(N3CCN(CCCC4CCc5c([nH]c6ccc(F)cc56)C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL568103;199640;UNDEFINED;0;Human;Binding;pKi;=;50,00;7,30;-;1;-;PDSP KiDatabase;448,2;5;2;4;4,45;O=c1[nH]c2cccc(N3CCN(CCCC4CCc5c([nH]c6ccc(F)cc56)C4)CC3)c2o1;-
CHEMBL56843;199708;None;0;Human;Binding;Kd;=;7,94;8,10;-;3;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;325,2;6;0;2;4,67;O=C(CCCN1CCC(c2ccccc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL56843;199708;None;0;Human;Binding;Ki;=;7,76;8,11;-;3;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;325,2;6;0;2;4,67;O=C(CCCN1CCC(c2ccccc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL568538;199729;None;0;Human;Binding;Ki;=;24,00;7,62;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;435,2;5;3;4;3,73;O=C1Cc2c(ccc3c2OC[C@H](CNCCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL568538;199729;None;0;Human;Binding;Ki;=;24,00;7,62;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;435,2;5;3;4;3,73;O=C1Cc2c(ccc3c2OC[C@H](CNCCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL568801;199771;None;0;Human;Binding;Ki;=;4,89;8,31;-12;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;458,3;8;0;5;4,63;CCCN(CCN1CCN(c2ccnc3ccccc23)CC1)C1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL568822;199777;None;0;Human;Binding;Ki;=;5,22;8,28;-4;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;444,3;7;1;5;4,33;CCCN(CCN1CCN(c2cccc3ncccc23)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL569003;199805;None;0;Human;Binding;Ki;=;8,85;8,05;-12;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;443,3;7;1;4;4,94;CCCN(CCN1CCN(c2ccc3ccccc3c2)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL569107;199818;None;0;Human;Binding;Ki;=;57,70;7,24;-47;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;450,3;7;1;7;3,67;CCCN(CCN1CCN(c2cccc3ncccc23)CC1)[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL569251;199833;None;0;Human;Binding;Ki;=;3,00;8,52;-1;3;Displacement of [3H]spiperone from D2 receptor;ChEMBL;421,2;4;3;4;3,34;O=C1Cc2c(ccc3c2OC[C@H](CNCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL569251;199833;None;0;Human;Binding;Ki;=;3,00;8,52;-1;3;Displacement of [3H]spiperone from D2 receptor;ChEMBL;421,2;4;3;4;3,34;O=C1Cc2c(ccc3c2OC[C@H](CNCC2CCc4[nH]c5ccc(F)cc5c4C2)O3)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL569322;199844;None;0;Human;Binding;Ki;=;21,70;7,66;-50;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;444,3;7;1;5;4,33;CCCN(CCN1CCN(c2nccc3ccccc23)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL569476;199857;None;0;Human;Binding;Ki;=;720,00;6,14;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;463,2;6;2;4;5,03;O=c1[nH]c2cccc(OCC3CCN(CCC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL569476;199857;UNDEFINED;0;Human;Binding;pKi;=;720,00;6,14;-;1;-;PDSP KiDatabase;463,2;6;2;4;5,03;O=c1[nH]c2cccc(OCC3CCN(CCC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;-
CHEMBL569513;199864;None;0;Human;Binding;Ki;=;60,00;7,22;3;3;Displacement of [3H]spiperone from D2 receptor;ChEMBL;420,2;3;2;4;3,67;O=c1[nH]c2cccc(N3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL569513;199864;None;0;Human;Binding;Ki;=;17,00;7,77;3;3;Displacement of [3H]spiperone from D2 receptor;ChEMBL;420,2;3;2;4;3,67;O=c1[nH]c2cccc(N3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL569513;199864;UNDEFINED;0;Human;Binding;pKi;=;60,00;7,22;3;3;-;PDSP KiDatabase;420,2;3;2;4;3,67;O=c1[nH]c2cccc(N3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;-
CHEMBL569513;199864;UNDEFINED;0;Human;Binding;pKi;=;17,00;7,77;3;3;-;PDSP KiDatabase;420,2;3;2;4;3,67;O=c1[nH]c2cccc(N3CCN(CC4CCc5[nH]c6ccc(F)cc6c5C4)CC3)c2o1;-
CHEMBL569746;199910;None;0;Human;Binding;Ki;=;47,50;7,32;-83;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;460,3;7;2;4;3,90;CCCN(CCN1CCN(C(=O)c2cc3ccccc3[nH]2)CC1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL569747;199911;None;0;Human;Binding;Ki;=;13,50;7,87;-30;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;443,3;7;1;4;4,94;CCCN(CCN1CCN(c2cccc3ccccc23)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL569977;199948;None;0;Human;Binding;Ki;=;3,74;8,43;-19;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;458,3;8;0;5;4,63;CCCN(CCN1CCN(c2ccnc3ccccc23)CC1)[C@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL570187;199988;None;0;Human;Binding;Ki;=;7,08;8,15;-2;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;444,3;7;1;5;4,33;CCCN(CCN1CCN(c2ccnc3ccccc23)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL570188;199989;None;0;Human;Binding;Ki;=;270,00;6,57;-56;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;476,3;8;1;7;4,18;CCCN(CCN1CCN(c2ccc(-c3ccncc3)cc2)CC1)[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL57019;199990;None;0;Human;Binding;Ki;=;10000,00;5,00;-501;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;375,2;6;0;4;4,53;COc1cc2ccccc2cc1C(=O)OCC1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1021/jm960017l
CHEMBL571464;200182;None;0;Human;Binding;Ki;=;15,00;7,82;-;1;Displacement of [3H]spiperone from D2 receptor;ChEMBL;418,2;3;2;3;3,73;O=C1Cc2c(cccc2N2CCN(CC3CCc4[nH]c5ccc(F)cc5c4C3)CC2)N1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
CHEMBL571464;200182;UNDEFINED;0;Human;Binding;pKi;=;15,00;7,82;-;1;-;PDSP KiDatabase;418,2;3;2;3;3,73;O=C1Cc2c(cccc2N2CCN(CC3CCc4[nH]c5ccc(F)cc5c4C3)CC2)N1;-
CHEMBL571464;200182;UNDEFINED;0;Human;Binding;pKi;=;15,00;7,82;-;1;-;PDSP KiDatabase;418,2;3;2;3;3,73;O=C1Cc2c(cccc2N2CCN(CC3CCc4[nH]c5ccc(F)cc5c4C3)CC2)N1;-
CHEMBL57176;200221;None;0;Human;Binding;Ki;=;580,00;6,24;-112;6;Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;265,2;3;1;2;2,32;C#Cc1c[nH]c(CN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL57176;200221;None;0;Human;Binding;Ki;=;770,00;6,11;-112;6;Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;265,2;3;1;2;2,32;C#Cc1c[nH]c(CN2CCN(c3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL571992;200248;None;0;Human;Binding;Ki;=;269,00;6,57;-120;4;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;450,3;7;1;7;3,67;CCCN(CCN1CCN(c2nccc3ccccc23)CC1)[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL57219;200274;None;0;Human;Binding;Ki;=;398,11;6,40;-251;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;588,2;12;1;5;6,36;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(cccc2OS(=O)(=O)C(F)(F)F)C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL57219;200274;None;0;Human;Binding;Ki;=;398,11;6,40;-251;2;Displacement [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;588,2;12;1;5;6,36;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(cccc2OS(=O)(=O)C(F)(F)F)C1;https://dx.doi.org/10.1016/s0960-894x(98)00699-4
CHEMBL572379;200294;None;0;Human;Binding;Ki;=;53,00;7,28;-1;4;Binding affinity to human cloned dopamine D2-long expressed in CHO cells;ChEMBL;559,2;12;1;8;4,52;O=C(CCCc1cn(-c2ccc([N+](=O)[O-])cc2)nn1)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL572379;200294;None;0;Human;Binding;Ki;=;44,00;7,36;-1;4;Binding affinity to human cloned dopamine D2-short expressed in CHO cells;ChEMBL;559,2;12;1;8;4,52;O=C(CCCc1cn(-c2ccc([N+](=O)[O-])cc2)nn1)NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL572708;200342;None;0;Human;Binding;Ki;=;158,49;6,80;-6;5;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;380,2;3;0;6;3,38;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2ncncc21;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
CHEMBL572867;200360;None;0;Human;Binding;Ki;=;68,00;7,17;10;4;Binding affinity to human cloned dopamine D2-short expressed in CHO cells;ChEMBL;544,2;12;1;7;4,62;COc1ccc(-n2cc(CCCC(=O)NCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nn2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL572867;200360;None;0;Human;Binding;Ki;=;1,00;9,00;10;4;Binding affinity to human cloned dopamine D2-long expressed in CHO cells;ChEMBL;544,2;12;1;7;4,62;COc1ccc(-n2cc(CCCC(=O)NCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nn2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL573791;200465;None;0;Human;Binding;Ki;=;6,50;8,19;-8;4;Binding affinity to human cloned dopamine D2-long expressed in CHO cells;ChEMBL;451,2;8;1;9;1,74;COc1ccccc1N1CCN(CCNC(=O)c2cn(-c3ccc([N+](=O)[O-])cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL573791;200465;None;0;Human;Binding;Ki;=;280,00;6,55;-8;4;Binding affinity to human cloned dopamine D2-short expressed in CHO cells;ChEMBL;451,2;8;1;9;1,74;COc1ccccc1N1CCN(CCNC(=O)c2cn(-c3ccc([N+](=O)[O-])cc3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL573792;200466;None;0;Human;Binding;Ki;=;17,00;7,77;-20;4;Binding affinity to human cloned dopamine D2-short expressed in CHO cells;ChEMBL;517,1;9;1;8;3,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cn(-c2ccc([N+](=O)[O-])cc2)nn1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL573792;200466;None;0;Human;Binding;Ki;=;810,00;6,09;-20;4;Binding affinity to human cloned dopamine D2-long expressed in CHO cells;ChEMBL;517,1;9;1;8;3,81;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cn(-c2ccc([N+](=O)[O-])cc2)nn1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL574030;200494;None;0;Human;Binding;Ki;=;1700,00;5,77;-6;4;Binding affinity to human cloned dopamine D2-short expressed in CHO cells;ChEMBL;502,2;9;1;7;3,92;COc1ccc(-n2cc(C(=O)NCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nn2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL574030;200494;None;0;Human;Binding;Ki;=;49,00;7,31;-6;4;Binding affinity to human cloned dopamine D2-long expressed in CHO cells;ChEMBL;502,2;9;1;7;3,92;COc1ccc(-n2cc(C(=O)NCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)nn2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.06.041
CHEMBL57407;200507;None;0;Human;Binding;Ki;=;1000,00;6,00;-31;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;375,2;7;0;3;5,28;COc1cc2ccccc2cc1COCC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm960017l
CHEMBL574534;200571;None;0;Human;Binding;Ki;=;2000,00;5,70;-17;5;Displacement of [3H]spiperone from human cloned dopamine D2long receptor expressed in CHO cells;ChEMBL;1046,6;23;2;14;8,65;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3cn(Cc4ccc(-c5ccc(Cn6cc(-c7ccc(C(=O)NCCCCN8CCN(c9ccccc9OC)CC8)cc7)nn6)cc5)cc4)nn3)cc2)CC1;https://dx.doi.org/10.1021/jm901120h
CHEMBL574534;200571;None;0;Human;Binding;Ki;=;770,00;6,11;-17;5;Displacement of [3H]spiperone from human cloned dopamine D2short receptor expressed in CHO cells;ChEMBL;1046,6;23;2;14;8,65;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3cn(Cc4ccc(-c5ccc(Cn6cc(-c7ccc(C(=O)NCCCCN8CCN(c9ccccc9OC)CC8)cc7)nn6)cc5)cc4)nn3)cc2)CC1;https://dx.doi.org/10.1021/jm901120h
CHEMBL574569;200574;None;0;Human;Binding;Ki;=;10000,00;5,00;-53;5;Displacement of [3H]spiperone from human cloned dopamine D2short receptor expressed in CHO cells;ChEMBL;1046,6;23;2;14;8,65;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(-c3cn(Cc4ccc(-c5ccc(Cn6cc(-c7cccc(C(=O)NCCCCN8CCN(c9ccccc9OC)CC8)c7)nn6)cc5)cc4)nn3)c2)CC1;https://dx.doi.org/10.1021/jm901120h
CHEMBL574569;200574;None;0;Human;Binding;Ki;=;15000,00;4,82;-53;5;Displacement of [3H]spiperone from human cloned dopamine D2long receptor expressed in CHO cells;ChEMBL;1046,6;23;2;14;8,65;COc1ccccc1N1CCN(CCCCNC(=O)c2cccc(-c3cn(Cc4ccc(-c5ccc(Cn6cc(-c7cccc(C(=O)NCCCCN8CCN(c9ccccc9OC)CC8)c7)nn6)cc5)cc4)nn3)c2)CC1;https://dx.doi.org/10.1021/jm901120h
CHEMBL574595;200575;None;0;Human;Binding;Ki;=;39,10;7,41;2;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting;ChEMBL;610,4;11;2;9;4,84;COc1ccccc1N1CCN(CCCn2cc(CCCN3CCc4cc(O)c(O)cc4C(c4ccccc4C)C3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.06.019
CHEMBL574700;200592;None;0;Human;Binding;Ki;=;19,10;7,72;5;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting;ChEMBL;610,4;11;2;9;4,84;COc1ccccc1N1CCN(CCCc2cn(CCCN3CCc4cc(O)c(O)cc4C(c4ccccc4C)C3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.06.019
CHEMBL57478;200608;None;24;Human;Binding;Ki;=;5500,00;5,26;-9;3;Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand;ChEMBL;228,2;2;1;1;3,40;CC1CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm9600712
CHEMBL57546;200690;None;0;Human;Binding;Ki;=;2200,00;5,66;-154;6;Binding affinity for human Dopamine receptor D2;ChEMBL;373,2;4;0;4;2,66;O=C1CC2(CCCC2)CC(=O)N1CCN1CCN(c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/jm0491391
CHEMBL575760;200719;None;0;Human;Binding;Ki;=;630,96;6,20;-2;2;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;367,2;4;0;5;2,96;O=C1CC(CN2CCC(C(=O)c3ccc(F)cc3)CC2)Cc2ncncc21;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
CHEMBL575788;200724;None;0;Human;Binding;Ki;=;33,88;7,47;3;2;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;456,2;4;0;6;5,05;O=C1CC(CN2CCC(c3noc4cc(F)ccc34)CC2)Cc2nc(-c3ccccc3)ncc21;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
CHEMBL576756;200843;None;0;Human;Binding;Ki;=;48,98;7,31;-20;4;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;409,2;4;1;7;3,42;CNc1ncc2c(n1)CC(CN1CCC(c3noc4cc(F)ccc34)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
CHEMBL577073;200876;None;0;Human;Binding;Ki;=;109,00;6,96;-41;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;450,3;7;1;7;3,67;CCCN(CCN1CCN(c2ccnc3ccccc23)CC1)[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm901184n
CHEMBL582945;201200;None;0;Human;Binding;Ki;=;80,00;7,10;1;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting;ChEMBL;624,4;12;2;9;5,23;COc1ccccc1N1CCN(CCCn2cc(CCCCN3CCc4cc(O)c(O)cc4C(c4cccc(C)c4)C3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.06.019
CHEMBL58296;201201;None;0;Human;Binding;Ki;=;160,00;6,80;-3;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;386,1;4;0;3;6,03;Clc1ccc(CN2CCC(c3cc(-c4ccc(Cl)cc4)on3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL58296;201201;None;0;Human;Binding;Ki;=;160,00;6,80;-3;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;386,1;4;0;3;6,03;Clc1ccc(CN2CCC(c3cc(-c4ccc(Cl)cc4)on3)CC2)cc1;https://dx.doi.org/10.1021/jm960072u
CHEMBL58377;201304;None;11;Human;Binding;Ki;=;5,00;8,30;-5;4;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;357,2;6;1;4;2,39;COc1ccccc1N1CCN(CCNC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL583772;201305;None;0;Human;Binding;Ki;=;234,42;6,63;-36;2;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;396,2;5;1;6;3,00;CNc1ncc2c(n1)CC(CN1CCC(C(=O)c3ccc(F)cc3)CC1)CC2=O;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
CHEMBL584554;201381;None;0;Human;Binding;IC50;=;1590,00;5,80;-;14;Inhibition of dopamine D2 receptor;ChEMBL;428,2;4;2;2;4,51;CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C(=O)Nc2ccccc2)C1;https://dx.doi.org/10.1016/j.bmcl.2009.09.002
CHEMBL585740;201470;None;0;Human;Binding;Ki;=;115,00;6,94;1;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting;ChEMBL;610,4;11;2;9;4,84;COc1ccccc1N1CCN(CCCn2cc(CCCN3CCc4cc(O)c(O)cc4C(c4cccc(C)c4)C3)nn2)CC1;https://dx.doi.org/10.1016/j.bmc.2009.06.019
CHEMBL585741;201471;None;0;Human;Binding;Ki;=;200,00;6,70;1;3;Displacement of [3H]spiperone from dopamine D2 receptor expressed in HEK293 cells by liquid scintillation counting;ChEMBL;637,3;10;2;10;5,44;Cc1cccc(C2CN(CCCc3cn(CCCN4CCN(c5nsc6ccccc56)CC4)nn3)CCc3cc(O)c(O)cc32)c1;https://dx.doi.org/10.1016/j.bmc.2009.06.019
CHEMBL58662;201519;None;0;Human;Binding;Ki;=;550,00;6,26;-7;4;Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;341,2;3;1;2;3,74;C(#Cc1c[nH]c(CN2CCN(c3ccccc3)CC2)c1)c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL58662;201519;None;0;Human;Binding;Ki;=;760,00;6,12;-7;4;Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;341,2;3;1;2;3,74;C(#Cc1c[nH]c(CN2CCN(c3ccccc3)CC2)c1)c1ccccc1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL58669;201520;None;0;Human;Binding;Ki;=;25,12;7,60;-125;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;456,3;10;2;3;5,84;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL59075;201813;None;0;Human;Binding;Ki;=;1584,89;5,80;-63;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;375,2;7;0;3;5,53;COc1cc2ccccc2cc1OCCC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm960017l
CHEMBL59103;201846;None;0;Human;Binding;Ki;=;110,00;6,96;-4;3;Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand;ChEMBL;290,2;3;1;1;4,55;c1ccc(C2CCN(Cc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm9600712
CHEMBL591685;201936;None;0;Human;Binding;Ki;=;2100,00;5,68;-741;3;Binding affinity to dopamine D2 receptor;ChEMBL;328,1;0;2;3;3,56;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(N)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL592377;202011;None;1;Human;Binding;Ki;=;35,00;7,46;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;267,2;3;1;2;3,77;Oc1cccc(C2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm901689v
CHEMBL592377;202011;None;1;Human;Binding;Ki;=;285,00;6,54;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;267,2;3;1;2;3,77;Oc1cccc(C2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm901689v
CHEMBL592377;202011;UNDEFINED;1;Human;Binding;pKi;=;285,00;6,55;-;1;-;PDSP KiDatabase;267,2;3;1;2;3,77;Oc1cccc(C2CCN(Cc3ccccc3)CC2)c1;-
CHEMBL592377;202011;UNDEFINED;1;Human;Binding;pKi;=;35,00;7,46;-;1;-;PDSP KiDatabase;267,2;3;1;2;3,77;Oc1cccc(C2CCN(Cc3ccccc3)CC2)c1;-
CHEMBL592618;202047;None;1;Human;Binding;Ki;=;349,00;6,46;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;219,2;3;1;2;2,98;CCCN1CCC(c2cccc(O)c2)CC1;https://dx.doi.org/10.1021/jm901689v
CHEMBL592618;202047;None;1;Human;Binding;Ki;=;2570,00;5,59;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;219,2;3;1;2;2,98;CCCN1CCC(c2cccc(O)c2)CC1;https://dx.doi.org/10.1021/jm901689v
CHEMBL592618;202047;UNDEFINED;1;Human;Binding;pKi;=;2570,00;5,59;-;1;-;PDSP KiDatabase;219,2;3;1;2;2,98;CCCN1CCC(c2cccc(O)c2)CC1;-
CHEMBL592618;202047;UNDEFINED;1;Human;Binding;pKi;=;349,00;6,46;-;1;-;PDSP KiDatabase;219,2;3;1;2;2,98;CCCN1CCC(c2cccc(O)c2)CC1;-
CHEMBL592752;202074;None;10;Human;Binding;Ki;=;85,11;7,07;-436;8;Displacement of [3H]Spiperone from human recombinant dopamine D2S receptor expressed in CHO cells;ChEMBL;304,2;3;0;2;4,18;Cc1ccc2c(c1)c1c(n2CCc2ccccc2)CCN(C)C1;https://dx.doi.org/10.1016/j.bmcl.2009.11.037
CHEMBL59324;202155;None;10;Human;Binding;Ki;=;120,00;6,92;-15;3;Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand;ChEMBL;291,2;3;1;2;3,49;c1ccc(N2CCN(Cc3c[nH]c4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm9600712
CHEMBL59326;202157;None;0;Human;Binding;Ki;=;3162,28;5,50;-630;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;389,2;6;0;4;4,92;COc1cc2ccccc2cc1C(=O)OCC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm960017l
CHEMBL593897;202239;None;0;Human;Binding;Ki;=;486,00;6,31;-12;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting;ChEMBL;251,1;0;1;2;3,05;Oc1ccc2c(c1)CCN1Cc3ccccc3CC21;https://dx.doi.org/10.1016/j.bmc.2009.08.028
CHEMBL594127;202267;None;0;Human;Binding;Ki;=;7371,00;5,13;-3;3;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting;ChEMBL;281,2;3;0;2;3,77;COc1ccc2c(c1)CCN(C)C2Cc1ccccc1C;https://dx.doi.org/10.1016/j.bmc.2009.08.028
CHEMBL594798;202386;None;0;Human;Binding;Ki;=;2724,00;5,57;1;2;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting;ChEMBL;267,2;2;1;2;3,47;Cc1ccccc1CC1c2ccc(O)cc2CCN1C;https://dx.doi.org/10.1016/j.bmc.2009.08.028
CHEMBL595489;202489;None;28;Human;Binding;Ki;=;115,50;6,94;-20;3;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)C1Cc3ccc(O)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2016.03.037
CHEMBL59554;202490;None;0;Human;Binding;Ki;=;316,23;6,50;-25;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;442,3;9;1;3;5,36;COc1cccc2c1CCC(N(C)CCCCNC(=O)c1ccc(-c3ccccc3)cc1)C2;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL59603;202559;None;0;Human;Binding;Ki;=;1819,70;5,74;-6;2;Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone;ChEMBL;259,1;1;2;2;3,28;Oc1cc2c(cc1Cl)CNC[C@H]2c1ccccc1;https://dx.doi.org/10.1021/jm00129a006
CHEMBL59642;202617;None;0;Human;Binding;Ki;=;125,89;6,90;-50;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;428,2;8;2;3;5,06;CN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL596448;202619;None;0;Human;Binding;Ki;=;320,00;6,50;-1;5;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting;ChEMBL;265,1;1;0;2;3,35;COc1ccc2c(c1)CCN1Cc3ccccc3CC21;https://dx.doi.org/10.1016/j.bmc.2009.08.028
CHEMBL59662;202643;None;0;Human;Binding;Ki;=;251,19;6,60;-3;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;295,2;3;0;3;3,30;COc1ccc2c(c1)OCC1CN(Cc3ccccc3)CC21;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL596622;202644;None;0;Human;Binding;Ki;=;2000,00;5,70;-2238;3;Binding affinity to dopamine D2 receptor;ChEMBL;370,2;4;2;3;4,31;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccc(CNC3CCC3)cc2)C1;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL596800;202677;None;0;Human;Binding;Ki;=;841,00;6,08;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;329,1;4;0;3;3,47;CS(=O)(=O)c1cccc(C2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm901689v
CHEMBL596800;202677;None;0;Human;Binding;Ki;=;392,00;6,41;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;329,1;4;0;3;3,47;CS(=O)(=O)c1cccc(C2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm901689v
CHEMBL596800;202677;UNDEFINED;0;Human;Binding;pKi;=;392,00;6,41;-;1;-;PDSP KiDatabase;329,1;4;0;3;3,47;CS(=O)(=O)c1cccc(C2CCN(Cc3ccccc3)CC2)c1;-
CHEMBL596800;202677;UNDEFINED;0;Human;Binding;pKi;=;841,00;6,08;-;1;-;PDSP KiDatabase;329,1;4;0;3;3,47;CS(=O)(=O)c1cccc(C2CCN(Cc3ccccc3)CC2)c1;-
CHEMBL596801;202678;None;0;Human;Binding;Ki;=;1211,00;5,92;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;282,1;4;0;4;1,62;CCCN1CCN(c2cccc(S(C)(=O)=O)c2)CC1;https://dx.doi.org/10.1021/jm901689v
CHEMBL596801;202678;None;0;Human;Binding;Ki;=;664,00;6,18;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;282,1;4;0;4;1,62;CCCN1CCN(c2cccc(S(C)(=O)=O)c2)CC1;https://dx.doi.org/10.1021/jm901689v
CHEMBL596801;202678;UNDEFINED;0;Human;Binding;pKi;=;1211,00;5,92;-;1;-;PDSP KiDatabase;282,1;4;0;4;1,62;CCCN1CCN(c2cccc(S(C)(=O)=O)c2)CC1;-
CHEMBL596801;202678;UNDEFINED;0;Human;Binding;pKi;=;664,00;6,18;-;1;-;PDSP KiDatabase;282,1;4;0;4;1,62;CCCN1CCN(c2cccc(S(C)(=O)=O)c2)CC1;-
CHEMBL596824;202682;None;0;Human;Binding;Ki;=;159,00;6,80;-794;3;Binding affinity to dopamine D2 receptor;ChEMBL;412,2;4;1;3;4,57;CC(=O)N(Cc1ccc([C@H]2CN(C)CCc3cc(Cl)c(O)cc32)cc1)C1CCC1;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL59702;202710;None;0;Human;Binding;Ki;=;8650,00;5,06;-31;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;347,2;6;1;4;4,10;c1ccc(CN2CCC(NCc3coc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL59702;202710;None;0;Human;Binding;Ki;=;14000,00;4,85;-31;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;347,2;6;1;4;4,10;c1ccc(CN2CCC(NCc3coc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL597100;202715;None;0;Human;Binding;Ki;=;312,00;6,51;-346;2;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;425,1;1;1;2;5,92;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4cc(F)cc(F)c4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL59713;202721;None;0;Human;Binding;Ki;=;58,80;7,23;-28;5;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;543,1;9;1;5;5,11;COc1cc(Br)cc(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1OC;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL59713;202721;None;0;Human;Binding;Ki;=;58,80;7,23;-28;5;Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay;ChEMBL;543,1;9;1;5;5,11;COc1cc(Br)cc(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)c1OC;https://dx.doi.org/10.1021/jm301545c
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;1000,00;6,00;-1513;10;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cell membranes by radioligand competition binding assay;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2015.07.050
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;3600,00;5,44;-1513;10;Binding affinity for human dopamine receptor D2 long;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm049612a
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;2600,00;5,58;-1513;10;Binding affinity towards Dopamine D2S receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;64,70;7,19;-1513;10;Binding affinity for human dopamine D2 receptor;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm049465g
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;3600,00;5,44;-1513;10;Binding affinity towards Dopamine D2L receptor using CHO cell line and [3H]spiperone as radioligand;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmcl.2005.07.037
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;170,00;6,77;-1513;10;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm020952a
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;3630,78;5,44;-1513;10;Binding affinity to dopamine D2;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm0611152
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;3600,00;5,44;-1513;10;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmc.2013.03.074
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;2600,00;5,58;-1513;10;Binding affinity towards human D2 short receptor using [3H]spiperone expressed in CHO cells;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;64,70;7,19;-1513;10;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm040190e
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;3600,00;5,44;-1513;10;Binding affinity for human Dopamine receptor D2 (long) by [3H]- spiperone displacement.;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm025558r
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;3600,00;5,44;-1513;10;Binding affinity towards human D2 long receptor using [3H]spiperone expressed in CHO cells;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1016/j.bmcl.2004.05.052
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;42,50;7,37;-1513;10;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm040190e
CHEMBL59725;202741;None;32;Human;Binding;Ki;=;2600,00;5,58;-1513;10;Binding affinity for human Dopamine receptor D2 (short) by [3H]- spiperone displacement.;ChEMBL;461,1;7;1;4;5,54;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2ccccc2s1;https://dx.doi.org/10.1021/jm025558r
CHEMBL597310;202745;None;0;Human;Binding;Ki;=;12,00;7,92;-16;2;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;432,2;2;1;3;5,71;CN(C)c1ccc(-c2cccc3c2CC[C@H]2[C@H]3c3cc(O)c(Cl)cc3CCN2C)cc1;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL597413;202769;None;0;Human;Binding;Ki;=;1923,00;5,72;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;330,1;4;0;4;2,41;CS(=O)(=O)c1cccc(N2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm901689v
CHEMBL597413;202769;None;0;Human;Binding;Ki;=;431,00;6,37;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;330,1;4;0;4;2,41;CS(=O)(=O)c1cccc(N2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm901689v
CHEMBL597413;202769;UNDEFINED;0;Human;Binding;pKi;=;431,00;6,37;-;1;-;PDSP KiDatabase;330,1;4;0;4;2,41;CS(=O)(=O)c1cccc(N2CCN(Cc3ccccc3)CC2)c1;-
CHEMBL597413;202769;UNDEFINED;0;Human;Binding;pKi;=;1923,00;5,72;-;1;-;PDSP KiDatabase;330,1;4;0;4;2,41;CS(=O)(=O)c1cccc(N2CCN(Cc3ccccc3)CC2)c1;-
CHEMBL59749;202778;None;0;Human;Binding;Ki;=;7950,00;5,10;-16;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;363,2;7;1;4;4,42;c1ccc(CN2CC[C@@H](CNCc3csc(-c4ccccc4)n3)C2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL59749;202778;None;0;Human;Binding;Ki;=;5050,00;5,30;-16;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;363,2;7;1;4;4,42;c1ccc(CN2CC[C@@H](CNCc3csc(-c4ccccc4)n3)C2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL59749;202778;None;0;Human;Binding;Ki;=;7900,00;5,10;-16;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;363,2;7;1;4;4,42;c1ccc(CN2CC[C@@H](CNCc3csc(-c4ccccc4)n3)C2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL59749;202778;None;0;Human;Binding;Ki;=;6400,00;5,19;-16;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;363,2;7;1;4;4,42;c1ccc(CN2CC[C@@H](CNCc3csc(-c4ccccc4)n3)C2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL597503;202780;None;0;Human;Binding;Ki;=;51,00;7,29;-85;2;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;428,2;1;2;2;6,13;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4ccc5[nH]ccc5c4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL59752;202782;None;0;Human;Binding;Ki;=;4,25;8,37;-2;5;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;282,1;6;2;3;2,35;O=C1Cc2c(cccc2OCCNCc2ccccc2)N1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL597702;202807;None;0;Human;Binding;Ki;=;552,00;6,26;-776;2;Binding affinity to dopamine D2 receptor;ChEMBL;518,2;6;1;3;7,15;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccc(CN(Cc3ccccc3)c3ccc(F)cc3F)cc2)C1;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL597900;202834;None;0;Human;Binding;Ki;=;93,00;7,03;-104;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;395,1;1;1;3;5,71;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4cccs4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL597909;202837;None;0;Human;Binding;Ki;=;3000,00;5,52;-6025;3;Binding affinity to dopamine D2 receptor;ChEMBL;406,1;2;2;4;3,35;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccc(NS(C)(=O)=O)cc3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL598104;202863;None;0;Human;Binding;Ki;=;223,00;6,65;-562;2;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;407,1;1;1;2;5,79;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4cccc(F)c4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL598105;202864;None;0;Human;Binding;Ki;=;584,00;6,23;-977;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;414,1;1;1;3;5,52;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4cccc(C#N)c4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL598515;202921;None;0;Human;Binding;Ki;=;5400,00;5,27;-758;3;Binding affinity to dopamine D2 receptor;ChEMBL;328,1;0;2;3;3,56;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccc(N)cc3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL598730;202959;None;0;Human;Binding;Ki;=;923,00;6,04;-398;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;371,1;1;1;4;3,77;COC(=O)c1cccc2c1CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL598915;202989;None;0;Human;Binding;Ki;=;420,00;6,38;-10;2;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;357,1;1;2;3;3,68;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(C(=O)O)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL598949;202994;None;0;Human;Binding;Ki;=;1370,00;5,86;-446;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;396,2;1;1;3;4,11;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(N4CCCC4=O)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL599116;203030;None;0;Human;Binding;Ki;=;1647,00;5,78;-831;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;343,1;1;2;3;3,47;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(CO)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL599134;203034;None;0;Human;Binding;Ki;=;483,00;6,32;-109;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;370,1;2;1;4;3,96;CO/N=C/c1cccc2c1CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL599135;203035;None;0;Human;Binding;Ki;=;69,00;7,16;-346;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;446,2;4;1;4;5,53;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(/C=N/OCc4ccccc4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL599282;203064;None;0;Human;Binding;Ki;=;2000,00;5,70;-3981;3;Binding affinity to dopamine D2 receptor;ChEMBL;448,2;5;1;4;3,98;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccc(CN(C3CCC3)S(C)(=O)=O)cc2)C1;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL59942;203086;None;0;Human;Binding;IC50;=;49,00;7,31;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;348,2;4;0;4;3,60;Fc1ccc(-c2cccc(CN3CCN(c4ncccn4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL599487;203095;None;0;Human;Binding;Ki;=;331,00;6,48;-549;4;Binding affinity to dopamine D2 receptor;ChEMBL;470,1;5;1;4;4,49;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccc(CN(C)S(=O)(=O)c3ccccc3)cc2)C1;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL599528;203099;None;0;Human;Binding;Ki;=;79,00;7,10;-398;2;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;389,2;1;1;2;5,65;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4ccccc4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL59960;203109;None;0;Human;Binding;Ki;=;630,96;6,20;-158;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;483,3;11;2;3;5,23;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(cccc2C(N)=O)C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL599635;203114;None;0;Human;Binding;Ki;=;4,55;8,34;-8;2;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;460,3;7;2;6;4,04;CCCN(CCN1CCN(c2ccnc3c(O)cccc23)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL599635;203114;None;0;Human;Binding;Ki;=;15,90;7,80;-8;2;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;460,3;7;2;6;4,04;CCCN(CCN1CCN(c2ccnc3c(O)cccc23)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL599636;203115;None;0;Human;Binding;Ki;=;20,70;7,68;-4;2;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;460,3;7;2;6;4,04;CCCN(CCN1CCN(c2ccnc3c(O)cccc23)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL599636;203115;None;0;Human;Binding;Ki;=;3,75;8,43;-4;2;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;460,3;7;2;6;4,04;CCCN(CCN1CCN(c2ccnc3c(O)cccc23)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL599636;203115;None;0;Human;Binding;Ki;=;13,80;7,86;-4;2;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;460,3;7;2;6;4,04;CCCN(CCN1CCN(c2ccnc3c(O)cccc23)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL599841;203144;None;0;Human;Binding;Ki;=;41,40;7,38;-11;2;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;460,3;7;2;6;4,04;CCCN(CCN1CCN(c2ccc(O)c3ncccc23)CC1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL599977;203163;None;0;Human;Binding;Ki;=;1093,00;5,96;-1548;2;Binding affinity to dopamine D2 receptor;ChEMBL;515,1;2;3;3;6,93;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccc(NC(=O)Nc4c(Cl)cccc4Cl)cc3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL600083;203189;None;0;Human;Binding;Ki;=;1693,00;5,77;-562;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;391;0;1;2;4,74;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(Br)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL60038;203211;None;0;Human;Binding;Ki;=;251,19;6,60;-199;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;518,2;10;1;2;6,90;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(Br)cccc2C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL600986;203285;None;0;Human;Binding;Ki;=;3300,00;5,48;-4677;3;Binding affinity to dopamine D2 receptor;ChEMBL;420,1;3;2;4;3,74;CCS(=O)(=O)Nc1ccc2c(c1)CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL600987;203286;None;0;Human;Binding;Ki;=;6000,00;5,22;-3981;3;Binding affinity to dopamine D2 receptor;ChEMBL;399,2;2;3;3;4,12;CCNC(=O)Nc1ccc2c(c1)CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL600998;203288;None;0;Human;Binding;Ki;=;26,00;7,58;8;2;Binding affinity to dopamine D2 receptor;ChEMBL;410,2;2;1;3;4,97;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cc(CN4CCCCC4)ccc3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL601634;203368;None;0;Human;Binding;Ki;=;500,00;6,30;-218;2;Binding affinity to dopamine D2 receptor;ChEMBL;384,2;2;2;3;4,33;CCC(=O)Nc1cccc2c1CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL601635;203369;None;0;Human;Binding;Ki;=;1,30;8,89;117;2;Binding affinity to dopamine D2 receptor;ChEMBL;488,2;3;1;5;4,70;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cc(CN4CCN(c5ccccn5)CC4)ccc3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL60185;203405;None;0;Human;Binding;Ki;=;107,00;6,97;-269;5;Affinity for the Dopamine receptor D2S was determined using membranes from CHO cells labeled with [3H]spiperone;ChEMBL;292,2;4;2;2;3,65;c1ccc(CNC[C@H]2CCc3ccc4[nH]ccc4c3O2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00778-8
CHEMBL602052;203437;None;0;Human;Binding;Ki;=;618,00;6,21;-107;2;Binding affinity to dopamine D2 receptor;ChEMBL;420,1;3;2;4;3,74;CCS(=O)(=O)Nc1cccc2c1CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL602065;203440;None;0;Human;Binding;Ki;=;3,74;8,43;-19;2;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;444,3;7;1;5;4,33;CCCN(CCN1CCN(c2ccnc3ccccc23)CC1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL602264;203470;None;0;Human;Binding;Ki;=;86,00;7,07;-15;2;Displacement of [3H]spiperone from cloned dopamine D2L receptor expressed in HEK cells;ChEMBL;460,3;7;2;6;4,04;CCCN(CCN1CCN(c2ccc(O)c3ncccc23)CC1)C1CCc2ccc(O)cc2C1;https://dx.doi.org/10.1021/jm901618d
CHEMBL602659;203514;None;0;Human;Binding;Ki;=;2137,00;5,67;-371;2;Binding affinity to dopamine D2 receptor;ChEMBL;396,2;2;2;3;4,33;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(NC(=O)C4CC4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL603485;203651;None;0;Human;Binding;Ki;=;3900,00;5,41;-2754;3;Binding affinity to dopamine D2 receptor;ChEMBL;400,2;2;2;4;4,55;CCOC(=O)Nc1ccc2c(c1)CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL603872;203713;None;0;Human;Binding;Ki;=;550,00;6,26;-776;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;419,2;2;1;3;5,66;COc1ccc(-c2cccc3c2CC[C@H]2[C@H]3c3cc(O)c(Cl)cc3CCN2C)cc1;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL603901;203718;None;0;Human;Binding;Ki;=;6000,00;5,22;-12022;2;Binding affinity to dopamine D2 receptor;ChEMBL;408,1;4;1;4;3,06;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccc(CN(C)S(C)(=O)=O)cc2)C1;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL604102;203757;None;0;Human;Binding;Ki;=;2910,00;5,54;-645;6;Binding affinity to dopamine D2 receptor;ChEMBL;392,1;3;2;5;3,09;N[C@@H]1CCN(c2ccc3[nH]nc(S(=O)(=O)c4cccc5ccccc45)c3c2)C1;https://dx.doi.org/10.1021/jm901674f
CHEMBL604108;203758;None;0;Human;Binding;Ki;=;2000,00;5,70;-999;2;Binding affinity to dopamine D2 receptor;ChEMBL;392,2;4;2;3;5,28;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccc(CNc3ccccc3)cc2)C1;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL604127;203762;None;0;Human;Binding;Ki;=;1328,00;5,88;-467;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;338,1;0;1;3;3,85;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(C#N)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL604129;203763;None;0;Human;Binding;Ki;=;566,00;6,25;-79;2;Binding affinity to dopamine D2 receptor;ChEMBL;515,1;2;3;3;6,93;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(NC(=O)Nc4c(Cl)cccc4Cl)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL604132;203766;None;0;Human;Binding;Ki;=;900,00;6,05;-371;2;Binding affinity to dopamine D2 receptor;ChEMBL;399,2;2;3;3;4,12;CCNC(=O)Nc1cccc2c1CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL604135;203767;None;0;Human;Binding;Ki;=;1000,00;6,00;-213;2;Binding affinity to dopamine D2 receptor;ChEMBL;406,1;2;2;4;3,35;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(NS(C)(=O)=O)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
CHEMBL604176;203773;None;0;Human;Binding;Ki;=;89,00;7,05;-125;2;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;419,2;2;2;3;5,14;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4ccc(CO)cc4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL604314;203795;None;0;Human;Binding;Ki;=;440,00;6,36;-724;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;329,1;0;2;3;3,69;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(O)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL604316;203796;None;0;Human;Binding;Ki;=;1371,00;5,86;-537;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;341,1;1;1;3;3,79;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(C=O)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL604383;203805;None;0;Human;Binding;Ki;=;1612,00;5,79;-707;2;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;473,1;2;1;3;6,55;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4cccc(OC(F)(F)F)c4)c3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL604525;203835;None;0;Human;Binding;Ki;=;217,00;6,66;-120;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;384,2;3;1;4;4,35;CCO/N=C/c1cccc2c1CC[C@H]1[C@H]2c2cc(O)c(Cl)cc2CCN1C;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL604732;203875;None;0;Human;Binding;Ki;=;882,00;6,05;-562;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;356,1;1;2;4;3,79;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(/C=N/O)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL605127;203950;None;0;Human;Binding;Ki;=;756,00;6,12;-2511;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;390,1;1;1;3;5,04;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4ccncc4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL605339;203991;None;0;Human;Binding;Ki;=;618,00;6,21;-1023;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;434,1;2;1;4;5,55;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(-c4cccc([N+](=O)[O-])c4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL605354;203993;None;0;Human;Binding;Ki;=;124,00;6,91;-123;4;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;432,2;3;1;4;5,39;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3cccc(/C=N/Oc4ccccc4)c3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
CHEMBL605405;204004;None;3;Human;Binding;Ki;=;34,67;7,46;-165;8;Displacement of [3H]Spiperone from human recombinant dopamine D2S receptor expressed in CHO cells;ChEMBL;302,2;2;0;2;4,57;Cc1ccc2c(c1)c1c(n2/C=C\c2ccccc2)CCN(C)C1;https://dx.doi.org/10.1016/j.bmcl.2009.11.037
CHEMBL606939;204265;None;1;Human;Binding;Ki;=;60,00;7,22;107;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)[C@@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL60708;204297;None;1;Human;Binding;Ki;=;39,81;7,40;-10;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;360,2;5;1;3;3,85;COc1cc2ccccc2cc1C(=O)NC1CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1021/jm960017l
CHEMBL60713;204310;None;0;Human;Binding;Ki;=;316,23;6,50;-199;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;440,3;10;1;2;6,13;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2ccccc2C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL60815;204452;None;0;Human;Binding;Ki;=;230,00;6,64;-16;7;Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;317,2;4;1;2;4,00;c1ccc(-c2c[nH]c(CN3CCN(c4ccccc4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL60815;204452;None;0;Human;Binding;Ki;=;170,00;6,77;-16;7;Displacement of [3H]spiperone from human cloned dopamine D2(short) receptor expressed in CHO cells;ChEMBL;317,2;4;1;2;4,00;c1ccc(-c2c[nH]c(CN3CCN(c4ccccc4)CC3)c2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL60815;204452;None;0;Human;Binding;Ki;=;230,00;6,64;-16;7;Displacement of [3H]spiperone from human cloned dopamine D2(long) receptor expressed in CHO cells;ChEMBL;317,2;4;1;2;4,00;c1ccc(-c2c[nH]c(CN3CCN(c4ccccc4)CC3)c2)cc1;https://dx.doi.org/10.1016/j.bmcl.2006.02.075
CHEMBL60815;204452;None;0;Human;Binding;Ki;=;170,00;6,77;-16;7;Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;317,2;4;1;2;4,00;c1ccc(-c2c[nH]c(CN3CCN(c4ccccc4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
CHEMBL608530;204502;None;1;Human;Binding;IC50;=;837,00;6,08;-2;5;Concentration required to inhibit [3H]YM-09151-2 binding to human D2 dopamine receptor;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL608530;204502;None;1;Human;Binding;IC50;=;1173,00;5,93;-2;5;Concentration required to inhibit [3H]YM-09151-2 binding to human D2 dopamine receptor;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL608530;204502;None;1;Human;Binding;Ki;=;426,00;6,37;-2;5;Binding affinity towards human D2 dopamine receptor was determined by using [3H]YM-09151-2 as radioligand;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL608530;204502;None;1;Human;Binding;Ki;=;304,00;6,52;-2;5;Binding affinity towards human D2 dopamine receptor was determined by using [3H]YM-09151-2 as radioligand;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL609151;204600;None;5;Human;Binding;Ki;=;2,00;8,70;676;2;Affinity towards Dopamine receptor D2;ChEMBL;345;1;2;2;2,29;CN1C[C@H](C(N)=O)C=C2c3cccc4[nH]c(Br)c(c34)C[C@H]21;https://dx.doi.org/10.1021/jm9800292
CHEMBL60957;204647;None;0;Human;Binding;IC50;=;450,00;6,35;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;349,2;4;0;5;3,00;Fc1ccc(-c2cncc(CN3CCN(c4cnccn4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL61079;204856;None;0;Human;Binding;Ki;=;290,00;6,54;-239;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;379,2;5;1;2;5,46;Cc1c(C2CCN(CCc3ccccc3)CC2)n[nH]c1-c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL61079;204856;None;0;Human;Binding;Ki;=;290,00;6,54;-239;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;379,2;5;1;2;5,46;Cc1c(C2CCN(CCc3ccccc3)CC2)n[nH]c1-c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm960072u
CHEMBL61080;204859;None;10;Human;Binding;Ki;=;240,00;6,62;-3;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;385,1;4;1;2;5,76;Clc1ccc(CN2CCC(c3cc(-c4ccc(Cl)cc4)[nH]n3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL61080;204859;None;10;Human;Binding;Ki;=;240,00;6,62;-3;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;385,1;4;1;2;5,76;Clc1ccc(CN2CCC(c3cc(-c4ccc(Cl)cc4)[nH]n3)CC2)cc1;https://dx.doi.org/10.1021/jm960072u
CHEMBL61090;204878;None;0;Human;Binding;Ki;=;1258,93;5,90;-6;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;387,2;7;0;3;5,26;COc1cc2ccccc2cc1CC(=O)CC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm960017l
CHEMBL611207;204931;None;0;Human;Binding;IC50;=;77,00;7,11;-2;6;Concentration required to inhibit [3H]YM-09151-2 binding to human D2 dopamine receptor;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL611207;204931;None;0;Human;Binding;IC50;=;63,00;7,20;-2;6;Concentration required to inhibit [3H]YM-09151-2 binding to human D2 dopamine receptor;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL611207;204931;None;0;Human;Binding;Ki;=;2,20;8,66;-2;6;High binding affinity towards human D2 dopamine receptor was determined by using [3H]YM-09151-2 as radioligand;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL611207;204931;None;0;Human;Binding;Ki;=;1841,00;5,74;-2;6;Low binding affinity towards human D2 dopamine receptor was determined by using [3H]YM-09151-2 as radioligand;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL611207;204931;None;0;Human;Binding;Ki;=;1,20;8,92;-2;6;High binding affinity towards human D2 dopamine receptor was determined by using [3H]YM-09151-2 as radioligand;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL611207;204931;None;0;Human;Binding;Ki;=;1545,00;5,81;-2;6;Low binding affinity towards human D2 dopamine receptor was determined by using [3H]YM-09151-2 as radioligand;ChEMBL;386,1;4;0;4;4,90;CN1CCCC[C@@H]1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21;https://dx.doi.org/10.1016/j.bmcl.2004.06.078
CHEMBL611801;205021;None;12;Human;Binding;Ki;=;340,00;6,47;-5;4;Affinity towards Dopamine receptor D2;ChEMBL;207,1;1;2;3;1,52;CN(C)C1CCc2cc(O)c(O)cc2C1;https://dx.doi.org/10.1021/jm9800292
CHEMBL61195;205046;None;0;Human;Binding;Ki;=;130,00;6,89;-35;3;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;386,1;4;0;3;6,03;Clc1ccc(CN2CCC(c3cc(-c4ccc(Cl)cc4)no3)CC2)cc1;https://dx.doi.org/10.1021/jm960072u
CHEMBL61195;205046;None;0;Human;Binding;Ki;=;130,00;6,89;-35;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;386,1;4;0;3;6,03;Clc1ccc(CN2CCC(c3cc(-c4ccc(Cl)cc4)no3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL611991;205051;None;0;Human;Binding;Kd;=;40,74;7,39;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL611991;205051;None;0;Human;Binding;Ki;=;38,02;7,42;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1cccc(F)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL612083;205062;None;0;Human;Binding;Ki;=;2,10;8,68;3;5;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL612083;205062;None;0;Human;Binding;Ki;=;20,00;7,70;3;5;Affinity towards Dopamine receptor D2;ChEMBL;309,2;6;1;2;4,20;CCCN(CCc1ccccc1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm9800292
CHEMBL61248;205085;None;0;Human;Binding;Ki;=;126,00;6,90;-6;2;Displacement of [3H]spiperone from human cloned dopamine D2L receptor;ChEMBL;388,2;6;1;3;4,49;COc1cc2ccccc2cc1C(=O)NCC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.12.096
CHEMBL61248;205085;None;0;Human;Binding;Ki;=;125,89;6,90;-6;2;Binding affinity against cloned human Dopamine receptor D2 (long) using [125I]iodosulpiride as radioligand;ChEMBL;388,2;6;1;3;4,49;COc1cc2ccccc2cc1C(=O)NCC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm960017l
CHEMBL61444;205120;None;0;Human;Binding;Ki;=;794,33;6,10;-316;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;510,3;13;1;3;6,92;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(cccc2OCC2CC2)C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL61565;205141;None;4;Human;Binding;Ki;=;39,81;7,40;-39;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;361,2;4;1;4;3,17;CC(=O)Nc1ccc(CCN2CC3COc4ccc(C#N)cc4C3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL61657;205155;None;0;Human;Binding;IC50;=;60,00;7,22;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;348,2;4;0;4;3,60;Fc1ccc(-c2cncc(CN3CCN(c4ccccn4)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL61682;205163;None;0;Human;Binding;IC50;=;25,00;7,60;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;365,2;4;0;3;4,35;Fc1ccc(-c2cncc(CN3CCN(c4ccccc4F)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL61717;205169;None;0;Human;Binding;Ki;=;125,89;6,90;-158;2;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;470,3;11;1;3;6,14;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/S0960-894X(97)00350-8
CHEMBL61789;205178;None;0;Human;Binding;Ki;=;3800,00;5,42;-524;4;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;563,1;8;1;4;6,25;COc1c(C(=O)NCCCCN2CCN(c3cccc(Cl)c3Cl)CC2)cc(Br)c2ccccc12;https://dx.doi.org/10.1021/jm020952a
CHEMBL62416;205289;None;0;Human;Binding;Ki;=;12,59;7,90;-1;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;347,2;3;1;4;3,13;CC(=O)Nc1ccc(CN2C[C@@H]3c4cc(C#N)ccc4OC[C@H]3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL62601;205330;None;0;Human;Binding;Ki;=;17500,00;4,76;-4;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;505,1;8;1;5;5,88;COc1c(-c2nc(CNC[C@@H]3CCN(Cc4ccccc4)C3)co2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62601;205330;None;0;Human;Binding;Ki;=;45500,00;4,34;-4;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;505,1;8;1;5;5,88;COc1c(-c2nc(CNC[C@@H]3CCN(Cc4ccccc4)C3)co2)cc(Br)c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62602;205331;None;0;Human;Binding;Ki;=;320,00;6,50;-25;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;455,1;8;1;5;4,72;COc1ccc(Br)cc1-c1nc(CNC[C@@H]2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62602;205331;None;0;Human;Binding;Ki;=;245,00;6,61;-25;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;455,1;8;1;5;4,72;COc1ccc(Br)cc1-c1nc(CNC[C@@H]2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62624;205332;None;0;Human;Binding;Ki;=;195,00;6,71;1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;471,1;7;1;5;5,33;COc1ccc(Br)cc1-c1nc(CNC2CCN(Cc3ccccc3)CC2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62624;205332;None;0;Human;Binding;Ki;=;105,00;6,98;1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;471,1;7;1;5;5,33;COc1ccc(Br)cc1-c1nc(CNC2CCN(Cc3ccccc3)CC2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62703;205349;None;1;Human;Binding;Ki;=;27500,00;4,56;-16;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;333,2;5;0;4;3,66;c1ccc(CN2CCN(Cc3coc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62703;205349;None;1;Human;Binding;Ki;=;21500,00;4,67;-16;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;333,2;5;0;4;3,66;c1ccc(CN2CCN(Cc3coc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62823;205380;None;14;Human;Binding;Ki;=;39,81;7,40;-12;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;361,2;4;1;4;3,17;CC(=O)Nc1ccc(CCN2C[C@H]3COc4ccc(C#N)cc4[C@@H]3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL62829;205381;None;0;Human;Binding;IC50;=;81,00;7,09;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;348,2;4;0;4;3,60;Fc1cccc(-c2cccc(CN3CCN(c4ncccn4)CC3)c2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL62996;205418;None;0;Human;Binding;Ki;=;6650,00;5,18;-9;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;413,1;4;1;5;4,13;Oc1ccc(Br)cc1-c1nc(CN2CCN(c3ccccc3)CC2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL62996;205418;None;0;Human;Binding;Ki;=;4400,00;5,36;-9;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;413,1;4;1;5;4,13;Oc1ccc(Br)cc1-c1nc(CN2CCN(c3ccccc3)CC2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL63209;205462;None;0;Human;Binding;Ki;=;7367,00;5,13;-3;2;Binding affinity at human Dopamine receptor D2 by [3H]- YM 09151 displacement.;ChEMBL;383,2;3;0;3;3,44;CN1C(=O)C(N2CCN(Cc3ccc(Cl)cc3)CC2)CCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(00)00421-2
CHEMBL63329;205481;None;16;Human;Binding;Ki;=;5940,00;5,23;-281;7;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;307,2;0;1;5;2,77;Cc1ccc2c(c1)C(N1CCN(C)CC1)=Nc1cccnc1N2;https://dx.doi.org/10.1021/jm0104825
CHEMBL63449;205498;None;0;Human;Binding;Ki;=;423,00;6,37;-2137;4;In vitro binding affinity against dopamine receptor D2 using [3H]raclopride as radioligand in CHO cells (sc);ChEMBL;312,2;6;1;2;4,35;CCCN(CCC)[C@H]1CCc2ccc3[nH]cc(C(C)=O)c3c2C1;https://dx.doi.org/10.1021/jm00067a002
CHEMBL63576;205511;None;0;Human;Binding;Ki;=;2235,00;5,65;-93;4;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;327,1;0;1;5;3,12;CN1CCN(C2=Nc3cccnc3Nc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm0104825
CHEMBL64043;205576;None;5;Human;Binding;Ki;=;28000,00;4,55;-39;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;349,2;5;0;4;4,13;c1ccc(CN2CCN(Cc3csc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64043;205576;None;5;Human;Binding;Ki;=;19500,00;4,71;-39;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;349,2;5;0;4;4,13;c1ccc(CN2CCN(Cc3csc(-c4ccccc4)n3)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64117;205589;None;0;Human;Binding;Ki;=;144,54;6,84;-5;2;Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone;ChEMBL;287,1;2;1;2;3,82;CN1CCc2cc(Cl)c(O)cc2[C@@H]1Cc1ccccc1;https://dx.doi.org/10.1021/jm00129a006
CHEMBL64139;205596;None;0;Human;Binding;Ki;=;420,00;6,38;-3;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;471,1;8;1;5;5,19;COc1ccc(Br)cc1-c1nc(CNC[C@@H]2CCN(Cc3ccccc3)C2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64139;205596;None;0;Human;Binding;Ki;=;280,00;6,55;-3;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;471,1;8;1;5;5,19;COc1ccc(Br)cc1-c1nc(CNC[C@@H]2CCN(Cc3ccccc3)C2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64157;205603;None;0;Human;Binding;Ki;=;25,12;7,60;-3;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;308,1;2;0;3;3,31;N#Cc1ccc2c(c1)[C@H]1CN(Cc3ccc(F)cc3)C[C@@H]1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL6416;205604;None;0;Human;Binding;Ki;=;520,00;6,28;-95;2;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;365,2;5;1;2;5,15;Clc1ccc(-c2cc(C3CCN(CCc4ccccc4)CC3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm960072u
CHEMBL6416;205604;None;0;Human;Binding;Ki;=;520,00;6,28;-95;2;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;365,2;5;1;2;5,15;Clc1ccc(-c2cc(C3CCN(CCc4ccccc4)CC3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL64260;205638;None;0;Human;Binding;Ki;=;2850,00;5,54;1;4;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in HEK cells;ChEMBL;384,2;7;1;5;2,81;COc1cc2c(cc1OC)CN(CCNC(=O)c1cc(C)ccc1OC)CC2;https://dx.doi.org/10.1016/j.bmcl.2011.04.098
CHEMBL64283;205646;None;0;Human;Binding;Ki;=;81,80;7,09;-4;5;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;266,1;6;2;2;3,34;c1ccc(CNCCOc2cccc3[nH]ccc23)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL64288;205649;None;0;Human;Binding;Ki;=;330,00;6,48;-1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;427,1;5;0;5;4,43;COc1ccc(Br)cc1-c1nc(CN2CCN(c3ccccc3)CC2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64288;205649;None;0;Human;Binding;Ki;=;690,00;6,16;-1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;427,1;5;0;5;4,43;COc1ccc(Br)cc1-c1nc(CN2CCN(c3ccccc3)CC2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64325;205654;None;0;Human;Binding;Ki;=;440,00;6,36;1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;443,1;5;0;5;4,90;COc1ccc(Br)cc1-c1nc(CN2CCN(c3ccccc3)CC2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64325;205654;None;0;Human;Binding;Ki;=;610,00;6,21;1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;443,1;5;0;5;4,90;COc1ccc(Br)cc1-c1nc(CN2CCN(c3ccccc3)CC2)cs1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64376;205665;None;5;Human;Binding;Ki;=;1060,00;5,97;-3;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;335,1;4;0;4;4,13;c1ccc(-c2nc(CN3CCN(c4ccccc4)CC3)cs2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64376;205665;None;5;Human;Binding;Ki;=;2300,00;5,64;-3;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;335,1;4;0;4;4,13;c1ccc(-c2nc(CN3CCN(c4ccccc4)CC3)cs2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64487;205693;None;0;Human;Binding;IC50;=;360,00;6,44;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;360,2;5;0;5;3,47;COc1ccccc1-c1cccc(CN2CCN(c3ncccn3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL64508;205694;None;2;Human;Binding;Ki;=;75,80;7,12;-6;6;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;243,1;6;2;3;2,56;Oc1cccc(OCCNCc2ccccc2)c1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL64508;205694;None;2;Human;Binding;Ki;=;75,80;7,12;-6;6;Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone;ChEMBL;243,1;6;2;3;2,56;Oc1cccc(OCCNCc2ccccc2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00014-6
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;10,40;7,98;-60;7;Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1016/s0960-894x(98)00014-6
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;1,23;8,91;-60;7;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;39,81;7,40;-60;7;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;186,21;6,73;-60;7;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;2,98;8,53;-60;7;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;736,00;6,13;-60;7;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;70,20;7,15;-60;7;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm401384w
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;10,40;7,98;-60;7;Binding affinity at human Dopamine receptor D2 (hD2) using [3H]spiperone radioligand.;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1021/jm9703653
CHEMBL64553;205703;None;0;Human;Binding;Ki;=;10,40;7,98;-60;7;Affinity for the Dopamine receptor D2S was determined using membranes from CHO cells labeled with [3H]spiperone;ChEMBL;269,1;4;2;3;2,88;Oc1ccc2c(c1)O[C@@H](CNCc1ccccc1)CC2;https://dx.doi.org/10.1016/s0960-894x(01)00778-8
CHEMBL64566;205709;None;0;Human;Binding;Ki;=;2750,00;5,56;-3;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;454,1;8;2;4;4,46;COc1ccc(Br)cc1-c1nc(CNC[C@@H]2CCN(Cc3ccccc3)C2)c[nH]1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64566;205709;None;0;Human;Binding;Ki;=;6250,00;5,20;-3;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;454,1;8;2;4;4,46;COc1ccc(Br)cc1-c1nc(CNC[C@@H]2CCN(Cc3ccccc3)C2)c[nH]1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64597;205716;None;0;Human;Binding;IC50;=;300,00;6,52;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;336,1;4;0;5;3,53;c1cnc(N2CCN(Cc3cccc(-c4ccsc4)c3)CC2)nc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL64668;205733;None;0;Human;Binding;Ki;=;3800,00;5,42;-5;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;469,1;8;0;5;5,07;COc1ccc(Br)cc1-c1nc(CN(C)C[C@@H]2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64668;205733;None;0;Human;Binding;Ki;=;3250,00;5,49;-5;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;469,1;8;0;5;5,07;COc1ccc(Br)cc1-c1nc(CN(C)C[C@@H]2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64671;205736;None;0;Human;Binding;IC50;=;490,00;6,31;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;360,2;5;0;5;3,47;COc1cccc(-c2cccc(CN3CCN(c4ncccn4)CC3)c2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
CHEMBL64696;205742;None;0;Human;Binding;Ki;=;1500,00;5,82;-1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;441,1;6;0;5;4,43;COc1ccc(Br)cc1-c1nc(CN2CCN(Cc3ccccc3)CC2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64696;205742;None;0;Human;Binding;Ki;=;790,00;6,10;-1;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;441,1;6;0;5;4,43;COc1ccc(Br)cc1-c1nc(CN2CCN(Cc3ccccc3)CC2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64721;205749;None;0;Human;Binding;Ki;=;79,43;7,10;-10;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;308,1;2;0;3;3,31;N#Cc1ccc2c(c1)C1CN(Cc3ccc(F)cc3)CC1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL64752;205756;None;0;Human;Binding;Ki;=;2450,00;5,61;-56;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;441,1;7;1;5;4,48;COc1ccc(Br)cc1-c1nc(CN[C@@H]2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64752;205756;None;0;Human;Binding;Ki;=;2000,00;5,70;-56;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;441,1;7;1;5;4,48;COc1ccc(Br)cc1-c1nc(CN[C@@H]2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL64875;205782;None;7;Human;Binding;Ki;=;7,30;8,14;-11;10;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;344,1;1;0;3;4,34;CN1CCN([C@@H]2Cc3ccccc3Sc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CHEMBL65071;205809;None;0;Human;Binding;Ki;=;25,12;7,60;-1;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;347,2;3;1;4;3,13;CC(=O)Nc1ccc(CN2CC3COc4ccc(C#N)cc4C3C2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL65122;205814;None;0;Human;Binding;Ki;=;39,81;7,40;-2;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;308,1;2;0;3;3,31;N#Cc1ccc2c(c1)[C@@H]1CN(Cc3ccc(F)cc3)C[C@H]1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL65274;205833;None;0;Human;Binding;Ki;=;17,00;7,77;-85;4;In vitro binding affinity against dopamine receptor D2 using [3H]raclopride as radioligand in CHO cells (sc);ChEMBL;312,2;6;1;2;4,35;CCCN(CCC)[C@@H]1CCc2ccc3[nH]cc(C(C)=O)c3c2C1;https://dx.doi.org/10.1021/jm00067a002
CHEMBL65397;205844;None;0;Human;Binding;Ki;=;3715,35;5,43;-26;4;Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone;ChEMBL;259,1;1;2;2;3,28;Oc1cc2c(cc1Cl)CCN[C@H]2c1ccccc1;https://dx.doi.org/10.1021/jm00129a006
CHEMBL65641;205877;None;0;Human;Binding;Ki;=;1100,00;5,96;-9;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;469,1;9;1;5;5,11;COc1ccc(Br)cc1-c1nc(CNCC[C@@H]2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL65641;205877;None;0;Human;Binding;Ki;=;1070,00;5,97;-9;4;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;469,1;9;1;5;5,11;COc1ccc(Br)cc1-c1nc(CNCC[C@@H]2CCN(Cc3ccccc3)C2)co1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
CHEMBL65847;205907;None;0;Human;Binding;Ki;=;415,00;6,38;-11;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;297,2;5;0;1;4,59;CCCN(Cc1ccccc1)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL65847;205907;None;0;Human;Binding;Ki;=;179,00;6,75;-11;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;297,2;5;0;1;4,59;CCCN(Cc1ccccc1)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL65847;205907;None;0;Human;Binding;Ki;=;415,00;6,38;-11;3;Inhibition of [3H]raclopride binding to human dopamine D2A receptor expressed in LtK cells;ChEMBL;297,2;5;0;1;4,59;CCCN(Cc1ccccc1)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL65847;205907;None;0;Human;Binding;Ki;=;179,00;6,75;-11;3;Inhibition of [3H]quinpirole binding to human dopamine D2A receptor expressed in LtK cells;ChEMBL;297,2;5;0;1;4,59;CCCN(Cc1ccccc1)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL65896;205914;None;1;Human;Binding;Ki;=;1310,00;5,88;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;267,2;4;1;2;3,34;COc1cccc2c1CC[C@@H](NCc1ccccc1)C2;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL65896;205914;None;1;Human;Binding;Ki;=;1010,00;6,00;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;267,2;4;1;2;3,34;COc1cccc2c1CC[C@@H](NCc1ccccc1)C2;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL66080;205939;None;0;Human;Binding;Ki;=;50,12;7,30;-79;2;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;451,2;7;1;4;4,84;N#Cc1ccc2c(c1)[C@@H]1CN(CCCCNC(=O)c3ccc(-c4ccccc4)cc3)C[C@H]1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
CHEMBL67222;206101;None;0;Human;Binding;Ki;=;1373,00;5,86;-13;2;Binding affinity at human Dopamine receptor D2 by [3H]- YM 09151 displacement.;ChEMBL;355,1;3;1;3;3,02;O=C1Nc2ccccc2CC1N1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/s0960-894x(00)00421-2
CHEMBL67750;206186;None;0;Human;Binding;Ki;=;2570,00;5,59;-23;5;Binding affinity at human dopamine receptor D2;ChEMBL;479,2;6;1;3;5,51;O=C(NCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm010146o
CHEMBL67923;206213;None;0;Human;Binding;Ki;=;22,00;7,66;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;339,2;7;0;3;4,47;CCCN(Cc1ccc(OC)cc1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL67923;206213;None;0;Human;Binding;Ki;=;64,10;7,19;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;339,2;7;0;3;4,47;CCCN(Cc1ccc(OC)cc1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL68191;206239;None;0;Human;Binding;Ki;=;21,00;7,68;-5;2;Binding affinity at human Dopamine receptor D2 by [3H]- YM 09151 displacement.;ChEMBL;383,2;4;0;3;3,44;CCN1C(=O)C(N2CCN(Cc3ccc(Cl)cc3)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(00)00421-2
CHEMBL68191;206239;None;0;Human;Binding;Ki;=;21,00;7,68;-5;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;383,2;4;0;3;3,44;CCN1C(=O)C(N2CCN(Cc3ccc(Cl)cc3)CC2)Cc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL68545;206293;None;0;Human;Binding;Ki;=;75,00;7,12;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;309,2;6;0;2;4,46;CCCN(Cc1ccccc1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL68545;206293;None;0;Human;Binding;Ki;=;65,60;7,18;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;309,2;6;0;2;4,46;CCCN(Cc1ccccc1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL68573;206301;None;0;Human;Binding;Ki;=;6,35;8,20;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;261,2;6;0;2;3,67;CCCN(CCC)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL68573;206301;None;0;Human;Binding;Ki;=;46,00;7,34;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;261,2;6;0;2;3,67;CCCN(CCC)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL68720;206326;None;0;Human;Binding;Ki;=;5,00;8,30;-2;5;Binding affinity at human dopamine receptor D2;ChEMBL;521,2;8;1;4;5,93;O=C(NCCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc2c1-c1ccccc1C2=O;https://dx.doi.org/10.1021/jm010146o
CHEMBL68740;206329;None;0;Human;Binding;IC50;=;564,40;6,25;-95;6;Antagonist activity at human dopamine D2 receptor expressed in CHO cells assessed as inhibition of quinpirole-stimulated mitogenesis;ChEMBL;462,1;7;2;3;4,95;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(F)ccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL68740;206329;None;0;Human;Binding;Ki;=;36,80;7,43;-95;6;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor (unknown origin) expressed in HEK293 cells after 1 hr by liquid scintillation counting;ChEMBL;462,1;7;2;3;4,95;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1cc2cc(F)ccc2[nH]1;https://dx.doi.org/10.1021/acs.jmedchem.5b00776
CHEMBL68860;206343;None;0;Human;Binding;Ki;=;414,00;6,38;-17;5;Binding affinity at human dopamine receptor D2;ChEMBL;479,2;6;1;3;5,43;O=C(NCCCN1CCN(c2cccc(Cl)c2Cl)CC1)C1c2ccccc2-c2ccccc21;https://dx.doi.org/10.1021/jm010146o
CHEMBL69355;206412;None;2;Human;Binding;Ki;=;600,00;6,22;-120;3;Displacement of [3H]spiperone from human dopamine D2 receptor in CHO cells;ChEMBL;306,1;3;0;3;4,59;C1=C(c2nc3ccccc3s2)CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/S0960-894X(97)00402-2
CHEMBL69385;206422;None;0;Human;Binding;Ki;=;348,00;6,46;-40;6;The compound was tested for CNS binding affinity towards Dopamine receptor D2 from cloned Human membranes;ChEMBL;395,2;6;1;5;2,62;COc1ccc(N2CCN(CCC3OCCc4cc(C(N)=O)ccc43)CC2)cc1;https://dx.doi.org/10.1021/jm980137o
CHEMBL69451;206431;None;4;Human;Binding;Ki;=;24,80;7,61;-64;7;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;482,2;8;1;4;5,39;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm0704200
CHEMBL69451;206431;None;4;Human;Binding;Ki;=;61,20;7,21;-64;7;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;482,2;8;1;4;5,39;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL69451;206431;None;4;Human;Binding;Ki;=;24,80;7,61;-64;7;Binding affinity for human dopamine D2 receptor;ChEMBL;482,2;8;1;4;5,39;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL69451;206431;None;4;Human;Binding;Ki;=;24,80;7,61;-64;7;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;482,2;8;1;4;5,39;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL69571;206450;None;0;Human;Binding;Ki;=;62,90;7,20;-3;5;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;491,2;6;1;3;5,67;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1cccc2c1-c1ccccc1C2;https://dx.doi.org/10.1021/jm040190e
CHEMBL69584;206455;None;11;Human;Binding;IC50;=;690,00;6,16;-436;2;Inhibitory concentration against dopamine receptor D2;ChEMBL;369,2;4;0;3;3,05;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2ccccc21;https://dx.doi.org/10.1021/jm058225d
CHEMBL69584;206455;None;11;Human;Binding;Ki;=;690,00;6,16;-436;2;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;369,2;4;0;3;3,05;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
CHEMBL69584;206455;None;11;Human;Binding;Ki;=;690,00;6,16;-436;2;Binding affinity towards human Dopamine receptor D2 was determined via standard competitive displacement assay using [3H]-YM 09151 as radioligand;ChEMBL;369,2;4;0;3;3,05;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
CHEMBL69584;206455;None;11;Human;Binding;Ki;=;690,00;6,16;-436;2;Binding affinity at human Dopamine receptor D2 by [3H]- YM 09151 displacement.;ChEMBL;369,2;4;0;3;3,05;O=C(CN1CCN(Cc2ccc(Cl)cc2)CC1)N1CCc2ccccc21;https://dx.doi.org/10.1016/s0960-894x(00)00421-2
CHEMBL69706;206475;None;0;Human;Binding;Ki;=;152,00;6,82;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;315,2;6;0;3;4,53;CCCN(Cc1cccs1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL69706;206475;None;0;Human;Binding;Ki;=;339,00;6,47;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;315,2;6;0;3;4,53;CCCN(Cc1cccs1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL69717;206478;None;6;Human;Binding;Ki;=;120,00;6,92;-29;5;Binding affinity at human dopamine receptor D2;ChEMBL;431,1;6;0;4;4,19;O=C1c2ccccc2C(=O)N1CCCCN1CCN(c2cccc(Cl)c2Cl)CC1;https://dx.doi.org/10.1021/jm010146o
CHEMBL69985;206513;None;0;Human;Binding;Ki;=;201,00;6,70;-8;3;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;249,2;5;0;1;3,81;CCCN(CCC)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL69985;206513;None;0;Human;Binding;Ki;=;26,00;7,58;-8;3;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;249,2;5;0;1;3,81;CCCN(CCC)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1021/jm960350p
CHEMBL69985;206513;None;0;Human;Binding;Ki;=;26,00;7,58;-8;3;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;249,2;5;0;1;3,81;CCCN(CCC)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL69985;206513;None;0;Human;Binding;Ki;=;201,00;6,70;-8;3;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;249,2;5;0;1;3,81;CCCN(CCC)[C@@H]1CCc2c(F)cccc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL70215;206553;None;0;Human;Binding;Ki;=;2000,00;5,70;-95;3;Displacement of [3H]spiperone from human dopamine D2 receptor in CHO cells;ChEMBL;374;3;0;3;5,89;Clc1ccc(CN2CC=C(c3nc4cc(Cl)ccc4s3)CC2)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00402-2
CHEMBL70267;206562;None;2;Human;Binding;Ki;=;240,00;6,62;-2;3;Displacement of [3H]spiperone from human dopamine D2 receptor in CHO cells;ChEMBL;290,1;3;0;3;4,12;C1=C(c2nc3ccccc3o2)CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/S0960-894X(97)00402-2
CHEMBL70319;206572;None;12;Human;Binding;IC50;=;30,00;7,52;-;7;Binding affinity towards human Dopamine receptor D2;ChEMBL;474,1;2;1;7;3,95;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccc(OS(=O)(=O)C(F)(F)F)cc32)CC1;https://dx.doi.org/10.1021/jm991005d
CHEMBL70565;206612;None;20;Human;Binding;Ki;=;43,00;7,37;-18;10;Displacement of [3H]spiperone from human D2 receptor transfected in HEK293 cell membrane measured after 50 mins by competitive radioligand binding analysis;ChEMBL;249,1;2;1;4;1,94;CCCN1CCO[C@@H]2c3cc(O)ccc3OC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2021.128269
CHEMBL70565;206612;None;20;Human;Binding;Ki;=;1180,00;5,93;-18;10;Tested for antagonist binding affinity by measuring displacement of [3H]spiperone from Human Dopamine receptor D2L expressed in CHO K-1 cells;ChEMBL;249,1;2;1;4;1,94;CCCN1CCO[C@@H]2c3cc(O)ccc3OC[C@H]21;https://dx.doi.org/10.1021/jm0000113
CHEMBL70565;206612;None;20;Human;Binding;Ki;=;28,00;7,55;-18;10;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cells after 90 mins by microbeta counting based assay;ChEMBL;249,1;2;1;4;1,94;CCCN1CCO[C@@H]2c3cc(O)ccc3OC[C@H]21;https://dx.doi.org/10.1021/acsmedchemlett.9b00660
CHEMBL70866;206664;None;0;Human;Binding;Ki;=;100,00;7,00;-31;3;Binding affinity towards mouse LtK- cells transfected with human D2 receptor using [3H]spiperone;ChEMBL;475,1;9;1;5;3,80;COc1ccc(OC)c(N2CCN(CCCCNC(=O)c3ccc(Br)cc3)CC2)c1;https://dx.doi.org/10.1016/0960-894X(95)00011-H
CHEMBL71173;206721;None;7;Human;Binding;Ki;=;1400,00;5,85;-15;3;Displacement of [3H]spiperone from human dopamine D2 receptor in CHO cells;ChEMBL;289,2;3;1;2;3,85;C1=C(c2nc3ccccc3[nH]2)CCN(Cc2ccccc2)C1;https://dx.doi.org/10.1016/S0960-894X(97)00402-2
CHEMBL71216;206726;None;0;Human;Binding;Ki;=;330,00;6,48;-33;3;Displacement of [3H]spiperone from human dopamine D2 receptor in CHO cells;ChEMBL;357,1;3;1;2;5,16;Clc1ccc(CN2CC=C(c3nc4cc(Cl)ccc4[nH]3)CC2)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00402-2
CHEMBL71275;206738;None;9;Human;Binding;Ki;=;82,30;7,08;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;219,2;4;1;2;2,55;CCCN[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL71275;206738;None;9;Human;Binding;Ki;=;114,00;6,94;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;219,2;4;1;2;2,55;CCCN[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL71324;206748;None;2;Human;Binding;Ki;=;590,00;6,23;-22;3;Displacement of [3H]spiperone from human dopamine D2 receptor in CHO cells;ChEMBL;323,1;3;1;2;4,51;Clc1ccc2[nH]c(C3=CCN(Cc4ccccc4)CC3)nc2c1;https://dx.doi.org/10.1016/S0960-894X(97)00402-2
CHEMBL71327;206749;None;0;Human;Binding;Ki;=;2,90;8,54;-6;4;Binding affinity for human dopamine D2 receptor;ChEMBL;403,1;6;1;3;4,10;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm049465g
CHEMBL71327;206749;None;0;Human;Binding;Ki;=;23,40;7,63;-6;4;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;403,1;6;1;3;4,10;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL71327;206749;None;0;Human;Binding;Ki;=;2,90;8,54;-6;4;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;403,1;6;1;3;4,10;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL71599;206801;None;0;Human;Binding;Ki;=;69,70;7,16;-;1;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;327,2;6;0;2;4,60;CCCN(Cc1ccc(F)cc1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL71599;206801;None;0;Human;Binding;Ki;=;43,80;7,36;-;1;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;327,2;6;0;2;4,60;CCCN(Cc1ccc(F)cc1)[C@@H]1CCc2c(cccc2OC)C1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
CHEMBL71635;206808;None;0;Human;Binding;Ki;=;325,00;6,49;-85;5;The compound was tested for CNS binding affinity towards Dopamine receptor D2 from cloned Human membranes.;ChEMBL;395,2;6;1;5;2,62;COc1ccc(N2CCN(CC[C@@H]3OCCc4cc(C(N)=O)ccc43)CC2)cc1;https://dx.doi.org/10.1021/jm980137o
CHEMBL71707;206819;None;0;Human;Binding;Ki;=;1258,93;5,90;-31;7;Binding affinity relative to indolopiperidine (compound 1) for Dopamine receptor D2 was determined;ChEMBL;551,2;6;3;3;7,28;O=C(/C=C/c1ccc(Cl)c(Cl)c1)N[C@H]1CC[C@@H](CN2[C@H]3CC[C@@H]2C[C@@H](c2c[nH]c4ccc(O)cc24)C3)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00397-3
CHEMBL71724;206823;None;0;Human;Binding;Ki;=;1431,00;5,84;-1023;10;The compound was tested for CNS binding affinity towards Dopamine receptor D2 from cloned Human membranes.;ChEMBL;352,2;5;0;4;3,52;COc1ccc(N2CCN(CCC3OCCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/jm980137o
CHEMBL71798;206838;None;4;Human;Binding;Ki;=;158,00;6,80;1;3;The compound was tested for CNS binding affinity towards Dopamine receptor D2 from cloned Human membranes.;ChEMBL;409,2;6;1;5;2,88;CNC(=O)c1ccc2c(c1)CCO[C@@H]2CCN1CCN(c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1021/jm980137o
CHEMBL71865;206845;None;0;Human;Binding;Ki;=;15,20;7,82;-6;4;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;403,1;6;1;3;4,10;O=C(NC/C=C\CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL71865;206845;None;0;Human;Binding;Ki;=;2,50;8,60;-6;4;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;403,1;6;1;3;4,10;O=C(NC/C=C\CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccccc1;https://dx.doi.org/10.1021/jm040190e
CHEMBL71894;206846;None;0;Human;Binding;Ki;=;398,11;6,40;-63;3;Binding affinity towards mouse LtK- cells transfected with human D2 receptor using [3H]spiperone;ChEMBL;415,1;7;1;3;3,78;O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc(Br)cc1;https://dx.doi.org/10.1016/0960-894X(95)00011-H
CHEMBL71907;206850;None;0;Human;Binding;Ki;=;386,00;6,41;-1;4;The compound was tested for CNS binding affinity towards Dopamine receptor D2 from cloned Human membranes.;ChEMBL;395,2;6;1;5;2,62;COc1ccc(N2CCN(CC[C@H]3OCCc4cc(C(N)=O)ccc43)CC2)cc1;https://dx.doi.org/10.1021/jm980137o
CHEMBL71960;206860;None;0;Human;Binding;Ki;=;39,81;7,40;-79;5;Binding affinity towards mouse LtK- cells transfected with human D2 receptor using [3H]spiperone;ChEMBL;445,1;8;1;4;3,79;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(Br)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(95)00011-H
CHEMBL72292;206921;None;15;Human;Binding;IC50;=;140,00;6,85;-;8;Binding affinity towards human Dopamine receptor D2;ChEMBL;440,1;2;1;7;3,30;CN1CCN(C2=Nc3ccccc3Nc3ccc(OS(=O)(=O)C(F)(F)F)cc32)CC1;https://dx.doi.org/10.1021/jm991005d
CHEMBL73538;207096;None;42;Human;Binding;Ki;=;2500,00;5,60;-30;4;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;292,2;0;1;4;3,07;CN1CCN(C2=Nc3ccccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL73589;207103;None;0;Human;Binding;IC50;=;23,00;7,64;-;7;Binding affinity towards human Dopamine receptor D2;ChEMBL;457,1;2;0;7;3,71;CN1CCN(C2=Nc3ccccc3Sc3ccc(OS(=O)(=O)C(F)(F)F)cc32)CC1;https://dx.doi.org/10.1021/jm991005d
CHEMBL73665;207115;None;0;Human;Binding;Ki;=;19,95;7,70;-99;4;Binding affinity towards mouse LtK- cells transfected with human D2 receptor using [3H]spiperone;ChEMBL;458,3;9;2;5;4,28;COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(-c3ccc(N)cc3)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(95)00011-H
CHEMBL7393;207145;3H-YM 09151-2;19;Human;Binding;pKi;=;345,50;6,46;-8;26;-;PDSP KiDatabase;219,2;3;1;2;2,98;CCCN1CCC[C@H](c2cccc(O)c2)C1;-
CHEMBL7393;207145;3H-NMSP;19;Human;Binding;pKi;=;2161,00;5,67;-8;26;-;PDSP KiDatabase;219,2;3;1;2;2,98;CCCN1CCC[C@H](c2cccc(O)c2)C1;-
CHEMBL7430;207187;None;0;Human;Binding;Ki;=;560,00;6,25;-186;3;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;323,1;1;0;1;5,13;CN1CCC(C2=Cc3cc(Cl)ccc3Cc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL74805;207234;None;0;Human;Binding;Ki;=;2,90;8,54;7;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;404,2;4;1;6;4,06;Oc1nc2cccc(N3CCN(Cc4ccnc(-c5ccc(F)cc5)c4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL75621;207313;None;0;Human;Binding;Ki;=;2,20;8,66;14;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;391,1;4;1;6;4,58;Oc1nc2cccc(N3CCN(Cc4cccc(-c5cccs5)c4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL75860;207344;None;0;Human;Binding;Ki;=;620,00;6,21;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;397,2;8;0;2;6,05;C(COCC1CCN(Cc2ccccc2)CC1)=C(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL76090;207368;None;0;Human;Binding;Ki;=;125,00;6,90;-13;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;351,1;4;1;2;5,11;Clc1ccc(-c2cc(C3CCN(Cc4ccccc4)CC3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL7617;207379;None;0;Human;Binding;Ki;=;1,00;9,00;1;4;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;324,1;1;0;2;3,99;CN1CCN(C2=Cc3ccccc3Cc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL76237;207382;None;20;Human;Binding;Ki;=;210,00;6,68;-104;10;Binding affinity against dopamine receptor D2 using [3H]spiperone radioligand in CHO cells;ChEMBL;358,1;6;0;5;2,99;COc1ccc2c(c1)c(CCN(C)C)cn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1021/jm010943m
CHEMBL76355;207395;None;0;Human;Binding;Ki;=;120,00;6,92;-1;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;337,1;4;1;2;4,72;Clc1ccc(-c2cc(C3CCN(Cc4ccccc4)C3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL76402;207401;None;1;Human;Binding;Ki;=;1,60;8,80;-15;5;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;386,1;6;2;5;2,39;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Br)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL76402;207401;None;1;Human;Binding;Ki;=;0,65;9,19;-15;5;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;386,1;6;2;5;2,39;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Br)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
CHEMBL76908;207477;None;0;Human;Binding;Ki;=;10,00;8,00;2;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;479,2;6;1;4;5,86;Cc1ccc(C(=O)N[C@H]2CC[C@H](CCN3CCN(c4cccc(Cl)c4Cl)CC3)CC2)s1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL76927;207479;None;0;Human;Binding;Ki;=;1837,00;5,74;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;365,2;7;0;2;4,54;Fc1ccc(CCN2CCC(CCOCC#Cc3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL76990;207487;None;0;Human;Binding;Ki;=;1,80;8,74;4;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;386,2;4;1;6;3,92;Oc1nc2cccc(N3CCN(Cc4cncc(-c5ccccc5)c4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL77015;207492;None;1;Human;Binding;Ki;=;650,00;6,19;-1;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;255,2;3;1;2;3,10;Cc1cc(C2CCN(Cc3ccccc3)CC2)[nH]n1;https://dx.doi.org/10.1021/jm970111h
CHEMBL77017;207493;None;0;Human;Binding;Ki;=;560,00;6,25;-5;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;379,2;6;1;2;5,54;Clc1ccc(-c2cc(C3CCN(CCCc4ccccc4)CC3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL77148;207510;None;0;Human;Binding;Ki;=;310,00;6,51;-1;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;331,2;5;1;2;4,38;c1ccc(Cc2cc(C3CCN(Cc4ccccc4)CC3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL77206;207517;None;0;Human;Binding;Ki;=;241,00;6,62;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;335,2;8;0;2;4,67;C(=C/c1ccccc1)\COCC1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL77334;207532;None;0;Human;Binding;Ki;=;12,00;7,92;3;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;403,2;4;1;5;4,66;Oc1nc2cccc(N3CCN(Cc4cc(-c5ccccc5)ccc4F)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL77411;207537;None;0;Human;Binding;Ki;=;339,00;6,47;-15;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;517,3;6;1;3;6,40;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)C12CC3CC(CC(C3)C1)C2;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL77472;207544;None;0;Human;Binding;Ki;=;1,70;8,77;-1;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;386,2;4;0;4;4,45;c1ccc(-c2cccc(CN3CCN(c4cccc5c4OCCO5)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL77563;207550;None;0;Human;Binding;EC50;=;7,20;8,14;-;2;Agonist activity at human D2R expressed in HEK293 cells incubated for 3 mins by FLIPR analysis;ChEMBL;326,1;3;1;3;3,54;Clc1ccccc1N1CCN(Cc2nc3ccccc3[nH]2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL77743;207569;None;0;Human;Binding;Ki;=;65,00;7,19;-3;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;337,2;5;1;3;4,56;c1ccc(CCN2CCC(c3cc(-c4cccs4)[nH]n3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL77744;207570;None;0;Human;Binding;Ki;=;61,00;7,21;-6;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;337,3;5;1;2;4,88;c1ccc(CCN2CCC(c3cc(C4CCCCC4)n[nH]3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL77934;207586;None;0;Human;Binding;Ki;=;18,00;7,75;2;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;419,1;4;1;5;5,18;Oc1nc2cccc(N3CCN(Cc4cccc(-c5cccc(Cl)c5)c4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL78058;207598;None;0;Human;Binding;Ki;=;4,60;8,34;1;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;384,2;5;2;6;2,22;O=C(NCCN1CCN(c2cccc3nc(O)oc23)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL7806;207599;None;8;Human;Binding;Ki;=;24,00;7,62;-1;4;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1ccsc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL7806;207599;None;8;Human;Binding;Ki;=;0,14;9,85;-1;4;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1ccsc1)C1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
CHEMBL78067;207601;None;0;Human;Binding;Ki;=;131,00;6,88;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;347,2;7;0;2;4,40;C(#Cc1ccccc1)COCCC1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL78195;207621;None;0;Human;Binding;Ki;=;12,00;7,92;-2;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;479,2;6;1;3;6,15;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)C1CCCCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78241;207627;None;0;Human;Binding;Ki;=;10,00;8,00;1;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;372,2;4;0;4;4,40;c1ccc(-c2cccc(CN3CCN(c4cccc5c4OCO5)CC3)c2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL78287;207634;None;0;Human;Binding;Ki;=;570,00;6,24;-9;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;385,1;4;1;2;5,76;Clc1ccc(-c2cc(C3CCN(Cc4cccc(Cl)c4)CC3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL78368;207645;None;0;Human;Binding;Ki;=;6,50;8,19;-3;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;431,2;6;1;4;4,90;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78406;207651;None;0;Human;Binding;Ki;=;71,00;7,15;-16;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;398,2;6;1;5;3,64;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccccn3)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78617;207673;None;0;Human;Binding;Ki;=;1,70;8,77;2;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;451,2;6;1;3;5,37;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)C1CCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78655;207678;None;0;Human;Binding;Ki;=;18,00;7,75;-9;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;465,1;6;1;4;5,56;O=C(NC1CCC(CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78791;207697;None;0;Human;Binding;Ki;=;3,40;8,47;-4;3;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;397,2;6;1;4;4,25;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccccc3)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78791;207697;None;0;Human;Binding;Ki;=;3,40;8,47;-4;3;Binding affinity determined by measuring its ability to displace [3H]N-0437 radioligand in CHO-K1 cells on Cloned Human Dopamine receptor D2;ChEMBL;397,2;6;1;4;4,25;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccccc3)CC2)CC1)c1cccs1;https://dx.doi.org/10.1021/jm9707378
CHEMBL78800;207699;None;0;Human;Binding;Ki;=;1,00;9,00;-1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;431,2;6;1;4;4,90;O=C(N[C@H]1CC[C@H](CCN2CCN(c3ccccc3Cl)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78860;207706;None;0;Human;Binding;Ki;=;182,00;6,74;-2;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;507,3;8;0;3;6,88;CCCN(C(=O)C1CCCCC1)[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78916;207712;None;0;Human;Binding;Ki;=;10,00;8,00;-3;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;329,2;5;1;3;2,89;CC(=O)N[C@H]1CC[C@H](CCN2CCN(c3ccccc3)CC2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL78923;207713;None;0;Human;Binding;Ki;=;8,60;8,07;-8;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;378,2;4;1;4;4,76;Nc1nc(-c2ccc(Cl)cc2)cc(C2CCN(Cc3ccccc3)CC2)n1;https://dx.doi.org/10.1021/jm970111h
CHEMBL78933;207716;None;1;Human;Binding;Ki;=;35,00;7,46;-22;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;379,2;5;1;2;5,67;CCc1c(C2CCN(Cc3ccccc3)CC2)n[nH]c1-c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL78950;207720;None;0;Human;Binding;Ki;=;1,40;8,85;-2;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;427,2;7;1;5;4,26;COc1ccccc1N1CCN(CC[C@H]2CC[C@H](NC(=O)c3cccs3)CC2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL79098;207741;None;0;Human;Binding;Ki;=;1300,00;5,89;-24;2;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;332,2;5;1;3;3,89;c1ccc(CCN2CCC(c3cc(-c4ccncc4)[nH]n3)CC2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL80156;207873;None;0;Human;Binding;Ki;=;6,00;8,22;3;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;410,2;4;1;6;4,39;N#Cc1cccc(-c2cccc(CN3CCN(c4cccc5nc(O)oc45)CC3)c2)c1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL80207;207884;None;0;Human;Binding;Ki;=;240,00;6,62;-5;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;365,2;4;1;2;5,28;CC1(c2cc(-c3ccc(Cl)cc3)[nH]n2)CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm970111h
CHEMBL80230;207889;None;0;Human;Binding;Ki;=;0,41;9,39;18;2;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;401,2;4;2;6;4,23;Oc1nc2cccc(N3CCN(Cc4ccc(O)c(-c5ccccc5)c4)CC3)c2o1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
CHEMBL80315;207898;None;0;Human;Binding;Ki;=;16,50;7,78;-3;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;479,2;6;0;4;5,90;CN(C(=O)c1cccs1)[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL80318;207900;None;0;Human;Binding;Ki;=;90,00;7,05;-28;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;343,2;5;1;2;4,72;Cc1c(-c2ccccc2)n[nH]c1C1=CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm970111h
CHEMBL80571;207942;None;0;Human;Binding;Ki;=;100,00;7,00;-50;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;397,3;6;1;3;4,45;O=C(NC1CCC(CCN2CCN(c3ccccc3)CC2)CC1)C1CCCCC1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL80615;207948;None;0;Human;Binding;Ki;=;5,60;8,25;-1;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;425,3;6;1;3;5,07;Cc1ccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)C4CCCCC4)CC3)CC2)cc1C;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL80656;207954;None;2;Human;Binding;Ki;=;554,00;6,26;-;2;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;323,2;8;0;2;4,55;c1ccc(CCCOCC2CCN(Cc3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL80833;207976;None;0;Human;Binding;Ki;=;960,00;6,02;-3;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;351,1;4;1;2;5,11;Clc1ccc(-c2cc(C3CCCN(Cc4ccccc4)C3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL80845;207977;None;0;Human;Binding;Ki;=;230,00;6,64;-10;5;Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D2 long (high/low affinity is given as 230/53000);ChEMBL;215,1;2;0;3;2,10;CCCN1CCc2nn3ccccc3c2C1;https://dx.doi.org/10.1016/s0960-894x(02)00390-6
CHEMBL80845;207977;None;0;Human;Binding;Ki;=;130,00;6,89;-10;5;Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D2 short (high/low affinity is given as 130/50000);ChEMBL;215,1;2;0;3;2,10;CCCN1CCc2nn3ccccc3c2C1;https://dx.doi.org/10.1016/s0960-894x(02)00390-6
CHEMBL80863;207981;None;0;Human;Binding;Ki;=;3400,00;5,47;-1;3;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;351,1;4;1;2;5,46;Clc1ccc(-c2cc(C3CCCCN3Cc3ccccc3)[nH]n2)cc1;https://dx.doi.org/10.1021/jm970111h
CHEMBL80875;207982;None;0;Human;Binding;Ki;=;6,30;8,20;-2;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;411,2;6;1;4;4,56;Cc1cccc(N2CCN(CC[C@H]3CC[C@H](NC(=O)c4cccs4)CC3)CC2)c1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL80919;207986;None;0;Human;Binding;Ki;=;0,60;9,22;-30;2;Ability to displace radioligand [3H]N-0437 from human dopamine D2 receptor transfected chinese hamster ovary cell membranes.;ChEMBL;465,1;6;1;4;5,56;O=C(N[C@H]1CC[C@H](CCN2CCN(c3cccc(Cl)c3Cl)CC2)CC1)c1cccs1;https://dx.doi.org/10.1016/S0960-894X(97)00443-5
CHEMBL80968;207994;None;0;Human;Binding;Ki;=;2183,00;5,66;-;1;Binding affinity towards Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;339,2;7;0;2;4,77;Fc1ccc(/C=C/COCC2CCN(Cc3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(94)85038-0
CHEMBL81330;208031;None;3;Human;Binding;Ki;=;199,00;6,70;-66;12;Inhibition of human dopamine D2 receptor;ChEMBL;340,2;4;0;3;3,65;Fc1ccc(N2CCN(CCC3OCCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
CHEMBL81330;208031;None;3;Human;Binding;Ki;=;199,00;6,70;-66;12;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;340,2;4;0;3;3,65;Fc1ccc(N2CCN(CCC3OCCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
CHEMBL81485;208051;None;0;Human;Binding;IC50;=;1698,24;5,77;-;9;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;280,2;2;1;3;3,06;CNCC1CC2c3ccccc3Cc3ccccc3N2O1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
CHEMBL81675;208075;None;0;Human;Binding;Ki;=;68,00;7,17;-1;5;Binding affinity to human dopamine D2 receptor;ChEMBL;205,1;3;1;2;2,59;CCCN1CCC(c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
CHEMBL82527;208178;None;0;Human;Binding;Ki;=;1100,00;5,96;1;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;337,2;4;0;4;3,37;c1ccc(C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CS2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL82527;208178;None;0;Human;Binding;Ki;=;1100,00;5,96;1;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;337,2;4;0;4;3,37;c1ccc(C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CS2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL82527;208178;None;0;Human;Binding;Ki;=;720,00;6,14;1;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;337,2;4;0;4;3,37;c1ccc(C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CS2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL82527;208178;None;0;Human;Binding;Ki;=;1500,00;5,82;1;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;337,2;4;0;4;3,37;c1ccc(C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CS2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL82864;208222;None;0;Human;Binding;Ki;=;316,23;6,50;-19;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;440,3;5;2;3;4,82;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cc4ccccc4[nH]3)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL83306;208277;None;0;Human;Binding;Ki;=;3200,00;5,50;-2;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;335,2;4;0;4;3,04;C[C@@H]1OC(c2ccccc2)=N[C@H]1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL83306;208277;None;0;Human;Binding;Ki;=;1900,00;5,72;-2;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;335,2;4;0;4;3,04;C[C@@H]1OC(c2ccccc2)=N[C@H]1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL83306;208277;None;0;Human;Binding;Ki;=;820,00;6,09;-2;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;335,2;4;0;4;3,04;C[C@@H]1OC(c2ccccc2)=N[C@H]1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL83306;208277;None;0;Human;Binding;Ki;=;320,00;6,50;-2;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;335,2;4;0;4;3,04;C[C@@H]1OC(c2ccccc2)=N[C@H]1CN1CCN(c2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL83617;208306;None;0;Human;Binding;Ki;=;4,70;8,33;2;4;Inhibition constant against dopamine receptor D2;ChEMBL;419,2;5;2;3;4,20;NC(=O)c1ccc2c(c1)CCOC2CCN1CC=C(c2c[nH]c3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm058225d
CHEMBL83658;208308;None;0;Human;Binding;IC50;=;870,96;6,06;-;13;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;294,2;2;0;3;3,40;CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
CHEMBL83658;208308;None;0;Human;Binding;IC50;=;870,96;6,06;-;13;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;294,2;2;0;3;3,40;CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
CHEMBL83658;208308;None;0;Human;Binding;IC50;=;870,96;6,06;-;13;Binding affinity against Dopamine receptor D2L;ChEMBL;294,2;2;0;3;3,40;CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1;https://dx.doi.org/10.1016/s0960-894x(02)00796-5
CHEMBL83722;208315;None;0;Human;Binding;Ki;=;3945,00;5,40;-14;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;876,5;18;0;10;10,16;C(=C/Cn1c(-c2ccc(OCCCN3CCN(c4ccccc4)CC3)cc2)nc2ccccc21)\Cn1c(-c2ccc(OCCCN3CCN(c4ccccc4)CC3)cc2)nc2ccccc21;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL84819;208452;None;0;Human;Binding;Ki;=;1403,00;5,85;-9;2;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;446,2;7;1;4;5,47;Clc1cccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)c1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL84819;208452;None;0;Human;Binding;Ki;=;1403,00;5,85;-9;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;446,2;7;1;4;5,47;Clc1cccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)c1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL84931;208467;None;0;Human;Binding;IC50;=;36,31;7,44;-;11;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;312,2;2;0;3;3,54;CN(C)CC1CC2c3ccccc3Cc3ccc(F)cc3N2O1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
CHEMBL85441;208526;None;0;Human;Binding;Ki;=;406,00;6,39;-269;2;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;412,2;7;1;4;4,82;c1ccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL85441;208526;None;0;Human;Binding;Ki;=;406,00;6,39;-269;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;412,2;7;1;4;4,82;c1ccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)cc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL85711;208561;None;0;Human;Binding;Ki;=;1258,93;5,90;-63;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;451,3;5;1;3;5,49;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cccc4ccccc34)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL85735;208566;None;0;Human;Binding;IC50;=;54,95;7,26;-;5;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;308,2;2;0;3;3,71;Cc1ccc2c(c1)N1OC(CN(C)C)CC1c1ccccc1C2;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
CHEMBL85882;208578;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-6918;3;-;PDSP KiDatabase;287;1;1;1;3,44;NCC1c2ccccc2Cc2cc(Br)ccc21;-
CHEMBL85972;208588;None;0;Human;Binding;Ki;=;269,00;6,57;-17;2;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;414,2;7;1;6;3,61;c1cnc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)nc1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL85972;208588;None;0;Human;Binding;Ki;=;269,00;6,57;-17;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;414,2;7;1;6;3,61;c1cnc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)nc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL86032;208597;None;0;Human;Binding;Ki;=;794,33;6,10;-125;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;472,2;5;2;5;3,67;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccc4c(c3)NC(=O)CO4)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL86060;208599;None;0;Human;Binding;Ki;=;1100,00;5,96;-2;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;321,2;4;0;4;2,65;c1ccc(C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CO2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL86060;208599;None;0;Human;Binding;Ki;=;1700,00;5,77;-2;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;321,2;4;0;4;2,65;c1ccc(C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CO2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL86060;208599;None;0;Human;Binding;Ki;=;330,00;6,48;-2;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells;ChEMBL;321,2;4;0;4;2,65;c1ccc(C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CO2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL86060;208599;None;0;Human;Binding;Ki;=;690,00;6,16;-2;4;In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells;ChEMBL;321,2;4;0;4;2,65;c1ccc(C2=N[C@@H](CN3CCN(c4ccccc4)CC3)CO2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
CHEMBL86127;208606;None;0;Human;Binding;Ki;=;1995,26;5,70;-158;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;452,3;5;1;4;4,89;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3cccc4ncccc34)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL86129;208607;None;0;Human;Binding;Ki;=;517,00;6,29;-51;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;722,4;16;0;8;9,49;C(=C/Cn1c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc21)\Cn1c(-c2ccc(OCCCN3CCCCC3)cc2)nc2ccccc21;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL86183;208612;None;0;Human;Binding;Ki;=;501,19;6,30;-125;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;502,3;7;2;4;4,83;CC(=O)Nc1cccc(/C=C/C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(C#N)cc4CC3)CC2)c1F;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL86249;208619;None;0;Human;Binding;Ki;=;803,00;6,09;-42;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;787,5;19;0;9;9,68;CCN(CC)CCCOc1ccc(-c2nc3ccccc3n2C/C=C/Cn2c(-c3ccc(OCCCN4CCN(c5ccccc5)CC4)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL86402;208643;None;0;Human;Binding;Ki;=;3162,28;5,50;-158;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;451,3;5;1;3;5,49;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccc4ccccc4c3)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL86504;208662;None;0;Human;Binding;Ki;=;32,40;7,49;-11;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;369,1;6;2;3;4,40;FC(F)(F)c1nc2c(OCCNCc3ccccc3)cc(Cl)cc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL86760;208701;None;0;Human;Binding;Ki;=;6280,00;5,20;-891;3;Displacement of [3H]spiperone from dopamine D2 receptor;ChEMBL;293,2;6;1;1;4,80;CCCCCCc1ccc2c(c1)Cc1ccccc1C2CN;https://dx.doi.org/10.1021/jm800771x
CHEMBL86760;208701;UNDEFINED;0;Human;Binding;pKi;=;6280,00;5,20;-891;3;-;PDSP KiDatabase;293,2;6;1;1;4,80;CCCCCCc1ccc2c(c1)Cc1ccccc1C2CN;-
CHEMBL87067;208756;None;0;Human;Binding;Ki;=;15,20;7,82;-1;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;281,2;6;2;3;3,04;Cc1nc2c(OCCNCc3ccccc3)cccc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL87137;208768;None;0;Human;Binding;Ki;=;79,80;7,10;-12;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;267,1;6;2;3;2,73;c1ccc(CNCCOc2cccc3[nH]ncc23)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL87187;208774;None;0;Human;Binding;Ki;=;11,00;7,96;-3;3;Binding ability of compound to human Dopamine receptor D2;ChEMBL;409,2;5;1;5;4,24;Nc1cccc(-c2ccc(CCN3CCN(c4cccc5cccnc45)CC3)cc2)n1;https://dx.doi.org/10.1016/s0960-894x(99)00432-1
CHEMBL87192;208775;None;0;Human;Binding;Ki;=;1,75;8,76;-2;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;335,1;6;2;3;3,75;FC(F)(F)c1nc2c(OCCNCc3ccccc3)cccc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL87260;208784;None;0;Human;Binding;Ki;=;865,00;6,06;-32;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;446,2;7;1;4;5,47;Clc1ccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)cc1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL87260;208784;None;0;Human;Binding;Ki;=;865,00;6,06;-32;2;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;446,2;7;1;4;5,47;Clc1ccc(N2CCN(CCCOc3ccc(-c4nc5ccccc5[nH]4)cc3)CC2)cc1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL87478;208821;None;0;Human;Binding;Ki;=;8,00;8,10;-6;2;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;486,2;10;1;5;6,32;CCCSc1ccccc1N1CCN(CCCOc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL87478;208821;None;0;Human;Binding;Ki;=;8,00;8,10;-6;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;486,2;10;1;5;6,32;CCCSc1ccccc1N1CCN(CCCOc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL87600;208837;None;0;Human;Binding;Ki;=;630,96;6,20;-199;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;457,3;7;1;4;4,75;COc1cccc(/C=C/C(=O)N[C@H]2CC[C@H](CCN3CCc4ccc(C#N)cc4CC3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL87625;208841;None;0;Human;Binding;Ki;=;4985,00;5,30;-34;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;642,4;16;0;8;7,64;CN(C)CCCOc1ccc(-c2nc3ccccc3n2C/C=C/Cn2c(-c3ccc(OCCCN(C)C)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL87716;208854;None;0;Human;Binding;Ki;=;472,00;6,33;-58;2;Binding affinity towards human cloned Dopamine D2 receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;810,6;28;0;8;12,32;CCCCN(CCCC)CCCOc1ccc(-c2nc3ccccc3n2C/C=C/Cn2c(-c3ccc(OCCCN(CCCC)CCCC)cc3)nc3ccccc32)cc1;https://dx.doi.org/10.1016/0960-894X(95)00446-Z
CHEMBL87753;208859;None;0;Human;Binding;Ki;=;501,19;6,30;-50;2;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;468,3;5;2;5;4,59;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccc4ccc(O)nc4c3)CC1)CC2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
CHEMBL88058;208906;None;0;Human;Binding;Ki;=;126,00;6,90;-7;2;Binding affinity towards cloned human Dopamine D2 receptor in CHO cells using [3H]spiperone as radioligand;ChEMBL;446,2;7;1;4;5,47;Clc1ccccc1N1CCN(CCCOc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1;https://dx.doi.org/10.1016/0960-894X(95)00447-2
CHEMBL88058;208906;None;0;Human;Binding;Ki;=;126,00;6,90;-7;2;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;446,2;7;1;4;5,47;Clc1ccccc1N1CCN(CCCOc2ccc(-c3nc4ccccc4[nH]3)cc2)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
CHEMBL88289;208951;None;0;Human;Binding;Ki;=;4,10;8,39;-3;4;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;360,2;3;1;3;3,90;FC(F)(F)c1nc2c(N3CCN(Cc4ccccc4)CC3)cccc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL88365;208963;None;0;Human;Binding;Ki;=;4,60;8,34;-1;3;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;268,2;3;1;3;2,71;Oc1cccc(N2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm901689v
CHEMBL88365;208963;None;0;Human;Binding;Ki;=;246,00;6,61;-1;3;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;268,2;3;1;3;2,71;Oc1cccc(N2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL88365;208963;None;0;Human;Binding;Ki;=;115,00;6,94;-1;3;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;268,2;3;1;3;2,71;Oc1cccc(N2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1021/jm901689v
CHEMBL88365;208963;None;0;Human;Binding;Ki;=;246,00;6,61;-1;3;Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone;ChEMBL;268,2;3;1;3;2,71;Oc1cccc(N2CCN(Cc3ccccc3)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00014-6
CHEMBL88365;208963;UNDEFINED;0;Human;Binding;pKi;=;4,60;8,34;-1;3;-;PDSP KiDatabase;268,2;3;1;3;2,71;Oc1cccc(N2CCN(Cc3ccccc3)CC2)c1;-
CHEMBL88365;208963;UNDEFINED;0;Human;Binding;pKi;=;115,00;6,94;-1;3;-;PDSP KiDatabase;268,2;3;1;3;2,71;Oc1cccc(N2CCN(Cc3ccccc3)CC2)c1;-
CHEMBL88464;208977;None;0;Human;Binding;Ki;=;8,70;8,06;-9;3;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;326,1;1;0;3;4,19;CN1CCN(C2=Cc3cc(Cl)ccc3Oc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL88837;209035;None;0;Human;Binding;Ki;=;257,50;6,59;-7;4;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;292,2;3;1;3;2,88;c1ccc(CN2CCN(c3cccc4[nH]cnc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL88870;209040;None;0;Human;Binding;Ki;=;290,00;6,54;-2;5;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;330,2;1;0;2;4,59;CC(C)=C1c2ccccc2C=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL88937;209052;None;0;Human;Binding;Ki;=;31000,00;4,51;-35;4;Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cccc4ccnn34)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
CHEMBL88937;209052;None;0;Human;Binding;Ki;=;67000,00;4,17;-35;4;Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cccc4ccnn34)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
CHEMBL88937;209052;None;0;Human;Binding;Ki;=;31000,00;4,51;-35;4;Binding affinity for human dopamine receptor D2 long;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cccc4ccnn34)CC2)cc1;https://dx.doi.org/10.1021/jm049612a
CHEMBL89037;209067;None;0;Human;Binding;Ki;=;6,50;8,19;-6;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;333,1;6;3;4;3,67;Sc1nc2c(OCCNCc3ccccc3)cc(Cl)cc2[nH]1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL89420;209126;None;0;Human;Binding;Ki;=;85,60;7,07;-2;4;Inhibition of [3H]spiperone binding to human Dopamine receptor D2 in CHO cell membranes;ChEMBL;267,1;6;2;3;2,73;c1ccc(CNCCOc2cccc3[nH]cnc23)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00434-5
CHEMBL89719;209163;None;0;Human;Binding;Ki;=;730,00;6,14;-2;3;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;301,2;1;0;1;4,95;C[C@H]1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL89921;209190;None;0;Human;Binding;Ki;=;1170,00;5,93;-107;2;Binding affinity to human D2 receptor assessed as inhibition constant;ChEMBL;339,1;2;0;3;4,31;Cc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccc(Cl)cc1)CC3;https://dx.doi.org/10.1016/j.ejmech.2020.113034
CHEMBL89921;209190;None;0;Human;Binding;Ki;=;1170,00;5,93;-107;2;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;339,1;2;0;3;4,31;Cc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccc(Cl)cc1)CC3;https://dx.doi.org/10.1021/jm970170v
CHEMBL89970;209202;None;3;Human;Binding;Ki;=;21,00;7,68;-10;3;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;292,2;1;0;3;3,54;CN1CCN(C2=Cc3ccccc3Oc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL89970;209202;None;3;Human;Binding;Ki;=;21,00;7,68;-10;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;292,2;1;0;3;3,54;CN1CCN(C2=Cc3ccccc3Oc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL89971;209203;None;0;Human;Binding;Ki;=;38,00;7,42;-34;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;381,2;4;1;4;5,05;Cc1c(-c2ccccc2Cl)nc(O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL90005;209206;None;0;Human;Binding;Ki;=;7,80;8,11;-7;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;353,2;4;1;5;4,46;Cc1c(-c2cccs2)nc(O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL90263;209247;None;0;Human;Binding;Ki;=;21,00;7,68;-114;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;318,2;4;1;1;5,25;C[C@@H]1CCCCN1CCc1c(-c2ccccc2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL90359;209263;None;0;Human;Binding;Ki;=;48,00;7,32;1;5;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;351,1;5;0;4;3,50;CCCN1CCC[C@@H](c2cccc(OS(=O)(=O)C(F)(F)F)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL90374;209265;None;0;Human;Binding;Ki;=;21000,00;4,68;-281;4;Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cccn4nccc34)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
CHEMBL90374;209265;None;0;Human;Binding;Ki;=;16000,00;4,80;-281;4;Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cccn4nccc34)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
CHEMBL90433;209278;None;0;Human;Binding;Ki;=;199,53;6,70;-398;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;462,2;10;2;5;5,17;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL90476;209288;None;0;Human;Binding;Ki;=;47,00;7,33;-18;4;Affinity towards human Dopamine receptor D2 expressed in CHO cells using [3H]spiperone;ChEMBL;369,1;3;1;2;4,25;Brc1ccc(N2CCN(Cc3ccccc3)CC2)c2cc[nH]c12;https://dx.doi.org/10.1016/s0960-894x(98)00474-0
CHEMBL90569;209306;None;0;Human;Binding;Ki;=;5500,00;5,26;-323;3;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;355,1;3;0;4;4,01;COc1ccc2c3c(c(=O)oc2c1)CN(Cc1cccc(Cl)c1)CC3;https://dx.doi.org/10.1021/jm970170v
CHEMBL90569;209306;None;0;Human;Binding;Ki;=;5500,00;5,26;-323;3;Binding affinity to human D2 receptor assessed as inhibition constant;ChEMBL;355,1;3;0;4;4,01;COc1ccc2c3c(c(=O)oc2c1)CN(Cc1cccc(Cl)c1)CC3;https://dx.doi.org/10.1016/j.ejmech.2020.113034
CHEMBL90654;209317;None;0;Human;Binding;Ki;=;640,00;6,19;-9;3;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;301,2;1;0;1;4,95;C[C@@H]1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL90662;209319;None;0;Human;Binding;Ki;=;1040,00;5,98;1;3;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;200,1;1;0;2;2,37;CN1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL90739;209339;None;0;Human;Binding;Ki;=;290,00;6,54;-72;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;318,2;4;1;1;5,25;C[C@H]1CCCCN1CCc1c(-c2ccccc2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL90746;209341;None;0;Human;Binding;Ki;=;125,89;6,90;-100;3;The compound's binding affinity against Dopamine receptor D2;ChEMBL;443,3;8;1;5;4,08;CN(C)C(=O)c1cccnc1NCCCN1CCN(c2ccccc2-c2ccccc2)CC1;https://dx.doi.org/10.1021/jm970166j
CHEMBL90798;209348;None;0;Human;Binding;Ki;=;235,00;6,63;2;3;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;214,1;2;0;2;2,76;CCN1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL90837;209354;None;0;Human;Binding;Ki;=;39,00;7,41;-275;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;323,2;6;1;3;4,24;CCN(C)CCc1c(-c2cccc([N+](=O)[O-])c2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL90882;209363;None;4;Human;Binding;Ki;=;2,50;8,60;-4;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;326,1;1;0;3;4,19;CN1CCN(C2=Cc3ccccc3Oc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm00004a016
CHEMBL90882;209363;None;4;Human;Binding;Ki;=;2,50;8,60;-4;3;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;326,1;1;0;3;4,19;CN1CCN(C2=Cc3ccccc3Oc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm00043a008
CHEMBL90897;209367;None;0;Human;Binding;Ki;=;1584,89;5,80;-63;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;485,3;11;1;5;4,99;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2nc(N(C)C)ncc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL90911;209368;None;0;Human;Binding;Ki;=;17,00;7,77;-131;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;346,2;5;1;1;5,35;CCN(C)CCc1c(-c2cccc(C(F)(F)F)c2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL90977;209375;None;0;Human;Binding;Ki;=;730,00;6,14;-10;4;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;316,2;1;0;2;4,20;C/C=C1/c2ccccc2C=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL91122;209395;None;0;Human;Binding;Ki;=;3000,00;5,52;-1;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;334,2;6;1;2;4,49;COC[C@H]1CCCN1CCc1c(-c2ccccc2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL91155;209404;None;0;Human;Binding;Ki;=;900,00;6,05;-1380;2;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;377,2;5;1;5;4,41;COc1cccc(CN2CCC(n3c(O)nc(-c4ccccc4)c3C)CC2)c1;https://dx.doi.org/10.1021/jm991029k
CHEMBL91156;209405;None;0;Human;Binding;Ki;=;501,19;6,30;-158;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;430,3;10;2;3;4,86;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2n[nH]cc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL91157;209406;None;0;Human;Binding;Ki;=;230,00;6,64;-758;7;Inhibition of [3H]spiperone binding to Dopamine receptor D2;ChEMBL;463,2;7;0;7;3,54;COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2;https://dx.doi.org/10.1021/jm049619s
CHEMBL91162;209407;None;0;Human;Binding;Ki;=;56,00;7,25;-93;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;347,2;4;1;4;4,40;Cc1c(-c2ccccc2)nc(O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL91197;209411;None;0;Human;Binding;Ki;=;150,00;6,82;-501;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;296,2;5;1;1;4,47;CCN(C)CCc1c(-c2ccccc2F)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL91205;209413;None;0;Human;Binding;Ki;=;900,00;6,05;-338;3;Ability to displace [3H]-spiperone from CHO cells expressing human Dopamine receptor D2 was determined;ChEMBL;304,2;4;1;1;4,86;c1ccc(-c2[nH]c3ccccc3c2CCN2CCCCC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00558-8
CHEMBL91205;209413;None;0;Human;Binding;Ki;=;896,00;6,05;-338;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;304,2;4;1;1;4,86;c1ccc(-c2[nH]c3ccccc3c2CCN2CCCCC2)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL91228;209415;None;0;Human;Binding;Ki;=;1178,00;5,93;-;1;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;224,1;2;0;2;2,37;C#CCN1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL91229;209416;None;0;Human;Binding;Ki;=;220,00;6,66;-389;2;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;361,2;5;1;4;4,44;Cc1c(-c2ccccc2)nc(O)n1C1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL91272;209421;None;1;Human;Binding;Ki;=;190,00;6,72;-1;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;310,2;4;2;3;2,87;O=C(Nc1ccccn1)NC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL91310;209432;None;0;Human;Binding;Ki;=;57,00;7,24;-12;5;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;302,2;1;0;2;3,81;C=C1c2ccccc2C=C(N2CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL91350;209438;None;0;Human;Binding;Ki;=;680,00;6,17;-7;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;301,2;1;0;1;4,95;CC1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00004a016
CHEMBL91350;209438;None;0;Human;Binding;Ki;=;680,00;6,17;-7;3;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;301,2;1;0;1;4,95;CC1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL91362;209442;None;0;Human;Binding;Ki;=;37000,00;4,43;-6;4;Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone;ChEMBL;398,2;5;0;6;3,49;CCOC(=O)c1cnn2cccc(CN3CCN(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1021/jm015522j
CHEMBL91362;209442;None;0;Human;Binding;Ki;=;45000,00;4,35;-6;4;Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone;ChEMBL;398,2;5;0;6;3,49;CCOC(=O)c1cnn2cccc(CN3CCN(c4ccc(Cl)cc4)CC3)c12;https://dx.doi.org/10.1021/jm015522j
CHEMBL91446;209462;None;0;Human;Binding;Ki;=;92,00;7,04;-354;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;334,2;6;1;2;4,49;COC[C@@H]1CCCN1CCc1c(-c2ccccc2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL91460;209466;None;0;Human;Binding;Ki;=;158,49;6,80;-199;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;457,3;10;2;5;4,50;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2nc(N)ncc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL91463;209468;None;0;Human;Binding;Ki;=;250,00;6,60;-72;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;312,1;5;1;1;4,98;CCN(C)CCc1c(-c2ccc(Cl)cc2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL91498;209475;None;0;Human;Binding;Ki;=;26,00;7,58;-30;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;361,2;5;1;4;4,66;CCc1c(-c2ccccc2)nc(O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL91510;209477;None;0;Human;Binding;Ki;=;2511,89;5,60;-158;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;471,3;11;2;5;4,96;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2nc(NC)ncc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL91542;209482;None;0;Human;Binding;Ki;=;0,42;9,38;6;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;303,2;5;1;2;4,20;CCN(C)CCc1c(-c2ccc(C#N)cc2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL91549;209484;None;0;Human;Binding;Ki;=;85,00;7,07;-602;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;278,2;5;1;1;4,33;CCN(C)CCc1c(-c2ccccc2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL91553;209486;None;0;Human;Binding;Ki;=;270,00;6,57;-60;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;348,2;4;1;5;3,80;Cc1c(-c2ccccn2)nc(O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL91621;209499;None;23;Human;Binding;Ki;=;86,00;7,07;4;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;309,2;4;2;2;3,47;O=C(Nc1ccccc1)NC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL91669;209505;None;0;Human;Binding;Ki;=;11,00;7,96;-13;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;347,2;4;0;4;3,69;Cn1c(-c2ccccc2)cn(C2CCN(Cc3ccccc3)CC2)c1=O;https://dx.doi.org/10.1021/jm991029k
CHEMBL91821;209531;None;9;Human;Binding;Ki;=;280,00;6,55;-3;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;347,2;4;1;4;4,40;Cc1nc(O)n(C2CCN(Cc3ccccc3)CC2)c1-c1ccccc1;https://dx.doi.org/10.1021/jm991029k
CHEMBL91938;209548;None;0;Human;Binding;Ki;=;3700,00;5,43;-457;3;Binding affinity to human D2 receptor assessed as inhibition constant;ChEMBL;389,1;3;0;4;4,38;COc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccc(C(F)(F)F)cc1)CC3;https://dx.doi.org/10.1016/j.ejmech.2020.113034
CHEMBL91938;209548;None;0;Human;Binding;Ki;=;3700,00;5,43;-457;3;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;389,1;3;0;4;4,38;COc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccc(C(F)(F)F)cc1)CC3;https://dx.doi.org/10.1021/jm970170v
CHEMBL92139;209578;None;0;Human;Binding;Ki;=;1600,00;5,80;-1047;9;Binding affinity against dopamine receptor D2 using [3H]spiperone radioligand in CHO cells;ChEMBL;328,1;5;0;4;2,98;CN(C)CCc1cccc2c1ccn2S(=O)(=O)c1ccccc1;https://dx.doi.org/10.1021/jm010943m
CHEMBL92183;209585;None;1;Human;Binding;Ki;=;265,00;6,58;1;4;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;228,2;3;0;2;3,15;CCCN1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL92183;209585;None;1;Human;Binding;Ki;=;119,00;6,92;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;228,2;3;0;2;3,15;CCCN1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL92189;209587;None;0;Human;Binding;Ki;=;290,00;6,54;-169;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;365,2;4;1;4;4,54;Cc1c(-c2ccc(F)cc2)nc(O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL92416;209629;None;0;Human;Binding;Ki;=;78,00;7,11;-45;3;Displacement of [3H]spiperone from CHO cells expressing human Dopamine receptor D2.;ChEMBL;284,1;5;1;2;4,39;CCN(C)CCc1c(-c2cccs2)[nH]c2ccccc12;https://dx.doi.org/10.1016/s0960-894x(00)00557-6
CHEMBL92438;209632;None;0;Human;Binding;Ki;=;1258,93;5,90;-10;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;442,3;10;1;4;4,92;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2ncncc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL92439;209633;None;0;Human;Binding;Ki;=;1584,89;5,80;-125;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;498,3;10;1;4;6,22;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2nc(C(C)(C)C)ncc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL92489;209641;None;0;Human;Binding;Ki;=;774,00;6,11;-213;3;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;305,1;2;0;3;3,66;Cc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccccc1)CC3;https://dx.doi.org/10.1021/jm970170v
CHEMBL92489;209641;None;0;Human;Binding;Ki;=;774,00;6,11;-213;3;Binding affinity to human D2 receptor assessed as inhibition constant;ChEMBL;305,1;2;0;3;3,66;Cc1ccc2c3c(c(=O)oc2c1)CN(Cc1ccccc1)CC3;https://dx.doi.org/10.1016/j.ejmech.2020.113034
CHEMBL92578;209654;None;0;Human;Binding;Ki;=;145,00;6,84;-1;4;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;231,2;4;0;2;3,09;CCCN1CCC[C@@H](c2cccc(C=O)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL92649;209665;None;0;Human;Binding;Ki;=;0,66;9,18;151;2;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;677,3;12;1;10;6,36;O=C(CCCN1CCC2(CC1)C(=O)N(CCc1ccc(Nc3ccc([N+](=O)[O-])c4nonc34)cc1)CN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00115a012
CHEMBL92713;209679;None;0;Human;Binding;Ki;=;3960,00;5,40;-741;3;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;387,2;7;1;4;3,29;COc1cccc(C(=O)NCCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL92713;209679;None;0;Human;Binding;Ki;=;3950,00;5,40;-741;3;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;387,2;7;1;4;3,29;COc1cccc(C(=O)NCCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm991138z
CHEMBL92817;209688;None;0;Human;Binding;Ki;=;170,00;6,77;1;4;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;281,1;3;0;1;4,04;CCCN1CCC[C@@H](c2cccc(Br)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL92859;209695;None;0;Human;Binding;Ki;=;95,00;7,02;-288;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;361,2;4;1;4;4,71;Cc1cccc(CN2CCC(n3c(O)nc(-c4ccccc4)c3C)CC2)c1;https://dx.doi.org/10.1021/jm991029k
CHEMBL92887;209704;None;3;Human;Binding;Ki;=;22,00;7,66;12;2;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;234,2;4;0;3;2,23;CCCN1CCN(c2ccccc2OC)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL92887;209704;None;3;Human;Binding;Ki;=;19,95;7,70;12;2;Displacement of [3H]7-OH-DPAT from human D2S receptor high affinity site expressed in HEK293 cells;ChEMBL;234,2;4;0;3;2,23;CCCN1CCN(c2ccccc2OC)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.12.031
CHEMBL92939;209714;None;0;Human;Binding;Ki;=;984,00;6,01;-;1;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;238,1;2;0;2;2,85;C=CCN1CCC2c3cccc(C#N)c3CCC21;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93101;209731;None;0;Human;Binding;Ki;=;240,00;6,62;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;233,2;4;1;2;2,77;CCCN1CCC[C@@H](c2cccc(CO)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93212;209748;None;0;Human;Binding;Ki;=;254,00;6,59;2;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;226,1;3;0;2;2,92;C=CCN1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93336;209764;None;0;Human;Binding;Ki;=;2511,89;5,60;-316;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;456,3;10;1;4;5,23;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2nc(C)ncc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL93383;209772;None;0;Human;Binding;Ki;=;106,00;6,97;2;3;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;228,2;2;0;2;3,15;CC(C)N1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93403;209774;None;7;Human;Binding;Ki;=;1900,00;5,72;-47863;5;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;373,2;6;1;4;2,90;COc1cccc(C(=O)NCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm991138z
CHEMBL93403;209774;None;7;Human;Binding;Ki;=;1900,00;5,72;-47863;5;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;373,2;6;1;4;2,90;COc1cccc(C(=O)NCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm020952a
CHEMBL93432;209779;None;0;Human;Binding;Ki;=;8,80;8,06;-1;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;423,2;5;0;4;5,45;Cc1c(-c2ccccc2)n(-c2ccccc2)c(=O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL93570;209798;None;0;Human;Binding;Ki;=;11,00;7,96;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;296,1;3;0;3;4,57;CCc1sccc1N1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93570;209798;None;0;Human;Binding;Ki;=;134,00;6,87;1;4;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;296,1;3;0;3;4,57;CCc1sccc1N1CCC[C@@H](c2cccc(C#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93582;209799;None;0;Human;Binding;Ki;=;602,00;6,22;2;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;233,2;4;0;2;3,29;CCCN1CCC[C@@H](c2cccc(OC)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93594;209800;None;0;Human;Binding;Ki;=;192,00;6,72;5;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;297,1;5;0;4;2,61;CCCN1CCC[C@@H](c2cccc(OS(C)(=O)=O)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93646;209813;None;0;Human;Binding;Ki;=;22,00;7,66;2;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;290,2;4;0;2;3,98;N#Cc1cccc([C@@H]2CCCN(CCc3ccccc3)C2)c1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93682;209820;None;2;Human;Binding;Ki;=;314,00;6,50;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;186,1;1;1;2;2,02;N#Cc1cccc([C@@H]2CCCNC2)c1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93703;209824;None;0;Human;Binding;Ki;=;1584,89;5,80;-158;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;429,3;8;2;5;3,73;CN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2nc(N)ncc2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL93753;209833;None;0;Human;Binding;Ki;=;67,00;7,17;-3;4;Affinity for the Dopamine receptor D2S was determined using membranes from CHO cells labeled with [3H]spiperone;ChEMBL;309,1;4;3;4;2,75;Oc1nc2c3c(ccc2[nH]1)CC[C@@H](CNCc1ccccc1)O3;https://dx.doi.org/10.1016/s0960-894x(01)00778-8
CHEMBL93779;209838;None;0;Human;Binding;Ki;=;5,00;8,30;-5;4;Affinity for the Dopamine receptor D2S was determined using membranes from CHO cells labeled with [3H]spiperone;ChEMBL;309,1;4;3;4;2,75;Oc1nc2c3c(ccc2[nH]1)CCC(CNCc1ccccc1)O3;https://dx.doi.org/10.1016/s0960-894x(01)00778-8
CHEMBL93794;209841;None;0;Human;Binding;Ki;=;1584,89;5,80;-501;2;Tested for the ability to displace [125I]iodosulpiride from human cloned Dopamine receptor D2, expressed in CHO cells.;ChEMBL;472,3;11;1;5;4,93;CCCN(CCCCNC(=O)c1ccc(-c2ccccc2)cc1)C1CCc2ncnc(OC)c2C1;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL93832;209845;None;0;Human;Binding;Ki;=;1300,00;5,89;-2818;2;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;381,2;4;1;4;5,05;Cc1c(-c2ccccc2)nc(O)n1C1CCN(Cc2cccc(Cl)c2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL93868;209853;None;0;Human;Binding;Ki;=;62,00;7,21;-18;9;Binding affinity against dopamine receptor D2 using [3H]spiperone radioligand in CHO cells;ChEMBL;328,1;5;0;4;2,98;CN(C)CCc1cn(S(=O)(=O)c2ccccc2)c2ccccc12;https://dx.doi.org/10.1021/jm010943m
CHEMBL93917;209863;None;1;Human;Binding;Ki;=;69,00;7,16;7;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;242,2;4;0;2;3,34;CCCN1CCC[C@@H](c2cccc(CC#N)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93946;209866;None;0;Human;Binding;Ki;=;820,00;6,09;1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;301,2;5;0;2;4,22;CCCN1CCC[C@@H](c2cccc(OCC(F)(F)F)c2)C1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL93958;209870;None;0;Human;Binding;Ki;=;82,00;7,09;-4;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;333,2;4;1;4;4,09;Oc1nc(-c2ccccc2)cn1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL93969;209872;None;0;Human;Binding;Ki;=;60,00;7,22;-46;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;381,2;4;1;4;5,05;Cc1c(-c2ccccc2)nc(O)n1C1CCN(Cc2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL94015;209880;None;0;Human;Binding;Ki;=;42,00;7,38;-95;3;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;249,1;2;1;4;1,94;CCCN1COC[C@@H]2c3cc(O)ccc3OC[C@H]21;https://dx.doi.org/10.1021/jm960345l
CHEMBL94015;209880;None;0;Human;Binding;Ki;=;2511,89;5,60;-95;3;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;249,1;2;1;4;1,94;CCCN1COC[C@@H]2c3cc(O)ccc3OC[C@H]21;https://dx.doi.org/10.1016/s0960-894x(99)00454-0
CHEMBL94015;209880;None;0;Human;Binding;Ki;=;1183,00;5,93;-95;3;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;249,1;2;1;4;1,94;CCCN1COC[C@@H]2c3cc(O)ccc3OC[C@H]21;https://dx.doi.org/10.1021/jm960345l
CHEMBL94023;209882;None;0;Human;Binding;Ki;=;170,00;6,77;-239;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;381,2;4;1;4;5,05;Cc1c(-c2ccc(Cl)cc2)nc(O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL94067;209890;None;0;Human;Binding;Ki;=;570,00;6,24;-1;3;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;327,2;1;0;1;5,64;CC(C)=C1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL94067;209890;None;0;Human;Binding;Ki;=;570,00;6,24;-1;3;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;327,2;1;0;1;5,64;CC(C)=C1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00004a016
CHEMBL94067;209890;None;0;Human;Binding;Ki;=;520,00;6,28;-1;3;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;327,2;1;0;1;5,64;CC(C)=C1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL94067;209890;None;0;Human;Binding;Ki;=;790,00;6,10;-1;3;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;327,2;1;0;1;5,64;CC(C)=C1c2ccccc2C=C(C2=CCN(C)CC2)c2ccccc21;https://dx.doi.org/10.1021/jm00043a008
CHEMBL94283;209927;None;0;Human;Binding;Ki;=;73,00;7,14;-13;3;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;381,2;4;1;4;5,05;Cc1c(-c2cccc(Cl)c2)nc(O)n1C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1021/jm991029k
CHEMBL94371;209944;None;1;Human;Binding;Kd;=;144,54;6,84;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;361,1;5;1;3;4,04;O=C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL94371;209944;None;1;Human;Binding;Ki;=;131,83;6,88;-;1;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;361,1;5;1;3;4,04;O=C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHEMBL94811;210020;None;0;Human;Binding;Ki;=;60,00;7,22;-1;4;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;304,2;5;0;2;4,37;N#Cc1cccc([C@@H]2CCCN(CCCc3ccccc3)C2)c1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL94811;210020;None;0;Human;Binding;Ki;=;29,00;7,54;-1;4;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;304,2;5;0;2;4,37;N#Cc1cccc([C@@H]2CCCN(CCCc3ccccc3)C2)c1;https://dx.doi.org/10.1021/jm00043a013
CHEMBL94984;210052;None;0;Human;Binding;Ki;=;630,96;6,20;-63;11;Binding affinity towards Dopamine receptor D2 (human cloned receptor) in CHO cells using [125I]iodosulpiride radioligand.;ChEMBL;386,2;5;0;3;4,12;CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc3ccccc23)CC1;https://dx.doi.org/10.1021/jm991151j
CHEMBL95743;210193;None;0;Human;Binding;Ki;=;501,19;6,30;-31;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;438,3;7;1;2;6,06;O=C(NCCCCN1CCC[C@@H]2c3ccccc3CC[C@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL95759;210196;None;0;Human;Binding;Ki;=;501,19;6,30;-63;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;454,3;7;2;3;5,76;O=C(NCCCCN1CCC[C@H]2c3ccc(O)cc3CC[C@@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL96462;210312;None;0;Human;Binding;Ki;=;5000,00;5,30;-218;2;In vitro binding affinity at human Dopamine receptor D2 (long) by [3H]spiroperidol displacement.;ChEMBL;359,2;7;1;4;3,26;COc1cccc(CNCCN2CCN(c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1021/jm991138z
CHEMBL96799;210382;None;0;Human;Binding;Ki;=;3170,00;5,50;-75;3;In vitro binding affinity towards human Dopamine receptor D2L, using [3H]spiroperidol radioligand in Sf9 baculovirus expression.;ChEMBL;399,2;5;0;4;3,17;COc1cccc2c1CCN(CCN1CCN(c3ccc(Cl)cc3)CC1)C2=O;https://dx.doi.org/10.1021/jm991138z
CHEMBL97107;210418;None;0;Human;Binding;Ki;=;501,19;6,30;-10;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;424,3;7;1;2;5,67;O=C(NCCCCN1CC[C@@H]2c3ccccc3CC[C@@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL97118;210421;None;0;Human;Binding;Ki;=;630,96;6,20;-39;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;454,3;8;1;3;5,68;COc1cccc2c1CC[C@H]1[C@H]2CCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL97149;210428;None;1;Human;Binding;Ki;=;794,33;6,10;1;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;468,3;8;1;3;6,07;COc1cccc2c1CC[C@@H]1[C@@H]2CCCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL97440;210487;None;0;Human;Binding;Ki;=;1995,26;5,70;-10;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;532,2;9;1;5;5,40;CS(=O)(=O)Oc1ccc2c(c1)CC[C@H]1[C@H]2CCCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL97840;210557;None;0;Human;Binding;Ki;=;794,33;6,10;-3;2;Displacement of [125I]iodosulpiride from Dopamine receptor D2 expressed in CHO cells;ChEMBL;438,3;7;1;2;6,06;O=C(NCCCCN1CCC[C@@H]2c3ccccc3CC[C@@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL97856;210560;None;0;Human;Binding;Ki;=;316,23;6,50;-25;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;440,2;7;2;3;5,37;O=C(NCCCCN1CC[C@H]2c3ccc(O)cc3CC[C@@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL98197;210613;None;0;Human;Binding;Ki;=;854,00;6,07;3;2;Tested for agonist binding affinity by measuring displacement of [3H]NPA from Human Dopamine receptor D2L expressed in CHO K-1 cells;ChEMBL;265,1;2;1;4;2,65;CCCN1CCO[C@H]2c3cc(O)ccc3SC[C@@H]21;https://dx.doi.org/10.1021/jm0000113
CHEMBL98241;210620;None;4;Human;Binding;Ki;=;580,00;6,24;-407;13;Binding affinity for human Dopamine receptor D2;ChEMBL;423,2;4;0;4;3,32;C[C@H](CN1CCN(c2cc(F)c(F)cc2F)CC1)N1C(=O)CC2(CCCC2)CC1=O;https://dx.doi.org/10.1021/jm0491391
CHEMBL98305;210628;None;0;Human;Binding;Ki;=;1,14;8,94;2;5;Tested for agonist binding affinity by measuring displacement of [3H]NPA from Human Dopamine receptor D2L expressed in CHO K-1 cells;ChEMBL;265,1;2;1;4;2,65;CCCN1CCO[C@@H]2c3cc(O)ccc3SC[C@H]21;https://dx.doi.org/10.1021/jm0000113
CHEMBL98452;210657;None;0;Human;Binding;Ki;=;501,19;6,30;-31;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;424,3;7;1;2;5,67;O=C(NCCCCN1CC[C@H]2c3ccccc3CC[C@@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL98830;210721;None;0;Human;Binding;Ki;=;462,00;6,33;-17;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;218,1;0;0;3;2,86;Cc1sc(C)c2c1CCc1cnn(C)c1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL98836;210724;None;0;Human;Binding;Ki;=;74,00;7,13;-20;5;Tested for agonist binding affinity by measuring displacement of [3H]NPA from Human Dopamine receptor D2L expressed in CHO K-1 cells;ChEMBL;265,1;2;1;4;2,65;CCCN1CCO[C@@H]2c3cc(O)ccc3SC[C@@H]21;https://dx.doi.org/10.1021/jm0000113
CHEMBL98945;210739;None;0;Human;Binding;Ki;=;489,00;6,31;-2;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;286;1;0;3;4,43;CCn1ncc2c1-c1c(Cl)sc(Cl)c1CCC2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL98946;210740;None;0;Human;Binding;Ki;=;416,00;6,38;-29;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;272;0;0;3;3,94;Cn1ncc2c1-c1c(Cl)sc(Cl)c1CCC2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL99198;210784;None;0;Human;Binding;Ki;=;25,12;7,60;-25;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;454,3;7;2;3;5,76;O=C(NCCCCN1CCC[C@H]2c3cccc(O)c3CC[C@@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL99198;210784;None;0;Human;Binding;Ki;=;25,00;7,60;-25;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;454,3;7;2;3;5,76;O=C(NCCCCN1CCC[C@H]2c3cccc(O)c3CC[C@@H]21)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1021/jm030836n
CHEMBL99208;210785;None;0;Human;Binding;Ki;=;402,00;6,40;-18;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;246,1;1;0;3;3,74;CCn1ncc2c1-c1c(C)sc(C)c1CCC2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL99355;210801;None;0;Human;Binding;Ki;=;197,00;6,71;-6;2;Tested for agonist binding affinity by measuring displacement of [3H]NPA from Human Dopamine receptor D2L expressed in CHO K-1 cells;ChEMBL;281,1;2;1;4;1,67;CCCN1CCOC2c3cc(O)ccc3[S+]([O-])CC21;https://dx.doi.org/10.1021/jm0000113
CHEMBL99649;210855;None;0;Human;Binding;Ki;=;555,00;6,26;-3;2;Binding affinity towards cloned human Dopamine receptor D2 was determined;ChEMBL;260,1;1;0;3;4,30;Cc1sc(C)c2c1CCCc1cnn(C(C)C)c1-2;https://dx.doi.org/10.1016/s0960-894x(03)00587-0
CHEMBL99849;210883;None;0;Human;Binding;Ki;=;37,60;7,42;-3;4;Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone;ChEMBL;320,1;8;2;4;2,23;CS(=O)(=O)Nc1cccc(OCCNCc2ccccc2)c1;https://dx.doi.org/10.1016/s0960-894x(98)00014-6
CHEMBL99876;210887;None;0;Human;Binding;Ki;=;316,23;6,50;-63;2;Binding affinity at Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;518,2;9;1;5;5,01;CS(=O)(=O)Oc1cccc2c1CC[C@H]1[C@H]2CCN1CCCCNC(=O)c1ccc(-c2ccccc2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00512-5
CHEMBL99913;210892;None;0;Human;Binding;Ki;=;75,80;7,12;-34;3;Binding affinity towards human cloned dopamine (hD2s) receptors expressed in CHO cell membranes using [3H]spiperone;ChEMBL;354,1;8;2;4;2,88;CS(=O)(=O)Nc1cc(OCCNCc2ccccc2)ccc1Cl;https://dx.doi.org/10.1016/s0960-894x(98)00014-6
CHEMBL99967;210900;None;3;Human;Binding;Ki;=;2190,00;5,66;-257;3;Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151;ChEMBL;319,2;4;1;4;2,79;c1ccc(-c2nc(CN3CCN(c4ccccn4)CC3)c[nH]2)cc1;https://dx.doi.org/10.1021/jm960637m
CHLORHEXIDINE;207729;None;57;Human;Binding;AC50;=;4200,00;5,38;-;27;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;504,2;9;10;4;4,17;N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
CHLOROHALOPERIDOL;124388;None;12;Human;Binding;Kd;=;5,01;8,30;8;3;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;391,1;6;1;3;4,94;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
CHLOROHALOPERIDOL;124388;None;12;Human;Binding;Ki;=;190,00;6,72;8;3;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;391,1;6;1;3;4,94;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/jm060383x
CHLOROHALOPERIDOL;124388;None;12;Human;Binding;Ki;=;5,01;8,30;8;3;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;391,1;6;1;3;4,94;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(Cl)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
chlorproethazine;218933;None;0;Human;Binding;pKi;=;7,98;8,10;1;3;None;Drug Central;346,1;6;0;3;5,67;CCN(CC)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorproethazine;218933;R-SAT;0;Human;Binding;pKi;=;10,00;8,00;1;3;-;PDSP KiDatabase;346,1;6;0;3;5,67;CCN(CC)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorproethazine;218933;R-SAT;0;Human;Binding;pKi;=;11,00;7,96;1;3;-;PDSP KiDatabase;346,1;6;0;3;5,67;CCN(CC)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;None;48;Human;Binding;AC50;=;52,50;7,28;-2;77;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1038/s41467-023-40064-9
chlorpromazine;919;None;48;Human;Binding;IC50;=;12,00;7,92;-2;77;Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1021/jm400856t
chlorpromazine;919;None;48;Human;Binding;IC50;=;54,00;7,27;-2;77;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;None;48;Human;Binding;Ki;=;1,20;8,92;-2;77;Displacement of [3H]-N-methylspiperone from human dopamine D2long receptor expressed in HEK293 cells after 30 mins by scintillation counting;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmc.2012.08.058
chlorpromazine;919;None;48;Human;Binding;Ki;=;10,00;8,00;-2;77;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1021/jm070516u
chlorpromazine;919;None;48;Human;Binding;Ki;=;1,80;8,74;-2;77;Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.ejmech.2019.01.031
chlorpromazine;919;None;48;Human;Binding;Ki;=;2,34;8,63;-2;77;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
chlorpromazine;919;None;48;Human;Binding;Ki;=;8,00;8,10;-2;77;Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1021/jm0604979
chlorpromazine;919;None;48;Human;Binding;Ki;=;6,10;8,21;-2;77;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1021/jm5004123
chlorpromazine;919;None;48;Human;Binding;Ki;=;4,06;8,39;-2;77;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
chlorpromazine;919;None;48;Human;Binding;Ki;=;1,80;8,74;-2;77;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
chlorpromazine;919;None;48;Human;Binding;Ki;=;18,00;7,75;-2;77;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;None;48;Human;Binding;Ki;=;3,00;8,52;-2;77;Compound was evaluated for the binding affinity against [3H]U-86,170-labeled D2 sites in cloned CHO cells;ChEMBL;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1021/jm00060a015
chlorpromazine;919;None;48;Human;Binding;pKi;=;8,15;8,09;-2;77;None;Drug Central;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;None;48;Human;Binding;pKi;None;-;7,30;-2;77;Unclassified;Guide to Pharmacology;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://pubmed.ncbi.nlm.nih.gov/1354163
chlorpromazine;919;None;48;Human;Binding;pKi;None;-;7,30;-2;77;Unclassified;Guide to Pharmacology;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;https://pubmed.ncbi.nlm.nih.gov/8301582
chlorpromazine;919;3H-RACLOPRIDE;48;Human;Binding;pKi;=;1,30;8,89;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;UNDEFINED;48;Human;Binding;pKi;=;18,86;7,72;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;125I-IODOSULPRIDE;48;Human;Binding;pKi;=;2,30;8,64;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;UNDEFINED;48;Human;Binding;pKi;=;4,06;8,39;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-NEMONAPRIDE;48;Human;Binding;pKi;=;14,00;7,85;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-SPIPERONE;48;Human;Binding;pKi;=;19,00;7,72;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;R-SAT;48;Human;Binding;pKi;=;1,70;8,77;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;R-SAT;48;Human;Binding;pKi;=;8,10;8,09;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-Chlorpromazine;48;Human;Binding;pKi;=;0,66;9,18;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-YM 09151-2;48;Human;Binding;pKi;=;3,00;8,52;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-SPIPERONE;48;Human;Binding;pKi;=;4,80;8,32;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-SPIPERONE;48;Human;Binding;pKi;=;4,80;8,32;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-NMSP;48;Human;Binding;pKi;=;2,00;8,70;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;UNDEFINED;48;Human;Binding;pKi;=;0,66;9,18;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-NMSP;48;Human;Binding;pKi;=;4,00;8,40;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-NEMONAPRIDE;48;Human;Binding;pKi;=;13,00;7,89;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-SPIPERONE;48;Human;Binding;pKi;=;1,50;8,82;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-YM 09151-2;48;Human;Binding;pKi;=;1,30;8,89;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-NMSP;48;Human;Binding;pKi;=;6,70;8,17;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-RACLOPRIDE;48;Human;Binding;pKi;=;1,50;8,82;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-SPIPERONE;48;Human;Binding;pKi;=;0,66;9,18;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;3H-RACLOPRIDE;48;Human;Binding;pKi;=;1,30;8,89;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorpromazine;919;125I-IODOSULPRIDE;48;Human;Binding;pKi;=;8,00;8,10;-2;77;-;PDSP KiDatabase;318,1;4;0;3;4,89;CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21;-
chlorprothixene;920;None;44;Human;Binding;Ki;=;2,96;8,53;-4;33;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;315,1;3;0;2;5,19;CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
chlorprothixene;920;None;44;Human;Binding;pKi;=;8,53;8,07;-4;33;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;Drug Central;315,1;3;0;2;5,19;CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21;-
chlorprothixene;920;None;44;Human;Binding;pKi;=;-;8,53;-4;33;Unclassified;Guide to Pharmacology;315,1;3;0;2;5,19;CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21;https://pubmed.ncbi.nlm.nih.gov/19091563
chlorprothixene;920;UNDEFINED;44;Human;Binding;pKi;=;3,30;8,48;-4;33;-;PDSP KiDatabase;315,1;3;0;2;5,19;CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21;-
chlorprothixene;920;3H-SPIPERONE;44;Human;Binding;pKi;=;8,00;8,10;-4;33;-;PDSP KiDatabase;315,1;3;0;2;5,19;CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21;-
chlorprothixene;920;UNDEFINED;44;Human;Binding;pKi;=;2,96;8,53;-4;33;-;PDSP KiDatabase;315,1;3;0;2;5,19;CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21;-
CI-1007;116064;None;4;Human;Binding;Ki;=;25,50;7,59;-1;4;Tested for binding affinity towards human D2L receptor using [3H]spiperone as radioligand;ChEMBL;329,2;4;0;1;5,66;C1=C(c2ccccc2)CCN(C[C@@H]2CCC=C(c3ccccc3)C2)C1;https://dx.doi.org/10.1021/jm00047a010
CI-1007;116064;None;4;Human;Binding;Ki;=;25,50;7,59;-1;4;Binding affinity towards human Dopamine receptor D2L evaluated using [3H]spiperone;ChEMBL;329,2;4;0;1;5,66;C1=C(c2ccccc2)CCN(C[C@@H]2CCC=C(c3ccccc3)C2)C1;https://dx.doi.org/10.1021/jm00026a007
CI-1007;116064;None;4;Human;Binding;Ki;=;8,40;8,08;-1;4;Binding affinity towards human Dopamine receptor D2L evaluated using [3H]N-0437;ChEMBL;329,2;4;0;1;5,66;C1=C(c2ccccc2)CCN(C[C@@H]2CCC=C(c3ccccc3)C2)C1;https://dx.doi.org/10.1021/jm00026a007
cinacalcet;938;None;48;Human;Binding;AC50;=;3600,00;5,44;-;31;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;357,2;6;1;1;6,14;C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12;https://dx.doi.org/10.1038/s41467-023-40064-9
CINITAPRIDE;78202;None;29;Human;Binding;AC50;=;38,00;7,42;-;13;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;402,2;7;2;6;3,13;CCOc1cc(N)c([N+](=O)[O-])cc1C(=O)NC1CCN(CC2CC=CCC2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
cinnarizine;940;None;51;Human;Binding;AC50;=;15000,00;4,82;-6;28;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;368,2;6;0;2;5,11;C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
cinnarizine;940;None;51;Human;Binding;IC50;=;776,00;6,11;-6;28;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;368,2;6;0;2;5,11;C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1;-
cinnarizine;940;None;51;Human;Binding;Ki;=;259,00;6,59;-6;28;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;368,2;6;0;2;5,11;C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1;-
cinnarizine;940;None;51;Human;Binding;pKi;=;6,59;8,18;-6;28;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;368,2;6;0;2;5,11;C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1;-
Cis-N-Methyl-2'-methyl-2',3'-dihydrofuro[m]aporphine;220001;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1023;3;-;PDSP KiDatabase;291,2;0;0;2;3,76;CC1Cc2ccc3c(c2O1)-c1cccc2c1C(C3)N(C)CC2;-
Cis-N-Methyl-2'-methyl-2',3'-dihydrofuro[m]aporphine;220001;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1023;3;-;PDSP KiDatabase;291,2;0;0;2;3,76;CC1Cc2ccc3c(c2O1)-c1cccc2c1C(C3)N(C)CC2;-
Cis-N-Methyl-2'-methyl-2',3'-dihydrofuro[m]aporphine;220001;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-1023;3;-;PDSP KiDatabase;291,2;0;0;2;3,76;CC1Cc2ccc3c(c2O1)-c1cccc2c1C(C3)N(C)CC2;-
cisapride;944;None;25;Human;Binding;AC50;=;450,00;6,35;-31;31;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;465,2;9;2;6;3,36;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
cisapride;944;None;25;Human;Binding;IC50;=;227,00;6,64;-31;31;Binding affinity to dopamine receptor D2;ChEMBL;465,2;9;2;6;3,36;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;https://dx.doi.org/10.1021/jm0509501
cisapride;944;None;25;Human;Binding;IC50;=;473,00;6,33;-31;31;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;465,2;9;2;6;3,36;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;-
cisapride;944;None;25;Human;Binding;Ki;=;158,00;6,80;-31;31;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;465,2;9;2;6;3,36;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;-
cisapride;944;None;25;Human;Binding;pIC50;=;6,64;8,18;-31;31;Binding affinity to dopamine receptor D2;Drug Central;465,2;9;2;6;3,36;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC;-
CITALOPRAM;197264;3H-SPIPERONE;50;Human;Binding;pKi;=;10000,00;5,00;-120;31;-;PDSP KiDatabase;324,2;5;0;3;3,81;CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21;-
CLEBOPRIDE;110592;None;24;Human;Binding;AC50;=;10,00;8,00;-9;19;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;373,2;5;2;4;3,33;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
CLEBOPRIDE;110592;None;24;Human;Binding;Ki;=;18,00;7,75;-9;19;Displacement of [3H]spiperone [0.5 nM (Kd=0.1 nM)] from human recombinant dopamine receptor D2L expressed in CHO cells;ChEMBL;373,2;5;2;4;3,33;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CLEBOPRIDE;110592;None;24;Human;Binding;Ki;=;12,00;7,92;-9;19;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;ChEMBL;373,2;5;2;4;3,33;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(03)00678-4
CLEBOPRIDE;110592;None;24;Human;Binding;pKi;=;7,92;8,10;-9;19;Displacement of [3H]-spiperone [0.5 nM (Kd=0.2-0.45 nM)] from human recombinant dopamine receptor D2S expressed in CHO cells at 0.5 nM concentration;Drug Central;373,2;5;2;4;3,33;COc1cc(N)c(Cl)cc1C(=O)NC1CCN(Cc2ccccc2)CC1;-
clemastine;949;None;27;Human;Binding;AC50;=;1200,00;5,92;-66;34;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;343,2;6;0;2;5,10;CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
clemastine;949;None;27;Human;Binding;IC50;=;136,00;6,87;-66;34;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;343,2;6;0;2;5,10;CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1;-
clemastine;949;None;27;Human;Binding;Ki;=;45,00;7,35;-66;34;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;343,2;6;0;2;5,10;CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1;-
clemastine;949;None;27;Human;Binding;pKi;=;7,35;8,13;-66;34;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;343,2;6;0;2;5,10;CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1;-
CLOFAZIMINE;19387;None;54;Human;Binding;AC50;=;8961,00;5,05;-;7;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;472,1;4;1;4;7,49;CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
clomipramine;954;None;43;Human;Binding;AC50;=;390,00;6,41;-7;42;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;314,2;4;0;2;4,53;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;https://dx.doi.org/10.1038/s41467-023-40064-9
clomipramine;954;None;43;Human;Binding;IC50;=;413,00;6,38;-7;42;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;314,2;4;0;2;4,53;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;-
clomipramine;954;None;43;Human;Binding;Ki;=;138,00;6,86;-7;42;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;314,2;4;0;2;4,53;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;-
clomipramine;954;None;43;Human;Binding;pKi;=;6,95;8,16;-7;42;None;Drug Central;314,2;4;0;2;4,53;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;-
clomipramine;954;3H-YM 09151-2;43;Human;Binding;pKi;=;162,00;6,79;-7;42;-;PDSP KiDatabase;314,2;4;0;2;4,53;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;-
clomipramine;954;3H-SPIPERONE;43;Human;Binding;pKi;=;77,60;7,11;-7;42;-;PDSP KiDatabase;314,2;4;0;2;4,53;CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21;-
CLOROTEPINE;205632;None;17;Human;Binding;Ki;=;0,67;9,17;-1;16;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;344,1;1;0;3;4,34;CN1CCN(C2Cc3ccccc3Sc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm100652h
CLOROTEPINE;205632;None;17;Human;Binding;pKi;=;9,17;8,04;-1;16;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;Drug Central;344,1;1;0;3;4,34;CN1CCN(C2Cc3ccccc3Sc3ccc(Cl)cc32)CC1;-
CLOROTEPINE;205632;R-SAT;17;Human;Binding;pKi;=;0,20;9,70;-1;16;-;PDSP KiDatabase;344,1;1;0;3;4,34;CN1CCN(C2Cc3ccccc3Sc3ccc(Cl)cc32)CC1;-
CLOROTEPINE;205632;R-SAT;17;Human;Binding;pKi;=;0,70;9,15;-1;16;-;PDSP KiDatabase;344,1;1;0;3;4,34;CN1CCN(C2Cc3ccccc3Sc3ccc(Cl)cc32)CC1;-
CLOTHIAPINE;102785;None;36;Human;Binding;AC50;=;200,00;6,70;1;21;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;343,1;0;0;4;4,13;CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
CLOTHIAPINE;102785;None;36;Human;Binding;Ki;=;0,49;9,31;1;21;Binding Assay: The ability of test compounds to displace 3H-raclopride at the D2s receptor can be determined on membranes from D2s-transfected CHO cells (Bmax 13 pmol/mg protein). An assay can use a standard 96-well glass-fiber filter plate to retain radioligand bound by the receptor. Retained 3H can be determined in a TopCount scintillation plate counter following the addition of a liquid scintillant to each well. Compounds can be evaluated for their potency using competition curve analysis, resulting in calculated Ki values.;ChEMBL;343,1;0;0;4;4,13;CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1;-
CLOTHIAPINE;102785;None;36;Human;Binding;pKi;=;9,31;8,03;1;21;None;Drug Central;343,1;0;0;4;4,13;CN1CCN(C2=Nc3ccccc3Sc3ccc(Cl)cc32)CC1;-
CLOTRIMAZOLE;4781;None;63;Human;Binding;AC50;=;4900,00;5,31;-30;46;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;344,1;4;0;2;5,38;Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1;https://dx.doi.org/10.1038/s41467-023-40064-9
CLOTRIMAZOLE;4781;None;63;Human;Binding;IC50;=;12186,00;4,91;-30;46;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;344,1;4;0;2;5,38;Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1;-
CLOTRIMAZOLE;4781;None;63;Human;Binding;Ki;=;4062,00;5,39;-30;46;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;344,1;4;0;2;5,38;Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1;-
CLOTRIMAZOLE;4781;None;63;Human;Binding;pKi;=;5,39;8,27;-30;46;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;344,1;4;0;2;5,38;Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1;-
clozapine;958;None;57;Human;Binding;AC50;=;718,60;6,14;-51;98;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
clozapine;958;None;57;Human;Binding;IC50;=;140,00;6,85;-51;98;Antagonist activity at D2L receptor (unknown origin) expressed in human HTLA cells assessed as inhibition of dopamine-stimulated beta-arrestin2 recruitment measured after 20 to 22 hrs by brightglo-luciferase reporter gene assay;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/acs.jmedchem.9b00508
clozapine;958;None;57;Human;Binding;IC50;=;9,00;8,05;-51;98;Inhibitory concentration against dopamine receptor D2;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm058225d
clozapine;958;None;57;Human;Binding;IC50;=;206,00;6,69;-51;98;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
clozapine;958;None;57;Human;Binding;IC50;=;204,17;6,69;-51;98;Inhibition of human dopamine D2L receptor expressed in intact CHO FlpIn cells assessed as inhibition of receptor-mediated mediated ERK1/2 phosphorylation by Alpha-Screen plate-based assay;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
clozapine;958;None;57;Human;Binding;IC50;=;230,00;6,64;-51;98;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm981041x
clozapine;958;None;57;Human;Binding;IC50;=;113,00;6,95;-51;98;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm990562x
clozapine;958;None;57;Human;Binding;IC50;=;387,00;6,41;-51;98;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;None;57;Human;Binding;IC50;=;260,00;6,58;-51;98;Binding affinity towards human Dopamine receptor D2;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm991005d
clozapine;958;None;57;Human;Binding;Ki;=;138,00;6,86;-51;98;Binding affinity towards Dopamine receptor D2 was determined via standard competitive displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
clozapine;958;None;57;Human;Binding;Ki;=;150,00;6,82;-51;98;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by Microbeta plate reader method;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114193
clozapine;958;None;57;Human;Binding;Ki;=;220,00;6,66;-51;98;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
clozapine;958;None;57;Human;Binding;Ki;=;250,00;6,60;-51;98;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
clozapine;958;None;57;Human;Binding;Ki;=;223,87;6,65;-51;98;Displacement of [3H]spiperone human cloned dopamine D2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2007.06.045
clozapine;958;None;57;Human;Binding;Ki;=;102,33;6,99;-51;98;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
clozapine;958;None;57;Human;Binding;Ki;=;41,00;7,39;-51;98;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
clozapine;958;None;57;Human;Binding;Ki;=;41,00;7,39;-51;98;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
clozapine;958;None;57;Human;Binding;Ki;=;190,00;6,72;-51;98;Binding affinity towards human D2 dopamine receptor.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm0002432
clozapine;958;None;57;Human;Binding;Ki;=;431,00;6,37;-51;98;Displacement of [3H]N-methylspiperone from human cloned D2 dopamine receptor expressed in human fibroblasts incubated for 90 mins by scintillation counting based radioligand binding assay;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1039/C5MD00258C
clozapine;958;None;57;Human;Binding;Ki;=;130,00;6,89;-51;98;Binding affinity to human dopamine D2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.038
clozapine;958;None;57;Human;Binding;Ki;=;190,00;6,72;-51;98;Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;None;57;Human;Binding;Ki;=;130,00;6,89;-51;98;Inhibition of D2 receptor (unknown origin);ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2016.05.053
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
clozapine;958;None;57;Human;Binding;Ki;=;74,00;7,13;-51;98;Affinity to displace [3H]spiperone from cloned human Dopamine receptor D2 stably expressed in CHO cell lines;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm991029k
clozapine;958;None;57;Human;Binding;Ki;=;129,00;6,89;-51;98;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;None;57;Human;Binding;Ki;=;41,00;7,39;-51;98;Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
clozapine;958;None;57;Human;Binding;Ki;=;113,00;6,95;-51;98;Displacement of [3H]-YM 09151 from D2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(02)01056-9
clozapine;958;None;57;Human;Binding;Ki;=;389,00;6,41;-51;98;Binding affinity to human dopamine D2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127563
clozapine;958;None;57;Human;Binding;Ki;=;223,87;6,65;-51;98;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm800602w
clozapine;958;None;57;Human;Binding;Ki;=;125,89;6,90;-51;98;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070516u
clozapine;958;None;57;Human;Binding;Ki;=;130,00;6,89;-51;98;In vitro ability to inhibit the binding of [3H]spiperone to cloned human Dopamine receptor D2 using apomorphine induced climbing test in male Swiss mice;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2003.07.015
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2 short form expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
clozapine;958;None;57;Human;Binding;Ki;=;39,00;7,41;-51;98;In vitro displacement of [3H]spiperone from the recombinant human dopamine receptor D2L stably expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(00)00405-4
clozapine;958;None;57;Human;Binding;Ki;=;876,00;6,06;-51;98;In vitro binding affinity towards Dopamine receptor D2L, using [3H]spiroperidol radioligand in Sf9 baculovirus expression.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm991138z
clozapine;958;None;57;Human;Binding;Ki;=;106,00;6,97;-51;98;Displacement of [3H]-spiperone from human dopamine D2L receptor expressed in CHO FlpIn cell membrane measured after 60 mins by topcount scintillation counting;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm201420s
clozapine;958;None;57;Human;Binding;Ki;=;155,00;6,81;-51;98;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
clozapine;958;None;57;Human;Binding;Ki;=;134,90;6,87;-51;98;Cataleptogenic effect against cloned human Dopamine receptor D2 in male Sprague-Dawley rats in a bar test;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2003.07.015
clozapine;958;None;57;Human;Binding;Ki;=;72,00;7,14;-51;98;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
clozapine;958;None;57;Human;Binding;Ki;=;41,00;7,39;-51;98;Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm015522j
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm015522j
clozapine;958;None;57;Human;Binding;Ki;=;58,04;7,24;-51;98;Displacement of [3H]spiperone from human dopamine D2S receptor S5.43T/S5.46A mutant expressed in CHO-K1 cell membrane after 2 hrs by beta counting;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.02.058
clozapine;958;None;57;Human;Binding;Ki;=;57,54;7,24;-51;98;Displacement of [3H]spiperone from human dopamine D2S receptor S5.43T/S5.46A mutant expressed in CHO-K1 cell membrane after 2 hrs by beta counting;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.02.058
clozapine;958;None;57;Human;Binding;Ki;=;89,13;7,05;-51;98;Displacement of [3H]spiperone from wild-type human dopamine D2S receptor expressed in CHO-K1 cell membrane after 2 hrs by beta counting;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.02.058
clozapine;958;None;57;Human;Binding;Ki;=;220,00;6,66;-51;98;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00004a016
clozapine;958;None;57;Human;Binding;Ki;=;88,65;7,05;-51;98;Displacement of [3H]spiperone from wild-type human dopamine D2S receptor expressed in CHO-K1 cell membrane after 2 hrs by beta counting;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.02.058
clozapine;958;None;57;Human;Binding;Ki;=;138,00;6,86;-51;98;Binding affinity towards human dopamine D2 receptor, using [3H]YM-09151 as a radioligand;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(02)00655-8
clozapine;958;None;57;Human;Binding;Ki;=;372,00;6,43;-51;98;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm0104825
clozapine;958;None;57;Human;Binding;Ki;=;260,00;6,58;-51;98;In vitro binding affinity towards Dopamine receptor D2 in human using [3H]-spiperone as radioligand;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm0309811
clozapine;958;None;57;Human;Binding;Ki;=;74,00;7,13;-51;98;Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm9600712
clozapine;958;None;57;Human;Binding;Ki;=;223,87;6,65;-51;98;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1039/C1MD00202C
clozapine;958;None;57;Human;Binding;Ki;=;130,00;6,89;-51;98;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
clozapine;958;None;57;Human;Binding;Ki;=;1000,00;6,00;-51;98;Binding affinity to dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1039/C2MD00311B
clozapine;958;None;57;Human;Binding;Ki;=;223,87;6,65;-51;98;Binding affinity towards dopamine receptor D2;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
clozapine;958;None;57;Human;Binding;Ki;=;91,00;7,04;-51;98;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm970422s
clozapine;958;None;57;Human;Binding;Ki;=;83,00;7,08;-51;98;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
clozapine;958;None;57;Human;Binding;Ki;=;113,00;6,95;-51;98;Binding affinity at human Dopamine receptor D2 by [3H]- YM 09151 displacement.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(00)00421-2
clozapine;958;None;57;Human;Binding;Ki;=;223,87;6,65;-51;98;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
clozapine;958;None;57;Human;Binding;Ki;=;71,00;7,15;-51;98;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
clozapine;958;None;57;Human;Binding;Ki;=;74,00;7,13;-51;98;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm960072u
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2S stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
clozapine;958;None;57;Human;Binding;Ki;=;39,00;7,41;-51;98;Ability to displace [3H]spiperone from the cloned human Dopamine receptor D2L stably expressed in Chinese hamster ovary (CHO) cells was determined.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00302-9
clozapine;958;None;57;Human;Binding;Ki;=;77,62;7,11;-51;98;Binding affinity against Dopamine receptor D2;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.06.005
clozapine;958;None;57;Human;Binding;Ki;=;31,62;7,50;-51;98;In vitro binding affinity for Dopamine receptor D2;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00200-1
clozapine;958;None;57;Human;Binding;Ki;=;74,00;7,13;-51;98;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm970111h
clozapine;958;None;57;Human;Binding;Ki;=;210,00;6,68;-51;98;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm501119j
clozapine;958;None;57;Human;Binding;Ki;=;41,00;7,39;-51;98;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
clozapine;958;None;57;Human;Binding;Ki;=;208,00;6,68;-51;98;Displacement of [3H]methylspiperone from dopamine D2 receptor expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.034
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;Displacement of [3H]spiperone from human Dopamine receptor D2S expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
clozapine;958;None;57;Human;Binding;Ki;=;41,00;7,39;-51;98;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00540-5
clozapine;958;None;57;Human;Binding;Ki;=;208,00;6,68;-51;98;Displacement of [3H]methylspiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.06.022
clozapine;958;None;57;Human;Binding;Ki;=;150,00;6,82;-51;98;Binding affinity towards human Dopamine receptor D2;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm030480f
clozapine;958;None;57;Human;Binding;Ki;=;41,00;7,39;-51;98;Displacement of [3H]spiperone from human Dopamine receptor D2L expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm0009989
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;Competitive binding affinity against human Dopamine receptor D2S by displacing [3H]spiperone from CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm0009989
clozapine;958;None;57;Human;Binding;Ki;=;223,87;6,65;-51;98;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
clozapine;958;None;57;Human;Binding;Ki;=;7,11;8,15;-51;98;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1007/s00044-012-0055-5
clozapine;958;None;57;Human;Binding;Ki;=;69,00;7,16;-51;98;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
clozapine;958;None;57;Human;Binding;Ki;=;72,00;7,14;-51;98;Competitive antagonist activity against human dopamine D2 receptor short isoform by R-SAT assay;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;None;57;Human;Binding;Ki;=;254,00;6,59;-51;98;Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm960637m
clozapine;958;None;57;Human;Binding;Ki;=;91,00;7,04;-51;98;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm970170v
clozapine;958;None;57;Human;Binding;Ki;=;41,00;7,39;-51;98;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm060166w
clozapine;958;None;57;Human;Binding;Ki;=;28,00;7,55;-51;98;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm060166w
clozapine;958;None;57;Human;Binding;Ki;=;144,00;6,84;-51;98;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1021/jm049632c
clozapine;958;None;57;Human;Binding;Ki;=;74,00;7,13;-51;98;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(99)00169-9
clozapine;958;None;57;Human;Binding;pKi;=;6,86;8,16;-51;98;None;Drug Central;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;None;57;Human;Binding;pKi;=;-;6,35;-51;98;Unclassified;Guide to Pharmacology;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/7907989
clozapine;958;None;57;Human;Binding;pKi;=;-;6,35;-51;98;Unclassified;Guide to Pharmacology;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/18308814
clozapine;958;None;57;Human;Binding;pKi;=;-;6,35;-51;98;Unclassified;Guide to Pharmacology;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/1354163
clozapine;958;None;57;Human;Binding;pKi;=;-;6,35;-51;98;Unclassified;Guide to Pharmacology;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/8301592
clozapine;958;None;57;Human;Binding;pKi;=;-;6,35;-51;98;Unclassified;Guide to Pharmacology;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/8301582
clozapine;958;UNDEFINED;57;Human;Binding;pKi;=;28,00;7,55;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;189,00;6,72;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;190,00;6,72;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;44,00;7,36;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;138,00;6,86;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-Methoxy raclopride;57;Human;Binding;pKi;=;49,90;7,30;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-YM 09151-2;57;Human;Binding;pKi;=;81,90;7,09;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;260,00;6,59;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-NEMONAPRIDE;57;Human;Binding;pKi;=;420,00;6,38;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;180,00;6,74;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;UNDEFINED;57;Human;Binding;pKi;=;44,00;7,36;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;125I-Epidepride;57;Human;Binding;pKi;=;149,00;6,83;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-NEMONAPRIDE;57;Human;Binding;pKi;=;187,00;6,73;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-RACLOPRIDE;57;Human;Binding;pKi;=;59,00;7,23;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-NEMONAPRIDE;57;Human;Binding;pKi;=;385,00;6,41;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;125I-IODOSULPRIDE;57;Human;Binding;pKi;=;69,00;7,16;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-NMSP;57;Human;Binding;pKi;=;256,00;6,59;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;UNDEFINED;57;Human;Binding;pKi;=;178,57;6,75;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;220,00;6,66;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;144,00;6,84;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;125I-Epidepride;57;Human;Binding;pKi;=;143,00;6,84;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;R-SAT;57;Human;Binding;pKi;=;72,00;7,14;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;168,00;6,77;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-NMSP;57;Human;Binding;pKi;=;187,00;6,73;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;180,00;6,74;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-RACLOPRIDE;57;Human;Binding;pKi;=;60,00;7,22;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;125I-Epidepride;57;Human;Binding;pKi;=;130,00;6,89;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-Clozapine;57;Human;Binding;pKi;=;44,00;7,36;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;210,00;6,68;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-N-Methylspiporone;57;Human;Binding;pKi;=;130,00;6,89;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;125I-Epidepride;57;Human;Binding;pKi;=;330,00;6,48;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;UNDEFINED;57;Human;Binding;pKi;=;83,00;7,08;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;125I-Epidepride;57;Human;Binding;pKi;=;176,00;6,75;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-RACLOPRIDE;57;Human;Binding;pKi;=;82,00;7,09;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;150,00;6,82;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;UNDEFINED;57;Human;Binding;pKi;=;41,00;7,39;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;137,00;6,86;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-N-Methylspiperone;57;Human;Binding;pKi;=;134,90;6,87;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;190,00;6,72;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-NMS;57;Human;Binding;pKi;=;291,00;6,54;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-RACLOPRIDE;57;Human;Binding;pKi;=;82,00;7,09;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;UNDEFINED;57;Human;Binding;pKi;=;130,00;6,89;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;125I-IODOSULPRIDE;57;Human;Binding;pKi;=;38,00;7,42;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;R-SAT;57;Human;Binding;pKi;=;71,00;7,15;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;260,00;6,59;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;159,00;6,80;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-SPIPERONE;57;Human;Binding;pKi;=;180,00;6,74;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
clozapine;958;3H-NMSP;57;Human;Binding;pKi;=;431,00;6,37;-51;98;-;PDSP KiDatabase;326,1;0;1;4;3,72;CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1;-
COCAINE;133590;3H-NMSP;7;Human;Binding;pKi;=;10000,00;5,00;-1778;45;-;PDSP KiDatabase;303,1;3;0;5;1,87;COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C;-
COCAINE;133590;3H-YM 09151-2;7;Human;Binding;pKi;=;10000,00;5,00;-1778;45;-;PDSP KiDatabase;303,1;3;0;5;1,87;COC(=O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@@H]2CC[C@H]1N2C;-
compound 1a [PMID: 18573659];1010;None;6;Human;Binding;Ki;=;100,00;7,00;-25;8;Binding affinity to dopamine D2 receptor;ChEMBL;525,1;6;2;4;4,89;O=C(N[C@H]1CCN(Cc2ccc(OC3CCNCC3)c(Br)c2)C1)c1ccc(Cl)c(Cl)c1;https://dx.doi.org/10.1016/j.bmcl.2008.06.019
compound 28.1 [PMID: 36847646];1052;None;4;Human;Binding;Ki;=;16000,00;4,80;-9;4;Displacement of [3H]methylspiperone from human D2L receptor stably expressed in CHO cells by Cheng-Prusoff equation analysis;ChEMBL;321,1;3;2;6;2,73;Cc1cc(C(F)(F)F)nc(Nc2ccccc2-c2nnn[nH]2)n1;https://dx.doi.org/10.1021/acs.jmedchem.2c01997
compound 28.1 [PMID: 36847646];1052;None;4;Human;Binding;Ki;=;7300,00;5,14;-9;4;Displacement of [3H]methylspiperone from human D2S receptor stably expressed in CHO cells by Cheng-Prusoff equation analysis;ChEMBL;321,1;3;2;6;2,73;Cc1cc(C(F)(F)F)nc(Nc2ccccc2-c2nnn[nH]2)n1;https://dx.doi.org/10.1021/acs.jmedchem.2c01997
compound 3 [PMID: 23134120];1091;None;1;Human;Binding;Ki;=;118,00;6,93;-19;4;Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells;ChEMBL;295,2;8;1;2;3,89;Oc1cccc(CCN(CCc2ccccc2)CC2CC2)c1;https://dx.doi.org/10.1021/jm301258w
compound 3 [PMID: 23134120];1091;None;1;Human;Binding;pKi;=;-;6,93;-19;4;Unclassified;Guide to Pharmacology;295,2;8;1;2;3,89;Oc1cccc(CCN(CCc2ccccc2)CC2CC2)c1;https://pubmed.ncbi.nlm.nih.gov/23134120
CP-226269;1177;None;34;Human;Binding;Ki;=;120,00;6,92;-301;7;Binding affinity towards human Dopamine receptor D2;ChEMBL;310,2;3;1;3;3,02;Fc1ccc2[nH]c(CN3CCN(c4ccccn4)CC3)cc2c1;https://dx.doi.org/10.1021/jm030505a
cyamemazine;1274;None;0;Human;Binding;pKi;=;8,24;8,08;-2;15;None;Drug Central;323,1;4;0;4;4,36;CC(CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21;-
cyamemazine;1274;3H-Butaclamol(+);0;Human;Binding;pKi;=;5,80;8,24;-2;15;-;PDSP KiDatabase;323,1;4;0;4;4,36;CC(CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21;-
CYCLOBENZAPRINE;206050;None;27;Human;Binding;AC50;=;3600,00;5,44;-;17;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;275,2;3;0;1;4,55;CN(C)CCC=C1c2ccccc2C=Cc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
cyproheptadine;1301;None;39;Human;Binding;IC50;=;164,00;6,79;-61;53;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;287,2;0;0;1;4,70;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;-
cyproheptadine;1301;None;39;Human;Binding;Ki;=;112,00;6,95;-61;53;Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;287,2;0;0;1;4,70;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2004.02.014
cyproheptadine;1301;None;39;Human;Binding;Ki;=;55,00;7,26;-61;53;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;287,2;0;0;1;4,70;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;-
cyproheptadine;1301;None;39;Human;Binding;pKi;=;6,95;8,16;-61;53;None;Drug Central;287,2;0;0;1;4,70;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;-
cyproheptadine;1301;3H-YM 09151-2;39;Human;Binding;pKi;=;112,00;6,95;-61;53;-;PDSP KiDatabase;287,2;0;0;1;4,70;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;-
cyproheptadine;1301;3H-Methylspiperone;39;Human;Binding;pKi;=;74,00;7,13;-61;53;-;PDSP KiDatabase;287,2;0;0;1;4,70;CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1;-
D-cystine;218798;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;33;-;PDSP KiDatabase;240;7;4;6;-0,81;NC(CSSCC(N)C(=O)O)C(=O)O;-
D-cystine;218798;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;33;-;PDSP KiDatabase;240;7;4;6;-0,81;NC(CSSCC(N)C(=O)O)C(=O)O;-
D-methionine;218799;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;33;-;PDSP KiDatabase;149,1;4;2;3;0,15;CSCCC(N)C(=O)O;-
D-methionine;218799;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;33;-;PDSP KiDatabase;149,1;4;2;3;0,15;CSCCC(N)C(=O)O;-
DACOMITINIB ANHYDROUS;78425;None;58;Human;Binding;AC50;=;8000,00;5,10;-;5;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;469,2;7;2;6;5,16;COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1;https://dx.doi.org/10.1038/s41467-023-40064-9
darifenacin;1324;None;32;Human;Binding;AC50;=;10999,90;4,96;-;22;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;426,2;7;1;3;3,96;NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1;https://dx.doi.org/10.1038/s41467-023-40064-9
darifenacin;1324;None;32;Human;Binding;IC50;=;25118,86;4,60;-;22;Binding affinity to dopamine 2 receptor;ChEMBL;426,2;7;1;3;3,96;NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
DAUNORUBICIN;62505;None;35;Human;Binding;AC50;=;13769,60;4,86;-;21;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;527,2;4;5;11;1,03;COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1;https://dx.doi.org/10.1038/s41467-023-40064-9
DEPRENYL;218480;3H-YM 09151-2;0;Human;Binding;pKi;=;10000,00;5,00;-1;4;-;PDSP KiDatabase;187,1;4;0;1;2,18;C#CCN(C)C(C)Cc1ccccc1;-
DESIPRAMINE;206863;None;31;Human;Binding;AC50;=;8400,00;5,08;-43;31;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;266,2;4;1;2;3,53;CNCCCN1c2ccccc2CCc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
DESIPRAMINE;206863;None;31;Human;Binding;pKi;=;5,63;8,25;-43;31;None;Drug Central;266,2;4;1;2;3,53;CNCCCN1c2ccccc2CCc2ccccc21;-
DESIPRAMINE;206863;3H-YM 09151-2;31;Human;Binding;pKi;=;1561,00;5,81;-43;31;-;PDSP KiDatabase;266,2;4;1;2;3,53;CNCCCN1c2ccccc2CCc2ccccc21;-
DESIPRAMINE;206863;3H-SPIPERONE;31;Human;Binding;pKi;=;3500,00;5,46;-43;31;-;PDSP KiDatabase;266,2;4;1;2;3,53;CNCCCN1c2ccccc2CCc2ccccc21;-
desloratadine;1389;None;72;Human;Binding;AC50;=;1600,00;5,80;-;27;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;310,1;0;1;2;4,02;Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1;https://dx.doi.org/10.1038/s41467-023-40064-9
DESMETHYLOLANZAPINE;9587;None;44;Human;Binding;Ki;=;9,00;8,05;2;3;In vitro binding affinity of compound against neuronal Dopamine receptor D2;ChEMBL;298,1;0;2;5;3,10;Cc1cc2c(s1)Nc1ccccc1N=C2N1CCNCC1;https://dx.doi.org/10.1016/S0960-894X(96)00567-7
Desmethylsertraline;218589;3H-SPIPERONE;0;Human;Binding;pKi;=;10000,00;5,00;-6;8;-;PDSP KiDatabase;291,1;1;1;1;4,92;NC1CCC(c2ccc(Cl)c(Cl)c2)c2ccccc21;-
Desvenlafaxine;218980;3H-RACLOPRIDE;0;Human;Binding;pKi;=;10000,00;5,00;-1;14;-;PDSP KiDatabase;399,2;7;4;5;1,84;CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1.O.O=C(O)CCC(=O)O;-
dexamfetamine;1401;3H-YM 09151-2;9;Human;Binding;pKi;=;10000,00;5,00;-53;10;-;PDSP KiDatabase;135,1;2;1;1;1,58;C[C@H](N)Cc1ccccc1;-
DEXPRAMIPEXOLE;94207;None;39;Human;Binding;Ki;=;1000,00;6,00;-1513;3;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;211,1;3;2;4;1,58;CCCN[C@@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
DHE;218428;3H-YM 09151-2;0;Human;Binding;pKi;=;5,00;8,30;-83;20;-;PDSP KiDatabase;583,3;4;3;6;2,08;CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)CC2c3cccc4[nH]cc(c34)CC21;-
DIBENZEPIN;35931;None;28;Human;Binding;Ki;=;30200,00;4,52;-1513;12;Binding affinity to D2 receptor (unknown origin);ChEMBL;295,2;3;0;3;2,98;CN(C)CCN1C(=O)c2ccccc2N(C)c2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2020.127493
Diclofenac sodium salt;218878;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;29;-;PDSP KiDatabase;317;4;1;3;0,03;O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+];-
DIETHYLSTILBESTROL;160344;None;54;Human;Binding;IC50;=;13321,00;4,88;-30;32;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;268,1;4;2;2;4,83;CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1;-
DIETHYLSTILBESTROL;160344;None;54;Human;Binding;Ki;=;4440,00;5,35;-30;32;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;268,1;4;2;2;4,83;CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1;-
DIETHYLSTILBESTROL;160344;None;54;Human;Binding;pKi;=;5,35;8,27;-30;32;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;268,1;4;2;2;4,83;CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1;-
DIFLUOROBENZTROPINE;107426;None;4;Human;Binding;Ki;=;767,36;6,12;-128;19;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;343,2;4;0;2;4,70;CN1C2CCC1CC(OC(c1ccc(F)cc1)c1ccc(F)cc1)C2;https://dx.doi.org/10.6019/CHEMBL5442175
DIHYDREXIDINE;95827;None;16;Human;Binding;EC50;=;1610,00;5,79;-79;16;Adenylate cyclase assay carried out in LTK cells transfected with human Dopamine receptor D2;ChEMBL;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;https://dx.doi.org/10.1021/jm00018a002
DIHYDREXIDINE;95827;None;16;Human;Binding;Ki;=;58,00;7,24;-79;16;Binding affinity to dopamine D2 receptor;ChEMBL;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;https://dx.doi.org/10.1016/j.ejmech.2011.11.039
DIHYDREXIDINE;95827;None;16;Human;Binding;Ki;=;2607,00;5,58;-79;16;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells by scintillation counting;ChEMBL;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;https://dx.doi.org/10.1016/j.bmc.2009.08.028
DIHYDREXIDINE;95827;None;16;Human;Binding;Ki;=;240,00;6,62;-79;16;Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate;ChEMBL;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;https://dx.doi.org/10.1021/jm0604979
DIHYDREXIDINE;95827;None;16;Human;Binding;Ki;=;1520,00;5,82;-79;16;Binding affinity against cloned human Dopamine receptor D2 using [3H]spiperone as radioligand transfected in HEK cells;ChEMBL;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;https://dx.doi.org/10.1021/jm00018a002
DIHYDREXIDINE;95827;None;16;Human;Binding;Ki;=;1700,00;5,77;-79;16;Affinity towards Dopamine receptor D2;ChEMBL;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;https://dx.doi.org/10.1021/jm9800292
DIHYDREXIDINE;95827;None;16;Human;Binding;Ki;=;1520,00;5,82;-79;16;Binding affinity to human Dopamine receptor D2 by using radioligand [3H]spiperone in LTK cells;ChEMBL;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;https://dx.doi.org/10.1016/s0960-894x(99)00214-0
DIHYDREXIDINE;95827;3H-NMSP;16;Human;Binding;pKi;=;240,00;6,62;-79;16;-;PDSP KiDatabase;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;-
DIHYDREXIDINE;95827;3H-SPIPERONE;16;Human;Binding;pKi;=;2607,00;5,58;-79;16;-;PDSP KiDatabase;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;-
DIHYDREXIDINE;95827;3H-SPIPERONE;16;Human;Binding;pKi;=;1520,00;5,82;-79;16;-;PDSP KiDatabase;267,1;0;3;3;2,65;Oc1cc2c(cc1O)[C@H]1c3ccccc3CN[C@@H]1CC2;-
DIHYDROERGOCRISTINE;203402;None;16;Human;Binding;IC50;=;1,47;8,83;-5;22;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;611,3;5;3;6;2,72;CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O;-
DIHYDROERGOCRISTINE;203402;None;16;Human;Binding;Ki;=;0,49;9,31;-5;22;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;611,3;5;3;6;2,72;CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O;-
DIHYDROERGOCRISTINE;203402;None;16;Human;Binding;pKi;=;9,31;8,03;-5;22;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;611,3;5;3;6;2,72;CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O;-
dihydroergotamine;1420;None;13;Human;Binding;AC50;=;40,00;7,40;-30;42;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;583,3;4;3;6;2,08;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1038/s41467-023-40064-9
dihydroergotamine;1420;None;13;Human;Binding;IC50;=;8,88;8,05;-30;42;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;583,3;4;3;6;2,08;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
dihydroergotamine;1420;None;13;Human;Binding;Ki;=;2,96;8,53;-30;42;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;583,3;4;3;6;2,08;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
dihydroergotamine;1420;None;13;Human;Binding;Ki;=;60,92;7,21;-30;42;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;583,3;4;3;6;2,08;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.6019/CHEMBL5442175
dihydroergotamine;1420;None;13;Human;Binding;pKi;=;8,53;8,07;-30;42;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;583,3;4;3;6;2,08;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
diphenidol;1433;None;30;Human;Binding;IC50;=;3290,00;5,48;-1;14;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;309,2;6;1;2;4,19;OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1;-
diphenidol;1433;None;30;Human;Binding;Ki;=;1097,00;5,96;-1;14;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;309,2;6;1;2;4,19;OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1;-
diphenidol;1433;None;30;Human;Binding;pKi;=;5,96;8,22;-1;14;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;309,2;6;1;2;4,19;OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1;-
DISULFIRAM;210300;None;60;Human;Binding;IC50;=;23018,00;4,64;-5;24;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;296,1;4;0;4;3,62;CCN(CC)C(=S)SSC(=S)N(CC)CC;-
DISULFIRAM;210300;None;60;Human;Binding;Ki;=;7673,00;5,12;-5;24;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;296,1;4;0;4;3,62;CCN(CC)C(=S)SSC(=S)N(CC)CC;-
DISULFIRAM;210300;None;60;Human;Binding;pKi;=;5,12;8,29;-5;24;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;296,1;4;0;4;3,62;CCN(CC)C(=S)SSC(=S)N(CC)CC;-
DL-homocysteic acid;218805;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;29;-;PDSP KiDatabase;183;4;3;4;-1,32;NC(CCS(=O)(=O)O)C(=O)O;-
DL-homocysteine;218800;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;33;-;PDSP KiDatabase;135;3;3;3;-0,28;NC(CCS)C(=O)O;-
dobutamine;1454;None;27;Human;Binding;AC50;=;8199,90;5,09;-;17;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;301,2;7;4;4;2,96;CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
DOMIPHEN;12618;None;11;Human;Binding;AC50;=;2000,00;5,70;-;26;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;334,3;15;0;1;6,06;CCCCCCCCCCCC[N+](C)(C)CCOc1ccccc1;https://dx.doi.org/10.1038/s41467-023-40064-9
domperidone;1462;None;65;Human;Binding;AC50;=;6,00;8,22;-2;33;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
domperidone;1462;None;65;Human;Binding;IC50;=;2,65;8,58;-2;33;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;-
domperidone;1462;None;65;Human;Binding;Ki;=;1,30;8,89;-2;33;Radioligand Binding Assay: The pharmacological profile of metopimazine, metopimazine acid (MPZA), domperidone, and metoclopramide were assessed by radioligand binding and by a functional antagonist assay. For the radioligand binding assay, cell membranes of dopamine D2 receptor expressing cells were incubated with [3H]spiperone and competing drugs in buffer. The assay was terminated by rapid filtration, and the bound radioactive signal was determined by liquid scintillation counting.;ChEMBL;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;-
domperidone;1462;None;65;Human;Binding;Ki;=;0,88;9,05;-2;33;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;-
domperidone;1462;None;65;Human;Binding;pKi;=;8,40;8,08;-2;33;None;Drug Central;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;-
domperidone;1462;None;65;Human;Binding;pKi;=;-;8,15;-2;33;Unclassified;Guide to Pharmacology;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/8301582
domperidone;1462;None;65;Human;Binding;pKi;=;-;8,15;-2;33;Unclassified;Guide to Pharmacology;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/1354163
domperidone;1462;3H-SPIPERONE;65;Human;Binding;pKi;=;4,90;8,31;-2;33;-;PDSP KiDatabase;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;-
domperidone;1462;3H-S-Sulpiride;65;Human;Binding;pKi;=;3,30;8,48;-2;33;-;PDSP KiDatabase;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;-
domperidone;1462;125I-IODOSULPRIDE;65;Human;Binding;pKi;=;0,58;9,24;-2;33;-;PDSP KiDatabase;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;-
domperidone;1462;125I-IODOSULPRIDE;65;Human;Binding;pKi;=;1,30;8,89;-2;33;-;PDSP KiDatabase;425,2;5;2;5;3,35;O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1;-
dopamine;1465;None;47;Human;Binding;EC50;=;170,00;6,77;-40;40;Adenylate cyclase assay carried out in LTK cells transfected with human Dopamine receptor D2;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm00018a002
dopamine;1465;None;47;Human;Binding;EC50;=;390,00;6,41;-40;40;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
dopamine;1465;None;47;Human;Binding;EC50;=;160,00;6,80;-40;40;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
dopamine;1465;None;47;Human;Binding;EC50;=;6,70;8,17;-40;40;Agonist activity at dopamine D2 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 by FLIPR assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm400408r
dopamine;1465;None;47;Human;Binding;EC50;=;3,98;8,40;-40;40;Agonist activity at dopamine D2 receptor short isoform (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;None;47;Human;Binding;EC50;=;0,67;9,17;-40;40;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
dopamine;1465;None;47;Human;Binding;EC50;=;4,50;8,35;-40;40;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
dopamine;1465;None;47;Human;Binding;EC50;=;3,90;8,41;-40;40;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
dopamine;1465;None;47;Human;Binding;EC50;=;2,80;8,55;-40;40;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
dopamine;1465;None;47;Human;Binding;EC50;=;18,00;7,75;-40;40;In vitro effective concentration tested on HEK293 cells co-transfected with human Dopamine receptor D2 using FLIPR assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm030505a
dopamine;1465;None;47;Human;Binding;EC50;=;0,78;9,11;-40;40;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
dopamine;1465;None;47;Human;Binding;EC50;=;226,00;6,65;-40;40;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
dopamine;1465;None;47;Human;Binding;EC50;=;163,00;6,79;-40;40;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
dopamine;1465;None;47;Human;Binding;EC50;=;0,69;9,16;-40;40;Agonist activity at D2 receptor (unknown origin) expressed in CHOK1 cells co-expressing G-alpha 15 by fluo-4 dye based FLIPR assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.ejmech.2016.07.038
dopamine;1465;None;47;Human;Binding;EC50;=;156,00;6,81;-40;40;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
dopamine;1465;None;47;Human;Binding;EC50;=;7,70;8,11;-40;40;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
dopamine;1465;None;47;Human;Binding;EC50;=;5,00;8,30;-40;40;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
dopamine;1465;None;47;Human;Binding;EC50;=;200,41;6,70;-40;40;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2022.117131
dopamine;1465;None;47;Human;Binding;IC50;=;100000,00;4,00;-40;40;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;IC50;=;1000,00;6,00;-40;40;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;110,00;6,96;-40;40;Displacement of [3H]spiperone from human dopamine D2short receptor expressed in CHO cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
dopamine;1465;None;47;Human;Binding;Ki;=;190,00;6,72;-40;40;Displacement of [3H]spiperone from human dopamine D2long receptor expressed in CHO cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2013.01.065
dopamine;1465;None;47;Human;Binding;Ki;=;2,00;8,70;-40;40;Displacement of [3H]-raclopride from high-affinity state of human dopamine D2L receptor (443 amino acids) expressed in LTK deficient mouse fibroblasts after 60 mins by liquid scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;2100,00;5,68;-40;40;Displacement of [3H]raclopride from human D2L receptor expressed in HEK293 cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.ejmech.2012.07.025
dopamine;1465;None;47;Human;Binding;Ki;=;572,00;6,24;-40;40;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm960350p
dopamine;1465;None;47;Human;Binding;Ki;=;920,00;6,04;-40;40;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;8,00;8,10;-40;40;Displacement of [3H]-NPA from dopamine D2L receptor (unknown origin) expressed in CHO cell membranes;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401318w
dopamine;1465;None;47;Human;Binding;Ki;=;260,00;6,58;-40;40;Binding affinity against cloned human Dopamine receptor D2 using [3H]spiperone as radioligand transfected in HEK cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm00018a002
dopamine;1465;None;47;Human;Binding;Ki;=;107,15;6,97;-40;40;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;2,90;8,54;-40;40;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm901689v
dopamine;1465;None;47;Human;Binding;Ki;=;16,00;7,80;-40;40;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
dopamine;1465;None;47;Human;Binding;Ki;=;56,00;7,25;-40;40;Displacement of [3H]-iodosulpiride from recombinant high-affinity state of human dopamine D2L receptor;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;20,00;7,70;-40;40;Binding affinity on High Affinity Site of Dopamine receptor D2L;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm991098z
dopamine;1465;None;47;Human;Binding;Ki;=;360,00;6,44;-40;40;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm800895v
dopamine;1465;None;47;Human;Binding;Ki;=;450,00;6,35;-40;40;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm800895v
dopamine;1465;None;47;Human;Binding;Ki;=;17,00;7,77;-40;40;Binding Affinity on High Affinity Site of Dopamine receptor D2S;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm991098z
dopamine;1465;None;47;Human;Binding;Ki;=;1900,00;5,72;-40;40;Binding Affinity was tested on low Affinity Site of Dopamine receptor D2L;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm991098z
dopamine;1465;None;47;Human;Binding;Ki;=;48,00;7,32;-40;40;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
dopamine;1465;None;47;Human;Binding;Ki;=;1100,00;5,96;-40;40;Binding Affinity of Compound of Dopamine receptor D2S;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm991098z
dopamine;1465;None;47;Human;Binding;Ki;=;42,00;7,38;-40;40;Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D2L;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm991098z
dopamine;1465;None;47;Human;Binding;Ki;=;1,89;8,72;-40;40;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
dopamine;1465;None;47;Human;Binding;Ki;=;759,00;6,12;-40;40;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
dopamine;1465;None;47;Human;Binding;Ki;=;34,00;7,47;-40;40;Binding Affinity was tested on relative proportion of High Affinity Site of Dopamine receptor D2S;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm991098z
dopamine;1465;None;47;Human;Binding;Ki;=;15000,00;4,82;-40;40;Binding Affinity was determined in the presence of 100 micro M Gpp(NH)p for decoupling of the ternary complex of Compound to Dopamine receptor D2L;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm991098z
dopamine;1465;None;47;Human;Binding;Ki;=;7940,00;5,10;-40;40;Affinity towards Dopamine receptor D2;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm9800292
dopamine;1465;None;47;Human;Binding;Ki;=;22,00;7,66;-40;40;Displacement of [3H]-iodosulpiride from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;15000,00;4,82;-40;40;Binding Affinity was determined in the presence of 100 micro M Gpp(NH)p for decoupling of the ternary complex of Compound to Dopamine receptor D2S;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm991098z
dopamine;1465;None;47;Human;Binding;Ki;=;3690,00;5,43;-40;40;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
dopamine;1465;None;47;Human;Binding;Ki;=;2100,00;5,68;-40;40;Displacement of [3H]raclopride from human dopamine D2L receptor expressed in HEK293 cells by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2013.05.014
dopamine;1465;None;47;Human;Binding;Ki;=;422,00;6,38;-40;40;Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm301258w
dopamine;1465;None;47;Human;Binding;Ki;=;8,73;8,06;-40;40;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
dopamine;1465;None;47;Human;Binding;Ki;=;2100,00;5,68;-40;40;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm901689v
dopamine;1465;None;47;Human;Binding;Ki;=;1,89;8,72;-40;40;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm960350p
dopamine;1465;None;47;Human;Binding;Ki;=;11600,00;4,94;-40;40;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;231,00;6,64;-40;40;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;870,96;6,06;-40;40;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;Ki;=;5623,41;5,25;-40;40;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://dx.doi.org/10.1021/jm401384w
dopamine;1465;None;47;Human;Binding;pKi;=;9,00;8,05;-40;40;None;Drug Central;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;None;47;Human;Binding;pKi;=;-;5,95;-40;40;Unclassified;Guide to Pharmacology;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://pubmed.ncbi.nlm.nih.gov/8301582
dopamine;1465;None;47;Human;Binding;pKi;=;-;5,95;-40;40;Unclassified;Guide to Pharmacology;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://pubmed.ncbi.nlm.nih.gov/7756621
dopamine;1465;None;47;Human;Binding;pKi;=;-;5,95;-40;40;Unclassified;Guide to Pharmacology;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;https://pubmed.ncbi.nlm.nih.gov/7576010
dopamine;1465;3H-SPIPERONE;47;Human;Binding;pKi;=;1606,00;5,79;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;3H-SPIPERONE;47;Human;Binding;pKi;=;200,00;6,70;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;125I-7-OH-PIPAT;47;Human;Binding;pKi;=;17,00;7,77;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;UNDEFINED;47;Human;Binding;pKi;=;360,00;6,44;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;3H-SPIPERONE;47;Human;Binding;pKi;=;260,00;6,59;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;UNDEFINED;47;Human;Binding;pKi;=;450,00;6,35;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;UNDEFINED;47;Human;Binding;pKi;=;2,90;8,54;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;125I-IODOSULPRIDE;47;Human;Binding;pKi;=;544,00;6,26;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;3H-thymidine;47;Human;Binding;pKi;=;20,00;7,70;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;125I-IODOSULPRIDE;47;Human;Binding;pKi;=;540,00;6,27;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;3H-S-Sulpiride;47;Human;Binding;pKi;=;250,00;6,60;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;UNDEFINED;47;Human;Binding;pKi;=;2100,00;5,68;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;125I-IODOSULPRIDE;47;Human;Binding;pKi;=;710,00;6,15;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;3H-RACLOPRIDE;47;Human;Binding;pKi;=;10000,00;5,00;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;3H-YM 09151-2;47;Human;Binding;pKi;=;422,00;6,37;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
dopamine;1465;3H-SPIPERONE;47;Human;Binding;pKi;=;576,00;6,24;-40;40;-;PDSP KiDatabase;153,1;2;3;3;0,60;NCCc1ccc(O)c(O)c1;-
DOTHIEPIN;41735;None;12;Human;Binding;AC50;=;14000,10;4,85;-;18;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;295,1;3;0;2;4,68;CN(C)CC/C=C1\c2ccccc2CSc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
DOXANTHRINE;82438;None;1;Human;Binding;Ki;=;3700,00;5,43;-1348;9;Displacement of [3H]spiperone from dopamine D2-like receptor in porcine striata homogenate;ChEMBL;269,1;0;3;4;2,09;Oc1cc2c(cc1O)C1c3ccccc3CNC1CO2;https://dx.doi.org/10.1021/jm0604979
DOXANTHRINE;82438;None;1;Human;Binding;Ki;=;1910,00;5,72;-1348;9;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;269,1;0;3;4;2,09;Oc1cc2c(cc1O)C1c3ccccc3CNC1CO2;https://dx.doi.org/10.1021/jm0604979
doxepin;1471;3H-SPIPERONE;18;Human;Binding;pKi;=;360,00;6,44;-1288;29;-;PDSP KiDatabase;279,2;3;0;2;3,96;CN(C)CC/C=C1\c2ccccc2COc2ccccc21;-
DOXEPIN;56283;None;21;Human;Binding;AC50;=;1400,00;5,85;-;28;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;279,2;3;0;2;3,96;CN(C)CCC=C1c2ccccc2COc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
DROPERIDOL;9264;None;62;Human;Binding;IC50;=;2,41;8,62;-1;21;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;379,2;6;1;4;3,68;O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;-
DROPERIDOL;9264;None;62;Human;Binding;Ki;=;0,80;9,10;-1;21;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;379,2;6;1;4;3,68;O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;-
DROPERIDOL;9264;None;62;Human;Binding;pKi;=;9,60;8,02;-1;21;None;Drug Central;379,2;6;1;4;3,68;O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;-
DROPERIDOL;9264;UNDEFINED;62;Human;Binding;pKi;=;0,25;9,60;-1;21;-;PDSP KiDatabase;379,2;6;1;4;3,68;O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1;-
duloxetine;1508;None;46;Human;Binding;AC50;=;6599,90;5,18;-97;44;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;297,1;6;1;3;4,63;CNCC[C@H](Oc1cccc2ccccc12)c1cccs1;https://dx.doi.org/10.1038/s41467-023-40064-9
duloxetine;1508;3H-SPIPERONE;46;Human;Binding;pKi;=;10000,00;5,00;-97;44;-;PDSP KiDatabase;297,1;6;1;3;4,63;CNCC[C@H](Oc1cccc2ccccc12)c1cccs1;-
EBASTINE;102913;None;65;Human;Binding;AC50;=;3900,00;5,41;-74;33;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;469,3;9;0;3;7,22;CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
EBASTINE;102913;None;65;Human;Binding;IC50;=;61,00;7,21;-74;33;Compound is evaluated for in vitro receptor binding affinity against Dopamine receptor D2;ChEMBL;469,3;9;0;3;7,22;CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm00020a018
EBASTINE;102913;None;65;Human;Binding;IC50;=;1149,10;5,94;-74;33;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;469,3;9;0;3;7,22;CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1;-
EBASTINE;102913;None;65;Human;Binding;Ki;=;383,00;6,42;-74;33;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;469,3;9;0;3;7,22;CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1;-
EBASTINE;102913;None;65;Human;Binding;pIC50;=;7,21;8,14;-74;33;Compound is evaluated for in vitro receptor binding affinity against Dopamine receptor D2;Drug Central;469,3;9;0;3;7,22;CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1;-
ECONAZOLE;207971;None;50;Human;Binding;IC50;=;12807,00;4,89;-30;38;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;380;6;0;3;5,80;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1;-
ECONAZOLE;207971;None;50;Human;Binding;Ki;=;4269,00;5,37;-30;38;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;380;6;0;3;5,80;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1;-
ECONAZOLE;207971;None;50;Human;Binding;pKi;=;5,37;8,27;-30;38;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;380;6;0;3;5,80;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1;-
ecopipam;1529;None;25;Human;Binding;Ki;=;1240,00;5,91;-616;7;Binding affinity to human dopamine D2 receptor;ChEMBL;313,1;0;1;2;3,98;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccccc3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2020.127563
ecopipam;1529;None;25;Human;Binding;Ki;=;980,00;6,01;-616;7;Binding affinity to dopamine D2 receptor;ChEMBL;313,1;0;1;2;3,98;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccccc3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
ecopipam;1529;None;25;Human;Binding;Ki;=;980,00;6,01;-616;7;Displacement of [3H]methylspiperon from dopamine D2 receptor expressed in mouse LTK cells by scintillation counting;ChEMBL;313,1;0;1;2;3,98;CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccccc3CC[C@@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.12.094
EGIS-11150;1536;None;0;Human;Binding;pKi;=;-;6,92;-38;4;Unclassified;Guide to Pharmacology;405,1;5;1;7;3,01;Cn1ncc(NCCN2CCC(c3noc4cc(F)ccc34)CC2)c(Cl)c1=O;https://pubmed.ncbi.nlm.nih.gov/22824189
ELOPIPRAZOLE;100706;None;14;Human;Binding;Ki;=;0,42;9,38;1;3;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;375,2;4;1;3;4,89;Fc1ccc(-c2ccc(CN3CCN(c4cccc5ccoc45)CC3)[nH]2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
EMETINE;188904;None;34;Human;Binding;AC50;=;16000,00;4,80;-;12;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;480,3;7;1;6;4,94;CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21;https://dx.doi.org/10.1038/s41467-023-40064-9
endo-8-(1H-Indol-3-ylmethyl)-3-(4-chlorophenyl)-8-azabicyclo-[3.2.1]octan-3-ol;219649;UNDEFINED;0;Human;Binding;pKi;=;160,30;6,80;-6;3;-;PDSP KiDatabase;366,1;3;2;2;4,84;OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2Cc1c[nH]c2ccccc12;-
EPALRESTAT;198942;None;55;Human;Binding;AC50;=;9100,00;5,04;-;19;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;319;4;1;4;2,92;CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1;https://dx.doi.org/10.1038/s41467-023-40064-9
Ephedrine,(-);218667;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-4;40;-;PDSP KiDatabase;165,1;3;2;2;1,33;CNC(C)C(O)c1ccccc1;-
Ephedrine,(-);218667;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-4;40;-;PDSP KiDatabase;165,1;3;2;2;1,33;CNC(C)C(O)c1ccccc1;-
Ephedrine,(-);218667;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-4;40;-;PDSP KiDatabase;165,1;3;2;2;1,33;CNC(C)C(O)c1ccccc1;-
Ephedrine,(-);218667;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-4;40;-;PDSP KiDatabase;165,1;3;2;2;1,33;CNC(C)C(O)c1ccccc1;-
EPIDEPRIDE;218542;3H-NEMONAPRIDE;0;Human;Binding;pKi;=;0,27;9,57;1;4;-;PDSP KiDatabase;418,1;6;1;4;2,52;CCN1CCCC1CNC(=O)c1cc(I)cc(OC)c1OC;-
EPIDEPRIDE;218542;3H-RACLOPRIDE;0;Human;Binding;pKi;=;0,03;10,52;1;4;-;PDSP KiDatabase;418,1;6;1;4;2,52;CCN1CCCC1CNC(=O)c1cc(I)cc(OC)c1OC;-
EPIDEPRIDE;218542;UNDEFINED;0;Human;Binding;pKi;=;0,01;11,00;1;4;-;PDSP KiDatabase;418,1;6;1;4;2,52;CCN1CCCC1CNC(=O)c1cc(I)cc(OC)c1OC;-
EPIDEPRIDE;218542;3H-SPIPERONE;0;Human;Binding;pKi;=;0,06;10,22;1;4;-;PDSP KiDatabase;418,1;6;1;4;2,52;CCN1CCCC1CNC(=O)c1cc(I)cc(OC)c1OC;-
ERGOCORNINE;29624;None;14;Human;Binding;IC50;=;5,03;8,30;-2;18;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;561,3;4;3;6;2,04;CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
ERGOCORNINE;29624;None;14;Human;Binding;Ki;=;1,68;8,78;-2;18;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;561,3;4;3;6;2,04;CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12;-
ERGOLINE;95005;None;0;Human;Binding;Kd;=;56,23;7,25;-275;10;Binding affinity to human dopamine D2 receptor;ChEMBL;523,2;2;1;5;2,94;CN1C[C@H](C(=O)N2CCN(c3cccc(=O)n3C)CC2)C[C@@H]2c3cccc4[nH]c(Br)c(c34)C[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2007.12.030
ERGOLINE;95005;None;0;Human;Binding;Kd;=;56,23;7,25;-275;10;Binding affinity to dopamine D2 receptor;ChEMBL;523,2;2;1;5;2,94;CN1C[C@H](C(=O)N2CCN(c3cccc(=O)n3C)CC2)C[C@@H]2c3cccc4[nH]c(Br)c(c34)C[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2009.01.072
ergometrine;1581;None;13;Human;Binding;IC50;=;552,00;6,26;-288;17;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;325,2;3;3;3;1,53;C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
ergometrine;1581;None;13;Human;Binding;Ki;=;184,00;6,74;-288;17;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;325,2;3;3;3;1,53;C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
ergotamine;1582;None;6;Human;Binding;AC50;=;2200,00;5,66;-15;32;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;581,3;4;3;6;1,99;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1038/s41467-023-40064-9
ergotamine;1582;None;6;Human;Binding;IC50;=;4,30;8,37;-15;32;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;581,3;4;3;6;1,99;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21;-
ergotamine;1582;None;6;Human;Binding;Ki;=;1,43;8,84;-15;32;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;581,3;4;3;6;1,99;CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21;-
ERGOTAMINE;218443;None;0;Human;Binding;pKi;=;8,85;8,05;-4168;62;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;581,3;4;3;6;1,99;CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)CC21;-
ERGOTAMINE;218443;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-4168;62;-;PDSP KiDatabase;581,3;4;3;6;1,99;CN1CC(C(=O)NC2(C)OC3(O)C4CCCN4C(=O)C(Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)CC21;-
eticlopride;1593;None;13;Human;Binding;Ki;=;0,26;9,59;1;4;Displacement of [3H]N-methylspiperone from human D2R expressed in HEK293 cell membranes incubated for 1 hr by radioligand binding assay;ChEMBL;340,2;6;2;4;2,83;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CC)c1O;https://dx.doi.org/10.1021/acs.jmedchem.6b01373
eticlopride;1593;None;13;Human;Binding;Ki;=;0,12;9,93;1;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by MicroBeta scintillation counting method;ChEMBL;340,2;6;2;4;2,83;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CC)c1O;https://dx.doi.org/10.1021/acs.jmedchem.1c01353
eticlopride;1593;None;13;Human;Binding;Ki;=;0,09;10,07;1;4;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;340,2;6;2;4;2,83;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CC)c1O;https://dx.doi.org/10.1021/jm401798r
eticlopride;1593;None;13;Human;Binding;pKi;None;-;9,20;1;4;Unclassified;Guide to Pharmacology;340,2;6;2;4;2,83;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CC)c1O;https://pubmed.ncbi.nlm.nih.gov/7907989
eticlopride;1593;None;13;Human;Binding;pKi;None;-;9,20;1;4;Unclassified;Guide to Pharmacology;340,2;6;2;4;2,83;CCc1cc(Cl)c(OC)c(C(=O)NC[C@@H]2CCCN2CC)c1O;https://pubmed.ncbi.nlm.nih.gov/8301592
ETICLOPRIDE,S(-);218481;3H-YM 09151-2;0;Human;Binding;pKi;=;0,10;10,00;-1;13;-;PDSP KiDatabase;340,2;6;2;4;2,83;CCc1cc(Cl)c(OC)c(C(=O)NCC2CCCN2CC)c1O;-
ETOLOXAMINE;127606;None;7;Human;Binding;Ki;=;2024,00;5,69;-1;3;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;283,2;8;0;2;4,00;CCN(CC)CCOc1ccccc1Cc1ccccc1;https://dx.doi.org/10.1021/jm049720x
Etoperidone;218632;None;0;Human;Binding;pKi;=;5,64;8,25;-4;8;None;Drug Central;377,2;7;0;6;2,49;CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC;-
Etoperidone;218632;3H-SPIPERONE;0;Human;Binding;pKi;=;2300,00;5,64;-4;8;-;PDSP KiDatabase;377,2;7;0;6;2,49;CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC;-
ETORICOXIB;218880;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1412;27;-;PDSP KiDatabase;358,1;3;0;4;4,18;Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1;-
FALLYPRIDE;146470;None;18;Human;Binding;Ki;=;2,20;8,66;2;4;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;364,2;10;1;4;2,99;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCF)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
FALLYPRIDE;146470;None;18;Human;Binding;Ki;=;2,10;8,68;2;4;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;364,2;10;1;4;2,99;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCF)cc(OC)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
FALLYPRIDE;146470;None;18;Human;Binding;Ki;=;0,10;10,01;2;4;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;364,2;10;1;4;2,99;C=CCN1CCC[C@H]1CNC(=O)c1cc(CCCF)cc(OC)c1OC;https://dx.doi.org/10.1021/jm5004123
FANANSERIN;208351;None;35;Human;Binding;Ki;=;180,00;6,75;-426;19;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;425,2;5;0;4;3,70;O=S1(=O)c2cccc3cccc(c23)N1CCCN1CCN(c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/jm011030v
FAUC 113;207760;None;18;Human;Binding;Ki;=;3200,00;5,50;-1122;10;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
FAUC 113;207760;None;18;Human;Binding;Ki;=;2200,00;5,66;-1122;10;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
FAUC 113;207760;None;18;Human;Binding;Ki;=;3200,00;5,50;-1122;10;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
FAUC 113;207760;None;18;Human;Binding;Ki;=;3200,00;5,50;-1122;10;Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
FAUC 113;207760;None;18;Human;Binding;Ki;=;4300,00;5,37;-1122;10;Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
FAUC 113;207760;None;18;Human;Binding;Ki;=;2900,00;5,54;-1122;10;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
FAUC 113;207760;None;18;Human;Binding;Ki;=;4300,00;5,37;-1122;10;Displacement of [3H]spiperone from human dopamine receptor D2(short) in CHO cell membrane;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
FAUC 113;207760;None;18;Human;Binding;Ki;=;3200,00;5,50;-1122;10;Displacement of [3H]spiperone from human dopamine receptor D2(long) in CHO cell membrane;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm060166w
FAUC 113;207760;None;18;Human;Binding;Ki;=;4300,00;5,37;-1122;10;Inhibition of human dopamine D2 (short) receptor;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
FAUC 113;207760;None;18;Human;Binding;Ki;=;3200,00;5,50;-1122;10;Inhibition of human dopamine D2 (long) receptor (unknown origin);ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
FAUC 113;207760;None;18;Human;Binding;Ki;=;4300,00;5,37;-1122;10;Ability to displace [3H]spiperone radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
FAUC 113;207760;None;18;Human;Binding;Ki;=;3200,00;5,50;-1122;10;Ability to displace [3H]SCH-23390 radioligand from cloned human Dopamine receptor D2 in CHO cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00316-5
FAUC 113;207760;None;18;Human;Binding;Ki;=;4300,00;5,37;-1122;10;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
FAUC 113;207760;None;18;Human;Binding;Ki;=;3200,00;5,50;-1122;10;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
FAUC 113;207760;None;18;Human;Binding;Ki;=;2818,38;5,55;-1122;10;Binding affinity to dopamine D2;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
FAUC 113;207760;None;18;Human;Binding;Ki;=;3200,00;5,50;-1122;10;Binding affinity for human dopamine receptor D2 long;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cnn4ccccc34)CC2)cc1;https://dx.doi.org/10.1021/jm049612a
FAUC213;1625;None;42;Human;Binding;Ki;=;3400,00;5,47;-4570;8;Displacement of [3H]spiperone from cloned human dopamine D2L receptor expressed in CHO cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
FAUC213;1625;None;42;Human;Binding;Ki;=;3400,00;5,47;-4570;8;Displacement of [3H]spiperone from human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm900690y
FAUC213;1625;None;42;Human;Binding;Ki;=;6300,00;5,20;-4570;8;Displacement of [3H]spiperone from cloned human dopamine D2S receptor expressed in CHO cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm701375u
FAUC213;1625;None;42;Human;Binding;Ki;=;1310,00;5,88;-4570;8;Binding affinity against human Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm0305669
FAUC213;1625;None;42;Human;Binding;Ki;=;6300,00;5,20;-4570;8;Binding affinity against dopamine receptor D2S using radioligand [3H]spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
FAUC213;1625;None;42;Human;Binding;Ki;=;3200,00;5,50;-4570;8;Displacement of [3H]spiperone from human dopamine D2 receptor;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2013.07.033
FAUC213;1625;None;42;Human;Binding;Ki;=;2300,00;5,64;-4570;8;Displacement of [3H]spiperone from wild type human cloned dopamine D2L receptor expressed in HEK293 cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm900690y
FAUC213;1625;None;42;Human;Binding;Ki;=;6300,00;5,20;-4570;8;Inhibition of human dopamine D2 (short) receptor;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
FAUC213;1625;None;42;Human;Binding;Ki;=;3400,00;5,47;-4570;8;Binding affinity for human dopamine receptor D2 long;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm049612a
FAUC213;1625;None;42;Human;Binding;Ki;=;47000,00;4,33;-4570;8;Displacement of [3H]spiperone from human cloned dopamine D2L receptor E181V/I183S mutant expressed in HEK293 cells;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm900690y
FAUC213;1625;None;42;Human;Binding;Ki;=;3400,00;5,47;-4570;8;Binding affinity to human D2R assessed as inhibition constant;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
FAUC213;1625;None;42;Human;Binding;Ki;=;3400,00;5,47;-4570;8;Binding affinity to human dopamine D2 long receptor;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.12.026
FAUC213;1625;None;42;Human;Binding;Ki;=;3400,00;5,47;-4570;8;Binding affinity against dopamine receptor D2L using radioligand [3H]-spiperone;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm015522j
FAUC213;1625;None;42;Human;Binding;Ki;=;3388,44;5,47;-4570;8;Binding affinity to dopamine D2;ChEMBL;326,1;3;0;4;3,31;Clc1ccc(N2CCN(Cc3cc4ccccn4n3)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
Fe complex;70426;None;0;Human;Binding;Ki;=;31,00;7,51;-38;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 long expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
Fe complex;70426;None;0;Human;Binding;Ki;=;19,00;7,72;-38;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 short expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
Fe complex;133644;None;0;Human;Binding;Ki;=;120,00;6,92;-7;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 short expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
Fe complex;133644;None;0;Human;Binding;Ki;=;170,00;6,77;-7;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 long expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
Femoxetine;218633;None;0;Human;Binding;pKi;None;6,23;8,21;-2;12;None;Drug Central;311,2;5;0;3;3,81;COc1ccc(OCC2CN(C)CCC2c2ccccc2)cc1;-
Femoxetine;218633;3H-SPIPERONE;0;Human;Binding;pKi;=;590,00;6,23;-2;12;-;PDSP KiDatabase;311,2;5;0;3;3,81;COc1ccc(OCC2CN(C)CCC2c2ccccc2)cc1;-
FENFLURAMINE;208825;3H-NMSP;14;Human;Binding;pKi;=;10000,00;5,00;-1513;42;-;PDSP KiDatabase;231,1;4;1;1;3,25;CCNC(C)Cc1cccc(C(F)(F)F)c1;-
FENFLURAMINE;208825;3H-NMSP;14;Human;Binding;pKi;=;10000,00;5,00;-1513;42;-;PDSP KiDatabase;231,1;4;1;1;3,25;CCNC(C)Cc1cccc(C(F)(F)F)c1;-
FENFLURAMINE;208825;3H-NMSP;14;Human;Binding;pKi;=;10000,00;5,00;-1513;42;-;PDSP KiDatabase;231,1;4;1;1;3,25;CCNC(C)Cc1cccc(C(F)(F)F)c1;-
fenoldopam;1628;None;36;Human;Binding;AC50;=;3800,00;5,42;-24;18;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;305,1;1;4;4;2,73;Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
fenoldopam;1628;None;36;Human;Binding;Ki;=;810,00;6,09;-24;18;Affinity towards Dopamine receptor D2;ChEMBL;305,1;1;4;4;2,73;Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1;https://dx.doi.org/10.1021/jm9800292
fenoldopam;1628;None;36;Human;Binding;pKi;=;6,09;8,22;-24;18;Affinity towards Dopamine receptor D2;Drug Central;305,1;1;4;4;2,73;Oc1ccc(C2CNCCc3c2cc(O)c(O)c3Cl)cc1;-
fentanyl;1630;None;10;Human;Binding;Ki;=;21000,00;4,68;-18197;19;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;336,2;6;0;2;4,14;CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
fexofenadine;1633;None;50;Human;Binding;Ki;=;8806,43;5,05;-144;6;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;501,3;10;3;4;5,51;CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;https://dx.doi.org/10.6019/CHEMBL5442175
flibanserin;1651;None;58;Human;Binding;pKi;=;6,52;8,19;-1;16;None;Drug Central;390,2;4;1;4;3,17;O=c1[nH]c2ccccc2n1CCN1CCN(c2cccc(C(F)(F)F)c2)CC1;-
flunarizine;1657;None;39;Human;Binding;IC50;=;352,00;6,45;-5;28;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;404,2;6;0;2;5,38;Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1;-
flunarizine;1657;None;39;Human;Binding;Ki;=;117,00;6,93;-5;28;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;404,2;6;0;2;5,38;Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1;-
flunarizine;1657;None;39;Human;Binding;pKi;=;6,93;8,16;-5;28;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;404,2;6;0;2;5,38;Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1;-
fluoxetine;1658;None;52;Human;Binding;AC50;=;7056,90;5,15;-1862;44;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;309,1;6;1;2;4,43;CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1;https://dx.doi.org/10.1038/s41467-023-40064-9
fluoxetine;1658;3H-SPIPERONE;52;Human;Binding;pKi;=;10000,00;5,00;-1862;44;-;PDSP KiDatabase;309,1;6;1;2;4,43;CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1;-
fluparoxan;1659;3H-SPIPERONE;0;Human;Binding;pKi;=;1000,00;6,00;-794;16;-;PDSP KiDatabase;195,1;0;1;3;0,94;Fc1cccc2c1O[C@H]1CNC[C@@H]1O2;-
flupentixol;1660;None;22;Human;Binding;pKi;=;8,82;8,05;-1;18;None;Drug Central;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;None;22;Human;Binding;pKi;=;-;8,82;-1;18;Unclassified;Guide to Pharmacology;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;https://pubmed.ncbi.nlm.nih.gov/8301582
flupentixol;1660;None;22;Human;Binding;pKi;=;-;6,92;-1;18;Unclassified;Guide to Pharmacology;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;https://pubmed.ncbi.nlm.nih.gov/8301582
flupentixol;1660;3H-SPIPERONE;22;Human;Binding;pKi;=;3,50;8,46;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;3H-YM 09151-2;22;Human;Binding;pKi;=;1,50;8,82;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;125I-Epidepride;22;Human;Binding;pKi;=;0,73;9,14;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;R-SAT;22;Human;Binding;pKi;=;17,00;7,77;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;3H-SPIPERONE;22;Human;Binding;pKi;=;400,00;6,40;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;UNDEFINED;22;Human;Binding;pKi;=;0,14;9,85;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;3H-S-Sulpiride;22;Human;Binding;pKi;=;470,00;6,33;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;125I-IODOSULPRIDE;22;Human;Binding;pKi;=;1,50;8,82;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;3H-S-Sulpiride;22;Human;Binding;pKi;=;2,70;8,57;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;125I-Epidepride;22;Human;Binding;pKi;=;0,66;9,18;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;125I-Epidepride;22;Human;Binding;pKi;=;2,50;8,60;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;R-SAT;22;Human;Binding;pKi;=;21,00;7,68;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;R-SAT;22;Human;Binding;pKi;=;0,50;9,30;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;125I-Epidepride;22;Human;Binding;pKi;=;2,30;8,64;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;R-SAT;22;Human;Binding;pKi;=;0,20;9,70;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;125I-IODOSULPRIDE;22;Human;Binding;pKi;=;120,00;6,92;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
flupentixol;1660;125I-Epidepride;22;Human;Binding;pKi;=;0,60;9,22;-1;18;-;PDSP KiDatabase;434,2;5;1;4;4,60;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;None;37;Human;Binding;AC50;=;3,80;8,42;-1;69;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
fluphenazine;1662;None;37;Human;Binding;IC50;=;1,62;8,79;-1;69;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;None;37;Human;Binding;Ki;=;0,54;9,27;-1;69;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;None;37;Human;Binding;Ki;=;1,44;8,84;-1;69;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
fluphenazine;1662;None;37;Human;Binding;pKi;=;9,27;8,03;-1;69;None;Drug Central;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;None;37;Human;Binding;pKi;=;-;8,84;-1;69;Unclassified;Guide to Pharmacology;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;https://pubmed.ncbi.nlm.nih.gov/17826096
fluphenazine;1662;UNDEFINED;37;Human;Binding;pKi;=;0,32;9,49;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-SPIPERONE;37;Human;Binding;pKi;=;0,80;9,10;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;UNDEFINED;37;Human;Binding;pKi;=;0,80;9,10;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;R-SAT;37;Human;Binding;pKi;=;0,20;9,70;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-YM 09151-2;37;Human;Binding;pKi;=;0,90;9,05;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-NMSP;37;Human;Binding;pKi;=;0,54;9,27;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;UNDEFINED;37;Human;Binding;pKi;=;0,32;9,49;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-RACLOPRIDE;37;Human;Binding;pKi;=;0,53;9,28;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-SPIPERONE;37;Human;Binding;pKi;=;1,20;8,92;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-NMSP;37;Human;Binding;pKi;=;0,60;9,22;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-SPIPERONE;37;Human;Binding;pKi;=;0,32;9,49;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;UNDEFINED;37;Human;Binding;pKi;=;1,44;8,84;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;R-SAT;37;Human;Binding;pKi;=;0,40;9,40;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-NMSP;37;Human;Binding;pKi;=;0,54;9,27;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine;1662;3H-NEMONAPRIDE;37;Human;Binding;pKi;=;1,90;8,72;-1;69;-;PDSP KiDatabase;437,2;6;1;5;4,31;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluphenazine enanthate;220197;None;0;Human;Binding;pKi;=;9,27;8,03;-1;26;None;Drug Central;549,3;12;0;6;6,83;CCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
fluspirilene;1664;None;37;Human;Binding;AC50;=;43,00;7,37;-1;48;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;475,2;7;1;3;5,30;O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2;https://dx.doi.org/10.1038/s41467-023-40064-9
fluspirilene;1664;None;37;Human;Binding;pKi;=;9,44;8,03;-1;48;None;Drug Central;475,2;7;1;3;5,30;O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2;-
fluspirilene;1664;3H-SPIPERONE;37;Human;Binding;pKi;=;0,67;9,17;-1;48;-;PDSP KiDatabase;475,2;7;1;3;5,30;O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2;-
fluspirilene;1664;R-SAT;37;Human;Binding;pKi;=;0,20;9,70;-1;48;-;PDSP KiDatabase;475,2;7;1;3;5,30;O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2;-
fluspirilene;1664;R-SAT;37;Human;Binding;pKi;=;0,20;9,70;-1;48;-;PDSP KiDatabase;475,2;7;1;3;5,30;O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2;-
fluspirilene;1664;3H-SPIPERONE;37;Human;Binding;pKi;=;1,20;8,92;-1;48;-;PDSP KiDatabase;475,2;7;1;3;5,30;O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2;-
formoterol;1677;None;37;Human;Binding;Ki;=;13000,00;4,89;-1023;8;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;344,2;9;4;5;2,22;COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
frovatriptan;1692;None;20;Human;Binding;Ki;=;694,23;6,16;-128;8;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;243,1;2;4;2;2,13;CN[C@@H]1CCc2[nH]c3ccc(C(=N)O)cc3c2C1;https://dx.doi.org/10.6019/CHEMBL5442175
GALLOPAMIL;189330;None;32;Human;Binding;AC50;=;10000,00;5,00;-;10;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;484,3;14;0;7;5,10;COc1ccc(CCN(C)CCCC(C#N)(c2cc(OC)c(OC)c(OC)c2)C(C)C)cc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
GBR-12909;218482;3H-YM 09151-2;0;Human;Binding;pKi;=;737,00;6,13;-79;10;-;PDSP KiDatabase;522,2;10;0;3;6,17;Cl.Cl.Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1;-
GEPIRONE;99671;None;43;Human;Binding;Ki;=;4320,00;5,37;-5;8;Displacement of [3H]methylspiperone from human D2 receptor expressed in HEK cells;ChEMBL;359,2;6;0;6;1,55;CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1;https://dx.doi.org/10.1021/acs.jmedchem.7b00315
GEPIRONE;99671;None;43;Human;Binding;Ki;=;58,00;7,24;-5;8;Binding affinity to D2 receptor by radioligand binding assay;ChEMBL;359,2;6;0;6;1,55;CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1;https://dx.doi.org/10.1021/jm0508641
GEPIRONE;99671;None;43;Human;Binding;pKi;=;7,24;8,14;-5;8;Binding affinity to D2 receptor by radioligand binding assay;Drug Central;359,2;6;0;6;1,55;CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1;-
GR 218,231;1850;None;13;Human;Binding;Ki;=;501,19;6,30;-398;3;Binding affinity against human Dopamine receptor D2 in mouse LtK- cells using [3H]spiperone.;ChEMBL;415,2;9;0;4;4,65;CCCN(CCC)[C@@H]1CCc2cc(CS(=O)(=O)c3ccc(OC)cc3)ccc2C1;https://dx.doi.org/10.1016/0960-894X(96)00043-1
GSI-NC;216481;None;0;Human;Binding;Ki;=;1258,93;5,90;-57;14;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.6019/CHEMBL4507288
GSI-NC;216481;None;0;Human;Binding;Ki;=;1219,00;5,91;-57;14;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.6019/CHEMBL4507288
GSI-NC;216481;None;0;Human;Binding;Ki;=;1219,00;5,91;-57;14;Selectivity interaction (GPCR panel (PDSP screen)) EUB0000741a DRD2;ChEMBL;-;-;-;-;-;CC(C)(C)OC(=O)N1CCCC1CNC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.6019/CHEMBL5212743
GSK163090;56410;None;41;Human;Binding;Ki;=;501,19;6,30;-2511;11;Binding affinity to human recombinant dopamine D2 receptor by radioligand displacement assay;ChEMBL;415,2;5;1;4;3,44;Cc1ccc2c(N3CCN(CCc4cccc(N5CCNC5=O)c4)CC3)cccc2n1;https://dx.doi.org/10.1021/jm100714c
GSK778;216505;None;21;Human;Binding;IC50;=;3162,28;5,50;-;4;Cross screening panel;ChEMBL;-;-;-;-;-;COCc1nc2cnc3cc(-c4c(C)noc4C)c(OC[C@H]4CCNC4)cc3c2n1[C@H](C)c1ccccc1;https://dx.doi.org/10.6019/CHEMBL4630907
GSK973;216503;None;9;Human;Binding;Ki;=;812,83;6,09;-3;3;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CNC(=O)c1cc(C(=O)N[C@@H]2[C@H]3COC[C@H]32)cc2c1O[C@H](CF)[C@H]2c1ccccc1;https://dx.doi.org/10.6019/CHEMBL4630902
GSK973;216503;None;9;Human;Binding;Ki;=;967,00;6,01;-3;3;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CNC(=O)c1cc(C(=O)N[C@@H]2[C@H]3COC[C@H]32)cc2c1O[C@H](CF)[C@H]2c1ccccc1;https://dx.doi.org/10.6019/CHEMBL4630902
HALOPEMIDE;93425;None;33;Human;Binding;IC50;=;7,00;8,15;-;1;Inhibition of dopamine receptor D2 (unknown origin);ChEMBL;416,1;5;2;4;3,19;O=C(NCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm301782e
haloperidol;1911;None;63;Human;Binding;AC50;=;12,20;7,91;-1;93;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
haloperidol;1911;None;63;Human;Binding;IC50;=;4,10;8,39;-1;93;In vitro binding affinity at human cloned Dopamine receptor D2 by [3H]spiroperidol displacement.;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm981041x
haloperidol;1911;None;63;Human;Binding;IC50;=;0,70;9,15;-1;93;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm5004039
haloperidol;1911;None;63;Human;Binding;IC50;=;4,00;8,40;-1;93;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm990562x
haloperidol;1911;None;63;Human;Binding;IC50;=;0,16;9,80;-1;93;Antagonist activity against human D2LR expressed in CHOK1 cells assessed as inhibition of pergolide-induced beta-arrestin translocation by beta-galactosidase based beta-arrestin recruitment assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm500801r
haloperidol;1911;None;63;Human;Binding;IC50;=;6,59;8,18;-1;93;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;None;63;Human;Binding;IC50;=;0,71;9,15;-1;93;Antagonist activity at human dopamine D2 short receptor transiently expressed in HEK293 cells assessed as inhibition of beta-arrestin recruitment after 6 hrs by chemiluminescence assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm5004039
haloperidol;1911;None;63;Human;Binding;IC50;=;4,90;8,31;-1;93;Binding affinity towards human Dopamine receptor D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm991005d
haloperidol;1911;None;63;Human;Binding;Kd;=;0,49;9,31;-1;93;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
haloperidol;1911;None;63;Human;Binding;Ki;=;1,12;8,95;-1;93;Binding affinity to dopamine D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm0611152
haloperidol;1911;None;63;Human;Binding;Ki;=;0,42;9,38;-1;93;Displacement of [3H]spiperone from human D2long receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2017.06.034
haloperidol;1911;None;63;Human;Binding;Ki;=;0,50;9,30;-1;93;Tested for binding affinity towards human D2L receptor using [3H]spiperone as radioligand;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00047a010
haloperidol;1911;None;63;Human;Binding;Ki;=;1,10;8,96;-1;93;Displacement of [3H]spiperone from human DRD2 short receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm2009919
haloperidol;1911;None;63;Human;Binding;Ki;=;1,50;8,82;-1;93;Displacement of [3H]spiperone from human DRD2 Long receptor expressed in chinese hamster CHO cells by radioligand binding assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm2009919
haloperidol;1911;None;63;Human;Binding;Ki;=;0,44;9,36;-1;93;Displacement of [3H]spiperone from CHO-K1 cell membranes expressing human dopamine receptor D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00076a022
haloperidol;1911;None;63;Human;Binding;Ki;=;4,00;8,40;-1;93;Displacement of [3H]N-methylspiperone from human recombinant D2 receptor expressed in CHO-K1 cell membrane after 60 mins by liquid scintillation counting analysis;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm401895u
haloperidol;1911;None;63;Human;Binding;Ki;=;18,00;7,75;-1;93;Displacement of the radioligand [3H]spiperone from the cloned human Dopamine receptor D2 long expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00179-8
haloperidol;1911;None;63;Human;Binding;Ki;=;3,70;8,43;-1;93;In vitro binding affinity towards Dopamine receptor D2 in human using [3H]-spiperone as radioligand;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm0309811
haloperidol;1911;None;63;Human;Binding;Ki;=;1,86;8,73;-1;93;Displacement of [3H]-methylspiperone from recombinant human D2 receptor expressed in CHOK1 cell membranes measured after 60 mins by microbeta counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.112149
haloperidol;1911;None;63;Human;Binding;Ki;=;1,97;8,71;-1;93;Binding affinity to human D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127053
haloperidol;1911;None;63;Human;Binding;Ki;=;2,00;8,70;-1;93;In vitro inhibitory constant against [3H]spiperone binding to human dopamine D2 receptor expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm050148z
haloperidol;1911;None;63;Human;Binding;Ki;=;2,50;8,60;-1;93;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm049632c
haloperidol;1911;None;63;Human;Binding;Ki;=;3,00;8,52;-1;93;Displacement of [3H]spiperone from D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2009.08.050
haloperidol;1911;None;63;Human;Binding;Ki;=;3,60;8,44;-1;93;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
haloperidol;1911;None;63;Human;Binding;Ki;=;1,40;8,85;-1;93;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
haloperidol;1911;None;63;Human;Binding;Ki;=;5,58;8,25;-1;93;Displacement of [3H]-N-Methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells incubated for 90 mins by microbeta counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2020.115578
haloperidol;1911;None;63;Human;Binding;Ki;=;0,81;9,09;-1;93;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
haloperidol;1911;None;63;Human;Binding;Ki;=;0,47;9,33;-1;93;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
haloperidol;1911;None;63;Human;Binding;Ki;=;0,87;9,06;-1;93;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100899z
haloperidol;1911;None;63;Human;Binding;Ki;=;3,00;8,52;-1;93;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
haloperidol;1911;None;63;Human;Binding;Ki;=;4,80;8,32;-1;93;Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm960637m
haloperidol;1911;None;63;Human;Binding;Ki;=;0,60;9,22;-1;93;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
haloperidol;1911;None;63;Human;Binding;Ki;=;5,58;8,25;-1;93;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2020.127305
haloperidol;1911;None;63;Human;Binding;Ki;=;0,89;9,05;-1;93;In vitro ability to inhibit the binding of [3H]spiperone to cloned human Dopamine receptor D2 using apomorphine induced climbing test in male Swiss mice;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2003.07.015
haloperidol;1911;None;63;Human;Binding;Ki;=;0,25;9,60;-1;93;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cell membranes by radioligand binding assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2017.06.034
haloperidol;1911;None;63;Human;Binding;Ki;=;0,89;9,05;-1;93;Cataleptogenic effect against cloned human Dopamine receptor D2 in male Sprague-Dawley rats in a bar test;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2003.07.015
haloperidol;1911;None;63;Human;Binding;Ki;=;0,12;9,92;-1;93;Antagonist activity at dopamine D2 receptor (unknown origin);ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.0c01192
haloperidol;1911;None;63;Human;Binding;Ki;=;5,01;8,30;-1;93;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm070516u
haloperidol;1911;None;63;Human;Binding;Ki;=;0,26;9,58;-1;93;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cells co-expressing CRE-Luc incubated for 60 mins by microbeta scintillation counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2021.113190
haloperidol;1911;None;63;Human;Binding;Ki;=;3,00;8,52;-1;93;Displacement of [3H]spiperone form human dopamine D2 receptor by liquid scintillation counting;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2010.02.105
haloperidol;1911;None;63;Human;Binding;Ki;=;3,55;8,45;-1;93;Displacement of [3H]N-Methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2013.12.024
haloperidol;1911;None;63;Human;Binding;Ki;=;0,12;9,92;-1;93;Binding affinity towards human Dopamine receptor D2 using [3H]spiroperidol as radioligand;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm020952a
haloperidol;1911;None;63;Human;Binding;Ki;=;2,20;8,66;-1;93;Binding affinity for human recombinant dopamine D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm049720x
haloperidol;1911;None;63;Human;Binding;Ki;=;0,60;9,22;-1;93;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm800602w
haloperidol;1911;None;63;Human;Binding;Ki;=;9,60;8,02;-1;93;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2016.03.037
haloperidol;1911;None;63;Human;Binding;Ki;=;0,16;9,80;-1;93;Displacement of [3H]quinpirole from Dopamine receptor D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm960350p
haloperidol;1911;None;63;Human;Binding;Ki;=;0,60;9,22;-1;93;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
haloperidol;1911;None;63;Human;Binding;Ki;=;0,89;9,05;-1;93;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
haloperidol;1911;None;63;Human;Binding;Ki;=;3,30;8,48;-1;93;Displacement of [3H]spiperone from human cloned dopamine receptor D2 long expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2006.12.030
haloperidol;1911;None;63;Human;Binding;Ki;=;0,60;9,22;-1;93;Binding affinity towards dopamine receptor D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2003.11.064
haloperidol;1911;None;63;Human;Binding;Ki;=;0,60;9,22;-1;93;Displacement of [3H]spiperone human cloned dopamine D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2007.06.045
haloperidol;1911;None;63;Human;Binding;Ki;=;0,44;9,36;-1;93;Displacement of [3H]raclopride from human dopamine D2A receptors expressed in LtK cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
haloperidol;1911;None;63;Human;Binding;Ki;=;2,00;8,70;-1;93;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm070487n
haloperidol;1911;None;63;Human;Binding;Ki;=;7,41;8,13;-1;93;Displacement of [3H]-spiperone from human D2s receptor expressed in CHO-K1 cells membrane incubated for 1 hr by microbeta liquid scintillation counting analysis;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2023.115285
haloperidol;1911;None;63;Human;Binding;Ki;=;0,60;9,22;-1;93;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1039/C1MD00202C
haloperidol;1911;None;63;Human;Binding;Ki;=;1,10;8,96;-1;93;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
haloperidol;1911;None;63;Human;Binding;Ki;=;1,40;8,85;-1;93;Displacement of [3H]-methylspiperone from human D2 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00839
haloperidol;1911;None;63;Human;Binding;Ki;=;1,10;8,96;-1;93;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm100899z
haloperidol;1911;None;63;Human;Binding;Ki;=;0,16;9,80;-1;93;Displacement of [3H]quinpirole from human dopamine D2A receptors expressed in LtK cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00345-5
haloperidol;1911;None;63;Human;Binding;Ki;=;0,79;9,10;-1;93;In vitro binding affinity for Dopamine receptor D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00200-1
haloperidol;1911;None;63;Human;Binding;Ki;=;1,40;8,85;-1;93;Binding affinity towards human Dopamine receptor D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm030480f
haloperidol;1911;None;63;Human;Binding;Ki;=;1,10;8,96;-1;93;Displacement of [3H]spiperone from human D2short receptor expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm2004859
haloperidol;1911;None;63;Human;Binding;Ki;=;1,00;9,00;-1;93;Binding affinity towards mouse LtK- cells transfected with human D2 receptor using [3H]spiperone;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/0960-894X(95)00011-H
haloperidol;1911;None;63;Human;Binding;Ki;=;1,00;9,00;-1;93;Binding affinity towards Dopamine type 2 receptor was determined by displacement assays using [3H]-YM 09151 as the competitive ligand;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00656-x
haloperidol;1911;None;63;Human;Binding;Ki;=;1,90;8,72;-1;93;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm901689v
haloperidol;1911;None;63;Human;Binding;Ki;=;0,70;9,15;-1;93;Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;None;63;Human;Binding;Ki;=;0,66;9,18;-1;93;Inhibition of [3H]raclopride binding to Dopamine receptor D2;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm960350p
haloperidol;1911;None;63;Human;Binding;Ki;=;1,50;8,82;-1;93;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
haloperidol;1911;None;63;Human;Binding;Ki;=;2,20;8,66;-1;93;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;None;63;Human;Binding;Ki;=;1,10;8,96;-1;93;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
haloperidol;1911;None;63;Human;Binding;Ki;=;2,00;8,70;-1;93;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
haloperidol;1911;None;63;Human;Binding;Ki;=;6,33;8,20;-1;93;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
haloperidol;1911;None;63;Human;Binding;Ki;=;1,60;8,80;-1;93;Binding affinity against cloned human dopamine receptor D2 expressed in Chinese hamster ovary (CHO) K-1 cells by displacement of [3H]spiperone.;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm970422s
haloperidol;1911;None;63;Human;Binding;Ki;=;6,31;8,20;-1;93;Displacement of [3H]-N-methylspiperone from D2 receptor (unknown origin) expressed in HEK293T cell membranes measured after 2 hrs by microbeta scintillation counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c01327
haloperidol;1911;None;63;Human;Binding;Ki;=;0,96;9,02;-1;93;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acsmedchemlett.5b00131
haloperidol;1911;None;63;Human;Binding;Ki;=;4,50;8,35;-1;93;Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.01.031
haloperidol;1911;None;63;Human;Binding;Ki;=;2,61;8,58;-1;93;Binding affinity to dopamine D2S receptor (unknown origin) by radioligand displacement assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2022.128573
haloperidol;1911;None;63;Human;Binding;Ki;=;3,55;8,45;-1;93;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
haloperidol;1911;None;63;Human;Binding;Ki;=;1,40;8,85;-1;93;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm960072u
haloperidol;1911;None;63;Human;Binding;Ki;=;1,40;8,85;-1;93;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
haloperidol;1911;None;63;Human;Binding;Ki;=;3,50;8,46;-1;93;Displacement of [3H]N-Methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2013.12.024
haloperidol;1911;None;63;Human;Binding;Ki;=;0,85;9,07;-1;93;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm5004123
haloperidol;1911;None;63;Human;Binding;Ki;=;1,86;8,73;-1;93;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
haloperidol;1911;None;63;Human;Binding;Ki;=;0,84;9,08;-1;93;In vitro binding affinity against human D2 dopamine receptor in CHO cells by [3H]spiperone displacement.;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00108-5
haloperidol;1911;None;63;Human;Binding;Ki;=;6400,00;5,19;-1;93;Displacement of [3H]spiroperidol from human cloned dopaminergic D2 receptor expressed in rat C6 cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm800928j
haloperidol;1911;None;63;Human;Binding;Ki;=;4,00;8,40;-1;93;Displacement of [3H]N-methylspiperone from human recombinant dopamine D2 receptor expressed in CHOK1 cells incubated for 60 mins by scintillation counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2014.12.045
haloperidol;1911;None;63;Human;Binding;Ki;=;1,40;8,85;-1;93;Ability to displace [3H]spiperone from human dopamine receptor D2 stably expressed in CHO cells.;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm970111h
haloperidol;1911;None;63;Human;Binding;Ki;=;5,60;8,25;-1;93;In vitro binding affinity towards Dopamine receptor D2L, using [3H]spiroperidol radioligand in Sf9 baculovirus expression.;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm991138z
haloperidol;1911;None;63;Human;Binding;Ki;=;1,30;8,89;-1;93;Binding affinity for human dopamine receptor D2 long;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm049612a
haloperidol;1911;None;63;Human;Binding;Ki;=;4,20;8,38;-1;93;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor by liquid scintillation counting;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.11.044
haloperidol;1911;None;63;Human;Binding;Ki;=;8,50;8,07;-1;93;In vitro binding affinity at human cloned Dopamine receptor D2L expressed in Sf9 cell membranes;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm0104825
haloperidol;1911;None;63;Human;Binding;Ki;=;1,40;8,85;-1;93;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm500126s
haloperidol;1911;None;63;Human;Binding;Ki;=;4,20;8,38;-1;93;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm800615e
haloperidol;1911;None;63;Human;Binding;Ki;=;6,17;8,21;-1;93;Displacement of [3H]spiperone from human D2S receptor expressed in CHO-K1 cells by radioligand competitive binding analysis;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jnatprod.9b00921
haloperidol;1911;None;63;Human;Binding;Ki;=;6,22;8,21;-1;93;Displacement of [3H]spiperone from human D2S receptor expressed in CHO-K1 cells by radioligand competitive binding analysis;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jnatprod.9b00921
haloperidol;1911;None;63;Human;Binding;Ki;=;1,00;9,00;-1;93;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm901689v
haloperidol;1911;None;63;Human;Binding;Ki;=;3,00;8,52;-1;93;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/s0960-894x(02)00996-4
haloperidol;1911;None;63;Human;Binding;Ki;=;1,40;8,85;-1;93;Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm9600712
haloperidol;1911;None;63;Human;Binding;Ki;=;5,90;8,23;-1;93;Displacement of [3H]methylspiperonee from recombinant human D2 receptor expressed in HEK293 cells cell membranes after 60 mins by liquid scintillation counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
haloperidol;1911;None;63;Human;Binding;Ki;=;0,85;9,07;-1;93;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
haloperidol;1911;None;63;Human;Binding;Ki;=;2,84;8,55;-1;93;Inhibition of human dopamine D2 receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm1013693
haloperidol;1911;None;63;Human;Binding;Ki;=;2,60;8,59;-1;93;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm070721+
haloperidol;1911;None;63;Human;Binding;Ki;=;5,09;8,29;-1;93;Displacement of [3H]YM-09151-2 from human dopamine D2S receptor in membrane suspensions by liquid scintillation counter;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.08.061
haloperidol;1911;None;63;Human;Binding;Ki;=;4,50;8,35;-1;93;Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.07.027
haloperidol;1911;None;63;Human;Binding;Ki;=;3,25;8,49;-1;93;Displacement of [3H]Spiperone from human D2S receptor expressed in CHOK1 cell membranes measured after 120 mins;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.ejmech.2019.07.050
haloperidol;1911;None;63;Human;Binding;Ki;=;9,60;8,02;-1;93;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor assessed as inhibition constant;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.3c00976
haloperidol;1911;None;63;Human;Binding;Ki;=;1,00;9,00;-1;93;Displacement of [3H]N-methylspiperone from human D2 receptor expressed in HEK cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2011.04.098
haloperidol;1911;None;63;Human;Binding;Ki;=;1,60;8,80;-1;93;Ability to displace [3H]spiperone from human cloned Dopamine receptor D2 expressed in CHO K-1 cells in vitro.;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm970170v
haloperidol;1911;None;63;Human;Binding;Ki;=;1,50;8,82;-1;93;Displacement of [3H]SCH23390 from human D2long receptor expressed in CHO cells;ChEMBL;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm2004859
haloperidol;1911;None;63;Human;Binding;pKi;=;9,15;8,04;-1;93;None;Drug Central;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;None;63;Human;Binding;pKi;=;-;8,10;-1;93;Unclassified;Guide to Pharmacology;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://pubmed.ncbi.nlm.nih.gov/7862709
haloperidol;1911;None;63;Human;Binding;pKi;=;-;8,10;-1;93;Unclassified;Guide to Pharmacology;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://pubmed.ncbi.nlm.nih.gov/7664822
haloperidol;1911;None;63;Human;Binding;pKi;=;-;8,10;-1;93;Unclassified;Guide to Pharmacology;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://pubmed.ncbi.nlm.nih.gov/1354163
haloperidol;1911;None;63;Human;Binding;pKi;=;-;8,10;-1;93;Unclassified;Guide to Pharmacology;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://pubmed.ncbi.nlm.nih.gov/8301582
haloperidol;1911;None;63;Human;Binding;pKi;=;-;8,10;-1;93;Unclassified;Guide to Pharmacology;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://pubmed.ncbi.nlm.nih.gov/7907989
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;0,16;9,80;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;1,80;8,74;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;2,00;8,70;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;0,35;9,46;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-NMSP;63;Human;Binding;pKi;=;2,40;8,62;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-NMSP;63;Human;Binding;pKi;=;4,00;8,40;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-N-Methylspiperone;63;Human;Binding;pKi;=;1,35;8,87;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;1,10;8,96;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;2,90;8,54;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;6400,00;5,19;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-Methoxy raclopride;63;Human;Binding;pKi;=;0,70;9,15;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;3,30;8,48;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;3,00;8,52;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;4,00;8,40;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-NMS;63;Human;Binding;pKi;=;2,30;8,64;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;2,10;8,68;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;1,00;9,00;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;2,60;8,59;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;2,20;8,66;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;5,09;8,29;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;125I-IODOSULPRIDE;63;Human;Binding;pKi;=;0,60;9,22;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-NEMONAPRIDE;63;Human;Binding;pKi;=;9,50;8,02;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-NEMONAPRIDE;63;Human;Binding;pKi;=;9,60;8,02;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;2,80;8,55;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;1,40;8,85;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-RACLOPRIDE;63;Human;Binding;pKi;=;0,47;9,33;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;2,50;8,60;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;1,90;8,72;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;2,20;8,66;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;3,70;8,43;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-RACLOPRIDE;63;Human;Binding;pKi;=;1,10;8,96;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;0,63;9,20;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIROPERIDOL;63;Human;Binding;pKi;=;0,12;9,92;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-NEMONAPRIDE;63;Human;Binding;pKi;=;0,89;9,05;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;R-SAT;63;Human;Binding;pKi;=;0,60;9,22;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;125I-IODOSULPRIDE;63;Human;Binding;pKi;=;2,60;8,59;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;125I-IODOSULPRIDE;63;Human;Binding;pKi;=;0,43;9,37;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;4,90;8,31;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-domperidone;63;Human;Binding;pKi;=;2,40;8,62;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;1,40;8,85;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;1,00;9,00;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;125I-IODOSULPRIDE;63;Human;Binding;pKi;=;0,41;9,39;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;3,00;8,52;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;2,60;8,59;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-YM 09151-2;63;Human;Binding;pKi;=;0,50;9,30;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-YM 09151-2;63;Human;Binding;pKi;=;0,90;9,05;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-RACLOPRIDE;63;Human;Binding;pKi;=;0,67;9,17;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;4,20;8,38;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-SPIPERONE;63;Human;Binding;pKi;=;4,00;8,40;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;R-SAT;63;Human;Binding;pKi;=;0,80;9,10;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-RACLOPRIDE;63;Human;Binding;pKi;=;0,70;9,15;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;125I-7-OH-PIPAT;63;Human;Binding;pKi;=;0,30;9,52;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;1,10;8,96;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-Haloperidol;63;Human;Binding;pKi;=;0,35;9,46;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;0,35;9,46;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;3H-NMSP;63;Human;Binding;pKi;=;2,00;8,70;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
haloperidol;1911;UNDEFINED;63;Human;Binding;pKi;=;4,20;8,38;-1;93;-;PDSP KiDatabase;375,1;6;1;3;4,43;O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;-
HALOPERIDOL DECANOATE;14456;None;39;Human;Binding;Ki;=;0,46;9,34;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;529,3;15;0;4;8,12;CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
HALOPERIDOL DECANOATE;14456;None;39;Human;Binding;Ki;=;1,80;8,74;2;4;Displacement of [3H]spiperone from human D2long receptor stably expressed in CHO cell membranes by competitive binding assay;ChEMBL;529,3;15;0;4;8,12;CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.06.079
HALOPERIDOL DECANOATE;14456;None;39;Human;Binding;pKi;=;9,34;8,03;2;4;Displacement of [3H]spiperone from human D2short receptor stably expressed in CHO cell membranes by competitive binding assay;Drug Central;529,3;15;0;4;8,12;CCCCCCCCCC(=O)OC1(c2ccc(Cl)cc2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
HEXAMETHYL PARAROSANILINE;176253;None;16;Human;Binding;IC50;=;3178,00;5,50;-2;25;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;372,2;4;0;2;4,46;CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1;-
HEXAMETHYL PARAROSANILINE;176253;None;16;Human;Binding;Ki;=;1059,00;5,97;-2;25;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;372,2;4;0;2;4,46;CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1;-
HEXAMETHYL PARAROSANILINE;176253;None;16;Human;Binding;pKi;=;5,97;8,22;-2;25;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;372,2;4;0;2;4,46;CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1;-
HIGENAMINE;69605;None;41;Human;Binding;Ki;=;3900,00;5,41;-1;2;Potency was measured by the displacement of [3H]spiperone binding to human D2 dopaminergic receptor;ChEMBL;271,1;2;4;4;2,23;Oc1ccc(CC2NCCc3cc(O)c(O)cc32)cc1;https://dx.doi.org/10.1016/S0960-894X(97)00194-7
HS665;1944;None;4;Human;Binding;Ki;=;450,00;6,35;-912;5;Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells;ChEMBL;309,2;8;1;2;4,28;Oc1cccc(CCN(CCc2ccccc2)CC2CCC2)c1;https://dx.doi.org/10.1021/jm301258w
HS665;1944;None;4;Human;Binding;pKi;=;-;6,35;-912;5;Unclassified;Guide to Pharmacology;309,2;8;1;2;4,28;Oc1cccc(CCN(CCc2ccccc2)CC2CCC2)c1;https://pubmed.ncbi.nlm.nih.gov/23134120
HYDROXYHALOPERIDOL;4731;None;32;Human;Binding;Kd;=;91,20;7,04;2;3;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;377,2;6;2;3;4,28;OC(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
HYDROXYHALOPERIDOL;4731;None;32;Human;Binding;Ki;=;91,20;7,04;2;3;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;377,2;6;2;3;4,28;OC(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
hydroxyzine;1957;None;46;Human;Binding;AC50;=;2400,00;5,62;-5;16;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;374,2;8;1;4;3,06;OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
hydroxyzine;1957;None;46;Human;Binding;Ki;=;378,00;6,42;-5;16;Binding affinity to D2 receptor (unknown origin);ChEMBL;374,2;8;1;4;3,06;OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.04.059
hydroxyzine;1957;None;46;Human;Binding;pKi;=;6,42;8,19;-5;16;Binding affinity to D2 receptor (unknown origin);Drug Central;374,2;8;1;4;3,06;OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1;-
IBOGAINE;84670;3H-YM 09151-2;2;Human;Binding;pKi;=;10000,00;5,00;-1;13;-;PDSP KiDatabase;310,2;2;1;2;3,94;CC[C@H]1C[C@H]2C[C@H]3c4[nH]c5ccc(OC)cc5c4CCN(C2)[C@@H]13;-
IBOPAMINE;103167;None;14;Human;Binding;AC50;=;28000,10;4,55;-;7;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;307,2;7;1;5;2,57;CNCCc1ccc(OC(=O)C(C)C)c(OC(=O)C(C)C)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
IBUPROFEN;192642;3H-NMSP;78;Human;Binding;pKi;=;10000,00;5,00;-1;29;-;PDSP KiDatabase;206,1;4;1;1;3,07;CC(C)Cc1ccc(C(C)C(=O)O)cc1;-
ICS 205-930;218430;3H-YM 09151-2;0;Human;Binding;pKi;=;10000,00;5,00;-1778;19;-;PDSP KiDatabase;284,2;2;1;3;2,95;CN1C2CCC1CC(OC(=O)c1c[nH]c3ccccc13)C2;-
idalopirdine;1987;None;42;Human;Binding;Ki;=;1215,00;5,92;-1445;7;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;398,1;9;2;2;4,92;Fc1ccc2c(CCNCc3cccc(OCC(F)(F)C(F)F)c3)c[nH]c2c1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
IDARUBICIN;9427;None;34;Human;Binding;AC50;=;10999,90;4,96;-;13;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;497,2;3;5;10;1,02;CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O;https://dx.doi.org/10.1038/s41467-023-40064-9
idazoxan;1988;3H-YM 09151-2;24;Human;Binding;pKi;=;10000,00;5,00;-6606;18;-;PDSP KiDatabase;204,1;1;1;4;0,83;c1ccc2c(c1)OCC(C1=NCCN1)O2;-
IFENPRODIL;102826;None;36;Human;Binding;AC50;=;2700,00;5,57;-;16;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;325,2;5;2;3;3,77;CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
iloperidone;2006;None;61;Human;Binding;AC50;=;45,40;7,34;-7;48;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;426,2;8;0;6;4,83;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
iloperidone;2006;None;61;Human;Binding;IC50;=;110,00;6,96;-7;48;Binding affinity against Dopamine receptor D2 was determined using [ [3H]-spiperone radioligand;ChEMBL;426,2;8;0;6;4,83;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;https://dx.doi.org/10.1021/jm00007a009
iloperidone;2006;None;61;Human;Binding;pKi;=;8,97;8,05;-7;48;None;Drug Central;426,2;8;0;6;4,83;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;-
iloperidone;2006;3H-SPIPERONE;61;Human;Binding;pKi;=;21,37;7,67;-7;48;-;PDSP KiDatabase;426,2;8;0;6;4,83;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;-
iloperidone;2006;UNDEFINED;61;Human;Binding;pKi;=;0,35;9,46;-7;48;-;PDSP KiDatabase;426,2;8;0;6;4,83;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;-
iloperidone;2006;3H-NMS;61;Human;Binding;pKi;=;6,30;8,20;-7;48;-;PDSP KiDatabase;426,2;8;0;6;4,83;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;-
iloperidone;2006;3H-SPIPERONE;61;Human;Binding;pKi;=;3,30;8,48;-7;48;-;PDSP KiDatabase;426,2;8;0;6;4,83;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;-
iloperidone;2006;3H-SPIPERONE;61;Human;Binding;pKi;=;13,30;7,88;-7;48;-;PDSP KiDatabase;426,2;8;0;6;4,83;COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1;-
imipramine;2013;None;42;Human;Binding;AC50;=;1300,00;5,89;-20;44;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;280,2;4;0;2;3,88;CN(C)CCCN1c2ccccc2CCc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
imipramine;2013;None;42;Human;Binding;IC50;=;410,00;6,39;-20;44;Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay;ChEMBL;280,2;4;0;2;3,88;CN(C)CCCN1c2ccccc2CCc2ccccc21;https://dx.doi.org/10.1021/jm400856t
imipramine;2013;None;42;Human;Binding;Ki;=;726,00;6,14;-20;44;Binding affinity towards dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;280,2;4;0;2;3,88;CN(C)CCCN1c2ccccc2CCc2ccccc21;https://dx.doi.org/10.1016/j.bmcl.2004.02.014
imipramine;2013;None;42;Human;Binding;pKi;=;6,17;8,21;-20;44;None;Drug Central;280,2;4;0;2;3,88;CN(C)CCCN1c2ccccc2CCc2ccccc21;-
imipramine;2013;3H-YM 09151-2;42;Human;Binding;pKi;=;726,00;6,14;-20;44;-;PDSP KiDatabase;280,2;4;0;2;3,88;CN(C)CCCN1c2ccccc2CCc2ccccc21;-
imipramine;2013;3H-SPIPERONE;42;Human;Binding;pKi;=;620,00;6,21;-20;44;-;PDSP KiDatabase;280,2;4;0;2;3,88;CN(C)CCCN1c2ccccc2CCc2ccccc21;-
indacaterol;2025;None;43;Human;Binding;pIC50;=;4,60;8,34;-;10;Binding affinity to dopamine 2 receptor;Drug Central;392,2;6;4;4;3,15;CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2;-
INDOCYANINE GREEN ACID FORM;14499;None;5;Human;Binding;AC50;=;8799,90;5,06;-;25;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;752,3;14;1;6;8,71;CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21;https://dx.doi.org/10.1038/s41467-023-40064-9
intepirdine;2055;None;52;Human;Binding;Ki;=;997,00;6,00;-4265;6;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting method;ChEMBL;353,1;3;1;5;2,48;O=S(=O)(c1ccccc1)c1cnc2c(N3CCNCC3)cccc2c1;https://dx.doi.org/10.1016/j.ejmech.2017.12.053
Iodosulpride;218634;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;0,50;9,30;1;4;-;PDSP KiDatabase;506,1;8;1;5;2,70;CCS(=O)(=O)c1cc(C(=O)NCC2CCCN2CC2CC2)c(OC)cc1I;-
IOLOPRIDE;97179;None;14;Human;Binding;Ki;=;4,20;8,38;-10;6;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;404,1;5;2;4;2,22;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O;https://dx.doi.org/10.1016/j.bmc.2007.07.017
IOLOPRIDE;97179;None;14;Human;Binding;Ki;=;4,20;8,38;-10;6;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;404,1;5;2;4;2,22;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(I)c1O;https://dx.doi.org/10.1016/j.bmc.2007.07.017
IPRINDOLE;17999;None;26;Human;Binding;AC50;=;6200,00;5,21;-;25;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;284,2;4;0;2;4,25;CN(C)CCCn1c2c(c3ccccc31)CCCCCC2;https://dx.doi.org/10.1038/s41467-023-40064-9
ipsapirone;2063;None;41;Human;Binding;Ki;=;1224,00;5,91;-64;23;Displacement of [3H]-raclopride from human D2R expressed in human HEK293 cells;ChEMBL;401,2;6;0;7;1,22;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2021.128028
ipsapirone;2063;None;41;Human;Binding;Ki;=;1224,00;5,91;-64;23;Displacement of [3H]raclopride from human cloned D2 receptor expressed in HEK293 cells by radioligand binding assay;ChEMBL;401,2;6;0;7;1,22;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/j.bmcl.2019.126667
ipsapirone;2063;None;41;Human;Binding;Ki;=;110,00;6,96;-64;23;Binding affinity to D2 receptor by radioligand binding assay;ChEMBL;401,2;6;0;7;1,22;O=C1c2ccccc2S(=O)(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/jm0508641
ISOCLOZAPINE;162011;None;16;Human;Binding;IC50;=;34,00;7,47;-4;7;Binding affinity towards human Dopamine receptor D2;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3ccccc3Nc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm991005d
ISOCLOZAPINE;162011;None;16;Human;Binding;Ki;=;47,00;7,33;-4;7;Affinity was evaluated as inhibition constant for dopamine D-2 receptor;ChEMBL;326,1;0;1;4;3,72;CN1CCN(C2=Nc3ccccc3Nc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm00043a008
ISOCONAZOLE;50314;None;27;Human;Binding;AC50;=;8900,00;5,05;-;5;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;414;6;0;3;6,46;Clc1ccc(C(Cn2ccnc2)OCc2c(Cl)cccc2Cl)c(Cl)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
ISOLOXAPINE;207632;None;0;Human;Binding;Ki;=;150,00;6,82;-7;5;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;327,1;0;0;4;3,77;CN1CCN(C2=Nc3cc(Cl)ccc3Oc3ccccc32)CC1;https://dx.doi.org/10.1021/jm00043a008
isoprenaline;2091;None;34;Human;Binding;Ki;=;48000,00;4,32;-204;49;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;211,1;4;4;4;1,13;CC(C)NCC(O)c1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
isoprenaline;2091;None;34;Human;Binding;Ki;=;12000,00;4,92;-204;49;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;211,1;4;4;4;1,13;CC(C)NCC(O)c1ccc(O)c(O)c1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
isoprenaline;2091;None;34;Human;Binding;pKi;=;4,92;8,31;-204;49;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;Drug Central;211,1;4;4;4;1,13;CC(C)NCC(O)c1ccc(O)c(O)c1;-
ITOPRIDE;78319;None;35;Human;Binding;AC50;=;9600,00;5,02;-;3;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;358,2;9;1;5;2,57;COc1ccc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
JNJ-37822681;109934;None;22;Human;Binding;Ki;=;158,00;6,80;7;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;372,1;4;1;4;3,85;Fc1ccc(CN2CCC(Nc3ccc(C(F)(F)F)nn3)CC2)cc1F;https://dx.doi.org/10.1021/jm500126s
KETAMINE;207176;3H-N-Methylspiperone;11;Human;Binding;pKi;=;10000,00;5,00;-1;19;-;PDSP KiDatabase;237,1;2;1;2;2,90;CNC1(c2ccccc2Cl)CCCCC1=O;-
ketanserin;2181;None;61;Human;Binding;AC50;=;2500,00;5,60;-177;56;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;395,2;5;1;5;2,42;O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
ketanserin;2181;None;61;Human;Binding;Ki;=;240,00;6,62;-177;56;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;ChEMBL;395,2;5;1;5;2,42;O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1;https://dx.doi.org/10.1016/s0960-894x(00)00030-5
ketanserin;2181;None;61;Human;Binding;pKi;=;6,62;8,18;-177;56;Binding affinity for Dopamine receptor D2 by displacement of [3H]-spiperone;Drug Central;395,2;5;1;5;2,42;O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1;-
ketanserin;2181;3H-YM 09151-2;61;Human;Binding;pKi;=;10000,00;5,00;-177;56;-;PDSP KiDatabase;395,2;5;1;5;2,42;O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1;-
Ketorolac tris salt;218879;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;28;-;PDSP KiDatabase;376,2;6;5;7;-0,05;NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O;-
ketotifen;2182;None;36;Human;Binding;Ki;=;1726,64;5,76;-1778;31;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;309,1;0;0;3;4,01;CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1;https://dx.doi.org/10.6019/CHEMBL5442175
L-741,626;2241;None;40;Human;Binding;Ki;=;11,20;7,95;5;15;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
L-741,626;2241;None;40;Human;Binding;Ki;=;87,45;7,06;5;15;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.6019/CHEMBL5442175
L-741,626;2241;None;40;Human;Binding;Ki;=;11,20;7,95;5;15;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm800532x
L-741,626;2241;None;40;Human;Binding;Ki;=;11,20;7,95;5;15;Displacement of [125I]IABN from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmcl.2006.10.076
L-741,626;2241;None;40;Human;Binding;Ki;=;10,00;8,00;5;15;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1016/j.bmc.2010.05.052
L-741,626;2241;None;40;Human;Binding;Ki;=;2,40;8,62;5;15;Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm9600712
L-741,626;2241;None;40;Human;Binding;Ki;=;7,50;8,12;5;15;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://dx.doi.org/10.1021/jm500126s
L-741,626;2241;None;40;Human;Binding;pKi;=;-;8,20;5;15;Unclassified;Guide to Pharmacology;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://pubmed.ncbi.nlm.nih.gov/8642550
L-741,626;2241;None;40;Human;Binding;pKi;=;-;8,20;5;15;Unclassified;Guide to Pharmacology;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;https://pubmed.ncbi.nlm.nih.gov/17095222
L-741,626;2241;UNDEFINED;40;Human;Binding;pKi;=;11,20;7,95;5;15;-;PDSP KiDatabase;340,1;3;2;2;4,30;OC1(c2ccc(Cl)cc2)CCN(Cc2c[nH]c3ccccc23)CC1;-
L-cysteic acid;218804;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;38;-;PDSP KiDatabase;169;3;3;4;-1,71;NC(CS(=O)(=O)O)C(=O)O;-
L-cysteine;218801;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;33;-;PDSP KiDatabase;121;2;3;3;-0,67;NC(CS)C(=O)O;-
L-cysteine sulfinic acid;218803;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;39;-;PDSP KiDatabase;153;3;3;3;-1,38;NC(CS(=O)O)C(=O)O;-
L-homocysteine thiolactone;218802;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;28;-;PDSP KiDatabase;117;0;1;3;-0,02;NC1CCSC1=O;-
L745870;2244;None;39;Human;Binding;IC50;=;360,00;6,44;-6165;17;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
L745870;2244;None;39;Human;Binding;Ki;=;960,00;6,02;-6165;17;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by PDSP assay;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2014.04.026
L745870;2244;None;39;Human;Binding;Ki;=;38000,00;4,42;-6165;17;In vitro binding affinity at human cloned dopamine receptor D2 (short) stably expressed in CHO cells by [3H]spiperone displacement.;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
L745870;2244;None;39;Human;Binding;Ki;=;54000,00;4,27;-6165;17;In vitro binding affinity at human cloned dopamine receptor D2 (long) stably expressed in CHO cells by [3H]-Spiperone displacement.;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(01)00814-9
L745870;2244;None;39;Human;Binding;Ki;=;960,00;6,02;-6165;17;Binding affinity towards cloned human Dopamine receptor D2 stably expressed in CHO cells was evaluated using [3H]spiperone as radioligand;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/jm9600712
L745870;2244;None;39;Human;Binding;Ki;=;54000,00;4,27;-6165;17;Displacement of [3H]SCH23390 from human cloned dopamine D2 long receptor expressed in CHO cells;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
L745870;2244;None;39;Human;Binding;Ki;=;448,00;6,35;-6165;17;Binding affinity against human Dopamine receptor D2 using [3H]spiperone as radioligand;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/jm0305669
L745870;2244;None;39;Human;Binding;Ki;=;47000,00;4,33;-6165;17;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
L745870;2244;None;39;Human;Binding;Ki;=;908,00;6,04;-6165;17;Binding affinity at Dopamine receptor D2 in CHO cells by radioligand displacement.;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/jm990277d
L745870;2244;None;39;Human;Binding;Ki;=;960,00;6,02;-6165;17;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2008.12.054
L745870;2244;None;39;Human;Binding;Ki;=;1621,81;5,79;-6165;17;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane incubated for 1 hr by MicroBeta scintillation counting method;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.2c00840
L745870;2244;None;39;Human;Binding;Ki;=;53703,18;4,27;-6165;17;Binding affinity to dopamine D2;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/jm0611152
L745870;2244;None;39;Human;Binding;Ki;=;960,00;6,02;-6165;17;Inhibition of human dopamine D2 receptor;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
L745870;2244;None;39;Human;Binding;Ki;=;960,00;6,02;-6165;17;Binding affinity for dopamine D2 receptor;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmcl.2004.09.046
L745870;2244;None;39;Human;Binding;Ki;=;960,00;6,02;-6165;17;Binding affinity to D2R (unknown origin) assessed as inhibition constant;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
L745870;2244;None;39;Human;Binding;Ki;=;920,00;6,04;-6165;17;In vitro binding affinity was measured at the cloned human Dopamine receptor D2 using [3H]spiroperidol as radioligand.;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/jm981041x
L745870;2244;None;39;Human;Binding;Ki;=;38000,00;4,42;-6165;17;Displacement of [3H]spiroperidol from human cloned dopamine D2 short receptor expressed in CHO cells;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/j.bmc.2009.05.015
L745870;2244;None;39;Human;Binding;Ki;=;908,00;6,04;-6165;17;Displacement of [3H]spiperone from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(98)00252-2
L745870;2244;None;39;Human;Binding;Ki;=;960,00;6,02;-6165;17;Ability to displace [3H]spiperone from cloned human dopamine D2 receptor stably expressed in CHO cells;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1016/s0960-894x(99)00025-6
L745870;2244;None;39;Human;Binding;Ki;=;33000,00;4,48;-6165;17;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
L745870;2244;UNDEFINED;39;Human;Binding;pKi;=;10000,00;5,00;-6165;17;-;PDSP KiDatabase;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;-
L745870;2244;UNDEFINED;39;Human;Binding;pKi;=;960,00;6,02;-6165;17;-;PDSP KiDatabase;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;-
L745870;2244;R-SAT;39;Human;Binding;pKi;=;343,00;6,46;-6165;17;-;PDSP KiDatabase;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;-
L745870;2244;UNDEFINED;39;Human;Binding;pKi;=;10000,00;5,00;-6165;17;-;PDSP KiDatabase;326,1;3;1;3;3,54;Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1;-
LASOFOXIFENE;111644;None;40;Human;Binding;AC50;=;8600,00;5,07;-;23;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;413,2;6;1;3;5,73;Oc1ccc2c(c1)CC[C@H](c1ccccc1)[C@@H]2c1ccc(OCCN2CCCC2)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
LATREPIRDINE;201608;None;42;Human;Binding;Ki;=;630,96;6,20;-91;19;Displacement of [3H]Spiperone from human recombinant dopamine D2S receptor expressed in CHO cells;ChEMBL;319,2;3;0;3;3,88;Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1;https://dx.doi.org/10.1016/j.bmcl.2009.11.037
LATREPIRDINE;201608;None;42;Human;Binding;Ki;=;1547,75;5,81;-91;19;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;319,2;3;0;3;3,88;Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1;https://dx.doi.org/10.6019/CHEMBL5442175
LEVODOPA;4324;3H-YM 09151-2;68;Human;Binding;pKi;=;10000,00;5,00;-1;6;-;PDSP KiDatabase;197,1;3;4;4;0,05;N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O;-
LIDAMIDINE;172649;None;27;Human;Binding;AC50;=;1600,00;5,80;-;3;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;220,1;1;3;2;1,37;CN=C(N)NC(=O)Nc1c(C)cccc1C;https://dx.doi.org/10.1038/s41467-023-40064-9
LIDOFLAZINE;209699;None;30;Human;Binding;AC50;=;1500,00;5,82;-;18;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;491,3;9;1;3;5,75;Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
lisuride;2325;None;21;Human;Binding;EC50;=;0,01;11,00;-2;44;Agonist activity at dopamine D2 receptor short isoform (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay;ChEMBL;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
lisuride;2325;None;21;Human;Binding;IC50;=;2,86;8,54;-2;44;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
lisuride;2325;None;21;Human;Binding;Ki;=;0,66;9,18;-2;44;Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins;ChEMBL;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://dx.doi.org/10.1021/jm5003759
lisuride;2325;None;21;Human;Binding;Ki;=;0,80;9,10;-2;44;Affinity towards Dopamine receptor D2;ChEMBL;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://dx.doi.org/10.1021/jm9800292
lisuride;2325;None;21;Human;Binding;Ki;=;0,66;9,18;-2;44;Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins;ChEMBL;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://dx.doi.org/10.1021/jm5003759
lisuride;2325;None;21;Human;Binding;Ki;=;0,50;9,30;-2;44;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://dx.doi.org/10.1021/jm960360q
lisuride;2325;None;21;Human;Binding;Ki;=;0,95;9,02;-2;44;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
lisuride;2325;None;21;Human;Binding;Ki;=;0,34;9,47;-2;44;Binding affinity to dopamine D2 receptor (unknown origin) assessed as inhibition constant;ChEMBL;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://dx.doi.org/10.1039/d3md00677h
lisuride;2325;None;21;Human;Binding;pKi;=;9,30;8,03;-2;44;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;Drug Central;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
lisuride;2325;None;21;Human;Binding;pKi;None;-;9,35;-2;44;Unclassified;Guide to Pharmacology;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://pubmed.ncbi.nlm.nih.gov/12388666
lisuride;2325;125I-IODOSULPRIDE;21;Human;Binding;pKi;=;0,34;9,47;-2;44;-;PDSP KiDatabase;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
lisuride;2325;125I-IODOSULPRIDE;21;Human;Binding;pKi;=;1,40;8,85;-2;44;-;PDSP KiDatabase;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
lisuride;2325;3H-thymidine;21;Human;Binding;pKi;=;0,18;9,74;-2;44;-;PDSP KiDatabase;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
lisuride;2325;125I-IODOSULPRIDE;21;Human;Binding;pKi;=;0,66;9,18;-2;44;-;PDSP KiDatabase;338,2;3;2;2;2,84;CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
LOFEPRAMINE;208853;None;39;Human;Binding;AC50;=;18999,80;4,72;-15;25;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;418,2;7;0;3;5,78;CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
LOFEPRAMINE;208853;None;39;Human;Binding;pKi;=;5,70;8,24;-15;25;None;Drug Central;418,2;7;0;3;5,78;CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1;-
LOFEPRAMINE;208853;3H-SPIPERONE;39;Human;Binding;pKi;=;2000,00;5,70;-15;25;-;PDSP KiDatabase;418,2;7;0;3;5,78;CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1;-
LOMERIZINE;100668;None;35;Human;Binding;AC50;=;7000,00;5,16;-;16;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;468,2;8;0;5;4,90;COc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)c(OC)c1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
LONAZOLAC;23640;None;36;Human;Binding;AC50;=;830,00;6,08;-;1;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;312,1;4;1;3;3,82;O=C(O)Cc1cn(-c2ccccc2)nc1-c1ccc(Cl)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
loperamide;2341;None;28;Human;Binding;Ki;=;5790,00;5,24;-5754;40;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;476,2;7;1;3;5,09;CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
loxapine;2348;None;42;Human;Binding;AC50;=;58,30;7,23;-4;52;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
loxapine;2348;None;42;Human;Binding;IC50;=;54,00;7,27;-4;52;Compound was tested in vitro for its binding affinity towards human Dopamine receptor D2;ChEMBL;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm991005d
loxapine;2348;None;42;Human;Binding;Ki;=;21,00;7,68;-4;52;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;ChEMBL;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm00043a008
loxapine;2348;None;42;Human;Binding;Ki;=;21,00;7,68;-4;52;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm00004a016
loxapine;2348;None;42;Human;Binding;pKi;=;7,68;8,11;-4;52;Affinity was evaluated by inhibition of [3H]spiperone binding to COS cells transfected with human dopamine D-2(long) receptor;Drug Central;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;None;42;Human;Binding;pKi;=;-;8,11;-4;52;Unclassified;Guide to Pharmacology;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;https://pubmed.ncbi.nlm.nih.gov/9015795
loxapine;2348;None;42;Human;Binding;pKi;=;-;8,11;-4;52;Unclassified;Guide to Pharmacology;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;https://pubmed.ncbi.nlm.nih.gov/12629531
loxapine;2348;3H-SPIPERONE;42;Human;Binding;pKi;=;5,20;8,28;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;UNDEFINED;42;Human;Binding;pKi;=;5,20;8,28;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;UNDEFINED;42;Human;Binding;pKi;=;5,20;8,28;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-SPIPERONE;42;Human;Binding;pKi;=;21,00;7,68;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;UNDEFINED;42;Human;Binding;pKi;=;71,42;7,15;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-NEMONAPRIDE;42;Human;Binding;pKi;=;45,00;7,35;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-YM 09151-2;42;Human;Binding;pKi;=;9,90;8,00;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-SPIPERONE;42;Human;Binding;pKi;=;70,00;7,15;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-RACLOPRIDE;42;Human;Binding;pKi;=;10,10;8,00;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-NEMONAPRIDE;42;Human;Binding;pKi;=;39,00;7,41;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-SPIPERONE;42;Human;Binding;pKi;=;30,00;7,52;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-NMSP;42;Human;Binding;pKi;=;10,00;8,00;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-RACLOPRIDE;42;Human;Binding;pKi;=;9,80;8,01;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-SPIPERONE;42;Human;Binding;pKi;=;19,00;7,72;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-SPIPERONE;42;Human;Binding;pKi;=;54,00;7,27;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-SPIPERONE;42;Human;Binding;pKi;=;23,00;7,64;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
loxapine;2348;3H-NMSP;42;Human;Binding;pKi;=;12,00;7,92;-4;52;-;PDSP KiDatabase;327,1;0;0;4;3,77;CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1;-
LP-12;2350;None;5;Human;Binding;Ki;=;224,00;6,65;-1737;6;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;481,3;9;1;3;6,23;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NC1CCCc2ccccc21;https://dx.doi.org/10.1021/jm070487n
LP-12;2350;None;5;Human;Binding;pKi;=;-;6,65;-1737;6;Unclassified;Guide to Pharmacology;481,3;9;1;3;6,23;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NC1CCCc2ccccc21;https://pubmed.ncbi.nlm.nih.gov/17649988
LP-12;2350;UNDEFINED;5;Human;Binding;pKi;=;224,00;6,65;-1737;6;-;PDSP KiDatabase;481,3;9;1;3;6,23;O=C(CCCCCN1CCN(c2ccccc2-c2ccccc2)CC1)NC1CCCc2ccccc21;-
LP-211;2351;None;38;Human;Binding;Ki;=;142,00;6,85;-295;8;Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in cell membrane measured after 1.5 hrs by scintillation counting method;ChEMBL;466,3;10;1;4;5,22;N#Cc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1039/C8MD00313K
LP-211;2351;None;38;Human;Binding;Ki;=;242,00;6,62;-295;8;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;466,3;10;1;4;5,22;N#Cc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1016/j.ejmech.2016.05.005
LP-211;2351;None;38;Human;Binding;Ki;=;142,00;6,85;-295;8;Displacement of [3H]spiroperidol from human cloned dopamine D2L receptor expressed in rat C6 cells;ChEMBL;466,3;10;1;4;5,22;N#Cc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;https://dx.doi.org/10.1021/jm800615e
LP-211;2351;None;38;Human;Binding;pKi;=;-;6,85;-295;8;Unclassified;Guide to Pharmacology;466,3;10;1;4;5,22;N#Cc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;https://pubmed.ncbi.nlm.nih.gov/18800769
LP-211;2351;UNDEFINED;38;Human;Binding;pKi;=;142,00;6,85;-295;8;-;PDSP KiDatabase;466,3;10;1;4;5,22;N#Cc1ccc(CNC(=O)CCCCCN2CCN(c3ccccc3-c3ccccc3)CC2)cc1;-
LP-44;2353;None;4;Human;Binding;Ki;=;7,30;8,14;-33;9;Displacement of [3H]spiroperidol from human recombinant Dopamine D2 long receptor;ChEMBL;451,3;9;1;4;5,29;CSc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://dx.doi.org/10.1021/jm070487n
LP-44;2353;None;4;Human;Binding;pKi;=;-;8,14;-33;9;Unclassified;Guide to Pharmacology;451,3;9;1;4;5,29;CSc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/17649988
LP-44;2353;UNDEFINED;4;Human;Binding;pKi;=;7,30;8,14;-33;9;-;PDSP KiDatabase;451,3;9;1;4;5,29;CSc1ccccc1N1CCN(CCCCCC(=O)NC2CCCc3ccccc32)CC1;-
lumateperone;2383;None;0;Human;Binding;pKi;=;-;7,49;-64;2;Unclassified;Guide to Pharmacology;393,2;5;0;4;3,92;CN1CCN2c3c(cccc31)C1CN(CCCC(=O)c3ccc(F)cc3)CCC12;https://pubmed.ncbi.nlm.nih.gov/25120104
lumateperone;2383;None;0;Human;Binding;pKi;=;-;7,49;-64;2;Unclassified;Guide to Pharmacology;393,2;5;0;4;3,92;CN1CCN2c3c(cccc31)C1CN(CCCC(=O)c3ccc(F)cc3)CCC12;https://pubmed.ncbi.nlm.nih.gov/24559051
LUMATEPERONE;112868;None;31;Human;Binding;IC50;=;4,10;8,39;-3;9;Partial agonist activity at presynaptic D2 receptor (unknown origin);ChEMBL;393,2;5;0;4;3,92;CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12;https://dx.doi.org/10.1016/j.ejmech.2020.112667
LUMATEPERONE;112868;None;31;Human;Binding;IC50;=;3,20;8,49;-3;9;Antagonist activity at postsynaptic D2 receptor (unknown origin);ChEMBL;393,2;5;0;4;3,92;CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12;https://dx.doi.org/10.1016/j.ejmech.2020.112667
LUMATEPERONE;112868;None;31;Human;Binding;pKi;=;7,49;8,13;-3;9;None;Drug Central;393,2;5;0;4;3,92;CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12;-
lurasidone;2385;None;44;Human;Binding;AC50;=;18,00;7,75;-2;19;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;492,3;5;0;6;4,26;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
lurasidone;2385;None;44;Human;Binding;Ki;=;1,70;8,77;-2;19;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells incubated for 1 hr by liquid scintillation counting method;ChEMBL;492,3;5;0;6;4,26;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.111736
lurasidone;2385;None;44;Human;Binding;pKi;=;9,00;8,05;-2;19;Mechanism of Action;Drug Central;492,3;5;0;6;4,26;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1;-
Lysergide;2429;None;10;Human;Binding;Ki;=;125,89;6,90;-398;44;Binding affinity against human Dopamine receptor D2 in CHO cells using [125I]iodosulpiride;ChEMBL;323,2;3;1;2;2,91;CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://dx.doi.org/10.1021/jm0341204
Lysergide;2429;None;10;Human;Binding;Ki;=;120,00;6,92;-398;44;Binding affinity towards Dopamine receptor D2;ChEMBL;323,2;3;1;2;2,91;CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://dx.doi.org/10.1021/jm020153s
MADURAMICIN;67820;None;12;Human;Binding;IC50;=;702,00;6,15;-295;15;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;916,5;13;4;16;4,32;CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC;-
MADURAMICIN;67820;None;12;Human;Binding;Ki;=;234,00;6,63;-295;15;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;916,5;13;4;16;4,32;CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC;-
MANIDIPINE 6300;7228;None;58;Human;Binding;AC50;=;6599,90;5,18;-;6;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;610,3;10;1;9;4,95;COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)C1c1cccc([N+](=O)[O-])c1;https://dx.doi.org/10.1038/s41467-023-40064-9
MAPROTILINE;82440;None;34;Human;Binding;AC50;=;12999,90;4,89;-128;29;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;277,2;4;1;1;4,21;CNCCCC12CCC(c3ccccc31)c1ccccc12;https://dx.doi.org/10.1038/s41467-023-40064-9
MAPROTILINE;82440;None;34;Human;Binding;IC50;=;3463,00;5,46;-128;29;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;277,2;4;1;1;4,21;CNCCCC12CCC(c3ccccc31)c1ccccc12;-
MAPROTILINE;82440;None;34;Human;Binding;Ki;=;1154,00;5,94;-128;29;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;277,2;4;1;1;4,21;CNCCCC12CCC(c3ccccc31)c1ccccc12;-
MAPROTILINE;82440;None;34;Human;Binding;Ki;=;665,00;6,18;-128;29;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells;ChEMBL;277,2;4;1;1;4,21;CNCCCC12CCC(c3ccccc31)c1ccccc12;https://dx.doi.org/10.1016/j.bmcl.2008.09.012
MAPROTILINE;82440;None;34;Human;Binding;pKi;=;6,18;8,21;-128;29;None;Drug Central;277,2;4;1;1;4,21;CNCCCC12CCC(c3ccccc31)c1ccccc12;-
MAPROTILINE;82440;UNDEFINED;34;Human;Binding;pKi;=;665,00;6,18;-128;29;-;PDSP KiDatabase;277,2;4;1;1;4,21;CNCCCC12CCC(c3ccccc31)c1ccccc12;-
MASOPROCOL;106495;None;32;Human;Binding;AC50;=;6900,00;5,16;-;14;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;302,2;5;4;4;3,57;C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
MASOPROCOL;106495;None;32;Human;Binding;AC50;=;10000,00;5,00;-;14;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;302,2;5;4;4;3,57;C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
mavorixafor;2462;None;36;Human;Binding;IC50;=;4100,00;5,39;-;4;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;349,2;7;2;4;3,58;NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21;https://dx.doi.org/10.1021/acs.jmedchem.1c01564
MAZAPERTINE;4309;None;16;Human;Binding;Ki;=;2,20;8,66;-147;13;Compound was measured in vivo for its binding affinity at Dopamine receptor D2 using [3H]spiperone as radioligand.;ChEMBL;421,3;6;0;4;4,42;CC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1;https://dx.doi.org/10.1016/S0960-894X(97)00074-7
MAZAPERTINE;4309;UNDEFINED;16;Human;Binding;pKi;=;4,00;8,40;-147;13;-;PDSP KiDatabase;421,3;6;0;4;4,42;CC(C)Oc1ccccc1N1CCN(Cc2cccc(C(=O)N3CCCCC3)c2)CC1;-
MEBEVERINE;99367;None;27;Human;Binding;AC50;=;21000,00;4,68;-;13;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;429,3;13;0;6;4,60;CCN(CCCCOC(=O)c1ccc(OC)c(OC)c1)C(C)Cc1ccc(OC)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
meclinertant;2481;3H-N-Methylspiporone;38;Human;Binding;pKi;=;10000,00;5,00;-2818;12;-;PDSP KiDatabase;586,2;7;2;7;5,77;COc1cccc(OC)c1-c1cc(C(=O)NC2(C(=O)O)C3CC4CC(C3)CC2C4)nn1-c1ccnc2cc(Cl)ccc12;-
MECLIZINE;55838;None;37;Human;Binding;AC50;=;3100,00;5,51;-;19;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;390,2;5;0;2;5,56;Cc1cccc(CN2CCN(C(c3ccccc3)c3ccc(Cl)cc3)CC2)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
MECOPROP;98073;3H-SPIPERONE;55;Human;Binding;pKi;=;10000,00;5,00;-524;34;-;PDSP KiDatabase;214;3;1;2;2,50;Cc1cc(Cl)ccc1OC(C)C(=O)O;-
MELITRACEN;9159;None;27;Human;Binding;AC50;=;5400,00;5,27;-;21;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;291,2;3;0;1;4,71;CN(C)CCC=C1c2ccccc2C(C)(C)c2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
MELOXICAM;203007;3H-NMSP;67;Human;Binding;pKi;=;10000,00;5,00;-1;32;-;PDSP KiDatabase;351;2;2;6;1,95;Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1;-
MELPERONE;45836;None;41;Human;Binding;pKi;=;6,98;8,16;-9;26;None;Drug Central;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;UNDEFINED;41;Human;Binding;pKi;=;50,00;7,30;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;3H-YM 09151-2;41;Human;Binding;pKi;=;181,50;6,74;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;3H-SPIPERONE;41;Human;Binding;pKi;=;180,00;6,74;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;R-SAT;41;Human;Binding;pKi;=;3,60;8,44;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;3H-RACLOPRIDE;41;Human;Binding;pKi;=;105,00;6,98;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;3H-NEMONAPRIDE;41;Human;Binding;pKi;=;520,00;6,28;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;3H-SPIPERONE;41;Human;Binding;pKi;=;88,00;7,06;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;UNDEFINED;41;Human;Binding;pKi;=;50,00;7,30;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MELPERONE;45836;3H-SPIPERONE;41;Human;Binding;pKi;=;300,00;6,52;-9;26;-;PDSP KiDatabase;263,2;5;0;2;3,52;CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
MEMANTINE;207959;3H-NMSP;46;Human;Binding;pKi;=;10000,00;5,00;-1;39;-;PDSP KiDatabase;179,2;0;1;1;2,69;CC12CC3CC(C)(C1)CC(N)(C3)C2;-
MEQUITAZINE;207084;None;54;Human;Binding;AC50;=;8600,00;5,07;-;19;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;322,1;2;0;3;4,63;c1ccc2c(c1)Sc1ccccc1N2CC1CN2CCC1CC2;https://dx.doi.org/10.1038/s41467-023-40064-9
mesoridazine;2492;None;34;Human;Binding;pKi;=;7,72;8,11;-1;25;None;Drug Central;386,1;4;0;4;4,90;CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21;-
mesoridazine;2492;None;34;Human;Binding;pKi;=;-;8,66;-1;25;Unclassified;Guide to Pharmacology;386,1;4;0;4;4,90;CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21;https://pubmed.ncbi.nlm.nih.gov/15357957
mesoridazine;2492;3H-SPIPERONE;34;Human;Binding;pKi;=;19,00;7,72;-1;25;-;PDSP KiDatabase;386,1;4;0;4;4,90;CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21;-
mesoridazine;2492;UNDEFINED;34;Human;Binding;pKi;=;18,86;7,72;-1;25;-;PDSP KiDatabase;386,1;4;0;4;4,90;CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21;-
mesoridazine;2492;R-SAT;34;Human;Binding;pKi;=;4,30;8,37;-1;25;-;PDSP KiDatabase;386,1;4;0;4;4,90;CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21;-
MESPIPERONE;97204;None;10;Human;Binding;Kd;=;0,10;10,01;-1;5;Affinity constant of compound was evaluated in human brain;ChEMBL;409,2;6;0;4;3,56;CN1CN(c2ccccc2)C2(CCN(CCCC(=O)c3ccc(F)cc3)CC2)C1=O;https://dx.doi.org/10.1021/jm00400a027
MESPIPERONE;97204;None;10;Human;Binding;Ki;=;0,13;9,88;-1;5;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;409,2;6;0;4;3,56;CN1CN(c2ccccc2)C2(CCN(CCCC(=O)c3ccc(F)cc3)CC2)C1=O;https://dx.doi.org/10.1021/jm401798r
metergoline;2496;None;39;Human;Binding;IC50;=;63,00;7,20;-23;49;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;403,2;4;1;4;4,07;CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21;-
metergoline;2496;None;39;Human;Binding;Ki;=;21,00;7,68;-23;49;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;403,2;4;1;4;4,07;CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21;-
metergoline;2496;None;39;Human;Binding;pKi;=;7,68;8,11;-23;49;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;403,2;4;1;4;4,07;CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21;-
METHAMPHETAMINE;14473;3H-YM 09151-2;7;Human;Binding;pKi;=;10000,00;5,00;-147;12;-;PDSP KiDatabase;149,1;3;1;1;1,84;CN[C@@H](C)Cc1ccccc1;-
Methcathinone, (-);218813;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-16;40;-;PDSP KiDatabase;163,1;3;1;2;1,48;CNC(C)C(=O)c1ccccc1;-
methylergonovine;2509;None;14;Human;Binding;IC50;=;829,00;6,08;-31;20;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;339,2;4;3;3;1,93;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
methylergonovine;2509;None;14;Human;Binding;Ki;=;276,00;6,56;-31;20;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;339,2;4;3;3;1,93;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
methylergonovine;2509;None;14;Human;Binding;pKi;=;6,56;8,18;-31;20;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;339,2;4;3;3;1,93;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
METHYLPHENIDATE;207799;3H-YM 09151-2;13;Human;Binding;pKi;=;10000,00;5,00;-141;21;-;PDSP KiDatabase;233,1;3;1;3;2,08;COC(=O)C(c1ccccc1)C1CCCCN1;-
methysergide;2514;None;19;Human;Binding;AC50;=;310,00;6,51;-223;69;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;353,2;4;2;4;1,94;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;https://dx.doi.org/10.1038/s41467-023-40064-9
methysergide;2514;None;19;Human;Binding;IC50;=;807,00;6,09;-223;69;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;353,2;4;2;4;1,94;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;-
methysergide;2514;None;19;Human;Binding;Ki;=;269,00;6,57;-223;69;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;353,2;4;2;4;1,94;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;-
methysergide;2514;None;19;Human;Binding;pKi;=;6,57;8,18;-223;69;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;353,2;4;2;4;1,94;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;-
methysergide;2514;3H-NMSP;19;Human;Binding;pKi;=;10000,00;5,00;-223;69;-;PDSP KiDatabase;353,2;4;2;4;1,94;CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1;-
metoclopramide;2518;None;51;Human;Binding;AC50;=;110,00;6,96;-2;27;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;299,1;7;2;4;2,00;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
metoclopramide;2518;None;51;Human;Binding;IC50;=;127,00;6,90;-2;27;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;299,1;7;2;4;2,00;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;-
metoclopramide;2518;None;51;Human;Binding;Ki;=;42,00;7,38;-2;27;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;299,1;7;2;4;2,00;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;-
metoclopramide;2518;None;51;Human;Binding;Ki;=;64,00;7,19;-2;27;Radioligand Binding Assay: The pharmacological profile of metopimazine, metopimazine acid (MPZA), domperidone, and metoclopramide were assessed by radioligand binding and by a functional antagonist assay. For the radioligand binding assay, cell membranes of dopamine D2 receptor expressing cells were incubated with [3H]spiperone and competing drugs in buffer. The assay was terminated by rapid filtration, and the bound radioactive signal was determined by liquid scintillation counting.;ChEMBL;299,1;7;2;4;2,00;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;-
metoclopramide;2518;None;51;Human;Binding;pKi;=;7,19;8,14;-2;27;None;Drug Central;299,1;7;2;4;2,00;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;-
metoclopramide;2518;3H-YM 09151-2;51;Human;Binding;pKi;=;64,00;7,19;-2;27;-;PDSP KiDatabase;299,1;7;2;4;2,00;CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC;-
metopimazine;2519;None;33;Human;Binding;Ki;=;0,07;10,15;2;3;Radioligand Binding Assay: The pharmacological profile of metopimazine, metopimazine acid (MPZA), domperidone, and metoclopramide were assessed by radioligand binding and by a functional antagonist assay. For the radioligand binding assay, cell membranes of dopamine D2 receptor expressing cells were incubated with [3H]spiperone and competing drugs in buffer. The assay was terminated by rapid filtration, and the bound radioactive signal was determined by liquid scintillation counting.;ChEMBL;445,1;6;1;6;3,28;CS(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(C(N)=O)CC1)c1ccccc1S2;-
metopimazine;2519;None;33;Human;Binding;pKi;=;10,15;7,99;2;3;Radioligand Binding Assay: The pharmacological profile of metopimazine, metopimazine acid (MPZA), domperidone, and metoclopramide were assessed by radioligand binding and by a functional antagonist assay. For the radioligand binding assay, cell membranes of dopamine D2 receptor expressing cells were incubated with [3H]spiperone and competing drugs in buffer. The assay was terminated by rapid filtration, and the bound radioactive signal was determined by liquid scintillation counting.;Drug Central;445,1;6;1;6;3,28;CS(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(C(N)=O)CC1)c1ccccc1S2;-
MEZILAMINE;157327;None;20;Human;Binding;Ki;=;5,40;8,27;79;2;Binding affinity to Dopamine receptor D2 was determined;ChEMBL;287,1;3;1;6;1,65;CNc1nc(Cl)c(SC)c(N2CCN(C)CC2)n1;https://dx.doi.org/10.1016/s0960-894x(01)00167-6
mianserin;2532;None;33;Human;Binding;AC50;=;3200,00;5,50;-316;63;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;264,2;0;0;2;3,08;CN1CCN2c3ccccc3Cc3ccccc3C2C1;https://dx.doi.org/10.1038/s41467-023-40064-9
mianserin;2532;None;33;Human;Binding;IC50;=;7079,46;5,15;-316;63;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;264,2;0;0;2;3,08;CN1CCN2c3ccccc3Cc3ccccc3C2C1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
mianserin;2532;None;33;Human;Binding;IC50;=;7079,46;5,15;-316;63;Binding affinity for human cloned Dopamine receptor D2L;ChEMBL;264,2;0;0;2;3,08;CN1CCN2c3ccccc3Cc3ccccc3C2C1;https://dx.doi.org/10.1016/s0960-894x(01)00721-1
mianserin;2532;None;33;Human;Binding;Ki;=;2197,00;5,66;-316;63;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;264,2;0;0;2;3,08;CN1CCN2c3ccccc3Cc3ccccc3C2C1;https://dx.doi.org/10.1021/jm049632c
mianserin;2532;None;33;Human;Binding;pKi;=;5,66;8,25;-316;63;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;Drug Central;264,2;0;0;2;3,08;CN1CCN2c3ccccc3Cc3ccccc3C2C1;-
mianserin;2532;3H-domperidone;33;Human;Binding;pKi;=;2685,00;5,57;-316;63;-;PDSP KiDatabase;264,2;0;0;2;3,08;CN1CCN2c3ccccc3Cc3ccccc3C2C1;-
mianserin;2532;3H-YM 09151-2;33;Human;Binding;pKi;=;1274,00;5,89;-316;63;-;PDSP KiDatabase;264,2;0;0;2;3,08;CN1CCN2c3ccccc3Cc3ccccc3C2C1;-
mianserin;2532;3H-SPIPERONE;33;Human;Binding;pKi;=;2197,00;5,66;-316;63;-;PDSP KiDatabase;264,2;0;0;2;3,08;CN1CCN2c3ccccc3Cc3ccccc3C2C1;-
MICONAZOLE;209380;None;58;Human;Binding;IC50;=;12504,00;4,90;-29;36;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;414;6;0;3;6,46;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1;-
MICONAZOLE;209380;None;58;Human;Binding;Ki;=;4168,00;5,38;-29;36;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;414;6;0;3;6,46;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1;-
MICONAZOLE;209380;None;58;Human;Binding;pKi;=;5,38;8,27;-29;36;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;414;6;0;3;6,46;Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1;-
MIDOMAFETAMINE;167894;3H-NMSP;12;Human;Binding;pKi;=;10000,00;5,00;-26;44;-;PDSP KiDatabase;193,1;3;1;3;1,57;CNC(C)Cc1ccc2c(c1)OCO2;-
MIDOMAFETAMINE;167894;3H-NMSP;12;Human;Binding;pKi;=;10000,00;5,00;-26;44;-;PDSP KiDatabase;193,1;3;1;3;1,57;CNC(C)Cc1ccc2c(c1)OCO2;-
mirtazapine;2540;None;64;Human;Binding;pKi;None;5,26;8,28;-363;22;None;Drug Central;265,2;0;0;3;2,48;CN1CCN2c3ncccc3Cc3ccccc3C2C1;-
mirtazapine;2540;3H-SPIPERONE;64;Human;Binding;pKi;=;5454,00;5,26;-363;22;-;PDSP KiDatabase;265,2;0;0;3;2,48;CN1CCN2c3ncccc3Cc3ccccc3C2C1;-
MK-7246;198593;None;41;Human;Binding;Ki;=;3981,07;5,40;-1513;5;GPCRScan assay: inhibition of D2;ChEMBL;416,1;5;1;4;3,04;CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1;https://dx.doi.org/10.6019/CHEMBL4507290
MK-7246;198593;None;41;Human;Binding;Ki;=;3746,00;5,43;-1513;5;Selectivity interaction (GPCR panel (PDSP screen)) EUB0000297b DRD2;ChEMBL;416,1;5;1;4;3,04;CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1;https://dx.doi.org/10.6019/CHEMBL5212743
MK-7246;198593;None;41;Human;Binding;Ki;=;3746,00;5,43;-1513;5;GPCRScan assay: inhibition of D2;ChEMBL;416,1;5;1;4;3,04;CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1;https://dx.doi.org/10.6019/CHEMBL4507290
ML321;2572;None;1;Human;Binding;AC50;=;725,00;6,14;40;2;Antagonist activity at ProLink-tagged D2 receptor (unknown origin) expressed in CHO cells assessed as inhibition of dopamine-stimulated beta-arrestin binding treated for 90 mins prior to dopamine challenge by PathHunter DiscoveRx assay;ChEMBL;410,1;4;1;4;3,48;CN1C(=O)c2ccccc2[S@](=O)c2ccc(C(=O)NCCc3cccs3)cc21;https://dx.doi.org/10.1021/jm500126s
ML321;2572;None;1;Human;Binding;Ki;=;100,00;7,00;40;2;Displacement of [3H]methylspiperone from human D2L receptor expressed in HEK cell membrane after 90 mins by scintillation counting analysis;ChEMBL;410,1;4;1;4;3,48;CN1C(=O)c2ccccc2[S@](=O)c2ccc(C(=O)NCCc3cccs3)cc21;https://dx.doi.org/10.1021/jm500126s
ML321;2572;None;1;Human;Binding;pKi;=;-;7,00;40;2;Unclassified;Guide to Pharmacology;410,1;4;1;4;3,48;CN1C(=O)c2ccccc2[S@](=O)c2ccc(C(=O)NCCc3cccs3)cc21;https://pubmed.ncbi.nlm.nih.gov/24666157
ML321;2572;None;1;Human;Binding;pKi;=;-;7,00;40;2;Unclassified;Guide to Pharmacology;410,1;4;1;4;3,48;CN1C(=O)c2ccccc2[S@](=O)c2ccc(C(=O)NCCc3cccs3)cc21;https://pubmed.ncbi.nlm.nih.gov/24260782
MLS1547;2580;None;37;Human;Binding;pKi;=;-;8,23;-;2;Biased agonist for G-protein coupling to Gi.;Guide to Pharmacology;354,1;3;1;5;3,31;Oc1c(CN2CCN(c3ccccn3)CC2)cc(Cl)c2cccnc12;https://pubmed.ncbi.nlm.nih.gov/24755247
molindone;2590;None;33;Human;Binding;AC50;=;209,40;6,68;-3;31;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;https://dx.doi.org/10.1038/s41467-023-40064-9
molindone;2590;UNDEFINED;33;Human;Binding;pKi;=;6,00;8,22;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;3H-NMSP;33;Human;Binding;pKi;=;63,00;7,20;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;R-SAT;33;Human;Binding;pKi;=;20,00;7,70;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;UNDEFINED;33;Human;Binding;pKi;=;120,48;6,92;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;3H-RACLOPRIDE;33;Human;Binding;pKi;=;9,60;8,02;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;UNDEFINED;33;Human;Binding;pKi;=;6,00;8,22;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;3H-SPIPERONE;33;Human;Binding;pKi;=;15,00;7,82;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;3H-NEMONAPRIDE;33;Human;Binding;pKi;=;31,00;7,51;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;R-SAT;33;Human;Binding;pKi;=;3,80;8,42;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;3H-SPIPERONE;33;Human;Binding;pKi;=;120,00;6,92;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
molindone;2590;3H-SPIPERONE;33;Human;Binding;pKi;=;6,00;8,22;-3;31;-;PDSP KiDatabase;276,2;3;1;3;1,96;CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2;-
MOPERONE;78208;None;26;Human;Binding;Kd;=;0,95;9,02;-1;5;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;355,2;6;1;3;4,08;Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
MOPERONE;78208;None;26;Human;Binding;Ki;=;0,72;9,14;-1;5;Displacement of PPHT-red from SNAP-tagged human D2LR expressed in CHOK1 cell membranes by TR-FRET assay;ChEMBL;355,2;6;1;3;4,08;Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.9b00864
MOPERONE;78208;None;26;Human;Binding;pKi;=;9,00;8,05;-1;5;None;Drug Central;355,2;6;1;3;4,08;Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;-
MOPERONE;78208;R-SAT;26;Human;Binding;pKi;=;1,00;9,00;-1;5;-;PDSP KiDatabase;355,2;6;1;3;4,08;Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;-
MOPERONE;78208;R-SAT;26;Human;Binding;pKi;=;0,70;9,15;-1;5;-;PDSP KiDatabase;355,2;6;1;3;4,08;Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;-
MOPERONE;78208;UNDEFINED;26;Human;Binding;pKi;=;1,80;8,74;-1;5;-;PDSP KiDatabase;355,2;6;1;3;4,08;Cc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;80,00;7,10;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;106,00;6,97;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;104,00;6,98;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;92,00;7,04;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;66,00;7,18;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;79,00;7,10;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;159,00;6,80;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;187,00;6,73;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;57,00;7,24;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;101,00;7,00;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;42,00;7,38;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;52,00;7,28;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;42,00;7,38;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;259,00;6,59;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;129,00;6,89;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;36,00;7,44;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;284,00;6,55;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;86,00;7,07;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;82,00;7,09;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;62,00;7,21;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;62,00;7,21;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;110,00;6,96;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;15,00;7,82;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;71,00;7,15;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;139,00;6,86;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;191,00;6,72;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;271,00;6,57;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;37,00;7,43;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;60,00;7,22;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;61,00;7,21;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;198,00;6,70;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;45,00;7,35;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;55,00;7,26;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;51,00;7,29;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;71,00;7,15;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;104,00;6,98;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;58,00;7,24;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;81,00;7,09;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;43,00;7,37;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;64,00;7,19;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;76,00;7,12;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;130,00;6,89;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;123,00;6,91;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;55,00;7,26;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;144,00;6,84;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;78,00;7,11;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;85,00;7,07;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;173,00;6,76;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;50,00;7,30;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;178,00;6,75;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;14,00;7,85;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;810,00;6,09;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;129,00;6,89;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;149,00;6,83;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;588,00;6,23;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;83,00;7,08;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;31,00;7,51;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;39,00;7,41;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;201,00;6,70;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;23,00;7,64;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;37,00;7,43;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;2,40;8,62;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;27,00;7,57;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;276,00;6,56;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;194,00;6,71;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;1,90;8,72;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;118,00;6,93;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;133,00;6,88;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;55,00;7,26;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;79,00;7,10;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;74,00;7,13;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;94,00;7,03;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;94,00;7,03;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;356,00;6,45;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;425,00;6,37;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;78,00;7,11;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;69,00;7,16;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;18,00;7,74;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;111,00;6,95;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;88,00;7,06;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;154,00;6,81;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;430,00;6,37;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;34,00;7,47;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;154,00;6,81;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;122,00;6,91;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;69,00;7,16;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1r,4r)-4-(4-(2-cyclopropoxyphenyl)piperidin-1-yl)cyclohexyl)benzo[d][1,3]dioxole-5-sulfonamide;219053;UNDEFINED;0;Human;Binding;pKi;=;144,00;6,84;-8;6;-;PDSP KiDatabase;158,1;7;0;2;2,57;CCCCN(CCCC)N=O;-
N-((1s,4s)-4-(4-(2-isopropoxyphenyl)piperazin-1-yl)cyclohexyl)(phenyl)methanesulfonamide;219112;UNDEFINED;0;Human;Binding;pKi;=;24,00;7,62;-11;4;-;PDSP KiDatabase;359,2;1;2;3;5,28;Cc1ccccc1N1c2ccccc2C(C)(O)CC(C)(O)c2ccccc21;-
N-(4-Acetamidophenyl)indomethacinamide;218882;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-7;29;-;PDSP KiDatabase;517,2;8;2;5;5,16;COc1ccc2c(c1)c(CC(=O)NCCc1ccc(NC(C)=O)cc1)c(C)n2C(=O)c1ccc(Cl)cc1;-
N-Benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-1-methyl-1H-pyrazol-3-yloxy]-acetamide;219619;UNDEFINED;0;Human;Binding;pKi;=;285,00;6,55;-87;11;-;PDSP KiDatabase;116,1;4;0;2;1,40;CCCCN(C)N=O;-
N-desmethylclozapine;2035;UNDEFINED;50;Human;Binding;pKi;=;100,00;7,00;-52;41;-;PDSP KiDatabase;312,1;1;2;4;1,69;Clc1ccc2c(c1)NC(N1CCNCC1)=c1ccccc1=N2;-
N-desmethylclozapine;2035;R-SAT;50;Human;Binding;pKi;=;89,00;7,05;-52;41;-;PDSP KiDatabase;312,1;1;2;4;1,69;Clc1ccc2c(c1)NC(N1CCNCC1)=c1ccccc1=N2;-
N-desmethylclozapine;2035;3H-NMSP;50;Human;Binding;pKi;=;115,20;6,94;-52;41;-;PDSP KiDatabase;312,1;1;2;4;1,69;Clc1ccc2c(c1)NC(N1CCNCC1)=c1ccccc1=N2;-
N-Methyl-2'-methyl-furo[m]aporphine;220004;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-346;3;-;PDSP KiDatabase;289,1;0;0;2;4,49;Cc1cc2ccc3c(c2o1)-c1cccc2c1C(C3)N(C)CC2;-
N-Propyl-2',2'-bismethyl-2',3'-dihydrofuro[m]noraporphine;220011;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-15;3;-;PDSP KiDatabase;333,2;2;0;2;4,93;CCCN1CCc2cccc3c2C1Cc1ccc2c(c1-3)OC(C)(C)C2;-
N-Propyl-2',3'-bismethyl-furo[m]noraporphine;220008;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-19;3;-;PDSP KiDatabase;331,2;2;0;2;5,58;CCCN1CCc2cccc3c2C1Cc1ccc2c(C)c(C)oc2c1-3;-
N-Propyl-2'-methyl-furo[m]noraporphine;220009;UNDEFINED;0;Human;Binding;pKi;=;10000,00;5,00;-30;3;-;PDSP KiDatabase;317,2;2;0;2;5,27;CCCN1CCc2cccc3c2C1Cc1ccc2cc(C)oc2c1-3;-
N-propylnorapomorphine;2877;3H-SPIPERONE;0;Human;Binding;pKi;=;2391,00;5,62;-169;10;-;PDSP KiDatabase;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
N-propylnorapomorphine;2877;3H-SPIPERONE;0;Human;Binding;pKi;=;9,00;8,05;-169;10;-;PDSP KiDatabase;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
N-propylnorapomorphine;2877;3H-SPIPERONE;0;Human;Binding;pKi;=;14,00;7,85;-169;10;-;PDSP KiDatabase;295,2;2;2;3;3,63;CCCN1CCc2cccc3c2C1Cc1ccc(O)c(O)c1-3;-
N-{4-[4-(2-Methoxy-phenyl)-piperazin-1-yl]-butyl}-3-(4-tri-tert-butylstannanyl-phenyl)-acrylamide;18247;None;0;Human;Binding;Ki;=;729,00;6,14;-7;2;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm030836n
N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1-ferra-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2',4,4'-tetraene-6-carboxamide;125256;None;0;Human;Binding;Ki;=;78,00;7,11;-181;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 short expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1-ferra-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2',4,4'-tetraene-6-carboxamide;125256;None;0;Human;Binding;Ki;=;110,00;6,96;-181;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 long expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1-ruthena-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2',4,4'-tetraene-6-carboxamide;68677;None;0;Human;Binding;Ki;=;60,00;7,22;-229;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 short expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
N-{4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl}-1-ruthena-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2',4,4'-tetraene-6-carboxamide;68677;None;0;Human;Binding;Ki;=;120,00;6,92;-229;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 long expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
N-{4-[4-(3-chloro-2-methoxyphenyl)piperazin-1-yl]butyl}-1-ferra-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2',4,4'-tetraene-6-carboxamide;70803;None;0;Human;Binding;Ki;=;99,00;7,00;-93;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 long expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
N-{4-[4-(3-chloro-2-methoxyphenyl)piperazin-1-yl]butyl}-1-ferra-1,1'-spirobi[pentacyclo[2.2.0.0^{1,3}.0^{1,5}.0^{2,6}]hexane]-2,2',4,4'-tetraene-6-carboxamide;70803;None;0;Human;Binding;Ki;=;72,00;7,14;-93;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 short expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
nafadotride;2714;None;29;Human;Binding;pKi;None;-;8,50;-10;5;Unclassified;Guide to Pharmacology;365,2;7;1;4;3,71;CCCCN1CCCC1CNC(=O)c1cc(C#N)c2ccccc2c1OC;https://pubmed.ncbi.nlm.nih.gov/8531087
NAFAMOSTAT;98126;None;43;Human;Binding;AC50;=;20000,00;4,70;-;15;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;347,1;4;5;4;2,65;N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
NAFTIFINE;205329;None;22;Human;Binding;AC50;=;3900,00;5,41;-;6;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;287,2;5;0;1;4,99;CN(C/C=C/c1ccccc1)Cc1cccc2ccccc12;https://dx.doi.org/10.1038/s41467-023-40064-9
NAFTOPIDIL;34231;None;58;Human;Binding;AC50;=;1000,00;6,00;-;21;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;392,2;7;1;5;3,41;COc1ccccc1N1CCN(CC(O)COc2cccc3ccccc23)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
NAN 190;2729;None;18;Human;Binding;Ki;=;50,00;7,30;-144;13;Binding affinity for human dopamine receptor D2 by displacing [125I]iodosulpiride expressed in CHO cells;ChEMBL;393,2;7;0;5;2,89;COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1;https://dx.doi.org/10.1021/jm030836n
NAN-190;218461;3H-YM 09151-2;0;Human;Binding;pKi;=;47,00;7,33;-56;14;-;PDSP KiDatabase;473,1;7;0;5;3,47;Br.COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1;-
NAN-190;218461;3H-8-OH-DPAT;0;Human;Binding;pKi;=;14,00;7,85;-56;14;-;PDSP KiDatabase;473,1;7;0;5;3,47;Br.COc1ccccc1N1CCN(CCCCN2C(=O)c3ccccc3C2=O)CC1;-
NANTENINE;178677;None;4;Human;Binding;Ki;=;858,00;6,07;-426;22;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor;ChEMBL;339,1;2;0;5;3,19;COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4;https://dx.doi.org/10.1016/j.bmcl.2009.11.053
NAPROXEN;46814;3H-NMSP;58;Human;Binding;pKi;=;10000,00;5,00;-1;31;-;PDSP KiDatabase;230,1;3;1;2;3,04;COc1ccc2cc([C@H](C)C(=O)O)ccc2c1;-
Naproxen sodium,(-);218877;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;29;-;PDSP KiDatabase;230,1;3;1;2;3,04;COc1ccc2cc(C(C)C(=O)O)ccc2c1;-
NAXAGOLIDE;206397;None;31;Human;Binding;Ki;=;20,89;7,68;-13;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;247,2;2;1;3;2,49;CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21;https://dx.doi.org/10.1021/jm401384w
NAXAGOLIDE;206397;None;31;Human;Binding;Ki;=;1,50;8,82;-13;3;Binding affinity to high-affinity state of D2L receptor (unknown origin);ChEMBL;247,2;2;1;3;2,49;CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21;https://dx.doi.org/10.1021/jm401384w
NAXAGOLIDE;206397;None;31;Human;Binding;Ki;=;0,34;9,47;-13;3;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;247,2;2;1;3;2,49;CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21;https://dx.doi.org/10.1021/jm401384w
NAXAGOLIDE;206397;None;31;Human;Binding;Ki;=;16,98;7,77;-13;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;247,2;2;1;3;2,49;CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21;https://dx.doi.org/10.1021/jm401384w
NAXAGOLIDE;206397;None;31;Human;Binding;Ki;=;0,45;9,35;-13;3;Displacement of [3H]spiperone from high-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;247,2;2;1;3;2,49;CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21;https://dx.doi.org/10.1021/jm401384w
NAXAGOLIDE;206397;None;31;Human;Binding;Ki;=;21,40;7,67;-13;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2L receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;247,2;2;1;3;2,49;CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21;https://dx.doi.org/10.1021/jm401384w
NAXAGOLIDE;206397;None;31;Human;Binding;Ki;=;18,70;7,73;-13;3;Displacement of [3H]spiperone from low-affinity state of human dopamine D2S receptor transfected in HEK293 cells after 2 hrs by scintillation counting analysis;ChEMBL;247,2;2;1;3;2,49;CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21;https://dx.doi.org/10.1021/jm401384w
NAXAGOLIDE;206397;None;31;Human;Binding;Ki;=;8,50;8,07;-13;3;Binding affinity to human dopamine D2 receptor expressed in CHO cells;ChEMBL;247,2;2;1;3;2,49;CCCN1CCO[C@@H]2c3cc(O)ccc3CC[C@H]21;https://dx.doi.org/10.1016/j.bmcl.2010.09.142
nebivolol;2757;None;41;Human;Binding;AC50;=;3500,00;5,46;-;24;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;405,2;6;3;5;2,36;OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1;https://dx.doi.org/10.1038/s41467-023-40064-9
nefazodone;2759;None;31;Human;Binding;AC50;=;270,00;6,57;-20;40;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;469,2;10;0;7;3,55;CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1;https://dx.doi.org/10.1038/s41467-023-40064-9
nefazodone;2759;None;31;Human;Binding;Ki;=;735,53;6,13;-20;40;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;469,2;10;0;7;3,55;CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1;https://dx.doi.org/10.6019/CHEMBL5442175
nefazodone;2759;None;31;Human;Binding;pKi;=;6,75;8,17;-20;40;None;Drug Central;469,2;10;0;7;3,55;CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1;-
nefazodone;2759;3H-SPIPERONE;31;Human;Binding;pKi;=;910,00;6,04;-20;40;-;PDSP KiDatabase;469,2;10;0;7;3,55;CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1;-
nemonapride;2762;None;13;Human;Binding;AC50;=;0,30;9,52;-3;31;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;387,2;6;2;4;3,78;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;https://dx.doi.org/10.1038/s41467-023-40064-9
nemonapride;2762;None;13;Human;Binding;Ki;=;2,61;8,58;-3;31;Displacement of [3H]N-methylspiperone from dopamine D2 receptor (unknown origin);ChEMBL;387,2;6;2;4;3,78;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;https://dx.doi.org/10.1016/j.bmcl.2021.128047
nemonapride;2762;3H-YM 09151-2;13;Human;Binding;pKi;=;0,10;10,00;-3;31;-;PDSP KiDatabase;387,2;6;2;4;3,78;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;-
nemonapride;2762;3H-RACLOPRIDE;13;Human;Binding;pKi;=;0,01;11,00;-3;31;-;PDSP KiDatabase;387,2;6;2;4;3,78;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;-
nemonapride;2762;3H-SPIPERONE;13;Human;Binding;pKi;=;0,09;10,05;-3;31;-;PDSP KiDatabase;387,2;6;2;4;3,78;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;-
nemonapride;2762;3H-NEMONAPRIDE;13;Human;Binding;pKi;=;0,08;10,10;-3;31;-;PDSP KiDatabase;387,2;6;2;4;3,78;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;-
nemonapride;2762;3H-SPIPERONE;13;Human;Binding;pKi;=;0,04;10,40;-3;31;-;PDSP KiDatabase;387,2;6;2;4;3,78;CNc1cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)C2C)cc1Cl;-
NERATINIB;63562;None;59;Human;Binding;AC50;=;9900,10;5,00;-;6;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;556,2;11;2;8;5,93;CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C;https://dx.doi.org/10.1038/s41467-023-40064-9
NGB 2904;2817;None;23;Human;Binding;Ki;=;112,00;6,95;-141;8;Displacement of [125I]ABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting analysis;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1016/j.bmc.2013.03.074
NGB 2904;2817;None;23;Human;Binding;Ki;=;112,00;6,95;-141;8;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm0704200
NGB 2904;2817;None;23;Human;Binding;Ki;=;112,00;6,95;-141;8;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm200288r
NGB 2904;2817;None;23;Human;Binding;Ki;=;698,00;6,16;-141;8;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm040190e
NGB 2904;2817;None;23;Human;Binding;Ki;=;112,00;6,95;-141;8;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm040190e
NGB 2904;2817;None;23;Human;Binding;Ki;=;217,00;6,66;-141;8;Compound was evaluated for binding affinity against Dopamine receptor D2 subtype from primate;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1016/s0960-894x(98)00469-7
NGB 2904;2817;None;23;Human;Binding;Ki;=;54,70;7,26;-141;8;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm501512b
NGB 2904;2817;None;23;Human;Binding;Ki;=;112,00;6,95;-141;8;Binding affinity for human dopamine D2 receptor;ChEMBL;493,2;7;1;3;5,90;O=C(NCCCCN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc2c(c1)Cc1ccccc1-2;https://dx.doi.org/10.1021/jm049465g
NGD 94-1;2818;None;30;Human;Binding;Ki;=;2230,00;5,65;-7079;4;Inhibition of human dopamine D2 receptor;ChEMBL;320,2;4;1;5;2,19;c1ccc(-c2ncc(CN3CCN(c4ncccn4)CC3)[nH]2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
NGD 94-1;2818;None;30;Human;Binding;Ki;=;2250,00;5,65;-7079;4;Binding affinity on human Dopamine receptor D2 expressed in CHO cells using radioligand [3H]-YM 09151;ChEMBL;320,2;4;1;5;2,19;c1ccc(-c2ncc(CN3CCN(c4ncccn4)CC3)[nH]2)cc1;https://dx.doi.org/10.1021/jm960637m
NIMESULIDE;198991;3H-NMSP;63;Human;Binding;pKi;=;10000,00;5,00;-1;42;-;PDSP KiDatabase;308;5;1;5;2,76;CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1;-
NITAZOXANIDE;31229;None;62;Human;Binding;AC50;=;14000,10;4,85;-;32;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;307;4;1;7;2,23;CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1;https://dx.doi.org/10.1038/s41467-023-40064-9
NITRACRINE;96601;None;25;Human;Binding;AC50;=;14000,10;4,85;-;13;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;324,2;6;1;5;3,66;CN(C)CCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12;https://dx.doi.org/10.1038/s41467-023-40064-9
NITROXOLINE;37419;None;62;Human;Binding;AC50;=;6400,00;5,19;-;10;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;190;1;1;4;1,85;O=[N+]([O-])c1ccc(O)c2ncccc12;https://dx.doi.org/10.1038/s41467-023-40064-9
NOMIFENSINE;98179;3H-YM 09151-2;50;Human;Binding;pKi;=;10000,00;5,00;-120;13;-;PDSP KiDatabase;238,1;1;1;2;2,85;CN1Cc2c(N)cccc2C(c2ccccc2)C1;-
noradrenaline;2858;3H-YM 09151-2;34;Human;Binding;pKi;=;10000,00;5,00;-100;35;-;PDSP KiDatabase;169,1;2;4;4;0,09;NCC(O)c1ccc(O)c(O)c1;-
norfenfluramine;2862;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-354;36;-;PDSP KiDatabase;203,1;2;1;1;2,60;CC(N)Cc1cccc(C(F)(F)F)c1;-
norfenfluramine;2862;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-354;36;-;PDSP KiDatabase;203,1;2;1;1;2,60;CC(N)Cc1cccc(C(F)(F)F)c1;-
norfenfluramine;2862;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-354;36;-;PDSP KiDatabase;203,1;2;1;1;2,60;CC(N)Cc1cccc(C(F)(F)F)c1;-
norfluoxetine;2863;3H-SPIPERONE;0;Human;Binding;pKi;=;10000,00;5,00;-109;12;-;PDSP KiDatabase;295,1;5;1;2;4,17;NCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1;-
NORMETHADONE;119662;None;5;Human;Binding;Ki;=;34900,00;4,46;-977;3;Displacement of [3H]-N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 60 mins by microbeta scintillation counting analysis;ChEMBL;295,2;7;0;2;3,90;CCC(=O)C(CCN(C)C)(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1021/acs.jmedchem.1c00611
nortriptyline;2866;None;32;Human;Binding;AC50;=;5699,90;5,24;-17;35;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;263,2;3;1;1;3,83;CNCCC=C1c2ccccc2CCc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
nortriptyline;2866;None;32;Human;Binding;pKi;None;5,59;8,25;-17;35;None;Drug Central;263,2;3;1;1;3,83;CNCCC=C1c2ccccc2CCc2ccccc21;-
nortriptyline;2866;3H-SPIPERONE;32;Human;Binding;pKi;=;2570,00;5,59;-17;35;-;PDSP KiDatabase;263,2;3;1;1;3,83;CNCCC=C1c2ccccc2CCc2ccccc21;-
NPA,(+);218716;3H-SPIPERONE;0;Human;Binding;pKi;=;3243,00;5,49;-15;2;-;PDSP KiDatabase;291,1;3;2;2;3,79;O=C(O)c1ccccc1C(=O)Nc1cccc2ccccc12;-
NPA,(+);218716;3H-SPIPERONE;0;Human;Binding;pKi;=;257,00;6,59;-15;2;-;PDSP KiDatabase;291,1;3;2;2;3,79;O=C(O)c1ccccc1C(=O)Nc1cccc2ccccc12;-
NPA,(+);218716;3H-YM 09151-2;0;Human;Binding;pKi;=;290,70;6,54;-15;2;-;PDSP KiDatabase;291,1;3;2;2;3,79;O=C(O)c1ccccc1C(=O)Nc1cccc2ccccc12;-
ocaperidone;2905;R-SAT;0;Human;Binding;pKi;=;0,40;9,40;7;6;-;PDSP KiDatabase;420,2;4;0;6;4,01;Cc1nc2c(C)cccn2c(=O)c1CCN1CCC(c2noc3cc(F)ccc23)CC1;-
ocaperidone;2905;R-SAT;0;Human;Binding;pKi;=;0,10;10,00;7;6;-;PDSP KiDatabase;420,2;4;0;6;4,01;Cc1nc2c(C)cccn2c(=O)c1CCN1CCC(c2noc3cc(F)ccc23)CC1;-
olanzapine;2914;None;65;Human;Binding;AC50;=;71,00;7,15;-10;67;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
olanzapine;2914;None;65;Human;Binding;IC50;=;118,00;6,93;-10;67;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;None;65;Human;Binding;IC50;=;10,00;8,00;-10;67;Displacement of [3H]raclopride from D2 receptor in human corpus striatum after 30 mins by scintillation counting;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.02.045
olanzapine;2914;None;65;Human;Binding;Ki;=;17,00;7,77;-10;67;Binding affinity towards human Dopamine receptor D2;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1021/jm030480f
olanzapine;2914;None;65;Human;Binding;Ki;=;100,00;7,00;-10;67;Binding affinity to dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1039/C2MD00311B
olanzapine;2914;None;65;Human;Binding;Ki;=;19,95;7,70;-10;67;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1021/jm070516u
olanzapine;2914;None;65;Human;Binding;Ki;=;58,00;7,24;-10;67;Binding affinity to human dopamine D2 receptor;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.bmcl.2020.127563
olanzapine;2914;None;65;Human;Binding;Ki;=;9,00;8,05;-10;67;Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2019.06.022
olanzapine;2914;None;65;Human;Binding;Ki;=;7,00;8,15;-10;67;Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2012.07.043
olanzapine;2914;None;65;Human;Binding;Ki;=;20,00;7,70;-10;67;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1021/jm501119j
olanzapine;2914;None;65;Human;Binding;Ki;=;31,00;7,51;-10;67;Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;None;65;Human;Binding;Ki;=;23,45;7,63;-10;67;Displacement of [3H]spiperone from wild-type human dopamine D2S receptor expressed in CHO-K1 cell membrane after 2 hrs by beta counting;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.02.058
olanzapine;2914;None;65;Human;Binding;Ki;=;4,00;8,40;-10;67;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
olanzapine;2914;None;65;Human;Binding;Ki;=;23,44;7,63;-10;67;Displacement of [3H]spiperone from wild-type human dopamine D2S receptor expressed in CHO-K1 cell membrane after 2 hrs by beta counting;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.02.058
olanzapine;2914;None;65;Human;Binding;Ki;=;9,00;8,05;-10;67;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2018.01.093
olanzapine;2914;None;65;Human;Binding;Ki;=;173,78;6,76;-10;67;Displacement of [3H]spiperone from human dopamine D2S receptor S5.43T/S5.46A mutant expressed in CHO-K1 cell membrane after 2 hrs by beta counting;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.02.058
olanzapine;2914;None;65;Human;Binding;Ki;=;20,00;7,70;-10;67;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.bmcl.2014.07.018
olanzapine;2914;None;65;Human;Binding;Ki;=;39,00;7,41;-10;67;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;None;65;Human;Binding;Ki;=;20,00;7,70;-10;67;In vitro binding affinity of compound against neuronal Dopamine receptor D2;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/S0960-894X(96)00567-7
olanzapine;2914;None;65;Human;Binding;Ki;=;173,90;6,76;-10;67;Displacement of [3H]spiperone from human dopamine D2S receptor S5.43T/S5.46A mutant expressed in CHO-K1 cell membrane after 2 hrs by beta counting;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2014.02.058
olanzapine;2914;None;65;Human;Binding;Ki;=;6,10;8,21;-10;67;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1021/jm901689v
olanzapine;2914;None;65;Human;Binding;Ki;=;78,00;7,11;-10;67;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1021/jm049632c
olanzapine;2914;None;65;Human;Binding;Ki;=;2,10;8,68;-10;67;Binding affinity towards human D2 dopamine receptor.;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1021/jm0002432
olanzapine;2914;None;65;Human;Binding;Ki;=;16,98;7,77;-10;67;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
olanzapine;2914;None;65;Human;Binding;Ki;=;9,00;8,05;-10;67;Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2016.02.024
olanzapine;2914;None;65;Human;Binding;Ki;=;53,00;7,28;-10;67;Displacement of [3H]N-methylspiperone from human cloned D2 dopamine receptor expressed in human fibroblasts incubated for 90 mins by scintillation counting based radioligand binding assay;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1039/C5MD00258C
olanzapine;2914;None;65;Human;Binding;Ki;=;11,00;7,96;-10;67;Displacement of [3H]raclopride from D2 receptor in human corpus striatum after 30 mins by scintillation counting;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.bmcl.2013.02.045
olanzapine;2914;None;65;Human;Binding;Ki;=;20,00;7,70;-10;67;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
olanzapine;2914;None;65;Human;Binding;Ki;=;9,00;8,05;-10;67;Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.112529
olanzapine;2914;None;65;Human;Binding;Ki;=;32,00;7,50;-10;67;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://dx.doi.org/10.1021/jm901689v
olanzapine;2914;None;65;Human;Binding;pKi;=;8,52;8,07;-10;67;None;Drug Central;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;None;65;Human;Binding;pKi;=;-;8,68;-10;67;Unclassified;Guide to Pharmacology;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;https://pubmed.ncbi.nlm.nih.gov/9430133
olanzapine;2914;3H-NMSP;65;Human;Binding;pKi;=;72,00;7,14;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;31,00;7,51;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;UNDEFINED;65;Human;Binding;pKi;=;6,10;8,21;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-NEMONAPRIDE;65;Human;Binding;pKi;=;45,00;7,35;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;UNDEFINED;65;Human;Binding;pKi;=;20,00;7,70;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-RACLOPRIDE;65;Human;Binding;pKi;=;6,40;8,19;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;78,00;7,11;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;30,30;7,52;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-NEMONAPRIDE;65;Human;Binding;pKi;=;52,00;7,28;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;35,00;7,46;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-NMSP;65;Human;Binding;pKi;=;31,00;7,51;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;20,00;7,70;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;UNDEFINED;65;Human;Binding;pKi;=;3,00;8,52;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-NMS;65;Human;Binding;pKi;=;37,70;7,42;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;UNDEFINED;65;Human;Binding;pKi;=;32,00;7,49;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-Olanzapine;65;Human;Binding;pKi;=;3,00;8,52;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-Methylspiperone;65;Human;Binding;pKi;=;31,80;7,50;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;UNDEFINED;65;Human;Binding;pKi;=;20,00;7,70;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;3,70;8,43;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-NMSP;65;Human;Binding;pKi;=;34,00;7,47;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-RACLOPRIDE;65;Human;Binding;pKi;=;10,00;8,00;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;21,00;7,68;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;31,00;7,51;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;R-SAT;65;Human;Binding;pKi;=;106,00;6,97;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-N-Methylspiperone;65;Human;Binding;pKi;=;20,42;7,69;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
olanzapine;2914;3H-SPIPERONE;65;Human;Binding;pKi;=;21,00;7,68;-10;67;-;PDSP KiDatabase;312,1;1;1;5;1,75;Cc1cc2c(s1)=Nc1ccccc1NC=2N1CCN(C)CC1;-
OLICERIDINE;93198;None;26;Human;Binding;Ki;=;83200,00;4,08;-19952;7;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293T cell membrane assessed as inhibition constant incubated for 60 mins by MicroBeta scintillation counting method;ChEMBL;386,2;7;1;5;4,69;COc1ccsc1CNCC[C@@]1(c2ccccn2)CCOC2(CCCC2)C1;https://dx.doi.org/10.1021/acs.jmedchem.3c00417
Ondansetron HCl;218483;3H-N-Methylspiperone;0;Human;Binding;pKi;=;10000,00;5,00;-1;27;-;PDSP KiDatabase;329,1;2;0;4;3,55;Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O.Cl;-
Ondansetron HCl;218483;3H-YM 09151-2;0;Human;Binding;pKi;=;10000,00;5,00;-1;27;-;PDSP KiDatabase;329,1;2;0;4;3,55;Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O.Cl;-
OPIPRAMOL;133581;None;40;Human;Binding;AC50;=;884,60;6,05;-;15;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;363,2;6;1;4;3,31;OCCN1CCN(CCCN2c3ccccc3C=Cc3ccccc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
OSIMERTINIB;115628;None;61;Human;Binding;AC50;=;7100,00;5,15;-;16;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;499,3;10;2;8;4,51;C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C;https://dx.doi.org/10.1038/s41467-023-40064-9
OTILONIUM;35070;None;5;Human;Binding;AC50;=;4300,00;5,37;-;28;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;483,3;16;1;4;6,32;CCCCCCCCOc1ccccc1C(=O)Nc1ccc(C(=O)OCC[N+](C)(CC)CC)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
OXAPROZIN;5393;None;62;Human;Binding;AC50;=;1180,00;5,93;-;10;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;293,1;5;1;3;4,03;O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1;https://dx.doi.org/10.1038/s41467-023-40064-9
OXATOMIDE;29284;None;49;Human;Binding;AC50;=;330,00;6,48;-;20;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;426,2;7;1;4;4,13;O=c1[nH]c2ccccc2n1CCCN1CCN(C(c2ccccc2)c2ccccc2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
OXIPEROMIDE;76379;None;27;Human;Binding;Ki;=;5,50;8,26;-;2;Displacement of [3H]raclopride from human D2L receptor expressed in CHO cells after 60 mins by scintillation proximity assay;ChEMBL;337,2;5;1;4;3,05;O=c1[nH]c2ccccc2n1C1CCN(CCOc2ccccc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2012.05.048
OXYPERTINE;78295;None;23;Human;Binding;AC50;=;920,00;6,04;-;11;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;379,2;6;1;4;3,86;COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
PALIPERIDONE;55601;None;68;Human;Binding;pKi;=;8,47;8,07;-2;54;None;Drug Central;426,2;4;1;7;3,08;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O;-
PALIPERIDONE;55601;R-SAT;68;Human;Binding;pKi;=;0,40;9,40;-2;54;-;PDSP KiDatabase;426,2;4;1;7;3,08;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O;-
PALIPERIDONE;55601;3H-NMSP;68;Human;Binding;pKi;=;9,40;8,03;-2;54;-;PDSP KiDatabase;426,2;4;1;7;3,08;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O;-
PALIPERIDONE;55601;3H-SPIPERONE;68;Human;Binding;pKi;=;2,80;8,55;-2;54;-;PDSP KiDatabase;426,2;4;1;7;3,08;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O;-
PALIPERIDONE;55601;3H-SPIPERONE;68;Human;Binding;pKi;=;4,80;8,32;-2;54;-;PDSP KiDatabase;426,2;4;1;7;3,08;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O;-
PALIPERIDONE;55601;R-SAT;68;Human;Binding;pKi;=;1,00;9,00;-2;54;-;PDSP KiDatabase;426,2;4;1;7;3,08;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O;-
PALIPERIDONE;55601;3H-SPIPERONE;68;Human;Binding;pKi;=;4,10;8,39;-2;54;-;PDSP KiDatabase;426,2;4;1;7;3,08;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O;-
palosuran;2995;None;41;Human;Binding;Ki;=;595,52;6,22;-151;7;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;418,2;6;3;4;3,73;Cc1cc(NC(=O)NCCN2CCC(O)(Cc3ccccc3)CC2)c2ccccc2n1;https://dx.doi.org/10.6019/CHEMBL5442175
PARECOXIB;218881;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;30;-;PDSP KiDatabase;370,1;5;1;5;3,53;CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1;-
PAROXETINE;187026;3H-SPIPERONE;38;Human;Binding;pKi;=;10000,00;5,00;-1995;36;-;PDSP KiDatabase;329,1;4;1;4;3,33;Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1;-
pasireotide;3007;None;26;Human;Binding;AC50;=;3800,00;5,42;-;22;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1038/s41467-023-40064-9
PBR28;218975;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-4570;27;-;PDSP KiDatabase;347,2;6;0;3;5,04;COc1ccccc1CN(C(C)=O)c1ccccc1Oc1ccccc1;-
PD 128907;3022;None;16;Human;Binding;Ki;=;7580,00;5,12;-61;3;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human D2L receptor expressed in HEK293 cells after 90 mins by microbeta counting based assay;ChEMBL;249,1;2;1;4;1,94;CCCN1CCO[C@H]2c3cc(O)ccc3OC[C@@H]21;https://dx.doi.org/10.1021/acsmedchemlett.9b00660
PD 128907;3022;None;16;Human;Binding;pKi;None;-;5,90;-61;3;Unclassified;Guide to Pharmacology;249,1;2;1;4;1,94;CCCN1CCO[C@H]2c3cc(O)ccc3OC[C@@H]21;https://pubmed.ncbi.nlm.nih.gov/7756621
PD 128907;3022;None;16;Human;Binding;pKi;None;-;5,90;-61;3;Unclassified;Guide to Pharmacology;249,1;2;1;4;1,94;CCCN1CCO[C@H]2c3cc(O)ccc3OC[C@@H]21;https://pubmed.ncbi.nlm.nih.gov/8531103
PD168,077;3034;None;16;Human;Binding;Ki;=;3740,00;5,43;-1445;10;Binding affinity for human Dopamine receptor D2 expressed in CHO K1 transfected cells using [3H]spiperone as radioligand;ChEMBL;334,2;4;1;4;2,38;Cc1cccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)c1;https://dx.doi.org/10.1021/jm970021c
PD168,077;3034;None;16;Human;Binding;Ki;=;2300,00;5,64;-1445;10;Displacement of [3H] Spiperone from human D2L receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;334,2;4;1;4;2,38;Cc1cccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
PD168,077;3034;None;16;Human;Binding;Ki;=;3740,00;5,43;-1445;10;Binding affinity towards cloned human Dopamine receptor D2;ChEMBL;334,2;4;1;4;2,38;Cc1cccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)c1;https://dx.doi.org/10.1016/s0960-894x(00)00633-8
PD168,077;3034;None;16;Human;Binding;Ki;=;1100,00;5,96;-1445;10;Displacement of [3H] Spiperone from human D2S receptor expressed in CHO cells by competitive radioligand binding assay;ChEMBL;334,2;4;1;4;2,38;Cc1cccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)c1;https://dx.doi.org/10.1021/acs.jmedchem.9b01085
PD168,077;3034;None;16;Human;Binding;Ki;=;2818,38;5,55;-1445;10;Binding affinity towards human dopamine receptor D2 was determined by using [3H]spiperone as radioligand;ChEMBL;334,2;4;1;4;2,38;Cc1cccc(C(=O)NCN2CCN(c3ccccc3C#N)CC2)c1;https://dx.doi.org/10.1016/j.bmcl.2005.02.012
PENFLURIDOL;179063;None;62;Human;Binding;Ki;=;159,00;6,80;-5;27;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;ChEMBL;523,2;7;1;2;7,53;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmcl.2018.10.036
PENFLURIDOL;179063;None;62;Human;Binding;pKi;=;6,80;8,17;-5;27;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in stable fibroblast cells by radioligand binding assay;Drug Central;523,2;7;1;2;7,53;OC1(c2ccc(Cl)c(C(F)(F)F)c2)CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pergolide;3054;None;28;Human;Binding;AC50;=;110,30;6,96;-26;38;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1038/s41467-023-40064-9
pergolide;3054;None;28;Human;Binding;EC50;=;0,35;9,45;-26;38;Agonist activity at dopamine D2 receptor short isoform (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay;ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
pergolide;3054;None;28;Human;Binding;IC50;=;111,00;6,96;-26;38;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
pergolide;3054;None;28;Human;Binding;Ki;=;0,62;9,21;-26;38;Binding affinity to dopamine D2 receptor (unknown origin) assessed as inhibition constant;ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1039/d3md00677h
pergolide;3054;None;28;Human;Binding;Ki;=;26,00;7,58;-26;38;Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins;ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1021/jm5003759
pergolide;3054;None;28;Human;Binding;Ki;=;25,70;7,59;-26;38;Displacement of [125]iodosulpride from human recombinant dopamine D2L receptor expressed in CHO cells after 30 mins;ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1021/jm5003759
pergolide;3054;None;28;Human;Binding;Ki;=;4,00;8,40;-26;38;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1021/jm960360q
pergolide;3054;None;28;Human;Binding;Ki;=;37,00;7,43;-26;38;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
pergolide;3054;None;28;Human;Binding;Ki;=;50,00;7,30;-26;38;Affinity towards Dopamine receptor D2;ChEMBL;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://dx.doi.org/10.1021/jm9800292
pergolide;3054;None;28;Human;Binding;pKi;None;-;7,55;-26;38;Unclassified;Guide to Pharmacology;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/12388666
pergolide;3054;125I-IODOSULPRIDE;28;Human;Binding;pKi;=;31,62;7,50;-26;38;-;PDSP KiDatabase;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
pergolide;3054;125I-IODOSULPRIDE;28;Human;Binding;pKi;=;19,00;7,72;-26;38;-;PDSP KiDatabase;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
pergolide;3054;125I-IODOSULPRIDE;28;Human;Binding;pKi;=;25,70;7,59;-26;38;-;PDSP KiDatabase;314,2;4;1;2;4,27;CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21;-
PERLAPINE;118210;None;31;Human;Binding;pKi;=;7,22;8,14;-2;11;None;Drug Central;291,2;0;0;3;2,92;CN1CCN(C2=Nc3ccccc3Cc3ccccc32)CC1;-
PERLAPINE;118210;UNDEFINED;31;Human;Binding;pKi;=;60,00;7,22;-2;11;-;PDSP KiDatabase;291,2;0;0;3;2,92;CN1CCN(C2=Nc3ccccc3Cc3ccccc32)CC1;-
PERLAPINE;118210;3H-SPIPERONE;31;Human;Binding;pKi;=;60,00;7,22;-2;11;-;PDSP KiDatabase;291,2;0;0;3;2,92;CN1CCN(C2=Nc3ccccc3Cc3ccccc32)CC1;-
perospirone;3056;None;34;Human;Binding;pKi;=;9,22;8,04;-2;11;None;Drug Central;426,2;6;0;6;3,37;O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1;-
perospirone;3056;None;34;Human;Binding;pKi;=;-;9,22;-2;11;Unclassified;Guide to Pharmacology;426,2;6;0;6;3,37;O=C1[C@H]2CCCC[C@H]2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1;https://pubmed.ncbi.nlm.nih.gov/1060115
Perospirone;218765;UNDEFINED;0;Human;Binding;pKi;=;0,60;9,22;-6;11;-;PDSP KiDatabase;426,2;6;0;6;3,37;O=C1C2CCCCC2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1;-
perphenazine;3057;None;57;Human;Binding;AC50;=;17,00;7,77;-1;38;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
perphenazine;3057;None;57;Human;Binding;IC50;=;0,30;9,52;-1;38;Antagonist activity at dopamine D2 receptor (unknown origin) expressed in CHOK1 cells coexpressing Galpha15 assessed as inhibition of agonist-induced response incubated for 60 mins in incubator followed by 15 mins at room temperature by FLIPR assay;ChEMBL;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1021/jm400408r
perphenazine;3057;None;57;Human;Binding;pKi;=;9,32;8,03;-1;38;None;Drug Central;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
perphenazine;3057;None;57;Human;Binding;pKi;=;-;9,22;-1;38;Unclassified;Guide to Pharmacology;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;https://pubmed.ncbi.nlm.nih.gov/12629531
perphenazine;3057;UNDEFINED;57;Human;Binding;pKi;=;1,40;8,85;-1;38;-;PDSP KiDatabase;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
perphenazine;3057;UNDEFINED;57;Human;Binding;pKi;=;0,16;9,80;-1;38;-;PDSP KiDatabase;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
perphenazine;3057;3H-RACLOPRIDE;57;Human;Binding;pKi;=;0,26;9,59;-1;38;-;PDSP KiDatabase;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
perphenazine;3057;3H-SPIPERONE;57;Human;Binding;pKi;=;0,48;9,32;-1;38;-;PDSP KiDatabase;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
perphenazine;3057;3H-NMSP;57;Human;Binding;pKi;=;1,40;8,85;-1;38;-;PDSP KiDatabase;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
perphenazine;3057;3H-SPIPERONE;57;Human;Binding;pKi;=;1,40;8,85;-1;38;-;PDSP KiDatabase;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
perphenazine;3057;UNDEFINED;57;Human;Binding;pKi;=;0,16;9,80;-1;38;-;PDSP KiDatabase;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
perphenazine;3057;3H-NEMONAPRIDE;57;Human;Binding;pKi;=;0,92;9,04;-1;38;-;PDSP KiDatabase;403,1;6;1;5;3,94;OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
PF-00217830;61964;None;18;Human;Binding;Ki;=;0,81;9,09;-5;3;Displacement of [3H]Spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;430,2;7;1;5;4,10;O=C1CCc2ccc(OCCCCN3CCN(c4cccc5ccccc45)CC3)nc2N1;https://dx.doi.org/10.1016/j.bmcl.2011.01.059
PG01037;3074;None;4;Human;Binding;Ki;=;106,00;6,97;-123;6;Inhibition of [3H]YM-09151-2 binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;480,1;7;1;4;5,16;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm040190e
PG01037;3074;None;4;Human;Binding;Ki;=;93,30;7,03;-123;6;Displacement of [125I]-IABN from human dopamine D2L receptor expressed in HEK293 cells after 60 mins by gamma counting;ChEMBL;480,1;7;1;4;5,16;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm200288r
PG01037;3074;None;4;Human;Binding;Ki;=;93,30;7,03;-123;6;Displacement of [125I]IABN from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;480,1;7;1;4;5,16;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm0704200
PG01037;3074;None;4;Human;Binding;Ki;=;74,00;7,13;-123;6;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;480,1;7;1;4;5,16;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm501512b
PG01037;3074;None;4;Human;Binding;Ki;=;93,30;7,03;-123;6;Inhibition of [125I]IABN binding to human Dopamine D2L receptor expressed in HEK 293 cells;ChEMBL;480,1;7;1;4;5,16;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm040190e
PG01037;3074;None;4;Human;Binding;Ki;=;93,30;7,03;-123;6;Binding affinity for human dopamine D2 receptor;ChEMBL;480,1;7;1;4;5,16;O=C(NC/C=C/CN1CCN(c2cccc(Cl)c2Cl)CC1)c1ccc(-c2ccccn2)cc1;https://dx.doi.org/10.1021/jm049465g
PHENAZOPYRIDINE;16656;None;34;Human;Binding;AC50;=;3300,00;5,48;-;16;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;213,1;2;2;5;2,66;Nc1ccc(/N=N/c2ccccc2)c(N)n1;https://dx.doi.org/10.1038/s41467-023-40064-9
phenoxybenzamine;3095;None;24;Human;Binding;AC50;=;5000,00;5,30;-;25;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;303,1;8;0;2;4,20;CC(COc1ccccc1)N(CCCl)Cc1ccccc1;https://dx.doi.org/10.1038/s41467-023-40064-9
phentolamine;3096;3H-SPIPERONE;36;Human;Binding;pKi;=;1200,00;5,92;-1318;40;-;PDSP KiDatabase;281,2;4;2;4;2,84;Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1;-
phentolamine;3096;3H-YM 09151-2;36;Human;Binding;pKi;=;10000,00;5,00;-1318;40;-;PDSP KiDatabase;281,2;4;2;4;2,84;Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1;-
PHENYLPROPANOLAMINE;204731;3H-NMSP;11;Human;Binding;pKi;=;10000,00;5,00;-1949;44;-;PDSP KiDatabase;151,1;2;2;2;1,07;CC(N)C(O)c1ccccc1;-
PHENYLPROPANOLAMINE;204731;3H-NMSP;11;Human;Binding;pKi;=;10000,00;5,00;-1949;44;-;PDSP KiDatabase;151,1;2;2;2;1,07;CC(N)C(O)c1ccccc1;-
PHENYLPROPANOLAMINE;204731;3H-NMSP;11;Human;Binding;pKi;=;10000,00;5,00;-1949;44;-;PDSP KiDatabase;151,1;2;2;2;1,07;CC(N)C(O)c1ccccc1;-
PHENYLTOLOXAMINE;66980;None;21;Human;Binding;Ki;=;2740,00;5,56;-10;5;Binding affinity for human recombinant dopamine receptor D2L;ChEMBL;255,2;6;0;2;3,22;CN(C)CCOc1ccccc1Cc1ccccc1;https://dx.doi.org/10.1021/jm049720x
PHENYLTOLOXAMINE;66980;None;21;Human;Binding;pKi;=;5,56;8,25;-10;5;Binding affinity for human recombinant dopamine receptor D2L;Drug Central;255,2;6;0;2;3,22;CN(C)CCOc1ccccc1Cc1ccccc1;-
pimozide;3125;None;49;Human;Binding;AC50;=;16,00;7,80;-11;53;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
pimozide;3125;None;49;Human;Binding;Kd;=;29,00;7,54;-11;53;Inhibition of dopamine D2 receptor;ChEMBL;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.bmc.2010.06.082
pimozide;3125;None;49;Human;Binding;Ki;=;1,40;8,85;-11;53;Binding affinity to dopamine D2 receptor (unknown origin) assessed as inhibition constant;ChEMBL;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2022.114716
pimozide;3125;None;49;Human;Binding;Ki;=;11,70;7,93;-11;53;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/jm300975f
pimozide;3125;None;49;Human;Binding;Ki;=;12,00;7,92;-11;53;Binding affinity towards Dopamine receptor D2;ChEMBL;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.1021/jm0205651
pimozide;3125;None;49;Human;Binding;pKi;=;8,86;8,05;-11;53;None;Drug Central;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;None;49;Human;Binding;pKi;=;-;7,90;-11;53;Unclassified;Guide to Pharmacology;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://pubmed.ncbi.nlm.nih.gov/1354163
pimozide;3125;None;49;Human;Binding;pKi;=;-;7,90;-11;53;Unclassified;Guide to Pharmacology;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://pubmed.ncbi.nlm.nih.gov/8301582
pimozide;3125;3H-NEMONAPRIDE;49;Human;Binding;pKi;=;0,85;9,07;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;3H-RACLOPRIDE;49;Human;Binding;pKi;=;0,13;9,89;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;3H-SPIPERONE;49;Human;Binding;pKi;=;29,00;7,54;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;UNDEFINED;49;Human;Binding;pKi;=;0,06;10,22;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;125I-IODOSULPRIDE;49;Human;Binding;pKi;=;9,80;8,01;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;UNDEFINED;49;Human;Binding;pKi;=;0,60;9,22;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;3H-YM 09151-2;49;Human;Binding;pKi;=;2,20;8,66;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;3H-SPIPERONE;49;Human;Binding;pKi;=;29,00;7,54;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;3H-NMSP;49;Human;Binding;pKi;=;0,65;9,19;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;R-SAT;49;Human;Binding;pKi;=;0,50;9,30;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;3H-SPIPERONE;49;Human;Binding;pKi;=;0,33;9,48;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;3H-Methylspiperone;49;Human;Binding;pKi;=;11,70;7,93;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;125I-IODOSULPRIDE;49;Human;Binding;pKi;=;0,39;9,41;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pimozide;3125;R-SAT;49;Human;Binding;pKi;=;2,40;8,62;-11;53;-;PDSP KiDatabase;461,2;7;1;3;5,86;O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
pindolol;3127;3H-8-OH-DPAT;40;Human;Binding;pKi;=;10000,00;5,00;-31622;31;-;PDSP KiDatabase;248,2;6;3;3;1,91;CC(C)NCC(O)COc1cccc2[nH]ccc12;-
PIPAMAZINE;67821;None;11;Human;Binding;IC50;=;4,05;8,39;-1;18;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;401,1;5;1;4;4,53;NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
PIPAMAZINE;67821;None;11;Human;Binding;Ki;=;1,35;8,87;-1;18;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;401,1;5;1;4;4,53;NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
PIPAMAZINE;67821;None;11;Human;Binding;pKi;=;8,87;8,05;-1;18;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;401,1;5;1;4;4,53;NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
pipamperone;3128;None;36;Human;Binding;pKi;=;6,94;8,16;-7;38;None;Drug Central;375,2;7;1;4;2,59;NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
pipamperone;3128;3H-SPIPERONE;36;Human;Binding;pKi;=;110,00;6,96;-7;38;-;PDSP KiDatabase;375,2;7;1;4;2,59;NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
pipamperone;3128;3H-SPIPERONE;36;Human;Binding;pKi;=;120,00;6,92;-7;38;-;PDSP KiDatabase;375,2;7;1;4;2,59;NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1;-
PIPERACETAZINE;51685;None;37;Human;Binding;AC50;=;13,00;7,89;-;15;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;410,2;7;1;5;4,98;CC(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2;https://dx.doi.org/10.1038/s41467-023-40064-9
pipotiazine;3129;None;27;Human;Binding;pKi;=;-;9,70;1;10;Unclassified;Guide to Pharmacology;475,2;8;1;6;4,02;CN(C)S(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2;https://pubmed.ncbi.nlm.nih.gov/1586393
pipotiazine;3129;125I-IODOSULPRIDE;27;Human;Binding;pKi;=;0,20;9,70;1;10;-;PDSP KiDatabase;475,2;8;1;6;4,02;CN(C)S(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(CCO)CC1)c1ccccc1S2;-
pipotiazine palmitate;220206;None;0;Human;Binding;pKi;=;9,70;8,01;-1;2;None;Drug Central;713,4;23;0;7;10,06;CCCCCCCCCCCCCCCC(=O)OCCC1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
PIRENOXINE;27995;None;38;Human;Binding;AC50;=;9499,90;5,02;-;10;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;308;1;2;6;2,25;O=C(O)c1cc(O)c2c3nc4ccccc4oc-3cc(=O)c2n1;https://dx.doi.org/10.1038/s41467-023-40064-9
piribedil;3132;None;63;Human;Binding;AC50;=;5479,00;5,26;-1;23;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;298,1;3;0;6;1,53;c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1;https://dx.doi.org/10.1038/s41467-023-40064-9
piribedil;3132;None;63;Human;Binding;pKi;=;6,90;8,16;-1;23;None;Drug Central;298,1;3;0;6;1,53;c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1;-
piribedil;3132;None;63;Human;Binding;pKi;None;-;6,85;-1;23;Unclassified;Guide to Pharmacology;298,1;3;0;6;1,53;c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1;https://pubmed.ncbi.nlm.nih.gov/12388666
piribedil;3132;125I-IODOSULPRIDE;63;Human;Binding;pKi;=;131,83;6,88;-1;23;-;PDSP KiDatabase;298,1;3;0;6;1,53;c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1;-
piribedil;3132;125I-IODOSULPRIDE;63;Human;Binding;pKi;=;131,83;6,88;-1;23;-;PDSP KiDatabase;298,1;3;0;6;1,53;c1cnc(N2CCN(Cc3ccc4c(c3)OCO4)CC2)nc1;-
PIROXICAM;193723;3H-NMSP;67;Human;Binding;pKi;=;10000,00;5,00;-1;29;-;PDSP KiDatabase;331,1;2;2;5;1,58;CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O;-
pizotifen;3134;None;58;Human;Binding;AC50;=;210,00;6,68;-1;24;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;295,1;0;0;2;4,37;CN1CCC(=C2c3ccccc3CCc3sccc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
pizotifen;3134;None;58;Human;Binding;Ki;=;2,40;8,62;-1;24;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;295,1;0;0;2;4,37;CN1CCC(=C2c3ccccc3CCc3sccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2013.10.010
pizotifen;3134;None;58;Human;Binding;pKi;=;8,62;8,06;-1;24;Binding affinity to dopamine D2 receptor (unknown origin);Drug Central;295,1;0;0;2;4,37;CN1CCC(=C2c3ccccc3CCc3sccc32)CC1;-
PNU109291;3146;None;18;Human;Binding;Ki;=;241,00;6,62;-269;7;Displacement of PNU-86170 from human dopamine D2 receptor expressed in CHO cell membrane incubated for 1 hr by competitive radioligand binding assay based;ChEMBL;409,2;6;1;5;2,88;CNC(=O)c1ccc2c(c1)CCO[C@H]2CCN1CCN(c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113073
PNU109291;3146;None;18;Human;Binding;Ki;=;241,00;6,62;-269;7;The compound was tested for CNS binding affinity towards Dopamine receptor D2 from cloned Human membranes.;ChEMBL;409,2;6;1;5;2,88;CNC(=O)c1ccc2c(c1)CCO[C@H]2CCN1CCN(c2ccc(OC)cc2)CC1;https://dx.doi.org/10.1021/jm980137o
PONATINIB;10802;None;64;Human;Binding;AC50;=;15000,00;4,82;-;20;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;532,2;4;1;6;4,46;Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12;https://dx.doi.org/10.1038/s41467-023-40064-9
pramipexole;3159;None;58;Human;Binding;AC50;=;14000,10;4,85;-63;41;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1038/s41467-023-40064-9
pramipexole;3159;None;58;Human;Binding;EC50;=;7,08;8,15;-63;41;Agonist activity at dopamine D2 receptor short isoform (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;-
pramipexole;3159;None;58;Human;Binding;EC50;=;251,00;6,60;-63;41;Agonist activity at human D2 receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding by Perkin elmer analysis;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/j.bmc.2022.117131
pramipexole;3159;None;58;Human;Binding;EC50;=;9,60;8,02;-63;41;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
pramipexole;3159;None;58;Human;Binding;EC50;=;27,00;7,57;-63;41;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
pramipexole;3159;None;58;Human;Binding;Kd;=;0,01;10,83;-63;41;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK incubated for 140 mins by radioligand competition binding based assay;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
pramipexole;3159;None;58;Human;Binding;Kd;=;0,01;10,83;-63;41;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
pramipexole;3159;None;58;Human;Binding;Ki;=;21,00;7,68;-63;41;High inhibition constant against [3H]spiperone binding to human Dopamine receptor D2S expressed in CHO cells;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm049269+
pramipexole;3159;None;58;Human;Binding;Ki;=;40,00;7,40;-63;41;Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D2 short (high/low affinity is given as 40/3600);ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/s0960-894x(02)00390-6
pramipexole;3159;None;58;Human;Binding;Ki;=;1900,00;5,72;-63;41;Low inhibition constant against [3H]spiperone binding to human Dopamine receptor D2S expressed in CHO cells;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm049269+
pramipexole;3159;None;58;Human;Binding;Ki;=;60,00;7,22;-63;41;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/j.bmc.2016.04.028
pramipexole;3159;None;58;Human;Binding;Ki;=;25,70;7,59;-63;41;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at high concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
pramipexole;3159;None;58;Human;Binding;Ki;=;1900,00;5,72;-63;41;Low binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm0503805
pramipexole;3159;None;58;Human;Binding;Ki;=;6300,00;5,20;-63;41;Low binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm0503805
pramipexole;3159;None;58;Human;Binding;Ki;=;21,00;7,68;-63;41;High binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm0503805
pramipexole;3159;None;58;Human;Binding;Ki;=;21,00;7,68;-63;41;High inhibition constant against [3H]spiperone binding to human Dopamine receptor D2L expressed in CHO cells;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm049269+
pramipexole;3159;None;58;Human;Binding;Ki;=;3,90;8,41;-63;41;Binding affinity to human D2 receptor assessed as inhibition constant;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/j.ejmech.2023.115172
pramipexole;3159;None;58;Human;Binding;Ki;=;6300,00;5,20;-63;41;Low inhibition constant against [3H]spiperone binding to human Dopamine receptor D2L expressed in CHO cells;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm049269+
pramipexole;3159;None;58;Human;Binding;Ki;=;21,00;7,68;-63;41;High binding affinity towards human dopamine receptor 2 (long) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm0503805
pramipexole;3159;None;58;Human;Binding;Ki;=;139,00;6,86;-63;41;in vitro low binding affinity was determined on human Dopamine receptor D2L expressed in chinese hamster ovary(CHO) K-1 cells using [3H]-spiperone as radioligand.;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/jm000087z
pramipexole;3159;None;58;Human;Binding;Ki;=;27,00;7,57;-63;41;Binding affinity of compound measured using [3H]-spiperone for the cloned human dopamine receptor D2 long (high/low affinity is given as 27/5400);ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1016/s0960-894x(02)00390-6
pramipexole;3159;None;58;Human;Binding;Ki;=;1000,00;6,00;-63;41;Displacement of [3H]N-methylspiperone from human D2 long receptor stably expressed in HEK293T cells co-expressing luciferase and CEK at low concentration incubated for 140 mins by radioligand competition binding based assay;ChEMBL;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://dx.doi.org/10.1021/acs.jmedchem.1c00692
pramipexole;3159;None;58;Human;Binding;pKi;=;-;6,25;-63;41;Unclassified;Guide to Pharmacology;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://pubmed.ncbi.nlm.nih.gov/7756621
pramipexole;3159;None;58;Human;Binding;pKi;=;-;6,25;-63;41;Unclassified;Guide to Pharmacology;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;https://pubmed.ncbi.nlm.nih.gov/7664822
pramipexole;3159;125I-IODOSULPRIDE;58;Human;Binding;pKi;=;790,00;6,10;-63;41;-;PDSP KiDatabase;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;-
pramipexole;3159;3H-NMSP;58;Human;Binding;pKi;=;743,70;6,13;-63;41;-;PDSP KiDatabase;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;-
pramipexole;3159;3H-thymidine;58;Human;Binding;pKi;=;3,10;8,51;-63;41;-;PDSP KiDatabase;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;-
pramipexole;3159;125I-IODOSULPRIDE;58;Human;Binding;pKi;=;1698,24;5,77;-63;41;-;PDSP KiDatabase;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;-
pramipexole;3159;125I-IODOSULPRIDE;58;Human;Binding;pKi;=;954,99;6,02;-63;41;-;PDSP KiDatabase;211,1;3;2;4;1,58;CCCN[C@H]1CCc2nc(N)sc2C1;-
PRECLAMOL;207299;None;9;Human;Binding;Ki;=;8,50;8,07;-1;27;In vitro binding affinity against cloned mammalian dopamine D2 autoreceptor, expressed in CHO-K1 cells, using [3H]U-86170 as radioligand;ChEMBL;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;https://dx.doi.org/10.1021/jm00043a013
PRECLAMOL;207299;None;9;Human;Binding;Ki;=;17,40;7,76;-1;27;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;https://dx.doi.org/10.1021/jm901689v
PRECLAMOL;207299;None;9;Human;Binding;Ki;=;27,00;7,57;-1;27;Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D2 short (high/low affinity is given as 27/1800);ChEMBL;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;https://dx.doi.org/10.1016/s0960-894x(02)00390-6
PRECLAMOL;207299;None;9;Human;Binding;Ki;=;39,00;7,41;-1;27;Affinity against recombinant dopamine receptor (DA) D2 expressed in CHO-K1 cells, using [3H]-spiperone as radioligand;ChEMBL;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;https://dx.doi.org/10.1021/jm00043a013
PRECLAMOL;207299;None;9;Human;Binding;Ki;=;137,00;6,86;-1;27;Binding affinity to human dopamine D2 receptor;ChEMBL;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;https://dx.doi.org/10.1016/j.bmcl.2018.03.084
PRECLAMOL;207299;None;9;Human;Binding;Ki;=;2268,00;5,64;-1;27;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;https://dx.doi.org/10.1021/jm901689v
PRECLAMOL;207299;None;9;Human;Binding;Ki;=;9,00;8,05;-1;27;Binding affinity of compound measured using [3H]spiperone for the cloned human dopamine receptor D2 long (high/low affinity is given as 9.0/1800);ChEMBL;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;https://dx.doi.org/10.1016/s0960-894x(02)00390-6
PRECLAMOL;207299;3H-YM 09151-2;9;Human;Binding;pKi;=;192,00;6,72;-1;27;-;PDSP KiDatabase;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;-
PRECLAMOL;207299;3H-NMSP;9;Human;Binding;pKi;=;810,00;6,09;-1;27;-;PDSP KiDatabase;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;-
PRECLAMOL;207299;UNDEFINED;9;Human;Binding;pKi;=;2268,00;5,64;-1;27;-;PDSP KiDatabase;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;-
PRECLAMOL;207299;UNDEFINED;9;Human;Binding;pKi;=;17,40;7,76;-1;27;-;PDSP KiDatabase;219,2;3;1;2;2,98;CCCN1CCC[C@@H](c2cccc(O)c2)C1;-
PRENYLAMINE;91619;None;25;Human;Binding;AC50;=;2900,00;5,54;-;16;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;329,2;8;1;1;5,43;CC(Cc1ccccc1)NCCC(c1ccccc1)c1ccccc1;https://dx.doi.org/10.1038/s41467-023-40064-9
PRIDOPIDINE;202679;None;53;Human;Binding;Ki;=;17550,00;4,76;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells;ChEMBL;281,1;4;0;3;2,68;CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1;https://dx.doi.org/10.1021/jm901689v
PRIDOPIDINE;202679;None;53;Human;Binding;Ki;=;7500,00;5,12;-;1;Binding affinity to dopamine D2 (high) receptor (unknown origin);ChEMBL;281,1;4;0;3;2,68;CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.0c01192
PRIDOPIDINE;202679;None;53;Human;Binding;Ki;=;7521,00;5,12;-;1;Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells;ChEMBL;281,1;4;0;3;2,68;CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1;https://dx.doi.org/10.1021/jm901689v
PRIDOPIDINE;202679;None;53;Human;Binding;Ki;=;17500,00;4,76;-;1;Binding affinity to dopamine D2 (low) receptor (unknown origin);ChEMBL;281,1;4;0;3;2,68;CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1;https://dx.doi.org/10.1021/acs.jmedchem.0c01192
PRIDOPIDINE;202679;None;53;Human;Binding;Ki;=;10000,00;5,00;-;1;Binding affinity to D2R receptor (unknown origin);ChEMBL;281,1;4;0;3;2,68;CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1;https://dx.doi.org/10.1016/j.bmc.2022.117032
PRIDOPIDINE;202679;UNDEFINED;53;Human;Binding;pKi;=;10000,00;5,00;-;1;-;PDSP KiDatabase;281,1;4;0;3;2,68;CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1;-
PRIDOPIDINE;202679;UNDEFINED;53;Human;Binding;pKi;=;7521,00;5,12;-;1;-;PDSP KiDatabase;281,1;4;0;3;2,68;CCCN1CCC(c2cccc(S(C)(=O)=O)c2)CC1;-
procaterol;3172;None;21;Human;Binding;Ki;=;86000,00;4,07;-1445;4;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;290,2;5;4;4;2,04;CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12;https://dx.doi.org/10.1016/j.bmc.2016.04.028
procaterol;220209;None;0;Human;Binding;pKi;=;4,07;8,39;-;2;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;Drug Central;290,2;5;4;4;2,04;CC[C@@H](NC(C)C)[C@@H](O)c1ccc(O)c2[nH]c(=O)ccc12;-
prochlorperazine;3173;None;38;Human;Binding;AC50;=;44,00;7,36;1;44;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
prochlorperazine;3173;None;38;Human;Binding;IC50;=;11,00;7,96;1;44;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;None;38;Human;Binding;Ki;=;3,61;8,44;1;44;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;None;38;Human;Binding;pKi;=;8,76;8,06;1;44;None;Drug Central;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;None;38;Human;Binding;pKi;=;-;8,44;1;44;Unclassified;Guide to Pharmacology;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;UNDEFINED;38;Human;Binding;pKi;=;7,14;8,15;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;3H-SPIPERONE;38;Human;Binding;pKi;=;7,00;8,15;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;3H-SPIPERONE;38;Human;Binding;pKi;=;4,00;8,40;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;R-SAT;38;Human;Binding;pKi;=;0,20;9,70;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;3H-RACLOPRIDE;38;Human;Binding;pKi;=;1,70;8,77;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;3H-NEMONAPRIDE;38;Human;Binding;pKi;=;5,30;8,28;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;UNDEFINED;38;Human;Binding;pKi;=;1,20;8,92;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;R-SAT;38;Human;Binding;pKi;=;1,10;8,96;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;125I-IODOSULPRIDE;38;Human;Binding;pKi;=;0,40;9,40;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
prochlorperazine;3173;UNDEFINED;38;Human;Binding;pKi;=;1,20;8,92;1;44;-;PDSP KiDatabase;373,1;4;0;4;4,58;CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1;-
promazine;3182;None;26;Human;Binding;AC50;=;400,00;6,40;-41;37;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;284,1;4;0;3;4,24;CN(C)CCCN1c2ccccc2Sc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
promazine;3182;None;26;Human;Binding;IC50;=;505,00;6,30;-41;37;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;284,1;4;0;3;4,24;CN(C)CCCN1c2ccccc2Sc2ccccc21;-
promazine;3182;None;26;Human;Binding;Ki;=;168,00;6,78;-41;37;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;284,1;4;0;3;4,24;CN(C)CCCN1c2ccccc2Sc2ccccc21;-
promazine;3182;None;26;Human;Binding;pKi;=;6,70;8,17;-41;37;None;Drug Central;284,1;4;0;3;4,24;CN(C)CCCN1c2ccccc2Sc2ccccc21;-
promazine;3182;None;26;Human;Binding;pKi;=;-;6,52;-41;37;Unclassified;Guide to Pharmacology;284,1;4;0;3;4,24;CN(C)CCCN1c2ccccc2Sc2ccccc21;https://pubmed.ncbi.nlm.nih.gov/16135699
promazine;3182;UNDEFINED;26;Human;Binding;pKi;=;161,29;6,79;-41;37;-;PDSP KiDatabase;284,1;4;0;3;4,24;CN(C)CCCN1c2ccccc2Sc2ccccc21;-
promazine;3182;R-SAT;26;Human;Binding;pKi;=;300,00;6,52;-41;37;-;PDSP KiDatabase;284,1;4;0;3;4,24;CN(C)CCCN1c2ccccc2Sc2ccccc21;-
promazine;3182;3H-SPIPERONE;26;Human;Binding;pKi;=;160,00;6,80;-41;37;-;PDSP KiDatabase;284,1;4;0;3;4,24;CN(C)CCCN1c2ccccc2Sc2ccccc21;-
promethazine;3183;None;36;Human;Binding;AC50;=;1040,00;5,98;-18;35;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;284,1;3;0;3;4,24;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;https://dx.doi.org/10.1038/s41467-023-40064-9
promethazine;3183;None;36;Human;Binding;IC50;=;779,00;6,11;-18;35;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;284,1;3;0;3;4,24;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;-
promethazine;3183;None;36;Human;Binding;IC50;=;100,00;7,00;-18;35;Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay;ChEMBL;284,1;3;0;3;4,24;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;https://dx.doi.org/10.1021/jm400856t
promethazine;3183;None;36;Human;Binding;Ki;=;260,00;6,58;-18;35;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;284,1;3;0;3;4,24;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;-
promethazine;3183;None;36;Human;Binding;pKi;=;6,61;8,18;-18;35;None;Drug Central;284,1;3;0;3;4,24;CC(CN1c2ccccc2Sc2ccccc21)N(C)C;-
PROPIOMAZINE;14476;None;26;Human;Binding;AC50;=;2600,00;5,58;-;15;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;340,2;5;0;4;4,83;CCC(=O)c1ccc2c(c1)N(CC(C)N(C)C)c1ccccc1S2;https://dx.doi.org/10.1038/s41467-023-40064-9
PROPRANOLOL;218435;3H-YM 09151-2;0;Human;Binding;pKi;=;10000,00;5,00;-42657;29;-;PDSP KiDatabase;259,2;6;2;3;2,58;CC(C)NCC(O)COc1cccc2ccccc12;-
PROTRIPTYLINE;206037;None;20;Human;Binding;AC50;=;5200,00;5,28;-;19;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;263,2;4;1;1;4,30;CNCCCC1c2ccccc2C=Cc2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
prucalopride;3202;3H-SPIPERONE;61;Human;Binding;pKi;=;10000,00;5,00;-1096;36;-;PDSP KiDatabase;367,2;6;2;5;2,09;COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1;-
PSILOCYBINE;70324;3H-NMSP;12;Human;Binding;pKi;=;10000,00;5,00;-102;33;-;PDSP KiDatabase;284,1;5;3;3;1,74;CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12;-
PYRVINIUM;14498;None;13;Human;Binding;AC50;=;10000,00;5,00;-;25;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;382,2;4;0;2;5,31;Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1;https://dx.doi.org/10.1038/s41467-023-40064-9
quetiapine;3256;None;51;Human;Binding;AC50;=;710,00;6,15;-28;64;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
quetiapine;3256;None;51;Human;Binding;IC50;=;1329,90;5,88;-28;64;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;None;51;Human;Binding;Ki;=;443,30;6,35;-28;64;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;None;51;Human;Binding;Ki;=;63,10;7,20;-28;64;In vitro binding affinity for Dopamine receptor D2;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00200-1
quetiapine;3256;None;51;Human;Binding;Ki;=;1000,00;6,00;-28;64;Binding affinity to dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1039/C2MD00311B
quetiapine;3256;None;51;Human;Binding;Ki;=;400,00;6,40;-28;64;Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;None;51;Human;Binding;Ki;=;69,00;7,16;-28;64;Binding affinity towards human D2 dopamine receptor.;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1021/jm0002432
quetiapine;3256;None;51;Human;Binding;Ki;=;309,03;6,51;-28;64;Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1021/acs.jmedchem.1c00497
quetiapine;3256;None;51;Human;Binding;Ki;=;140,00;6,85;-28;64;Binding affinity to human dopamine D2 receptor;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2016.06.038
quetiapine;3256;None;51;Human;Binding;Ki;=;310,00;6,51;-28;64;Binding affinity towards human Dopamine receptor D2;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1021/jm030480f
quetiapine;3256;None;51;Human;Binding;Ki;=;180,00;6,75;-28;64;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
quetiapine;3256;None;51;Human;Binding;pKi;=;-;7,20;-28;64;Unclassified;Guide to Pharmacology;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;https://pubmed.ncbi.nlm.nih.gov/9430133
quetiapine;3256;UNDEFINED;51;Human;Binding;pKi;=;78,00;7,11;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-NEMONAPRIDE;51;Human;Binding;pKi;=;1000,00;6,00;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-SPIPERONE;51;Human;Binding;pKi;=;770,00;6,11;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-NEMONAPRIDE;51;Human;Binding;pKi;=;1400,00;5,85;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;UNDEFINED;51;Human;Binding;pKi;=;180,00;6,74;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-SPIPERONE;51;Human;Binding;pKi;=;680,00;6,17;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-SPIPERONE;51;Human;Binding;pKi;=;500,00;6,30;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;R-SAT;51;Human;Binding;pKi;=;16,00;7,80;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-NMS;51;Human;Binding;pKi;=;706,00;6,15;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-N-Methylspiperone;51;Human;Binding;pKi;=;177,83;6,75;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-SPIPERONE;51;Human;Binding;pKi;=;78,00;7,11;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-NMSP;51;Human;Binding;pKi;=;700,00;6,15;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-SCH23390;51;Human;Binding;pKi;=;779,00;6,11;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-SPIPERONE;51;Human;Binding;pKi;=;390,00;6,41;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-RACLOPRIDE;51;Human;Binding;pKi;=;155,00;6,81;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-RACLOPRIDE;51;Human;Binding;pKi;=;105,00;6,98;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-Methylspiperone;51;Human;Binding;pKi;=;1000,00;6,00;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-NMSP;51;Human;Binding;pKi;=;567,00;6,25;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-SPIPERONE;51;Human;Binding;pKi;=;700,00;6,15;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-NMSP;51;Human;Binding;pKi;=;245,00;6,61;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;UNDEFINED;51;Human;Binding;pKi;=;78,00;7,11;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
quetiapine;3256;3H-SPIPERONE;51;Human;Binding;pKi;=;700,00;6,15;-28;64;-;PDSP KiDatabase;383,2;5;1;6;2,86;OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1;-
QUINAGOLIDE;84404;None;3;Human;Binding;AC50;=;15,20;7,82;-;11;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;395,2;7;2;4;2,14;CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21;https://dx.doi.org/10.1038/s41467-023-40064-9
quinelorane;3259;None;18;Human;Binding;pKi;None;-;5,60;-363;4;Unclassified;Guide to Pharmacology;246,2;2;1;4;1,65;CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/1354163
quinelorane;3259;None;18;Human;Binding;pKi;None;-;5,60;-363;4;Unclassified;Guide to Pharmacology;246,2;2;1;4;1,65;CCCN1CCC[C@@H]2Cc3nc(N)ncc3C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/7473180
Quinelorane;218829;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;316,23;6,50;-87;19;-;PDSP KiDatabase;246,2;2;1;4;1,65;CCCN1CCCC2Cc3nc(N)ncc3CC21;-
Quinelorane;218829;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;707,95;6,15;-87;19;-;PDSP KiDatabase;246,2;2;1;4;1,65;CCCN1CCCC2Cc3nc(N)ncc3CC21;-
QUINIDINE;19421;None;48;Human;Binding;AC50;=;10000,00;5,00;-;11;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;324,2;4;1;4;3,17;C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12;https://dx.doi.org/10.1038/s41467-023-40064-9
quinpirole;3261;None;19;Human;Binding;EC50;=;295,00;6,53;-61;30;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-1 recruitment after 15 mins by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
quinpirole;3261;None;19;Human;Binding;EC50;=;38,70;7,41;-61;30;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
quinpirole;3261;None;19;Human;Binding;EC50;=;52,00;7,28;-61;30;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
quinpirole;3261;None;19;Human;Binding;EC50;=;3,00;8,52;-61;30;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai1 after 10 mins by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
quinpirole;3261;None;19;Human;Binding;EC50;=;64,00;7,19;-61;30;Agonist activity at ARMS2-PK2 tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of EA-tagged beta-arrestin-2 recruitment incubated for 5 hrs measured after 60 mins by PathHunter assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
quinpirole;3261;None;19;Human;Binding;EC50;=;5,90;8,23;-61;30;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai3 after 10 mins by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
quinpirole;3261;None;19;Human;Binding;EC50;=;5,10;8,29;-61;30;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged Galphai2 after 10 mins by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
quinpirole;3261;None;19;Human;Binding;EC50;=;2,46;8,61;-61;30;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as beta-arrestin recruitment preincubated for 10 mins with coelenterazine followed by compound addition and measured after 10 mins by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
quinpirole;3261;None;19;Human;Binding;EC50;=;51,00;7,29;-61;30;Activity at pro-link-tagged D2S-ARMS2PK2 (unknown origin) expressed in HEK293 cells by beta-arrestin-2 recruitment assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/j.bmc.2015.07.050
quinpirole;3261;None;19;Human;Binding;EC50;=;2,40;8,62;-61;30;Partial agonist activity at human D2L receptor expressed in HEK293T cells co-expressing Galpahi1/Gbeta1/GFP2-Ggamma2 assessed as Galphai1 dissociation after 15 mins in presence of coelenterazine 400a by luciferase reporter gene assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.9b00508
quinpirole;3261;None;19;Human;Binding;EC50;=;353,20;6,45;-61;30;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
quinpirole;3261;None;19;Human;Binding;EC50;=;83,00;7,08;-61;30;Agonist activity at ARMS2-PK2-tagged human dopamine D2S receptor expressed in HEK293 cells co-expressing (EA)-tagged beta arrestin fusion protein assessed as recruitment of beta-arrestin-2 after 5 hrs by chemiluminescence assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm501889t
quinpirole;3261;None;19;Human;Binding;EC50;=;2,20;8,66;-61;30;Effective concentration was determined as thymidine uptake in CHO-L6 cells transfected with the rat Dopamine receptor D2L by mitogenesis assay (intrinsic activity);ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm000087z
quinpirole;3261;None;19;Human;Binding;EC50;=;86,00;7,07;-61;30;Agonist activity at ARMS2-PK-tagged D2S receptor (unknown origin) transfected in HEK293 cells after 5 hrs by beta-arrestin assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/j.bmc.2016.04.028
quinpirole;3261;None;19;Human;Binding;EC50;=;147,60;6,83;-61;30;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
quinpirole;3261;None;19;Human;Binding;EC50;=;151,00;6,82;-61;30;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells assessed as induction of renilla luciferase 2-tagged beta-arrestin-2 recruitment after 15 mins by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
quinpirole;3261;None;19;Human;Binding;EC50;=;1,20;8,92;-61;30;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoA after 10 mins by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
quinpirole;3261;None;19;Human;Binding;EC50;=;73,00;7,14;-61;30;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/j.bmc.2017.08.037
quinpirole;3261;None;19;Human;Binding;EC50;=;3,70;8,43;-61;30;Effective dose was measured by the stimulation of mitogenesis at Dopamine receptor D4.2;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm0009989
quinpirole;3261;None;19;Human;Binding;EC50;=;8,20;8,09;-61;30;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
quinpirole;3261;None;19;Human;Binding;EC50;=;1,20;8,92;-61;30;Agonist activity at N-terminal flag-tagged D2S receptor (unknown origin) expressed in HEK293 cells coexpressing renilla luciferase 2-tagged GalphaoB after 10 mins by BRET assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01857
quinpirole;3261;None;19;Human;Binding;EC50;=;16,00;7,80;-61;30;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
quinpirole;3261;None;19;Human;Binding;IC50;=;2,63;8,58;-61;30;Partial agonist activity at human D2 receptor expressed in HEK293T cells assessed as inhibition of forskolin-induced cAMP production incubated for 1 hr by HTRF analysis;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.1c00704
quinpirole;3261;None;19;Human;Binding;Ki;=;3000,00;5,52;-61;30;Binding affinity (low) towards human dopamine receptor 2 short against radioligand [3H]spiperone, expressed in Chinese hamster ovary cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm0503805
quinpirole;3261;None;19;Human;Binding;Ki;=;31000,00;4,51;-61;30;"In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells; Low binding affinity";ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
quinpirole;3261;None;19;Human;Binding;Ki;=;18,00;7,75;-61;30;Displacement of [3H]7-OH-DPAT from human dopamine D2L receptor expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm400520c
quinpirole;3261;None;19;Human;Binding;Ki;=;70,00;7,16;-61;30;Displacement of [3H]spiperone from human dopamine D2S receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm501889t
quinpirole;3261;None;19;Human;Binding;Ki;=;64,00;7,19;-61;30;"In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 long receptor expressed in CHO cells; high binding affinity";ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
quinpirole;3261;None;19;Human;Binding;Ki;=;13,10;7,88;-61;30;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
quinpirole;3261;None;19;Human;Binding;Ki;=;52,00;7,28;-61;30;"In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells; high binding affinity";ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
quinpirole;3261;None;19;Human;Binding;Ki;=;4000,00;5,40;-61;30;"In vitro for its ability to displace [3H]- spiperone from cloned human dopamine D2 short receptor expressed in CHO cells; Low binding affinity";ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/s0960-894x(01)00484-x
quinpirole;3261;None;19;Human;Binding;Ki;=;1185,00;5,93;-61;30;Displacement of [3H]YM-09151-2 from human dopamine D2 receptor expressed in CHOp cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm301258w
quinpirole;3261;None;19;Human;Binding;Ki;=;260,00;6,58;-61;30;Displacement of [3H]spiperone from human dopamine D2L receptor expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm400520c
quinpirole;3261;None;19;Human;Binding;Ki;=;3000,00;5,52;-61;30;Low inhibition constant against [3H]spiperone binding to human Dopamine receptor D2S expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm049269+
quinpirole;3261;None;19;Human;Binding;Ki;=;52,00;7,28;-61;30;In vitro binding affinity to displace [3H]-spiperone from the cloned human dopamine receptor D2 short in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
quinpirole;3261;None;19;Human;Binding;Ki;=;64,00;7,19;-61;30;In vitro binding affinity to displace [3H]spiperone from the cloned human dopamine receptor D2 long in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/s0960-894x(03)00004-0
quinpirole;3261;None;19;Human;Binding;Ki;=;35,00;7,46;-61;30;High inhibition constant against [3H]spiperone binding to human Dopamine receptor D2S expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm049269+
quinpirole;3261;None;19;Human;Binding;Ki;=;3100,00;5,51;-61;30;Low inhibition constant against [3H]spiperone binding to human Dopamine receptor D2L expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm049269+
quinpirole;3261;None;19;Human;Binding;Ki;=;63,00;7,20;-61;30;High inhibition constant against [3H]spiperone binding to human Dopamine receptor D2L expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm049269+
quinpirole;3261;None;19;Human;Binding;Ki;=;35,00;7,46;-61;30;High binding affinity towards human dopamine receptor 2 (short) expressed in Chinese hamster ovary cells using [3H]spiperone (0.5 nM) as radioligand;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm0503805
quinpirole;3261;None;19;Human;Binding;Ki;=;260,00;6,58;-61;30;Displacement of [3H]Spiperone from human dopamine D2 long receptor expressed in CHO cells by competitive binding assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm5004039
quinpirole;3261;None;19;Human;Binding;Ki;=;70,00;7,16;-61;30;Displacement of [3H]Spiperone from human dopamine D2 short receptor expressed in CHO cells by competitive binding assay;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm5004039
quinpirole;3261;None;19;Human;Binding;Ki;=;3100,00;5,51;-61;30;Binding affinity (low) towards human dopamine receptor 2 (long) against radioligand [3H]spiperone, expressed in Chinese hamster ovary cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm0503805
quinpirole;3261;None;19;Human;Binding;Ki;=;70,00;7,16;-61;30;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/j.bmc.2016.04.028
quinpirole;3261;None;19;Human;Binding;Ki;=;260,00;6,58;-61;30;Displacement of [3H]spiperone from human dopamine D2L receptor transfected in CHO cells after 1 hr by scintillation counting analysis;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm501889t
quinpirole;3261;None;19;Human;Binding;Ki;=;5,56;8,26;-61;30;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
quinpirole;3261;None;19;Human;Binding;Ki;=;2950,00;5,53;-61;30;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
quinpirole;3261;None;19;Human;Binding;Ki;=;70,00;7,16;-61;30;Displacement of [3H]spiperone from human dopamine D2S receptor expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm400520c
quinpirole;3261;None;19;Human;Binding;Ki;=;2570,00;5,59;-61;30;Affinity towards Dopamine receptor D2;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm9800292
quinpirole;3261;None;19;Human;Binding;Ki;=;950,00;6,02;-61;30;Displacement of [3H]spiperone from human cloned dopamine D2long receptor expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm901120h
quinpirole;3261;None;19;Human;Binding;Ki;=;870,00;6,06;-61;30;Displacement of [3H]spiperone from human cloned dopamine D2short receptor expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1021/jm901120h
quinpirole;3261;None;19;Human;Binding;Ki;=;260,00;6,58;-61;30;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://dx.doi.org/10.1016/j.bmc.2016.04.028
quinpirole;3261;None;19;Human;Binding;pKi;=;-;6,30;-61;30;Unclassified;Guide to Pharmacology;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/8967990
quinpirole;3261;None;19;Human;Binding;pKi;=;-;6,30;-61;30;Unclassified;Guide to Pharmacology;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/7576010
quinpirole;3261;None;19;Human;Binding;pKi;=;-;6,30;-61;30;Unclassified;Guide to Pharmacology;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/1975644
quinpirole;3261;None;19;Human;Binding;pKi;=;-;6,30;-61;30;Unclassified;Guide to Pharmacology;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/7664822
quinpirole;3261;None;19;Human;Binding;pKi;=;-;6,30;-61;30;Unclassified;Guide to Pharmacology;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/1840645
quinpirole;3261;None;19;Human;Binding;pKi;=;-;6,30;-61;30;Unclassified;Guide to Pharmacology;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;https://pubmed.ncbi.nlm.nih.gov/1354163
quinpirole;3261;3H-SPIPERONE;19;Human;Binding;pKi;=;2158,00;5,67;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;125I-IODOSULPRIDE;19;Human;Binding;pKi;=;1400,00;5,85;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;3H-SPIPERONE;19;Human;Binding;pKi;=;634,00;6,20;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;125I-IODOSULPRIDE;19;Human;Binding;pKi;=;891,25;6,05;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;3H-YM 09151-2;19;Human;Binding;pKi;=;1185,00;5,93;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;3H-thymidine;19;Human;Binding;pKi;=;2,80;8,55;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;125I-IODOSULPRIDE;19;Human;Binding;pKi;=;1402,00;5,85;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;3H-SPIPERONE;19;Human;Binding;pKi;=;14,00;7,85;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;125I-7-OH-PIPAT;19;Human;Binding;pKi;=;9,50;8,02;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;125I-IODOSULPRIDE;19;Human;Binding;pKi;=;600,00;6,22;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
quinpirole;3261;125I-IODOSULPRIDE;19;Human;Binding;pKi;=;1445,44;5,84;-61;30;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCC[C@@H]2Cc3[nH]ncc3C[C@H]21;-
Quinpirole,(+);218865;3H-SPIPERONE;0;Human;Binding;pKi;=;5000,00;5,30;-1;2;-;PDSP KiDatabase;219,2;2;1;2;2,00;CCCN1CCCC2Cc3[nH]ncc3CC21;-
quipazine;3262;3H-YM 09151-2;58;Human;Binding;pKi;=;10000,00;5,00;-114;24;-;PDSP KiDatabase;213,1;1;1;3;1,64;c1ccc2nc(N3CCNCC3)ccc2c1;-
R-(-)-2,3:[4,5-b]-2'-Aminothiazolo-10,11-dihydroxyaporphine;219446;UNDEFINED;0;Human;Binding;pKi;=;328,00;6,48;7;2;-;PDSP KiDatabase;339,1;0;3;6;3,04;CN1CCc2c3c(cc4nc(N)sc24)-c2c(ccc(O)c2O)CC31;-
R-VK4-40;3418;None;1;Human;Binding;Ki;=;75,80;7,12;-263;5;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes measured after 60 mins by scintillation counting method;ChEMBL;454,2;8;3;4;3,69;CCc1cccc(N2CCN(C[C@H](O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://dx.doi.org/10.1021/acs.jmedchem.9b00607
R-VK4-40;3418;None;1;Human;Binding;pKi;=;-;7,12;-263;5;Unclassified;Guide to Pharmacology;454,2;8;3;4;3,69;CCc1cccc(N2CCN(C[C@H](O)CCNC(=O)c3cc4ccccc4[nH]3)CC2)c1Cl;https://pubmed.ncbi.nlm.nih.gov/30974107
raclopride;3281;None;40;Human;Binding;IC50;=;1,83;8,74;1;18;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
raclopride;3281;None;40;Human;Binding;IC50;=;1,82;8,74;1;18;Antagonist activity at C-terminal RLuc8-fused D2 long receptor (unknown origin) transfected in human HEK293T cells co-expressing N-terminal Venus-tagged beta-arrestin2 assessed as increase in beta-arrestin2 recruitment measured after 5 mins in presence of coelenterazine H by BRET assay;ChEMBL;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;https://dx.doi.org/10.1021/acsmedchemlett.9b00575
raclopride;3281;None;40;Human;Binding;Ki;=;12,70;7,90;1;18;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor expressed in HEK293 cells after 1 hr by liquid scintillation counting analysis;ChEMBL;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;https://dx.doi.org/10.1021/jm401798r
raclopride;3281;None;40;Human;Binding;Ki;=;12,70;7,90;1;18;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;https://dx.doi.org/10.1021/acs.jmedchem.6b00860
raclopride;3281;None;40;Human;Binding;Ki;=;31,00;7,51;1;18;Displacement of [3H]spiperone from dopamine D2short receptor in CHO cells;ChEMBL;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
raclopride;3281;None;40;Human;Binding;Ki;=;1,21;8,92;1;18;Displacement of [3H]spiperone from human D2 receptor transfected in HEK cells;ChEMBL;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;https://dx.doi.org/10.1021/jm5004123
raclopride;3281;None;40;Human;Binding;Ki;=;17,00;7,77;1;18;Displacement of [3H]spiperone from dopamine D2long receptor in CHO cells;ChEMBL;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;https://dx.doi.org/10.1016/j.bmc.2007.07.017
raclopride;3281;None;40;Human;Binding;pKi;=;-;8,00;1;18;Unclassified;Guide to Pharmacology;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;https://pubmed.ncbi.nlm.nih.gov/7473180
raclopride;3281;3H-NEMONAPRIDE;40;Human;Binding;pKi;=;22,00;7,66;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-RACLOPRIDE;40;Human;Binding;pKi;=;0,64;9,19;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;R-SAT;40;Human;Binding;pKi;=;2,40;8,62;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;UNDEFINED;40;Human;Binding;pKi;=;0,64;9,19;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-SPIPERONE;40;Human;Binding;pKi;=;3,20;8,49;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-RACLOPRIDE;40;Human;Binding;pKi;=;1,60;8,80;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-RACLOPRIDE;40;Human;Binding;pKi;=;1,15;8,94;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;R-SAT;40;Human;Binding;pKi;=;0,50;9,30;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-NMSP;40;Human;Binding;pKi;=;1,15;8,94;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-RACLOPRIDE;40;Human;Binding;pKi;=;0,60;9,22;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-SPIPERONE;40;Human;Binding;pKi;=;0,64;9,19;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-SPIPERONE;40;Human;Binding;pKi;=;10,50;7,98;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-SPIPERONE;40;Human;Binding;pKi;=;5,00;8,30;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-SPIPERONE;40;Human;Binding;pKi;=;7,20;8,14;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raclopride;3281;3H-YM 09151-2;40;Human;Binding;pKi;=;2,00;8,70;1;18;-;PDSP KiDatabase;346,1;5;2;4;2,92;CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC;-
raloxifene;3286;None;44;Human;Binding;AC50;=;950,00;6,02;-7;29;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;473,2;7;2;6;6,08;O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12;https://dx.doi.org/10.1038/s41467-023-40064-9
raloxifene;3286;None;44;Human;Binding;IC50;=;1174,00;5,93;-7;29;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;473,2;7;2;6;6,08;O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12;-
raloxifene;3286;None;44;Human;Binding;Ki;=;391,00;6,41;-7;29;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;473,2;7;2;6;6,08;O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12;-
raloxifene;3286;None;44;Human;Binding;pKi;=;6,41;8,19;-7;29;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;473,2;7;2;6;6,08;O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12;-
RBI257;3294;None;4;Human;Binding;Ki;=;568,00;6,25;-2238;6;Displacement of [3H]-spiperone from human D2 receptor expressed in Sf9 cells assessed as inhibition constant;ChEMBL;465,1;6;0;4;4,57;CC(C)Oc1cccnc1N(C)C1CCN(Cc2ccc(I)cc2)CC1;https://dx.doi.org/10.1016/j.ejmech.2020.113141
REBOXETINE;35339;3H-SPIPERONE;12;Human;Binding;pKi;=;10000,00;5,00;-1584;16;-;PDSP KiDatabase;313,2;6;1;4;3,19;CCOc1ccccc1OC(c1ccccc1)C1CNCCO1;-
REMOXIPRIDE;84687;None;24;Human;Binding;AC50;=;1161,90;5,93;-1;26;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
REMOXIPRIDE;84687;None;24;Human;Binding;IC50;=;880,00;6,06;-1;26;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;ChEMBL;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;https://dx.doi.org/10.1021/jm990562x
REMOXIPRIDE;84687;None;24;Human;Binding;pIC50;=;6,06;8,22;-1;26;Binding affinity to dopamine receptor D2 cloned from human, using [3H]- YM09151 as competitive ligand;Drug Central;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;3H-NEMONAPRIDE;24;Human;Binding;pKi;=;900,00;6,05;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;3H-RACLOPRIDE;24;Human;Binding;pKi;=;80,00;7,10;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;3H-SPIPERONE;24;Human;Binding;pKi;=;30,00;7,52;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;R-SAT;24;Human;Binding;pKi;=;105,00;6,98;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;125I-IODOSULPRIDE;24;Human;Binding;pKi;=;198,00;6,70;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;3H-RACLOPRIDE;24;Human;Binding;pKi;=;125,00;6,90;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;UNDEFINED;24;Human;Binding;pKi;=;30,00;7,52;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;3H-SPIPERONE;24;Human;Binding;pKi;=;800,00;6,10;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;UNDEFINED;24;Human;Binding;pKi;=;30,00;7,52;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
REMOXIPRIDE;84687;R-SAT;24;Human;Binding;pKi;=;16,00;7,80;-1;26;-;PDSP KiDatabase;370,1;6;1;4;2,68;CCN1CCC[C@H]1CNC(=O)c1c(OC)ccc(Br)c1OC;-
RESERPINE;207516;None;57;Human;Binding;pKi;=;6,23;8,21;1;12;None;Drug Central;608,3;8;1;10;4,17;COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC;-
RESERPINE;207516;3H-YM 09151-2;57;Human;Binding;pKi;=;586,00;6,23;1;12;-;PDSP KiDatabase;608,3;8;1;10;4,17;COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC;-
RIFAMPIN;137055;None;20;Human;Binding;AC50;=;9200,00;5,04;-;28;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;822,4;4;6;15;4,33;CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C;https://dx.doi.org/10.1038/s41467-023-40064-9
RIMCAZOLE;98500;125I-IODOSULPRIDE;22;Human;Binding;pKi;=;8700,00;5,06;-1;6;-;PDSP KiDatabase;321,2;4;1;3;3,87;C[C@H]1CN(CCCn2c3ccccc3c3ccccc32)C[C@@H](C)N1;-
risperidone;3331;None;72;Human;Binding;AC50;=;20,80;7,68;-7;71;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1038/s41467-023-40064-9
risperidone;3331;None;72;Human;Binding;IC50;=;20,00;7,70;-7;71;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;None;72;Human;Binding;Ki;=;3,10;8,51;-7;71;Binding affinity for dopamine receptor D2 determined using [3H]spiperone;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1016/s0960-894x(01)00425-5
risperidone;3331;None;72;Human;Binding;Ki;=;2,70;8,57;-7;71;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1021/jm300975f
risperidone;3331;None;72;Human;Binding;Ki;=;10,00;8,00;-7;71;Binding affinity to dopamine D2 receptor (unknown origin) by PDSP assay;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1039/C2MD00311B
risperidone;3331;None;72;Human;Binding;Ki;=;1,40;8,85;-7;71;Ability to inhibit the binding of [3H]spiperone to the Dopamine receptor D2L in COS7 cells;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1021/jm00004a016
risperidone;3331;None;72;Human;Binding;Ki;=;3,30;8,48;-7;71;Binding affinity towards human Dopamine receptor D2;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1021/jm030480f
risperidone;3331;None;72;Human;Binding;Ki;=;3,80;8,42;-7;71;Binding affinity to D2 receptor (unknown origin);ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1016/j.bmcl.2020.127506
risperidone;3331;None;72;Human;Binding;Ki;=;6,31;8,20;-7;71;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1021/jm070516u
risperidone;3331;None;72;Human;Binding;Ki;=;6,17;8,21;-7;71;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1016/j.bmcl.2009.09.041
risperidone;3331;None;72;Human;Binding;Ki;=;3,90;8,41;-7;71;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1016/j.bmcl.2021.127909
risperidone;3331;None;72;Human;Binding;Ki;=;6,17;8,21;-7;71;Displacement of [3H]spiperone from human D2 receptor;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1016/j.ejmech.2013.10.066
risperidone;3331;None;72;Human;Binding;Ki;=;0,44;9,36;-7;71;Binding affinity towards human D2 dopamine receptor.;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1021/jm0002432
risperidone;3331;None;72;Human;Binding;Ki;=;3,80;8,42;-7;71;Binding affinity to dopamine D2 receptor (unknown origin);ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1021/jm501119j
risperidone;3331;None;72;Human;Binding;Ki;=;6,54;8,18;-7;71;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;None;72;Human;Binding;Ki;=;5,90;8,23;-7;71;Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;None;72;Human;Binding;Ki;=;0,60;9,22;-7;71;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
risperidone;3331;None;72;Human;Binding;Ki;=;6,17;8,21;-7;71;Displacement of [3H]spiperone from human cloned D2 receptor by in vitro binding assay;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1039/C1MD00202C
risperidone;3331;None;72;Human;Binding;Ki;=;6,40;8,19;-7;71;Inhibition of [3H]-spiperone binding to human Dopamine receptor D2;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1021/jm049632c
risperidone;3331;None;72;Human;Binding;Ki;=;2,20;8,66;-7;71;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://dx.doi.org/10.1016/j.bmc.2008.06.030
risperidone;3331;None;72;Human;Binding;pKi;=;8,49;8,07;-7;71;None;Drug Central;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;None;72;Human;Binding;pKi;=;-;9,36;-7;71;Unclassified;Guide to Pharmacology;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;https://pubmed.ncbi.nlm.nih.gov/9430133
risperidone;3331;3H-NMS;72;Human;Binding;pKi;=;2,70;8,57;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-RACLOPRIDE;72;Human;Binding;pKi;=;1,70;8,77;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;1,40;8,85;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-RACLOPRIDE;72;Human;Binding;pKi;=;1,00;9,00;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-NEMONAPRIDE;72;Human;Binding;pKi;=;19,00;7,72;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;4,00;8,40;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-NEMONAPRIDE;72;Human;Binding;pKi;=;27,00;7,57;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;3,77;8,42;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-NMSP;72;Human;Binding;pKi;=;4,90;8,31;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-RACLOPRIDE;72;Human;Binding;pKi;=;1,60;8,80;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;4,70;8,33;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-N-Methylspiperone;72;Human;Binding;pKi;=;2,14;8,67;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;6,20;8,21;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;UNDEFINED;72;Human;Binding;pKi;=;0,30;9,52;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;3,30;8,48;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;3,10;8,51;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;UNDEFINED;72;Human;Binding;pKi;=;0,30;9,52;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;R-SAT;72;Human;Binding;pKi;=;0,60;9,22;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-NMSP;72;Human;Binding;pKi;=;1,65;8,78;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;5,90;8,23;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-Methylspiperone;72;Human;Binding;pKi;=;2,70;8,57;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;6,40;8,19;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;0,30;9,52;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;UNDEFINED;72;Human;Binding;pKi;=;2,20;8,66;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;5,90;8,23;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;R-SAT;72;Human;Binding;pKi;=;0,30;9,52;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-SPIPERONE;72;Human;Binding;pKi;=;4,50;8,35;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
risperidone;3331;3H-NMSP;72;Human;Binding;pKi;=;6,50;8,19;-7;71;-;PDSP KiDatabase;410,2;4;0;6;3,59;Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2;-
ritanserin;3332;None;53;Human;Binding;Ki;=;184,04;6,74;-81;44;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;477,2;5;0;5;5,48;Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1;https://dx.doi.org/10.6019/CHEMBL5442175
ritanserin;3332;3H-YM 09151-2;53;Human;Binding;pKi;=;84,00;7,08;-81;44;-;PDSP KiDatabase;477,2;5;0;5;5,48;Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
ritanserin;3332;UNDEFINED;53;Human;Binding;pKi;=;10,00;8,00;-81;44;-;PDSP KiDatabase;477,2;5;0;5;5,48;Cc1nc2sccn2c(=O)c1CCN1CCC(=C(c2ccc(F)cc2)c2ccc(F)cc2)CC1;-
ROFECOXIB;15568;3H-NMSP;65;Human;Binding;pKi;=;10000,00;5,00;-1348;33;-;PDSP KiDatabase;314,1;3;0;4;2,56;CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1;-
ropinirole;3370;None;38;Human;Binding;AC50;=;7999,40;5,10;-3;33;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;https://dx.doi.org/10.1038/s41467-023-40064-9
ropinirole;3370;None;38;Human;Binding;EC50;=;30,00;7,52;-3;33;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
ropinirole;3370;None;38;Human;Binding;EC50;=;89,00;7,05;-3;33;Agonist activity at human D2SR expressed in HEK293 cells incubated for 5 hrs by beta-Arrestin 2 recruitment assay;ChEMBL;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;https://dx.doi.org/10.1016/j.bmc.2017.08.037
ropinirole;3370;None;38;Human;Binding;EC50;=;89,00;7,05;-3;33;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
ropinirole;3370;None;38;Human;Binding;EC50;=;6,46;8,19;-3;33;Agonist activity at dopamine D2 receptor short isoform (unknown origin) expressed in mouse NIH/3T3 cells by R-SAT assay;ChEMBL;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;-
ropinirole;3370;None;38;Human;Binding;Ki;=;3,70;8,43;-3;33;Binding affinity to human dopamine D2 receptor;ChEMBL;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;https://dx.doi.org/10.1039/C4MD00066H
ropinirole;3370;None;38;Human;Binding;Ki;=;7,20;8,14;-3;33;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;https://dx.doi.org/10.1021/jm960360q
ropinirole;3370;None;38;Human;Binding;Ki;=;691,83;6,16;-3;33;Displacement of [3H]spiperone form human cloned dopamine D2L receptor expressed in CHO cells;ChEMBL;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;https://dx.doi.org/10.1016/j.bmcl.2009.03.015
ropinirole;3370;None;38;Human;Binding;pKi;=;8,14;8,09;-3;33;None;Drug Central;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;-
ropinirole;3370;None;38;Human;Binding;pKi;=;-;8,14;-3;33;Unclassified;Guide to Pharmacology;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;https://pubmed.ncbi.nlm.nih.gov/9057850
ropinirole;3370;125I-IODOSULPRIDE;38;Human;Binding;pKi;=;676,08;6,17;-3;33;-;PDSP KiDatabase;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;-
ropinirole;3370;125I-IODOSULPRIDE;38;Human;Binding;pKi;=;676,08;6,17;-3;33;-;PDSP KiDatabase;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;-
ropinirole;3370;125I-IODOSULPRIDE;38;Human;Binding;pKi;=;933,25;6,03;-3;33;-;PDSP KiDatabase;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;-
ropinirole;3370;125I-IODOSULPRIDE;38;Human;Binding;pKi;=;933,25;6,03;-3;33;-;PDSP KiDatabase;260,2;7;1;2;3,50;CCCN(CCC)CCc1cccc2c1CC(O)=N2;-
rotigotine;3372;None;50;Human;Binding;AC50;=;121,60;6,92;5;21;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1038/s41467-023-40064-9
rotigotine;3372;None;50;Human;Binding;EC50;=;4,10;8,39;5;21;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
rotigotine;3372;None;50;Human;Binding;EC50;=;4,40;8,36;5;21;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
rotigotine;3372;None;50;Human;Binding;Ki;=;0,06;10,22;5;21;In vitro binding affinity at human Dopamine receptor D2 expressed in CHO K1 cells was measured by its ability to displace [3H]- N-0437;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm001015a
rotigotine;3372;None;50;Human;Binding;Ki;=;0,06;10,22;5;21;Binding affinity was evaluated by calculating competition for [3H]N-0437 binding on Dopamine receptor D2L of CHO K-1 cells;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
rotigotine;3372;None;50;Human;Binding;Ki;=;20,00;7,70;5;21;Binding affinity was evaluated by calculating competition for [3H]spiperone binding on Dopamine receptor D2L of CHO K-1 cells.;ChEMBL;315,2;6;1;3;4,27;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;https://dx.doi.org/10.1021/jm960345l
rotigotine;3372;None;50;Human;Binding;pKi;=;10,22;7,99;5;21;None;Drug Central;315,2;6;1;3;4,27;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;-
rotigotine;3372;None;50;Human;Binding;pKi;=;-;10,22;5;21;Unclassified;Guide to Pharmacology;315,2;6;1;3;4,27;CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1;https://pubmed.ncbi.nlm.nih.gov/12086487
roxindole;3373;None;19;Human;Binding;pKi;None;-;8,60;-19;23;Unclassified;Guide to Pharmacology;346,2;6;2;2;4,99;Oc1ccc2[nH]cc(CCCCN3CC=C(c4ccccc4)CC3)c2c1;https://pubmed.ncbi.nlm.nih.gov/12388666
roxindole;3373;None;19;Human;Binding;pKi;None;-;8,60;-19;23;Unclassified;Guide to Pharmacology;346,2;6;2;2;4,99;Oc1ccc2[nH]cc(CCCCN3CC=C(c4ccccc4)CC3)c2c1;https://pubmed.ncbi.nlm.nih.gov/12388666
roxindole;3373;125I-IODOSULPRIDE;19;Human;Binding;pKi;=;2,82;8,55;-19;23;-;PDSP KiDatabase;346,2;6;2;2;4,99;Oc1ccc2[nH]cc(CCCCN3CC=C(c4ccccc4)CC3)c2c1;-
roxindole;3373;125I-IODOSULPRIDE;19;Human;Binding;pKi;=;4,37;8,36;-19;23;-;PDSP KiDatabase;346,2;6;2;2;4,99;Oc1ccc2[nH]cc(CCCCN3CC=C(c4ccccc4)CC3)c2c1;-
RS 100235;3386;None;6;Human;Binding;Ki;=;316,23;6,50;-8912;12;Compound was evaluated for binding affinity against Dopamine D2 receptor using radioligand binding assay;ChEMBL;502,2;10;1;7;5,02;COc1ccc(CCCN2CCC(CCC(=O)c3cc(Cl)c(N)c4c3OCCO4)CC2)cc1OC;https://dx.doi.org/10.1016/0960-894X(95)00358-Z
RU 24926;218670;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;38,00;7,42;-5;2;-;PDSP KiDatabase;299,2;8;2;3;3,60;CCCN(CCc1cccc(O)c1)CCc1cccc(O)c1;-
RU 24926;218670;3H-thymidine;0;Human;Binding;pKi;=;1,20;8,92;-5;2;-;PDSP KiDatabase;299,2;8;2;3;3,60;CCCN(CCc1cccc(O)c1)CCc1cccc(O)c1;-
Ruthenium complex;133197;None;0;Human;Binding;Ki;=;43,00;7,37;-38;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 long expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
Ruthenium complex;133197;None;0;Human;Binding;Ki;=;12,00;7,92;-38;5;Inhibition of [3H]spiperone binding to human dopamine receptor D2 short expressed in Chinese hamster ovary cells;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1021/jm050170s
S(+)-niguldipine;3634;None;20;Human;Binding;Ki;=;279,64;6,55;-741;37;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;609,3;10;1;8;6,02;COC(=O)C1=C(C)NC(C)=C(C(=O)OCCCN2CCC(c3ccccc3)(c3ccccc3)CC2)[C@H]1c1cccc([N+](=O)[O-])c1;https://dx.doi.org/10.6019/CHEMBL5442175
S-15535;3430;3H-8-OH-DPAT;34;Human;Binding;pKi;=;132,00;6,88;-74;7;-;PDSP KiDatabase;336,2;2;0;4;2,75;c1ccc2c(c1)CC(N1CCN(c3cccc4c3OCCO4)CC1)C2;-
S33084;3440;None;11;Human;Binding;Ki;=;31,62;7,50;-112;9;Ability to displace [125I]iodosulpiride from human dopamine D2 (hD2) receptor transfected into CHO cells.;ChEMBL;451,2;7;1;4;4,84;N#Cc1ccc2c(c1)[C@H]1CN(CCCCNC(=O)c3ccc(-c4ccccc4)cc3)C[C@@H]1CO2;https://dx.doi.org/10.1016/s0960-894x(99)00312-1
salmeterol;3463;None;53;Human;Binding;AC50;=;7200,00;5,14;-100;27;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;415,3;16;4;5;4,11;OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O;https://dx.doi.org/10.1038/s41467-023-40064-9
salmeterol;3463;None;53;Human;Binding;Ki;=;32000,00;4,50;-100;27;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;ChEMBL;415,3;16;4;5;4,11;OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O;https://dx.doi.org/10.1016/j.bmc.2016.04.028
salmeterol;3463;None;53;Human;Binding;pKi;=;4,50;8,35;-100;27;Displacement of [3H]spiperone from human D2S receptor expressed in CHO cells;Drug Central;415,3;16;4;5;4,11;OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O;-
salvinorin A;3464;3H-NMSP;24;Human;Binding;pKi;=;10000,00;5,00;-2344;41;-;PDSP KiDatabase;432,2;3;0;8;3,00;COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C;-
SAQUINAVIR;9838;None;41;Human;Binding;AC50;=;10000,00;5,00;-;11;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;670,4;12;5;7;3,09;CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1;https://dx.doi.org/10.1038/s41467-023-40064-9
SB 204070;3490;3H-IODOSULPIRIDE;23;Human;Binding;pKi;=;10000,00;5,00;-371535;23;-;PDSP KiDatabase;382,2;6;1;6;3,36;CCCCN1CCC(COC(=O)c2cc(Cl)c(N)c3c2OCCO3)CC1;-
SB 204741;3491;UNDEFINED;49;Human;Binding;pKi;=;10000,00;5,00;-478;16;-;PDSP KiDatabase;286,1;2;2;4;3,59;Cc1cc(NC(=O)Nc2ccc3c(ccn3C)c2)sn1;-
SB 206553;3492;125H-IODOSULPRIDE;32;Human;Binding;pKi;=;10000,00;5,00;-4168;19;-;PDSP KiDatabase;292,1;1;1;3;3,17;Cn1ccc2cc3c(cc21)CCN3C(=O)Nc1cccnc1;-
SB 258719;3510;None;28;Human;Binding;Ki;=;3981,00;5,40;-125;5;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;338,2;6;0;3;3,13;Cc1cccc(S(=O)(=O)N(C)[C@H](C)CCN2CCC(C)CC2)c1;https://dx.doi.org/10.1021/jm0108505
SB 258719;3510;None;28;Human;Binding;Ki;=;3981,07;5,40;-125;5;The compound was tested for its binding affinity towards cloned human Dopamine receptor D2 in CHO cells using [125I]iodosulpiride.;ChEMBL;338,2;6;0;3;3,13;Cc1cccc(S(=O)(=O)N(C)[C@H](C)CCN2CCC(C)CC2)c1;https://dx.doi.org/10.1021/jm970519e
SB 271046;3513;None;37;Human;Binding;Ki;=;460,00;6,34;-724;24;Displacement of [3H]spiperone from human cloned dopamine D2 receptor;ChEMBL;451,1;5;2;6;4,08;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1;https://dx.doi.org/10.1016/j.bmcl.2007.11.045
SB 271046;3513;None;37;Human;Binding;Ki;=;2511,89;5,60;-724;24;Compound was tested for its binding affinity against Dopamine receptor D2 in human cloned receptors in CHO cells using [125 I]iodosulpride;ChEMBL;451,1;5;2;6;4,08;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1;https://dx.doi.org/10.1021/jm980532e
SB 271046;3513;None;37;Human;Binding;Ki;=;2511,89;5,60;-724;24;The compound was tested for the binding affinity towards human cloned Dopamine receptor D2 in CHO cells, using [125I]iodosulpride as radioligand;ChEMBL;451,1;5;2;6;4,08;COc1ccc(NS(=O)(=O)c2sc3ccc(Cl)cc3c2C)cc1N1CCNCC1;https://dx.doi.org/10.1016/s0960-894x(02)00172-5
SB 277011-A;3515;None;36;Human;Binding;Ki;=;501,19;6,30;-112;7;Displacement of [125I]-7-OH-PIPAT from rat brain dopamine D2 receptor after 45 mins by microplate scintillation counting analysis;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2015.12.081
SB 277011-A;3515;None;36;Human;Binding;Ki;=;398,11;6,40;-112;7;Binding affinity to human DRD2 receptor by GTPgammaS binding assay;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1016/j.bmcl.2009.07.055
SB 277011-A;3515;None;36;Human;Binding;Ki;=;1000,00;6,00;-112;7;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1021/jm000090i
SB 277011-A;3515;None;36;Human;Binding;Ki;=;489,78;6,31;-112;7;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes coexpressing Galpha16 after 120 mins by liquid scintillation counting;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1021/acs.jmedchem.6b00972
SB 277011-A;3515;None;36;Human;Binding;Ki;=;1000,00;6,00;-112;7;Binding affinity towards human Dopamine receptor D2 by displacement of [125I]iodosulpiride expressed in CHO cells;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1016/s0960-894x(00)00505-9
SB 277011-A;3515;None;36;Human;Binding;Ki;=;1000,00;6,00;-112;7;Displacement of [125I]iodosulpiride from human Dopamine receptor D2 expressed in CHO cells;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1016/s0960-894x(01)00037-3
SB 277011-A;3515;None;36;Human;Binding;Ki;=;5160,00;5,29;-112;7;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
SB 277011-A;3515;None;36;Human;Binding;Ki;=;1050,00;5,98;-112;7;Inhibition of [125I]iodosulpiride binding to human Dopamine D2L receptor expressed in CHO cells;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1021/jm040190e
SB 277011-A;3515;None;36;Human;Binding;Ki;=;501,19;6,30;-112;7;Displacement of [3H]-spiperone from human dopamine D2 receptor expressed in CHO-K1 cell membranes after 120 mins by liquid scintillation counter method;ChEMBL;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CC[C@H]1CC[C@H](NC(=O)c3ccnc4ccccc34)CC1)C2;https://dx.doi.org/10.1016/j.bmc.2016.02.031
SB 649915;3531;None;14;Human;Binding;Ki;=;1258,93;5,90;-1000;9;Displacement of [125I]iodosulpiride from human cloned D2 receptor expressed in CHO cells;ChEMBL;431,2;6;1;5;4,21;Cc1ccc2c(OCCN3CCC(Cc4ccc5c(c4)NC(=O)CO5)CC3)cccc2n1;https://dx.doi.org/10.1016/j.bmcl.2006.11.031
SB 699551;3534;None;21;Human;Binding;Ki;=;1258,93;5,90;-199;13;Binding affinity towards human dopamine receptor D2 expressed in CHO cells using the radioligand [125I]iodosulpiride;ChEMBL;511,4;14;1;3;6,55;CN(C)CCN(Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)C(=O)CCC1CCCC1;https://dx.doi.org/10.1016/j.bmcl.2005.06.024
SB 714786;3536;None;27;Human;Binding;Ki;=;3162,28;5,50;-3981;12;Binding affinity for human dopamine receptor D2;ChEMBL;412,2;6;0;5;4,29;Cc1ccc2c(OCCN3CCN(Cc4cccc5cccnc45)CC3)cccc2n1;https://dx.doi.org/10.1021/jm049039v
SB-258741;18002;None;4;Human;Binding;Ki;=;1584,89;5,80;-512;7;Binding affinity towards Dopamine receptor D2. (human cloned receptor) in CHO cells using [125I]iodosulpiride radioligand.;ChEMBL;350,2;5;0;3;3,27;Cc1cccc(S(=O)(=O)N2CCC[C@@H]2CCN2CCC(C)CC2)c1;https://dx.doi.org/10.1021/jm991151j
SB-277011-A;218701;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;1047,12;5,98;-97;15;-;PDSP KiDatabase;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CCC1CCC(NC(=O)c3ccnc4ccccc34)CC1)C2;-
SB-277011-A;218701;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;1050,00;5,98;-97;15;-;PDSP KiDatabase;438,2;5;1;4;4,84;N#Cc1ccc2c(c1)CCN(CCC1CCC(NC(=O)c3ccnc4ccccc34)CC1)C2;-
SB-282241;3516;None;4;Human;Binding;Ki;=;15,85;7,80;-5;13;Binding affinity for Dopamine receptor D2 was determined;ChEMBL;499,2;9;3;3;6,36;O=C(/C=C/c1ccc(Cl)c(Cl)c1)NCCCCCN1CCC(c2c[nH]c3ccc(O)cc23)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00397-3
SB-408124;3522;None;58;Human;Binding;Ki;=;9765,62;5,01;-316;6;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;356,1;3;2;3;4,53;Cc1cc(NC(=O)Nc2ccc(N(C)C)cc2)c2cc(F)cc(F)c2n1;https://dx.doi.org/10.6019/CHEMBL5442175
SB269652;3511;None;30;Human;Binding;Ki;=;485,00;6,31;-112;4;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in HEK293 cell membranes after 1 hr by liquid scintillation counting analysis;ChEMBL;426,2;5;2;3;4,78;N#Cc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)c3cc4ccccc4[nH]3)CC1)CC2;https://dx.doi.org/10.1021/acs.jmedchem.6b01688
SB269652;3511;None;30;Human;Binding;Ki;=;100,00;7,00;-112;4;Binding affinity for human Dopamine receptor D2 expressed in CHO cells;ChEMBL;426,2;5;2;3;4,78;N#Cc1ccc2c(c1)CN(CC[C@H]1CC[C@H](NC(=O)c3cc4ccccc4[nH]3)CC1)CC2;https://dx.doi.org/10.1021/jm000090i
SB269970;3512;None;28;Human;Binding;Ki;=;316,23;6,50;-234;18;Binding affinity towards Dopamine receptor D2 (human cloned receptor) in CHO cells using [125I]iodosulpiride radioligand.;ChEMBL;352,2;5;1;4;2,67;CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1;https://dx.doi.org/10.1021/jm991151j
SB269970;3512;None;28;Human;Binding;Ki;=;316,00;6,50;-234;18;Displacement of [3H]raclopride from human dopamine receptor D2A expressed in mouse Ltk cells;ChEMBL;352,2;5;1;4;2,67;CC1CCN(CC[C@H]2CCCN2S(=O)(=O)c2cccc(O)c2)CC1;https://dx.doi.org/10.1021/jm0108505
SCH-23390;3549;125I-IODOSULPRIDE;8;Human;Binding;pKi;=;520,00;6,28;-239;9;-;PDSP KiDatabase;287,1;1;1;2;3,67;CN1CCc2cc(Cl)c(O)cc2C(c2ccccc2)C1;-
SCH-23390;3549;3H-YM 09151-2;8;Human;Binding;pKi;=;431,00;6,37;-239;9;-;PDSP KiDatabase;287,1;1;1;2;3,67;CN1CCc2cc(Cl)c(O)cc2C(c2ccccc2)C1;-
SCH-23390;205211;None;16;Human;Binding;Ki;=;1000,00;6,00;-4786;35;Binding affinity to dopamine D2 receptor;ChEMBL;287,1;1;1;2;3,67;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccccc2)C1;https://dx.doi.org/10.1016/j.bmcl.2009.12.100
SCH-23390;205211;None;16;Human;Binding;Ki;=;891,25;6,05;-4786;35;Binding potency of compound for Dopamine receptor D2 by displacement of [3H]spiperone;ChEMBL;287,1;1;1;2;3,67;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccccc2)C1;https://dx.doi.org/10.1021/jm00129a006
SCH-23390;205211;3H-SPIPERONE;16;Human;Binding;pKi;=;913,00;6,04;-4786;35;-;PDSP KiDatabase;287,1;1;1;2;3,67;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccccc2)C1;-
SCH-23390;205211;3H-domperidone;16;Human;Binding;pKi;=;2145,00;5,67;-4786;35;-;PDSP KiDatabase;287,1;1;1;2;3,67;CN1CCc2cc(Cl)c(O)cc2[C@@H](c2ccccc2)C1;-
SCOULERINE;16505;None;34;Human;Binding;Ki;=;214,00;6,67;-9;2;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;327,1;2;2;5;2,77;COc1cc2c(cc1O)[C@@H]1Cc3ccc(OC)c(O)c3CN1CC2;https://dx.doi.org/10.1016/j.bmc.2012.12.016
SDZ-HDC-912;218717;3H-YM 09151-2;0;Human;Binding;pKi;=;0,90;9,05;3;2;-;PDSP KiDatabase;359,2;1;2;2;3,70;CN1CC(NC(=O)C(C)(C)C)CC2c3cccc4[nH]c(Cl)c(c34)CC21;-
sertindole;3590;None;59;Human;Binding;AC50;=;140,00;6,85;-5;56;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
sertindole;3590;None;59;Human;Binding;Ki;=;0,38;9,42;-5;56;Binding affinity to dopamine D2 receptor (unknown origin) assessed as inhibition constant;ChEMBL;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1039/d3md00677h
sertindole;3590;None;59;Human;Binding;Ki;=;0,45;9,35;-5;56;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;ChEMBL;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1021/jm100652h
sertindole;3590;None;59;Human;Binding;Ki;=;0,45;9,35;-5;56;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in CHO cells after 30 mins by scintillation counting analysis;ChEMBL;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1016/j.bmc.2012.10.049
sertindole;3590;None;59;Human;Binding;Ki;=;7,40;8,13;-5;56;Binding affinity towards human Dopamine receptor D2;ChEMBL;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;https://dx.doi.org/10.1021/jm030480f
sertindole;3590;None;59;Human;Binding;pKi;=;9,35;8,03;-5;56;Displacement of [3H]prozosin from human cloned dopamine D2 receptor expressed in CHO cells;Drug Central;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;None;59;Human;Binding;pKi;=;-;8,48;-5;56;Unclassified;Guide to Pharmacology;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;https://pubmed.ncbi.nlm.nih.gov/12176106
sertindole;3590;None;59;Human;Binding;pKi;=;-;8,48;-5;56;Unclassified;Guide to Pharmacology;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;https://pubmed.ncbi.nlm.nih.gov/12629531
sertindole;3590;3H-SPIPERONE;59;Human;Binding;pKi;=;7,00;8,15;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-SPIPERONE;59;Human;Binding;pKi;=;0,95;9,02;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-Methylspiperone;59;Human;Binding;pKi;=;6,55;8,18;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-NEMONAPRIDE;59;Human;Binding;pKi;=;8,20;8,09;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-RACLOPRIDE;59;Human;Binding;pKi;=;0,62;9,21;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;R-SAT;59;Human;Binding;pKi;=;2,00;8,70;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-RACLOPRIDE;59;Human;Binding;pKi;=;1,20;8,92;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-SPIPERONE;59;Human;Binding;pKi;=;5,80;8,24;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-SPIPERONE;59;Human;Binding;pKi;=;6,50;8,19;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;R-SAT;59;Human;Binding;pKi;=;2,70;8,57;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-SPIPERONE;59;Human;Binding;pKi;=;2,70;8,57;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;UNDEFINED;59;Human;Binding;pKi;=;1,60;8,80;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-NMSP;59;Human;Binding;pKi;=;9,10;8,04;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-SPIPERONE;59;Human;Binding;pKi;=;7,00;8,15;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
sertindole;3590;3H-Sertindole;59;Human;Binding;pKi;=;2,60;8,59;-5;56;-;PDSP KiDatabase;440,2;5;1;3;4,63;O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1;-
SERTRALINE;207985;None;33;Human;Binding;AC50;=;10999,90;4,96;-1445;38;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;305,1;2;1;1;5,18;CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21;https://dx.doi.org/10.1038/s41467-023-40064-9
SERTRALINE;207985;3H-SPIPERONE;33;Human;Binding;pKi;=;10000,00;5,00;-1445;38;-;PDSP KiDatabase;305,1;2;1;1;5,18;CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21;-
SIBENADET;208197;None;20;Human;Binding;IC50;=;100,00;7,00;-;3;Binding affinity to dopamine 2 receptor;ChEMBL;464,1;13;3;8;2,90;O=S(=O)(CCCOCCc1ccccc1)CCNCCc1ccc(O)c2nc(O)sc12;https://dx.doi.org/10.1016/j.bmcl.2011.05.097
silodosin;3607;None;59;Human;Binding;Ki;=;989,13;6,00;-1862;20;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;495,2;13;3;6;3,07;C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F;https://dx.doi.org/10.6019/CHEMBL5442175
SIROLIMUS;161721;None;39;Human;Binding;AC50;=;980,00;6,01;-;8;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;913,6;6;3;13;6,18;CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C;https://dx.doi.org/10.1038/s41467-023-40064-9
SKF-38393;3613;None;17;Human;Binding;Ki;=;8800,00;5,06;-165;17;The compound was evaluated for the binding affinity towards Dopamine receptor D2 at low affinity state;ChEMBL;255,1;1;3;3;2,38;Oc1cc2c(cc1O)C(c1ccccc1)CNCC2;https://dx.doi.org/10.1021/jm00116a004
SKF-38393;3613;None;17;Human;Binding;Ki;=;160,00;6,80;-165;17;The compound was evaluated for the binding affinity towards Dopamine receptor D2 at high affinity state;ChEMBL;255,1;1;3;3;2,38;Oc1cc2c(cc1O)C(c1ccccc1)CNCC2;https://dx.doi.org/10.1021/jm00116a004
SKF-38393;3613;3H-SPIPERONE;17;Human;Binding;pKi;=;4670,00;5,33;-165;17;-;PDSP KiDatabase;255,1;1;3;3;2,38;Oc1cc2c(cc1O)C(c1ccccc1)CNCC2;-
SKF-38393;3613;3H-YM 09151-2;17;Human;Binding;pKi;=;10000,00;5,00;-165;17;-;PDSP KiDatabase;255,1;1;3;3;2,38;Oc1cc2c(cc1O)C(c1ccccc1)CNCC2;-
SKF-75670;3614;None;1;Human;Binding;Ki;=;1900,00;5,72;-954;3;The compound was evaluated for the binding affinity towards dopamine receptor D2 at high affinity state.;ChEMBL;269,1;1;2;3;2,72;CN1CCc2cc(O)c(O)cc2C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
SKF-81297;3616;None;23;Human;Binding;Ki;=;310,00;6,51;-1479;10;The compound was evaluated for the binding affinity towards dopamine receptor D2 at high affinity state.;ChEMBL;289,1;1;3;3;3,03;Oc1cc2c(c(Cl)c1O)CCNCC2c1ccccc1;https://dx.doi.org/10.1021/jm00116a004
SKF-81297;3616;None;23;Human;Binding;Ki;=;8000,00;5,10;-1479;10;The compound was evaluated for the binding affinity towards dopamine receptor D2 at low affinity state.;ChEMBL;289,1;1;3;3;3,03;Oc1cc2c(c(Cl)c1O)CCNCC2c1ccccc1;https://dx.doi.org/10.1021/jm00116a004
SKF-81297;3616;3H-YM 09151-2;23;Human;Binding;pKi;=;10000,00;5,00;-1479;10;-;PDSP KiDatabase;289,1;1;3;3;3,03;Oc1cc2c(c(Cl)c1O)CCNCC2c1ccccc1;-
SKF-82958;3617;None;24;Human;Binding;Ki;=;1300,00;5,89;-46;7;The compound was evaluated for the binding affinity towards Dopamine receptor D2 at low affinity state;ChEMBL;329,1;3;2;3;3,93;C=CCN1CCc2c(cc(O)c(O)c2Cl)C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
SKF-82958;3617;None;24;Human;Binding;Ki;=;55,00;7,26;-46;7;The compound was evaluated for the binding affinity towards Dopamine receptor D2 at high affinity state.;ChEMBL;329,1;3;2;3;3,93;C=CCN1CCc2c(cc(O)c(O)c2Cl)C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00116a004
SKF-82958;3617;3H-YM 09151-2;24;Human;Binding;pKi;=;136,00;6,87;-46;7;-;PDSP KiDatabase;329,1;3;2;3;3,93;C=CCN1CCc2c(cc(O)c(O)c2Cl)C(c2ccccc2)C1;-
SKF-83566;3618;None;30;Human;Binding;Ki;=;1360,00;5,87;-2511;15;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;331,1;1;1;2;3,77;CN1CCc2cc(Br)c(O)cc2C(c2ccccc2)C1;https://dx.doi.org/10.1021/jm00115a012
SNAP-7941;3632;None;13;Human;Binding;Ki;=;2800,00;5,55;-10232;4;Displacement of [3H]spiperone from human recombinant dopamine D2 receptor;ChEMBL;613,3;10;3;7;4,04;COCC1=C(C(=O)OC)[C@H](c2ccc(F)c(F)c2)N(C(=O)NCCCN2CCC(c3cccc(NC(C)=O)c3)CC2)C(=O)N1;https://dx.doi.org/10.1021/jm060383x
sonepiprazole;3638;None;36;Human;Binding;Ki;=;5147,00;5,29;-1621;4;Inhibition of human dopamine D2 receptor;ChEMBL;401,2;5;1;5;2,16;NS(=O)(=O)c1ccc(N2CCN(CC[C@@H]3OCCc4ccccc43)CC2)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b00151
spiperone;3653;None;40;Human;Binding;AC50;=;0,40;9,40;-5;69;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
spiperone;3653;None;40;Human;Binding;IC50;=;1,27;8,90;-5;69;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2012.05.057
spiperone;3653;None;40;Human;Binding;IC50;=;2,56;8,59;-5;69;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;None;40;Human;Binding;IC50;=;0,25;9,60;-5;69;Displacement of [3H]Spiperone from human recombinant dopamine D2S receptor expressed in CHO cells after 2 hrs;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2013.01.025
spiperone;3653;None;40;Human;Binding;Kd;=;0,16;9,80;-5;69;Binding affinity to dopamine D2 receptor in human brain caudate nucleus;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2016.06.011
spiperone;3653;None;40;Human;Binding;Ki;=;0,09;10,05;-5;69;Displacement of [3H]Spiperone from human recombinant dopamine D2S receptor expressed in CHO cells after 2 hrs;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2013.01.025
spiperone;3653;None;40;Human;Binding;Ki;=;0,50;9,30;-5;69;"Reception Binding Assay: Different concentrations (10^−5 M-10^−11 M) of the compound of the invention and corresponding isotope receptor ligand as well as receptor protein were loaded into the reaction tube and incubated in 30° C. water bath for 60 minutes. The reaction was terminated in a refrigerator. The reaction mixture was put in a Millipore filter (millipore) cell sample collector, filtered through suction filtration using GF/C glass fiber filter paper, and dried. The resulting sample was placed into 0.5 mL tube. 500 μL liquid scintillation fluid was added and intensity of radioactivity was determined by counting. For dopamine D1 receptor: isotope receptor ligands [3H] SCH23390 (85.0 Ci/mmol) (D1-selective, purchased from Amersham Corporation), D1 receptor protein expressed in HEK-293 cells; For D2 dopamine receptor: isotope receptor ligands [3H] Spiperone (77.0 Ci/mmol) (D2-selective, purchased from Amersham Corporation); D2 receptor protein expressed in HEK-293 cells; For 5-HT1A receptor: isotope receptor ligands [3H] 8-OH-DPAT; 5-HT1A receptor protein expressed in HEK-293 cells; For 5-HT2A receptor: isotope receptor ligands [3H]-Ketanserin; 5-HT2A receptor protein expressed in HEK-293 cells.";ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;None;40;Human;Binding;Ki;=;0,44;9,36;-5;69;Displacement of [3H]spiperone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2008.05.077
spiperone;3653;None;40;Human;Binding;Ki;=;0,12;9,92;-5;69;Binding affinity for human dopamine receptor D2 long;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm049612a
spiperone;3653;None;40;Human;Binding;Ki;=;1,08;8,97;-5;69;Displacement of [3H]-spiperone from dopamine D2 receptor (unknown origin) expressed in HEK293 cell membranes incubated for 15 mins by liquid scintillation spectrometry;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmcl.2015.07.030
spiperone;3653;None;40;Human;Binding;Ki;=;0,20;9,70;-5;69;Tested for binding affinity against dopamine receptor D2;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00069a010
spiperone;3653;None;40;Human;Binding;Ki;=;1,20;8,92;-5;69;Displacement of [3H]spiperone from dopamine D2 receptor (unknown origin) expressed in human HEK293 cells by liquid scintillation counter;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2012.12.016
spiperone;3653;None;40;Human;Binding;Ki;=;0,06;10,22;-5;69;Displacement of [125I]ABN from human dopamine D2 long receptor expressed in HEK293 cell membranes after 60 mins by scintillation counting method;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1021/acs.jmedchem.7b01248
spiperone;3653;None;40;Human;Binding;Ki;=;0,10;10,00;-5;69;Displacement of [3H]sulpiride from dopamine D2 receptor;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1021/np50094a001
spiperone;3653;None;40;Human;Binding;Ki;=;0,28;9,55;-5;69;Displacement of [3H]Spiprone from human dopamine D2 receptor expressed in HEK293 cells;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1016/j.bmc.2012.05.057
spiperone;3653;None;40;Human;Binding;Ki;=;0,06;10,22;-5;69;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;ChEMBL;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;https://dx.doi.org/10.1021/jm00115a012
spiperone;3653;None;40;Human;Binding;pKi;=;10,22;7,99;-5;69;Binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand in caudate-putamen of monkey;Drug Central;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-NEMONAPRIDE;40;Human;Binding;pKi;=;0,13;9,89;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-SPIPERONE;40;Human;Binding;pKi;=;0,28;9,55;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;UNDEFINED;40;Human;Binding;pKi;=;0,44;9,36;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-YM 09151-2;40;Human;Binding;pKi;=;0,10;10,00;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-SPIPERONE;40;Human;Binding;pKi;=;0,05;10,28;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-RACLOPRIDE;40;Human;Binding;pKi;=;0,03;10,52;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;R-SAT;40;Human;Binding;pKi;=;0,30;9,52;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;UNDEFINED;40;Human;Binding;pKi;=;0,16;9,80;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-SPIPERONE;40;Human;Binding;pKi;=;0,03;10,52;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;125I-Epidepride;40;Human;Binding;pKi;=;0,08;10,10;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-SPIPERONE;40;Human;Binding;pKi;=;0,16;9,80;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-SPIPERONE;40;Human;Binding;pKi;=;0,06;10,22;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;125I-Epidepride;40;Human;Binding;pKi;=;0,07;10,15;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-S-Sulpiride;40;Human;Binding;pKi;=;0,39;9,41;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;125I-Epidepride;40;Human;Binding;pKi;=;0,06;10,22;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;R-SAT;40;Human;Binding;pKi;=;0,03;10,52;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;125I-Epidepride;40;Human;Binding;pKi;=;0,05;10,30;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;125I-Epidepride;40;Human;Binding;pKi;=;0,07;10,15;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-domperidone;40;Human;Binding;pKi;=;0,12;9,90;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiperone;3653;3H-SPIPERONE;40;Human;Binding;pKi;=;0,05;10,30;-5;69;-;PDSP KiDatabase;395,2;6;1;4;3,22;O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1;-
spiramide;3655;None;35;Human;Binding;Ki;=;9,62;8,02;-1;26;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;383,2;6;1;4;3,02;O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccc(F)cc1)CC2;https://dx.doi.org/10.6019/CHEMBL5442175
spiramide;3655;None;35;Human;Binding;Ki;=;3,00;8,52;-1;26;Tested for binding affinity against dopamine receptor D2;ChEMBL;383,2;6;1;4;3,02;O=C1NCN(c2ccccc2)C12CCN(CCCOc1ccc(F)cc1)CC2;https://dx.doi.org/10.1021/jm00069a010
spiroxatrine;3656;None;31;Human;Binding;Ki;=;6,71;8,17;-21;26;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;379,2;3;1;5;2,25;O=C1NCN(c2ccccc2)C12CCN(CC1COc3ccccc3O1)CC2;https://dx.doi.org/10.6019/CHEMBL5442175
SR-144528;140794;UNDEFINED;4;Human;Binding;pKi;=;10000,00;5,00;-89125;37;-;PDSP KiDatabase;475,2;5;1;3;6,81;Cc1ccc(Cn2nc(C(=O)NC3C4(C)CCC(C4)C3(C)C)cc2-c2ccc(Cl)c(C)c2)cc1;-
SULCONAZOLE;15583;None;40;Human;Binding;AC50;=;23999,90;4,62;-;18;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;396;6;0;3;6,52;Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1;https://dx.doi.org/10.1038/s41467-023-40064-9
sulforidazine;218934;None;0;Human;Binding;pKi;=;9,61;8,02;3;2;None;Drug Central;402,1;4;0;5;4,57;CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)(=O)=O)cc21;-
sulforidazine;218934;R-SAT;0;Human;Binding;pKi;=;0,30;9,52;3;2;-;PDSP KiDatabase;402,1;4;0;5;4,57;CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)(=O)=O)cc21;-
sulforidazine;218934;R-SAT;0;Human;Binding;pKi;=;0,20;9,70;3;2;-;PDSP KiDatabase;402,1;4;0;5;4,57;CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)(=O)=O)cc21;-
SULPIRIDE,(-);218439;3H-SPIPERONE;0;Human;Binding;pKi;=;10,00;8,00;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;520,00;6,28;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-RACLOPRIDE;0;Human;Binding;pKi;=;5450,00;5,26;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-NEMONAPRIDE;0;Human;Binding;pKi;=;20,00;7,70;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-S-Sulpiride;0;Human;Binding;pKi;=;20,00;7,70;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-SPIPERONE;0;Human;Binding;pKi;=;46,00;7,34;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;10,00;8,00;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-SPIPERONE;0;Human;Binding;pKi;=;1200,00;5,92;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-SPIPERONE;0;Human;Binding;pKi;=;684,00;6,16;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-SPIPERONE;0;Human;Binding;pKi;=;31,00;7,51;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-S-Sulpiride;0;Human;Binding;pKi;=;300,00;6,52;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-RACLOPRIDE;0;Human;Binding;pKi;=;46,00;7,34;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-SPIPERONE;0;Human;Binding;pKi;=;38,00;7,42;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;6,00;8,22;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;UNDEFINED;0;Human;Binding;pKi;=;5,00;8,30;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-RACLOPRIDE;0;Human;Binding;pKi;=;8,00;8,10;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;3H-SPIPERONE;0;Human;Binding;pKi;=;31,00;7,51;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULPIRIDE,(-);218439;UNDEFINED;0;Human;Binding;pKi;=;5,00;8,30;-3;12;-;PDSP KiDatabase;341,1;6;2;5;0,56;CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC;-
SULTOPRIDE;98790;None;31;Human;Binding;AC50;=;11,00;7,96;-1;7;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;354,2;7;1;5;1,70;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
SULTOPRIDE;98790;None;31;Human;Binding;Ki;=;6,31;8,20;-1;7;Binding affinity towards human Dopamine receptor D2 expressed in CHO cells by [125I]iodosulpiride displacement.;ChEMBL;354,2;7;1;5;1,70;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC;https://dx.doi.org/10.1016/0960-894X(96)00202-8
SULTOPRIDE;98790;None;31;Human;Binding;pKi;=;8,57;8,07;-1;7;None;Drug Central;354,2;7;1;5;1,70;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC;-
SULTOPRIDE;98790;R-SAT;31;Human;Binding;pKi;=;4,50;8,35;-1;7;-;PDSP KiDatabase;354,2;7;1;5;1,70;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC;-
SULTOPRIDE;98790;R-SAT;31;Human;Binding;pKi;=;1,60;8,80;-1;7;-;PDSP KiDatabase;354,2;7;1;5;1,70;CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)ccc1OC;-
sumanirole;3706;None;25;Human;Binding;EC50;=;543,30;6,26;1;4;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused Galphai1/GFP10-fused Ggamma2 by BRET assay;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
sumanirole;3706;None;25;Human;Binding;EC50;=;60,10;7,22;1;4;Agonist activity at human D2 receptor transfected in HEK293T cells by BRET based G0 activation assay;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
sumanirole;3706;None;25;Human;Binding;EC50;=;64,70;7,19;1;4;Agonist activity at recombinant human D2 receptor expressing in CHOp cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation after 24 hrs by scintillation spectrometry;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
sumanirole;3706;None;25;Human;Binding;EC50;=;4,60;8,34;1;4;Agonist activity at recombinant human D2 receptor expressing in CHO cells assessed as receptor mediated stimulation of mitogenesis measured as [3H]thymidine incorporation by beta plate counter;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
sumanirole;3706;None;25;Human;Binding;EC50;=;74,80;7,13;1;4;Agonist activity at human dopamine D2 receptor expressed in HEK293 cells coexpressing renilla luciferase-fused GalphaoA/GFP10-fused Ggamma2 by BRET assay;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
sumanirole;3706;None;25;Human;Binding;EC50;=;501,20;6,30;1;4;Agonist activity at renilla luciferase-tagged human dopamine D2 receptor expressed in HEK293 cells coexpressing mVenus-fused beta-arrestin 2 assessed as induction of beta-arrestin 2 recruitment by BRET assay;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
sumanirole;3706;None;25;Human;Binding;Ki;=;16300,00;4,79;1;4;Displacement of [3H]N-methylspiperone from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
sumanirole;3706;None;25;Human;Binding;Ki;=;46,30;7,33;1;4;Displacement of [3H]-(R)-(+)-7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes after 90 mins by micro beta scintillation counting analysis;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.6b01875
sumanirole;3706;None;25;Human;Binding;Ki;=;80,60;7,09;1;4;Displacement of [3H]-(R)-(+)7-OH-DPAT from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
sumanirole;3706;None;25;Human;Binding;Ki;=;9,00;8,05;1;4;Binding affinity towards Dopamine receptor D2 by displacement of [3H]U-86170.;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/jm960360q
sumanirole;3706;None;25;Human;Binding;Ki;=;17,10;7,77;1;4;Displacement of [3H]7-OH-DPAT from human D2 receptor transfected in HEK293 cells measured after 60 mins by liquid scintillation counter;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.5b01612
sumanirole;3706;None;25;Human;Binding;Ki;=;16300,00;4,79;1;4;Displacement of [3H]-methylscopolamine from human dopamine D2 receptor expressed in HEK293 cell membranes incubated for 90 mins by microbeta scintillation counting analysis;ChEMBL;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://dx.doi.org/10.1021/acs.jmedchem.1c01433
sumanirole;3706;None;25;Human;Binding;pKi;=;-;8,10;1;4;Unclassified;Guide to Pharmacology;203,1;1;2;3;0,47;CN[C@@H]1Cc2cccc3[nH]c(=O)n(c23)C1;https://pubmed.ncbi.nlm.nih.gov/15980060
SUNITINIB;194838;None;50;Human;Binding;AC50;=;1148,90;5,94;-;37;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;398,2;7;3;3;3,33;CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C;https://dx.doi.org/10.1038/s41467-023-40064-9
T3-CLK-N;216491;None;5;Human;Binding;Ki;=;2344,23;5,63;-2;20;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1;https://dx.doi.org/10.6019/CHEMBL4507307
T3-CLK-N;216491;None;5;Human;Binding;Ki;=;2752,36;5,56;-2;20;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1;https://dx.doi.org/10.6019/CHEMBL4507307
T3-CLK-N;216491;None;5;Human;Binding;Ki;=;2752,00;5,56;-2;20;Selectivity interaction (GPCR panel (PDSP screen)) EUB0000705a DRD2;ChEMBL;-;-;-;-;-;CN1CCN(C(=O)C(C)(C)c2ccc(C(=O)Nc3cn4cc(-c5cc(C(C)(C)C)cc(C(C)(C)C)c5)ccc4n3)cc2)CC1;https://dx.doi.org/10.6019/CHEMBL5212743
TALIPEXOLE;98934;None;37;Human;Binding;AC50;=;29000,10;4,54;-5;25;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;209,1;2;1;4;1,31;C=CCN1CCc2nc(N)sc2CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
TALIPEXOLE;98934;None;37;Human;Binding;Ki;=;616,60;6,21;-5;25;Displacement of [125I]iodosupride from human recombinant dopamine D2S receptor expressed in CHO cells incubated for 30 mins by competitive radioligand binding analysis;ChEMBL;209,1;2;1;4;1,31;C=CCN1CCc2nc(N)sc2CC1;https://dx.doi.org/10.1039/C9MD00379G
TALIPEXOLE;98934;None;37;Human;Binding;pKi;=;6,31;8,20;-5;25;None;Drug Central;209,1;2;1;4;1,31;C=CCN1CCc2nc(N)sc2CC1;-
TALIPEXOLE;98934;3H-thymidine;37;Human;Binding;pKi;=;1,30;8,89;-5;25;-;PDSP KiDatabase;209,1;2;1;4;1,31;C=CCN1CCc2nc(N)sc2CC1;-
TALIPEXOLE;98934;125I-IODOSULPRIDE;37;Human;Binding;pKi;=;977,24;6,01;-5;25;-;PDSP KiDatabase;209,1;2;1;4;1,31;C=CCN1CCc2nc(N)sc2CC1;-
TALIPEXOLE;98934;125I-IODOSULPRIDE;37;Human;Binding;pKi;=;390,00;6,41;-5;25;-;PDSP KiDatabase;209,1;2;1;4;1,31;C=CCN1CCc2nc(N)sc2CC1;-
TALIPEXOLE;98934;125I-IODOSULPRIDE;37;Human;Binding;pKi;=;616,60;6,21;-5;25;-;PDSP KiDatabase;209,1;2;1;4;1,31;C=CCN1CCc2nc(N)sc2CC1;-
tamoxifen;3747;None;45;Human;Binding;AC50;=;3200,00;5,50;-30;41;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;371,2;8;0;2;6,00;CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1;https://dx.doi.org/10.1038/s41467-023-40064-9
tamoxifen;3747;None;45;Human;Binding;IC50;=;13885,00;4,86;-30;41;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;371,2;8;0;2;6,00;CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1;-
tamoxifen;3747;None;45;Human;Binding;Ki;=;4628,00;5,33;-30;41;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;371,2;8;0;2;6,00;CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1;-
tamoxifen;3747;None;45;Human;Binding;pKi;=;5,33;8,27;-30;41;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;371,2;8;0;2;6,00;CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1;-
tamsulosin;3749;None;48;Human;Binding;AC50;=;100,00;7,00;-125;22;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;408,2;11;2;6;2,34;CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
tamsulosin;3749;None;48;Human;Binding;Ki;=;13,00;7,89;-125;22;Binding affinity towards recombinant human Dopamine receptor D2L was determined using [3H]spiperone as radioligand;ChEMBL;408,2;11;2;6;2,34;CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1;https://dx.doi.org/10.1021/jm9905918
tamsulosin;3749;None;48;Human;Binding;Ki;=;78,00;7,11;-125;22;Binding affinity towards recombinant human Dopamine receptor D2S was determined using [3H]spiperone as radioligand;ChEMBL;408,2;11;2;6;2,34;CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1;https://dx.doi.org/10.1021/jm9905918
tamsulosin;3749;None;48;Human;Binding;pKi;=;7,89;8,10;-125;22;Binding affinity towards recombinant human Dopamine receptor D2L was determined using [3H]spiperone as radioligand;Drug Central;408,2;11;2;6;2,34;CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1;-
tandospirone;3751;None;39;Human;Binding;Ki;=;460,00;6,34;-6;4;Binding affinity to Dopamine receptor D2 was determined;ChEMBL;383,2;6;0;6;1,41;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1016/s0960-894x(01)00167-6
tandospirone;3751;None;39;Human;Binding;Ki;=;28,00;7,55;-6;4;Binding affinity for DA2 receptor;ChEMBL;383,2;6;0;6;1,41;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(c2ncccn2)CC1;https://dx.doi.org/10.1021/jm00075a006
tandospirone;3751;None;39;Human;Binding;pKi;=;7,55;8,12;-6;4;Binding affinity for DA2 receptor;Drug Central;383,2;6;0;6;1,41;O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1CCCCN1CCN(c2ncccn2)CC1;-
TEFLUDAZINE;210176;R-SAT;10;Human;Binding;pKi;=;0,70;9,15;2;5;-;PDSP KiDatabase;408,2;4;1;3;4,03;OCCN1CCN([C@@H]2C[C@@H](c3ccc(F)cc3)c3ccc(C(F)(F)F)cc32)CC1;-
TEFLUDAZINE;210176;R-SAT;10;Human;Binding;pKi;=;0,30;9,52;2;5;-;PDSP KiDatabase;408,2;4;1;3;4,03;OCCN1CCN([C@@H]2C[C@@H](c3ccc(F)cc3)c3ccc(C(F)(F)F)cc32)CC1;-
tegaserod;3773;None;26;Human;Binding;AC50;=;3100,00;5,51;-38;39;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;301,2;7;3;3;2,60;CCCCCN=C(N)N/N=C/c1c[nH]c2ccc(OC)cc12;https://dx.doi.org/10.1038/s41467-023-40064-9
tegaserod;3773;None;26;Human;Binding;Ki;=;296,96;6,53;-38;39;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;301,2;7;3;3;2,60;CCCCCN=C(N)N/N=C/c1c[nH]c2ccc(OC)cc12;https://dx.doi.org/10.6019/CHEMBL5442175
TENAMFETAMINE;206113;3H-YM 09151-2;13;Human;Binding;pKi;=;10000,00;5,00;-81;9;-;PDSP KiDatabase;179,1;2;1;3;1,30;CC(N)Cc1ccc2c(c1)OCO2;-
terfenadine;3779;None;53;Human;Binding;IC50;=;6167,00;5,21;-8;32;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;471,3;8;2;3;6,45;CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;-
terfenadine;3779;None;53;Human;Binding;Ki;=;2056,00;5,69;-8;32;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;471,3;8;2;3;6,45;CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;-
terfenadine;3779;None;53;Human;Binding;pKi;=;5,69;8,25;-8;32;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;471,3;8;2;3;6,45;CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1;-
terguride;3780;None;25;Human;Binding;AC50;=;16,00;7,80;1;26;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://dx.doi.org/10.1038/s41467-023-40064-9
terguride;3780;None;25;Human;Binding;pKi;=;9,10;8,04;1;26;None;Drug Central;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
terguride;3780;None;25;Human;Binding;pKi;None;-;8,90;1;26;Unclassified;Guide to Pharmacology;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://pubmed.ncbi.nlm.nih.gov/12388666
terguride;3780;None;25;Human;Binding;pKi;None;-;9,10;1;26;Unclassified;Guide to Pharmacology;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;https://pubmed.ncbi.nlm.nih.gov/12388666
terguride;3780;3H-YM 09151-2;25;Human;Binding;pKi;=;0,70;9,15;1;26;-;PDSP KiDatabase;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
terguride;3780;125I-IODOSULPRIDE;25;Human;Binding;pKi;=;0,81;9,09;1;26;-;PDSP KiDatabase;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
terguride;3780;3H-SPIPERONE;25;Human;Binding;pKi;=;0,36;9,44;1;26;-;PDSP KiDatabase;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
terguride;3780;125I-7-OH-PIPAT;25;Human;Binding;pKi;=;0,16;9,80;1;26;-;PDSP KiDatabase;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
terguride;3780;125I-IODOSULPRIDE;25;Human;Binding;pKi;=;1,15;8,94;1;26;-;PDSP KiDatabase;340,2;3;2;2;2,93;CCN(CC)C(=O)N[C@H]1C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1;-
tertatolol;3783;125I-IODOSULPRIDE;23;Human;Binding;pKi;=;10000,00;5,00;-2187;11;-;PDSP KiDatabase;295,2;5;2;4;2,85;CC(C)(C)NCC(O)COc1cccc2c1SCCC2;-
TETRABENAZINE;11069;None;60;Human;Binding;pKi;=;5,68;8,25;1;6;None;Drug Central;317,2;4;0;4;3,24;COc1cc2c(cc1OC)C1CC(=O)C(CC(C)C)CN1CC2;-
TETRAHYDROPALMATINE;186224;None;46;Human;Binding;Ki;=;1125,00;5,95;-6;4;Displacement of [3H]SCH23390 from human FLAG-tagged dopamine D2 receptor expressed in HEK293 cells after 1 hr;ChEMBL;355,2;4;0;5;3,38;COc1cc2c(cc1OC)[C@@H]1Cc3ccc(OC)c(OC)c3CN1CC2;https://dx.doi.org/10.1016/j.bmcl.2017.01.090
THIETHYLPERAZINE;28732;None;28;Human;Binding;AC50;=;100,00;7,00;-1;18;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;399,2;6;0;5;5,04;CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2;https://dx.doi.org/10.1038/s41467-023-40064-9
THIETHYLPERAZINE;28732;None;28;Human;Binding;pKi;=;8,70;8,06;-1;18;None;Drug Central;399,2;6;0;5;5,04;CCSc1ccc2c(c1)N(CCCN1CCN(C)CC1)c1ccccc1S2;-
THIMEROSAL;189074;None;0;Human;Binding;AC50;=;2500,00;5,60;-;15;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;-;-;-;-;-;-;https://dx.doi.org/10.1038/s41467-023-40064-9
THIOPROPERAZINE;204590;None;44;Human;Binding;AC50;=;21,00;7,68;-9;21;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;446,2;6;0;6;3,18;CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
THIOPROPERAZINE;204590;None;44;Human;Binding;pKi;=;9,35;8,03;-9;21;None;Drug Central;446,2;6;0;6;3,18;CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
THIOPROPERAZINE;204590;125I-IODOSULPRIDE;44;Human;Binding;pKi;=;0,45;9,35;-9;21;-;PDSP KiDatabase;446,2;6;0;6;3,18;CN1CCN(CCCN2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
thioridazine;3805;None;44;Human;Binding;AC50;=;250,00;6,60;-3;64;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;https://dx.doi.org/10.1038/s41467-023-40064-9
thioridazine;3805;None;44;Human;Binding;IC50;=;35,00;7,46;-3;64;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;None;44;Human;Binding;Ki;=;12,00;7,92;-3;64;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;None;44;Human;Binding;Ki;=;27,00;7,57;-3;64;Binding affinity towards Dopamine receptor D2;ChEMBL;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;https://dx.doi.org/10.1021/jm0205651
thioridazine;3805;3H-NMSP;44;Human;Binding;pKi;=;11,00;7,96;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-SPIPERONE;44;Human;Binding;pKi;=;5,20;8,28;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-NEMONAPRIDE;44;Human;Binding;pKi;=;18,50;7,73;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-YM 09151-2;44;Human;Binding;pKi;=;2,80;8,55;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-SPIPERONE;44;Human;Binding;pKi;=;4,00;8,40;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-SPIPERONE;44;Human;Binding;pKi;=;26,00;7,59;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;UNDEFINED;44;Human;Binding;pKi;=;0,40;9,40;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-NEMONAPRIDE;44;Human;Binding;pKi;=;19,00;7,72;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-NMSP;44;Human;Binding;pKi;=;10,00;8,00;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-RACLOPRIDE;44;Human;Binding;pKi;=;1,10;8,96;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;UNDEFINED;44;Human;Binding;pKi;=;0,40;9,40;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;R-SAT;44;Human;Binding;pKi;=;21,00;7,68;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;UNDEFINED;44;Human;Binding;pKi;=;26,31;7,58;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-SPIPERONE;44;Human;Binding;pKi;=;0,40;9,40;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-RACLOPRIDE;44;Human;Binding;pKi;=;1,60;8,80;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
thioridazine;3805;3H-Methylspiperone;44;Human;Binding;pKi;=;26,70;7,57;-3;64;-;PDSP KiDatabase;370,2;4;0;4;5,89;CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2;-
THIOTEPA;206077;None;58;Human;Binding;AC50;=;21000,00;4,68;-;14;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;189;3;0;1;0,16;S=P(N1CC1)(N1CC1)N1CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
thiothixene;3806;None;35;Human;Binding;AC50;=;2,70;8,57;5;32;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;443,2;5;0;5;3,47;CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
thiothixene;3806;None;35;Human;Binding;pKi;=;9,35;8,03;5;32;None;Drug Central;443,2;5;0;5;3,47;CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
thiothixene;3806;UNDEFINED;35;Human;Binding;pKi;=;0,12;9,92;5;32;-;PDSP KiDatabase;443,2;5;0;5;3,47;CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
THIOTHIXENE,cis-;218469;3H-SPIPERONE;0;Human;Binding;pKi;=;0,45;9,35;1;43;-;PDSP KiDatabase;443,2;5;0;5;3,47;CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
THIOTHIXENE,cis-;218469;3H-NMSP;0;Human;Binding;pKi;=;1,40;8,85;1;43;-;PDSP KiDatabase;443,2;5;0;5;3,47;CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
THIOTHIXENE,cis-;218469;UNDEFINED;0;Human;Binding;pKi;=;0,45;9,35;1;43;-;PDSP KiDatabase;443,2;5;0;5;3,47;CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
THIOTHIXENE,cis-;218469;R-SAT;0;Human;Binding;pKi;=;0,03;10,52;1;43;-;PDSP KiDatabase;443,2;5;0;5;3,47;CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
THIOTHIXENE,cis-;218469;R-SAT;0;Human;Binding;pKi;=;0,20;9,70;1;43;-;PDSP KiDatabase;443,2;5;0;5;3,47;CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
THIOTHIXENE,cis-;218469;3H-NMSP;0;Human;Binding;pKi;=;0,63;9,20;1;43;-;PDSP KiDatabase;443,2;5;0;5;3,47;CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1;-
TIAPRIDE;208386;None;26;Human;Binding;AC50;=;300,00;6,52;-6;8;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;328,1;8;1;5;1,17;CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
TIAPRIDE;208386;None;26;Human;Binding;IC50;=;1232,00;5,91;-6;8;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;328,1;8;1;5;1,17;CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC;-
TIAPRIDE;208386;None;26;Human;Binding;Ki;=;411,00;6,39;-6;8;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;328,1;8;1;5;1,17;CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC;-
TIAPRIDE;208386;None;26;Human;Binding;pKi;=;7,08;8,15;-6;8;None;Drug Central;328,1;8;1;5;1,17;CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC;-
TIAPRIDE;208386;R-SAT;26;Human;Binding;pKi;=;31,00;7,51;-6;8;-;PDSP KiDatabase;328,1;8;1;5;1,17;CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC;-
TIAPRIDE;208386;R-SAT;26;Human;Binding;pKi;=;226,00;6,65;-6;8;-;PDSP KiDatabase;328,1;8;1;5;1,17;CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC;-
TIOCONAZOLE;14425;None;55;Human;Binding;AC50;=;12000,00;4,92;-;13;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;386;6;0;4;5,86;Clc1ccc(C(Cn2ccnc2)OCc2ccsc2Cl)c(Cl)c1;https://dx.doi.org/10.1038/s41467-023-40064-9
TIQ-15;3832;None;11;Human;Binding;IC50;=;5700,00;5,24;-;7;Inhibition of dopamine D2 receptor (unknown origin);ChEMBL;364,3;7;2;4;3,21;NCCCCN(C[C@H]1Cc2ccccc2CN1)[C@H]1CCCc2cccnc21;https://dx.doi.org/10.1021/acs.jmedchem.1c01564
trazodone;3853;None;34;Human;Binding;AC50;=;3000,00;5,52;-23;46;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;371,2;5;0;6;2,36;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;https://dx.doi.org/10.1038/s41467-023-40064-9
trazodone;3853;None;34;Human;Binding;pKi;None;5,46;8,26;-23;46;None;Drug Central;371,2;5;0;6;2,36;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;-
trazodone;3853;3H-NMSP;34;Human;Binding;pKi;=;4142,00;5,38;-23;46;-;PDSP KiDatabase;371,2;5;0;6;2,36;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;-
trazodone;3853;3H-SPIPERONE;34;Human;Binding;pKi;=;3500,00;5,46;-23;46;-;PDSP KiDatabase;371,2;5;0;6;2,36;O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12;-
trifluoperazine;3860;None;43;Human;Binding;AC50;=;14,80;7,83;-2;44;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
trifluoperazine;3860;None;43;Human;Binding;pKi;=;8,84;8,05;-2;44;None;Drug Central;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;None;43;Human;Binding;pKi;=;-;8,96;-2;44;Unclassified;Guide to Pharmacology;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;https://pubmed.ncbi.nlm.nih.gov/12629531
trifluoperazine;3860;None;43;Human;Binding;pKi;=;-;8,96;-2;44;Unclassified;Guide to Pharmacology;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;https://pubmed.ncbi.nlm.nih.gov/9015795
trifluoperazine;3860;UNDEFINED;43;Human;Binding;pKi;=;2,63;8,58;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;3H-YM 09151-2;43;Human;Binding;pKi;=;1,10;8,96;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;3H-SPIPERONE;43;Human;Binding;pKi;=;0,96;9,02;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;UNDEFINED;43;Human;Binding;pKi;=;0,96;9,02;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;3H-RACLOPRIDE;43;Human;Binding;pKi;=;1,60;8,80;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;3H-NMSP;43;Human;Binding;pKi;=;1,30;8,89;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;3H-SPIPERONE;43;Human;Binding;pKi;=;2,60;8,59;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;3H-SPIPERONE;43;Human;Binding;pKi;=;3,80;8,42;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;3H-NEMONAPRIDE;43;Human;Binding;pKi;=;6,80;8,17;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
trifluoperazine;3860;UNDEFINED;43;Human;Binding;pKi;=;0,96;9,02;-2;44;-;PDSP KiDatabase;407,2;4;0;4;4,95;CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1;-
TRIFLUPERIDOL;42816;None;18;Human;Binding;pKi;None;9,70;8,01;1;9;None;Drug Central;409,2;6;1;3;4,79;O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1;-
TRIFLUPERIDOL;42816;R-SAT;18;Human;Binding;pKi;=;0,40;9,40;1;9;-;PDSP KiDatabase;409,2;6;1;3;4,79;O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1;-
TRIFLUPERIDOL;42816;R-SAT;18;Human;Binding;pKi;=;0,20;9,70;1;9;-;PDSP KiDatabase;409,2;6;1;3;4,79;O=C(CCCN1CCC(O)(c2cccc(C(F)(F)F)c2)CC1)c1ccc(F)cc1;-
TRIFLUPROMAZINE;199956;None;21;Human;Binding;pKi;=;8,55;8,07;-2;18;None;Drug Central;352,1;4;0;3;5,26;CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21;-
TRIFLUPROMAZINE;199956;3H-SPIPERONE;21;Human;Binding;pKi;=;2,80;8,55;-2;18;-;PDSP KiDatabase;352,1;4;0;3;5,26;CN(C)CCCN1c2ccccc2Sc2ccc(C(F)(F)F)cc21;-
TRIMETHOBENZAMIDE;14485;None;39;Human;Binding;AC50;=;6900,00;5,16;-;2;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;388,2;10;1;6;2,58;COc1cc(C(=O)NCc2ccc(OCCN(C)C)cc2)cc(OC)c1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
U101958;3899;None;4;Human;Binding;IC50;=;620,00;6,21;-;4;Binding affinity to cloned human Dopamine receptor D2 expressed in A9L cells by [3H]spiperone displacement.;ChEMBL;339,2;6;0;4;3,97;CC(C)Oc1cccnc1N(C)C1CCN(Cc2ccccc2)CC1;https://dx.doi.org/10.1016/s0960-894x(98)00361-8
U92016A;3905;None;5;Human;Binding;Ki;=;35,00;7,46;-245;4;Displacement of [3H]U-86170 from human D2-dopamine receptor expressed in CHO K1 cells;ChEMBL;295,2;5;1;2;4,02;CCCN(CCC)[C@@H]1CCc2ccc3[nH]c(C#N)cc3c2C1;https://dx.doi.org/10.1021/jm00067a003
UCSF924;119841;None;26;Human;Binding;Ki;=;4328,00;5,36;-2884;33;GPCRScan assay: inhibition of D2;ChEMBL;322,2;7;2;4;3,81;Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1;https://dx.doi.org/10.6019/CHEMBL4507309
UCSF924;119841;None;26;Human;Binding;Ki;=;3981,07;5,40;-2884;33;GPCRScan assay: inhibition of D2;ChEMBL;322,2;7;2;4;3,81;Cc1ccc2nc(CNCCCOc3ccccc3)cc(O)c2c1;https://dx.doi.org/10.6019/CHEMBL4507309
UH232(+);218618;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;9,00;8,05;-2;5;-;PDSP KiDatabase;273,2;6;0;2;4,32;CCCN(CCC)C1C=Cc2c(OC)cccc2C1C;-
UH232(+);218618;125I-IODOSULPRIDE;0;Human;Binding;pKi;=;36,00;7,44;-2;5;-;PDSP KiDatabase;273,2;6;0;2;4,32;CCCN(CCC)C1C=Cc2c(OC)cccc2C1C;-
UH232(+);218618;3H-YM 09151-2;0;Human;Binding;pKi;=;29,40;7,53;-2;5;-;PDSP KiDatabase;273,2;6;0;2;4,32;CCCN(CCC)C1C=Cc2c(OC)cccc2C1C;-
ulotaront;3938;None;17;Human;Binding;EC50;=;10000,00;5,00;-;3;Agonist activity at D2 (unknown origin) by HTRF assay;ChEMBL;183,1;2;1;3;1,58;CNC[C@@H]1OCCc2ccsc21;https://dx.doi.org/10.1039/D1MD00096A
ulotaront;3938;None;17;Human;Binding;IC50;=;24000,00;4,62;-;3;Agonist activity at D2 (unknown origin) by beta-arrestin recruitment assay;ChEMBL;183,1;2;1;3;1,58;CNC[C@@H]1OCCc2ccsc21;https://dx.doi.org/10.1039/D1MD00096A
UNC0006;3940;None;4;Human;Binding;EC50;=;270,00;6,57;-2;9;Partial agonist activity at human D2SR expressed in HEK293T cells co-expressing (EA)beta-arrestin2 and GRK2 assessed as induction of beta-arrestin2 recruitment after 5 hrs by chemiluminescence assay;ChEMBL;461,2;7;1;4;5,25;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
UNC0006;3940;None;4;Human;Binding;Ki;=;3,60;8,44;-2;9;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;461,2;7;1;4;5,25;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
UNC0006;3940;None;4;Human;Binding;Ki;=;3,60;8,44;-2;9;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;461,2;7;1;4;5,25;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/jm300603y
UNC0006;3940;None;4;Human;Binding;Ki;=;0,53;9,28;-2;9;Displacement of [3H]spiperone from human D2LR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;461,2;7;1;4;5,25;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
UNC0006;3940;None;4;Human;Binding;Ki;=;0,20;9,70;-2;9;Displacement of [3H]spiperone from human D2SR expressed in CHO cell membranes by radioligand binding assay;ChEMBL;461,2;7;1;4;5,25;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://dx.doi.org/10.1021/acs.jmedchem.7b00363
UNC0006;3940;None;4;Human;Binding;Ki;=;5,00;8,30;-2;9;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;461,2;7;1;4;5,25;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;-
UNC0006;3940;None;4;Human;Binding;pKi;=;-;8,30;-2;9;β-arrestin 2 biased agonist.;Guide to Pharmacology;461,2;7;1;4;5,25;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)cc2N1;https://pubmed.ncbi.nlm.nih.gov/22025698
UNC9975;3941;None;6;Human;Binding;Ki;=;1,20;8,92;-1;9;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;462,2;7;1;5;4,64;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)nc2N1;-
UNC9975;3941;None;6;Human;Binding;Ki;=;1,20;8,92;-1;9;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;462,2;7;1;5;4,64;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)nc2N1;https://dx.doi.org/10.1021/jm300603y
UNC9975;3941;None;6;Human;Binding;Ki;=;2,60;8,59;-1;9;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;462,2;7;1;5;4,64;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)nc2N1;-
UNC9975;3941;None;6;Human;Binding;pKi;=;-;8,59;-1;9;β-arrestin 2 biased agonist.;Guide to Pharmacology;462,2;7;1;5;4,64;O=C1CCc2ccc(OCCCCN3CCCN(c4cccc(Cl)c4Cl)CC3)nc2N1;https://pubmed.ncbi.nlm.nih.gov/22025698
UNC9994;3942;None;7;Human;Binding;EC50;=;50,00;7,30;-;1;pERK High-Content Assay: Cell Culture: Chinese Hamster Ovary (CHO) cells stably expressing the hD2L dopamine receptor (Urban et al., Neuropsychopharmacology 32:67 (2007)) were maintained in Ham's F12 medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 ug/mL streptomycin, and 0.5 ug/ml G418. On day 1 of the assay, cells were seeded onto black clear-bottom tissue culture-treated 96-well plates (Greiner, BioOne). On day 2 of the assay, cells were washed with serum-free medium (Ham's F-12, penicillin and streptomycin) and incubated in 100 uL serum-free medium overnight.Immunofluorescence: Automatic multichannel pipetters were used for liquid handling and multichannel vacuum manifolds for aspirations. Each tested concentration was typically measured in triplicate or quadruplicate. For concentration curves, half-log-dilutions were used. Drug dilutions were prepared in stimulation medium (serum-free medium, 100 mg/L ascorbic acid).;ChEMBL;420,1;6;0;4;6,25;Clc1cccc(C2CCN(CCCOc3ccc4scnc4c3)CC2)c1Cl;-
UNC9994;3942;None;7;Human;Binding;Ki;=;75,00;7,12;-;1;Radioligand Binding Assay: Membranes prepared as above were resuspended to 1 ug protein/ul (measured by Bradford assay using BSA as standard), and 50 ul were added to each well of a polypropylene 96-well plate containing (per well): 50 ul of buffer (20 mM HEPES, 10 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 100 mM N-methyl-D-gluconate, pH 7.4), 50 ul of 1.5 nM [3H]N-methylspiperone (final concentration 0.3 nM) and reference or D2 test ligand at various concentrations ranging from 50 uM to 50 uM (final concentrations ranging from 10 uM to 10 uM, triplicate determinations for each concentration of D2 test ligand). After a 1.5-hr incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4 using a Perkin-Elmer Filtermate 96-well harvester. The filters were subsequently dried, placed on a hot plate (100° C.), and Melitilex-A (Wallac) scintillant was applied.;ChEMBL;420,1;6;0;4;6,25;Clc1cccc(C2CCN(CCCOc3ccc4scnc4c3)CC2)c1Cl;-
UNC9994;3942;None;7;Human;Binding;Ki;=;75,00;7,12;-;1;Displacement of [3H]N-methylspiperone from human D2L receptor expressed in CHO cells after 1.5 hrs by microbeta counting method;ChEMBL;420,1;6;0;4;6,25;Clc1cccc(C2CCN(CCCOc3ccc4scnc4c3)CC2)c1Cl;https://dx.doi.org/10.1021/jm300603y
UNC9994;3942;None;7;Human;Binding;pKi;=;-;7,10;-;1;β-arrestin 2 biased agonist.;Guide to Pharmacology;420,1;6;0;4;6,25;Clc1cccc(C2CCN(CCCOc3ccc4scnc4c3)CC2)c1Cl;https://pubmed.ncbi.nlm.nih.gov/22025698
URAPIDIL;98949;None;48;Human;Binding;AC50;=;5900,00;5,23;-;16;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;387,2;7;1;8;0,72;COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
UTP;3966;None;29;Human;Binding;Ki;=;3845,92;5,42;2;9;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;484;8;7;12;-2,50;O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1;https://dx.doi.org/10.6019/CHEMBL5442175
VALDECOXIB;208661;3H-NMSP;64;Human;Binding;pKi;=;10000,00;5,00;-97;33;-;PDSP KiDatabase;314,1;3;1;4;2,96;Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1;-
valeryl salicylate;218876;3H-NMSP;0;Human;Binding;pKi;=;10000,00;5,00;-1;30;-;PDSP KiDatabase;222,1;5;1;3;2,48;CCCCC(=O)Oc1ccccc1C(=O)O;-
VENLAFAXINE;205524;3H-SPIPERONE;56;Human;Binding;pKi;=;10000,00;5,00;-79;45;-;PDSP KiDatabase;277,2;5;1;3;3,04;COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1;-
VENLAFAXINE;205524;3H-SPIPERONE;56;Human;Binding;pKi;=;10000,00;5,00;-79;45;-;PDSP KiDatabase;277,2;5;1;3;3,04;COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1;-
VENLAFAXINE;205524;3H-SPIPERONE;56;Human;Binding;pKi;=;10000,00;5,00;-79;45;-;PDSP KiDatabase;277,2;5;1;3;3,04;COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1;-
VERALIPRIDE;78239;None;45;Human;Binding;AC50;=;57,10;7,24;-;9;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;383,2;8;2;6;0,73;C=CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)cc(OC)c1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
VERAPAMIL;206466;None;47;Human;Binding;AC50;=;4400,00;5,36;-;21;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;454,3;13;0;6;5,09;COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC;https://dx.doi.org/10.1038/s41467-023-40064-9
vilazodone;3992;None;57;Human;Binding;Ki;=;666,00;6,18;-223;30;Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting;ChEMBL;441,2;7;2;5;4,03;N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1;https://dx.doi.org/10.1016/j.ejmech.2012.03.042
vilazodone;3992;None;57;Human;Binding;Ki;=;552,71;6,26;-223;30;PDSP Secondary Binding target: DRD2 - Compounds are tested at 10 uM concentration, plate are incubated at room temperature in the dark for 90 minutes. Reaction are stopped by vacuum filtration onto 0.3% polyethyleneimine soaked filter mats using Filtermate harvester. Scintillation cocktail is then melted onto microwave-dried filters on a hot plate and the radio activity is counted in Microbia counter. Compounds showing a minimum of 50% inhibition at 10 uM concentration are carried forward in this secondary binding assay to determine equilibrium binding affinity.;ChEMBL;441,2;7;2;5;4,03;N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1;https://dx.doi.org/10.6019/CHEMBL5442175
volinanserin;4006;None;43;Human;Binding;Ki;=;2250,00;5,65;-10471;37;Binding affinity to dopamine D2 receptor by competitive binding experiment;ChEMBL;373,2;7;1;4;3,83;COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC;https://dx.doi.org/10.1016/j.bmc.2009.03.021
volinanserin;4006;None;43;Human;Binding;Ki;=;1300,00;5,89;-10471;37;Ability to displace [3H]-spiperone from CHO cells expressing human Dopamine receptor D2 was determined;ChEMBL;373,2;7;1;4;3,83;COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC;https://dx.doi.org/10.1016/s0960-894x(00)00558-8
volinanserin;4006;None;43;Human;Binding;Ki;=;1300,00;5,89;-10471;37;Binding affinity for displacement of [3H]spiperone to human dopamine D2 (hD2) receptors stably expressed in CHO cells;ChEMBL;373,2;7;1;4;3,83;COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC;https://dx.doi.org/10.1021/jm011030v
volinanserin;4006;None;43;Human;Binding;Ki;=;1300,00;5,89;-10471;37;Binding affinity against human Dopamine receptor D2;ChEMBL;373,2;7;1;4;3,83;COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC;https://dx.doi.org/10.1016/j.bmcl.2005.05.104
volinanserin;4006;UNDEFINED;43;Human;Binding;pKi;=;9000,00;5,05;-10471;37;-;PDSP KiDatabase;373,2;7;1;4;3,83;COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC;-
volinanserin;4006;3H-NMSP;43;Human;Binding;pKi;=;10000,00;5,00;-10471;37;-;PDSP KiDatabase;373,2;7;1;4;3,83;COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC;-
volinanserin;4006;3H-SPIPERONE;43;Human;Binding;pKi;=;2250,00;5,65;-10471;37;-;PDSP KiDatabase;373,2;7;1;4;3,83;COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC;-
WAY 100,635;218509;3H-NMSP;0;Human;Binding;pKi;=;940,00;6,03;-741;37;-;PDSP KiDatabase;530,2;7;0;5;5,09;COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1.Cl.Cl.Cl;-
WAY 100,635;218509;3H-8-OH-DPAT;0;Human;Binding;pKi;=;78,00;7,11;-741;37;-;PDSP KiDatabase;530,2;7;0;5;5,09;COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1.Cl.Cl.Cl;-
WAY 100,635;218509;3H-RACLOPRIDE;0;Human;Binding;pKi;=;79,00;7,10;-741;37;-;PDSP KiDatabase;530,2;7;0;5;5,09;COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1.Cl.Cl.Cl;-
WM-1119;216401;None;42;Human;Binding;Ki;=;397,52;6,40;-;1;Selectivity interaction (GPCR panel (PDSP screen)) EUB0000329a DRD2;ChEMBL;-;-;-;-;-;O=C(NNS(=O)(=O)c1ccccc1F)c1cc(F)cc(-c2ccccn2)c1;https://dx.doi.org/10.6019/CHEMBL5212743
WM-1119;216401;None;42;Human;Binding;Ki;=;397,52;6,40;-;1;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;O=C(NNS(=O)(=O)c1ccccc1F)c1cc(F)cc(-c2ccccn2)c1;https://dx.doi.org/10.6019/CHEMBL4507321
WM-1119;216401;None;42;Human;Binding;Ki;=;389,05;6,41;-;1;GPCRScan assay: inhibition of D2;ChEMBL;-;-;-;-;-;O=C(NNS(=O)(=O)c1ccccc1F)c1cc(F)cc(-c2ccccn2)c1;https://dx.doi.org/10.6019/CHEMBL4507321
xanomeline;4097;None;50;Human;Binding;pKi;=;6,00;8,22;-11;26;None;Drug Central;281,2;7;0;5;3,22;CCCCCCOc1nsnc1C1=CCCN(C)C1;-
xanomeline;4097;125I-IODOSULPRIDE;50;Human;Binding;pKi;=;1000,00;6,00;-11;26;-;PDSP KiDatabase;281,2;7;0;5;3,22;CCCCCCOc1nsnc1C1=CCCN(C)C1;-
xylometazoline;4107;None;38;Human;Binding;AC50;=;15000,00;4,82;-;22;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;244,2;2;1;2;3,15;Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1;https://dx.doi.org/10.1038/s41467-023-40064-9
yohimbine;4127;None;36;Human;Binding;AC50;=;188,90;6,72;-3715;53;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;354,2;1;2;4;2,65;COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21;https://dx.doi.org/10.1038/s41467-023-40064-9
yohimbine;4127;None;36;Human;Binding;AC50;=;2545,60;5,59;-3715;53;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;354,2;1;2;4;2,65;COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21;https://dx.doi.org/10.1038/s41467-023-40064-9
yohimbine;4127;None;36;Human;Binding;IC50;=;2060,00;5,69;-3715;53;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;354,2;1;2;4;2,65;COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21;-
yohimbine;4127;None;36;Human;Binding;Ki;=;687,00;6,16;-3715;53;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);ChEMBL;354,2;1;2;4;2,65;COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21;-
yohimbine;4127;None;36;Human;Binding;pKi;=;6,16;8,21;-3715;53;DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone);Drug Central;354,2;1;2;4;2,65;COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21;-
yohimbine;4127;3H-SPIPERONE;36;Human;Binding;pKi;=;398,10;6,40;-3715;53;-;PDSP KiDatabase;354,2;1;2;4;2,65;COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21;-
yohimbine;4127;3H-YM 09151-2;36;Human;Binding;pKi;=;280,00;6,55;-3715;53;-;PDSP KiDatabase;354,2;1;2;4;2,65;COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21;-
ZICRONAPINE;102453;None;23;Human;Binding;Ki;=;4,10;8,39;-39;19;Displacement of [3H]7-OH-DPAT from recombinant human D2S receptor measured after 60 mins by scintillation counting analysis;ChEMBL;354,2;2;0;2;4,94;CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C;https://dx.doi.org/10.1016/j.bmcl.2022.128879
ZICRONAPINE;102453;None;23;Human;Binding;Ki;=;28,00;7,55;-39;19;Binding affinity to human dopamine D2 receptor;ChEMBL;354,2;2;0;2;4,94;CN1CCN([C@@H]2C[C@@H](c3ccccc3)c3ccc(Cl)cc32)CC1(C)C;https://dx.doi.org/10.1016/j.bmcl.2020.127563
ZIMELDINE;138516;None;29;Human;Binding;AC50;=;23000,10;4,64;-;10;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;316,1;4;0;2;3,84;CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1;https://dx.doi.org/10.1038/s41467-023-40064-9
ZIMELDINE;138516;None;29;Human;Binding;pKi;None;5,73;8,24;-;10;None;Drug Central;316,1;4;0;2;3,84;CN(C)C/C=C(/c1ccc(Br)cc1)c1cccnc1;-
ZIMELIDINE;218484;3H-YM 09151-2;0;Human;Binding;pKi;=;1874,00;5,73;-2;4;-;PDSP KiDatabase;316,1;4;0;2;3,84;CN(C)CC=C(c1ccc(Br)cc1)c1cccnc1;-
ziprasidone;4143;None;47;Human;Binding;AC50;=;26,00;7,58;-7;56;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1038/s41467-023-40064-9
ziprasidone;4143;None;47;Human;Binding;IC50;=;5,00;8,30;-7;56;Inhibitory concentration against dopamine receptor D2;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1021/jm058225d
ziprasidone;4143;None;47;Human;Binding;Ki;=;2,10;8,68;-7;56;Displacement of [3H]-raclopride from human D2R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2019.111857
ziprasidone;4143;None;47;Human;Binding;Ki;=;12,59;7,90;-7;56;Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1021/jm070516u
ziprasidone;4143;None;47;Human;Binding;Ki;=;2,10;8,68;-7;56;Displacement of [3H]-Raclopride from D2L receptor (unknown origin);ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1021/acsmedchemlett.6b00482
ziprasidone;4143;None;47;Human;Binding;Ki;=;2,80;8,55;-7;56;Binding affinity towards human D2 dopamine receptor.;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1021/jm0002432
ziprasidone;4143;None;47;Human;Binding;Ki;=;0,90;9,05;-7;56;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
ziprasidone;4143;None;47;Human;Binding;Ki;=;3,10;8,51;-7;56;Binding affinity to human cloned dopamine D2 receptor;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1016/j.bmc.2008.06.030
ziprasidone;4143;None;47;Human;Binding;Ki;=;0,85;9,07;-7;56;Displacement of [3H]-methylspiperone from human D2 long receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2019.06.001
ziprasidone;4143;None;47;Human;Binding;Ki;=;9,70;8,01;-7;56;Binding affinity towards human Dopamine receptor D2;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1021/jm030480f
ziprasidone;4143;None;47;Human;Binding;Ki;=;5,00;8,30;-7;56;Displacement of [3H]spiperone from human D2L receptor expressed in CHO cells;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1016/j.bmcl.2007.11.106
ziprasidone;4143;None;47;Human;Binding;Ki;=;5,00;8,30;-7;56;Binding Assay: Binding assay using 5-HT2A, Dopamine D2, SERT, αA1, 5-HT2C and H1 Receptors.;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;None;47;Human;Binding;Ki;=;8,50;8,07;-7;56;Displacement of [3H]methylspiperone from human low affinity Dopamine D2S receptor by competition binding assay;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1021/jm300975f
ziprasidone;4143;None;47;Human;Binding;Ki;=;0,90;9,05;-7;56;Displacement of [3H] raclopride from human recombinant D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2019.03.017
ziprasidone;4143;None;47;Human;Binding;Ki;=;4,80;8,32;-7;56;Binding affinity to dopamine D2 receptor (unknown origin) by radioligand binding assay;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1021/jm400856t
ziprasidone;4143;None;47;Human;Binding;Ki;=;0,80;9,10;-7;56;Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method;ChEMBL;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://dx.doi.org/10.1016/j.ejmech.2018.01.002
ziprasidone;4143;None;47;Human;Binding;pKi;=;8,32;8,08;-7;56;None;Drug Central;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;None;47;Human;Binding;pKi;=;-;8,55;-7;56;Unclassified;Guide to Pharmacology;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;https://pubmed.ncbi.nlm.nih.gov/9430133
ziprasidone;4143;UNDEFINED;47;Human;Binding;pKi;=;3,10;8,51;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;3H-SPIPERONE;47;Human;Binding;pKi;=;4,20;8,38;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;3H-SPIPERONE;47;Human;Binding;pKi;=;4,60;8,34;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;UNDEFINED;47;Human;Binding;pKi;=;5,00;8,30;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;R-SAT;47;Human;Binding;pKi;=;5,70;8,24;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;3H-Methylspiperone;47;Human;Binding;pKi;=;8,50;8,07;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;3H-SPIPERONE;47;Human;Binding;pKi;=;2,60;8,59;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;3H-SPIPERONE;47;Human;Binding;pKi;=;4,60;8,34;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;UNDEFINED;47;Human;Binding;pKi;=;1,20;8,92;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;3H-NMSP;47;Human;Binding;pKi;=;4,00;8,40;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;3H-NMSP;47;Human;Binding;pKi;=;9,70;8,01;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;3H-N-Methylspiperone;47;Human;Binding;pKi;=;3,16;8,50;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
ziprasidone;4143;R-SAT;47;Human;Binding;pKi;=;3,00;8,52;-7;56;-;PDSP KiDatabase;412,1;4;1;5;3,81;O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1;-
zotepine;4153;None;44;Human;Binding;AC50;=;52,40;7,28;-9;60;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1038/s41467-023-40064-9
zotepine;4153;None;44;Human;Binding;Ki;=;13,00;7,89;-9;60;Binding affinity towards human Dopamine receptor D2;ChEMBL;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1021/jm030480f
zotepine;4153;None;44;Human;Binding;Ki;=;11,00;7,96;-9;60;Binding affinity towards human D2 dopamine receptor.;ChEMBL;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;https://dx.doi.org/10.1021/jm0002432
zotepine;4153;None;44;Human;Binding;pKi;=;7,96;8,10;-9;60;Binding affinity towards human D2 dopamine receptor.;Drug Central;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;-
zotepine;4153;None;44;Human;Binding;pKi;=;-;7,96;-9;60;Unclassified;Guide to Pharmacology;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;https://pubmed.ncbi.nlm.nih.gov/8935801
zotepine;4153;3H-SPIPERONE;44;Human;Binding;pKi;=;5,40;8,27;-9;60;-;PDSP KiDatabase;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;-
zotepine;4153;3H-SPIPERONE;44;Human;Binding;pKi;=;8,00;8,10;-9;60;-;PDSP KiDatabase;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;-
zotepine;4153;3H-SPIPERONE;44;Human;Binding;pKi;=;11,00;7,96;-9;60;-;PDSP KiDatabase;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;-
zotepine;4153;3H-NMSP;44;Human;Binding;pKi;=;25,00;7,60;-9;60;-;PDSP KiDatabase;331,1;4;0;3;4,88;CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21;-
ZUCLOPENTHIXOL;194927;None;32;Human;Binding;AC50;=;45,00;7,35;-;13;Binding affinity towards human DRD2 in an in vitro assay with cellular components measured by membrane filtration, scintillation proximity assay;ChEMBL;400,1;5;1;4;4,24;OCCN1CCN(CC/C=C2/c3ccccc3Sc3ccc(Cl)cc32)CC1;https://dx.doi.org/10.1038/s41467-023-40064-9
{3-[2-Chloro-thioxanthenylidene]-propyl}-methyl-[4-(3-piperidin-1-yl-propoxy)-benzyl]-amine;219647;UNDEFINED;0;Human;Binding;pKi;=;52,00;7,28;-33;6;-;PDSP KiDatabase;532,2;10;0;4;8,01;CN(CCC=C1c2ccccc2Sc2ccc(Cl)cc21)Cc1ccc(OCCCN2CCCCC2)cc1;-
